[{"link": "https://www.wsj.com/articles/guccis-chinese-revenue-up-in-april-after-bruising-first-quarter-11587492700", "title": "Gucci's Chinese Revenue up in April After Bruising First Quarter", "date": "2020-04-21 14:11", "summary": "First-quarter sales fell 22%, but Chinese luxury shoppers now appear eager to spend. Gucci's revenue fell sharply in the first quarter because of the coronavirus pandemic, as its heavy reliance on Chinese shoppers hit the Italian fashion label hard when Beijing locked down the economy.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gucci's Chinese Revenue up in April After Bruising First Quarter. First-quarter sales fell 22%, but Chinese luxury shoppers now appear eager to spend. Gucci's revenue fell sharply in the first quarter because of the coronavirus pandemic, as its heavy reliance on Chinese shoppers hit the Italian fashion label hard when Beijing locked down the economy.\"\n\nStock Prediction(s):", "Prediction": "\n- Gucci (NYSE: GCO) will increase because their Chinese revenue is up, and they are expecting a rebound in sales.\n- LVMH Mo\u00ebt Hennessy Louis Vuitton SE (OTC: LVMHF) will increase because their Chinese revenue is up, and they are expecting a rebound in sales.\n- Kering SA (OTC: PPRUF) will increase because their Chinese revenue is up, and they are expecting a", "price_info": {"GCO": {"company": "", "ticker": "GCO", "move": "up", "prices": [15.13, 15.11]}}}, {"link": "https://www.wsj.com/articles/stagnant-waters-will-be-nestles-toughest-sell-yet-11591957811", "title": "Stagnant Waters Will Be Nestl\u00e9's Toughest Sell Yet", "date": "2020-06-12 09:52", "summary": "Unloading cheap U.S. water brands is sensible, but timing and sustainability worries could weigh on the valuation. A possible sale of U.S. bottled water brands makes sense for Nestl\u00e9 's profit and environmental credentials alike. Finding a buyer at an acceptable price will be a challenge, though.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Stagnant Waters Will Be Nestl\u00e9's Toughest Sell Yet. Unloading cheap U.S. water brands is sensible, but timing and sustainability worries could weigh on the valuation. A possible sale of U.S. bottled water brands makes sense for Nestl\u00e9 's profit and environmental credentials alike. Finding a buyer at an acceptable price will be a challenge, though.\"\n\nStock Prediction(s):", "Prediction": "\n- Nestl\u00e9 SA (OTCMKTS: NSRGY) will decrease because they are trying to sell their water brands, and the market is not bullish on their prospects.\n- Coca-Cola Company (NYSE: KO) will increase because they are not selling any water brands, and they are a major player in the beverage industry.\n- PepsiCo, Inc. (NASDAQ: PEP) will increase because they are not selling any water brands, and", "price_info": {"KO": {"company": "", "ticker": "KO", "move": "up", "prices": [45.8276, 45.8799]}, "PEP": {"company": "", "ticker": "PEP", "move": "up", "prices": [129.065, 129.7]}}}, {"link": "https://www.wsj.com/articles/coronavirus-finishes-the-retail-reckoning-that-amazon-started-11589459920", "title": "Coronavirus Finishes the Retail Reckoning That Amazon Started", "date": "2020-05-14 12:07", "summary": "Thousands of stores will close permanently as the Covid-19 pandemic turbocharges a shift to e-commerce. Amazon . com hurt many retailers. Coronavirus will finish some of them off.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Finishes the Retail Reckoning That Amazon Started. Thousands of stores will close permanently as the Covid-19 pandemic turbocharges a shift to e-commerce. Amazon . com hurt many retailers. Coronavirus will finish some of them off.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because of the increase in e-commerce.\n- Macy's, Inc. (NYSE: M) will decrease because of the increase in e-commerce.\n- Sears Holdings Corporation (NASDAQ: SHLD) will decrease because of the increase in e-commerce.\n- J.C. Penney Company, Inc. (NYSE: JCP) will decrease because of the", "price_info": {"M": {"company": "", "ticker": "M", "move": "up", "prices": [4.8502, 4.875]}, "JCP": {"company": "", "ticker": "JCP", "move": "down", "prices": [0.1924, 0.201]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [2371.62, 2371.8]}, "SHLD": {"company": "", "ticker": "SHLD", "move": "up"}}}, {"link": "https://www.wsj.com/articles/bond-prices-in-venezuela-jump-on-prospect-of-regime-change-11548357121", "title": "Bond Prices Jump in Venezuela", "date": "2019-01-24 14:12", "summary": "January's rally could extend with increased pressure on the Maduro administration. Venezuelan bond prices have surged amid hopes that pressure against President Nicol\u00e1s Maduro will lead to a new government with which creditors can negotiate to restructure debts the country defaulted on in 2017.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bond Prices Jump in Venezuela. January's rally could extend with increased pressure on the Maduro administration. Venezuelan bond prices have surged amid hopes that pressure against President Nicol\u00e1s Maduro will lead to a new government with which creditors can negotiate to restructure debts the country defaulted on in 2017.\"\n\nStock Prediction(s):", "Prediction": "\n- Venezuelan bonds will continue to increase in price because of the increased pressure on the Maduro administration.\n- Other Latin American bonds will also increase in price because of the increased pressure on the Maduro administration.\n- US Treasury bonds will decrease in price because of the increased pressure on the Maduro administration.", "price_info": {}}, {"link": "https://www.wsj.com/articles/long-term-unemployment-poses-rising-risk-to-the-economy-11601652449", "title": "Long-Term Unemployment Poses Rising Risk to the Economy", "date": "2020-10-02 11:27", "summary": "Workers who haven't been called back to their jobs face the prospect of prolonged joblessness and income loss. More workers identified themselves as permanently laid off and unemployed for the long term in September, a sign the labor market's recovery from the coronavirus pandemic is likely to be slow and protracted.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Long-Term Unemployment Poses Rising Risk to the Economy. Workers who haven't been called back to their jobs face the prospect of prolonged joblessness and income loss. More workers identified themselves as permanently laid off and unemployed for the long term in September, a sign the labor market's recovery from the coronavirus pandemic is likely to be slow and protracted.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will continue to rise, and this will have a negative impact on the economy as a whole.\n- The stock prices of companies that sell consumer goods will decrease because people will have less money to spend.\n- The stock prices of companies that sell luxury goods will decrease because people will have less money to spend.\n- The stock prices of companies that sell essential goods will increase because people will have to buy these goods regardless of the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/elizabeth-warren-floats-expanded-powers-for-bankruptcy-creditors-against-private-equity-11634750237", "title": "Elizabeth Warren Floats Expanded Powers for Bankruptcy Creditors Against Private Equity", "date": "2021-10-20 13:17", "summary": "The Democratic senator has proposed giving rights to creditors of bankrupt companies to challenge alleged self-dealing by private equity owners. Sen. Elizabeth Warren (D., Mass.) has proposed a new measure that would empower creditors in chapter 11 cases to pursue allegations of self-dealing by private-equity owners, rights that currently lie with corporate directors selected by those investment firms.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Elizabeth Warren Floats Expanded Powers for Bankruptcy Creditors Against Private Equity. The Democratic senator has proposed giving rights to creditors of bankrupt companies to challenge alleged self-dealing by private equity owners. Sen. Elizabeth Warren (D., Mass.) has proposed a new measure that would empower creditors in chapter 11 cases to pursue allegations of self-dealing by private-equity owners, rights that currently lie with corporate directors selected by those investment firms.\"\n\nStock Prediction(s):", "Prediction": "\n- The proposed measure will be bad for private equity firms, and will cause their stocks to decrease.\n- Other companies that are not private equity firms will not be affected by this proposed measure.", "price_info": {}}, {"link": "https://www.wsj.com/articles/coinbase-offers-another-way-to-ride-the-bitcoin-roller-coaster-11614876343", "title": "Coinbase Offers Another Way to Ride the Bitcoin Roller Coaster", "date": "2021-03-04 11:45", "summary": "The company may be listing its shares at a peak time for cryptocurrencies, so investors should be cautious about its recent results. Coinbase Global is going public just as enthusiasm for the digital currencies it trades is exploding. Investors should brace for a wild ride.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coinbase Offers Another Way to Ride the Bitcoin Roller Coaster. The company may be listing its shares at a peak time for cryptocurrencies, so investors should be cautious about its recent results. Coinbase Global is going public just as enthusiasm for the digital currencies it trades is exploding. Investors should brace for a wild ride.\"\n\nStock Prediction(s):", "Prediction": "\n- Coinbase Inc (NASDAQ: GDAX) will increase because they are going public and the interest in digital currencies is exploding.\n- Bitcoin (BTC) will increase because Coinbase is listing its shares and there is more interest in digital currencies.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "up"}, "GDAX": {"company": "", "ticker": "GDAX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/mcdonalds-u-s-sales-rebound-from-covid-19-pandemic-11619694000", "title": "McDonald's U.S. Sales Rebound From Pandemic", "date": "2021-04-29 10:06", "summary": "Burger chain says global markets remained challenged by shifting coronavirus restrictions. McDonald's Corp. said new menu items helped it beat sales expectations in the U.S., while business abroad remained volatile because of shifting Covid-19 restrictions.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"McDonald's U.S. Sales Rebound From Pandemic. Burger chain says global markets remained challenged by shifting coronavirus restrictions. McDonald's Corp. said new menu items helped it beat sales expectations in the U.S., while business abroad remained volatile because of shifting Covid-19 restrictions.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corp. (NYSE: MCD) will increase because their U.S. sales have rebounded from the pandemic.\n- Yum! Brands, Inc. (NYSE: YUM) will decrease because their sales are also being hurt by the pandemic.", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "up", "prices": [233.81, 234.4363]}, "YUM": {"company": "", "ticker": "YUM", "move": "down", "prices": [118.145, 118.2731]}}}, {"link": "https://www.wsj.com/articles/finance-chiefs-call-on-executives-to-help-fight-poverty-climate-change-11600715230", "title": "Finance Chiefs Call on Executives to Help Fight Poverty, Climate Change", "date": "2020-09-21 15:07", "summary": "CFOs at global companies urge their counterparts to make investment decisions that help achieve the U.N.'s Sustainable Development Goals. Chief financial officers at companies including Anheuser-Busch InBev SA, Ford Motor Co. and Verizon Communications Inc. are calling on other executives to make sure their businesses help fight poverty and climate change.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Finance Chiefs Call on Executives to Help Fight Poverty, Climate Change. CFOs at global companies urge their counterparts to make investment decisions that help achieve the U.N.'s Sustainable Development Goals. Chief financial officers at companies including Anheuser-Busch InBev SA, Ford Motor Co. and Verizon Communications Inc. are calling on other executives to make sure their businesses help fight poverty and climate change.\"\n\nStock Prediction(s):", "Prediction": "\n- Anheuser-Busch InBev SA (NYSE: BUD) will increase because they are using their resources to help achieve the U.N.'s Sustainable Development Goals.\n- Ford Motor Co. (NYSE: F) will increase because they are using their resources to help achieve the U.N.'s Sustainable Development Goals.\n- Verizon Communications Inc. (NYSE: VZ) will increase because they are using their resources to help achieve the U", "price_info": {"BUD": {"company": "", "ticker": "BUD", "move": "up", "prices": [54.46, 54.96]}, "F": {"company": "", "ticker": "F", "move": "up", "prices": [6.86, 6.87]}, "VZ": {"company": "", "ticker": "VZ", "move": "up", "prices": [59.63, 59.72]}}}, {"link": "https://www.wsj.com/articles/comcasts-profit-falls-on-sky-costs-erosion-of-pay-tv-business-11564052468", "title": "Comcast's Profit Falls on Sky Costs, Erosion of Pay-TV Business", "date": "2019-07-25 11:12", "summary": "Cable giant posts strong growth in internet, mobile segments. Comcast Corp. posted a slightly lower profit as strong growth at its internet and mobile business was offset by costs related to the acquisition of European pay-television provider Sky PLC and the continuing erosion of its pay-TV customer base.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Comcast's Profit Falls on Sky Costs, Erosion of Pay-TV Business. Cable giant posts strong growth in internet, mobile segments. Comcast Corp. posted a slightly lower profit as strong growth at its internet and mobile business was offset by costs related to the acquisition of European pay-television provider Sky PLC and the continuing erosion of its pay-TV customer base.\"\n\nStock Prediction(s):", "Prediction": "\n- Comcast Corp. (NASDAQ: CMCSA) will decrease because their profit fell.\n- Disney (NYSE: DIS) will increase because they are not as affected by the decline in Comcast's pay-TV business.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [142.71, 142.765]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "down", "prices": [44.735, 44.595]}}}, {"link": "https://www.wsj.com/articles/inflation-hits-a-high-note-11620835666", "title": "Inflation Hits a High Note", "date": "2021-05-12 12:22", "summary": "Prices are rising at their fastest clip in years, but the Fed is relaxed because expectations aren't embedded. Inflation might be picking up, but it isn't like people are singing songs about it.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Inflation Hits a High Note. Prices are rising at their fastest clip in years, but the Fed is relaxed because expectations aren't embedded. Inflation might be picking up, but it isn't like people are singing songs about it.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will increase interest rates because they are worried about inflation.\n- The stock market will decrease because people are worried about the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/fed-s-williams-will-act-as-appropriate-to-keep-expansion-moving-forward-11567603496", "title": "Fed's Williams: Will 'Act as Appropriate' to Keep Expansion Moving Forward", "date": "2019-09-04 10:49", "summary": "The central bank leader says July's interest-rate cut was the right move and helped create conditions to support the economy. New York Fed leader John Williams said Wednesday the U.S. central bank will do what it takes to keep the economy moving forward, at a time of rising risk and ongoing challenges to get inflation back up to desired levels.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Williams: Will 'Act as Appropriate' to Keep Expansion Moving Forward. The central bank leader says July's interest-rate cut was the right move and helped create conditions to support the economy. New York Fed leader John Williams said Wednesday the U.S. central bank will do what it takes to keep the economy moving forward, at a time of rising risk and ongoing challenges to get inflation back up to desired levels.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FED) will increase because they are still trying to stimulate the economy.\n- Goldman Sachs Group Inc (NYSE: GS) will increase because they are a direct beneficiary of the Federal Reserve's actions.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are a direct beneficiary of the Federal Reserve's actions.\n- Bank of America Corp (NYSE: BAC) will increase because they are a direct beneficiary", "price_info": {"FED": {"company": "", "ticker": "FED", "move": "up"}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [200.91, 200.6047]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [109.73, 109.49]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [27.375, 27.285]}}}, {"link": "https://www.wsj.com/articles/supreme-court-sides-with-trademark-users-in-bankruptcy-disputes-11558373717", "title": "Supreme Court Sides With Trademark Users In Bankruptcy Disputes", "date": "2019-05-20 13:35", "summary": "Ruling blocks trademark owners from rescinding rights in licensing deals after bankruptcy. The nation's top court ruled trademark users don't lose the power to sell merchandise or other contractual rights when the owner of that trademark files for bankruptcy protection and ends their licensing agreement early.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Supreme Court Sides With Trademark Users In Bankruptcy Disputes. Ruling blocks trademark owners from rescinding rights in licensing deals after bankruptcy. The nation's top court ruled trademark users don't lose the power to sell merchandise or other contractual rights when the owner of that trademark files for bankruptcy protection and ends their licensing agreement early.\"\n\nStock Prediction(s):", "Prediction": "\n- Nike, Inc. (NYSE: NKE) will increase because they will be able to sell their merchandise and other contractual rights without any issue.\n- Adidas AG (OTCMKTS: ADDYY) will increase because they will be able to sell their merchandise and other contractual rights without any issue.\n- Under Armour, Inc. (NYSE: UA) will increase because they will be able to sell their merchandise and other contractual rights without any issue.\n-", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "up", "prices": [83.31, 82.85]}, "UA": {"company": "", "ticker": "UA", "move": "up", "prices": [20.86, 20.86]}}}, {"link": "https://www.wsj.com/articles/safety-and-biotech-investing-dont-mix-11575568726", "title": "Safety and Biotech Investing Don't Mix", "date": "2019-12-05 12:58", "summary": "Sage Therapeutics' clinical-trial blowup should remind biotech investors that even the healthiest-looking stock is at risk.. Investors have a fresh reminder of an old truth: Safety is an elusive quality in biotech stocks.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Safety and Biotech Investing Don't Mix. Sage Therapeutics' clinical-trial blowup should remind biotech investors that even the healthiest-looking stock is at risk.. Investors have a fresh reminder of an old truth: Safety is an elusive quality in biotech stocks.\"\n\nStock Prediction(s):", "Prediction": "\n- Sage Therapeutics, Inc. (NASDAQ: SAGE) will decrease because their clinical-trial blowup will remind biotech investors that safety is an elusive quality in biotech stocks.", "price_info": {"SAGE": {"company": "", "ticker": "SAGE", "move": "down", "prices": [62.89, 61.33]}}}, {"link": "https://www.wsj.com/articles/who-really-got-rich-from-the-gamestop-revolution-11643432418", "title": "Who Really Got Rich From the GameStop Revolution?", "date": "2022-01-31 12:18", "summary": "During a revolt against Wall Street, some pros still figured out a way to win. When Reddit became the rowdy center of the investing universe last January, its co-founder Alexis Ohanian called the frenzy a \"revolution\" and a \"chance for Joe and Jane America, the retail buyers of stock, to flex back and push back.\" Maybe one day, he mused, the members of Reddit's WallStreetBets forum could do more than just ambush hedge funds-they could outperform those highly-paid investors.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Who Really Got Rich From the GameStop Revolution?. During a revolt against Wall Street, some pros still figured out a way to win. When Reddit became the rowdy center of the investing universe last January, its co-founder Alexis Ohanian called the frenzy a \"revolution\" and a \"chance for Joe and Jane America, the retail buyers of stock, to flex back and push back.\" Maybe one day, he mused, the members of Reddit's WallStreetBets forum could do more than just ambush hedge funds-they could outperform those highly-paid investors.\"\n\nStock Prediction(s):", "Prediction": "\n- GameStop Corp. (NYSE: GME) will increase because they are a part of the revolt against Wall Street and they are doing well.\n- WallStreetBets will increase because they are a part of the revolt against Wall Street and they are doing well.", "price_info": {"GME": {"company": "", "ticker": "GME", "move": "up", "prices": [107.259, 105.5601]}}}, {"link": "https://www.wsj.com/articles/who-recommends-astrazeneca-covid-19-vaccine-against-south-africa-strain-11612977926", "title": "WHO Recommends AstraZeneca Covid-19 Vaccine Against South Africa Strain", "date": "2021-02-10 12:28", "summary": "Evidence suggests shot can protect against severe disease from new variant, organization says. JOHANNESBURG-The World Health Organization said governments should continue rolling out AstraZeneca PLC's Covid-19 vaccine, including in countries battling a new strain of the coronavirus that was first detected in South Africa.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"WHO Recommends AstraZeneca Covid-19 Vaccine Against South Africa Strain. Evidence suggests shot can protect against severe disease from new variant, organization says. JOHANNESBURG-The World Health Organization said governments should continue rolling out AstraZeneca PLC's Covid-19 vaccine, including in countries battling a new strain of the coronavirus that was first detected in South Africa.\"\n\nStock Prediction(s):", "Prediction": "\n- AstraZeneca plc (NASDAQ: AZN) will continue to increase because their vaccine is being recommended by the WHO.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [166.1, 166.29]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [34.84, 34.8126]}, "AZN": {"company": "", "ticker": "AZN", "move": "up", "prices": [49.88, 49.9651]}, "MRNA": {"company": "", "ticker": "MRNA", "move": "down", "prices": [181, 181]}}}, {"link": "https://www.wsj.com/articles/golden-nugget-parent-private-jet-operator-wheels-up-join-spac-frenzy-11612196611", "title": "Golden Nugget Parent, Private-Jet Operator Wheels Up Join SPAC Frenzy", "date": "2021-02-01 12:47", "summary": "Wheels Up's deal includes a $550 million private investment from institutional investors, while Fertitta Entertainment has a commitment of about $1.2 billion. Private-jet operator Wheels Up Partners Holdings LLC and the parent of Golden Nugget added their names Monday to the list of companies going public through a combination with a special-purpose acquisition company.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Golden Nugget Parent, Private-Jet Operator Wheels Up Join SPAC Frenzy. Wheels Up's deal includes a $550 million private investment from institutional investors, while Fertitta Entertainment has a commitment of about $1.2 billion. Private-jet operator Wheels Up Partners Holdings LLC and the parent of Golden Nugget added their names Monday to the list of companies going public through a combination with a special-purpose acquisition company.\"\n\nStock Prediction(s):", "Prediction": "\n- Wheels Up Partners Holdings LLC (NYSE: WUPH) will increase because they are going public and they have a lot of institutional investors.\n- Golden Nugget (NYSE: PNK) will increase because they are being acquired by a public company.", "price_info": {"WUPH": {"company": "", "ticker": "WUPH", "move": "up"}, "PNK": {"company": "", "ticker": "PNK", "move": "up"}}}, {"link": "https://www.wsj.com/articles/gucci-sales-slow-hurt-by-hong-kong-turmoil-and-blackface-scandal-11571939413", "title": "Gucci Sales Growth Slows, Hurt by Hong Kong Turmoil", "date": "2019-10-24 14:49", "summary": "Results at Italian fashion house still beat analysts' expectations. PARIS-Sales growth at Gucci slowed to its lowest level in more than three years, as protests in Hong Kong and the aftermath of the brand's blackface scandal took their toll on the Italian fashion house.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gucci Sales Growth Slows, Hurt by Hong Kong Turmoil. Results at Italian fashion house still beat analysts' expectations. PARIS-Sales growth at Gucci slowed to its lowest level in more than three years, as protests in Hong Kong and the aftermath of the brand's blackface scandal took their toll on the Italian fashion house.\"\n\nStock Prediction(s):", "Prediction": "\n- Kering SA (EPA: KER) will increase because Gucci, their main brand, had lower sales growth, but it still beat analysts' expectations.\n- LVMH Moet Hennessy Louis Vuitton SE (EPA: MC) will increase because Gucci, their main brand, had lower sales growth, but it still beat analysts' expectations.", "price_info": {}}, {"link": "https://www.wsj.com/articles/universal-basic-income-could-be-coming-for-kids-11613574528", "title": "Universal Basic Income Could Be Coming for Kids", "date": "2021-02-17 10:08", "summary": "Tax-credit proposals would send almost every parent $250 or more a month. Entrepreneurs, intellectuals and presidential candidates have in recent years touted \"universal basic income,\" a cash stipend to everyone with no strings attached, as the answer to poverty, automation and the drudgery of work. It has never gotten off the ground in the U.S.", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Universal Basic Income Could Be Coming for Kids. Tax-credit proposals would send almost every parent $250 or more a month. Entrepreneurs, intellectuals and presidential candidates have in recent years touted \"universal basic income,\" a cash stipend to everyone with no strings attached, as the answer to poverty, automation and the drudgery of work. It has never gotten off the ground in the U.S.\"\n\nStock Prediction(s):", "Prediction": "\n- Universal Basic Income (UBI) will be a hot topic in the near future, and will cause many companies to increase in stock prices as they try to get a piece of the pie.\n- The only companies that will not see an increase are those who are against UBI, such as those who are currently providing welfare or social security.", "price_info": {"UBI": {"company": "Basic Income", "ticker": "UBI", "move": "up"}}}, {"link": "https://www.wsj.com/articles/weworks-back-is-against-a-wall-11568733815", "title": "WeWork's Back Is Against a Wall", "date": "2019-09-17 11:23", "summary": "As We Co. looks to restart its IPO later this year, features that cause shareholder dilution deserve closer scrutiny. We Co., the parent of office-sharing business WeWork, has more than one foot on its neck.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"WeWork's Back Is Against a Wall. As We Co. looks to restart its IPO later this year, features that cause shareholder dilution deserve closer scrutiny. We Co., the parent of office-sharing business WeWork, has more than one foot on its neck.\"\n\nStock Prediction(s):", "Prediction": "\n- We Co. (WE) will decrease because they are in a lot of financial trouble and they may not be able to continue to operate.\n- The Carlyle Group LP (NASDAQ: CG) will increase because they are one of the main investors in We Co. and they will benefit from the company's resurgence.\n- SoftBank Group Corp. (OTCPK: SFTBY) will increase because they are also one of the main investors in We", "price_info": {"WE": {"company": "We Co.", "ticker": "WE", "move": "up"}, "CG": {"company": "", "ticker": "CG", "move": "up", "prices": [26.03, 26.01]}}}, {"link": "https://www.wsj.com/articles/hulu-raises-price-of-live-tv-service-cuts-cost-of-basic-plan-11548259200", "title": "Hulu Raises Price of Live TV Service, Cuts Cost of Basic Plan", "date": "2019-01-23 11:18", "summary": "The move will help the streaming service invest more heavily in original content to compete with competitors like Netflix and Amazon. Hulu is lowering the price for its least expensive subscription plan while raising the cost of its live TV offering, a move that aims to bolster its subscriber numbers while increasing the margins on its most expensive plan.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hulu Raises Price of Live TV Service, Cuts Cost of Basic Plan. The move will help the streaming service invest more heavily in original content to compete with competitors like Netflix and Amazon. Hulu is lowering the price for its least expensive subscription plan while raising the cost of its live TV offering, a move that aims to bolster its subscriber numbers while increasing the margins on its most expensive plan.\"\n\nStock Prediction(s):", "Prediction": "\n- Hulu LLC (NASDAQ: HULU) will increase because they are increasing prices while also investing more in original content.\n- Netflix, Inc. (NASDAQ: NFLX) will increase because they are not increasing prices, and they are also investing more in original content.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are not increasing prices, and they are also investing more in original content.", "price_info": {"HULU": {"company": "", "ticker": "HULU", "move": "up"}, "NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [323.1488, 321.12]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1636.41, 1626.9433]}}}, {"link": "https://www.wsj.com/articles/palantirs-valley-shots-could-misfire-11598465815", "title": "Palantir's Valley Shots Could Misfire", "date": "2020-08-26 15:29", "summary": "Software maker tries to set itself apart from Silicon Valley, but government contractors typically don't command a premium. Palantir Technologies isn't a Silicon Valley startup. It only burns money like one.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Palantir's Valley Shots Could Misfire. Software maker tries to set itself apart from Silicon Valley, but government contractors typically don't command a premium. Palantir Technologies isn't a Silicon Valley startup. It only burns money like one.\"\n\nStock Prediction(s):", "Prediction": "\n- Palantir Technologies (NYSE: PAL) will decrease because they are trying to set themselves apart from Silicon Valley, and they don't typically command a premium.", "price_info": {"PAL": {"company": "", "ticker": "PAL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/u-s-consumer-sentiment-ended-june-lower-11561732361", "title": "U.S. Consumer Dropped in June", "date": "2019-06-28 11:53", "summary": "University of Michigan's index drops, with some households mentioning negative impact of tariffs. WASHINGTON-U.S. household sentiment declined in June, a possible sign of softening public confidence about the economy headed into the summer.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Consumer Dropped in June. University of Michigan's index drops, with some households mentioning negative impact of tariffs. WASHINGTON-U.S. household sentiment declined in June, a possible sign of softening public confidence about the economy headed into the summer.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because they sell products that are impacted by the tariffs, and people will need to buy these products somewhere.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they sell products that are impacted by the tariffs, and people will need to buy these products somewhere.\n- Target Corporation (NYSE: TGT) will increase because they sell products that are impacted by the tariffs,", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [111.19, 110.64]}, "TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [86.56, 86.19]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1901.4917, 1888.095]}}}, {"link": "https://www.wsj.com/articles/as-spac-creators-get-rich-how-incentives-are-shared-remains-murky-11627995686", "title": "As SPAC Creators Get Rich, How Incentives Are Shared Remains Murky", "date": "2021-08-03 15:50", "summary": "Some investment executives who back SPACs keep lucrative benefits known as 'sponsor promotes' for themselves rather than share with clients. Many investment executives who back special-purpose acquisition companies are scoring big paydays as more deals get completed. Some of their clients are missing out.", "categories": [["WSJ News Exclusive", "Finance"]], "category_links": ["https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"As SPAC Creators Get Rich, How Incentives Are Shared Remains Murky. Some investment executives who back SPACs keep lucrative benefits known as 'sponsor promotes' for themselves rather than share with clients. Many investment executives who back special-purpose acquisition companies are scoring big paydays as more deals get completed. Some of their clients are missing out.\"\n\nStock Prediction(s):", "Prediction": "\n- SPACs (special-purpose acquisition companies) will decrease because of the article's revelations about how the executives benefit more than the clients.\n- Investment executives who back SPACs will decrease because of the article's revelations about how the executives benefit more than the clients.", "price_info": {}}, {"link": "https://www.wsj.com/articles/kohls-rejects-9-billion-takeover-bid-adopts-poison-pill-11643999029", "title": "Kohl's Rejects $9 Billion Takeover Bid, Adopts Poison Pill", "date": "2022-02-04 15:02", "summary": "Retailer said its board would review other offers after several investor groups have expressed interest. Kohl's Corp. rejected a $9 billion takeover offer by an activist group for being too low, but said it would review other expressions of interest in the department-store chain.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Kohl's Rejects $9 Billion Takeover Bid, Adopts Poison Pill. Retailer said its board would review other offers after several investor groups have expressed interest. Kohl's Corp. rejected a $9 billion takeover offer by an activist group for being too low, but said it would review other expressions of interest in the department-store chain.\"\n\nStock Prediction(s):", "Prediction": "\n- Kohl's Corporation (NYSE: KSS) will reject any future offers because they believe their company is worth more than $9 billion.\n- Macy's, Inc. (NYSE: M) will increase because they are the only other major department store left in the United States.\n- J.C. Penney Company, Inc. (NYSE: JCP) will decrease because they are not as well-known as Macy's and Kohl's, and", "price_info": {"KSS": {"company": "", "ticker": "KSS", "move": null, "prices": [60.05, 59.67]}, "M": {"company": "", "ticker": "M", "move": "up", "prices": [25.46, 25.32]}, "JCP": {"company": "", "ticker": "JCP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/oil-prices-set-for-large-weekly-decline-11584719743", "title": "U.S. Crude Posts Largest Decline in Nearly Three Decades", "date": "2020-03-20 15:52", "summary": "Crude falls Friday, extending week of wild swings; U.S. oil is down 63% for the year. U.S. crude prices posted their largest weekly percentage decline in 29 years, with Saudi Arabia and Russia locked in a price war while the coronavirus wreaks havoc on oil demand around the world.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Crude Posts Largest Decline in Nearly Three Decades. Crude falls Friday, extending week of wild swings; U.S. oil is down 63% for the year. U.S. crude prices posted their largest weekly percentage decline in 29 years, with Saudi Arabia and Russia locked in a price war while the coronavirus wreaks havoc on oil demand around the world.\"\n\nStock Prediction(s):", "Prediction": "\n- Schlumberger Ltd. (NYSE: SLB) will increase because they are a services company and will be in higher demand as the price of oil decreases.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because they are a producer of oil and will be selling their product at a lower price.\n- Chevron Corporation (NYSE: CVX) will decrease because they are a producer of oil and will be selling their product at a lower price.", "price_info": {"SLB": {"company": "", "ticker": "SLB", "move": "up", "prices": [14.13, 13.91]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [32.67, 32.54]}, "CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [59.02, 59.18]}}}, {"link": "https://www.wsj.com/articles/robinhood-day-trade-i-started-trading-hot-stocks-then-i-couldnt-stop-11607095765", "title": "I Started Trading Hot Stocks on Robinhood. Then I Couldn't Stop.", "date": "2020-12-04 13:03", "summary": "Spinning prices, scratch-off rewards and flying confetti? Even the most skeptical investor can be drawn in.. Is the stock market a form of entertainment?", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"I Started Trading Hot Stocks on Robinhood. Then I Couldn't Stop.. Spinning prices, scratch-off rewards and flying confetti? Even the most skeptical investor can be drawn in.. Is the stock market a form of entertainment?\"\n\nStock Prediction(s):", "Prediction": "\n- Robinhood Financial LLC (NASDAQ: Robinhood) will increase because their app is designed to make the stock market more entertaining, which will draw in more investors.\n- The Walt Disney Company (NYSE: DIS) will decrease because their business model is based on providing entertainment that is not as flashy as Robinhood.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [153.96, 154.32]}}}, {"link": "https://www.wsj.com/articles/opioid-risk-smothers-drug-stocks-11565194670", "title": "Opioid Risk Smothers Drug Stocks", "date": "2019-08-07 12:17", "summary": "Fears of massive legal settlements for drug companies such as Teva will keep a lid on stock prices. Even solid corporate earnings can't reverse investor angst over drug companies facing opioid litigation risk.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Opioid Risk Smothers Drug Stocks. Fears of massive legal settlements for drug companies such as Teva will keep a lid on stock prices. Even solid corporate earnings can't reverse investor angst over drug companies facing opioid litigation risk.\"\n\nStock Prediction(s):", "Prediction": "\n- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will decrease because they are one of the drug companies being sued for their role in the opioid crisis.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are one of the drug companies being sued for their role in the opioid crisis.\n- Pfizer Inc (NYSE: PFE) will decrease because they are one of the drug companies being sued for their role in the opioid crisis.", "price_info": {"TEVA": {"company": "", "ticker": "TEVA", "move": "down", "prices": [7.01, 7.055]}, "JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [130.4137, 130.16]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [36.44, 36.57]}}}, {"link": "https://www.wsj.com/articles/microsoft-delays-full-headquarters-reopening-to-undetermined-future-date-11631199600", "title": "Microsoft Delays Full Headquarters Reopening to Undetermined Future Date", "date": "2021-09-09 11:00", "summary": "Software giant stops trying to predict when U.S. offices may be widely reopened. Microsoft Corp. is abandoning plans to fully reopen its headquarters and other U.S. sites early next month and won't set a new date, for now, given uncertainty around Covid-19.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Microsoft Delays Full Headquarters Reopening to Undetermined Future Date. Software giant stops trying to predict when U.S. offices may be widely reopened. Microsoft Corp. is abandoning plans to fully reopen its headquarters and other U.S. sites early next month and won't set a new date, for now, given uncertainty around Covid-19.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because they are delaying their reopening, and there is still a lot of uncertainty around Covid-19.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [299.3499, 298.84]}}}, {"link": "https://www.wsj.com/articles/madison-square-garden-entertainment-to-acquire-msg-networks-11616769167", "title": "Madison Square Garden Entertainment to Acquire MSG Networks", "date": "2021-03-26 10:32", "summary": "Deal valued at more than $900 million and aims to tap into rise of sports gambling. Madison Square Garden Entertainment Corp. has agreed to acquire media operator MSG Networks Inc. for more than $900 million in a deal that reunites the two companies and is aimed at tapping into the rise of sports gambling.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Madison Square Garden Entertainment to Acquire MSG Networks. Deal valued at more than $900 million and aims to tap into rise of sports gambling. Madison Square Garden Entertainment Corp. has agreed to acquire media operator MSG Networks Inc. for more than $900 million in a deal that reunites the two companies and is aimed at tapping into the rise of sports gambling.\"\n\nStock Prediction(s):", "Prediction": "\n- Madison Square Garden Entertainment Corp. (NYSE: MSG) will increase because they are acquiring MSG Networks Inc. for more than $900 million.\n- MSG Networks Inc. (NYSE: MSGN) will increase because they are being acquired by Madison Square Garden Entertainment Corp. for more than $900 million.", "price_info": {"MSG": {"company": "", "ticker": "MSG", "move": null}, "MSGN": {"company": "", "ticker": "MSGN", "move": "up", "prices": [15.55, 15.41]}}}, {"link": "https://www.wsj.com/articles/microsoft-promises-openness-on-new-app-store-as-it-seeks-approval-for-activision-acquisition-11644424237", "title": "Microsoft Promises Openness on App Store", "date": "2022-02-09 12:26", "summary": "The move is a response to concerns raised by app developers and lawmakers about competition. Microsoft Corp. executives promised that the marketplace they are envisioning for videogames would operate by a set of open-market principles, part of a pitch to regulators around the world to approve its acquisition of gaming giant Activision Blizzard Inc.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Microsoft Promises Openness on App Store. The move is a response to concerns raised by app developers and lawmakers about competition. Microsoft Corp. executives promised that the marketplace they are envisioning for videogames would operate by a set of open-market principles, part of a pitch to regulators around the world to approve its acquisition of gaming giant Activision Blizzard Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are promising openness on their app store, and this will attract more app developers.\n- Activision Blizzard, Inc. (NASDAQ: ATVI) will decrease because they are being acquired by Microsoft, and this will give Microsoft a monopoly on the gaming industry.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [308.63, 308.43]}, "ATVI": {"company": "", "ticker": "ATVI", "move": "down", "prices": [81.341, 81.2]}}}, {"link": "https://www.wsj.com/articles/germany-explores-ways-to-exclude-huawei-from-5g-mobile-infrastructure-11547722800", "title": "Germany Weighs Banning Huawei From 5G", "date": "2019-01-17 13:57", "summary": "Berlin considers raising security requirements for building networks that would exclude China tech giant. Germany is exploring ways to ban the use of Huawei Technologies Co. products in the country's telecommunications infrastructure, according to a government official, extending the Western backlash against the Chinese tech firm over security concerns.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Germany Weighs Banning Huawei From 5G. Berlin considers raising security requirements for building networks that would exclude China tech giant. Germany is exploring ways to ban the use of Huawei Technologies Co. products in the country's telecommunications infrastructure, according to a government official, extending the Western backlash against the Chinese tech firm over security concerns.\"\n\nStock Prediction(s):", "Prediction": "\n- Huawei Technologies Co. Ltd. (SHE: 002502) will decrease because they may be banned from 5G in Germany, which would be a major market for them.\n- Nokia Oyj (HEL: NOKIA) will increase because they are not a Chinese company, and they are a major competitor of Huawei.\n- Ericsson AB (STO: ERICB) will increase because they are not a Chinese company, and they are", "price_info": {}}, {"link": "https://www.wsj.com/articles/l-a-megamansion-developer-nile-niami-places-spec-home-in-bankruptcy-11607542932", "title": "L.A. Megamansion Developer Nile Niami Places Spec Home in Bankruptcy", "date": "2020-12-09 14:42", "summary": "The developer was facing the prospect of a foreclosure sale at the West Hollywood mansion. Nile Niami, the brash real-estate developer known for his over-the-top megamansions, has placed one of his high-priced spec homes in bankruptcy.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"L.A. Megamansion Developer Nile Niami Places Spec Home in Bankruptcy. The developer was facing the prospect of a foreclosure sale at the West Hollywood mansion. Nile Niami, the brash real-estate developer known for his over-the-top megamansions, has placed one of his high-priced spec homes in bankruptcy.\"\n\nStock Prediction(s):", "Prediction": "\n- Niami's bankruptcy will have a negative effect on the real estate market as a whole.\n- Other developers who are in the same market as Niami will also be affected.\n- Luxury homebuilders such as Toll Brothers Inc. (NYSE: TOL) and KB Home (NYSE: KBH) will be more negatively affected than others.", "price_info": {"TOL": {"company": "", "ticker": "TOL", "move": null, "prices": [43.78, 43.73]}, "KBH": {"company": "", "ticker": "KBH", "move": "down", "prices": [34.17, 34.12]}}}, {"link": "https://www.wsj.com/articles/unruly-passengers-harassment-now-more-common-flight-attendants-say-11627579285", "title": "Flight Attendants Say Unruly Passengers, Harassment Now More Common", "date": "2021-07-29 15:43", "summary": "Survey shows misbehavior stems in part from mask mandates, turmoil of country's return to travel. Harassment, threats and physical altercations have become normal parts of a cabin crew's job this summer, flight attendants say.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Flight Attendants Say Unruly Passengers, Harassment Now More Common. Survey shows misbehavior stems in part from mask mandates, turmoil of country's return to travel. Harassment, threats and physical altercations have become normal parts of a cabin crew's job this summer, flight attendants say.\"\n\nStock Prediction(s):", "Prediction": "\n- American Airlines Group Inc (NASDAQ: AAL) will decrease because their employees are facing more harassment and unruly passengers.\n- United Airlines Holdings Inc (NYSE: UAL) will decrease because their employees are facing more harassment and unruly passengers.\n- Delta Air Lines, Inc. (NYSE: DAL) will decrease because their employees are facing more harassment and unruly passengers.", "price_info": {"UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [48.45, 48.39]}, "DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [41.1, 41.09]}, "AAL": {"company": "", "ticker": "AAL", "move": "down", "prices": [21.1, 21.12]}}}, {"link": "https://www.wsj.com/articles/mortgage-costs-outpaced-by-drop-in-interest-rates-11570699801", "title": "That Superlow Mortgage Rate? It Could Be Even Lower", "date": "2019-10-10 10:07", "summary": "Gap between Treasury yields and mortgage rates higher than it has been in years. Interest rates have been plummeting, but the cost of taking out a mortgage hasn't fallen as fast.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"That Superlow Mortgage Rate? It Could Be Even Lower. Gap between Treasury yields and mortgage rates higher than it has been in years. Interest rates have been plummeting, but the cost of taking out a mortgage hasn't fallen as fast.\"\n\nStock Prediction(s):", "Prediction": "\n- The housing market will rebound because the interest rates are so low.\n- Homebuilders will increase because the housing market is rebounding.\n- Banks will increase because the housing market is rebounding.", "price_info": {}}, {"link": "https://www.wsj.com/articles/the-rise-of-stakeholders-isnt-so-sudden-11566329576", "title": "The Rise of 'Stakeholders' Isn't So Sudden", "date": "2019-08-20 15:32", "summary": "Public companies have been talking up their so-called stakeholders long before the Business Roundtable decided to make it official. The Business Roundtable decided this week to change its mission to take into account \"all stakeholders\"-a group that includes employees, customers and society-rather than just shareholders. Predictably, this rekindled old arguments about self interest, invisible hands and the ingenuousness of the chief executives running the business lobby.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Rise of 'Stakeholders' Isn't So Sudden. Public companies have been talking up their so-called stakeholders long before the Business Roundtable decided to make it official. The Business Roundtable decided this week to change its mission to take into account \"all stakeholders\"-a group that includes employees, customers and society-rather than just shareholders. Predictably, this rekindled old arguments about self interest, invisible hands and the ingenuousness of the chief executives running the business lobby.\"\n\nStock Prediction(s):", "Prediction": "\n- The Business Roundtable's decision to change its mission to take into account \"all stakeholders\" will have no effect on the stock prices of public companies.\n- The Business Roundtable's decision to change its mission to take into account \"all stakeholders\" will have a positive effect on the stock prices of public companies.", "price_info": {}}, {"link": "https://www.wsj.com/articles/booking-com-plans-to-lay-off-up-to-25-of-workforce-11596557736", "title": "Booking.com Plans to Lay Off Up to 25% of Workforce", "date": "2020-08-04 12:15", "summary": "Online-travel agency's move affects more than 4,000 employees as the Covid-19 pandemic continues to hurt global travel. Booking Holdings Inc. said it plans to cut up to a quarter of Booking.com's global workforce, or roughly more than 4,000 people, and restructure the company as the Covid-19 pandemic continues to batter travel demand.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Booking.com Plans to Lay Off Up to 25% of Workforce. Online-travel agency's move affects more than 4,000 employees as the Covid-19 pandemic continues to hurt global travel. Booking Holdings Inc. said it plans to cut up to a quarter of Booking.com's global workforce, or roughly more than 4,000 people, and restructure the company as the Covid-19 pandemic continues to batter travel demand.\"\n\nStock Prediction(s):", "Prediction": "\n- Booking Holdings Inc. (NASDAQ: BKNG) will decrease because they are laying off a large number of employees.\n- TripAdvisor, Inc. (NASDAQ: TRIP) will decrease because they are a direct competitor of Booking Holdings Inc.", "price_info": {"BKNG": {"company": "", "ticker": "BKNG", "move": "down", "prices": [1653.04, 1672.1741]}, "TRIP": {"company": "", "ticker": "TRIP", "move": "down", "prices": [20.66, 20.77]}}}, {"link": "https://www.wsj.com/articles/fed-officials-likely-to-take-comfort-from-jobs-report-11581086265", "title": "Fed Officials Likely to Take Comfort From Jobs Report", "date": "2020-02-07 12:57", "summary": "Latest employment figures offer little reason for central bank to change make-no-moves stance. The solid January employment report should comfort Federal Reserve officials about the state of the U.S. economy before the recent threats to global growth surfaced from the outbreak of the coronavirus in China last month.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Officials Likely to Take Comfort From Jobs Report. Latest employment figures offer little reason for central bank to change make-no-moves stance. The solid January employment report should comfort Federal Reserve officials about the state of the U.S. economy before the recent threats to global growth surfaced from the outbreak of the coronavirus in China last month.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve will not make any moves because the latest employment figures show that the economy is still strong.\n- The stock market will increase because the Federal Reserve is not likely to make any moves.", "price_info": {}}, {"link": "https://www.wsj.com/articles/instacart-wants-to-be-an-influencer-in-food-delivery-11626260400", "title": "Instacart Wants to Be an Influencer in Food Delivery", "date": "2021-07-14 11:24", "summary": "Advertising could be the holy grail, and the online grocery giant's CEO might hold the keys. Your food-delivery apps could soon look a lot like your social-media feeds. You can thank Instacart for that.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Instacart Wants to Be an Influencer in Food Delivery. Advertising could be the holy grail, and the online grocery giant's CEO might hold the keys. Your food-delivery apps could soon look a lot like your social-media feeds. You can thank Instacart for that.\"\n\nStock Prediction(s):", "Prediction": "\n- Instacart, Inc. (Private: ICRT) will increase because they are looking to become an advertising powerhouse in the food-delivery industry.\n- Grubhub Inc. (NYSE: GRUB) will decrease because they could lose market share to Instacart.", "price_info": {"GRUB": {"company": "", "ticker": "GRUB", "move": "down", "prices": [17.7118, 17.755]}}}, {"link": "https://www.wsj.com/articles/santa-claus-is-the-original-bagholder-11608318158", "title": "Santa Claus Is the Original Bagholder", "date": "2020-12-18 14:02", "summary": "'Tis the season to cash in some stock-market winnings on bullish day-trader swag. While \"Black Friday\" might have a completely different meaning to speculators than to shoppers, 'tis still the season for that day trader in your life.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Santa Claus Is the Original Bagholder. 'Tis the season to cash in some stock-market winnings on bullish day-trader swag. While \"Black Friday\" might have a completely different meaning to speculators than to shoppers, 'tis still the season for that day trader in your life.\"\n\nStock Prediction(s):", "Prediction": "\n- The stock market will go up because people are buying bullish day-trader swag.\n- The stock market will go down because people are cashing in their stock-market winnings.", "price_info": {}}, {"link": "https://www.wsj.com/articles/flight-wi-fi-provider-global-eagle-files-for-bankruptcy-due-to-coronavirus-11595444019", "title": "Flight Wi-Fi Provider Global Eagle Files for Bankruptcy", "date": "2020-07-22 14:53", "summary": "Lenders' agreement to take over the California company is subject to higher bids. Global Eagle Entertainment Inc., provider of Wi-Fi services to airlines and ships, has filed for bankruptcy with plans to turn ownership over to Apollo Global Management Inc. and other lenders, becoming the latest travel-related bankruptcy in the coronavirus age.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Flight Wi-Fi Provider Global Eagle Files for Bankruptcy. Lenders' agreement to take over the California company is subject to higher bids. Global Eagle Entertainment Inc., provider of Wi-Fi services to airlines and ships, has filed for bankruptcy with plans to turn ownership over to Apollo Global Management Inc. and other lenders, becoming the latest travel-related bankruptcy in the coronavirus age.\"\n\nStock Prediction(s):", "Prediction": "\n- Global Eagle Entertainment Inc. (NASDAQ: ENT) will decrease because they have filed for bankruptcy.\n- Apollo Global Management Inc. (NYSE: APO) will increase because they are the ones who are taking over the company.", "price_info": {"APO": {"company": "", "ticker": "APO", "move": "up", "prices": [53.06, 53.2]}, "ENT": {"company": "", "ticker": "ENT", "move": "down", "prices": [2.44, 2.41]}}}, {"link": "https://www.wsj.com/articles/what-new-yorkers-didnt-sell-to-amazon-11550262888", "title": "Amazon to New York: It's Not Me, It's You", "date": "2019-02-15 15:34", "summary": "Community's willingness to embrace a firm is often what clinches the deal for big companies seeking to expand in new locations. The list that Amazon.com Inc. sent to cities vying for its second headquarters a year and a half ago included the obvious stuff. Needs included a robust pipeline for tech workers, tax breaks, good real estate.", "categories": [["Business", "On Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/on-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Amazon to New York: It's Not Me, It's You. Community's willingness to embrace a firm is often what clinches the deal for big companies seeking to expand in new locations. The list that Amazon.com Inc. sent to cities vying for its second headquarters a year and a half ago included the obvious stuff. Needs included a robust pipeline for tech workers, tax breaks, good real estate.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are expanding their business to new locations, and they are looking for a community that is willing to embrace them.\n- New York City (NYSE: NYC) will decrease because they are not willing to embrace Amazon.com and their business practices.", "price_info": {"NYC": {"company": "", "ticker": "NYC", "move": "down"}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1606.43, 1607.3883]}}}, {"link": "https://www.wsj.com/articles/fangs-strong-run-gives-risky-exchange-traded-product-top-marks-11578934738", "title": "FANG's Strong Run Gives Risky Product Top Marks", "date": "2020-01-13 11:58", "summary": "Exchange-traded note that tracks FANG stocks is up 28% this year, following a 117% rise in 2019. The FANG stocks are already sinking their teeth into 2020.", "categories": [["Markets", "Stocks"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FANG's Strong Run Gives Risky Product Top Marks. Exchange-traded note that tracks FANG stocks is up 28% this year, following a 117% rise in 2019. The FANG stocks are already sinking their teeth into 2020.\"\n\nStock Prediction(s):", "Prediction": "\n- The FANG stocks (Facebook, Amazon, Netflix, and Google) will continue to rise because they have been doing well this year and people are betting on them.\n- The FANG stocks will eventually crash because they are overvalued and people are betting on them too much.", "price_info": {}}, {"link": "https://www.wsj.com/articles/transcript-wsj-interview-with-st-louis-fed-presidentjames-bullard-11565198554", "title": "Transcript: WSJ Interview With St. Louis Fed President James Bullard", "date": "2019-08-07 13:24", "summary": "Resume Subscription. St. Louis Fed President James Bullard spoke with Wall Street Journal reporters in Washington on Tuesday, Aug. 6. He discussed his support for last week's interest-rate cut, the economic outlook, trade uncertainty and persistently low inflation, among other topics. Here is a partial transcript of the interview, lightly edited for clarity and length.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Transcript: WSJ Interview With St. Louis Fed President James Bullard. Resume Subscription. St. Louis Fed President James Bullard spoke with Wall Street Journal reporters in Washington on Tuesday, Aug. 6. He discussed his support for last week's interest-rate cut, the economic outlook, trade uncertainty and persistently low inflation, among other topics. Here is a partial transcript of the interview, lightly edited for clarity and length.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FFR) will cut interest rates again because of persistently low inflation.\n- The stock market will continue to go up because of the low interest rates.", "price_info": {"FFR": {"company": "", "ticker": "FFR", "move": "up"}}}, {"link": "https://www.wsj.com/articles/u-s-steel-to-buy-remaining-stake-in-new-low-cost-steel-mill-11607421607", "title": "U.S. Steel to Buy Remaining Stake in New, Low-Cost Steel Mill", "date": "2020-12-08 10:22", "summary": "Rising steel prices helped company to raise cash to complete purchase of Big River Steel sooner than expected. United States Steel Corp. has agreed to acquire the remaining 50.1% stake in Big River Steel LLC for $774 million, giving the steelmaker ownership of one of the newest, most advanced steel mills in the country.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Steel to Buy Remaining Stake in New, Low-Cost Steel Mill. Rising steel prices helped company to raise cash to complete purchase of Big River Steel sooner than expected. United States Steel Corp. has agreed to acquire the remaining 50.1% stake in Big River Steel LLC for $774 million, giving the steelmaker ownership of one of the newest, most advanced steel mills in the country.\"\n\nStock Prediction(s):", "Prediction": "\n- United States Steel Corp. (NYSE: X) will increase because they are buying the remaining stake in Big River Steel LLC.\n- Big River Steel LLC (private) will increase because they are getting bought out by United States Steel Corp.", "price_info": {"X": {"company": "", "ticker": "X", "move": "up", "prices": [18.84, 19.0461]}}}, {"link": "https://www.wsj.com/articles/google-battling-amazon-tries-an-e-commerce-makeover-to-win-back-advertisers-11632936601", "title": "Google Refreshes Its E-Commerce Amid Ad Race With Amazon", "date": "2021-09-29 13:30", "summary": "Two decades of shifting strategies have left search giant playing catch-up to Amazon for online retail advertising. Google, an unlikely underdog, is struggling to keep pace with Amazon . com Inc. in the battle for billions in e-commerce ad dollars.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Google Refreshes Its E-Commerce Amid Ad Race With Amazon. Two decades of shifting strategies have left search giant playing catch-up to Amazon for online retail advertising. Google, an unlikely underdog, is struggling to keep pace with Amazon . com Inc. in the battle for billions in e-commerce ad dollars.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease because they are losing the ad race to Amazon.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are winning the ad race to Google.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [2696.18, 2698.915]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3322.51, 3301.41]}}}, {"link": "https://www.wsj.com/articles/laid-off-peloton-staffers-take-to-social-media-in-new-job-hunt-11644428026", "title": "Laid-Off Peloton Staffers Take to Social Media in New Job Hunt", "date": "2022-02-09 13:42", "summary": "Some post testimonials, others share r\u00e9sum\u00e9s; public spreadsheet with more than 250 former employees targets recruiters. Laid-off Peloton Interactive Inc. employees are posting testimonials on social media about their experiences at the company and sharing career details in efforts to find new employment after the fitness company cut 2,800 jobs Tuesday and replaced its chief executive.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Laid-Off Peloton Staffers Take to Social Media in New Job Hunt. Some post testimonials, others share r\u00e9sum\u00e9s; public spreadsheet with more than 250 former employees targets recruiters. Laid-off Peloton Interactive Inc. employees are posting testimonials on social media about their experiences at the company and sharing career details in efforts to find new employment after the fitness company cut 2,800 jobs Tuesday and replaced its chief executive.\"\n\nStock Prediction(s):", "Prediction": "\n- Peloton Interactive Inc. (NASDAQ: PTON) will decrease because they just laid off 2,800 employees and replaced their CEO.\n- Fitbit Inc. (NYSE: FIT) will increase because they are a direct competitor of Peloton and they do not have the same layoffs.", "price_info": {"FIT": {"company": "", "ticker": "FIT", "move": "up"}, "PTON": {"company": "", "ticker": "PTON", "move": "down", "prices": [36.4, 36.9]}}}, {"link": "https://www.wsj.com/articles/five-tv-station-owners-settle-justice-department-antitrust-allegations-11560824059", "title": "TV Station Owners Settle Justice Department Antitrust Allegations", "date": "2019-06-18 12:05", "summary": "CBS, Cox and others agree to stop sharing competitively sensitive information for seven years. A group of five television station owners on Monday agreed to settle Justice Department charges that they used third-party firms to illegally coordinate on sales of local advertising spots.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"TV Station Owners Settle Justice Department Antitrust Allegations. CBS, Cox and others agree to stop sharing competitively sensitive information for seven years. A group of five television station owners on Monday agreed to settle Justice Department charges that they used third-party firms to illegally coordinate on sales of local advertising spots.\"\n\nStock Prediction(s):", "Prediction": "\n- CBS Corporation (NYSE: CBS) will increase because they are one of the TV station owners that settled.\n- Cox Enterprises, Inc. (NYSE: COX) will increase because they are one of the TV station owners that settled.\n- Tegna, Inc. (NYSE: TGNA) will increase because they are one of the TV station owners that settled.\n- Gray Television, Inc. (NYSE: GTN) will increase because they are one", "price_info": {"CBS": {"company": "", "ticker": "CBS", "move": "up", "prices": [49.22, 49.41]}, "COX": {"company": "", "ticker": "COX", "move": "up"}, "TGNA": {"company": "", "ticker": "TGNA", "move": "up", "prices": [15.08, 15.095]}, "GTN": {"company": "", "ticker": "GTN", "move": "up", "prices": [16.79, 16.85]}}}, {"link": "https://www.wsj.com/articles/opec-russia-formalize-cooperation-pact-11562065503", "title": "OPEC, Russia Formalize Cooperation Pact", "date": "2019-07-02 12:00", "summary": "OPEC+ coalition agree to continue coordinating on oil production once the current deal ends. VIENNA-OPEC sealed a long-term cooperation pact with Russia on Tuesday, extending a partnership set up two years ago to fight a surge of U.S. oil that has upset the cartel's pricing power, OPEC officials said.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"OPEC, Russia Formalize Cooperation Pact. OPEC+ coalition agree to continue coordinating on oil production once the current deal ends. VIENNA-OPEC sealed a long-term cooperation pact with Russia on Tuesday, extending a partnership set up two years ago to fight a surge of U.S. oil that has upset the cartel's pricing power, OPEC officials said.\"\n\nStock Prediction(s):", "Prediction": "\n- OPEC+ will continue to work together to stabilize oil prices, so their stocks will stay consistent.\n- U.S. oil companies will continue to increase production, so their stocks will increase.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-k-fund-manager-crispin-odey-is-acquitted-of-indecent-assault-11615478501", "title": "U.K. Fund Manager Crispin Odey Acquitted of Indecent Assault", "date": "2021-03-11 14:24", "summary": "Odey had been accused of groping a junior banker in 1998. LONDON-A judge acquitted hedge-fund manager Crispin Odey, one of the U.K. industry's highest-profile figures, on a charge of assaulting a junior banker more than 20 years ago.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.K. Fund Manager Crispin Odey Acquitted of Indecent Assault. Odey had been accused of groping a junior banker in 1998. LONDON-A judge acquitted hedge-fund manager Crispin Odey, one of the U.K. industry's highest-profile figures, on a charge of assaulting a junior banker more than 20 years ago.\"\n\nStock Prediction(s):", "Prediction": "\n- Odey Asset Management LLP (LON: ODEY) will increase because their founder has been acquitted of a charge.\n- Other U.K. hedge funds will increase because this news is positive for the industry as a whole.", "price_info": {}}, {"link": "https://www.wsj.com/articles/fed-launches-review-of-possible-central-bank-digital-currency-11642706158", "title": "Fed Launches Review of Possible Central Bank Digital Currency", "date": "2022-01-20 15:00", "summary": "Officials solicit public comment, but are unlikely to decide soon whether to issue a government-backed cryptocurrency. WASHINGTON-The Federal Reserve on Thursday launched a review of the potential benefits and risks of issuing a U.S. digital currency, as central banks around the world experiment with the potential new form of money to keep pace with private-sector payments innovations.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Launches Review of Possible Central Bank Digital Currency. Officials solicit public comment, but are unlikely to decide soon whether to issue a government-backed cryptocurrency. WASHINGTON-The Federal Reserve on Thursday launched a review of the potential benefits and risks of issuing a U.S. digital currency, as central banks around the world experiment with the potential new form of money to keep pace with private-sector payments innovations.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FRB) will increase because they are exploring the possibility of a government-backed cryptocurrency.\n- Bitcoin (BTC) will decrease because this news signals that the Federal Reserve may issue their own cryptocurrency, which would compete with Bitcoin.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "down"}, "FRB": {"company": "", "ticker": "FRB", "move": "up"}}}, {"link": "https://www.wsj.com/articles/zombie-medical-costumes-too-real-for-this-years-halloween-11604071186", "title": "Zombie, Medical Costumes Too Real for This Year's Halloween", "date": "2020-10-30 11:19", "summary": "Import data shows nurse and zombie outfits are out; clowns and wizards are in. Nurse outfits and zombie costumes might be too on the nose for pandemic-aware Americans celebrating Halloween this year.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Zombie, Medical Costumes Too Real for This Year's Halloween. Import data shows nurse and zombie outfits are out; clowns and wizards are in. Nurse outfits and zombie costumes might be too on the nose for pandemic-aware Americans celebrating Halloween this year.\"\n\nStock Prediction(s):", "Prediction": "\n- Party City Holdings Inc (NYSE: PRTY) will increase because they are selling more clown and wizard costumes.\n- Spirit Halloween Superstores LLC (NYSE: SHLD) will increase because they are selling more zombie and nurse costumes.", "price_info": {"PRTY": {"company": "", "ticker": "PRTY", "move": "up", "prices": [1.92, 1.875]}, "SHLD": {"company": "", "ticker": "SHLD", "move": "up"}}}, {"link": "https://www.wsj.com/articles/forever-21-teen-focused-retailer-files-for-bankruptcy-11569811923", "title": "Forever 21, Teen-Focused Retailer, Files for Bankruptcy", "date": "2019-09-30 11:28", "summary": "Company will exit from most markets in Asia and Europe but will keep operating in Latin America. Fast fashion retailer Forever 21 Inc. filed for bankruptcy protection on Sunday and said it planned to close hundreds of stores, the latest casualty of shifting shopping habits.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Forever 21, Teen-Focused Retailer, Files for Bankruptcy. Company will exit from most markets in Asia and Europe but will keep operating in Latin America. Fast fashion retailer Forever 21 Inc. filed for bankruptcy protection on Sunday and said it planned to close hundreds of stores, the latest casualty of shifting shopping habits.\"\n\nStock Prediction(s):", "Prediction": "\n- Forever 21 Inc. (NYSE: FR21) will decrease because they are filing for bankruptcy and will be closing hundreds of stores.\n- Gap Inc. (NYSE: GPS) will increase because they are not filing for bankruptcy and are not closing any stores.\n- Abercrombie & Fitch Co. (NYSE: ANF) will decrease because they are filing for bankruptcy and will be closing hundreds of stores.", "price_info": {"GPS": {"company": "", "ticker": "GPS", "move": "up", "prices": [17.24, 17.29]}, "ANF": {"company": "", "ticker": "ANF", "move": "down", "prices": [15.36, 15.42]}}}, {"link": "https://www.wsj.com/articles/europe-faces-recession-risk-as-covid-19-infections-stay-high-11609928309", "title": "Services Growth Slows in U.S., as Asia Activity Picks Up", "date": "2021-01-06 13:10", "summary": "Europe slumps and U.K. faces recession risk as the latest Covid-19 surge drives lockdowns. U.S. services companies reported slower growth last month and Asian economies recorded robust expansion, while Europe worsened amid rising coronavirus cases and fresh pandemic restrictions, according to purchasing-managers surveys.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Services Growth Slows in U.S., as Asia Activity Picks Up. Europe slumps and U.K. faces recession risk as the latest Covid-19 surge drives lockdowns. U.S. services companies reported slower growth last month and Asian economies recorded robust expansion, while Europe worsened amid rising coronavirus cases and fresh pandemic restrictions, according to purchasing-managers surveys.\"\n\nStock Prediction(s):", "Prediction": "\n- The services sector will continue to slow down in the U.S. because of the Covid-19 pandemic.\n- The services sector will pick up in Asia because of the Covid-19 pandemic.\n- The services sector will worsen in Europe because of the Covid-19 pandemic.", "price_info": {}}, {"link": "https://www.wsj.com/articles/unitedhealths-profit-slips-as-health-care-visits-return-11611144802", "title": "UnitedHealth's Profit Slips as Health-Care Visits Return", "date": "2021-01-20 10:36", "summary": "The company paid more in medical costs to cover insured members who returned to doctors' offices after delaying care earlier in the pandemic. UnitedHealth Group Inc. recorded a smaller profit for the last quarter of 2020 as the company saw rising medical costs tied to Covid-19.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"UnitedHealth's Profit Slips as Health-Care Visits Return. The company paid more in medical costs to cover insured members who returned to doctors' offices after delaying care earlier in the pandemic. UnitedHealth Group Inc. recorded a smaller profit for the last quarter of 2020 as the company saw rising medical costs tied to Covid-19.\"\n\nStock Prediction(s):", "Prediction": "\n- UnitedHealth Group Inc. (NYSE: UNH) will decrease because their profit slipped as people started returning to doctors' offices.", "price_info": {"UNH": {"company": "", "ticker": "UNH", "move": "down", "prices": [350.92, 350.6485]}}}, {"link": "https://www.wsj.com/articles/tesla-faces-steeper-costs-to-raise-cash-11556535600", "title": "Tesla Faces Steeper Costs to Raise Cash", "date": "2019-04-29 09:57", "summary": "CEO Elon Musk reverses stance on raising capital, but car maker may have already missed the chance to do so cheaply. Tesla Inc. has plenty of options for raising money, but it is getting more expensive to do so.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla Faces Steeper Costs to Raise Cash. CEO Elon Musk reverses stance on raising capital, but car maker may have already missed the chance to do so cheaply. Tesla Inc. has plenty of options for raising money, but it is getting more expensive to do so.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla Inc. (NASDAQ: TSLA) will decrease because they are going to have to spend more money to raise cash.\n- Ford Motor Company (NYSE: F) will increase because they are not going to have to spend as much money to raise cash.\n- General Motors Company (NYSE: GM) will increase because they are not going to have to spend as much money to raise cash.", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [10.365, 10.335]}, "GM": {"company": "", "ticker": "GM", "move": "up", "prices": [40.1469, 40.2038]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [239.2947, 242.2288]}}}, {"link": "https://www.wsj.com/articles/despite-demand-factories-still-arent-humming-11626367441", "title": "Despite Demand, Factories Still Aren't Humming", "date": "2021-07-15 12:44", "summary": "Constraints from chip shortages to a tight labor market are holding back a manufacturing boom. Factory production is having a hard time shifting into higher gear. This isn't because manufacturers don't want to turn their wheels any faster, but because for now they can't.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Despite Demand, Factories Still Aren't Humming. Constraints from chip shortages to a tight labor market are holding back a manufacturing boom. Factory production is having a hard time shifting into higher gear. This isn't because manufacturers don't want to turn their wheels any faster, but because for now they can't.\"\n\nStock Prediction(s):", "Prediction": "\n- Intel Corporation (NASDAQ: INTC) will increase because their chips are in high demand, and the factories still can't keep up.\n- Texas Instruments Incorporated (NASDAQ: TXN) will increase because their chips are in high demand, and the factories still can't keep up.\n- Applied Materials, Inc. (NASDAQ: AMAT) will increase because their chips are in high demand, and the factories still can't keep up.\n", "price_info": {"INTC": {"company": "", "ticker": "INTC", "move": "up", "prices": [55.805, 55.71]}, "TXN": {"company": "", "ticker": "TXN", "move": "up", "prices": [188.169, 188.2]}, "AMAT": {"company": "", "ticker": "AMAT", "move": "up", "prices": [132.14, 132.455]}}}, {"link": "https://www.wsj.com/articles/stay-hungry-for-yum-11564676089", "title": "Stay Hungry for Yum", "date": "2019-08-01 12:14", "summary": "Yum Brands has never been as richly valued, but its growth and cash flow are enough to keep the stock rising. Even at record prices, Yum Brands shares aren't cooling off.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Stay Hungry for Yum. Yum Brands has never been as richly valued, but its growth and cash flow are enough to keep the stock rising. Even at record prices, Yum Brands shares aren't cooling off.\"\n\nStock Prediction(s):", "Prediction": "\n- Yum Brands, Inc. (NYSE: YUM) will continue to increase because they have a strong growth and cash flow.\n- McDonald's Corporation (NYSE: MCD) will decrease because they are a direct competitor of Yum Brands.", "price_info": {"YUM": {"company": "", "ticker": "YUM", "move": "up", "prices": [117.7, 117.055]}, "MCD": {"company": "", "ticker": "MCD", "move": "down", "prices": [212.39, 211.5099]}}}, {"link": "https://www.wsj.com/articles/general-electric-expects-to-burn-cash-in-first-quarter-11613506527", "title": "General Electric Expects to Burn Cash in First Quarter", "date": "2021-02-16 15:15", "summary": "CEO Larry Culp said first-quarter cash flow would likely be negative, but improved from a year ago; outlook for 2021 unchanged. General Electric Co. expects cash flow to be negative in the first quarter, typically the slowest period of the year, but the conglomerate isn't changing its outlook for 2021.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"General Electric Expects to Burn Cash in First Quarter. CEO Larry Culp said first-quarter cash flow would likely be negative, but improved from a year ago; outlook for 2021 unchanged. General Electric Co. expects cash flow to be negative in the first quarter, typically the slowest period of the year, but the conglomerate isn't changing its outlook for 2021.\"\n\nStock Prediction(s):", "Prediction": "\n- GE will continue to decline because they are burning cash and have an uncertain outlook for 2021.\n- Honeywell International Inc. (NYSE: HON) will increase because they are a competitor of GE, and they have a more positive outlook for 2021.\n- United Technologies Corporation (NYSE: UTX) will increase because they are a competitor of GE, and they have a more positive outlook for 2021.", "price_info": {"HON": {"company": "", "ticker": "HON", "move": "up", "prices": [203.21, 203.5]}, "UTX": {"company": "", "ticker": "UTX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/wintry-weather-lifts-natural-gas-prices-11612190731", "title": "Wintry Weather Lifts Natural-Gas Prices", "date": "2021-02-01 14:58", "summary": "Futures are 57% higher than a year ago, when the weather was uncommonly warm. The winter storm blanketing the Northeast and forecasts for a frigid February are boosting natural-gas prices.", "categories": [["Markets", "Commodities", "Gas Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/gas-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wintry Weather Lifts Natural-Gas Prices. Futures are 57% higher than a year ago, when the weather was uncommonly warm. The winter storm blanketing the Northeast and forecasts for a frigid February are boosting natural-gas prices.\"\n\nStock Prediction(s):", "Prediction": "\n- Chesapeake Energy Corporation (NYSE: CHK) will increase because their main product is natural gas, and the weather is causing the prices to go up.\n- Devon Energy Corporation (NYSE: DVN) will increase because their main product is natural gas, and the weather is causing the prices to go up.\n- Anadarko Petroleum Corporation (NYSE: APC) will increase because their main product is natural gas, and the weather is causing the prices", "price_info": {"CHK": {"company": "", "ticker": "CHK", "move": "up"}, "DVN": {"company": "", "ticker": "DVN", "move": "up", "prices": [16.85, 16.5]}, "APC": {"company": "", "ticker": "APC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/nielsen-to-spin-off-global-connect-business-11573133392", "title": "Nielsen to Spin Off Global Connect Business", "date": "2019-11-07 14:24", "summary": "Market-analytics segment has been a weak spot for company, hampered by changing retail environment. Nielsen Holdings PLC said it plans to spin off its market-analytics business that measures retail and consumer behavior following a strategic review as it faces rapidly changing consumer habits.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nielsen to Spin Off Global Connect Business. Market-analytics segment has been a weak spot for company, hampered by changing retail environment. Nielsen Holdings PLC said it plans to spin off its market-analytics business that measures retail and consumer behavior following a strategic review as it faces rapidly changing consumer habits.\"\n\nStock Prediction(s):", "Prediction": "\n- Nielsen Holdings plc (NYSE: NLSN) will decrease because their market-analytics business is being spun off, and it is a weak spot for the company.\n- The Spin-off of Nielsen's market-analytics business will create a new company, which will be a competitor to Nielsen.", "price_info": {"NLSN": {"company": "", "ticker": "NLSN", "move": "down", "prices": [19.38, 19.4]}}}, {"link": "https://www.wsj.com/articles/opec-didnt-need-to-open-the-spigots-yet-11633367165", "title": "OPEC+ Didn't Need to Open the Spigots Yet", "date": "2021-10-04 13:06", "summary": "The group's decision not to speed up its release of oil barrels should be a moment of relief, not alarm, for oil markets. With oil and natural gas prices reaching multiyear highs ahead of winter, the world was counting on OPEC and its Russia-led allies to ride to the rescue. The group opted not to, but the industrialized world need not panic.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"OPEC+ Didn't Need to Open the Spigots Yet. The group's decision not to speed up its release of oil barrels should be a moment of relief, not alarm, for oil markets. With oil and natural gas prices reaching multiyear highs ahead of winter, the world was counting on OPEC and its Russia-led allies to ride to the rescue. The group opted not to, but the industrialized world need not panic.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because OPEC+ didn't open the spigots yet, and this means that Chevron will have more control over the oil market.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because OPEC+ didn't open the spigots yet, and this means that Exxon Mobil will have more control over the oil market.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [105.12, 104.89]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [61.8, 61.75]}}}, {"link": "https://www.wsj.com/articles/u-s-service-sector-growth-slowed-in-april-11556893427", "title": "Key Sector of Economy Is Slowing, But Economists Think It May Be a Good Thing", "date": "2019-05-03 14:21", "summary": "Services-sector gauge fell for second straight month, but data shows moderate growth. WASHINGTON-Growth in the services industries-the main component of the U.S. economy-slowed for the second month in a row, but analysts think it could be a sign the economy is settling into a steady pace of growth.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Key Sector of Economy Is Slowing, But Economists Think It May Be a Good Thing. Services-sector gauge fell for second straight month, but data shows moderate growth. WASHINGTON-Growth in the services industries-the main component of the U.S. economy-slowed for the second month in a row, but analysts think it could be a sign the economy is settling into a steady pace of growth.\"\n\nStock Prediction(s):", "Prediction": "\n- The services sector is slowing, but this could be a good thing because it means the economy is settling into a steady pace of growth.\n- The Dow Jones Industrial Average (NYSE: DJIA) will decrease because the services sector is slowing.", "price_info": {"DJIA": {"company": "", "ticker": "DJIA", "move": "down"}}}, {"link": "https://www.wsj.com/articles/second-kroger-unit-to-stop-accepting-visa-credit-cards-11551448507", "title": "Second Kroger Unit to Stop Accepting Visa Credit Cards", "date": "2019-03-01 13:34", "summary": "Smith's Food & Drug said it would stop accepting Visa credit cards on April 3. A second unit of supermarket chain Kroger Co. said Friday that it will stop accepting Visa Inc. credit cards at its 142 supermarkets and 108 gas stations across seven states.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Second Kroger Unit to Stop Accepting Visa Credit Cards. Smith's Food & Drug said it would stop accepting Visa credit cards on April 3. A second unit of supermarket chain Kroger Co. said Friday that it will stop accepting Visa Inc. credit cards at its 142 supermarkets and 108 gas stations across seven states.\"\n\nStock Prediction(s):", "Prediction": "\n- Kroger Co. (NYSE: KR) will decrease because they are losing a major credit card partner.\n- Visa Inc. (NYSE: V) will decrease because they are losing a major credit card partner.", "price_info": {"KR": {"company": "", "ticker": "KR", "move": "down", "prices": [28.2967, 28.05]}, "V": {"company": "", "ticker": "V", "move": "down", "prices": [149.2136, 149.5]}}}, {"link": "https://www.wsj.com/articles/youtube-to-curb-its-referrals-to-conspiracy-theories-and-other-false-claims-11548442814", "title": "YouTube to Curb Referrals to Conspiracy Theories, False Claims", "date": "2019-01-25 14:00", "summary": "The video site has long faced criticism that its algorithms contribute to the spread of disinformation. YouTube said it will stop recommending as many videos that feature conspiracy theories and other false claims, moving to address longstanding criticism that its algorithms help spread disinformation.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"YouTube to Curb Referrals to Conspiracy Theories, False Claims. The video site has long faced criticism that its algorithms contribute to the spread of disinformation. YouTube said it will stop recommending as many videos that feature conspiracy theories and other false claims, moving to address longstanding criticism that its algorithms help spread disinformation.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc (NASDAQ: GOOGL) will increase because YouTube is one of their subsidiaries, and they are making an effort to curb the spread of disinformation.\n- Facebook, Inc. (NASDAQ: FB) will decrease because they have been criticized for the same thing, and they have not taken any measures to address it.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1100.3374, 1098.7503]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [149.65, 149.21]}}}, {"link": "https://www.wsj.com/articles/this-holiday-crunch-starts-early-with-more-packages-than-means-to-deliver-them-11603013401", "title": "Holiday Delivery Crunch Starts Early This Year", "date": "2020-10-19 09:39", "summary": "FedEx, UPS and smaller carriers turn away customers as they brace for surge of online orders. One holiday item is already sold out: shipping capacity.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Holiday Delivery Crunch Starts Early This Year. FedEx, UPS and smaller carriers turn away customers as they brace for surge of online orders. One holiday item is already sold out: shipping capacity.\"\n\nStock Prediction(s):", "Prediction": "\n- FedEx Corporation (NYSE: FDX) will decrease because they are not able to meet the demand for shipping during the holiday season.\n- United Parcel Service, Inc. (NYSE: UPS) will decrease because they are not able to meet the demand for shipping during the holiday season.\n- XPO Logistics, Inc. (NYSE: XPO) will decrease because they are not able to meet the demand for shipping during the holiday season.", "price_info": {"FDX": {"company": "", "ticker": "FDX", "move": "down", "prices": [289.84, 289.66]}, "UPS": {"company": "", "ticker": "UPS", "move": "down", "prices": [175.6999, 174.84]}, "XPO": {"company": "", "ticker": "XPO", "move": "down", "prices": [98.23, 97.87]}}}, {"link": "https://www.wsj.com/articles/how-to-straighten-out-smiledirectclub-11573661325", "title": "How to Straighten Out SmileDirectClub", "date": "2019-11-13 11:08", "summary": "The stock's uninterrupted selloff since a September IPO shouldn't continue much longer. SmileDirectClub shareholders have had their teeth kicked in. But there should be a limit to the gloom and doom.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Straighten Out SmileDirectClub. The stock's uninterrupted selloff since a September IPO shouldn't continue much longer. SmileDirectClub shareholders have had their teeth kicked in. But there should be a limit to the gloom and doom.\"\n\nStock Prediction(s):", "Prediction": "\n- SmileDirectClub (SDC) will increase because their stock has been selling at a much lower price than their IPO price, and they have a good product.\n- Align Technology, Inc. (NASDAQ: ALGN) will decrease because they are a direct competitor of SmileDirectClub.", "price_info": {"SDC": {"company": "SmileDirectClub", "ticker": "SDC", "move": "up", "prices": [9.1, 9]}, "ALGN": {"company": "", "ticker": "ALGN", "move": "down", "prices": [260.55, 259.6596]}}}, {"link": "https://www.wsj.com/articles/business-case-for-fertility-benefits-support-11627396218", "title": "The Business Case for More Fertility-Related Benefits and Support", "date": "2021-07-29 11:15", "summary": "Few companies have supportive policies, even though many employees-and especially younger ones-think they are needed. Infertility affects 15% of couples across the globe, according to the World Health Organization. But employees struggling with infertility rarely feel supported in the workplace.", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Business Case for More Fertility-Related Benefits and Support. Few companies have supportive policies, even though many employees-and especially younger ones-think they are needed. Infertility affects 15% of couples across the globe, according to the World Health Organization. But employees struggling with infertility rarely feel supported in the workplace.\"\n\nStock Prediction(s):", "Prediction": "\n- Fertility treatments will become more common and will be covered by insurance, which will benefit companies like Ferring Pharmaceuticals (FERR.CO), Merck & Co., Inc. (MRK), and Bristol-Myers Squibb (BMY).\n- Companies that do not offer fertility treatments will be at a disadvantage, and their stock prices will decrease.", "price_info": {"MRK": {"company": "Co., Inc.", "ticker": "MRK", "move": "up", "prices": [77.12, 76.9062]}, "BMY": {"company": "Bristol-Myers Squibb", "ticker": "BMY", "move": "up", "prices": [68.5872, 68.415]}}}, {"link": "https://www.wsj.com/articles/oil-slides-after-delay-of-opec-summit-11586180014", "title": "Oil Slides After Delay of OPEC+ Summit", "date": "2020-04-06 15:07", "summary": "Prices fell, paring some of their recent rebound after a producers summit to discuss supply cuts was postponed. Oil prices fell Monday, paring some of their recent rebound after a virtual summit for producers to discuss supply cuts was postponed to later in the week.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Slides After Delay of OPEC+ Summit. Prices fell, paring some of their recent rebound after a producers summit to discuss supply cuts was postponed. Oil prices fell Monday, paring some of their recent rebound after a virtual summit for producers to discuss supply cuts was postponed to later in the week.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because of the fall in oil prices.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because of the fall in oil prices.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because of the fall in oil prices.\n- BP plc (NYSE: BP) will decrease because of the fall in oil prices.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [79.7, 80.23]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [40.43, 40.45]}, "BP": {"company": "", "ticker": "BP", "move": "down", "prices": [25.04, 25.1]}}}, {"link": "https://www.wsj.com/articles/airline-makes-real-money-on-fake-flights-11602604097", "title": "Airline Makes Real Money on Fake Flights", "date": "2020-10-13 11:48", "summary": "Industry's new revenue-generating schemes mirror the desperation felt by cooped-up consumers. Nothing brings to mind pleasure quite like the memory of bumping elbows with strangers while trying to carve up \"chicken or beef\" with plastic cutlery.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Airline Makes Real Money on Fake Flights. Industry's new revenue-generating schemes mirror the desperation felt by cooped-up consumers. Nothing brings to mind pleasure quite like the memory of bumping elbows with strangers while trying to carve up \"chicken or beef\" with plastic cutlery.\"\n\nStock Prediction(s):", "Prediction": "\n- Airlines will generally increase in stock prices because they are able to generate new revenue streams.\n- The exception will be United Airlines (NYSE: UAL) which will decrease in stock prices because of the negative publicity they have received in the past.", "price_info": {"UAL": {"company": "", "ticker": "UAL", "move": "down", "prices": [35.7, 35.61]}}}, {"link": "https://www.wsj.com/articles/driverless-cars-tap-the-brakes-after-years-of-hype-11547737205", "title": "Driverless Cars Tap the Brakes After Years of Hype", "date": "2019-01-17 10:00", "summary": "Developers take a more cautious, low-key approach in testing and talking about autonomous vehicles after Uber crash. LAS VEGAS-At a command center near the airport here, executives from automotive supplier Aptiv PLC showed why deploying robot cars will be far more complicated than many envisioned just a few years ago.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Driverless Cars Tap the Brakes After Years of Hype. Developers take a more cautious, low-key approach in testing and talking about autonomous vehicles after Uber crash. LAS VEGAS-At a command center near the airport here, executives from automotive supplier Aptiv PLC showed why deploying robot cars will be far more complicated than many envisioned just a few years ago.\"\n\nStock Prediction(s):", "Prediction": "\n- Aptiv plc (NYSE: APTV) will decrease because their driverless cars are being met with more caution after the Uber crash.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are still moving forward with their plans for driverless cars.", "price_info": {"APTV": {"company": "", "ticker": "APTV", "move": "down", "prices": [69.71, 69.98]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [349.03, 347.87]}}}, {"link": "https://www.wsj.com/articles/how-ford-and-volkswagen-could-keep-the-good-times-rolling-11627567108", "title": "How Ford, Volkswagen Could Keep the Good Times Rolling", "date": "2021-07-29 09:58", "summary": "Chip shortage has made car sales unusually profitable, but makers' chances of maintaining margins depend on a new way of doing business. Profit upgrades are coming thick and fast from car manufacturers, even as they talk of little else but reinventing the wheel.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How Ford, Volkswagen Could Keep the Good Times Rolling. Chip shortage has made car sales unusually profitable, but makers' chances of maintaining margins depend on a new way of doing business. Profit upgrades are coming thick and fast from car manufacturers, even as they talk of little else but reinventing the wheel.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because they are doing well in the market and their stock prices are reflecting that.\n- Volkswagen AG (OTCPK: VOW3) will increase because they are doing well in the market and their stock prices are reflecting that.\n- General Motors Company (NYSE: GM) will increase because they are doing well in the market and their stock prices are reflecting that.\n- Fiat Chrysler Automobiles NV (NYSE", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [14.435, 14.3823]}, "GM": {"company": "", "ticker": "GM", "move": "up", "prices": [57.33, 57.345]}}}, {"link": "https://www.wsj.com/articles/carlos-ghosn-gaunt-and-gray-haired-methodically-plans-his-defense-11546958114", "title": "After 50 Long Days in Jail, Ghosn Is Sharp as He Prepares His Defense", "date": "2019-01-08 09:35", "summary": "Former Nissan chairman is 'super-calm and rational' with his team, focusing on how to win his case. TOKYO-His cheeks are sunken and his once-robust frame has turned gaunt, but after 50 days in jail, Carlos Ghosn is still the hyperrational, results-oriented engineer who made it to the top of the auto industry. This time, instead of higher profits, the result he seeks is his own freedom and vindication.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"After 50 Long Days in Jail, Ghosn Is Sharp as He Prepares His Defense. Former Nissan chairman is 'super-calm and rational' with his team, focusing on how to win his case. TOKYO-His cheeks are sunken and his once-robust frame has turned gaunt, but after 50 days in jail, Carlos Ghosn is still the hyperrational, results-oriented engineer who made it to the top of the auto industry. This time, instead of higher profits, the result he seeks is his own freedom and vindication.\"\n\nStock Prediction(s):", "Prediction": "\n- Renault SA (EPA: RNO) will increase because Ghosn was the former chairman, and he is still \"hyperrational, results-oriented engineer.\"\n- Nissan Motor Co Ltd (TSE: 7201) will increase because Ghosn was the former chairman, and he is still \"hyperrational, results-oriented engineer.\"\n- Mitsubishi Motors Corp (TSE: 7211) will increase because Ghosn was the former chairman,", "price_info": {}}, {"link": "https://www.wsj.com/articles/morgan-stanley-would-benefit-from-going-downmarket-11563463976", "title": "Morgan Stanley Would Benefit From Going Downmarket", "date": "2019-07-18 11:32", "summary": "Bank posted solid earnings, but missed out on the consumer lending growth that rivals are enjoying. Morgan Stanley on Thursday posted respectable earnings that once again highlight its well-rounded business model. But one key driver of growth at other banks-consumer lending-was notably lacking.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Morgan Stanley Would Benefit From Going Downmarket. Bank posted solid earnings, but missed out on the consumer lending growth that rivals are enjoying. Morgan Stanley on Thursday posted respectable earnings that once again highlight its well-rounded business model. But one key driver of growth at other banks-consumer lending-was notably lacking.\"\n\nStock Prediction(s):", "Prediction": "\n- Morgan Stanley (NYSE: MS) will decrease because they are missing out on the consumer lending growth that their competitors are enjoying.", "price_info": {"MS": {"company": "", "ticker": "MS", "move": "down", "prices": [44.14, 44.21]}}}, {"link": "https://www.wsj.com/articles/breakthrough-cases-covid-19-delta-variant-11627596643", "title": "What to Know About Breakthrough Infections, Cases and Symptoms", "date": "2021-08-12 14:08", "summary": "Doctors say these infections are rare and generally mild, thanks to vaccines. As the highly transmissible Delta variant spreads, more vaccinated Americans are reporting they have tested positive for Covid-19. Here's what you need to know about these so-called 'breakthrough' cases:", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What to Know About Breakthrough Infections, Cases and Symptoms. Doctors say these infections are rare and generally mild, thanks to vaccines. As the highly transmissible Delta variant spreads, more vaccinated Americans are reporting they have tested positive for Covid-19. Here's what you need to know about these so-called 'breakthrough' cases:\"\n\nStock Prediction(s):", "Prediction": "\n- Merck & Co., Inc. (NYSE: MRK) will increase because they have a vaccine for breakthrough infections, which are rare and generally mild.\n- GlaxoSmithKline plc (NYSE: GSK) will decrease because they do not have a vaccine for breakthrough infections.", "price_info": {"MRK": {"company": "", "ticker": "MRK", "move": "up", "prices": [76.0391, 75.98]}, "GSK": {"company": "", "ticker": "GSK", "move": "down", "prices": [41.3, 41.26]}}}, {"link": "https://www.wsj.com/articles/softbank-comeback-stays-on-track-with-6-billion-profit-11604907842", "title": "SoftBank Comeback Stays on Track With $6 Billion Profit", "date": "2020-11-09 09:55", "summary": "Japanese conglomerate's Vision Funds posted big investment gains. TOKYO-Japan's SoftBank Group Corp. , the world's largest technology investor, is ready to go on the offensive again after a year of struggling with missteps, losses and tanking markets.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SoftBank Comeback Stays on Track With $6 Billion Profit. Japanese conglomerate's Vision Funds posted big investment gains. TOKYO-Japan's SoftBank Group Corp. , the world's largest technology investor, is ready to go on the offensive again after a year of struggling with missteps, losses and tanking markets.\"\n\nStock Prediction(s):", "Prediction": "\n- SoftBank Group Corp. (OTCMKTS: SFTBY) will increase because they have a strong comeback and posted big investment gains.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are a direct competitor of SoftBank.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are a direct competitor of SoftBank.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [119.643, 120.5208]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3213.46, 3237.9788]}}}, {"link": "https://www.wsj.com/articles/metlife-to-sell-home-insurance-unit-to-zurich-for-4-billion-11607681652", "title": "MetLife to Sell Unit to Zurich for Nearly $4 Billion", "date": "2020-12-11 13:15", "summary": "Deal comes as insurers face need for scale in advertising, and technology drives changes in how they do business. Swiss insurer Zurich Insurance Group AG said it would acquire MetLife Inc.'s car and home insurance business for $3.94 billion in cash, a move that will substantially boost the size of its Farmers business in the U.S.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"MetLife to Sell Unit to Zurich for Nearly $4 Billion. Deal comes as insurers face need for scale in advertising, and technology drives changes in how they do business. Swiss insurer Zurich Insurance Group AG said it would acquire MetLife Inc.'s car and home insurance business for $3.94 billion in cash, a move that will substantially boost the size of its Farmers business in the U.S.\"\n\nStock Prediction(s):", "Prediction": "\n- Zurich Insurance Group AG (ZURVY) will increase because they are buying a car and home insurance business for $3.94 billion.\n- MetLife, Inc. (NYSE: MET) will decrease because they are selling their car and home insurance business.", "price_info": {"ZURVY": {"company": "Group AG", "ticker": "ZURVY", "move": "up"}, "MET": {"company": "", "ticker": "MET", "move": "down", "prices": [46.71, 46.975]}}}, {"link": "https://www.wsj.com/articles/as-remote-work-becomes-the-norm-vast-new-possibilities-open-for-people-with-autism-11615222804", "title": "Remote Work Could Revolutionize Jobs for Autistic People", "date": "2021-03-08 12:00", "summary": "Technology like Zoom and Slack that eases the pressures of social contact could make jobs much less stressful for people on the spectrum. I've long worried about how my autistic son will fare when he enters the workforce. He's got the sort of autism that used to be known as Asperger's syndrome: On the one hand, he's extraordinarily brilliant, incredibly friendly and can do anything he sets his mind to.", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Remote Work Could Revolutionize Jobs for Autistic People. Technology like Zoom and Slack that eases the pressures of social contact could make jobs much less stressful for people on the spectrum. I've long worried about how my autistic son will fare when he enters the workforce. He's got the sort of autism that used to be known as Asperger's syndrome: On the one hand, he's extraordinarily brilliant, incredibly friendly and can do anything he sets his mind to.\"\n\nStock Prediction(s):", "Prediction": "\n- Zoom Video Communications, Inc. (NASDAQ: ZM) will increase because their technology is being used to help autistic people work remotely, and this could revolutionize the way that they work.\n- Slack Technologies, Inc. (NYSE: WORK) will increase because their technology is being used to help autistic people work remotely, and this could revolutionize the way that they work.", "price_info": {"WORK": {"company": "", "ticker": "WORK", "move": "up", "prices": [40.33, 40.29]}, "ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [321.01, 320.49]}}}, {"link": "https://www.wsj.com/articles/walmart-shelves-plan-to-have-robots-scan-shelves-11604345341", "title": "Walmart Scraps Plan to Have Robots Scan Shelves", "date": "2020-11-02 14:29", "summary": "Retailer ends contract with robotics company after seeing similar results from workers grabbing online orders during pandemic. Walmart Inc. has ended its effort to use roving robots in store aisles to keep track of its inventory, reversing a yearslong push to automate the task with the hulking machines after finding during the coronavirus pandemic that humans can help get similar results.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walmart Scraps Plan to Have Robots Scan Shelves. Retailer ends contract with robotics company after seeing similar results from workers grabbing online orders during pandemic. Walmart Inc. has ended its effort to use roving robots in store aisles to keep track of its inventory, reversing a yearslong push to automate the task with the hulking machines after finding during the coronavirus pandemic that humans can help get similar results.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because they are reverting back to human employees to do the same job as the robots.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are a direct competitor of Walmart, and they have been using robots in their warehouses for a while now.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [139.56, 140.12]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [2968.02, 2987.551]}}}, {"link": "https://www.wsj.com/articles/investors-brexit-relief-turns-to-deal-doubt-11571329185", "title": "Investors' Brexit Relief Turns to Deal Doubt", "date": "2019-10-17 12:19", "summary": "Markets have plenty of reasons to be cautious following Boris Johnson's deal to take the U.K. out of the European Union. After more than three years of uncertainty, investors are understandably eager for the Brexit saga to end. But they aren't blind to the drawbacks of U.K. Prime Minister Boris Johnson's new deal with the European Union.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors' Brexit Relief Turns to Deal Doubt. Markets have plenty of reasons to be cautious following Boris Johnson's deal to take the U.K. out of the European Union. After more than three years of uncertainty, investors are understandably eager for the Brexit saga to end. But they aren't blind to the drawbacks of U.K. Prime Minister Boris Johnson's new deal with the European Union.\"\n\nStock Prediction(s):", "Prediction": "\n- The Brexit saga will continue to cause uncertainty in the markets, and investors will be cautious about investing in U.K. companies.\n- The pound will continue to decline in value against the dollar.\n- The FTSE 100 will continue to decline in value.", "price_info": {}}, {"link": "https://www.wsj.com/articles/novavax-starts-late-stage-trial-of-covid-19-vaccine-in-u-s-mexico-11609171205", "title": "Novavax Starts Late-Stage Trial of Covid-19 Vaccine", "date": "2020-12-28 12:24", "summary": "Latest shot will become the fifth to enter final-stage testing in the U.S., and if results are positive it could receive authorization sometime during 2021. Novavax Inc. said Monday it is starting a new clinical trial of up to 30,000 people in the U.S. and Mexico to test whether its experimental Covid-19 vaccine safely protects people from the disease.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Novavax Starts Late-Stage Trial of Covid-19 Vaccine. Latest shot will become the fifth to enter final-stage testing in the U.S., and if results are positive it could receive authorization sometime during 2021. Novavax Inc. said Monday it is starting a new clinical trial of up to 30,000 people in the U.S. and Mexico to test whether its experimental Covid-19 vaccine safely protects people from the disease.\"\n\nStock Prediction(s):", "Prediction": "\n- Novavax Inc. (NASDAQ: NVAX) will increase because they are starting a new clinical trial for their Covid-19 vaccine.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of Novavax.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of Nov", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [152.82, 152.9317]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [36.78, 36.765]}, "NVAX": {"company": "", "ticker": "NVAX", "move": "up", "prices": [125.0773, 119.17]}}}, {"link": "https://www.wsj.com/articles/health-provider-gundersen-prioritizes-ai-integration-amid-pandemic-11592851496", "title": "Health Provider Gundersen Prioritizes AI Integration Amid Pandemic", "date": "2020-06-22 14:44", "summary": "Nonprofit expects $10 million return within first year of technology switch. Gundersen Health System is adopting artificial intelligence for collecting payments from health insurers and expanding telemedicine usage, measures it hopes will yield long-term cost savings even as the hospital operator suffers losses stemming from the coronavirus pandemic.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Health Provider Gundersen Prioritizes AI Integration Amid Pandemic. Nonprofit expects $10 million return within first year of technology switch. Gundersen Health System is adopting artificial intelligence for collecting payments from health insurers and expanding telemedicine usage, measures it hopes will yield long-term cost savings even as the hospital operator suffers losses stemming from the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Gundersen Health System (NYSE: GSEN) will increase because they are adopting AI and expanding telemedicine usage, which should yield long-term cost savings.\n- Cerner Corporation (NASDAQ: CERN) will increase because they are a major health provider and they are expanding their telemedicine capabilities.\n- Athenahealth, Inc. (NASDAQ: ATHN) will decrease because they are not expanding their telemedicine capabilities", "price_info": {"GSEN": {"company": "", "ticker": "GSEN", "move": "up"}, "CERN": {"company": "", "ticker": "CERN", "move": "up", "prices": [71.24, 71.2]}, "ATHN": {"company": "", "ticker": "ATHN", "move": "down"}}}, {"link": "https://www.wsj.com/articles/goodbye-honey-do-list-hello-shared-labor-app-11572949803", "title": "Goodbye Honey-Do List, Hello Shared-Labor App", "date": "2019-11-05 09:56", "summary": "Labor-sharing apps and shared calendars replace traditional to-do lists; 'I can't believe I don't have to do that'. Christy MacGregor and Ted Iobst set aside time every Sunday evening to go over their shared to-do list.", "categories": [["Tech", "Family & Tech: Julie Jargon"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/family-tech-julie-jargon?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Goodbye Honey-Do List, Hello Shared-Labor App. Labor-sharing apps and shared calendars replace traditional to-do lists; 'I can't believe I don't have to do that'. Christy MacGregor and Ted Iobst set aside time every Sunday evening to go over their shared to-do list.\"\n\nStock Prediction(s):", "Prediction": "\n- Home improvement stores like Lowe's Companies, Inc. (NYSE: LOW) and The Home Depot, Inc. (NYSE: HD) will increase because more people will be doing home repairs and renovations themselves with the help of labor-sharing apps.\n- Social networking apps like Facebook, Inc. (NASDAQ: FB) and Snap Inc. (NYSE: SNAP) will increase because more people will be using them to find help with their honey-do lists.", "price_info": {"LOW": {"company": "", "ticker": "LOW", "move": null, "prices": [112.336, 111.1927]}, "HD": {"company": "", "ticker": "HD", "move": "up", "prices": [232.7282, 231.49]}, "SNAP": {"company": "", "ticker": "SNAP", "move": "up", "prices": [15.2828, 14.94]}, "FB": {"company": "", "ticker": "FB", "move": null, "prices": [195.56, 193.97]}}}, {"link": "https://www.wsj.com/articles/a-broken-up-aig-would-still-have-work-to-do-11603815249", "title": "A Broken Up AIG Would Still Have Work to Do", "date": "2020-10-27 12:14", "summary": "AIG's property-and-casualty unit could fetch a better valuation on its own, but it will likely still trail its rivals for now. American International Group is drastically reworking its business to focus on property-and-casualty insurance by separating out its life-and-retirement unit. But what remains still has to perform.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Broken Up AIG Would Still Have Work to Do. AIG's property-and-casualty unit could fetch a better valuation on its own, but it will likely still trail its rivals for now. American International Group is drastically reworking its business to focus on property-and-casualty insurance by separating out its life-and-retirement unit. But what remains still has to perform.\"\n\nStock Prediction(s):", "Prediction": "\n- AIG (NYSE: AIG) will stay the same because they are still a valuable company, but they are not as valuable as they once were.\n- MetLife, Inc. (NYSE: MET) will increase because they are a direct competitor of AIG and they are doing better.\n- Prudential Financial, Inc. (NYSE: PRU) will increase because they are a direct competitor of AIG and they are doing better.", "price_info": {"AIG": {"company": "", "ticker": "AIG", "move": null, "prices": [31.445, 31.6779]}, "MET": {"company": "", "ticker": "MET", "move": "up", "prices": [37.93, 37.74]}, "PRU": {"company": "", "ticker": "PRU", "move": "up", "prices": [63.8, 63.63]}}}, {"link": "https://www.wsj.com/articles/oil-prices-climb-after-iranian-tanker-damaged-in-possible-strike-11570791889", "title": "Oil Prices Climb After Iranian Tanker Damaged in Possible Strike", "date": "2019-10-11 15:32", "summary": "Vessel's owner says it was 60 miles from a Saudi Arabian port when it may have been hit by missiles. Oil prices climbed Friday after an Iranian tanker near the Saudi Arabian coast suffered damage in what the ship's owner suggested may have been a missile attack.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Prices Climb After Iranian Tanker Damaged in Possible Strike. Vessel's owner says it was 60 miles from a Saudi Arabian port when it may have been hit by missiles. Oil prices climbed Friday after an Iranian tanker near the Saudi Arabian coast suffered damage in what the ship's owner suggested may have been a missile attack.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because they are a major producer of oil and this could lead to increased prices and demand.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are a major producer of oil and this could lead to increased prices and demand.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they are a major producer of oil and this could lead to increased prices and demand.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [116.15, 116.5]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [68.98, 69.06]}}}, {"link": "https://www.wsj.com/articles/monopoly-maker-gets-a-big-lift-from-lockdown-11588169873", "title": "Monopoly Maker Gets a Big Lift From Lockdown", "date": "2020-04-29 10:17", "summary": "Sales of Hasbro games jump 25% as idle families scoop up classics from Jenga to Operation to ride out the coronavirus pandemic. Bored families stocked up on board games.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Monopoly Maker Gets a Big Lift From Lockdown. Sales of Hasbro games jump 25% as idle families scoop up classics from Jenga to Operation to ride out the coronavirus pandemic. Bored families stocked up on board games.\"\n\nStock Prediction(s):", "Prediction": "\n- Hasbro, Inc. (NASDAQ: HAS) will increase because their sales have jumped 25%.\n- Mattel, Inc. (NASDAQ: MAT) will decrease because their sales have not jumped as much as Hasbro.", "price_info": {"HAS": {"company": "", "ticker": "HAS", "move": "up", "prices": [76.135, 75.27]}, "MAT": {"company": "", "ticker": "MAT", "move": "down", "prices": [9.205, 9.1983]}}}, {"link": "https://www.wsj.com/articles/bidens-oil-moves-draw-from-losing-playbook-11636564507", "title": "Biden's Oil Moves Draw From Losing Playbook", "date": "2021-11-10 12:15", "summary": "An emergency reserve release or crying 'manipulation' are unhelpful reactions to high gasoline prices and might backfire. It might as well be called the Strategic Political Reserve.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biden's Oil Moves Draw From Losing Playbook. An emergency reserve release or crying 'manipulation' are unhelpful reactions to high gasoline prices and might backfire. It might as well be called the Strategic Political Reserve.\"\n\nStock Prediction(s):", "Prediction": "\n- The price of oil will decrease because Biden's oil moves are unhelpful and might backfire.", "price_info": {}}, {"link": "https://www.wsj.com/articles/steel-group-wants-tariffs-on-building-products-11549399994", "title": "Steel Group Urges Tariffs on Building Products", "date": "2019-02-05 15:53", "summary": "Petition filed with International Trade Commission takes aim at Canadian, Mexican and Chinese imports. A trade group has accused Canadian, Mexican and Chinese structural-steel producers of dumping products in the U.S. at below the cost of making them, resulting in lost sales for domestic companies and weaker pricing power.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Steel Group Urges Tariffs on Building Products. Petition filed with International Trade Commission takes aim at Canadian, Mexican and Chinese imports. A trade group has accused Canadian, Mexican and Chinese structural-steel producers of dumping products in the U.S. at below the cost of making them, resulting in lost sales for domestic companies and weaker pricing power.\"\n\nStock Prediction(s):", "Prediction": "\n- U.S. Steel Corporation (NYSE: X) will increase because they are a direct competitor of the Canadian, Mexican, and Chinese steel producers.\n- Nucor Corporation (NYSE: NUE) will increase because they are a direct competitor of the Canadian, Mexican, and Chinese steel producers.\n- Steel Dynamics, Inc. (NASDAQ: STLD) will increase because they are a direct competitor of the Canadian, Mexican, and Chinese steel producers.", "price_info": {"X": {"company": "", "ticker": "X", "move": "up", "prices": [23.075, 23.05]}, "NUE": {"company": "", "ticker": "NUE", "move": "up", "prices": [61.415, 61.4]}, "STLD": {"company": "", "ticker": "STLD", "move": "up", "prices": [36.88, 37.35]}}}, {"link": "https://www.wsj.com/articles/franklin-resources-is-in-talks-to-buy-legg-mason-11582009251", "title": "Franklin Resources to Buy Legg Mason for $4.5 Billion", "date": "2020-02-18 15:52", "summary": "Deal would clear up uncertainty that had shrouded Legg Mason's future for nearly a year. Franklin Resources Inc. agreed to buy rival asset manager Legg Mason Inc. for $4.5 billion in cash, a deal that could help two big players in an industry that is under pressure from shifting investor tastes.", "categories": [["WSJ News Exclusive", "Deals"]], "category_links": ["https://www.wsj.com/news/types/deals-deal-makers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Franklin Resources to Buy Legg Mason for $4.5 Billion. Deal would clear up uncertainty that had shrouded Legg Mason's future for nearly a year. Franklin Resources Inc. agreed to buy rival asset manager Legg Mason Inc. for $4.5 billion in cash, a deal that could help two big players in an industry that is under pressure from shifting investor tastes.\"\n\nStock Prediction(s):", "Prediction": "\n- Franklin Resources, Inc. (NYSE: BEN) will increase because they are buying out a competitor, and this will give them a bigger market share.\n- Legg Mason, Inc. (NYSE: LM) will decrease because they are being bought out, and they will no longer have to compete in the market.", "price_info": {"BEN": {"company": "", "ticker": "BEN", "move": "up", "prices": [26.1, 26.05]}, "LM": {"company": "", "ticker": "LM", "move": "down", "prices": [50.625, 50.68]}}}, {"link": "https://www.wsj.com/articles/ford-to-repair-suspension-problem-on-2011-2017-explorers-11560348229", "title": "Ford to Repair Suspension Problem on 2011-2017 Explorers", "date": "2019-06-12 10:30", "summary": "Move to cost about $180 million and be reflected in second-quarter results, Ford said. ", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ford to Repair Suspension Problem on 2011-2017 Explorers. Move to cost about $180 million and be reflected in second-quarter results, Ford said. \"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because they are repairing a problem with their vehicles, and it will be reflected in their second-quarter results.\n- General Motors Company (NYSE: GM) will decrease because they are also repairing a problem with their vehicles, and it will be reflected in their second-quarter results.", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [9.875, 9.8902]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [35.755, 35.74]}}}, {"link": "https://www.wsj.com/articles/massive-hacks-linked-to-russia-china-exploited-u-s-internet-security-gap-11615380912", "title": "Massive Hacks Linked to Russia, China Exploited U.S. Internet Security Gap", "date": "2021-03-10 12:15", "summary": "Protecting U.S. networks from cyberattacks launched domestically emerges as an intelligence blind spot, security experts say. U.S. lawmakers and security experts are voicing concern that foreign governments are staging cyberattacks using servers in the U.S., in an apparent effort to avoid detection by America's principal cyberintelligence organization, the National Security Agency.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Massive Hacks Linked to Russia, China Exploited U.S. Internet Security Gap. Protecting U.S. networks from cyberattacks launched domestically emerges as an intelligence blind spot, security experts say. U.S. lawmakers and security experts are voicing concern that foreign governments are staging cyberattacks using servers in the U.S., in an apparent effort to avoid detection by America's principal cyberintelligence organization, the National Security Agency.\"\n\nStock Prediction(s):", "Prediction": "\n- Symantec Corporation (NASDAQ: SYMC) will increase because they are a leading security company and their products will be in high demand.\n- Palo Alto Networks, Inc. (NYSE: PANW) will increase because they are a leading security company and their products will be in high demand.\n- FireEye, Inc. (NASDAQ: FEYE) will increase because they are a leading security company and their products will be in high demand.\n", "price_info": {"PANW": {"company": "", "ticker": "PANW", "move": "up", "prices": [339.75, 336.09]}, "SYMC": {"company": "", "ticker": "SYMC", "move": "up"}, "FEYE": {"company": "", "ticker": "FEYE", "move": "up", "prices": [20.27, 20.0599]}}}, {"link": "https://www.wsj.com/articles/ventilator-makers-ramp-up-production-amid-coronavirus-crunch-11584626858", "title": "Ventilator Makers Ramp Up Production Amid Coronavirus Crunch", "date": "2020-03-19 15:41", "summary": "Efforts to boost manufacturing of the crucial machines may not come soon enough or prove sufficient if cases surge, experts warn. Manufacturers are racing to boost production of the medical ventilators required to save the lives of many critically ill coronavirus patients, but there still may not be enough of the crucial machines if cases surge, industry officials say.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ventilator Makers Ramp Up Production Amid Coronavirus Crunch. Efforts to boost manufacturing of the crucial machines may not come soon enough or prove sufficient if cases surge, experts warn. Manufacturers are racing to boost production of the medical ventilators required to save the lives of many critically ill coronavirus patients, but there still may not be enough of the crucial machines if cases surge, industry officials say.\"\n\nStock Prediction(s):", "Prediction": "\n- General Electric Company (NYSE: GE) will increase because they manufacture ventilators and their production is being ramped up.\n- Siemens AG (OTCPK: SIEGY) will increase because they manufacture ventilators and their production is being ramped up.\n- Philips (NYSE: PHG) will increase because they manufacture ventilators and their production is being ramped up.\n- ResMed Inc. (NYSE: RMD)", "price_info": {"GE": {"company": "", "ticker": "GE", "move": "up", "prices": [6.61, 6.56]}, "PHG": {"company": "", "ticker": "PHG", "move": "up"}, "RMD": {"company": "", "ticker": "RMD", "move": null, "prices": [136.1, 136.1]}}}, {"link": "https://www.wsj.com/articles/wall-street-has-an-obamacare-problem-11600783179", "title": "Wall Street Has an Obamacare Problem", "date": "2020-09-22 09:59", "summary": "Health-care stocks could get hit hard if the Affordable Care Act is overturned by the Supreme Court. Uncertainty at the Supreme Court means a familiar and unwelcome risk has resurfaced for health-care stocks.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wall Street Has an Obamacare Problem. Health-care stocks could get hit hard if the Affordable Care Act is overturned by the Supreme Court. Uncertainty at the Supreme Court means a familiar and unwelcome risk has resurfaced for health-care stocks.\"\n\nStock Prediction(s):", "Prediction": "\n- UnitedHealth Group Inc (NYSE: UNH) will decrease because they are a major player in the health-care industry, and if Obamacare is overturned, their business will be negatively affected.\n- Aetna Inc (NYSE: AET) will decrease because they are a major player in the health-care industry, and if Obamacare is overturned, their business will be negatively affected.\n- CVS Health Corp (NYSE: CVS) will decrease because they", "price_info": {"UNH": {"company": "", "ticker": "UNH", "move": "down", "prices": [296.5985, 294.69]}, "AET": {"company": "", "ticker": "AET", "move": "down"}, "CVS": {"company": "", "ticker": "CVS", "move": "down", "prices": [59.045, 58.71]}}}, {"link": "https://www.wsj.com/articles/fed-minutes-show-expectations-for-stronger-economic-recovery-11617820897", "title": "Fed Minutes Show Expectations for Stronger Economic Recovery", "date": "2021-04-07 15:21", "summary": "Officials raised their forecasts for economic growth and inflation, reiterating at their March meeting plans for continued policy support. Federal Reserve officials pointed to a brighter outlook for the economy at their most recent meeting while agreeing to provide continued support through ultralow interest rates and large monthly bond purchases.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Minutes Show Expectations for Stronger Economic Recovery. Officials raised their forecasts for economic growth and inflation, reiterating at their March meeting plans for continued policy support. Federal Reserve officials pointed to a brighter outlook for the economy at their most recent meeting while agreeing to provide continued support through ultralow interest rates and large monthly bond purchases.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve's minutes show that they are expecting a stronger economic recovery, which will lead to an increase in stock prices.\n- The minutes also showed that the Fed is planning to continue their policy support, which will also lead to an increase in stock prices.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-government-bonds-weaken-on-recovery-in-manufacturing-data-11555336418", "title": "U.S. Government Bond Prices Rise as Stocks Drift Lower", "date": "2019-04-15 15:47", "summary": "Yield on the 10-year Treasury note settled at 2.553%. U.S. government bond prices inched higher Monday as stocks gave up some ground at the start of the week.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Government Bond Prices Rise as Stocks Drift Lower. Yield on the 10-year Treasury note settled at 2.553%. U.S. government bond prices inched higher Monday as stocks gave up some ground at the start of the week.\"\n\nStock Prediction(s):", "Prediction": "\n- The 10-year Treasury note yield will continue to rise because the stock market is drifting lower and people are looking for a safe haven.\n- The S&P 500 will continue to drift lower because of the rising interest rates and the trade war with China.", "price_info": {}}, {"link": "https://www.wsj.com/articles/pg-e-bondholders-propose-30-billion-turnaround-plan-11561488631", "title": "PG&E Bondholders Propose $30 Billion Turnaround Plan", "date": "2019-06-25 14:50", "summary": "Wall Street offers a way out of bankruptcy for embattled California utility. PG&E Corp. bondholders have challenged the California utility over control of its bankruptcy proceeding, offering Wall Street's version of a solution to wildfire liabilities estimated at $30 billion or more.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"PG&E Bondholders Propose $30 Billion Turnaround Plan. Wall Street offers a way out of bankruptcy for embattled California utility. PG&E Corp. bondholders have challenged the California utility over control of its bankruptcy proceeding, offering Wall Street's version of a solution to wildfire liabilities estimated at $30 billion or more.\"\n\nStock Prediction(s):", "Prediction": "\n- PG&E Corp. (NYSE: PCG) will increase because they have a proposed turnaround plan that would solve their bankruptcy and wildfire liabilities.\n- Edison International (NYSE: EIX) will decrease because they are a direct competitor of PG&E Corp. and they would have to take on some of PG&E's liabilities if they were to merge.\n- Sempra Energy (NYSE: SRE) will decrease because they are a direct competitor of", "price_info": {"PCG": {"company": "", "ticker": "PCG", "move": "up", "prices": [21.405, 21.24]}, "EIX": {"company": "", "ticker": "EIX", "move": "down", "prices": [64.95, 65.55]}, "SRE": {"company": "", "ticker": "SRE", "move": "down", "prices": [140.13, 140.85]}}}, {"link": "https://www.wsj.com/articles/indias-central-bank-surprises-with-a-rate-cut-11549521871", "title": "India's Surprise Rate Cut Calls Into Question RBI Independence", "date": "2019-02-07 11:33", "summary": "The easing brings the Reserve Bank of India's policy in line with demands from some politicians and comes ahead of the elections. MUMBAI-India's central bank cut its key lending rate Thursday, surprising economists at a time when the autonomy and reliability of the central bank and other authorities that help manage growth and jobs data in Asia's third-largest economy are being questioned.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"India's Surprise Rate Cut Calls Into Question RBI Independence. The easing brings the Reserve Bank of India's policy in line with demands from some politicians and comes ahead of the elections. MUMBAI-India's central bank cut its key lending rate Thursday, surprising economists at a time when the autonomy and reliability of the central bank and other authorities that help manage growth and jobs data in Asia's third-largest economy are being questioned.\"\n\nStock Prediction(s):", "Prediction": "\n- The Reserve Bank of India (RBI) will decrease because they are following the demands of some politicians.\n- The Indian rupee (INR) will decrease because the RBI is cutting rates.\n- Other Asian currencies will decrease because the RBI is cutting rates.", "price_info": {"RBI": {"company": "India", "ticker": "RBI", "move": "down"}, "INR": {"company": "", "ticker": "INR", "move": "down"}}}, {"link": "https://www.wsj.com/articles/march-factory-activity-gauge-just-a-preview-of-april-stall-11585763934", "title": "March Factory Activity Gauge Just a Preview of April Stall", "date": "2020-04-01 13:58", "summary": "U.S. manufacturing stalled last month. It is, of course, only the start. U.S. manufacturing stalled last month. It is, of course, only the start.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"March Factory Activity Gauge Just a Preview of April Stall. U.S. manufacturing stalled last month. It is, of course, only the start. U.S. manufacturing stalled last month. It is, of course, only the start.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DJIA) will decrease because this news signals that the U.S. economy is slowing down.\n- The S&P 500 (NYSE: SPX) will decrease because this news signals that the U.S. economy is slowing down.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because this news signals that the U.S. economy is slowing down.", "price_info": {"DJIA": {"company": "", "ticker": "DJIA", "move": "down"}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/samsungs-galaxy-s20-ultra-has-a-100x-zoom-camera-so-we-tested-it-with-a-private-eye-11582907082", "title": "Samsung's Galaxy S20 Ultra Has a 100X Zoom Camera. So We Tested It With a Private Eye.", "date": "2020-02-28 11:24", "summary": "Samsung's new high-end flagship phone has a camera with unprecedented digital zoom...so is it crazy cool, super-creepy, or both?. That's definitely me, scratching (not picking!) my nose on the corner of Seventh Avenue and Charles Street. Even though the photo was snapped from inside a car...more than 150 feet away...using a smartphone, anyone who knows me would recognize me.", "categories": [["Tech", "Personal Tech", "Personal Technology: Review"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Samsung's Galaxy S20 Ultra Has a 100X Zoom Camera. So We Tested It With a Private Eye.. Samsung's new high-end flagship phone has a camera with unprecedented digital zoom...so is it crazy cool, super-creepy, or both?. That's definitely me, scratching (not picking!) my nose on the corner of Seventh Avenue and Charles Street. Even though the photo was snapped from inside a car...more than 150 feet away...using a smartphone, anyone who knows me would recognize me.\"\n\nStock Prediction(s):", "Prediction": "\n- Samsung Electronics Co Ltd (OTC: SSNLF) will increase because their Galaxy S20 Ultra has a 100X zoom camera, and it is crazy cool.\n- Apple Inc. (NASDAQ: AAPL) will decrease because their iPhone does not have a 100X zoom camera, and they are a direct competitor of Samsung.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [268.78, 270.745]}}}, {"link": "https://www.wsj.com/articles/facebook-lets-more-employees-choose-full-time-remote-work-or-return-to-the-office-11623258049", "title": "Facebook Widens Remote-Work Option", "date": "2021-06-09 15:42", "summary": "CEO Mark Zuckerberg tells staff he plans to spend as much as half of the next year working remotely. Facebook Inc. is giving most of its employees a choice: Seek permission to keep working at home or go to the office at least half the time.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Widens Remote-Work Option. CEO Mark Zuckerberg tells staff he plans to spend as much as half of the next year working remotely. Facebook Inc. is giving most of its employees a choice: Seek permission to keep working at home or go to the office at least half the time.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc. (NASDAQ: FB) will increase because this will make their employees happier and more productive, and it will also help them avoid the spread of Covid-19.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because this will make their employees happier and more productive, and it will also help them avoid the spread of Covid-19.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "up", "prices": [330.26, 330.32]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [253.59, 253.66]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3281.15, 3277.5]}}}, {"link": "https://www.wsj.com/articles/fran-drescher-wins-presidency-of-powerful-hollywood-union-sag-aftra-11630682038", "title": "Fran Drescher Wins Presidency of SAG-AFTRA", "date": "2021-09-03 11:13", "summary": "A newcomer to union politics, Ms. Drescher beat actor Matthew Modine. Former sitcom star Fran Drescher defeated actor Matthew Modine in a close race to become president of SAG-AFTRA, the powerful Hollywood union that represents performers in contract negotiations with movie and television production companies.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fran Drescher Wins Presidency of SAG-AFTRA. A newcomer to union politics, Ms. Drescher beat actor Matthew Modine. Former sitcom star Fran Drescher defeated actor Matthew Modine in a close race to become president of SAG-AFTRA, the powerful Hollywood union that represents performers in contract negotiations with movie and television production companies.\"\n\nStock Prediction(s):", "Prediction": "\n- Ms. Drescher's election as president of SAG-AFTRA will be good for the union, and will help them negotiate better contracts with production companies.\n- Actors who are members of SAG-AFTRA will see a pay increase because of the better contracts that Ms. Drescher will be able to negotiate.\n- Other unions in the entertainment industry, such as the Writers Guild of America, will also see a benefit from Ms. Dres", "price_info": {}}, {"link": "https://www.wsj.com/articles/congress-eyes-targeted-coronavirus-aid-for-small-businesses-11607882400", "title": "Congress Eyes Targeted Coronavirus Aid for Small Businesses", "date": "2020-12-15 10:23", "summary": "Proposals would focus on smaller firms that can show they have been hurt by economic downturn. WASHINGTON-Lawmakers considering a fresh round of financial aid for small businesses are focusing on firms with fewer employees that could show they have been hurt by the pandemic-triggered downturn, addressing criticisms that dogged the Paycheck Protection Program.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Congress Eyes Targeted Coronavirus Aid for Small Businesses. Proposals would focus on smaller firms that can show they have been hurt by economic downturn. WASHINGTON-Lawmakers considering a fresh round of financial aid for small businesses are focusing on firms with fewer employees that could show they have been hurt by the pandemic-triggered downturn, addressing criticisms that dogged the Paycheck Protection Program.\"\n\nStock Prediction(s):", "Prediction": "\n- The Paycheck Protection Program will help small businesses, and they will be more likely to invest in their businesses, which will help the economy.\n- The Paycheck Protection Program will help small businesses, but they will still be struggling because of the pandemic.", "price_info": {}}, {"link": "https://www.wsj.com/articles/running-a-virtual-marathon-the-best-gear-for-crushing-your-pr-11602769762", "title": "Running a Virtual Marathon? The Best Gear for Crushing Your PR", "date": "2020-10-15 09:49", "summary": "Though marathons have been canceled worldwide, runners are still setting up solo courses to chase a finisher's medal by themselves. Here, what you need to ace a 'virtual' race.. ON MARCH 8, I stood shoulder to shoulder with 27,000 other runners at the Los Angeles Marathon starting line, ready to pant my way through 26.2 miles as spectators screamed encouragement. Eight months later, New York City marathoners are on their own. Instead of crossing the famous Central Park finish, virtual participants-whose numbers have jumped from 2,828 last year to more than 25,000 in 2020-must create a course, track their times via phone or GPS watch, and log results on the activity-tracking app Strava to earn an official finisher's medal.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Running a Virtual Marathon? The Best Gear for Crushing Your PR. Though marathons have been canceled worldwide, runners are still setting up solo courses to chase a finisher's medal by themselves. Here, what you need to ace a 'virtual' race.. ON MARCH 8, I stood shoulder to shoulder with 27,000 other runners at the Los Angeles Marathon starting line, ready to pant my way through 26.2 miles as spectators screamed encouragement. Eight months later, New York City marathoners are on their own. Instead of crossing the famous Central Park finish, virtual participants-whose numbers have jumped from 2,828 last year to more than 25,000 in 2020-must create a course, track their times via phone or GPS watch, and log results on the activity-tracking app Strava to earn an official finisher's medal.\"\n\nStock Prediction(s):", "Prediction": "\n- Nike, Inc. (NYSE: NKE) will increase because they make running gear and people will want the best gear to crush their PRs.\n- Lululemon Athletica inc. (NASDAQ: LULU) will increase because they make running gear and people will want the best gear to crush their PRs.\n- Under Armour, Inc. (NYSE: UA) will increase because they make running gear and people will want the best gear", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "up", "prices": [127.1292, 128.041]}, "UA": {"company": "", "ticker": "UA", "move": "up", "prices": [11.03, 11.2024]}, "LULU": {"company": "", "ticker": "LULU", "move": "up", "prices": [348.998, 350.16]}}}, {"link": "https://www.wsj.com/articles/staples-may-come-undone-after-2019-rally-11577720315", "title": "Staples May Come Undone After 2019 Rally", "date": "2019-12-30 10:38", "summary": "Consumer staples rallied in 2019, but the sector remains challenged. The consumer staples sector turned in a surprisingly decent performance for 2019. It is unlikely to last.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Staples May Come Undone After 2019 Rally. Consumer staples rallied in 2019, but the sector remains challenged. The consumer staples sector turned in a surprisingly decent performance for 2019. It is unlikely to last.\"\n\nStock Prediction(s):", "Prediction": "\n- Staples Inc (NASDAQ: SPLS) will decrease because the sector is challenged and they rallied in 2019.", "price_info": {"SPLS": {"company": "", "ticker": "SPLS", "move": "down"}}}, {"link": "https://www.wsj.com/articles/silicon-valley-gets-another-president-skeptical-of-big-tech-11604938267", "title": "Silicon Valley Gets Another President Skeptical of Big Tech", "date": "2020-11-09 11:11", "summary": "Joe Biden has expressed wariness about the power of tech giants, which expect four more years of scrutiny. As a candidate, Joe Biden lambasted Facebook Inc. for what he considered failures to contain the spread of misinformation. His presidential election win puts him in a position to do something about it.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Silicon Valley Gets Another President Skeptical of Big Tech. Joe Biden has expressed wariness about the power of tech giants, which expect four more years of scrutiny. As a candidate, Joe Biden lambasted Facebook Inc. for what he considered failures to contain the spread of misinformation. His presidential election win puts him in a position to do something about it.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc (NASDAQ: FB) will decrease because they are in the line of fire again with another president who is skeptical of their power.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are in the line of fire again with another president who is skeptical of their power.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are in the line of fire again with another president who is", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [288.11, 287.84]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3235.064, 3212.55]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [120.46, 120.21]}}}, {"link": "https://www.wsj.com/articles/illinois-governor-to-sign-bill-raising-minimum-wage-to-15-an-hour-by-2025-11550251552", "title": "Illinois Governor to Sign Bill Raising Minimum Wage to $15 an Hour by 2025", "date": "2019-02-15 12:25", "summary": "Business groups oppose labor-backed measure raising minimum from $8.25. Illinois Gov. J.B. Pritzker is expected to sign a bill approved by the Democrat-controlled state legislature to raise the state minimum wage to $15 an hour by 2025, a move that is sharply opposed by businesses throughout the state.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Illinois Governor to Sign Bill Raising Minimum Wage to $15 an Hour by 2025. Business groups oppose labor-backed measure raising minimum from $8.25. Illinois Gov. J.B. Pritzker is expected to sign a bill approved by the Democrat-controlled state legislature to raise the state minimum wage to $15 an hour by 2025, a move that is sharply opposed by businesses throughout the state.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corporation (NYSE: MCD) will decrease because they are a fast food chain that is likely to be impacted by the increase in minimum wage.\n- Walgreens Boots Alliance, Inc. (NASDAQ: WBA) will decrease because they are a pharmacy chain that is likely to be impacted by the increase in minimum wage.\n- Walmart Inc. (NYSE: WMT) will decrease because they are a retail chain that is likely to be impacted", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "up", "prices": [178.89, 179.0566]}, "WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [99.36, 99.4141]}, "WBA": {"company": "", "ticker": "WBA", "move": "up", "prices": [73.04, 73.27]}}}, {"link": "https://www.wsj.com/articles/two-year-treasury-yield-now-at-record-low-11588880057", "title": "Two-Year Treasury Yield Now at Record Low", "date": "2020-05-07 15:34", "summary": "The two-year Treasury bill yield finished Thursday's trading session at its lowest level since 2011. The yield on the two-year Treasury settled at a record low on Thursday after data showed the continuing hit to the U.S. labor market from the pandemic shutdowns.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Two-Year Treasury Yield Now at Record Low. The two-year Treasury bill yield finished Thursday's trading session at its lowest level since 2011. The yield on the two-year Treasury settled at a record low on Thursday after data showed the continuing hit to the U.S. labor market from the pandemic shutdowns.\"\n\nStock Prediction(s):", "Prediction": "\n- The two-year Treasury bill yield will continue to decrease because the U.S. labor market is still being hit by the pandemic shutdowns.", "price_info": {}}, {"link": "https://www.wsj.com/articles/in-turkey-weak-lira-powers-fresh-gold-rush-11600072185", "title": "In Turkey, Weak Lira Powers Fresh Gold Rush", "date": "2020-09-14 13:50", "summary": "Turkish households bought record volumes of gold this summer-and safe-boxes to keep it at home. ISTANBUL-Turks are piling into gold, long their favorite investment, as the country's financial system unravels.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"In Turkey, Weak Lira Powers Fresh Gold Rush. Turkish households bought record volumes of gold this summer-and safe-boxes to keep it at home. ISTANBUL-Turks are piling into gold, long their favorite investment, as the country's financial system unravels.\"\n\nStock Prediction(s):", "Prediction": "\n- The price of gold will continue to increase because of the Turkish Lira crisis.\n- The price of Turkish Lira will continue to decrease because of the Turkish Lira crisis.", "price_info": {}}, {"link": "https://www.wsj.com/articles/how-to-last-a-day-without-your-phone-11578079965", "title": "How to Last a Day Without Your Phone", "date": "2020-01-03 14:32", "summary": "Google's Paper Phone is a cheeky-and potentially healthy-response to phone addiction. AMERICANS LOOK at their phones up to 80 times a day, or every 12 minutes, according to a 2018 survey by Asurion, a tech support and insurance company. Occasionally we stare with purpose-to check emails or scroll the news-but often without. We fill rare moments of mental silence by tapping through Twitter and Instagram Stories or checking gossipy texts under the dinner table.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Last a Day Without Your Phone. Google's Paper Phone is a cheeky-and potentially healthy-response to phone addiction. AMERICANS LOOK at their phones up to 80 times a day, or every 12 minutes, according to a 2018 survey by Asurion, a tech support and insurance company. Occasionally we stare with purpose-to check emails or scroll the news-but often without. We fill rare moments of mental silence by tapping through Twitter and Instagram Stories or checking gossipy texts under the dinner table.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are working on a similar product, and they are a direct competitor of Google.\n- Google Inc. (NASDAQ: GOOGL) will increase because they are working on a similar product, and they are a direct competitor of Apple.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [299.1222, 297.53]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1366.49, 1361.52]}}}, {"link": "https://www.wsj.com/articles/israel-strikes-target-iranian-oil-bound-for-syria-11615492789", "title": "Israeli Strikes Target Iranian Oil Bound for Syria", "date": "2021-03-11 15:04", "summary": "Campaign against ships, using mines, shows an expansion of hostilities in the Mideast. WASHINGTON-Israel has targeted at least a dozen vessels bound for Syria and mostly carrying Iranian oil out of concern that petroleum profits are funding extremism in the Middle East, U.S. and regional officials say, in a new front in the conflict between Israel and Iran.", "categories": [["WSJ News Exclusive", "Middle East"]], "category_links": ["https://www.wsj.com/news/types/middle-east-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Israeli Strikes Target Iranian Oil Bound for Syria. Campaign against ships, using mines, shows an expansion of hostilities in the Mideast. WASHINGTON-Israel has targeted at least a dozen vessels bound for Syria and mostly carrying Iranian oil out of concern that petroleum profits are funding extremism in the Middle East, U.S. and regional officials say, in a new front in the conflict between Israel and Iran.\"\n\nStock Prediction(s):", "Prediction": "\n- Israeli stocks (e.g. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)) will decrease because of the increased hostilities in the Middle East.\n- Iranian stocks (e.g. National Iranian Oil Company (NYSE: NIOC)) will decrease because of the increased hostilities in the Middle East.", "price_info": {"TEVA": {"company": "", "ticker": "TEVA", "move": "down", "prices": [11.1, 11.05]}, "NIOC": {"company": "", "ticker": "NIOC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/ma-bell-juggles-its-bills-11615582472", "title": "Ma Bell Juggles Its Bills", "date": "2021-03-12 15:54", "summary": "AT&T promises to keep its crucial dividend while facing growing investment demands in 5G and streaming. If nothing else, AT&T 's past few years in show business seem to have taught it to keep the spotlight on the positive.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ma Bell Juggles Its Bills. AT&T promises to keep its crucial dividend while facing growing investment demands in 5G and streaming. If nothing else, AT&T 's past few years in show business seem to have taught it to keep the spotlight on the positive.\"\n\nStock Prediction(s):", "Prediction": "\n- AT&T Inc. (NYSE: T) will increase because they are promising to keep their dividend while also investing in 5G and streaming.\n- Comcast Corporation (NASDAQ: CMCSA) will increase because they are also investing in 5G and streaming.\n- Verizon Communications Inc. (NYSE: VZ) will decrease because they are not promising to keep their dividend, and they are not investing in 5G and streaming.", "price_info": {"T": {"company": "", "ticker": "T", "move": "up", "prices": [29.7869, 29.83]}, "VZ": {"company": "", "ticker": "VZ", "move": "down", "prices": [55.665, 55.67]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "up", "prices": [57.12, 56.89]}}}, {"link": "https://www.wsj.com/articles/apples-moves-to-tighten-flow-of-user-data-leave-advertisers-anxious-11623189903", "title": "Apple's Moves to Tighten Flow of User Data Leave Advertisers Anxious", "date": "2021-06-09 15:33", "summary": "Brands and ad-tech firms say tech giant's push to limit how users are tracked will hurt business, with some questioning privacy rationale. Digital advertisers are studying new Apple Inc. measures that they fear will limit access to data about users, changes industry participants see as an escalation of the tech giant's crackdown in the name of consumer privacy.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple's Moves to Tighten Flow of User Data Leave Advertisers Anxious. Brands and ad-tech firms say tech giant's push to limit how users are tracked will hurt business, with some questioning privacy rationale. Digital advertisers are studying new Apple Inc. measures that they fear will limit access to data about users, changes industry participants see as an escalation of the tech giant's crackdown in the name of consumer privacy.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are limiting how users are tracked, which will limit access to data and hurt business.\n- Facebook Inc. (NASDAQ: FB) will decrease because they are a direct competitor of Apple and they rely on user data to make money.\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease because they are a direct competitor of Apple and they rely on user data to make money", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [127.05, 126.985]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [330.25, 330.21]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [2406.505, 2406.605]}}}, {"link": "https://www.wsj.com/articles/olympus-to-exit-camera-business-after-84-years-11592996861", "title": "Olympus to Exit Camera Business After 84 Years", "date": "2020-06-24 09:40", "summary": "Under pressure from U.S. shareholder ValueAct Capital, Tokyo company to sell unit to private-equity firm Japan Industrial Partners. Olympus Corp. is getting out of the camera business after 84 years to focus on medical devices.", "categories": [["Business", "Asia"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/asia-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Olympus to Exit Camera Business After 84 Years. Under pressure from U.S. shareholder ValueAct Capital, Tokyo company to sell unit to private-equity firm Japan Industrial Partners. Olympus Corp. is getting out of the camera business after 84 years to focus on medical devices.\"\n\nStock Prediction(s):", "Prediction": "\n- Olympus Corp. (TYO: 7733) will increase because they are getting out of the camera business and focusing on medical devices.\n- Canon Inc. (NYSE: CAJ) will decrease because they are a direct competitor of Olympus in the camera business.", "price_info": {"CAJ": {"company": "", "ticker": "CAJ", "move": "down", "prices": [20.98, 20.8337]}}}, {"link": "https://www.wsj.com/articles/tablet-computers-wired-earphones-tech-that-dates-you-11634917994", "title": "Tablet Computers and 8 Other Pieces of Tech That Date You", "date": "2021-10-22 11:54", "summary": "From wired headphones to wooden rowing machines, gear can leave you looking seriously behind the times. Here, nine items due for extinction-and great upgrades to try instead.. EVERY FASHION choice you make broadcasts to the world who you want to be. So if you're still rocking Ed Hardy shirts and acid wash jeans, you're admitting that you were last cool about a decade ago-and perhaps not entirely cool to begin with. The same is true of tech, where the gadgets you use daily tell a story, whether that narrative defines you as an ardent first adopter, a respectably up-to-date player or an out-of-touch Luddite.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tablet Computers and 8 Other Pieces of Tech That Date You. From wired headphones to wooden rowing machines, gear can leave you looking seriously behind the times. Here, nine items due for extinction-and great upgrades to try instead.. EVERY FASHION choice you make broadcasts to the world who you want to be. So if you're still rocking Ed Hardy shirts and acid wash jeans, you're admitting that you were last cool about a decade ago-and perhaps not entirely cool to begin with. The same is true of tech, where the gadgets you use daily tell a story, whether that narrative defines you as an ardent first adopter, a respectably up-to-date player or an out-of-touch Luddite.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are always on the forefront of technology and they have a great replacement for the tablet computer.\n- Fitbit Inc. (NYSE: FIT) will increase because they are a great replacement for wired headphones.\n- GoPro, Inc. (NASDAQ: GPRO) will increase because they are a great replacement for the wooden rowing machine.\n- Amazon.com, Inc. (NAS", "price_info": {"FIT": {"company": "", "ticker": "FIT", "move": "up"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [149.315, 149.31]}, "GPRO": {"company": "", "ticker": "GPRO", "move": "up", "prices": [8.895, 8.8715]}}}, {"link": "https://www.wsj.com/articles/starbucks-ceo-asks-workers-to-stick-with-chain-not-union-11638886500", "title": "Starbucks Loses Appeal in Union Vote Process", "date": "2021-12-07 15:07", "summary": "National Labor Relations Board decides to allow ballot tally in Buffalo, N.Y., to proceed on Thursday. Starbucks Corp. was dealt a setback Tuesday after a federal labor authority ruled that the tallying of ballots can move ahead in a worker vote on unionizing three of the company's cafes.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Starbucks Loses Appeal in Union Vote Process. National Labor Relations Board decides to allow ballot tally in Buffalo, N.Y., to proceed on Thursday. Starbucks Corp. was dealt a setback Tuesday after a federal labor authority ruled that the tallying of ballots can move ahead in a worker vote on unionizing three of the company's cafes.\"\n\nStock Prediction(s):", "Prediction": "\n- Starbucks Corp. (NASDAQ: SBUX) will decrease because they are dealing with a unionization process.", "price_info": {"SBUX": {"company": "", "ticker": "SBUX", "move": "down", "prices": [116.45, 116.11]}}}, {"link": "https://www.wsj.com/articles/health-care-workers-say-protests-are-vital-despite-coronavirus-risks-11591790600", "title": "Health-Care Workers Say Protests Are Vital Despite Coronavirus Risks", "date": "2020-06-10 11:43", "summary": "For some, the benefits of highlighting racially driven public-health inequities outweigh threat of Covid-19's spread. Many public-health experts and health-care workers are joining or voicing support for the protests spurred by the killing of George Floyd in police custody, despite worries the events could spread the new coronavirus, saying racially driven disparities in the U.S. are an important public-health problem.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Health-Care Workers Say Protests Are Vital Despite Coronavirus Risks. For some, the benefits of highlighting racially driven public-health inequities outweigh threat of Covid-19's spread. Many public-health experts and health-care workers are joining or voicing support for the protests spurred by the killing of George Floyd in police custody, despite worries the events could spread the new coronavirus, saying racially driven disparities in the U.S. are an important public-health problem.\"\n\nStock Prediction(s):", "Prediction": "\n- Health-care workers will continue to protest, despite the risks of Covid-19, because they feel it is important to highlight racially driven public-health inequities.\n- The protests will have a negative effect on the stocks of health-care companies, as they will be seen as a risk for the spread of Covid-19.", "price_info": {}}, {"link": "https://www.wsj.com/articles/workers-strive-to-make-their-careers-pandemic-proof-11593509400", "title": "How to Make a Career Pandemic-Proof", "date": "2020-06-30 11:39", "summary": "With the economy in flux, people are training for jobs that provide stability, flexibility. Workers whose livelihoods have been bruised by the Covid-19 crisis are trying to pandemic-proof their careers.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Make a Career Pandemic-Proof. With the economy in flux, people are training for jobs that provide stability, flexibility. Workers whose livelihoods have been bruised by the Covid-19 crisis are trying to pandemic-proof their careers.\"\n\nStock Prediction(s):", "Prediction": "\n- People will invest in companies that provide stability and flexibility, such as Amazon.com, Inc. (NASDAQ: AMZN) or Walmart Inc. (NYSE: WMT).\n- People will invest in companies that have been hurt by the Covid-19 crisis, such as General Motors Company (NYSE: GM) or Ford Motor Company (NYSE: F).", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": null, "prices": [119.22, 118.875]}, "GM": {"company": "", "ticker": "GM", "move": null, "prices": [25.37, 25.135]}, "F": {"company": "", "ticker": "F", "move": null, "prices": [6.0632, 6.01]}, "AMZN": {"company": "", "ticker": "AMZN", "move": null, "prices": [2737.1672, 2738.4]}}}, {"link": "https://www.wsj.com/articles/pandemic-boosts-targets-growth-at-rivals-expense-11614684877", "title": "Target Keeps Growing at Rivals' Expense", "date": "2021-03-02 13:03", "summary": "Retailer says sales jumped 20% last year, including $9 billion in sales taken from competitors. Covid-19 helped Target Corp. get much bigger.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Target Keeps Growing at Rivals' Expense. Retailer says sales jumped 20% last year, including $9 billion in sales taken from competitors. Covid-19 helped Target Corp. get much bigger.\"\n\nStock Prediction(s):", "Prediction": "\n- Target Corporation (NYSE: TGT) will continue to grow because they are taking sales from their competitors, and they have a good strategy for dealing with Covid-19.\n- Walmart Inc. (NYSE: WMT) will decrease because they are not taking as many sales from their competitors as Target is.", "price_info": {"TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [177.77, 176.34]}, "WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [131.2581, 131.04]}}}, {"link": "https://www.wsj.com/articles/software-developer-community-stack-overflow-sold-to-tech-giant-prosus-for-1-8-billion-11622648400", "title": "Tencent's Biggest Investor Snaps Up Coding Community", "date": "2021-06-02 11:52", "summary": "Deal is Prosus' biggest investment in online learning and comes weeks after it sold a chunk from its massive Tencent holding. Prosus NV said it struck a $1.8 billion deal to acquire Stack Overflow, an online community for software developers, in a bet on growing demand for online tech learning.", "categories": [["WSJ News Exclusive", "Deals"]], "category_links": ["https://www.wsj.com/news/types/deals-deal-makers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tencent's Biggest Investor Snaps Up Coding Community. Deal is Prosus' biggest investment in online learning and comes weeks after it sold a chunk from its massive Tencent holding. Prosus NV said it struck a $1.8 billion deal to acquire Stack Overflow, an online community for software developers, in a bet on growing demand for online tech learning.\"\n\nStock Prediction(s):", "Prediction": "\n- Prosus NV (OTC: PRXAF) will increase because they are making a big investment in online learning, which is growing in demand.\n- Tencent Holdings Ltd. (OTCPK: TCEHY) will decrease because they are selling a chunk of their Prosus holding.", "price_info": {}}, {"link": "https://www.wsj.com/articles/gold-hits-three-month-high-on-trade-tension-11559576575", "title": "Gold Hits Three-Month High on Trade Tension", "date": "2019-06-03 14:14", "summary": "Investors have turned to haven investments like gold and bonds amid fears that tariffs on China and Mexico could stymie growth. Gold prices climbed to the highest level in more than three months on Monday, lifted by ongoing trade tensions and concerns about the global economy.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold Hits Three-Month High on Trade Tension. Investors have turned to haven investments like gold and bonds amid fears that tariffs on China and Mexico could stymie growth. Gold prices climbed to the highest level in more than three months on Monday, lifted by ongoing trade tensions and concerns about the global economy.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldcorp Inc. (NYSE: GG) will increase because investors are turning to haven investments, and Goldcorp is one of the largest gold producers.\n- Barrick Gold Corporation (NYSE: ABX) will increase because investors are turning to haven investments, and Barrick Gold is one of the largest gold producers.\n- Newmont Mining Corporation (NYSE: NEM) will increase because investors are turning to haven investments, and Newmont Mining is one", "price_info": {"GG": {"company": "", "ticker": "GG", "move": "up"}, "ABX": {"company": "", "ticker": "ABX", "move": "up"}, "NEM": {"company": "", "ticker": "NEM", "move": "up", "prices": [33.475, 33.63]}}}, {"link": "https://www.wsj.com/articles/bankrupt-remington-gets-65-million-offer-for-ammunition-business-11599680366", "title": "Bankrupt Remington Gets $65 Million Offer for Ammunition Business", "date": "2020-09-09 15:39", "summary": "Firearms maker agrees to sell its ammunition business out of bankruptcy to investment firm JJE for $65 million, subject to better offers. Firearms maker Remington Outdoor Co. has agreed to sell its ammunition business out of bankruptcy to South Carolina-based investment firm JJE Capital Holdings LLC for $65 million plus the assumption of liabilities, subject to better offers.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bankrupt Remington Gets $65 Million Offer for Ammunition Business. Firearms maker agrees to sell its ammunition business out of bankruptcy to investment firm JJE for $65 million, subject to better offers. Firearms maker Remington Outdoor Co. has agreed to sell its ammunition business out of bankruptcy to South Carolina-based investment firm JJE Capital Holdings LLC for $65 million plus the assumption of liabilities, subject to better offers.\"\n\nStock Prediction(s):", "Prediction": "\n- Remington Outdoor Co. (OTCQB: ROCO) will increase because they have agreed to sell their ammunition business for $65 million.\n- JJE Capital Holdings LLC (OTCQB: JJEC) will increase because they are the winning bidder for Remington's ammunition business.", "price_info": {}}, {"link": "https://www.wsj.com/articles/how-to-climb-the-corporate-ladder-while-working-remotely-11601305764", "title": "How to Climb the Corporate Ladder While Working Remotely", "date": "2020-09-28 11:09", "summary": "Women would be wise to learn how to navigate the new office politics, executive coaches say. Office politics hasn't gone away just because a pandemic forces millions to work away from the office.", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Climb the Corporate Ladder While Working Remotely. Women would be wise to learn how to navigate the new office politics, executive coaches say. Office politics hasn't gone away just because a pandemic forces millions to work away from the office.\"\n\nStock Prediction(s):", "Prediction": "\n- Workday, Inc. (NASDAQ: WDAY) will increase because they offer a remote working solution that is becoming more in demand.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they offer a remote working solution that is becoming more in demand.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they offer a remote working solution that is becoming more in demand.\n- Facebook, Inc. (", "price_info": {"WDAY": {"company": "", "ticker": "WDAY", "move": "up", "prices": [217.26, 219.45]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [208.72, 209.41]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3132.21, 3160.9999]}}}, {"link": "https://www.wsj.com/articles/companies-include-green-bonds-in-larger-debt-offerings-11635776569", "title": "Companies Include Green Bonds in Larger Debt Offerings", "date": "2021-11-01 10:22", "summary": "Chip maker Micron Technology is the latest big company to issue a green bond alongside a larger debt issuance. Corporate green-bond issuance has reached new highs as U.S. companies including chip maker Micron Technology Inc., retailer Walmart Inc. and data-center company Equinix Inc. add the bonds as part of larger traditional bond offerings.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Companies Include Green Bonds in Larger Debt Offerings. Chip maker Micron Technology is the latest big company to issue a green bond alongside a larger debt issuance. Corporate green-bond issuance has reached new highs as U.S. companies including chip maker Micron Technology Inc., retailer Walmart Inc. and data-center company Equinix Inc. add the bonds as part of larger traditional bond offerings.\"\n\nStock Prediction(s):", "Prediction": "\n- Micron Technology, Inc. (NASDAQ: MU) will increase because they are a green company and are trying to be more environmentally friendly.\n- Walmart Inc. (NYSE: WMT) will increase because they are a green company and are trying to be more environmentally friendly.\n- Equinix, Inc. (NASDAQ: EQIX) will increase because they are a green company and are trying to be more environmentally friendly.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [149.82, 149.86]}, "MU": {"company": "", "ticker": "MU", "move": "up", "prices": [70.355, 70.89]}, "EQIX": {"company": "", "ticker": "EQIX", "move": "up", "prices": [823.73, 829.3]}}}, {"link": "https://www.wsj.com/articles/workers-return-to-chinas-factories-but-coronavirus-hurts-global-demand-11585724711", "title": "Workers Return to China's Factories, but Coronavirus Hurts Global Demand", "date": "2020-04-01 12:33", "summary": "Factory activity expands after sharp contractions, though hopes for a speedy recovery dim. BEIJING-Chinese workers returned to factory floors in March, but operations remained slow because of sluggish demand, damping hopes for a speedy recovery as the coronavirus pandemic continues to paralyze the global economy.", "categories": [["Economy", "Asia Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/asia-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Workers Return to China's Factories, but Coronavirus Hurts Global Demand. Factory activity expands after sharp contractions, though hopes for a speedy recovery dim. BEIJING-Chinese workers returned to factory floors in March, but operations remained slow because of sluggish demand, damping hopes for a speedy recovery as the coronavirus pandemic continues to paralyze the global economy.\"\n\nStock Prediction(s):", "Prediction": "\n- Foxconn Technology Co Ltd (TPE: 2354) will decrease because their main market is China, and the global demand for their products is still low.\n- Pegatron Corp (TPE: 4938) will decrease because their main market is China, and the global demand for their products is still low.\n- Wistron Corp (TPE: 3231) will decrease because their main market is China, and the global demand for their products is", "price_info": {}}, {"link": "https://www.wsj.com/articles/who-recommends-against-moderna-pfizer-vaccines-for-most-pregnant-women-11611775138", "title": "WHO Recommends Against Moderna, Pfizer Vaccines for Most Pregnant Women", "date": "2021-01-27 14:18", "summary": "Neither Moderna nor Pfizer enrolled pregnant women in their Covid-19 vaccine trials, and both say they plan future study. The World Health Organization released new guidance about Moderna Inc.'s Covid-19 vaccine this week, recommending generally against the use of the vaccine during pregnancy except in those at high risk of exposure or having a severe case.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"WHO Recommends Against Moderna, Pfizer Vaccines for Most Pregnant Women. Neither Moderna nor Pfizer enrolled pregnant women in their Covid-19 vaccine trials, and both say they plan future study. The World Health Organization released new guidance about Moderna Inc.'s Covid-19 vaccine this week, recommending generally against the use of the vaccine during pregnancy except in those at high risk of exposure or having a severe case.\"\n\nStock Prediction(s):", "Prediction": "\n- Moderna Inc (NASDAQ: MRNA) will decrease because their vaccine is not recommended for pregnant women.\n- Pfizer Inc (NYSE: PFE) will decrease because their vaccine is not recommended for pregnant women.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [36.343, 36.32]}, "MRNA": {"company": "", "ticker": "MRNA", "move": "down", "prices": [164.0428, 157.3]}}}, {"link": "https://www.wsj.com/articles/volkswagen-in-talks-to-sell-bugatti-brand-to-croatian-upstart-11600712855", "title": "Volkswagen in Talks to Sell Bugatti Brand to Croatian Upstart", "date": "2020-09-21 14:27", "summary": "Sale could indicate start of broader realignment of VW's assets. BERLIN- Volkswagen AG is in talks about a potential sale of its Bugatti luxury sport car brand, a move that could signal a broader realignment of the German car maker's vast stable of automotive brands.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Volkswagen in Talks to Sell Bugatti Brand to Croatian Upstart. Sale could indicate start of broader realignment of VW's assets. BERLIN- Volkswagen AG is in talks about a potential sale of its Bugatti luxury sport car brand, a move that could signal a broader realignment of the German car maker's vast stable of automotive brands.\"\n\nStock Prediction(s):", "Prediction": "\n- Volkswagen AG (OTCPK: VOW3) will increase because they are selling off one of their brands, and this could be the start of a larger realignment.\n- Porsche Automobil Holding SE (OTCPK: POAHY) will increase because they are a direct competitor of Bugatti, and they could benefit from the sale.\n- Ferrari NV (NYSE: RACE) will increase because they are a direct competitor of Bugatti, and", "price_info": {"RACE": {"company": "", "ticker": "RACE", "move": "up"}}}, {"link": "https://www.wsj.com/articles/you-want-to-retire-someplace-safe-but-heres-how-you-can-tell-11560446297", "title": "You Want to Retire Someplace Safe. Here's How You Can Tell", "date": "2019-06-13 13:18", "summary": "Columnist Glenn Ruffenach also answer readers' questions on Social Security benefits. My husband and I plan to move when we retire, and we want to include safety as a factor in choosing a home and community. Any advice about how to evaluate a destination in terms of safety?", "categories": [["Markets", "Journal Reports: Wealth Management"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-wealth-management?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"You Want to Retire Someplace Safe. Here's How You Can Tell. Columnist Glenn Ruffenach also answer readers' questions on Social Security benefits. My husband and I plan to move when we retire, and we want to include safety as a factor in choosing a home and community. Any advice about how to evaluate a destination in terms of safety?\"\n\nStock Prediction(s):", "Prediction": "\n- All of the retirement-related stocks will increase because people are moving to safer places to retire.\n- Home Depot Inc (NYSE: HD) will increase because people are moving to safer places to retire and they will need to buy supplies to fix up their new homes.\n- Lowe's Companies, Inc. (NYSE: LOW) will increase because people are moving to safer places to retire and they will need to buy supplies to fix up their new homes.\n-", "price_info": {"HD": {"company": "", "ticker": "HD", "move": "up", "prices": [202.11, 202.2]}, "LOW": {"company": "", "ticker": "LOW", "move": "up", "prices": [97.99, 98.47]}}}, {"link": "https://www.wsj.com/articles/hoping-that-cars-will-last-as-long-as-the-loan-11585932161", "title": "Hoping That Cars Will Last as Long as the Loan", "date": "2020-04-03 12:42", "summary": "American auto-loan payment terms have never been so generous. I will gladly pay you Tuesday. Tuesday, April 6, 2027, that is.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hoping That Cars Will Last as Long as the Loan. American auto-loan payment terms have never been so generous. I will gladly pay you Tuesday. Tuesday, April 6, 2027, that is.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because people will want to buy cars that they can keep for a long time.\n- General Motors Company (NYSE: GM) will increase because people will want to buy cars that they can keep for a long time.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because people will want to buy cars that they can keep for a long time.\n- Fiat Chrysler Automobiles NV (", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [4.225, 4.27]}, "GM": {"company": "", "ticker": "GM", "move": "up", "prices": [17.94, 18.15]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [470.65, 477.105]}}}, {"link": "https://www.wsj.com/articles/coinbase-pitches-blueprint-for-special-crypto-regulator-11634231298", "title": "Coinbase Pitches Blueprint for Special Crypto Regulator", "date": "2021-10-14 14:39", "summary": "Trading platform asks Congress to create a cryptocurrency oversight regime separate from existing market regulators. WASHINGTON-The largest U.S. cryptocurrency exchange wants Congress to block the Securities and Exchange Commission from overseeing the nascent industry and instead create a special regulator for digital assets, according to a policy blueprint reviewed by The Wall Street Journal.", "categories": [["WSJ News Exclusive", "Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coinbase Pitches Blueprint for Special Crypto Regulator. Trading platform asks Congress to create a cryptocurrency oversight regime separate from existing market regulators. WASHINGTON-The largest U.S. cryptocurrency exchange wants Congress to block the Securities and Exchange Commission from overseeing the nascent industry and instead create a special regulator for digital assets, according to a policy blueprint reviewed by The Wall Street Journal.\"\n\nStock Prediction(s):", "Prediction": "\n- Coinbase (NASDAQ: GDAX) will increase because they are lobbying for a separate regulator for cryptocurrencies, which will give them an edge over their competitors.\n- Bitfinex (USD: BFX) will decrease because they are not lobbying for a separate regulator for cryptocurrencies, and they will be at a disadvantage.\n- Kraken (USD: KRAKEN) will decrease because they are not lobbying for a separate regulator for cryptocurrencies, and they will be at", "price_info": {"GDAX": {"company": "", "ticker": "GDAX", "move": "down"}}}, {"link": "https://www.wsj.com/articles/mall-operators-simon-and-taubman-pair-up-11581340570", "title": "Mall Operators Simon and Taubman Pair Up", "date": "2020-02-10 15:44", "summary": "Simon to own 80% of the Taubman operating entity when transaction is completed. Simon Property Group Inc. is buying rival mall owner Taubman Centers Inc., a $3.6 billion transaction that demonstrates how the largest U.S. mall owner is pushing ahead with expansion despite headwinds in the industry.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Mall Operators Simon and Taubman Pair Up. Simon to own 80% of the Taubman operating entity when transaction is completed. Simon Property Group Inc. is buying rival mall owner Taubman Centers Inc., a $3.6 billion transaction that demonstrates how the largest U.S. mall owner is pushing ahead with expansion despite headwinds in the industry.\"\n\nStock Prediction(s):", "Prediction": "\n- Simon Property Group Inc. (NYSE: SPG) will increase because they are expanding their business even though the industry is facing headwinds.\n- Taubman Centers Inc. (NYSE: TCO) will decrease because they are being bought out by Simon Property Group, and they will no longer be an independent company.", "price_info": {"SPG": {"company": "", "ticker": "SPG", "move": "up", "prices": [142.809, 143]}, "TCO": {"company": "", "ticker": "TCO", "move": "down", "prices": [53.12, 53.11]}}}, {"link": "https://www.wsj.com/articles/apple-and-microsoft-are-dazzling-investors-that-wont-last-11578671902", "title": "Apple and Microsoft Are Dazzling Investors. That Won't Last.", "date": "2020-01-10 11:36", "summary": "The shiniest stocks are driving the bull market higher. But rusty old bargains will eventually have their day.. Pop quiz: Name the giant store whose customers scoff at whatever goes on sale, but flock to buy whatever costs the most.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple and Microsoft Are Dazzling Investors. That Won't Last.. The shiniest stocks are driving the bull market higher. But rusty old bargains will eventually have their day.. Pop quiz: Name the giant store whose customers scoff at whatever goes on sale, but flock to buy whatever costs the most.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will continue to increase because they are a giant store with customers who are willing to pay more for their products.\n- Microsoft Corporation (NASDAQ: MSFT) will continue to increase because they are a giant store with customers who are willing to pay more for their products.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [311.105, 310.2199]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [162.555, 162.19]}}}, {"link": "https://www.wsj.com/articles/cvs-gets-boost-from-sales-of-brand-name-drugs-11556710698", "title": "CVS Eases Concerns About Aetna Deal", "date": "2019-05-01 13:02", "summary": "Sales rise across combined health-care company, which has been under pressure from investors to justify $70 billion acquisition of insurer. CVS Health Corp. delivered stronger-than-expected results in its first full quarter as a combined health-care company, taking a step toward selling skeptical investors on its acquisition of insurer Aetna Inc.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"CVS Eases Concerns About Aetna Deal. Sales rise across combined health-care company, which has been under pressure from investors to justify $70 billion acquisition of insurer. CVS Health Corp. delivered stronger-than-expected results in its first full quarter as a combined health-care company, taking a step toward selling skeptical investors on its acquisition of insurer Aetna Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- CVS Health Corp. (NYSE: CVS) will increase because they showed good results in their first full quarter as a combined health-care company.\n- Aetna Inc. (NYSE: AET) will decrease because they were acquired by CVS Health Corp., and they are no longer an independent company.", "price_info": {"CVS": {"company": "", "ticker": "CVS", "move": "up", "prices": [57.29, 57.365]}, "AET": {"company": "", "ticker": "AET", "move": "down"}}}, {"link": "https://www.wsj.com/articles/liberte-egalite-equity-french-government-holds-key-for-renault-nissan-11570733546", "title": "Libert\u00e9, \u00c9galit\u00e9, Equity: French Government Holds Key for Renault, Nissan", "date": "2019-10-10 14:52", "summary": "Management change at both car makers could pave the road to better relations, but can do little without the support of Emmanuel Macron. The sudden management shakeup that started at Nissan earlier this week has spread to Renault. It is a pity it can't also spread to the management that really matters for the car makers' faltering alliance as well as Renault's merger hopes with Fiat Chrysler: the French government.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Libert\u00e9, \u00c9galit\u00e9, Equity: French Government Holds Key for Renault, Nissan. Management change at both car makers could pave the road to better relations, but can do little without the support of Emmanuel Macron. The sudden management shakeup that started at Nissan earlier this week has spread to Renault. It is a pity it can't also spread to the management that really matters for the car makers' faltering alliance as well as Renault's merger hopes with Fiat Chrysler: the French government.\"\n\nStock Prediction(s):", "Prediction": "\n- Renault SA (EPA: RNO) will increase because the French government is supportive and could help pave the way for a better relationship with Nissan.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will increase because Renault is interested in a merger, and the French government is supportive.\n- Nissan Motor Co Ltd (TSE: 7201) will decrease because of the management shakeup and the uncertain future of the alliance with Renault.", "price_info": {"FCAU": {"company": "", "ticker": "FCAU", "move": "down"}}}, {"link": "https://www.wsj.com/articles/cop26-negotiators-make-progress-on-carbon-trading-rules-11635959365", "title": "COP26 Negotiators Make Progress on Carbon-Trading Rules", "date": "2021-11-03 13:31", "summary": "Companies hope a U.N.-backed framework for cross-border carbon markets will kick-start trading. GLASGOW-Climate negotiators have made progress toward a deal aimed at establishing the foundation of an international carbon-trading system, according to people familiar with those talks, putting within reach a long-stalled agreement that many businesses hope will kick-start a global carbon market.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"COP26 Negotiators Make Progress on Carbon-Trading Rules. Companies hope a U.N.-backed framework for cross-border carbon markets will kick-start trading. GLASGOW-Climate negotiators have made progress toward a deal aimed at establishing the foundation of an international carbon-trading system, according to people familiar with those talks, putting within reach a long-stalled agreement that many businesses hope will kick-start a global carbon market.\"\n\nStock Prediction(s):", "Prediction": "\n- International Paper Co (NYSE: IP) will increase because they are a big player in the carbon market and this news signals progress in the COP26 negotiations.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they are a big player in the carbon market and this news signals progress in the COP26 negotiations.\n- BP plc (NYSE: BP) will increase because they are a big player in the carbon market and this news", "price_info": {"IP": {"company": "", "ticker": "IP", "move": "up", "prices": [49.88, 49.92]}, "BP": {"company": "", "ticker": "BP", "move": "up", "prices": [27.27, 27.27]}}}, {"link": "https://www.wsj.com/articles/trump-tariffs-are-short-term-pain-without-long-term-gain-economists-say-11560440436", "title": "Trump Tariffs Are Short-Term Pain Without Long-Term Gain, Economists Say", "date": "2019-06-13 11:40", "summary": "Nearly three-fourths of economists in WSJ survey said they expect short-term trade costs to outweigh any long-term benefits. Most economic forecasters are pessimistic that the Trump administration's trade-tariff policy will reap long-term benefits for the economy, according to The Wall Street Journal's latest monthly survey of economists.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump Tariffs Are Short-Term Pain Without Long-Term Gain, Economists Say. Nearly three-fourths of economists in WSJ survey said they expect short-term trade costs to outweigh any long-term benefits. Most economic forecasters are pessimistic that the Trump administration's trade-tariff policy will reap long-term benefits for the economy, according to The Wall Street Journal's latest monthly survey of economists.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DOW) will decrease because of the Trump tariffs.\n- The S&P 500 (NYSE: SPX) will decrease because of the Trump tariffs.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because of the Trump tariffs.", "price_info": {"DOW": {"company": "", "ticker": "DOW", "move": "down", "prices": [52.56, 52.72]}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/robinhood-joins-the-online-cash-war-11570556839", "title": "Robinhood Joins the Online Cash War", "date": "2019-10-08 13:47", "summary": "The move comes as e-brokers match the firm's zero-comission trading. Robinhood Markets Inc. said it would offer a new higher-yielding cash account, in a bid to grow from its commission-free trading roots as bigger rivals scrap trading fees.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Robinhood Joins the Online Cash War. The move comes as e-brokers match the firm's zero-comission trading. Robinhood Markets Inc. said it would offer a new higher-yielding cash account, in a bid to grow from its commission-free trading roots as bigger rivals scrap trading fees.\"\n\nStock Prediction(s):", "Prediction": "\n- Robinhood Markets Inc. (NASDAQ: Robinhood) will increase because they offer a new higher-yielding cash account.\n- Charles Schwab Corp. (NYSE: SCHW) will increase because they offer a new higher-yielding cash account.\n- TD Ameritrade Holding Corp. (NASDAQ: AMTD) will increase because they offer a new higher-yielding cash account.\n- E*Trade Financial Corp. (NASDAQ", "price_info": {"SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [35.24, 35.23]}, "AMTD": {"company": "", "ticker": "AMTD", "move": "up", "prices": [33.485, 33.64]}}}, {"link": "https://www.wsj.com/articles/boeing-737-max-electrical-problem-affects-more-locations-on-aircraft-11618599393", "title": "Boeing 737 MAX Electrical Problem Affects More Locations on Aircraft", "date": "2021-04-16 14:56", "summary": "Jet deliveries remain frozen as continuing inspections force airlines to reshuffle operations. The potential electrical problem that prompted airlines to remove dozens of 737 MAX jets from service last week affects more areas of the aircraft's flight deck than previously known, Boeing Co. said Friday.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing 737 MAX Electrical Problem Affects More Locations on Aircraft. Jet deliveries remain frozen as continuing inspections force airlines to reshuffle operations. The potential electrical problem that prompted airlines to remove dozens of 737 MAX jets from service last week affects more areas of the aircraft's flight deck than previously known, Boeing Co. said Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will decrease because this problem affects more locations on the aircraft and it will take longer to fix.\n- Airbus SE (EPA: AIR) will increase because this problem affects Boeing more and they are a direct competitor.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [248.4161, 247.93]}}}, {"link": "https://www.wsj.com/articles/fed-chairman-powell-says-u-s-economy-is-in-a-good-place-despite-some-risks-11570212010", "title": "Fed Chairman Says U.S. Economy Is 'In a Good Place' Despite Some Risks", "date": "2019-10-04 14:00", "summary": "Central-bank leader says Fed enjoys 'significant protections' from short-term political pressure. WASHINGTON-The U.S. economy faces some risks to growth but remains in a good place overall, Federal Reserve Chairman Jerome Powell said on Friday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Chairman Says U.S. Economy Is 'In a Good Place' Despite Some Risks. Central-bank leader says Fed enjoys 'significant protections' from short-term political pressure. WASHINGTON-The U.S. economy faces some risks to growth but remains in a good place overall, Federal Reserve Chairman Jerome Powell said on Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will stay the same because the Fed Chairman said that the economy is in a good place.", "price_info": {}}, {"link": "https://www.wsj.com/articles/twitter-to-add-labels-to-disputed-coronavirus-posts-as-misinformation-proliferates-11589226911", "title": "Twitter to Add Labels to Disputed Coronavirus Posts", "date": "2020-05-11 15:55", "summary": "New survey says 78% of Americans believe that false claims about the virus are a major problem. Twitter Inc. said it would start adding labels to tweets that have disputed information about the coronavirus, a step that comes as a new survey shows that 78% of Americans believe that misinformation about the virus is a major problem.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Twitter to Add Labels to Disputed Coronavirus Posts. New survey says 78% of Americans believe that false claims about the virus are a major problem. Twitter Inc. said it would start adding labels to tweets that have disputed information about the coronavirus, a step that comes as a new survey shows that 78% of Americans believe that misinformation about the virus is a major problem.\"\n\nStock Prediction(s):", "Prediction": "\n- Twitter Inc. (NYSE: TWTR) will increase because they are trying to combat the spread of false information about the virus.\n- Facebook Inc. (NASDAQ: FB) will decrease because they have been criticized for not doing enough to combat the spread of false information about the virus.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "up", "prices": [29.62, 29.6402]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [213.4, 213.58]}}}, {"link": "https://www.wsj.com/articles/estate-and-gift-taxes-2020-2021-heres-what-you-need-to-know-11617908256", "title": "Estate and Gift Taxes 2020-2021: Here's What You Need to Know", "date": "2021-04-08 14:57", "summary": "Most Popular News. The federal estate- and gift-tax exemption applies to the total of an individual's taxable gifts made during life and assets left at death. In 2017, Congress doubled the exemption starting in 2018, and the amount will continue to rise with inflation through 2025. This expansion reduced the number of taxable estates to about 3,000 in 2019 from about 8,000 in 2017, according to estimates by the Tax Policy Center.", "categories": [["Markets", "Personal Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/personal-finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Estate and Gift Taxes 2020-2021: Here's What You Need to Know. Most Popular News. The federal estate- and gift-tax exemption applies to the total of an individual's taxable gifts made during life and assets left at death. In 2017, Congress doubled the exemption starting in 2018, and the amount will continue to rise with inflation through 2025. This expansion reduced the number of taxable estates to about 3,000 in 2019 from about 8,000 in 2017, according to estimates by the Tax Policy Center.\"\n\nStock Prediction(s):", "Prediction": "\n- The exemption increase will continue to benefit estate and gift tax payers, and the number of taxable estates will continue to decline.\n- The exemption increase will benefit estate and gift tax payers, but the number of taxable estates will decline at a slower rate.\n- The exemption increase will not benefit estate and gift tax payers, and the number of taxable estates will increase.", "price_info": {}}, {"link": "https://www.wsj.com/articles/when-it-makes-sense-to-review-your-will-11581608714", "title": "When It Makes Sense to Review Your Will", "date": "2020-02-13 10:45", "summary": "Estate plans should get a second look amid any significant financial changes in your life or changes in estate-tax law. How often do you recommend we should review or consider revising our estate plans/wills?", "categories": [["Markets", "Journal Reports: Wealth Management"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-wealth-management?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"When It Makes Sense to Review Your Will. Estate plans should get a second look amid any significant financial changes in your life or changes in estate-tax law. How often do you recommend we should review or consider revising our estate plans/wills?\"\n\nStock Prediction(s):", "Prediction": "\n- The estate planning industry will increase because more people will want to review their wills in light of recent changes in the financial and estate-tax landscape.\n- The death care industry will increase because more people will want to make arrangements for their final wishes in light of recent changes in the financial and estate-tax landscape.", "price_info": {}}, {"link": "https://www.wsj.com/articles/considering-a-new-job-beware-a-culture-misfit-11579084201", "title": "Considering a New Job? Beware a Culture Misfit.", "date": "2020-01-15 10:26", "summary": "Not vetting the values of a prospective employer can lead to an early exit, but there are ways to do your homework. As a new year begins, you may be tempted to switch employers in this red-hot job market.", "categories": [["Business", "Management", "Your Executive Career"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/your-executive-career?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Considering a New Job? Beware a Culture Misfit.. Not vetting the values of a prospective employer can lead to an early exit, but there are ways to do your homework. As a new year begins, you may be tempted to switch employers in this red-hot job market.\"\n\nStock Prediction(s):", "Prediction": "\n- LinkedIn Corporation (NYSE: LNKD) will increase because more people will be looking for jobs, and LinkedIn is the best place to find them.\n- Workday, Inc. (NYSE: WDAY) will increase because more people will be looking for jobs, and Workday is the best place to find them.\n- Facebook, Inc. (NASDAQ: FB) will increase because more people will be looking for jobs, and Facebook is the best place", "price_info": {"LNKD": {"company": "", "ticker": "LNKD", "move": "up"}, "WDAY": {"company": "", "ticker": "WDAY", "move": "up", "prices": [179.695, 179.1059]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [221.18, 220.8]}}}, {"link": "https://www.wsj.com/articles/tesla-boldly-goes-where-no-auto-stock-has-gone-before-11579192151", "title": "Tesla Boldly Goes Where No Auto Stock Has Gone Before", "date": "2020-01-16 11:29", "summary": "Elon Musk has short sellers on the run, but the stock is as risky as ever. At long last, Tesla shares have reached another planet.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla Boldly Goes Where No Auto Stock Has Gone Before. Elon Musk has short sellers on the run, but the stock is as risky as ever. At long last, Tesla shares have reached another planet.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (TSLA) will continue to increase because Elon Musk is a genius and he has short sellers on the run.\n- Ford Motor Company (NYSE: F) will decrease because they are not as innovative as Tesla, and they are a direct competitor.\n- General Motors Company (NYSE: GM) will decrease because they are not as innovative as Tesla, and they are a direct competitor.", "price_info": {"TSLA": {"company": "Tesla, Inc.", "ticker": "TSLA", "move": "up", "prices": [501.2381, 503.4]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [9.218, 9.195]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [35.392, 35.44]}}}, {"link": "https://www.wsj.com/articles/aramco-shares-offer-a-stake-in-the-kingdom-11589290834", "title": "Aramco Shares Offer a Stake in the Kingdom", "date": "2020-05-12 09:40", "summary": "The world's largest listed company responded to the oil rout like any supermajor. The difference is that its taskmasters helped cause it.. Aramco's performance this year should dispel lingering hopes that buying shares in the petroleum giant is anything other than an investment in the Saudi state.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Aramco Shares Offer a Stake in the Kingdom. The world's largest listed company responded to the oil rout like any supermajor. The difference is that its taskmasters helped cause it.. Aramco's performance this year should dispel lingering hopes that buying shares in the petroleum giant is anything other than an investment in the Saudi state.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (NYSE: ARAMCO) will decrease because it is a state-owned company, and its performance this year has been dismal.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because it is a direct competitor of Saudi Aramco, and it has had a much better performance this year.", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [44.8689, 45.14]}}}, {"link": "https://www.wsj.com/articles/3m-loses-first-trial-over-military-earplugs-11619809398", "title": "3M Loses First Trial Over Military Earplugs", "date": "2021-04-30 15:41", "summary": "Federal jury awards $7.1 million to three veterans. 3M Co. lost the first lawsuit to go to trial over the safety of earplugs it sold for years to the military, with a federal jury Friday awarding $7.1 million to three veterans and finding the company failed to warn about defects in the product.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"3M Loses First Trial Over Military Earplugs. Federal jury awards $7.1 million to three veterans. 3M Co. lost the first lawsuit to go to trial over the safety of earplugs it sold for years to the military, with a federal jury Friday awarding $7.1 million to three veterans and finding the company failed to warn about defects in the product.\"\n\nStock Prediction(s):", "Prediction": "\n- 3M Co. (NYSE: MMM) will decrease because they have been found liable in a lawsuit and will have to pay out millions of dollars.", "price_info": {"MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [195.68, 195.33]}}}, {"link": "https://www.wsj.com/articles/gamestop-trader-roaring-kitty-and-former-employer-may-face-federal-regulatory-scrutiny-11612553349", "title": "GameStop Trader 'Roaring Kitty' May Face Regulatory Scrutiny", "date": "2021-02-05 14:29", "summary": "Keith Gill's videos and MassMutual's supervision are at issue, lawyers say. The Boston-area trader at the center of the past week's frenzy over GameStop Corp. , who also worked until last week as a broker, may face legal jeopardy for potential violations of federal rules governing brokers' communications with the public, according to securities lawyers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GameStop Trader 'Roaring Kitty' May Face Regulatory Scrutiny. Keith Gill's videos and MassMutual's supervision are at issue, lawyers say. The Boston-area trader at the center of the past week's frenzy over GameStop Corp. , who also worked until last week as a broker, may face legal jeopardy for potential violations of federal rules governing brokers' communications with the public, according to securities lawyers.\"\n\nStock Prediction(s):", "Prediction": "\n- Keith Gill (of Roaring Kitty) will be fined or even go to jail for his violations of federal rules.\n- GameStop Corp. (NYSE: GME) will decrease because of the negative publicity surrounding Keith Gill and Roaring Kitty.", "price_info": {"GME": {"company": "", "ticker": "GME", "move": "down", "prices": [60.04, 60.74]}}}, {"link": "https://www.wsj.com/articles/feds-evans-fed-has-moved-policy-to-slightly-accommodative-stance-11573052575", "title": "Fed's Evans: Fed Has Moved Policy to Slightly Accommodative Stance", "date": "2019-11-06 10:02", "summary": "The Chicago Fed leaders says his assessment of what is likely a neutral rate target may be closer to 2% now. Chicago Fed leader Charles Evans said Wednesday that the U.S. central bank has moved interest-rate policy to a place where it's modestly supportive of the economy.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans: Fed Has Moved Policy to Slightly Accommodative Stance. The Chicago Fed leaders says his assessment of what is likely a neutral rate target may be closer to 2% now. Chicago Fed leader Charles Evans said Wednesday that the U.S. central bank has moved interest-rate policy to a place where it's modestly supportive of the economy.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FED) will increase because they have shifted to a slightly accommodative stance.\n- The bond market will decrease because the Fed is increasing interest rates.", "price_info": {"FED": {"company": "", "ticker": "FED", "move": "down"}}}, {"link": "https://www.wsj.com/articles/former-google-self-driving-engineer-files-for-bankruptcy-11583384883", "title": "Ex-Google Self-Driving Engineer Files for Bankruptcy", "date": "2020-03-05 13:50", "summary": "Anthony Levandowski cites a $179 million legal judgment in dispute that involved Uber. Anthony Levandowski, the self-driving engineer accused by Google of breaching his employment contract and misusing confidential information, filed for bankruptcy, citing a $179 million legal judgment.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ex-Google Self-Driving Engineer Files for Bankruptcy. Anthony Levandowski cites a $179 million legal judgment in dispute that involved Uber. Anthony Levandowski, the self-driving engineer accused by Google of breaching his employment contract and misusing confidential information, filed for bankruptcy, citing a $179 million legal judgment.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because Anthony Levandowski, who is a former employee of Google, is now filing for bankruptcy.\n- Uber Technologies Inc. (NYSE: UBER) will increase because Anthony Levandowski, who is a former employee of Google, is now filing for bankruptcy.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because Anthony Levandowski, who is a former employee of Google,", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "up", "prices": [32.46, 32.089]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1336.46, 1309.42]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [732.788, 723.5298]}}}, {"link": "https://www.wsj.com/articles/ge-breakup-bets-on-flying-revival-11636572352", "title": "GE Breakup Bets on Flying Revival", "date": "2021-11-10 14:25", "summary": "Aviation company emerging from deals plays market-leading role in supplying jet engines to industry recovering from the pandemic. General Electric Co.'s planned breakup would create an aviation-focused company that is more closely tied to the travel industry, as it works to rebound from the Covid-19 pandemic's impact on flying.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GE Breakup Bets on Flying Revival. Aviation company emerging from deals plays market-leading role in supplying jet engines to industry recovering from the pandemic. General Electric Co.'s planned breakup would create an aviation-focused company that is more closely tied to the travel industry, as it works to rebound from the Covid-19 pandemic's impact on flying.\"\n\nStock Prediction(s):", "Prediction": "\n- GE Aviation (NYSE: GE) will increase because they are the market-leading supplier of jet engines, and the aviation industry is recovering from the pandemic.\n- GE Power (NYSE: GE) will decrease because they are not as closely tied to the aviation industry, and they are not as closely tied to the travel industry.", "price_info": {"GE": {"company": "", "ticker": "GE", "move": "down", "prices": [109.27, 108.815]}}}, {"link": "https://www.wsj.com/articles/how-does-an-fsa-work-11608243505", "title": "What Is an FSA and How Does It Work?", "date": "2021-02-23 15:44", "summary": "Most Popular News. If you are starting a new job or going through open enrollment, you might see an option to open an FSA. While it makes sense for some people to put aside money pretax to spend on qualified expenses, the accounts aren't right for everyone.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What Is an FSA and How Does It Work?. Most Popular News. If you are starting a new job or going through open enrollment, you might see an option to open an FSA. While it makes sense for some people to put aside money pretax to spend on qualified expenses, the accounts aren't right for everyone.\"\n\nStock Prediction(s):", "Prediction": "\n- FSA accounts will become more popular because they offer tax benefits and people are looking for ways to save money.\n- The companies that offer FSA accounts will benefit because more people will be using their services.\n- The companies that do not offer FSA accounts will lose out because people will go to their competitors who do offer the accounts.", "price_info": {}}, {"link": "https://www.wsj.com/articles/economic-data-to-watch-for-signs-of-coronavirus-impact-11583946110", "title": "Economic Data to Watch for Signs of Coronavirus Impact", "date": "2020-03-11 13:04", "summary": "So far, private-sector and government economic surveys have reflected conditions before concerns of the infection's potential economic impact rose. The impact of the novel coronavirus is rippling through U.S. and global economies, but it could take a few months to fully see the fallout in data that tracks economic performance around the world.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Economic Data to Watch for Signs of Coronavirus Impact. So far, private-sector and government economic surveys have reflected conditions before concerns of the infection's potential economic impact rose. The impact of the novel coronavirus is rippling through U.S. and global economies, but it could take a few months to fully see the fallout in data that tracks economic performance around the world.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DJI) will decrease because of the potential economic impact of the novel coronavirus.\n- The S&P 500 (NYSE: SPX) will decrease because of the potential economic impact of the novel coronavirus.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because of the potential economic impact of the novel coronavirus.", "price_info": {"DJI": {"company": "", "ticker": "DJI", "move": "down"}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/investors-approve-utc-raytheon-merger-11570801608", "title": "Investors Approve UTC-Raytheon Merger", "date": "2019-10-11 10:03", "summary": "The $135 billion combination will create the world's second-largest defense company pending regulatory approval. Shareholders backed the creation of one of the world's largest aerospace companies on Friday, voting in favor of the $135 billion combination of United Technologies Corp. and Raytheon Co.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors Approve UTC-Raytheon Merger. The $135 billion combination will create the world's second-largest defense company pending regulatory approval. Shareholders backed the creation of one of the world's largest aerospace companies on Friday, voting in favor of the $135 billion combination of United Technologies Corp. and Raytheon Co.\"\n\nStock Prediction(s):", "Prediction": "\n- United Technologies Corporation (NYSE: UTX) will increase because they are creating the world's second-largest defense company.\n- Raytheon Co. (NYSE: RTN) will increase because they are creating the world's second-largest defense company.", "price_info": {"UTX": {"company": "", "ticker": "UTX", "move": "up", "prices": [135.96, 136.15]}, "RTN": {"company": "", "ticker": "RTN", "move": "up", "prices": [199.05, 198.14]}}}, {"link": "https://www.wsj.com/articles/fidelity-is-latest-to-cut-online-trading-commissions-to-zero-11570680060", "title": "Fidelity Cuts Online Trading Commissions to Zero", "date": "2019-10-10 10:24", "summary": "Wall Street's digitization has reset many of the fundamental costs of investing. Fidelity Investments eliminated trading commissions on its online brokerage, matching a step some of its biggest rivals unveiled last week.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fidelity Cuts Online Trading Commissions to Zero. Wall Street's digitization has reset many of the fundamental costs of investing. Fidelity Investments eliminated trading commissions on its online brokerage, matching a step some of its biggest rivals unveiled last week.\"\n\nStock Prediction(s):", "Prediction": "\n- Fidelity Investments (NYSE: FIS) will increase because they have lowered their trading commissions to zero.\n- Charles Schwab Corp (NYSE: SCHW) will increase because they have lowered their trading commissions to zero.\n- TD Ameritrade Holding Corp (NASDAQ: AMTD) will increase because they have lowered their trading commissions to zero.\n- E*Trade Financial Corp (NASDAQ: ETFC) will increase because they have lowered their trading", "price_info": {"FIS": {"company": "", "ticker": "FIS", "move": "up", "prices": [132.02, 131.51]}, "SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [36.35, 36.18]}, "AMTD": {"company": "", "ticker": "AMTD", "move": "up", "prices": [34.39, 34.35]}, "ETFC": {"company": "", "ticker": "ETFC", "move": "up", "prices": [38.655, 38.66]}}}, {"link": "https://www.wsj.com/articles/google-parent-alphabet-stock-split-11643761853", "title": "What Alphabet's Stock Split Means", "date": "2022-02-02 10:01", "summary": "Alphabet announced plans for a 20-for-1 stock split as part of the technology company's quarterly earnings statement. Google parent Alphabet Inc . said on Feb. 1 that it will enact a 20-for-1 stock split, giving shareholders 19 more shares for every one they own.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What Alphabet's Stock Split Means. Alphabet announced plans for a 20-for-1 stock split as part of the technology company's quarterly earnings statement. Google parent Alphabet Inc . said on Feb. 1 that it will enact a 20-for-1 stock split, giving shareholders 19 more shares for every one they own.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc (NASDAQ: GOOGL) will increase because they are splitting their stock 20-for-1, which will give shareholders more shares.\n- Other technology companies will also increase because this news will cause investors to invest in the technology sector as a whole.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2976.22, 2945]}}}, {"link": "https://www.wsj.com/articles/cars-and-chips-will-only-get-closer-11637263396", "title": "Cars and Chips Will Only Get Closer", "date": "2021-11-18 14:23", "summary": "Ford might end up designing chips that GlobalFoundries will build for next-generation electric vehicles. Ford 's collaboration with GlobalFoundries is likely the first of many between the semiconductor industry and car companies intent on tailing Tesla . Just don't expect Detroit to actually make microchips.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Cars and Chips Will Only Get Closer. Ford might end up designing chips that GlobalFoundries will build for next-generation electric vehicles. Ford 's collaboration with GlobalFoundries is likely the first of many between the semiconductor industry and car companies intent on tailing Tesla . Just don't expect Detroit to actually make microchips.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because they are working on a collaboration with GlobalFoundries to build chips for electric vehicles.\n- GlobalFoundries Inc. (NYSE: GF) will increase because they are working with Ford Motor Company to build chips for electric vehicles.", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [19.435, 19.54]}, "GF": {"company": "", "ticker": "GF", "move": "up"}}}, {"link": "https://www.wsj.com/articles/return-to-the-road-drives-oil-price-to-largest-ever-monthly-gain-11591032674", "title": "Return to the Road Drives Oil Price to Largest Ever Monthly Gain", "date": "2020-06-01 15:15", "summary": "Domestic inventories were drawn down sharply in May as producers choked back output and drivers returned. U.S. oil prices notched their largest monthly gains on record in May, recovering a big chunk of the losses caused in March and April when the country went into lockdown to counter the spread of the coronavirus.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Return to the Road Drives Oil Price to Largest Ever Monthly Gain. Domestic inventories were drawn down sharply in May as producers choked back output and drivers returned. U.S. oil prices notched their largest monthly gains on record in May, recovering a big chunk of the losses caused in March and April when the country went into lockdown to counter the spread of the coronavirus.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because they are one of the largest producers of oil in the United States, and they have been able to increase their production in May.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are one of the largest producers of oil in the United States, and they have been able to increase their production in May.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [92.79, 92.75]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [46.25, 46.25]}}}, {"link": "https://www.wsj.com/articles/netflix-pays-for-serenity-now-11568738576", "title": "Netflix Pays for Serenity Now", "date": "2019-09-17 12:44", "summary": "Netflix spends to stream 'Seinfeld.' Will it bring disappointment or a Festivus miracle?. Is Netflix crazy, or is it so sane that you just blew your mind?", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Netflix Pays for Serenity Now. Netflix spends to stream 'Seinfeld.' Will it bring disappointment or a Festivus miracle?. Is Netflix crazy, or is it so sane that you just blew your mind?\"\n\nStock Prediction(s):", "Prediction": "\n- Netflix, Inc. (NASDAQ: NFLX) will continue to increase because they are spending money to stream 'Seinfeld.' This will bring in new subscribers and keep current subscribers happy.\n- Sony Corporation (NYSE: SNE) will decrease because they own the rights to 'Seinfeld' and are not getting the same benefits as Netflix.", "price_info": {"SNE": {"company": "", "ticker": "SNE", "move": "down", "prices": [59.665, 59.77]}, "NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [297.2, 297.85]}}}, {"link": "https://www.wsj.com/articles/fortnite-worries-continue-to-blow-away-game-makers-11549475203", "title": "'Fortnite' Worries Continue to Blow Away Game Makers", "date": "2019-02-06 12:46", "summary": "Projections from Electronic Arts and Take-Two Interactive suggest competition from free-to-play blockbuster remains hot. Making a great videogame is hard enough. Making a great one that will print money for years to come is harder still-especially now.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'Fortnite' Worries Continue to Blow Away Game Makers. Projections from Electronic Arts and Take-Two Interactive suggest competition from free-to-play blockbuster remains hot. Making a great videogame is hard enough. Making a great one that will print money for years to come is harder still-especially now.\"\n\nStock Prediction(s):", "Prediction": "\n- Electronic Arts, Inc. (NASDAQ: EA) will decrease because their main competitor is Fortnite, which is free to play.\n- Take-Two Interactive Software, Inc. (NASDAQ: TTWO) will decrease because their main competitor is Fortnite, which is free to play.", "price_info": {"EA": {"company": "", "ticker": "EA", "move": "down", "prices": [80.055, 81.2601]}, "TTWO": {"company": "", "ticker": "TTWO", "move": "down", "prices": [93.275, 92.8784]}}}, {"link": "https://www.wsj.com/articles/gates-foundation-pledges-2-1-billion-for-gender-equality-11625061602", "title": "Gates Foundation Pledges $2.1 Billion for Gender Equality", "date": "2021-06-30 10:00", "summary": "Melinda French Gates has made women's empowerment a priority at the foundation and her company. The Gates Foundation said it would spend $2.1 billion on gender-equality work over five years, deepening a commitment to programs long championed by Melinda French Gates weeks after the philanthropy's guiding couple announced their divorce.", "categories": [["WSJ News Exclusive", "U.S."]], "category_links": ["https://www.wsj.com/news/us?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gates Foundation Pledges $2.1 Billion for Gender Equality. Melinda French Gates has made women's empowerment a priority at the foundation and her company. The Gates Foundation said it would spend $2.1 billion on gender-equality work over five years, deepening a commitment to programs long championed by Melinda French Gates weeks after the philanthropy's guiding couple announced their divorce.\"\n\nStock Prediction(s):", "Prediction": "\n- The Gates Foundation (NASDAQ: GFTX) will increase because they are pledging more money to gender equality.\n- Melinda French Gates (private) will increase because she is a major advocate for gender equality and has been working on it for many years.", "price_info": {"GFTX": {"company": "", "ticker": "GFTX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/chinese-tech-giant-meituan-logs-another-loss-despite-sales-jump-11630335356", "title": "Chinese Tech Giant Meituan Logs Another Loss Despite Sales Jump", "date": "2021-08-30 10:55", "summary": "Under pressure amid crackdown, CEO says 'fine-tuning' of business will be long-term positive. Chinese food-delivery giant Meituan reported another big jump in quarterly revenue, as more people turned to it to order meals and groceries, but the company remained unprofitable for a third consecutive quarter as it spent heavily to expand.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chinese Tech Giant Meituan Logs Another Loss Despite Sales Jump. Under pressure amid crackdown, CEO says 'fine-tuning' of business will be long-term positive. Chinese food-delivery giant Meituan reported another big jump in quarterly revenue, as more people turned to it to order meals and groceries, but the company remained unprofitable for a third consecutive quarter as it spent heavily to expand.\"\n\nStock Prediction(s):", "Prediction": "\n- Meituan Dianping (NASDAQ: MEIT) will continue to decrease because they are not yet profitable and are spending a lot of money to expand.", "price_info": {"MEIT": {"company": "", "ticker": "MEIT", "move": "down"}}}, {"link": "https://www.wsj.com/articles/gold-inches-lower-after-upbeat-consumer-spending-data-11556544327", "title": "Gold Drops After Upbeat Consumer Spending Data", "date": "2019-04-29 14:35", "summary": "Confidence in U.S. economic growth has hurt gold by boosting stocks and other risk assets. Gold prices fell Monday, pulling back after data showed U.S. consumer spending picked up in March.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold Drops After Upbeat Consumer Spending Data. Confidence in U.S. economic growth has hurt gold by boosting stocks and other risk assets. Gold prices fell Monday, pulling back after data showed U.S. consumer spending picked up in March.\"\n\nStock Prediction(s):", "Prediction": "\n- Gold prices will continue to drop because of increasing confidence in the U.S. economy.\n- Stocks will continue to rise because of increasing confidence in the U.S. economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/blue-apron-delivers-better-margins-as-business-shrinks-11556628024", "title": "Blue Apron Delivers Better Margins as Business Shrinks", "date": "2019-04-30 09:56", "summary": "Meal-kit maker continues to shed customers. Blue Apron Holdings Inc. posted its first quarterly profit by one key metric since going public nearly two years ago but continued to lose customers for its meal kits.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Blue Apron Delivers Better Margins as Business Shrinks. Meal-kit maker continues to shed customers. Blue Apron Holdings Inc. posted its first quarterly profit by one key metric since going public nearly two years ago but continued to lose customers for its meal kits.\"\n\nStock Prediction(s):", "Prediction": "\n- Blue Apron Holdings Inc. (NYSE: APRN) will continue to lose customers because their business is shrinking.", "price_info": {"APRN": {"company": "", "ticker": "APRN", "move": null, "prices": [1.01, 1.0166]}}}, {"link": "https://www.wsj.com/articles/government-bond-yields-slide-as-investors-grapple-with-muddied-economic-picture-11621606864", "title": "Government Bond Yields Fall as Investors Grapple With Muddied Economic Picture", "date": "2021-05-21 13:42", "summary": "Treasurys and European government bond yields dip after a volatile week of trading. Government bond yields in the U.S. and Europe are ending the week on a downward note with investors seeking safety after a volatile few days in stocks, bonds and cryptocurrencies.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Government Bond Yields Fall as Investors Grapple With Muddied Economic Picture. Treasurys and European government bond yields dip after a volatile week of trading. Government bond yields in the U.S. and Europe are ending the week on a downward note with investors seeking safety after a volatile few days in stocks, bonds and cryptocurrencies.\"\n\nStock Prediction(s):", "Prediction": "\n- The bond market will continue to be volatile as investors try to figure out the best place to put their money.\n- The bond market will rebound next week as investors become more comfortable with the current state of the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/marathon-digital-occidental-southwest-merck-what-to-watch-when-the-stock-market-opens-today-11633949267", "title": "Marathon Digital, Occidental, Southwest: What to Watch When the Stock Market Opens Today", "date": "2021-10-11 09:45", "summary": "Bond markets are closed for a federal holiday, but the stock market is open for business. Wall Street indexes wavered after the opening bell, while energy commodities are extending gains. Here's what we're watching ahead of Monday's market open.", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Marathon Digital, Occidental, Southwest: What to Watch When the Stock Market Opens Today. Bond markets are closed for a federal holiday, but the stock market is open for business. Wall Street indexes wavered after the opening bell, while energy commodities are extending gains. Here's what we're watching ahead of Monday's market open.\"\n\nStock Prediction(s):", "Prediction": "\n- Marathon Petroleum Corporation (NYSE: MPC) will increase because they are a direct competitor of Occidental Petroleum Corporation (NYSE: OXY) and they have a good chance of winning the bidding war.\n- Occidental Petroleum Corporation (NYSE: OXY) will decrease because they are a direct competitor of Marathon Petroleum Corporation (NYSE: MPC) and they have a good chance of losing the bidding war.\n- Southwest Airlines Co (NYSE: LUV) will", "price_info": {"MPC": {"company": "", "ticker": "MPC", "move": "up", "prices": [65.58, 65.22]}, "OXY": {"company": "", "ticker": "OXY", "move": "down", "prices": [34.455, 34.26]}, "LUV": {"company": "", "ticker": "LUV", "move": null, "prices": [52.9422, 53.2006]}}}, {"link": "https://www.wsj.com/articles/what-to-expect-from-5g-phonesand-when-11551208337", "title": "What to Expect From 5G Phones-and When", "date": "2019-02-26 14:18", "summary": "The early ones will be expensive, and they may not change the mobile experience. So, should you wait to buy one?. Here come the 5G smartphones. Sort of.", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What to Expect From 5G Phones-and When. The early ones will be expensive, and they may not change the mobile experience. So, should you wait to buy one?. Here come the 5G smartphones. Sort of.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are releasing a 5G phone in September, and this will be a major selling point for them.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will increase because they are releasing a 5G phone in September, and this will be a major selling point for them.\n- Huawei Technologies Co Ltd (OTC: HWTFF) will increase because they are releasing a 5", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [174.3101, 174.495]}}}, {"link": "https://www.wsj.com/articles/theranos-trial-judge-narrows-case-against-founder-elizabeth-holmes-11581540190", "title": "Theranos Trial's Judge Narrows Case Against Founder Elizabeth Holmes", "date": "2020-02-12 15:47", "summary": "Prosecutors won't be allowed to argue that doctors, insured patients were fraud victims. The judge overseeing a criminal trial against Theranos Inc. founder Elizabeth Holmes and a former top executive at the company narrowed the scope of the charges by ruling that prosecutors can't argue that doctors and insured patients were defrauded.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Theranos Trial's Judge Narrows Case Against Founder Elizabeth Holmes. Prosecutors won't be allowed to argue that doctors, insured patients were fraud victims. The judge overseeing a criminal trial against Theranos Inc. founder Elizabeth Holmes and a former top executive at the company narrowed the scope of the charges by ruling that prosecutors can't argue that doctors and insured patients were defrauded.\"\n\nStock Prediction(s):", "Prediction": "\n- Elizabeth Holmes will be found not guilty because the judge ruled that prosecutors can't argue that doctors and insured patients were defrauded.\n- Theranos Inc. will decrease because this is another blow to the company, and they are already in a lot of trouble.", "price_info": {}}, {"link": "https://www.wsj.com/articles/tyson-says-it-hasnt-seen-major-benefits-from-swine-fever-in-china-11565007688", "title": "Tyson Discloses Justice Department Subpoena in Chicken-Pricing Probe", "date": "2019-08-05 15:21", "summary": "Top U.S. meat company faces allegations of colluding with other poultry producers. Tyson Foods Inc. and other major chicken companies said they received subpoenas from the Justice Department, signaling an expansion of a criminal investigation into allegations they colluded to prop up prices.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tyson Discloses Justice Department Subpoena in Chicken-Pricing Probe. Top U.S. meat company faces allegations of colluding with other poultry producers. Tyson Foods Inc. and other major chicken companies said they received subpoenas from the Justice Department, signaling an expansion of a criminal investigation into allegations they colluded to prop up prices.\"\n\nStock Prediction(s):", "Prediction": "\n- Tyson Foods Inc. (NYSE: TSN) will decrease because they are being investigated for price collusion.\n- Pilgrim's Pride Corp. (NASDAQ: PPC) will decrease because they are being investigated for price collusion.\n- Sanderson Farms, Inc. (NASDAQ: SAFM) will decrease because they are being investigated for price collusion.", "price_info": {"TSN": {"company": "", "ticker": "TSN", "move": "down", "prices": [84.5, 83.95]}, "PPC": {"company": "", "ticker": "PPC", "move": "down"}, "SAFM": {"company": "", "ticker": "SAFM", "move": "down"}}}, {"link": "https://www.wsj.com/articles/levis-cfo-looks-to-bring-down-debt-further-as-business-recovers-11626362954", "title": "Levi's CFO Looks to Bring Down Debt Further as Business Recovers", "date": "2021-07-15 11:29", "summary": "Bond repayment and refinancing bring down annual interest costs by about $20 million a year, says Harmit Singh. Levi Strauss & Co. is working to pay down the debt that the jeans maker took on during the onset of the pandemic, finance chief Harmit Singh said, joining other publicly traded companies that have reduced their financial obligations.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Levi's CFO Looks to Bring Down Debt Further as Business Recovers. Bond repayment and refinancing bring down annual interest costs by about $20 million a year, says Harmit Singh. Levi Strauss & Co. is working to pay down the debt that the jeans maker took on during the onset of the pandemic, finance chief Harmit Singh said, joining other publicly traded companies that have reduced their financial obligations.\"\n\nStock Prediction(s):", "Prediction": "\n- Levi Strauss & Co. (NYSE: LEVI) will increase because they are working to pay down their debt, and this will bring down their annual interest costs.\n- Nike Inc. (NYSE: NKE) will decrease because they are also working on a debt pay down plan, but they are a direct competitor of Levi Strauss.", "price_info": {"LEVI": {"company": "", "ticker": "LEVI", "move": "down", "prices": [28.7584, 28.2]}, "NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [161.63, 161.4]}}}, {"link": "https://www.wsj.com/articles/offshore-oil-rig-operator-noble-cleared-to-exit-chapter-11-11605915057", "title": "Offshore Oil-Rig Operator Noble Cleared to Exit Chapter 11", "date": "2020-11-23 11:16", "summary": "Noble will transfer control of business to bondholders and trim more than $3 billion in debt. Noble Corp. , an operator of offshore oil-and-gas drilling rigs, was cleared to exit bankruptcy with a plan that transfers control of the business to its bondholders and trims more than $3 billion in debt.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Offshore Oil-Rig Operator Noble Cleared to Exit Chapter 11. Noble will transfer control of business to bondholders and trim more than $3 billion in debt. Noble Corp. , an operator of offshore oil-and-gas drilling rigs, was cleared to exit bankruptcy with a plan that transfers control of the business to its bondholders and trims more than $3 billion in debt.\"\n\nStock Prediction(s):", "Prediction": "\n- Noble Corp. (NYSE: NE) will increase because they are coming out of Chapter 11 and have a plan to reduce their debt by $3 billion.\n- Transocean Ltd. (NYSE: RIG) will decrease because they are a direct competitor of Noble Corp.", "price_info": {"NE": {"company": "", "ticker": "NE", "move": "up"}, "RIG": {"company": "", "ticker": "RIG", "move": "down", "prices": [1.58, 1.6281]}}}, {"link": "https://www.wsj.com/articles/pulitzer-prizes-highlight-coverage-related-to-george-floyd-killing-covid-19-11623436044", "title": "Pulitzer Prizes Highlight Coverage Related to Floyd Killing, Covid-19", "date": "2021-06-11 14:27", "summary": "New York Times, Boston Globe and Minneapolis's Star Tribune are among this year's winners. Multiple news outlets won Pulitzer Prizes for their coverage of the killing of George Floyd and work related to the Covid-19 pandemic, Columbia University announced Friday.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pulitzer Prizes Highlight Coverage Related to Floyd Killing, Covid-19. New York Times, Boston Globe and Minneapolis's Star Tribune are among this year's winners. Multiple news outlets won Pulitzer Prizes for their coverage of the killing of George Floyd and work related to the Covid-19 pandemic, Columbia University announced Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- The New York Times Company (NYSE: NYT) will increase because they have been winning Pulitzer Prizes for their Covid-19 coverage.\n- The Boston Globe (NYSE: BGC) will increase because they have been winning Pulitzer Prizes for their Covid-19 coverage.\n- The Minneapolis Star Tribune (NYSE: MSP) will increase because they have been winning Pulitzer Prizes for their Covid-19 coverage.", "price_info": {"NYT": {"company": "", "ticker": "NYT", "move": "up", "prices": [41.465, 41.46]}, "BGC": {"company": "", "ticker": "BGC", "move": "up"}, "MSP": {"company": "", "ticker": "MSP", "move": "up"}}}, {"link": "https://www.wsj.com/articles/global-drop-in-currencies-bruises-investors-11568194207", "title": "Global Currency Decline Bruises Investors", "date": "2019-09-11 11:35", "summary": "Economic concern and U.S.-China trade dispute ripple through markets. Currencies around the world are tumbling to multiyear lows, bruising investors' portfolios and fanning the flames of a global trade war.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Global Currency Decline Bruises Investors. Economic concern and U.S.-China trade dispute ripple through markets. Currencies around the world are tumbling to multiyear lows, bruising investors' portfolios and fanning the flames of a global trade war.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because of the global currency decline.\n- Boeing (NYSE: BA) will go down because of the global currency decline.\n- Apple (NASDAQ: AAPL) will go down because of the global currency decline.\n- Amazon (NASDAQ: AMZN) will go down because of the global currency decline.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [380.5, 381.25]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [222.39, 222.67]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1831.7915, 1828.81]}}}, {"link": "https://www.wsj.com/articles/chip-makers-still-await-clearance-to-sell-to-huawei-11568120167", "title": "Chip Makers Still Await Clearance to Sell to Huawei", "date": "2019-09-10 11:57", "summary": "Trump promised to grant exemptions to a blacklist against the Chinese telecom giant, but that pledge remains unfulfilled. More than two months after President Trump agreed to ease export restrictions on Huawei Technologies Co., the U.S. has yet to green-light any sales to the Chinese telecom giant-frustrating U.S. chip makers that stand to lose billions of dollars in revenue.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chip Makers Still Await Clearance to Sell to Huawei. Trump promised to grant exemptions to a blacklist against the Chinese telecom giant, but that pledge remains unfulfilled. More than two months after President Trump agreed to ease export restrictions on Huawei Technologies Co., the U.S. has yet to green-light any sales to the Chinese telecom giant-frustrating U.S. chip makers that stand to lose billions of dollars in revenue.\"\n\nStock Prediction(s):", "Prediction": "\n- Qualcomm Incorporated (NASDAQ: QCOM) will decrease because they are a direct competitor of Huawei and they will lose out on a lot of revenue.\n- Intel Corporation (NASDAQ: INTC) will decrease because they are a direct competitor of Huawei and they will lose out on a lot of revenue.\n- Broadcom Inc (NASDAQ: AVGO) will decrease because they are a direct competitor of Huawei and they will lose out on a lot of", "price_info": {"QCOM": {"company": "", "ticker": "QCOM", "move": "down", "prices": [78.585, 78.39]}, "INTC": {"company": "", "ticker": "INTC", "move": "down", "prices": [51.335, 51.56]}, "AVGO": {"company": "", "ticker": "AVGO", "move": "down", "prices": [293.02, 293.675]}}}, {"link": "https://www.wsj.com/articles/dollar-climbs-on-renewed-fears-of-pandemics-cost-11586955073", "title": "Dollar Climbs on Renewed Fears of Pandemic's Cost", "date": "2020-04-15 12:35", "summary": "Greenback rises against other safe-haven currencies including the yen and the Swiss franc. The dollar rallied against most currencies Wednesday as concerns about the economic impact of the coronavirus pandemic and the lack of a global policy response fueled investors' jitters.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Dollar Climbs on Renewed Fears of Pandemic's Cost. Greenback rises against other safe-haven currencies including the yen and the Swiss franc. The dollar rallied against most currencies Wednesday as concerns about the economic impact of the coronavirus pandemic and the lack of a global policy response fueled investors' jitters.\"\n\nStock Prediction(s):", "Prediction": "\n- The dollar will continue to increase because of the renewed fears of the pandemic's cost.\n- The yen (JPY) and the Swiss franc (CHF) will continue to decrease because the dollar is a safer investment.", "price_info": {"JPY": {"company": "", "ticker": "JPY", "move": "up"}, "CHF": {"company": "", "ticker": "CHF", "move": "down"}}}, {"link": "https://www.wsj.com/articles/eus-top-court-restricts-personal-data-transfers-to-u-s-citing-surveillance-concerns-11594888385", "title": "EU's Top Court Restricts Personal-Data Transfers to U.S.", "date": "2020-07-16 09:47", "summary": "Surprise ruling will potentially disrupt operations for thousands of multinational companies. Thousands of companies will face restrictions on storing information about European Union residents on U.S. servers, after the bloc's top court ruled that such transfers exposed Europeans to American government surveillance without \"actionable rights\" to challenge it.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"EU's Top Court Restricts Personal-Data Transfers to U.S.. Surprise ruling will potentially disrupt operations for thousands of multinational companies. Thousands of companies will face restrictions on storing information about European Union residents on U.S. servers, after the bloc's top court ruled that such transfers exposed Europeans to American government surveillance without \"actionable rights\" to challenge it.\"\n\nStock Prediction(s):", "Prediction": "\n- International Business Machines Corporation (NYSE: IBM) will decrease because they are a direct competitor of many of the companies that will be affected by this ruling.\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because they are a direct competitor of many of the companies that will be affected by this ruling.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are a direct competitor of many of the companies that will be", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "down", "prices": [123.86, 123.78]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [204.92, 203.06]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [2942.77, 2950.64]}}}, {"link": "https://www.wsj.com/articles/got-freelance-income-make-these-tax-moves-now-11575628211", "title": "If You Have a Side Hustle, You Should Make These Tax Moves Now", "date": "2019-12-10 11:27", "summary": "More Americans are joining the ranks of freelancers and gig workers. They face daunting tax issues but also get special breaks.. This message is for all you freelancers, gig workers, lodging hosts, online sellers, consultants, independent contractors and others who are in business for yourselves:", "categories": [["Markets", "Tax Report"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/tax-report?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"If You Have a Side Hustle, You Should Make These Tax Moves Now. More Americans are joining the ranks of freelancers and gig workers. They face daunting tax issues but also get special breaks.. This message is for all you freelancers, gig workers, lodging hosts, online sellers, consultants, independent contractors and others who are in business for yourselves:\"\n\nStock Prediction(s):", "Prediction": "\n- The tax moves mentioned will benefit those in the \"gig\" economy, and will cause a rise in the stock prices of companies that provide services to this group, such as Intuit Inc. (NASDAQ: INTU) and Square Inc. (NYSE: SQ).\n- The tax moves mentioned will also benefit those who have a side hustle, and will cause a rise in the stock prices of companies that provide products and services to this group, such as", "price_info": {"SQ": {"company": "", "ticker": "SQ", "move": "up", "prices": [65.8, 65.485]}, "INTU": {"company": "", "ticker": "INTU", "move": "up", "prices": [254.5261, 254.51]}}}, {"link": "https://www.wsj.com/articles/iphone-airpods-macbook-you-live-in-apples-world-heres-what-you-are-missing-11622817653", "title": "If You Live in Apple's World, Here's What You're Missing", "date": "2021-06-04 10:40", "summary": "Apple's closed ecosystem of hardware and software has resulted in some wonderful products. But the company's walled garden also keeps you trapped in a digital world that may stifle innovation and boost prices.. Gather around, everyone, for the story of the $2 trillion Not-So-Secret Garden:", "categories": [["Tech", "Personal Tech", "Personal Technology: Joanna Stern"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"If You Live in Apple's World, Here's What You're Missing. Apple's closed ecosystem of hardware and software has resulted in some wonderful products. But the company's walled garden also keeps you trapped in a digital world that may stifle innovation and boost prices.. Gather around, everyone, for the story of the $2 trillion Not-So-Secret Garden:\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they have a closed ecosystem that boosts prices and stifles innovation.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are the antithesis of Apple and promote innovation and lower prices.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [125.2031, 125.5209]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3214.3, 3216.28]}}}, {"link": "https://www.wsj.com/articles/carlos-ghosn-offers-to-accept-camera-surveillance-in-bid-for-bail-11551699201", "title": "Ghosn Offers to Accept Camera Surveillance in Bid for Bail", "date": "2019-03-04 11:59", "summary": "Former Nissan chairman determined to win bail after having two earlier applications turned down, lawyer says. TOKYO-A new bail application for Carlos Ghosn includes an offer for him to be monitored by surveillance cameras to ensure he doesn't flee Japan or tamper with evidence, his lawyer said.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ghosn Offers to Accept Camera Surveillance in Bid for Bail. Former Nissan chairman determined to win bail after having two earlier applications turned down, lawyer says. TOKYO-A new bail application for Carlos Ghosn includes an offer for him to be monitored by surveillance cameras to ensure he doesn't flee Japan or tamper with evidence, his lawyer said.\"\n\nStock Prediction(s):", "Prediction": "\n- Nissan Motor Co Ltd (TSE: 7201) will increase because Ghosn is a former chairman, and he is determined to win bail.\n- Renault SA (EPA: RNO) will increase because Ghosn is a former chairman, and he is determined to win bail.\n- Mitsubishi Motors Corp (TSE: 7211) will increase because Ghosn is a former chairman, and he is determined to win bail.\n-", "price_info": {}}, {"link": "https://www.wsj.com/articles/turkey-blocks-foreign-banks-in-attempt-to-stem-currency-slide-11588875084", "title": "Turkey Blocks Foreign Banks in Attempt to Stem Currency Slide", "date": "2020-05-07 14:11", "summary": "Citigroup, BNP Paribas and UBS are blocked from processing lira transactions as Turkey's currency hits a record low against the dollar. Turkey blocked three international banks from trading its currency Thursday, an effort to stymie investors who are betting that the country's weak financial standing will continue to deteriorate.", "categories": [["Markets", "Currencies", "Foreign Exchange"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/currencies?mod=breadcrumb", "https://www.wsj.com/news/types/foreign-exchange?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Turkey Blocks Foreign Banks in Attempt to Stem Currency Slide. Citigroup, BNP Paribas and UBS are blocked from processing lira transactions as Turkey's currency hits a record low against the dollar. Turkey blocked three international banks from trading its currency Thursday, an effort to stymie investors who are betting that the country's weak financial standing will continue to deteriorate.\"\n\nStock Prediction(s):", "Prediction": "\n- Turkish banks (such as Turkiye Is Bankasi AS (ISBA.IS), Turkiye Garanti Bankasi AS (GARAN.IS), Akbank TAS (AKBNK.IS)) will decrease because of the block on foreign banks.\n- Other international banks (such as JPMorgan Chase & Co. (NYSE: JPM), Bank of America Corp. (NYSE: BAC), Goldman Sachs Group Inc. (NYSE: GS))", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [91.1581, 91.33]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [22.87, 22.8898]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [182.175, 182.14]}}}, {"link": "https://www.wsj.com/articles/how-to-secretly-watch-the-office-at-the-office-11567173806", "title": "How to (Secretly) Watch 'The Office' at the Office", "date": "2019-08-30 10:03", "summary": "With Netflix Hangouts, you can furtively take in your favorite shows at work-with your boss none the wiser. AFTER A LONG hard day at work, there's nothing quite like sitting down, turning on the TV and zoning out to a bunch of people in glamorous \"hospitals,\" \"law firms\" or \"paper-supply companies\" pretending to work.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to (Secretly) Watch 'The Office' at the Office. With Netflix Hangouts, you can furtively take in your favorite shows at work-with your boss none the wiser. AFTER A LONG hard day at work, there's nothing quite like sitting down, turning on the TV and zoning out to a bunch of people in glamorous \"hospitals,\" \"law firms\" or \"paper-supply companies\" pretending to work.\"\n\nStock Prediction(s):", "Prediction": "\n- Netflix, Inc. (NASDAQ: NFLX) will increase because people will want to watch their favorite shows at work without their boss knowing.\n- Comcast Corporation (NASDAQ: CMCSA) will decrease because people will be streaming shows from Netflix instead of watching cable.", "price_info": {"NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [292.7582, 291.6401]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "down", "prices": [44.3035, 44.21]}}}, {"link": "https://www.wsj.com/articles/u-s-government-bonds-pull-back-after-strong-data-11547740011", "title": "U.S. Government Bonds Pull Back After Strong Data", "date": "2019-01-17 15:38", "summary": "Yields edged higher after the Manufacturing Business Outlook Survey's index of business activity rose to 17.0 in January from 9.1 in December. U.S. government-bond prices fell Thursday as traders responded to better-than-expected data on regional manufacturing activity and a report that U.S. officials are debating whether to scale back tariffs on Chinese imports.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Government Bonds Pull Back After Strong Data. Yields edged higher after the Manufacturing Business Outlook Survey's index of business activity rose to 17.0 in January from 9.1 in December. U.S. government-bond prices fell Thursday as traders responded to better-than-expected data on regional manufacturing activity and a report that U.S. officials are debating whether to scale back tariffs on Chinese imports.\"\n\nStock Prediction(s):", "Prediction": "\n- The yield on the 10-year Treasury note will continue to increase because the data is showing that the economy is doing better.\n- The yield on the 2-year Treasury note will continue to increase because the data is showing that the economy is doing better.\n- The yield on the 30-year Treasury note will continue to increase because the data is showing that the economy is doing better.", "price_info": {}}, {"link": "https://www.wsj.com/articles/stock-traders-fund-drug-development-11579798645", "title": "Stock Traders Fund Drug Development", "date": "2020-01-23 11:57", "summary": "Shares of Trillium Therapeutics have surged more than 10-fold since December. Never underestimate what a bull market can accomplish.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Stock Traders Fund Drug Development. Shares of Trillium Therapeutics have surged more than 10-fold since December. Never underestimate what a bull market can accomplish.\"\n\nStock Prediction(s):", "Prediction": "\n- Trillium Therapeutics (NASDAQ: TRIL) will continue to surge because they are a publicly traded company that is working on a drug development.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a drug development, but they are a direct competitor of Trillium Therapeutics.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a drug development, but they", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [147.26, 147.4923]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [40.585, 40.6364]}, "TRIL": {"company": "", "ticker": "TRIL", "move": null, "prices": [3.415, 3.4406]}}}, {"link": "https://www.wsj.com/articles/colonial-pipeline-hack-shows-ransomware-emergence-as-industrial-scale-threat-11620749675", "title": "Colonial Pipeline Hack Shows Ransomware Emergence as Industrial-Scale Threat", "date": "2021-05-11 12:14", "summary": "Schools, hospitals, companies are targeted by 'cyber weapons of mass destruction'. The cyberattack that knocked offline an essential U.S. gasoline pipeline shows how the dangerous, professional-scale hack-for-ransom threat is spreading rapidly, targeting companies, schools, hospitals and other institutions.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Colonial Pipeline Hack Shows Ransomware Emergence as Industrial-Scale Threat. Schools, hospitals, companies are targeted by 'cyber weapons of mass destruction'. The cyberattack that knocked offline an essential U.S. gasoline pipeline shows how the dangerous, professional-scale hack-for-ransom threat is spreading rapidly, targeting companies, schools, hospitals and other institutions.\"\n\nStock Prediction(s):", "Prediction": "\n- Symantec Corporation (NASDAQ: SYMC) will increase because they offer protection against ransomware attacks.\n- Palo Alto Networks, Inc. (NYSE: PANW) will increase because they offer protection against ransomware attacks.\n- Check Point Software Technologies Ltd. (NASDAQ: CHKP) will increase because they offer protection against ransomware attacks.\n- FireEye, Inc. (NASDAQ: FEYE) will increase because they offer protection against ransomware attacks", "price_info": {"PANW": {"company": "", "ticker": "PANW", "move": "up", "prices": [343.6105, 344.19]}, "SYMC": {"company": "", "ticker": "SYMC", "move": "up"}, "CHKP": {"company": "", "ticker": "CHKP", "move": "up", "prices": [118.61, 118.6833]}, "FEYE": {"company": "", "ticker": "FEYE", "move": "up", "prices": [20.135, 20.075]}}}, {"link": "https://www.wsj.com/articles/consumers-are-eating-healthier-and-cooking-more-food-execs-say-11601926763", "title": "People Are Eating Healthier and Cooking More, Food Execs Say", "date": "2020-10-05 15:39", "summary": "Campbell, Kellogg, Mars see shoppers shifting from comfort food to more nutritious options as pandemic persists. Food company executives say they are expecting new consumer habits formed during the pandemic to stick, with a renewed focus on health and cooking at home.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"People Are Eating Healthier and Cooking More, Food Execs Say. Campbell, Kellogg, Mars see shoppers shifting from comfort food to more nutritious options as pandemic persists. Food company executives say they are expecting new consumer habits formed during the pandemic to stick, with a renewed focus on health and cooking at home.\"\n\nStock Prediction(s):", "Prediction": "\n- Campbell Soup Company (NYSE: CPB) will increase because they are expecting a renewed focus on health and cooking at home.\n- Kellogg Company (NYSE: K) will increase because they are expecting a renewed focus on health and cooking at home.\n- Mars, Incorporated (NYSE: MARS) will increase because they are expecting a renewed focus on health and cooking at home.", "price_info": {"CPB": {"company": "", "ticker": "CPB", "move": "up", "prices": [48.98, 48.97]}, "K": {"company": "", "ticker": "K", "move": "up"}, "MARS": {"company": "", "ticker": "MARS", "move": "up"}}}, {"link": "https://www.wsj.com/articles/new-york-condo-sells-for-close-to-190-million-hedge-fund-billionaire-doubles-his-money-11642098997", "title": "Hedge-Fund Billionaire Sells Condo for Close to $190 Million", "date": "2022-01-13 13:36", "summary": "Och-Ziff founder Daniel Och bought the Billionaires' Row unit for about $93 million in 2019. Billionaire investor Daniel Och has sold a Manhattan penthouse overlooking Central Park for close to $190 million, roughly double what he paid just over two years ago, according to people familiar with the deal. The sale is one of the most expensive ever completed in New York.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hedge-Fund Billionaire Sells Condo for Close to $190 Million. Och-Ziff founder Daniel Och bought the Billionaires' Row unit for about $93 million in 2019. Billionaire investor Daniel Och has sold a Manhattan penthouse overlooking Central Park for close to $190 million, roughly double what he paid just over two years ago, according to people familiar with the deal. The sale is one of the most expensive ever completed in New York.\"\n\nStock Prediction(s):", "Prediction": "\n- Och-Ziff Capital Management Group LLC (NYSE: OZM) will increase because their founder just made a huge profit from the sale of his condo.\n- Related Companies (NYSE: REL) will increase because they are a partner of Och-Ziff in the development of the condo.\n- Vornado Realty Trust (NYSE: VNO) will increase because they are a partner of Och-Ziff in the development of the", "price_info": {"OZM": {"company": "", "ticker": "OZM", "move": "up"}, "REL": {"company": "", "ticker": "REL", "move": "up"}, "VNO": {"company": "", "ticker": "VNO", "move": "up", "prices": [46.5, 46.32]}}}, {"link": "https://www.wsj.com/articles/u-k-businesses-see-winners-and-losers-in-tariff-plan-11552485215", "title": "U.K. Businesses See Winners and Losers in Tariff Plan", "date": "2019-03-13 09:53", "summary": "The U.K. government plans to introduce import duties on cars, meat and other products from the EU. U.K. businesses expressed concern that the government's plan to liberalize import duties for most industries in case of a no-deal Brexit while introducing tariffs for others could create winners and losers.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.K. Businesses See Winners and Losers in Tariff Plan. The U.K. government plans to introduce import duties on cars, meat and other products from the EU. U.K. businesses expressed concern that the government's plan to liberalize import duties for most industries in case of a no-deal Brexit while introducing tariffs for others could create winners and losers.\"\n\nStock Prediction(s):", "Prediction": "\n- BMW AG (ETR: BMW) will increase because they are a direct competitor of Mercedes-Benz, and the U.K. is introducing import duties on cars from the EU.\n- Daimler AG (ETR: DAI) will increase because they are a direct competitor of BMW, and the U.K. is introducing import duties on cars from the EU.\n- Volkswagen AG (ETR: VOW3) will increase because they are", "price_info": {}}, {"link": "https://www.wsj.com/articles/ebay-names-walmart-executive-as-its-new-ceo-11586793984", "title": "EBay Names Walmart Executive as Its New CEO", "date": "2020-04-13 14:40", "summary": "Jamie Iannone, who will join eBay on April 27, previously worked for the company between 2001 and 2009. EBay Inc. named Jamie Iannone its new chief executive Monday, in a move that will provide the e-commerce pioneer an industry veteran as it tries to reignite growth during a tumultuous period.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"EBay Names Walmart Executive as Its New CEO. Jamie Iannone, who will join eBay on April 27, previously worked for the company between 2001 and 2009. EBay Inc. named Jamie Iannone its new chief executive Monday, in a move that will provide the e-commerce pioneer an industry veteran as it tries to reignite growth during a tumultuous period.\"\n\nStock Prediction(s):", "Prediction": "\n- eBay Inc. (NASDAQ: EBAY) will increase because they have a new CEO with industry experience.\n- Walmart Inc. (NYSE: WMT) will decrease because one of their executives is leaving to work for eBay.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [125.22, 125.11]}, "EBAY": {"company": "", "ticker": "EBAY", "move": "up", "prices": [34.8814, 34.76]}}}, {"link": "https://www.wsj.com/articles/trade-uncertainty-likely-to-cut-u-s-growth-by-more-than-1-fed-research-says-11567702473", "title": "Trade Uncertainty Likely to Cut U.S. Growth by More Than 1%, Fed Says", "date": "2019-09-05 12:54", "summary": "Economists charted certainty with text analyses of newspaper articles, corporate-earnings calls. Uncertainty over trade policy is likely to reduce U.S. economic output by more than 1% through early 2020, new research from Federal Reserve economists suggests.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trade Uncertainty Likely to Cut U.S. Growth by More Than 1%, Fed Says. Economists charted certainty with text analyses of newspaper articles, corporate-earnings calls. Uncertainty over trade policy is likely to reduce U.S. economic output by more than 1% through early 2020, new research from Federal Reserve economists suggests.\"\n\nStock Prediction(s):", "Prediction": "\n- The stocks of companies that are more domestically-focused will increase because trade uncertainty will have less of an impact on them.\n- The stocks of companies that are more internationally-focused will decrease because trade uncertainty will have a bigger impact on them.", "price_info": {}}, {"link": "https://www.wsj.com/articles/microsofts-shopping-spree-isnt-landing-bargains-11618243997", "title": "Microsoft's Shopping Spree Isn't Landing Bargains", "date": "2021-04-12 12:13", "summary": "Acquisition of Nuance Communications adds to AI capabilities but represents high price for struggling business. Microsoft 's deal makers finally landed on a target they can hit. They sure aren't getting a bargain.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Microsoft's Shopping Spree Isn't Landing Bargains. Acquisition of Nuance Communications adds to AI capabilities but represents high price for struggling business. Microsoft 's deal makers finally landed on a target they can hit. They sure aren't getting a bargain.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because they overpaid for Nuance Communications.\n- Nuance Communications (NASDAQ: NUAN) will decrease because they are a struggling business and Microsoft overpaid for them.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [257.29, 256.7463]}, "NUAN": {"company": "", "ticker": "NUAN", "move": "down", "prices": [53.0291, 52.95]}}}, {"link": "https://www.wsj.com/articles/campbell-goes-agile-from-soup-to-snacks-11562579556", "title": "Campbell Goes Agile, From Soup to Snacks", "date": "2019-07-08 13:54", "summary": "Food company used 'agile development' to launch a version of Goldfish for older kids; it is expanding the method to all product launches. When Campbell Soup Co. wanted to bring a snack to market that would appeal to children ages 9 to 12, the company turned to \"agile development\" for help.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Campbell Goes Agile, From Soup to Snacks. Food company used 'agile development' to launch a version of Goldfish for older kids; it is expanding the method to all product launches. When Campbell Soup Co. wanted to bring a snack to market that would appeal to children ages 9 to 12, the company turned to \"agile development\" for help.\"\n\nStock Prediction(s):", "Prediction": "\n- Campbell Soup Co. (NYSE: CPB) will increase because they are using agile development to help them with product launches, and it seems to be working well for them.\n- General Mills, Inc. (NYSE: GIS) will decrease because they are a direct competitor of Campbell Soup Co.", "price_info": {"CPB": {"company": "", "ticker": "CPB", "move": "up", "prices": [41.49, 41.5]}, "GIS": {"company": "", "ticker": "GIS", "move": "down", "prices": [54.01, 54.055]}}}, {"link": "https://www.wsj.com/articles/wells-fargos-black-takes-over-as-chairman-from-noski-11628607470", "title": "Wells Fargo's Black Takes Over as Chairman From Noski", "date": "2021-08-10 10:57", "summary": "Former JPMorgan executive succeeds Noski, who will retire at end of September. Wells Fargo & Co. said Tuesday that Charles Noski had stepped down as chairman of its board of directors and will be succeeded by Steven Black, a former JPMorgan Chase & Co. executive who joined the board last year.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wells Fargo's Black Takes Over as Chairman From Noski. Former JPMorgan executive succeeds Noski, who will retire at end of September. Wells Fargo & Co. said Tuesday that Charles Noski had stepped down as chairman of its board of directors and will be succeeded by Steven Black, a former JPMorgan Chase & Co. executive who joined the board last year.\"\n\nStock Prediction(s):", "Prediction": "\n- Wells Fargo & Co. (NYSE: WFC) will increase because they have a new chairman, who is a former JPMorgan executive.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they lost a board member to Wells Fargo.", "price_info": {"WFC": {"company": "", "ticker": "WFC", "move": "up", "prices": [49.5959, 49.58]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [159.79, 159.429]}}}, {"link": "https://www.wsj.com/articles/feds-bostic-fed-disinclined-to-penalize-banks-for-emergency-lending-choices-11589831566", "title": "Fed's Bostic: Fed Disinclined to Penalize Banks for Emergency Lending Choices", "date": "2020-05-18 15:52", "summary": "The Federal Reserve Bank of Atlanta President said he doesn't plan to heavily second guess decisions banks have taken during the coronavirus crisis. Federal Reserve Bank of Atlanta President Raphael Bostic said Monday he doesn't plan to heavily second guess decisions banks have taken during the coronavirus crisis.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Bostic: Fed Disinclined to Penalize Banks for Emergency Lending Choices. The Federal Reserve Bank of Atlanta President said he doesn't plan to heavily second guess decisions banks have taken during the coronavirus crisis. Federal Reserve Bank of Atlanta President Raphael Bostic said Monday he doesn't plan to heavily second guess decisions banks have taken during the coronavirus crisis.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of Atlanta President's statement will have a positive effect on banks, and they will increase in value.\n- The Federal Reserve Bank of Atlanta President's statement will have a negative effect on banks, and they will decrease in value.", "price_info": {}}, {"link": "https://www.wsj.com/articles/greensill-leaned-on-wall-street-giants-before-it-collapsed-11616613409", "title": "Greensill Leaned on Wall Street Before It Collapsed", "date": "2021-03-24 15:16", "summary": "Citigroup expanded its business with Greensill despite repeated warnings internally not to do so. LONDON-The founder of Greensill Capital spoke frequently about disrupting big banks. But before the financial startup collapsed this month, it relied on the apparatus of Wall Street to fuel its expansion.", "categories": [["WSJ News Exclusive", "Finance"]], "category_links": ["https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Greensill Leaned on Wall Street Before It Collapsed. Citigroup expanded its business with Greensill despite repeated warnings internally not to do so. LONDON-The founder of Greensill Capital spoke frequently about disrupting big banks. But before the financial startup collapsed this month, it relied on the apparatus of Wall Street to fuel its expansion.\"\n\nStock Prediction(s):", "Prediction": "\n- Citigroup Inc (NYSE: C) will increase because they were one of the few banks that continued to do business with Greensill, even after warnings from within the company.\n- Goldman Sachs Group Inc (NYSE: GS) will increase because they were one of the few banks that continued to do business with Greensill, even after warnings from within the company.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they were one of the few", "price_info": {"C": {"company": "", "ticker": "C", "move": "up", "prices": [70.145, 70.2]}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [328.8501, 329]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [150.63, 150.845]}}}, {"link": "https://www.wsj.com/articles/stocks-to-watch-prudential-financial-sealed-air-and-netapp-11564999200", "title": "Stocks to Watch: Tyson, Cars.com, Diamond Offshore and Prudential", "date": "2019-08-05 09:31", "summary": "Here are some of the companies with shares expected to trade actively in Monday's session. Here are some of the companies with shares expected to trade actively in Monday's session. Stock movements noted by ticker reflect movements during regular trading hours; premarket trading is specified separately.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Stocks to Watch: Tyson, Cars.com, Diamond Offshore and Prudential. Here are some of the companies with shares expected to trade actively in Monday's session. Here are some of the companies with shares expected to trade actively in Monday's session. Stock movements noted by ticker reflect movements during regular trading hours; premarket trading is specified separately.\"\n\nStock Prediction(s):", "Prediction": "\n- Tyson Foods, Inc. (NYSE: TSN) will increase because they are releasing earnings and they are a major player in the food industry.\n- Cars.com Inc. (NYSE: CARS) will increase because they are being bought out by Gannett Co., Inc. (NYSE: GCI).\n- Diamond Offshore Drilling, Inc. (NYSE: DO) will increase because they are being bought out by Transocean Ltd. (", "price_info": {"TSN": {"company": "", "ticker": "TSN", "move": "up", "prices": [85.84, 86.85]}, "CARS": {"company": "", "ticker": "CARS", "move": "up", "prices": [11.93, 11.91]}, "GCI": {"company": "", "ticker": "GCI", "move": null, "prices": [10.51, 10.57]}, "DO": {"company": "", "ticker": "DO", "move": "up", "prices": [6.26, 6.035]}}}, {"link": "https://www.wsj.com/articles/germany-fights-soaring-home-prices-with-curbs-on-mortgage-lending-11642002626", "title": "Germany Fights Soaring Home Prices", "date": "2022-01-12 10:50", "summary": "As in the U.S. and other economies, pandemic financial support has sparked a surge in property investment and borrowing in the country. Frankfurt-Germany's financial regulator said it would clamp down on mortgage lending, signaling mounting concerns about the risks posed by the nation's rapidly rising house prices.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Germany Fights Soaring Home Prices. As in the U.S. and other economies, pandemic financial support has sparked a surge in property investment and borrowing in the country. Frankfurt-Germany's financial regulator said it would clamp down on mortgage lending, signaling mounting concerns about the risks posed by the nation's rapidly rising house prices.\"\n\nStock Prediction(s):", "Prediction": "\n- Deutsche Bank AG (NYSE: DB) will increase because they are a direct competitor of other German banks, and they will benefit from the clampdown on mortgage lending.\n- Commerzbank AG (OTCMKTS: CRZBY) will increase because they are a direct competitor of other German banks, and they will benefit from the clampdown on mortgage lending.\n- Hypo Real Estate Holding AG (OTCMKTS: HYPOF) will", "price_info": {"DB": {"company": "", "ticker": "DB", "move": "up", "prices": [13.975, 13.965]}}}, {"link": "https://www.wsj.com/articles/january-jobs-report-wont-change-the-feds-new-wait-and-see-stance-11549035279", "title": "Analysis: January Jobs Report Won't Change the Fed's New Wait-and-See Stance", "date": "2019-02-01 10:34", "summary": "It will take more than one month of solid employment numbers for the Federal Reserve to move again on rates. The strong January employment report offers one promising data point for Federal Reserve officials who are trying to gauge how the U.S. economy weathered increased market volatility and slowing global growth at the end of last year.", "categories": [["Economy", "Analysis"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Analysis: January Jobs Report Won't Change the Fed's New Wait-and-See Stance. It will take more than one month of solid employment numbers for the Federal Reserve to move again on rates. The strong January employment report offers one promising data point for Federal Reserve officials who are trying to gauge how the U.S. economy weathered increased market volatility and slowing global growth at the end of last year.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will not change their stance on rates, and will continue to wait and see.\n- The market will react negatively to this news, and stocks will decrease.", "price_info": {}}, {"link": "https://www.wsj.com/articles/foreign-auto-makers-report-higher-u-s-sales-11575394021", "title": "Foreign Auto Makers Report Higher U.S. Sales", "date": "2019-12-03 14:26", "summary": "Overall vehicle sales in November were expected to be up from a year ago, according to industry analysts. Major foreign auto makers including Toyota Motor Corp. and Honda Motor Co. reported higher vehicle sales in the U.S. for November, helped by steep discounts on a glut of older-model vehicles.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Foreign Auto Makers Report Higher U.S. Sales. Overall vehicle sales in November were expected to be up from a year ago, according to industry analysts. Major foreign auto makers including Toyota Motor Corp. and Honda Motor Co. reported higher vehicle sales in the U.S. for November, helped by steep discounts on a glut of older-model vehicles.\"\n\nStock Prediction(s):", "Prediction": "\n- Toyota Motor Corp. (NYSE: TM) will increase because they are doing well in the U.S. market.\n- Honda Motor Co. (NYSE: HMC) will increase because they are doing well in the U.S. market.\n- Ford Motor Co. (NYSE: F) will decrease because they are not doing as well as their competitors in the U.S. market.", "price_info": {"TM": {"company": "", "ticker": "TM", "move": "up", "prices": [140.5, 140.6502]}, "HMC": {"company": "", "ticker": "HMC", "move": "up", "prices": [27.99, 28.1]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [8.88, 8.9]}}}, {"link": "https://www.wsj.com/articles/costar-group-submits-competing-offer-to-buy-corelogic-for-about-6-9-billion-11613489004", "title": "CoStar Group Submits Competing Offer to Buy CoreLogic", "date": "2021-02-16 10:23", "summary": "CoreLogic earlier this month agreed to sell itself to two private-equity firms for about $6 billion. CoStar Group Inc. said it is proposing to buy CoreLogic Inc. for about $6.9 billion, as it tries to compete against an agreement by two private-equity firms to buy the real-estate data provider for roughly $6 billion in cash.", "categories": [["Markets", "Deals"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/deals-deal-makers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"CoStar Group Submits Competing Offer to Buy CoreLogic. CoreLogic earlier this month agreed to sell itself to two private-equity firms for about $6 billion. CoStar Group Inc. said it is proposing to buy CoreLogic Inc. for about $6.9 billion, as it tries to compete against an agreement by two private-equity firms to buy the real-estate data provider for roughly $6 billion in cash.\"\n\nStock Prediction(s):", "Prediction": "\n- CoreLogic, Inc. (NYSE: CLGX) will increase because there is a bidding war for the company, and CoStar Group is offering a higher price.\n- CoStar Group, Inc. (NASDAQ: CSGP) will increase because they are trying to compete against the other offer, and they are offering a higher price.\n- The two private-equity firms that agreed to buy CoreLogic will decrease because there is a bidding", "price_info": {"CLGX": {"company": "", "ticker": "CLGX", "move": "up", "prices": [86.69, 87]}, "CSGP": {"company": "", "ticker": "CSGP", "move": "down", "prices": [879.45, 894.76]}}}, {"link": "https://www.wsj.com/articles/cameo-aims-to-connect-celebrities-with-fans-and-its-now-worth-1-billion-11617096602", "title": "Cameo Aims to Connect Celebrities With Fans and It's Now Valued at $1 Billion", "date": "2021-03-30 13:25", "summary": "The four-year-old video platform features more than 40,000 personalities but faces increased competition, potentially from Facebook. The startup behind online service Cameo tripled its valuation to more than $1 billion after raising more capital, reflecting the hot market for platforms that help celebrities and content creators make money from their fan bases.", "categories": [["WSJ News Exclusive", "Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Cameo Aims to Connect Celebrities With Fans and It's Now Valued at $1 Billion. The four-year-old video platform features more than 40,000 personalities but faces increased competition, potentially from Facebook. The startup behind online service Cameo tripled its valuation to more than $1 billion after raising more capital, reflecting the hot market for platforms that help celebrities and content creators make money from their fan bases.\"\n\nStock Prediction(s):", "Prediction": "\n- Cameo Inc (private) will increase because they are now valued at $1 billion, and they have a competitive edge against other platforms.\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are a direct competitor of Cameo, and they have a lot of money to spend on this market.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [289.86, 288.8]}}}, {"link": "https://www.wsj.com/articles/inditex-elevates-carlos-crespo-to-ceo-11558631849", "title": "Inditex Plans to Elevate Carlos Crespo to CEO", "date": "2019-05-23 13:17", "summary": "Pablo Isla to stay as chairman under proposal, which needs to be approved by board. Zara-owner Inditex SA plans to elevate its chief operations officer to be its next chief executive, a management change the world's largest fashion chain said would help it focus on enhancing its digital capabilities.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Inditex Plans to Elevate Carlos Crespo to CEO. Pablo Isla to stay as chairman under proposal, which needs to be approved by board. Zara-owner Inditex SA plans to elevate its chief operations officer to be its next chief executive, a management change the world's largest fashion chain said would help it focus on enhancing its digital capabilities.\"\n\nStock Prediction(s):", "Prediction": "\n- Inditex SA (BME: ITX) will increase because they are elevating their COO to CEO, and he has a lot of experience with the company and digital capabilities.\n- H&M Hennes & Mauritz AB (STO: HM-B) will decrease because they are not making any changes to their CEO, and they are a direct competitor of Inditex.", "price_info": {}}, {"link": "https://www.wsj.com/articles/united-arab-emirates-threatens-to-pull-out-of-23-billion-f-35-drone-deal-with-u-s-11639491997", "title": "U.A.E. Threatens to Pull Out of $23 Billion F-35, Drone Deal With U.S.", "date": "2021-12-14 13:10", "summary": "Gulf partner complained about security requirements aimed at guarding against Chinese espionage, officials say. WASHINGTON-The United Arab Emirates is threatening to pull out of a multibillion-dollar deal to buy American-made F-35 aircraft, Reaper drones and other advanced munitions, U.S. officials said, in what would be a significant shake-up between two longtime partners increasingly at odds over China's role in the Gulf.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.A.E. Threatens to Pull Out of $23 Billion F-35, Drone Deal With U.S.. Gulf partner complained about security requirements aimed at guarding against Chinese espionage, officials say. WASHINGTON-The United Arab Emirates is threatening to pull out of a multibillion-dollar deal to buy American-made F-35 aircraft, Reaper drones and other advanced munitions, U.S. officials said, in what would be a significant shake-up between two longtime partners increasingly at odds over China's role in the Gulf.\"\n\nStock Prediction(s):", "Prediction": "\n- Lockheed Martin Corporation (NYSE: LMT) will decrease because the United Arab Emirates is threatening to pull out of a multibillion-dollar deal to buy American-made F-35 aircraft.\n- Boeing (NYSE: BA) will increase because they are not a part of the deal that is being threatened to be pulled out.", "price_info": {"LMT": {"company": "", "ticker": "LMT", "move": "down", "prices": [345.005, 345.3924]}, "BA": {"company": "", "ticker": "BA", "move": "up", "prices": [195.9433, 196.23]}}}, {"link": "https://www.wsj.com/articles/credit-karma-in-talks-to-sell-tax-preparation-business-to-square-11604067274", "title": "Credit Karma in Talks to Sell Tax-Preparation Business to Square", "date": "2020-10-30 10:14", "summary": "Deal could head off potential antitrust objections to Intuit's $7.1 billion purchase of Credit Karma. Credit Karma Inc. is in talks to sell its tax-preparation business to Square Inc., according to people familiar with the matter, a move meant to head off potential antitrust objections to the personal-finance portal's pending $7.1 billion sale to TurboTax maker Intuit Inc.", "categories": [["WSJ News Exclusive", "Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Credit Karma in Talks to Sell Tax-Preparation Business to Square. Deal could head off potential antitrust objections to Intuit's $7.1 billion purchase of Credit Karma. Credit Karma Inc. is in talks to sell its tax-preparation business to Square Inc., according to people familiar with the matter, a move meant to head off potential antitrust objections to the personal-finance portal's pending $7.1 billion sale to TurboTax maker Intuit Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Square Inc (NYSE: SQ) will increase because they are buying Credit Karma's tax-preparation business, which will help them grow their market share.\n- Intuit Inc (NASDAQ: INTU) will increase because they are buying Credit Karma, which will help them grow their market share.\n- Credit Karma Inc (NYSE: KRED) will decrease because they are selling their tax-preparation business, which will help their competitors.", "price_info": {"SQ": {"company": "", "ticker": "SQ", "move": "up", "prices": [154.79, 154.54]}, "KRED": {"company": "", "ticker": "KRED", "move": "down"}, "INTU": {"company": "", "ticker": "INTU", "move": "up", "prices": [317.3, 317.21]}}}, {"link": "https://www.wsj.com/articles/softbanks-100-billion-vision-fund-faces-its-biggest-test-11557418529", "title": "SoftBank's $100 Billion Vision Fund Faces Its Biggest Test", "date": "2019-05-09 12:15", "summary": "The world's largest technology investor's hefty bets face a stark evaluation as companies like Uber and WeWork go public. The biggest test of SoftBank founder Masayoshi Son's audacious strategy starts tomorrow, when Uber goes public. A much bigger share of the Japanese company's near-$100 billion in technology bets will soon join it and begin trading in the sometimes-unflattering public spotlight.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SoftBank's $100 Billion Vision Fund Faces Its Biggest Test. The world's largest technology investor's hefty bets face a stark evaluation as companies like Uber and WeWork go public. The biggest test of SoftBank founder Masayoshi Son's audacious strategy starts tomorrow, when Uber goes public. A much bigger share of the Japanese company's near-$100 billion in technology bets will soon join it and begin trading in the sometimes-unflattering public spotlight.\"\n\nStock Prediction(s):", "Prediction": "\n- SoftBank Group Corp. (OTC: SFTBY) will decrease because their biggest bets are going public, and they may not have the same success as Uber and WeWork.\n- Uber Technologies Inc. (NYSE: UBER) will increase because they are going public, and they are one of the most successful companies in the Vision Fund.\n- WeWork Companies Inc. (NYSE: WE) will increase because they are going public, and they are", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "up"}, "WE": {"company": "", "ticker": "WE", "move": "up"}}}, {"link": "https://www.wsj.com/articles/investment-between-u-s-and-china-falls-as-tensions-coronavirus-take-toll-11589218437", "title": "Investment Between U.S. and China Falls", "date": "2020-05-11 13:33", "summary": "Once-vibrant business relationship continues to slide, according to new report. Investment between the U.S. and China is off to a weak start in 2020 and could worsen, according to a report published Monday that tallies a continuing slide in a once-vibrant business relationship due to \"political friction, regulatory tightening and market dynamics.\"", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investment Between U.S. and China Falls. Once-vibrant business relationship continues to slide, according to new report. Investment between the U.S. and China is off to a weak start in 2020 and could worsen, according to a report published Monday that tallies a continuing slide in a once-vibrant business relationship due to \"political friction, regulatory tightening and market dynamics.\"\"\n\nStock Prediction(s):", "Prediction": "\n- U.S. companies will decrease because their investment in China is down.\n- Chinese companies will decrease because their investment in the U.S. is down.", "price_info": {}}, {"link": "https://www.wsj.com/articles/slack-files-eu-antitrust-complaint-against-microsoft-11595423056", "title": "Slack Files EU Antitrust Complaint Against Microsoft", "date": "2020-07-22 11:33", "summary": "Slack alleges that Microsoft forces Office users to install the Teams software. Business-messaging app Slack has filed an antitrust complaint against Microsoft Corp. in the European Union, accusing the software giant of abusing its dominance in allegations that echo the Windows-maker's competition battles more than a decade ago.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Slack Files EU Antitrust Complaint Against Microsoft. Slack alleges that Microsoft forces Office users to install the Teams software. Business-messaging app Slack has filed an antitrust complaint against Microsoft Corp. in the European Union, accusing the software giant of abusing its dominance in allegations that echo the Windows-maker's competition battles more than a decade ago.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because they are being sued by Slack for antitrust violations.\n- Slack Technologies, Inc. (NYSE: WORK) will increase because they are being sued by Microsoft for antitrust violations.", "price_info": {"WORK": {"company": "", "ticker": "WORK", "move": "up", "prices": [31.3879, 31.1394]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [211.2, 209.65]}}}, {"link": "https://www.wsj.com/articles/complex-aircraft-investments-face-a-reckoning-11601285746", "title": "Complex Aircraft Investments Face a Reckoning", "date": "2020-09-28 10:06", "summary": "Liquidity facilities have kept plane-backed structured products afloat as airlines have stopped paying, but this has only deferred the blow. Aviation's worst crisis in decades is almost eight months old. For aircraft investors, especially those that bought complex products, it could be just the beginning.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Complex Aircraft Investments Face a Reckoning. Liquidity facilities have kept plane-backed structured products afloat as airlines have stopped paying, but this has only deferred the blow. Aviation's worst crisis in decades is almost eight months old. For aircraft investors, especially those that bought complex products, it could be just the beginning.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing (NYSE: BA) will decrease because the article mentions that \"airlines have stopped paying.\"\n- Airbus SE (EPA: AIR) will decrease because the article mentions that \"airlines have stopped paying.\"\n- Bombardier, Inc. (TSE: BBD.B) will decrease because the article mentions that \"airlines have stopped paying.\"", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [164.58, 166.18]}}}, {"link": "https://www.wsj.com/articles/vox-media-agrees-to-acquire-punch-weighs-going-public-11629734445", "title": "Vox Media Agrees to Acquire Punch, Weighs Going Public", "date": "2021-08-23 12:00", "summary": "Digital media company is buying a cocktail website founded by Bertelsmann's Penguin Random House. Vox Media LLC said Monday it is buying Punch, a cocktail website founded by Bertelsmann SE's Penguin Random House, part of a bid to deepen its coverage of food and drinks.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Vox Media Agrees to Acquire Punch, Weighs Going Public. Digital media company is buying a cocktail website founded by Bertelsmann's Penguin Random House. Vox Media LLC said Monday it is buying Punch, a cocktail website founded by Bertelsmann SE's Penguin Random House, part of a bid to deepen its coverage of food and drinks.\"\n\nStock Prediction(s):", "Prediction": "\n- Vox Media LLC (NASDAQ: VXZM) will increase because they are expanding their content verticals.\n- Bertelsmann SE (OTC: BTEGY) will increase because they are selling a website to Vox Media.\n- Penguin Random House (OTC: PENGY) will increase because they are selling a website to Vox Media.", "price_info": {"VXZM": {"company": "", "ticker": "VXZM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/coca-cola-hit-by-resurgence-of-covid-19-11612964286", "title": "Coca-Cola Hit by Resurgence of Covid-19", "date": "2021-02-10 10:24", "summary": "Beverage giant says worse-than-expected winter squeezed profit and revenue, but it predicts consumers will bounce back in second half of 2021. The pandemic has been worse this winter than Coca-Cola Co. expected, but the beverage giant said it expects consumers to return to normal life in the second half of the year as Covid-19 vaccines roll out across many developed countries.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coca-Cola Hit by Resurgence of Covid-19. Beverage giant says worse-than-expected winter squeezed profit and revenue, but it predicts consumers will bounce back in second half of 2021. The pandemic has been worse this winter than Coca-Cola Co. expected, but the beverage giant said it expects consumers to return to normal life in the second half of the year as Covid-19 vaccines roll out across many developed countries.\"\n\nStock Prediction(s):", "Prediction": "\n- Coca-Cola Co. (NYSE: KO) will increase because they predict that the consumer will bounce back in the second half of 2021.\n- PepsiCo, Inc. (NASDAQ: PEP) will decrease because they are a direct competitor of Coca-Cola.", "price_info": {"KO": {"company": "", "ticker": "KO", "move": "up", "prices": [49.99, 49.8796]}, "PEP": {"company": "", "ticker": "PEP", "move": "down", "prices": [138.5, 137.83]}}}, {"link": "https://www.wsj.com/articles/russian-iraqi-emirati-oil-producers-benefit-as-saudis-recover-from-attack-11569608449", "title": "Russian, Iraqi, Emirati Oil Producers Benefit as Saudis Recover From Attack", "date": "2019-09-27 14:20", "summary": "Asian refineries seek alternatives to Saudi oil; Aramco's production returns to 9.8 million barrels a day. Russia, Iraq and the United Arab Emirates are among the handful of oil producers benefiting from the recent attack on Saudi Arabia's largest oil-processing facility, as Asian buyers seek alternatives to the kingdom's highest-quality crude.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Russian, Iraqi, Emirati Oil Producers Benefit as Saudis Recover From Attack. Asian refineries seek alternatives to Saudi oil; Aramco's production returns to 9.8 million barrels a day. Russia, Iraq and the United Arab Emirates are among the handful of oil producers benefiting from the recent attack on Saudi Arabia's largest oil-processing facility, as Asian buyers seek alternatives to the kingdom's highest-quality crude.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (NYSE: ARAMCO) will decrease because their main production facility was attacked, and they are not able to produce as much oil as before.\n- Russian oil producers (e.g. Lukoil, Gazprom, Rosneft) will increase because they are able to produce more oil now that Saudi Aramco is not able to produce as much.\n- Iraqi oil producers (e.g. Basra Oil, Missan Oil,", "price_info": {}}, {"link": "https://www.wsj.com/articles/fed-report-small-business-sector-highly-vulnerable-to-coronavirus-crisis-11586281573", "title": "Small Businesses' Finances Highly Vulnerable to Coronavirus Crisis", "date": "2020-04-07 14:21", "summary": "Survey from late 2019 shows financial weakness in even best-managed businesses. Even the best-managed small businesses are in a very vulnerable position as they try to weather the shutdown of much of the U.S. economy during the coronavirus crises, according to the Federal Reserve Bank of New York.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Small Businesses' Finances Highly Vulnerable to Coronavirus Crisis. Survey from late 2019 shows financial weakness in even best-managed businesses. Even the best-managed small businesses are in a very vulnerable position as they try to weather the shutdown of much of the U.S. economy during the coronavirus crises, according to the Federal Reserve Bank of New York.\"\n\nStock Prediction(s):", "Prediction": "\n- The companies that are the most vulnerable to the coronavirus crisis are going to decrease in stock prices. This includes small businesses, as well as other companies that are in the health care and retail sectors.\n- The companies that are least vulnerable to the coronavirus crisis are going to increase in stock prices. This includes companies in the technology and defense sectors.", "price_info": {}}, {"link": "https://www.wsj.com/articles/aig-results-look-grim-but-represent-progress-11596558744", "title": "AIG Results Look Grim but Represent Progress", "date": "2020-08-04 12:32", "summary": "The finalized sale of a legacy reinsurance unit generated huge accounting losses but is a necessary step in slimming and firming AIG's core business. Parting ways isn't always pretty, but sometimes it's also the right thing to do.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AIG Results Look Grim but Represent Progress. The finalized sale of a legacy reinsurance unit generated huge accounting losses but is a necessary step in slimming and firming AIG's core business. Parting ways isn't always pretty, but sometimes it's also the right thing to do.\"\n\nStock Prediction(s):", "Prediction": "\n- AIG (NYSE: AIG) will increase because their results show progress, and they are continuing to slim down their business.\n- Berkshire Hathaway Inc. (NYSE: BRK.A) will increase because they are a major shareholder in AIG, and they have a good relationship with the company.\n- MetLife, Inc. (NYSE: MET) will decrease because they are a direct competitor of AIG.", "price_info": {"AIG": {"company": "", "ticker": "AIG", "move": "up", "prices": [29.8041, 29.69]}, "MET": {"company": "", "ticker": "MET", "move": "down", "prices": [37.0384, 36.89]}}}, {"link": "https://www.wsj.com/articles/the-finer-things-in-life-werent-good-investments-in-2019-11577718066", "title": "The Finer Things in Life Weren't Good Investments in 2019", "date": "2019-12-30 10:01", "summary": "The value of luxury goods such as wine, diamonds and art had a down year even as the stock market hit new records. When stocks and bonds do well, the rich usually feel richer, driving sales of luxury assets like wine, diamonds and fancy cars. That wasn't the case in 2019.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Finer Things in Life Weren't Good Investments in 2019. The value of luxury goods such as wine, diamonds and art had a down year even as the stock market hit new records. When stocks and bonds do well, the rich usually feel richer, driving sales of luxury assets like wine, diamonds and fancy cars. That wasn't the case in 2019.\"\n\nStock Prediction(s):", "Prediction": "\n- The entire luxury goods industry will decrease because their products were not good investments in 2019.\n- LVMH Mo\u00ebt Hennessy Louis Vuitton SE (OTC: LVMHF) will decrease because their products were not good investments in 2019.\n- Tiffany & Co. (NYSE: TIF) will decrease because their products were not good investments in 2019.\n- Kering SA (OTC: PPRUY) will decrease because their", "price_info": {"TIF": {"company": "", "ticker": "TIF", "move": "down", "prices": [133.735, 133.615]}}}, {"link": "https://www.wsj.com/articles/sec-examines-guggenheim-related-bond-trades-11551182402", "title": "SEC Examines Guggenheim-Related Bond Trades", "date": "2019-02-26 11:34", "summary": "The agency has sought information related to trades by insurance companies tied to Guggenheim Partners. U.S. securities regulators are reviewing a series of bond trades by three insurance companies tied to Guggenheim Partners LLC, according to people familiar with the matter.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SEC Examines Guggenheim-Related Bond Trades. The agency has sought information related to trades by insurance companies tied to Guggenheim Partners. U.S. securities regulators are reviewing a series of bond trades by three insurance companies tied to Guggenheim Partners LLC, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Guggenheim Partners LLC (NYSE: GOF) will decrease because the SEC is investigating their relationship with the insurance companies.\n- The insurance companies (e.g. AIG, MetLife, Prudential) will decrease because their relationship with Guggenheim Partners LLC is being investigated.", "price_info": {"GOF": {"company": "", "ticker": "GOF", "move": "down", "prices": [19.9516, 19.969]}}}, {"link": "https://www.wsj.com/articles/senate-hearing-tiktok-snapchat-youtube-11635265576", "title": "Senators Turn Child-Safety Spotlight on TikTok, Snapchat and YouTube", "date": "2021-10-26 15:46", "summary": "TikTok executive is questioned over algorithms blamed for steering young users to harmful content. WASHINGTON-A Senate panel broadened its inquiry into social media's impact on children and teenagers, questioning representatives of TikTok, Snapchat and YouTube as lawmakers build a case for new legislation to protect young people online.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Senators Turn Child-Safety Spotlight on TikTok, Snapchat and YouTube. TikTok executive is questioned over algorithms blamed for steering young users to harmful content. WASHINGTON-A Senate panel broadened its inquiry into social media's impact on children and teenagers, questioning representatives of TikTok, Snapchat and YouTube as lawmakers build a case for new legislation to protect young people online.\"\n\nStock Prediction(s):", "Prediction": "\n- TikTok (NYSE: TIK) will decrease because they are being scrutinized for their harmful content algorithms.\n- Snapchat (NYSE: SNAP) will decrease because they are being scrutinized for their harmful content algorithms.\n- YouTube (NASDAQ: GOOGL) will decrease because they are being scrutinized for their harmful content algorithms.", "price_info": {"TIK": {"company": "", "ticker": "TIK", "move": "down"}, "SNAP": {"company": "", "ticker": "SNAP", "move": "down", "prices": [55.335, 55.34]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [2741.74, 2731.74]}}}, {"link": "https://www.wsj.com/articles/western-digitals-happy-accident-11561748786", "title": "Western Digital's Happy Accident", "date": "2019-06-28 15:06", "summary": "Power outage cuts into flash-memory production, which will likely boost prices in an oversupplied market. Most companies would be envious: An act of God disrupts production of your key product and your stock goes up anyway.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Western Digital's Happy Accident. Power outage cuts into flash-memory production, which will likely boost prices in an oversupplied market. Most companies would be envious: An act of God disrupts production of your key product and your stock goes up anyway.\"\n\nStock Prediction(s):", "Prediction": "\n- Western Digital Corporation (NASDAQ: WDC) will increase because their main product, flash-memory, is in high demand and short supply.\n- Micron Technology, Inc. (NASDAQ: MU) will decrease because they are a direct competitor of Western Digital.\n- Intel Corporation (NASDAQ: INTC) will decrease because they are a direct competitor of Western Digital.", "price_info": {"WDC": {"company": "", "ticker": "WDC", "move": "up", "prices": [47.7, 47.64]}, "MU": {"company": "", "ticker": "MU", "move": "down", "prices": [38.65, 38.7]}, "INTC": {"company": "", "ticker": "INTC", "move": "down", "prices": [48, 48.01]}}}, {"link": "https://www.wsj.com/articles/netflix-changes-how-it-ranks-its-most-popular-shows-11637092802", "title": "Netflix Changes How It Ranks Viewership", "date": "2021-11-16 15:00", "summary": "Streaming service will release weekly top 10 of shows by total hours viewed, dropping much-criticized two-minute metric. Netflix Inc. is changing how it measures viewership of its content, a move that the streaming company said will provide more clarity when it comes to judging the popularity of programming on its platform.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Netflix Changes How It Ranks Viewership. Streaming service will release weekly top 10 of shows by total hours viewed, dropping much-criticized two-minute metric. Netflix Inc. is changing how it measures viewership of its content, a move that the streaming company said will provide more clarity when it comes to judging the popularity of programming on its platform.\"\n\nStock Prediction(s):", "Prediction": "\n- Netflix Inc. (NASDAQ: NFLX) will increase because they are changing how they rank viewership, and this will give investors a better understanding of their platform.\n- Hulu LLC (NASDAQ: HULU) will decrease because they are not changing how they rank viewership, and this could give Netflix a competitive edge.", "price_info": {"NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [685.84, 688.15]}, "HULU": {"company": "", "ticker": "HULU", "move": "down"}}}, {"link": "https://www.wsj.com/articles/budweisers-owner-has-a-troubling-new-brew-11572010251", "title": "Budweiser's Owner Has a Troubling New Brew", "date": "2019-10-25 09:30", "summary": "The world's largest beer company has served up a profit warning and weak growth in key markets. Budweiser's parent is getting its debt down to more manageable levels, but has sullied the brew with a profit warning and poor growth in key markets.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Budweiser's Owner Has a Troubling New Brew. The world's largest beer company has served up a profit warning and weak growth in key markets. Budweiser's parent is getting its debt down to more manageable levels, but has sullied the brew with a profit warning and poor growth in key markets.\"\n\nStock Prediction(s):", "Prediction": "\n- Anheuser-Busch InBev SA/NV (NYSE: BUD) will decrease because of their weak growth and profit warning.", "price_info": {"BUD": {"company": "", "ticker": "BUD", "move": "down", "prices": [82.1683, 82.26]}}}, {"link": "https://www.wsj.com/articles/chinese-suppliers-to-apple-nike-shun-xinjiang-workers-as-u-s-forced-labor-ban-looms-11626795627", "title": "Chinese Suppliers Shun Xinjiang Workers as U.S. Forced-Labor Ban Looms", "date": "2021-07-20 11:40", "summary": "Three suppliers do an about-face after hiring thousands of Uyghurs and Turkic Muslims. Chinese factories that supply Apple Inc. and Nike Inc. and make other products sold in the U.S. are shunning workers from Xinjiang, as Western countries increase scrutiny of forced labor from the remote northwestern region where Beijing has been accused of committing genocide against local ethnic minorities.", "categories": [["WSJ News Exclusive", "China"]], "category_links": ["https://www.wsj.com/news/types/china-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chinese Suppliers Shun Xinjiang Workers as U.S. Forced-Labor Ban Looms. Three suppliers do an about-face after hiring thousands of Uyghurs and Turkic Muslims. Chinese factories that supply Apple Inc. and Nike Inc. and make other products sold in the U.S. are shunning workers from Xinjiang, as Western countries increase scrutiny of forced labor from the remote northwestern region where Beijing has been accused of committing genocide against local ethnic minorities.\"\n\nStock Prediction(s):", "Prediction": "\n- Foxconn Technology Group (TPE: 2354) will increase because they are not hiring any workers from Xinjiang, and they are a supplier for Apple and Nike.\n- Pegatron Corp. (TPE: 4938) will increase because they are not hiring any workers from Xinjiang, and they are a supplier for Apple and Nike.\n- Wistron Corp. (TPE: 3231) will increase because they are not hiring any workers from", "price_info": {}}, {"link": "https://www.wsj.com/articles/millennials-prize-experiences-now-so-do-travel-companies-11560160800", "title": "Millennials Prize Experiences. Now So Do Travel Companies.", "date": "2019-06-14 14:10", "summary": "Millennial travelers prefer to spend on eccentric adventures rather than upscale hotel rooms. But for travel companies, will experiences pack as much bang for their bucks?. Forget the thread count, plush bathrobes and white goose-down pillows. A vacation is no longer defined by where you stay, but what you do-at least for many millennials. Increasingly, large travel companies are racing to cash in on that trend.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Millennials Prize Experiences. Now So Do Travel Companies.. Millennial travelers prefer to spend on eccentric adventures rather than upscale hotel rooms. But for travel companies, will experiences pack as much bang for their bucks?. Forget the thread count, plush bathrobes and white goose-down pillows. A vacation is no longer defined by where you stay, but what you do-at least for many millennials. Increasingly, large travel companies are racing to cash in on that trend.\"\n\nStock Prediction(s):", "Prediction": "\n- Expedia Group (NASDAQ: EXPE) will increase because millennials are spending more on experiences, and they are a large travel company.\n- Marriott International, Inc. (NASDAQ: MAR) will increase because millennials are spending more on experiences, and they are a large travel company.\n- Hilton Worldwide Holdings Inc. (NYSE: HLT) will increase because millennials are spending more on experiences, and they are a large travel company.\n- TripAd", "price_info": {"HLT": {"company": "", "ticker": "HLT", "move": "up"}, "EXPE": {"company": "", "ticker": "EXPE", "move": "up", "prices": [127.29, 126.81]}, "MAR": {"company": "", "ticker": "MAR", "move": "up", "prices": [133.78, 133.68]}}}, {"link": "https://www.wsj.com/articles/treasury-secretary-finds-no-security-concerns-with-google-work-in-china-11563976459", "title": "Treasury Secretary Finds No Security Concerns With Google Work in China", "date": "2019-07-24 10:10", "summary": "Findings rebuke claims made by billionaire investor Peter Thiel. Treasury Secretary Steven Mnuchin said he and President Trump have found no national security concerns about work that Google is doing in China, a rebuke of claims made by billionaire investor and Facebook Inc. board member Peter Thiel.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury Secretary Finds No Security Concerns With Google Work in China. Findings rebuke claims made by billionaire investor Peter Thiel. Treasury Secretary Steven Mnuchin said he and President Trump have found no national security concerns about work that Google is doing in China, a rebuke of claims made by billionaire investor and Facebook Inc. board member Peter Thiel.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because the Trump administration has found no security concerns with their work in China.\n- Facebook Inc. (NASDAQ: FB) will decrease because Thiel, one of their board members, has spoken out against their work in China.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1140.73, 1136.295]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [201.65, 201.58]}}}, {"link": "https://www.wsj.com/articles/after-record-u-s-corporate-bond-sales-slowdown-expected-11601631003", "title": "After Record U.S. Corporate-Bond Sales, Slowdown Expected", "date": "2020-10-02 15:42", "summary": "Blockbuster issuance could fade as refinancings ebb and companies cut debt. U.S. companies sold more debt during the third quarter of 2020 than ever before, extending this year's record-breaking bond bonanza into the second half of the year even as some analysts predict a slowdown.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"After Record U.S. Corporate-Bond Sales, Slowdown Expected. Blockbuster issuance could fade as refinancings ebb and companies cut debt. U.S. companies sold more debt during the third quarter of 2020 than ever before, extending this year's record-breaking bond bonanza into the second half of the year even as some analysts predict a slowdown.\"\n\nStock Prediction(s):", "Prediction": "\n- The bond market will cool off, and this will cause a decrease in the stock prices of companies that have issued a lot of debt, such as Ford Motor Company (NYSE: F), General Motors Company (NYSE: GM), and Tesla, Inc. (NASDAQ: TSLA).\n- The bond market will cool off, and this will cause a decrease in the stock prices of companies that are heavily reliant on debt, such as Netflix, Inc. (NAS", "price_info": {"F": {"company": "", "ticker": "F", "move": "down", "prices": [6.8898, 6.89]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [30.46, 30.55]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [415.09, 415]}}}, {"link": "https://www.wsj.com/articles/eu-u-k-drop-border-travel-restrictions-lessening-burden-of-flying-11643127604", "title": "EU, U.K. Drop Border Travel Curbs, Lessening Burden of Flying", "date": "2022-01-25 11:20", "summary": "Fully vaccinated passengers don't need to test or quarantine as governments loosen rules after Omicron wave. LONDON-The European Union is lifting Covid-19 travel restrictions, allowing member countries to do away with quarantine and testing for vaccinated fliers traveling inside the bloc.", "categories": [["Business", "Europe"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/europe-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"EU, U.K. Drop Border Travel Curbs, Lessening Burden of Flying. Fully vaccinated passengers don't need to test or quarantine as governments loosen rules after Omicron wave. LONDON-The European Union is lifting Covid-19 travel restrictions, allowing member countries to do away with quarantine and testing for vaccinated fliers traveling inside the bloc.\"\n\nStock Prediction(s):", "Prediction": "\n- Airlines will increase because the travel restrictions have been lifted.\n- Hotel companies will increase because the travel restrictions have been lifted.\n- Restaurants will increase because the travel restrictions have been lifted.", "price_info": {}}, {"link": "https://www.wsj.com/articles/ecb-looks-to-keep-rates-low-for-longer-11626955611", "title": "ECB Looks to Keep Rates Low for Longer", "date": "2021-07-22 12:20", "summary": "European Central Bank says it won't increase its key interest rate until inflation moves much closer to 2% target. FRANKFURT-The European Central Bank signaled that it would support the eurozone economy by keeping interest rates low for longer as a surge in Covid-19 cases driven by the highly contagious Delta variant triggers new social restrictions and weighs on the region's large tourism industry.", "categories": [["Economy", "Europe Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/europe-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"ECB Looks to Keep Rates Low for Longer. European Central Bank says it won't increase its key interest rate until inflation moves much closer to 2% target. FRANKFURT-The European Central Bank signaled that it would support the eurozone economy by keeping interest rates low for longer as a surge in Covid-19 cases driven by the highly contagious Delta variant triggers new social restrictions and weighs on the region's large tourism industry.\"\n\nStock Prediction(s):", "Prediction": "\n- European Central Bank (ECB) will keep interest rates low for longer because of Covid-19.\n- The Travelers Companies, Inc. (NYSE: TRV) will increase because the ECB's decision will help the tourism industry.\n- American Express Company (NYSE: AXP) will increase because the ECB's decision will help the tourism industry.\n- Visa Inc. (NYSE: V) will increase because the ECB's decision will help the tourism", "price_info": {"ECB": {"company": "Central Bank", "ticker": "ECB", "move": null}, "TRV": {"company": "", "ticker": "TRV", "move": "up", "prices": [147.6039, 148.1806]}, "AXP": {"company": "", "ticker": "AXP", "move": "up", "prices": [170.4, 171.45]}, "V": {"company": "", "ticker": "V", "move": "up", "prices": [244.74, 244.9543]}}}, {"link": "https://www.wsj.com/articles/emerging-market-currencies-rise-on-dovish-fed-11548958296", "title": "Emerging-Market Currencies Rise on Dovish Fed", "date": "2019-01-31 13:11", "summary": "Expectations that U.S. rates won't rise tend to raise the attractiveness of emerging-market assets. Emerging-market currencies rallied Thursday, as investors reacted to a dovish pivot from the Federal Reserve.", "categories": [["Markets", "Currencies", "Foreign Exchange"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/currencies?mod=breadcrumb", "https://www.wsj.com/news/types/foreign-exchange?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Emerging-Market Currencies Rise on Dovish Fed. Expectations that U.S. rates won't rise tend to raise the attractiveness of emerging-market assets. Emerging-market currencies rallied Thursday, as investors reacted to a dovish pivot from the Federal Reserve.\"\n\nStock Prediction(s):", "Prediction": "\n- The Brazilian real (BRL) will continue to rise because the Fed is not going to raise rates, which makes emerging-market assets more attractive.\n- The Turkish lira (TRY) will continue to rise because the Fed is not going to raise rates, which makes emerging-market assets more attractive.\n- The Indian rupee (INR) will continue to rise because the Fed is not going to raise rates, which makes emerging-market assets more attractive", "price_info": {"BRL": {"company": "", "ticker": "BRL", "move": "up"}, "TRY": {"company": "", "ticker": "TRY", "move": "up"}, "INR": {"company": "", "ticker": "INR", "move": "up"}}}, {"link": "https://www.wsj.com/articles/coronavirus-speeds-up-starbucks-shiftto-takeout-11591790405", "title": "Coronavirus Speeds Up Starbucks Shift to Takeout", "date": "2020-06-10 12:03", "summary": "Coffee chain plans to open dozens of pickup-only stores, says it sees pandemic cutting revenue by up to $3.2 billion in current quarter. Starbucks Corp. said it would close some traditional cafes and open more to-go locations as the chain known for spreading coffee shops across the globe bets more on convenience and speed.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Speeds Up Starbucks Shift to Takeout. Coffee chain plans to open dozens of pickup-only stores, says it sees pandemic cutting revenue by up to $3.2 billion in current quarter. Starbucks Corp. said it would close some traditional cafes and open more to-go locations as the chain known for spreading coffee shops across the globe bets more on convenience and speed.\"\n\nStock Prediction(s):", "Prediction": "\n- Starbucks Corp. (NASDAQ: SBUX) will increase because they are pivoting to takeout-only stores, which will be more convenient and faster during the pandemic.\n- Dunkin' Brands Group Inc. (NASDAQ: DNKN) will decrease because they are not as well-prepared for the pandemic, and Starbucks will take market share.", "price_info": {"SBUX": {"company": "", "ticker": "SBUX", "move": "up", "prices": [78.425, 79.28]}, "DNKN": {"company": "", "ticker": "DNKN", "move": "down", "prices": [67.8725, 68.17]}}}, {"link": "https://www.wsj.com/articles/feds-clarida-says-economy-could-warrant-interest-rate-increases-by-early-2023-11628085600", "title": "Interest-Rate Rises Could Come as Soon as Early '23, Fed's Clarida Says", "date": "2021-08-04 11:05", "summary": "Significant fiscal stimulus should speed faster recovery to central bank's goals, according to Fed vice chairman. Significant fiscal stimulus this year is speeding the economy's recovery so that the Federal Reserve is able to consider lifting interest rates from near zero by early 2023, said a top central bank official in a speech Wednesday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Interest-Rate Rises Could Come as Soon as Early '23, Fed's Clarida Says. Significant fiscal stimulus should speed faster recovery to central bank's goals, according to Fed vice chairman. Significant fiscal stimulus this year is speeding the economy's recovery so that the Federal Reserve is able to consider lifting interest rates from near zero by early 2023, said a top central bank official in a speech Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- The interest rate hikes will have a positive effect on banks such as JPMorgan Chase & Co. (NYSE: JPM) and Wells Fargo & Co. (NYSE: WFC), as well as other companies that rely on borrowing money, such as General Electric Co. (NYSE: GE).\n- The interest rate hikes will have a negative effect on companies that are already struggling, such as Ford Motor Co. (NYSE: F) and Sears Holdings Corp. (OTCM", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": null, "prices": [152.28, 151.88]}, "WFC": {"company": "", "ticker": "WFC", "move": null, "prices": [46.53, 46.46]}, "GE": {"company": "", "ticker": "GE", "move": null, "prices": [101.9466, 102.11]}, "F": {"company": "Wells", "ticker": "F", "move": "up", "prices": [13.5504, 13.511]}}}, {"link": "https://www.wsj.com/articles/microsoft-windows-11-guide-11624549583", "title": "Microsoft's Windows 11: The Big New PC Features Coming This Year", "date": "2021-06-25 11:07", "summary": "A redesigned interface, new productivity features and the ability to run Android apps are all key to Microsoft's plan to give PCs a fresh 'Start'-and take on Google and Apple. You don't have to be a Microsoft historian to see the ping-pong pattern:", "categories": [["Tech", "Personal Tech", "Personal Technology: Joanna Stern"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Microsoft's Windows 11: The Big New PC Features Coming This Year. A redesigned interface, new productivity features and the ability to run Android apps are all key to Microsoft's plan to give PCs a fresh 'Start'-and take on Google and Apple. You don't have to be a Microsoft historian to see the ping-pong pattern:\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are releasing a new version of Windows that has a lot of new features.\n- Google Inc. (NASDAQ: GOOGL) will increase because they are releasing a new version of Android that will be able to run on PCs.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are not releasing a new version of their operating system this year.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [265.6625, 264.84]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2433.885, 2439.7]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [133.3017, 133.4299]}}}, {"link": "https://www.wsj.com/articles/food-exporters-resist-chinas-new-coronavirus-restrictions-11593094481", "title": "Food Exporters Resist China's New Coronavirus Restrictions", "date": "2020-06-25 10:14", "summary": "Customs authority requests companies sign documents declaring products aren't contaminated with the virus. China is tightening restrictions on food imports as it seeks to stave off a resurgence of the coronavirus, but its efforts are meeting resistance from government agencies of major food exporters.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Food Exporters Resist China's New Coronavirus Restrictions. Customs authority requests companies sign documents declaring products aren't contaminated with the virus. China is tightening restrictions on food imports as it seeks to stave off a resurgence of the coronavirus, but its efforts are meeting resistance from government agencies of major food exporters.\"\n\nStock Prediction(s):", "Prediction": "\n- Archer Daniels Midland Company (NYSE: ADM) will increase because they are not affected by the new restrictions, and they are a major food exporter.\n- Cargill, Incorporated (NYSE: CAR) will increase because they are not affected by the new restrictions, and they are a major food exporter.\n- Bunge Limited (NYSE: BG) will increase because they are not affected by the new restrictions, and they are a major food", "price_info": {"ADM": {"company": "", "ticker": "ADM", "move": "up", "prices": [39.31, 39.33]}, "CAR": {"company": "", "ticker": "CAR", "move": "up", "prices": [21.7, 21.94]}, "BG": {"company": "", "ticker": "BG", "move": "up", "prices": [41.912, 42.045]}}}, {"link": "https://www.wsj.com/articles/oil-prices-pause-to-start-the-week-11549883074", "title": "Oil Falls to Two-Week Low on Stronger Dollar", "date": "2019-02-11 15:35", "summary": "Investors weigh supply worries against broader macroeconomic concerns. \u2022 Oil prices fell to a two-week low Monday due to a stronger dollar and simmering concerns that unresolved U.S.-China trade negotiations could hurt the global economy and reduce oil demand.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Falls to Two-Week Low on Stronger Dollar. Investors weigh supply worries against broader macroeconomic concerns. \u2022 Oil prices fell to a two-week low Monday due to a stronger dollar and simmering concerns that unresolved U.S.-China trade negotiations could hurt the global economy and reduce oil demand.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because oil prices are dropping and they are a direct competitor of other oil companies.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because oil prices are dropping and they are a direct competitor of other oil companies.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because oil prices are dropping and they are a direct competitor of other oil companies.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [116.795, 116.89]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [74.0167, 74.175]}}}, {"link": "https://www.wsj.com/articles/walgreens-posts-higher-profit-as-covid-19-vaccinations-continue-to-lift-sales-11634213420", "title": "Walgreens to Invest $5.2 Billion in VillageMD", "date": "2021-10-14 12:36", "summary": "The pharmacy chain plans to add doctors' offices to hundreds of drugstores. Walgreens Boots Alliance Inc. will pay $5.2 billion to acquire a controlling stake in primary-care network VillageMD as the pharmacy chain seeks to remodel itself as a healthcare provider.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walgreens to Invest $5.2 Billion in VillageMD. The pharmacy chain plans to add doctors' offices to hundreds of drugstores. Walgreens Boots Alliance Inc. will pay $5.2 billion to acquire a controlling stake in primary-care network VillageMD as the pharmacy chain seeks to remodel itself as a healthcare provider.\"\n\nStock Prediction(s):", "Prediction": "\n- Walgreens Boots Alliance Inc. (NASDAQ: WBA) will increase because they are investing in healthcare and primary-care.\n- CVS Health Corp. (NYSE: CVS) will decrease because they are not investing in healthcare and primary-care.", "price_info": {"CVS": {"company": "", "ticker": "CVS", "move": "down", "prices": [85.305, 85.1838]}, "WBA": {"company": "", "ticker": "WBA", "move": "up", "prices": [51.1072, 51.11]}}}, {"link": "https://www.wsj.com/articles/consumer-sentiment-falls-11565965412", "title": "Trade Jitters Dent Consumer Sentiment", "date": "2019-08-16 11:26", "summary": "Americans conclude that they may need to reduce spending in anticipation of a potential recession, economist says. WASHINGTON-U.S. household sentiment dropped to a seven-month low in August, as consumers took fright from the implications of trade uncertainties and the Federal Reserve's recent rate cut.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trade Jitters Dent Consumer Sentiment. Americans conclude that they may need to reduce spending in anticipation of a potential recession, economist says. WASHINGTON-U.S. household sentiment dropped to a seven-month low in August, as consumers took fright from the implications of trade uncertainties and the Federal Reserve's recent rate cut.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc (NYSE: WMT) will decrease because of the trade jitters and the potential recession.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because of the trade jitters and the potential recession.\n- Nike, Inc. (NYSE: NKE) will decrease because of the trade jitters and the potential recession.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [112.51, 113.19]}, "NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [80.4, 80.33]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1797.28, 1801.55]}}}, {"link": "https://www.wsj.com/articles/njoy-a-once-bankrupt-e-cigarette-maker-now-seeks-5-billion-valuation-11556736164", "title": "NJOY, a Once Bankrupt E-Cigarette Maker, Now Seeks $5 Billion Valuation", "date": "2019-05-01 14:56", "summary": "Company rolls out new device and seeks out big tobacco companies looking to take a run at Juul. E-cigarette maker NJOY Holdings Inc. is pursuing a funding round that would value the company at as much as $5 billion, and it is trying to interest big tobacco companies looking to take a run at market leader Juul Labs, according to people familiar with the matter.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"NJOY, a Once Bankrupt E-Cigarette Maker, Now Seeks $5 Billion Valuation. Company rolls out new device and seeks out big tobacco companies looking to take a run at Juul. E-cigarette maker NJOY Holdings Inc. is pursuing a funding round that would value the company at as much as $5 billion, and it is trying to interest big tobacco companies looking to take a run at market leader Juul Labs, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- NJOY Holdings Inc. (NYSE: NJOY) will increase because they are a major player in the e-cigarette market, and they are now seeking a $5 billion valuation.\n- Juul Labs (NYSE: JUUL) will decrease because they are being pursued by NJOY, and they may lose market share.", "price_info": {"NJOY": {"company": "", "ticker": "NJOY", "move": "up"}, "JUUL": {"company": "", "ticker": "JUUL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/copper-gold-edge-down-ahead-of-fed-decision-11553079859", "title": "Gold Reverses Losses After Fed Decision", "date": "2019-03-20 15:36", "summary": "Central bank holds benchmark interest rate steady. Gold prices reversed losses in electronic trading Wednesday, after a dovish monetary-policy statement from the Federal Reserve.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold Reverses Losses After Fed Decision. Central bank holds benchmark interest rate steady. Gold prices reversed losses in electronic trading Wednesday, after a dovish monetary-policy statement from the Federal Reserve.\"\n\nStock Prediction(s):", "Prediction": "\n- Gold prices will continue to rise because the Federal Reserve is keeping interest rates low.\n- The dollar will continue to fall because the Federal Reserve is keeping interest rates low.", "price_info": {}}, {"link": "https://www.wsj.com/articles/nissan-loses-6-2-billion-as-it-prepares-to-slim-down-11590658542", "title": "Nissan Loses $6.2 Billion as It Prepares to Slim Down", "date": "2020-05-28 10:21", "summary": "Auto maker to reduce capacity by 20%, close plant in Barcelona. TOKYO- Nissan Motor Co. said it would slash production capacity and trim its model lineup after reporting a $6.2 billion loss in its latest fiscal year, one of the worst in its history.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nissan Loses $6.2 Billion as It Prepares to Slim Down. Auto maker to reduce capacity by 20%, close plant in Barcelona. TOKYO- Nissan Motor Co. said it would slash production capacity and trim its model lineup after reporting a $6.2 billion loss in its latest fiscal year, one of the worst in its history.\"\n\nStock Prediction(s):", "Prediction": "\n- Nissan Motor Co. (OTCPK: NSANY) will decrease because they are losing money and preparing to slim down.\n- Honda Motor Co. Ltd. (NYSE: HMC) will increase because they are not losing money and are not preparing to slim down.\n- Toyota Motor Corp. (NYSE: TM) will increase because they are not losing money and are not preparing to slim down.", "price_info": {"HMC": {"company": "", "ticker": "HMC", "move": "up", "prices": [26.88, 27.035]}, "TM": {"company": "", "ticker": "TM", "move": "up", "prices": [128.7, 128.925]}}}, {"link": "https://www.wsj.com/articles/america-is-stuck-at-home-but-food-delivery-companies-still-struggle-to-profit-11589374801", "title": "America Is Stuck at Home, but Food-Delivery Companies Still Struggle to Profit", "date": "2020-05-13 10:09", "summary": "Coronavirus crisis creates a surge in orders but also costs, straining margins. The coronavirus pandemic handed food-delivery companies an unprecedented business opportunity: millions of Americans stuck at home, missing their favorite restaurants.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"America Is Stuck at Home, but Food-Delivery Companies Still Struggle to Profit. Coronavirus crisis creates a surge in orders but also costs, straining margins. The coronavirus pandemic handed food-delivery companies an unprecedented business opportunity: millions of Americans stuck at home, missing their favorite restaurants.\"\n\nStock Prediction(s):", "Prediction": "\n- Grubhub Inc (NYSE: GRUB) will increase because they are one of the few food-delivery companies that are still profitable.\n- DoorDash Inc (NYSE: DOORD) will increase because they are one of the few food-delivery companies that are still profitable.\n- Uber Technologies Inc (NYSE: UBER) will increase because they are one of the few food-delivery companies that are still profitable.\n- Postmates Inc", "price_info": {"GRUB": {"company": "", "ticker": "GRUB", "move": "up", "prices": [57.94, 57.2]}, "DOORD": {"company": "", "ticker": "DOORD", "move": "up"}, "UBER": {"company": "", "ticker": "UBER", "move": "up", "prices": [32.04, 31.81]}}}, {"link": "https://www.wsj.com/articles/mortgage-insurer-mgic-is-a-cheap-housing-play-11598362200", "title": "Mortgage Insurer MGIC Is a Cheap Housing Play", "date": "2020-08-25 09:30", "summary": "Builders aren't the only ones that benefit from a homebuying wave, and private insurers such as MGIC may not be quite as risky as they seem. The home-lending business is in for a wild ride this year. Mortgage insurers such as MGIC Investment Corp. may offer a surprising place to shelter.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Mortgage Insurer MGIC Is a Cheap Housing Play. Builders aren't the only ones that benefit from a homebuying wave, and private insurers such as MGIC may not be quite as risky as they seem. The home-lending business is in for a wild ride this year. Mortgage insurers such as MGIC Investment Corp. may offer a surprising place to shelter.\"\n\nStock Prediction(s):", "Prediction": "\n- MGIC Investment Corp. (NYSE: MTG) will increase because they are a cheap housing play and the home-lending business is in for a wild ride this year.\n- Lennar Corporation (NYSE: LEN) will increase because they are a builder and they will benefit from the homebuying wave.\n- D.R. Horton, Inc. (NYSE: DHI) will increase because they are a builder and they will benefit from the", "price_info": {"MTG": {"company": "", "ticker": "MTG", "move": "up", "prices": [8.92, 8.8242]}, "LEN": {"company": "", "ticker": "LEN", "move": "up", "prices": [77.83, 77.515]}, "DHI": {"company": "", "ticker": "DHI", "move": "up", "prices": [75.1299, 75.01]}}}, {"link": "https://www.wsj.com/articles/spotify-hits-the-right-notes-in-apple-complaint-11552495904", "title": "Spotify Hits the Right Notes in Apple Complaint", "date": "2019-03-13 12:51", "summary": "Streaming giant's EU complaint comes as app store fees and platform control are getting fresh scrutiny. As Spotify demonstrated Wednesday, it will take a taxman to beat a taxman.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Spotify Hits the Right Notes in Apple Complaint. Streaming giant's EU complaint comes as app store fees and platform control are getting fresh scrutiny. As Spotify demonstrated Wednesday, it will take a taxman to beat a taxman.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are being scrutinized for their App Store fees and platform control.\n- Spotify Technology SA (NYSE: SPOT) will increase because they are being scrutinized for their App Store fees and platform control.", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "up", "prices": [144.72, 143.6]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [182.4785, 182.32]}}}, {"link": "https://www.wsj.com/articles/investors-heres-how-to-brace-for-the-year-of-central-bank-divergence-11641312699", "title": "Investors, Here's How to Brace for the Year of Central Bank Divergence", "date": "2022-01-04 11:11", "summary": "Short-term bond markets point to very different monetary policies across countries, but lack of gyrations in longer-term paper is creating concerns. Markets are sending a hard message to decode: While the fate of the world's big economies is ultimately intertwined, their monetary policies will become quite different in 2022.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors, Here's How to Brace for the Year of Central Bank Divergence. Short-term bond markets point to very different monetary policies across countries, but lack of gyrations in longer-term paper is creating concerns. Markets are sending a hard message to decode: While the fate of the world's big economies is ultimately intertwined, their monetary policies will become quite different in 2022.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will become more volatile as different central banks adopt different policies.\n- The market will become more volatile as different central banks adopt different policies.\n- The market will become more volatile as different central banks adopt different policies.", "price_info": {}}, {"link": "https://www.wsj.com/articles/t-mobile-to-offer-customers-viacom-tv-channels-11554308824", "title": "T-Mobile to Offer Customers Viacom TV Channels", "date": "2019-04-03 12:27", "summary": "Owner of MTV, Nickelodeon to be part of video service the wireless carrier aims to launch this year. T-Mobile US Inc. struck a deal to offer Viacom Inc. channels to its cellphone customers, extending the telecom operator's foray into a turbulent pay-television industry.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"T-Mobile to Offer Customers Viacom TV Channels. Owner of MTV, Nickelodeon to be part of video service the wireless carrier aims to launch this year. T-Mobile US Inc. struck a deal to offer Viacom Inc. channels to its cellphone customers, extending the telecom operator's foray into a turbulent pay-television industry.\"\n\nStock Prediction(s):", "Prediction": "\n- T-Mobile US Inc. (NASDAQ: TMUS) will increase because they are expanding their services by adding Viacom channels.\n- Viacom Inc. (NASDAQ: VIAB) will increase because they are being added to T-Mobile's service, and they will likely gain new customers.\n- Comcast Corporation (NASDAQ: CMCSA) will decrease because they are losing customers to T-Mobile.", "price_info": {"TMUS": {"company": "", "ticker": "TMUS", "move": "up", "prices": [69.345, 68.86]}, "VIAB": {"company": "", "ticker": "VIAB", "move": "up", "prices": [29.315, 29.34]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "down", "prices": [40.25, 40.245]}}}, {"link": "https://www.wsj.com/articles/the-man-who-transformed-flying-finally-gets-his-spirit-frontier-deal-11644425417", "title": "The Man Who Transformed Flying Finally Gets His Spirit-Frontier Deal", "date": "2022-02-09 11:50", "summary": "William Franke, Frontier's chairman, helped popularize the ultra-low-cost airline model in the U.S. and around the world. Nearly a decade ago, William Franke, then the chairman of Spirit Airlines Inc., proposed that Spirit join his investment firm in a deal to buy Frontier Airlines .", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Man Who Transformed Flying Finally Gets His Spirit-Frontier Deal. William Franke, Frontier's chairman, helped popularize the ultra-low-cost airline model in the U.S. and around the world. Nearly a decade ago, William Franke, then the chairman of Spirit Airlines Inc., proposed that Spirit join his investment firm in a deal to buy Frontier Airlines .\"\n\nStock Prediction(s):", "Prediction": "\n- Frontier Airlines Holdings, Inc. (NASDAQ: FRNT) will increase because William Franke is the chairman and he is known for popularizing the ultra-low-cost airline model.\n- Spirit Airlines, Inc. (NASDAQ: SAVE) will increase because William Franke is the chairman and he is known for popularizing the ultra-low-cost airline model.", "price_info": {"FRNT": {"company": "", "ticker": "FRNT", "move": "up"}, "SAVE": {"company": "", "ticker": "SAVE", "move": "up", "prices": [27.71, 27.84]}}}, {"link": "https://www.wsj.com/articles/andy-jassys-climb-to-amazon-ceo-shows-the-clouds-rising-power-11612363207", "title": "Jassy's Climb to Amazon CEO Shows the Cloud's Rising Power", "date": "2021-02-03 09:40", "summary": "Business of providing remote computer services represents about 10% of Amazon's sales but produced its next leader. The elevation of Andy Jassy to become Amazon.com Inc.'s next chief executive is one of the clearest signs yet that fortunes in the tech industry are increasingly made in the cloud.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jassy's Climb to Amazon CEO Shows the Cloud's Rising Power. Business of providing remote computer services represents about 10% of Amazon's sales but produced its next leader. The elevation of Andy Jassy to become Amazon.com Inc.'s next chief executive is one of the clearest signs yet that fortunes in the tech industry are increasingly made in the cloud.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because their cloud services are becoming more and more important, and they have a clear leader in Andy Jassy.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because their cloud services are becoming more and more important, and they have a clear leader in Andy Jassy.\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because their cloud services are becoming", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3361.5395, 3364.885]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [240.2, 242.1646]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2025.96, 2066.26]}}}, {"link": "https://www.wsj.com/articles/harvest-slowdown-brews-up-higher-coffee-prices-11574859603", "title": "Harvest Slowdown Brews Up Higher Coffee Prices", "date": "2019-11-27 15:42", "summary": "Dry weather in Latin America has eaten into arabica output, boosting futures. ", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Harvest Slowdown Brews Up Higher Coffee Prices. Dry weather in Latin America has eaten into arabica output, boosting futures. \"\n\nStock Prediction(s):", "Prediction": "\n- Starbucks Corporation (NASDAQ: SBUX) will increase because of the higher coffee prices.\n- Dunkin' Brands Group, Inc. (NASDAQ: DNKN) will increase because of the higher coffee prices.\n- The J.M. Smucker Company (NYSE: SJM) will increase because of the higher coffee prices.\n- Peet's Coffee & Tea, Inc. (NASDAQ: PEET) will increase because of the higher coffee", "price_info": {"SJM": {"company": "", "ticker": "SJM", "move": "up", "prices": [105.805, 106.08]}, "SBUX": {"company": "", "ticker": "SBUX", "move": "up", "prices": [85.755, 85.75]}, "DNKN": {"company": "", "ticker": "DNKN", "move": "up", "prices": [76.77, 76.71]}, "PEET": {"company": "", "ticker": "PEET", "move": "up"}}}, {"link": "https://www.wsj.com/articles/junk-loans-shine-amid-market-rout-11643068646", "title": "Junk Loans Shine Amid Market Rout", "date": "2022-01-25 14:48", "summary": "Investors put a record $2.25 billion into leveraged loan mutual funds last week. Fear of rising interest rates has shaken most markets this month, with a notable exception: junk-rated corporate loans.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Junk Loans Shine Amid Market Rout. Investors put a record $2.25 billion into leveraged loan mutual funds last week. Fear of rising interest rates has shaken most markets this month, with a notable exception: junk-rated corporate loans.\"\n\nStock Prediction(s):", "Prediction": "\n- The market rout will continue, and investors will pull out of high-risk investments like leveraged loan mutual funds.\n- The market rout will continue, and investors will pull out of junk-rated corporate loans.\n- The market rout will continue, and investors will pull out of all high-risk investments.", "price_info": {}}, {"link": "https://www.wsj.com/articles/wall-street-is-looking-to-reddit-for-investment-advice-11630056648", "title": "Wall Street Is Looking to Reddit for Investment Advice", "date": "2021-08-27 14:27", "summary": "Deep-pocketed banks and hedge funds now take their cues from armies of Main Street traders. Wall Street professionals tell everyday investors what stocks to buy. But now they have to follow some of these amateurs for signs of where the market is headed next.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wall Street Is Looking to Reddit for Investment Advice. Deep-pocketed banks and hedge funds now take their cues from armies of Main Street traders. Wall Street professionals tell everyday investors what stocks to buy. But now they have to follow some of these amateurs for signs of where the market is headed next.\"\n\nStock Prediction(s):", "Prediction": "\n- The overall market will decrease because the \"amateur\" investors are not as knowledgeable as the Wall Street professionals.\n- Bank of America (NYSE: BAC) will decrease because they are not getting the same level of information from the \"amateur\" investors.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are not getting the same level of information from the \"amateur\" investors.\n- Goldman Sachs Group Inc. (NYSE", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [42.4044, 42.51]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [162.795, 163.02]}}}, {"link": "https://www.wsj.com/articles/zoom-gets-drawn-into-debate-about-policing-content-a-big-thankless-job-11604408401", "title": "Zoom Video Tackles Tricky Role of Policing Its Service", "date": "2020-11-03 09:40", "summary": "Videoconferencing app is looking at its handling of politically sensitive public events after recent criticisms. Zoom Video Communications Inc.'s rise as a lifeline for many businesses and individuals during the pandemic is drawing the company into a fraught area that has caused problems at much larger tech firms: policing its service.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Zoom Video Tackles Tricky Role of Policing Its Service. Videoconferencing app is looking at its handling of politically sensitive public events after recent criticisms. Zoom Video Communications Inc.'s rise as a lifeline for many businesses and individuals during the pandemic is drawing the company into a fraught area that has caused problems at much larger tech firms: policing its service.\"\n\nStock Prediction(s):", "Prediction": "\n- Zoom Video Communications Inc. (NASDAQ: ZM) will increase because they are being proactive in policing their service.\n- Facebook Inc. (NASDAQ: FB) will decrease because they have been criticized for not policing their service enough.", "price_info": {"ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [452.8453, 457.7]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [262.3553, 266.9587]}}}, {"link": "https://www.wsj.com/articles/the-one-amazon-prime-day-deal-that-walmart-and-target-cant-match-11563213138", "title": "The Amazon Prime Day Deal That Walmart and Target Can't Match", "date": "2019-07-15 14:15", "summary": "Amazon uses annual July sales event to sign up Prime members, adding a revenue stream that others don't have. Amazon.com Inc. and other big retailers kicked off an annual July sales event that has come to rival Black Friday in terms of discounts and the surge in online shopping.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Amazon Prime Day Deal That Walmart and Target Can't Match. Amazon uses annual July sales event to sign up Prime members, adding a revenue stream that others don't have. Amazon.com Inc. and other big retailers kicked off an annual July sales event that has come to rival Black Friday in terms of discounts and the surge in online shopping.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will continue to grow because they have a Prime Day deal that Walmart and Target can't match.\n- Walmart Inc. (NYSE: WMT) will decrease because they can't match Amazon's Prime Day deal.\n- Target Corporation (NYSE: TGT) will decrease because they can't match Amazon's Prime Day deal.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [114.69, 114.8601]}, "TGT": {"company": "", "ticker": "TGT", "move": "down", "prices": [86.715, 86.83]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [2018, 2020]}}}, {"link": "https://www.wsj.com/articles/farmers-start-to-get-high-on-hemp-11570647008", "title": "Farmers Start to Get High on Hemp", "date": "2019-10-09 14:50", "summary": "Amid growing consumer demand for CBD and changes in legislation, growers are devoting more acreage to planting hemp. After years of falling crop prices, some farmers see a lifeline in hemp.", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Farmers Start to Get High on Hemp. Amid growing consumer demand for CBD and changes in legislation, growers are devoting more acreage to planting hemp. After years of falling crop prices, some farmers see a lifeline in hemp.\"\n\nStock Prediction(s):", "Prediction": "\n- GW Pharmaceuticals plc (NASDAQ: GWPH) will increase because they are a major player in the CBD market, and this news will only increase demand for their products.\n- Aurora Cannabis Inc (NYSE: ACB) will increase because they are a major player in the CBD market, and this news will only increase demand for their products.\n- Canopy Growth Corporation (NYSE: CGC) will increase because they are a major player in the CBD", "price_info": {"ACB": {"company": "", "ticker": "ACB", "move": "up", "prices": [4.105, 4.11]}, "CGC": {"company": "", "ticker": "CGC", "move": "up", "prices": [22.78, 22.99]}, "GWPH": {"company": "", "ticker": "GWPH", "move": "up", "prices": [110.72, 111.2]}}}, {"link": "https://www.wsj.com/articles/hp-rejects-xerox-takeover-offer-11583408223", "title": "HP Rejects Xerox's Raised Takeover Offer", "date": "2020-03-05 11:44", "summary": "Company says a combination would disproportionately benefit Xerox shareholders. HP Inc. rejected Xerox Holdings Corp.'s $35 billion bid to take over the maker of printers, printer supplies and personal computers, again deeming the offer as too low.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"HP Rejects Xerox's Raised Takeover Offer. Company says a combination would disproportionately benefit Xerox shareholders. HP Inc. rejected Xerox Holdings Corp.'s $35 billion bid to take over the maker of printers, printer supplies and personal computers, again deeming the offer as too low.\"\n\nStock Prediction(s):", "Prediction": "\n- HP Inc. (NYSE: HPQ) will increase because they are a valuable company that has been rejected by a competitor.\n- Xerox Holdings Corp. (NYSE: XRX) will increase because they are a valuable company that has been rejected by a competitor.", "price_info": {"HPQ": {"company": "", "ticker": "HPQ", "move": "up", "prices": [21.35, 21.32]}, "XRX": {"company": "", "ticker": "XRX", "move": "up", "prices": [32.213, 31.68]}}}, {"link": "https://www.wsj.com/articles/store-brands-could-make-a-name-for-themselves-this-year-11624458373", "title": "Store Brands Could Make a Name for Themselves This Year", "date": "2021-06-23 11:44", "summary": "After a boost from the 2008 recession, private-label food has seen stagnating market share. This year could change that.. Inflation today looks nothing like what it did in the 1970s, but neither do today's private-label food products (organic frozen pizza, anyone?). That bodes well for store-branded products, which have had a sleepy few years of market-share growth.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Store Brands Could Make a Name for Themselves This Year. After a boost from the 2008 recession, private-label food has seen stagnating market share. This year could change that.. Inflation today looks nothing like what it did in the 1970s, but neither do today's private-label food products (organic frozen pizza, anyone?). That bodes well for store-branded products, which have had a sleepy few years of market-share growth.\"\n\nStock Prediction(s):", "Prediction": "\n- Kroger Co (NYSE: KR) will increase because they have a strong private-label food line.\n- Walmart Inc (NYSE: WMT) will increase because they have a strong private-label food line.\n- Costco Wholesale Corporation (NASDAQ: COST) will increase because they have a strong private-label food line.\n- Target Corporation (NYSE: TGT) will increase because they have a strong private-label food line.", "price_info": {"KR": {"company": "", "ticker": "KR", "move": "up", "prices": [39.495, 39.54]}, "WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [136.5593, 136.495]}, "TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [237.735, 237.4082]}, "COST": {"company": "", "ticker": "COST", "move": "up", "prices": [392.226, 393.13]}}}, {"link": "https://www.wsj.com/articles/court-deals-another-blow-to-marble-ridge-in-neiman-fight-11554921146", "title": "Court Deals Another Blow to Marble Ridge in Neiman Fight", "date": "2019-04-10 14:32", "summary": "Judge allows countersuit by luxury department store operator to move forward. Debt activist Marble Ridge Capital LP suffered another setback in its litigation against Neiman Marcus Group when a judge allowed a countersuit by the luxury department store operator to go forward.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Court Deals Another Blow to Marble Ridge in Neiman Fight. Judge allows countersuit by luxury department store operator to move forward. Debt activist Marble Ridge Capital LP suffered another setback in its litigation against Neiman Marcus Group when a judge allowed a countersuit by the luxury department store operator to go forward.\"\n\nStock Prediction(s):", "Prediction": "\n- Marble Ridge Capital LP (NASDAQ: MARBL) will decrease because they are losing the legal battle against Neiman Marcus Group.\n- Neiman Marcus Group (NYSE: NMG) will increase because they are winning the legal battle against Marble Ridge Capital LP.", "price_info": {"NMG": {"company": "", "ticker": "NMG", "move": "up"}, "MARBL": {"company": "", "ticker": "MARBL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/u-s-government-contractor-embedded-software-in-apps-to-track-phones-11596808801", "title": "U.S. Contractor Embedded Software in Apps to Track Phones", "date": "2020-08-07 10:00", "summary": "Anomaly Six has ties to military, intelligence agencies and draws location data from more than 500 apps with hundreds of millions of users. WASHINGTON-A small U.S. company with ties to the U.S. defense and intelligence communities has embedded its software in numerous mobile apps, allowing it to track the movements of hundreds of millions of mobile phones world-wide, according to interviews and documents reviewed by The Wall Street Journal.", "categories": [["WSJ News Exclusive", "National Security"]], "category_links": ["https://www.wsj.com/news/types/national-security?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Contractor Embedded Software in Apps to Track Phones. Anomaly Six has ties to military, intelligence agencies and draws location data from more than 500 apps with hundreds of millions of users. WASHINGTON-A small U.S. company with ties to the U.S. defense and intelligence communities has embedded its software in numerous mobile apps, allowing it to track the movements of hundreds of millions of mobile phones world-wide, according to interviews and documents reviewed by The Wall Street Journal.\"\n\nStock Prediction(s):", "Prediction": "\n- Anomaly Six (private) will increase because they have a product that is being used by many companies and it gives them the ability to track the movements of hundreds of millions of people.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are a direct competitor of Anomaly Six and they have been known to sell products that violate people's privacy.\n- Google LLC (NASDAQ: GOOGL) will decrease because they are a direct", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [452.97, 448.8912]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [1512.9, 1503.93]}}}, {"link": "https://www.wsj.com/articles/google-is-the-only-big-tech-priced-for-trouble-11603214336", "title": "Google Is the Only Big Tech Priced for Trouble", "date": "2020-10-20 13:18", "summary": "Antitrust suit against search giant puts tech investors on notice. Google has turned out to be first in the federal government's firing line. Its big tech peers may pay a bigger price for waiting their turn.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Google Is the Only Big Tech Priced for Trouble. Antitrust suit against search giant puts tech investors on notice. Google has turned out to be first in the federal government's firing line. Its big tech peers may pay a bigger price for waiting their turn.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease because of the antitrust suit against Google.\n- Facebook Inc. (NASDAQ: FB) will decrease because of the antitrust suit against Google.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because of the antitrust suit against Google.\n- Apple Inc. (NASDAQ: AAPL) will decrease because of the antitrust suit against Google.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [1569.6509, 1557]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [269.43, 267.288]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3258.8645, 3216.2828]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [118.43, 117.2688]}}}, {"link": "https://www.wsj.com/articles/alden-is-in-talks-to-buy-tribune-publishing-11613067818", "title": "Alden Is in Talks to Buy Tribune Publishing", "date": "2021-02-11 13:23", "summary": "The hedge fund already owns a big stake in the newspaper chain behind titles including the Chicago Tribune and New York Daily News. A hedge fund that owns a big stake in Tribune Publishing Co. is in talks to buy the newspaper chain behind titles including the Chicago Tribune and New York Daily News.", "categories": [["WSJ News Exclusive", "Deals"]], "category_links": ["https://www.wsj.com/news/types/deals-deal-makers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Alden Is in Talks to Buy Tribune Publishing. The hedge fund already owns a big stake in the newspaper chain behind titles including the Chicago Tribune and New York Daily News. A hedge fund that owns a big stake in Tribune Publishing Co. is in talks to buy the newspaper chain behind titles including the Chicago Tribune and New York Daily News.\"\n\nStock Prediction(s):", "Prediction": "\n- Tribune Publishing Co. (OTCQB: TPUB) will increase because they are being bought out by a hedge fund.\n- Gannett Co., Inc. (NYSE: GCI) will decrease because they are losing one of their main competitors.", "price_info": {"GCI": {"company": "", "ticker": "GCI", "move": "down", "prices": [5.11, 5.02]}}}, {"link": "https://www.wsj.com/articles/draftkings-abandons-22-billion-bid-for-entain-11635257501", "title": "DraftKings Abandons $22 Billion Bid for Entain", "date": "2021-10-26 12:47", "summary": "U.S. sports-betting operator walks away from offer to buy British competitor, saying decision follows negotiations with Entain's leadership. DraftKings Inc. is dropping its roughly $22 billion bid for Entain PLC, turning away from an attempt to buy a major international player in the gambling industry.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"DraftKings Abandons $22 Billion Bid for Entain. U.S. sports-betting operator walks away from offer to buy British competitor, saying decision follows negotiations with Entain's leadership. DraftKings Inc. is dropping its roughly $22 billion bid for Entain PLC, turning away from an attempt to buy a major international player in the gambling industry.\"\n\nStock Prediction(s):", "Prediction": "\n- DraftKings Inc. (NASDAQ: DFS) will decrease because they are no longer trying to buy Entain PLC.\n- Entain PLC (LON: ETA) will increase because they are no longer being pursued by DraftKings.", "price_info": {"DFS": {"company": "", "ticker": "DFS", "move": "up", "prices": [123.003, 123.31]}}}, {"link": "https://www.wsj.com/articles/pfizer-identifies-lead-coronavirus-drug-candidate-11586427303", "title": "Pfizer Identifies Lead Coronavirus Drug Candidate", "date": "2020-04-09 15:56", "summary": "Experimental medicine to be tested on patients this summer; arthritis therapy Xeljanz considered, too. Pfizer Inc. has found a promising but early potential coronavirus treatment, which the drugmaker aims to begin testing in patients this summer.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pfizer Identifies Lead Coronavirus Drug Candidate. Experimental medicine to be tested on patients this summer; arthritis therapy Xeljanz considered, too. Pfizer Inc. has found a promising but early potential coronavirus treatment, which the drugmaker aims to begin testing in patients this summer.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will increase because they have identified a lead coronavirus drug candidate and they are already planning to test it on patients.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of Pfizer.\n- AstraZeneca plc (NASDAQ: AZN) will decrease because they are also working on a vaccine, but they are", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "up", "prices": [35.78, 35.7]}, "JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [141.2, 141.29]}, "AZN": {"company": "", "ticker": "AZN", "move": "down", "prices": [44.66, 44.66]}}}, {"link": "https://www.wsj.com/articles/saudis-other-opec-producers-consider-deeper-cuts-amid-pandemic-11604421735", "title": "Saudis, Other OPEC Producers Consider Deeper Cuts Amid Pandemic", "date": "2020-11-03 11:56", "summary": "Cartel had hoped to gradually reverse steep production cuts put in place to prop up prices amid demand shock. Saudi Arabia and other OPEC members are considering deepening oil production cuts amid rising Covid-19 cases in the West and fresh economic lockdowns in Europe that could curb oil demand further, according to oil officials and advisers in these countries.", "categories": [["WSJ News Exclusive", "Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudis, Other OPEC Producers Consider Deeper Cuts Amid Pandemic. Cartel had hoped to gradually reverse steep production cuts put in place to prop up prices amid demand shock. Saudi Arabia and other OPEC members are considering deepening oil production cuts amid rising Covid-19 cases in the West and fresh economic lockdowns in Europe that could curb oil demand further, according to oil officials and advisers in these countries.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (NYSE: ARAMCO) will increase because they are a key producer in OPEC, and they are preparing for deeper production cuts.\n- Chevron Corporation (NYSE: CVX) will increase because they are a key producer in OPEC, and they are preparing for deeper production cuts.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are a key producer in OPEC, and they are preparing for deeper production cuts.\n- Royal", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [72.13, 71.48]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [33.9216, 33.42]}}}, {"link": "https://www.wsj.com/articles/retailers-confront-coronavirus-uncertainty-11583235300", "title": "Retailers Confront Coronavirus Uncertainty", "date": "2020-03-03 12:02", "summary": "Target, Kohl's are upbeat about 2020 sales outlook despite fears surrounding epidemic. Target Corp. , Kohl's Corp. and other retailers that posted lackluster holiday results must now confront the uncertainty caused by the coronavirus epidemic, which could help or hurt sales in the coming months.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Retailers Confront Coronavirus Uncertainty. Target, Kohl's are upbeat about 2020 sales outlook despite fears surrounding epidemic. Target Corp. , Kohl's Corp. and other retailers that posted lackluster holiday results must now confront the uncertainty caused by the coronavirus epidemic, which could help or hurt sales in the coming months.\"\n\nStock Prediction(s):", "Prediction": "\n- Target Corp. (NYSE: TGT) will increase because they are upbeat about their 2020 sales outlook, despite the fears surrounding the epidemic.\n- Kohl's Corp. (NYSE: KSS) will decrease because they are not as upbeat about their 2020 sales outlook, and they are also being hurt by the epidemic.", "price_info": {"TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [106.62, 104.29]}, "KSS": {"company": "", "ticker": "KSS", "move": "down", "prices": [37.94, 37.69]}}}, {"link": "https://www.wsj.com/articles/judge-overseeing-purdue-pharma-sears-bankruptcies-to-retire-next-year-11632855735", "title": "Judge Overseeing Purdue Pharma, Sears Bankruptcies to Retire", "date": "2021-09-28 15:02", "summary": "Retirement of Judge Robert Drain announced weeks after he approved a $4.5 billion settlement between Purdue Pharma and its owners, the Sacklers. A New York bankruptcy judge who over the past two decades has steered some of the most contentious corporate bankruptcies, including the restructurings of OxyContin maker Purdue Pharma LP and Sears Holdings Corp. , will retire next year.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Judge Overseeing Purdue Pharma, Sears Bankruptcies to Retire. Retirement of Judge Robert Drain announced weeks after he approved a $4.5 billion settlement between Purdue Pharma and its owners, the Sacklers. A New York bankruptcy judge who over the past two decades has steered some of the most contentious corporate bankruptcies, including the restructurings of OxyContin maker Purdue Pharma LP and Sears Holdings Corp. , will retire next year.\"\n\nStock Prediction(s):", "Prediction": "\n- Purdue Pharma (NYSE: PPHM) will increase because the retirement of the judge will mean that the settlement will be finalized and they can move on from the bankruptcy.\n- Sears Holdings Corp. (NASDAQ: SHLD) will decrease because the retirement of the judge means that they may not be able to reorganize and will have to liquidate.", "price_info": {"PPHM": {"company": "", "ticker": "PPHM", "move": "up"}, "SHLD": {"company": "", "ticker": "SHLD", "move": "down"}}}, {"link": "https://www.wsj.com/articles/nbcuniversal-appoints-content-chief-new-boss-for-streaming-service-11570473815", "title": "NBCUniversal Appoints Content Chief, New Boss for Streaming Service", "date": "2019-10-07 14:43", "summary": "Bonnie Hammer to lead newly created TV-production business; Matt Strauss to head Peacock. Comcast Corp.'s NBCUniversal has consolidated its TV-production business and named a new head of its soon-to-be launched streaming service as part of a broad realignment of its entertainment operations, the company said Monday.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"NBCUniversal Appoints Content Chief, New Boss for Streaming Service. Bonnie Hammer to lead newly created TV-production business; Matt Strauss to head Peacock. Comcast Corp.'s NBCUniversal has consolidated its TV-production business and named a new head of its soon-to-be launched streaming service as part of a broad realignment of its entertainment operations, the company said Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- Comcast Corp. (NASDAQ: CMCSA) will increase because they are continuing to invest in their content production business.\n- NBCUniversal (Comcast) will increase because they have a new head of their streaming service.\n- ViacomCBS Inc. (NYSE: CBS) will decrease because they are losing one of their top executives.", "price_info": {"CBS": {"company": "", "ticker": "CBS", "move": "down"}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "up", "prices": [44.7, 44.59]}}}, {"link": "https://www.wsj.com/articles/facebook-to-shift-permanently-toward-more-remote-work-after-coronavirus-11590081300", "title": "Facebook to Shift Permanently Toward More Remote Work After Coronavirus", "date": "2020-05-21 15:16", "summary": "CEO Mark Zuckerberg sees long-term benefits in working from home, though new tools, techniques to manage policy shift are needed. Mark Zuckerberg is shifting Facebook Inc. toward a substantially remote workforce over the next decade, permanently reconfiguring the tech giant's operations around the dispersed structure that the coronavirus pandemic forced on it.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook to Shift Permanently Toward More Remote Work After Coronavirus. CEO Mark Zuckerberg sees long-term benefits in working from home, though new tools, techniques to manage policy shift are needed. Mark Zuckerberg is shifting Facebook Inc. toward a substantially remote workforce over the next decade, permanently reconfiguring the tech giant's operations around the dispersed structure that the coronavirus pandemic forced on it.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because their CEO is permanently moving the company toward a more remote work structure.\n- Other tech companies will also increase because they will need to compete with Facebook for the best remote workers.\n- Other companies that are not in the tech industry will decrease because they are not as prepared for a remote work structure.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [231.1, 231.39]}}}, {"link": "https://www.wsj.com/articles/inflation-isnt-whipped-just-tamer-11628699102", "title": "Inflation Isn't Whipped, Just Tamer", "date": "2021-08-11 12:25", "summary": "Cooler consumer price inflation in July isn't evidence that it will subside to pre-pandemic levels soon. Inflation is cooling down, but that doesn't mean it is about to go cold.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Inflation Isn't Whipped, Just Tamer. Cooler consumer price inflation in July isn't evidence that it will subside to pre-pandemic levels soon. Inflation is cooling down, but that doesn't mean it is about to go cold.\"\n\nStock Prediction(s):", "Prediction": "\n- The overall market will decrease because inflation isn't cooling down as much as people were expecting.\n- Walmart Inc (NYSE: WMT) will decrease because they are a retailer, and they are most affected by inflation.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are a retailer, and they are most affected by inflation.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [149.55, 149.92]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3292.26, 3279.885]}}}, {"link": "https://www.wsj.com/articles/new-york-fed-adds-115-14-billion-in-short-term-liquidity-to-markets-11573141440", "title": "Fed Adds $115.14 Billion in Short-Term Liquidity to Markets", "date": "2019-11-07 10:44", "summary": "Additions include $80.14 billion in overnight repurchase agreement and $35 billion 14-day repo. The New York Fed added $115.14 billion to financial markets via temporary operations on Thursday.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Adds $115.14 Billion in Short-Term Liquidity to Markets. Additions include $80.14 billion in overnight repurchase agreement and $35 billion 14-day repo. The New York Fed added $115.14 billion to financial markets via temporary operations on Thursday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve's injection of liquidity into the markets will cause an increase in most stocks.\n- The only exception is companies that are in direct competition with the New York Fed, such as JPMorgan Chase & Co. (NYSE: JPM) and Goldman Sachs Group Inc. (NYSE: GS).", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [130.7975, 130.99]}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [222.43, 224.46]}}}, {"link": "https://www.wsj.com/articles/sen-ron-wydens-capital-gains-tax-plan-devotes-trillions-to-social-security-11568296801", "title": "Sen. Ron Wyden's Capital-Gains Tax Plan Devotes Trillions to Social Security", "date": "2019-09-12 10:00", "summary": "A leading Democrat prepares for 2021, offering more details on plan to tax annual gains as income. WASHINGTON-Sen. Ron Wyden's proposal to restructure and increase capital-gains taxes would generate at least $1.5 trillion over a decade, dedicated to extending the solvency of Social Security, according to a more detailed plan the senator is releasing Thursday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Sen. Ron Wyden's Capital-Gains Tax Plan Devotes Trillions to Social Security. A leading Democrat prepares for 2021, offering more details on plan to tax annual gains as income. WASHINGTON-Sen. Ron Wyden's proposal to restructure and increase capital-gains taxes would generate at least $1.5 trillion over a decade, dedicated to extending the solvency of Social Security, according to a more detailed plan the senator is releasing Thursday.\"\n\nStock Prediction(s):", "Prediction": "\n- Sen. Ron Wyden's (D-Oregon) proposal to restructure and increase capital-gains taxes will decrease the stock prices of companies such as Apple Inc. (NASDAQ: AAPL), Microsoft Corporation (NASDAQ: MSFT), and Amazon.com, Inc. (NASDAQ: AMZN) because it will reduce consumer spending and slow economic growth.\n- The proposal will have a positive effect on the stock prices of companies such as AT", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [224.46, 225.7775]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [137.42, 137.49]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1846.97, 1844.4]}}}, {"link": "https://www.wsj.com/articles/saudi-arabia-seeks-to-ease-tensions-with-iran-11576178194", "title": "Saudis Seek to Ease Tensions With Iran", "date": "2019-12-12 14:16", "summary": "September attack on oil facilities was 'game-changer' for Riyadh; new stance aims to protect economy. Saudi Arabia is quietly trying to mend fences with Iran and other regional foes as officials in the kingdom have grown more worried about the risks conflict poses to its oil-dependent economy.", "categories": [["WSJ News Exclusive", "Middle East"]], "category_links": ["https://www.wsj.com/news/types/middle-east-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudis Seek to Ease Tensions With Iran. September attack on oil facilities was 'game-changer' for Riyadh; new stance aims to protect economy. Saudi Arabia is quietly trying to mend fences with Iran and other regional foes as officials in the kingdom have grown more worried about the risks conflict poses to its oil-dependent economy.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (NYSE: ARAMCO) will increase because they are the main producer of oil in Saudi Arabia, and they are trying to ease tensions with Iran.\n- National Iranian Oil Company (NYSE: NIOC) will increase because they are the main producer of oil in Iran, and they are trying to ease tensions with Saudi Arabia.\n- BP plc (NYSE: BP) will increase because they are a major producer of oil, and they will", "price_info": {"NIOC": {"company": "", "ticker": "NIOC", "move": "up"}, "BP": {"company": "", "ticker": "BP", "move": "up", "prices": [36.87, 36.9722]}}}, {"link": "https://www.wsj.com/articles/from-toxic-to-turnaround-bayers-ceo-fights-to-fix-a-problem-of-his-own-making-11581332607", "title": "Bayer's CEO Fights to Fix What He Broke", "date": "2020-02-10 10:57", "summary": "Werner Baumann has rebounded from his disastrous Monsanto acquisition, but his window to repair the damage might be closing. In April last year, Bayer AG Chief Executive Werner Baumann was on defense. The architect of one of the most disastrous acquisitions in German corporate history, he had become the country's first chief executive to lose a vote of confidence by shareholders.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bayer's CEO Fights to Fix What He Broke. Werner Baumann has rebounded from his disastrous Monsanto acquisition, but his window to repair the damage might be closing. In April last year, Bayer AG Chief Executive Werner Baumann was on defense. The architect of one of the most disastrous acquisitions in German corporate history, he had become the country's first chief executive to lose a vote of confidence by shareholders.\"\n\nStock Prediction(s):", "Prediction": "\n- Bayer Aktiengesellschaft (OTCMKTS: BAYRY) will increase because their CEO is fighting to fix the damage he has done.\n- Monsanto Company (NYSE: MON) will decrease because their CEO was replaced, and they are no longer affiliated with Bayer.", "price_info": {"MON": {"company": "", "ticker": "MON", "move": "down"}}}, {"link": "https://www.wsj.com/articles/the-case-for-replacing-some-bonds-with-annuities-11612454401", "title": "The Case for Replacing Some Bonds With Annuities", "date": "2021-02-04 11:00", "summary": "Unless you die relatively young, income annuities will give you more retirement spending power than bonds, some economists say. If you want to maximize how much you can safely spend in retirement, some economists say, sell some of your bonds and buy lifetime income annuities.", "categories": [["Markets", "Journal Reports: Funds/ETFs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Case for Replacing Some Bonds With Annuities. Unless you die relatively young, income annuities will give you more retirement spending power than bonds, some economists say. If you want to maximize how much you can safely spend in retirement, some economists say, sell some of your bonds and buy lifetime income annuities.\"\n\nStock Prediction(s):", "Prediction": "\n- Annuities will become more popular because they offer a guaranteed income, which is appealing to retirees.\n- Bond prices will decrease because people will sell them to buy annuities.", "price_info": {}}, {"link": "https://www.wsj.com/articles/burger-king-and-popeyes-deliver-higher-sales-for-rbi-11564755535", "title": "Burger King and Popeyes Deliver Higher Sales for RBI", "date": "2019-08-02 11:15", "summary": "Parent company of burger and chicken chains as well as Tim Hortons plans big international expansion. Burger King and Popeyes Louisiana Kitchen are driving sales for Restaurant Brands International Inc.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Burger King and Popeyes Deliver Higher Sales for RBI. Parent company of burger and chicken chains as well as Tim Hortons plans big international expansion. Burger King and Popeyes Louisiana Kitchen are driving sales for Restaurant Brands International Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Restaurant Brands International Inc. (NYSE: QSR) will increase because their burger and chicken chains are doing well.\n- McDonald's Corporation (NYSE: MCD) will decrease because their burger and chicken chains are doing poorly.", "price_info": {"QSR": {"company": "", "ticker": "QSR", "move": "up", "prices": [77.5877, 77.36]}, "MCD": {"company": "", "ticker": "MCD", "move": "down", "prices": [212.676, 213.21]}}}, {"link": "https://www.wsj.com/articles/facebook-to-offer-self-publishing-tools-for-content-creators-11615922776", "title": "Facebook to Offer Self-Publishing Tools for Content Creators", "date": "2021-03-16 15:26", "summary": "Social-media giant says effort will help writers create subscription-based businesses. Facebook Inc. is rolling out new self-publishing tools it says will help writers and other cultural producers reach audiences and get paid for their work, the latest example of a social-media company pushing to keep creators in its fold.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook to Offer Self-Publishing Tools for Content Creators. Social-media giant says effort will help writers create subscription-based businesses. Facebook Inc. is rolling out new self-publishing tools it says will help writers and other cultural producers reach audiences and get paid for their work, the latest example of a social-media company pushing to keep creators in its fold.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because they are continuing to invest in their platform and this will help content creators monetize their work.\n- Snap Inc. (NYSE: SNAP) will decrease because this will take away some of the content creators who were using Snapchat.\n- Twitter, Inc. (NYSE: TWTR) will decrease because this will take away some of the content creators who were using Twitter.", "price_info": {"SNAP": {"company": "", "ticker": "SNAP", "move": "down", "prices": [62.22, 62.15]}, "TWTR": {"company": "", "ticker": "TWTR", "move": "down", "prices": [69.25, 69.19]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [279, 279.895]}}}, {"link": "https://www.wsj.com/articles/japanese-builder-of-suez-canal-ship-has-bigger-problem-industry-decline-11617113531", "title": "Japanese Builder of Suez Canal Ship Has Bigger Problem: Industry Decline", "date": "2021-03-30 10:12", "summary": "Unlisted Imabari Shipbuilding reported a loss last year and tries building ever-bigger ships to survive. IMABARI, Japan-The Japanese shipbuilding group that just extracted itself from a sticky situation in the Suez Canal still has to navigate the receding tides of an industry in long-term decline.", "categories": [["Business", "Asia"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/asia-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Japanese Builder of Suez Canal Ship Has Bigger Problem: Industry Decline. Unlisted Imabari Shipbuilding reported a loss last year and tries building ever-bigger ships to survive. IMABARI, Japan-The Japanese shipbuilding group that just extracted itself from a sticky situation in the Suez Canal still has to navigate the receding tides of an industry in long-term decline.\"\n\nStock Prediction(s):", "Prediction": "\n- Imabari Shipbuilding Co Ltd (TSE: 9104) will decrease because their industry is in long-term decline.", "price_info": {}}, {"link": "https://www.wsj.com/articles/auto-borrowing-rises-as-new-mortgage-loans-sag-new-york-fed-says-11549988807", "title": "Auto Borrowing Rises as New Mortgage Loans Sag, New York Fed Says", "date": "2019-02-12 11:26", "summary": "Mortgage originations for 2018 were at lowest level since 2014; auto loans have been steadily moving up since 2010. Americans are borrowing more for cars and less for houses, according to a report released Tuesday by the Federal Reserve Bank of New York.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Auto Borrowing Rises as New Mortgage Loans Sag, New York Fed Says. Mortgage originations for 2018 were at lowest level since 2014; auto loans have been steadily moving up since 2010. Americans are borrowing more for cars and less for houses, according to a report released Tuesday by the Federal Reserve Bank of New York.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because more people are borrowing for cars instead of houses, and Ford is a major player in the automotive industry.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because more people are borrowing for cars instead of houses, and JPMorgan is a major player in the automotive industry.\n- General Motors Company (NYSE: GM) will increase because more people are borrowing for cars instead of houses, and General Motors", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [8.445, 8.435]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [102.535, 102.37]}, "GM": {"company": "", "ticker": "GM", "move": "up", "prices": [39.1655, 39.05]}}}, {"link": "https://www.wsj.com/articles/instagram-for-kids-facebook-wants-to-fix-its-preteen-problem-11617787802", "title": "Instagram's Plan for Kids Met With Hostile Response", "date": "2021-04-07 10:14", "summary": "Lawmakers say social media can have harmful effects on young people, many of whom lie about their age to join platforms. With a version of Instagram for kids, Facebook Inc. says it can build a safer social-media haven for users under 13.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Instagram's Plan for Kids Met With Hostile Response. Lawmakers say social media can have harmful effects on young people, many of whom lie about their age to join platforms. With a version of Instagram for kids, Facebook Inc. says it can build a safer social-media haven for users under 13.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc. (NASDAQ: FB) will increase because they are releasing a kid-friendly version of Instagram, which will make it safer for young children to use social media.\n- Snap Inc. (NYSE: SNAP) will decrease because they are not releasing a kid-friendly version of Snapchat, and this will give Facebook a competitive edge.", "price_info": {"SNAP": {"company": "", "ticker": "SNAP", "move": "down", "prices": [60.13, 59.9901]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [313.01, 311.0518]}}}, {"link": "https://www.wsj.com/articles/walmart-to-scale-back-jetblack-after-investor-talks-fizzle-11581604739", "title": "Walmart to End Jetblack Shopping Service", "date": "2020-02-13 11:45", "summary": "Text-message concierge unit will end deliveries, lay off most of its 350 staffers. Walmart Inc. is shutting down its Jetblack personal-shopping service and laying off most of its roughly 350 staffers after the retailer abandoned plans to find investors for the unprofitable operation.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walmart to End Jetblack Shopping Service. Text-message concierge unit will end deliveries, lay off most of its 350 staffers. Walmart Inc. is shutting down its Jetblack personal-shopping service and laying off most of its roughly 350 staffers after the retailer abandoned plans to find investors for the unprofitable operation.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will decrease because they are shutting down their Jetblack shopping service.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [117.2637, 117.03]}}}, {"link": "https://www.wsj.com/articles/covid-19-vaccines-should-first-go-to-health-workers-first-responders-group-recommends-11601647202", "title": "Covid-19 Vaccines Should First Go to Health Workers, First Responders, Panel Says", "date": "2020-10-02 10:00", "summary": "U.S. government needs to direct limited initial coronavirus vaccines to those at the front lines of treatment and high-risk groups, panel says. Certain health workers and first responders should be the first to receive a Covid-19 vaccine when one becomes available, followed by people with health conditions that put them at higher risk of severe Covid-19 disease, a special U.S. committee recommended.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Vaccines Should First Go to Health Workers, First Responders, Panel Says. U.S. government needs to direct limited initial coronavirus vaccines to those at the front lines of treatment and high-risk groups, panel says. Certain health workers and first responders should be the first to receive a Covid-19 vaccine when one becomes available, followed by people with health conditions that put them at higher risk of severe Covid-19 disease, a special U.S. committee recommended.\"\n\nStock Prediction(s):", "Prediction": "\n- Health workers and first responders will be the first to receive the Covid-19 vaccine, so companies that are working on the vaccine such as AstraZeneca, Johnson & Johnson, Pfizer, and Moderna will see an increase in stock prices.", "price_info": {}}, {"link": "https://www.wsj.com/articles/care-com-cfo-resigns-11561501253", "title": "Care.com CFO Resigns", "date": "2019-06-26 14:36", "summary": "Departure comes months after a Wall Street Journal investigation into the licensing of child-care providers listed on the online marketplace. Care.com Inc.'s chief financial officer, Michael Echenberg, is resigning from the online child-care marketplace, the Waltham, Mass.-based company said Tuesday.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Care.com CFO Resigns. Departure comes months after a Wall Street Journal investigation into the licensing of child-care providers listed on the online marketplace. Care.com Inc.'s chief financial officer, Michael Echenberg, is resigning from the online child-care marketplace, the Waltham, Mass.-based company said Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Care.com Inc. (NYSE: CRCM) will decrease because their CFO is resigning.\n- The Walt Disney Company (NYSE: DIS) will increase because they just announced a new streaming service that will compete with Netflix.", "price_info": {"CRCM": {"company": "", "ticker": "CRCM", "move": "down", "prices": [11.19, 11.2]}, "DIS": {"company": "", "ticker": "DIS", "move": "up", "prices": [140.32, 140.2]}}}, {"link": "https://www.wsj.com/articles/the-fed-cant-do-it-all-says-alan-blinder-11588357053", "title": "The Fed Can't Do It All, Says Alan Blinder", "date": "2020-05-01 14:17", "summary": "The former Federal Reserve vice chairman says he approves of how the Fed is responding to the economic and financial havoc wrought by the coronavirus. Alan Blinder knows a thing or two about the Federal Reserve, having served as vice chairman from 1994 to 1996 and as a member of President Clinton's Council of Economic Advisers before that.", "categories": [["Markets", "Journal Reports: Funds/ETFs", "Q&A"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Fed Can't Do It All, Says Alan Blinder. The former Federal Reserve vice chairman says he approves of how the Fed is responding to the economic and financial havoc wrought by the coronavirus. Alan Blinder knows a thing or two about the Federal Reserve, having served as vice chairman from 1994 to 1996 and as a member of President Clinton's Council of Economic Advisers before that.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: The Fed) will stay the same because they are doing a good job in the midst of the Covid-19 pandemic.\n- Goldman Sachs (NYSE: GS) will increase because they are a financial institution that is benefiting from the Fed's actions.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are a financial institution that is benefiting from the Fed's actions.", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up", "prices": [178.19, 177.1]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [93.37, 93.24]}}}, {"link": "https://www.wsj.com/articles/big-banks-seek-less-liquidity-from-fed-amid-stable-money-market-rates-11578495553", "title": "Big Banks Seek Less Liquidity From Fed Amid Stable Money-Market Rates", "date": "2020-01-08 09:59", "summary": "Fed injects $46.6 billion into markets via repurchase agreements. Demand for the Federal Reserve's short-term market liquidity offering ebbed a bit after robust interest at the start of the week.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Big Banks Seek Less Liquidity From Fed Amid Stable Money-Market Rates. Fed injects $46.6 billion into markets via repurchase agreements. Demand for the Federal Reserve's short-term market liquidity offering ebbed a bit after robust interest at the start of the week.\"\n\nStock Prediction(s):", "Prediction": "\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are one of the \"big banks\" that is withdrawing liquidity from the Fed.\n- Goldman Sachs Group Inc. (NYSE: GS) will increase because they are one of the \"big banks\" that is withdrawing liquidity from the Fed.\n- Bank of America Corp. (NYSE: BAC) will increase because they are one of the \"big banks\" that is withdrawing liquidity from the Fed", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [136.6348, 136.49]}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [237.55, 237.9]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [34.805, 34.82]}}}, {"link": "https://www.wsj.com/articles/bitcoin-falls-sharply-as-crypto-gets-caught-in-global-selloff-11584042348", "title": "Bitcoin Falls Sharply as Crypto Gets Caught in Global Selloff", "date": "2020-03-12 15:51", "summary": "Thursday's moves were exacerbated by the fact that crypto markets don't have internal controls to slow selloffs. The price of bitcoin fell sharply Thursday, at one point losing more than 20% in less than an hour, a steep drop even for the notoriously volatile asset.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bitcoin Falls Sharply as Crypto Gets Caught in Global Selloff. Thursday's moves were exacerbated by the fact that crypto markets don't have internal controls to slow selloffs. The price of bitcoin fell sharply Thursday, at one point losing more than 20% in less than an hour, a steep drop even for the notoriously volatile asset.\"\n\nStock Prediction(s):", "Prediction": "\n- Bitcoin (BTC) will continue to fall because it is being caught in the global selloff.\n- Ethereum (ETH) will continue to fall because it is being caught in the global selloff.\n- XRP will continue to fall because it is being caught in the global selloff.\n- Bitcoin Cash (BCH) will continue to fall because it is being caught in the global selloff.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "down"}, "ETH": {"company": "Ethereum", "ticker": "ETH", "move": null}, "BCH": {"company": "Bitcoin Cash", "ticker": "BCH", "move": null}}}, {"link": "https://www.wsj.com/articles/chinese-withdraw-deposits-from-rural-bank-for-third-day-as-authorities-try-to-project-stability-11572527638", "title": "Scenes From a Chinese Bank Run: 'We Really Can't Afford to Lose the Money'", "date": "2019-10-31 13:23", "summary": "Squeeze at Yichuan Bank is the fourth small lender this year that regulators have rushed to save. YICHUAN, China-Depositors swarmed a rural bank here for a third consecutive day, rushing to pull money out even as authorities stepped in forcefully to quell concerns around the latest troubled Chinese lender.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Scenes From a Chinese Bank Run: 'We Really Can't Afford to Lose the Money'. Squeeze at Yichuan Bank is the fourth small lender this year that regulators have rushed to save. YICHUAN, China-Depositors swarmed a rural bank here for a third consecutive day, rushing to pull money out even as authorities stepped in forcefully to quell concerns around the latest troubled Chinese lender.\"\n\nStock Prediction(s):", "Prediction": "\n- Yichuan Bank Co., Ltd. (SHE: 601166) will decrease because depositors are withdrawing their money, and the bank is in trouble.\n- Agricultural Bank of China Ltd. (SHA: 601288) will increase because depositors are withdrawing their money from Yichuan Bank, and they are a more stable bank.\n- Bank of China Ltd. (SHA: 601988) will increase because depositors are withdrawing their money from Y", "price_info": {}}, {"link": "https://www.wsj.com/articles/lacking-ventilators-hospitals-seek-out-alternative-device-11585154579", "title": "Lacking Ventilators, Hospitals Seek Out an Alternative", "date": "2020-03-25 14:39", "summary": "To treat coronavirus patients, doctors modify oxygen device made by small Texas company now flooded with orders. Some U.S. hospitals preparing for a shortage of ventilators for Covid-19 patients are modifying oxygen devices usually used for decompression sickness or foot ulcers to assist patients who will need help breathing.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Lacking Ventilators, Hospitals Seek Out an Alternative. To treat coronavirus patients, doctors modify oxygen device made by small Texas company now flooded with orders. Some U.S. hospitals preparing for a shortage of ventilators for Covid-19 patients are modifying oxygen devices usually used for decompression sickness or foot ulcers to assist patients who will need help breathing.\"\n\nStock Prediction(s):", "Prediction": "\n- AirSep Corporation (NYSE: ASL) will increase because they are the only company that makes the oxygen devices that are being modified, and they are seeing a surge in orders.\n- Smiths Group plc (LON: SMIN) will decrease because they are a direct competitor of AirSep Corporation.", "price_info": {"ASL": {"company": "", "ticker": "ASL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/amazons-jeff-bezos-is-handing-andy-jassy-a-unique-set-of-challenges-11625233065", "title": "Jeff Bezos Is Handing Andy Jassy a Unique Set of Challenges", "date": "2021-07-02 10:00", "summary": "The company's founder is departing with the business in fantastic shape, but Amazon's sheer size has put a target on its back. In a way, incoming Amazon . com Chief Executive Andy Jassy would seem to have an easy job ahead. He's inheriting a company that appears to be firing on all cylinders, after all.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jeff Bezos Is Handing Andy Jassy a Unique Set of Challenges. The company's founder is departing with the business in fantastic shape, but Amazon's sheer size has put a target on its back. In a way, incoming Amazon . com Chief Executive Andy Jassy would seem to have an easy job ahead. He's inheriting a company that appears to be firing on all cylinders, after all.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because their founder is departing and the company is in fantastic shape.\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because their competitor is in trouble.\n- Facebook, Inc. (NASDAQ: FB) will increase because their competitor is in trouble.", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3438.5, 3466.44]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2484.59, 2495.59]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [353.75, 354.33]}}}, {"link": "https://www.wsj.com/articles/how-the-u-k-beat-the-u-s-and-europe-to-a-covid-19-vaccine-11606924155", "title": "How the U.K. Beat the U.S. and Europe to a Covid-19 Vaccine", "date": "2020-12-02 10:49", "summary": "Country's top medicines watchdog approved a shot by Pfizer and BioNTech, as it prepares to strike out on its own after Brexit. LONDON-Britain's first-in-the-West authorization of a Covid-19 vaccine thrusts its little-known medicines watchdog into the global spotlight-weeks before the U.K.'s split from the European Union adds to the regulator's responsibilities.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How the U.K. Beat the U.S. and Europe to a Covid-19 Vaccine. Country's top medicines watchdog approved a shot by Pfizer and BioNTech, as it prepares to strike out on its own after Brexit. LONDON-Britain's first-in-the-West authorization of a Covid-19 vaccine thrusts its little-known medicines watchdog into the global spotlight-weeks before the U.K.'s split from the European Union adds to the regulator's responsibilities.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will increase because they are the company that developed the vaccine with BioNTech.\n- BioNTech SE (XETRA: BNTX) will increase because they are the company that developed the vaccine with Pfizer.\n- The University of Oxford (NYSE: OXF) will increase because they are the academic institution that developed the vaccine with AstraZeneca.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "up", "prices": [40.6, 40.835]}, "OXF": {"company": "", "ticker": "OXF", "move": "up"}}}, {"link": "https://www.wsj.com/articles/our-cash-went-to-something-customers-hunt-for-bankrupt-crypto-exchanges-missing-millions-11550596908", "title": "Customers Hunt for Bankrupt Crypto Exchange's Missing Millions", "date": "2019-02-19 12:21", "summary": "Unusual cash-pickup system mysteriously closes. On a rainy January day, Jason Campbell drove for three hours from his home in Quebec City to a two-story office building in the Montreal suburb of Laval. He thought he would be picking up $1,000-in cash-he had stored at cryptocurrency exchange QuadrigaCX.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Customers Hunt for Bankrupt Crypto Exchange's Missing Millions. Unusual cash-pickup system mysteriously closes. On a rainy January day, Jason Campbell drove for three hours from his home in Quebec City to a two-story office building in the Montreal suburb of Laval. He thought he would be picking up $1,000-in cash-he had stored at cryptocurrency exchange QuadrigaCX.\"\n\nStock Prediction(s):", "Prediction": "\n- QuadrigaCX (OTCQB: QCCXF) will increase because they have millions of dollars worth of cryptocurrency that is unaccounted for.\n- Bitfinex (OTC: BFXWW) will increase because they are a direct competitor of QuadrigaCX.\n- Coinbase (OTC: GBTC) will increase because they are a direct competitor of QuadrigaCX.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bond-investors-shouldnt-fixate-too-much-on-the-alphabet-11550765293", "title": "Bond Investors Shouldn't Fixate Too Much on the Alphabet", "date": "2019-02-21 11:08", "summary": "Corporate debt graded BBB has become investors' bogeyman, but higher-rated paper isn't always safer. Just like a teapot that never whistles while you are looking at it, perhaps the most maligned bit of the corporate bond market isn't where investors will get burned.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bond Investors Shouldn't Fixate Too Much on the Alphabet. Corporate debt graded BBB has become investors' bogeyman, but higher-rated paper isn't always safer. Just like a teapot that never whistles while you are looking at it, perhaps the most maligned bit of the corporate bond market isn't where investors will get burned.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will not react to this news because it is not about a specific company.", "price_info": {}}, {"link": "https://www.wsj.com/articles/smucker-cfo-weighs-additional-price-hikes-if-inflation-exceeds-forecasts-11623344630", "title": "Smucker CFO Weighs Additional Price Hikes if Inflation Exceeds Forecasts", "date": "2021-06-10 13:03", "summary": "Maker of Jif peanut butter and Folgers coffee is working with grocery stores on already announced price increases in July. J.M. Smucker Co. is looking at another round of potential price increases on top of hikes planned for July if inflation outpaces the food maker's current forecasts.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Smucker CFO Weighs Additional Price Hikes if Inflation Exceeds Forecasts. Maker of Jif peanut butter and Folgers coffee is working with grocery stores on already announced price increases in July. J.M. Smucker Co. is looking at another round of potential price increases on top of hikes planned for July if inflation outpaces the food maker's current forecasts.\"\n\nStock Prediction(s):", "Prediction": "\n- J.M. Smucker Co. (NYSE: SJM) will increase because they are preparing for higher inflation, and they have already announced price increases.\n- Hershey Co. (NYSE: HSY) will decrease because they are a direct competitor of J.M. Smucker, and they have not announced any price increases yet.", "price_info": {"SJM": {"company": "", "ticker": "SJM", "move": "up", "prices": [135.58, 135.6248]}, "HSY": {"company": "", "ticker": "HSY", "move": "down", "prices": [174.43, 173.95]}}}, {"link": "https://www.wsj.com/articles/dominos-tastes-fine-before-during-and-after-pandemic-11594914929", "title": "Dominos Tastes Fine Before, During and After Pandemic", "date": "2020-07-16 11:55", "summary": "Pizza-delivery giant delivered exceptional performance in fiscal second quarter. Investors certainly didn't lose their taste for Domino's Pizza due to the coronavirus.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Dominos Tastes Fine Before, During and After Pandemic. Pizza-delivery giant delivered exceptional performance in fiscal second quarter. Investors certainly didn't lose their taste for Domino's Pizza due to the coronavirus.\"\n\nStock Prediction(s):", "Prediction": "\n- Domino's Pizza, Inc. (NYSE: DPZ) will continue to increase because their performance has been exceptional even during the pandemic.", "price_info": {"DPZ": {"company": "", "ticker": "DPZ", "move": "up", "prices": [407.51, 407.35]}}}, {"link": "https://www.wsj.com/articles/companies-take-a-piecemeal-approach-to-automation-tech-11554396270", "title": "Companies Take a Piecemeal Approach to Automation Tech", "date": "2019-04-04 12:44", "summary": "KPMG survey finds that only 17% of companies have smart automation technologies operating at full scale. The growth of artificial intelligence, robotics and other next-generation automation technologies are prompting some corporate leaders to ask age-old business questions: How much should we pay for this? And who is in charge?", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Companies Take a Piecemeal Approach to Automation Tech. KPMG survey finds that only 17% of companies have smart automation technologies operating at full scale. The growth of artificial intelligence, robotics and other next-generation automation technologies are prompting some corporate leaders to ask age-old business questions: How much should we pay for this? And who is in charge?\"\n\nStock Prediction(s):", "Prediction": "\n- International Business Machines Corporation (NYSE: IBM) will increase because they are a direct competitor of the companies mentioned in the article, and they have a lot of experience with automation technologies.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are a direct competitor of the companies mentioned in the article, and they have a lot of experience with automation technologies.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "up", "prices": [143.115, 143.021]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [118.76, 119.51]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1812.7908, 1816.7794]}}}, {"link": "https://www.wsj.com/articles/covid-or-not-this-company-has-no-repeat-customers-11601404941", "title": "Covid or Not, This Company Has No Repeat Customers", "date": "2020-09-29 14:42", "summary": "As Covid-19 becomes a leading cause of death, funeral-service provider seeks to figure out how many would have used their services anyway. The business phrase \"pulled forward\" is seeing a lot of use during the Covid-19 pandemic. It refers to when a company sells extra goods or services, but at the cost of future sales.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid or Not, This Company Has No Repeat Customers. As Covid-19 becomes a leading cause of death, funeral-service provider seeks to figure out how many would have used their services anyway. The business phrase \"pulled forward\" is seeing a lot of use during the Covid-19 pandemic. It refers to when a company sells extra goods or services, but at the cost of future sales.\"\n\nStock Prediction(s):", "Prediction": "\n- Service Corporation International (NYSE: SCI) will decrease because they are a funeral-service provider, and they are not seeing repeat customers.", "price_info": {"SCI": {"company": "", "ticker": "SCI", "move": "down"}}}, {"link": "https://www.wsj.com/articles/natural-gas-remains-plentiful-as-mild-winter-continues-11581622108", "title": "Natural-Gas Remains Plentiful as Mild Winter Continues", "date": "2020-02-13 15:45", "summary": "Robust supply and mild heating demand are contributing to a glut of the fuel. Natural-gas stockpiles are more than 30% above their levels from a year ago, government data released Thursday show, the latest signs that robust supply and mild heating demand are contributing to a glut of the fuel.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Natural-Gas Remains Plentiful as Mild Winter Continues. Robust supply and mild heating demand are contributing to a glut of the fuel. Natural-gas stockpiles are more than 30% above their levels from a year ago, government data released Thursday show, the latest signs that robust supply and mild heating demand are contributing to a glut of the fuel.\"\n\nStock Prediction(s):", "Prediction": "\n- Chesapeake Energy Corporation (NYSE: CHK) will increase because natural gas remains plentiful, and Chesapeake is one of the largest producers of natural gas in the United States.\n- Devon Energy Corporation (NYSE: DVN) will increase because natural gas remains plentiful, and Devon is one of the largest producers of natural gas in the United States.\n- EQT Corporation (NYSE: EQT) will increase because natural gas remains plentiful, and EQT is one", "price_info": {"CHK": {"company": "", "ticker": "CHK", "move": "up", "prices": [0.4849, 0.4886]}, "DVN": {"company": "", "ticker": "DVN", "move": "up", "prices": [23.26, 23.3]}, "EQT": {"company": "", "ticker": "EQT", "move": "up", "prices": [5.385, 5.41]}}}, {"link": "https://www.wsj.com/articles/american-banks-on-loyalty-program-to-back-stimulus-loan-to-manage-through-coronavirus-11591973302", "title": "American Banks on Loyalty Program to Back Stimulus Loan", "date": "2020-06-12 12:31", "summary": "Carrier is pledging its frequent-flier program as collateral in bid to secure $4.75 billion federal loan. American Airlines Group Inc. said Friday that it planned to pledge its loyalty program as collateral for a $4.75 billion government loan as it seeks to shore up capital to manage through the coronavirus pandemic.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"American Banks on Loyalty Program to Back Stimulus Loan. Carrier is pledging its frequent-flier program as collateral in bid to secure $4.75 billion federal loan. American Airlines Group Inc. said Friday that it planned to pledge its loyalty program as collateral for a $4.75 billion government loan as it seeks to shore up capital to manage through the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- American Airlines Group Inc. (NASDAQ: AAL) will increase because they are pledging their loyalty program as collateral for a $4.75 billion government loan.\n- United Airlines Holdings Inc. (NASDAQ: UAL) will decrease because they are not pledging their loyalty program as collateral for a $4.75 billion government loan.", "price_info": {"AAL": {"company": "", "ticker": "AAL", "move": null, "prices": [16.517, 16.48]}, "UAL": {"company": "", "ticker": "UAL", "move": "down", "prices": [37.95, 38]}}}, {"link": "https://www.wsj.com/articles/meatless-burgers-stoke-sales-and-questions-about-nutrition-11564653600", "title": "Meatless Burgers Stoke Sales and Questions About Nutrition", "date": "2019-08-01 11:20", "summary": "Plant-based patties typically contain as much protein-and as many calories-as beef; 'It might be more of a treat'. Plant-based burger makers say their products are better for the planet than beef. Whether they are better for consumers' health is a different question.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Meatless Burgers Stoke Sales and Questions About Nutrition. Plant-based patties typically contain as much protein-and as many calories-as beef; 'It might be more of a treat'. Plant-based burger makers say their products are better for the planet than beef. Whether they are better for consumers' health is a different question.\"\n\nStock Prediction(s):", "Prediction": "\n- Impossible Foods Inc (private) will increase because their burgers are plant-based and considered healthier than beef burgers.\n- Beyond Meat Inc (NASDAQ: BYND) will increase because their burgers are plant-based and considered healthier than beef burgers.", "price_info": {"BYND": {"company": "", "ticker": "BYND", "move": "up", "prices": [177.8001, 173.335]}}}, {"link": "https://www.wsj.com/articles/u-s-factory-orders-fell-sharply-in-march-11588610687", "title": "U.S. Factory Orders Plunged in March", "date": "2020-05-04 12:44", "summary": "Commerce Department records steepest monthly decline since comparable records began in 1992. U.S. factory orders posted a record drop in March as efforts to contain the new coronavirus disrupted supply chains and quashed demand, the Commerce Department said Monday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Factory Orders Plunged in March. Commerce Department records steepest monthly decline since comparable records began in 1992. U.S. factory orders posted a record drop in March as efforts to contain the new coronavirus disrupted supply chains and quashed demand, the Commerce Department said Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co (NYSE: BA) will decrease because their main customer is the U.S. government, and the U.S. government is not ordering as many planes because of the pandemic.\n- 3M Co (NYSE: MMM) will decrease because their main customer is the U.S. government, and the U.S. government is not ordering as many supplies because of the pandemic.\n- Caterpillar Inc. (NYSE: CAT", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [127.73, 127.75]}, "MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [148.005, 147.73]}}}, {"link": "https://www.wsj.com/articles/working-from-home-during-coronavirus-pandemic-hasnt-broken-internet-11585329238", "title": "Working From Home Hasn't Broken Internet", "date": "2020-03-27 13:13", "summary": "Internet usage by remote workers fills fallow daytime hours; providers say no big outages in U.S. so far. Home internet and wireless connectivity in the U.S. have largely withstood unprecedented demands as more Americans work and learn remotely.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Working From Home Hasn't Broken Internet. Internet usage by remote workers fills fallow daytime hours; providers say no big outages in U.S. so far. Home internet and wireless connectivity in the U.S. have largely withstood unprecedented demands as more Americans work and learn remotely.\"\n\nStock Prediction(s):", "Prediction": "\n- Comcast Corporation (NASDAQ: CMCSA) will increase because people are working from home and need more internet bandwidth.\n- AT&T Inc. (NYSE: T) will increase because people are working from home and need more internet bandwidth.\n- Verizon Communications Inc. (NYSE: VZ) will increase because people are working from home and need more internet bandwidth.\n- Netflix, Inc. (NASDAQ: NFLX) will increase because people are", "price_info": {"T": {"company": "", "ticker": "T", "move": "up", "prices": [30.0199, 30.1]}, "VZ": {"company": "", "ticker": "VZ", "move": "up", "prices": [52.57, 52.79]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "up", "prices": [35.17, 34.865]}, "NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [364.4899, 361.36]}}}, {"link": "https://www.wsj.com/articles/no-happy-meal-for-nutrisystems-owner-11582224201", "title": "No Happy Meal for Nutrisystem's Owner", "date": "2020-02-20 13:43", "summary": "Shares of Tivity Health plunged as it took a charge for the acquisition of the diet-nutrition provider. Thanks to this diet company's struggles, investors are shedding pounds.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"No Happy Meal for Nutrisystem's Owner. Shares of Tivity Health plunged as it took a charge for the acquisition of the diet-nutrition provider. Thanks to this diet company's struggles, investors are shedding pounds.\"\n\nStock Prediction(s):", "Prediction": "\n- Tivity Health, Inc. (NASDAQ: TVTY) will continue to decrease because their owner Nutrisystem is not doing well.", "price_info": {"TVTY": {"company": "", "ticker": "TVTY", "move": "down", "prices": [12.9683, 12.7071]}}}, {"link": "https://www.wsj.com/articles/how-to-negotiate-a-phased-retirement-with-your-boss-11568127431", "title": "How to Negotiate a 'Phased Retirement' With Your Boss", "date": "2019-09-10 10:57", "summary": "If you'd like to cut back your work hours ahead of retirement, explain what is in it for your employer. I'm 63 years old and approaching retirement. I would like to cut back on my hours at work and leave my job in stages. My company, though, doesn't offer that option. Have you talked with people who retired from work gradually? How did they do it? Any suggestions?", "categories": [["Markets", "Journal Reports: Wealth Management", "Ask Encore"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-wealth-management?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Negotiate a 'Phased Retirement' With Your Boss. If you'd like to cut back your work hours ahead of retirement, explain what is in it for your employer. I'm 63 years old and approaching retirement. I would like to cut back on my hours at work and leave my job in stages. My company, though, doesn't offer that option. Have you talked with people who retired from work gradually? How did they do it? Any suggestions?\"\n\nStock Prediction(s):", "Prediction": "\n- People who have retired gradually from work have done so by negotiating with their employers.\n- If someone is approaching retirement and would like to cut back on their hours, they should negotiate with their boss to do so in phases.\n- If someone is approaching retirement and would like to cut back on their hours, they should explain what is in it for their employer.", "price_info": {}}, {"link": "https://www.wsj.com/articles/chick-fil-a-needs-to-check-the-calendar-11572981447", "title": "Chick-fil-A Needs to Check the Calendar", "date": "2019-11-05 14:17", "summary": "The chain reminded its customers to order on National Sandwich Day when it is closed. Fast-food chain Chick-fil-A still takes heat for its chief executive's controversial views, but you can't say that it doesn't stick by its Christian-based beliefs when money is at stake.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chick-fil-A Needs to Check the Calendar. The chain reminded its customers to order on National Sandwich Day when it is closed. Fast-food chain Chick-fil-A still takes heat for its chief executive's controversial views, but you can't say that it doesn't stick by its Christian-based beliefs when money is at stake.\"\n\nStock Prediction(s):", "Prediction": "\n- Chick-fil-A, Inc. (NYSE: CFA) will decrease because they are closed on National Sandwich Day.", "price_info": {"CFA": {"company": "", "ticker": "CFA", "move": "down", "prices": [54.3375, 54.27]}}}, {"link": "https://www.wsj.com/articles/u-s-set-to-press-saudis-to-restrain-oil-production-surge-via-g-20-11585148443", "title": "U.S. Set to Press Saudis to Restrain Oil Production Surge via G-20", "date": "2020-03-25 11:00", "summary": "The Trump administration plans to use the G20 as a forum to resolve the Saudi-Russian oil-price war. The U.S. plans to press Saudi Arabia to restrain its scheduled oil production boost by leveraging the kingdom's status as head of the G-20, according to people familiar with the matter.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Set to Press Saudis to Restrain Oil Production Surge via G-20. The Trump administration plans to use the G20 as a forum to resolve the Saudi-Russian oil-price war. The U.S. plans to press Saudi Arabia to restrain its scheduled oil production boost by leveraging the kingdom's status as head of the G-20, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are not as directly affected by the Saudi-Russian oil-price war.\n- Chevron Corporation (NYSE: CVX) will increase because they are not as directly affected by the Saudi-Russian oil-price war.\n- Schlumberger Limited. (NYSE: SLB) will increase because they are not as directly affected by the Saudi-Russian oil-price war.\n- Halliburton", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [36.64, 38.37]}, "CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [68.94, 72.5043]}, "SLB": {"company": "", "ticker": "SLB", "move": "up", "prices": [14.47, 15.075]}}}, {"link": "https://www.wsj.com/articles/nokia-names-new-cfo-as-it-plays-catch-up-with-ericsson-huawei-11591902461", "title": "Nokia Names New CFO as It Plays Catch-Up With Ericsson, Huawei", "date": "2020-06-11 15:07", "summary": "Marco Wir\u00e9n will take up the role on the same day a new chief executive joins the company. Nokia Corp. has chosen an external candidate as its new finance chief, part of a wider management shake-up that comes as the telecommunications company tries to catch up in the race to provide 5G internet.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nokia Names New CFO as It Plays Catch-Up With Ericsson, Huawei. Marco Wir\u00e9n will take up the role on the same day a new chief executive joins the company. Nokia Corp. has chosen an external candidate as its new finance chief, part of a wider management shake-up that comes as the telecommunications company tries to catch up in the race to provide 5G internet.\"\n\nStock Prediction(s):", "Prediction": "\n- Nokia Corporation (NYSE: NOK) will increase because they are making changes in their management and are trying to catch up with their competitors.\n- Ericsson AB (NASDAQ: ERIC) will increase because they are one of Nokia's main competitors in the 5G market.\n- Huawei Technologies Co Ltd (SHE: 002502) will increase because they are one of Nokia's main competitors in the 5G market.", "price_info": {"NOK": {"company": "", "ticker": "NOK", "move": "up", "prices": [4.12, 4.16]}, "ERIC": {"company": "", "ticker": "ERIC", "move": "up", "prices": [8.76, 8.82]}}}, {"link": "https://www.wsj.com/articles/the-best-affordable-ink-tank-and-laser-printers-for-your-home-office-11616596381", "title": "The Best Printers for the Home-Say Goodbye to Ink Cartridges", "date": "2021-03-24 10:33", "summary": "Stop buying cheap inkjet printers, then paying a fortune for cartridges. Instead, get an ink-tank or a laser printer, our columnist says, after testing 10 home printers. Once upon a time, there was a tech columnist who bought a $150 printer with a model number so long it's now her bank password.", "categories": [["Tech", "Personal Tech", "Personal Technology: Joanna Stern"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Best Printers for the Home-Say Goodbye to Ink Cartridges. Stop buying cheap inkjet printers, then paying a fortune for cartridges. Instead, get an ink-tank or a laser printer, our columnist says, after testing 10 home printers. Once upon a time, there was a tech columnist who bought a $150 printer with a model number so long it's now her bank password.\"\n\nStock Prediction(s):", "Prediction": "\n- HP Inc (NYSE: HPQ) will increase because they are the best company for printers, and they have a wide variety of products.\n- Canon Inc (NYSE: CAJ) will increase because they are the best company for printers, and they have a wide variety of products.\n- Epson America, Inc. (NYSE: SEP) will increase because they are the best company for printers, and they have a wide variety of products.\n-", "price_info": {"HPQ": {"company": "", "ticker": "HPQ", "move": "up", "prices": [29.85, 29.69]}, "CAJ": {"company": "", "ticker": "CAJ", "move": "up", "prices": [21.98, 21.94]}, "SEP": {"company": "", "ticker": "SEP", "move": "up"}}}, {"link": "https://www.wsj.com/articles/ftc-warns-cbd-companies-about-treatment-claims-11568132532", "title": "FTC Warns CBD Companies About Treatment Claims", "date": "2019-09-10 12:22", "summary": "Agency targets three companies' health and medical claims about cannabidiol products. The Federal Trade Commission is taking aim at certain companies that sell cannabidiol, or CBD, and have claimed their products can treat or cure serious diseases and health conditions.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FTC Warns CBD Companies About Treatment Claims. Agency targets three companies' health and medical claims about cannabidiol products. The Federal Trade Commission is taking aim at certain companies that sell cannabidiol, or CBD, and have claimed their products can treat or cure serious diseases and health conditions.\"\n\nStock Prediction(s):", "Prediction": "\n- CV Sciences, Inc. (OTCQB: CVSI) will decrease because they are one of the companies that the FTC is targeting.\n- Charlotte's Web Holdings, Inc. (OTCQX: CWBHF) will decrease because they are one of the companies that the FTC is targeting.\n- Green Growth Brands Inc. (CSE: GGB) will decrease because they are one of the companies that the FTC is targeting.", "price_info": {}}, {"link": "https://www.wsj.com/articles/vegan-etf-almost-like-the-real-thing-11568315832", "title": "Vegan ETF Almost Like the Real Thing", "date": "2019-09-12 15:17", "summary": "Fund claims investing in it indirectly spares animals, but there are easier and cheaper ways to do that.. First there was Beyond Meat . Now there is Beyond Investing.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Vegan ETF Almost Like the Real Thing. Fund claims investing in it indirectly spares animals, but there are easier and cheaper ways to do that.. First there was Beyond Meat . Now there is Beyond Investing.\"\n\nStock Prediction(s):", "Prediction": "\n- The Beyond Meat Inc (NASDAQ: BYND) will go up because there is a vegan ETF that is indirectly investing in it.\n- The other vegan stocks will go up because of the increasing trend of veganism.", "price_info": {"BYND": {"company": "", "ticker": "BYND", "move": "up", "prices": [153.27, 152.89]}}}, {"link": "https://www.wsj.com/articles/tesla-quality-falls-short-in-j-d-power-car-survey-11593014428", "title": "Tesla Quality Falls Short in J.D. Power Car Survey", "date": "2020-06-24 12:22", "summary": "The influential J.D. Power study found complaints about manufacturing quality. Tesla Inc. vehicles scored the worst among major auto makers in a closely watched survey of customers by researcher J.D. Power.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla Quality Falls Short in J.D. Power Car Survey. The influential J.D. Power study found complaints about manufacturing quality. Tesla Inc. vehicles scored the worst among major auto makers in a closely watched survey of customers by researcher J.D. Power.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla Inc. (TSLA) will decrease because their quality is not up to par.\n- Ford Motor Company (NYSE: F) will increase because their quality is up to par.\n- General Motors Company (NYSE: GM) will increase because their quality is up to par.", "price_info": {"TSLA": {"company": "Tesla Inc.", "ticker": "TSLA", "move": "up", "prices": [967.255, 961.17]}, "F": {"company": "", "ticker": "F", "move": "up", "prices": [5.98, 5.975]}, "GM": {"company": "", "ticker": "GM", "move": "up", "prices": [25.32, 25.33]}}}, {"link": "https://www.wsj.com/articles/7-elevens-21-billion-deal-could-be-a-marathon-11596451820", "title": "7-Eleven's $21 Billion Deal Could Be a Marathon", "date": "2020-08-03 10:10", "summary": "The massive deal makes strategic sense but still looks pricey, particularly given the struggling state of the U.S. petroleum industry. 7-Eleven is paying top price for its shopping trip in the U.S.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"7-Eleven's $21 Billion Deal Could Be a Marathon. The massive deal makes strategic sense but still looks pricey, particularly given the struggling state of the U.S. petroleum industry. 7-Eleven is paying top price for its shopping trip in the U.S.\"\n\nStock Prediction(s):", "Prediction": "\n- 7-Eleven, Inc. (NASDAQ: SE) will decrease because they overpaid for their acquisition.\n- Marathon Petroleum Corporation (NYSE: MPC) will decrease because of the struggling state of the U.S. petroleum industry.", "price_info": {"MPC": {"company": "", "ticker": "MPC", "move": "down", "prices": [38.9, 37.8]}, "SE": {"company": "", "ticker": "SE", "move": "down", "prices": [131.65, 131.61]}}}, {"link": "https://www.wsj.com/articles/boeing-defends-737-max-design-process-sees-software-fix-in-weeks-11553169291", "title": "Boeing Defends 737 MAX Design Process, Expects Software Fix in Weeks", "date": "2019-03-21 13:55", "summary": "The plane maker is updating the jetliner's flight-control system. A senior Boeing Co. executive defended the company's aircraft design and production processes following two fatal crashes of its 737 MAX airliner, and said fixes to software linked to at least one of those crashes should be ready within weeks.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Defends 737 MAX Design Process, Expects Software Fix in Weeks. The plane maker is updating the jetliner's flight-control system. A senior Boeing Co. executive defended the company's aircraft design and production processes following two fatal crashes of its 737 MAX airliner, and said fixes to software linked to at least one of those crashes should be ready within weeks.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will increase because they are expecting a software fix in weeks, and they have been very transparent about what went wrong.\n- Airbus SE (OTCMKTS: EADSY) will decrease because they are a direct competitor of Boeing, and this news gives Boeing a competitive edge.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [373.35, 372.84]}}}, {"link": "https://www.wsj.com/articles/industrial-commodities-extend-slide-as-coronavirus-dents-demand-11582815635", "title": "Industrial Commodities Extend Slide as Coronavirus Dents Demand", "date": "2020-02-27 15:33", "summary": "Oil, industrial metals fall on fears that ripple effects of virus could result in supply gluts for range of materials. Commodities from oil to copper kept dropping Thursday, continuing a recent slide as traders expect the spreading coronavirus to cripple demand.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Industrial Commodities Extend Slide as Coronavirus Dents Demand. Oil, industrial metals fall on fears that ripple effects of virus could result in supply gluts for range of materials. Commodities from oil to copper kept dropping Thursday, continuing a recent slide as traders expect the spreading coronavirus to cripple demand.\"\n\nStock Prediction(s):", "Prediction": "\n- Schlumberger Ltd. (NYSE: SLB) will decrease because of the global slowdown in demand for commodities.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because of the global slowdown in demand for commodities.\n- Chevron Corporation (NYSE: CVX) will decrease because of the global slowdown in demand for commodities.\n- Rio Tinto plc (NYSE: RIO) will decrease because of the global slowdown in demand for commodities.\n", "price_info": {"SLB": {"company": "", "ticker": "SLB", "move": "down", "prices": [27.04, 26.88]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [50.47, 49.94]}, "CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [95.42, 94.26]}, "RIO": {"company": "", "ticker": "RIO", "move": "down", "prices": [47.71, 47.26]}}}, {"link": "https://www.wsj.com/articles/eurozone-economy-slosws-as-demand-for-exports-stalls-11558619752", "title": "Eurozone Economy Slows as Demand for Exports Stalls", "date": "2019-05-23 10:27", "summary": "The apparent slowdown in the 19-nation eurozone echoes developments in other major economies including the U.S. and China. Europe's economic recovery appears to be stalling amid flagging international demand for its exports, according to a closely-watched business survey that puts fresh pressure on the European Central Bank to act to shore up growth.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Eurozone Economy Slows as Demand for Exports Stalls. The apparent slowdown in the 19-nation eurozone echoes developments in other major economies including the U.S. and China. Europe's economic recovery appears to be stalling amid flagging international demand for its exports, according to a closely-watched business survey that puts fresh pressure on the European Central Bank to act to shore up growth.\"\n\nStock Prediction(s):", "Prediction": "\n- The eurozone economy will continue to slow because of a lack of international demand.\n- The eurozone economy will rebound because of increased domestic demand.\n- The eurozone economy will stay the same because of a mix of domestic and international demand.", "price_info": {}}, {"link": "https://www.wsj.com/articles/more-than-940-000-crock-pot-multicookers-recalled-after-burn-injury-reports-11606250355", "title": "More Than 940,000 Crock-Pots Recalled on Burn-Injury Reports", "date": "2020-11-24 15:39", "summary": "Manufacturer to replace lids on pots after more than 100 reports of detachment during cooking, leading to first- through third-degree burns. More than 940,000 Crock-Pot multicookers are being recalled after reports of the lid suddenly detaching due to pressure, causing hot food and liquids to be ejected from the pot.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"More Than 940,000 Crock-Pots Recalled on Burn-Injury Reports. Manufacturer to replace lids on pots after more than 100 reports of detachment during cooking, leading to first- through third-degree burns. More than 940,000 Crock-Pot multicookers are being recalled after reports of the lid suddenly detaching due to pressure, causing hot food and liquids to be ejected from the pot.\"\n\nStock Prediction(s):", "Prediction": "\n- Whirlpool Corporation (NYSE: WHR) will decrease because their main competitor, Crock-Pot, is recalling their products.\n- Electrolux AB (OTC: ELUXY) will decrease because their main competitor, Crock-Pot, is recalling their products.\n- Viking Range Corporation (NASDAQ: VKGS) will decrease because their main competitor, Crock-Pot, is recalling their products.", "price_info": {"WHR": {"company": "", "ticker": "WHR", "move": "down", "prices": [200.8203, 200.43]}, "VKGS": {"company": "", "ticker": "VKGS", "move": "down"}}}, {"link": "https://www.wsj.com/articles/blackstone-adds-alphabet-finance-chief-porat-to-board-11593101156", "title": "Blackstone Adds Alphabet Finance Chief Porat to Board", "date": "2020-06-25 12:05", "summary": "Appointment boosts female representation to 25%. Blackstone Group Inc. Thursday said Ruth Porat, chief financial officer of Alphabet Inc. and its Google unit, has joined its board, expanding it to 12 directors and boosting female representation to 25%.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Blackstone Adds Alphabet Finance Chief Porat to Board. Appointment boosts female representation to 25%. Blackstone Group Inc. Thursday said Ruth Porat, chief financial officer of Alphabet Inc. and its Google unit, has joined its board, expanding it to 12 directors and boosting female representation to 25%.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because they have a new board member who is very experienced in the finance world.\n- Blackstone Group Inc. (NYSE: BX) will increase because they are expanding their board, and this is a good move for them.", "price_info": {"BX": {"company": "", "ticker": "BX", "move": "up", "prices": [57.01, 56.7]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1429.99, 1429.0953]}}}, {"link": "https://www.wsj.com/articles/china-borrows-at-negative-rates-for-the-first-time-11605769378", "title": "China Borrows at Negative Rates for the First Time", "date": "2020-11-19 13:46", "summary": "Including bonds with positive yields, the euro-denominated deal raised about $4.7 billion. Superlow interest rates in Europe helped China to sell its first negative-yielding debt, as it raised about $4.7 billion in a three-part deal in euros.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"China Borrows at Negative Rates for the First Time. Including bonds with positive yields, the euro-denominated deal raised about $4.7 billion. Superlow interest rates in Europe helped China to sell its first negative-yielding debt, as it raised about $4.7 billion in a three-part deal in euros.\"\n\nStock Prediction(s):", "Prediction": "\n- European Central Bank (ECB) will decrease because they are the reason why China was able to issue negative-yielding debt.\n- The People's Bank of China (PBoC) will increase because they are the issuer of the negative-yielding debt.", "price_info": {"ECB": {"company": "Central Bank", "ticker": "ECB", "move": "up"}}}, {"link": "https://www.wsj.com/articles/celadon-group-nearing-deal-to-sell-taylor-express-business-11578078016", "title": "Celadon Group Nearing Deal to Sell Taylor Express Business", "date": "2020-01-06 11:07", "summary": "Trucking carrier Celadon is in talks with two parties regarding a stalking horse bid to acquire Taylor Express, a lawyer said Friday. Celadon Group Inc. is nearing a deal to sell its Taylor Express Inc. business, a lawyer for the bankrupt freight trucking carrier said Friday.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Celadon Group Nearing Deal to Sell Taylor Express Business. Trucking carrier Celadon is in talks with two parties regarding a stalking horse bid to acquire Taylor Express, a lawyer said Friday. Celadon Group Inc. is nearing a deal to sell its Taylor Express Inc. business, a lawyer for the bankrupt freight trucking carrier said Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- Celadon Group Inc. (NASDAQ: CGI) will increase because they are selling their Taylor Express business, and this will free up some cash and improve their balance sheet.\n- J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT) will increase because they are a direct competitor of Celadon Group, and this will give them a larger market share.\n- Werner Enterprises, Inc. (NASDAQ: WERN)", "price_info": {"CGI": {"company": "", "ticker": "CGI", "move": "up"}, "JBHT": {"company": "", "ticker": "JBHT", "move": "up", "prices": [114.25, 114.51]}, "WERN": {"company": "", "ticker": "WERN", "move": null, "prices": [35.09, 35.2041]}}}, {"link": "https://www.wsj.com/articles/oil-makes-fresh-gains-amid-receding-oversupply-fears-11547202307", "title": "Oil Falls But Logs Big Weekly Gain", "date": "2019-01-11 15:43", "summary": "Crude climbs 8% this week as production cuts, a weaker dollar and export declines from Iran buoy prices. \u2022 Oil prices declined Friday, ending a nine-session streak of increases as a retreat in U.S. stock markets reduced risk appetite and spurred profit-taking. But the U.S. crude-oil benchmark still ended the week nearly 8% higher, as production cuts by major producers, a weaker dollar and further export declines from sanctioned Iran buoyed prices.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Falls But Logs Big Weekly Gain. Crude climbs 8% this week as production cuts, a weaker dollar and export declines from Iran buoy prices. \u2022 Oil prices declined Friday, ending a nine-session streak of increases as a retreat in U.S. stock markets reduced risk appetite and spurred profit-taking. But the U.S. crude-oil benchmark still ended the week nearly 8% higher, as production cuts by major producers, a weaker dollar and further export declines from sanctioned Iran buoyed prices.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because their production has been cut, and they are a major producer.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because their production has been cut, and they are a major producer.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because their production has been cut, and they are a major producer.\n- BP plc (NYSE: BP) will increase", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [112.735, 112.54]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [71.74, 71.66]}, "BP": {"company": "", "ticker": "BP", "move": "up", "prices": [40.29, 40.25]}}}, {"link": "https://www.wsj.com/articles/payless-shoesource-emerges-from-bankruptcy-11579188655", "title": "Payless ShoeSource Emerges From Bankruptcy", "date": "2020-01-16 10:30", "summary": "The retailer said it has named a new executive management team. Payless ShoeSource has emerged from the chapter 11 bankruptcy protection it filed for last February.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Payless ShoeSource Emerges From Bankruptcy. The retailer said it has named a new executive management team. Payless ShoeSource has emerged from the chapter 11 bankruptcy protection it filed for last February.\"\n\nStock Prediction(s):", "Prediction": "\n- Payless ShoeSource (NYSE: PS) will increase because they have a new executive management team, and they are now out of bankruptcy.\n- DSW Inc. (NYSE: DSW) will decrease because they are a direct competitor of Payless ShoeSource.", "price_info": {"PS": {"company": "", "ticker": "PS", "move": "up", "prices": [19.88, 19.91]}, "DSW": {"company": "", "ticker": "DSW", "move": "down"}}}, {"link": "https://www.wsj.com/articles/hard-to-throw-shade-at-this-jobs-number-11599234420", "title": "Hard to Throw Shade at This Jobs Number", "date": "2020-09-04 11:47", "summary": "Biggest danger lurking in the good jobs report is that it could fuel mission-accomplished sentiments in Washington. You can come up with caveats for why the August jobs report wasn't quite so good as it seemed on first blush. What you can't do is deny that it was a good report.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hard to Throw Shade at This Jobs Number. Biggest danger lurking in the good jobs report is that it could fuel mission-accomplished sentiments in Washington. You can come up with caveats for why the August jobs report wasn't quite so good as it seemed on first blush. What you can't do is deny that it was a good report.\"\n\nStock Prediction(s):", "Prediction": "\n- The good jobs report will fuel mission-accomplished sentiments in Washington, which will be good for the stock market.\n- The good jobs report will lead to the Federal Reserve raising interest rates, which will be bad for the stock market.", "price_info": {}}, {"link": "https://www.wsj.com/articles/coronavirus-slows-drug-production-in-china-the-worlds-pharmacy-11582900885", "title": "FDA Cites Shortage of One Drug, Exposing Supply-Line Worry", "date": "2020-02-28 09:41", "summary": "China is key supplier of chemical and raw materials and other pharmaceutical ingredients for medicines. Factory shutdowns across China because of the new coronavirus have exposed an uncomfortable health-care reality: Many medicines rely on raw materials that are made in that country.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FDA Cites Shortage of One Drug, Exposing Supply-Line Worry. China is key supplier of chemical and raw materials and other pharmaceutical ingredients for medicines. Factory shutdowns across China because of the new coronavirus have exposed an uncomfortable health-care reality: Many medicines rely on raw materials that are made in that country.\"\n\nStock Prediction(s):", "Prediction": "\n- The stocks of companies that rely on China for their ingredients will decrease because of the factory shutdowns.\n- The stocks of companies that do not rely on China for their ingredients will not be affected.", "price_info": {}}, {"link": "https://www.wsj.com/articles/goldman-posts-flat-second-quarter-profit-11594813533", "title": "Goldman's Traders, Bankers Keep Profit Steady While Rivals Falter", "date": "2020-07-15 12:16", "summary": "Trading revenue nearly doubled during a volatile stretch for markets; shares rise. Nobody is better at capitalizing on market chaos than Goldman Sachs Group Inc.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Goldman's Traders, Bankers Keep Profit Steady While Rivals Falter. Trading revenue nearly doubled during a volatile stretch for markets; shares rise. Nobody is better at capitalizing on market chaos than Goldman Sachs Group Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc (NYSE: GS) will continue to increase because they have been able to capitalize on the market chaos.\n- JPMorgan Chase & Co. (NYSE: JPM) will continue to decrease because they have not been able to capitalize on the market chaos.\n- Bank of America Corp (NYSE: BAC) will continue to decrease because they have not been able to capitalize on the market chaos.", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up", "prices": [215.935, 216.4]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [99.55, 99.0596]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [24.4821, 24.4121]}}}, {"link": "https://www.wsj.com/articles/trading-a-trade-war-markets-dont-appear-ready-for-that-11558517402", "title": "Trading a Trade Battle: 'Markets Don't Appear Ready for That'", "date": "2019-05-22 10:09", "summary": "Some investors are shunning stocks with significant exposure to China. How do you trade a trade fight? A previously abstract question is becoming more pressing for investors as U.S.-China trade relations fray.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trading a Trade Battle: 'Markets Don't Appear Ready for That'. Some investors are shunning stocks with significant exposure to China. How do you trade a trade fight? A previously abstract question is becoming more pressing for investors as U.S.-China trade relations fray.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing (NYSE: BA) will increase because they have a lot of exposure to China and they are a major U.S. company.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they have a lot of exposure to China and they are a major U.S. company.\n- Caterpillar Inc. (NYSE: CAT) will increase because they have a lot of exposure to China and they are a major U.S. company", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [354.73, 353.69]}, "CAT": {"company": "", "ticker": "CAT", "move": "up", "prices": [124.94, 124.4249]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [183.0488, 183.5179]}}}, {"link": "https://www.wsj.com/articles/fortnite-worries-continue-to-blow-away-game-makers-11549475203", "title": "'Fortnite' Worries Continue to Blow Away Game Makers", "date": "2019-02-06 12:46", "summary": "Projections from Electronic Arts and Take-Two Interactive suggest competition from free-to-play blockbuster remains hot. Making a great videogame is hard enough. Making a great one that will print money for years to come is harder still-especially now.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'Fortnite' Worries Continue to Blow Away Game Makers. Projections from Electronic Arts and Take-Two Interactive suggest competition from free-to-play blockbuster remains hot. Making a great videogame is hard enough. Making a great one that will print money for years to come is harder still-especially now.\"\n\nStock Prediction(s):", "Prediction": "\n- Electronic Arts Inc. (NASDAQ: EA) will decrease because their main competitor is free-to-play games.\n- Take-Two Interactive Software, Inc. (NASDAQ: TTWO) will decrease because their main competitor is free-to-play games.", "price_info": {"EA": {"company": "", "ticker": "EA", "move": "down", "prices": [80.055, 81.2601]}, "TTWO": {"company": "", "ticker": "TTWO", "move": "down", "prices": [93.275, 92.8784]}}}, {"link": "https://www.wsj.com/articles/microsoft-to-close-its-retail-stores-11593183453", "title": "Microsoft to Close Its Retail Stores", "date": "2020-06-26 10:57", "summary": "Tech giant says sales have grown online as product portfolio 'has evolved to largely digital offerings'. Microsoft Corp. is exiting bricks-and-mortar retail after opening its first location more than a decade ago, as the tech giant focuses on bolstering its digital storefronts.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Microsoft to Close Its Retail Stores. Tech giant says sales have grown online as product portfolio 'has evolved to largely digital offerings'. Microsoft Corp. is exiting bricks-and-mortar retail after opening its first location more than a decade ago, as the tech giant focuses on bolstering its digital storefronts.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because they are closing their retail stores.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are not closing their retail stores, and they are a direct competitor of Microsoft.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [198.3901, 197.6234]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [2759.08, 2748.79]}}}, {"link": "https://www.wsj.com/articles/gold-edges-up-as-dollar-falls-11558366887", "title": "Gold Edges Up as Dollar Falls", "date": "2019-05-20 14:33", "summary": "Copper drops on economic concerns following the U.S.-China trade dispute. Gold prices got a boost from a weaker U.S. dollar and anxiety over U.S.-China trade negotiations.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold Edges Up as Dollar Falls. Copper drops on economic concerns following the U.S.-China trade dispute. Gold prices got a boost from a weaker U.S. dollar and anxiety over U.S.-China trade negotiations.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldcorp Inc. (NYSE: GG) will increase because the dollar is weak and there is anxiety over the U.S.-China trade negotiations.\n- Freeport-McMoRan Inc. (NYSE: FCX) will decrease because the dollar is weak and there is anxiety over the U.S.-China trade negotiations.\n- Newmont Mining Corp. (NYSE: NEM) will decrease because the dollar is weak and there is anxiety over", "price_info": {"GG": {"company": "", "ticker": "GG", "move": "up"}, "FCX": {"company": "", "ticker": "FCX", "move": "down", "prices": [10.215, 10.2199]}, "NEM": {"company": "", "ticker": "NEM", "move": "down", "prices": [31.235, 31.17]}}}, {"link": "https://www.wsj.com/articles/why-hurricanes-can-take-gasoline-prices-for-a-wild-ride-11598458876", "title": "Why Hurricanes Can Take Gasoline Prices for a Wild Ride", "date": "2020-08-26 14:58", "summary": "Major Gulf storms such as Hurricane Laura often threaten vital refineries and risk supply disruptions. Investors are keeping a close eye on energy markets as Hurricane Laura moves toward the Texas-Louisiana border, the latest potential weather event that could disrupt supplies for gasoline.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Hurricanes Can Take Gasoline Prices for a Wild Ride. Major Gulf storms such as Hurricane Laura often threaten vital refineries and risk supply disruptions. Investors are keeping a close eye on energy markets as Hurricane Laura moves toward the Texas-Louisiana border, the latest potential weather event that could disrupt supplies for gasoline.\"\n\nStock Prediction(s):", "Prediction": "\n- Marathon Petroleum Corporation (NYSE: MPC) will increase because they are a direct competitor of the other refineries in the Gulf region.\n- Valero Energy Corporation (NYSE: VLO) will increase because they are a direct competitor of the other refineries in the Gulf region.\n- Phillips 66 (NYSE: PSX) will increase because they are a direct competitor of the other refineries in the Gulf region.\n- Tesoro Corporation (NYSE: T", "price_info": {"MPC": {"company": "", "ticker": "MPC", "move": "up", "prices": [35.37, 35.48]}, "VLO": {"company": "", "ticker": "VLO", "move": "up", "prices": [53.74, 53.71]}, "PSX": {"company": "", "ticker": "PSX", "move": "up", "prices": [60.085, 60.24]}}}, {"link": "https://www.wsj.com/articles/shooting-rich-people-into-space-isnt-the-final-frontier-11562678612", "title": "Shooting Rich People Into Space Isn't the Final Frontier", "date": "2019-07-10 13:11", "summary": "Richard Branson's Virgin Galactic will be the first publicly traded space-tourism company, but not the most attractive. British billionaire Richard Branson's dream of shooting people into space may echo Apollo 11's epic moon landing 50 years ago this month, but for investors it could end up looking more like the Apollo 13 fiasco.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Shooting Rich People Into Space Isn't the Final Frontier. Richard Branson's Virgin Galactic will be the first publicly traded space-tourism company, but not the most attractive. British billionaire Richard Branson's dream of shooting people into space may echo Apollo 11's epic moon landing 50 years ago this month, but for investors it could end up looking more like the Apollo 13 fiasco.\"\n\nStock Prediction(s):", "Prediction": "\n- Virgin Galactic Holdings Inc (NYSE: SPCE) will decrease because their business model is not as attractive as other space-tourism companies.\n- Blue Origin LLC (private) will increase because they have a more attractive business model than Virgin Galactic Holdings Inc.", "price_info": {"SPCE": {"company": "", "ticker": "SPCE", "move": "up"}}}, {"link": "https://www.wsj.com/articles/shoppers-stock-up-on-comfort-food-amid-pandemic-11587726462", "title": "Comfort Foods Make a Comeback in the Coronavirus Age", "date": "2020-04-24 10:32", "summary": "Big brands, which have struggled to grow, see boost as homebound consumers reach for familiar products. Comfort foods from big brands are seeing a resurgence, executives say, as consumers seek familiarity and convenience amid the coronavirus pandemic.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Comfort Foods Make a Comeback in the Coronavirus Age. Big brands, which have struggled to grow, see boost as homebound consumers reach for familiar products. Comfort foods from big brands are seeing a resurgence, executives say, as consumers seek familiarity and convenience amid the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- General Mills, Inc. (NYSE: GIS) will increase because their products are considered comfort foods.\n- The Hershey Company (NYSE: HSY) will increase because their products are considered comfort foods.\n- Mondelez International, Inc. (NASDAQ: MDLZ) will increase because their products are considered comfort foods.\n- PepsiCo, Inc. (NASDAQ: PEP) will increase because their products are considered comfort foods.", "price_info": {"GIS": {"company": "", "ticker": "GIS", "move": "up", "prices": [59.61, 59.86]}, "HSY": {"company": "", "ticker": "HSY", "move": "up", "prices": [134.9, 134.74]}, "MDLZ": {"company": "", "ticker": "MDLZ", "move": "up", "prices": [51.17, 51.06]}, "PEP": {"company": "", "ticker": "PEP", "move": "up", "prices": [132.42, 132.765]}}}, {"link": "https://www.wsj.com/articles/hospitalized-covid-19-patients-recovered-faster-with-arthritis-drug-11600095383", "title": "Lilly's Arthritis Drug Helped Covid-19 Patients Recover Faster", "date": "2020-09-14 11:12", "summary": "Drugmaker will seek emergency-use authorization for rheumatoid-arthritis drug Olumiant in coronavirus cases based on NIH study. Eli Lilly & Co. and Incyte Corp. said they will seek U.S. emergency-use authorization for their rheumatoid-arthritis drug Olumiant as a treatment for Covid-19, after a study showed that it helped hospitalized patients recover sooner.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Lilly's Arthritis Drug Helped Covid-19 Patients Recover Faster. Drugmaker will seek emergency-use authorization for rheumatoid-arthritis drug Olumiant in coronavirus cases based on NIH study. Eli Lilly & Co. and Incyte Corp. said they will seek U.S. emergency-use authorization for their rheumatoid-arthritis drug Olumiant as a treatment for Covid-19, after a study showed that it helped hospitalized patients recover sooner.\"\n\nStock Prediction(s):", "Prediction": "\n- Eli Lilly & Co. (NYSE: LLY) will increase because their arthritis drug helped Covid-19 patients recover faster.\n- Incyte Corp. (NASDAQ: INCY) will increase because their arthritis drug helped Covid-19 patients recover faster.", "price_info": {"LLY": {"company": "", "ticker": "LLY", "move": "up", "prices": [149.27, 150.39]}, "INCY": {"company": "", "ticker": "INCY", "move": "up", "prices": [94.36, 94.06]}}}, {"link": "https://www.wsj.com/articles/common-job-interview-questions-and-how-to-answer-them-11606489538", "title": "Common Job Interview Questions and How to Answer Them", "date": "2021-03-04 10:48", "summary": "Most Popular News. In the process of preparing for your interview, you have researched the company, figured out how your skills align with the job requirements and come up with some thoughtful questions to ask. You might not be able to predict exactly which questions you will be asked during the interview, but there are many common questions that you will likely be asked, and it is helpful to have a strategy for answering them.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Common Job Interview Questions and How to Answer Them. Most Popular News. In the process of preparing for your interview, you have researched the company, figured out how your skills align with the job requirements and come up with some thoughtful questions to ask. You might not be able to predict exactly which questions you will be asked during the interview, but there are many common questions that you will likely be asked, and it is helpful to have a strategy for answering them.\"\n\nStock Prediction(s):", "Prediction": "\n- The following stocks will increase because they are related to the job industry:\n- Monster Beverage Corporation (NASDAQ: MNST)\n- Starbucks Corporation (NASDAQ: SBUX)\n- Chipotle Mexican Grill, Inc. (NYSE: CMG)\n- The following stocks will decrease because they are related to the job industry:\n- McDonald's Corporation (NYSE: MCD)\n- Yum! Brands, Inc. (NYSE: YUM", "price_info": {"CMG": {"company": "", "ticker": "CMG", "move": "down", "prices": [1372.3, 1386.175]}, "MCD": {"company": "", "ticker": "MCD", "move": "up", "prices": [206.42, 206.9917]}, "MNST": {"company": "", "ticker": "MNST", "move": "up", "prices": [85.77, 86.02]}, "SBUX": {"company": "", "ticker": "SBUX", "move": "up", "prices": [106.84, 106.81]}}}, {"link": "https://www.wsj.com/articles/martin-shkreli-steers-his-company-from-prisonwith-contraband-cellphone-11551973574", "title": "Martin Shkreli Steers His Old Company From Prison-With Contraband Cellphone", "date": "2019-03-07 14:10", "summary": "Having made friends including 'Krispy' and 'D-Block,' the disgraced pharmaceutical executive is planning his billion-dollar comeback. From a top bunk in a 12-person prison cell in Fort Dix, N.J., Martin Shkreli is at work on a big second act.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Martin Shkreli Steers His Old Company From Prison-With Contraband Cellphone. Having made friends including 'Krispy' and 'D-Block,' the disgraced pharmaceutical executive is planning his billion-dollar comeback. From a top bunk in a 12-person prison cell in Fort Dix, N.J., Martin Shkreli is at work on a big second act.\"\n\nStock Prediction(s):", "Prediction": "\n- Turing Pharmaceuticals AG (private) will increase because Martin Shkreli is back at the helm and he is planning a billion-dollar comeback.\n- KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) will increase because Martin Shkreli is back at the helm and he is planning a billion-dollar comeback.\n- Vyera Pharmaceuticals, Inc. (private) will increase because Martin Shkreli is", "price_info": {"KBIO": {"company": "", "ticker": "KBIO", "move": "up"}}}, {"link": "https://www.wsj.com/articles/glencore-ceo-ivan-glasenberg-to-retire-in-2021-11607091758", "title": "Glencore CEO Glasenberg to Retire After 18 Years at the Helm", "date": "2020-12-04 13:24", "summary": "A successor to one-time-fugitive Marc Rich, he spearheaded the company's dominant position in coal mining. LONDON-Ivan Glasenberg, the longtime chief executive of Glencore PLC, is handing over the reins of the global mining and trading giant he built, saying Friday he would retire in the first half of next year.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Glencore CEO Glasenberg to Retire After 18 Years at the Helm. A successor to one-time-fugitive Marc Rich, he spearheaded the company's dominant position in coal mining. LONDON-Ivan Glasenberg, the longtime chief executive of Glencore PLC, is handing over the reins of the global mining and trading giant he built, saying Friday he would retire in the first half of next year.\"\n\nStock Prediction(s):", "Prediction": "\n- Glencore plc (LON: GLEN) will decrease because their CEO is retiring.\n- Anglo American plc (LON: AAL) will increase because they are a direct competitor of Glencore.", "price_info": {}}, {"link": "https://www.wsj.com/articles/be-carefulthese-stocks-have-weak-tickers-11574789189", "title": "Be Careful-These Stocks Have Weak Tickers", "date": "2019-11-26 12:26", "summary": "Single-letter ticker symbols used to have prestige. Now they attract an unusual degree of skepticism. These aren't love letters.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Be Careful-These Stocks Have Weak Tickers. Single-letter ticker symbols used to have prestige. Now they attract an unusual degree of skepticism. These aren't love letters.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc (NASDAQ: GOOGL) will increase because their ticker symbol is \"GOOGL\" and it has prestige.\n- Facebook Inc (NASDAQ: FB) will increase because their ticker symbol is \"FB\" and it has prestige.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because their ticker symbol is \"AMZN\" and it has prestige.\n- Apple Inc. (", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1310.9327, 1311.23]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [199.44, 199]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1792.7, 1793.66]}}}, {"link": "https://www.wsj.com/articles/how-couples-can-talk-about-their-finances-including-student-debt-11559324344", "title": "How Couples Can Talk About Their Finances, Including Student Debt", "date": "2019-05-31 14:26", "summary": "In this edition of the WSJ's 'Secrets of Wealthy Women,' a panel discusses millennials taking control of their money. When couples start to commit, it is important for them to share details about their financial lives with each other.", "categories": [["Markets", "Your Money"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/undefined?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How Couples Can Talk About Their Finances, Including Student Debt. In this edition of the WSJ's 'Secrets of Wealthy Women,' a panel discusses millennials taking control of their money. When couples start to commit, it is important for them to share details about their financial lives with each other.\"\n\nStock Prediction(s):", "Prediction": "\n- American Express Company (NYSE: AXP) will increase because more couples will be using their credit cards to consolidate their finances.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because more couples will be using their credit cards to consolidate their finances.\n- Goldman Sachs Group, Inc. (NYSE: GS) will increase because more couples will be using their credit cards to consolidate their finances.\n- Visa Inc. (NYSE: V) will increase", "price_info": {"AXP": {"company": "", "ticker": "AXP", "move": "up", "prices": [114.88, 114.71]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [105.93, 105.96]}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [182.69, 182.49]}, "V": {"company": "", "ticker": "V", "move": "up", "prices": [161.34, 161.33]}}}, {"link": "https://www.wsj.com/articles/funds-get-put-on-mute-due-to-lack-of-need-11600877169", "title": "Funds Get Put on 'MUTE' Due to 'LACK' of 'NEED'", "date": "2020-09-23 12:06", "summary": "As exchange-traded funds bite the dust, so do some clever ticker symbols.. It is a \"DOG\" eat dog world for exchange-traded funds.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Funds Get Put on 'MUTE' Due to 'LACK' of 'NEED'. As exchange-traded funds bite the dust, so do some clever ticker symbols.. It is a \"DOG\" eat dog world for exchange-traded funds.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because investors are pulling out of the market because of the lack of need for funds.\n- The market will go up because some clever ticker symbols are being put on \"mute.\"", "price_info": {}}, {"link": "https://www.wsj.com/articles/ethanol-prices-climb-on-strong-demand-for-fuel-as-drivers-hit-road-11636545600", "title": "Ethanol Prices Climb on Strong Fuel Demand", "date": "2021-11-10 15:30", "summary": "Cost of corn, ethanol's main ingredient, has trended higher, with refineries scrambling to supply gasoline additive. Demand for fuel as drivers return to the road is pushing ethanol prices close to an all-time high.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ethanol Prices Climb on Strong Fuel Demand. Cost of corn, ethanol's main ingredient, has trended higher, with refineries scrambling to supply gasoline additive. Demand for fuel as drivers return to the road is pushing ethanol prices close to an all-time high.\"\n\nStock Prediction(s):", "Prediction": "\n- Archer Daniels Midland Company (NYSE: ADM) will increase because they are a main supplier of corn, and ethanol prices are trending higher.\n- Green Plains Inc. (NASDAQ: GPRE) will increase because they are a main supplier of ethanol.\n- Valero Energy Corporation (NYSE: VLO) will increase because they are a main supplier of gasoline, and ethanol prices are trending higher.", "price_info": {"ADM": {"company": "", "ticker": "ADM", "move": "up", "prices": [65.325, 65.39]}, "VLO": {"company": "", "ticker": "VLO", "move": "up", "prices": [77.19, 76.86]}, "GPRE": {"company": "", "ticker": "GPRE", "move": "up"}}}, {"link": "https://www.wsj.com/articles/job-postings-level-off-as-delta-variant-cools-demand-for-in-person-workers-11631093400", "title": "Job Openings Remain Robust, Though In-Person Postings Slip", "date": "2021-09-08 15:11", "summary": "Supply of labor remained constrained as pandemic-related unemployment benefits came to an end. Demand for workers in the U.S. remained strong-but leveled off-in the late summer due to an easing of job openings for in-person services positions as the economic recovery showed signs of slowing due to the Delta variant of Covid-19.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Job Openings Remain Robust, Though In-Person Postings Slip. Supply of labor remained constrained as pandemic-related unemployment benefits came to an end. Demand for workers in the U.S. remained strong-but leveled off-in the late summer due to an easing of job openings for in-person services positions as the economic recovery showed signs of slowing due to the Delta variant of Covid-19.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will continue to decline because more people are finding jobs.\n- The stock prices of companies that provide in-person services will decrease because there is less demand for their services.\n- The stock prices of companies that provide online services will increase because there is more demand for their services.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bluecrest-capital-management-to-pay-170-million-to-settle-sec-claims-11607437429", "title": "BlueCrest Capital Management to Pay $170 Million to Settle SEC Claims", "date": "2020-12-08 11:29", "summary": "Firm misled clients about an internal fund that invested its traders' own money, SEC says. BlueCrest Capital Management Ltd. will pay $170 million to settle claims that it misled clients about an internal fund that invested its traders' own money, while its flagship fund was managed by an underperforming algorithm, the Securities and Exchange Commission said Tuesday.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"BlueCrest Capital Management to Pay $170 Million to Settle SEC Claims. Firm misled clients about an internal fund that invested its traders' own money, SEC says. BlueCrest Capital Management Ltd. will pay $170 million to settle claims that it misled clients about an internal fund that invested its traders' own money, while its flagship fund was managed by an underperforming algorithm, the Securities and Exchange Commission said Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- BlueCrest Capital Management Ltd. (OTCMKTS: BCSTF) will decrease because they have been caught misleading their clients.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are not involved in this scandal.", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [122.15, 122.0278]}}}, {"link": "https://www.wsj.com/articles/cirque-du-soleil-positions-lenders-to-take-control-from-tpg-11594830528", "title": "Cirque du Soleil Positions Lenders to Take Control From TPG", "date": "2020-07-15 12:28", "summary": "Bankrupt circus producer prepares to sign deal that would strip TPG and other shareholders of their ownership stakes. Cirque du Soleil Entertainment Group is preparing to reject a buyout offer from shareholders in favor of a competing proposal from lenders that have offered to supply $375 million in new loans while taking control of the bankrupt company, according to people familiar with the matter.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Cirque du Soleil Positions Lenders to Take Control From TPG. Bankrupt circus producer prepares to sign deal that would strip TPG and other shareholders of their ownership stakes. Cirque du Soleil Entertainment Group is preparing to reject a buyout offer from shareholders in favor of a competing proposal from lenders that have offered to supply $375 million in new loans while taking control of the bankrupt company, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Cirque du Soleil Entertainment Group (OTCQB: CDSE) will increase because the lenders are offering to supply $375 million in new loans while taking control of the bankrupt company.\n- TPG (NYSE: TPG) will decrease because they are losing control of the bankrupt company.", "price_info": {"TPG": {"company": "", "ticker": "TPG", "move": "down"}}}, {"link": "https://www.wsj.com/articles/u-s-government-bonds-steady-as-fed-meeting-looms-11552922007", "title": "U.S. Government BondsEdge Lower as Fed Meeting Looms", "date": "2019-03-18 15:32", "summary": "Treasury yields barely budged in the overnight session after falling last week in response to weaker-than-expected U.S. economic data. U.S. government-bond prices edged lower Monday, but yields remained near the bottom of their recent range as investors looked ahead to this week's Federal Reserve meeting.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Government BondsEdge Lower as Fed Meeting Looms. Treasury yields barely budged in the overnight session after falling last week in response to weaker-than-expected U.S. economic data. U.S. government-bond prices edged lower Monday, but yields remained near the bottom of their recent range as investors looked ahead to this week's Federal Reserve meeting.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. government bond market will continue to edge lower because the Federal Reserve is likely to continue to raise interest rates.\n- The yield on the 10-year U.S. Treasury note will continue to rise because the Federal Reserve is likely to continue to raise interest rates.", "price_info": {}}, {"link": "https://www.wsj.com/articles/energy-transfer-blames-edgemarc-creditors-for-failed-bankruptcy-auction-11572447329", "title": "Energy Transfer Blames EdgeMarc Creditors for Failed Bankruptcy Auction", "date": "2019-10-30 10:55", "summary": "Pipeline builder says fracker and its creditors scrapped an auction for Pennsylvania properties. Pipeline giant Energy Transfer LP is blaming fracker EdgeMarc Energy Holdings LLC and its creditors for a failed auction of Pennsylvania natural gas drill sites left stranded by an explosion.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Energy Transfer Blames EdgeMarc Creditors for Failed Bankruptcy Auction. Pipeline builder says fracker and its creditors scrapped an auction for Pennsylvania properties. Pipeline giant Energy Transfer LP is blaming fracker EdgeMarc Energy Holdings LLC and its creditors for a failed auction of Pennsylvania natural gas drill sites left stranded by an explosion.\"\n\nStock Prediction(s):", "Prediction": "\n- Energy Transfer LP (NYSE: ET) will decrease because their auction failed, and they are blaming EdgeMarc Energy Holdings LLC and its creditors.\n- EdgeMarc Energy Holdings LLC (OTC: EMCH) will increase because they are being blamed for the failed auction, and they are a direct competitor of Energy Transfer LP.", "price_info": {"ET": {"company": "", "ticker": "ET", "move": "up", "prices": [12.33, 12.29]}}}, {"link": "https://www.wsj.com/articles/inflation-cuts-both-ways-for-gm-11628098022", "title": "Inflation Cuts Both Ways for GM", "date": "2021-08-04 13:27", "summary": "Rising raw-material prices add to costs across automotive industry, but Detroit peers Ford, Stellantis probably have more ways to mitigate problem. Inflation in vehicle prices has been very helpful for car makers lately. Now investors are seeing the flip side of the coin.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Inflation Cuts Both Ways for GM. Rising raw-material prices add to costs across automotive industry, but Detroit peers Ford, Stellantis probably have more ways to mitigate problem. Inflation in vehicle prices has been very helpful for car makers lately. Now investors are seeing the flip side of the coin.\"\n\nStock Prediction(s):", "Prediction": "\n- General Motors Company (NYSE: GM) will decrease because their profits will be cut by the inflation of raw-material prices.\n- Ford Motor Company (NYSE: F) will increase because they have more ways to mitigate the problem of inflation.\n- Stellantis Holdings Inc. (NASDAQ: STL) will increase because they are a direct competitor of General Motors.", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "down", "prices": [52.625, 52.74]}, "F": {"company": "", "ticker": "F", "move": "up", "prices": [13.4599, 13.32]}, "STL": {"company": "", "ticker": "STL", "move": "up", "prices": [22.145, 21.98]}}}, {"link": "https://www.wsj.com/articles/recession-rises-on-list-of-ceo-fears-for-2020-11577962921", "title": "Recession Fears Rise for CEOs as Trade Concerns Linger", "date": "2020-01-02 12:25", "summary": "Economic slowdown and trade uncertainty are top concerns in survey of global business leaders. U.S. chief executives are getting worried about a recession.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Recession Fears Rise for CEOs as Trade Concerns Linger. Economic slowdown and trade uncertainty are top concerns in survey of global business leaders. U.S. chief executives are getting worried about a recession.\"\n\nStock Prediction(s):", "Prediction": "\n- The stock prices of companies such as Coca-Cola (NYSE: KO), PepsiCo (NASDAQ: PEP), and Procter & Gamble (NYSE: PG) will decrease because a recession means that people will be buying less of their products.\n- The stock prices of companies such as Amazon (NASDAQ: AMZN) and Walmart (NYSE: WMT) will increase because a recession means that people will be buying less of other types of products", "price_info": {"KO": {"company": "", "ticker": "KO", "move": null, "prices": [54.835, 54.905]}, "PG": {"company": "", "ticker": "PG", "move": "down", "prices": [123.1302, 123.25]}, "WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [118.79, 118.775]}, "PEP": {"company": "", "ticker": "PEP", "move": null, "prices": [135.315, 135.66]}, "AMZN": {"company": "", "ticker": "AMZN", "move": null, "prices": [1874.0045, 1877.53]}}}, {"link": "https://www.wsj.com/articles/who-moved-kraft-heinzs-cheese-11565284749", "title": "Who Moved Kraft Heinz's Cheese?", "date": "2019-08-08 13:19", "summary": "The food company's shares fell sharply after it reported sliding sales, but challenges are hardly over. The best thing that can be said about Kraft Heinz's results on Thursday is that it was only the second worst day of 2019 for the sprawling food company-so far, at least.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Who Moved Kraft Heinz's Cheese?. The food company's shares fell sharply after it reported sliding sales, but challenges are hardly over. The best thing that can be said about Kraft Heinz's results on Thursday is that it was only the second worst day of 2019 for the sprawling food company-so far, at least.\"\n\nStock Prediction(s):", "Prediction": "\n- Kraft Heinz Co (NASDAQ: KHC) will continue to decline because their sales are sliding and they are having a difficult time.\n- Mondelez International Inc (NASDAQ: MDLZ) will increase because they are not affiliated with Kraft Heinz and they are doing well.\n- PepsiCo, Inc. (NASDAQ: PEP) will increase because they are not affiliated with Kraft Heinz and they are doing well.", "price_info": {"KHC": {"company": "", "ticker": "KHC", "move": "down", "prices": [27.7999, 27.44]}, "MDLZ": {"company": "", "ticker": "MDLZ", "move": "up", "prices": [54.85, 54.99]}, "PEP": {"company": "", "ticker": "PEP", "move": "up", "prices": [129.21, 129.6]}}}, {"link": "https://www.wsj.com/articles/wayfair-copied-amazon-to-grow-fast-now-it-searches-for-profits-11582894032", "title": "Wayfair Copied Amazon to Grow Fast. Now, It Searches for Profits", "date": "2020-02-28 10:37", "summary": "Online furniture seller's quarterly loss more than doubles as spending outstrips sales growth. In nearly two decades, online home-goods seller Wayfair Inc. has grown quickly by burning through profits.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wayfair Copied Amazon to Grow Fast. Now, It Searches for Profits. Online furniture seller's quarterly loss more than doubles as spending outstrips sales growth. In nearly two decades, online home-goods seller Wayfair Inc. has grown quickly by burning through profits.\"\n\nStock Prediction(s):", "Prediction": "\n- Wayfair Inc (NYSE: W) will continue to increase because they are still growing quickly, and they have not found a way to turn a profit yet.\n- Amazon.com, Inc. (NASDAQ: AMZN) will continue to decrease because they are a direct competitor of Wayfair, and Wayfair is growing faster.", "price_info": {"W": {"company": "", "ticker": "W", "move": "up", "prices": [57.33, 61.09]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1840, 1866.058]}}}, {"link": "https://www.wsj.com/articles/a-scramble-for-gold-is-redrawing-the-map-of-the-market-11591867007", "title": "A Scramble for Gold Is Redrawing the Map of the Market", "date": "2020-06-11 15:27", "summary": "More than 20 million troy ounces of gold have landed in New York vaults over the past three months. New York faces a gold rush after the pandemic threw precious-metal markets into disarray, setting off a scramble by traders to cut their losses.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Scramble for Gold Is Redrawing the Map of the Market. More than 20 million troy ounces of gold have landed in New York vaults over the past three months. New York faces a gold rush after the pandemic threw precious-metal markets into disarray, setting off a scramble by traders to cut their losses.\"\n\nStock Prediction(s):", "Prediction": "\n- Newmont Mining Corporation (NYSE: NEM) will increase because they are one of the largest gold miners in the world, and they will benefit from the increased demand for gold.\n- Barrick Gold Corporation (NYSE: ABX) will increase because they are one of the largest gold miners in the world, and they will benefit from the increased demand for gold.\n- Goldcorp Inc. (NYSE: GG) will increase because they are one of the", "price_info": {"NEM": {"company": "", "ticker": "NEM", "move": "up", "prices": [56.21, 56.05]}, "ABX": {"company": "", "ticker": "ABX", "move": "up"}, "GG": {"company": "", "ticker": "GG", "move": "up"}}}, {"link": "https://www.wsj.com/articles/u-s-service-industries-feel-weight-of-coronoavirus-uncertainty-11583354368", "title": "U.S. Service Industries Feel Weight of Coronoavirus Uncertainty", "date": "2020-03-04 15:39", "summary": "Surveys show disruptions in sourcing materials and declining demand in wide range of sectors. WASHINGTON-Concerns about the novel coronavirus epidemic clouded the outlook in February for U.S. businesses in service industries, posing a new risk to economic growth.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Service Industries Feel Weight of Coronoavirus Uncertainty. Surveys show disruptions in sourcing materials and declining demand in wide range of sectors. WASHINGTON-Concerns about the novel coronavirus epidemic clouded the outlook in February for U.S. businesses in service industries, posing a new risk to economic growth.\"\n\nStock Prediction(s):", "Prediction": "\n- Service industries will continue to feel the weight of the coronavirus, leading to a decline in demand and economic growth.\n- Boeing Co (NYSE: BA) will decrease because of the decline in demand for service industries.\n- General Electric Co (NYSE: GE) will decrease because of the decline in demand for service industries.\n- 3M Co (NYSE: MMM) will decrease because of the decline in demand for service industries.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [281.78, 282.23]}, "GE": {"company": "", "ticker": "GE", "move": "down", "prices": [10.915, 10.94]}, "MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [153.3129, 153.82]}}}, {"link": "https://www.wsj.com/articles/computers-were-going-to-upend-home-buying-they-didnt-see-the-coronavirus-coming-11587115806", "title": "Computers Were Going to Upend Home Buying. They Didn't See the Coronavirus Coming.", "date": "2020-04-17 11:31", "summary": "Companies like Zillow and Opendoor were supposed to lead a revolution in real estate by using algorithms to flip homes. A global pandemic brought those plans to a screeching halt.. BMW -driving, blazer-wearing real-estate agents should have gone the way of VHS tapes and paper maps by now-rendered an anachronism. Yet, while the internet has transformed the way we hunt for homes and snoop how much our neighbors paid for theirs, the labor and paper-intensive process of the actual home transaction persists.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Computers Were Going to Upend Home Buying. They Didn't See the Coronavirus Coming.. Companies like Zillow and Opendoor were supposed to lead a revolution in real estate by using algorithms to flip homes. A global pandemic brought those plans to a screeching halt.. BMW -driving, blazer-wearing real-estate agents should have gone the way of VHS tapes and paper maps by now-rendered an anachronism. Yet, while the internet has transformed the way we hunt for homes and snoop how much our neighbors paid for theirs, the labor and paper-intensive process of the actual home transaction persists.\"\n\nStock Prediction(s):", "Prediction": "\n- Zillow Group, Inc. (NASDAQ: Z) will decrease because their business model is based on computerized home buying, which is no longer feasible because of the coronavirus.\n- Redfin Corporation (NASDAQ: RDFN) will decrease because their business model is based on computerized home buying, which is no longer feasible because of the coronavirus.\n- Opendoor Holdings, Inc. (NYSE: ONDO) will", "price_info": {"ONDO": {"company": "", "ticker": "ONDO", "move": null}, "Z": {"company": "", "ticker": "Z", "move": "down", "prices": [35.635, 35.53]}, "RDFN": {"company": "", "ticker": "RDFN", "move": "down", "prices": [18.05, 18.17]}}}, {"link": "https://www.wsj.com/articles/airbus-puts-squeeze-on-boeings-737-max-as-crisis-drags-11581581121", "title": "Airbus Puts Squeeze on Boeing's 737 MAX as Crisis Drags", "date": "2020-02-13 15:34", "summary": "European plane maker is ramping up production of the A320neo. TOULOUSE, France- Airbus SE is ramping up production of its bestselling single-aisle jet, moving to fill a hole in the market created by the prolonged grounding of rival Boeing Co. 's 737 MAX.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Airbus Puts Squeeze on Boeing's 737 MAX as Crisis Drags. European plane maker is ramping up production of the A320neo. TOULOUSE, France- Airbus SE is ramping up production of its bestselling single-aisle jet, moving to fill a hole in the market created by the prolonged grounding of rival Boeing Co. 's 737 MAX.\"\n\nStock Prediction(s):", "Prediction": "\n- Airbus SE (EPA: AIR) will increase because they are ramping up production of their bestselling single-aisle jet.\n- Boeing Co. (NYSE: BA) will decrease because their 737 MAX is still grounded, and Airbus is taking market share.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [343.435, 342.88]}}}, {"link": "https://www.wsj.com/articles/puff-bar-e-cigarette-maker-under-investigation-by-north-carolina-attorney-general-11637081589", "title": "Puff Bar E-Cigarette Maker Under Investigation by North Carolina Attorney General", "date": "2021-11-16 14:27", "summary": "Company behind the most popular e-cigarette among teens has sidestepped FDA jurisdiction by reformulating products with synthetic nicotine. North Carolina's attorney general is launching an investigation into Puff Bar, placing new scrutiny on the e-cigarette that has unseated Juul as the most popular vaping brand among children and teens.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Puff Bar E-Cigarette Maker Under Investigation by North Carolina Attorney General. Company behind the most popular e-cigarette among teens has sidestepped FDA jurisdiction by reformulating products with synthetic nicotine. North Carolina's attorney general is launching an investigation into Puff Bar, placing new scrutiny on the e-cigarette that has unseated Juul as the most popular vaping brand among children and teens.\"\n\nStock Prediction(s):", "Prediction": "\n- Reynolds American Inc (NYSE: RAI) will increase because they are the company behind Puff Bar, and this will bring more attention to their product.\n- Altria Group Inc (NYSE: MO) will increase because they are the company behind Marlboro, and this will bring more attention to their product.\n- British American Tobacco plc (NYSE: BTI) will increase because they are the company behind Camel, and this will bring more attention to", "price_info": {"RAI": {"company": "", "ticker": "RAI", "move": "up"}, "MO": {"company": "", "ticker": "MO", "move": "up", "prices": [44.715, 44.4734]}, "BTI": {"company": "", "ticker": "BTI", "move": "up", "prices": [35.06, 34.905]}}}, {"link": "https://www.wsj.com/articles/fidelity-is-latest-to-cut-online-trading-commissions-to-zero-11570680060", "title": "Fidelity Cuts Online Trading Commissions to Zero", "date": "2019-10-10 10:24", "summary": "Wall Street's digitization has reset many of the fundamental costs of investing. Fidelity Investments eliminated trading commissions on its online brokerage, matching a step some of its biggest rivals unveiled last week.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fidelity Cuts Online Trading Commissions to Zero. Wall Street's digitization has reset many of the fundamental costs of investing. Fidelity Investments eliminated trading commissions on its online brokerage, matching a step some of its biggest rivals unveiled last week.\"\n\nStock Prediction(s):", "Prediction": "\n- Fidelity Investments (NYSE: FIS) will increase because they have lowered their trading commissions to zero.\n- Charles Schwab Corp (NYSE: SCHW) will increase because they have lowered their trading commissions to zero.\n- TD Ameritrade Holding Corp (NASDAQ: AMTD) will increase because they have lowered their trading commissions to zero.\n- E*Trade Financial Corp (NASDAQ: ETFC) will increase because they have lowered their trading", "price_info": {"FIS": {"company": "", "ticker": "FIS", "move": "up", "prices": [132.02, 131.51]}, "SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [36.35, 36.18]}, "AMTD": {"company": "", "ticker": "AMTD", "move": "up", "prices": [34.39, 34.35]}, "ETFC": {"company": "", "ticker": "ETFC", "move": "up", "prices": [38.655, 38.66]}}}, {"link": "https://www.wsj.com/articles/crashing-amazons-third-party-11605039631", "title": "Crashing Amazon's Third Party", "date": "2020-11-10 15:20", "summary": "The European Union's action is likely just the first of regulatory moves for which Amazon investors aren't prepared. Can regulators put the brakes on Amazon.com 's flywheel? Investors don't seem concerned.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Crashing Amazon's Third Party. The European Union's action is likely just the first of regulatory moves for which Amazon investors aren't prepared. Can regulators put the brakes on Amazon.com 's flywheel? Investors don't seem concerned.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because of the EU's regulatory action.\n- Facebook, Inc. (NASDAQ: FB) will increase because of the EU's regulatory action.\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because of the EU's regulatory action.", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3037.2, 3039.02]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [272.3131, 272.5]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1734.68, 1738]}}}, {"link": "https://www.wsj.com/articles/spotify-ad-business-boosted-by-podcasts-11635328801", "title": "Spotify Ad Business Boosted by Podcasts", "date": "2021-10-27 13:41", "summary": "Strong user growth resumed in the third quarter, with the audiostreaming service reporting overall active users and paying subscribers both up 19%. Spotify Technology SA's big bet on podcasts appears to be paying off.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Spotify Ad Business Boosted by Podcasts. Strong user growth resumed in the third quarter, with the audiostreaming service reporting overall active users and paying subscribers both up 19%. Spotify Technology SA's big bet on podcasts appears to be paying off.\"\n\nStock Prediction(s):", "Prediction": "\n- Spotify Technology SA (NYSE: SPOT) will increase because their podcasting business is doing well.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are not as invested in podcasts as Spotify is.", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "up", "prices": [275.2, 272.26]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [149.65, 149.225]}}}, {"link": "https://www.wsj.com/articles/u-s-auto-makers-sweat-under-threat-of-tariffs-on-mexican-imports-11559308036", "title": "U.S. Auto Makers Sweat Under Threat of Tariffs on Mexican Imports", "date": "2019-05-31 12:53", "summary": "Mexico-built cars accounted for 17% of Detroit Big Three's overall U.S. sales in 2018. President Trump's threat to impose escalating tariffs on Mexican imports foists fresh bad news on the U.S. auto industry, which had pinned hopes on a tentative deal reached last year to preserve free trade between the countries.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Auto Makers Sweat Under Threat of Tariffs on Mexican Imports. Mexico-built cars accounted for 17% of Detroit Big Three's overall U.S. sales in 2018. President Trump's threat to impose escalating tariffs on Mexican imports foists fresh bad news on the U.S. auto industry, which had pinned hopes on a tentative deal reached last year to preserve free trade between the countries.\"\n\nStock Prediction(s):", "Prediction": "\n- General Motors Company (NYSE: GM) will decrease because their cars are built in Mexico and will be subject to tariffs.\n- Ford Motor Company (NYSE: F) will decrease because their cars are built in Mexico and will be subject to tariffs.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will decrease because their cars are built in Mexico and will be subject to tariffs.", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "down", "prices": [33.33, 33.52]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [9.5, 9.4772]}, "FCAU": {"company": "", "ticker": "FCAU", "move": "down", "prices": [12.705, 12.71]}}}, {"link": "https://www.wsj.com/articles/tesla-pinterest-ibm-intel-what-to-watch-when-the-stock-market-opens-today-11634813873", "title": "Tesla, Pinterest, IBM, Intel: What to Watch in the Stock Market Today", "date": "2021-10-21 09:37", "summary": "Shares of the SPAC that is merging with Donald Trump's media company jumped; IBM posted revenue that missed forecasts. Wall Street indexes opened with muted losses amid a flurry of earnings reports and after jobless claims fell to a pandemic low. Here's what's moving in Thursday's session:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla, Pinterest, IBM, Intel: What to Watch in the Stock Market Today. Shares of the SPAC that is merging with Donald Trump's media company jumped; IBM posted revenue that missed forecasts. Wall Street indexes opened with muted losses amid a flurry of earnings reports and after jobless claims fell to a pandemic low. Here's what's moving in Thursday's session:\"\n\nStock Prediction(s):", "Prediction": "\n- The SPAC that is merging with Donald Trump's media company (TheStreet, Inc. (NASDAQ: TST)) will increase because they have a good partnership with a well-known president.\n- IBM (NYSE: IBM) will decrease because they missed revenue forecasts.\n- Intel (NASDAQ: INTC) will decrease because they missed revenue forecasts.\n- Pinterest (NYSE: PINS) will increase because they beat revenue forecasts.\n- Tesla", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "down", "prices": [131.19, 130.793]}, "PINS": {"company": "", "ticker": "PINS", "move": "up", "prices": [61.76, 61.3]}, "TST": {"company": "", "ticker": "TST", "move": "up"}, "INTC": {"company": "", "ticker": "INTC", "move": "down", "prices": [55.53, 55.53]}}}, {"link": "https://www.wsj.com/articles/covid-19-variant-omicron-threatens-u-s-global-economies-11638268200", "title": "Covid-19 Variant Omicron Threatens U.S., Global Economies", "date": "2021-11-30 13:39", "summary": "Latest virus strain could slow global growth but any hit is likely to be modest, economists say. The global economy could suffer a modest blow from the Omicron variant of Covid-19, though the scale of damage will hinge on the potency of the strain itself, economists say.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Variant Omicron Threatens U.S., Global Economies. Latest virus strain could slow global growth but any hit is likely to be modest, economists say. The global economy could suffer a modest blow from the Omicron variant of Covid-19, though the scale of damage will hinge on the potency of the strain itself, economists say.\"\n\nStock Prediction(s):", "Prediction": "\n- The global economy will slow down because of the Omicron variant of Covid-19, but it is not likely to be a major hit.\n- The economies of the United States and other countries will also slow down because of the Omicron variant of Covid-19, but it is not likely to be a major hit.", "price_info": {}}, {"link": "https://www.wsj.com/articles/regulators-investors-zero-in-on-corporate-debt-market-11558958401", "title": "Regulators, Investors Zero In on Corporate Debt Market", "date": "2019-05-28 10:14", "summary": "An increase in corporate issuance, coupled with more lower-quality borrowing, has raised concerns. A decadelong rise in corporate borrowing is prompting new scrutiny about how debt markets might hold up in an economic downturn.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Regulators, Investors Zero In on Corporate Debt Market. An increase in corporate issuance, coupled with more lower-quality borrowing, has raised concerns. A decadelong rise in corporate borrowing is prompting new scrutiny about how debt markets might hold up in an economic downturn.\"\n\nStock Prediction(s):", "Prediction": "\n- Moody's Corporation (NYSE: MCO) will decrease because they are a credit rating agency and investors will be worried about the quality of debt.\n- Goldman Sachs Group Inc. (NYSE: GS) will decrease because they are a major investment bank and they will be selling their debt products less.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are a major investment bank and they will be selling their debt products less.\n- Bank", "price_info": {"MCO": {"company": "", "ticker": "MCO", "move": "down", "prices": [190.26, 190.51]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [191.8614, 191.051]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [109.53, 109.39]}}}, {"link": "https://www.wsj.com/articles/delta-says-air-travel-recovery-still-far-off-amid-pandemic-11602592322", "title": "Delta Says Air Travel Recovery Still Far Off Amid Pandemic", "date": "2020-10-13 11:46", "summary": "Airline expects to burn through cash into spring, but CEO says demand is starting to show signs of life. Delta Air Lines Inc. offered cautious optimism that demand for travel is starting to return but said its losses were mounting, as the coronavirus pandemic looks likely to continue weighing on travel for years.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Delta Says Air Travel Recovery Still Far Off Amid Pandemic. Airline expects to burn through cash into spring, but CEO says demand is starting to show signs of life. Delta Air Lines Inc. offered cautious optimism that demand for travel is starting to return but said its losses were mounting, as the coronavirus pandemic looks likely to continue weighing on travel for years.\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines Inc. (NYSE: DAL) will continue to decrease because the pandemic is still ongoing and people are still not traveling as much.\n- American Airlines Group Inc. (NASDAQ: AAL) will increase because they are not as affected by the pandemic as Delta is.\n- United Airlines Holdings Inc. (NYSE: UAL) will increase because they are not as affected by the pandemic as Delta is.", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [31.7625, 31.96]}, "UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [35.665, 35.63]}, "AAL": {"company": "", "ticker": "AAL", "move": "up", "prices": [12.4553, 12.415]}}}, {"link": "https://www.wsj.com/articles/coronavirus-crisis-could-delay-u-s-boost-from-deal-with-china-kudlow-says-11580838140", "title": "Coronavirus Crisis Could Delay U.S. Boost From Deal With China, Kudlow Says", "date": "2020-02-04 13:30", "summary": "Economic official said he expected longer-term impact to be minimal. WASHINGTON-White House National Economic Council Director Larry Kudlow said Tuesday he expected the fallout from the deadly coronavirus to delay-but not derail-the economic boost the U.S. anticipated from the first phase of the trade deal with China.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Crisis Could Delay U.S. Boost From Deal With China, Kudlow Says. Economic official said he expected longer-term impact to be minimal. WASHINGTON-White House National Economic Council Director Larry Kudlow said Tuesday he expected the fallout from the deadly coronavirus to delay-but not derail-the economic boost the U.S. anticipated from the first phase of the trade deal with China.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DIA) will decrease because the coronavirus crisis could delay the U.S. boost from the trade deal with China.\n- The S&P 500 (NYSE: SPY) will decrease because the coronavirus crisis could delay the U.S. boost from the trade deal with China.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because the coronavirus crisis could delay the U", "price_info": {"DIA": {"company": "", "ticker": "DIA", "move": "down", "prices": [288.4032, 288.57]}, "SPY": {"company": "", "ticker": "SPY", "move": "down", "prices": [329.29, 329.58]}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/stitch-fix-is-nearing-the-end-of-its-vertical-runway-11600855381", "title": "Stitch Fix Is Nearing the End of Its Vertical Runway", "date": "2020-09-23 12:01", "summary": "Sneak peek of the online styling company's fiscal first quarter fails to inspire. Online styling company Stitch Fix 's fiscal fourth-quarter results on Tuesday were clearly not the showstopper Wall Street had hoped for.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Stitch Fix Is Nearing the End of Its Vertical Runway. Sneak peek of the online styling company's fiscal first quarter fails to inspire. Online styling company Stitch Fix 's fiscal fourth-quarter results on Tuesday were clearly not the showstopper Wall Street had hoped for.\"\n\nStock Prediction(s):", "Prediction": "\n- Stitch Fix, Inc. (NASDAQ: SFIX) will continue to decrease because their growth is slowing and they are not meeting investor expectations.", "price_info": {"SFIX": {"company": "", "ticker": "SFIX", "move": "down", "prices": [26.65, 25.82]}}}, {"link": "https://www.wsj.com/articles/the-hollywood-drama-that-cost-a-blackrock-fund-75-million-11582917564", "title": "The Hollywood Drama That Cost a BlackRock Fund $75 Million", "date": "2020-02-28 14:19", "summary": "The investment giant fired a fund manager over a conflict of interest after his daughter got a screen role in a movie he financed. Take a break from the market turmoil to ponder the drama at a little fund run by the world's biggest asset manager. It involves allegations of fraud and forgery, not to mention a fund manager's daughter landing a part in a movie the fund financed.", "categories": [["WSJ News Exclusive", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Hollywood Drama That Cost a BlackRock Fund $75 Million. The investment giant fired a fund manager over a conflict of interest after his daughter got a screen role in a movie he financed. Take a break from the market turmoil to ponder the drama at a little fund run by the world's biggest asset manager. It involves allegations of fraud and forgery, not to mention a fund manager's daughter landing a part in a movie the fund financed.\"\n\nStock Prediction(s):", "Prediction": "\n- BlackRock, Inc. (NYSE: BLK) will decrease because one of their fund managers was fired for a conflict of interest.\n- The Walt Disney Company (NYSE: DIS) will increase because one of their subsidiaries is involved in the movie that the fund manager's daughter landed a part in.", "price_info": {"BLK": {"company": "", "ticker": "BLK", "move": "down", "prices": [453.6799, 459.53]}, "DIS": {"company": "", "ticker": "DIS", "move": "up", "prices": [115.41, 115.68]}}}, {"link": "https://www.wsj.com/articles/u-k-bolsters-foreign-takeover-defences-as-pandemic-drives-protectionist-moves-11592822432", "title": "U.K. Bolsters Foreign-Takeover Defenses as Pandemic Drives Protectionist Moves", "date": "2020-06-22 10:22", "summary": "Moves are to guard against unwanted acquisitions of domestic companies developing coronavirus vaccines or manufacturing personal protective equipment. The U.K. is strengthening its takeover defenses, joining a wave of protectionism that is sweeping Europe as countries try to shield companies deemed vulnerable to unwanted approaches by foreign acquirers in the wake of pandemic lockdowns.", "categories": [["Markets", "Stocks", "Europe Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb", "https://www.wsj.com/news/types/europe-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.K. Bolsters Foreign-Takeover Defenses as Pandemic Drives Protectionist Moves. Moves are to guard against unwanted acquisitions of domestic companies developing coronavirus vaccines or manufacturing personal protective equipment. The U.K. is strengthening its takeover defenses, joining a wave of protectionism that is sweeping Europe as countries try to shield companies deemed vulnerable to unwanted approaches by foreign acquirers in the wake of pandemic lockdowns.\"\n\nStock Prediction(s):", "Prediction": "\n- AstraZeneca plc (NASDAQ: AZN) will increase because they are a British company and the U.K. is trying to protect them from foreign takeover.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [142.3001, 142.75]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [33.005, 33.06]}, "AZN": {"company": "", "ticker": "AZN", "move": "up", "prices": [53.09, 53.355]}}}, {"link": "https://www.wsj.com/articles/for-royal-caribbean-a-good-ground-game-strengthens-sea-legs-in-china-11550595601", "title": "For Royal Caribbean, a Good Ground Game Strengthens Sea Legs in China", "date": "2019-02-19 12:00", "summary": "The cruise line has hired hundreds of salespeople to boost brand awareness. Royal Caribbean Cruises Ltd. 's effort to tempt more Chinese vacationers aboard its ships is showing signs of bearing fruit.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"For Royal Caribbean, a Good Ground Game Strengthens Sea Legs in China. The cruise line has hired hundreds of salespeople to boost brand awareness. Royal Caribbean Cruises Ltd. 's effort to tempt more Chinese vacationers aboard its ships is showing signs of bearing fruit.\"\n\nStock Prediction(s):", "Prediction": "\n- Royal Caribbean Cruises Ltd. (NYSE: RCL) will increase because they are doing well in China, and they have been hiring more salespeople.\n- Carnival Corporation (NYSE: CCL) will decrease because they are a direct competitor of Royal Caribbean.", "price_info": {"RCL": {"company": "", "ticker": "RCL", "move": null, "prices": [120.5, 120.079]}, "CCL": {"company": "", "ticker": "CCL", "move": "down", "prices": [58.47, 58.415]}}}, {"link": "https://www.wsj.com/articles/fed-s-rosengren-says-u-s-economy-will-need-more-monetary-fiscal-support-11592576221", "title": "Fed's Rosengren Says U.S. Economy Will Need More Monetary, Fiscal Support", "date": "2020-06-19 11:55", "summary": "Federal Reserve Bank of Boston leader also was upbeat about the central bank's Main Street lending facility. Federal Reserve Bank of Boston President Eric Rosengren said the U.S. central bank and broader government will need to do more to help the economy emerge from the ongoing impact of the coronavirus pandemic.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Rosengren Says U.S. Economy Will Need More Monetary, Fiscal Support. Federal Reserve Bank of Boston leader also was upbeat about the central bank's Main Street lending facility. Federal Reserve Bank of Boston President Eric Rosengren said the U.S. central bank and broader government will need to do more to help the economy emerge from the ongoing impact of the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of Boston (FRB) will increase because they are optimistic about the economy and the central bank's Main Street lending facility.\n- The Federal Reserve (FR) will decrease because they are not as optimistic as the FRB and they have not done enough to help the economy.", "price_info": {"FRB": {"company": "Boston", "ticker": "FRB", "move": null}, "FR": {"company": "Boston", "ticker": "FR", "move": "down", "prices": [37.91, 38.14]}}}, {"link": "https://www.wsj.com/articles/elon-musk-once-a-washington-outsider-courts-military-business-11604517046", "title": "Elon Musk's SpaceX, Once a Washington Outsider, Courts Military Business", "date": "2020-11-04 14:10", "summary": "The entrepreneur's SpaceX company has amassed billions of dollars in orders, becoming a threat to Boeing and Lockheed Martin. Elon Musk's SpaceX was dismissed by Pentagon brass during its early years. But now, the billionaire entrepreneur and his company are enjoying more success than ever in snaring Pentagon business.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Elon Musk's SpaceX, Once a Washington Outsider, Courts Military Business. The entrepreneur's SpaceX company has amassed billions of dollars in orders, becoming a threat to Boeing and Lockheed Martin. Elon Musk's SpaceX was dismissed by Pentagon brass during its early years. But now, the billionaire entrepreneur and his company are enjoying more success than ever in snaring Pentagon business.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing (NYSE: BA) will decrease because they are a direct competitor of SpaceX.\n- Lockheed Martin (NYSE: LMT) will decrease because they are a direct competitor of SpaceX.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [152.93, 151.96]}, "LMT": {"company": "", "ticker": "LMT", "move": "down", "prices": [378.33, 376]}}}, {"link": "https://www.wsj.com/articles/thanksgiving-dinner-staples-might-be-hard-to-find-thanks-to-supply-chain-issues-11636453800", "title": "Thanksgiving Dinner Staples Are Low in Stock", "date": "2021-11-09 14:52", "summary": "Turkeys, yams and pies are low in supply, though aluminum foil to cover it all will be easier to find than last year. The supply-chain crunch is about to hit another part of American life: Thanksgiving dinner.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Thanksgiving Dinner Staples Are Low in Stock. Turkeys, yams and pies are low in supply, though aluminum foil to cover it all will be easier to find than last year. The supply-chain crunch is about to hit another part of American life: Thanksgiving dinner.\"\n\nStock Prediction(s):", "Prediction": "\n- Aluminum Foil (NYSE: AA) will increase because there is a shortage of it, and it is needed for Thanksgiving dinner.\n- Turkeys (NYSE: TUR) will decrease because there is a shortage of them, and they are needed for Thanksgiving dinner.\n- Yams (NYSE: Yam) will decrease because there is a shortage of them, and they are needed for Thanksgiving dinner.\n- Pies (NYSE: Pie) will decrease because there", "price_info": {"AA": {"company": "", "ticker": "AA", "move": "up", "prices": [46.855, 47.14]}, "TUR": {"company": "", "ticker": "TUR", "move": "down", "prices": [22.65, 22.71]}}}, {"link": "https://www.wsj.com/articles/american-standard-owner-brings-back-ex-ceo-11561470073", "title": "Battle at Bathroom Company Ends With Ex-CEO's Return", "date": "2019-06-25 09:41", "summary": "Activist shareholders help ousted CEO of Japan's Lixil Group achieve a rare comeback. TOKYO-In a rare corporate comeback, the ousted chief executive of Lixil Group Corp. recovered his job at the Japanese bath and kitchen company with the support of some foreign activist shareholders.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Battle at Bathroom Company Ends With Ex-CEO's Return. Activist shareholders help ousted CEO of Japan's Lixil Group achieve a rare comeback. TOKYO-In a rare corporate comeback, the ousted chief executive of Lixil Group Corp. recovered his job at the Japanese bath and kitchen company with the support of some foreign activist shareholders.\"\n\nStock Prediction(s):", "Prediction": "\n- Lixil Group Corp. (TYO: 5938) will increase because the activist shareholders helped the CEO achieve a comeback, and he is now back in charge.\n- Panasonic Corporation (TYO: 6752) will decrease because they are a direct competitor of Lixil Group Corp.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-consumer-spending-rose-0-4-in-november-11576854094", "title": "Consumer Spending Strengthens as Year Winds Down", "date": "2019-12-20 13:21", "summary": "U.S. household spending, a key driver of the economy, rose in November, along with higher income and more positive views of the economy. WASHINGTON-Consumers boosted spending as they headed into the end of the year, buoyed by a rise in income and an optimistic outlook for the U.S. economy.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer Spending Strengthens as Year Winds Down. U.S. household spending, a key driver of the economy, rose in November, along with higher income and more positive views of the economy. WASHINGTON-Consumers boosted spending as they headed into the end of the year, buoyed by a rise in income and an optimistic outlook for the U.S. economy.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc (NYSE: WMT) will increase because consumer spending is up, and Walmart is one of the biggest retailers in the United States.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because consumer spending is up, and Amazon is one of the biggest retailers in the United States.\n- Target Corporation (NYSE: TGT) will increase because consumer spending is up, and Target is one of the biggest retailers in the", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [120.62, 120.59]}, "TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [129.58, 129.712]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1797.9565, 1796.24]}}}, {"link": "https://www.wsj.com/articles/blackrock-names-sandra-boss-new-corporate-watchdog-11588260962", "title": "BlackRock Names Sandra Boss New Corporate Watchdog", "date": "2020-04-30 11:36", "summary": "She joins the money manager as it has tried to build a brand as an arbiter of corporate behavior. Money-management giant BlackRock Inc. installed a new executive to lead shareholder interactions with companies.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"BlackRock Names Sandra Boss New Corporate Watchdog. She joins the money manager as it has tried to build a brand as an arbiter of corporate behavior. Money-management giant BlackRock Inc. installed a new executive to lead shareholder interactions with companies.\"\n\nStock Prediction(s):", "Prediction": "\n- BlackRock, Inc. (NYSE: BLK) will increase because they are trying to build a brand as an arbiter of corporate behavior.\n- Goldman Sachs Group, Inc. (NYSE: GS) will increase because they are also trying to build a brand as an arbiter of corporate behavior.", "price_info": {"BLK": {"company": "", "ticker": "BLK", "move": "up", "prices": [498.865, 500.2802]}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [183.8568, 183.2702]}}}, {"link": "https://www.wsj.com/articles/novavax-tesla-netflix-united-what-to-watch-when-the-stock-market-opens-today-11634726665", "title": "Novavax, Tesla, Netflix, United: What to Watch in the Stock Market Today", "date": "2021-10-20 09:33", "summary": "Novavax shares plummeted; Tesla's earnings are due after the close. Wall Street indexes inched up in early trading as investors digested another big batch of earnings reports. Here's what we're watching in Wednesday's session:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Novavax, Tesla, Netflix, United: What to Watch in the Stock Market Today. Novavax shares plummeted; Tesla's earnings are due after the close. Wall Street indexes inched up in early trading as investors digested another big batch of earnings reports. Here's what we're watching in Wednesday's session:\"\n\nStock Prediction(s):", "Prediction": "\n- Novavax, Inc. (NASDAQ: NVAX) will decrease because their earnings report was not good.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because their earnings report was good.\n- Netflix, Inc. (NASDAQ: NFLX) will increase because their earnings report was good.\n- United Airlines Holdings, Inc. (NYSE: UAL) will increase because their earnings report was good.", "price_info": {"UAL": {"company": "", "ticker": "UAL", "move": "up", "prices": [46.495, 46.1]}, "NVAX": {"company": "", "ticker": "NVAX", "move": "down", "prices": [139.0357, 143.26]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [867.78, 867.57]}, "NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [636.5, 632.03]}}}, {"link": "https://www.wsj.com/articles/fedex-adds-peak-fees-on-shipments-during-holiday-season-11597760207", "title": "FedEx Adds Peak Fees on Shipments During Holiday Season", "date": "2020-08-18 15:19", "summary": "Delivery giant joins UPS and USPS in raising prices amid coronavirus pandemic and expected e-commerce surge. FedEx Corp. is adding extra fees on shipments during the holidays, joining United Parcel Service Inc. and the U.S. Postal Service in implementing surcharges to offset costs and control shipping volumes during what is expected to be a busy online shopping season.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FedEx Adds Peak Fees on Shipments During Holiday Season. Delivery giant joins UPS and USPS in raising prices amid coronavirus pandemic and expected e-commerce surge. FedEx Corp. is adding extra fees on shipments during the holidays, joining United Parcel Service Inc. and the U.S. Postal Service in implementing surcharges to offset costs and control shipping volumes during what is expected to be a busy online shopping season.\"\n\nStock Prediction(s):", "Prediction": "\n- FedEx Corporation (NYSE: FDX) will increase because they are implementing surcharges to offset costs and control shipping volumes.\n- United Parcel Service Inc. (NYSE: UPS) will increase because they are implementing surcharges to offset costs and control shipping volumes.\n- The U.S. Postal Service (NYSE: USPS) will increase because they are implementing surcharges to offset costs and control shipping volumes.", "price_info": {"FDX": {"company": "", "ticker": "FDX", "move": "up", "prices": [206.6, 206.94]}, "UPS": {"company": "", "ticker": "UPS", "move": null, "prices": [159, 160]}, "USPS": {"company": "", "ticker": "USPS", "move": "up"}}}, {"link": "https://www.wsj.com/articles/facebook-ftc-privacy-kids-11635289993", "title": "Facebook Faces FTC Probe Over Its Internal Research", "date": "2021-10-27 12:38", "summary": "Lawmakers want agency to determine if Facebook engaged in deceptive conduct; company says internal research is mischaracterized. WASHINGTON-Federal Trade Commission staffers have begun looking into disclosures that Facebook Inc.'s internal company research had identified ill effects from its products, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Faces FTC Probe Over Its Internal Research. Lawmakers want agency to determine if Facebook engaged in deceptive conduct; company says internal research is mischaracterized. WASHINGTON-Federal Trade Commission staffers have begun looking into disclosures that Facebook Inc.'s internal company research had identified ill effects from its products, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are being investigated by the FTC.\n- Google, Inc. (NASDAQ: GOOGL) will increase because they are not being investigated by the FTC.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [315.82, 315.105]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2955.7663, 2948.565]}}}, {"link": "https://www.wsj.com/articles/aluminum-prices-push-toward-2020-high-on-sanction-worries-demand-11608308859", "title": "Aluminum Prices Push Toward 2020 High", "date": "2020-12-18 15:35", "summary": "The metal has gained more than 13% year-to-date. Aluminum prices are trading near their highest levels in almost two years, fueled by soaring demand for raw materials and worries that potential new U.S. sanctions on one of the world's largest producers could limit global supplies of the metal.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Aluminum Prices Push Toward 2020 High. The metal has gained more than 13% year-to-date. Aluminum prices are trading near their highest levels in almost two years, fueled by soaring demand for raw materials and worries that potential new U.S. sanctions on one of the world's largest producers could limit global supplies of the metal.\"\n\nStock Prediction(s):", "Prediction": "\n- Alcoa Corporation (NYSE: AA) will increase because of the high demand for aluminum.\n- Century Aluminum Company (NASDAQ: CENX) will increase because of the high demand for aluminum.\n- Kaiser Aluminum Corporation (NASDAQ: KALU) will increase because of the high demand for aluminum.", "price_info": {"AA": {"company": "", "ticker": "AA", "move": "up", "prices": [21.98, 22.09]}, "CENX": {"company": "", "ticker": "CENX", "move": "up"}, "KALU": {"company": "", "ticker": "KALU", "move": "up", "prices": [94.0818, 93.73]}}}, {"link": "https://www.wsj.com/articles/this-lawsuit-doesnt-smell-right-11546891433", "title": "This Lawsuit Doesn't Smell Right", "date": "2019-01-07 15:03", "summary": "The maker of Pooey Puitton sued LVMH, owner of Louis Vuitton, but the reason may have little to do with trademarks. Last month toy maker MGA Entertainment said it was seeking a court declaration that a product it sells wasn't interfering with trademarks held by luxury-goods giant LVMH.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"This Lawsuit Doesn't Smell Right. The maker of Pooey Puitton sued LVMH, owner of Louis Vuitton, but the reason may have little to do with trademarks. Last month toy maker MGA Entertainment said it was seeking a court declaration that a product it sells wasn't interfering with trademarks held by luxury-goods giant LVMH.\"\n\nStock Prediction(s):", "Prediction": "\n- MGA Entertainment, Inc. (NASDAQ: LLL) will increase because they are being sued by a large company, but they have a good chance of winning.\n- LVMH Mo\u00ebt Hennessy Louis Vuitton SE (OTC: LVMHF) will decrease because they are being sued by a small company, and they may not have the resources to win.", "price_info": {"LLL": {"company": "", "ticker": "LLL", "move": "down", "prices": [170.28, 170.85]}}}, {"link": "https://www.wsj.com/articles/kraft-heinz-draws-customers-back-to-familiar-brands-11603974420", "title": "Kraft Heinz Draws Customers Back to Familiar Brands", "date": "2020-10-29 12:42", "summary": "Food company booked big sales increase as pandemic continues to boost grocery sales. Kraft Heinz Co. said higher grocery demand during the coronavirus pandemic is setting the food maker up to exceed sales expectations for next year.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Kraft Heinz Draws Customers Back to Familiar Brands. Food company booked big sales increase as pandemic continues to boost grocery sales. Kraft Heinz Co. said higher grocery demand during the coronavirus pandemic is setting the food maker up to exceed sales expectations for next year.\"\n\nStock Prediction(s):", "Prediction": "\n- Kraft Heinz Co. (NASDAQ: KHC) will increase because they are seeing an increase in sales due to the pandemic.\n- General Mills, Inc. (NYSE: GIS) will decrease because they are a direct competitor of Kraft Heinz.", "price_info": {"GIS": {"company": "", "ticker": "GIS", "move": "down", "prices": [59.26, 59.83]}, "KHC": {"company": "", "ticker": "KHC", "move": "up", "prices": [29.905, 30.32]}}}, {"link": "https://www.wsj.com/articles/treasury-to-sell-203-billion-in-debt-11558629243", "title": "Treasury to Sell $203 Billion in Debt", "date": "2019-05-23 12:34", "summary": "U.S. Treasury Department next week plans auctions of securities ranging from 13-week bills to seven-year notes. The U.S. Treasury Department will auction $203 billion in securities next week, comprising $149 billion in new debt and $54 billion in previously sold debt. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury to Sell $203 Billion in Debt. U.S. Treasury Department next week plans auctions of securities ranging from 13-week bills to seven-year notes. The U.S. Treasury Department will auction $203 billion in securities next week, comprising $149 billion in new debt and $54 billion in previously sold debt. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Treasury Department will auction $203 billion in securities next week, and this will have a positive effect on the stock prices of the companies that are involved in this process.\n- The U.S. Treasury Department will auction $203 billion in securities next week, and this will have a negative effect on the stock prices of the companies that are involved in this process.", "price_info": {}}, {"link": "https://www.wsj.com/articles/squares-future-needs-to-take-shape-11636123168", "title": "Square's Future Needs to Take Shape", "date": "2021-11-05 10:39", "summary": "Without the tailwind of stimulus checks, Square has to see some of its longer-term moves start to pay off. Square 's area greatly expanded during the depths of the pandemic. Now it needs to fill in that space.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Square's Future Needs to Take Shape. Without the tailwind of stimulus checks, Square has to see some of its longer-term moves start to pay off. Square 's area greatly expanded during the depths of the pandemic. Now it needs to fill in that space.\"\n\nStock Prediction(s):", "Prediction": "\n- Square Inc (NYSE: SQ) will increase because they have been expanding their services and now need to see some payoff from their long-term moves.\n- PayPal Holdings, Inc. (NASDAQ: PYPL) will increase because they have been expanding their services and now need to see some payoff from their long-term moves.", "price_info": {"SQ": {"company": "", "ticker": "SQ", "move": "up", "prices": [241.145, 241.28]}, "PYPL": {"company": "", "ticker": "PYPL", "move": "up", "prices": [225.74, 225.15]}}}, {"link": "https://www.wsj.com/articles/federal-reserve-sent-lower-remittances-to-u-s-treasury-in-2019-11578668401", "title": "Federal Reserve Sent Lower Remittances to U.S. Treasury in 2019", "date": "2020-01-10 11:58", "summary": "The Fed paid $10 billion less to the government last year after repurchase activities drove up costs. WASHINGTON-Federal Reserve payments to the U.S. Treasury declined in 2019 to a decade low, as the central bank's expenses rose and income declined.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Federal Reserve Sent Lower Remittances to U.S. Treasury in 2019. The Fed paid $10 billion less to the government last year after repurchase activities drove up costs. WASHINGTON-Federal Reserve payments to the U.S. Treasury declined in 2019 to a decade low, as the central bank's expenses rose and income declined.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FRB) will decrease because their payments to the U.S. Treasury declined in 2019.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are not as directly tied to the Federal Reserve.\n- Goldman Sachs Group Inc. (NYSE: GS) will increase because they are not as directly tied to the Federal Reserve.", "price_info": {"FRB": {"company": "", "ticker": "FRB", "move": "down"}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [136.1865, 136.57]}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [242.665, 242.9]}}}, {"link": "https://www.wsj.com/articles/u-s-government-bond-yields-tick-lower-after-mixed-economic-data-11600961369", "title": "Treasury Yields Tick Lower After Mixed Economic Data", "date": "2020-09-24 11:29", "summary": "Data on jobs and housing signal erratic economic rebound. U.S. government-bond yields edged lower Thursday after mixed data on jobs and housing signaled an erratic economic rebound.", "categories": [["Markets", "Treasurys"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/treasurys?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury Yields Tick Lower After Mixed Economic Data. Data on jobs and housing signal erratic economic rebound. U.S. government-bond yields edged lower Thursday after mixed data on jobs and housing signaled an erratic economic rebound.\"\n\nStock Prediction(s):", "Prediction": "\n- The yield on the 10-year Treasury note will decrease because the economic rebound is erratic.\n- The yield on the 2-year Treasury note will decrease because the economic rebound is erratic.\n- The yield on the 30-year Treasury note will decrease because the economic rebound is erratic.", "price_info": {}}, {"link": "https://www.wsj.com/articles/l-brands-faces-pressure-to-separate-victorias-secret-bath-body-works-11551761941", "title": "L Brands Faces Pressure to Separate Victoria's Secret, Bath & Body Works", "date": "2019-03-05 13:47", "summary": "Hedge fund Barington Capital Group is urging the company to split the two retail chains. An activist investor plans to push Victoria's Secret parent L Brands Inc. to break up.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"L Brands Faces Pressure to Separate Victoria's Secret, Bath & Body Works. Hedge fund Barington Capital Group is urging the company to split the two retail chains. An activist investor plans to push Victoria's Secret parent L Brands Inc. to break up.\"\n\nStock Prediction(s):", "Prediction": "\n- L Brands Inc. (NYSE: LB) will decrease because they are being pressured to split up their company.\n- Victoria's Secret (NYSE: LB) will decrease because they are a part of L Brands Inc., and they will be forced to split up.\n- Bath & Body Works (NYSE: LB) will increase because they will be a standalone company, and they will be able to focus on their own brand.", "price_info": {"LB": {"company": "", "ticker": "LB", "move": "up", "prices": [26.74, 26.83]}}}, {"link": "https://www.wsj.com/articles/anthems-pbm-plans-boost-earnings-expectations-11548862696", "title": "Anthem's PBM Plans Boost Earnings Expectations", "date": "2019-01-30 10:38", "summary": "Anthem said it will exit the Express Scripts contract on March 1, with members beginning to migrate in the second quarter. Anthem Inc. will accelerate the launch of its in-house pharmacy-benefit manager IngenioRx to March, a move that sharply pushed up the big insurer's projected earnings for 2019.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Anthem's PBM Plans Boost Earnings Expectations. Anthem said it will exit the Express Scripts contract on March 1, with members beginning to migrate in the second quarter. Anthem Inc. will accelerate the launch of its in-house pharmacy-benefit manager IngenioRx to March, a move that sharply pushed up the big insurer's projected earnings for 2019.\"\n\nStock Prediction(s):", "Prediction": "\n- Anthem Inc. (NYSE: ANTM) will increase because they are exiting the Express Scripts contract and are launching their own PBM.\n- CVS Health Corporation (NYSE: CVS) will decrease because they are losing Anthem's business.", "price_info": {"ANTM": {"company": "", "ticker": "ANTM", "move": "up", "prices": [299.3687, 300.2869]}, "CVS": {"company": "", "ticker": "CVS", "move": "down", "prices": [65.7867, 66.14]}}}, {"link": "https://www.wsj.com/articles/biden-to-have-a-better-economy-in-2021-than-in-2009-but-worse-options-11606926003", "title": "To Tackle Recovery, Biden Has Fewer Tools Than Obama, Trump", "date": "2020-12-02 11:20", "summary": "President-elect inherits a Fed largely out of ammo and faces a potentially divided Congress. Joe Biden has been here before. Twelve years ago, as Barack Obama's newly elected vice president, Mr. Biden inherited an economy laid low by a once-in-a-century crisis.", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"To Tackle Recovery, Biden Has Fewer Tools Than Obama, Trump. President-elect inherits a Fed largely out of ammo and faces a potentially divided Congress. Joe Biden has been here before. Twelve years ago, as Barack Obama's newly elected vice president, Mr. Biden inherited an economy laid low by a once-in-a-century crisis.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will not react much to this news because it is not really news.\n- The market will not react much to this news because it is not really news.", "price_info": {}}, {"link": "https://www.wsj.com/articles/investors-took-may-vacation-from-stock-funds-11559671991", "title": "Investors Took May Vacation From Stock Funds", "date": "2019-06-04 14:13", "summary": "Exchange-traded funds that invest in companies around the world shed record of almost $20 billion in assets. Investors dumped stock funds in May at a record clip as trade disputes sent markets tumbling.", "categories": [["Markets", "ETFs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors Took May Vacation From Stock Funds. Exchange-traded funds that invest in companies around the world shed record of almost $20 billion in assets. Investors dumped stock funds in May at a record clip as trade disputes sent markets tumbling.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will rebound as investors realize that the trade disputes are only temporary and that the fundamentals of the companies are still strong.\n- The market will rebound as investors realize that the trade disputes are only temporary and that the fundamentals of the companies are still strong, but some sectors (such as technology) will rebound faster than others.\n- The market will rebound as investors realize that the trade disputes are only temporary and that the fundamentals of the companies are still strong, but", "price_info": {}}, {"link": "https://www.wsj.com/articles/this-gym-chain-has-reason-to-sweat-11584986375", "title": "This Gym Chain Has Reason to Sweat", "date": "2020-03-23 13:59", "summary": "Budget gym chain Planet Fitness says it was too late to call off plans to charge customers for March, and customers can cancel their memberships by visiting its locations-which are closed. Planet Fitness might have just given \"the judgement free zone\" new meaning. In a questionable move, the chain charged its customers for March dues through a direct debit to their bank accounts despite closing its facilities nationwide due to the novel coronavirus pandemic.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"This Gym Chain Has Reason to Sweat. Budget gym chain Planet Fitness says it was too late to call off plans to charge customers for March, and customers can cancel their memberships by visiting its locations-which are closed. Planet Fitness might have just given \"the judgement free zone\" new meaning. In a questionable move, the chain charged its customers for March dues through a direct debit to their bank accounts despite closing its facilities nationwide due to the novel coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Planet Fitness Inc (NYSE: PLNT) will decrease because they are being scorned by the public for their decision to charge customers during the pandemic.", "price_info": {"PLNT": {"company": "", "ticker": "PLNT", "move": "down", "prices": [36.21, 37.41]}}}, {"link": "https://www.wsj.com/articles/employment-picture-darkening-even-more-than-jobs-figures-suggest-11607101266", "title": "Employment Picture Darkening, Even More than Jobs Figures Suggest", "date": "2020-12-04 12:01", "summary": "Situation has already gotten worse since the November jobs report was compiled. The job market is in danger of stalling. With the Covid epidemic worsening across the country, that should hardly count as a surprise, but perhaps it will stir both Congress and the Federal Reserve to move faster than they otherwise might have.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Employment Picture Darkening, Even More than Jobs Figures Suggest. Situation has already gotten worse since the November jobs report was compiled. The job market is in danger of stalling. With the Covid epidemic worsening across the country, that should hardly count as a surprise, but perhaps it will stir both Congress and the Federal Reserve to move faster than they otherwise might have.\"\n\nStock Prediction(s):", "Prediction": "\n- The employment picture will continue to worsen, and this will cause stocks such as General Motors Company (NYSE: GM) and Ford Motor Company (NYSE: F) to decrease.\n- The employment picture will start to improve, and this will cause stocks such as Amazon.com, Inc. (NASDAQ: AMZN) and Facebook, Inc. (NASDAQ: FB) to increase.", "price_info": {"GM": {"company": "", "ticker": "GM", "move": null, "prices": [44.5, 44.445]}, "F": {"company": "", "ticker": "F", "move": null, "prices": [9.4, 9.3972]}, "AMZN": {"company": "", "ticker": "AMZN", "move": null, "prices": [3163.57, 3175.39]}, "FB": {"company": "", "ticker": "FB", "move": null, "prices": [280.17, 280.62]}}}, {"link": "https://www.wsj.com/articles/u-s-consumer-confidence-ticks-up-in-january-11611684747", "title": "U.S. Consumer Confidence Ticks Up in January", "date": "2021-01-26 13:12", "summary": "Consumers' expectations for the economy and jobs brighten, though coronavirus pandemic weakens assessment of current conditions. Consumer confidence in the U.S. rose in January as expectations for the economy and the labor market improved, according to data from the Conference Board released Tuesday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Consumer Confidence Ticks Up in January. Consumers' expectations for the economy and jobs brighten, though coronavirus pandemic weakens assessment of current conditions. Consumer confidence in the U.S. rose in January as expectations for the economy and the labor market improved, according to data from the Conference Board released Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- The overall market will increase because consumer confidence is up.\n- The stocks of companies that sell durable goods will increase because people will be more confident in buying big-ticket items.\n- The stocks of companies that sell discretionary goods will decrease because people will be more likely to save their money.", "price_info": {}}, {"link": "https://www.wsj.com/articles/saudis-renew-push-for-output-cuts-as-coronavirus-weakens-oil-business-11583163297", "title": "Saudis Renew Push for Output Cuts as Coronavirus Weakens Oil Business", "date": "2020-03-02 13:54", "summary": "Outbreak is fueling Saudi Arabia's push for supply cuts, hurting the oil industry's profits and leading to project delays. Saudi Arabia is trying to persuade Russia to join oil producers in an emergency crude-production cut, as the industry grapples with oversupply and operational slowdowns resulting from the spread of the coronavirus.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudis Renew Push for Output Cuts as Coronavirus Weakens Oil Business. Outbreak is fueling Saudi Arabia's push for supply cuts, hurting the oil industry's profits and leading to project delays. Saudi Arabia is trying to persuade Russia to join oil producers in an emergency crude-production cut, as the industry grapples with oversupply and operational slowdowns resulting from the spread of the coronavirus.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (NYSE: ARAMCO) will increase because they are the main producer in Saudi Arabia, and they will need to increase production to make up for the cuts in other countries.\n- Schlumberger Ltd. (NYSE: SLB) will decrease because they are a service company, and they will not be able to make as much money if production is cut.\n- Halliburton Company (NYSE: HAL) will decrease because they are a", "price_info": {"SLB": {"company": "", "ticker": "SLB", "move": "down", "prices": [26.57, 26.565]}, "HAL": {"company": "", "ticker": "HAL", "move": "down", "prices": [16.6882, 16.68]}}}, {"link": "https://www.wsj.com/articles/inside-mondays-market-surge-11605028447", "title": "Inside Monday's Market Surge", "date": "2020-11-10 12:14", "summary": "Postelection trading turned financial markets upside down, as investors flocked to stocks hurt by pandemic. For most of 2020, thanks to the pandemic, investors couldn't get enough Peloton or Zoom, or get far away enough from airlines and energy firms. That all changed Monday. What's behind the sudden reversal of fortunes? We take a look.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Inside Monday's Market Surge. Postelection trading turned financial markets upside down, as investors flocked to stocks hurt by pandemic. For most of 2020, thanks to the pandemic, investors couldn't get enough Peloton or Zoom, or get far away enough from airlines and energy firms. That all changed Monday. What's behind the sudden reversal of fortunes? We take a look.\"\n\nStock Prediction(s):", "Prediction": "\n- Peloton Interactive Inc (NASDAQ: PTON) will increase because they are a fitness company that is benefiting from the pandemic.\n- Zoom Video Communications, Inc. (NASDAQ: ZM) will increase because they are a video conferencing company that is benefiting from the pandemic.\n- American Airlines Group, Inc. (NASDAQ: AAL) will decrease because they are a airline company that is being hurt by the pandemic.\n", "price_info": {"PTON": {"company": "", "ticker": "PTON", "move": "up", "prices": [106.4757, 105.755]}, "ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [390.772, 384.875]}, "AAL": {"company": "", "ticker": "AAL", "move": "down", "prices": [12.7756, 12.74]}}}, {"link": "https://www.wsj.com/articles/u-s-import-prices-climb-more-slowly-than-expected-11557850535", "title": "U.S. Import Prices Climb More Slowly Than Expected", "date": "2019-05-14 12:15", "summary": "Figure for April is tied to strengthening dollar. WASHINGTON-Prices of foreign-made goods imported to the U.S. rose in April at their slowest pace in three months, a sign that a strong dollar may be contributing to low U.S. inflation.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Import Prices Climb More Slowly Than Expected. Figure for April is tied to strengthening dollar. WASHINGTON-Prices of foreign-made goods imported to the U.S. rose in April at their slowest pace in three months, a sign that a strong dollar may be contributing to low U.S. inflation.\"\n\nStock Prediction(s):", "Prediction": "\n- The dollar will continue to strengthen, which will cause import prices to continue to rise at a slower pace.\n- This will have a negative effect on companies that import goods, such as Walmart (NYSE: WMT) and Target (NYSE: TGT).\n- It will also have a negative effect on companies that export goods, such as Boeing (NYSE: BA) and Caterpillar (NYSE: CAT).", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [100.52, 100.725]}, "TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [71.08, 71.585]}, "BA": {"company": "", "ticker": "BA", "move": "up", "prices": [344.55, 344.84]}, "CAT": {"company": "", "ticker": "CAT", "move": "up", "prices": [128.42, 128.17]}}}, {"link": "https://www.wsj.com/articles/amazon-to-shut-all-u-s-pop-up-stores-as-it-rethinks-physical-retail-strategy-11551902178", "title": "Amazon to Shut Its U.S. Pop-Up Stores Amid Strategy Shift", "date": "2019-03-06 15:58", "summary": "Retail giant to close 87 pop-up locations, ending yearslong experiment by late April. Amazon.com Inc. is shutting down all 87 of its U.S. pop-up stores, ending the retailer's yearslong experiment with these small shops as the company tinkers with an evolving bricks-and-mortar strategy.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Amazon to Shut Its U.S. Pop-Up Stores Amid Strategy Shift. Retail giant to close 87 pop-up locations, ending yearslong experiment by late April. Amazon.com Inc. is shutting down all 87 of its U.S. pop-up stores, ending the retailer's yearslong experiment with these small shops as the company tinkers with an evolving bricks-and-mortar strategy.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are closing their pop-up stores.\n- Walmart Inc. (NYSE: WMT) will increase because they have been expanding their physical stores, and this will give them an edge over Amazon.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [98.22, 98.26]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1669.26, 1669.9]}}}, {"link": "https://www.wsj.com/articles/business-groups-withdraw-suit-challenging-health-price-transparency-rule-11629998986", "title": "Business Groups Withdraw Suit Challenging Health-Price Rule", "date": "2021-08-26 13:29", "summary": "U.S. Chamber of Commerce and Texas affiliate had filed to block parts of federal rule requiring insurers and employers disclose prices they pay for healthcare services and drugs. The U.S. Chamber of Commerce and a Texas affiliate withdrew a suit filed to block parts of a federal rule requiring insurers and employers to disclose prices they pay for healthcare services and drugs.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Business Groups Withdraw Suit Challenging Health-Price Rule. U.S. Chamber of Commerce and Texas affiliate had filed to block parts of federal rule requiring insurers and employers disclose prices they pay for healthcare services and drugs. The U.S. Chamber of Commerce and a Texas affiliate withdrew a suit filed to block parts of a federal rule requiring insurers and employers to disclose prices they pay for healthcare services and drugs.\"\n\nStock Prediction(s):", "Prediction": "\n- UnitedHealth Group Inc (NYSE: UNH) will increase because they are not part of the lawsuit, and they are one of the largest healthcare providers in the United States.\n- CVS Health Corp (NYSE: CVS) will increase because they are not part of the lawsuit, and they are one of the largest pharmacy chains in the United States.\n- Walmart Inc (NYSE: WMT) will increase because they are not part of the lawsuit, and", "price_info": {"UNH": {"company": "", "ticker": "UNH", "move": "up", "prices": [417, 416.98]}, "CVS": {"company": "", "ticker": "CVS", "move": "up", "prices": [82.635, 83.025]}, "WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [147.47, 147.265]}}}, {"link": "https://www.wsj.com/articles/getting-over-the-slump-in-sports-betting-11586796649", "title": "Getting Over the Slump in Sports Betting", "date": "2020-04-13 12:50", "summary": "Online businesses work to keep things exciting with most major sports indefinitely closed. Alleviating the boredom caused by the coronavirus crisis is a major challenge. Online sports books deserve an A for effort.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Getting Over the Slump in Sports Betting. Online businesses work to keep things exciting with most major sports indefinitely closed. Alleviating the boredom caused by the coronavirus crisis is a major challenge. Online sports books deserve an A for effort.\"\n\nStock Prediction(s):", "Prediction": "\n- The major sports betting companies such as William Hill plc (LON: WMH), GVC Holdings plc (LON: GVC), and Paddy Power Betfair plc (LON: PPB) will increase because the industry is trying to keep people entertained.\n- The major social media companies such as Facebook Inc (NASDAQ: FB), Twitter Inc (NYSE: TWTR), and Snap Inc (NYSE: SNAP) will increase because people", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "up", "prices": [27.125, 27.1199]}, "SNAP": {"company": "", "ticker": "SNAP", "move": "up", "prices": [13.565, 13.5221]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [172.826, 173.81]}}}, {"link": "https://www.wsj.com/articles/the-end-of-exceptionalism-for-bmw-11553096129", "title": "The End of Exceptionalism for BMW", "date": "2019-03-20 11:35", "summary": "The once-reliable Bavarian auto maker's second profit warning in six months is a sign that the car industry really is getting tough. BMW used to be the blue-chip auto maker that didn't give investors nasty surprises. Not any more.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The End of Exceptionalism for BMW. The once-reliable Bavarian auto maker's second profit warning in six months is a sign that the car industry really is getting tough. BMW used to be the blue-chip auto maker that didn't give investors nasty surprises. Not any more.\"\n\nStock Prediction(s):", "Prediction": "\n- BMW AG (ETR: BMW) will decrease because they are not the reliable blue-chip company that they used to be.\n- Volkswagen AG (ETR: VOW3) will increase because they are a reliable blue-chip company that doesn't give investors nasty surprises.", "price_info": {}}, {"link": "https://www.wsj.com/articles/the-electrifying-stories-behind-rocks-most-famous-guitars-11553711505", "title": "The Electrifying Stories Behind Rock's Most Famous Guitars", "date": "2019-03-27 14:31", "summary": "You can finally get your fingers on a rock god's legendary ax with these faithful recreations. The back stories are pretty good, too. ENTHRALLED BY a handsome black Les Paul he spied on the cover of Smokey Robinson and his band's 1963 album \"The Fabulous Miracles,\" Peter Frampton had long sought a similar model to suit his rocker needs- eBay wasn't an option then. So he was giddy when a fan of his band Humble Pie gifted him a striking \"lamp black\" 1954 Gibson Les Paul Deluxe. That same night, he played it while recording his band's 1971 breakout album, \"Performance Rockin' The Fillmore.\"", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Electrifying Stories Behind Rock's Most Famous Guitars. You can finally get your fingers on a rock god's legendary ax with these faithful recreations. The back stories are pretty good, too. ENTHRALLED BY a handsome black Les Paul he spied on the cover of Smokey Robinson and his band's 1963 album \"The Fabulous Miracles,\" Peter Frampton had long sought a similar model to suit his rocker needs- eBay wasn't an option then. So he was giddy when a fan of his band Humble Pie gifted him a striking \"lamp black\" 1954 Gibson Les Paul Deluxe. That same night, he played it while recording his band's 1971 breakout album, \"Performance Rockin' The Fillmore.\"\"\n\nStock Prediction(s):", "Prediction": "\n- Gibson Brands, Inc. (NYSE: GBX) will increase because their guitars are being used by famous rock stars, and they are the only company that is licensed to produce them.\n- Fender Musical Instruments Corporation (NYSE: Fender) will increase because their guitars are being used by famous rock stars, and they are the only company that is licensed to produce them.\n- PRS Guitars (NASDAQ: PRSG) will increase because their guitars", "price_info": {"GBX": {"company": "", "ticker": "GBX", "move": "up"}, "PRSG": {"company": "", "ticker": "PRSG", "move": "up"}}}, {"link": "https://www.wsj.com/articles/kelloggs-operating-profit-weakens-in-north-america-11556801628", "title": "Weak Cereal Sales Weigh on Kellogg's Business", "date": "2019-05-02 13:11", "summary": "Food company names Amit Banati as new finance chief; shares fall.. Kellogg Co. said first-quarter sales in North America dropped as it grappled with weaker demand for cereals and a recall of protein bars.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Weak Cereal Sales Weigh on Kellogg's Business. Food company names Amit Banati as new finance chief; shares fall.. Kellogg Co. said first-quarter sales in North America dropped as it grappled with weaker demand for cereals and a recall of protein bars.\"\n\nStock Prediction(s):", "Prediction": "\n- Kellogg Co. (NYSE: K) will decrease because of their weak cereal sales.\n- General Mills, Inc. (NYSE: GIS) will increase because of their strong cereal sales.", "price_info": {"K": {"company": "", "ticker": "K", "move": "down", "prices": [57.57, 57.14]}, "GIS": {"company": "", "ticker": "GIS", "move": "up", "prices": [51.215, 51.17]}}}, {"link": "https://www.wsj.com/articles/hospitality-workers-are-pushed-into-new-careers-as-pandemic-begins-second-year-11613999342", "title": "Pandemic Pushes Hospitality Workers Into New Careers", "date": "2021-02-22 11:27", "summary": "Faced with continuing furloughs and economic lockdowns, workers in the hospitality industry are pushed into new careers as the pandemic persists. The head waiter has become a grocery manager. The conference coordinator works at a software company. And the hotel-sales boss is now in marketing.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pandemic Pushes Hospitality Workers Into New Careers. Faced with continuing furloughs and economic lockdowns, workers in the hospitality industry are pushed into new careers as the pandemic persists. The head waiter has become a grocery manager. The conference coordinator works at a software company. And the hotel-sales boss is now in marketing.\"\n\nStock Prediction(s):", "Prediction": "\n- Marriott International, Inc. (NASDAQ: MAR) will increase because they are one of the largest hospitality companies in the world, and they are expanding their services into other industries.\n- Hilton Worldwide Holdings Inc. (NYSE: HLT) will decrease because they are one of the largest hospitality companies in the world, and they are expanding their services into other industries.\n- Hyatt Hotels Corporation (NYSE: H) will decrease because they are one of the", "price_info": {"HLT": {"company": "", "ticker": "HLT", "move": "down", "prices": [120.39, 121.71]}, "H": {"company": "", "ticker": "H", "move": "down", "prices": [84.142, 84.8399]}, "MAR": {"company": "", "ticker": "MAR", "move": "up", "prices": [143.64, 144.603]}}}, {"link": "https://www.wsj.com/articles/safety-first-for-cvs-shareholders-11588778710", "title": "Safety First for CVS Shareholders", "date": "2020-05-06 11:25", "summary": "Investors shouldn't expect much excitement from CVS shares after strong earnings, but that is a good thing. CVS Health is no investor's idea of an exciting stock, but strong first-quarter results from the retail-and-insurance giant show that boring can be beautiful.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Safety First for CVS Shareholders. Investors shouldn't expect much excitement from CVS shares after strong earnings, but that is a good thing. CVS Health is no investor's idea of an exciting stock, but strong first-quarter results from the retail-and-insurance giant show that boring can be beautiful.\"\n\nStock Prediction(s):", "Prediction": "\n- CVS Health Corporation (NYSE: CVS) will increase because they have strong first-quarter results and are a reliable company.\n- Walgreens Boots Alliance, Inc. (NASDAQ: WBA) will decrease because they are a direct competitor of CVS.", "price_info": {"CVS": {"company": "", "ticker": "CVS", "move": "up", "prices": [61.84, 62.21]}, "WBA": {"company": "", "ticker": "WBA", "move": "down", "prices": [41.5401, 41.31]}}}, {"link": "https://www.wsj.com/articles/colin-kaepernicks-nike-platform-grows-with-a-signature-shoe-11577117821", "title": "Kaepernick's Nike Platform Grows With a New Shoe", "date": "2019-12-23 11:17", "summary": "Nike has deepened its partnership with the controversial athlete by releasing a new shoe just ahead of Christmas. It has been three years since Colin Kaepernick played in the National Football League, one year since Nike Inc. made him the face of a controversial advertising campaign and one month since the sneaker giant was caught in a firefight between the exiled quarterback and the league over a failed workout.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Kaepernick's Nike Platform Grows With a New Shoe. Nike has deepened its partnership with the controversial athlete by releasing a new shoe just ahead of Christmas. It has been three years since Colin Kaepernick played in the National Football League, one year since Nike Inc. made him the face of a controversial advertising campaign and one month since the sneaker giant was caught in a firefight between the exiled quarterback and the league over a failed workout.\"\n\nStock Prediction(s):", "Prediction": "\n- Nike Inc. (NYSE: NKE) will increase because they continue to back Kaepernick, even though it has caused some backlash.\n- Under Armour, Inc. (NYSE: UA) will decrease because they have been seen as the anti-Kaepernick company.", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "up", "prices": [99.909, 100.17]}, "UA": {"company": "", "ticker": "UA", "move": "down", "prices": [19.39, 19.46]}}}, {"link": "https://www.wsj.com/articles/former-black-franchisees-sue-mcdonalds-alleging-discrimination-11598963169", "title": "Black Ex-Franchise Owners Sue McDonald's Alleging Discrimination", "date": "2020-09-01 11:31", "summary": "Lawsuit accuses burger company of setting former franchisees up for poor results. Several dozen former McDonald's Corp. franchisees sued the burger giant, alleging it unfairly treated Black owners by selling them subpar stores and failing to support their businesses.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Black Ex-Franchise Owners Sue McDonald's Alleging Discrimination. Lawsuit accuses burger company of setting former franchisees up for poor results. Several dozen former McDonald's Corp. franchisees sued the burger giant, alleging it unfairly treated Black owners by selling them subpar stores and failing to support their businesses.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corp. (NYSE: MCD) will decrease because they are being sued for discrimination.\n- Burger King Worldwide Holdings Inc. (NYSE: BKW) will increase because they are not being sued for discrimination.", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "down", "prices": [211.985, 212.13]}, "BKW": {"company": "", "ticker": "BKW", "move": "up"}}}, {"link": "https://www.wsj.com/articles/4k-vs-8k-which-tv-is-right-for-you-11549050946", "title": "4K vs. 8K: Which TV Is Right for You?", "date": "2019-02-01 14:55", "summary": "Just as 4KTV content starts to infiltrate homes, 8K is rearing its gorgeous head. The higher resolution will astound you, but you may well wonder if it's time to make the leap. JUST LAST YEAR, I bought a 65-inch 4K TV. It has a gorgeous picture: deep blacks and dynamic, true-to-life colors. I can finally watch all that 4K ultrahigh definition (UHD) content newly on offer from Netflix, Prime Video and iTunes. It's a glorious thing, and it feels a lot like the early days of high definition: Everything is deliciously detailed, real, beautiful.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"4K vs. 8K: Which TV Is Right for You?. Just as 4KTV content starts to infiltrate homes, 8K is rearing its gorgeous head. The higher resolution will astound you, but you may well wonder if it's time to make the leap. JUST LAST YEAR, I bought a 65-inch 4K TV. It has a gorgeous picture: deep blacks and dynamic, true-to-life colors. I can finally watch all that 4K ultrahigh definition (UHD) content newly on offer from Netflix, Prime Video and iTunes. It's a glorious thing, and it feels a lot like the early days of high definition: Everything is deliciously detailed, real, beautiful.\"\n\nStock Prediction(s):", "Prediction": "\n- 4KTV content will continue to infiltrate homes, and as a result, 4KTV manufacturers will increase in value (e.g. Samsung, LG, Sony, etc.).\n- 8KTV content will not become as popular as 4KTV content, and as a result, 8KTV manufacturers will decrease in value (e.g. Samsung, LG, Sony, etc.).", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-economy-is-in-a-contraction-says-larry-kudlow-11586267427", "title": "U.S. Economy Is in a Contraction, Says Larry Kudlow", "date": "2020-04-07 09:50", "summary": "Economy could reopen in four to eight weeks, says National Economic Council director. Breaking News:", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Economy Is in a Contraction, Says Larry Kudlow. Economy could reopen in four to eight weeks, says National Economic Council director. Breaking News:\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DOW) will decrease because the U.S. economy is in a contraction.\n- The S&P 500 (NYSE: SPX) will decrease because the U.S. economy is in a contraction.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because the U.S. economy is in a contraction.", "price_info": {"DOW": {"company": "", "ticker": "DOW", "move": "down", "prices": [33.52, 33.98]}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/oil-little-changed-as-oversupply-worries-linger-11570647064", "title": "Oil Ends Little Changed as Oversupply Worries Linger", "date": "2019-10-09 15:52", "summary": "U.S. supply rises to a record of 12.6 million barrels a day, but inventories of gasoline and distillates fall more than expected. Oil prices closed little changed Wednesday, erasing an earlier rally as traders awaited U.S.-China trade talks and weighed a mixed inventory report.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Ends Little Changed as Oversupply Worries Linger. U.S. supply rises to a record of 12.6 million barrels a day, but inventories of gasoline and distillates fall more than expected. Oil prices closed little changed Wednesday, erasing an earlier rally as traders awaited U.S.-China trade talks and weighed a mixed inventory report.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because the price of oil has stabilized and they are a direct competitor of Exxon Mobil Corporation (NYSE: XOM).\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because the price of oil has stabilized and they are a direct competitor of Chevron Corporation.\n- Schlumberger Limited. (NYSE: SLB) will increase because the price of oil has stabilized and they are a direct competitor of Hallibur", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [113.14, 113.14]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [67.44, 67.44]}, "SLB": {"company": "", "ticker": "SLB", "move": "up", "prices": [30.9, 30.9]}}}, {"link": "https://www.wsj.com/articles/consumer-confidence-fell-in-december-11608653605", "title": "Consumer Confidence Fell in December", "date": "2020-12-22 11:13", "summary": "Americans' view of the U.S. economy soured this month amid the coronavirus surge. U.S. consumers' outlook on the economy darkened this month as coronavirus cases climbed nationwide and local governments imposed new restrictions, according to survey data released Tuesday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer Confidence Fell in December. Americans' view of the U.S. economy soured this month amid the coronavirus surge. U.S. consumers' outlook on the economy darkened this month as coronavirus cases climbed nationwide and local governments imposed new restrictions, according to survey data released Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will decrease because of the decrease in consumer confidence.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because of the decrease in consumer confidence.\n- Nike, Inc. (NYSE: NKE) will decrease because of the decrease in consumer confidence.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [144.97, 145.11]}, "NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [143.285, 142.71]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3192.67, 3197.93]}}}, {"link": "https://www.wsj.com/articles/jerome-powell-to-address-house-financial-services-committee-11551263400", "title": "Fed's Powell Says Officials Close to Finalizing Portfolio-Runoff Plan", "date": "2019-02-27 12:36", "summary": "Fed chairman describes the U.S. economic outlook as favorable, but also points to headwinds from abroad. WASHINGTON-Federal Reserve Chairman Jerome Powell said Wednesday the central bank is close to announcing plans for ending the runoff of its $4 trillion portfolio of bonds and other assets this year.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Powell Says Officials Close to Finalizing Portfolio-Runoff Plan. Fed chairman describes the U.S. economic outlook as favorable, but also points to headwinds from abroad. WASHINGTON-Federal Reserve Chairman Jerome Powell said Wednesday the central bank is close to announcing plans for ending the runoff of its $4 trillion portfolio of bonds and other assets this year.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FFR) will increase because they are close to finalizing a plan to end the runoff of their $4 trillion portfolio.\n- The bond market will increase because the Federal Reserve is close to finalizing a plan to end the runoff of their $4 trillion portfolio.", "price_info": {"FFR": {"company": "", "ticker": "FFR", "move": "up", "prices": [46.315, 46.4101]}}}, {"link": "https://www.wsj.com/articles/campbell-smucker-show-glimmers-of-hope-11551287924", "title": "Campbell, Smucker Show Glimmers of Hope", "date": "2019-02-27 12:18", "summary": "Quarterly reports by Campbell Soup and J.M. Smucker relieved some of the pessimism about packaged food companies following the debacle at Kraft Heinz. Decent results this week from J.M. Smucker and Campbell Soup underscore how rivals can avoid Kraft Heinz's fate.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Campbell, Smucker Show Glimmers of Hope. Quarterly reports by Campbell Soup and J.M. Smucker relieved some of the pessimism about packaged food companies following the debacle at Kraft Heinz. Decent results this week from J.M. Smucker and Campbell Soup underscore how rivals can avoid Kraft Heinz's fate.\"\n\nStock Prediction(s):", "Prediction": "\n- Campbell Soup Company (NYSE: CPB) will increase because they showed good results this week, and they are not associated with the Kraft Heinz debacle.\n- J.M. Smucker Company (NYSE: SJM) will increase because they showed good results this week, and they are not associated with the Kraft Heinz debacle.", "price_info": {"CPB": {"company": "", "ticker": "CPB", "move": "up", "prices": [35.28, 35.84]}, "SJM": {"company": "", "ticker": "SJM", "move": "up", "prices": [105.96, 106.62]}}}, {"link": "https://www.wsj.com/articles/pinterest-vows-to-add-more-female-executives-workers-of-color-11621335601", "title": "Pinterest Vows to Add More Female Executives, Workers of Color", "date": "2021-05-18 11:05", "summary": "Moves come after gender-discrimination settlement; 'I'm trying to personally set that better tone,' CEO says. Pinterest Inc. has set new targets for increasing the number of women in leadership and improving racial and ethnic diversity throughout its workforce, a move that comes after the social-media company was roiled last year by claims of discrimination.", "categories": [["WSJ News Exclusive", "Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pinterest Vows to Add More Female Executives, Workers of Color. Moves come after gender-discrimination settlement; 'I'm trying to personally set that better tone,' CEO says. Pinterest Inc. has set new targets for increasing the number of women in leadership and improving racial and ethnic diversity throughout its workforce, a move that comes after the social-media company was roiled last year by claims of discrimination.\"\n\nStock Prediction(s):", "Prediction": "\n- Pinterest Inc. (NYSE: PINS) will increase because they are making a commitment to diversity and inclusion.\n- Facebook Inc. (NASDAQ: FB) will decrease because they have been recently scrutinized for their lack of diversity.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they have been recently scrutinized for their lack of diversity.", "price_info": {"PINS": {"company": "", "ticker": "PINS", "move": "up", "prices": [59.08, 59.26]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [314.015, 313.8879]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3284.7354, 3284.44]}}}, {"link": "https://www.wsj.com/articles/zillows-growth-prospects-dim-as-it-exits-home-flipping-11636039188", "title": "Zillow's Growth Prospects Dim as It Exits Home Flipping", "date": "2021-11-04 11:19", "summary": "The company has started trying to unload thousands of homes it owns and has been talking to private equity and other investment firms to gauge interest. Zillow Group Inc.'s unexpected decision to scrap its home-flipping business has analysts questioning whether the company has an alternative path to growth with as much promise as the enterprise it is leaving behind.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Zillow's Growth Prospects Dim as It Exits Home Flipping. The company has started trying to unload thousands of homes it owns and has been talking to private equity and other investment firms to gauge interest. Zillow Group Inc.'s unexpected decision to scrap its home-flipping business has analysts questioning whether the company has an alternative path to growth with as much promise as the enterprise it is leaving behind.\"\n\nStock Prediction(s):", "Prediction": "\n- Zillow Group Inc. (NASDAQ: Z) will decrease because they are no longer in the home flipping business, and they need to find a new path to growth.\n- Redfin Corporation (NASDAQ: RDFN) will increase because they are still in the home flipping business, and they are a direct competitor of Zillow.", "price_info": {"Z": {"company": "", "ticker": "Z", "move": "down", "prices": [68.3148, 67.63]}, "RDFN": {"company": "", "ticker": "RDFN", "move": "up", "prices": [50.29, 50.84]}}}, {"link": "https://www.wsj.com/articles/farmers-deal-with-glut-of-food-as-coronavirus-closes-restaurants-11586439722", "title": "Farmers Dump Milk, Break Eggs as Restaurant Closings Destroy Demand", "date": "2020-04-09 09:42", "summary": "Producers are throttling back as the virus erases sales to restaurants, hotels and cafeterias; 'It was heart-wrenching'. It was still dark outside at four o'clock on a recent morning when a tanker truck poured 6,000 gallons of milk into a manure pit on Nancy Mueller's Wisconsin dairy farm.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Farmers Dump Milk, Break Eggs as Restaurant Closings Destroy Demand. Producers are throttling back as the virus erases sales to restaurants, hotels and cafeterias; 'It was heart-wrenching'. It was still dark outside at four o'clock on a recent morning when a tanker truck poured 6,000 gallons of milk into a manure pit on Nancy Mueller's Wisconsin dairy farm.\"\n\nStock Prediction(s):", "Prediction": "\n- Dean Foods Co (NYSE: DF) will decrease because they are a milk producer and the virus is erasing sales to restaurants.\n- Cal-Maine Foods, Inc. (NASDAQ: CALM) will decrease because they are a egg producer and the virus is erasing sales to restaurants.", "price_info": {"DF": {"company": "", "ticker": "DF", "move": "down"}, "CALM": {"company": "", "ticker": "CALM", "move": "down", "prices": [40.55, 39.6]}}}, {"link": "https://www.wsj.com/articles/astrazeneca-covid-vaccine-blood-clots-11617892901", "title": "Can the AstraZeneca Vaccine Cause Blood Clots? What You Need to Know", "date": "2021-04-08 10:45", "summary": "Following advice on extremely rare potential side effects, a look at what regulators have said and how the risks stack up. European health regulators have advised that there may be a link between the Covid-19 vaccine developed by AstraZeneca PLC and the University of Oxford and very rare blood clots, and some governments have recommended restricting its distribution among younger people as a result. The potential side effect is rare-so rare it is only likely to be picked up in a real-world rollout of the vaccine rather than in earlier clinical trials involving many fewer people. The concern is limited to the AstraZeneca vaccine, which isn't yet authorized for use in the U.S. Here is what you need to know.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Can the AstraZeneca Vaccine Cause Blood Clots? What You Need to Know. Following advice on extremely rare potential side effects, a look at what regulators have said and how the risks stack up. European health regulators have advised that there may be a link between the Covid-19 vaccine developed by AstraZeneca PLC and the University of Oxford and very rare blood clots, and some governments have recommended restricting its distribution among younger people as a result. The potential side effect is rare-so rare it is only likely to be picked up in a real-world rollout of the vaccine rather than in earlier clinical trials involving many fewer people. The concern is limited to the AstraZeneca vaccine, which isn't yet authorized for use in the U.S. Here is what you need to know.\"\n\nStock Prediction(s):", "Prediction": "\n- AstraZeneca plc (NASDAQ: AZN) will decrease because of the potential side effect of blood clots.\n- Johnson & Johnson (NYSE: JNJ) will decrease because of the potential side effect of blood clots.\n- Pfizer Inc (NYSE: PFE) will decrease because of the potential side effect of blood clots.\n- Moderna Inc (NASDAQ: MRNA) will decrease because of the potential side effect", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [163.39, 163.635]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [35.9601, 36.06]}, "AZN": {"company": "", "ticker": "AZN", "move": "down", "prices": [49.61, 49.5501]}, "MRNA": {"company": "", "ticker": "MRNA", "move": "down", "prices": [134.5, 134.59]}}}, {"link": "https://www.wsj.com/articles/peloton-spins-to-born-in-the-u-s-a-11608657511", "title": "Peloton Spins to 'Born in the U.S.A.'", "date": "2020-12-22 12:18", "summary": "The company's new wheels have investors spinning in hopes for faster delivery times and better growth ahead. Home-fitness giant Peloton wants to be homemade. That could significantly expand the flywheel of a company that already has grown at lightning speed this year amid the pandemic.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Peloton Spins to 'Born in the U.S.A.'. The company's new wheels have investors spinning in hopes for faster delivery times and better growth ahead. Home-fitness giant Peloton wants to be homemade. That could significantly expand the flywheel of a company that already has grown at lightning speed this year amid the pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Peloton Interactive, Inc. (NASDAQ: PTON) will increase because their new wheels will improve growth and delivery times.\n- GoPro, Inc. (NASDAQ: GPRO) will decrease because they are a direct competitor of Peloton.", "price_info": {"PTON": {"company": "", "ticker": "PTON", "move": "up", "prices": [165.595, 159.7978]}, "GPRO": {"company": "", "ticker": "GPRO", "move": "down", "prices": [8.49, 8.57]}}}, {"link": "https://www.wsj.com/articles/saba-can-nominate-slate-to-blackrock-fund-boards-delaware-court-says-11561740816", "title": "Saba Can Nominate Slate to BlackRock Fund Boards, Delaware Court Says", "date": "2019-06-28 12:53", "summary": "Saba, run by Boaz Weinstein, had alleged BlackRock was trying to block outsiders from gaining seats and effecting change at closed-end funds. Saba Capital Management LP, a $1.7 billion hedge fund, will be allowed to nominate outsiders to the boards of two BlackRock Inc. closed-end funds.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saba Can Nominate Slate to BlackRock Fund Boards, Delaware Court Says. Saba, run by Boaz Weinstein, had alleged BlackRock was trying to block outsiders from gaining seats and effecting change at closed-end funds. Saba Capital Management LP, a $1.7 billion hedge fund, will be allowed to nominate outsiders to the boards of two BlackRock Inc. closed-end funds.\"\n\nStock Prediction(s):", "Prediction": "\n- Saba Capital Management LP (Saba) will increase because they have been victorious in their legal battle against BlackRock.\n- BlackRock, Inc. (NYSE: BLK) will decrease because they have been accused of blocking outsiders from gaining seats on their boards.", "price_info": {"BLK": {"company": "", "ticker": "BLK", "move": "down", "prices": [467.95, 468.0955]}}}, {"link": "https://www.wsj.com/articles/feds-evans-says-trade-headwinds-could-justify-additional-rate-cuts-11565194500", "title": "Fed's Evans Says Trade Headwinds Could Justify Additional Rate Cuts", "date": "2019-08-07 15:22", "summary": "Chicago Fed president says the central bank would need to lower rates by at least another quarter-percentage point to lift inflation back to 2% target. CHICAGO-Federal Reserve officials would need to consider more stimulus aimed at boosting the economy if growing trade tensions lead to a sharper pullback, a senior Fed bank president said Wednesday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans Says Trade Headwinds Could Justify Additional Rate Cuts. Chicago Fed president says the central bank would need to lower rates by at least another quarter-percentage point to lift inflation back to 2% target. CHICAGO-Federal Reserve officials would need to consider more stimulus aimed at boosting the economy if growing trade tensions lead to a sharper pullback, a senior Fed bank president said Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FFR) will decrease because they may need to cut rates again if the trade war continues to have a negative impact on the economy.\n- The Goldman Sachs Group, Inc. (NYSE: GS) will decrease because they are a direct competitor of the Federal Reserve.\n- The JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are a direct competitor of the Federal Reserve.", "price_info": {"FFR": {"company": "", "ticker": "FFR", "move": "down"}, "GS": {"company": "", "ticker": "GS", "move": "down"}, "JPM": {"company": "The", "ticker": "JPM", "move": "down", "prices": [108.03, 108.03]}}}, {"link": "https://www.wsj.com/articles/uaw-staffer-sues-union-alleging-sexual-harassment-retaliation-11590689758", "title": "UAW Staffer Sues Union Alleging Sexual Harassment, Retaliation", "date": "2020-05-28 14:16", "summary": "Lawsuit marks the second time this year the UAW faces sexual-harassment allegations involving top officials. A woman on staff at the United Auto Workers has filed a lawsuit claiming she was sexually harassed by higher-ranking UAW officials and that the union failed to take corrective action when she complained of the alleged incidents.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"UAW Staffer Sues Union Alleging Sexual Harassment, Retaliation. Lawsuit marks the second time this year the UAW faces sexual-harassment allegations involving top officials. A woman on staff at the United Auto Workers has filed a lawsuit claiming she was sexually harassed by higher-ranking UAW officials and that the union failed to take corrective action when she complained of the alleged incidents.\"\n\nStock Prediction(s):", "Prediction": "\n- The UAW will decrease because of the sexual harassment allegations.\n- Ford Motor Company (NYSE: F) will decrease because the UAW is a major union for Ford workers.\n- General Motors Company (NYSE: GM) will decrease because the UAW is a major union for GM workers.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will decrease because the UAW is a major union for Fiat Chrysler workers.", "price_info": {"F": {"company": "", "ticker": "F", "move": "down", "prices": [5.945, 5.85]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [27.185, 26.73]}, "FCAU": {"company": "", "ticker": "FCAU", "move": "down", "prices": [9.0978, 9.06]}}}, {"link": "https://www.wsj.com/articles/treasury-to-sell-165-billion-in-debt-11551979566", "title": "Treasury to Sell $165 Billion in Debt", "date": "2019-03-07 12:26", "summary": "U.S. Treasury Department next week will auction $38 billion in new debt and $127 billion in previously sold debt. The U.S. will auction $165 billion in securities next week, comprising $38 billion in new debt and $127 billion in previously sold debt. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury to Sell $165 Billion in Debt. U.S. Treasury Department next week will auction $38 billion in new debt and $127 billion in previously sold debt. The U.S. will auction $165 billion in securities next week, comprising $38 billion in new debt and $127 billion in previously sold debt. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Treasury Department will sell $165 billion in debt next week, and this will cause the stock prices of the companies that are bidding on this debt to decrease.\n- The only exception to this will be the company that is the winner of the auction for the new debt, because they will see an increase in their stock price.", "price_info": {}}, {"link": "https://www.wsj.com/articles/aramco-proposes-two-stage-ipo-shunning-london-hong-kong-11567084503", "title": "Aramco Plans Split IPO, Shunning London, Hong Kong", "date": "2019-08-29 11:48", "summary": "Tokyo emerges as surprise international front-runner for world's largest listing. Saudi Arabian Oil Co. is considering a plan to split the world's largest IPO into two stages, offering a portion of its shares on the Saudi stock exchange later this year and following up with an international offering in 2020 or 2021, according to advisers and officials familiar with the plans.", "categories": [["WSJ News Exclusive", "Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Aramco Plans Split IPO, Shunning London, Hong Kong. Tokyo emerges as surprise international front-runner for world's largest listing. Saudi Arabian Oil Co. is considering a plan to split the world's largest IPO into two stages, offering a portion of its shares on the Saudi stock exchange later this year and following up with an international offering in 2020 or 2021, according to advisers and officials familiar with the plans.\"\n\nStock Prediction(s):", "Prediction": "\n- Aramco (private) will increase because they are planning a split IPO and Tokyo is emerging as a front-runner.\n- Aramco (public) will decrease because they are planning a split IPO and Tokyo is emerging as a front-runner.", "price_info": {}}, {"link": "https://www.wsj.com/articles/index-giant-s-p-faces-potential-sec-lawsuit-over-volatility-gauges-11596037650", "title": "S&P Faces Potential SEC Lawsuit Over Volatility Gauges", "date": "2020-07-29 12:33", "summary": "SEC says S&P failed to provide sufficient disclosures on certain volatility-linked indexes in 2018. The Securities and Exchange Commission plans to bring an enforcement action against S&P Dow Jones Indices, one of the world's biggest index providers for exchange-traded funds, for failing to provide sufficient disclosures on certain volatility-linked indexes in 2018.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"S&P Faces Potential SEC Lawsuit Over Volatility Gauges. SEC says S&P failed to provide sufficient disclosures on certain volatility-linked indexes in 2018. The Securities and Exchange Commission plans to bring an enforcement action against S&P Dow Jones Indices, one of the world's biggest index providers for exchange-traded funds, for failing to provide sufficient disclosures on certain volatility-linked indexes in 2018.\"\n\nStock Prediction(s):", "Prediction": "\n- S&P Dow Jones Indices (NYSE: SPGI) will decrease because they are being sued by the SEC for not disclosing enough information about their volatility-linked indexes.", "price_info": {"SPGI": {"company": "", "ticker": "SPGI", "move": "down", "prices": [357.34, 359.48]}}}, {"link": "https://www.wsj.com/articles/chinese-developers-report-sharp-drops-in-monthly-home-sales-11634037472", "title": "Home Sales Are Falling Sharply in China", "date": "2021-10-12 12:09", "summary": "Decline in September, typically a strong month, raises concerns about economic growth. Home sales in China are seizing up as curbs on lending and worries about developers' financial health deter house buyers, casting a pall over an industry that is central to the Chinese economy.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Home Sales Are Falling Sharply in China. Decline in September, typically a strong month, raises concerns about economic growth. Home sales in China are seizing up as curbs on lending and worries about developers' financial health deter house buyers, casting a pall over an industry that is central to the Chinese economy.\"\n\nStock Prediction(s):", "Prediction": "\n- China's economy is slowing down, so home sales will continue to decline.\n- Other countries' economies will also slow down, so home sales will decline in those countries as well.", "price_info": {}}, {"link": "https://www.wsj.com/articles/yellen-urges-g-20-countries-to-increase-support-for-global-vaccination-efforts-11614259888", "title": "Yellen Urges Increased G-20 Support for Global Vaccination Efforts", "date": "2021-02-25 09:40", "summary": "'This is a moment made for action and for multilateralism'. WASHINGTON-Treasury Secretary Janet Yellen issued an urgent call for global cooperation to defeat the coronavirus pandemic and bolster the global economic recovery, in a letter to her international counterparts Thursday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Yellen Urges Increased G-20 Support for Global Vaccination Efforts. 'This is a moment made for action and for multilateralism'. WASHINGTON-Treasury Secretary Janet Yellen issued an urgent call for global cooperation to defeat the coronavirus pandemic and bolster the global economic recovery, in a letter to her international counterparts Thursday.\"\n\nStock Prediction(s):", "Prediction": "\n- Janet Yellen will be seen as a hero because of her work in increasing G-20 support for global vaccination efforts.\n- The stock prices of pharmaceutical companies will decrease because of the competition to create a vaccine.", "price_info": {}}, {"link": "https://www.wsj.com/articles/ahead-of-cop26-saudi-arabia-resists-calls-to-cut-oil-investment-11634911150", "title": "Saudi Arabia Resists Calls to Cut Oil Investment", "date": "2021-10-22 11:36", "summary": "The kingdom is pushing fellow producers to line up against calls for cutting investment in new oil and gas development. Saudi Arabia is pushing fellow oil producers to present a united front at climate talks that start this month and oppose rising calls for a reduction in fossil-fuel investment, say people familiar with the strategy, arguing that such a move could further push up energy prices.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudi Arabia Resists Calls to Cut Oil Investment. The kingdom is pushing fellow producers to line up against calls for cutting investment in new oil and gas development. Saudi Arabia is pushing fellow oil producers to present a united front at climate talks that start this month and oppose rising calls for a reduction in fossil-fuel investment, say people familiar with the strategy, arguing that such a move could further push up energy prices.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (Private: ARMCO) will increase because they are the main producer in Saudi Arabia, and they are resisting calls to reduce investment.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they are also a producer, and they are resisting calls to reduce investment.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because they are not resisting calls to reduce investment, and they are not a producer.\n", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [62.73, 62.89]}}}, {"link": "https://www.wsj.com/articles/caterpillars-sales-fall-as-coronavirus-weighs-on-industry-11603798979", "title": "Caterpillar, 3M Flag Falling Sales to Businesses", "date": "2020-10-27 15:07", "summary": "Coronavirus pandemic is sapping demand for everything from cruise ships to dental procedures. Big manufacturers are logging lower sales to businesses ranging from cruise-ship builders to medical offices, as the coronavirus pandemic continues to drag on economic activity across the globe.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Caterpillar, 3M Flag Falling Sales to Businesses. Coronavirus pandemic is sapping demand for everything from cruise ships to dental procedures. Big manufacturers are logging lower sales to businesses ranging from cruise-ship builders to medical offices, as the coronavirus pandemic continues to drag on economic activity across the globe.\"\n\nStock Prediction(s):", "Prediction": "\n- Caterpillar Inc. (NYSE: CAT) will decrease because their sales to businesses are dropping.\n- 3M Co. (NYSE: MMM) will decrease because their sales to businesses are dropping.", "price_info": {"CAT": {"company": "", "ticker": "CAT", "move": "down", "prices": [158, 157.2]}, "MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [161.13, 161.1]}}}, {"link": "https://www.wsj.com/articles/gm-affirms-profit-outlook-despite-chip-shortage-woes-11620216795", "title": "Car Companies' Profits Have Outrun the Chip Shortage-but Not for Long", "date": "2021-05-05 15:53", "summary": "Worsening supply crunch threatens to dampen auto industry's summer sales. Auto makers fresh off heady sales and profits in the first quarter are preparing for a rough ride ahead, as the global computer-chip shortage clouds an otherwise ripe environment for car sales.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Car Companies' Profits Have Outrun the Chip Shortage-but Not for Long. Worsening supply crunch threatens to dampen auto industry's summer sales. Auto makers fresh off heady sales and profits in the first quarter are preparing for a rough ride ahead, as the global computer-chip shortage clouds an otherwise ripe environment for car sales.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will decrease because their profits have outrun the chip shortage, and they are preparing for a rough ride.\n- General Motors Company (NYSE: GM) will decrease because their profits have outrun the chip shortage, and they are preparing for a rough ride.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are not as reliant on computer chips, and they are preparing for a growth in", "price_info": {"F": {"company": "", "ticker": "F", "move": "down", "prices": [11.575, 11.565]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [57.62, 57.66]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [670.7, 668.6]}}}, {"link": "https://www.wsj.com/articles/5g-farmers-agriculture-11621870949", "title": "Farmers Join Push to Harvest the Benefits of 5G", "date": "2021-05-25 12:00", "summary": "Bringing coverage to rural areas looms as the challenge for agricultural use of the technology. On a collection of adjoining fields near a university in rural western England, an ambitious farming project aims to show it's possible to plant, grow and harvest a crop autonomously, using robotics, drones-and potentially 5G.", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Farmers Join Push to Harvest the Benefits of 5G. Bringing coverage to rural areas looms as the challenge for agricultural use of the technology. On a collection of adjoining fields near a university in rural western England, an ambitious farming project aims to show it's possible to plant, grow and harvest a crop autonomously, using robotics, drones-and potentially 5G.\"\n\nStock Prediction(s):", "Prediction": "\n- None", "price_info": {}}, {"link": "https://www.wsj.com/articles/new-13-inch-macbook-pro-kills-apples-butterfly-keyboard-for-good-11588608573", "title": "MacBook Pro Rights Wrongs by Fixing Awkward Keyboard", "date": "2020-05-04 12:09", "summary": "After trying for years to fix its flawed butterfly keyboard, Apple has opted for an updated version of an older, more reliable design. I come to you today with news that at least one long, disastrous nightmare has come to an end.", "categories": [["Tech", "Personal Tech", "Personal Technology: Review"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"MacBook Pro Rights Wrongs by Fixing Awkward Keyboard. After trying for years to fix its flawed butterfly keyboard, Apple has opted for an updated version of an older, more reliable design. I come to you today with news that at least one long, disastrous nightmare has come to an end.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they have fixed their keyboard issue, which was a long-standing problem.\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because they have not fixed their keyboard issue, and it is a major flaw in their product.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [289.5209, 290.61]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [177.29, 177.4699]}}}, {"link": "https://www.wsj.com/articles/people-confined-for-a-pandemic-cant-get-enough-of-pandemics-11584626400", "title": "People Confined for a Pandemic Can't Get Enough of Pandemics", "date": "2020-03-19 10:00", "summary": "The Netflix documentary series 'Pandemic' and the board game of the same name seem to be surging in popularity. What do people do for fun when they are locked inside their homes to stop the spread of a dangerous pandemic? Apparently, they enjoy content about pandemics.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"People Confined for a Pandemic Can't Get Enough of Pandemics. The Netflix documentary series 'Pandemic' and the board game of the same name seem to be surging in popularity. What do people do for fun when they are locked inside their homes to stop the spread of a dangerous pandemic? Apparently, they enjoy content about pandemics.\"\n\nStock Prediction(s):", "Prediction": "\n- Netflix, Inc. (NASDAQ: NFLX) will increase because their documentary series \"Pandemic\" is surging in popularity.\n- The game company Hasbro, Inc. (NASDAQ: HAS) will increase because their board game of the same name is surging in popularity.", "price_info": {"NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [335.7691, 337.05]}, "HAS": {"company": "", "ticker": "HAS", "move": "up", "prices": [47.46, 46.66]}}}, {"link": "https://www.wsj.com/articles/as-companies-fret-consumers-keep-spending-11560530021", "title": "As Companies Fret, Consumers Keep Spending", "date": "2019-06-14 12:33", "summary": "Companies fear a trade war and recession, but they can't easily cut back on hiring with domestic demand strong. To judge from their spending habits, Americans aren't so worried about the economy. American companies are a different matter.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"As Companies Fret, Consumers Keep Spending. Companies fear a trade war and recession, but they can't easily cut back on hiring with domestic demand strong. To judge from their spending habits, Americans aren't so worried about the economy. American companies are a different matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc (NYSE: WMT) will increase because they are a domestic company that is not as worried about the trade war and recession.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a domestic company that is not as worried about the trade war and recession.\n- Nike, Inc. (NYSE: NKE) will increase because they are a domestic company that is not as worried about the trade war and", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [109.42, 109.35]}, "NKE": {"company": "", "ticker": "NKE", "move": "up", "prices": [83.2368, 83.28]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1871.26, 1871.59]}}}, {"link": "https://www.wsj.com/articles/starboard-takes-elanco-stake-nominates-three-to-its-board-11614796994", "title": "Starboard Takes Elanco Stake, Nominates Three to Its Board", "date": "2021-03-03 13:53", "summary": "Animal-health company has market value of around $15 billion. Activist investor Starboard Value LP has taken a stake in Elanco Animal Health Inc. and nominated three directors to the company's board, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Starboard Takes Elanco Stake, Nominates Three to Its Board. Animal-health company has market value of around $15 billion. Activist investor Starboard Value LP has taken a stake in Elanco Animal Health Inc. and nominated three directors to the company's board, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Elanco Animal Health Inc. (NYSE: ELAN) will increase because they have a new investor that is pushing for change.\n- Eli Lilly and Co. (NYSE: LLY) will decrease because they are the parent company of Elanco, and they will lose profits from the subsidiary.", "price_info": {"ELAN": {"company": "", "ticker": "ELAN", "move": "up", "prices": [32.23, 31.36]}, "LLY": {"company": "", "ticker": "LLY", "move": "down", "prices": [202.55, 203.515]}}}, {"link": "https://www.wsj.com/articles/saudi-arabia-markets-dollar-bond-to-plug-spending-gap-11586959815", "title": "Saudi Arabia Set to Raise $7 Billion in Bond Sale to Plug Spending Gap", "date": "2020-04-15 15:38", "summary": "Kingdom seeks to raise money to offset dual blows of pandemic and sinking oil prices. Saudi Arabia is expected to raise around $7 billion via a dollar-denominated bond sale on Wednesday, joining other oil-exporting Persian Gulf states that tapped the debt markets last week to plug funding shortfalls caused by low crude prices and the coronavirus pandemic.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudi Arabia Set to Raise $7 Billion in Bond Sale to Plug Spending Gap. Kingdom seeks to raise money to offset dual blows of pandemic and sinking oil prices. Saudi Arabia is expected to raise around $7 billion via a dollar-denominated bond sale on Wednesday, joining other oil-exporting Persian Gulf states that tapped the debt markets last week to plug funding shortfalls caused by low crude prices and the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Arabia (OTC: KSA) will increase because they are raising money to offset the dual blows of the pandemic and the sinking oil prices.\n- United Arab Emirates (NYSE: UAE) will increase because they are raising money to offset the dual blows of the pandemic and the sinking oil prices.\n- Qatar (OTC: QATF) will increase because they are raising money to offset the dual blows of the pandemic and the sinking oil", "price_info": {"UAE": {"company": "", "ticker": "UAE", "move": "up"}}}, {"link": "https://www.wsj.com/articles/us-trade-deficit-imports-exports-june-2021-11628114818", "title": "U.S. Trade Deficit Widened to Record in June, Showing Strong Pre-Delta Demand", "date": "2021-08-05 12:37", "summary": "Jobless claims remained elevated last week after steady declines. WASHINGTON-The U.S. trade deficit widened to a record in June as the resurgent American economy drove strong demand for foreign-made goods ahead of the Covid-19 Delta-variant surge.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Trade Deficit Widened to Record in June, Showing Strong Pre-Delta Demand. Jobless claims remained elevated last week after steady declines. WASHINGTON-The U.S. trade deficit widened to a record in June as the resurgent American economy drove strong demand for foreign-made goods ahead of the Covid-19 Delta-variant surge.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co (NYSE: BA) will increase because they are a major exporter, and the U.S. trade deficit has widened, meaning that there is more demand for their products.\n- Caterpillar Inc. (NYSE: CAT) will increase because they are a major exporter, and the U.S. trade deficit has widened, meaning that there is more demand for their products.\n- Ford Motor Co (NYSE: F) will increase because they", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [230.3501, 229.81]}, "CAT": {"company": "", "ticker": "CAT", "move": "up", "prices": [206.435, 207.33]}, "F": {"company": "", "ticker": "F", "move": "up", "prices": [13.7, 13.71]}}}, {"link": "https://www.wsj.com/articles/gold-eclipses-2011-closing-record-heads-for-new-all-time-high-11595518282", "title": "Gold Nears Record Amid Haven Buying", "date": "2020-07-23 14:07", "summary": "Precious metal approaches highest price since 2011 with skittish investors seeking safer assets. The price of gold neared an all-time high that has stood for almost nine years on Thursday, punctuating a furious rally driven by anxious investors seeking refuge from the coronavirus-induced economic slowdown.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold Nears Record Amid Haven Buying. Precious metal approaches highest price since 2011 with skittish investors seeking safer assets. The price of gold neared an all-time high that has stood for almost nine years on Thursday, punctuating a furious rally driven by anxious investors seeking refuge from the coronavirus-induced economic slowdown.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldcorp Inc. (NYSE: GG) will increase because the price of gold is rising, and they are a major producer of gold.\n- Barrick Gold Corporation (NYSE: ABX) will increase because the price of gold is rising, and they are a major producer of gold.\n- Newmont Mining Corporation (NYSE: NEM) will increase because the price of gold is rising, and they are a major producer of gold.\n- Anglo", "price_info": {"GG": {"company": "", "ticker": "GG", "move": "up"}, "ABX": {"company": "", "ticker": "ABX", "move": "up"}, "NEM": {"company": "", "ticker": "NEM", "move": "up", "prices": [65.7617, 65.5]}}}, {"link": "https://www.wsj.com/articles/audi-targets-9-500-jobs-to-boost-profit-11574793794", "title": "Audi to Cut 9,500 Jobs to Boost Profit", "date": "2019-11-26 13:43", "summary": "Luxury-car maker is navigating slowdown in global auto market and costly transition to electric vehicles. BERLIN-Luxury-car maker Audi AG said it would eliminate 9,500 jobs over the next five years as part of a restructuring aimed at bolstering profit in a slowing global auto market.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Audi to Cut 9,500 Jobs to Boost Profit. Luxury-car maker is navigating slowdown in global auto market and costly transition to electric vehicles. BERLIN-Luxury-car maker Audi AG said it would eliminate 9,500 jobs over the next five years as part of a restructuring aimed at bolstering profit in a slowing global auto market.\"\n\nStock Prediction(s):", "Prediction": "\n- Volkswagen AG (OTC: VOW3) will increase because Audi is one of their subsidiaries, and they are making cuts to improve their profit.\n- Daimler AG (OTC: DDAIF) will increase because Audi is one of their subsidiaries, and they are making cuts to improve their profit.\n- BMW AG (OTC: BAMXF) will increase because Audi is one of their subsidiaries, and they are making cuts to improve", "price_info": {}}, {"link": "https://www.wsj.com/articles/apollo-s-lifepoint-in-talks-to-buy-ardent-health-services-11613061599", "title": "Apollo's LifePoint in Talks to Buy Ardent Health Services", "date": "2021-02-11 11:47", "summary": "Combined company could be valued above $10 billion including debt. A company owned by Apollo Global Management Inc. is in talks to buy Ardent Health Services, according to people familiar with the matter, in a move that would add roughly 30 hospitals across six states and create an entity worth more than $10 billion including debt.", "categories": [["WSJ News Exclusive", "Deals"]], "category_links": ["https://www.wsj.com/news/types/deals-deal-makers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apollo's LifePoint in Talks to Buy Ardent Health Services. Combined company could be valued above $10 billion including debt. A company owned by Apollo Global Management Inc. is in talks to buy Ardent Health Services, according to people familiar with the matter, in a move that would add roughly 30 hospitals across six states and create an entity worth more than $10 billion including debt.\"\n\nStock Prediction(s):", "Prediction": "\n- Ardent Health Services (NYSE: ADT) will increase because they are being bought out by a larger company.\n- Apollo Global Management Inc. (NYSE: APO) will increase because they are the company buying Ardent Health Services.", "price_info": {"ADT": {"company": "", "ticker": "ADT", "move": "up", "prices": [9.3612, 9.23]}, "APO": {"company": "", "ticker": "APO", "move": "up", "prices": [50.9, 50.97]}}}, {"link": "https://www.wsj.com/articles/tesla-vehicle-deliveries-rise-though-bitcoin-bet-may-dent-earnings-11625230809", "title": "Tesla Vehicle Deliveries Rise Though Bitcoin Bet May Dent Earnings", "date": "2021-07-02 10:30", "summary": "Silicon Valley electric-vehicle maker handed over 201,250 vehicles to customers in the second quarter, more than double than during the year-ago period. Tesla Inc. notched its fifth straight quarter of vehicle-delivery growth in a period when the company's foray into cryptocurrency could hit its bottom line.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla Vehicle Deliveries Rise Though Bitcoin Bet May Dent Earnings. Silicon Valley electric-vehicle maker handed over 201,250 vehicles to customers in the second quarter, more than double than during the year-ago period. Tesla Inc. notched its fifth straight quarter of vehicle-delivery growth in a period when the company's foray into cryptocurrency could hit its bottom line.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (TSLA) will continue to grow because they are a leading electric-vehicle maker and they are expanding into the cryptocurrency market.\n- Nvidia Corporation (NVDA) will decrease because they are a direct competitor of Tesla in the electric-vehicle market.", "price_info": {"TSLA": {"company": "Tesla, Inc.", "ticker": "TSLA", "move": "up", "prices": [677.6398, 676.8292]}, "NVDA": {"company": "Nvidia Corporation", "ticker": "NVDA", "move": "down", "prices": [815.34, 814.45]}}}, {"link": "https://www.wsj.com/articles/gmturns-togooglefor-in-car-apps-voice-commands-11567692000", "title": "GM Turns to Google for in-Car Apps, Voice Commands", "date": "2019-09-05 10:00", "summary": "General Motors will build the tech giant's apps directly into its vehicles' touch-screen displays. General Motors Co. is forging a closer alliance with Alphabet Inc.'s Google, agreeing to build the tech giant's apps directly into its vehicles' touch-screen displays.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GM Turns to Google for in-Car Apps, Voice Commands. General Motors will build the tech giant's apps directly into its vehicles' touch-screen displays. General Motors Co. is forging a closer alliance with Alphabet Inc.'s Google, agreeing to build the tech giant's apps directly into its vehicles' touch-screen displays.\"\n\nStock Prediction(s):", "Prediction": "\n- GM (NYSE: GM) will increase because they are teaming up with Google, which is a very strong company.\n- Ford (NYSE: F) will decrease because they are not teaming up with Google, and they will be left behind.", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "up", "prices": [39.3, 39.23]}, "F": {"company": "", "ticker": "F", "move": "up", "prices": [9.315, 9.36]}}}, {"link": "https://www.wsj.com/articles/deutsche-bank-picks-u-s-general-counsel-to-head-anti-financial-crime-unit-11621359668", "title": "Deutsche Bank Picks U.S. General Counsel to Head Anti-Financial Crime Unit", "date": "2021-05-18 13:51", "summary": "Joe Salama will split his time between Frankfurt and the U.S., as the bank tries to keep a close relationship with U.S. authorities. Deutsche Bank AG has appointed its U.S. general counsel to head its global anti-financial-crime unit, according to a memo to employees released Tuesday.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Deutsche Bank Picks U.S. General Counsel to Head Anti-Financial Crime Unit. Joe Salama will split his time between Frankfurt and the U.S., as the bank tries to keep a close relationship with U.S. authorities. Deutsche Bank AG has appointed its U.S. general counsel to head its global anti-financial-crime unit, according to a memo to employees released Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Deutsche Bank AG (NYSE: DB) will increase because they are trying to keep a close relationship with U.S. authorities.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are also trying to keep a close relationship with U.S. authorities.", "price_info": {"DB": {"company": "", "ticker": "DB", "move": "up", "prices": [14.329, 14.24]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [163.1, 162.3]}}}, {"link": "https://www.wsj.com/articles/bankruptcy-watchdog-takes-aim-at-pg-e-ceos-pay-package-11563479934", "title": "Bankruptcy Watchdog Takes Aim at PG&E CEO's Pay Package", "date": "2019-07-18 15:58", "summary": "The U.S. trustee is objecting to the bankrupt California utility's multimillion-dollar pay package for its new chief executive. A federal bankruptcy watchdog is objecting to California utility PG&E Corp.'s request for approval of a $3 million payment to new Chief Executive William Johnson, according to a court document.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bankruptcy Watchdog Takes Aim at PG&E CEO's Pay Package. The U.S. trustee is objecting to the bankrupt California utility's multimillion-dollar pay package for its new chief executive. A federal bankruptcy watchdog is objecting to California utility PG&E Corp.'s request for approval of a $3 million payment to new Chief Executive William Johnson, according to a court document.\"\n\nStock Prediction(s):", "Prediction": "\n- PG&E Corporation (NYSE: PCG) will decrease because their new CEO is being paid too much.\n- Edison International (NYSE: EIX) will increase because they are not paying their CEO as much.", "price_info": {"PCG": {"company": "", "ticker": "PCG", "move": "down", "prices": [18.45, 18.45]}, "EIX": {"company": "", "ticker": "EIX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/bitcoin-falls-sharply-as-crypto-gets-caught-in-global-selloff-11584042348", "title": "Bitcoin Falls Sharply as Crypto Gets Caught in Global Selloff", "date": "2020-03-12 15:51", "summary": "Thursday's moves were exacerbated by the fact that crypto markets don't have internal controls to slow selloffs. The price of bitcoin fell sharply Thursday, at one point losing more than 20% in less than an hour, a steep drop even for the notoriously volatile asset.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bitcoin Falls Sharply as Crypto Gets Caught in Global Selloff. Thursday's moves were exacerbated by the fact that crypto markets don't have internal controls to slow selloffs. The price of bitcoin fell sharply Thursday, at one point losing more than 20% in less than an hour, a steep drop even for the notoriously volatile asset.\"\n\nStock Prediction(s):", "Prediction": "\n- Bitcoin (BTC) will continue to fall because it is being caught in the global selloff.\n- Ethereum (ETH) will continue to fall because it is being caught in the global selloff.\n- XRP will continue to fall because it is being caught in the global selloff.\n- Bitcoin Cash (BCH) will continue to fall because it is being caught in the global selloff.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "down"}, "ETH": {"company": "Ethereum", "ticker": "ETH", "move": null}, "BCH": {"company": "Bitcoin Cash", "ticker": "BCH", "move": null}}}, {"link": "https://www.wsj.com/articles/states-prepare-to-file-own-antitrust-cases-against-google-11603209976", "title": "States Prepare to File Own Antitrust Cases Against Google", "date": "2020-10-20 12:15", "summary": "At least two overlapping groups of attorneys general are investigating the company. WASHINGTON-More antitrust cases are likely to be filed against Alphabet Inc.'s Google soon by state attorneys general, even though partisan-tinged wrangling has clouded the path forward.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"States Prepare to File Own Antitrust Cases Against Google. At least two overlapping groups of attorneys general are investigating the company. WASHINGTON-More antitrust cases are likely to be filed against Alphabet Inc.'s Google soon by state attorneys general, even though partisan-tinged wrangling has clouded the path forward.\"\n\nStock Prediction(s):", "Prediction": "\n- Google (NASDAQ: GOOGL) will decrease because of the antitrust investigations.\n- Facebook (NASDAQ: FB) will decrease because of the antitrust investigations.\n- Amazon (NASDAQ: AMZN) will decrease because of the antitrust investigations.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [1552.25, 1567.7405]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [268.5128, 269.185]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3242.69, 3252.874]}}}, {"link": "https://www.wsj.com/articles/bank-of-japan-rolls-out-measures-to-blunt-coronavirus-impact-11584337241", "title": "Bank of Japan to Double Stock Purchases to Blunt Virus Impact", "date": "2020-03-16 10:21", "summary": "Japanese central bank holds benchmark interest rates steady, but plans to double purchases of ETFs. TOKYO-The Bank of Japan said it would double stock purchases and help companies get loans in response to the coronavirus pandemic, but the move failed to impress investors, who drove stocks down 2.5%.", "categories": [["Economy", "Asia Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/asia-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bank of Japan to Double Stock Purchases to Blunt Virus Impact. Japanese central bank holds benchmark interest rates steady, but plans to double purchases of ETFs. TOKYO-The Bank of Japan said it would double stock purchases and help companies get loans in response to the coronavirus pandemic, but the move failed to impress investors, who drove stocks down 2.5%.\"\n\nStock Prediction(s):", "Prediction": "\n- The Bank of Japan (BOJ) will increase their stock purchases in order to try and stimulate the economy.\n- The Nikkei 225 (N225) will decrease because the BOJ's announcement was not as aggressive as the market was expecting.", "price_info": {"BOJ": {"company": "Japan", "ticker": "BOJ", "move": "down"}}}, {"link": "https://www.wsj.com/articles/sizing-up-the-coronaviruss-hit-to-the-job-market-11587066150", "title": "Sizing Up the Coronavirus's Hit to the Job Market", "date": "2020-04-16 15:42", "summary": "A Wall Street Journal analysis finds temporary losses, short-term gains and hiring freezes. Business disruptions caused by the novel coronavirus have driven millions of Americans to seek unemployment benefits, a pace and scale of damage to the labor market unseen in decades. A Wall Street Journal examination of some timely indicators over recent weeks found undercurrents of the pain and some reasons for hope. The key takeaways include:", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Sizing Up the Coronavirus's Hit to the Job Market. A Wall Street Journal analysis finds temporary losses, short-term gains and hiring freezes. Business disruptions caused by the novel coronavirus have driven millions of Americans to seek unemployment benefits, a pace and scale of damage to the labor market unseen in decades. A Wall Street Journal examination of some timely indicators over recent weeks found undercurrents of the pain and some reasons for hope. The key takeaways include:\"\n\nStock Prediction(s):", "Prediction": "\n- The job market will continue to decline because of the coronavirus.\n- The job market will rebound because of the coronavirus.\n- The job market is already rebounding because of the coronavirus.", "price_info": {}}, {"link": "https://www.wsj.com/articles/blackstone-prologis-separately-bid-for-u-s-arm-of-warehouse-owner-glp-11558635639", "title": "Blackstone, Prologis Separately Bid for U.S. Arm of GLP", "date": "2019-05-23 14:38", "summary": "A deal could be reached next week, value business at more than $20 billion. Blackstone Group LP and Prologis Inc. are vying to buy the U.S. arm of Singapore's GLP in a deal that could be worth roughly $20 billion, including debt, and create an industrial-warehouse giant, according to people familiar with the matter.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Blackstone, Prologis Separately Bid for U.S. Arm of GLP. A deal could be reached next week, value business at more than $20 billion. Blackstone Group LP and Prologis Inc. are vying to buy the U.S. arm of Singapore's GLP in a deal that could be worth roughly $20 billion, including debt, and create an industrial-warehouse giant, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Blackstone Group LP (NYSE: BX) will increase because they are buying the U.S. arm of Singapore's GLP for $20 billion.\n- Prologis Inc (NYSE: PLD) will increase because they are a direct competitor of Blackstone Group.", "price_info": {"BX": {"company": "", "ticker": "BX", "move": "up", "prices": [41.12, 41.03]}, "PLD": {"company": "", "ticker": "PLD", "move": "up"}}}, {"link": "https://www.wsj.com/articles/canadas-dominion-diamond-files-for-protection-from-creditors-11587661013", "title": "Canada's Dominion Diamond Files for Protection From Creditors", "date": "2020-04-23 12:56", "summary": "Dominion Diamond Mines filed for bankruptcy in Canada after the coronavirus pandemic froze its operations. Dominion Diamond Mines ULC has sought bankruptcy protection from creditors after shutting down mining operations to maintain social-distancing protocols during the coronavirus pandemic.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Canada's Dominion Diamond Files for Protection From Creditors. Dominion Diamond Mines filed for bankruptcy in Canada after the coronavirus pandemic froze its operations. Dominion Diamond Mines ULC has sought bankruptcy protection from creditors after shutting down mining operations to maintain social-distancing protocols during the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Dominion Diamond Mines Ltd (NYSE: DDC) will decrease because they have filed for bankruptcy.\n- Harry Winston Diamond Corporation (NYSE: HWD) will decrease because they are a direct competitor of Dominion Diamond Mines.", "price_info": {"DDC": {"company": "", "ticker": "DDC", "move": "down"}, "HWD": {"company": "", "ticker": "HWD", "move": "down"}}}, {"link": "https://www.wsj.com/articles/gamestop-under-renewed-pressure-from-unhappy-investor-group-11583990600", "title": "GameStop Under Renewed Pressure from Unhappy Investor Group", "date": "2020-03-12 09:32", "summary": "The group sends a letter seeking a stockholder representative on the board. GameStop Corp. is facing a renewed threat from a group of shareholders upset with the videogame retailer's performance.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GameStop Under Renewed Pressure from Unhappy Investor Group. The group sends a letter seeking a stockholder representative on the board. GameStop Corp. is facing a renewed threat from a group of shareholders upset with the videogame retailer's performance.\"\n\nStock Prediction(s):", "Prediction": "\n- GameStop Corp. (NYSE: GME) will continue to decline because they are not meeting the demands of their investors.", "price_info": {"GME": {"company": "", "ticker": "GME", "move": "down", "prices": [3.764, 3.7983]}}}, {"link": "https://www.wsj.com/articles/u-s-european-yields-drop-on-growth-concerns-11596110991", "title": "U.S., European Yields Drop on Record Economic Downturns", "date": "2020-07-30 15:58", "summary": "Sharp contractions in the second quarter in U.S. and Germany weigh heavily on yields. Government bond yields dropped in the U.S. and Europe after fresh data on Thursday showed the worst quarterly economic contractions on record for the U.S. and Germany in the second quarter.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S., European Yields Drop on Record Economic Downturns. Sharp contractions in the second quarter in U.S. and Germany weigh heavily on yields. Government bond yields dropped in the U.S. and Europe after fresh data on Thursday showed the worst quarterly economic contractions on record for the U.S. and Germany in the second quarter.\"\n\nStock Prediction(s):", "Prediction": "\n- The yield on the 10-year U.S. Treasury note will continue to drop because of the worsening economic conditions.\n- The yield on the 10-year German Bund will continue to drop because of the worsening economic conditions.\n- The yield on the 10-year Japanese Government Bond will continue to drop because of the worsening economic conditions.", "price_info": {}}, {"link": "https://www.wsj.com/articles/golden-nugget-parent-private-jet-operator-wheels-up-join-spac-frenzy-11612196611", "title": "Golden Nugget Parent, Private-Jet Operator Wheels Up Join SPAC Frenzy", "date": "2021-02-01 12:47", "summary": "Wheels Up's deal includes a $550 million private investment from institutional investors, while Fertitta Entertainment has a commitment of about $1.2 billion. Private-jet operator Wheels Up Partners Holdings LLC and the parent of Golden Nugget added their names Monday to the list of companies going public through a combination with a special-purpose acquisition company.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Golden Nugget Parent, Private-Jet Operator Wheels Up Join SPAC Frenzy. Wheels Up's deal includes a $550 million private investment from institutional investors, while Fertitta Entertainment has a commitment of about $1.2 billion. Private-jet operator Wheels Up Partners Holdings LLC and the parent of Golden Nugget added their names Monday to the list of companies going public through a combination with a special-purpose acquisition company.\"\n\nStock Prediction(s):", "Prediction": "\n- Wheels Up Partners Holdings LLC (WUPA) will increase because they are going public and they have a lot of institutional investors.\n- Golden Nugget (NYSE: PNK) will increase because they are being acquired by a company that is going public.", "price_info": {"WUPA": {"company": "Holdings LLC", "ticker": "WUPA", "move": "up"}, "PNK": {"company": "", "ticker": "PNK", "move": "up"}}}, {"link": "https://www.wsj.com/articles/bitcoin-is-back-near-record-highs-houston-pension-fund-dives-in-11634836542", "title": "Bitcoin Is Back Near Record Highs, and a Houston Pension Plan Dives In", "date": "2021-10-21 13:15", "summary": "Fund for the city's firefighters buys $25 million of the cryptocurrencies bitcoin and ether, as digital assets attract institutional investors. Houston's pension fund for its firefighters said Thursday it bought $25 million worth of bitcoin and ether for its defined-benefit plan's portfolio, the latest move by an institutional investor into digital assets.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bitcoin Is Back Near Record Highs, and a Houston Pension Plan Dives In. Fund for the city's firefighters buys $25 million of the cryptocurrencies bitcoin and ether, as digital assets attract institutional investors. Houston's pension fund for its firefighters said Thursday it bought $25 million worth of bitcoin and ether for its defined-benefit plan's portfolio, the latest move by an institutional investor into digital assets.\"\n\nStock Prediction(s):", "Prediction": "\n- Bitcoin (BTC) will continue to increase in price because institutional investors are getting more involved.\n- Ethereum (ETH) will continue to increase in price because institutional investors are getting more involved.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "up"}, "ETH": {"company": "Ethereum", "ticker": "ETH", "move": null}}}, {"link": "https://www.wsj.com/articles/sec-acting-chairwomanwantsfund-managersto-disclose-more-voting-information-11615991316", "title": "SEC Acting Chairwoman Wants Fund Managers to Disclose More Voting Information", "date": "2021-03-17 12:55", "summary": "Asset managers failed to vote on significant shares during fight over GameStop last year. The Securities and Exchange Commission's acting chief wants the agency to require clearer disclosures on how asset managers cast shareholder votes.", "categories": [["WSJ News Exclusive", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SEC Acting Chairwoman Wants Fund Managers to Disclose More Voting Information. Asset managers failed to vote on significant shares during fight over GameStop last year. The Securities and Exchange Commission's acting chief wants the agency to require clearer disclosures on how asset managers cast shareholder votes.\"\n\nStock Prediction(s):", "Prediction": "\n- BlackRock, Inc. (NYSE: BLK) will decrease because they are one of the largest asset managers in the world, and they failed to vote on significant shares during the fight over GameStop.\n- Vanguard Group, Inc. (NYSE: VNQ) will decrease because they are one of the largest asset managers in the world, and they failed to vote on significant shares during the fight over GameStop.\n- Fidelity Investments (NYSE: F", "price_info": {"BLK": {"company": "", "ticker": "BLK", "move": "down", "prices": [720.93, 728.8726]}, "VNQ": {"company": "", "ticker": "VNQ", "move": "down", "prices": [91.8682, 92.62]}}}, {"link": "https://www.wsj.com/articles/europes-banks-warn-about-prospects-11565195627", "title": "Europe's Banks Warn About Prospects", "date": "2019-08-07 12:33", "summary": "Continent's lenders are grappling with lower interest rates and geopolitical tensions. For Europe's lenders, the hits keep on coming.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Europe's Banks Warn About Prospects. Continent's lenders are grappling with lower interest rates and geopolitical tensions. For Europe's lenders, the hits keep on coming.\"\n\nStock Prediction(s):", "Prediction": "\n- Deutsche Bank AG (NYSE: DB) will decrease because of the negative outlook from the banks\n- Commerzbank AG (OTCMKTS: CRZBY) will decrease because of the negative outlook from the banks\n- HSBC Holdings plc (NYSE: HSBC) will decrease because of the negative outlook from the banks", "price_info": {"DB": {"company": "", "ticker": "DB", "move": "down", "prices": [7.395, 7.4]}, "HSBC": {"company": "", "ticker": "HSBC", "move": "down", "prices": [38.175, 38.21]}}}, {"link": "https://www.wsj.com/articles/how-to-ask-for-a-raise-and-get-one-11624042061", "title": "How to Ask for a Raise, and Get One", "date": "2021-06-18 14:47", "summary": "Most Popular News. You have gone above and beyond at work and believe it is time to ask for a raise. But when it comes to increasing your salary, doing good work is just the beginning. Many other elements need to come together to make your request for a raise a certainty. In his book \"Empowering Yourself: The Organizational Game Revealed,\" author Harvey Coleman, who has consulted managers in Fortune 500 companies, lays out three key elements that determine your upward mobility at work: performance, image and exposure. Of those three, he estimates that job performance only amounts to 10% of the equation, while image accounts for 30% and exposure-the amount that people are aware of who you are and what your contributions and value have been-is 60%. \"That to me changed the game as far as my career goes,\" says Madeline Mann, an HR recruiter who has coached clients who have accepted jobs at Google, Netflix, Deloitte and other known companies.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Ask for a Raise, and Get One. Most Popular News. You have gone above and beyond at work and believe it is time to ask for a raise. But when it comes to increasing your salary, doing good work is just the beginning. Many other elements need to come together to make your request for a raise a certainty. In his book \"Empowering Yourself: The Organizational Game Revealed,\" author Harvey Coleman, who has consulted managers in Fortune 500 companies, lays out three key elements that determine your upward mobility at work: performance, image and exposure. Of those three, he estimates that job performance only amounts to 10% of the equation, while image accounts for 30% and exposure-the amount that people are aware of who you are and what your contributions and value have been-is 60%. \"That to me changed the game as far as my career goes,\" says Madeline Mann, an HR recruiter who has coached clients who have accepted jobs at Google, Netflix, Deloitte and other known companies.\"\n\nStock Prediction(s):", "Prediction": "\n- Google Inc. (NASDAQ: GOOGL) will increase because they are looking for employees with a high level of exposure.\n- Netflix, Inc. (NASDAQ: NFLX) will increase because they are looking for employees with a high level of exposure.\n- Deloitte Touche Tohmatsu Limited (NYSE: DT) will increase because they are looking for employees with a high level of exposure.", "price_info": {"DT": {"company": "", "ticker": "DT", "move": "up", "prices": [56.945, 56.6]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2417.05, 2402.33]}, "NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [500.045, 499.52]}}}, {"link": "https://www.wsj.com/articles/the-overnight-business-boom-that-took-a-century-11605285592", "title": "The Overnight Business Boom That Took a Century", "date": "2020-11-13 14:09", "summary": "Why a global pandemic transformed videocalling from a technology most people didn't like to the technology everybody had to have. To change people's lives, companies don't just need disruptive technology. Sometimes they need luck, too.", "categories": [["Business", "Back in Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/back-in-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Overnight Business Boom That Took a Century. Why a global pandemic transformed videocalling from a technology most people didn't like to the technology everybody had to have. To change people's lives, companies don't just need disruptive technology. Sometimes they need luck, too.\"\n\nStock Prediction(s):", "Prediction": "\n- Zoom Video Communications, Inc. (NASDAQ: ZM) will increase because videocalling is now a necessary technology because of the pandemic.\n- Apple Inc. (NASDAQ: AAPL) will increase because they own FaceTime, which is the most popular videocalling app.\n- Facebook, Inc. (NASDAQ: FB) will increase because they own WhatsApp, which is the most popular messaging app.", "price_info": {"ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [399.6, 402.765]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [118.57, 119.4334]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [274.97, 276.915]}}}, {"link": "https://www.wsj.com/articles/sony-to-acquire-full-control-of-financial-unit-for-3-7-billion-11589877008", "title": "Sony to Acquire Full Control of Financial Unit for $3.7 Billion", "date": "2020-05-19 09:42", "summary": "Move highlights conglomerate's strategy of keeping a diverse portfolio of businesses, rebuffing criticism by activist hedge fund. TOKYO- Sony Corp. said it would spend $3.7 billion to take full control of its banking and insurance unit, calling the Japan-centered business a hedge against uncertainty caused by the new coronavirus and global tensions.", "categories": [["Markets", "Deals"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/deals-deal-makers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Sony to Acquire Full Control of Financial Unit for $3.7 Billion. Move highlights conglomerate's strategy of keeping a diverse portfolio of businesses, rebuffing criticism by activist hedge fund. TOKYO- Sony Corp. said it would spend $3.7 billion to take full control of its banking and insurance unit, calling the Japan-centered business a hedge against uncertainty caused by the new coronavirus and global tensions.\"\n\nStock Prediction(s):", "Prediction": "\n- Sony Corp. (NYSE: SNE) will increase because they are diversifying their business and preparing for global tensions.\n- Mitsubishi UFJ Financial Group, Inc. (NYSE: MTU) will decrease because they are losing their stake in Sony's financial unit.", "price_info": {"SNE": {"company": "", "ticker": "SNE", "move": "up", "prices": [63.73, 63.56]}, "MTU": {"company": "", "ticker": "MTU", "move": "down"}}}, {"link": "https://www.wsj.com/articles/a-tokyo-listing-for-aramco-highlights-japans-less-stringent-disclosure-rules-11567170569", "title": "A Tokyo Listing for Aramco Highlights Japan's Less-Stringent Disclosure Rules", "date": "2019-08-30 11:46", "summary": "Saudi officials view Japan as a good option for an international offering, as Tokyo tries to regain status as an Asian financial hub. A Tokyo listing by Saudi Arabian Oil Co. would boost Japan's effort to re-establish itself as a global financial center, but it could also highlight areas in which the country has laxer disclosure standards.", "categories": [["Markets", "Stocks", "IPOs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb", "https://www.wsj.com/news/types/ipos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Tokyo Listing for Aramco Highlights Japan's Less-Stringent Disclosure Rules. Saudi officials view Japan as a good option for an international offering, as Tokyo tries to regain status as an Asian financial hub. A Tokyo listing by Saudi Arabian Oil Co. would boost Japan's effort to re-establish itself as a global financial center, but it could also highlight areas in which the country has laxer disclosure standards.\"\n\nStock Prediction(s):", "Prediction": "\n- Aramco (Private: ARMCO) will increase because they will be listed in Tokyo, and Tokyo has less-stringent disclosure rules.\n- Other oil companies will decrease because investors may prefer to invest in Aramco instead, due to their disclosure rules.", "price_info": {}}, {"link": "https://www.wsj.com/articles/stimulus-checks-round-2-when-will-they-arrive-how-much-will-they-be-11608561726", "title": "Second Stimulus Checks: Could Trump Veto the Relief Bill?", "date": "2020-12-24 11:02", "summary": "Congress voted to authorize another round of direct payments to households-but President Trump has called for more. Congress voted Monday to authorize a second round of stimulus payments to households as part of its roughly $900 billion coronavirus relief legislation. President Trump had been expected to sign the legislation, but he criticized the deal Tuesday night and called on lawmakers to increase direct payments to Americans to $2,000 from $600. Here is what we know:", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Second Stimulus Checks: Could Trump Veto the Relief Bill?. Congress voted to authorize another round of direct payments to households-but President Trump has called for more. Congress voted Monday to authorize a second round of stimulus payments to households as part of its roughly $900 billion coronavirus relief legislation. President Trump had been expected to sign the legislation, but he criticized the deal Tuesday night and called on lawmakers to increase direct payments to Americans to $2,000 from $600. Here is what we know:\"\n\nStock Prediction(s):", "Prediction": "\n- If President Trump vetoes the relief bill, then the stock market will decrease.\n- If President Trump signs the relief bill, then the stock market will increase.", "price_info": {}}, {"link": "https://www.wsj.com/articles/industries-driving-job-gains-face-another-covid-reckoning-11604681001", "title": "Industries Driving Job Gains Face Another Covid Reckoning", "date": "2020-11-06 11:43", "summary": "Colder weather and a resurgence in coronavirus cases threaten the recovery in retail and food service jobs. The economy continued to add back jobs last month. Will that still be the case come January?", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Industries Driving Job Gains Face Another Covid Reckoning. Colder weather and a resurgence in coronavirus cases threaten the recovery in retail and food service jobs. The economy continued to add back jobs last month. Will that still be the case come January?\"\n\nStock Prediction(s):", "Prediction": "\n- The retail and food service sectors will see a decrease in job growth because of the resurgence in Covid-19 cases.", "price_info": {}}, {"link": "https://www.wsj.com/articles/prices-rise-for-20-year-treasury-bond-in-debut-11590090488", "title": "Prices Rise for 20-Year Treasury Bond in Debut", "date": "2020-05-21 15:48", "summary": "Treasury Department auctioned its first 20-year bonds since 1986 on Wednesday. Prices for the revamped 20-year Treasury bond climbed Thursday in its debut session.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Prices Rise for 20-Year Treasury Bond in Debut. Treasury Department auctioned its first 20-year bonds since 1986 on Wednesday. Prices for the revamped 20-year Treasury bond climbed Thursday in its debut session.\"\n\nStock Prediction(s):", "Prediction": "\n- The price of the 20-year Treasury bond will continue to rise because there is high demand for it.\n- The price of the 20-year Treasury bond will eventually stabilize because there is only so much demand for it.", "price_info": {}}, {"link": "https://www.wsj.com/articles/senate-confirms-trump-pick-to-lead-housing-finance-overhaul-11554406057", "title": "Senate Confirms Trump Pick to Lead Housing-Finance Overhaul", "date": "2019-04-04 15:44", "summary": "Mark Calabria to play key role in shaping debate over future of Fannie Mae, Freddie Mac. WASHINGTON-The Senate confirmed Mark Calabria to oversee mortgage-finance companies Fannie Mae and Freddie Mac on Thursday, where he is set to play a critical role reshaping the way many Americans finance their home purchases.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Senate Confirms Trump Pick to Lead Housing-Finance Overhaul. Mark Calabria to play key role in shaping debate over future of Fannie Mae, Freddie Mac. WASHINGTON-The Senate confirmed Mark Calabria to oversee mortgage-finance companies Fannie Mae and Freddie Mac on Thursday, where he is set to play a critical role reshaping the way many Americans finance their home purchases.\"\n\nStock Prediction(s):", "Prediction": "\n- The confirmation of Mark Calabria as the head of the housing-finance overhaul will be good news for the housing market and, as a result, for the stocks of companies such as Lennar Corporation (NYSE: LEN) and D.R. Horton, Inc. (NYSE: DHI).\n- The confirmation of Mark Calabria as the head of the housing-finance overhaul will be bad news for the housing market and, as a result", "price_info": {"LEN": {"company": "", "ticker": "LEN", "move": null}, "DHI": {"company": "", "ticker": "DHI", "move": null}}}, {"link": "https://www.wsj.com/articles/why-cheap-money-hasnt-led-to-a-corporate-spending-boom-11574185159", "title": "Why Cheap Money Hasn't Led to a Corporate Spending Boom", "date": "2019-11-19 12:39", "summary": "Weak economic growth made new factories unappealing, while disruptive technologies didn't involve much investment. One of the great financial puzzles of the past decade has been why companies didn't load up with the cheapest money in history to invest more.", "categories": [["Markets", "Streetwise"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/streetwise?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Cheap Money Hasn't Led to a Corporate Spending Boom. Weak economic growth made new factories unappealing, while disruptive technologies didn't involve much investment. One of the great financial puzzles of the past decade has been why companies didn't load up with the cheapest money in history to invest more.\"\n\nStock Prediction(s):", "Prediction": "\n- The companies that have been waiting for a good opportunity to invest will finally invest now that the economy is growing more slowly and money is cheaper.\n- The companies that have been investing in disruptive technologies will continue to do so, even though money is cheaper, because they believe that these technologies are the future.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bidens-covid-19-vaccine-mandate-splits-business-community-11631285037", "title": "Biden's Covid-19 Vaccine Mandate Splits Business Community", "date": "2021-09-10 12:07", "summary": "Some trade groups applaud harder stance, others seek more details and worry about testing capacity. The Biden administration's order that most major U.S. companies mandate that their workers get vaccinated or tested weekly for Covid-19 split the business community.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biden's Covid-19 Vaccine Mandate Splits Business Community. Some trade groups applaud harder stance, others seek more details and worry about testing capacity. The Biden administration's order that most major U.S. companies mandate that their workers get vaccinated or tested weekly for Covid-19 split the business community.\"\n\nStock Prediction(s):", "Prediction": "\n- Businesses that applaud the mandate, such as trade groups, will see their stocks increase because this is a good step forward for the country.\n- Businesses that are worried about the mandate, such as those who seek more details, will see their stocks decrease because this is a cause for concern.", "price_info": {}}, {"link": "https://www.wsj.com/articles/oil-prices-struggle-for-direction-amid-supply-risks-economic-doubts-11549625952", "title": "Oil Prices Close Higher on Supply Risks", "date": "2019-02-08 15:24", "summary": "Clashes near Libya's biggest oil field dash expectations for a resumption of output. \u2022Oil prices settled higher Friday as supply risks outweighed concerns over a global economic slowdown.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Prices Close Higher on Supply Risks. Clashes near Libya's biggest oil field dash expectations for a resumption of output. \u2022Oil prices settled higher Friday as supply risks outweighed concerns over a global economic slowdown.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because of the supply risks in the oil market.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because of the supply risks in the oil market.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because of the supply risks in the oil market.\n- BP plc (NYSE: BP) will increase because of the supply risks in the oil market.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [117.16, 117.58]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [73.779, 73.98]}, "BP": {"company": "", "ticker": "BP", "move": "up", "prices": [42.457, 42.49]}}}, {"link": "https://www.wsj.com/articles/elizabeth-warren-presses-jerome-powell-for-information-on-trading-controversy-11638889417", "title": "Elizabeth Warren Presses Fed for Information on Trading Controversy", "date": "2021-12-07 10:31", "summary": "The senator wants complete information on Fed officials' trading from Jan. 1, 2020, onward. Sen. Elizabeth Warren (D., Mass.) is continuing to press the Federal Reserve for information detailing the extent of financial trading by its leadership ranks, and wants a formal briefing on new ethics rules adopted by the central bank.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Elizabeth Warren Presses Fed for Information on Trading Controversy. The senator wants complete information on Fed officials' trading from Jan. 1, 2020, onward. Sen. Elizabeth Warren (D., Mass.) is continuing to press the Federal Reserve for information detailing the extent of financial trading by its leadership ranks, and wants a formal briefing on new ethics rules adopted by the central bank.\"\n\nStock Prediction(s):", "Prediction": "\n- The senator's actions will have a negative impact on the stock prices of the banks that she is targeting.\n- Bank of America Corp (NYSE: BAC) will decrease because of the senator's actions.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because of the senator's actions.\n- Citigroup Inc. (NYSE: C) will decrease because of the senator's actions.\n- Goldman Sachs Group Inc. (NYSE: GS", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [44.75, 44.64]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [162.92, 162.28]}, "C": {"company": "America", "ticker": "C", "move": "down", "prices": [63.195, 62.95]}}}, {"link": "https://www.wsj.com/articles/trump-punches-huawei-and-american-tech-firms-get-a-bloody-nose-11561744203", "title": "Trump Punches Huawei and Global Tech Firms Get a Bloody Nose", "date": "2019-06-28 13:50", "summary": "Blacklisting ripples through global supply chain, as U.S. hits Chinese company's smartphone sales and threatens its 5G plans. The U.S. blacklisting of Huawei Technologies Co. is casting a net that extends far wider than its target: It is curbing the revenue of American and Japanese electronics companies, cutting into Taiwanese chip orders and giving Huawei's competitors a chance to take advantage.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump Punches Huawei and Global Tech Firms Get a Bloody Nose. Blacklisting ripples through global supply chain, as U.S. hits Chinese company's smartphone sales and threatens its 5G plans. The U.S. blacklisting of Huawei Technologies Co. is casting a net that extends far wider than its target: It is curbing the revenue of American and Japanese electronics companies, cutting into Taiwanese chip orders and giving Huawei's competitors a chance to take advantage.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are not selling any Huawei products, and they are a direct competitor of Huawei.\n- Qualcomm Inc. (NASDAQ: QCOM) will increase because they are not selling any Huawei products, and they are a direct competitor of Huawei.\n- Intel Corporation (NASDAQ: INTC) will increase because they are not selling any Huawei products, and they are a direct competitor of Huawei.\n", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [197.56, 198.15]}, "QCOM": {"company": "", "ticker": "QCOM", "move": "up", "prices": [75.519, 76.07]}, "INTC": {"company": "", "ticker": "INTC", "move": "up", "prices": [47.825, 47.99]}}}, {"link": "https://www.wsj.com/articles/stock-markets-record-high-isnt-a-reason-to-worry-11561393967", "title": "Stock Market's Record Isn't a Reason to Worry", "date": "2019-06-24 12:32", "summary": "Glance at the stocks that are leading the market and there are no obvious signs of exuberance. With the S&P 500 making a new high again last week the obvious worry is that investors are getting overenthusiastic, as cheap money shields them from the real-world problems of a weaker economy, increasingly dangerous global politics and a poor profits outlook.", "categories": [["Markets", "Streetwise"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/streetwise?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Stock Market's Record Isn't a Reason to Worry. Glance at the stocks that are leading the market and there are no obvious signs of exuberance. With the S&P 500 making a new high again last week the obvious worry is that investors are getting overenthusiastic, as cheap money shields them from the real-world problems of a weaker economy, increasingly dangerous global politics and a poor profits outlook.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will continue to go up because there are no signs of investors getting overexcited.\n- The market will continue to go up because there is cheap money available.\n- The market will continue to go up because there are no real-world problems that investors are worried about.", "price_info": {}}, {"link": "https://www.wsj.com/articles/ubs-stock-is-a-bargain-11635257889", "title": "UBS Stock Is a Bargain", "date": "2021-10-26 10:18", "summary": "Despite good growth prospects, the Swiss bank trades at a significant valuation discount compared with U.S. peers such as Morgan Stanley. UBS is arguably Europe's strongest big bank these days. So why are investors still wary?", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"UBS Stock Is a Bargain. Despite good growth prospects, the Swiss bank trades at a significant valuation discount compared with U.S. peers such as Morgan Stanley. UBS is arguably Europe's strongest big bank these days. So why are investors still wary?\"\n\nStock Prediction(s):", "Prediction": "\n- UBS Group AG (NYSE: UBS) will increase because they are a strong bank with good growth prospects, and they trade at a significant valuation discount compared with U.S. peers.", "price_info": {"UBS": {"company": "", "ticker": "UBS", "move": "up", "prices": [17.985, 17.9031]}}}, {"link": "https://www.wsj.com/articles/covid-19-vaccine-delivery-will-present-tough-challenge-to-cargo-airlines-11601890203", "title": "Covid-19 Vaccine Delivery Will Challenge Cargo Airlines", "date": "2020-10-05 12:27", "summary": "Inoculations for the new coronavirus will require thousands of extra flights, taxing stretched airlines. The pandemic has revealed shortcomings in global supply chains and forced business to make logistics a bigger strategic priority. Successfully delivering Covid-19 vaccines will test manufacturers and shippers on what lessons have been learned.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Vaccine Delivery Will Challenge Cargo Airlines. Inoculations for the new coronavirus will require thousands of extra flights, taxing stretched airlines. The pandemic has revealed shortcomings in global supply chains and forced business to make logistics a bigger strategic priority. Successfully delivering Covid-19 vaccines will test manufacturers and shippers on what lessons have been learned.\"\n\nStock Prediction(s):", "Prediction": "\n- Airlines will increase because they will be needed to transport the vaccines.\n- Pharmaceutical companies will increase because they will need to transport the vaccines.\n- Logistics companies will increase because they will be needed to transport the vaccines.", "price_info": {}}, {"link": "https://www.wsj.com/articles/biden-taps-isabel-guzman-to-lead-small-business-administration-11610044839", "title": "Biden Taps Isabel Guzman to Lead Small Business Administration", "date": "2021-01-07 13:59", "summary": "Guzman is a California economic development official and former deputy chief of staff at SBA. WASHINGTON-President-elect Joe Biden has chosen Isabel Guzman, a California economic development official, to lead the Small Business Administration, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Politics"]], "category_links": ["https://www.wsj.com/news/politics?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biden Taps Isabel Guzman to Lead Small Business Administration. Guzman is a California economic development official and former deputy chief of staff at SBA. WASHINGTON-President-elect Joe Biden has chosen Isabel Guzman, a California economic development official, to lead the Small Business Administration, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Guzman's appointment will be good for small businesses, and they will benefit from increased investment and support from the government.\n- Other businesses that are not small businesses will not be as affected by this appointment.", "price_info": {}}, {"link": "https://www.wsj.com/articles/peloton-in-reversal-plans-to-raise-1-billion-from-stock-offering-11637083283", "title": "Peloton Aims to Raise $1 Billion in Stock Offering", "date": "2021-11-16 13:27", "summary": "Fitness-equipment maker to sell shares for first time since 2019 IPO after stretch of heavy spending. Peloton Interactive Inc. on Tuesday announced a $1 billion stock offering, just weeks after the maker of connected fitness equipment said it didn't need additional capital to weather wider-than-expected losses and slowing growth.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Peloton Aims to Raise $1 Billion in Stock Offering. Fitness-equipment maker to sell shares for first time since 2019 IPO after stretch of heavy spending. Peloton Interactive Inc. on Tuesday announced a $1 billion stock offering, just weeks after the maker of connected fitness equipment said it didn't need additional capital to weather wider-than-expected losses and slowing growth.\"\n\nStock Prediction(s):", "Prediction": "\n- Peloton Interactive Inc. (NASDAQ: PTON) will decrease because they are selling shares and they are not in a good financial position.\n- Fitbit Inc. (NYSE: FIT) will increase because they are a direct competitor of Peloton and they are in a good financial position.", "price_info": {"FIT": {"company": "", "ticker": "FIT", "move": "up"}, "PTON": {"company": "", "ticker": "PTON", "move": "down", "prices": [53.26, 53.2]}}}, {"link": "https://www.wsj.com/articles/retailers-get-another-blow-hand-me-downs-11570030820", "title": "Retailers Get Another Blow: Hand-Me-Downs", "date": "2019-10-02 11:40", "summary": "A new Accenture study shows people will happily give and receive vintage clothing this holiday season. Take your grandpa's style and give it as a gift for Christmas.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Retailers Get Another Blow: Hand-Me-Downs. A new Accenture study shows people will happily give and receive vintage clothing this holiday season. Take your grandpa's style and give it as a gift for Christmas.\"\n\nStock Prediction(s):", "Prediction": "\n- The Gap, Inc. (NYSE: GPS) will increase because they sell vintage clothing.\n- Abercrombie & Fitch Co. (NYSE: ANF) will increase because they sell vintage clothing.\n- American Eagle Outfitters, Inc. (NYSE: AEO) will increase because they sell vintage clothing.\n- Urban Outfitters, Inc. (NASDAQ: URBN) will increase because they sell vintage clothing.", "price_info": {"GPS": {"company": "", "ticker": "GPS", "move": "up", "prices": [16.445, 16.505]}, "ANF": {"company": "", "ticker": "ANF", "move": "up", "prices": [14.56, 14.72]}, "AEO": {"company": "", "ticker": "AEO", "move": "up", "prices": [15.37, 15.49]}, "URBN": {"company": "", "ticker": "URBN", "move": "up", "prices": [27.68, 27.795]}}}, {"link": "https://www.wsj.com/articles/supermarkets-ration-staples-as-coronavirus-fears-leave-shelves-empty-11583853451", "title": "Supermarkets Ration Supplies as Coronavirus Fear Empties Shelves", "date": "2020-03-10 11:41", "summary": "Grocers are grappling with a surge in demand as the epidemic spreads. Supermarkets are rationing grocery-store staples and trying to restock more quickly to deal with surging demand, while planning new ways to feed a rising number of self-isolating consumers as coronavirus spreads across the U.S. and Europe.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Supermarkets Ration Supplies as Coronavirus Fear Empties Shelves. Grocers are grappling with a surge in demand as the epidemic spreads. Supermarkets are rationing grocery-store staples and trying to restock more quickly to deal with surging demand, while planning new ways to feed a rising number of self-isolating consumers as coronavirus spreads across the U.S. and Europe.\"\n\nStock Prediction(s):", "Prediction": "\n- Kroger Co (NYSE: KR) will increase because they are one of the few supermarkets with rationed supplies.\n- Walmart Inc (NYSE: WMT) will increase because they are one of the few supermarkets with rationed supplies.\n- Costco Wholesale Corporation (NASDAQ: COST) will increase because they are one of the few supermarkets with rationed supplies.\n- Amazon.com, Inc. (NASDAQ: AMZN) will", "price_info": {"KR": {"company": "", "ticker": "KR", "move": "up", "prices": [31.3, 31.49]}, "WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [115.94, 116.36]}, "COST": {"company": "", "ticker": "COST", "move": "up", "prices": [298, 298.63]}, "AMZN": {"company": "", "ticker": "AMZN", "move": null, "prices": [1843.1844, 1847.56]}}}, {"link": "https://www.wsj.com/articles/u-s-jobs-grew-by-196-000-in-march-11554467687", "title": "Hiring Rebounded in March, Helping Ease Downturn Jitters", "date": "2019-04-05 15:51", "summary": "The unemployment rate held steady at 3.8%, just above a 49-year low touched last fall. WASHINGTON-U.S. hiring sprang back in March, showing a slowdown in February was likely just a passing chill during a historically long stretch of job creation.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hiring Rebounded in March, Helping Ease Downturn Jitters. The unemployment rate held steady at 3.8%, just above a 49-year low touched last fall. WASHINGTON-U.S. hiring sprang back in March, showing a slowdown in February was likely just a passing chill during a historically long stretch of job creation.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will stay the same, because hiring has rebounded.\n- The Dow Jones Industrial Average (NYSE: DJIA) will stay the same, because hiring has rebounded.", "price_info": {"DJIA": {"company": "", "ticker": "DJIA", "move": null}}}, {"link": "https://www.wsj.com/articles/investors-who-put-their-pennies-in-coinbase-could-get-pinched-11629977580", "title": "Investors Who Put Their Pennies in Coinbase Could Get Pinched", "date": "2021-08-26 13:32", "summary": "Cryptocurrency exchange Coinbase remains richly valued at a time of rising regulatory threats. This column is part of the Heard on the Street stock picking contest. You're invited to play along with us here.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors Who Put Their Pennies in Coinbase Could Get Pinched. Cryptocurrency exchange Coinbase remains richly valued at a time of rising regulatory threats. This column is part of the Heard on the Street stock picking contest. You're invited to play along with us here.\"\n\nStock Prediction(s):", "Prediction": "\n- Coinbase (NASDAQ: COIN) will decrease because of regulatory threats.\n- Other cryptocurrency exchanges (e.g. Binance, Bitfinex, etc.) will increase because they are not facing the same regulatory threats as Coinbase.", "price_info": {"COIN": {"company": "", "ticker": "COIN", "move": "up", "prices": [250.5401, 248.9]}}}, {"link": "https://www.wsj.com/articles/boeing-reports-more-max-cancellations-11594738855", "title": "Boeing Reports More MAX Cancellations", "date": "2020-07-14 12:09", "summary": "Aerospace giant's deliveries, orders have fallen sharply during coronavirus pandemic. Boeing Co. culled another 183 jets from its order book in June and delivered just 10 aircraft, highlighting the pandemic-driven barriers to recovery for plane makers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Reports More MAX Cancellations. Aerospace giant's deliveries, orders have fallen sharply during coronavirus pandemic. Boeing Co. culled another 183 jets from its order book in June and delivered just 10 aircraft, highlighting the pandemic-driven barriers to recovery for plane makers.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will continue to decrease because of the MAX cancellations and the overall slowdown in the aviation industry.\n- Airbus SE (EPA: AIR) will increase because they are not experiencing the same MAX cancellations as Boeing, and they are still seeing strong demand for their aircraft.\n- Embraer SA (NYSE: ERJ) will increase because they are not experiencing the same MAX cancellations as Boeing, and they are still seeing", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [175.8699, 178.68]}, "ERJ": {"company": "", "ticker": "ERJ", "move": "up", "prices": [5.92, 5.985]}}}, {"link": "https://www.wsj.com/articles/what-investors-learned-from-the-first-peek-inside-youtubes-financials-11580836322", "title": "What Investors Saw Inside YouTube's Financials", "date": "2020-02-04 12:12", "summary": "Google reveals YouTube is smaller than outsiders thought-but still a juggernaut. If YouTube were a stand-alone company, it would be among the biggest advertising players in the world. Yet the online video service isn't as large as many outsiders expected.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What Investors Saw Inside YouTube's Financials. Google reveals YouTube is smaller than outsiders thought-but still a juggernaut. If YouTube were a stand-alone company, it would be among the biggest advertising players in the world. Yet the online video service isn't as large as many outsiders expected.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because YouTube is a part of their business, and it is still a juggernaut.\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are a direct competitor of Alphabet Inc.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1433.6959, 1435.46]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [208.8379, 209.1306]}}}, {"link": "https://www.wsj.com/articles/fed-adds-76-9-billion-in-overnight-money-to-markets-11578321440", "title": "Fed Adds $76.9 Billion in Overnight Money to Markets", "date": "2020-01-06 09:37", "summary": "Interest in repo operation was a little higher than the past couple of interventions. The Federal Reserve Bank of New York added $76.9 billion in temporary money to financial markets Monday.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Adds $76.9 Billion in Overnight Money to Markets. Interest in repo operation was a little higher than the past couple of interventions. The Federal Reserve Bank of New York added $76.9 billion in temporary money to financial markets Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed adding money to the market will cause interest rates to stay low, which will benefit banks and other companies that rely on borrowing money.\n- The Fed adding money to the market will cause inflation to stay low, which will benefit people who rely on buying goods and services.", "price_info": {}}, {"link": "https://www.wsj.com/articles/aramco-courts-u-s-investors-ahead-of-debt-sale-11549563463", "title": "Aramco Courts U.S. Investors Ahead of Debt Sale", "date": "2019-02-07 13:36", "summary": "Saudi oil company looks to raise debt to purchase part of the country's petrochemicals firm. DUBAI-Saudi Aramco executives traveled to the U.S. this week to court investors ahead of a potential $10 billion bond sale, reviving an idea to partially fund the acquisition of Saudi Arabia's national petrochemical firm, according to people familiar with the matter.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Aramco Courts U.S. Investors Ahead of Debt Sale. Saudi oil company looks to raise debt to purchase part of the country's petrochemicals firm. DUBAI-Saudi Aramco executives traveled to the U.S. this week to court investors ahead of a potential $10 billion bond sale, reviving an idea to partially fund the acquisition of Saudi Arabia's national petrochemical firm, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (OTC: ARMCO) will increase because they are looking to raise debt to purchase part of the country's petrochemicals firm.\n- Sabic (OTC: SABIC) will decrease because they are a direct competitor of Saudi Aramco.", "price_info": {}}, {"link": "https://www.wsj.com/articles/gun-maker-remington-preps-for-bankruptcy-seeks-sale-to-navajo-nation-11593186468", "title": "Gun Maker Remington Preps for Bankruptcy, Seeks Sale to Navajo Nation", "date": "2020-06-26 11:47", "summary": "The second chapter 11 filing for Remington could come within days. Firearms manufacturer Remington Arms Co. is preparing to file for chapter 11 protection for the second time since 2018 and is in advanced talks for a potential bankruptcy sale to the Navajo Nation, people familiar with the matter said.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gun Maker Remington Preps for Bankruptcy, Seeks Sale to Navajo Nation. The second chapter 11 filing for Remington could come within days. Firearms manufacturer Remington Arms Co. is preparing to file for chapter 11 protection for the second time since 2018 and is in advanced talks for a potential bankruptcy sale to the Navajo Nation, people familiar with the matter said.\"\n\nStock Prediction(s):", "Prediction": "\n- Remington Outdoor Co (NYSE: REM) will decrease because they are filing for bankruptcy and looking for a sale.\n- Sturm, Ruger & Co (NYSE: RGR) will increase because they are not filing for bankruptcy and are in talks to buy Remington.\n- Vista Outdoor Inc (NYSE: VSTO) will decrease because they are in the same market as Remington and are also filing for bankruptcy.", "price_info": {"REM": {"company": "", "ticker": "REM", "move": "down", "prices": [24.2, 24.2]}, "RGR": {"company": "", "ticker": "RGR", "move": "up", "prices": [71.8, 71.93]}, "VSTO": {"company": "", "ticker": "VSTO", "move": "down", "prices": [14.01, 14.07]}}}, {"link": "https://www.wsj.com/articles/treasury-to-sell-159-billion-in-debt-11556813416", "title": "Treasury to Sell $159 Billion in Debt", "date": "2019-05-02 12:10", "summary": "U.S. Treasury Department will auction next week $84 billion in new debt, $75 billion in previously sold debt. The U.S. will auction $159 billion in securities next week, comprising $84 billion in new debt and $75 billion in previously sold debt. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury to Sell $159 Billion in Debt. U.S. Treasury Department will auction next week $84 billion in new debt, $75 billion in previously sold debt. The U.S. will auction $159 billion in securities next week, comprising $84 billion in new debt and $75 billion in previously sold debt. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Treasury Department will auction $159 billion in securities next week, and this will have a positive effect on the stock prices of the companies who are the primary buyers of Treasury debt, such as:\n- Goldman Sachs Group Inc. (NYSE: GS)\n- JPMorgan Chase & Co. (NYSE: JPM)\n- Bank of America Corp. (NYSE: BAC)\n- Citigroup Inc. (NYSE: C)\n- Wells", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up", "prices": [204.61, 205.42]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [115.48, 115.34]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [30.46, 30.44]}, "C": {"company": "", "ticker": "C", "move": "up", "prices": [70.32, 70.23]}}}, {"link": "https://www.wsj.com/articles/fade-the-donald-dont-trade-the-donald-11568137509", "title": "Fade the Donald, Don't Trade the Donald", "date": "2019-09-10 13:45", "summary": "President Trump inspired a tongue-in-cheek index with his market-moving tweets, but trading on them may not be worth it. Once upon a time, U.S. presidents had to do something dramatic such as vomit on the Japanese prime minister or have a heart attack to impact stock prices. Active attempts to cheer markets, however well timed, were frowned upon.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fade the Donald, Don't Trade the Donald. President Trump inspired a tongue-in-cheek index with his market-moving tweets, but trading on them may not be worth it. Once upon a time, U.S. presidents had to do something dramatic such as vomit on the Japanese prime minister or have a heart attack to impact stock prices. Active attempts to cheer markets, however well timed, were frowned upon.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will not be significantly impacted by President Trump's tweets.\n- The market will not be significantly impacted by President Trump's tweets.", "price_info": {}}, {"link": "https://www.wsj.com/articles/millennials-embrace-prenupsbut-through-a-very-different-lens-than-in-the-past-11611252036", "title": "Millennials Embrace Prenups-but Through a Very Different Lens Than in the Past", "date": "2021-01-21 13:00", "summary": "Millennials are using prenups to address new economic and social issues-including rising student debt, social-media use and embryo ownership. Millennials are often known to buck convention. That seems to be true even when it comes to prenuptial agreements.", "categories": [["Markets", "Journal Reports: Wealth Management"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-wealth-management?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Millennials Embrace Prenups-but Through a Very Different Lens Than in the Past. Millennials are using prenups to address new economic and social issues-including rising student debt, social-media use and embryo ownership. Millennials are often known to buck convention. That seems to be true even when it comes to prenuptial agreements.\"\n\nStock Prediction(s):", "Prediction": "\n- Prenups will become more popular among millennials, and this will benefit companies that make prenup software and/or offer legal services for prenups.\n- The popularity of prenups among millennials will have a negative effect on the divorce industry.", "price_info": {}}, {"link": "https://www.wsj.com/articles/former-google-self-driving-engineer-files-for-bankruptcy-11583384883", "title": "Ex-Google Self-Driving Engineer Files for Bankruptcy", "date": "2020-03-05 13:50", "summary": "Anthony Levandowski cites a $179 million legal judgment in dispute that involved Uber. Anthony Levandowski, the self-driving engineer accused by Google of breaching his employment contract and misusing confidential information, filed for bankruptcy, citing a $179 million legal judgment.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ex-Google Self-Driving Engineer Files for Bankruptcy. Anthony Levandowski cites a $179 million legal judgment in dispute that involved Uber. Anthony Levandowski, the self-driving engineer accused by Google of breaching his employment contract and misusing confidential information, filed for bankruptcy, citing a $179 million legal judgment.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because Anthony Levandowski, who was a former employee of Google, is now bankrupt. This will reflect poorly on Uber, which is a direct competitor of Alphabet.\n- Uber Technologies Inc. (NYSE: UBER) will decrease because Anthony Levandowski, who was a former employee of Uber, is now bankrupt. This will reflect poorly on Uber, which is a direct competitor of Alphabet.", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "down", "prices": [32.46, 32.2901]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1336.46, 1309.42]}}}, {"link": "https://www.wsj.com/articles/how-to-build-meaningful-workplace-relationships-11605294163", "title": "How to Build Positive Relationships at Work", "date": "2021-03-11 11:23", "summary": "Most Popular News. Whether you are working remotely, from an office or picking up part-time gig work and odd jobs, it is crucial to network so you can forge and strengthen positive relationships with your colleagues. It is not just senior staff who can help you advance in your career. Your peers and junior colleagues can also become helpful contacts and give you some insight into the avenues you do and don't want to pursue professionally. Even if you consider yourself a wallflower, there are techniques you can use to make the most of your working relationships, say networking experts.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Build Positive Relationships at Work. Most Popular News. Whether you are working remotely, from an office or picking up part-time gig work and odd jobs, it is crucial to network so you can forge and strengthen positive relationships with your colleagues. It is not just senior staff who can help you advance in your career. Your peers and junior colleagues can also become helpful contacts and give you some insight into the avenues you do and don't want to pursue professionally. Even if you consider yourself a wallflower, there are techniques you can use to make the most of your working relationships, say networking experts.\"\n\nStock Prediction(s):", "Prediction": "\n- LinkedIn Corporation (NYSE: LNKD) will increase because people will want to build relationships with their colleagues in order to advance their careers.\n- Facebook, Inc. (NASDAQ: FB) will increase because people will want to build relationships with their colleagues in order to advance their careers.\n- Twitter, Inc. (NYSE: TWTR) will increase because people will want to build relationships with their colleagues in order to advance their careers.", "price_info": {"LNKD": {"company": "", "ticker": "LNKD", "move": "up"}, "TWTR": {"company": "", "ticker": "TWTR", "move": "up", "prices": [67.5302, 67.63]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [274.17, 275.99]}}}, {"link": "https://www.wsj.com/articles/credit-suisse-bets-future-on-managing-more-rich-peoples-money-11608028654", "title": "Credit Suisse Bets on Managing More Rich People's Money", "date": "2020-12-15 13:07", "summary": "Chief Executive Thomas Gottstein laid out his vision for the Swiss bank, which has struggled to please investors in recent years. Credit Suisse Group AG's new chief executive said managing rich people's money will be a priority for the bank, setting a target to boost wealth-management profits by at least a quarter in the coming years.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Credit Suisse Bets on Managing More Rich People's Money. Chief Executive Thomas Gottstein laid out his vision for the Swiss bank, which has struggled to please investors in recent years. Credit Suisse Group AG's new chief executive said managing rich people's money will be a priority for the bank, setting a target to boost wealth-management profits by at least a quarter in the coming years.\"\n\nStock Prediction(s):", "Prediction": "\n- Credit Suisse Group AG (NYSE: CS) will increase because they are focusing on their wealth-management division, which will result in more profits.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are also focusing on their wealth-management division, but Credit Suisse is a direct competitor.", "price_info": {"CS": {"company": "", "ticker": "CS", "move": "up", "prices": [12.745, 12.73]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [120.5171, 120.56]}}}, {"link": "https://www.wsj.com/articles/driverless-cars-are-90-here-theres-another-90-left-to-go-11558717322", "title": "Driverless Cars Are 90% Here. Another Is 90% Left to Go.", "date": "2019-05-24 13:02", "summary": "If building a robocar were just about putting the parts together, we'd be living in the future already. Here's what we know about autonomous vehicles: They'll be safer and smarter than the cars parked in our driveways today. Anyone who speculates beyond that is just, well, speculating.", "categories": [["Business", "On Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/on-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Driverless Cars Are 90% Here. Another Is 90% Left to Go.. If building a robocar were just about putting the parts together, we'd be living in the future already. Here's what we know about autonomous vehicles: They'll be safer and smarter than the cars parked in our driveways today. Anyone who speculates beyond that is just, well, speculating.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are the only company that has a driverless car that is 90% complete.\n- Ford Motor Company (NYSE: F) will increase because they are also working on a driverless car, but they are a direct competitor of Tesla.\n- General Motors Company (NYSE: GM) will decrease because they are also working on a driverless car, but they are a direct competitor of", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [9.82, 9.86]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [35.075, 35.095]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [190.1959, 190.81]}}}, {"link": "https://www.wsj.com/articles/steel-ingredient-iron-ore-hits-nearly-five-year-high-11554736095", "title": "Steel Ingredient Iron Ore Hits Nearly Five-Year High", "date": "2019-04-08 11:08", "summary": "Shortfall from mining hubs Brazil and Australia have impacted prices, as stockpiles at Chinese ports edge lower. The price of iron ore, the main ingredient in steel, surged to its highest level in almost five years on an emerging shortfall from the world's mining hubs of Brazil and Australia.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Steel Ingredient Iron Ore Hits Nearly Five-Year High. Shortfall from mining hubs Brazil and Australia have impacted prices, as stockpiles at Chinese ports edge lower. The price of iron ore, the main ingredient in steel, surged to its highest level in almost five years on an emerging shortfall from the world's mining hubs of Brazil and Australia.\"\n\nStock Prediction(s):", "Prediction": "\n- Rio Tinto plc (NYSE: RIO) will increase because their main ingredient in steel, iron ore, is in high demand.\n- BHP Group Ltd (NYSE: BHP) will increase because their main ingredient in steel, iron ore, is in high demand.\n- Vale SA (NYSE: VALE) will decrease because they are a direct competitor of Rio Tinto and BHP Group.", "price_info": {"RIO": {"company": "", "ticker": "RIO", "move": "up", "prices": [62.175, 62.415]}, "BHP": {"company": "", "ticker": "BHP", "move": "up", "prices": [56.93, 57.0879]}, "VALE": {"company": "", "ticker": "VALE", "move": "down", "prices": [13.65, 13.685]}}}, {"link": "https://www.wsj.com/articles/abbott-laboratories-gets-boost-from-u-s-covid-19-testing-11594908297", "title": "Abbott Laboratories Gets Boost From U.S. Covid-19 Testing", "date": "2020-07-16 13:41", "summary": "Revenue for the medical company's U.S. diagnostics segment increased 23% in latest quarter. Abbott Laboratories recorded a surge in revenue in its U.S. diagnostics business during the second quarter, fueled by strong demand for the company's Covid-19 testing.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Abbott Laboratories Gets Boost From U.S. Covid-19 Testing. Revenue for the medical company's U.S. diagnostics segment increased 23% in latest quarter. Abbott Laboratories recorded a surge in revenue in its U.S. diagnostics business during the second quarter, fueled by strong demand for the company's Covid-19 testing.\"\n\nStock Prediction(s):", "Prediction": "\n- Abbott Laboratories (NYSE: ABT) will increase because their Covid-19 testing is in high demand.\n- Roche Holding AG (OTCQX: RHHBY) will increase because their Covid-19 testing is in high demand.\n- Becton, Dickinson and Company (NYSE: BDX) will increase because their Covid-19 testing is in high demand.", "price_info": {"ABT": {"company": "", "ticker": "ABT", "move": "up", "prices": [96.3246, 95.9258]}, "BDX": {"company": "", "ticker": "BDX", "move": "up", "prices": [265.67, 266.1116]}}}, {"link": "https://www.wsj.com/articles/europes-economy-springs-back-to-life-but-shortages-boost-prices-11621590647", "title": "Services Businesses in U.S. and Europe See Pickup", "date": "2021-05-21 12:03", "summary": "U.S. services businesses in early May saw their sharpest increase in activity in more than a decade. U.S. services businesses in early May saw their sharpest increase in activity in more than a decade, according to surveys of purchasing managers released Friday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Services Businesses in U.S. and Europe See Pickup. U.S. services businesses in early May saw their sharpest increase in activity in more than a decade. U.S. services businesses in early May saw their sharpest increase in activity in more than a decade, according to surveys of purchasing managers released Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- ServiceNow, Inc. (NYSE: NOW) will increase because their services business is seeing a pickup in the United States and Europe.\n- Oracle Corporation (NYSE: ORCL) will increase because their services business is seeing a pickup in the United States and Europe.\n- Adobe Inc. (NASDAQ: ADBE) will increase because their services business is seeing a pickup in the United States and Europe.\n- Salesforce.com, inc. (NYSE", "price_info": {"NOW": {"company": "", "ticker": "NOW", "move": "up", "prices": [473.88, 471.73]}, "ORCL": {"company": "", "ticker": "ORCL", "move": "up", "prices": [79.1828, 79.2]}, "ADBE": {"company": "", "ticker": "ADBE", "move": "up", "prices": [488.973, 489.195]}}}, {"link": "https://www.wsj.com/articles/kohls-should-reject-short-sighted-investor-activism-11614706172", "title": "Kohl's Should Reject Short-Sighted Activism", "date": "2021-03-02 12:29", "summary": "Some activist criticisms of the chain are justified, but others seem excessively aimed at the near term. Sometimes, an outside perspective is just the kind of push a company needs to make much-needed changes. In Kohl's case, it risks being a distraction.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Kohl's Should Reject Short-Sighted Activism. Some activist criticisms of the chain are justified, but others seem excessively aimed at the near term. Sometimes, an outside perspective is just the kind of push a company needs to make much-needed changes. In Kohl's case, it risks being a distraction.\"\n\nStock Prediction(s):", "Prediction": "\n- Kohl's Corporation (NYSE: KSS) will increase because they are being pushed to make changes, and an outside perspective could be just what they need.\n- Macy's, Inc. (NYSE: M) will decrease because they are in direct competition with Kohl's, and they may not be able to handle the extra competition.", "price_info": {"KSS": {"company": "", "ticker": "KSS", "move": "up", "prices": [58.7099, 57.625]}, "M": {"company": "", "ticker": "M", "move": "down", "prices": [15.49, 15.43]}}}, {"link": "https://www.wsj.com/articles/apples-october-event-expect-new-macbook-pro-and-airpods-11634566798", "title": "Apple Unveils Redesigned MacBook Pro, New AirPods", "date": "2021-10-18 14:54", "summary": "At 'Unleashed' streamed event, company reveals newest high-end laptops and Apple-designed chips. A pair of MacBook Pro laptops-and a pair of chips-shared center stage at Apple Inc.'s streamed Monday event, which also included the debut of new AirPods.", "categories": [["Tech", "Personal Tech", "Personal Technology: Review"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-wilson-rothman?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Unveils Redesigned MacBook Pro, New AirPods. At 'Unleashed' streamed event, company reveals newest high-end laptops and Apple-designed chips. A pair of MacBook Pro laptops-and a pair of chips-shared center stage at Apple Inc.'s streamed Monday event, which also included the debut of new AirPods.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they have released a new product that is likely to be successful.\n- Intel Corporation (NASDAQ: INTC) will decrease because they are a direct competitor of Apple.\n- Qualcomm Inc. (NASDAQ: QCOM) will decrease because they are a direct competitor of Apple.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [146.7, 146.68]}, "INTC": {"company": "", "ticker": "INTC", "move": "down", "prices": [54.44, 54.515]}, "QCOM": {"company": "", "ticker": "QCOM", "move": "down", "prices": [129.95, 130.23]}}}, {"link": "https://www.wsj.com/articles/u-k-companies-penalized-for-failing-to-pay-suppliers-on-time-11563385671", "title": "U.K. Companies Penalized for Failing to Pay Suppliers on Time", "date": "2019-07-17 13:47", "summary": "Citations come amid proposals to improve British companies' payments culture. A professional body for the credit management industry took action against Prudential PLC, BT Group PLC, British American Tobacco PLC and other British companies for failing to pay suppliers on time.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.K. Companies Penalized for Failing to Pay Suppliers on Time. Citations come amid proposals to improve British companies' payments culture. A professional body for the credit management industry took action against Prudential PLC, BT Group PLC, British American Tobacco PLC and other British companies for failing to pay suppliers on time.\"\n\nStock Prediction(s):", "Prediction": "\n- Prudential plc (NYSE: PRU) will decrease because they were penalized for not paying their suppliers on time.\n- BT Group plc (NYSE: BT) will decrease because they were penalized for not paying their suppliers on time.\n- British American Tobacco plc (NYSE: BTI) will decrease because they were penalized for not paying their suppliers on time.", "price_info": {"PRU": {"company": "", "ticker": "PRU", "move": "down", "prices": [100.3876, 100.18]}, "BT": {"company": "", "ticker": "BT", "move": null, "prices": [12.065, 12.08]}, "BTI": {"company": "", "ticker": "BTI", "move": "down", "prices": [36.3799, 36.48]}}}, {"link": "https://www.wsj.com/articles/citrix-activist-could-clean-up-on-messy-cloud-transition-11631129942", "title": "Citrix Activist Could Clean Up on Messy Cloud Transition", "date": "2021-09-08 15:39", "summary": "Company's disastrous earnings report brings Elliott Management back as software M&A remains strong. It's easy to see why Elliott Management got interested in Citrix again. Perhaps the second time will be the real charm.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Citrix Activist Could Clean Up on Messy Cloud Transition. Company's disastrous earnings report brings Elliott Management back as software M&A remains strong. It's easy to see why Elliott Management got interested in Citrix again. Perhaps the second time will be the real charm.\"\n\nStock Prediction(s):", "Prediction": "\n- Citrix Systems, Inc. (NASDAQ: CTXS) will increase because Elliott Management is back, and they are interested in the company.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are a direct competitor of Citrix, and Elliott Management is interested in them as well.\n- VMware, Inc. (NYSE: VMW) will increase because they are a direct competitor of Citrix, and Elliott Management is interested in them", "price_info": {"VMW": {"company": "", "ticker": "VMW", "move": "up", "prices": [145.73, 145.73]}, "CTXS": {"company": "", "ticker": "CTXS", "move": "up", "prices": [106.59, 106.59]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [300.11, 300]}}}, {"link": "https://www.wsj.com/articles/chrysler-plans-all-electric-vehicle-lineup-by-2028-11641399923", "title": "Chrysler Plans All-Electric Lineup by 2028", "date": "2022-01-05 12:45", "summary": "Storied U.S. brand is latest auto maker to set out ambitious EV targets. Chrysler plans to become an all-electric auto maker by 2028 as parent company Stellantis NV seeks to revive the fortunes of the nearly 100-year-old car brand.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chrysler Plans All-Electric Lineup by 2028. Storied U.S. brand is latest auto maker to set out ambitious EV targets. Chrysler plans to become an all-electric auto maker by 2028 as parent company Stellantis NV seeks to revive the fortunes of the nearly 100-year-old car brand.\"\n\nStock Prediction(s):", "Prediction": "\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will increase because they are investing in electric vehicles, which is the future of the automotive industry.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are the leading electric vehicle manufacturer, and this news will give them a competitive edge.\n- Ford Motor Company (NYSE: F) will decrease because they are not investing in electric vehicles, and they will be left behind in", "price_info": {"FCAU": {"company": "", "ticker": "FCAU", "move": "up"}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [24.6112, 24.4817]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [1136.63, 1125.18]}}}, {"link": "https://www.wsj.com/articles/ways-to-help-pay-for-college-when-money-is-tight-11620320409", "title": "How to Help Pay for College When Money Is Tight", "date": "2021-05-06 13:00", "summary": "After the pandemic lockdowns disrupted many people's finances, it pays for parents and students to consider the options. The pandemic and related lockdowns have taken a toll on some families' finances, forcing many students to rethink how they are going to pay for college.", "categories": [["Markets", "Journal Reports: Funds/ETFs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Help Pay for College When Money Is Tight. After the pandemic lockdowns disrupted many people's finances, it pays for parents and students to consider the options. The pandemic and related lockdowns have taken a toll on some families' finances, forcing many students to rethink how they are going to pay for college.\"\n\nStock Prediction(s):", "Prediction": "\n- The College Board (SAT) will increase because they offer scholarships and financial aid to help students pay for college.\n- The University of Phoenix (NASDAQ: APOL) will increase because they offer scholarships and financial aid to help students pay for college.\n- DeVry Education Group Inc. (NYSE: DV) will increase because they offer scholarships and financial aid to help students pay for college.\n- Bridgepoint Education Inc. (NYSE: BPI)", "price_info": {"SAT": {"company": "College Board", "ticker": "SAT", "move": "up"}, "DV": {"company": "", "ticker": "DV", "move": "up", "prices": [34.4101, 34.25]}, "BPI": {"company": "", "ticker": "BPI", "move": null}, "APOL": {"company": "", "ticker": "APOL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/fed-inching-toward-discussion-of-slowing-bond-purchases-11622835666", "title": "Fed Inching Toward Discussion of Slowing Bond Purchases", "date": "2021-06-04 15:41", "summary": "May jobs report shows progress toward central bank goals, but a formal 'tapering' debate remains a ways off. WASHINGTON-Friday's jobs report keeps the Federal Reserve on track to begin informal internal discussions about reducing the pace of its large bond-buying programs, though a concrete plan for winding down the purchases isn't imminent.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Inching Toward Discussion of Slowing Bond Purchases. May jobs report shows progress toward central bank goals, but a formal 'tapering' debate remains a ways off. WASHINGTON-Friday's jobs report keeps the Federal Reserve on track to begin informal internal discussions about reducing the pace of its large bond-buying programs, though a concrete plan for winding down the purchases isn't imminent.\"\n\nStock Prediction(s):", "Prediction": "\n- The bond market will decrease because the Fed is hinting at tapering its bond purchases.\n- The stock market will increase because the Fed is hinting at tapering its bond purchases.", "price_info": {}}, {"link": "https://www.wsj.com/articles/its-slow-going-but-stuff-like-wheat-and-oil-can-spice-up-your-returns-11574437225", "title": "It's Slow Going, but Stuff Like Wheat and Oil Can Spice Up Your Returns", "date": "2019-11-22 11:07", "summary": "Investing in commodities can pay off. Just don't expect to get rich quick.. The best time to get interested in an investing strategy is when its performance is at its worst. By that standard, commodities are starting to look intriguing.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"It's Slow Going, but Stuff Like Wheat and Oil Can Spice Up Your Returns. Investing in commodities can pay off. Just don't expect to get rich quick.. The best time to get interested in an investing strategy is when its performance is at its worst. By that standard, commodities are starting to look intriguing.\"\n\nStock Prediction(s):", "Prediction": "\n- Archer Daniels Midland Company (NYSE: ADM) will increase because the price of commodities is starting to go up, and they are a major player in the industry.\n- Bunge Limited (NYSE: BG) will increase because the price of commodities is starting to go up, and they are a major player in the industry.\n- Cargill, Incorporated (NYSE: CARG) will increase because the price of commodities is starting to go up,", "price_info": {"ADM": {"company": "", "ticker": "ADM", "move": "up", "prices": [42.64, 42.825]}, "BG": {"company": "", "ticker": "BG", "move": "up", "prices": [54.44, 54.5]}, "CARG": {"company": "", "ticker": "CARG", "move": "up", "prices": [40.2, 39.99]}}}, {"link": "https://www.wsj.com/articles/chinese-regulators-summon-ant-leaders-amid-record-ipo-11604327306", "title": "Chinese Regulators Summon Ant Leaders Ahead of Record IPO", "date": "2020-11-02 12:50", "summary": "Financial technology giant pledges to embrace regulation and promote economic development and stability in China. China's central bank and its securities, banking and foreign-exchange regulators met with billionaire Jack Ma and the top two executives of Ant Group Co. on Monday, just days before the financial technology giant's stock is set to begin trading publicly.", "categories": [["Markets", "Stocks", "IPOs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb", "https://www.wsj.com/news/types/ipos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chinese Regulators Summon Ant Leaders Ahead of Record IPO. Financial technology giant pledges to embrace regulation and promote economic development and stability in China. China's central bank and its securities, banking and foreign-exchange regulators met with billionaire Jack Ma and the top two executives of Ant Group Co. on Monday, just days before the financial technology giant's stock is set to begin trading publicly.\"\n\nStock Prediction(s):", "Prediction": "\n- Alibaba Group Holding Ltd. (NYSE: BABA) will increase because Ant Group Co. is a subsidiary of Alibaba, and they are pledging to embrace regulation.\n- JD.com, Inc. (NASDAQ: JD) will increase because Ant Group Co. is a subsidiary of Alibaba, and they are pledging to embrace regulation.\n- Baidu, Inc. (NASDAQ: BIDU) will increase because Ant Group Co. is a subsidiary of", "price_info": {"BABA": {"company": "", "ticker": "BABA", "move": "up", "prices": [308.14, 308.07]}, "JD": {"company": "", "ticker": "JD", "move": "up", "prices": [80.97, 81.185]}, "BIDU": {"company": "", "ticker": "BIDU", "move": "up", "prices": [134.11, 133.3327]}}}, {"link": "https://www.wsj.com/articles/judge-dismisses-new-mexico-lawsuit-against-google-over-childrens-data-privacy-11601392392", "title": "Judge Dismisses New Mexico Lawsuit Against Google Over Children's Data Privacy", "date": "2020-09-29 11:13", "summary": "Federal judge rules the internet giant didn't violate prohibition on companies from collecting data on children under 13 without parental consent. A federal court dismissed a New Mexico lawsuit alleging that Alphabet Inc.'s Google knowingly spied on students and their families through its suite of cloud-based products for schools.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Judge Dismisses New Mexico Lawsuit Against Google Over Children's Data Privacy. Federal judge rules the internet giant didn't violate prohibition on companies from collecting data on children under 13 without parental consent. A federal court dismissed a New Mexico lawsuit alleging that Alphabet Inc.'s Google knowingly spied on students and their families through its suite of cloud-based products for schools.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because they were just cleared of any wrongdoing in a lawsuit.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are a direct competitor of Alphabet Inc.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1458.6668, 1458.76]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [208.34, 207.6]}}}, {"link": "https://www.wsj.com/articles/equifax-reaches-700-million-settlement-over-data-breach-11563798429", "title": "Equifax to Pay Up to $700 Million in Data Breach Settlement", "date": "2019-07-22 11:00", "summary": "Deal clears cloud that has hung over credit-reporting firm since 2017 hack exposed data of millions of Americans. Equifax Inc. on Monday struck a settlement of up to $700 million to resolve investigations and lawsuits stemming from its 2017 data breach that exposed the personal data of nearly 150 million Americans.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Equifax to Pay Up to $700 Million in Data Breach Settlement. Deal clears cloud that has hung over credit-reporting firm since 2017 hack exposed data of millions of Americans. Equifax Inc. on Monday struck a settlement of up to $700 million to resolve investigations and lawsuits stemming from its 2017 data breach that exposed the personal data of nearly 150 million Americans.\"\n\nStock Prediction(s):", "Prediction": "\n- Equifax Inc. (NYSE: EFX) will increase because they have resolved their investigations and lawsuits, and this will clear the cloud that has been hanging over them.\n- Experian plc (LON: EXPN) will increase because they are a direct competitor of Equifax.\n- TransUnion (NYSE: TRU) will increase because they are a direct competitor of Equifax.", "price_info": {"EFX": {"company": "", "ticker": "EFX", "move": "up", "prices": [137.98, 138.47]}, "TRU": {"company": "", "ticker": "TRU", "move": "up", "prices": [75.35, 75.82]}}}, {"link": "https://www.wsj.com/articles/july-jobs-report-unemployment-claims-2020-11596771828", "title": "Unemployment Rate Fell to 10.2% in July, U.S. Employers Added 1.8 Million Jobs", "date": "2020-08-07 14:40", "summary": "Resume Subscription. Hiring increased in July for the third straight month, though overall gains have yet to restore half of the U.S. jobs lost due to the coronavirus pandemic.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Unemployment Rate Fell to 10.2% in July, U.S. Employers Added 1.8 Million Jobs. Resume Subscription. Hiring increased in July for the third straight month, though overall gains have yet to restore half of the U.S. jobs lost due to the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will continue to decrease because more and more people are getting hired.\n- The stock prices of companies that provide resume subscription services will increase because more people will be looking for jobs.", "price_info": {}}, {"link": "https://www.wsj.com/articles/fatburger-owner-to-acquire-johnny-rockets-11597312801", "title": "Fatburger Owner to Acquire Johnny Rockets for $25 Million", "date": "2020-08-13 10:52", "summary": "Fat Brands says casual-dining demand is recovering from coronavirus pandemic. Fat Brands Inc. is buying burger chain Johnny Rockets Group Inc., expanding its stable of restaurant brands in a bet that casual-dining demand will bounce back from the coronavirus pandemic.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fatburger Owner to Acquire Johnny Rockets for $25 Million. Fat Brands says casual-dining demand is recovering from coronavirus pandemic. Fat Brands Inc. is buying burger chain Johnny Rockets Group Inc., expanding its stable of restaurant brands in a bet that casual-dining demand will bounce back from the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Fat Brands Inc. (NASDAQ: FAT) will increase because they are expanding their business, and the burger industry is recovering from the pandemic.\n- Johnny Rockets Group Inc. (NYSE: JRI) will increase because they are being acquired by Fat Brands, and the burger industry is recovering from the pandemic.", "price_info": {"JRI": {"company": "", "ticker": "JRI", "move": "up", "prices": [12.4825, 12.47]}, "FAT": {"company": "", "ticker": "FAT", "move": "up", "prices": [7.8496, 7.1899]}}}, {"link": "https://www.wsj.com/articles/why-the-oil-market-is-shrugging-at-venezuela-11548351202", "title": "Why the Oil Market Is Shrugging at Venezuela", "date": "2019-01-24 12:33", "summary": "Venezuela's diminished importance to the global oil market has led to an ambivalent price reaction. Venezuela just ain't what it used to be.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why the Oil Market Is Shrugging at Venezuela. Venezuela's diminished importance to the global oil market has led to an ambivalent price reaction. Venezuela just ain't what it used to be.\"\n\nStock Prediction(s):", "Prediction": "\n- The price of oil will not change because Venezuela is no longer a major player in the oil market.", "price_info": {}}, {"link": "https://www.wsj.com/articles/general-atlantic-taps-three-for-roles-near-top-of-firm-11572973200", "title": "General Atlantic Taps Three for Roles Near Top of Firm", "date": "2019-11-05 12:00", "summary": "Levy, Caillaux and Escobari to become co-presidents in succession-planning move. Private-equity firm General Atlantic is promoting three executives to the newly created role of co-president, the latest in a recent spate of firms to lay the groundwork for leadership succession.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"General Atlantic Taps Three for Roles Near Top of Firm. Levy, Caillaux and Escobari to become co-presidents in succession-planning move. Private-equity firm General Atlantic is promoting three executives to the newly created role of co-president, the latest in a recent spate of firms to lay the groundwork for leadership succession.\"\n\nStock Prediction(s):", "Prediction": "\n- General Atlantic LLC (NYSE: GA) will increase because they are preparing for leadership succession.\n- KKR & Co. L.P. (NYSE: KKR) will decrease because they are not preparing for leadership succession.", "price_info": {"GA": {"company": "", "ticker": "GA", "move": "up"}, "KKR": {"company": "", "ticker": "KKR", "move": "down", "prices": [29.4722, 29.475]}}}, {"link": "https://www.wsj.com/articles/netflixs-videogame-gambit-is-taking-shape-as-streaming-competition-grows-11626375983", "title": "Netflix's Videogame Gambit Is Taking Shape", "date": "2021-07-15 15:06", "summary": "The company has hired a Facebook executive to oversee a new unit dedicated to making games. Netflix Inc. co-founder Reed Hastings has often said he sees videogames as the streaming company's biggest competitor for customers.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Netflix's Videogame Gambit Is Taking Shape. The company has hired a Facebook executive to oversee a new unit dedicated to making games. Netflix Inc. co-founder Reed Hastings has often said he sees videogames as the streaming company's biggest competitor for customers.\"\n\nStock Prediction(s):", "Prediction": "\n- Netflix, Inc. (NASDAQ: NFLX) will increase because they are expanding their business into a new market.\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are losing a key executive to a competitor.", "price_info": {"NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [541.645, 542.47]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [344.29, 344.28]}}}, {"link": "https://www.wsj.com/articles/teslas-short-shorts-are-a-bit-like-its-cars-11594134014", "title": "Tesla's Short Shorts Are a Bit Like Its Cars", "date": "2020-07-07 11:00", "summary": "Elon Musk poked some fun at short sellers with an offer that critics can chuckle about too. Where is the fun in running the world's most valuable car company if you can't engage in some juvenile humor?", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla's Short Shorts Are a Bit Like Its Cars. Elon Musk poked some fun at short sellers with an offer that critics can chuckle about too. Where is the fun in running the world's most valuable car company if you can't engage in some juvenile humor?\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (NASDAQ: TSLA) will increase because Elon Musk is poking fun at the short sellers.\n- Ford Motor Company (NYSE: F) will decrease because they are not as juvenile as Tesla.", "price_info": {"F": {"company": "", "ticker": "F", "move": "down", "prices": [6.1464, 6.16]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [1399.11, 1397.7099]}}}, {"link": "https://www.wsj.com/articles/ab-inbev-explores-ipo-for-asia-business-11549298920", "title": "AB InBev Explores IPO for Asia Business", "date": "2019-02-04 14:50", "summary": "Budweiser brewer looks to raise cash and allay fears about its $109 billion debt pile. After years of swallowing up beer brands and loading up on debt, Anheuser-Busch InBev SA is looking to slim down and exploring a stock-market listing of its Asia business.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AB InBev Explores IPO for Asia Business. Budweiser brewer looks to raise cash and allay fears about its $109 billion debt pile. After years of swallowing up beer brands and loading up on debt, Anheuser-Busch InBev SA is looking to slim down and exploring a stock-market listing of its Asia business.\"\n\nStock Prediction(s):", "Prediction": "\n- AB InBev SA (NYSE: BUD) will decrease because they are looking to IPO their Asia business, and this will raise cash that can be used to pay down their debt.\n- Molson Coors Brewing Company (NYSE: TAP) will increase because AB InBev is looking to IPO their Asia business, and this will take away market share from them.", "price_info": {"BUD": {"company": "", "ticker": "BUD", "move": "down", "prices": [77.42, 77.325]}, "TAP": {"company": "", "ticker": "TAP", "move": "up", "prices": [65.89, 65.53]}}}, {"link": "https://www.wsj.com/articles/bidens-oil-moves-draw-from-losing-playbook-11636564507", "title": "Biden's Oil Moves Draw From Losing Playbook", "date": "2021-11-10 12:15", "summary": "An emergency reserve release or crying 'manipulation' are unhelpful reactions to high gasoline prices and might backfire. It might as well be called the Strategic Political Reserve.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biden's Oil Moves Draw From Losing Playbook. An emergency reserve release or crying 'manipulation' are unhelpful reactions to high gasoline prices and might backfire. It might as well be called the Strategic Political Reserve.\"\n\nStock Prediction(s):", "Prediction": "\n- The price of oil will decrease because of the release of the emergency reserve.\n- The price of gasoline will decrease because of the release of the emergency reserve.", "price_info": {}}, {"link": "https://www.wsj.com/articles/wells-fargo-to-tech-vendors-please-send-us-a-check-11564756857", "title": "Wells Fargo to Tech Vendors: Please Send Us a Check", "date": "2019-08-02 10:40", "summary": "The bank, trying to cut costs, says tech vendors benefited from its regulatory problems. Wells Fargo & Co., in cost-cutting mode, recently asked outside technology consultants to refund some of the money the bank has spent with them in the past year.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wells Fargo to Tech Vendors: Please Send Us a Check. The bank, trying to cut costs, says tech vendors benefited from its regulatory problems. Wells Fargo & Co., in cost-cutting mode, recently asked outside technology consultants to refund some of the money the bank has spent with them in the past year.\"\n\nStock Prediction(s):", "Prediction": "\n- Oracle Corporation (NYSE: ORCL) will increase because Wells Fargo is a major customer, and they may be looking to shift their business to Oracle.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because Wells Fargo is a major customer, and they may be looking to shift their business to Microsoft.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because Wells Fargo is a major customer, and they may be looking", "price_info": {"ORCL": {"company": "", "ticker": "ORCL", "move": "up", "prices": [55.46, 55.64]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [135.655, 135.7]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1812.13, 1813.6801]}}}, {"link": "https://www.wsj.com/articles/love-grandma-how-grandparents-can-help-pay-for-college-11548960033", "title": "Love, Grandma: How Grandparents Can Help Pay for College", "date": "2019-01-31 13:40", "summary": "When grandparents own the '529,' there can be advantages. But don't run afoul of rules for aid consideration.. Readers wrote to us with questions about saving for college and tax-advantaged \"529\" accounts. We asked experts to help us answer them.", "categories": [["Markets", "Journal Reports: Funds/ETFs", "Saving for College"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Love, Grandma: How Grandparents Can Help Pay for College. When grandparents own the '529,' there can be advantages. But don't run afoul of rules for aid consideration.. Readers wrote to us with questions about saving for college and tax-advantaged \"529\" accounts. We asked experts to help us answer them.\"\n\nStock Prediction(s):", "Prediction": "\n- Grandparents who own a 529 account for their grandchildren will see an increase in their stock prices as they save for college.\n- Other stocks that will benefit from this news are those that offer college savings plans, such as Fidelity, Vanguard, and T. Rowe Price.", "price_info": {}}, {"link": "https://www.wsj.com/articles/johnson-johnson-to-pay-117-million-over-surgical-device-marketing-11571334613", "title": "J&J to Pay $117 Million Over Surgical Device Marketing", "date": "2019-10-17 15:18", "summary": "Multistate settlement follows allegations the company misled patients, health care providers about transvaginal mesh products. Johnson & Johnson and its subsidiary Ethicon Inc. have reached a settlement of about $116.9 million with 41 states and the District of Columbia for allegedly misleading marketing of transvaginal surgical-mesh devices.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"J&J to Pay $117 Million Over Surgical Device Marketing. Multistate settlement follows allegations the company misled patients, health care providers about transvaginal mesh products. Johnson & Johnson and its subsidiary Ethicon Inc. have reached a settlement of about $116.9 million with 41 states and the District of Columbia for allegedly misleading marketing of transvaginal surgical-mesh devices.\"\n\nStock Prediction(s):", "Prediction": "\n- Johnson & Johnson (NYSE: JNJ) will decrease because they have to pay $117 million to states for allegedly misleading marketing of surgical-mesh devices.", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [136.17, 135.9]}}}, {"link": "https://www.wsj.com/articles/starbucks-steps-up-cafe-cleaning-due-to-coronavirus-outbreak-11583341054", "title": "Starbucks Steps Up Cafe Cleaning Due to Coronavirus Outbreak", "date": "2020-03-04 15:46", "summary": "Restaurant chains in U.S., with traffic already stagnant, are adjusting operations as virus gains ground. Starbucks Corp. has instructed employees to step up cleaning at its thousands of U.S. cafes, as a domestic restaurant industry already working against stagnant demand reacts to a new threat to sales and public health.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Starbucks Steps Up Cafe Cleaning Due to Coronavirus Outbreak. Restaurant chains in U.S., with traffic already stagnant, are adjusting operations as virus gains ground. Starbucks Corp. has instructed employees to step up cleaning at its thousands of U.S. cafes, as a domestic restaurant industry already working against stagnant demand reacts to a new threat to sales and public health.\"\n\nStock Prediction(s):", "Prediction": "\n- Starbucks Corporation (NASDAQ: SBUX) will decrease because of the increased cleaning measures that are being put into place.\n- Dunkin' Brands Group, Inc. (NASDAQ: DNKN) will decrease because of the increased cleaning measures that are being put into place.\n- Yum! Brands, Inc. (NYSE: YUM) will decrease because of the increased cleaning measures that are being put into place.", "price_info": {"YUM": {"company": "", "ticker": "YUM", "move": "down", "prices": [94.59, 94.62]}, "SBUX": {"company": "", "ticker": "SBUX", "move": "down", "prices": [79.6117, 79.64]}, "DNKN": {"company": "", "ticker": "DNKN", "move": "down", "prices": [69.72, 69.75]}}}, {"link": "https://www.wsj.com/articles/the-story-behind-the-markets-hottest-funds-thematic-etfs-arkg-vegn-11610722419", "title": "The Story Behind the Market's Hottest Funds", "date": "2021-01-15 10:00", "summary": "Thematic ETFs allow investors to bet on trends and concepts-but their narrow focus increases their risk. Investors used to love \"story stocks.\" Now they love story ETFs.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Story Behind the Market's Hottest Funds. Thematic ETFs allow investors to bet on trends and concepts-but their narrow focus increases their risk. Investors used to love \"story stocks.\" Now they love story ETFs.\"\n\nStock Prediction(s):", "Prediction": "\n- Thematic ETFs will continue to be popular because they allow investors to bet on trends and concepts.\n- Thematic ETFs will be more popular than traditional ETFs because they offer more diversification.\n- Thematic ETFs will be more volatile than traditional ETFs because they are more focused.", "price_info": {}}, {"link": "https://www.wsj.com/articles/apple-taps-greg-joswiak-as-marketing-chief-11596563771", "title": "Phil Schiller, Friend of Steve Jobs Who Helped Remake Apple, to Be 'Apple Fellow'", "date": "2020-08-04 15:41", "summary": "Apple executive to step aside as marketing chief. Phil Schiller, a close friend of Steve Jobs who helped remake Apple Inc. from a struggling computer maker into the world's largest company, is stepping aside as the tech company's head of marketing and will become an \"Apple Fellow.\"", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Phil Schiller, Friend of Steve Jobs Who Helped Remake Apple, to Be 'Apple Fellow'. Apple executive to step aside as marketing chief. Phil Schiller, a close friend of Steve Jobs who helped remake Apple Inc. from a struggling computer maker into the world's largest company, is stepping aside as the tech company's head of marketing and will become an \"Apple Fellow.\"\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because Phil Schiller is moving to a new position within the company and has a lot of experience with marketing.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a direct competitor of Apple and Phil Schiller's departure could give them an edge in the market.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [438.66, 438.6]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3134.2, 3131.54]}}}, {"link": "https://www.wsj.com/articles/exxon-chevron-tie-up-not-as-crazy-as-it-sounds-11612201759", "title": "Exxon-Chevron Tie-Up Not as Crazy as It Sounds", "date": "2021-02-01 14:28", "summary": "The oil megamergers that started in the late 1990s were preceded by circumstances similar to today's. Today's tech stock exuberance is a flashback to the 1990s. Now oil investors are experiencing their own d\u00e9j\u00e0 vu.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Exxon-Chevron Tie-Up Not as Crazy as It Sounds. The oil megamergers that started in the late 1990s were preceded by circumstances similar to today's. Today's tech stock exuberance is a flashback to the 1990s. Now oil investors are experiencing their own d\u00e9j\u00e0 vu.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because they are in a good position to merge with Exxon Mobil Corporation (NYSE: XOM) and create a stronger company.\n- Exxon Mobil Corporation will increase because they are in a good position to merge with Chevron Corporation and create a stronger company.\n- BP plc (NYSE: BP) will decrease because they are not in a good position to merge with anyone and will lose market share.\n- Royal Dutch", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [86.63, 86.595]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [45.035, 44.915]}, "BP": {"company": "", "ticker": "BP", "move": "down", "prices": [22.145, 22.15]}}}, {"link": "https://www.wsj.com/articles/oil-prices-to-slide-despite-opec-cuts-banks-predict-11577112085", "title": "Oil to Slide Despite OPEC Cuts, Banks Predict", "date": "2019-12-23 15:09", "summary": "WSJ poll shows December gains aren't expected to last. Oil prices are likely to shed the gains that followed OPEC's decision to deepen output cuts as a global glut of crude continues to weigh on the market, investment banks predict.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil to Slide Despite OPEC Cuts, Banks Predict. WSJ poll shows December gains aren't expected to last. Oil prices are likely to shed the gains that followed OPEC's decision to deepen output cuts as a global glut of crude continues to weigh on the market, investment banks predict.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because oil prices are going to slide and they are a direct competitor of other oil companies.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because oil prices are going to slide and they are a direct competitor of other oil companies.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because oil prices are going to slide and they are a direct competitor of other oil companies.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [120.22, 120.31]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [70.08, 70.24]}}}, {"link": "https://www.wsj.com/articles/u-s-new-home-sales-fell-in-april-11558620316", "title": "U.S. New-Home Sales Fell in April", "date": "2019-05-23 12:13", "summary": "Sales declined in all regions but the Northeast, with purchases in the Midwest and West notching the biggest monthly drops since December 2018. WASHINGTON-New-home sales in the U.S. declined in April, posting the largest monthly drop since the end of last year, but there are signs the market for new homes is brightening.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. New-Home Sales Fell in April. Sales declined in all regions but the Northeast, with purchases in the Midwest and West notching the biggest monthly drops since December 2018. WASHINGTON-New-home sales in the U.S. declined in April, posting the largest monthly drop since the end of last year, but there are signs the market for new homes is brightening.\"\n\nStock Prediction(s):", "Prediction": "\n- Toll Brothers Inc (NYSE: TOL) will increase because the housing market is recovering, and they are a major player in the market.\n- KB Home (NYSE: KBH) will increase because the housing market is recovering, and they are a major player in the market.\n- Lennar Corporation (NYSE: LEN) will increase because the housing market is recovering, and they are a major player in the market.\n- PulteGroup,", "price_info": {"TOL": {"company": "", "ticker": "TOL", "move": "up", "prices": [35.7, 35.54]}, "KBH": {"company": "", "ticker": "KBH", "move": "up", "prices": [26.52, 26.345]}, "LEN": {"company": "", "ticker": "LEN", "move": "up", "prices": [51.44, 51.0499]}}}, {"link": "https://www.wsj.com/articles/occidental-chief-defends-anadarko-deal-to-shareholders-11557513040", "title": "Occidental Chief Defends Anadarko Deal to Shareholders", "date": "2019-05-10 14:30", "summary": "In sign of dissent, Occidental board sees lowest vote totals in years. Occidental Petroleum Corp. Chief Executive Vicki Hollub defended her aggressive and ultimately successful pursuit of Anadarko Petroleum Corp. in her first public remarks to investors after striking the $38 billion deal.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Occidental Chief Defends Anadarko Deal to Shareholders. In sign of dissent, Occidental board sees lowest vote totals in years. Occidental Petroleum Corp. Chief Executive Vicki Hollub defended her aggressive and ultimately successful pursuit of Anadarko Petroleum Corp. in her first public remarks to investors after striking the $38 billion deal.\"\n\nStock Prediction(s):", "Prediction": "\n- Occidental Petroleum Corp. (NYSE: OXY) will increase because their CEO was able to defend the acquisition to shareholders.\n- Anadarko Petroleum Corp. (NYSE: APC) will decrease because they were acquired by Occidental Petroleum.", "price_info": {"OXY": {"company": "", "ticker": "OXY", "move": "up", "prices": [55.01, 55.24]}, "APC": {"company": "", "ticker": "APC", "move": "down", "prices": [73.15, 73.06]}}}, {"link": "https://www.wsj.com/articles/u-s-trade-deficit-widened-in-july-11599137582", "title": "U.S. Trade Deficit Widest Since 2008 in July as Imports Outpaced Exports", "date": "2020-09-03 10:31", "summary": "Foreign-trade gap in goods and services expanded 19% from June, with monthly goods deficit at widest level on record. WASHINGTON-The U.S. trade deficit widened in July as Americans' appetite for foreign-made goods bounced back while exports rose more modestly.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Trade Deficit Widest Since 2008 in July as Imports Outpaced Exports. Foreign-trade gap in goods and services expanded 19% from June, with monthly goods deficit at widest level on record. WASHINGTON-The U.S. trade deficit widened in July as Americans' appetite for foreign-made goods bounced back while exports rose more modestly.\"\n\nStock Prediction(s):", "Prediction": "\n- The United States Trade Deficit will continue to increase because the import of goods is outpacing the export of goods.\n- The United States Trade Deficit will have a negative effect on the stock market because it means that the United States is importing more than it is exporting, and this will have a negative effect on the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/swine-fever-resurgence-damps-hopes-for-u-s-soybean-farmers-11615892400", "title": "Swine Fever Resurgence Damps Hopes for U.S. Soybean Farmers", "date": "2021-03-16 12:05", "summary": "New cases of African swine fever reported in China may dent demand for U.S. agricultural exports. A resurgence of a lethal pig disease is putting new strain on China's efforts to rebuild its herds-a threat to U.S. farmers' hopes to sell more soybeans there this year.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Swine Fever Resurgence Damps Hopes for U.S. Soybean Farmers. New cases of African swine fever reported in China may dent demand for U.S. agricultural exports. A resurgence of a lethal pig disease is putting new strain on China's efforts to rebuild its herds-a threat to U.S. farmers' hopes to sell more soybeans there this year.\"\n\nStock Prediction(s):", "Prediction": "\n- Archer Daniels Midland Company (NYSE: ADM) will decrease because they are a competitor of U.S. soybean farmers.\n- Bunge Limited (NYSE: BG) will decrease because they are a competitor of U.S. soybean farmers.\n- Cargill, Incorporated (NYSE: CARG) will decrease because they are a competitor of U.S. soybean farmers.", "price_info": {"ADM": {"company": "", "ticker": "ADM", "move": "down", "prices": [57.8, 57.81]}, "BG": {"company": "", "ticker": "BG", "move": "down", "prices": [79.45, 79.18]}, "CARG": {"company": "", "ticker": "CARG", "move": "down", "prices": [25.47, 25.4076]}}}, {"link": "https://www.wsj.com/articles/mcdonalds-to-pay-26-million-to-settle-wage-suit-11574690422", "title": "McDonald's to Pay $26 Million in Wage Suit", "date": "2019-11-25 13:37", "summary": "Class-action lawsuit from 2013 involved claims made by restaurant workers in California. McDonald's Corp. agreed to pay $26 million to settle a long-running labor dispute over allegations that the fast-food giant underpaid staff in certain California restaurants.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"McDonald's to Pay $26 Million in Wage Suit. Class-action lawsuit from 2013 involved claims made by restaurant workers in California. McDonald's Corp. agreed to pay $26 million to settle a long-running labor dispute over allegations that the fast-food giant underpaid staff in certain California restaurants.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corp. (NYSE: MCD) will increase because they have agreed to pay $26 million to settle a wage suit.\n- Yum! Brands, Inc. (NYSE: YUM) will decrease because they are a direct competitor of McDonald's.", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "up", "prices": [191.74, 191.87]}, "YUM": {"company": "", "ticker": "YUM", "move": "down", "prices": [98.04, 97.98]}}}, {"link": "https://www.wsj.com/articles/us-economy-may-2021-retail-sales-11623701250", "title": "Retail Sales Drop as Spending Habits Shift", "date": "2021-06-15 12:24", "summary": "Consumers trimmed purchases of big-ticket items and spent more on dining out. Retail sales dropped in May, marking a shift in consumer spending from big-ticket items to goods and services related to going out amid business reopenings and higher vaccination rates.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Retail Sales Drop as Spending Habits Shift. Consumers trimmed purchases of big-ticket items and spent more on dining out. Retail sales dropped in May, marking a shift in consumer spending from big-ticket items to goods and services related to going out amid business reopenings and higher vaccination rates.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will decrease because their main product is big-ticket items, and people are now spending their money on dining out.\n- McDonald's Corporation (NYSE: MCD) will increase because their main product is dining out, and people are now spending their money on dining out.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [140.0456, 139.9488]}, "MCD": {"company": "", "ticker": "MCD", "move": "up", "prices": [236, 236.0806]}}}, {"link": "https://www.wsj.com/articles/martin-sorrell-s4-wpp-comeback-11643734528", "title": "Martin Sorrell's Comeback Plan: Take Down WPP and Other Giants", "date": "2022-02-01 11:59", "summary": "The fallen ad chief is taking potshots at the giant he built over three decades, before quitting under pressure.. LONDON-Martin Sorrell built WPP PLC into the world's largest advertising agency over three decades through a combination of impatience, drive and the occasional angry outburst.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Martin Sorrell's Comeback Plan: Take Down WPP and Other Giants. The fallen ad chief is taking potshots at the giant he built over three decades, before quitting under pressure.. LONDON-Martin Sorrell built WPP PLC into the world's largest advertising agency over three decades through a combination of impatience, drive and the occasional angry outburst.\"\n\nStock Prediction(s):", "Prediction": "\n- WPP plc (NASDAQ: WPP) will decrease because Martin Sorrell is no longer with the company and is taking potshots at it.\n- Omnicom Group Inc. (NYSE: OMC) will decrease because Martin Sorrell is no longer with the company and is taking potshots at it.\n- Publicis Groupe SA (EPA: PUB) will decrease because Martin Sorrell is no longer with the company and is taking", "price_info": {"OMC": {"company": "", "ticker": "OMC", "move": "down", "prices": [75.87, 75.6487]}, "WPP": {"company": "", "ticker": "WPP", "move": "down", "prices": [78.5, 78.315]}}}, {"link": "https://www.wsj.com/articles/facebook-to-counter-apple-privacy-update-with-its-own-prompt-11612191604", "title": "Facebook to Counter Apple Privacy Update With Its Own Prompt", "date": "2021-02-01 11:17", "summary": "Social-media company plans to show users a screen describing how it uses their data to personalize ads. Facebook Inc. plans to roll out an in-app prompt aimed at educating users about the handling of their data as it battles Apple Inc. over the iPhone maker's new privacy changes that would require users' consent to track their behavior and make targeted ads more difficult.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook to Counter Apple Privacy Update With Its Own Prompt. Social-media company plans to show users a screen describing how it uses their data to personalize ads. Facebook Inc. plans to roll out an in-app prompt aimed at educating users about the handling of their data as it battles Apple Inc. over the iPhone maker's new privacy changes that would require users' consent to track their behavior and make targeted ads more difficult.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because they are fighting back against Apple's privacy changes.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are being forced to get user consent for tracking, which will make targeted ads more difficult.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "up", "prices": [257.345, 261.55]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [133.45, 134.6515]}}}, {"link": "https://www.wsj.com/articles/drug-distributors-look-vulnerable-without-finality-11574880378", "title": "Drug Distributors Look Vulnerable Without Finality", "date": "2019-11-27 13:46", "summary": "Investor hopes for a global opioid settlement with drug companies are premature. Word of a fresh federal investigation is the latest sign that drug distributors haven't resolved their legal problems stemming from the opioid crisis. Investors should reassess whether their buoyant stock prices reflect that uncertain reality.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Drug Distributors Look Vulnerable Without Finality. Investor hopes for a global opioid settlement with drug companies are premature. Word of a fresh federal investigation is the latest sign that drug distributors haven't resolved their legal problems stemming from the opioid crisis. Investors should reassess whether their buoyant stock prices reflect that uncertain reality.\"\n\nStock Prediction(s):", "Prediction": "\n- McKesson Corporation (NYSE: MCK) will decrease because of the new federal investigation into their role in the opioid crisis.\n- Cardinal Health, Inc. (NYSE: CAH) will decrease because of the new federal investigation into their role in the opioid crisis.\n- AmerisourceBergen Corporation (NYSE: ABC) will decrease because of the new federal investigation into their role in the opioid crisis.", "price_info": {"MCK": {"company": "", "ticker": "MCK", "move": "down", "prices": [145.82, 146.085]}, "CAH": {"company": "", "ticker": "CAH", "move": "down", "prices": [54.92, 55.05]}, "ABC": {"company": "", "ticker": "ABC", "move": "down", "prices": [87.96, 88.07]}}}, {"link": "https://www.wsj.com/articles/weekly-jobless-claims-09-02-2021-11630527461", "title": "Jobless Claims Edge Down to Pandemic Low", "date": "2021-09-02 10:05", "summary": "Businesses have kept layoffs in check despite concerns about Delta variant of Covid-19. Jobless claims fell to a new pandemic low as businesses held on to workers despite the surging Delta variant.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jobless Claims Edge Down to Pandemic Low. Businesses have kept layoffs in check despite concerns about Delta variant of Covid-19. Jobless claims fell to a new pandemic low as businesses held on to workers despite the surging Delta variant.\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Airlines (NYSE: DAL) will increase because the Covid-19 pandemic is causing less layoffs than expected.\n- American Airlines (NASDAQ: AAL) will increase because the Covid-19 pandemic is causing less layoffs than expected.\n- United Airlines (NYSE: UAL) will increase because the Covid-19 pandemic is causing less layoffs than expected.\n- Boeing (NYSE: BA) will increase because the Covid", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [40.815, 40.95]}, "UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [47.055, 47.365]}, "BA": {"company": "", "ticker": "BA", "move": "up", "prices": [220.9935, 223.076]}, "AAL": {"company": "", "ticker": "AAL", "move": "up", "prices": [19.844, 19.9187]}}}, {"link": "https://www.wsj.com/articles/a-new-low-cost-revolution-in-air-travel-11556888401", "title": "Flying to Europe in Business Class Is About to Get a Whole Lot Cheaper", "date": "2019-05-03 09:53", "summary": "JetBlue's flights to London will test whether medium-haul routes can be budget airlines' next growth hope. Flying across the Atlantic in a luxury cabin may be about to become much cheaper for business travelers. It could even set the stage for a new air revolution-or so many in the aviation industry are betting.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Flying to Europe in Business Class Is About to Get a Whole Lot Cheaper. JetBlue's flights to London will test whether medium-haul routes can be budget airlines' next growth hope. Flying across the Atlantic in a luxury cabin may be about to become much cheaper for business travelers. It could even set the stage for a new air revolution-or so many in the aviation industry are betting.\"\n\nStock Prediction(s):", "Prediction": "\n- JetBlue Airways Corporation (NASDAQ: JBLU) will increase because they are offering cheaper flights to Europe.\n- American Airlines Group Inc (NASDAQ: AAL) will decrease because they are a direct competitor of JetBlue.\n- Delta Air Lines, Inc. (NYSE: DAL) will decrease because they are a direct competitor of JetBlue.", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [57.525, 57.835]}, "JBLU": {"company": "", "ticker": "JBLU", "move": "up", "prices": [18.675, 18.75]}, "AAL": {"company": "", "ticker": "AAL", "move": "down", "prices": [34.42, 34.647]}}}, {"link": "https://www.wsj.com/articles/bank-of-mexico-cuts-2019-economic-growth-estimate-11559148797", "title": "Bank of Mexico Cuts 2019 Economic Growth Estimate", "date": "2019-05-29 12:53", "summary": "Central bank expects lower GDP growth of between 0.8% and 1.8%. MEXICO CITY-Bank of Mexico lowered its economic growth forecast for this year after output of goods and services contracted in the first quarter, and said it would take longer than expected for inflation to return to its 3% target.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bank of Mexico Cuts 2019 Economic Growth Estimate. Central bank expects lower GDP growth of between 0.8% and 1.8%. MEXICO CITY-Bank of Mexico lowered its economic growth forecast for this year after output of goods and services contracted in the first quarter, and said it would take longer than expected for inflation to return to its 3% target.\"\n\nStock Prediction(s):", "Prediction": "\n- Banco de Mexico (BMV: BMA) will decrease because their economic growth is lower than expected.\n- Grupo Financiero Banorte (OTCPK: GFNORTEO) will decrease because their economic growth is lower than expected.\n- Walmart de Mexico SAB (NYSE: WMMVY) will decrease because their economic growth is lower than expected.", "price_info": {"WMMVY": {"company": "", "ticker": "WMMVY", "move": "down"}}}, {"link": "https://www.wsj.com/articles/smartphone-coronavirus-test-apps-would-listen-to-your-cough-11587055803", "title": "Smartphone Coronavirus Test? Apps Would Listen to Your Cough", "date": "2020-04-16 12:50", "summary": "Researchers aim to use AI to judge people's coughs; critics say such screenings could be misleading and unreliable. Smartphones already know a lot about us, but now some researchers are betting the devices can also be trained to detect whether we are infected with the new coronavirus-just by listening.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Smartphone Coronavirus Test? Apps Would Listen to Your Cough. Researchers aim to use AI to judge people's coughs; critics say such screenings could be misleading and unreliable. Smartphones already know a lot about us, but now some researchers are betting the devices can also be trained to detect whether we are infected with the new coronavirus-just by listening.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they have a lot of money to invest in this technology, and they are already a leader in the smartphone market.\n- Google Inc. (NASDAQ: GOOGL) will increase because they have a lot of money to invest in this technology, and they are already a leader in the smartphone market.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they have a lot of", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [284.57, 284.43]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1247.2431, 1239]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [174.7837, 175.24]}}}, {"link": "https://www.wsj.com/articles/where-to-check-up-on-the-health-of-your-pension-plan-11591278517", "title": "Where to Check Up on the Health of Your Pension Plan", "date": "2020-06-04 09:48", "summary": "Also: Answering a reader's question on Social Security benefits. I will be eligible for a pension when I retire, but the markets and the Covid-19 outbreak have me worried about the health of my retirement plan. How can I figure out where my pension stands?", "categories": [["Markets", "Journal Reports: Funds/ETFs", "Ask Encore"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Where to Check Up on the Health of Your Pension Plan. Also: Answering a reader's question on Social Security benefits. I will be eligible for a pension when I retire, but the markets and the Covid-19 outbreak have me worried about the health of my retirement plan. How can I figure out where my pension stands?\"\n\nStock Prediction(s):", "Prediction": "\n- Prudential Financial, Inc. (NYSE: PRU) will increase because they offer a variety of retirement services, and their stock price has been decreasing recently.\n- Voya Financial, Inc. (NYSE: VOYA) will increase because they offer a variety of retirement services, and their stock price has been decreasing recently.\n- The Charles Schwab Corporation (NYSE: SCHW) will increase because they offer a variety of retirement services, and their", "price_info": {"PRU": {"company": "", "ticker": "PRU", "move": "up", "prices": [65.1, 64.84]}, "VOYA": {"company": "", "ticker": "VOYA", "move": "up", "prices": [49.06, 48.8618]}, "SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [40.52, 40.225]}}}, {"link": "https://www.wsj.com/articles/warner-boss-doesnt-see-omicron-slowing-down-production-of-shows-this-year-11641414611", "title": "Warner Boss Doesn't See Omicron Slowing Down Production of Shows", "date": "2022-01-05 15:30", "summary": "'This won't be a situation like we saw in 2020,' WarnerMedia CEO Jason Kilar says. WarnerMedia Chief Executive Jason Kilar doesn't expect the fast spread of the Omicron variant of the coronavirus to slow production of television shows and movies in 2022.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Warner Boss Doesn't See Omicron Slowing Down Production of Shows. 'This won't be a situation like we saw in 2020,' WarnerMedia CEO Jason Kilar says. WarnerMedia Chief Executive Jason Kilar doesn't expect the fast spread of the Omicron variant of the coronavirus to slow production of television shows and movies in 2022.\"\n\nStock Prediction(s):", "Prediction": "\n- WarnerMedia (NYSE: TWX) will increase because their CEO doesn't see the virus slowing down production.\n- Disney (NYSE: DIS) will decrease because their CEO has already said that the virus will slow production.", "price_info": {"TWX": {"company": "", "ticker": "TWX", "move": "down"}, "DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [156.0618, 155.22]}}}, {"link": "https://www.wsj.com/articles/net-worth-of-u-s-households-fell-in-first-quarter-11591891644", "title": "Net Worth of U.S. Households Dived in First Quarter", "date": "2020-06-11 15:20", "summary": "Fed report ties most of decline to plunging values of equities; early impact of pandemic is shown. WASHINGTON-The net worth of U.S. households saw a record decline in the first three months of this year as the coronavirus pandemic sent shock waves through the economy and caused equity prices to plummet.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Net Worth of U.S. Households Dived in First Quarter. Fed report ties most of decline to plunging values of equities; early impact of pandemic is shown. WASHINGTON-The net worth of U.S. households saw a record decline in the first three months of this year as the coronavirus pandemic sent shock waves through the economy and caused equity prices to plummet.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will continue to decline because the first quarter results show the early impact of the pandemic.\n- Bank of America Corporation (NYSE: BAC) will continue to decline because they are one of the largest holders of equities.\n- JPMorgan Chase & Co. (NYSE: JPM) will continue to decline because they are one of the largest holders of equities.\n- Goldman Sachs Group, Inc. (NYSE: GS) will continue to decline because", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [24.09, 24.11]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [97.74, 97.7]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [195.16, 194.88]}}}, {"link": "https://www.wsj.com/articles/fed-adds-51-15-billion-in-temporary-liquidity-11578063663", "title": "Fed Adds $51.15 Billion in Temporary Liquidity", "date": "2020-01-03 10:01", "summary": "Central bank's balance sheet rises to $4.17 trillion. The Federal Reserve Bank of New York added $51.15 billion in temporary money to financial markets Friday.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Adds $51.15 Billion in Temporary Liquidity. Central bank's balance sheet rises to $4.17 trillion. The Federal Reserve Bank of New York added $51.15 billion in temporary money to financial markets Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed's balance sheet will continue to grow as they add more liquidity to the market.\n- The market will react positively to this news as it shows that the Fed is taking action to help the economy.\n- Bank of America (NYSE: BAC) will increase because they are a direct beneficiary of the Fed's actions.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are a direct beneficiary of the Fed's actions.\n", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [34.825, 35.025]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [137.77, 138.51]}}}, {"link": "https://www.wsj.com/articles/a-familys-health-insurance-cost-more-than-22-000-in-2021-survey-finds-11636567200", "title": "Family Health Insurance Cost More Than $22,000 in 2021, Survey Finds", "date": "2021-11-10 13:00", "summary": "Covid-19 pandemic appeared to have little impact on cost, but companies expanded mental-health and telemedicine benefits. The average cost of employer health coverage for a family plan passed $22,000 this year, according to a new survey, rising at a rate that indicates the Covid-19 pandemic had little impact on the total expense.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Family Health Insurance Cost More Than $22,000 in 2021, Survey Finds. Covid-19 pandemic appeared to have little impact on cost, but companies expanded mental-health and telemedicine benefits. The average cost of employer health coverage for a family plan passed $22,000 this year, according to a new survey, rising at a rate that indicates the Covid-19 pandemic had little impact on the total expense.\"\n\nStock Prediction(s):", "Prediction": "\n- UnitedHealth Group Inc (NYSE: UNH) will increase because their health insurance is more expensive, and they are expanding their mental-health and telemedicine benefits.\n- Anthem Inc (NYSE: ANTM) will increase because their health insurance is more expensive, and they are expanding their mental-health and telemedicine benefits.\n- Aetna Inc (NYSE: AET) will increase because their health insurance is more expensive, and they", "price_info": {"UNH": {"company": "", "ticker": "UNH", "move": "up", "prices": [458.43, 458.33]}, "ANTM": {"company": "", "ticker": "ANTM", "move": "up", "prices": [426.175, 425.78]}, "AET": {"company": "", "ticker": "AET", "move": "up"}}}, {"link": "https://www.wsj.com/articles/boeing-lines-up-funding-options-11580503019", "title": "Boeing Lines Up Funding Options", "date": "2020-01-31 15:37", "summary": "Amid MAX crisis, company arranges $12 billion bank loan. Boeing Co. has lined up at least $12 billion in bank loans and may tap the commercial paper market to counter the cash drain from the 737 MAX crisis.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Lines Up Funding Options. Amid MAX crisis, company arranges $12 billion bank loan. Boeing Co. has lined up at least $12 billion in bank loans and may tap the commercial paper market to counter the cash drain from the 737 MAX crisis.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will increase because they have arranged $12 billion in bank loans.\n- Airbus SE (OTCMKTS: EADSY) will decrease because they are a direct competitor of Boeing.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [317.1763, 318.59]}}}, {"link": "https://www.wsj.com/articles/new-alnylam-pharmaceuticals-cfo-faces-competition-challenge-with-pfizer-11562872378", "title": "New Alnylam Pharmaceuticals CFO Faces Competition Challenge With Pfizer", "date": "2019-07-11 15:12", "summary": "The biopharmaceuticals company on Thursday named a former Shire-executive to become its next finance chief. Alnylam Pharmaceuticals Inc. named a new finance chief, a move that comes as the biopharmaceutical company faces new competition from drug giant Pfizer Inc.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"New Alnylam Pharmaceuticals CFO Faces Competition Challenge With Pfizer. The biopharmaceuticals company on Thursday named a former Shire-executive to become its next finance chief. Alnylam Pharmaceuticals Inc. named a new finance chief, a move that comes as the biopharmaceutical company faces new competition from drug giant Pfizer Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) will decrease because they are facing competition from Pfizer.\n- Pfizer Inc. (NYSE: PFE) will increase because they are a direct competitor of Alnylam Pharmaceuticals.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "up", "prices": [42.87, 42.98]}, "ALNY": {"company": "", "ticker": "ALNY", "move": "down"}}}, {"link": "https://www.wsj.com/articles/no-end-in-sight-for-big-oils-write-downs-11593529650", "title": "No End in Sight for Big Oil's Write-Downs", "date": "2020-06-30 11:07", "summary": "Stocks like Shell and BP are cheap because investors have to shoulder more risk for lower returns. Asset write-downs keep coming from the world's largest oil-and-gas companies. They are not cash expenses, but they do underline how the risks and rewards of investing in the supermajors have deteriorated.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"No End in Sight for Big Oil's Write-Downs. Stocks like Shell and BP are cheap because investors have to shoulder more risk for lower returns. Asset write-downs keep coming from the world's largest oil-and-gas companies. They are not cash expenses, but they do underline how the risks and rewards of investing in the supermajors have deteriorated.\"\n\nStock Prediction(s):", "Prediction": "\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because their stock is cheap because of the write-downs, and the risks and rewards of investing in them have deteriorated.\n- BP plc (NYSE: BP) will decrease because their stock is cheap because of the write-downs, and the risks and rewards of investing in them have deteriorated.", "price_info": {"BP": {"company": "", "ticker": "BP", "move": "down", "prices": [23.08, 23]}}}, {"link": "https://www.wsj.com/articles/canada-house-sales-fell-in-december-amid-froth-worries-11579104232", "title": "Canada House Sales Fell in December Amid Froth Worries", "date": "2020-01-15 11:09", "summary": "Decline ended nine-month streak that fueled rebound in sales and prices. ", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Canada House Sales Fell in December Amid Froth Worries. Decline ended nine-month streak that fueled rebound in sales and prices. \"\n\nStock Prediction(s):", "Prediction": "\n- Canadian Real Estate Investment Trusts (REITs) (TSE: REF.UN) will decrease because the housing market is cooling off.\n- Home Capital Group Inc. (TSE: HCG) will decrease because of the decrease in house sales.\n- Brookfield Asset Management Inc. (TSE: BAM.A) will increase because they are a major player in the Canadian real estate market.", "price_info": {}}, {"link": "https://www.wsj.com/articles/breaking-news-apollo-makes-bid-for-tennecos-powertrain-unit-sources-11575998488", "title": "Apollo Made Bid for Tenneco's Powertrain Unit", "date": "2019-12-10 13:42", "summary": "The private-equity firm's offer is valued at $4.3 billion including adjustments and excluding certain liabilities, but Tenneco is likely to reject it. Apollo Global Management Inc. has made an offer to acquire auto-parts supplier Tenneco Inc.'s powertrain division, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apollo Made Bid for Tenneco's Powertrain Unit. The private-equity firm's offer is valued at $4.3 billion including adjustments and excluding certain liabilities, but Tenneco is likely to reject it. Apollo Global Management Inc. has made an offer to acquire auto-parts supplier Tenneco Inc.'s powertrain division, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Tenneco Inc (NYSE: TEN) will increase because they are being pursued by Apollo Global Management, and they are a valuable asset.\n- Cummins Inc. (NYSE: CMI) will decrease because they are a direct competitor of Tenneco.", "price_info": {"TEN": {"company": "", "ticker": "TEN", "move": "up", "prices": [14.2907, 14.3]}, "CMI": {"company": "", "ticker": "CMI", "move": "down", "prices": [180.02, 180]}}}, {"link": "https://www.wsj.com/articles/las-vegas-monorail-files-for-bankruptcy-again-as-coronavirus-shuts-service-11599590799", "title": "Las Vegas Monorail Files for Bankruptcy Again Amid Pandemic", "date": "2020-09-08 14:46", "summary": "The Covid-19 pandemic has stopped the mass transit system from running for months. Las Vegas Monorail Co., a transit system financed with municipal debt that serves some of the city's marquee hotels, filed for bankruptcy for the second time in just over a decade after the coronavirus pandemic shut down service.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Las Vegas Monorail Files for Bankruptcy Again Amid Pandemic. The Covid-19 pandemic has stopped the mass transit system from running for months. Las Vegas Monorail Co., a transit system financed with municipal debt that serves some of the city's marquee hotels, filed for bankruptcy for the second time in just over a decade after the coronavirus pandemic shut down service.\"\n\nStock Prediction(s):", "Prediction": "\n- The Las Vegas Monorail will decrease because they are in bankruptcy and have stopped running due to Covid-19.", "price_info": {}}, {"link": "https://www.wsj.com/articles/adam-neumanns-ouster-wouldnt-change-wework-equation-11569342629", "title": "Adam Neumann's Ouster Won't Change WeWork Equation", "date": "2019-09-24 14:20", "summary": "Even before revelations on his personal behavior, the company's co-founder was creating problems that will be hard to fix. Adam Neumann's ouster at WeWork is too little too late.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Adam Neumann's Ouster Won't Change WeWork Equation. Even before revelations on his personal behavior, the company's co-founder was creating problems that will be hard to fix. Adam Neumann's ouster at WeWork is too little too late.\"\n\nStock Prediction(s):", "Prediction": "\n- WeWork Cos Inc (NYSE: WEWK) will continue to decrease because the company is in a lot of trouble, and Neumann's ouster is not going to fix anything.\n- The Real Estate Investment Trusts (REITs) such as Simon Property Group Inc (NYSE: SPG) and American Tower Corp (NYSE: AMT) will increase because WeWork is a big tenant for them, and they will be looking for new tenants.", "price_info": {"WEWK": {"company": "", "ticker": "WEWK", "move": "down"}, "SPG": {"company": "", "ticker": "SPG", "move": null, "prices": [153.6, 154]}, "AMT": {"company": "", "ticker": "AMT", "move": "up", "prices": [225.2192, 224.5]}}}, {"link": "https://www.wsj.com/articles/cyrusone-to-be-sold-in-15-billion-deal-to-kkr-and-global-infrastructure-partners-11636984742", "title": "CyrusOne to Be Sold in $15 Billion Deal", "date": "2021-11-15 10:30", "summary": "Real-estate investment trust CyrusOne designs, builds and operates data centers. CyrusOne Inc. said Monday that it is selling itself to buyout firms KKR & Co. and Global Infrastructure Partners LLC in a deal valued at about $15 billion including debt.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"CyrusOne to Be Sold in $15 Billion Deal. Real-estate investment trust CyrusOne designs, builds and operates data centers. CyrusOne Inc. said Monday that it is selling itself to buyout firms KKR & Co. and Global Infrastructure Partners LLC in a deal valued at about $15 billion including debt.\"\n\nStock Prediction(s):", "Prediction": "\n- CyrusOne Inc. (NASDAQ: CONE) will increase because they are being bought out for $15 billion.\n- KKR & Co. LP (NYSE: KKR) will increase because they are buying CyrusOne Inc.\n- Global Infrastructure Partners LLC (NYSE: GIP) will increase because they are buying CyrusOne Inc.", "price_info": {"KKR": {"company": "", "ticker": "KKR", "move": "up", "prices": [78.397, 78.0087]}, "GIP": {"company": "", "ticker": "GIP", "move": "up"}, "CONE": {"company": "", "ticker": "CONE", "move": "up", "prices": [89.155, 89.46]}}}, {"link": "https://www.wsj.com/articles/u-k-regulator-opens-investigation-into-thomas-cook-audits-11569950735", "title": "U.K. Regulator Opens Investigation Into Thomas Cook Audits", "date": "2019-10-01 13:26", "summary": "Move comes a week after the collapse of Britain's oldest travel company. The U.K. Financial Reporting Council on Tuesday opened an investigation into Ernst & Young LLP's audits of financial statements of Thomas Cook Group PLC, the British travel company that collapsed on Sept. 23 after rescue talks broke down.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.K. Regulator Opens Investigation Into Thomas Cook Audits. Move comes a week after the collapse of Britain's oldest travel company. The U.K. Financial Reporting Council on Tuesday opened an investigation into Ernst & Young LLP's audits of financial statements of Thomas Cook Group PLC, the British travel company that collapsed on Sept. 23 after rescue talks broke down.\"\n\nStock Prediction(s):", "Prediction": "\n- Ernst & Young LLP (NYSE: EY) will decrease because their audits are being investigated.\n- KPMG LLP (NYSE: KPM) will decrease because their audits are being investigated.\n- Deloitte LLP (NYSE: DLTE) will decrease because their audits are being investigated.", "price_info": {"EY": {"company": "", "ticker": "EY", "move": "down"}, "KPM": {"company": "", "ticker": "KPM", "move": "down"}, "DLTE": {"company": "", "ticker": "DLTE", "move": "down"}}}, {"link": "https://www.wsj.com/articles/natural-gas-prices-fall-on-putin-order-for-more-russian-exports-11635436936", "title": "Natural Gas Prices Fall on Putin Order for More Russian Exports", "date": "2021-10-28 12:02", "summary": "The Russian president told the state energy giant to pump more fuel to Germany and Austria to ease a supply crunch. Fears that Europe could run low on natural gas this winter eased, sending fuel prices lower, after Russian President Vladimir Putin told Gazprom PJSC to ship more gas westward.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Natural Gas Prices Fall on Putin Order for More Russian Exports. The Russian president told the state energy giant to pump more fuel to Germany and Austria to ease a supply crunch. Fears that Europe could run low on natural gas this winter eased, sending fuel prices lower, after Russian President Vladimir Putin told Gazprom PJSC to ship more gas westward.\"\n\nStock Prediction(s):", "Prediction": "\n- Cheniere Energy, Inc. (NYSEAMERICAN: LNG) will increase because this news signals that there will be less competition for natural gas exports, and Cheniere is a major player in the market.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because this news signals that there will be less competition for natural gas exports, and Exxon Mobil is a major player in the market.\n- Royal Dutch Shell plc (NYSE: RDS", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [63.875, 64.095]}}}, {"link": "https://www.wsj.com/articles/feds-evans-says-he-isnt-ready-to-call-for-changes-in-central-bank-monetary-policy-11607100597", "title": "Fed's Evans Isn't Ready for More Fed Stimulus", "date": "2020-12-04 15:18", "summary": "Chicago Fed leader says government aid is quickest way to deliver new support to the economy. Federal Reserve Bank of Chicago President Charles Evans said Friday that although the latest job creation data is disappointing, he wasn't yet ready to call for changes in central-bank monetary policy.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans Isn't Ready for More Fed Stimulus. Chicago Fed leader says government aid is quickest way to deliver new support to the economy. Federal Reserve Bank of Chicago President Charles Evans said Friday that although the latest job creation data is disappointing, he wasn't yet ready to call for changes in central-bank monetary policy.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will not react to this news because it is not about a specific company or industry.", "price_info": {}}, {"link": "https://www.wsj.com/articles/you-have-to-package-yourself-differently-company-veterans-explore-new-horizons-11550678469", "title": "'You Have to Package Yourself Differently'; Company Veterans Explore New Horizons", "date": "2019-02-20 11:01", "summary": "Long-tenured executives worry their skills may not translate, but firms increasingly are open to hiring outside leaders. Executives often find it hard to jump ship after helping to steer the same workplace for years.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/your-executive-career?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'You Have to Package Yourself Differently'; Company Veterans Explore New Horizons. Long-tenured executives worry their skills may not translate, but firms increasingly are open to hiring outside leaders. Executives often find it hard to jump ship after helping to steer the same workplace for years.\"\n\nStock Prediction(s):", "Prediction": "\n- Coca-Cola Co (NYSE: KO) will increase because they are looking for new executives with different skillsets to help them navigate the Covid-19 pandemic.\n- PepsiCo, Inc. (NASDAQ: PEP) will increase because they are looking for new executives with different skillsets to help them navigate the Covid-19 pandemic.", "price_info": {"KO": {"company": "", "ticker": "KO", "move": "up", "prices": [44.955, 45.0188]}, "PEP": {"company": "", "ticker": "PEP", "move": "up", "prices": [115.835, 115.6]}}}, {"link": "https://www.wsj.com/articles/occidentals-battle-has-just-begun-11557414110", "title": "Occidental's Battle Has Just Begun", "date": "2019-05-09 11:01", "summary": "CEO Vicki Hollub faces growing shareholder pressure as she reaches the last step in buying rival driller Anadarko Petroleum. Occidental Petroleum has work to do. The oil company is closer to sealing an arrangement with Anadarko Petroleum as rival Chevron bows out of the bidding battle, but mounting shareholder pressure against the company's management shouldn't be underestimated.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Occidental's Battle Has Just Begun. CEO Vicki Hollub faces growing shareholder pressure as she reaches the last step in buying rival driller Anadarko Petroleum. Occidental Petroleum has work to do. The oil company is closer to sealing an arrangement with Anadarko Petroleum as rival Chevron bows out of the bidding battle, but mounting shareholder pressure against the company's management shouldn't be underestimated.\"\n\nStock Prediction(s):", "Prediction": "\n- Occidental Petroleum Corporation (NYSE: OXY) will increase because they are the only company left in the bidding war, and they are likely to win.\n- Anadarko Petroleum Corporation (NYSE: APC) will decrease because they are being bought out by Occidental, and the shareholders are not happy with the deal.\n- Chevron Corporation (NYSE: CVX) will decrease because they are not going to buy Anadarko, and they are", "price_info": {"OXY": {"company": "", "ticker": "OXY", "move": "up", "prices": [56.53, 56.39]}, "APC": {"company": "", "ticker": "APC", "move": "down", "prices": [73.5, 73.59]}, "CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [120.3, 120.9046]}}}, {"link": "https://www.wsj.com/articles/columnist-nick-kristof-departs-new-york-times-to-pursue-oregon-governors-seat-11634224301", "title": "New York Times Columnist Nicholas Kristof Departs", "date": "2021-10-14 11:11", "summary": "The 37-year Times veteran has been considering a run for governor of Oregon, whose current Democratic leader faces term limits. Longtime New York Times opinion columnist Nick Kristof is leaving the organization ahead of a potential run for governor in his home state of Oregon, the newspaper's opinion editor said.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"New York Times Columnist Nicholas Kristof Departs. The 37-year Times veteran has been considering a run for governor of Oregon, whose current Democratic leader faces term limits. Longtime New York Times opinion columnist Nick Kristof is leaving the organization ahead of a potential run for governor in his home state of Oregon, the newspaper's opinion editor said.\"\n\nStock Prediction(s):", "Prediction": "\n- The New York Times Company (NYSE: NYT) will decrease because one of their most prominent columnists is leaving.\n- Other newspapers, such as The Washington Post Company (WPO) and Gannett Co., Inc. (GCI), will increase because they may benefit from the loss of The New York Times Company's talent.", "price_info": {"WPO": {"company": "Post Company", "ticker": "WPO", "move": null}, "GCI": {"company": "Co., Inc.", "ticker": "GCI", "move": "up", "prices": [6.18, 6.14]}, "NYT": {"company": "", "ticker": "NYT", "move": "down", "prices": [54.075, 54.2]}}}, {"link": "https://www.wsj.com/articles/best-performance-from-older-iphone-11630774555", "title": "Tips to Get the Best Performance From an Older iPhone", "date": "2021-09-07 12:40", "summary": "To rejuvenate your increasingly vintage model, check its battery health, free up storage and weigh your repair options. New iPhones are just around the corner-we expect them to appear on Sept.14, in Apple's just-announced streamed news event-but before you rush to buy one of the new ones, take a closer look at the one you've got.", "categories": [["Tech", "Personal Tech", "Personal Technology: Nicole Nguyen"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-nicole-nguyen?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tips to Get the Best Performance From an Older iPhone. To rejuvenate your increasingly vintage model, check its battery health, free up storage and weigh your repair options. New iPhones are just around the corner-we expect them to appear on Sept.14, in Apple's just-announced streamed news event-but before you rush to buy one of the new ones, take a closer look at the one you've got.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because people will want to buy a new phone, but they will also want to get the most out of their old phone first.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will decrease because they are a direct competitor of Apple.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [157.0725, 156.97]}}}, {"link": "https://www.wsj.com/articles/investors-inflation-bet-loses-some-steam-11622626202", "title": "Investors' Inflation Bet Loses Some Steam", "date": "2021-06-02 15:59", "summary": "A key measure of inflation expectations has slipped in recent days, stirring debate over whether it has peaked. A key measure of investors' inflation expectations has slipped in recent days, stirring debate over whether it has finally peaked after this year's near-relentless climb.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors' Inflation Bet Loses Some Steam. A key measure of inflation expectations has slipped in recent days, stirring debate over whether it has peaked. A key measure of investors' inflation expectations has slipped in recent days, stirring debate over whether it has finally peaked after this year's near-relentless climb.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because investors are starting to doubt that inflation will continue to rise.\n- The market will go up because investors are still confident that inflation will continue to rise.", "price_info": {}}, {"link": "https://www.wsj.com/articles/carbon-prices-jump-despite-record-drop-in-emissions-11608814801", "title": "Carbon Prices Jump Despite Record Drop in Emissions", "date": "2020-12-24 12:35", "summary": "European Union's decision to curb greenhouse gases is driving the latest rally, putting carbon credits on par with gold. Credits tied to carbon emissions are having a banner year despite a record drop in output from the power plants and steel mills that need them to operate.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Carbon Prices Jump Despite Record Drop in Emissions. European Union's decision to curb greenhouse gases is driving the latest rally, putting carbon credits on par with gold. Credits tied to carbon emissions are having a banner year despite a record drop in output from the power plants and steel mills that need them to operate.\"\n\nStock Prediction(s):", "Prediction": "\n- REC Silicon ASA (OTCMKTS:RECLF) will increase because they are a producer of silicon for solar energy, and the price of carbon credits is increasing.\n- Vestas Wind Systems A/S (OTCMKTS:VWDRY) will increase because they are a producer of wind turbines, and the price of carbon credits is increasing.\n- Tesla, Inc. (NASDAQ: TSLA) will decrease because they are not", "price_info": {"TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [662.05, 660.03]}}}, {"link": "https://www.wsj.com/articles/opioid-risk-smothers-drug-stocks-11565194670", "title": "Opioid Risk Smothers Drug Stocks", "date": "2019-08-07 12:17", "summary": "Fears of massive legal settlements for drug companies such as Teva will keep a lid on stock prices. Even solid corporate earnings can't reverse investor angst over drug companies facing opioid litigation risk.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Opioid Risk Smothers Drug Stocks. Fears of massive legal settlements for drug companies such as Teva will keep a lid on stock prices. Even solid corporate earnings can't reverse investor angst over drug companies facing opioid litigation risk.\"\n\nStock Prediction(s):", "Prediction": "\n- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will decrease because of the opioid litigation risk.\n- Allergan plc (NYSE: AGN) will decrease because of the opioid litigation risk.\n- Pfizer Inc (NYSE: PFE) will decrease because of the opioid litigation risk.\n- Merck & Co., Inc. (NYSE: MRK) will decrease because of the opioid litigation risk.", "price_info": {"TEVA": {"company": "", "ticker": "TEVA", "move": "down", "prices": [7.01, 7.055]}, "AGN": {"company": "", "ticker": "AGN", "move": "down", "prices": [159.07, 159.02]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [36.44, 36.57]}, "MRK": {"company": "", "ticker": "MRK", "move": "down", "prices": [84.02, 83.87]}}}, {"link": "https://www.wsj.com/articles/tpg-appoints-new-president-makes-other-management-changes-11632411000", "title": "TPG Appoints New President, Makes Other Management Changes", "date": "2021-09-23 11:30", "summary": "The private-equity firm is naming Todd Sisitsky, a veteran healthcare investor, to the new role of president. TPG is promoting a group of longtime partners to leadership roles as the private-equity firm prepares to launch an initial public offering of its shares.", "categories": [["WSJ News Exclusive", "Deals"]], "category_links": ["https://www.wsj.com/news/types/deals-deal-makers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"TPG Appoints New President, Makes Other Management Changes. The private-equity firm is naming Todd Sisitsky, a veteran healthcare investor, to the new role of president. TPG is promoting a group of longtime partners to leadership roles as the private-equity firm prepares to launch an initial public offering of its shares.\"\n\nStock Prediction(s):", "Prediction": "\n- TPG Capital LP (NYSE: TPG) will increase because they have made management changes and are preparing for an IPO.\n- KKR & Co. LP (NYSE: KKR) will increase because they have made management changes and are preparing for an IPO.\n- Carlyle Group LP (NASDAQ: CG) will increase because they have made management changes and are preparing for an IPO.", "price_info": {"TPG": {"company": "", "ticker": "TPG", "move": "up"}, "KKR": {"company": "", "ticker": "KKR", "move": "up", "prices": [63.72, 64.025]}, "CG": {"company": "", "ticker": "CG", "move": "up", "prices": [49.193, 49.28]}}}, {"link": "https://www.wsj.com/articles/will-the-economy-go-back-out-of-service-11594054603", "title": "Will the Economy Go Back Out of Service?", "date": "2020-07-06 12:56", "summary": "The service sector rebounded last month, but with Covid crisis intensifying, the bounceback's staying power is uncertain. The services sector rebounded in June. But with new Covid-19 cases rising in many parts of the country, the big question is whether the snapback will stick.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Will the Economy Go Back Out of Service?. The service sector rebounded last month, but with Covid crisis intensifying, the bounceback's staying power is uncertain. The services sector rebounded in June. But with new Covid-19 cases rising in many parts of the country, the big question is whether the snapback will stick.\"\n\nStock Prediction(s):", "Prediction": "\n- The service sector will rebound in the short term, but with the Covid crisis intensifying, the rebound's staying power is uncertain. This will have a negative effect on the stock prices of companies in the service sector.", "price_info": {}}, {"link": "https://www.wsj.com/articles/what-to-doand-not-doin-the-aftermath-of-a-cybersecurity-attack-11607461064", "title": "What to Do-and Not Do-in the Aftermath of a Breach", "date": "2020-12-08 15:57", "summary": "Among the most-important: Don't create fear and uncertainty by firing the people who may know best how to recover from the attack. The immediate aftermath of a breach is a critical time for the hacked organization. If leaders don't learn quickly what went wrong and act swiftly-in the right ways-to fix the problem, they risk exacerbating the damage in terms of financial and reputational harm.", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What to Do-and Not Do-in the Aftermath of a Breach. Among the most-important: Don't create fear and uncertainty by firing the people who may know best how to recover from the attack. The immediate aftermath of a breach is a critical time for the hacked organization. If leaders don't learn quickly what went wrong and act swiftly-in the right ways-to fix the problem, they risk exacerbating the damage in terms of financial and reputational harm.\"\n\nStock Prediction(s):", "Prediction": "\n- Symantec Corporation (NASDAQ: SYMC) will increase because they provide cybersecurity solutions and will be in high demand after this breach.\n- FireEye, Inc. (NASDAQ: FEYE) will increase because they provide cybersecurity solutions and will be in high demand after this breach.\n- Palo Alto Networks, Inc. (NYSE: PANW) will increase because they provide cybersecurity solutions and will be in high demand after this breach.\n- Check Point", "price_info": {"PANW": {"company": "", "ticker": "PANW", "move": "up", "prices": [310.4601, 310.8]}, "SYMC": {"company": "", "ticker": "SYMC", "move": "up"}, "FEYE": {"company": "", "ticker": "FEYE", "move": "up", "prices": [15.515, 14.28]}}}, {"link": "https://www.wsj.com/articles/tencent-buys-10-stake-in-record-label-of-billie-eilish-drake-11577793085", "title": "Tencent Buys 10% Stake in Record Label of Billie Eilish, Drake", "date": "2019-12-31 10:32", "summary": "Chinese internet giant has agreed to acquire a stake in Universal from Vivendi for $3.36 billion. Tencent Holdings Ltd. is buying a 10% stake in the music giant behind Ariana Grande, Drake and Billie Eilish for \u20ac3 billion ($3.36 billion) in a deal that bolsters the Chinese internet giant's growing presence in the record industry.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tencent Buys 10% Stake in Record Label of Billie Eilish, Drake. Chinese internet giant has agreed to acquire a stake in Universal from Vivendi for $3.36 billion. Tencent Holdings Ltd. is buying a 10% stake in the music giant behind Ariana Grande, Drake and Billie Eilish for \u20ac3 billion ($3.36 billion) in a deal that bolsters the Chinese internet giant's growing presence in the record industry.\"\n\nStock Prediction(s):", "Prediction": "\n- Universal Music Group (NYSE: UMG) will increase because Tencent Holdings Ltd. has agreed to acquire a stake in them.\n- Sony Corporation (NYSE: SNE) will decrease because they are also in the music industry, and they will be competing with Universal Music Group.", "price_info": {"UMG": {"company": "", "ticker": "UMG", "move": "up"}, "SNE": {"company": "", "ticker": "SNE", "move": "down", "prices": [67.68, 67.74]}}}, {"link": "https://www.wsj.com/articles/treasury-to-sell-75-billion-in-debt-11557415730", "title": "Treasury to Sell $75 Billion in Debt", "date": "2019-05-09 11:28", "summary": "Resume Subscription. The U.S. Treasury Department will auction $75 billion in securities next week. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury to Sell $75 Billion in Debt. Resume Subscription. The U.S. Treasury Department will auction $75 billion in securities next week. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Treasury Department will auction $75 billion in securities next week, and this will cause an increase in demand for debt securities.\n- The U.S. Treasury Department will resume subscription, and this will cause an increase in demand for debt securities.", "price_info": {}}, {"link": "https://www.wsj.com/articles/americas-cash-might-stay-on-the-sidelines-11632423163", "title": "America's Cash Might Stay on the Sidelines", "date": "2021-09-23 14:52", "summary": "Households are sitting on a lot of savings, and it isn't clear when they will feel comfortable spending it. If Americans ever feel comfortable again, they have a lot of money that they can spend. But who knows when that comfort will come?", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"America's Cash Might Stay on the Sidelines. Households are sitting on a lot of savings, and it isn't clear when they will feel comfortable spending it. If Americans ever feel comfortable again, they have a lot of money that they can spend. But who knows when that comfort will come?\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because they are one of the few companies that have been doing well recently, and people are more likely to spend their money at Walmart.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are one of the few companies that have been doing well recently, and people are more likely to spend their money at Amazon.\n- Apple Inc. (NASDAQ: AAPL", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [142.87, 142.835]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3420.8, 3413.5]}}}, {"link": "https://www.wsj.com/articles/u-s-income-tax-delay-to-strain-states-11585143724", "title": "U.S. Income Tax Delay to Strain States", "date": "2020-03-25 09:42", "summary": "Many state budgets run from July 1 to June 30, so new July 15 filing date means officials can't count on that money for current fiscal year. The Trump administration's decision to move the deadline for filing income taxes to July 15 because of the new coronavirus crisis is creating a cash crunch for state governments that were counting on an infusion of state income-tax revenue next month to pay bills.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Income Tax Delay to Strain States. Many state budgets run from July 1 to June 30, so new July 15 filing date means officials can't count on that money for current fiscal year. The Trump administration's decision to move the deadline for filing income taxes to July 15 because of the new coronavirus crisis is creating a cash crunch for state governments that were counting on an infusion of state income-tax revenue next month to pay bills.\"\n\nStock Prediction(s):", "Prediction": "\n- The delay in U.S. income taxes will cause state governments to have to borrow money or cut services.\n- State governments that have been struggling financially will be hit the hardest by this news.\n- The delay in U.S. income taxes will also cause the stock prices of companies that do business with state governments to decrease.", "price_info": {}}, {"link": "https://www.wsj.com/articles/cios-look-to-boost-tech-teams-diversity-11577469868", "title": "CIOs Look to Boost Tech Teams' Diversity", "date": "2019-12-27 13:04", "summary": "Recruiting more women and minorities could help with talent shortage, executives say. Chief information officers are pushing to bring more women and minorities onto corporate technology teams in the year ahead, using methods such as recruiting efforts, internal training and diversity programs.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"CIOs Look to Boost Tech Teams' Diversity. Recruiting more women and minorities could help with talent shortage, executives say. Chief information officers are pushing to bring more women and minorities onto corporate technology teams in the year ahead, using methods such as recruiting efforts, internal training and diversity programs.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are pushing for diversity in their tech teams, and they are a major player in the technology industry.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are pushing for diversity in their tech teams, and they are a major player in the technology industry.\n- Apple Inc. (NASDAQ: AAPL) will increase because they are pushing for diversity in", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [158.61, 158.94]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1887.4649, 1881.974]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [289.965, 290.27]}}}, {"link": "https://www.wsj.com/articles/should-fossil-fuel-companies-bear-responsibility-for-the-damage-their-products-do-to-the-environment-11574190219", "title": "Should Fossil-Fuel Companies Bear Responsibility for the Damage Their Products Do to the Environment?", "date": "2019-11-19 14:03", "summary": "Those in favor say the companies knew the damage their products were causing; those against contend that climate change is a matter for public policy, not courts. The oil-and-gas industry has faced a barrage of lawsuits in recent years from cities, counties and states across the U.S. seeking damages for the costs they say they have incurred as a result of climate change.", "categories": [["Business", "Energy", "Journal Reports: Energy"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/energy-oil-gas?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-energy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Should Fossil-Fuel Companies Bear Responsibility for the Damage Their Products Do to the Environment?. Those in favor say the companies knew the damage their products were causing; those against contend that climate change is a matter for public policy, not courts. The oil-and-gas industry has faced a barrage of lawsuits in recent years from cities, counties and states across the U.S. seeking damages for the costs they say they have incurred as a result of climate change.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because they are not being sued for their products' damage to the environment.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because they are being sued for their products' damage to the environment.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because they are being sued for their products' damage to the environment.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [117.115, 116.195]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [67.974, 67.88]}}}, {"link": "https://www.wsj.com/articles/supermarkets-get-new-looks-as-shoppers-adapt-to-pandemic-11604519627", "title": "Supermarkets Get New Looks as E-Commerce Grabs Hold", "date": "2020-11-04 14:53", "summary": "Food retailers are accelerating adoption of online ordering, while also creating more space for fresh foods and alcohol. Supermarkets are using pandemic-driven changes in shopping behavior to accelerate the shift to e-commerce they have been seeking but have been slow to realize in recent years.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Supermarkets Get New Looks as E-Commerce Grabs Hold. Food retailers are accelerating adoption of online ordering, while also creating more space for fresh foods and alcohol. Supermarkets are using pandemic-driven changes in shopping behavior to accelerate the shift to e-commerce they have been seeking but have been slow to realize in recent years.\"\n\nStock Prediction(s):", "Prediction": "\n- Kroger Co (NYSE: KR) will increase because they are accelerating their online ordering, and they are also creating more space for fresh foods and alcohol.\n- Walmart Inc (NYSE: WMT) will increase because they are accelerating their online ordering, and they are also creating more space for fresh foods and alcohol.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are the leading e-commerce company, and this", "price_info": {"KR": {"company": "", "ticker": "KR", "move": "up", "prices": [32.22, 32.12]}, "WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [143.064, 141.7]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3229.2685, 3242]}}}, {"link": "https://www.wsj.com/articles/job-slowdown-isnt-imaginary-11552576712", "title": "Job Slowdown Isn't Imaginary", "date": "2019-03-14 11:18", "summary": "Rising unemployment insurance claims add to evidence that the U.S. job market has softened. The job market really is slowing.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Job Slowdown Isn't Imaginary. Rising unemployment insurance claims add to evidence that the U.S. job market has softened. The job market really is slowing.\"\n\nStock Prediction(s):", "Prediction": "\n- The job market slowdown will continue, so companies like Walmart (NYSE: WMT) and Target (NYSE: TGT) will decrease in stock prices.\n- The job market slowdown will continue, so companies like Amazon (NASDAQ: AMZN) and Google (NASDAQ: GOOGL) will increase in stock prices.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": null, "prices": [98.15, 98.08]}, "TGT": {"company": "", "ticker": "TGT", "move": "down", "prices": [76.415, 76.44]}, "AMZN": {"company": "", "ticker": "AMZN", "move": null, "prices": [1697.8501, 1694.7786]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1197.78, 1196.43]}}}, {"link": "https://www.wsj.com/articles/joe-rogan-racial-slur-spotify-11644275660", "title": "What's Happening With Joe Rogan and Spotify", "date": "2022-02-08 12:07", "summary": "As Joe Rogan faces scrutiny surrounding past uses of racial slurs, here's what to know about the podcaster and Spotify's response. Joe Rogan has been facing public scrutiny for his past use of racial slurs. On Feb. 5, Mr. Rogan apologized after a compilation video emerged showing how he and some of his guests used the N-word numerous times on his show. On Feb. 6, Spotify Chief Executive Daniel Ek apologized to employees for the way Mr. Rogan's use of the slur in previous podcast episodes has impacted them.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What's Happening With Joe Rogan and Spotify. As Joe Rogan faces scrutiny surrounding past uses of racial slurs, here's what to know about the podcaster and Spotify's response. Joe Rogan has been facing public scrutiny for his past use of racial slurs. On Feb. 5, Mr. Rogan apologized after a compilation video emerged showing how he and some of his guests used the N-word numerous times on his show. On Feb. 6, Spotify Chief Executive Daniel Ek apologized to employees for the way Mr. Rogan's use of the slur in previous podcast episodes has impacted them.\"\n\nStock Prediction(s):", "Prediction": "\n- Joe Rogan will continue to be in the spotlight, and this will negatively impact his sponsorships, including Spotify.\n- Spotify will continue to be in the spotlight, and this will negatively impact their sponsorships, including Joe Rogan.", "price_info": {}}, {"link": "https://www.wsj.com/articles/consumer-agency-to-probe-tech-giants-including-apple-facebook-11634818130", "title": "Government Probes How Apple, Facebook, Amazon Use Consumer Financial Data", "date": "2021-10-21 12:01", "summary": "Consumer Financial Protection Bureau seeks information on how those firms and others use consumers' financial information. WASHINGTON-Big tech companies are facing questions from the government on another front: how they use consumers' financial and other information.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Government Probes How Apple, Facebook, Amazon Use Consumer Financial Data. Consumer Financial Protection Bureau seeks information on how those firms and others use consumers' financial information. WASHINGTON-Big tech companies are facing questions from the government on another front: how they use consumers' financial and other information.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will decrease because the government is investigating how they use consumer financial data.\n- Facebook Inc. (NASDAQ: FB) will decrease because the government is investigating how they use consumer financial data.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because the government is investigating how they use consumer financial data.\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [148.52, 148.4701]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [341.96, 340.46]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3435, 3431.56]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [2824.02, 2820.731]}}}, {"link": "https://www.wsj.com/articles/doordash-to-change-pay-model-for-delivery-workers-after-criticism-11563979844", "title": "DoorDash to Change Pay Model for Delivery Workers After Criticism", "date": "2019-07-24 10:50", "summary": "Chief Executive Tony Xu said the new compensation structure would ensure worker pay rises when customers tip on the DoorDash app. DoorDash Inc. plans to change how it pays food-delivery workers after facing criticism for applying customer tips to the minimum payments that workers receive for each drop-off.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"DoorDash to Change Pay Model for Delivery Workers After Criticism. Chief Executive Tony Xu said the new compensation structure would ensure worker pay rises when customers tip on the DoorDash app. DoorDash Inc. plans to change how it pays food-delivery workers after facing criticism for applying customer tips to the minimum payments that workers receive for each drop-off.\"\n\nStock Prediction(s):", "Prediction": "\n- DoorDash Inc. (NYSE: DASH) will increase because they are changing their pay model to ensure that workers are paid more.\n- Grubhub Inc. (NYSE: GRUB) will decrease because they are a direct competitor of DoorDash, and they have been criticized for their pay model in the past.", "price_info": {"DASH": {"company": "", "ticker": "DASH", "move": "up"}, "GRUB": {"company": "", "ticker": "GRUB", "move": "down", "prices": [72.78, 72.945]}}}, {"link": "https://www.wsj.com/articles/new-york-fed-adds-102-14-billion-to-markets-11572966654", "title": "New York Fed Adds $102.14 Billion to Markets, Buys More Treasury Bills", "date": "2019-11-05 15:49", "summary": "Fed intervention includes $71.05 billion in overnight repurchase agreements and $7.5 billion in T-bills. The New York Fed added $102.14 billion in temporary liquidity Tuesday, and it also added permanent liquidity with more Treasury bill purchases.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"New York Fed Adds $102.14 Billion to Markets, Buys More Treasury Bills. Fed intervention includes $71.05 billion in overnight repurchase agreements and $7.5 billion in T-bills. The New York Fed added $102.14 billion in temporary liquidity Tuesday, and it also added permanent liquidity with more Treasury bill purchases.\"\n\nStock Prediction(s):", "Prediction": "\n- The New York Fed's intervention will cause an increase in the stock prices of banks and other companies that benefit from a stable financial system, such as JPMorgan Chase & Co. (NYSE: JPM) and Goldman Sachs Group Inc. (NYSE: GS).\n- The New York Fed's intervention will also cause an increase in the stock prices of companies that produce consumer goods and services, such as Walmart Inc. (NYSE: WMT) and Amazon.com Inc. (", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [129.2733, 129.1]}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [218.93, 218.64]}, "WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [118.8033, 118.86]}}}, {"link": "https://www.wsj.com/articles/eu-judge-raises-prospect-of-increasing-multibillion-fine-against-google-11581698334", "title": "Google Challenged EU Fine. A Judge Spoke of Raising It.", "date": "2020-02-14 11:38", "summary": "Alphabet's appeal of ruling on alleged anticompetitive behavior risks backfiring. LUXEMBOURG- Alphabet Inc.'s appeal against a multibillion-dollar fine for alleged anticompetitive behavior by its Google unit risks backfiring after a European Union court floated the prospect of increasing the fine, rather than scrapping it.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Google Challenged EU Fine. A Judge Spoke of Raising It.. Alphabet's appeal of ruling on alleged anticompetitive behavior risks backfiring. LUXEMBOURG- Alphabet Inc.'s appeal against a multibillion-dollar fine for alleged anticompetitive behavior by its Google unit risks backfiring after a European Union court floated the prospect of increasing the fine, rather than scrapping it.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease because they are being fined more money, and this could set a precedent for other companies.\n- Facebook Inc. (NASDAQ: FB) will decrease because they are being fined more money, and this could set a precedent for other companies.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are being fined more money, and this could set a precedent", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [1515.3508, 1514.47]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [213.99, 213.5621]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [2146.39, 2136.1428]}}}, {"link": "https://www.wsj.com/articles/white-star-petroleum-seeks-bankruptcy-protection-11559060599", "title": "White Star Petroleum Seeks Bankruptcy Protection", "date": "2019-05-28 12:23", "summary": "Oklahoma driller seeks breathing room days after vendors make involuntary filing. White Star Petroleum LLC, founded by late oilman Aubrey McClendon, filed Tuesday for chapter 11, days after unpaid vendors tried to push the energy company into an involuntary bankruptcy.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"White Star Petroleum Seeks Bankruptcy Protection. Oklahoma driller seeks breathing room days after vendors make involuntary filing. White Star Petroleum LLC, founded by late oilman Aubrey McClendon, filed Tuesday for chapter 11, days after unpaid vendors tried to push the energy company into an involuntary bankruptcy.\"\n\nStock Prediction(s):", "Prediction": "\n- Chesapeake Energy Corporation (NYSE: CHK) will increase because White Star Petroleum was founded by Aubrey McClendon, who was also the co-founder of Chesapeake Energy.\n- WPX Energy, Inc. (NYSE: WPX) will increase because they are a direct competitor of Chesapeake Energy.", "price_info": {"CHK": {"company": "", "ticker": "CHK", "move": "up", "prices": [1.955, 1.96]}, "WPX": {"company": "", "ticker": "WPX", "move": "up", "prices": [11.21, 11.225]}}}, {"link": "https://www.wsj.com/articles/airline-earnings-fund-the-battle-for-latin-america-11579799531", "title": "Airline Earnings Fund the Battle for Latin America", "date": "2020-01-23 12:12", "summary": "In a period of strong profitability for U.S. carriers, Latin America offers juicy growth prospects-as long as competition doesn't get out of hand. When companies make a lot of money, they often look for a place to put it. In the case of U.S. airlines, that place could be Latin America.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Airline Earnings Fund the Battle for Latin America. In a period of strong profitability for U.S. carriers, Latin America offers juicy growth prospects-as long as competition doesn't get out of hand. When companies make a lot of money, they often look for a place to put it. In the case of U.S. airlines, that place could be Latin America.\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines, Inc. (NYSE: DAL) will increase because they are expanding their business into Latin America, and they are seeing strong profitability.\n- American Airlines Group Inc. (NASDAQ: AAL) will increase because they are expanding their business into Latin America, and they are seeing strong profitability.\n- United Airlines Holdings, Inc. (NASDAQ: UAL) will increase because they are expanding their business into Latin America, and they are", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [59.5, 59.4]}, "AAL": {"company": "", "ticker": "AAL", "move": null, "prices": [27.295, 27.67]}, "UAL": {"company": "", "ticker": "UAL", "move": "up", "prices": [83.81, 84.35]}}}, {"link": "https://www.wsj.com/articles/walgreens-grappling-with-cororavirus-as-quarterly-sales-rise-11585828873", "title": "Walgreens Sales Drop Off After Early Coronavirus Surge", "date": "2020-04-02 11:31", "summary": "The decline came in the final week of March, particularly in communities where residents have been directed to stay home. ", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walgreens Sales Drop Off After Early Coronavirus Surge. The decline came in the final week of March, particularly in communities where residents have been directed to stay home. \"\n\nStock Prediction(s):", "Prediction": "\n- Walgreens Boots Alliance, Inc. (NASDAQ: WBA) will decrease because their sales have dropped off after the early surge of the coronavirus.", "price_info": {"WBA": {"company": "", "ticker": "WBA", "move": "down", "prices": [39.63, 40.01]}}}, {"link": "https://www.wsj.com/articles/u-s-dollar-advances-against-canadian-currency-11551460659", "title": "U.S. Dollar Advances Against Canadian Currency", "date": "2019-03-01 12:17", "summary": "Canada's economy logs its worst quarterly performance in more than two years, data shows. The U.S. dollar rose against the Canadian currency after new data showed that Canada's economy slowed in the final three months of the year, logging its worst quarterly performance in more than two years.", "categories": [["Markets", "Currencies", "Foreign Exchange"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/currencies?mod=breadcrumb", "https://www.wsj.com/news/types/foreign-exchange?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Dollar Advances Against Canadian Currency. Canada's economy logs its worst quarterly performance in more than two years, data shows. The U.S. dollar rose against the Canadian currency after new data showed that Canada's economy slowed in the final three months of the year, logging its worst quarterly performance in more than two years.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. dollar will continue to rise against the Canadian currency.\n- The Canadian dollar will continue to decline against the U.S. dollar.", "price_info": {}}, {"link": "https://www.wsj.com/articles/the-delta-variant-and-covid-19-vaccines-what-to-know-11627079604", "title": "The Delta Variant, Covid-19 Symptoms and Vaccine Efficacy: What to Know", "date": "2021-09-24 15:50", "summary": "Places with higher vaccination rates are keeping hospitalizations and deaths in check. The Delta variant of the Covid-19 virus has driven up cases, hospitalizations and deaths across the U.S., particularly where vaccination rates are lower.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Delta Variant, Covid-19 Symptoms and Vaccine Efficacy: What to Know. Places with higher vaccination rates are keeping hospitalizations and deaths in check. The Delta variant of the Covid-19 virus has driven up cases, hospitalizations and deaths across the U.S., particularly where vaccination rates are lower.\"\n\nStock Prediction(s):", "Prediction": "\n- The Delta variant of the Covid-19 virus will have a negative impact on the stock prices of all vaccine manufacturers because it is driving up cases, hospitalizations, and deaths.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bp-considers-spinning-off-iraq-operations-11623423824", "title": "BP Considers Spinning Off Iraq Operations", "date": "2021-06-11 11:38", "summary": "Oil giant weighs whether to move its interest in the giant Rumaila oil field into a stand-alone company as it tries to pivot toward lower-carbon energy. LONDON-BP PLC is working on a plan to spin off its operations in Iraq into a stand-alone company, according to people familiar with the matter, as the oil giant shuffles its assets and investment plans in its pivot toward lower-carbon energy.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"BP Considers Spinning Off Iraq Operations. Oil giant weighs whether to move its interest in the giant Rumaila oil field into a stand-alone company as it tries to pivot toward lower-carbon energy. LONDON-BP PLC is working on a plan to spin off its operations in Iraq into a stand-alone company, according to people familiar with the matter, as the oil giant shuffles its assets and investment plans in its pivot toward lower-carbon energy.\"\n\nStock Prediction(s):", "Prediction": "\n- BP plc (NYSE: BP) will decrease because they are divesting their Iraq operations into a stand-alone company.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are not divesting their Iraq operations, and they are a direct competitor of BP.", "price_info": {"BP": {"company": "", "ticker": "BP", "move": "down", "prices": [27.5755, 27.605]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [62.62, 62.72]}}}, {"link": "https://www.wsj.com/articles/green-energy-producing-more-jobs-11636388750", "title": "Will 'Green Energy' Produce More Jobs? Three Experts Discuss.", "date": "2021-11-09 10:02", "summary": "Advocates believe that the expansion of renewables will result in a jobs explosion. Not so fast, others say.. As Washington considers increasing incentives for businesses moving to a clean-energy future, one of the big questions is: Will the \"greening\" of the economy result in more employment or less?", "categories": [["Business", "Energy", "Journal Reports: Energy"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/energy-oil-gas?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-energy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Will 'Green Energy' Produce More Jobs? Three Experts Discuss.. Advocates believe that the expansion of renewables will result in a jobs explosion. Not so fast, others say.. As Washington considers increasing incentives for businesses moving to a clean-energy future, one of the big questions is: Will the \"greening\" of the economy result in more employment or less?\"\n\nStock Prediction(s):", "Prediction": "\n- SunPower Corporation (NASDAQ: SPWR) will increase because they are a major player in the renewable energy industry and will benefit from the expansion of renewables.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are a major player in the renewable energy industry and will benefit from the expansion of renewables.\n- First Solar, Inc. (NASDAQ: FSLR) will decrease because they are a major player in the renewable", "price_info": {"SPWR": {"company": "", "ticker": "SPWR", "move": "up", "prices": [30.74, 31.8338]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [1073.0001, 1078]}, "FSLR": {"company": "", "ticker": "FSLR", "move": "down", "prices": [111.83, 113.55]}}}, {"link": "https://www.wsj.com/articles/edith-whartons-former-oceanfront-home-in-newport-fetches-8-6-million-11586461253", "title": "Edith Wharton's Former Oceanfront Home in Newport Fetches $8.6 Million", "date": "2020-04-09 15:40", "summary": "Known as Land's End, the Rhode Island home was first listed for $11.7 million nearly a year ago. An oceanfront estate in Newport, R.I., that once belonged to author Edith Wharton has sold for $8.6 million after almost a year on the market.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Edith Wharton's Former Oceanfront Home in Newport Fetches $8.6 Million. Known as Land's End, the Rhode Island home was first listed for $11.7 million nearly a year ago. An oceanfront estate in Newport, R.I., that once belonged to author Edith Wharton has sold for $8.6 million after almost a year on the market.\"\n\nStock Prediction(s):", "Prediction": "\n- The seller of the home, likely a real estate company, will increase because they just made a large profit.\n- The buyer of the home, likely a wealthy individual, will increase because they just bought a prestigious home.", "price_info": {}}, {"link": "https://www.wsj.com/articles/volkswagen-accelerates-investment-in-electric-cars-as-it-races-to-overtake-tesla-11605283260", "title": "Volkswagen Accelerates Investment in Electric Cars as It Races to Overtake Tesla", "date": "2020-11-13 11:01", "summary": "German company aims to become the world's leading maker of electric vehicles. Volkswagen AG plans to invest around $86 billion in the development of electric vehicles and other new technologies over the next five years, as the world's largest auto maker races to overtake Tesla Inc. as the leading maker of electric cars.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Volkswagen Accelerates Investment in Electric Cars as It Races to Overtake Tesla. German company aims to become the world's leading maker of electric vehicles. Volkswagen AG plans to invest around $86 billion in the development of electric vehicles and other new technologies over the next five years, as the world's largest auto maker races to overtake Tesla Inc. as the leading maker of electric cars.\"\n\nStock Prediction(s):", "Prediction": "\n- Volkswagen AG (OTCMKTS: VOW3) will increase because they are making a large investment in electric cars.\n- Tesla Inc. (NASDAQ: TSLA) will decrease because Volkswagen is making a large investment in electric cars, and Tesla is a direct competitor.", "price_info": {"TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [403.04, 405.7675]}}}, {"link": "https://www.wsj.com/articles/unitedhealth-posts-stronger-quarterly-results-as-membership-grows-11618487102", "title": "UnitedHealth Posts Stronger Quarterly Results as Membership Grows", "date": "2021-04-15 11:55", "summary": "The health-insurance company expects the pandemic to continue to weigh on the industry this year. UnitedHealth Group Inc. recorded a first-quarter profit that beat Wall Street's expectations and raised its projection on results for the full year, as membership grew in its insurance business and costs for Covid-19 care declined.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"UnitedHealth Posts Stronger Quarterly Results as Membership Grows. The health-insurance company expects the pandemic to continue to weigh on the industry this year. UnitedHealth Group Inc. recorded a first-quarter profit that beat Wall Street's expectations and raised its projection on results for the full year, as membership grew in its insurance business and costs for Covid-19 care declined.\"\n\nStock Prediction(s):", "Prediction": "\n- UnitedHealth Group Inc. (NYSE: UNH) will increase because they are expecting the pandemic to continue to weigh on the industry, but their own business is doing well.\n- Anthem Inc. (NYSE: ANTM) will decrease because they are expecting the pandemic to continue to weigh on the industry, and their own business is doing poorly.", "price_info": {"UNH": {"company": "", "ticker": "UNH", "move": "up", "prices": [388.49, 390.22]}, "ANTM": {"company": "", "ticker": "ANTM", "move": "down", "prices": [372.13, 373.2]}}}, {"link": "https://www.wsj.com/articles/u-k-balks-at-wholesale-airlines-bailout-clouding-global-recovery-efforts-11585076488", "title": "U.K. Balks at Wholesale Airlines Bailout, Clouding Global Recovery Efforts", "date": "2020-03-24 15:01", "summary": "As Washington finalizes its own industry response amid the coronavirus crisis, other governments face stark choice amid global meltdown. LONDON-The U.K. is balking at a full-scale bailout of its airlines, telling British carriers to seek out private-sector remedies first and making clear the uneven hurdles the global aviation industry faces in finding ways to survive the fallout of the new coronavirus outbreak.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.K. Balks at Wholesale Airlines Bailout, Clouding Global Recovery Efforts. As Washington finalizes its own industry response amid the coronavirus crisis, other governments face stark choice amid global meltdown. LONDON-The U.K. is balking at a full-scale bailout of its airlines, telling British carriers to seek out private-sector remedies first and making clear the uneven hurdles the global aviation industry faces in finding ways to survive the fallout of the new coronavirus outbreak.\"\n\nStock Prediction(s):", "Prediction": "\n- International Airlines Group SA (OTC: ICAGY) will decrease because the U.K. is balking at a bailout and they are a direct competitor.\n- Delta Air Lines, Inc. (NYSE: DAL) will decrease because the U.S. is finalizing their own industry response and they are a direct competitor.\n- American Airlines Group Inc. (NASDAQ: AAL) will decrease because the U.S. is finalizing", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": "down", "prices": [27, 27.82]}, "AAL": {"company": "", "ticker": "AAL", "move": "down", "prices": [13.86, 14.29]}}}, {"link": "https://www.wsj.com/articles/three-questions-with-ubss-jane-schwartzberg-about-women-and-money-11594396177", "title": "Three Questions With UBS's Jane Schwartzberg About Women and Money", "date": "2020-07-10 11:49", "summary": "Managing director at bank's wealth management says women should take ownership of their finances. Jane Schwartzberg, managing director at UBS wealth management, wants women to understand and take ownership of their finances.", "categories": [["Markets", "Personal Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/personal-finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Three Questions With UBS's Jane Schwartzberg About Women and Money. Managing director at bank's wealth management says women should take ownership of their finances. Jane Schwartzberg, managing director at UBS wealth management, wants women to understand and take ownership of their finances.\"\n\nStock Prediction(s):", "Prediction": "\n- UBS Group AG (NYSE: UBS) will increase because they are trying to get more women involved in their finances.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are trying to get more women involved in their finances.\n- Bank of America Corp (NYSE: BAC) will increase because they are trying to get more women involved in their finances.\n- Wells Fargo & Co. (NYSE: WFC) will increase", "price_info": {"UBS": {"company": "", "ticker": "UBS", "move": "up", "prices": [11.84, 11.9]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [94.493, 95.955]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [23.49, 23.87]}, "WFC": {"company": "", "ticker": "WFC", "move": "up", "prices": [24.955, 25.395]}}}, {"link": "https://www.wsj.com/articles/sec-joins-list-of-authorities-probing-money-laundering-at-danske-bank-11550746375", "title": "SEC Joins List of Authorities Probing Money Laundering at Danske Bank", "date": "2019-02-21 11:42", "summary": "The lender is also under investigation in Estonia, Denmark, the U.K. and France for allegedly facilitating the laundering of about $230 billion. U.S. securities regulators have joined a long list of authorities investigating Danish lender Danske Bank AS over a massive money-laundering scandal at its Estonian branch.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SEC Joins List of Authorities Probing Money Laundering at Danske Bank. The lender is also under investigation in Estonia, Denmark, the U.K. and France for allegedly facilitating the laundering of about $230 billion. U.S. securities regulators have joined a long list of authorities investigating Danish lender Danske Bank AS over a massive money-laundering scandal at its Estonian branch.\"\n\nStock Prediction(s):", "Prediction": "\n- Danske Bank A/S (OTCPK: DANSKE) will decrease because they are being investigated for money laundering.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are being investigated for money laundering.\n- Goldman Sachs Group, Inc. (NYSE: GS) will decrease because they are being investigated for money laundering.\n- Bank of America Corporation (NYSE: BAC) will decrease because they are being investigated for", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [105.105, 105.41]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [196.5482, 196.51]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [29.185, 29.295]}}}, {"link": "https://www.wsj.com/articles/coronavirus-afflicted-global-economy-is-almost-certainly-in-recession-11586867402", "title": "World Economy Is Almost Certainly in Recession", "date": "2020-04-14 13:34", "summary": "Severity is unmatched by anything aside from Great Depression, according to IMF outlook. WASHINGTON-The global economy has almost certainly entered a recession affecting most of the world, with a severity unmatched by anything aside from the Great Depression, the International Monetary Fund said Tuesday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"World Economy Is Almost Certainly in Recession. Severity is unmatched by anything aside from Great Depression, according to IMF outlook. WASHINGTON-The global economy has almost certainly entered a recession affecting most of the world, with a severity unmatched by anything aside from the Great Depression, the International Monetary Fund said Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- The global economy has almost certainly entered a recession affecting most of the world, so most stocks will decrease.\n- The only stocks that may increase are those that are not as dependent on the global economy, such as defense or technology stocks.", "price_info": {}}, {"link": "https://www.wsj.com/articles/turkeys-heavy-handed-crackdown-on-currency-speculators-11553707585", "title": "Turkey's Heavy-Handed Crackdown on Currency Speculators", "date": "2019-03-27 13:26", "summary": "Restrictions on borrowing have stabilized the lira, but at further cost to Turkey's credibility as a place to invest. Heavy-handedness has become the trademark of Turkish President Recep Tayyip Erdogan-also when dealing with financial markets. His officials' attempts to stop a currency selloff ahead of local elections Sunday could create a bigger problem than the one they solved.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Turkey's Heavy-Handed Crackdown on Currency Speculators. Restrictions on borrowing have stabilized the lira, but at further cost to Turkey's credibility as a place to invest. Heavy-handedness has become the trademark of Turkish President Recep Tayyip Erdogan-also when dealing with financial markets. His officials' attempts to stop a currency selloff ahead of local elections Sunday could create a bigger problem than the one they solved.\"\n\nStock Prediction(s):", "Prediction": "\n- Turkish President Recep Tayyip Erdogan's heavy-handed tactics will scare investors away from Turkey, causing the lira to continue to fall and the stock market to drop.\n- The only company that may benefit from this news is Halkbank A.S. (NYSE: HAKB), which is state-owned and may be less affected by the crackdown.", "price_info": {"HAKB": {"company": "", "ticker": "HAKB", "move": "up"}}}, {"link": "https://www.wsj.com/articles/weekly-jobless-claims-coronavirus-01-07-2021-11609978240", "title": "Jobless Claims Remain Elevated While Consumer Demand Boosts Goods Imports", "date": "2021-01-07 12:12", "summary": "Divergence in labor and trade figures points to uneven U.S. economic recovery during the pandemic. Workers continued to apply for unemployment aid at an elevated level at the end of 2020 and holiday-season demand for imported consumer products pushed the November trade deficit in goods to a record, signs of the uneven economic recovery.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jobless Claims Remain Elevated While Consumer Demand Boosts Goods Imports. Divergence in labor and trade figures points to uneven U.S. economic recovery during the pandemic. Workers continued to apply for unemployment aid at an elevated level at the end of 2020 and holiday-season demand for imported consumer products pushed the November trade deficit in goods to a record, signs of the uneven economic recovery.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will stay elevated because people are still applying for unemployment aid.\n- The trade deficit will continue to increase because of increased demand for imported goods.", "price_info": {}}, {"link": "https://www.wsj.com/articles/thierry-mugler-visionary-french-fashion-designer-dies-at-73-11643018929", "title": "Thierry Mugler, Visionary French Fashion Designer, Dies at 73", "date": "2022-01-24 11:41", "summary": "Known for an architectural style of haute couture, the designer created looks for stars including David Bowie, Grace Jones and Diana Ross. Manfred Thierry Mugler, the fashion designer who helped define the audacious, broad-shouldered aesthetic of French fashion in the 1980s and '90s, has died at 73.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Thierry Mugler, Visionary French Fashion Designer, Dies at 73. Known for an architectural style of haute couture, the designer created looks for stars including David Bowie, Grace Jones and Diana Ross. Manfred Thierry Mugler, the fashion designer who helped define the audacious, broad-shouldered aesthetic of French fashion in the 1980s and '90s, has died at 73.\"\n\nStock Prediction(s):", "Prediction": "\n- LVMH Mo\u00ebt Hennessy Louis Vuitton SE (OTCQX:LVMHF) will increase because they own the Thierry Mugler brand.\n- Kering SA (OTCPK:PPRUF) will increase because they own the Thierry Mugler brand.\n- Christian Dior SE (OTCPK:CHDRF) will increase because they own the Thierry Mugler brand.\n- Gu", "price_info": {}}, {"link": "https://www.wsj.com/articles/fda-weighing-dose-of-moderna-covid-19-booster-11630593980", "title": "FDA Weighing Dosage of Moderna Booster", "date": "2021-09-02 12:32", "summary": "Vaccine maker has asked agency to authorize booster at half the dose given in the first two shots. The Food and Drug Administration is considering whether to authorize a lower dose of Moderna Inc.'s Covid-19 vaccine for boosters than the dose given in the first two shots, people familiar with the deliberations said.", "categories": [["WSJ News Exclusive", "Health & Wellness"]], "category_links": ["https://www.wsj.com/news/types/health-wellness?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FDA Weighing Dosage of Moderna Booster. Vaccine maker has asked agency to authorize booster at half the dose given in the first two shots. The Food and Drug Administration is considering whether to authorize a lower dose of Moderna Inc.'s Covid-19 vaccine for boosters than the dose given in the first two shots, people familiar with the deliberations said.\"\n\nStock Prediction(s):", "Prediction": "\n- Moderna Inc (NASDAQ: MRNA) will decrease because their vaccine is not as effective as AstraZeneca's, and they are asking for a lower dosage.", "price_info": {"MRNA": {"company": "", "ticker": "MRNA", "move": "down", "prices": [396.56, 395.97]}}}, {"link": "https://www.wsj.com/articles/netflix-changes-how-it-ranks-its-most-popular-shows-11637092802", "title": "Netflix Changes How It Ranks Viewership", "date": "2021-11-16 15:00", "summary": "Streaming service will release weekly top 10 of shows by total hours viewed, dropping much-criticized two-minute metric. Netflix Inc. is changing how it measures viewership of its content, a move that the streaming company said will provide more clarity when it comes to judging the popularity of programming on its platform.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Netflix Changes How It Ranks Viewership. Streaming service will release weekly top 10 of shows by total hours viewed, dropping much-criticized two-minute metric. Netflix Inc. is changing how it measures viewership of its content, a move that the streaming company said will provide more clarity when it comes to judging the popularity of programming on its platform.\"\n\nStock Prediction(s):", "Prediction": "\n- Netflix, Inc. (NASDAQ: NFLX) will increase because they are changing how they rank viewership, which will give a more accurate depiction of their shows' popularity.\n- Disney (NYSE: DIS) will decrease because they own Hulu, which will now have a more accurate depiction of its shows' popularity compared to Netflix.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [159.0256, 158.94]}, "NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [685.84, 688.15]}}}, {"link": "https://www.wsj.com/articles/more-jobs-less-inflation-11615397120", "title": "More Jobs, Less Inflation?", "date": "2021-03-10 12:25", "summary": "A better labor market might actually alleviate some inflationary pressures in the months ahead. Tightening labor markets are supposed to make for higher inflation. But at least in the months ahead, the faster the job market recovers, the less serious some inflationary pressures might be.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"More Jobs, Less Inflation?. A better labor market might actually alleviate some inflationary pressures in the months ahead. Tightening labor markets are supposed to make for higher inflation. But at least in the months ahead, the faster the job market recovers, the less serious some inflationary pressures might be.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will continue to decline, which will be good news for the stock prices of companies such as Walmart Inc. (NYSE: WMT) and Target Corporation (NYSE: TGT).\n- The inflation rate will remain low, which will be good news for the stock prices of companies such as Walmart Inc. (NYSE: WMT) and Target Corporation (NYSE: TGT).", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": null, "prices": [131.53, 131.94]}, "TGT": {"company": "", "ticker": "TGT", "move": null, "prices": [178.5993, 179.546]}}}, {"link": "https://www.wsj.com/articles/tradebot-pioneer-of-high-speed-trading-struggles-with-profit-slump-11580739026", "title": "Tradebot, Pioneer of High-Speed Trading, Struggles With Profit Slump", "date": "2020-02-03 10:58", "summary": "An early high-frequency trader now faces falling income and an employee exodus. An early high-frequency trader that helped invent the business of buying and selling stocks in milliseconds now faces falling profits and an employee exodus.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tradebot, Pioneer of High-Speed Trading, Struggles With Profit Slump. An early high-frequency trader now faces falling income and an employee exodus. An early high-frequency trader that helped invent the business of buying and selling stocks in milliseconds now faces falling profits and an employee exodus.\"\n\nStock Prediction(s):", "Prediction": "\n- Tradebot will continue to struggle because their business model is no longer profitable.\n- Other high-frequency traders, like Virtu Financial (NASDAQ: VIRT) and Tower Research Capital (NASDAQ: TRRC), will benefit from Tradebot's struggles and increase in value.", "price_info": {"VIRT": {"company": "", "ticker": "VIRT", "move": null, "prices": [16.39, 16.215]}, "TRRC": {"company": "", "ticker": "TRRC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/electric-switch-old-planes-get-makeovers-in-race-for-the-skies-11563200318", "title": "Electric Airplanes Start to Take Off", "date": "2019-07-15 10:18", "summary": "Retrofitting existing planes draws interest from startups and big manufacturers, including Airbus. A five-passenger airplane took flight near Los Angeles recently with one important modification: an electric motor.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Electric Airplanes Start to Take Off. Retrofitting existing planes draws interest from startups and big manufacturers, including Airbus. A five-passenger airplane took flight near Los Angeles recently with one important modification: an electric motor.\"\n\nStock Prediction(s):", "Prediction": "\n- Airbus SE (EPA: AIR) will increase because they are a big manufacturer that is getting into the electric airplane market.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they make electric cars, and this is a similar technology.\n- Wright Electric Co. (private) will increase because they are a startup that is making electric airplanes.", "price_info": {"TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [246.5, 246.62]}}}, {"link": "https://www.wsj.com/articles/delta-kb-home-taiwan-semiconductor-what-to-watch-in-the-stock-market-today-11642075136", "title": "Delta, Virgin Galactic, KB Home, Taiwan Semiconductor: What to Watch in the Stock Market Today", "date": "2022-01-13 09:41", "summary": "Earnings season is back. Delta Air Lines shares rose after reporting quarterly results.. U.S. stocks and bond yields crept higher as fresh data on inflation and the labor market provided a mixed picture of the economic recovery. Here's what we're watching in Thursday's trading:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Delta, Virgin Galactic, KB Home, Taiwan Semiconductor: What to Watch in the Stock Market Today. Earnings season is back. Delta Air Lines shares rose after reporting quarterly results.. U.S. stocks and bond yields crept higher as fresh data on inflation and the labor market provided a mixed picture of the economic recovery. Here's what we're watching in Thursday's trading:\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines, Inc. (NYSE: DAL) will increase because their earnings report was good.\n- Virgin Galactic Holdings Ltd. (NYSE: SPCE) will increase because their earnings report was good.\n- KB Home (NYSE: KBH) will increase because their earnings report was good.\n- Taiwan Semiconductor Manufacturing Co Ltd (NYSE: TSM) will increase because their earnings report was good.", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": "up", "prices": [41.03, 41.72]}, "SPCE": {"company": "", "ticker": "SPCE", "move": "up", "prices": [10.525, 10.378]}, "KBH": {"company": "", "ticker": "KBH", "move": "up", "prices": [48.82, 48.04]}, "TSM": {"company": "", "ticker": "TSM", "move": "up", "prices": [143.94, 140.38]}}}, {"link": "https://www.wsj.com/articles/a-reminder-for-ceos-considering-a-shift-in-focus-shareholders-are-still-king-11567791772", "title": "A Reminder for CEOs: Shareholders Are Still King", "date": "2019-09-06 13:42", "summary": "While 181 CEOs say they are committed to serving 'all stakeholders,' when it comes to assessing their own performance, there is really only one master. ", "categories": [["Business", "On Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/on-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Reminder for CEOs: Shareholders Are Still King. While 181 CEOs say they are committed to serving 'all stakeholders,' when it comes to assessing their own performance, there is really only one master. \"\n\nStock Prediction(s):", "Prediction": "\n- The CEOs of public companies will continue to put their shareholders first, and this will result in an increase in stock prices.\n- The CEOs of private companies will put more emphasis on other stakeholders, and this will result in a decrease in stock prices.", "price_info": {}}, {"link": "https://www.wsj.com/articles/virgin-galactic-didi-lionheart-acquisition-what-to-watch-when-the-stock-market-opens-today-11626087836", "title": "Virgin Galactic, Didi, Lionheart Acquisition: What to Watch When the Stock Market Opens Today", "date": "2021-07-12 09:35", "summary": "U.S. stock futures were mixed after Friday's record close on Wall Street. Earnings season is set to kick off this week, starting with big banks, and investors will be watching to see if they can deliver on high expectations. Here's what we're watching ahead of Monday's open.", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Virgin Galactic, Didi, Lionheart Acquisition: What to Watch When the Stock Market Opens Today. U.S. stock futures were mixed after Friday's record close on Wall Street. Earnings season is set to kick off this week, starting with big banks, and investors will be watching to see if they can deliver on high expectations. Here's what we're watching ahead of Monday's open.\"\n\nStock Prediction(s):", "Prediction": "\n- Virgin Galactic Holdings Inc (NYSE: VGC) will increase because they announced a partnership with Didi Chuxing, and they are also working on a vaccine.\n- Lionheart Acquisition Corp (NASDAQ: LHC) will increase because they announced a merger with Virgin Galactic, and they are also working on a vaccine.", "price_info": {"VGC": {"company": "", "ticker": "VGC", "move": "up"}, "LHC": {"company": "", "ticker": "LHC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/home-price-growth-slows-heading-into-spring-11553605608", "title": "Home-Price Growth Slows Heading Into Spring", "date": "2019-03-26 10:20", "summary": "Once-hot housing markets like Seattle and San Francisco cool off, while Las Vegas continues to sizzle. Home-price growth slowed for the 10th straight month in January, providing critical relief to buyers heading into the spring selling season.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Home-Price Growth Slows Heading Into Spring. Once-hot housing markets like Seattle and San Francisco cool off, while Las Vegas continues to sizzle. Home-price growth slowed for the 10th straight month in January, providing critical relief to buyers heading into the spring selling season.\"\n\nStock Prediction(s):", "Prediction": "\n- Seattle-based Zillow Group, Inc. (NASDAQ: Z) will increase because the housing market is cooling off, and they are a major player in the online real estate market.\n- San Francisco-based Redfin Corporation (NASDAQ: RDFN) will increase because the housing market is cooling off, and they are a major player in the online real estate market.\n- Las Vegas-based HomeAway, Inc. (NASDAQ", "price_info": {"Z": {"company": "Seattle-based", "ticker": "Z", "move": "up", "prices": [35.8, 35.5]}, "RDFN": {"company": "", "ticker": "RDFN", "move": "up", "prices": [20.3015, 20.2]}}}, {"link": "https://www.wsj.com/articles/credit-suisse-faces-possible-charges-on-greensill-loan-11615884514", "title": "Credit Suisse Faces Possible Loss Over Greensill Collapse", "date": "2021-03-16 13:56", "summary": "Swiss bank says it received $50 million back so far from $140 million owed by the firm. Credit Suisse Group AG warned that the bank and investors in some of its funds face potential losses from the collapse of U.K. financial firm Greensill Capital earlier this month.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Credit Suisse Faces Possible Loss Over Greensill Collapse. Swiss bank says it received $50 million back so far from $140 million owed by the firm. Credit Suisse Group AG warned that the bank and investors in some of its funds face potential losses from the collapse of U.K. financial firm Greensill Capital earlier this month.\"\n\nStock Prediction(s):", "Prediction": "\n- Credit Suisse Group AG (NYSE: CS) will decrease because of the potential losses from the collapse of Greensill Capital.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because of the potential losses from the collapse of Greensill Capital.\n- Goldman Sachs Group Inc. (NYSE: GS) will decrease because of the potential losses from the collapse of Greensill Capital.", "price_info": {"CS": {"company": "", "ticker": "CS", "move": "down", "prices": [12.915, 12.91]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [153.96, 153.735]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [341.9, 341.94]}}}, {"link": "https://www.wsj.com/articles/amc-delays-reopening-theaters-to-late-july-11593458833", "title": "AMC Delays Reopening Theaters to Late July", "date": "2020-06-29 15:27", "summary": "Shift follows changes in release dates for Disney's 'Mulan' and Warner Bros.' 'Tenet'. AMC Entertainment Holdings , the country's largest theater chain, is postponing plans to reopen its U.S. locations by about two weeks, to July 30, following date changes for the upcoming releases of two major films.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AMC Delays Reopening Theaters to Late July. Shift follows changes in release dates for Disney's 'Mulan' and Warner Bros.' 'Tenet'. AMC Entertainment Holdings , the country's largest theater chain, is postponing plans to reopen its U.S. locations by about two weeks, to July 30, following date changes for the upcoming releases of two major films.\"\n\nStock Prediction(s):", "Prediction": "\n- AMC Entertainment Holdings (NYSE: AMC) will decrease because their theaters will not reopen until late July.\n- Disney (NYSE: DIS) will increase because their movie, Mulan, is being released in late July.\n- Warner Bros. (NYSE: TWX) will increase because their movie, Tenet, is being released in late July.", "price_info": {"AMC": {"company": "", "ticker": "AMC", "move": "down", "prices": [4.45, 4.48]}, "DIS": {"company": "", "ticker": "DIS", "move": "up", "prices": [111.59, 111.67]}, "TWX": {"company": "", "ticker": "TWX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/gold-ticks-higher-amid-growth-concerns-11553512398", "title": "Gold Rises on Haven Demand, Weaker Dollar", "date": "2019-03-25 15:11", "summary": "Prices have risen about 3.2% for the year; copper inches up.. Gold prices climbed for the third consecutive session Monday, boosted by safe-haven demand with investors around the world fearing a sharp slowdown in global economic growth.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold Rises on Haven Demand, Weaker Dollar. Prices have risen about 3.2% for the year; copper inches up.. Gold prices climbed for the third consecutive session Monday, boosted by safe-haven demand with investors around the world fearing a sharp slowdown in global economic growth.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldcorp Inc. (NYSE: GG) will increase because of the global slowdown and the increased demand for gold as a safe haven.\n- Barrick Gold Corp. (NYSE: ABX) will increase because of the global slowdown and the increased demand for gold as a safe haven.\n- Newmont Mining Corp. (NYSE: NEM) will increase because of the global slowdown and the increased demand for gold as a safe haven.\n- AngloGold", "price_info": {"GG": {"company": "", "ticker": "GG", "move": "up", "prices": [11.12, 11.1999]}, "ABX": {"company": "", "ticker": "ABX", "move": "up"}, "NEM": {"company": "", "ticker": "NEM", "move": "up", "prices": [34.9531, 34.8]}}}, {"link": "https://www.wsj.com/articles/collapsing-yields-could-head-even-lower-11553276276", "title": "Collapsing Yields Could Head Even Lower", "date": "2019-03-22 13:37", "summary": "Treasury yields have seen an epic and unusual collapse but, even without signs of a looming recession, they could head lower. When Treasury yields fall sharply, it is usually because something bad is happening, but the latest drop seems to be mostly about the Federal Reserve. That doesn't mean it can't go on for a while.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Collapsing Yields Could Head Even Lower. Treasury yields have seen an epic and unusual collapse but, even without signs of a looming recession, they could head lower. When Treasury yields fall sharply, it is usually because something bad is happening, but the latest drop seems to be mostly about the Federal Reserve. That doesn't mean it can't go on for a while.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will continue to go down because of the collapsing Treasury yields.\n- The market will rebound because the Federal Reserve is likely to cut interest rates in order to stimulate the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/tech-oriented-companies-profit-from-demand-for-select-products-earnings-at-a-glance-11595861357", "title": "Tech-Oriented Companies Profit From Demand for Select Products: Earnings at a Glance", "date": "2020-07-27 10:49", "summary": "Resume Subscription. Tech-oriented companies posted higher profits in the first half of the year despite the Covid-19 pandemic as customers paid for select products and services.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tech-Oriented Companies Profit From Demand for Select Products: Earnings at a Glance. Resume Subscription. Tech-oriented companies posted higher profits in the first half of the year despite the Covid-19 pandemic as customers paid for select products and services.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because their products are in high demand.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because their products are in high demand.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because their products are in high demand.\n- Facebook, Inc. (NASDAQ: FB) will increase because their products are in high demand.\n- Google LLC (", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [375.8, 377.2297]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3039.1034, 3042.4299]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [201.8, 202.6274]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [232.04, 233.235]}}}, {"link": "https://www.wsj.com/articles/meta-platforms-peloton-general-motors-what-to-watch-in-the-stock-market-today-11644322710", "title": "Peloton, Pfizer, Meta, General Motors: What to Watch in the Stock Market Today", "date": "2022-02-08 09:47", "summary": "Earnings are due after the market close from Lyft, Chipotle Mexican Grill and Peloton Interactive.. U.S. stock indexes wobbled in morning trading as investors awaited another docket of major earnings reports. Here's what we're following in markets Tuesday:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Peloton, Pfizer, Meta, General Motors: What to Watch in the Stock Market Today. Earnings are due after the market close from Lyft, Chipotle Mexican Grill and Peloton Interactive.. U.S. stock indexes wobbled in morning trading as investors awaited another docket of major earnings reports. Here's what we're following in markets Tuesday:\"\n\nStock Prediction(s):", "Prediction": "\n- Peloton Interactive, Inc. (NASDAQ: PTON) will increase because they have positive earnings and are a major player in the fitness industry.\n- Pfizer Inc. (NYSE: PFE) will decrease because they have negative earnings and are a major pharmaceutical company.\n- General Motors Company (NYSE: GM) will decrease because they have negative earnings and are a major automobile company.\n- Meta Company (NASDAQ: META) will decrease because", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [51.015, 50.396]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [47.755, 48.24]}, "PTON": {"company": "", "ticker": "PTON", "move": "up", "prices": [32.623, 35.4971]}, "META": {"company": "", "ticker": "META", "move": "down"}}}, {"link": "https://www.wsj.com/articles/tiktok-shutdown-argued-before-federal-judge-11604518470", "title": "TikTok Shutdown Argued Before Federal Judge", "date": "2020-11-04 14:34", "summary": "Chinese-owned video app aims to block Nov. 12 shutdown; no immediate ruling from bench. WASHINGTON-Lawyers for Chinese-owned video app TikTok clashed with Trump administration lawyers in federal court Wednesday as they fought to stave off a government-ordered shutdown later this month.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"TikTok Shutdown Argued Before Federal Judge. Chinese-owned video app aims to block Nov. 12 shutdown; no immediate ruling from bench. WASHINGTON-Lawyers for Chinese-owned video app TikTok clashed with Trump administration lawyers in federal court Wednesday as they fought to stave off a government-ordered shutdown later this month.\"\n\nStock Prediction(s):", "Prediction": "\n- ByteDance Ltd. (NYSE: BYT) will increase because they are the parent company of TikTok, and they are fighting to keep the app open.\n- Apple Inc. (NASDAQ: AAPL) will increase because they own a stake in ByteDance, and they will benefit from the app staying open.\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are in direct competition with TikTok, and the app", "price_info": {"BYT": {"company": "", "ticker": "BYT", "move": "up"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [114.8117, 115.07]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [288.2, 285.5901]}}}, {"link": "https://www.wsj.com/articles/freshworks-shouldnt-spoil-on-delivery-11632152233", "title": "Freshworks Shouldn't Spoil on Delivery", "date": "2021-09-20 11:37", "summary": "Cloud-software company's IPO should stand out for its reasonable valuation and path to profitability. Freshworks won't have the initial public offering world to itself this week, but the cloud-software company is appetizing enough to stand out in a crowded pack.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Freshworks Shouldn't Spoil on Delivery. Cloud-software company's IPO should stand out for its reasonable valuation and path to profitability. Freshworks won't have the initial public offering world to itself this week, but the cloud-software company is appetizing enough to stand out in a crowded pack.\"\n\nStock Prediction(s):", "Prediction": "\n- Freshworks Inc (NASDAQ: FRES) will increase because their IPO is reasonable and they are on a path to profitability.\n- Zoom Video Communications, Inc. (NASDAQ: ZM) will increase because their IPO is reasonable and they are on a path to profitability.\n- Crowdstrike Holdings, Inc. (NASDAQ: CRWD) will increase because their IPO is reasonable and they are on a path to profitability.\n- Okta, Inc", "price_info": {"FRES": {"company": "", "ticker": "FRES", "move": "up"}, "ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [278.36, 281.59]}, "CRWD": {"company": "", "ticker": "CRWD", "move": "up", "prices": [255.86, 255.1213]}}}, {"link": "https://www.wsj.com/articles/trump-makes-a-cookie-great-again-11589900809", "title": "Trump Makes a Cookie Great Again", "date": "2020-05-19 11:06", "summary": "Hydrox cookies got a surge in interest for the second time from the president, this time riding the coattails of hydroxychloroquine. Makers of an old malaria drug aren't the only ones cheering President Trump's surprise statement Monday that he takes it regularly to ward off coronavirus. A cookie company also got a boost, and it wasn't the first time.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump Makes a Cookie Great Again. Hydrox cookies got a surge in interest for the second time from the president, this time riding the coattails of hydroxychloroquine. Makers of an old malaria drug aren't the only ones cheering President Trump's surprise statement Monday that he takes it regularly to ward off coronavirus. A cookie company also got a boost, and it wasn't the first time.\"\n\nStock Prediction(s):", "Prediction": "\n- Mondelez International, Inc. (NASDAQ: MDLZ) will increase because their main competitor, Oreo, just lost market share to Hydrox.\n- Keebler Company (NYSE: KEB) will increase because their main competitor, Oreo, just lost market share to Hydrox.", "price_info": {"KEB": {"company": "", "ticker": "KEB", "move": "up"}, "MDLZ": {"company": "", "ticker": "MDLZ", "move": "up", "prices": [50.295, 50.29]}}}, {"link": "https://www.wsj.com/articles/our-cash-went-to-something-customers-hunt-for-bankrupt-crypto-exchanges-missing-millions-11550596908", "title": "Customers Hunt for Bankrupt Crypto Exchange's Missing Millions", "date": "2019-02-19 12:21", "summary": "Unusual cash-pickup system mysteriously closes. On a rainy January day, Jason Campbell drove for three hours from his home in Quebec City to a two-story office building in the Montreal suburb of Laval. He thought he would be picking up $1,000-in cash-he had stored at cryptocurrency exchange QuadrigaCX.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Customers Hunt for Bankrupt Crypto Exchange's Missing Millions. Unusual cash-pickup system mysteriously closes. On a rainy January day, Jason Campbell drove for three hours from his home in Quebec City to a two-story office building in the Montreal suburb of Laval. He thought he would be picking up $1,000-in cash-he had stored at cryptocurrency exchange QuadrigaCX.\"\n\nStock Prediction(s):", "Prediction": "\n- QuadrigaCX (OTCQB: QCX) will increase because they have millions of dollars worth of cryptocurrency that people are looking for.\n- Coinbase (OTCQB: GDAX) will increase because they are a direct competitor of QuadrigaCX and people will be looking for a new exchange to use.\n- Bitfinex (OTC: BFX) will increase because they are a direct competitor of QuadrigaCX", "price_info": {}}, {"link": "https://www.wsj.com/articles/covid-19-vaccines-to-cause-temporary-side-effects-doctors-say-11607536289", "title": "Covid-19 Vaccines Pose Potential Side Effects, Doctors Say", "date": "2020-12-09 13:39", "summary": "U.K. authorities warn people with severe allergies against receiving the Pfizer-BioNTech shots, after two Britons experience allergic reactions. Most people are unlikely to have severe allergic reactions to the Pfizer -BioNTech vaccine, doctors and vaccine experts say, but the shots might come with temporary side effects such as fever and muscle pain.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Vaccines Pose Potential Side Effects, Doctors Say. U.K. authorities warn people with severe allergies against receiving the Pfizer-BioNTech shots, after two Britons experience allergic reactions. Most people are unlikely to have severe allergic reactions to the Pfizer -BioNTech vaccine, doctors and vaccine experts say, but the shots might come with temporary side effects such as fever and muscle pain.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will decrease because their vaccine might have potential side effects.\n- BioNTech SE (XTRA: BNTX) will increase because they are a competitor of Pfizer, and their vaccine does not have any potential side effects.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "up", "prices": [41.4926, 41.9426]}}}, {"link": "https://www.wsj.com/articles/how-a-nursing-home-and-a-clock-merchant-got-masks-out-of-china-11589448601", "title": "How 400,000 Masks Were Shipped From China to a U.S. Nursing Home", "date": "2020-05-14 12:54", "summary": "Health-care executives and entrepreneurs are wading into the murky market for badly needed protective gear. Nursing homes, many at the center of outbreaks of the new coronavirus, are struggling to find masks and other supplies their workers need to confront the pandemic.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How 400,000 Masks Were Shipped From China to a U.S. Nursing Home. Health-care executives and entrepreneurs are wading into the murky market for badly needed protective gear. Nursing homes, many at the center of outbreaks of the new coronavirus, are struggling to find masks and other supplies their workers need to confront the pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- 3M Co (NYSE: MMM) will increase because they are one of the few companies that are able to produce large quantities of masks.\n- Kimberly-Clark Corp (NYSE: KMB) will increase because they are one of the few companies that are able to produce large quantities of masks.\n- Honeywell International Inc. (NYSE: HON) will increase because they are one of the few companies that are able to produce large quantities of masks.", "price_info": {"MMM": {"company": "", "ticker": "MMM", "move": "up", "prices": [133.55, 134.96]}, "KMB": {"company": "", "ticker": "KMB", "move": "up", "prices": [137.2674, 136.8498]}, "HON": {"company": "", "ticker": "HON", "move": "up", "prices": [124.4, 125.78]}}}, {"link": "https://www.wsj.com/articles/retail-tenants-leverage-pandemic-stress-for-rent-cuts-11610361000", "title": "Retail Tenants Leverage Pandemic Stress for Rent Cuts", "date": "2021-01-11 12:02", "summary": "Some retailers, restaurants, gyms and other businesses are experiencing improved lease terms as they gain the upper hand over landlords looking to retain tenants. U.S. commercial landlords have granted billions of dollars of rent relief to struggling storefronts as property owners strive to keep falling occupancy rates from triggering more severe financial consequences.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Retail Tenants Leverage Pandemic Stress for Rent Cuts. Some retailers, restaurants, gyms and other businesses are experiencing improved lease terms as they gain the upper hand over landlords looking to retain tenants. U.S. commercial landlords have granted billions of dollars of rent relief to struggling storefronts as property owners strive to keep falling occupancy rates from triggering more severe financial consequences.\"\n\nStock Prediction(s):", "Prediction": "\n- Retailers will increase because they are getting better lease terms from landlords.\n- Landlords will decrease because they are giving rent relief to struggling storefronts.", "price_info": {}}, {"link": "https://www.wsj.com/articles/top-occidental-petroleum-exec-out-as-company-grapples-with-oil-rout-11585764736", "title": "A Top Occidental Executive Is Out as Company Grapples With Oil Rout", "date": "2020-04-01 15:08", "summary": "Oscar Brown, a key lieutenant of CEO Vicki Hollub, played a substantial role in last year's acquisition of Anadarko Petroleum. A top Occidental Petroleum Corp. executive has been forced out of the company as it deals with the repercussions of an ill-timed acquisition, a precipitous decline in crude prices and hefty debt, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Top Occidental Executive Is Out as Company Grapples With Oil Rout. Oscar Brown, a key lieutenant of CEO Vicki Hollub, played a substantial role in last year's acquisition of Anadarko Petroleum. A top Occidental Petroleum Corp. executive has been forced out of the company as it deals with the repercussions of an ill-timed acquisition, a precipitous decline in crude prices and hefty debt, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Occidental Petroleum Corporation (NYSE: OXY) will decrease because they are losing a key executive during a difficult time.\n- Chevron Corporation (NYSE: CVX) will increase because they are not experiencing the same turmoil as Occidental Petroleum.", "price_info": {"OXY": {"company": "", "ticker": "OXY", "move": "down", "prices": [10.82, 10.84]}, "CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [68.6, 68.75]}}}, {"link": "https://www.wsj.com/articles/gig-worker-balances-big-paydays-against-coronavirus-risks-11584718716", "title": "Gig Worker Balances Big Paydays Against Virus Risks", "date": "2020-03-20 11:38", "summary": "Joseph Puma's Shipt deliveries include constant texting with customers, hauling 12-packs onto the bus. Is it worth being exposed for a $20 tip?. Before the coronavirus pandemic, Joseph Puma's best day as a gig worker was a $344 haul he notched last year. Last Friday, he nearly doubled that tally and followed up with another $602 over the weekend.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gig Worker Balances Big Paydays Against Virus Risks. Joseph Puma's Shipt deliveries include constant texting with customers, hauling 12-packs onto the bus. Is it worth being exposed for a $20 tip?. Before the coronavirus pandemic, Joseph Puma's best day as a gig worker was a $344 haul he notched last year. Last Friday, he nearly doubled that tally and followed up with another $602 over the weekend.\"\n\nStock Prediction(s):", "Prediction": "\n- Postmates Inc (NASDAQ: PTMTS) will increase because they are not as risky as other gig-worker platforms, and they offer a higher payout.\n- DoorDash Inc (NYSE: DASH) will decrease because they are more risky than Postmates, and they offer a lower payout.\n- Uber Technologies Inc (NYSE: UBER) will decrease because they are more risky than Postmates, and they offer a lower payout.", "price_info": {"DASH": {"company": "", "ticker": "DASH", "move": "down"}, "UBER": {"company": "", "ticker": "UBER", "move": "down", "prices": [20.94, 21.2325]}, "PTMTS": {"company": "", "ticker": "PTMTS", "move": "up"}}}, {"link": "https://www.wsj.com/articles/commodities-traders-face-limits-on-speculative-positions-under-u-s-proposal-11580410142", "title": "Commodities Traders Face Limits on Speculative Positions Under U.S. Proposal", "date": "2020-01-30 15:41", "summary": "The aim is to prevent speculators from causing unjustified price swings that could hurt consumers. WASHINGTON-Federal regulators on Thursday proposed so-called position limits in markets for commodities such as gold, sugar and crude oil while leaving exchanges with considerable leeway in deciding how to contain speculative bets.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Commodities Traders Face Limits on Speculative Positions Under U.S. Proposal. The aim is to prevent speculators from causing unjustified price swings that could hurt consumers. WASHINGTON-Federal regulators on Thursday proposed so-called position limits in markets for commodities such as gold, sugar and crude oil while leaving exchanges with considerable leeway in deciding how to contain speculative bets.\"\n\nStock Prediction(s):", "Prediction": "\n- Agricultural commodities traders will increase because the new proposal limits the amount of speculative positions that traders can have, which will prevent price swings.\n- Energy commodities traders will decrease because the new proposal limits the amount of speculative positions that traders can have, which will prevent price swings.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bitcoin-coinbase-shiba-inu-alibaba-what-to-watch-when-the-stock-market-opens-today-11638790682", "title": "Bitcoin, Coinbase, Shiba Inu, Alibaba: What to Watch in the Stock Market Today", "date": "2021-12-06 09:38", "summary": "An activist investor urged Kohl's to consider a sale; Alibaba is reorganizing its e-commerce teams. Wall Street indexes were mixed in morning trading as investors considered a small study suggesting that the Omicron variant may cause milder disease. Here's what we're watching in Monday's trading:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bitcoin, Coinbase, Shiba Inu, Alibaba: What to Watch in the Stock Market Today. An activist investor urged Kohl's to consider a sale; Alibaba is reorganizing its e-commerce teams. Wall Street indexes were mixed in morning trading as investors considered a small study suggesting that the Omicron variant may cause milder disease. Here's what we're watching in Monday's trading:\"\n\nStock Prediction(s):", "Prediction": "\n- Kohl's Corporation (NYSE: KSS) will increase because an activist investor is urging them to sell, and Alibaba is reorganizing their e-commerce teams which could lead to a partnership.\n- Alibaba Group Holding Ltd. (NYSE: BABA) will increase because they are reorganizing their e-commerce teams, and this could lead to a partnership with Kohl's.\n- Bitcoin (BTC) will decrease because of the small study suggesting that the O", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "down"}, "KSS": {"company": "", "ticker": "KSS", "move": "up", "prices": [50.8, 52.75]}, "BABA": {"company": "", "ticker": "BABA", "move": "up", "prices": [115.55, 119.4]}}}, {"link": "https://www.wsj.com/articles/ges-asset-sales-bode-well-for-balance-sheet-11551208711", "title": "GE's Asset Sales Bode Well for Balance Sheet", "date": "2019-02-26 14:18", "summary": "Conglomerate's plan to sell some businesses to reduce debt will need to be balanced against the cuts such sales make in its ability to generate cash, analysts say. General Electric Co. 's strategy to shed noncore assets to pay down its debt could sap the company's future cash flows, but the move is expected to ultimately help stabilize its balance sheet and allow the company to focus on organic growth, analysts say.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GE's Asset Sales Bode Well for Balance Sheet. Conglomerate's plan to sell some businesses to reduce debt will need to be balanced against the cuts such sales make in its ability to generate cash, analysts say. General Electric Co. 's strategy to shed noncore assets to pay down its debt could sap the company's future cash flows, but the move is expected to ultimately help stabilize its balance sheet and allow the company to focus on organic growth, analysts say.\"\n\nStock Prediction(s):", "Prediction": "\n- GE (NYSE: GE) will increase because they are selling some businesses to reduce debt, and this will help to stabilize their balance sheet.\n- Honeywell International Inc. (NYSE: HON) will increase because they are a direct competitor of GE, and they will benefit from GE's divestitures.\n- 3M Co. (NYSE: MMM) will increase because they are a direct competitor of GE, and they will benefit from GE's divestitures", "price_info": {"GE": {"company": "", "ticker": "GE", "move": "up", "prices": [10.5901, 10.65]}, "HON": {"company": "", "ticker": "HON", "move": "up", "prices": [154.13, 154.34]}, "MMM": {"company": "", "ticker": "MMM", "move": "up", "prices": [210.41, 209.77]}}}, {"link": "https://www.wsj.com/articles/global-chip-shortage-set-to-worsen-for-car-makers-11619708393", "title": "Global Chip Shortage Set to Worsen for Car Makers", "date": "2021-04-29 10:59", "summary": "Auto makers anticipate a slower recovery in chip supplies following the fire at Japan's Renesas semiconductor factory and the Texas freeze. Global auto makers who had expected the semiconductor supply crisis to subside in the spring are now warning that chips will remain scarce for months while a second-half recovery is fraught with uncertainty.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Global Chip Shortage Set to Worsen for Car Makers. Auto makers anticipate a slower recovery in chip supplies following the fire at Japan's Renesas semiconductor factory and the Texas freeze. Global auto makers who had expected the semiconductor supply crisis to subside in the spring are now warning that chips will remain scarce for months while a second-half recovery is fraught with uncertainty.\"\n\nStock Prediction(s):", "Prediction": "\n- Texas Instruments Incorporated (NASDAQ: TXN) will increase because they are not affected by the fire at the Renesas semiconductor factory.\n- Nvidia Corporation (NASDAQ: NVDA) will increase because they are not affected by the fire at the Renesas semiconductor factory.\n- Advanced Micro Devices, Inc. (NASDAQ: AMD) will increase because they are not affected by the fire at the Renesas semiconductor factory.\n", "price_info": {"TXN": {"company": "", "ticker": "TXN", "move": "up", "prices": [183.99, 184.09]}, "NVDA": {"company": "", "ticker": "NVDA", "move": "up", "prices": [607.2843, 606.1]}, "AMD": {"company": "", "ticker": "AMD", "move": "up", "prices": [83.3, 83.4891]}}}, {"link": "https://www.wsj.com/articles/how-tech-giants-get-you-to-click-this-and-not-that-11559315900", "title": "How Tech Giants Get You to Click This (and Not That)", "date": "2019-05-31 11:18", "summary": "Design tactics, known as dark patterns, are aimed at prompting users into actions that benefit the company but not necessarily the user. It's a common experience among consumers: You click on something when making a purchase or signing up for a new site, only to realize later that you agreed to something you never intended.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How Tech Giants Get You to Click This (and Not That). Design tactics, known as dark patterns, are aimed at prompting users into actions that benefit the company but not necessarily the user. It's a common experience among consumers: You click on something when making a purchase or signing up for a new site, only to realize later that you agreed to something you never intended.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will decrease because of the negative press around their use of dark patterns.\n- Google LLC (NASDAQ: GOOGL) will decrease because of the negative press around their use of dark patterns.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because of the negative press around their use of dark patterns.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [178.32, 178.8]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [1109.4034, 1109.8401]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1788.115, 1785.99]}}}, {"link": "https://www.wsj.com/articles/u-s-september-nonfarm-payrolls-grew-steadily-11570192288", "title": "U.S. Unemployment Hit 50-Year Low in September", "date": "2019-10-04 15:17", "summary": "Employers also added 136,000 jobs, suggesting the economy hasn't been affected by global weakening. U.S. unemployment dropped to a half-century low in September and job growth continued at a modest pace, signs the economy is holding up despite a broader global slowdown.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Unemployment Hit 50-Year Low in September. Employers also added 136,000 jobs, suggesting the economy hasn't been affected by global weakening. U.S. unemployment dropped to a half-century low in September and job growth continued at a modest pace, signs the economy is holding up despite a broader global slowdown.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate dropping will have a positive effect on the stock prices of companies such as Walmart Inc. (NYSE: WMT) and Target Corporation (NYSE: TGT) because it will mean that there are more people with money to spend.\n- The unemployment rate dropping will have a negative effect on the stock prices of companies such as Amazon.com, Inc. (NASDAQ: AMZN) and Netflix, Inc. (NASDAQ: NFLX)", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [118.1452, 118.16]}, "TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [109.09, 109.3]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1740.2, 1740.5]}, "NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [272.7, 272.78]}}}, {"link": "https://www.wsj.com/articles/feds-brainard-adjusts-outlook-to-fewer-rate-increases-11551979253", "title": "Fed's Brainard Adjusts Outlook to Fewer Rate Increases", "date": "2019-03-07 14:00", "summary": "Slowing global economy and high uncertainty underscore need for fewer interest-rate increases than expected earlier, Fed governor says. PRINCETON, N.J.-A top Federal Reserve official said Thursday a slowing global economy, risks to U.S. growth and uncertainty over the outlook bolster the case for fewer interest-rate increases than she had previously expected, adding any decision the Fed makes on monetary policy lies months down the road.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Brainard Adjusts Outlook to Fewer Rate Increases. Slowing global economy and high uncertainty underscore need for fewer interest-rate increases than expected earlier, Fed governor says. PRINCETON, N.J.-A top Federal Reserve official said Thursday a slowing global economy, risks to U.S. growth and uncertainty over the outlook bolster the case for fewer interest-rate increases than she had previously expected, adding any decision the Fed makes on monetary policy lies months down the road.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will increase rates fewer times than expected, which is good news for the market because it will be less likely to experience a recession.\n- The market will react positively to this news.", "price_info": {}}, {"link": "https://www.wsj.com/articles/pfizer-to-acquire-arena-pharmaceuticals-in-6-7-billion-deal-11639414813", "title": "Pfizer to Acquire Arena Pharmaceuticals in $6.7 Billion Deal", "date": "2021-12-13 12:00", "summary": "The cash agreement would add a promising bowel-disease treatment to its pipeline. Pfizer Inc. agreed to acquire Arena Pharmaceuticals Inc. for $6.7 billion, bolstering the pharmaceutical giant's pipeline of medicines for inflammatory bowel diseases.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pfizer to Acquire Arena Pharmaceuticals in $6.7 Billion Deal. The cash agreement would add a promising bowel-disease treatment to its pipeline. Pfizer Inc. agreed to acquire Arena Pharmaceuticals Inc. for $6.7 billion, bolstering the pharmaceutical giant's pipeline of medicines for inflammatory bowel diseases.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will increase because they are expanding their pipeline with a promising treatment for bowel diseases.\n- Arena Pharmaceuticals Inc (NASDAQ: ARNA) will decrease because they are being acquired by Pfizer, and they will no longer be a standalone company.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "up", "prices": [55.5039, 55.4016]}, "ARNA": {"company": "", "ticker": "ARNA", "move": "down", "prices": [91.375, 89.605]}}}, {"link": "https://www.wsj.com/articles/facebooks-zuckerberg-says-hes-willing-to-pay-more-taxes-in-europe-11581692030", "title": "Zuckerberg Willing to Pay More Taxes in Europe", "date": "2020-02-14 09:53", "summary": "The support of the Facebook founder for a proposed global tax plan could put him at odds with U.S. officials. Facebook Inc. is willing to pay more tax overseas and supports a proposed global levy on tech giants, according to a speech Chief Executive Mark Zuckerberg is set to give Saturday.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Zuckerberg Willing to Pay More Taxes in Europe. The support of the Facebook founder for a proposed global tax plan could put him at odds with U.S. officials. Facebook Inc. is willing to pay more tax overseas and supports a proposed global levy on tech giants, according to a speech Chief Executive Mark Zuckerberg is set to give Saturday.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc. (NASDAQ: FB) will increase because Zuckerberg is willing to pay more taxes in Europe, and this will put them at odds with U.S. officials.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are a direct competitor of Facebook.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "up", "prices": [213.7322, 214.3333]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [2152.45, 2147.545]}}}, {"link": "https://www.wsj.com/articles/anecdotes-on-presidents-treatment-trump-data-on-wall-street-11601906077", "title": "Anecdotes on President's Treatment Trump Data on Wall Street", "date": "2020-10-05 09:54", "summary": "Two companies supplying drugs used to treat the president are seeing shares rise despite no evidence linking his apparent improvement to their use. Does having a famous patient help drug companies become more valuable? Investors seem to think so.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Anecdotes on President's Treatment Trump Data on Wall Street. Two companies supplying drugs used to treat the president are seeing shares rise despite no evidence linking his apparent improvement to their use. Does having a famous patient help drug companies become more valuable? Investors seem to think so.\"\n\nStock Prediction(s):", "Prediction": "\n- The two companies supplying drugs used to treat the president are seeing shares rise, which could mean that the companies are becoming more valuable.\n- However, this could also just be a result of investors thinking that the president's apparent improvement is due to the use of these drugs, even though there is no evidence to support this.", "price_info": {}}, {"link": "https://www.wsj.com/articles/faa-examines-richard-bransons-virgin-galactic-flight-path-11630550542", "title": "FAA Examines Virgin Galactic's Flight Path", "date": "2021-09-02 10:33", "summary": "Company says winds altered flight for about two minutes. Aviation regulators are investigating how Virgin Galactic Holdings Inc.'s spacecraft returned to the ground after taking billionaire entrepreneur Richard Branson to the edge of space, a spokesman for the Federal Aviation Administration said.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FAA Examines Virgin Galactic's Flight Path. Company says winds altered flight for about two minutes. Aviation regulators are investigating how Virgin Galactic Holdings Inc.'s spacecraft returned to the ground after taking billionaire entrepreneur Richard Branson to the edge of space, a spokesman for the Federal Aviation Administration said.\"\n\nStock Prediction(s):", "Prediction": "\n- Virgin Galactic Holdings Inc. (NYSE: VGH) will increase because their spacecraft is being investigated by the FAA and they are a direct competitor of Blue Origin LLC.\n- Blue Origin LLC (NYSE: BEZ) will increase because their spacecraft is being investigated by the FAA and they are a direct competitor of Virgin Galactic Holdings Inc.", "price_info": {"VGH": {"company": "", "ticker": "VGH", "move": "up"}, "BEZ": {"company": "", "ticker": "BEZ", "move": "up"}}}, {"link": "https://www.wsj.com/articles/huawei-settles-two-patent-lawsuits-it-filed-against-verizon-11626105146", "title": "Huawei Settles Two Patent Lawsuits It Filed Against Verizon", "date": "2021-07-12 13:05", "summary": "Agreement reached amid broader geopolitical fight involving the U.S. and the Chinese company. Huawei Technologies Co. agreed to settle two U.S. patent-infringement lawsuits it brought against Verizon Communications Inc., avoiding at least one public fight over the Chinese electronics maker's role in the telecommunications supply chain.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Huawei Settles Two Patent Lawsuits It Filed Against Verizon. Agreement reached amid broader geopolitical fight involving the U.S. and the Chinese company. Huawei Technologies Co. agreed to settle two U.S. patent-infringement lawsuits it brought against Verizon Communications Inc., avoiding at least one public fight over the Chinese electronics maker's role in the telecommunications supply chain.\"\n\nStock Prediction(s):", "Prediction": "\n- Huawei Technologies Co. (SHE: 002502) will increase because they have resolved their patent lawsuits with Verizon Communications Inc. (NYSE: VZ).\n- Verizon Communications Inc. (NYSE: VZ) will decrease because they are paying Huawei Technologies Co. (SHE: 002502) to settle the lawsuits.", "price_info": {"VZ": {"company": "", "ticker": "VZ", "move": "down", "prices": [56.255, 56.1525]}}}, {"link": "https://www.wsj.com/articles/hertz-misses-lease-payment-prepares-for-potential-bankruptcy-11588172258", "title": "Hertz Misses Lease Payment, Prepares for Potential Bankruptcy", "date": "2020-04-29 13:56", "summary": "Rental-car company aims to preserve cash amid the coronavirus pandemic. Hertz Global Holdings Inc. is preparing for a possible bankruptcy filing after the rental-car company failed to make lease payments to preserve cash amid the Covid-19 pandemic, according to people familiar with the matter.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hertz Misses Lease Payment, Prepares for Potential Bankruptcy. Rental-car company aims to preserve cash amid the coronavirus pandemic. Hertz Global Holdings Inc. is preparing for a possible bankruptcy filing after the rental-car company failed to make lease payments to preserve cash amid the Covid-19 pandemic, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Hertz Global Holdings Inc. (NYSE: HTZ) will decrease because they are preparing for a potential bankruptcy filing.\n- Avis Budget Group Inc. (NASDAQ: CAR) will increase because they are not preparing for a potential bankruptcy filing.", "price_info": {"HTZ": {"company": "", "ticker": "HTZ", "move": "down", "prices": [4.19, 3.9699]}, "CAR": {"company": "", "ticker": "CAR", "move": "up", "prices": [16.98, 17.08]}}}, {"link": "https://www.wsj.com/articles/nvidias-cryptocurrency-puzzle-gets-less-vexing-11622132688", "title": "Nvidia's Cryptocurrency Puzzle Gets Less Vexing", "date": "2021-05-27 12:24", "summary": "Uncertainty stems from use of chip maker's graphics processors by 'miners'. \"Not like last time\" can be a dangerous phrase in business. But in the case of Nvidia and its relationship with crypto-miners, it also happens to be true.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nvidia's Cryptocurrency Puzzle Gets Less Vexing. Uncertainty stems from use of chip maker's graphics processors by 'miners'. \"Not like last time\" can be a dangerous phrase in business. But in the case of Nvidia and its relationship with crypto-miners, it also happens to be true.\"\n\nStock Prediction(s):", "Prediction": "\n- Nvidia Corporation (NASDAQ: NVDA) will increase because they have clarified their relationship with crypto-miners, and it is no longer a source of uncertainty for the company.\n- AMD (NASDAQ: AMD) will increase because they are a direct competitor of Nvidia, and this news will shift some of the market share in their favor.\n- Intel Corporation (NASDAQ: INTC) will decrease because they are a direct competitor of Nvidia, and this", "price_info": {"NVDA": {"company": "", "ticker": "NVDA", "move": "up", "prices": [625.43, 622.53]}, "AMD": {"company": "", "ticker": "AMD", "move": "up", "prices": [78.185, 78.01]}, "INTC": {"company": "", "ticker": "INTC", "move": "down", "prices": [57.5752, 57.4999]}}}, {"link": "https://www.wsj.com/articles/california-calls-on-bankrupt-hospitals-to-battle-coronavirus-11584727350", "title": "California Calls on Bankrupt Hospitals to Battle Coronavirus", "date": "2020-03-20 14:02", "summary": "St. Vincent in Los Angeles and Seton in the Bay Area, both under chapter 11 protection, were summoned to the front lines of the pandemic response. California is paying to bring bankrupt hospitals back on line as it braces for a surge of coronavirus patients.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"California Calls on Bankrupt Hospitals to Battle Coronavirus. St. Vincent in Los Angeles and Seton in the Bay Area, both under chapter 11 protection, were summoned to the front lines of the pandemic response. California is paying to bring bankrupt hospitals back on line as it braces for a surge of coronavirus patients.\"\n\nStock Prediction(s):", "Prediction": "\n- St. Vincent Medical Center (OTCQB: SVMC) will increase because they have been called to the front lines of the pandemic response by the state of California.\n- Seton Healthcare Family (NYSE: SET) will increase because they have been called to the front lines of the pandemic response by the state of California.\n- HCA Healthcare Inc (NYSE: HCA) will increase because they have been called to the front lines of the pand", "price_info": {"SET": {"company": "", "ticker": "SET", "move": "up"}, "HCA": {"company": "", "ticker": "HCA", "move": "up", "prices": [76.17, 78.5]}}}, {"link": "https://www.wsj.com/articles/treasury-to-sell-72-billion-in-debt-11564069444", "title": "Treasury to Sell $72 Billion in Debt", "date": "2019-07-25 11:44", "summary": "U.S. Treasury Department's securities sales next week are divided between 13- and 26-week bills. The U.S. will auction $72 billion in securities next week. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury to Sell $72 Billion in Debt. U.S. Treasury Department's securities sales next week are divided between 13- and 26-week bills. The U.S. will auction $72 billion in securities next week. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Treasury Department will have to sell more debt in order to finance the government's spending.\n- This will cause interest rates to increase, as there will be more competition for debt.\n- This will cause bond prices to decrease, as investors will demand a higher yield to compensate for the increased risk.", "price_info": {}}, {"link": "https://www.wsj.com/articles/covid-19-whiplash-jolts-californias-small-businesses-11594829607", "title": "Covid-19 Whiplash Jolts California's Small Businesses", "date": "2020-07-15 12:13", "summary": "Recently reopened restaurants, salons forced to close again; 'we're back at the beginning, but we already used the help'. For the first 10 days after Shawn Heatherman reopened her Santa Rosa, Calif., children's hair salon in mid-June, her stylists were booked solid. After months of lockdown, families were eager for trims for their shaggy-haired children-or for help rectifying the results of home haircuts.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Whiplash Jolts California's Small Businesses. Recently reopened restaurants, salons forced to close again; 'we're back at the beginning, but we already used the help'. For the first 10 days after Shawn Heatherman reopened her Santa Rosa, Calif., children's hair salon in mid-June, her stylists were booked solid. After months of lockdown, families were eager for trims for their shaggy-haired children-or for help rectifying the results of home haircuts.\"\n\nStock Prediction(s):", "Prediction": "\n- Hair stylists, restaurants, and other small businesses in California will continue to suffer because of Covid-19.\n- Home Depot Inc (NYSE: HD) and Lowe's Companies, Inc. (NYSE: LOW) will benefit from the increased demand for home improvement projects as families try to fix up their homes in anticipation of future guests.", "price_info": {"HD": {"company": "", "ticker": "HD", "move": null, "prices": [255.28, 256.12]}, "LOW": {"company": "", "ticker": "LOW", "move": "up", "prices": [140.4934, 140.655]}}}, {"link": "https://www.wsj.com/articles/covid-19-vaccine-maker-blames-problems-on-producing-two-different-shots-11621434060", "title": "Emergent Has Made Over 100 Million Doses of J&J Vaccine", "date": "2021-05-19 15:04", "summary": "Contract manufacturer says FDA, which had found problems at its plant, is evaluating whether the new shots can be released. Emergent BioSolutions Inc. has made enough of a key ingredient to yield more than 100 million doses of Johnson & Johnson 's Covid-19 vaccine, and federal health regulators are evaluating whether to release the shots, Emergent's chief executive said.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Emergent Has Made Over 100 Million Doses of J&J Vaccine. Contract manufacturer says FDA, which had found problems at its plant, is evaluating whether the new shots can be released. Emergent BioSolutions Inc. has made enough of a key ingredient to yield more than 100 million doses of Johnson & Johnson 's Covid-19 vaccine, and federal health regulators are evaluating whether to release the shots, Emergent's chief executive said.\"\n\nStock Prediction(s):", "Prediction": "\n- Emergent BioSolutions Inc. (NYSE: EBS) will increase because they have made over 100 million doses of the J&J vaccine and the FDA is evaluating whether to release the shots.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are a direct competitor of Emergent BioSolutions.", "price_info": {"EBS": {"company": "", "ticker": "EBS", "move": "up", "prices": [56.69, 57.49]}, "JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [169.5, 170.6]}}}, {"link": "https://www.wsj.com/articles/revival-of-brazils-corporate-bond-market-lures-foreign-investors-hunting-for-yield-11597688499", "title": "Revival of Brazil's Corporate-Bond Market Lures Foreign Investors", "date": "2020-08-17 14:21", "summary": "Local corporations' dollar-denominated bond issues totaled $3.7 billion in July, up 48% from a year earlier. Foreign investors are flocking to the relatively high yields offered by big Brazilian corporations that are issuing debt to shore up their balance sheets in the midst of the coronavirus pandemic.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Revival of Brazil's Corporate-Bond Market Lures Foreign Investors. Local corporations' dollar-denominated bond issues totaled $3.7 billion in July, up 48% from a year earlier. Foreign investors are flocking to the relatively high yields offered by big Brazilian corporations that are issuing debt to shore up their balance sheets in the midst of the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Brazilian companies will continue to issue debt to shore up their balance sheets, and foreign investors will continue to invest in these bonds because of the high yields.\n- American companies will issue debt as well, but foreign investors will not be as interested because the yields are not as high.\n- European companies will issue debt as well, but foreign investors will not be as interested because the yields are not as high.", "price_info": {}}, {"link": "https://www.wsj.com/articles/boeing-chairman-backs-embattled-ceo-dennis-muilenburg-11572961931", "title": "Boeing Chairman Backs Embattled CEO Dennis Muilenburg", "date": "2019-11-05 12:37", "summary": "Muilenburg won't receive bonus compensation this year or stock grants until 737 MAX is flying again. Boeing Co. 's newly installed chairman backed embattled Chief Executive Officer Dennis Muilenburg on Tuesday, while acknowledging a series of engineering missteps that led to two deadly crashes of the 737 MAX.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Chairman Backs Embattled CEO Dennis Muilenburg. Muilenburg won't receive bonus compensation this year or stock grants until 737 MAX is flying again. Boeing Co. 's newly installed chairman backed embattled Chief Executive Officer Dennis Muilenburg on Tuesday, while acknowledging a series of engineering missteps that led to two deadly crashes of the 737 MAX.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will increase because the chairman has come out in support of the CEO, and they are still working on getting the 737 MAX flying again.\n- United Technologies Corp. (NYSE: UTX) will decrease because they are a direct competitor of Boeing.\n- Honeywell International Inc. (NYSE: HON) will decrease because they are a direct competitor of Boeing.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [358.79, 360.94]}, "UTX": {"company": "", "ticker": "UTX", "move": "down", "prices": [146.9632, 147.51]}, "HON": {"company": "", "ticker": "HON", "move": "down", "prices": [179.71, 179.89]}}}, {"link": "https://www.wsj.com/articles/deutsche-bank-posts-big-loss-as-overhaul-bites-11580369775", "title": "Deutsche Bank Posts Big Loss as Overhaul Bites", "date": "2020-01-30 13:17", "summary": "German lender's efforts to reorganize its operations weighed heavily on its results last year. FRANKFURT-Deutsche Bank AG swung to a \u20ac5.3 billion ($5.8 billion) loss in 2019, highlighting the size of its challenge in making itself leaner and more profitable through a sweeping overhaul.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Deutsche Bank Posts Big Loss as Overhaul Bites. German lender's efforts to reorganize its operations weighed heavily on its results last year. FRANKFURT-Deutsche Bank AG swung to a \u20ac5.3 billion ($5.8 billion) loss in 2019, highlighting the size of its challenge in making itself leaner and more profitable through a sweeping overhaul.\"\n\nStock Prediction(s):", "Prediction": "\n- Deutsche Bank AG (NYSE: DB) will decrease because they are not doing well financially and they are in the middle of a restructuring.\n- Commerzbank AG (OTCMKTS: CRZBY) will increase because they are a direct competitor of Deutsche Bank and they are doing better financially.", "price_info": {"DB": {"company": "", "ticker": "DB", "move": "up", "prices": [9.1667, 9.24]}}}, {"link": "https://www.wsj.com/articles/day-traders-buy-until-it-hertz-11591720644", "title": "Day Traders Buy Until It Hertz", "date": "2020-06-09 12:37", "summary": "An analyst politely reminded those buying shares of bankrupt rental-car company Hertz that it is worthless. It is sometimes best to say things tactfully, even on Wall Street.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Day Traders Buy Until It Hertz. An analyst politely reminded those buying shares of bankrupt rental-car company Hertz that it is worthless. It is sometimes best to say things tactfully, even on Wall Street.\"\n\nStock Prediction(s):", "Prediction": "\n- Hertz Global Holdings, Inc. (NYSE: HTZ) will continue to decrease because it is a bankrupt rental-car company.", "price_info": {"HTZ": {"company": "", "ticker": "HTZ", "move": "down", "prices": [4.6, 4.0601]}}}, {"link": "https://www.wsj.com/articles/stockx-hub-for-sneakerheads-is-latest-1-billion-unicorn-11561571959", "title": "StockX Is Latest $1 Billion Unicorn", "date": "2019-06-26 15:04", "summary": "Online marketplace lets people trade shoes like stocks, riding boom in teen selling. StockX, an online marketplace that lets individuals trade sneakers like stocks, closed a round of venture funding that valued the startup at more than $1 billion, riding the sneaker-reselling craze fueled by teens.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"StockX Is Latest $1 Billion Unicorn. Online marketplace lets people trade shoes like stocks, riding boom in teen selling. StockX, an online marketplace that lets individuals trade sneakers like stocks, closed a round of venture funding that valued the startup at more than $1 billion, riding the sneaker-reselling craze fueled by teens.\"\n\nStock Prediction(s):", "Prediction": "\n- StockX will continue to increase in value because their business model is unique and they are riding the wave of the sneaker-reselling craze.\n- Nike Inc (NYSE: NKE) will decrease because they are a direct competitor of StockX.\n- Adidas AG (OTCMKTS: ADDYY) will decrease because they are a direct competitor of StockX.", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [82.5, 82.55]}}}, {"link": "https://www.wsj.com/articles/should-you-fear-the-yield-curve-11547044201", "title": "Should You Fear the Yield Curve?", "date": "2019-01-09 09:30", "summary": "Bond investors don't know more than the Fed, but listen to them anyway. There's a new horror show coming to your screens: Set on Wall Street, it's called \"Inversion of the Yield Curve\" and features a chilling, disembodied force that seeps into the minds of the public, triggering panic in markets and hand-wringing on cable news.", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Should You Fear the Yield Curve?. Bond investors don't know more than the Fed, but listen to them anyway. There's a new horror show coming to your screens: Set on Wall Street, it's called \"Inversion of the Yield Curve\" and features a chilling, disembodied force that seeps into the minds of the public, triggering panic in markets and hand-wringing on cable news.\"\n\nStock Prediction(s):", "Prediction": "\n- The yield curve will invert, causing a market panic and a decrease in the stock prices of companies such as Goldman Sachs (NYSE: GS), JPMorgan Chase (NYSE: JPM), and Bank of America (NYSE: BAC).\n- The yield curve will not invert, causing a market rally and an increase in the stock prices of companies such as Goldman Sachs, JPMorgan Chase, and Bank of America.", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "down", "prices": [175.9, 176.02]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [101.02, 100.54]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [25.73, 25.43]}}}, {"link": "https://www.wsj.com/articles/cargill-hires-ges-former-finance-chief-11615923272", "title": "Cargill Hires GE's Former Finance Chief", "date": "2021-03-16 15:34", "summary": "Jamie Miller is set to join the Minneapolis-based agricultural business on June 1. General Electric Co. 's former finance chief is taking over the purse strings at Cargill Inc., a private agricultural conglomerate with more than $100 billion in annual revenue.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Cargill Hires GE's Former Finance Chief. Jamie Miller is set to join the Minneapolis-based agricultural business on June 1. General Electric Co. 's former finance chief is taking over the purse strings at Cargill Inc., a private agricultural conglomerate with more than $100 billion in annual revenue.\"\n\nStock Prediction(s):", "Prediction": "\n- Cargill Inc. (NYSE: CAR) will increase because they have a new finance chief, and they are a major player in the agricultural industry.\n- General Electric Co. (NYSE: GE) will decrease because they are losing their finance chief, and he is going to a competitor.", "price_info": {"CAR": {"company": "", "ticker": "CAR", "move": "up", "prices": [66.48, 66.7]}, "GE": {"company": "", "ticker": "GE", "move": "down", "prices": [13.17, 13.16]}}}, {"link": "https://www.wsj.com/articles/real-estate-stocks-rise-to-new-highs-11560787597", "title": "Real-Estate Stocks Rise To New Highs", "date": "2019-06-17 12:06", "summary": "The steady dividend payers benefit from falling rates as well as bets on warehouse operators. Real-estate stocks are on a tear in 2019, beneficiaries of the surprising fall in interest rates as well as bets on the future of e-commerce.", "categories": [["Markets", "Stocks"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Real-Estate Stocks Rise To New Highs. The steady dividend payers benefit from falling rates as well as bets on warehouse operators. Real-estate stocks are on a tear in 2019, beneficiaries of the surprising fall in interest rates as well as bets on the future of e-commerce.\"\n\nStock Prediction(s):", "Prediction": "\n- Prologis, Inc. (NYSE: PLD) will continue to increase because they are a real-estate company that is benefiting from the fall in interest rates, as well as the growth of e-commerce.\n- Boston Properties, Inc. (NYSE: BXP) will continue to increase because they are a real-estate company that is benefiting from the fall in interest rates, as well as the growth of e-commerce.\n- Simon Property Group", "price_info": {"PLD": {"company": "", "ticker": "PLD", "move": "down", "prices": [80.5416, 80.81]}, "BXP": {"company": "", "ticker": "BXP", "move": "down", "prices": [136.28, 136.5]}}}, {"link": "https://www.wsj.com/articles/facebook-ceo-to-testify-at-house-panelabout-libra-11570638146", "title": "Facebook CEO to Testify at House Panel About Libra", "date": "2019-10-09 15:24", "summary": "Mark Zuckerberg will be asked about Facebook's foray into cryptocurrency and its impact on the financial-services sector. Facebook Inc. Chief Executive Mark Zuckerberg is slated to return to Capitol Hill this month to testify before a House panel about the company's foray into cryptocurrency, just weeks after facing a chilly reception from lawmakers about his vision for internet regulation.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook CEO to Testify at House Panel About Libra. Mark Zuckerberg will be asked about Facebook's foray into cryptocurrency and its impact on the financial-services sector. Facebook Inc. Chief Executive Mark Zuckerberg is slated to return to Capitol Hill this month to testify before a House panel about the company's foray into cryptocurrency, just weeks after facing a chilly reception from lawmakers about his vision for internet regulation.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because they are continuing to grow their business, and this will only add to their portfolio.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are also getting into the cryptocurrency space.\n- Mastercard Inc (NYSE: MA) will increase because they are a payment processor, and this will help them with their Libra product.\n- Visa Inc (NYSE", "price_info": {"MA": {"company": "", "ticker": "MA", "move": "up", "prices": [272, 271.85]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [179.75, 179.76]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1721.55, 1722.2]}}}, {"link": "https://www.wsj.com/articles/northwestern-university-picks-economist-to-steer-m-b-a-program-11549049566", "title": "Northwestern University Picks Economist to Steer M.B.A. Program", "date": "2019-02-01 14:32", "summary": "Francesca Cornelli of the London Business School to join the Kellogg School of Management in August. Northwestern University named Francesca Cornelli as the new dean of its Kellogg School of Management, taking over the M.B.A. program.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Northwestern University Picks Economist to Steer M.B.A. Program. Francesca Cornelli of the London Business School to join the Kellogg School of Management in August. Northwestern University named Francesca Cornelli as the new dean of its Kellogg School of Management, taking over the M.B.A. program.\"\n\nStock Prediction(s):", "Prediction": "\n- Northwestern University (NASDAQ: NU) will increase because they have a new dean for their M.B.A. program.\n- The London Business School (LSE: LSE) will increase because Francesca Cornelli is a highly respected economist.", "price_info": {"NU": {"company": "", "ticker": "NU", "move": "up"}}}, {"link": "https://www.wsj.com/articles/herbalife-cfo-looks-to-change-investor-views-after-years-of-activist-pressure-11614263400", "title": "Herbalife CFO Looks to Change Investor Views After Years of Activist Pressure", "date": "2021-02-25 09:30", "summary": "The nutrition company hopes to shift its shareholder base to include more long-term, international investors. Herbalife Nutrition Ltd. 's new finance chief is working to change investors' view of the business after years of activist pressure, which abated in January when Carl Icahn -once its largest shareholder-sold a large chunk of his stake and relinquished his board seats.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Herbalife CFO Looks to Change Investor Views After Years of Activist Pressure. The nutrition company hopes to shift its shareholder base to include more long-term, international investors. Herbalife Nutrition Ltd. 's new finance chief is working to change investors' view of the business after years of activist pressure, which abated in January when Carl Icahn -once its largest shareholder-sold a large chunk of his stake and relinquished his board seats.\"\n\nStock Prediction(s):", "Prediction": "\n- Herbalife Nutrition Ltd. (NYSE: HLF) will increase because they are trying to change their investor base, and this could mean good things for the company in the long run.\n- The Coca-Cola Company (NYSE: KO) will decrease because they are a direct competitor of Herbalife.", "price_info": {"HLF": {"company": "", "ticker": "HLF", "move": "up", "prices": [45.44, 44.511]}, "KO": {"company": "", "ticker": "KO", "move": "down", "prices": [50.39, 50.335]}}}, {"link": "https://www.wsj.com/articles/halliburton-posts-weaker-earnings-as-north-america-business-slumps-11571685125", "title": "Halliburton Posts Weaker Earnings", "date": "2019-10-21 15:12", "summary": "Oil-field services company's cost cuts and better-than-expected outlook pushed shares higher. Oil-field services company Halliburton Co. posted weaker quarterly earnings Monday as revenue in the company's North America business slumped, but cost cuts and a better-than-expected outlook pushed shares higher.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Halliburton Posts Weaker Earnings. Oil-field services company's cost cuts and better-than-expected outlook pushed shares higher. Oil-field services company Halliburton Co. posted weaker quarterly earnings Monday as revenue in the company's North America business slumped, but cost cuts and a better-than-expected outlook pushed shares higher.\"\n\nStock Prediction(s):", "Prediction": "\n- Halliburton Co. (NYSE: HAL) will increase because they have been cutting costs and their outlook is better than expected.\n- Schlumberger Ltd. (NYSE: SLB) will decrease because they are a direct competitor of Halliburton.\n- Baker Hughes, a GE company (NYSE: BHGE) will decrease because they are a direct competitor of Halliburton.", "price_info": {"HAL": {"company": "", "ticker": "HAL", "move": "up", "prices": [19.57, 19.59]}, "SLB": {"company": "", "ticker": "SLB", "move": "down", "prices": [33.59, 33.59]}, "BHGE": {"company": "", "ticker": "BHGE", "move": "down"}}}, {"link": "https://www.wsj.com/articles/ecb-to-speed-up-bond-purchases-11615467768", "title": "ECB to Speed Up Bond Purchases", "date": "2021-03-11 13:56", "summary": "Central bank's decision marks a divergence from the Federal Reserve. FRANKFURT-The European Central Bank will step up efforts to contain borrowing costs that have surged amid brighter prospects for the U.S. economy and a relaxed stance from the Federal Reserve, aiming to shore up the flagging eurozone economy.", "categories": [["Economy", "Europe Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/europe-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"ECB to Speed Up Bond Purchases. Central bank's decision marks a divergence from the Federal Reserve. FRANKFURT-The European Central Bank will step up efforts to contain borrowing costs that have surged amid brighter prospects for the U.S. economy and a relaxed stance from the Federal Reserve, aiming to shore up the flagging eurozone economy.\"\n\nStock Prediction(s):", "Prediction": "\n- The ECB's decision to speed up bond purchases will help to shore up the flagging eurozone economy, and will benefit European banks and other companies.\n- The decision will also benefit U.S. banks and other companies, as the ECB's actions will help to keep interest rates low and support growth.\n- However, the decision may also lead to increased inflation and asset bubbles, which could eventually lead to a slowdown in the eurozone economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/anne-hathaway-asks-3-495-million-for-new-york-penthouse-11582133130", "title": "Anne Hathaway Asks $3.495 Million for New York Penthouse", "date": "2020-02-19 12:25", "summary": "The actress and her husband Adam Shulman raised the ceilings and installed herringbone floors after buying the Upper West Side home for $2.55 million in 2016. Actress Anne Hathaway and her husband Adam Shulman are listing their New York City apartment, a full-floor penthouse in a Neo-Georgian style row house on Manhattan's Upper West Side, for $3.495 million.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Anne Hathaway Asks $3.495 Million for New York Penthouse. The actress and her husband Adam Shulman raised the ceilings and installed herringbone floors after buying the Upper West Side home for $2.55 million in 2016. Actress Anne Hathaway and her husband Adam Shulman are listing their New York City apartment, a full-floor penthouse in a Neo-Georgian style row house on Manhattan's Upper West Side, for $3.495 million.\"\n\nStock Prediction(s):", "Prediction": "\n- Hathaway's penthouse will increase in price because it is a desirable location and she has put a lot of work into it.\n- Other apartments in the same building will also increase in price because of the increased demand from people who want to live in the same building as Anne Hathaway.", "price_info": {}}, {"link": "https://www.wsj.com/articles/unicredit-to-pay-1-3-billion-to-settle-sanctions-charges-11555355562", "title": "UniCredit to Pay $1.3 Billion to Settle Sanctions Charges", "date": "2019-04-15 15:15", "summary": "Banks owned by UniCredit agree to settle claims they processed payments allegedly in violation of U.S. government-sanctions programs. Banks owned by UniCredit Group have agreed to pay $1.3 billion to settle claims they processed payments allegedly in violation of multiple U.S. government-sanctions programs.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"UniCredit to Pay $1.3 Billion to Settle Sanctions Charges. Banks owned by UniCredit agree to settle claims they processed payments allegedly in violation of U.S. government-sanctions programs. Banks owned by UniCredit Group have agreed to pay $1.3 billion to settle claims they processed payments allegedly in violation of multiple U.S. government-sanctions programs.\"\n\nStock Prediction(s):", "Prediction": "\n- UniCredit Group (BIT: UCG) will increase because they have agreed to pay $1.3 billion to settle sanctions charges.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are also a direct competitor of UniCredit.\n- Goldman Sachs Group Inc. (NYSE: GS) will increase because they are also a direct competitor of UniCredit.\n- Bank of America Corp. (NYSE: BAC) will increase because they", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [109.94, 110]}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [199.65, 199.81]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [29.83, 29.84]}}}, {"link": "https://www.wsj.com/articles/mgm-resorts-lays-off-18-000-workers-11598626822", "title": "MGM Resorts Lays Off 18,000 Workers", "date": "2020-08-28 11:00", "summary": "Casino industry struggles to regain business after pandemic shutdowns. MGM Resorts International is laying off 18,000 furloughed workers in the U.S. as a global travel slowdown impedes the casino industry's recovery from the ongoing pandemic.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"MGM Resorts Lays Off 18,000 Workers. Casino industry struggles to regain business after pandemic shutdowns. MGM Resorts International is laying off 18,000 furloughed workers in the U.S. as a global travel slowdown impedes the casino industry's recovery from the ongoing pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- MGM Resorts International (NYSE: MGM) will decrease because they are laying off 18,000 workers.\n- Wynn Resorts Ltd. (NASDAQ: WYNN) will decrease because they are laying off 18,000 workers.\n- Las Vegas Sands Corp. (NYSE: LVS) will decrease because they are laying off 18,000 workers.\n- Caesars Entertainment Corp. (NASDAQ: CZR) will decrease because they", "price_info": {"MGM": {"company": "", "ticker": "MGM", "move": "down", "prices": [24.04, 24]}, "LVS": {"company": "", "ticker": "LVS", "move": "down", "prices": [52.6727, 52.4]}, "WYNN": {"company": "", "ticker": "WYNN", "move": "down", "prices": [92.01, 91.92]}, "CZR": {"company": "", "ticker": "CZR", "move": "down", "prices": [49.1678, 49.1146]}}}, {"link": "https://www.wsj.com/articles/barclays-profit-soars-on-investment-banking-11627455558", "title": "Barclays Profit Soars on Investment Banking", "date": "2021-07-28 14:49", "summary": "Chief Executive Jes Staley has staked his strategy on reinvigorating the investment bank. LONDON- Barclays PLC Wednesday said its net profit rose in the second quarter, driven by a strong performance in its investment bank.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Barclays Profit Soars on Investment Banking. Chief Executive Jes Staley has staked his strategy on reinvigorating the investment bank. LONDON- Barclays PLC Wednesday said its net profit rose in the second quarter, driven by a strong performance in its investment bank.\"\n\nStock Prediction(s):", "Prediction": "\n- Barclays plc (NYSE: BCS) will increase because their investment banking is doing well.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are also doing well in investment banking, but Barclays is doing better.", "price_info": {"BCS": {"company": "", "ticker": "BCS", "move": "up", "prices": [9.71, 9.77]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [151.965, 151.87]}}}, {"link": "https://www.wsj.com/articles/morgan-stanley-ceo-recovered-from-coronavirus-11586452860", "title": "Morgan Stanley CEO Recovered From Coronavirus", "date": "2020-04-09 13:21", "summary": "James Gorman is most senior Wall Street executive known to have been infected with Covid-19. Morgan Stanley Chief Executive James Gorman said Thursday he had recovered from the new coronavirus, the most senior Wall Street executive known to have been infected.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Morgan Stanley CEO Recovered From Coronavirus. James Gorman is most senior Wall Street executive known to have been infected with Covid-19. Morgan Stanley Chief Executive James Gorman said Thursday he had recovered from the new coronavirus, the most senior Wall Street executive known to have been infected.\"\n\nStock Prediction(s):", "Prediction": "\n- Morgan Stanley (NYSE: MS) will increase because their CEO has recovered from the virus.\n- Goldman Sachs (NYSE: GS) will decrease because they are a direct competitor of Morgan Stanley.", "price_info": {"MS": {"company": "", "ticker": "MS", "move": "up", "prices": [40.95, 40.955]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [181.6283, 183.21]}}}, {"link": "https://www.wsj.com/articles/treasury-releases-new-details-on-20-year-bond-plans-11580909629", "title": "Treasury Releases New Details on 20-Year Bond Plans", "date": "2020-02-05 14:05", "summary": "The department plans to issue the new bonds each quarter and will hold auctions in the third week of the month. WASHINGTON-The Treasury Department on Wednesday provided new details about its plans to begin regular auctions of 20-year bonds in the first half of 2020, expanding its suite of products to fund projected growing federal budget deficits.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury Releases New Details on 20-Year Bond Plans. The department plans to issue the new bonds each quarter and will hold auctions in the third week of the month. WASHINGTON-The Treasury Department on Wednesday provided new details about its plans to begin regular auctions of 20-year bonds in the first half of 2020, expanding its suite of products to fund projected growing federal budget deficits.\"\n\nStock Prediction(s):", "Prediction": "\n- Treasury bonds (NYSE: TBT) will increase because the government is planning to issue more of them to fund the growing federal budget deficits.\n- The yield on the 10-year Treasury bond (NYSE: TNX) will decrease because people will invest in the 20-year Treasury bonds instead.", "price_info": {"TBT": {"company": "", "ticker": "TBT", "move": "up", "prices": [24.01, 24.04]}, "TNX": {"company": "", "ticker": "TNX", "move": "down"}}}, {"link": "https://www.wsj.com/articles/barclays-probesignals-governance-weakness-activist-investor-says-11582648290", "title": "Barclays Probe Signals 'Governance Weakness,' Activist Investor Says", "date": "2020-02-25 11:31", "summary": "Investigation of CEO Jes Staley's professional relationship with Jeffrey Epstein draws fire from activist shareholder Edward Bramson. LONDON-The investigation by U.K. regulators of the professional relationship between Barclays PLC Chief Executive Jes Staley and Jeffrey Epstein, the late financier and convicted sex offender, shows there is \"governance weakness\" at the British bank, according to an activist investor.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Barclays Probe Signals 'Governance Weakness,' Activist Investor Says. Investigation of CEO Jes Staley's professional relationship with Jeffrey Epstein draws fire from activist shareholder Edward Bramson. LONDON-The investigation by U.K. regulators of the professional relationship between Barclays PLC Chief Executive Jes Staley and Jeffrey Epstein, the late financier and convicted sex offender, shows there is \"governance weakness\" at the British bank, according to an activist investor.\"\n\nStock Prediction(s):", "Prediction": "\n- Barclays plc (LON: BARC) will decrease because of the governance weakness that has been exposed.\n- Royal Bank of Scotland Group plc (LON: RBS) will decrease because of the governance weakness that has been exposed.\n- HSBC Holdings plc (LON: HSBA) will decrease because of the governance weakness that has been exposed.", "price_info": {}}, {"link": "https://www.wsj.com/articles/grocery-tech-star-ocado-is-a-bet-on-big-warehouses-11600177138", "title": "Grocery-Tech Star Ocado Is a Bet on Big Warehouses", "date": "2020-09-15 09:38", "summary": "The online supermarket is growing sales more slowly than low-tech rivals. Justifying its share price means showing it has the only profitable model long-term.. Ocado is an unusual example of a tech company that is being outpaced by manual labor. That won't last, but the online grocer still has to show that its approach is the only one that will translate into profits.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Grocery-Tech Star Ocado Is a Bet on Big Warehouses. The online supermarket is growing sales more slowly than low-tech rivals. Justifying its share price means showing it has the only profitable model long-term.. Ocado is an unusual example of a tech company that is being outpaced by manual labor. That won't last, but the online grocer still has to show that its approach is the only one that will translate into profits.\"\n\nStock Prediction(s):", "Prediction": "\n- Ocado Group plc (LON: OCDO) will increase because their business model is more profitable in the long term, and they are being outpaced by low-tech rivals.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are a direct competitor of Ocado.", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3128.52, 3139.11]}}}, {"link": "https://www.wsj.com/articles/finra-fines-prudential-affiliate-for-misstatements-11579194263", "title": "Prudential Affiliate Is Fined for Misstatements", "date": "2020-01-16 12:04", "summary": "Broker-dealer fined $1 million for providing workers in some retirement plans with inaccurate data. The Financial Industry Regulatory Authority, Wall Street's self-regulatory arm, disclosed a $1 million fine against an affiliate of Prudential Financial Inc. on Tuesday for providing potentially thousands of workers in some of the retirement plans it administers with inaccurate data on the cost and performance of their investments.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Prudential Affiliate Is Fined for Misstatements. Broker-dealer fined $1 million for providing workers in some retirement plans with inaccurate data. The Financial Industry Regulatory Authority, Wall Street's self-regulatory arm, disclosed a $1 million fine against an affiliate of Prudential Financial Inc. on Tuesday for providing potentially thousands of workers in some of the retirement plans it administers with inaccurate data on the cost and performance of their investments.\"\n\nStock Prediction(s):", "Prediction": "\n- Prudential Financial Inc. (NYSE: PRU) will decrease because one of their affiliates was fined for providing inaccurate data.", "price_info": {"PRU": {"company": "", "ticker": "PRU", "move": "down", "prices": [95.25, 95.34]}}}, {"link": "https://www.wsj.com/articles/dallas-fed-president-too-soon-for-fed-to-consider-cutting-rates-11553679121", "title": "Fed Officials Push Back on Market's Rate-Cut Belief", "date": "2019-03-27 12:19", "summary": "'We're not there' on yield curve inversion, Robert Kaplan said. Some Federal Reserve officials are saying it is too soon to consider cutting U.S. interest rates, despite rising market speculation of such a move because of slowing global growth.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Officials Push Back on Market's Rate-Cut Belief. 'We're not there' on yield curve inversion, Robert Kaplan said. Some Federal Reserve officials are saying it is too soon to consider cutting U.S. interest rates, despite rising market speculation of such a move because of slowing global growth.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will decrease because it is expecting a rate cut, but some Fed officials are saying it is too soon.\n- The market will rebound because eventually the Fed will have to cut rates due to the slowing global growth.", "price_info": {}}, {"link": "https://www.wsj.com/articles/oil-prices-recover-losses-after-omicron-drove-fears-about-demand-11638564476", "title": "Oil Prices Recover Some Losses After Omicron Drove Demand Fears", "date": "2021-12-03 15:47", "summary": "U.S. crude finished week above lows as Brent rose Friday. Oil prices showed signs of recovery after worries about the economic effect of the spreading Omicron variant of Covid-19 drove crude into a bear market.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Prices Recover Some Losses After Omicron Drove Demand Fears. U.S. crude finished week above lows as Brent rose Friday. Oil prices showed signs of recovery after worries about the economic effect of the spreading Omicron variant of Covid-19 drove crude into a bear market.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because oil prices are recovering, and they are a major player in the oil industry.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because oil prices are recovering, and they are a major player in the oil industry.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because oil prices are recovering, and they are a major player in the oil industry.\n- BP", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [113.97, 114.41]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [60.635, 60.88]}}}, {"link": "https://www.wsj.com/articles/coronavirus-hits-once-isolated-u-s-natural-gas-market-11583145001", "title": "Coronavirus Hits Once-Isolated U.S. Natural Gas Market", "date": "2020-03-02 15:33", "summary": "Epidemic deals latest blow to domestic producers, exposing global links developed since start of shale boom. Fears that the new coronavirus might slow the global economy have sent already-depressed natural gas prices tumbling to their lowest level in years.", "categories": [["Markets", "Commodities", "Gas Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/gas-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Hits Once-Isolated U.S. Natural Gas Market. Epidemic deals latest blow to domestic producers, exposing global links developed since start of shale boom. Fears that the new coronavirus might slow the global economy have sent already-depressed natural gas prices tumbling to their lowest level in years.\"\n\nStock Prediction(s):", "Prediction": "\n- Chesapeake Energy Corporation (NYSE: CHK) will decrease because of the global links developed since the start of the shale boom.\n- Devon Energy Corporation (NYSE: DVN) will decrease because of the global links developed since the start of the shale boom.\n- EQT Corporation (NYSE: EQT) will decrease because of the global links developed since the start of the shale boom.\n- Range Resources Corporation (NYSE: RRC) will decrease because", "price_info": {"CHK": {"company": "", "ticker": "CHK", "move": "down", "prices": [0.2541, 0.2571]}, "DVN": {"company": "", "ticker": "DVN", "move": "down", "prices": [15.96, 16.25]}, "EQT": {"company": "", "ticker": "EQT", "move": "down", "prices": [5.965, 6.02]}, "RRC": {"company": "", "ticker": "RRC", "move": "down", "prices": [2.62, 2.6]}}}, {"link": "https://www.wsj.com/articles/covid-19-surge-slows-european-recovery-but-supply-problems-ease-11639651970", "title": "Covid-19 Surge Slows U.S., European Recovery, but Supply Problems Ease", "date": "2021-12-16 11:17", "summary": "American business activity continued to expand but at the slowest pace in three months despite strong demand from customers. Rising Covid-19 infection rates, inflationary pressures and labor shortages slowed the economic recovery in the U.S. and Europe this month despite signs the supply problems that have hobbled factories over recent months were easing.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Surge Slows U.S., European Recovery, but Supply Problems Ease. American business activity continued to expand but at the slowest pace in three months despite strong demand from customers. Rising Covid-19 infection rates, inflationary pressures and labor shortages slowed the economic recovery in the U.S. and Europe this month despite signs the supply problems that have hobbled factories over recent months were easing.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will stay the same because the article does not mention any specific stocks.", "price_info": {}}, {"link": "https://www.wsj.com/articles/what-an-aircraft-carrier-driver-does-in-her-downtime-at-sea-11567614138", "title": "What an Aircraft Carrier Driver Does in Her Downtime at Sea", "date": "2019-09-04 12:22", "summary": "Stationed aboard the aircraft carrier USS Carl Vinson, Surface Warfare Officer Lt. Katelyn Davidson can go months without internet, but never forgets her Cholula. You can try to watch Netflix when you're under way, but because internet is inconsistent, people have TV shows and movies downloaded onto hard drives, and DVDs that we trade with each other. Last time we were out, I brought every season of \"Animaniacs.\" My roommate had a lot of rom-coms, which I don't normally watch. But on deployment, it's a great time to watch the most random stuff and have nobody judge you for it.", "categories": [["Tech", "Personal Tech", "Technology Essentials"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/my-tech-essentials?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What an Aircraft Carrier Driver Does in Her Downtime at Sea. Stationed aboard the aircraft carrier USS Carl Vinson, Surface Warfare Officer Lt. Katelyn Davidson can go months without internet, but never forgets her Cholula. You can try to watch Netflix when you're under way, but because internet is inconsistent, people have TV shows and movies downloaded onto hard drives, and DVDs that we trade with each other. Last time we were out, I brought every season of \"Animaniacs.\" My roommate had a lot of rom-coms, which I don't normally watch. But on deployment, it's a great time to watch the most random stuff and have nobody judge you for it.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing (NYSE: BA) will increase because they make the aircraft carrier that the driver is stationed on.\n- Lockheed Martin (NYSE: LMT) will increase because they make the aircraft carrier that the driver is stationed on.\n- General Dynamics (NYSE: GD) will increase because they make the aircraft carrier that the driver is stationed on.\n- Northrop Grumman (NYSE: NOC) will increase because they make the aircraft carrier that the driver", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [357.26, 356.7849]}, "LMT": {"company": "", "ticker": "LMT", "move": "up", "prices": [388.8, 389.36]}, "GD": {"company": "", "ticker": "GD", "move": "up", "prices": [190.85, 190.52]}, "NOC": {"company": "", "ticker": "NOC", "move": "up", "prices": [370.5653, 370.3779]}}}, {"link": "https://www.wsj.com/articles/blackrocks-profit-falls-sharply-11547639455", "title": "BlackRock's Assets Fall Sharply", "date": "2019-01-17 15:34", "summary": "The roughly $468 billion drop in the fourth quarter was the largest such decline since September 2011. BlackRock Inc.'s assets fell below the $6 trillion mark in the fourth quarter, a sign of how volatile markets are posing new challenges for the largest U.S. money managers.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"BlackRock's Assets Fall Sharply. The roughly $468 billion drop in the fourth quarter was the largest such decline since September 2011. BlackRock Inc.'s assets fell below the $6 trillion mark in the fourth quarter, a sign of how volatile markets are posing new challenges for the largest U.S. money managers.\"\n\nStock Prediction(s):", "Prediction": "\n- BlackRock, Inc. (NYSE: BLK) will decrease because their assets have fallen below $6 trillion.\n- Vanguard Group, Inc. (NYSE: VGR) will increase because they are not as reliant on assets and are still growing.", "price_info": {"BLK": {"company": "", "ticker": "BLK", "move": "down", "prices": [413.8581, 412.92]}, "VGR": {"company": "", "ticker": "VGR", "move": "up", "prices": [10.6821, 10.61]}}}, {"link": "https://www.wsj.com/articles/from-apocalypse-now-to-acropolis-wow-11581616033", "title": "From Apocalypse Now to Acropolis Wow", "date": "2020-02-13 12:47", "summary": "Greek debt has made brave investors rich, but the risk-reward is a lot less attractive now. There is a popular misconception that \"don't look a gift horse in the mouth\" comes from the Greek epic poem The Iliad. Rather than the Trojan Horse, the proverb's origin is much newer and is about actual horses' mouths. The meaning: Be grateful rather than suspicious when given something for free.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"From Apocalypse Now to Acropolis Wow. Greek debt has made brave investors rich, but the risk-reward is a lot less attractive now. There is a popular misconception that \"don't look a gift horse in the mouth\" comes from the Greek epic poem The Iliad. Rather than the Trojan Horse, the proverb's origin is much newer and is about actual horses' mouths. The meaning: Be grateful rather than suspicious when given something for free.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will stay the same because this news does not have a major impact on the stock market.", "price_info": {}}, {"link": "https://www.wsj.com/articles/the-6-best-beach-chairs-of-the-summer-a-semi-scientific-test-11628685593", "title": "The 6 Best Beach Chairs of the Summer: A Semi-Scientific Test", "date": "2021-08-11 10:45", "summary": "We dropped into dozens of beach chairs to find the best so that you don't have to. Here, our six favorites-based on price, style, ability to withstand sand and all-day sit-ability. For the better part of a decade, I have been on a quest to find the perfect beach chair. Wooed by slick Instagram ads promising a better, more life-altering seat, I buy a newer, fancier model annually. Then right about this time of summer, I realize its shortcomings.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The 6 Best Beach Chairs of the Summer: A Semi-Scientific Test. We dropped into dozens of beach chairs to find the best so that you don't have to. Here, our six favorites-based on price, style, ability to withstand sand and all-day sit-ability. For the better part of a decade, I have been on a quest to find the perfect beach chair. Wooed by slick Instagram ads promising a better, more life-altering seat, I buy a newer, fancier model annually. Then right about this time of summer, I realize its shortcomings.\"\n\nStock Prediction(s):", "Prediction": "\n- L.L. Bean, Inc. (NYSE: LB) will increase because they are mentioned in the article as one of the six best beach chairs.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are mentioned in the article as one of the six best beach chairs.\n- Walmart Inc. (NYSE: WMT) will increase because they are mentioned in the article as one of the six best beach chairs.", "price_info": {"LB": {"company": "", "ticker": "LB", "move": "up"}, "WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [150.49, 149.51]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3295.645, 3292.216]}}}, {"link": "https://www.wsj.com/articles/feds-evans-if-inflation-weakens-fed-may-have-to-lower-rates-11556892905", "title": "Fed's Evans: If Inflation Weakens, Fed May Have To Lower Rates", "date": "2019-05-03 10:15", "summary": "The economy is growing swiftly and creating jobs, while at the same time stuck at inflation levels well short of the 2% target.. Federal Reserve Bank of Chicago President Charles Evans said Friday if inflation doesn't pick up, the central bank may need to consider lowering interest rates.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans: If Inflation Weakens, Fed May Have To Lower Rates. The economy is growing swiftly and creating jobs, while at the same time stuck at inflation levels well short of the 2% target.. Federal Reserve Bank of Chicago President Charles Evans said Friday if inflation doesn't pick up, the central bank may need to consider lowering interest rates.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of Chicago (NASDAQ: CME) will decrease because they are hinting at a potential interest rate cut.\n- The Goldman Sachs Group, Inc. (NYSE: GS) will decrease because they are also hinting at a potential interest rate cut.", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "down", "prices": [206.86, 207.77]}, "CME": {"company": "", "ticker": "CME", "move": "down", "prices": [173.17, 173.5299]}}}, {"link": "https://www.wsj.com/articles/grinch-bots-steal-christmas-again-11640798938", "title": "Grinch Bots Steal Christmas Again", "date": "2021-12-29 12:28", "summary": "Supply-chain issues and an increase in online sales are proving to be a gift for bad bots. Grinch bots are putting some grift into gifts.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Grinch Bots Steal Christmas Again. Supply-chain issues and an increase in online sales are proving to be a gift for bad bots. Grinch bots are putting some grift into gifts.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are selling more products online, and the bots are stealing from other retailers.\n- Walmart Inc. (NYSE: WMT) will decrease because they are not selling as many products online, and the bots are stealing from them.\n- Target Corporation (NYSE: TGT) will decrease because they are not selling as many products online, and the bots are stealing from them.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [142.76, 142.6892]}, "TGT": {"company": "", "ticker": "TGT", "move": "down", "prices": [229.195, 228.285]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3378.47, 3382.495]}}}, {"link": "https://www.wsj.com/articles/hedge-funds-that-cashed-in-when-oil-prices-cratered-11585145260", "title": "Hedge Funds That Cashed In When Oil Prices Cratered", "date": "2020-03-25 10:07", "summary": "Several funds wagered against crude before the coronavirus and the Russia-Saudi breakup slammed the energy market. The crash in oil prices this month has been a brutal comeuppance for the energy world. But it has also generated profits for a handful of niche hedge-fund managers.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hedge Funds That Cashed In When Oil Prices Cratered. Several funds wagered against crude before the coronavirus and the Russia-Saudi breakup slammed the energy market. The crash in oil prices this month has been a brutal comeuppance for the energy world. But it has also generated profits for a handful of niche hedge-fund managers.\"\n\nStock Prediction(s):", "Prediction": "\n- Energy XXI Gulf Coast Inc (NASDAQ: EXXI) will increase because they are a direct beneficiary of the hedge funds that profited from the oil price crash.\n- Marathon Oil Corporation (NYSE: MRO) will increase because they are a direct beneficiary of the hedge funds that profited from the oil price crash.\n- Chesapeake Energy Corporation (NYSE: CHK) will increase because they are a direct beneficiary of the hedge funds that profited", "price_info": {"MRO": {"company": "", "ticker": "MRO", "move": "up", "prices": [3.63, 3.72]}, "CHK": {"company": "", "ticker": "CHK", "move": "up", "prices": [0.181, 0.1852]}, "EXXI": {"company": "", "ticker": "EXXI", "move": "up"}}}, {"link": "https://www.wsj.com/articles/consumer-lenders-enter-fog-of-uncertainty-11587491972", "title": "Consumer Lenders Enter Fog of Uncertainty", "date": "2020-04-21 13:59", "summary": "Credit-card and auto lenders don't yet believe borrowers will perform as badly as they did in 2009. Consumer lenders are preparing for something pretty bad to happen to borrowers-but perhaps not bad enough.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer Lenders Enter Fog of Uncertainty. Credit-card and auto lenders don't yet believe borrowers will perform as badly as they did in 2009. Consumer lenders are preparing for something pretty bad to happen to borrowers-but perhaps not bad enough.\"\n\nStock Prediction(s):", "Prediction": "\n- Visa Inc (NYSE: V) will increase because they are a credit-card lender and they don't believe borrowers will perform as badly as they did in 2009.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are a credit-card lender and they don't believe borrowers will perform as badly as they did in 2009.\n- Ford Motor Company (NYSE: F) will increase because they are an auto lender and they don't believe", "price_info": {"V": {"company": "", "ticker": "V", "move": "up", "prices": [160.75, 161.25]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [89.02, 89.16]}, "F": {"company": "", "ticker": "F", "move": "up", "prices": [4.7572, 4.78]}}}, {"link": "https://www.wsj.com/articles/u-s-home-sales-decline-in-november-after-five-monthly-gains-11608650319", "title": "U.S. Home Sales Declined in November After Five Monthly Gains", "date": "2020-12-22 12:48", "summary": "Lack of houses constrained sales; consumer confidence slipped in December. Homes sales slipped in November as the supply of properties for sale fell to a new low, the latest sign strong economic momentum in the middle of the year is easing in 2020's final months.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Home Sales Declined in November After Five Monthly Gains. Lack of houses constrained sales; consumer confidence slipped in December. Homes sales slipped in November as the supply of properties for sale fell to a new low, the latest sign strong economic momentum in the middle of the year is easing in 2020's final months.\"\n\nStock Prediction(s):", "Prediction": "\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and KB Home (NYSE: KBH) will decrease because there is not as much demand for housing.\n- REITs such as Simon Property Group, Inc. (NYSE: SPG) and HCP, Inc. (NYSE: HCP) will decrease because there is not as much demand for housing.", "price_info": {"LEN": {"company": "", "ticker": "LEN", "move": null, "prices": [80.095, 80.3]}, "KBH": {"company": "", "ticker": "KBH", "move": "down", "prices": [35.42, 35.46]}, "SPG": {"company": "", "ticker": "SPG", "move": null, "prices": [82.26, 82.36]}, "HCP": {"company": "", "ticker": "HCP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/apple-music-gets-into-the-muzak-business-11574247603", "title": "Apple Music Gets Into the Muzak Business", "date": "2019-11-20 11:43", "summary": "No. 2 streaming service is now providing soundtracks for Harrods, Levi's stores. Apple Music is getting into the business of music for business.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Music Gets Into the Muzak Business. No. 2 streaming service is now providing soundtracks for Harrods, Levi's stores. Apple Music is getting into the business of music for business.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are expanding their business into providing soundtracks for stores.\n- Spotify Technology SA (NYSE: SPOT) will decrease because they are a direct competitor of Apple Music.", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "down", "prices": [136.4, 136.12]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [264.21, 261.2901]}}}, {"link": "https://www.wsj.com/articles/pg-e-outlines-board-shake-up-as-it-posts-quarterly-profit-11588340866", "title": "PG&E Outlines Board Shake-Up as It Posts Quarterly Profit", "date": "2020-05-01 09:47", "summary": "The California utility, facing billions in fire-related costs, had planned to overhaul its board to secure Gavin Newsom's support for its plan to exit bankruptcy. PG&E Corp. on Friday detailed a planned shake-up of its board of directors as it reported a rise in quarterly earnings.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"PG&E Outlines Board Shake-Up as It Posts Quarterly Profit. The California utility, facing billions in fire-related costs, had planned to overhaul its board to secure Gavin Newsom's support for its plan to exit bankruptcy. PG&E Corp. on Friday detailed a planned shake-up of its board of directors as it reported a rise in quarterly earnings.\"\n\nStock Prediction(s):", "Prediction": "\n- PG&E Corp. (NYSE: PCG) will increase because they have outlined a board shake-up and they are expecting support from Gavin Newsom.\n- Edison International (NYSE: EIX) will decrease because they are a direct competitor of PG&E.", "price_info": {"PCG": {"company": "", "ticker": "PCG", "move": "up", "prices": [10.23, 10.3]}, "EIX": {"company": "", "ticker": "EIX", "move": "down", "prices": [56.76, 56.44]}}}, {"link": "https://www.wsj.com/articles/u-s-trade-gap-narrowed-in-april-11559824480", "title": "U.S. Trade Gap Narrowed in April", "date": "2019-06-06 13:07", "summary": "Sharp declines in both imports and exports contributed to overall drop in deficit. WASHINGTON-The U.S. trade gap narrowed slightly at the start of the second quarter with large declines in both exports and imports, and economists said recently heightened trade tensions with China and Mexico complicate the outlook for the months ahead.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Trade Gap Narrowed in April. Sharp declines in both imports and exports contributed to overall drop in deficit. WASHINGTON-The U.S. trade gap narrowed slightly at the start of the second quarter with large declines in both exports and imports, and economists said recently heightened trade tensions with China and Mexico complicate the outlook for the months ahead.\"\n\nStock Prediction(s):", "Prediction": "\n- The trade gap will continue to narrow because of the decrease in imports and exports.\n- The trade gap will reverse course because of the increase in tariffs.", "price_info": {}}, {"link": "https://www.wsj.com/articles/household-wealth-broadly-rose-in-years-leading-up-to-pandemic-fed-report-concludes-11601309146", "title": "Household Wealth Rose in Years Before Pandemic, Fed Says", "date": "2020-09-28 15:57", "summary": "Those in lower-income and lower-wealth categories made relatively large gains, according to report. U.S. families' income and wealth rose in the years heading into the coronavirus pandemic, with those in lower-income and lower-wealth categories reaping relatively large gains, the Federal Reserve said in a report on household finances.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Household Wealth Rose in Years Before Pandemic, Fed Says. Those in lower-income and lower-wealth categories made relatively large gains, according to report. U.S. families' income and wealth rose in the years heading into the coronavirus pandemic, with those in lower-income and lower-wealth categories reaping relatively large gains, the Federal Reserve said in a report on household finances.\"\n\nStock Prediction(s):", "Prediction": "\n- The wealthy will continue to get wealthier, while the poor get poorer.\n- The stock prices of companies that cater to the wealthy, such as luxury car companies and high-end retailers, will go up.\n- The stock prices of companies that cater to the poor, such as discount retailers and fast food chains, will go down.", "price_info": {}}, {"link": "https://www.wsj.com/articles/oil-declines-as-u-s-crude-inventories-rise-unexpectedly-11553701954", "title": "Oil Drops as U.S. Inventories Rise Unexpectedly", "date": "2019-03-27 15:25", "summary": "A 2.8-million-barrel jump came after two weeks of declines, but a drop in gasoline stockpiles helped prevent a selloff. \u2022 Oil prices fell Wednesday because of an unanticipated increase in U.S. inventories of crude oil amid a sharp slowdown in refining activity.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Drops as U.S. Inventories Rise Unexpectedly. A 2.8-million-barrel jump came after two weeks of declines, but a drop in gasoline stockpiles helped prevent a selloff. \u2022 Oil prices fell Wednesday because of an unanticipated increase in U.S. inventories of crude oil amid a sharp slowdown in refining activity.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because of the news about the increase in U.S. inventories.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because of the news about the increase in U.S. inventories.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because of the news about the increase in U.S. inventories.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [125.0328, 122.79]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [80.34, 80.34]}}}, {"link": "https://www.wsj.com/articles/how-women-can-confidently-speak-up-for-what-they-want-11567183823", "title": "How Women Can Confidently Speak Up for What They Want", "date": "2019-08-30 12:50", "summary": "The courage to advocate for yourself is a learned skill, according to a panel of experts on WSJ's Secrets of Wealthy Women podcast. Some women struggle with confidence, and this has real implications for their career advancement and pay.", "categories": [["Markets", "Your Money"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/undefined?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How Women Can Confidently Speak Up for What They Want. The courage to advocate for yourself is a learned skill, according to a panel of experts on WSJ's Secrets of Wealthy Women podcast. Some women struggle with confidence, and this has real implications for their career advancement and pay.\"\n\nStock Prediction(s):", "Prediction": "\n- Female-led companies will increase in value because they promote and encourage female confidence.\n- Companies that have a poor track record with gender equality will decrease in value because they will be seen as not being supportive of women.", "price_info": {}}, {"link": "https://www.wsj.com/articles/new-york-attorney-general-files-new-allegations-against-opioid-maker-purdue-pharma-and-sackler-family-owners-11553781600", "title": "Purdue's Sackler Family Accused of Fraud in Transfers of Opioid Profits", "date": "2019-03-28 15:37", "summary": "Amended complaint argues Purdue profits paid to owners should be clawed back because of mounting lawsuits against the company. Members of the Sackler family who control OxyContin-maker Purdue Pharma LP allegedly used a web of corporate entities to transfer funds from the company to themselves, moves the New York attorney general says were fraudulent, on the basis that the company was already insolvent or close to it.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Purdue's Sackler Family Accused of Fraud in Transfers of Opioid Profits. Amended complaint argues Purdue profits paid to owners should be clawed back because of mounting lawsuits against the company. Members of the Sackler family who control OxyContin-maker Purdue Pharma LP allegedly used a web of corporate entities to transfer funds from the company to themselves, moves the New York attorney general says were fraudulent, on the basis that the company was already insolvent or close to it.\"\n\nStock Prediction(s):", "Prediction": "\n- Purdue Pharma LP (NYSE: PPHM) will decrease because of the allegations of fraud.\n- The Sackler family will also decrease in net worth because of the allegations of fraud.", "price_info": {"PPHM": {"company": "", "ticker": "PPHM", "move": "down"}}}, {"link": "https://www.wsj.com/articles/tips-if-youre-retiring-in-2020-11578071932", "title": "Tips if You're Retiring in 2020", "date": "2020-01-03 12:18", "summary": "Don't be complacent, no matter how well your nest egg performed this past year. I plan to retire this year. My nest egg, the markets and the economy all appear to be in good shape. My question: Am I missing something? Is there anything on the horizon, financially, that would make retiring in the near future more risky than not?", "categories": [["Markets", "Journal Reports: Funds/ETFs", "Ask Encore"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tips if You're Retiring in 2020. Don't be complacent, no matter how well your nest egg performed this past year. I plan to retire this year. My nest egg, the markets and the economy all appear to be in good shape. My question: Am I missing something? Is there anything on the horizon, financially, that would make retiring in the near future more risky than not?\"\n\nStock Prediction(s):", "Prediction": "\n- Vanguard Group (NYSE: VGR) will increase because a lot of people are retiring this year, and they are one of the largest retirement fund providers.\n- Fidelity Investments (NYSE: FIS) will increase because a lot of people are retiring this year, and they are one of the largest retirement fund providers.\n- Charles Schwab Corp (NYSE: SCHW) will increase because a lot of people are retiring this year, and they are one of", "price_info": {"VGR": {"company": "", "ticker": "VGR", "move": "up", "prices": [13.3325, 13.315]}, "FIS": {"company": "", "ticker": "FIS", "move": "up", "prices": [139.67, 139.46]}, "SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [47.43, 47.2]}}}, {"link": "https://www.wsj.com/articles/feds-clarida-says-findings-of-policy-review-will-be-shared-next-year-11559742300", "title": "Fed's Clarida Says Findings of Policy Review Will Be Shared Next Year", "date": "2019-06-05 09:45", "summary": "Framework used to set and communicate rate decisions will likely be completed in the first half of 2020. CHICAGO-Federal Reserve Vice Chairman Richard Clarida said the central bank's ongoing review of the framework it uses to set and communicate its rate policy decisions will probably be completed in the first half of 2020.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Clarida Says Findings of Policy Review Will Be Shared Next Year. Framework used to set and communicate rate decisions will likely be completed in the first half of 2020. CHICAGO-Federal Reserve Vice Chairman Richard Clarida said the central bank's ongoing review of the framework it uses to set and communicate its rate policy decisions will probably be completed in the first half of 2020.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve will increase rates in 2020 because their review is completed and they find that the current framework is effective.\n- The Federal Reserve will decrease rates in 2020 because their review is completed and they find that the current framework is not effective.", "price_info": {}}, {"link": "https://www.wsj.com/articles/freight-carrier-nemf-fighting-banks-on-bankruptcy-auction-11553107802", "title": "Freight Carrier NEMF Fighting Banks on Bankruptcy Auction", "date": "2019-03-20 14:50", "summary": "Bank lenders' worries cloud trucking industry sale of the decade. Bankrupt carrier New England Motor Freight Inc. told a judge this week it has corralled its rolling fleet and is preparing for the trucking industry sale of the decade.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Freight Carrier NEMF Fighting Banks on Bankruptcy Auction. Bank lenders' worries cloud trucking industry sale of the decade. Bankrupt carrier New England Motor Freight Inc. told a judge this week it has corralled its rolling fleet and is preparing for the trucking industry sale of the decade.\"\n\nStock Prediction(s):", "Prediction": "\n- NEMF will increase because they have a valuable fleet of trucks and are preparing for a successful auction.\n- J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT) will increase because they are a direct competitor of NEMF and are also preparing for the auction.\n- Schneider National, Inc. (NYSE: SNDR) will increase because they are a direct competitor of NEMF and are also preparing for the auction.", "price_info": {"SNDR": {"company": "", "ticker": "SNDR", "move": "up"}, "JBHT": {"company": "", "ticker": "JBHT", "move": "up"}}}, {"link": "https://www.wsj.com/articles/how-the-drug-lobby-lost-its-mojo-in-washington-11582132499", "title": "How the Drug Lobby Lost Its Mojo in Washington", "date": "2020-02-19 12:15", "summary": "A rift between the GOP and its longtime pharmaceutical-industry allies is shaking up policy, as Republicans and Democrats join to overhaul price regulations. WASHINGTON-The drug industry doesn't pack the lobbying punch it once did, and one sign is something rare in the capital today-a dose of bipartisanship.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How the Drug Lobby Lost Its Mojo in Washington. A rift between the GOP and its longtime pharmaceutical-industry allies is shaking up policy, as Republicans and Democrats join to overhaul price regulations. WASHINGTON-The drug industry doesn't pack the lobbying punch it once did, and one sign is something rare in the capital today-a dose of bipartisanship.\"\n\nStock Prediction(s):", "Prediction": "\n- The drug industry will decrease because of the rift between the GOP and its longtime pharmaceutical-industry allies.\n- Pfizer Inc (NYSE: PFE) will decrease because they are a part of the drug industry.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [36.404, 36.36]}}}, {"link": "https://www.wsj.com/articles/consolidation-may-be-coming-to-a-screen-near-you-11624025973", "title": "Consolidation May Be Coming to a Screen Near You", "date": "2021-06-18 11:48", "summary": "Meme cash lets AMC go 'on the offensive' while other chains are shopping, but final impact unclear. Far from killing the movie-exhibition industry, the pandemic may end up helping the big theater chains get even bigger.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consolidation May Be Coming to a Screen Near You. Meme cash lets AMC go 'on the offensive' while other chains are shopping, but final impact unclear. Far from killing the movie-exhibition industry, the pandemic may end up helping the big theater chains get even bigger.\"\n\nStock Prediction(s):", "Prediction": "\n- AMC Entertainment Holdings, Inc. (NYSE: AMC) will increase because they are in the process of being bought out, and the pandemic is making the industry more consolidated.\n- Cinemark Holdings, Inc. (NYSE: CNK) will decrease because they are not being bought out, and they are in direct competition with AMC.\n- Regal Entertainment Group (NYSE: RGC) will decrease because they are not being bought out, and they are in", "price_info": {"AMC": {"company": "", "ticker": "AMC", "move": "up", "prices": [61.27, 60.75]}, "CNK": {"company": "", "ticker": "CNK", "move": "down", "prices": [21.751, 21.6498]}, "RGC": {"company": "", "ticker": "RGC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/what-amazons-rise-to-no-1-says-about-the-stock-market-11547226248", "title": "What Amazon's Rise to No. 1 Says About the Stock Market", "date": "2019-01-11 12:04", "summary": "The biggest companies are still the most dominant. The biggest companies today make up less of the overall market than those in the past. And the biggest companies can still be toppled.. On Jan. 7, Amazon.com Inc. became the world's largest company by market capitalization. Its rise might make you think today's biggest technology companies are turning into unstoppable juggernauts of growth, or that turnover at the top is only accelerating.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What Amazon's Rise to No. 1 Says About the Stock Market. The biggest companies are still the most dominant. The biggest companies today make up less of the overall market than those in the past. And the biggest companies can still be toppled.. On Jan. 7, Amazon.com Inc. became the world's largest company by market capitalization. Its rise might make you think today's biggest technology companies are turning into unstoppable juggernauts of growth, or that turnover at the top is only accelerating.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will continue to increase in value because they are the largest company in the world.\n- Apple Inc. (NASDAQ: AAPL) will continue to decrease in value because they are not the largest company in the world.\n- Microsoft Corporation (NASDAQ: MSFT) will continue to increase in value because they are not the largest company in the world.", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1648.7417, 1641]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [152.45, 152.255]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [102.2977, 101.865]}}}, {"link": "https://www.wsj.com/articles/monthly-u-s-budget-gap-more-than-doubled-in-october-11605207695", "title": "Monthly U.S. Budget Gap More Than Doubled in October", "date": "2020-11-12 14:01", "summary": "Economy saw higher federal spending on health-care and safety-net programs, lower federal tax collection. WASHINGTON-The federal government ran a $284 billion budget deficit in the first month of the fiscal year, more than double the monthly shortfall a year ago, the Treasury Department said Thursday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Monthly U.S. Budget Gap More Than Doubled in October. Economy saw higher federal spending on health-care and safety-net programs, lower federal tax collection. WASHINGTON-The federal government ran a $284 billion budget deficit in the first month of the fiscal year, more than double the monthly shortfall a year ago, the Treasury Department said Thursday.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. budget deficit will continue to increase because of the increasing spending on health-care and safety-net programs.\n- The U.S. budget deficit will have a negative effect on the economy because it will lead to higher levels of government debt.\n- The U.S. budget deficit will lead to higher levels of inflation because the government will need to print more money to finance its debt.", "price_info": {}}, {"link": "https://www.wsj.com/articles/ride-sharing-gets-locked-down-by-coronavirus-11584553257", "title": "Ride-Sharing Gets Locked Down by Coronavirus", "date": "2020-03-18 13:40", "summary": "Coronavirus restrictions will cost Uber and Lyft and likely sideline their road to profitability. For a sign of how the coronavirus is hurting the ride-sharing business, consider this: It took a global pandemic to make Uber Technologies ' food-delivery business look appetizing.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ride-Sharing Gets Locked Down by Coronavirus. Coronavirus restrictions will cost Uber and Lyft and likely sideline their road to profitability. For a sign of how the coronavirus is hurting the ride-sharing business, consider this: It took a global pandemic to make Uber Technologies ' food-delivery business look appetizing.\"\n\nStock Prediction(s):", "Prediction": "\n- Uber Technologies (NYSE: UBER) will decrease because their main business is ride-sharing, and this is no longer an option with the coronavirus.\n- Lyft Inc (NASDAQ: LYFT) will decrease because their main business is ride-sharing, and this is no longer an option with the coronavirus.", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "down", "prices": [15.4, 14.2]}, "LYFT": {"company": "", "ticker": "LYFT", "move": "down", "prices": [15.54, 15.0106]}}}, {"link": "https://www.wsj.com/articles/apples-iphone-12-first-impressions-of-the-12-12-pro-12-pro-max-and-12-mini-11602629535", "title": "Apple's iPhone 12: Sizing Up the 12, 12 Pro, 12 Pro Max and 12 Mini", "date": "2020-10-14 12:00", "summary": "Apple introduced four new phones-and the high-speed 5G cellular compatibility isn't the feature to be most excited about. The latest iPhone 12 lineup has landed with the most significant design change in three years, support for high-speed 5G cellular networks-and a \"mini\" model for those of us who have felt that these increasingly huge phones are getting harder to hold.", "categories": [["Tech", "Personal Tech", "Personal Technology: Nicole Nguyen"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-nicole-nguyen?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple's iPhone 12: Sizing Up the 12, 12 Pro, 12 Pro Max and 12 Mini. Apple introduced four new phones-and the high-speed 5G cellular compatibility isn't the feature to be most excited about. The latest iPhone 12 lineup has landed with the most significant design change in three years, support for high-speed 5G cellular networks-and a \"mini\" model for those of us who have felt that these increasingly huge phones are getting harder to hold.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they released a new phone lineup that supports 5G cellular networks.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will decrease because they are a direct competitor of Apple, and they do not have a phone that supports 5G cellular networks.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [120.3298, 120.55]}}}, {"link": "https://www.wsj.com/articles/heathrow-sells-debt-to-allay-concerns-over-brexit-11551890984", "title": "Heathrow Sells Debt to Allay Concerns Over Brexit", "date": "2019-03-06 11:49", "summary": "Bond sales by U.K.-based companies have declined sharply ahead of the coming Brexit deadline. Europe's busiest airport raised \u20ac650 million ($735.4 million) from investors Wednesday amid concerns about how Brexit might affect the company's credit rating.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Heathrow Sells Debt to Allay Concerns Over Brexit. Bond sales by U.K.-based companies have declined sharply ahead of the coming Brexit deadline. Europe's busiest airport raised \u20ac650 million ($735.4 million) from investors Wednesday amid concerns about how Brexit might affect the company's credit rating.\"\n\nStock Prediction(s):", "Prediction": "\n- Heathrow Airport Holdings Ltd (OTC: HLEAF) will increase because they have raised money to help with Brexit concerns.\n- Ryanair Holdings plc (OTC: RYAAY) will increase because Heathrow Airport Holdings Ltd is a competitor, and they will need to keep up with them.\n- British Airways owner IAG SA (OTC: IAGSY) will increase because Heathrow Airport Holdings Ltd is a competitor, and they", "price_info": {}}, {"link": "https://www.wsj.com/articles/shale-drillers-may-spend-more-but-dont-expect-a-bonanza-even-at-80-oil-11634042534", "title": "Shale Drillers May Boost Spending, but Don't Expect an Oil Bonanza", "date": "2021-10-12 12:43", "summary": "American frackers are expected to lift U.S. oil-field spending 15% to 20% next year, but their investments are still well below pre-pandemic levels. Shale companies are on track to spend a little more money pumping oil next year, but most aren't opening up the spigots, even as prices top $80 a barrel.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Shale Drillers May Boost Spending, but Don't Expect an Oil Bonanza. American frackers are expected to lift U.S. oil-field spending 15% to 20% next year, but their investments are still well below pre-pandemic levels. Shale companies are on track to spend a little more money pumping oil next year, but most aren't opening up the spigots, even as prices top $80 a barrel.\"\n\nStock Prediction(s):", "Prediction": "\n- Schlumberger Ltd. (NYSE: SLB) will increase because they are one of the largest oilfield service companies, and they are expecting to see an increase in spending from shale drillers.\n- Halliburton Company (NYSE: HAL) will increase because they are one of the largest oilfield service companies, and they are expecting to see an increase in spending from shale drillers.\n- Baker Hughes, a GE company (NYSE: BHGE", "price_info": {"SLB": {"company": "", "ticker": "SLB", "move": "up", "prices": [33.075, 33.14]}, "HAL": {"company": "", "ticker": "HAL", "move": "up", "prices": [24.72, 24.61]}}}, {"link": "https://www.wsj.com/articles/ghosts-in-the-clouds-inside-chinas-major-corporate-hack-11577729061", "title": "Ghosts in the Clouds: Inside China's Major Corporate Hack", "date": "2019-12-30 13:04", "summary": "A Journal investigation finds the Cloud Hopper attack was much bigger than previously known. The hackers seemed to be everywhere.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ghosts in the Clouds: Inside China's Major Corporate Hack. A Journal investigation finds the Cloud Hopper attack was much bigger than previously known. The hackers seemed to be everywhere.\"\n\nStock Prediction(s):", "Prediction": "\n- IBM Corporation (NYSE: IBM) will decrease because they are a direct competitor of the Chinese company that was hacked.\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because they are a direct competitor of the Chinese company that was hacked.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are a direct competitor of the Chinese company that was hacked.", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "down", "prices": [133.43, 133.15]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [158, 157.9]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1854.282, 1847.14]}}}, {"link": "https://www.wsj.com/articles/list-of-macys-stores-set-to-close-11580856020", "title": "List of Macy's Stores Set to Close", "date": "2020-02-05 14:38", "summary": "Resume Subscription. Macy's Inc. is accelerating its restructuring efforts after a yearslong slump. Some of the retailer's stores that are set to close this year:", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"List of Macy's Stores Set to Close. Resume Subscription. Macy's Inc. is accelerating its restructuring efforts after a yearslong slump. Some of the retailer's stores that are set to close this year:\"\n\nStock Prediction(s):", "Prediction": "\n- Macy's Inc. (NYSE: M) will decrease because they are closing stores.", "price_info": {"M": {"company": "", "ticker": "M", "move": "down", "prices": [17.165, 17.4375]}}}, {"link": "https://www.wsj.com/articles/the-covid-19-vaccine-news-is-greatbut-you-just-issued-dirt-cheap-stock-11605203669", "title": "The Covid Vaccine News Is Great-but You Just Issued Dirt-Cheap Stock", "date": "2020-11-12 12:54", "summary": "Pfizer's coronavirus vaccine results have made the price of Rolls-Royce's rights issue appear very low in retrospect. Sometimes good news can come at an embarrassing time.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Covid Vaccine News Is Great-but You Just Issued Dirt-Cheap Stock. Pfizer's coronavirus vaccine results have made the price of Rolls-Royce's rights issue appear very low in retrospect. Sometimes good news can come at an embarrassing time.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Rolls-Royce Holdings plc (OTC: RYCEY) will decrease because their stock was just issued at a dirt-cheap price, and the market is not expecting good news from them.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [37.535, 37.465]}}}, {"link": "https://www.wsj.com/articles/west-virginia-gov-jim-justices-companies-look-to-surging-coal-prices-to-pay-off-debts-11627059479", "title": "West Virginia Governor's Companies Look to Pay Off Greensill Debts", "date": "2021-07-23 12:58", "summary": "Representatives of Credit Suisse and Mr. Justice's companies met to sort out nearly $850 million in loans tied to Greensill. West Virginia Gov. Jim Justice and Credit Suisse Group AG are looking to take advantage of surging coal prices to help him pay off nearly $850 million in loans his companies borrowed from now-collapsed Greensill Capital.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"West Virginia Governor's Companies Look to Pay Off Greensill Debts. Representatives of Credit Suisse and Mr. Justice's companies met to sort out nearly $850 million in loans tied to Greensill. West Virginia Gov. Jim Justice and Credit Suisse Group AG are looking to take advantage of surging coal prices to help him pay off nearly $850 million in loans his companies borrowed from now-collapsed Greensill Capital.\"\n\nStock Prediction(s):", "Prediction": "\n- James Justice Companies (OTC: JJC) will increase because they are looking to pay off their debts.\n- Credit Suisse Group AG (NYSE: CS) will increase because they are helping James Justice Companies pay off their debts.\n- Greensill Capital (OTC: GSC) will decrease because they are no longer in business.", "price_info": {"CS": {"company": "", "ticker": "CS", "move": "down", "prices": [10.085, 10.05]}}}, {"link": "https://www.wsj.com/articles/walmart-looks-to-hire-cryptocurrency-expert-11629128826", "title": "Walmart Looks to Hire Cryptocurrency Expert", "date": "2021-08-16 11:47", "summary": "Retailer posts headquarters job to develop digital-currency strategy. Walmart Inc. is seeking to hire a cryptocurrency expert, joining a growing number of companies looking to develop strategies for digital currencies such as bitcoin.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walmart Looks to Hire Cryptocurrency Expert. Retailer posts headquarters job to develop digital-currency strategy. Walmart Inc. is seeking to hire a cryptocurrency expert, joining a growing number of companies looking to develop strategies for digital currencies such as bitcoin.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because they are looking to hire a cryptocurrency expert, which will help them develop their own digital currency strategy.\n- J.P. Morgan Chase & Co. (NYSE: JPM) will decrease because they are also looking to hire a cryptocurrency expert, but they are a direct competitor of Walmart.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [150.975, 150.895]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [158.38, 158.4599]}}}, {"link": "https://www.wsj.com/articles/chinas-trade-frontman-points-with-laser-to-bright-side-of-u-s-tensions-11560422497", "title": "China's Trade Frontman Points, With Laser, to Bright Side of U.S. Tensions", "date": "2019-06-13 11:00", "summary": "External pressure serves the country's long-term interests, Vice Premier Liu He says. SHANGHAI-China's point man on trade talks with the U.S., Vice Premier Liu He, said external pressure serves his nation's long-term interests, providing rare insight into how he frames the high-stakes tussle between the world's two biggest economies.", "categories": [["Economy", "Asia Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/asia-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"China's Trade Frontman Points, With Laser, to Bright Side of U.S. Tensions. External pressure serves the country's long-term interests, Vice Premier Liu He says. SHANGHAI-China's point man on trade talks with the U.S., Vice Premier Liu He, said external pressure serves his nation's long-term interests, providing rare insight into how he frames the high-stakes tussle between the world's two biggest economies.\"\n\nStock Prediction(s):", "Prediction": "\n- The stock prices of Chinese companies will increase because the Vice Premier is optimistic about the future of US-China relations.\n- The stock prices of American companies will decrease because the Vice Premier is optimistic about the future of US-China relations.", "price_info": {}}, {"link": "https://www.wsj.com/articles/paneras-grocery-aisle-electric-vans-for-amazon-diversification-is-making-a-comeback-11587740399", "title": "Panera's Grocery Aisle? Electric Vans for Amazon? Diversification Is Making a Comeback.", "date": "2020-04-24 15:31", "summary": "Business leaders are employing a retro survival technique during the pandemic. Revenue diversification is as old as business itself. For companies like Panera Bread, the ancient strategy could represent a lifeline.", "categories": [["Business", "On Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/on-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Panera's Grocery Aisle? Electric Vans for Amazon? Diversification Is Making a Comeback.. Business leaders are employing a retro survival technique during the pandemic. Revenue diversification is as old as business itself. For companies like Panera Bread, the ancient strategy could represent a lifeline.\"\n\nStock Prediction(s):", "Prediction": "\n- Panera Bread (NASDAQ: PNRA) will increase because they are expanding their business model to include groceries.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are expanding their business model to include electric vans.\n- Starbucks Corporation (NASDAQ: SBUX) will decrease because they are not expanding their business model.", "price_info": {"PNRA": {"company": "", "ticker": "PNRA", "move": "up"}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [2409.8, 2409.21]}, "SBUX": {"company": "", "ticker": "SBUX", "move": "down", "prices": [75.5, 75.76]}}}, {"link": "https://www.wsj.com/articles/citigroups-profit-falls-34-as-it-sets-aside-more-money-for-bad-loans-11602592128", "title": "Citigroup Profit Falls 34%", "date": "2020-10-13 14:06", "summary": "Bank set aside $2.26 billion for potential loan losses, down from the more than $7 billion it set aside in each of the past two quarters. Citigroup Inc. said Tuesday that its third-quarter profit slumped 34%, with the bank continuing to prepare for a coronavirus-induced recession.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Citigroup Profit Falls 34%. Bank set aside $2.26 billion for potential loan losses, down from the more than $7 billion it set aside in each of the past two quarters. Citigroup Inc. said Tuesday that its third-quarter profit slumped 34%, with the bank continuing to prepare for a coronavirus-induced recession.\"\n\nStock Prediction(s):", "Prediction": "\n- Citigroup Inc. (NYSE: C) will decrease because of their profit slump and their preparations for a potential coronavirus-induced recession.", "price_info": {"C": {"company": "", "ticker": "C", "move": "down", "prices": [43.76, 43.73]}}}, {"link": "https://www.wsj.com/articles/child-tax-credit-payments-start-11626304415", "title": "Child Tax Credit Payments Totaling $15 Billion Arrive for Millions of Americans", "date": "2021-07-15 12:54", "summary": "IRS issues families payments of up to $300 per child under program aimed at combating poverty. WASHINGTON-Tens of millions of U.S. households can expect to see their bank balances grow Thursday, thanks to the first monthly payments of the expanded child tax credit.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Child Tax Credit Payments Totaling $15 Billion Arrive for Millions of Americans. IRS issues families payments of up to $300 per child under program aimed at combating poverty. WASHINGTON-Tens of millions of U.S. households can expect to see their bank balances grow Thursday, thanks to the first monthly payments of the expanded child tax credit.\"\n\nStock Prediction(s):", "Prediction": "\n- The child tax credit payments will help to stimulate the economy, and will cause an increase in spending.\n- The child tax credit payments will help to combat poverty, and will cause an increase in the standard of living for many Americans.\n- The child tax credit payments will help to increase the number of taxpayers, and will cause an increase in government revenue.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bank-of-mexico-cuts-economic-growth-forecasts-11574882047", "title": "Bank of Mexico Cuts Economic Growth Forecasts", "date": "2019-11-27 14:14", "summary": "Resume Subscription. ", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bank of Mexico Cuts Economic Growth Forecasts. Resume Subscription. \"\n\nStock Prediction(s):", "Prediction": "\n- Banco de Mexico (BMV: BMA) will decrease because they have lowered their economic growth forecasts.", "price_info": {}}, {"link": "https://www.wsj.com/articles/christmas-came-early-at-best-buy-11606239059", "title": "Christmas Came Early at Best Buy", "date": "2020-11-24 13:48", "summary": "Retailer saw impressive results last quarter but may have pulled forward some holiday demand. All eyes are on the holiday shopping season. That places uncomfortable pressure on Best Buy , which has set itself up for high expectations after posting strong results last quarter.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Christmas Came Early at Best Buy. Retailer saw impressive results last quarter but may have pulled forward some holiday demand. All eyes are on the holiday shopping season. That places uncomfortable pressure on Best Buy , which has set itself up for high expectations after posting strong results last quarter.\"\n\nStock Prediction(s):", "Prediction": "\n- Best Buy Co., Inc. (NYSE: BBY) will increase because they had a strong previous quarter, and they are expecting high results during the holiday season.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a direct competitor of Best Buy, and they are expecting high results during the holiday season.", "price_info": {"BBY": {"company": "", "ticker": "BBY", "move": "up", "prices": [114.935, 114.045]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3129.34, 3118.64]}}}, {"link": "https://www.wsj.com/articles/u-s-air-force-gives-lift-to-flying-taxis-11607596206", "title": "U.S. Air Force Gives Lift to Flying Taxis", "date": "2020-12-10 12:05", "summary": "Military endorsement could bring novel electric vehicles closer to reality. Flying taxis, which one day may whisk passengers around town without pilots, are getting a boost from the U.S. military.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Air Force Gives Lift to Flying Taxis. Military endorsement could bring novel electric vehicles closer to reality. Flying taxis, which one day may whisk passengers around town without pilots, are getting a boost from the U.S. military.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co (NYSE: BA) will increase because they are one of the main companies working on flying taxis.\n- Airbus SE (OTCMKTS: EADSY) will increase because they are one of the main companies working on flying taxis.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are one of the main companies working on flying taxis.\n- Uber Technologies Inc (NYSE: UBER) will increase because", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [235.3, 235.9549]}, "UBER": {"company": "", "ticker": "UBER", "move": "up", "prices": [53.08, 54.1264]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [614.11, 614.8795]}}}, {"link": "https://www.wsj.com/articles/westfields-owner-offers-two-unappealing-deals-11602770440", "title": "Westfield's Owner Offers Two Unappealing Deals", "date": "2020-10-15 10:00", "summary": "A small group of shareholders at the owner of Westfield shopping malls have proposed a risky new strategy to replace plans for a rights issue. Shareholders in Europe's largest property company have a choice between two bad options.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Westfield's Owner Offers Two Unappealing Deals. A small group of shareholders at the owner of Westfield shopping malls have proposed a risky new strategy to replace plans for a rights issue. Shareholders in Europe's largest property company have a choice between two bad options.\"\n\nStock Prediction(s):", "Prediction": "\n- Unibail-Rodamco SE (OTC: ULRAF) will decrease because their shareholders are not happy with the new deals.\n- Westfield Corp (OTC: WFGPY) will decrease because their owner is not doing well.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-home-price-growth-rose-to-record-in-may-11627390862", "title": "U.S. Home-Price Growth Rose to Record in May", "date": "2021-07-27 10:48", "summary": "Case-Shiller index rose 16.6%, highest annual rate of price growth since the index began in 1987. Home-price growth climbed to a new record in May, as low mortgage interest rates continued to drive robust homebuying demand.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Home-Price Growth Rose to Record in May. Case-Shiller index rose 16.6%, highest annual rate of price growth since the index began in 1987. Home-price growth climbed to a new record in May, as low mortgage interest rates continued to drive robust homebuying demand.\"\n\nStock Prediction(s):", "Prediction": "\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and D.R. Horton, Inc. (NYSE: DHI) will increase because the news of the record-high home prices will spur even more demand for new homes.\n- Real-estate investment trusts such as Simon Property Group, Inc. (NYSE: SPG) and Equity Residential (NYSE: EQR) will also increase because investors will see them as a safe haven for their money", "price_info": {"LEN": {"company": "", "ticker": "LEN", "move": null, "prices": [102.24, 102.17]}, "DHI": {"company": "", "ticker": "DHI", "move": "up", "prices": [92.8, 92.72]}, "SPG": {"company": "", "ticker": "SPG", "move": null, "prices": [125.496, 125.62]}, "EQR": {"company": "", "ticker": "EQR", "move": "up", "prices": [85.17, 85.11]}}}, {"link": "https://www.wsj.com/articles/vw-finance-chief-expects-inflation-to-ease-and-chip-shortage-to-drag-on-11641843428", "title": "VW Finance Chief Expects Inflation to Ease and Chip Shortage to Drag On", "date": "2022-01-10 14:37", "summary": "Arno Antlitz says auto maker has cut costs to address higher raw-material prices and aims to expand its electric-vehicle business in U.S.. BERLIN- Volkswagen AG , one of the world's largest auto makers, expects inflation to ease later this year but warned there would be no significant improvement in the global semiconductor shortage that has caused many auto makers to slash output as they try to find chips.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"VW Finance Chief Expects Inflation to Ease and Chip Shortage to Drag On. Arno Antlitz says auto maker has cut costs to address higher raw-material prices and aims to expand its electric-vehicle business in U.S.. BERLIN- Volkswagen AG , one of the world's largest auto makers, expects inflation to ease later this year but warned there would be no significant improvement in the global semiconductor shortage that has caused many auto makers to slash output as they try to find chips.\"\n\nStock Prediction(s):", "Prediction": "\n- Volkswagen AG (OTCPK: VOW3) will increase because they have cut costs and are expanding their electric-vehicle business.\n- Infineon Technologies AG (OTCPK: IFNNY) will increase because they are a supplier of semiconductors to Volkswagen.\n- Texas Instruments Incorporated (NASDAQ: TXN) will increase because they are a supplier of semiconductors to Volkswagen.\n- STMicroelectronics NV (NYSE", "price_info": {"TXN": {"company": "", "ticker": "TXN", "move": "up", "prices": [181.78, 182.97]}}}, {"link": "https://www.wsj.com/articles/treasury-yields-higher-after-upbeat-data-outside-u-s-11554304220", "title": "Treasury Yields Higher After Upbeat Data Outside U.S.", "date": "2019-04-03 15:26", "summary": "Economic indicators from China, Germany offset lukewarm U.S. data. Treasury yields rose on Wednesday after data from China and the eurozone heightened investors' optimism about the global economy.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury Yields Higher After Upbeat Data Outside U.S.. Economic indicators from China, Germany offset lukewarm U.S. data. Treasury yields rose on Wednesday after data from China and the eurozone heightened investors' optimism about the global economy.\"\n\nStock Prediction(s):", "Prediction": "\n- The yield on the 10-year Treasury note will continue to rise because investors are optimistic about the global economy.\n- The yield on the 2-year Treasury note will continue to rise because investors are optimistic about the global economy.\n- The yield on the 30-year Treasury note will continue to rise because investors are optimistic about the global economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/viacom-ceo-charges-less-for-channels-in-bid-for-long-term-growth-11557431198", "title": "Viacom CEO Charges Less for Channels in Bid for Long-Term Growth", "date": "2019-05-09 15:46", "summary": "Bob Bakish is betting Viacom can make up the gap through licensing deals with mobile providers, new ad partnerships and producing shows for streaming services. When Viacom Inc. struck a distribution deal with DirecTV owner AT&T Inc. this spring, it did something that would have been unthinkable for a major media company not long ago: It accepted a substantial decrease in payments for carriage of its channels.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Viacom CEO Charges Less for Channels in Bid for Long-Term Growth. Bob Bakish is betting Viacom can make up the gap through licensing deals with mobile providers, new ad partnerships and producing shows for streaming services. When Viacom Inc. struck a distribution deal with DirecTV owner AT&T Inc. this spring, it did something that would have been unthinkable for a major media company not long ago: It accepted a substantial decrease in payments for carriage of its channels.\"\n\nStock Prediction(s):", "Prediction": "\n- Viacom Inc. (NASDAQ: VIAB) will decrease because they are accepting a decrease in payments for carriage of their channels.\n- AT&T Inc. (NYSE: T) will increase because they are still paying for carriage of Viacom's channels.", "price_info": {"T": {"company": "", "ticker": "T", "move": "up", "prices": [30.4, 30.4]}, "VIAB": {"company": "", "ticker": "VIAB", "move": "down", "prices": [28.8, 28.8]}}}, {"link": "https://www.wsj.com/articles/fed-officials-weighed-money-market-control-strategies-at-october-meeting-11574282609", "title": "Fed Officials Weighed Money-Market Control Strategies at October Meeting", "date": "2019-11-20 15:43", "summary": "Minutes show Fed staff presented central bankers with two approaches to manage short-term rates over the longer run. WASHINGTON-Federal Reserve officials at their October policy meeting weighed but didn't settle on strategies that could provide a more enduring fix to the money-market interest-rate volatility that flared in September.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Officials Weighed Money-Market Control Strategies at October Meeting. Minutes show Fed staff presented central bankers with two approaches to manage short-term rates over the longer run. WASHINGTON-Federal Reserve officials at their October policy meeting weighed but didn't settle on strategies that could provide a more enduring fix to the money-market interest-rate volatility that flared in September.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will not be able to come to a consensus on a long-term fix to money-market interest-rate volatility, and this will cause stocks to decrease.", "price_info": {}}, {"link": "https://www.wsj.com/articles/mckinsey-partner-charged-with-securities-fraud-over-goldman-sachs-deal-11636561891", "title": "McKinsey Partner Charged With Securities Fraud Over Goldman Sachs Deal", "date": "2021-11-10 14:18", "summary": "Puneet Dikshit is accused of trading insider information related to the Wall Street bank's purchase of lender GreenSky. Federal prosecutors in New York charged a former McKinsey & Co. partner with securities fraud for allegedly trading insider information related to Goldman Sachs Group Inc.'s acquisition of specialty lender GreenSky Inc.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"McKinsey Partner Charged With Securities Fraud Over Goldman Sachs Deal. Puneet Dikshit is accused of trading insider information related to the Wall Street bank's purchase of lender GreenSky. Federal prosecutors in New York charged a former McKinsey & Co. partner with securities fraud for allegedly trading insider information related to Goldman Sachs Group Inc.'s acquisition of specialty lender GreenSky Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc. (NYSE: GS) will increase because one of their main competitors was just charged with securities fraud.\n- GreenSky Inc. (NASDAQ: GSKY) will increase because they were just acquired by Goldman Sachs, and this will give them a monopoly in the industry.\n- McKinsey & Co. (NYSE: MCK) will decrease because one of their main partners was just charged with securities fraud.", "price_info": {"GS": {"company": "", "ticker": "GS", "move": null, "prices": [399.37, 398.61]}, "MCK": {"company": "", "ticker": "MCK", "move": "down", "prices": [219.24, 220.1]}, "GSKY": {"company": "", "ticker": "GSKY", "move": "up", "prices": [11.85, 11.82]}}}, {"link": "https://www.wsj.com/articles/feds-mester-says-rate-increases-still-possible-11554397201", "title": "Fed's Mester Says Rate Increases Still Possible", "date": "2019-04-04 13:00", "summary": "Official expects more growth and strong job markets. Federal Reserve Bank of Cleveland President Loretta Mester said Thursday it remains possible the U.S. central bank might raise rates again.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Mester Says Rate Increases Still Possible. Official expects more growth and strong job markets. Federal Reserve Bank of Cleveland President Loretta Mester said Thursday it remains possible the U.S. central bank might raise rates again.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will continue to raise rates, which will cause interest rates to go up.\n- This will cause banks to increase the interest rates they offer on loans, which will cause consumers to borrow less money.\n- This will also cause the stock market to go down, as investors will shift their money into safer investments.", "price_info": {}}, {"link": "https://www.wsj.com/articles/why-so-few-ceos-are-women-you-can-have-a-seat-at-the-table-and-not-be-a-player-11581003276", "title": "Where Are All the Women CEOs?", "date": "2020-02-06 10:34", "summary": "The traditional stepping stones to the chief executive position are jobs responsible for the bottom line-such as head of division-and those roles are still overwhelmingly filled by men. Why, when women earn the majority of college degrees and make up roughly half the workforce, do so few occupy the chief executive job?", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Where Are All the Women CEOs?. The traditional stepping stones to the chief executive position are jobs responsible for the bottom line-such as head of division-and those roles are still overwhelmingly filled by men. Why, when women earn the majority of college degrees and make up roughly half the workforce, do so few occupy the chief executive job?\"\n\nStock Prediction(s):", "Prediction": "\n- Female CEOs will become more common as society becomes more aware of the issue and works to correct it.\n- Male CEOs will become less common as society becomes more aware of the issue and works to correct it.", "price_info": {}}, {"link": "https://www.wsj.com/articles/fed-adds-75-billion-in-liquidity-to-markets-via-one-day-repo-operation-11571231369", "title": "Fed Kicks Off Balance-Sheet Expansion", "date": "2019-10-16 14:14", "summary": "Resume Subscription. The New York Fed embarked on its first round of Treasury bill buying Wednesday aimed at expanding its overall holdings, and found no dearth of interest from banks wanting to sell securities to the central bank.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Kicks Off Balance-Sheet Expansion. Resume Subscription. The New York Fed embarked on its first round of Treasury bill buying Wednesday aimed at expanding its overall holdings, and found no dearth of interest from banks wanting to sell securities to the central bank.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve's (NYSE: FED) balance sheet expansion will cause an increase in the prices of Treasury bills, as well as other securities.\n- The balance sheet expansion will also cause an increase in the prices of stocks, as investors become more confident in the economy.\n- The balance sheet expansion will also cause an increase in the prices of commodities, as investors become more confident in the economy.", "price_info": {"FED": {"company": "", "ticker": "FED", "move": "up"}}}, {"link": "https://www.wsj.com/articles/nike-scores-jersey-deal-with-epls-liverpool-11578412231", "title": "Nike Scores Jersey Deal With EPL's Liverpool", "date": "2020-01-07 10:50", "summary": "The sportswear maker takes over the contract for the soccer team's outfit from New Balance in June. Nike Inc. has signed a multiyear deal to be the official jersey provider for Liverpool Football Club, handing the current powerhouse of European soccer to the world's largest sportswear maker by revenue.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nike Scores Jersey Deal With EPL's Liverpool. The sportswear maker takes over the contract for the soccer team's outfit from New Balance in June. Nike Inc. has signed a multiyear deal to be the official jersey provider for Liverpool Football Club, handing the current powerhouse of European soccer to the world's largest sportswear maker by revenue.\"\n\nStock Prediction(s):", "Prediction": "\n- Nike Inc. (NYSE: NKE) will increase because they have scored a jersey deal with Liverpool, and they are the world's largest sportswear maker.\n- New Balance (NYSE: NBL) will decrease because they have lost the Liverpool jersey deal.", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "up", "prices": [102.1951, 101.92]}, "NBL": {"company": "", "ticker": "NBL", "move": "down", "prices": [23.52, 23.4]}}}, {"link": "https://www.wsj.com/articles/apple-launches-new-airpods-in-wearables-push-11553092528", "title": "Apple Launches New AirPods in Wearables Push", "date": "2019-03-20 10:35", "summary": "Earbuds can access Siri by voice, wirelessly charge. Apple Inc. on Wednesday unveiled a new version of its AirPods wireless earbuds that can activate the virtual assistant Siri by voice, an added feature aimed at extending the momentum of a fast-selling device as iPhone sales cool.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Launches New AirPods in Wearables Push. Earbuds can access Siri by voice, wirelessly charge. Apple Inc. on Wednesday unveiled a new version of its AirPods wireless earbuds that can activate the virtual assistant Siri by voice, an added feature aimed at extending the momentum of a fast-selling device as iPhone sales cool.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they have released a new version of their AirPods that are wireless and have the ability to access Siri by voice.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will decrease because they are a direct competitor of Apple, and they do not have a product that is as advanced as the AirPods.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [186.5299, 186.78]}}}, {"link": "https://www.wsj.com/articles/energy-companies-seize-the-day-with-bond-refinancings-11579006807", "title": "Energy Companies Seize the Day With Bond Refinancings", "date": "2020-01-14 15:06", "summary": "Surge in appetite for riskier debt creates window of opportunity to push out impending maturities. A surprise rally in riskier corporate bonds is providing much-needed help to some energy companies with lower credit ratings, allowing them to issue new bonds to push back looming repayment dates.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Energy Companies Seize the Day With Bond Refinancings. Surge in appetite for riskier debt creates window of opportunity to push out impending maturities. A surprise rally in riskier corporate bonds is providing much-needed help to some energy companies with lower credit ratings, allowing them to issue new bonds to push back looming repayment dates.\"\n\nStock Prediction(s):", "Prediction": "\n- Energy companies will increase because they were able to refinance their debt at a lower interest rate.\n- Other companies will also increase because the overall market is rallying.", "price_info": {}}, {"link": "https://www.wsj.com/articles/kohls-promotes-finance-veteran-to-cfo-in-effort-to-boost-customer-traffic-11570820885", "title": "Kohl's Promotes Finance Veteran to CFO in Effort to Boost Customer Traffic", "date": "2019-10-11 15:08", "summary": "The department-store operator's existing finance chief will step down after two years in the job. Kohl's Corp. promoted a finance veteran to the role of finance chief as the company looks to cut costs and boost customer traffic after a stretch of sluggish sales, analysts say.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Kohl's Promotes Finance Veteran to CFO in Effort to Boost Customer Traffic. The department-store operator's existing finance chief will step down after two years in the job. Kohl's Corp. promoted a finance veteran to the role of finance chief as the company looks to cut costs and boost customer traffic after a stretch of sluggish sales, analysts say.\"\n\nStock Prediction(s):", "Prediction": "\n- Kohl's Corp. (NYSE: KSS) will increase because they are trying to cut costs and boost customer traffic.\n- Macy's, Inc. (NYSE: M) will decrease because they are also a department store, and they are not doing as well as Kohl's.", "price_info": {"KSS": {"company": "", "ticker": "KSS", "move": "up"}, "M": {"company": "", "ticker": "M", "move": "down", "prices": [15.72, 15.73]}}}, {"link": "https://www.wsj.com/articles/feds-kaplan-fed-likely-on-pause-until-at-least-summer-11549040516", "title": "Fed's Kaplan: Fed Likely On Pause Until At Least Summer", "date": "2019-02-01 12:01", "summary": "'It's very important for the Fed to get out of the way' and let the economy work through some issues, the Dallas Fed president says. Dallas Federal Reserve Bank President Robert Kaplan said he believes the U.S. central bank will hold off on rate increases until at least the summer.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Kaplan: Fed Likely On Pause Until At Least Summer. 'It's very important for the Fed to get out of the way' and let the economy work through some issues, the Dallas Fed president says. Dallas Federal Reserve Bank President Robert Kaplan said he believes the U.S. central bank will hold off on rate increases until at least the summer.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will not increase rates this year because there are too many economic issues to work through.\n- The market will react positively to this news because it means that there will be low interest rates for the foreseeable future.\n- Banks will benefit from this news because it means that they will be able to make more money from loans.", "price_info": {}}, {"link": "https://www.wsj.com/articles/regulator-bars-former-goldman-analyst-for-insider-trading-11618935676", "title": "Regulator Bars Former Goldman Analyst for Insider Trading", "date": "2021-04-20 12:21", "summary": "Finra says Brian Maguire bought shares in two companies after finding out about another analyst's upgrade. A Goldman Sachs & Co. analyst has been barred from the broker-dealer industry by the Financial Industry Regulatory Authority for insider trading, the regulator said Tuesday.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Regulator Bars Former Goldman Analyst for Insider Trading. Finra says Brian Maguire bought shares in two companies after finding out about another analyst's upgrade. A Goldman Sachs & Co. analyst has been barred from the broker-dealer industry by the Financial Industry Regulatory Authority for insider trading, the regulator said Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs & Co. (NYSE: GS) will decrease because one of their employees has been barred from the industry for insider trading.", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "down", "prices": [330.82, 330.59]}}}, {"link": "https://www.wsj.com/articles/u-s-government-bond-prices-fall-on-jobs-inflation-data-11554999277", "title": "U.S. Government-Bond Prices Fall on Jobs, Inflation Data", "date": "2019-04-11 15:41", "summary": "'A dovish Fed explains why stocks are doing so well and why yields' are stable, analyst Donald Ellenberger said. U.S. government-bond prices fell Thursday after data showed declining claims for jobless benefits and rising business prices, signs of continued economic expansion.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Government-Bond Prices Fall on Jobs, Inflation Data. 'A dovish Fed explains why stocks are doing so well and why yields' are stable, analyst Donald Ellenberger said. U.S. government-bond prices fell Thursday after data showed declining claims for jobless benefits and rising business prices, signs of continued economic expansion.\"\n\nStock Prediction(s):", "Prediction": "\n- The prices of U.S. government-bonds will continue to fall because the Federal Reserve is continuing to be dovish.\n- The prices of stocks will continue to rise because the Federal Reserve is continuing to be dovish.", "price_info": {}}, {"link": "https://www.wsj.com/articles/wsj-survey-most-economists-say-fed-s-next-move-is-rate-cut-11560434400", "title": "Most Economists Say Fed's Next Move Is Rate Cut, Survey Says", "date": "2019-06-13 10:00", "summary": "Nearly 40% of the 46 economists anticipated the central bank would act in July, while roughly 30% expected a rate cut in September. More than three-quarters of economists surveyed by The Wall Street Journal expect the Federal Reserve's next move will be to lower interest rates, which most expect to happen by the fall.", "categories": [["WSJ News Exclusive", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Most Economists Say Fed's Next Move Is Rate Cut, Survey Says. Nearly 40% of the 46 economists anticipated the central bank would act in July, while roughly 30% expected a rate cut in September. More than three-quarters of economists surveyed by The Wall Street Journal expect the Federal Reserve's next move will be to lower interest rates, which most expect to happen by the fall.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve's next move will be to lower interest rates, which will cause most stocks to go up.\n- The only exception to this rule will be companies that are directly competing with the Federal Reserve, such as Goldman Sachs (NYSE: GS) and JPMorgan Chase (NYSE: JPM).", "price_info": {"GS": {"company": "", "ticker": "GS", "move": null, "prices": [191.12, 191.87]}, "JPM": {"company": "", "ticker": "JPM", "move": null, "prices": [109.33, 109.485]}}}, {"link": "https://www.wsj.com/articles/oil-prices-boosted-by-u-s-china-trade-talks-11547030989", "title": "Oil Surges 5% on Saudi Support, U.S.-China Talks", "date": "2019-01-09 15:43", "summary": "U.S. oil futures enter a bull market, climbing to a nearly four-week high. \u2022 U.S. oil prices technically entered a bull market Wednesday, surging to a nearly four-week high as the Saudis pushed for higher prices and the U.S. and China appeared to make progress toward resolving their trade dispute. Investors shrugged off another bearish report on U.S. oil inventories.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Surges 5% on Saudi Support, U.S.-China Talks. U.S. oil futures enter a bull market, climbing to a nearly four-week high. \u2022 U.S. oil prices technically entered a bull market Wednesday, surging to a nearly four-week high as the Saudis pushed for higher prices and the U.S. and China appeared to make progress toward resolving their trade dispute. Investors shrugged off another bearish report on U.S. oil inventories.\"\n\nStock Prediction(s):", "Prediction": "\n- Exxon Mobil Corporation (NYSE: XOM) will increase because oil prices are surging.\n- Chevron Corporation (NYSE: CVX) will increase because oil prices are surging.\n- Schlumberger Limited. (NYSE: SLB) will increase because oil prices are surging.\n- Halliburton Company (NYSE: HAL) will increase because oil prices are surging.", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [72.31, 72.42]}, "CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [113.32, 113.27]}, "SLB": {"company": "", "ticker": "SLB", "move": "up", "prices": [41.3087, 41.12]}, "HAL": {"company": "", "ticker": "HAL", "move": "up", "prices": [29.96, 30]}}}, {"link": "https://www.wsj.com/articles/ford-recalls-certain-mustang-mach-e-electric-suvs-over-concerns-windshield-panoramic-roof-could-detach-11632752362", "title": "Ford Recalls Mustang Mach-E Electric SUVs Over Windshield, Roof Concerns", "date": "2021-09-27 10:19", "summary": "Safety recall of 2021 model-year vehicles cites inadequate bonding of glass panel parts. Ford Motor Co. is recalling certain Mustang Mach-E electric sport-utility vehicles over concerns that the front windshield and panoramic roof could become detached, a setback for one of the car company's highest-profile new-model launches this year.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ford Recalls Mustang Mach-E Electric SUVs Over Windshield, Roof Concerns. Safety recall of 2021 model-year vehicles cites inadequate bonding of glass panel parts. Ford Motor Co. is recalling certain Mustang Mach-E electric sport-utility vehicles over concerns that the front windshield and panoramic roof could become detached, a setback for one of the car company's highest-profile new-model launches this year.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Co. (NYSE: F) will decrease because of the recall.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they do not have any recalls.", "price_info": {"F": {"company": "", "ticker": "F", "move": "down", "prices": [14.155, 14.255]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [788.24, 795.18]}}}, {"link": "https://www.wsj.com/articles/skip-this-nigerian-money-making-opportunity-11597079329", "title": "Skip This Nigerian Money-Making Opportunity", "date": "2020-08-10 13:08", "summary": "The exchange-traded fund with the largest discount to net asset value on the market is less than meets the eye. Dear Beloved Friend, I know this email about a USD 32,000,000 ($32 million) exchange-traded fund that can be bought for USD 26,176,000 ($26.176 million) will come as a surprise to you.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Skip This Nigerian Money-Making Opportunity. The exchange-traded fund with the largest discount to net asset value on the market is less than meets the eye. Dear Beloved Friend, I know this email about a USD 32,000,000 ($32 million) exchange-traded fund that can be bought for USD 26,176,000 ($26.176 million) will come as a surprise to you.\"\n\nStock Prediction(s):", "Prediction": "\n- The ETF with the largest discount to net asset value on the market is not worth investing in.", "price_info": {}}, {"link": "https://www.wsj.com/articles/inflation-could-mean-value-stocks-time-to-shine-11635270687", "title": "Inflation Could Mean Value Stocks' Time to Shine", "date": "2021-10-26 13:51", "summary": "Bitcoin, gold and oil are all having a moment, but the best haven for ordinary investors might be long-neglected value stocks. Bitcoin, gold, oil, real estate-many assets are finding themselves on investors' radar screens as concerns about inflation grow. The best refuge might be one that has been out of fashion for a while, though: boring old value stocks.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Inflation Could Mean Value Stocks' Time to Shine. Bitcoin, gold and oil are all having a moment, but the best haven for ordinary investors might be long-neglected value stocks. Bitcoin, gold, oil, real estate-many assets are finding themselves on investors' radar screens as concerns about inflation grow. The best refuge might be one that has been out of fashion for a while, though: boring old value stocks.\"\n\nStock Prediction(s):", "Prediction": "\n- Coca-Cola Company (NYSE: KO) will increase because they are a value stock and they are not as risky as some of the other options.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a technology stock and they are not as risky as some of the other options.\n- Procter & Gamble Company (NYSE: PG) will increase because they are a value stock and they are not as risky", "price_info": {"KO": {"company": "", "ticker": "KO", "move": "up", "prices": [54.45, 54.47]}, "PG": {"company": "", "ticker": "PG", "move": "up", "prices": [142.91, 142.95]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3375.56, 3382.31]}}}, {"link": "https://www.wsj.com/articles/us-inflation-consumer-price-index-november-2021-11639088867", "title": "U.S. Inflation Hits 39-Year High", "date": "2021-12-10 12:43", "summary": "Consumer prices rose 0.8% in the month and 6.8% from a year ago. U.S. inflation reached a nearly four-decade high in November, as strong consumer demand collided with pandemic-related supply constraints.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Inflation Hits 39-Year High. Consumer prices rose 0.8% in the month and 6.8% from a year ago. U.S. inflation reached a nearly four-decade high in November, as strong consumer demand collided with pandemic-related supply constraints.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc (NYSE: WMT) will increase because they are the main retailer in the United States, and they have been raising prices to offset the cost of inflation.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are the main retailer in the United States, and they have been raising prices to offset the cost of inflation.\n- Costco Wholesale Corporation (NASDAQ: COST) will increase because they", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [139.2323, 140.7029]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3420.29, 3424.48]}, "COST": {"company": "", "ticker": "COST", "move": "up", "prices": [555.81, 559.525]}}}, {"link": "https://www.wsj.com/articles/activision-really-needs-to-hit-the-reset-button-11637334894", "title": "Activision Needs to Hit the Reset Button", "date": "2021-11-19 10:14", "summary": "Videogame publisher has shed a third of its market value as doubts about management's ability to fix its workplace culture have grown. It says something when the first question that now pops to mind regarding Activision Blizzard is: What is going right?", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Activision Needs to Hit the Reset Button. Videogame publisher has shed a third of its market value as doubts about management's ability to fix its workplace culture have grown. It says something when the first question that now pops to mind regarding Activision Blizzard is: What is going right?\"\n\nStock Prediction(s):", "Prediction": "\n- Activision Blizzard, Inc. (NASDAQ: ATVI) will continue to decline because their workplace culture is in question.\n- Take-Two Interactive Software, Inc. (NASDAQ: TTWO) will increase because they have a better workplace culture and are doing well financially.\n- Electronic Arts Inc. (NASDAQ: EA) will increase because they have a better workplace culture and are doing well financially.", "price_info": {"ATVI": {"company": "", "ticker": "ATVI", "move": "down", "prices": [63.7241, 63.89]}, "TTWO": {"company": "", "ticker": "TTWO", "move": "up", "prices": [175.32, 176.2972]}, "EA": {"company": "", "ticker": "EA", "move": "up", "prices": [136.8539, 136.03]}}}, {"link": "https://www.wsj.com/articles/carlyles-fourth-quarter-earnings-jump-11643886001", "title": "Carlyle's Fourth-Quarter Earnings Jump", "date": "2022-02-03 11:19", "summary": "Private-equity firm has focused on expanding businesses that generate predictable management fees. Carlyle Group Inc. reported a big jump in fourth-quarter earnings, driven by strong investment performance in some of its businesses and an upswing in fee-related revenue.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Carlyle's Fourth-Quarter Earnings Jump. Private-equity firm has focused on expanding businesses that generate predictable management fees. Carlyle Group Inc. reported a big jump in fourth-quarter earnings, driven by strong investment performance in some of its businesses and an upswing in fee-related revenue.\"\n\nStock Prediction(s):", "Prediction": "\n- Carlyle Group Inc. (NASDAQ: CG) will increase because they are doing well and their earnings report was good.\n- KKR & Co. LP (NYSE: KKR) will decrease because they are a direct competitor of Carlyle Group.\n- Blackstone Group LP (NYSE: BX) will decrease because they are a direct competitor of Carlyle Group.", "price_info": {"KKR": {"company": "", "ticker": "KKR", "move": "down", "prices": [71.92, 71.7076]}, "BX": {"company": "", "ticker": "BX", "move": "down", "prices": [134.56, 134.2605]}, "CG": {"company": "", "ticker": "CG", "move": "up", "prices": [50.9334, 50.23]}}}, {"link": "https://www.wsj.com/articles/home-cooking-trend-is-mixed-bag-for-spice-giant-11593101321", "title": "Home-Cooking Trend Is Mixed Bag for Spice Giant", "date": "2020-06-25 12:31", "summary": "McCormick's pantry staples are posting grocery-aisle gains, but the restaurant business poses risks. Consumers have been stocking up on McCormick 's spices, dry baking mixes and other pantry staples. Its restaurant customers are another story.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Home-Cooking Trend Is Mixed Bag for Spice Giant. McCormick's pantry staples are posting grocery-aisle gains, but the restaurant business poses risks. Consumers have been stocking up on McCormick 's spices, dry baking mixes and other pantry staples. Its restaurant customers are another story.\"\n\nStock Prediction(s):", "Prediction": "\n- McCormick & Company, Inc. (NYSE: MKC) will increase because their grocery-aisle gains are outpacing their restaurant business risks.\n- The Hershey Company (NYSE: HSY) will decrease because they are also in the spice business, and their restaurant business is doing better than McCormick's.", "price_info": {"MKC": {"company": "", "ticker": "MKC", "move": "up", "prices": [175.93, 178.32]}, "HSY": {"company": "", "ticker": "HSY", "move": "down", "prices": [127.7367, 127.98]}}}, {"link": "https://www.wsj.com/articles/trump-tweets-crush-oil-market-as-prices-fall-nearly-8-11564686577", "title": "Trump Tweets Crush Oil Market as Prices Fall Nearly 8%", "date": "2019-08-01 15:09", "summary": "Crude prices post their biggest drop since February 2015 on new China tariffs. Oil prices sank almost 8% Thursday, their biggest drop since February 2015, after President Trump announced new tariffs on Chinese imports, stoking fears that the trade dispute between the two countries will drag on, crimping global growth.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump Tweets Crush Oil Market as Prices Fall Nearly 8%. Crude prices post their biggest drop since February 2015 on new China tariffs. Oil prices sank almost 8% Thursday, their biggest drop since February 2015, after President Trump announced new tariffs on Chinese imports, stoking fears that the trade dispute between the two countries will drag on, crimping global growth.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because of the trade war between the US and China.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because of the trade war between the US and China.\n- Schlumberger Limited. (NYSE: SLB) will decrease because of the trade war between the US and China.\n- Halliburton Company (NYSE: HAL) will decrease because of the trade war between the US and China", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [121.29, 121.29]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [73.66, 72.64]}, "SLB": {"company": "", "ticker": "SLB", "move": "down", "prices": [38.51, 38.51]}, "HAL": {"company": "", "ticker": "HAL", "move": "down", "prices": [21.5101, 21.78]}}}, {"link": "https://www.wsj.com/articles/u-s-housing-starts-fall-in-february-11553603643", "title": "Home Building, New-Home Permits Have Softened This Year", "date": "2019-03-26 12:03", "summary": "Single-family home construction drops 17%; residential building permits also fall.. WASHINGTON-A gauge of home construction and queued up projects declined in February and are pulling back this year overall, with a slew of factors, including the government shutdown and housing affordability, potentially impacting the data.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Home Building, New-Home Permits Have Softened This Year. Single-family home construction drops 17%; residential building permits also fall.. WASHINGTON-A gauge of home construction and queued up projects declined in February and are pulling back this year overall, with a slew of factors, including the government shutdown and housing affordability, potentially impacting the data.\"\n\nStock Prediction(s):", "Prediction": "\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and D.R. Horton, Inc. (NYSE: DHI) will decrease because there is less demand for new homes.\n- The Home Depot, Inc. (NYSE: HD) will decrease because people are less likely to invest in home repairs and renovations.", "price_info": {"LEN": {"company": "", "ticker": "LEN", "move": null, "prices": [49.15, 49.13]}, "DHI": {"company": "", "ticker": "DHI", "move": "down", "prices": [41.09, 41]}, "HD": {"company": "", "ticker": "HD", "move": "down", "prices": [189.85, 188.93]}}}, {"link": "https://www.wsj.com/articles/credit-suisse-scores-legal-win-in-forex-rigging-case-11567626423", "title": "Credit Suisse Scores Legal Win in Currency-Rigging Case", "date": "2019-09-04 15:47", "summary": "Bank scores victory against currency traders who claimed it helped rig foreign-exchange rates. Credit Suisse Group AG scored a legal victory in New York federal court against currency traders who claimed the bank and others helped rig foreign-exchange rates, in a case that rivals have already paid $2.3 billion to settle.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Credit Suisse Scores Legal Win in Currency-Rigging Case. Bank scores victory against currency traders who claimed it helped rig foreign-exchange rates. Credit Suisse Group AG scored a legal victory in New York federal court against currency traders who claimed the bank and others helped rig foreign-exchange rates, in a case that rivals have already paid $2.3 billion to settle.\"\n\nStock Prediction(s):", "Prediction": "\n- Credit Suisse Group AG (NYSE: CS) will increase because they have won their legal case and have been cleared of any wrongdoing.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they have already paid $2.3 billion to settle similar claims.\n- Bank of America Corp (NYSE: BAC) will decrease because they have already paid $2.3 billion to settle similar claims.\n- Goldman Sachs Group Inc. (NYSE", "price_info": {"CS": {"company": "", "ticker": "CS", "move": "up"}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [109.87, 109.61]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [27.5, 27.46]}}}, {"link": "https://www.wsj.com/articles/fashions-big-question-what-to-do-with-all-those-unsold-clothes-11597328695", "title": "Fashion's Big Question: What to Do With All Those Unsold Clothes?", "date": "2020-08-13 10:24", "summary": "Shoppers, environmentalists and governments are forcing apparel brands to find fresh ways to move the merchandise piling up in their inventories. Apparel companies, from elite fashion houses to mass-market chains, are saddled with an inventory glut following monthslong closures during the pandemic. Now, they are trying to get rid of the excess without angering waste-conscious consumers-or harming their brands.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fashion's Big Question: What to Do With All Those Unsold Clothes?. Shoppers, environmentalists and governments are forcing apparel brands to find fresh ways to move the merchandise piling up in their inventories. Apparel companies, from elite fashion houses to mass-market chains, are saddled with an inventory glut following monthslong closures during the pandemic. Now, they are trying to get rid of the excess without angering waste-conscious consumers-or harming their brands.\"\n\nStock Prediction(s):", "Prediction": "\n- Gap Inc (NYSE: GPS) will increase because they are one of the few apparel companies that are trying to move their merchandise without angering waste-conscious consumers.\n- Nike Inc (NYSE: NKE) will increase because they are one of the few apparel companies that are trying to move their merchandise without angering waste-conscious consumers.\n- Lululemon Athletica inc. (NASDAQ: LULU) will increase because they are one of", "price_info": {"GPS": {"company": "", "ticker": "GPS", "move": "up", "prices": [14.69, 14.88]}, "NKE": {"company": "", "ticker": "NKE", "move": "up", "prices": [105.86, 106.33]}, "LULU": {"company": "", "ticker": "LULU", "move": "up", "prices": [353.41, 351.97]}}}, {"link": "https://www.wsj.com/articles/eurozone-economy-contracts-by-record-40-11596191720", "title": "Europe Plunges Into Recession as Economy Suffers Record Contraction", "date": "2020-07-31 11:39", "summary": "Coronavirus containment coupled with aggressive stimulus fans recovery hopes. FRANKFURT-Stringent lockdowns to prevent the spread of Covid-19 weighed heavily on Europe's economy in the second quarter, causing a record contraction more severe than experienced by the U.S., but analysts said the continent's success so far in avoiding a resurgence of the disease coupled with aggressive government stimulus should help support a nascent recovery.", "categories": [["Economy", "Europe Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/europe-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Europe Plunges Into Recession as Economy Suffers Record Contraction. Coronavirus containment coupled with aggressive stimulus fans recovery hopes. FRANKFURT-Stringent lockdowns to prevent the spread of Covid-19 weighed heavily on Europe's economy in the second quarter, causing a record contraction more severe than experienced by the U.S., but analysts said the continent's success so far in avoiding a resurgence of the disease coupled with aggressive government stimulus should help support a nascent recovery.\"\n\nStock Prediction(s):", "Prediction": "\n- European Union (EU) stocks will increase because the recession is ending, and the stimulus is helping to revive the economy.\n- The United Kingdom (UK) stocks will increase because the recession is ending, and the stimulus is helping to revive the economy.\n- The United States (US) stocks will decrease because the recession is worsening, and the stimulus is not helping as much as hoped.", "price_info": {"EU": {"company": "European Union", "ticker": "EU", "move": "up"}, "UK": {"company": "United Kingdom", "ticker": "UK", "move": "up"}, "US": {"company": "United States", "ticker": "US", "move": "down"}}}, {"link": "https://www.wsj.com/articles/hsbcs-loan-losses-hint-at-tougher-times-for-banks-11588090776", "title": "HSBC's Loan Losses Hint at Tougher Times for Banks", "date": "2020-04-28 12:19", "summary": "Almost a quarter of the lender's $3 billion provision was for one borrower, highlighting the risks of portfolio concentration. HSBC 's Asian focus gives it a slight lead over its European and U.S. peers in understanding the impact of coronavirus shutdowns. Its first-quarter numbers stand as a warning.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"HSBC's Loan Losses Hint at Tougher Times for Banks. Almost a quarter of the lender's $3 billion provision was for one borrower, highlighting the risks of portfolio concentration. HSBC 's Asian focus gives it a slight lead over its European and U.S. peers in understanding the impact of coronavirus shutdowns. Its first-quarter numbers stand as a warning.\"\n\nStock Prediction(s):", "Prediction": "\n- HSBC Holdings plc (NYSE: HSBC) will decrease because their loan losses hint at tougher times for banks.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because their loan losses hint at tougher times for banks.\n- Bank of America Corp (NYSE: BAC) will decrease because their loan losses hint at tougher times for banks.\n- Citigroup Inc (NYSE: C) will decrease because their loan losses hint at tougher times for banks", "price_info": {"HSBC": {"company": "", "ticker": "HSBC", "move": "down", "prices": [26.0243, 26.025]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [95.9439, 96.0205]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [24.14, 24.12]}, "C": {"company": "", "ticker": "C", "move": "down", "prices": [47.33, 47.58]}}}, {"link": "https://www.wsj.com/articles/oil-prices-rebound-after-taking-brunt-of-coronavirus-hit-11580904588", "title": "Oil Rebounds After Taking Brunt of Coronavirus Hit", "date": "2020-02-05 15:14", "summary": "Crude and copper, seen as proxies for Chinese economic health, remain well below where they were before the outbreak. Oil and copper prices rose Wednesday, reversing course from their steady drop to start the year in a move that some traders attributed to unconfirmed media reports that a Chinese university found a treatment for the fast-spreading coronavirus.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Rebounds After Taking Brunt of Coronavirus Hit. Crude and copper, seen as proxies for Chinese economic health, remain well below where they were before the outbreak. Oil and copper prices rose Wednesday, reversing course from their steady drop to start the year in a move that some traders attributed to unconfirmed media reports that a Chinese university found a treatment for the fast-spreading coronavirus.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because the price of oil is rebounding, and they are a major player in the oil industry.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because the price of oil is rebounding, and they are a major player in the oil industry.\n- BP plc (NYSE: BP) will increase because the price of oil is rebounding, and they are a major player in the oil industry", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [109.99, 110.28]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [62.595, 62.77]}, "BP": {"company": "", "ticker": "BP", "move": "up", "prices": [37.63, 37.7]}}}, {"link": "https://www.wsj.com/articles/facebooks-libra-hits-extra-regulatory-roadblocks-in-europe-11570541421", "title": "Facebook's Libra Hits Extra Regulatory Roadblocks in Europe", "date": "2019-10-08 09:30", "summary": "Valdis Dombrovskis, who is slated to stay on as vice president of the European Commission, says planned digital currency poses a risk to the euro. BRUSSELS-The European Union will introduce legislation aimed at preventing libra, Facebook Inc.'s proposed digital currency, from undermining Europe's single currency and being used as a money-laundering tool-representing one of the toughest regulatory responses so far.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook's Libra Hits Extra Regulatory Roadblocks in Europe. Valdis Dombrovskis, who is slated to stay on as vice president of the European Commission, says planned digital currency poses a risk to the euro. BRUSSELS-The European Union will introduce legislation aimed at preventing libra, Facebook Inc.'s proposed digital currency, from undermining Europe's single currency and being used as a money-laundering tool-representing one of the toughest regulatory responses so far.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will decrease because of the extra regulatory roadblocks in Europe.\n- Libra Association members (including Visa, Inc. (NYSE: V), Mastercard Incorporated (NYSE: MA), and PayPal Holdings, Inc. (NASDAQ: PYPL)) will decrease because of the extra regulatory roadblocks in Europe.", "price_info": {"V": {"company": "", "ticker": "V", "move": null, "prices": [172.6086, 173.0998]}, "MA": {"company": "", "ticker": "MA", "move": null, "prices": [268.45, 268.77]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [178.6, 178.665]}, "PYPL": {"company": "", "ticker": "PYPL", "move": "down", "prices": [99.8, 100.1872]}}}, {"link": "https://www.wsj.com/articles/hedge-fund-nominates-four-to-tegnas-board-setting-up-proxy-fight-11579116986", "title": "Hedge Fund Nominates Four to Tegna's Board, Setting Up Proxy Fight", "date": "2020-01-15 14:52", "summary": "Standard General pushes for seats after Apollo's failed takeover approach at broadcast company. Tegna Inc. is in the early stages of a potential proxy fight, after hedge fund Standard General LP nominated four candidates to the broadcast company's board of directors.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hedge Fund Nominates Four to Tegna's Board, Setting Up Proxy Fight. Standard General pushes for seats after Apollo's failed takeover approach at broadcast company. Tegna Inc. is in the early stages of a potential proxy fight, after hedge fund Standard General LP nominated four candidates to the broadcast company's board of directors.\"\n\nStock Prediction(s):", "Prediction": "\n- Tegna Inc (NYSE: TGNA) will increase because they are being targeted by a hedge fund, and they may go up in value as a result of a proxy fight.\n- Apollo Global Management LLC (NYSE: APO) will decrease because they made an unsuccessful takeover bid for Tegna, and they may go down in value as a result.", "price_info": {"TGNA": {"company": "", "ticker": "TGNA", "move": "up", "prices": [17.96, 17.94]}, "APO": {"company": "", "ticker": "APO", "move": "down", "prices": [49.175, 48.86]}}}, {"link": "https://www.wsj.com/articles/spotify-needs-joe-rogan-and-music-fans-11643912174", "title": "Spotify Needs Joe Rogan and Music Fans", "date": "2022-02-03 13:16", "summary": "Disappointing margin and subscriber forecasts sink stock and show why streaming platform needs all listeners tuned in. It is unclear if Spotify Technology is feeling any business impact from the Joe Rogan controversy so far. It is clear why the streaming platform is unlikely to pull the plug on him or any of its other podcast stars.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Spotify Needs Joe Rogan and Music Fans. Disappointing margin and subscriber forecasts sink stock and show why streaming platform needs all listeners tuned in. It is unclear if Spotify Technology is feeling any business impact from the Joe Rogan controversy so far. It is clear why the streaming platform is unlikely to pull the plug on him or any of its other podcast stars.\"\n\nStock Prediction(s):", "Prediction": "\n- Spotify Technology SA (NYSE: SPOT) will increase because they need all listeners tuned in, and Joe Rogan is a big part of that.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are a direct competitor of Spotify.", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "up", "prices": [159.09, 160.874]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [175.2113, 175.13]}}}, {"link": "https://www.wsj.com/articles/greek-bank-stocks-surge-and-one-lender-looks-to-take-advantage-11623246670", "title": "Greek Bank Stocks Surge, and One Lender Looks to Take Advantage", "date": "2021-06-09 10:34", "summary": "Alpha Services wants to raise $1 billion but major investor Paulson & Co. is against the deal, according to people familiar with the matter. Greek banks, once at the epicenter of Europe's financial troubles, have been a hot bet for investors anticipating a strong economic rebound from the Covid-19 pandemic.", "categories": [["WSJ News Exclusive", "Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Greek Bank Stocks Surge, and One Lender Looks to Take Advantage. Alpha Services wants to raise $1 billion but major investor Paulson & Co. is against the deal, according to people familiar with the matter. Greek banks, once at the epicenter of Europe's financial troubles, have been a hot bet for investors anticipating a strong economic rebound from the Covid-19 pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Alpha Bank AE (OTC: ALBKY) will increase because they are looking to raise $1 billion, and they have a major investor in Paulson & Co.\n- National Bank of Greece SA (OTC: NBG) will increase because they are looking to raise $1 billion, and they have a major investor in Paulson & Co.\n- Eurobank Ergasias SA (OTC: EUROB) will increase because they are looking", "price_info": {}}, {"link": "https://www.wsj.com/articles/bank-of-america-overhauls-top-management-ranks-11631281038", "title": "Bank of America Overhauls Top Management Ranks", "date": "2021-09-10 11:19", "summary": "Bank names new CFO and adds three women to its senior ranks in biggest leadership reshuffling in more than a decade. Bank of America Corp. said Friday it is shaking up its top leadership team, installing new finance, technology and legal chiefs and adding three women to its senior ranks.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bank of America Overhauls Top Management Ranks. Bank names new CFO and adds three women to its senior ranks in biggest leadership reshuffling in more than a decade. Bank of America Corp. said Friday it is shaking up its top leadership team, installing new finance, technology and legal chiefs and adding three women to its senior ranks.\"\n\nStock Prediction(s):", "Prediction": "\n- Bank of America Corp. (NYSE: BAC) will increase because they are making changes to their top management, and this will help them be more successful in the future.\n- Citigroup Inc. (NYSE: C) will decrease because they are also making changes to their top management, and this will help Bank of America be more successful in the future.", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [40.675, 40.527]}, "C": {"company": "America", "ticker": "C", "move": "down", "prices": [70.15, 70.115]}}}, {"link": "https://www.wsj.com/articles/consumer-spending-personal-income-inflation-november-2021-11640215420", "title": "Omicron Starts to Slow U.S. Economy as Consumer Spending Flags", "date": "2021-12-23 15:27", "summary": "Fewer people are dining in restaurants, and rising case numbers are leading many businesses to close for a short period. Signs are mounting that the U.S. economy is losing some steam as the Omicron variant of the Covid-19 virus spreads rapidly through parts of the country.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Omicron Starts to Slow U.S. Economy as Consumer Spending Flags. Fewer people are dining in restaurants, and rising case numbers are leading many businesses to close for a short period. Signs are mounting that the U.S. economy is losing some steam as the Omicron variant of the Covid-19 virus spreads rapidly through parts of the country.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corporation (NYSE: MCD) will decrease because people are not eating out as much because of the virus.\n- Starbucks Corporation (NASDAQ: SBUX) will decrease because people are not drinking coffee as much because of the virus.\n- Chipotle Mexican Grill, Inc. (NYSE: CMG) will decrease because people are not eating out as much because of the virus.\n- The Walt Disney Company (NYSE: DIS) will decrease because", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "down", "prices": [266.405, 265.95]}, "CMG": {"company": "", "ticker": "CMG", "move": "down", "prices": [1754.93, 1750.39]}, "DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [153.7798, 153.73]}, "SBUX": {"company": "", "ticker": "SBUX", "move": "down", "prices": [112.51, 112.43]}}}, {"link": "https://www.wsj.com/articles/jobs-wont-look-great-in-september-either-11630684035", "title": "Jobs Won't Look Great in September, Either", "date": "2021-09-03 11:48", "summary": "Delta variant weighed on U.S. labor market last month; for this month, expect more of the same. Covid-19 hit America's job market last month. The question is how much of that was because employers were less willing to hire and how much of it was because it cut into would-be employees' willingness to find work.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jobs Won't Look Great in September, Either. Delta variant weighed on U.S. labor market last month; for this month, expect more of the same. Covid-19 hit America's job market last month. The question is how much of that was because employers were less willing to hire and how much of it was because it cut into would-be employees' willingness to find work.\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines, Inc. (NYSE: DAL) will continue to decrease because the Covid-19 pandemic is continuing to have a negative impact on the labor market.\n- United Airlines Holdings, Inc. (NYSE: UAL) will continue to decrease because the Covid-19 pandemic is continuing to have a negative impact on the labor market.\n- American Airlines Group, Inc. (NASDAQ: AAL) will continue to decrease because", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [40.235, 40.36]}, "UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [46.08, 46.195]}, "AAL": {"company": "", "ticker": "AAL", "move": "down", "prices": [19.39, 19.43]}}}, {"link": "https://www.wsj.com/articles/cambridge-mobile-buys-rival-as-telematics-helps-set-car-insurance-payments-11623920400", "title": "Cambridge Mobile Buys Rival as Telematics Helps Set Car-Insurance Payments", "date": "2021-06-17 09:44", "summary": "Deal with TrueMotion aims to improve the gauges of drivers' habits sold to auto insurers and create new ones. Cambridge Mobile Telematics, one of the largest technology firms focused on the growing business of collecting information about individuals' driving habits directly from their vehicles, has purchased TrueMotion, one of its rivals.", "categories": [["WSJ News Exclusive", "Finance"]], "category_links": ["https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Cambridge Mobile Buys Rival as Telematics Helps Set Car-Insurance Payments. Deal with TrueMotion aims to improve the gauges of drivers' habits sold to auto insurers and create new ones. Cambridge Mobile Telematics, one of the largest technology firms focused on the growing business of collecting information about individuals' driving habits directly from their vehicles, has purchased TrueMotion, one of its rivals.\"\n\nStock Prediction(s):", "Prediction": "\n- Cambridge Mobile Telematics (NASDAQ: CMT) will increase because they are buying a rival and expanding their business.\n- TrueMotion (private) will increase because they are being bought by a larger company and will have access to more resources.", "price_info": {"CMT": {"company": "", "ticker": "CMT", "move": "up", "prices": [13.9, 13.8]}}}, {"link": "https://www.wsj.com/articles/zillow-state-street-valneva-coinbase-what-to-watch-when-the-stock-market-opens-today-11634553340", "title": "Zillow, State Street, Valneva, Upstart: What to Watch in the Stock Market Today", "date": "2021-10-18 09:32", "summary": "Zillow shares were down after reports that it would stop buying homes this year; Valneva soared on its vaccine test results. Wall Street indexes opened lower after China's third-quarter economic growth came in below economists' forecasts. Here's what we're watching in Monday's trading.", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Zillow, State Street, Valneva, Upstart: What to Watch in the Stock Market Today. Zillow shares were down after reports that it would stop buying homes this year; Valneva soared on its vaccine test results. Wall Street indexes opened lower after China's third-quarter economic growth came in below economists' forecasts. Here's what we're watching in Monday's trading.\"\n\nStock Prediction(s):", "Prediction": "\n- Zillow Group, Inc. (NASDAQ: Z) will decrease because they are stopping their home-buying program.\n- State Street Corporation (NYSE: STT) will decrease because they are a competitor of Zillow.\n- Valneva SE (NYSE: VLA) will increase because their vaccine test results were positive.\n- Upstart Co-operative, Inc. (UPST) will increase because they are a competitor of Val", "price_info": {"UPST": {"company": "Co-operative, Inc.", "ticker": "UPST", "move": "up", "prices": [376.69, 374.2]}, "STT": {"company": "", "ticker": "STT", "move": "down", "prices": [95.41, 96.68]}, "VLA": {"company": "", "ticker": "VLA", "move": "up"}, "Z": {"company": "", "ticker": "Z", "move": "down", "prices": [84.79, 85.97]}}}, {"link": "https://www.wsj.com/articles/google-aims-for-commercial-grade-quantum-computer-by-2029-11621359156", "title": "Google Aims for Commercial-Grade Quantum Computer by 2029", "date": "2021-05-18 13:58", "summary": "Tech giant is one of many companies racing to build a business around the nascent technology. Alphabet Inc.'s Google plans to spend several billion dollars to build a quantum computer by 2029 that can perform large-scale business and scientific calculations without errors, said Hartmut Neven, a distinguished scientist at Google who oversees the company's Quantum AI program. The company recently opened an expanded California-based campus focused on the effort, he said.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Google Aims for Commercial-Grade Quantum Computer by 2029. Tech giant is one of many companies racing to build a business around the nascent technology. Alphabet Inc.'s Google plans to spend several billion dollars to build a quantum computer by 2029 that can perform large-scale business and scientific calculations without errors, said Hartmut Neven, a distinguished scientist at Google who oversees the company's Quantum AI program. The company recently opened an expanded California-based campus focused on the effort, he said.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because they are investing in quantum computing, which is the future of computing.\n- IBM (NYSE: IBM) will decrease because they are also investing in quantum computing, but they are a direct competitor of Alphabet.", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "down", "prices": [143.8647, 143.89]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2271.19, 2263.11]}}}, {"link": "https://www.wsj.com/articles/copper-rebounds-on-hopes-for-economic-recovery-11588944516", "title": "Copper Rebounds on Hopes for Economic Recovery", "date": "2020-05-08 14:52", "summary": "Futures climb 1%, record fifth straight day of gains. Copper prices rose Friday, extending a recent rebound with investors anticipating an uptick in demand as parts of the world roll back lockdown measures and trade tensions ease.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Copper Rebounds on Hopes for Economic Recovery. Futures climb 1%, record fifth straight day of gains. Copper prices rose Friday, extending a recent rebound with investors anticipating an uptick in demand as parts of the world roll back lockdown measures and trade tensions ease.\"\n\nStock Prediction(s):", "Prediction": "\n- Freeport-McMoRan Inc. (NYSE: FCX) will increase because copper prices are rising, and Freeport-McMoRan is a major producer of copper.\n- Southern Copper Corp. (NYSE: SCCO) will increase because copper prices are rising, and Southern Copper is a major producer of copper.\n- BHP Group Ltd. (NYSE: BHP) will increase because copper prices are rising, and BHP Group", "price_info": {"FCX": {"company": "", "ticker": "FCX", "move": "up", "prices": [9.19, 9.22]}, "SCCO": {"company": "", "ticker": "SCCO", "move": "up"}, "BHP": {"company": "", "ticker": "BHP", "move": "up"}}}, {"link": "https://www.wsj.com/articles/m-t-shares-tumble-after-earnings-miss-lower-expectations-11563474954", "title": "M&T Shares Tumble After Earnings Miss, Lower Expectations", "date": "2019-07-18 14:35", "summary": "Lender says it expects its net interest income to increase less than previously forecast due to lower interest rates. Shares of M&T Bank Corp. fell 4.3% Thursday afternoon after the company said it expects its net interest income to increase less than previously forecast due to lower interest rates.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"M&T Shares Tumble After Earnings Miss, Lower Expectations. Lender says it expects its net interest income to increase less than previously forecast due to lower interest rates. Shares of M&T Bank Corp. fell 4.3% Thursday afternoon after the company said it expects its net interest income to increase less than previously forecast due to lower interest rates.\"\n\nStock Prediction(s):", "Prediction": "\n- M&T Bank Corp. (NYSE: MTB) will decrease because their earnings missed, and they lowered their expectations for the future.", "price_info": {"MTB": {"company": "", "ticker": "MTB", "move": "down", "prices": [162.375, 162.76]}}}, {"link": "https://www.wsj.com/articles/justin-timberlake-sells-new-york-apartment-for-29-million-11641839358", "title": "Justin Timberlake Sells New York Apartment for $29 Million", "date": "2022-01-13 11:25", "summary": "The buyer is a group represented by Alejandro Weinstein, a South American entrepreneur. Pop star Justin Timberlake has sold a New York City penthouse for $29 million in an off-market sale, records show.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Justin Timberlake Sells New York Apartment for $29 Million. The buyer is a group represented by Alejandro Weinstein, a South American entrepreneur. Pop star Justin Timberlake has sold a New York City penthouse for $29 million in an off-market sale, records show.\"\n\nStock Prediction(s):", "Prediction": "\n- The buyer of Justin Timberlake's penthouse is a group represented by Alejandro Weinstein, a South American entrepreneur. This could mean that Weinstein is looking to invest in the U.S. market, and will buy other properties in the near future.\n- Other real estate companies, such as Brookfield Property Partners LP (NYSE: BPY) and Simon Property Group, Inc. (NYSE: SPG), will increase because of the increasing demand for real estate in", "price_info": {"BPY": {"company": "", "ticker": "BPY", "move": null}, "SPG": {"company": "", "ticker": "SPG", "move": "up", "prices": [163.09, 163.2763]}}}, {"link": "https://www.wsj.com/articles/repsol-targets-net-zero-emissions-in-strategic-shift-11575360545", "title": "Spanish Energy Giant Repsol Writes Down Oil, Gas Assets", "date": "2019-12-03 11:16", "summary": "Along with warnings of a $5 billion impairment charge, the company said it aims to achieve net-zero emissions by 2050. Spanish energy company Repsol SA said it is cutting the value of its assets by billions of dollars because the global transition to a lower carbon economy is weakening the outlook for oil and gas prices.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Spanish Energy Giant Repsol Writes Down Oil, Gas Assets. Along with warnings of a $5 billion impairment charge, the company said it aims to achieve net-zero emissions by 2050. Spanish energy company Repsol SA said it is cutting the value of its assets by billions of dollars because the global transition to a lower carbon economy is weakening the outlook for oil and gas prices.\"\n\nStock Prediction(s):", "Prediction": "\n- Repsol SA (OTC: REPYY) will decrease because they are writing down their assets and their outlook is weakening.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they are not writing down their assets and their outlook is not weakening.\n- BP plc (NYSE: BP) will increase because they are not writing down their assets and their outlook is not weakening.", "price_info": {"BP": {"company": "", "ticker": "BP", "move": "down", "prices": [36.685, 36.81]}}}, {"link": "https://www.wsj.com/articles/bidens-two-pronged-attack-on-income-inequality-11610718820", "title": "Biden's Stimulus Is a Two-Pronged Attack on Income Inequality", "date": "2021-01-15 09:50", "summary": "The president-elect's plan could rapidly cut unemployment-but at a hefty price. There are two ways for the federal government to address income inequality. One is to redistribute more money to people at the bottom of the income ladder. The other is to use the tools of fiscal and monetary policy to drive unemployment low enough to drive up demand and wages for those workers.", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biden's Stimulus Is a Two-Pronged Attack on Income Inequality. The president-elect's plan could rapidly cut unemployment-but at a hefty price. There are two ways for the federal government to address income inequality. One is to redistribute more money to people at the bottom of the income ladder. The other is to use the tools of fiscal and monetary policy to drive unemployment low enough to drive up demand and wages for those workers.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go up because Biden's stimulus is a two-pronged attack on income inequality and it will rapidly cut unemployment.\n- The market will go down because the stimulus is a hefty price to pay.", "price_info": {}}, {"link": "https://www.wsj.com/articles/a-conclave-of-americas-top-ceos-talks-race-and-making-change-11591349402", "title": "A Conclave of America's Top CEOs Talks Race and Making Change", "date": "2020-06-05 10:54", "summary": "More than 300 chief executives, mayors and government officials gather online for a rare peer-to-peer conversation about race relations and social justice. Leaders of General Motors Co. , Johnson & Johnson , American Airlines Group Inc. and other big businesses gathered via Zoom this week for a roundtable about the business impacts of the coronavirus. With protests gaining momentum across the U.S., the participants quickly changed the subject.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Conclave of America's Top CEOs Talks Race and Making Change. More than 300 chief executives, mayors and government officials gather online for a rare peer-to-peer conversation about race relations and social justice. Leaders of General Motors Co. , Johnson & Johnson , American Airlines Group Inc. and other big businesses gathered via Zoom this week for a roundtable about the business impacts of the coronavirus. With protests gaining momentum across the U.S., the participants quickly changed the subject.\"\n\nStock Prediction(s):", "Prediction": "\n- GM Co. (NYSE: GM) will increase because they are a part of the conversation about race and social justice.\n- Johnson & Johnson (NYSE: JNJ) will increase because they are a part of the conversation about race and social justice.\n- American Airlines Group Inc. (NASDAQ: AAL) will increase because they are a part of the conversation about race and social justice.", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "up", "prices": [30.5, 30.5575]}, "JNJ": {"company": "", "ticker": "JNJ", "move": "up", "prices": [149, 148.77]}, "AAL": {"company": "", "ticker": "AAL", "move": "up", "prices": [19.6, 19.07]}}}, {"link": "https://www.wsj.com/articles/cios-look-beyond-economic-expansion-to-eventual-slowdown-11577973600", "title": "CIOs Look Beyond Economic Expansion to Eventual Slowdown", "date": "2020-01-02 13:06", "summary": "Though worries of immediate recession have ebbed, tech executives are making sure they are ready for a downturn. Concerns about an imminent economic slowdown or recession have receded in recent months, but chief information officers nonetheless are preparing for the prospect that the decade-plus expansion will falter at some point.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"CIOs Look Beyond Economic Expansion to Eventual Slowdown. Though worries of immediate recession have ebbed, tech executives are making sure they are ready for a downturn. Concerns about an imminent economic slowdown or recession have receded in recent months, but chief information officers nonetheless are preparing for the prospect that the decade-plus expansion will falter at some point.\"\n\nStock Prediction(s):", "Prediction": "\n- Oracle Corporation (NYSE: ORCL) will increase because they are a major player in the tech industry and they are preparing for a downturn.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are a major player in the tech industry and they are preparing for a downturn.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a major player in the tech industry and they are preparing for a downturn", "price_info": {"ORCL": {"company": "", "ticker": "ORCL", "move": "up", "prices": [53.66, 53.595]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [159.654, 159.875]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1876.6435, 1893.8333]}}}, {"link": "https://www.wsj.com/articles/commodities-fall-alongside-global-stocks-with-coronavirus-spreading-11579798171", "title": "Commodities Fall Alongside Global Stocks With Coronavirus Spreading", "date": "2020-01-23 15:06", "summary": "The slide comes amid signs that investors are bracing for a hit to economic growth in China. Commodities from oil to copper extended a recent slide Thursday with a deadly virus spreading and disrupting travel in China, the latest sign that investors are bracing for a hit to economic growth in the world's largest consumer of raw materials.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Commodities Fall Alongside Global Stocks With Coronavirus Spreading. The slide comes amid signs that investors are bracing for a hit to economic growth in China. Commodities from oil to copper extended a recent slide Thursday with a deadly virus spreading and disrupting travel in China, the latest sign that investors are bracing for a hit to economic growth in the world's largest consumer of raw materials.\"\n\nStock Prediction(s):", "Prediction": "\n- Energy companies (e.g. Exxon Mobil Corporation (NYSE: XOM)) will decrease because a hit to the Chinese economy will mean less demand for oil.\n- Mining companies (e.g. BHP Group Ltd. (NYSE: BHP)) will decrease because a hit to the Chinese economy will mean less demand for copper.", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [66.73, 66.77]}, "BHP": {"company": "", "ticker": "BHP", "move": "down", "prices": [55.495, 55.72]}}}, {"link": "https://www.wsj.com/articles/3g-capital-diversifies-away-from-food-with-hunter-douglas-deal-11640966951", "title": "3G Capital Diversifies Away From Food With Hunter Douglas Deal", "date": "2021-12-31 11:09", "summary": "Private-equity firm set to take control of the Dutch window-coverings maker, in its first deal since 2015. 3G Capital has agreed to buy a majority stake in Dutch window-coverings maker Hunter Douglas NV in a transaction that values the business at about $6.9 billion, expanding beyond its food-and-beverage focus for its first big deal since 2015.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"3G Capital Diversifies Away From Food With Hunter Douglas Deal. Private-equity firm set to take control of the Dutch window-coverings maker, in its first deal since 2015. 3G Capital has agreed to buy a majority stake in Dutch window-coverings maker Hunter Douglas NV in a transaction that values the business at about $6.9 billion, expanding beyond its food-and-beverage focus for its first big deal since 2015.\"\n\nStock Prediction(s):", "Prediction": "\n- 3G Capital (NYSE: TGP) will increase because they are expanding their business, and this is their first big deal in a while.\n- Hunter Douglas NV (AMS: HDG) will increase because they are being bought by a private-equity firm, and they will get a lot of new investment.", "price_info": {"TGP": {"company": "", "ticker": "TGP", "move": "up", "prices": [16.93, 16.93]}}}, {"link": "https://www.wsj.com/articles/shopifys-business-sells-itself-for-now-11596041071", "title": "Shopify's Business Sells Itself, for Now", "date": "2020-07-29 12:44", "summary": "E-commerce rush rockets Shopify shares amid coronavirus, but all good sales can eventually come to an end. Overall U.S. retail sales were down in the second quarter, according to Census Bureau data. You would never know it from Shopify 's results.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Shopify's Business Sells Itself, for Now. E-commerce rush rockets Shopify shares amid coronavirus, but all good sales can eventually come to an end. Overall U.S. retail sales were down in the second quarter, according to Census Bureau data. You would never know it from Shopify 's results.\"\n\nStock Prediction(s):", "Prediction": "\n- Shopify Inc (NYSE: SHOP) will continue to increase because their business is still doing well, despite the overall decline in retail sales.\n- Amazon.com, Inc. (NASDAQ: AMZN) will continue to increase because their business is still doing well, despite the overall decline in retail sales.", "price_info": {"SHOP": {"company": "", "ticker": "SHOP", "move": "down", "prices": [1065.01, 1061.4247]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3019.35, 3036.25]}}}, {"link": "https://www.wsj.com/articles/fed-chairman-powell-to-testify-before-house-financial-services-committee-on-feb-27-11549469856", "title": "Fed Chairman Powell to Testify Before House Committee on Feb. 27", "date": "2019-02-06 11:17", "summary": "The Senate Banking Committee hasn't announced when Mr. Powell will testify on the other side of Capitol Hill. Federal Reserve Chairman Jerome Powell will deliver his semiannual monetary policy report to the House Financial Services Committee on Feb. 27, the committee announced Wednesday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Chairman Powell to Testify Before House Committee on Feb. 27. The Senate Banking Committee hasn't announced when Mr. Powell will testify on the other side of Capitol Hill. Federal Reserve Chairman Jerome Powell will deliver his semiannual monetary policy report to the House Financial Services Committee on Feb. 27, the committee announced Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Powell's testimony will have a positive effect on the markets because it will be seen as a sign of confidence in the economy.\n- The markets will react negatively to any news that comes out of the testimony that suggests a slowdown in the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/remote-work-is-reshaping-san-francisco-as-tech-workers-flee-and-rents-fall-11597413602", "title": "Remote Work Is Reshaping San Francisco, as Tech Workers Flee and Rents Fall", "date": "2020-08-14 10:00", "summary": "By giving their employees the freedom to work from anywhere, Bay Area tech companies appear to have touched off an exodus. 'Why do we even want to be here?'. For years there's been talk of a potential exodus from the San Francisco Bay Area, spurred by the exorbitant cost of living and long, slogging commutes. But before coronavirus, leaving the area meant walking away from some of the best-paying and most prestigious jobs in America.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Remote Work Is Reshaping San Francisco, as Tech Workers Flee and Rents Fall. By giving their employees the freedom to work from anywhere, Bay Area tech companies appear to have touched off an exodus. 'Why do we even want to be here?'. For years there's been talk of a potential exodus from the San Francisco Bay Area, spurred by the exorbitant cost of living and long, slogging commutes. But before coronavirus, leaving the area meant walking away from some of the best-paying and most prestigious jobs in America.\"\n\nStock Prediction(s):", "Prediction": "\n- San Francisco will decrease in population because people are fleeing the high cost of living and long commutes.\n- Other cities in the Bay Area (i.e. Palo Alto, Berkeley, etc.) will increase in population because people are fleeing San Francisco.", "price_info": {}}, {"link": "https://www.wsj.com/articles/is-an-oscar-campaign-worth-the-time-and-money-11550849429", "title": "Is an Oscar Campaign Worth the Time and Money?", "date": "2019-02-22 10:30", "summary": "The box-office bump from a nomination can be slight, but the real value for studios is in keeping stars happy.. In Los Angeles, signs are everywhere of the millions of dollars movie studios spend campaigning for their most prestigious films to win Academy Awards. Billboards bearing Glenn Close's pained grimace in \"The Wife\" are erected outside the neighborhood grocery store. Luncheon after luncheon is served with Ryan Gosling on hand. Five-pound coffee-table books offering behind-the-scenes photographs on the making of \"Roma\" are shipped across town.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Is an Oscar Campaign Worth the Time and Money?. The box-office bump from a nomination can be slight, but the real value for studios is in keeping stars happy.. In Los Angeles, signs are everywhere of the millions of dollars movie studios spend campaigning for their most prestigious films to win Academy Awards. Billboards bearing Glenn Close's pained grimace in \"The Wife\" are erected outside the neighborhood grocery store. Luncheon after luncheon is served with Ryan Gosling on hand. Five-pound coffee-table books offering behind-the-scenes photographs on the making of \"Roma\" are shipped across town.\"\n\nStock Prediction(s):", "Prediction": "\n- Sony Pictures Entertainment Inc. (NYSE: SNE) will increase because they are one of the studios campaigning for their prestigious films to win Academy Awards.\n- Netflix, Inc. (NASDAQ: NFLX) will increase because they are also campaigning for their prestigious films to win Academy Awards.\n- Walt Disney Co (NYSE: DIS) will decrease because they are not campaigning for their prestigious films to win Academy Awards.", "price_info": {"SNE": {"company": "", "ticker": "SNE", "move": "up", "prices": [48.005, 48.035]}, "DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [114.46, 114.9049]}, "NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [362.55, 364.33]}}}, {"link": "https://www.wsj.com/articles/sec-to-review-brokers-restrictions-on-gamestop-amc-trading-11611932473", "title": "SEC to Review Brokers' Restrictions on GameStop, AMC Trading", "date": "2021-01-29 13:59", "summary": "Securities regulators say they are on the lookout for potentially manipulative trading. Securities regulators said Friday they plan to closely review the actions of some brokerage firms that restricted investors' ability to trade volatile stocks such as GameStop Corp. this week.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SEC to Review Brokers' Restrictions on GameStop, AMC Trading. Securities regulators say they are on the lookout for potentially manipulative trading. Securities regulators said Friday they plan to closely review the actions of some brokerage firms that restricted investors' ability to trade volatile stocks such as GameStop Corp. this week.\"\n\nStock Prediction(s):", "Prediction": "\n- GameStop Corp. (NYSE: GME) will increase because the SEC is looking into their stock and it may have been manipulated.\n- AMC Entertainment Holdings Inc. (NYSE: AMC) will increase because the SEC is looking into their stock and it may have been manipulated.\n- Tesla, Inc. (NASDAQ: TSLA) will decrease because the SEC is looking into their stock and it may have been manipulated.", "price_info": {"GME": {"company": "", "ticker": "GME", "move": "up", "prices": [278.79, 316.37]}, "AMC": {"company": "", "ticker": "AMC", "move": "up", "prices": [12.06, 13.7388]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [790.55, 787.46]}}}, {"link": "https://www.wsj.com/articles/ebay-expected-to-give-activist-shareholders-at-least-2-board-seats-11551296913", "title": "EBay Is Expected to Give Activist Shareholders at Least 2 Board Seats", "date": "2019-02-27 14:48", "summary": "Elliott partner Jesse Cohn is expected to join the eBay board, with a Starboard nominee filling the other new seat. The settlement deal eBay Inc. is nearing with shareholders Elliott Management Corp. and Starboard Value LP would give the activist investors one board seat each and could give them input on another seat in the future, according to people familiar with the matter.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"EBay Is Expected to Give Activist Shareholders at Least 2 Board Seats. Elliott partner Jesse Cohn is expected to join the eBay board, with a Starboard nominee filling the other new seat. The settlement deal eBay Inc. is nearing with shareholders Elliott Management Corp. and Starboard Value LP would give the activist investors one board seat each and could give them input on another seat in the future, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- eBay Inc. (NASDAQ: EBAY) will increase because they are giving activist shareholders at least 2 board seats.\n- Starboard Value LP (NYSE: STB) will increase because they are getting a board seat.", "price_info": {"STB": {"company": "", "ticker": "STB", "move": "up"}, "EBAY": {"company": "", "ticker": "EBAY", "move": "up", "prices": [37.7636, 37.59]}}}, {"link": "https://www.wsj.com/articles/citigroup-fourth-quarter-profit-beats-expectations-11579007935", "title": "Investment Banking Propels Citigroup's Profit", "date": "2020-01-14 14:02", "summary": "New York bank's earnings top expectations, revenue rises 7%. Citigroup Inc. said fourth-quarter profit rose 15%, beating expectations on a surge in investment-banking operations.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investment Banking Propels Citigroup's Profit. New York bank's earnings top expectations, revenue rises 7%. Citigroup Inc. said fourth-quarter profit rose 15%, beating expectations on a surge in investment-banking operations.\"\n\nStock Prediction(s):", "Prediction": "\n- Citigroup Inc (NYSE: C) will increase because their investment banking is doing well.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because their investment banking is doing worse.\n- Goldman Sachs Group Inc. (NYSE: GS) will decrease because their investment banking is doing worse.\n- Bank of America Corp (NYSE: BAC) will decrease because their investment banking is doing worse.", "price_info": {"C": {"company": "", "ticker": "C", "move": "up", "prices": [82.655, 81.975]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [139.2442, 139.253]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [247.1012, 246.27]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [35.475, 35.385]}}}, {"link": "https://www.wsj.com/articles/falling-industrial-metals-highlight-lingering-trade-concerns-11574350886", "title": "Falling Industrial Metals Highlight Lingering Trade Concerns", "date": "2019-11-21 15:08", "summary": "Copper prices have fallen 3.8% since hitting a 3\u00bd-month high earlier this month. Falling prices of industrial metals such as copper and aluminum signal that some investors remain wary of setbacks to a U.S.-China trade deal, countering the optimism that has kept stocks just below Monday's records.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Falling Industrial Metals Highlight Lingering Trade Concerns. Copper prices have fallen 3.8% since hitting a 3\u00bd-month high earlier this month. Falling prices of industrial metals such as copper and aluminum signal that some investors remain wary of setbacks to a U.S.-China trade deal, countering the optimism that has kept stocks just below Monday's records.\"\n\nStock Prediction(s):", "Prediction": "\n- Alcoa Corporation (NYSE: AA) will increase because falling industrial metals prices highlight lingering trade concerns.\n- Century Aluminum Co (NASDAQ: CENX) will increase because falling industrial metals prices highlight lingering trade concerns.\n- Freeport-McMoRan Inc. (NYSE: FCX) will increase because falling industrial metals prices highlight lingering trade concerns.\n- Southern Copper Corporation (NYSE: SCCO) will increase because falling industrial metals prices", "price_info": {"AA": {"company": "", "ticker": "AA", "move": "up", "prices": [20.245, 20.15]}, "FCX": {"company": "", "ticker": "FCX", "move": "up", "prices": [10.98, 11.01]}, "SCCO": {"company": "", "ticker": "SCCO", "move": "up"}, "CENX": {"company": "", "ticker": "CENX", "move": "up", "prices": [6.965, 6.92]}}}, {"link": "https://www.wsj.com/articles/nike-site-sells-out-of-kobe-bryant-merchandise-in-wake-of-stars-death-11580225861", "title": "Nike Site Sells Out of Kobe Bryant Merchandise in Wake of Star's Death", "date": "2020-01-28 10:37", "summary": "Sneaker giant says it didn't remove Kobe Bryant sneakers or merchandise from its website. Nike Inc. 's website sold out of Kobe Bryant merchandise in the wake of the basketball superstar's sudden death, the sportswear giant said, rebutting media reports it had pulled the products.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nike Site Sells Out of Kobe Bryant Merchandise in Wake of Star's Death. Sneaker giant says it didn't remove Kobe Bryant sneakers or merchandise from its website. Nike Inc. 's website sold out of Kobe Bryant merchandise in the wake of the basketball superstar's sudden death, the sportswear giant said, rebutting media reports it had pulled the products.\"\n\nStock Prediction(s):", "Prediction": "\n- Nike Inc. (NYSE: NKE) will increase because they are the only major retailer with Kobe Bryant merchandise, and there is high demand following his death.\n- Under Armour, Inc. (NYSE: UA) will decrease because they are a direct competitor of Nike, and they do not have any Kobe Bryant merchandise.", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "up", "prices": [100.39, 100.885]}, "UA": {"company": "", "ticker": "UA", "move": "down", "prices": [18.435, 18.4]}}}, {"link": "https://www.wsj.com/articles/at-t-dish-strike-5-billion-deal-to-support-boost-mobile-11626700846", "title": "AT&T, Dish Strike $5 Billion Deal to Support Boost Mobile", "date": "2021-07-19 10:22", "summary": "Agreement allows AT&T to carry Dish wireless customers while providing path for spectrum sharing. AT&T Inc. struck a deal to carry Dish Network Corp.'s existing cellphone customers over its wireless network, bringing two erstwhile rivals closer as they each pursue more advanced 5G technology.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AT&T, Dish Strike $5 Billion Deal to Support Boost Mobile. Agreement allows AT&T to carry Dish wireless customers while providing path for spectrum sharing. AT&T Inc. struck a deal to carry Dish Network Corp.'s existing cellphone customers over its wireless network, bringing two erstwhile rivals closer as they each pursue more advanced 5G technology.\"\n\nStock Prediction(s):", "Prediction": "\n- AT&T Inc. (NYSE: T) will increase because they are partnering with Dish Network Corp. to carry their cellphone customers.\n- Dish Network Corp. (NASDAQ: DISH) will increase because they are partnering with AT&T Inc. to carry their cellphone customers.", "price_info": {"T": {"company": "", "ticker": "T", "move": "up", "prices": [27.63, 27.5899]}, "DISH": {"company": "", "ticker": "DISH", "move": "up", "prices": [39.385, 39.2]}}}, {"link": "https://www.wsj.com/articles/vws-ceo-survives-labor-dispute-but-with-diminished-role-11639060120", "title": "VW's CEO Survives Labor Dispute but With Diminished Role", "date": "2021-12-09 12:57", "summary": "Europe's biggest auto maker accelerates investment in electric transformation. BERLIN- Volkswagen AG's besieged chief executive has survived a monthslong battle with labor leaders but he will now lead Europe's biggest auto maker on a shorter leash, raising questions about how fast and how far he can push through the electric transformation he started at the company.", "categories": [["Business", "Europe"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/europe-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"VW's CEO Survives Labor Dispute but With Diminished Role. Europe's biggest auto maker accelerates investment in electric transformation. BERLIN- Volkswagen AG's besieged chief executive has survived a monthslong battle with labor leaders but he will now lead Europe's biggest auto maker on a shorter leash, raising questions about how fast and how far he can push through the electric transformation he started at the company.\"\n\nStock Prediction(s):", "Prediction": "\n- Volkswagen AG (OTCPK: VOW3) will increase because their CEO survived the labor dispute, and they are accelerating their investment in electric transformation.\n- Ford Motor Company (NYSE: F) will decrease because they are not as aggressive in their electric transformation as Volkswagen.", "price_info": {"F": {"company": "", "ticker": "F", "move": "down", "prices": [19.82, 19.7199]}}}, {"link": "https://www.wsj.com/articles/india-threatens-jail-for-facebook-whatsapp-and-twitter-employees-11614964542", "title": "India Threatens Jail for Facebook, WhatsApp and Twitter Employees", "date": "2021-03-05 12:15", "summary": "Country flexes new powers over big platforms while companies are counting on world's second-largest population for growth. India's government has threatened to jail employees of Facebook Inc., its WhatsApp unit and Twitter Inc. as it seeks to quash political protests and gain far-reaching powers over discourse on foreign-owned tech platforms, people familiar with the warnings say.", "categories": [["WSJ News Exclusive", "Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"India Threatens Jail for Facebook, WhatsApp and Twitter Employees. Country flexes new powers over big platforms while companies are counting on world's second-largest population for growth. India's government has threatened to jail employees of Facebook Inc., its WhatsApp unit and Twitter Inc. as it seeks to quash political protests and gain far-reaching powers over discourse on foreign-owned tech platforms, people familiar with the warnings say.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc (NASDAQ: FB) will decrease because India is threatening to jail employees.\n- Twitter Inc (NYSE: TWTR) will decrease because India is threatening to jail employees.\n- WhatsApp Inc (owned by Facebook) (NASDAQ: FB) will decrease because India is threatening to jail employees.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down", "prices": [63.6519, 65.63]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [256.49, 260.07]}}}, {"link": "https://www.wsj.com/articles/disney-investors-could-look-goofy-soon-11597068000", "title": "Disney Investors Could Look Goofy Soon", "date": "2020-08-10 10:00", "summary": "Investors rushing to ride Disney on the hope of pandemic recovery could be in for a long and uncomfortable wait. Walt Disney investors are enjoying the recent show, but they might not get their happily ever after.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Disney Investors Could Look Goofy Soon. Investors rushing to ride Disney on the hope of pandemic recovery could be in for a long and uncomfortable wait. Walt Disney investors are enjoying the recent show, but they might not get their happily ever after.\"\n\nStock Prediction(s):", "Prediction": "\n- Disney (NYSE: DIS) will decrease because their investors might not get their happily ever after.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [129.1801, 129.74]}}}, {"link": "https://www.wsj.com/articles/general-electric-gets-most-of-shareholder-lawsuit-dismissed-11567189512", "title": "General Electric Gets Most of Shareholder Lawsuit Dismissed", "date": "2019-08-30 14:25", "summary": "Suit alleged yearslong fraud that inflated results in GE's insurance and power division; plaintiffs can amend claims. A federal judge dismissed much of a major shareholder lawsuit against General Electric Co. , knocking down several securities fraud allegations related to accounting at its insurance and power businesses.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"General Electric Gets Most of Shareholder Lawsuit Dismissed. Suit alleged yearslong fraud that inflated results in GE's insurance and power division; plaintiffs can amend claims. A federal judge dismissed much of a major shareholder lawsuit against General Electric Co. , knocking down several securities fraud allegations related to accounting at its insurance and power businesses.\"\n\nStock Prediction(s):", "Prediction": "\n- GE will increase because the majority of the lawsuit has been dismissed, and this will clear up some of the uncertainty around the company.\n- Honeywell International Inc. (NYSE: HON) will increase because they are a competitor of GE, and this news will give GE a competitive edge.\n- 3M Co. (NYSE: MMM) will decrease because they are a competitor of GE, and this news will give GE a competitive edge.", "price_info": {"HON": {"company": "", "ticker": "HON", "move": "up", "prices": [164.61, 164.62]}, "MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [161.24, 161.98]}}}, {"link": "https://www.wsj.com/articles/the-battle-to-lure-back-premium-travellers-has-begun-11624977777", "title": "The Battle to Lure Back Premium Travelers Has Begun", "date": "2021-06-29 10:42", "summary": "One reason for United Airlines' big move to renew its fleet may be the need to give its most lucrative clients a reason to leave home. Even as tourists fill U.S. planes again, business travelers have been slow to return to their old habits. Airlines may be willing to spend heavily to speed things up.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Battle to Lure Back Premium Travelers Has Begun. One reason for United Airlines' big move to renew its fleet may be the need to give its most lucrative clients a reason to leave home. Even as tourists fill U.S. planes again, business travelers have been slow to return to their old habits. Airlines may be willing to spend heavily to speed things up.\"\n\nStock Prediction(s):", "Prediction": "\n- United Airlines Holdings, Inc. (NYSE: UAL) will increase because they are renewing their fleet in order to attract more premium travelers.\n- American Airlines Group, Inc. (NASDAQ: AAL) will decrease because they are not renewing their fleet as much as United Airlines, and they may not be able to attract as many premium travelers.\n- Delta Air Lines, Inc. (NYSE: DAL) will decrease because they are not renew", "price_info": {"UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [52.79, 52.7489]}, "DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [43.265, 43.185]}, "AAL": {"company": "", "ticker": "AAL", "move": "down", "prices": [21.2301, 21.235]}}}, {"link": "https://www.wsj.com/articles/fed-adds-58-15-billion-in-liquidity-on-monday-11571666837", "title": "Fed Adds $58.15 Billion in Liquidity on Monday", "date": "2019-10-21 10:07", "summary": "Operation is part of an effort by the New York Fed to help tame volatility in short-term rate markets. The Federal Reserve Bank of New York injected $58.15 billion in overnight liquidity into financial markets.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Adds $58.15 Billion in Liquidity on Monday. Operation is part of an effort by the New York Fed to help tame volatility in short-term rate markets. The Federal Reserve Bank of New York injected $58.15 billion in overnight liquidity into financial markets.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will be stable because the Fed is injecting liquidity into the market.\n- The market will be volatile because the Fed is injecting liquidity into the market.", "price_info": {}}, {"link": "https://www.wsj.com/articles/a-recent-college-graduate-starts-his-engineering-career-in-5g-11616440475", "title": "A Recent College Graduate Starts His Engineering Career in 5G", "date": "2021-03-22 15:14", "summary": "Ryan Juraidini, 23, wishes more people understood just how significant the technology is. When Ryan Juraidini tells people he's a 5G systems engineer at Nokia Corp. , he's usually met with a blank stare. \"They're like, 'I have zero idea what you just said.' \"", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Recent College Graduate Starts His Engineering Career in 5G. Ryan Juraidini, 23, wishes more people understood just how significant the technology is. When Ryan Juraidini tells people he's a 5G systems engineer at Nokia Corp. , he's usually met with a blank stare. \"They're like, 'I have zero idea what you just said.' \"\"\n\nStock Prediction(s):", "Prediction": "\n- Nokia Corporation (NYSE: NOK) will increase because they are a major player in the 5G market, and they are hiring engineers.\n- Qualcomm Incorporated (NASDAQ: QCOM) will increase because they are a major player in the 5G market, and they are hiring engineers.\n- Ericsson (NASDAQ: ERIC) will increase because they are a major player in the 5G market, and they are hiring engineers.\n- Huawei", "price_info": {"NOK": {"company": "", "ticker": "NOK", "move": "up", "prices": [4.05, 4.05]}, "QCOM": {"company": "", "ticker": "QCOM", "move": "up", "prices": [134.08, 134.06]}, "ERIC": {"company": "", "ticker": "ERIC", "move": "up", "prices": [13.35, 13.38]}}}, {"link": "https://www.wsj.com/articles/for-manufacturers-an-unprecedented-hit-11588353311", "title": "For Manufacturers, an Unprecedented Hit", "date": "2020-05-01 13:15", "summary": "A close reading of survey data suggests U.S. manufacturers are seeing their toughest times since at least the end of World War II. Manufacturers have seen hard times before. But not like this.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"For Manufacturers, an Unprecedented Hit. A close reading of survey data suggests U.S. manufacturers are seeing their toughest times since at least the end of World War II. Manufacturers have seen hard times before. But not like this.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DOW) will decrease because of the news about the tough times for manufacturers.\n- The S&P 500 (NYSE: SPX) will decrease because of the news about the tough times for manufacturers.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because of the news about the tough times for manufacturers.", "price_info": {"DOW": {"company": "", "ticker": "DOW", "move": "down", "prices": [34.0424, 33.93]}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/amazon-lobbies-for-its-workers-to-receive-covid-19-vaccine-11608146673", "title": "Amazon Lobbies for Its Workers to Receive Covid-19 Vaccine", "date": "2020-12-16 14:24", "summary": "In letter to CDC, e-commerce giant requested that its front-line employees get inoculated 'at earliest appropriate time'. Amazon.com Inc. has asked the Centers for Disease Control and Prevention to give priority to its workers as vaccinations for Covid-19 begin to roll out.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Amazon Lobbies for Its Workers to Receive Covid-19 Vaccine. In letter to CDC, e-commerce giant requested that its front-line employees get inoculated 'at earliest appropriate time'. Amazon.com Inc. has asked the Centers for Disease Control and Prevention to give priority to its workers as vaccinations for Covid-19 begin to roll out.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are lobbying for their workers to get the vaccine.\n- Other e-commerce companies will decrease because Amazon will have a competitive edge.", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3225, 3240.02]}}}, {"link": "https://www.wsj.com/articles/feds-mester-makes-plea-for-more-fiscal-aid-in-television-interview-11605801565", "title": "Two Fed Officials Voice Concern on Economy as Virus Cases Surge", "date": "2020-11-19 15:22", "summary": "Cleveland Fed leader says it isn't clear how much more support the Fed could give the economy. Two Federal Reserve officials at the heart of central bank decision making this year sent warnings Thursday about what lies ahead for the economy as coronavirus cases spiral higher.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Two Fed Officials Voice Concern on Economy as Virus Cases Surge. Cleveland Fed leader says it isn't clear how much more support the Fed could give the economy. Two Federal Reserve officials at the heart of central bank decision making this year sent warnings Thursday about what lies ahead for the economy as coronavirus cases spiral higher.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because the Fed is unsure about what to do next.\n- The market will go down because two Fed officials are concerned about the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/covid-19-law-firm-work-from-home-11628254526", "title": "Covid-19 Threatens to Blow Up Law Firms' Intense Office Culture", "date": "2021-08-06 14:42", "summary": "Lawyers have spent more time in the office than many other professionals during the pandemic. Now they're demanding more work from home.. Between 100-hour workweeks and all-nighters at the office, young lawyers climbing the partner track have long been expected to put in copious amounts of face time.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Threatens to Blow Up Law Firms' Intense Office Culture. Lawyers have spent more time in the office than many other professionals during the pandemic. Now they're demanding more work from home.. Between 100-hour workweeks and all-nighters at the office, young lawyers climbing the partner track have long been expected to put in copious amounts of face time.\"\n\nStock Prediction(s):", "Prediction": "\n- Law firms will increase because they are in high demand and have a lot of work to do.\n- Big law firms will increase more than small law firms because they have more resources.\n- Lawyers will increase because they are in high demand and have a lot of work to do.", "price_info": {}}, {"link": "https://www.wsj.com/articles/fintech-firm-greensky-explores-possible-sale-11565106584", "title": "GreenSky Is Latest Online Lender to Tumble", "date": "2019-08-06 15:31", "summary": "Shares plunge after online lender says it is exploring a potential sale or merger and after missing profit expectations. Investors are falling out of love with online lenders.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GreenSky Is Latest Online Lender to Tumble. Shares plunge after online lender says it is exploring a potential sale or merger and after missing profit expectations. Investors are falling out of love with online lenders.\"\n\nStock Prediction(s):", "Prediction": "\n- GreenSky, Inc. (NASDAQ: GSKY) will continue to tumble because they are exploring a potential sale or merger.\n- LendingClub Corporation (NYSE: LC) will increase because they are not exploring a potential sale or merger.", "price_info": {"LC": {"company": "", "ticker": "LC", "move": "up", "prices": [13.3, 14.62]}, "GSKY": {"company": "", "ticker": "GSKY", "move": null, "prices": [6.99, 6.98]}}}, {"link": "https://www.wsj.com/articles/facebooks-zuckerberg-proposes-raising-bar-for-section-230-11616610616", "title": "Facebook's Zuckerberg Proposes Raising Bar for Section 230", "date": "2021-03-24 14:30", "summary": "Congress should consider requiring internet platforms to earn liability immunity, CEO says ahead of Thursday hearing. WASHINGTON- Facebook chief executive Mark Zuckerberg said Congress should consider forcing digital platforms to earn the legal immunity they enjoy hosting third-party content, a legal change that could affect a range of online businesses.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook's Zuckerberg Proposes Raising Bar for Section 230. Congress should consider requiring internet platforms to earn liability immunity, CEO says ahead of Thursday hearing. WASHINGTON- Facebook chief executive Mark Zuckerberg said Congress should consider forcing digital platforms to earn the legal immunity they enjoy hosting third-party content, a legal change that could affect a range of online businesses.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will decrease because they may have to start being liable for the content on their site.\n- Google LLC (NASDAQ: GOOGL) will decrease because they may have to start being liable for the content on their site.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they may have to start being liable for the content on their site.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [283.168, 282.51]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [2048.129, 2030.77]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3114.4299, 3085.785]}}}, {"link": "https://www.wsj.com/articles/two-juul-executives-leave-company-in-pullback-overseas-11582648187", "title": "Two Juul Executives Leave Company in Pullback Overseas", "date": "2020-02-25 13:31", "summary": "E-cigarette maker has scaled back plans in several countries after criticism of its marketing, regulatory pressure. Two executives overseeing international regions for Juul Labs Inc. are departing the e-cigarette maker as it scales back its overseas operations, the company said.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Two Juul Executives Leave Company in Pullback Overseas. E-cigarette maker has scaled back plans in several countries after criticism of its marketing, regulatory pressure. Two executives overseeing international regions for Juul Labs Inc. are departing the e-cigarette maker as it scales back its overseas operations, the company said.\"\n\nStock Prediction(s):", "Prediction": "\n- Juul Labs Inc. (NASDAQ: JUUL) will decrease because they are pulling back their plans in several countries.\n- Altria Group, Inc. (NYSE: MO) will increase because they are still investing in Juul, and they are the parent company of Philip Morris USA, which makes Marlboro cigarettes.", "price_info": {"MO": {"company": "", "ticker": "MO", "move": "up", "prices": [42.8602, 42.7799]}, "JUUL": {"company": "", "ticker": "JUUL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/why-the-odds-of-a-recession-are-rising-11548435696", "title": "Why the Odds of a Recession Are Rising", "date": "2019-01-25 15:24", "summary": "Indicators show growing risk of recession in year ahead, after government shutdown likely sapped economy's strength. Even in the best of times, investors can't dismiss entirely the risk that the U.S. will slide into a recession within the next year. These aren't the best of times.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why the Odds of a Recession Are Rising. Indicators show growing risk of recession in year ahead, after government shutdown likely sapped economy's strength. Even in the best of times, investors can't dismiss entirely the risk that the U.S. will slide into a recession within the next year. These aren't the best of times.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because there is a higher risk of recession.\n- The market will go up because there is a higher risk of recession.", "price_info": {}}, {"link": "https://www.wsj.com/articles/copper-edges-higher-on-trade-hopes-11558706076", "title": "Copper Prices Rise on Trade Hopes", "date": "2019-05-24 15:16", "summary": "Prices are up after falling in four consecutive sessions through Wednesday. Copper prices edged higher Friday, climbing for the second consecutive session as analysts looked ahead to developments on U.S.-China trade policy.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Copper Prices Rise on Trade Hopes. Prices are up after falling in four consecutive sessions through Wednesday. Copper prices edged higher Friday, climbing for the second consecutive session as analysts looked ahead to developments on U.S.-China trade policy.\"\n\nStock Prediction(s):", "Prediction": "\n- Freeport-McMoRan Inc. (NYSE: FCX) will increase because copper prices are rising.\n- Southern Copper Corp. (NYSE: SCCO) will increase because copper prices are rising.\n- BHP Group Ltd. (NYSE: BHP) will increase because copper prices are rising.\n- Rio Tinto plc (NYSE: RIO) will increase because copper prices are rising.", "price_info": {"FCX": {"company": "", "ticker": "FCX", "move": "up"}, "SCCO": {"company": "", "ticker": "SCCO", "move": "up"}, "BHP": {"company": "", "ticker": "BHP", "move": "up"}, "RIO": {"company": "", "ticker": "RIO", "move": "up", "prices": [59.71, 59.425]}}}, {"link": "https://www.wsj.com/articles/mcdonalds-sets-conditions-for-restaurant-reopenings-11589466556", "title": "No Soda Fountains, More Cleaning: McDonald's Sets Conditions for Reopenings", "date": "2020-05-14 12:02", "summary": "To ease coronavirus concerns, fast-food chain suggests closing public soda fountains and issues cleaning instructions in 59-page guide. McDonald's Corp. is asking restaurant owners in the U.S. to make dozens of changes to ease coronavirus concerns before reopening their dining rooms, including commitments to clean bathrooms every half-hour and digital kiosks after each order.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"No Soda Fountains, More Cleaning: McDonald's Sets Conditions for Reopenings. To ease coronavirus concerns, fast-food chain suggests closing public soda fountains and issues cleaning instructions in 59-page guide. McDonald's Corp. is asking restaurant owners in the U.S. to make dozens of changes to ease coronavirus concerns before reopening their dining rooms, including commitments to clean bathrooms every half-hour and digital kiosks after each order.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corp. (NYSE: MCD) will increase because they are taking precautions to ensure that their restaurants are clean and safe for customers.\n- Yum! Brands, Inc. (NYSE: YUM) will decrease because they own Taco Bell, KFC, and Pizza Hut, and those restaurants are likely to have more contamination issues.", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "up", "prices": [173.456, 173.06]}, "YUM": {"company": "", "ticker": "YUM", "move": "down", "prices": [81.93, 81.69]}}}, {"link": "https://www.wsj.com/articles/the-job-market-stays-stalled-11612544101", "title": "The Job Market Stays Stalled", "date": "2021-02-05 11:55", "summary": "Declines in retail and restaurant employment last month show a labor market still tightly in Covid-19's grip. The job market still hasn't found its footing.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Job Market Stays Stalled. Declines in retail and restaurant employment last month show a labor market still tightly in Covid-19's grip. The job market still hasn't found its footing.\"\n\nStock Prediction(s):", "Prediction": "\n- The job market will not improve in the near future, so stocks such as Walmart Inc. (NYSE: WMT) and McDonald's Corporation (NYSE: MCD) will continue to decline.\n- Other stocks that may be affected are those in the technology sector, as people may be hesitant to spend money on new gadgets and devices.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": null, "prices": [143.24, 144.4499]}, "MCD": {"company": "", "ticker": "MCD", "move": null, "prices": [212.635, 213.1278]}}}, {"link": "https://www.wsj.com/articles/deutsche-bank-seeks-to-bolster-capital-cushion-11589204107", "title": "Deutsche Bank Seeks to Bolster Capital Structure", "date": "2020-05-11 09:58", "summary": "German lender is taking advantage of easier rules to sell unsecured debt and boost risk buffers. Deutsche Bank AG is taking advantage of the stabilization in European debt markets to sell new bonds and boost its capital buffers.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Deutsche Bank Seeks to Bolster Capital Structure. German lender is taking advantage of easier rules to sell unsecured debt and boost risk buffers. Deutsche Bank AG is taking advantage of the stabilization in European debt markets to sell new bonds and boost its capital buffers.\"\n\nStock Prediction(s):", "Prediction": "\n- Deutsche Bank AG (NYSE: DB) will increase because they are taking advantage of easier rules to sell unsecured debt and boost risk buffers.\n- Commerzbank AG (OTCMKTS: CRZBY) will increase because they are a direct competitor of Deutsche Bank.\n- BNP Paribas SA (OTCMKTS: BNPQY) will increase because they are a direct competitor of Deutsche Bank.", "price_info": {"DB": {"company": "", "ticker": "DB", "move": "up", "prices": [6.85, 6.935]}}}, {"link": "https://www.wsj.com/articles/weekly-jobless-claims-02-03-2022-11643837687", "title": "U.S. Jobless Claims Fall for Second Straight Week", "date": "2022-02-03 10:23", "summary": "Trend points to continued tight labor market-a positive sign ahead of Friday's January jobs report that could show sluggish payrolls gains. Initial filings for unemployment benefits fell for the second week in a row at the end of January, a sign the labor market is bouncing back from the temporary disruption caused by the Omicron variant of Covid-19.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Jobless Claims Fall for Second Straight Week. Trend points to continued tight labor market-a positive sign ahead of Friday's January jobs report that could show sluggish payrolls gains. Initial filings for unemployment benefits fell for the second week in a row at the end of January, a sign the labor market is bouncing back from the temporary disruption caused by the Omicron variant of Covid-19.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. jobless claims falling for the second week in a row is a positive sign for the economy, and will likely lead to an increase in stocks such as The Boeing Company (NYSE: BA), Amazon.com, Inc. (NASDAQ: AMZN), and Facebook, Inc. (NASDAQ: FB).\n- The U.S. jobless claims falling for the second week in a row is a positive sign for the economy,", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [205.36, 206.83]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [2840.41, 2812.0057]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [247.06, 242.89]}}}, {"link": "https://www.wsj.com/articles/amazons-labor-unrest-may-show-at-the-margins-11617544801", "title": "Amazon's Labor Unrest May Show at the Margins", "date": "2021-04-09 14:44", "summary": "Unionization would be a challenge given Amazon's distribution scale, but impact could be felt on margin expansion. Would unionization hamstring Amazon.com 's business? The answer isn't clear-cut.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Amazon's Labor Unrest May Show at the Margins. Unionization would be a challenge given Amazon's distribution scale, but impact could be felt on margin expansion. Would unionization hamstring Amazon.com 's business? The answer isn't clear-cut.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because of the labor unrest and the possibility of unionization.\n- Walmart Inc. (NYSE: WMT) will increase because they are not facing the same labor unrest, and they are a direct competitor of Amazon.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [139.67, 139.5]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3364.115, 3368.505]}}}, {"link": "https://www.wsj.com/articles/coronavirus-kills-several-fedex-workers-at-newark-facility-11588619994", "title": "Coronavirus Kills Several FedEx Workers at Newark Facility", "date": "2020-05-04 15:19", "summary": "Sen. Cory Booker asks delivery giant about safety protocols after outbreak at Newark Liberty airport. Several FedEx Corp. workers at the company's Newark, N.J., air hub have died due to complications of the coronavirus, a sign of the toll that the outbreak has taken on front-line delivery workers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Kills Several FedEx Workers at Newark Facility. Sen. Cory Booker asks delivery giant about safety protocols after outbreak at Newark Liberty airport. Several FedEx Corp. workers at the company's Newark, N.J., air hub have died due to complications of the coronavirus, a sign of the toll that the outbreak has taken on front-line delivery workers.\"\n\nStock Prediction(s):", "Prediction": "\n- FedEx Corporation (NYSE: FDX) will decrease because of the deaths of their workers at the Newark facility.\n- United Parcel Service, Inc. (NYSE: UPS) will decrease because of the deaths of their workers at the Newark facility.", "price_info": {"FDX": {"company": "", "ticker": "FDX", "move": "down", "prices": [115.85, 115.8]}, "UPS": {"company": "", "ticker": "UPS", "move": "down", "prices": [90.3, 90.44]}}}, {"link": "https://www.wsj.com/articles/feds-evans-fed-has-time-to-take-stock-before-next-rate-hike-11547043529", "title": "Fed's Evans: Fed Has Time to Take Stock Before Next Rate Hike", "date": "2019-01-09 11:15", "summary": "The Federal Reserve Bank of Chicago president said the first half of this year very important to determine the course of monetary policy. Federal Reserve Bank of Chicago President Charles Evans said Wednesday the central bank can take some time before it raises rates again amid an uncertain economic outlook.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans: Fed Has Time to Take Stock Before Next Rate Hike. The Federal Reserve Bank of Chicago president said the first half of this year very important to determine the course of monetary policy. Federal Reserve Bank of Chicago President Charles Evans said Wednesday the central bank can take some time before it raises rates again amid an uncertain economic outlook.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of Chicago (NASDAQ: FRB Chicago) will decrease because they are hinting that there may not be another rate hike this year.\n- The Federal Reserve Bank of New York (NYSE: FRBNY) will increase because they are hinting that there may be another rate hike this year.", "price_info": {"FRBNY": {"company": "", "ticker": "FRBNY", "move": "up"}}}, {"link": "https://www.wsj.com/articles/fed-s-george-it-s-appropriate-to-hold-rates-steady-for-now-11579026000", "title": "Fed's George: It's 'Appropriate' to Hold Rates Steady for Now", "date": "2020-01-14 13:20", "summary": "Kansas City leader has an upbeat view on the economy for 2020. Kansas City Fed leader Esther George said Tuesday that while she opposed all three of last year's rate cuts, she is OK with holding monetary policy steady for now.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's George: It's 'Appropriate' to Hold Rates Steady for Now. Kansas City leader has an upbeat view on the economy for 2020. Kansas City Fed leader Esther George said Tuesday that while she opposed all three of last year's rate cuts, she is OK with holding monetary policy steady for now.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FFR) will stay the course and not cut interest rates, which will be good for the economy.\n- The bond market (NYSEARCA: TLT) will decrease because interest rates will not be dropping, meaning that bond prices will be dropping.\n- The stock market (NYSEARCA: SPY) will stay steady because the Fed is not cutting rates, which is good news for the economy.", "price_info": {"FFR": {"company": "", "ticker": "FFR", "move": "down", "prices": [48.61, 48.39]}}}, {"link": "https://www.wsj.com/articles/3m-lowers-profit-outlook-for-2019-11548768638", "title": "3M Lowers Profit Outlook for 2019", "date": "2019-01-29 12:56", "summary": "The maker of Post-it Notes and industrial adhesives also expects higher costs to be offset by higher prices. 3M Co. lowered its profit outlook for this year, the latest manufacturer to flag slack demand in China for its products.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"3M Lowers Profit Outlook for 2019. The maker of Post-it Notes and industrial adhesives also expects higher costs to be offset by higher prices. 3M Co. lowered its profit outlook for this year, the latest manufacturer to flag slack demand in China for its products.\"\n\nStock Prediction(s):", "Prediction": "\n- 3M Co. (NYSE: MMM) will decrease because of their lowered profit outlook.\n- Stanley Black & Decker, Inc. (NYSE: SWK) will increase because they are not as reliant on the Chinese market.", "price_info": {"MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [197.8313, 196.981]}, "SWK": {"company": "", "ticker": "SWK", "move": "up", "prices": [123.26, 123.69]}}}, {"link": "https://www.wsj.com/articles/federal-reserve-to-increase-frequency-of-dollar-transactions-with-foreign-central-banks-11584712851", "title": "Fed Adjusts Money-Market Lending Facility to Include Municipal Debt", "date": "2020-03-20 13:37", "summary": "Fed also will provide daily swap line operations with five other central banks. The Federal Reserve on Friday expanded a lending operation that will accept municipal debt as collateral amid funding strains that could intensify as cities and states combat the coronavirus pandemic.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Adjusts Money-Market Lending Facility to Include Municipal Debt. Fed also will provide daily swap line operations with five other central banks. The Federal Reserve on Friday expanded a lending operation that will accept municipal debt as collateral amid funding strains that could intensify as cities and states combat the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FED) will increase because they are expanding their lending operation to include municipal debt.\n- The municipal bond market will increase because the Federal Reserve is accepting municipal debt as collateral.", "price_info": {"FED": {"company": "", "ticker": "FED", "move": "up"}}}, {"link": "https://www.wsj.com/articles/u-s-producer-prices-slipped-from-record-peak-in-december-11642097965", "title": "Producer-Price Increases Slowed From Record Pace in December", "date": "2022-01-13 14:06", "summary": "Prices that suppliers charged businesses and other customers last month rose 0.2% from November, lowest increase in 13 months. Prices that suppliers are charging businesses and other customers closed out 2021 near the highest level in over a decade, though December showed a slight cooling of producer inflation.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Producer-Price Increases Slowed From Record Pace in December. Prices that suppliers charged businesses and other customers last month rose 0.2% from November, lowest increase in 13 months. Prices that suppliers are charging businesses and other customers closed out 2021 near the highest level in over a decade, though December showed a slight cooling of producer inflation.\"\n\nStock Prediction(s):", "Prediction": "\n- The producer-price index will continue to slow down because businesses are not able to keep up with the high prices.\n- The producer-price index will stay the same because businesses are still able to keep up with the high prices.", "price_info": {}}, {"link": "https://www.wsj.com/articles/honda-plans-to-shut-down-north-american-plants-for-six-days-due-to-virus-concerns-demand-decline-11584537844", "title": "Honda Plans to Shut Down North American Plants for Six Days Due to Virus Concerns, Demand Decline", "date": "2020-03-18 10:41", "summary": "Honda says temporary closures will start Monday, and workers will be paid; cut production by 40,000 vehicles. Honda Motor Co. said Wednesday it will temporarily close about a dozen factories in the U.S., Canada and Mexico for six days to respond to concerns about the rapidly spreading virus and in anticipation of lower consumer demand.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Honda Plans to Shut Down North American Plants for Six Days Due to Virus Concerns, Demand Decline. Honda says temporary closures will start Monday, and workers will be paid; cut production by 40,000 vehicles. Honda Motor Co. said Wednesday it will temporarily close about a dozen factories in the U.S., Canada and Mexico for six days to respond to concerns about the rapidly spreading virus and in anticipation of lower consumer demand.\"\n\nStock Prediction(s):", "Prediction": "\n- Honda Motor Co. (NYSE: HMC) will decrease because they are shutting down their factories for six days.\n- Ford Motor Company (NYSE: F) will decrease because they are also shutting down their factories for six days.\n- General Motors Company (NYSE: GM) will decrease because they are also shutting down their factories for six days.", "price_info": {"HMC": {"company": "", "ticker": "HMC", "move": "down", "prices": [20.79, 20.59]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [4.345, 4.3272]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [15.63, 15.95]}}}, {"link": "https://www.wsj.com/articles/california-governor-questions-11-billion-pg-e-insurance-deal-11573480172", "title": "California Governor Questions $11 Billion PG&E Insurance Deal", "date": "2019-11-11 13:30", "summary": "Gavin Newsom blasted financial creditors for \"unacceptable\" investment tactics in PG&E's bankruptcy proceedings. California Gov. Gavin Newsom questioned PG&E Corp.'s $11 billion settlement proposal for insurance losses tied to wildfires and said it could derail the utility's bankruptcy exit strategy.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"California Governor Questions $11 Billion PG&E Insurance Deal. Gavin Newsom blasted financial creditors for \"unacceptable\" investment tactics in PG&E's bankruptcy proceedings. California Gov. Gavin Newsom questioned PG&E Corp.'s $11 billion settlement proposal for insurance losses tied to wildfires and said it could derail the utility's bankruptcy exit strategy.\"\n\nStock Prediction(s):", "Prediction": "\n- PG&E Corp. (NYSE: PCG) will decrease because their insurance settlement is being questioned.\n- Edison International (NYSE: EIX) will increase because they are not involved in the PG&E insurance settlement.\n- Sempra Energy (NYSE: SRE) will increase because they are not involved in the PG&E insurance settlement.", "price_info": {"PCG": {"company": "", "ticker": "PCG", "move": "down", "prices": [6.01, 6.08]}, "EIX": {"company": "", "ticker": "EIX", "move": "up", "prices": [66.055, 66.36]}, "SRE": {"company": "", "ticker": "SRE", "move": "up", "prices": [142.0851, 142.19]}}}, {"link": "https://www.wsj.com/articles/zoom-outage-prevents-users-from-joining-video-meetings-11598280287", "title": "Zoom Restored After Outage Brings Down Virtual Meetings, Classrooms", "date": "2020-08-24 14:56", "summary": "The videoconferencing company said it has identified and resolved the issue that prevented users from joining meetings or remote classes. Users of videoconferencing app Zoom reported problems with the service Monday morning, just as many students in the U.S. returned to school for virtual classes dependent on the technology.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Zoom Restored After Outage Brings Down Virtual Meetings, Classrooms. The videoconferencing company said it has identified and resolved the issue that prevented users from joining meetings or remote classes. Users of videoconferencing app Zoom reported problems with the service Monday morning, just as many students in the U.S. returned to school for virtual classes dependent on the technology.\"\n\nStock Prediction(s):", "Prediction": "\n- Zoom Video Communications, Inc. (NASDAQ: ZM) will increase because their service was down for a brief period of time, but it has been resolved and they are back up and running.\n- Cisco Systems, Inc. (NASDAQ: CSCO) will decrease because they are a direct competitor of Zoom Video Communications.", "price_info": {"ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [281.9473, 282.41]}, "CSCO": {"company": "", "ticker": "CSCO", "move": "down", "prices": [42.12, 42.13]}}}, {"link": "https://www.wsj.com/articles/more-universities-shut-down-traditional-m-b-a-programs-as-popularity-wanes-11559727000", "title": "More Universities Find Full-Time M.B.A. Programs Aren't Worth It", "date": "2019-06-05 14:30", "summary": "Applications to full-time M.B.A. programs have been falling in the strong job market, leading business schools to shift resources online. The 42 University of Iowa graduates who got their master's in business administration degrees in May marked the end of an era for 160-year-old Tippie College of Business: They were its last class of full-time M.B.A.s.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"More Universities Find Full-Time M.B.A. Programs Aren't Worth It. Applications to full-time M.B.A. programs have been falling in the strong job market, leading business schools to shift resources online. The 42 University of Iowa graduates who got their master's in business administration degrees in May marked the end of an era for 160-year-old Tippie College of Business: They were its last class of full-time M.B.A.s.\"\n\nStock Prediction(s):", "Prediction": "\n- University of Iowa (NYSE: IOWA) will decrease because their full-time M.B.A. program is no longer worth it.\n- Harvard University (NYSE: HARV) will increase because their full-time M.B.A. program is still worth it.\n- Stanford University (NYSE: STAN) will increase because their full-time M.B.A. program is still worth it.", "price_info": {"IOWA": {"company": "", "ticker": "IOWA", "move": "down"}, "HARV": {"company": "", "ticker": "HARV", "move": "up"}, "STAN": {"company": "", "ticker": "STAN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/december-jobs-report-unemployment-rate-2021-11641513402", "title": "Hiring Hit Annual Record Despite December Slowdown", "date": "2022-01-07 14:43", "summary": "U.S added just 199,000 jobs in December, but total increase of 6.4 million in 2021 and tight labor market signal steady gains ahead. U.S. hiring moderated in December to close out a record year for job gains ahead of disruptions from the Omicron variant, with declining unemployment and robust wage growth suggesting the economy will grow solidly this year.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hiring Hit Annual Record Despite December Slowdown. U.S added just 199,000 jobs in December, but total increase of 6.4 million in 2021 and tight labor market signal steady gains ahead. U.S. hiring moderated in December to close out a record year for job gains ahead of disruptions from the Omicron variant, with declining unemployment and robust wage growth suggesting the economy will grow solidly this year.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will continue to decline, signaling that the economy is doing well.\n- The stock market will continue to rise as the economy grows.", "price_info": {}}, {"link": "https://www.wsj.com/articles/cfpb-chief-kathy-kraninger-sees-role-for-companies-in-preventing-consumer-harm-11551988530", "title": "Consumer-Finance Watchdog: Firms Have Role in Policing Themselves", "date": "2019-03-07 14:55", "summary": "Democrats press new CFPB director on the bureau's direction under Trump-appointed leaders. WASHINGTON-The Trump administration's new consumer-finance chief said she wants to work with businesses to prevent harm to consumers, pledging a collaborative approach to policing financial companies.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer-Finance Watchdog: Firms Have Role in Policing Themselves. Democrats press new CFPB director on the bureau's direction under Trump-appointed leaders. WASHINGTON-The Trump administration's new consumer-finance chief said she wants to work with businesses to prevent harm to consumers, pledging a collaborative approach to policing financial companies.\"\n\nStock Prediction(s):", "Prediction": "\n- The stocks of consumer-finance companies will increase because the CFPB is no longer going to be as aggressive in their regulation.\n- The stocks of credit-rating agencies will decrease because the CFPB is no longer going to be as aggressive in their regulation.", "price_info": {}}, {"link": "https://www.wsj.com/articles/fbi-director-hires-new-top-lawyer-from-old-law-firm-11595011758", "title": "FBI Director Hires New Top Lawyer From Old Law Firm", "date": "2020-07-17 14:49", "summary": "Agency's prior general counsel departed amid GOP criticism for role in Russia probe. FBI Director Christopher Wray has tapped a former law partner to be the bureau's next top lawyer as he tries to steady the agency after a series of controversies.", "categories": [["WSJ News Exclusive", "U.S."]], "category_links": ["https://www.wsj.com/news/us?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FBI Director Hires New Top Lawyer From Old Law Firm. Agency's prior general counsel departed amid GOP criticism for role in Russia probe. FBI Director Christopher Wray has tapped a former law partner to be the bureau's next top lawyer as he tries to steady the agency after a series of controversies.\"\n\nStock Prediction(s):", "Prediction": "\n- FBI Director Christopher Wray will be re-elected because he is trying to steady the agency after a series of controversies.\n- The FBI Director Christopher Wray will be successful in his re-election bid.", "price_info": {}}, {"link": "https://www.wsj.com/articles/flower-delivery-firm-ftd-says-it-could-go-out-of-business-by-summer-11552934843", "title": "Flower Delivery Firm FTD Says It Could Go Out of Business by Summer", "date": "2019-03-18 14:47", "summary": "Chicago-based company says it needs to find a buyer or pay down its $217.7 million in debt by June 1. Flower-delivery provider FTD Cos. on Monday warned that it could go out of business by this summer if it doesn't raise enough money to meet its debt obligations.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Flower Delivery Firm FTD Says It Could Go Out of Business by Summer. Chicago-based company says it needs to find a buyer or pay down its $217.7 million in debt by June 1. Flower-delivery provider FTD Cos. on Monday warned that it could go out of business by this summer if it doesn't raise enough money to meet its debt obligations.\"\n\nStock Prediction(s):", "Prediction": "\n- FTD Companies, Inc. (NASDAQ: FTD) will decrease because they may go out of business if they can't find a buyer.", "price_info": {"FTD": {"company": "", "ticker": "FTD", "move": "down"}}}, {"link": "https://www.wsj.com/articles/this-laser-war-has-gotten-expensive-11613490652", "title": "This Laser War Has Gotten Expensive", "date": "2021-02-16 10:50", "summary": "Competing acquisition offers for Coherent have pushed laser maker's valuation to decade high. Whoever ends up buying Coherent may have some explaining to do.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"This Laser War Has Gotten Expensive. Competing acquisition offers for Coherent have pushed laser maker's valuation to decade high. Whoever ends up buying Coherent may have some explaining to do.\"\n\nStock Prediction(s):", "Prediction": "\n- Coherent, Inc. (NASDAQ: COHR) will increase because they have been receiving multiple acquisition offers, and the most recent one pushed their stock valuation to a decade high.\n- Trumpf Inc. (NASDAQ: TRUMF) will decrease because they are a direct competitor of Coherent, and they may not be able to afford to outbid the other offers that have been made.\n- IPG Photonics Corporation (NASDAQ: IP", "price_info": {"COHR": {"company": "", "ticker": "COHR", "move": "up", "prices": [260.418, 259.55]}, "TRUMF": {"company": "", "ticker": "TRUMF", "move": "down"}}}, {"link": "https://www.wsj.com/articles/hoarding-is-an-upper-class-pastime-11588007355", "title": "Hoarding Is an Upper-Class Pastime", "date": "2020-04-27 13:09", "summary": "People with more money are also more likely to stockpile goods when they read scary headlines. Americans have come to intimately understand hoarding over the past month as toilet paper and other items have disappeared from store shelves, but it isn't the first time in recent history the phenomenon has appeared in the U.S.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hoarding Is an Upper-Class Pastime. People with more money are also more likely to stockpile goods when they read scary headlines. Americans have come to intimately understand hoarding over the past month as toilet paper and other items have disappeared from store shelves, but it isn't the first time in recent history the phenomenon has appeared in the U.S.\"\n\nStock Prediction(s):", "Prediction": "\n- Costco Wholesale Corporation (NASDAQ: COST) will increase because they are not affected by the hoarding, and people will want to buy their products to avoid the issue.\n- Walmart Inc. (NYSE: WMT) will decrease because they are affected by the hoarding, and their sales will be down.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [128.495, 128.3794]}, "COST": {"company": "", "ticker": "COST", "move": "up", "prices": [308.18, 309.3034]}}}, {"link": "https://www.wsj.com/articles/why-the-hybrid-workplace-is-a-cybersecurity-nightmare-11623164400", "title": "Why the Hybrid Workplace Is a Cybersecurity Nightmare", "date": "2021-06-08 11:00", "summary": "It's a hacker's dream: a constantly changing mix of office and remote workers, devices that move in and out of the company networks, and security staffs stretched thin. For many bosses and employees, there is a measure of relief in returning to the office-especially for those who have the flexibility of continuing to work from home part of the time. But for those teams working to protect their offices from hackers, the new hybrid workplaces aren't nearly as welcome.", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why the Hybrid Workplace Is a Cybersecurity Nightmare. It's a hacker's dream: a constantly changing mix of office and remote workers, devices that move in and out of the company networks, and security staffs stretched thin. For many bosses and employees, there is a measure of relief in returning to the office-especially for those who have the flexibility of continuing to work from home part of the time. But for those teams working to protect their offices from hackers, the new hybrid workplaces aren't nearly as welcome.\"\n\nStock Prediction(s):", "Prediction": "\n- Symantec Corporation (NASDAQ: SYMC) will increase because their products are necessary for companies to protect themselves from cyberattacks in a hybrid workplace.\n- Palo Alto Networks, Inc. (NYSE: PANW) will increase because their products are necessary for companies to protect themselves from cyberattacks in a hybrid workplace.\n- Check Point Software Technologies Ltd. (NASDAQ: CHKP) will increase because their products are necessary for companies to protect themselves from", "price_info": {"PANW": {"company": "", "ticker": "PANW", "move": "up", "prices": [353.4907, 353.9]}, "SYMC": {"company": "", "ticker": "SYMC", "move": "up"}, "CHKP": {"company": "", "ticker": "CHKP", "move": "up", "prices": [118.7, 118.66]}}}, {"link": "https://www.wsj.com/articles/ge-digital-to-play-scaled-back-role-in-split-11636509584", "title": "GE Digital to Play Scaled Back Role in Split", "date": "2021-11-10 15:30", "summary": "The tech venture was once at the forefront of GE's strategy, but it now will be tucked into a combined power and energy business as the conglomerate separates into three companies. General Electric Co. 's plan to break itself into three separate companies reserves a scaled back role for GE Digital, a technology venture that was once at the forefront of the company's strategy to reinvent itself as a software powerhouse, industry analysts say.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GE Digital to Play Scaled Back Role in Split. The tech venture was once at the forefront of GE's strategy, but it now will be tucked into a combined power and energy business as the conglomerate separates into three companies. General Electric Co. 's plan to break itself into three separate companies reserves a scaled back role for GE Digital, a technology venture that was once at the forefront of the company's strategy to reinvent itself as a software powerhouse, industry analysts say.\"\n\nStock Prediction(s):", "Prediction": "\n- GE (NYSE: GE) will decrease because their digital venture is being scaled back and tucked into a power and energy business.\n- Honeywell International Inc. (NYSE: HON) will increase because they are not part of GE Digital and will continue to grow as a standalone company.\n- IBM (NYSE: IBM) will increase because they are not part of GE Digital and will continue to grow as a standalone company.", "price_info": {"GE": {"company": "", "ticker": "GE", "move": "up", "prices": [108.8854, 108.82]}, "HON": {"company": "", "ticker": "HON", "move": "up", "prices": [225.49, 225.41]}, "IBM": {"company": "", "ticker": "IBM", "move": "up", "prices": [120.2525, 120.23]}}}, {"link": "https://www.wsj.com/articles/u-s-regulators-raise-concern-with-stablecoin-digital-currency-11639760446", "title": "U.S. Regulators Raise Concern With Stablecoin Digital Currency", "date": "2021-12-17 13:49", "summary": "Financial Stability Oversight Council is prepared to regulate space, but prefers Congressional action. Top U.S. financial regulators said they are prepared to take action to address risks to the financial system posed by stablecoins, but first are pushing Congress to enact comprehensive legislation providing oversight of the form of digital currency.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Regulators Raise Concern With Stablecoin Digital Currency. Financial Stability Oversight Council is prepared to regulate space, but prefers Congressional action. Top U.S. financial regulators said they are prepared to take action to address risks to the financial system posed by stablecoins, but first are pushing Congress to enact comprehensive legislation providing oversight of the form of digital currency.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are working on a stablecoin and this news signals that regulators are getting more involved in the space.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are also working on a stablecoin.\n- Goldman Sachs Group, Inc. (NYSE: GS) will decrease because they are also working on a stablecoin.", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [156.65, 156.9227]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [383.44, 384.382]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [335.17, 334.53]}}}, {"link": "https://www.wsj.com/articles/blue-apron-has-too-few-cooks-in-the-kitchen-11588180753", "title": "Blue Apron Has Too Few Cooks in the Kitchen", "date": "2020-04-29 13:19", "summary": "Meal-kit provider Blue Apron is cooking up safe-at-home specialties, but the tables have already emptied. Wall Street will turn up its nose at the most delicious meal if the portions are too small.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Blue Apron Has Too Few Cooks in the Kitchen. Meal-kit provider Blue Apron is cooking up safe-at-home specialties, but the tables have already emptied. Wall Street will turn up its nose at the most delicious meal if the portions are too small.\"\n\nStock Prediction(s):", "Prediction": "\n- Blue Apron Holdings Inc (NYSE: APRN) will decrease because they are not able to produce enough food for everyone.", "price_info": {"APRN": {"company": "", "ticker": "APRN", "move": "down", "prices": [9.425, 9.4872]}}}, {"link": "https://www.wsj.com/articles/weekly-jobless-claims-coronavirus-11-19-2020-11605753615", "title": "Jobless Claims Rise as Recovery Slows", "date": "2020-11-19 10:34", "summary": "Initial claims for unemployment benefits increased to 742,000 last week as pandemic weighs on labor market. The number of applications for unemployment benefits rose sharply last week, indicating continued challenges for the U.S. economic recovery as coronavirus infections increased around the country.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jobless Claims Rise as Recovery Slows. Initial claims for unemployment benefits increased to 742,000 last week as pandemic weighs on labor market. The number of applications for unemployment benefits rose sharply last week, indicating continued challenges for the U.S. economic recovery as coronavirus infections increased around the country.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will continue to rise, so unemployment-related stocks such as Monster Beverage Corporation (NASDAQ: MNST) and Ford Motor Company (NYSE: F) will decrease.\n- The market will rebound as the number of jobless claims decreases, so stocks such as Apple Inc. (NASDAQ: AAPL) and Amazon.com, Inc. (NASDAQ: AMZN) will increase.", "price_info": {"F": {"company": "", "ticker": "F", "move": null, "prices": [8.79, 8.805]}, "MNST": {"company": "", "ticker": "MNST", "move": null, "prices": [83.8, 83.67]}, "AAPL": {"company": "", "ticker": "AAPL", "move": null, "prices": [117.97, 118.245]}, "AMZN": {"company": "", "ticker": "AMZN", "move": null, "prices": [3108.41, 3116.59]}}}, {"link": "https://www.wsj.com/articles/u-s-government-bond-yields-climb-after-jobs-data-11599224733", "title": "Treasury Yields Climb After Jobs Data", "date": "2020-09-04 15:46", "summary": "Unemployment rate falls to 8.4%, dropping below double-digits for the first time since March. U.S. government bond yields rose after data showed the economy added more jobs than expected last month, driving down the unemployment rate.", "categories": [["Markets", "Treasurys"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/treasurys?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury Yields Climb After Jobs Data. Unemployment rate falls to 8.4%, dropping below double-digits for the first time since March. U.S. government bond yields rose after data showed the economy added more jobs than expected last month, driving down the unemployment rate.\"\n\nStock Prediction(s):", "Prediction": "\n- The yield on the 10-year Treasury note will continue to climb because the economy is doing well and the unemployment rate is dropping.\n- The yield on the 2-year Treasury note will continue to climb because the economy is doing well and the unemployment rate is dropping.", "price_info": {}}, {"link": "https://www.wsj.com/articles/house-subcommittee-hits-baby-food-makers-over-high-metal-content-11633118194", "title": "House Panel Hits Baby-Food Makers Over High Metal Content", "date": "2021-10-01 15:56", "summary": "Report by Democratic members calls out companies over arsenic levels, recalls and product-testing requirements. Some top baby-food makers didn't appropriately recall products that contained higher arsenic levels than allowed by the government, according to a recent congressional report.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"House Panel Hits Baby-Food Makers Over High Metal Content. Report by Democratic members calls out companies over arsenic levels, recalls and product-testing requirements. Some top baby-food makers didn't appropriately recall products that contained higher arsenic levels than allowed by the government, according to a recent congressional report.\"\n\nStock Prediction(s):", "Prediction": "\n- Gerber Products Company (NYSE: GIS) will decrease because they are one of the baby-food makers mentioned in the report.\n- Mead Johnson Nutrition Company (NYSE: MJN) will decrease because they are one of the baby-food makers mentioned in the report.\n- The Kraft Heinz Company (NASDAQ: KHC) will decrease because they are one of the baby-food makers mentioned in the report.", "price_info": {"GIS": {"company": "", "ticker": "GIS", "move": "down", "prices": [60.62, 60.62]}, "MJN": {"company": "", "ticker": "MJN", "move": "down"}, "KHC": {"company": "", "ticker": "KHC", "move": "down", "prices": [36.97, 36.83]}}}, {"link": "https://www.wsj.com/articles/fund-to-let-retail-investors-bet-on-early-tech-startups-11634216400", "title": "Fund to Let Retail Investors Bet on Early Tech Startups", "date": "2021-10-14 09:45", "summary": "Regulators typically limit the purchase of private shares to individual investors with a net worth of more than $1 million or annual income above $200,000. The founders of Forge Global Inc., an online marketplace for buying and selling shares of private firms, are launching a new money manager that invests in technology startups before they go public.", "categories": [["WSJ News Exclusive", "ETFs"]], "category_links": ["https://www.wsj.com/news/types/etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fund to Let Retail Investors Bet on Early Tech Startups. Regulators typically limit the purchase of private shares to individual investors with a net worth of more than $1 million or annual income above $200,000. The founders of Forge Global Inc., an online marketplace for buying and selling shares of private firms, are launching a new money manager that invests in technology startups before they go public.\"\n\nStock Prediction(s):", "Prediction": "\n- Forge Global Inc. (private) will increase because they offer a new way for retail investors to get into tech startups.\n- Facebook Inc (NASDAQ: FB) will increase because they are a major investor in Forge Global Inc.\n- Apple Inc. (NASDAQ: AAPL) will increase because they are a major investor in Forge Global Inc.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "up", "prices": [328.835, 328.82]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [142.945, 143.43]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3305.97, 3308.3]}}}, {"link": "https://www.wsj.com/articles/u-s-trade-gap-narrowed-sharply-in-january-11553690145", "title": "U.S. Trade Gap Narrowed Sharply in January", "date": "2019-03-27 12:41", "summary": "Deficit in goods with China shrinks 14%, explaining much of the reduction in overall gap. The U.S. trade deficit narrowed sharply in January, reflecting a slowing domestic economy and volatile trade dynamics with China amid the Trump administration's tariff negotiations.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Trade Gap Narrowed Sharply in January. Deficit in goods with China shrinks 14%, explaining much of the reduction in overall gap. The U.S. trade deficit narrowed sharply in January, reflecting a slowing domestic economy and volatile trade dynamics with China amid the Trump administration's tariff negotiations.\"\n\nStock Prediction(s):", "Prediction": "\n- The trade deficit will continue to narrow because the U.S. economy is slowing and the trade dynamics with China are unstable.\n- The trade deficit will widen because the U.S. economy is slowing and the trade dynamics with China are unstable.", "price_info": {}}, {"link": "https://www.wsj.com/articles/grubhub-has-some-finicky-investors-11564505375", "title": "Grubhub Has Some Finicky Investors", "date": "2019-07-30 12:49", "summary": "Grubhub continues to grow diners and restaurants in a crowded market, but investors' confidence in the business is slipping. Grubhub ate its meat but still doesn't get any pudding.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Grubhub Has Some Finicky Investors. Grubhub continues to grow diners and restaurants in a crowded market, but investors' confidence in the business is slipping. Grubhub ate its meat but still doesn't get any pudding.\"\n\nStock Prediction(s):", "Prediction": "\n- Grubhub Inc (NYSE: GRUB) will continue to slip because investors are losing confidence in the company.\n- Yelp Inc (NYSE: YELP) will increase because investors are looking for a competitor to Grubhub.", "price_info": {"GRUB": {"company": "", "ticker": "GRUB", "move": null, "prices": [72.8, 71.09]}, "YELP": {"company": "", "ticker": "YELP", "move": "up", "prices": [35.52, 35.48]}}}, {"link": "https://www.wsj.com/articles/mercks-spin-may-induce-motion-sickness-11580922994", "title": "Merck's Spin May Induce Motion Sickness", "date": "2020-02-05 12:16", "summary": "Spinning off older products will enhance Merck's growth profile but will also make the shares riskier. In the pharmaceuticals business, it is possible to give investors too much of a good thing.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Merck's Spin May Induce Motion Sickness. Spinning off older products will enhance Merck's growth profile but will also make the shares riskier. In the pharmaceuticals business, it is possible to give investors too much of a good thing.\"\n\nStock Prediction(s):", "Prediction": "\n- Merck & Co., Inc. (NYSE: MRK) will decrease because they are spinning off their older products, making the company riskier.", "price_info": {"MRK": {"company": "", "ticker": "MRK", "move": "down", "prices": [85.71, 85.8321]}}}, {"link": "https://www.wsj.com/articles/you-got-richer-during-the-pandemic-early-retirement-is-still-risky-11644575419", "title": "You Got Richer During the Pandemic. Early Retirement Is Still Risky.", "date": "2022-02-11 13:29", "summary": "Red-hot stocks and real estate convinced many people to start their golden years sooner. 'People forget that markets go down.'. If you own stocks or real estate, you're probably richer than you were when the pandemic began. That could put early retirement within reach. Taking such a step is still risky.", "categories": [["Markets", "Personal Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/personal-finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"You Got Richer During the Pandemic. Early Retirement Is Still Risky.. Red-hot stocks and real estate convinced many people to start their golden years sooner. 'People forget that markets go down.'. If you own stocks or real estate, you're probably richer than you were when the pandemic began. That could put early retirement within reach. Taking such a step is still risky.\"\n\nStock Prediction(s):", "Prediction": "\n- People who cashed out during the pandemic will regret their decision and will want to buy back in at a lower price.\n- People who are still in the market will see a decrease in their stock prices as the market corrects itself.", "price_info": {}}, {"link": "https://www.wsj.com/articles/natural-gas-prices-fall-on-milder-weather-11574101989", "title": "Natural-Gas Prices Fall on Milder Weather", "date": "2019-11-18 14:58", "summary": "Prices have also been under pressure from strong supply. The price of natural gas fell Monday, weighed down by expectations for milder weather in parts of the U.S.", "categories": [["Markets", "Commodities", "Gas Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/gas-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Natural-Gas Prices Fall on Milder Weather. Prices have also been under pressure from strong supply. The price of natural gas fell Monday, weighed down by expectations for milder weather in parts of the U.S.\"\n\nStock Prediction(s):", "Prediction": "\n- Chesapeake Energy Corporation (NYSE: CHK) will increase because natural gas prices have been falling, and they are a major producer of natural gas.\n- Devon Energy Corporation (NYSE: DVN) will increase because natural gas prices have been falling, and they are a major producer of natural gas.\n- EQT Corporation (NYSE: EQT) will increase because natural gas prices have been falling, and they are a major producer of natural gas.\n-", "price_info": {"CHK": {"company": "", "ticker": "CHK", "move": "up", "prices": [0.64105, 0.6485]}, "DVN": {"company": "", "ticker": "DVN", "move": "up", "prices": [21.88, 22.55]}, "EQT": {"company": "", "ticker": "EQT", "move": "up", "prices": [9.6492, 9.66]}}}, {"link": "https://www.wsj.com/articles/earnings-forecasts-are-too-dire-but-still-proceed-with-caution-11594230381", "title": "Earnings Forecasts Are Too Dire, but Still Proceed With Caution", "date": "2020-07-08 13:46", "summary": "Analysts' expectations for S&P 500 earnings seem far too pessimistic since they haven't adjusted for a partial economic rebound, but stocks might have priced that in already. The second quarter probably wasn't as horrible for U.S. companies as estimates suggest. That hardly counts as an all-clear signal as the Covid-19 crisis reasserts itself.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Earnings Forecasts Are Too Dire, but Still Proceed With Caution. Analysts' expectations for S&P 500 earnings seem far too pessimistic since they haven't adjusted for a partial economic rebound, but stocks might have priced that in already. The second quarter probably wasn't as horrible for U.S. companies as estimates suggest. That hardly counts as an all-clear signal as the Covid-19 crisis reasserts itself.\"\n\nStock Prediction(s):", "Prediction": "\n- The market has already priced in a potential rebound, so most stocks will stay the same or increase slightly.\n- There may be a slight uptick in certain stocks that are associated with the rebound, such as technology stocks or cyclical stocks.\n- Defensive stocks, such as utilities and consumer staples, may decrease slightly because they are not associated with a rebound.", "price_info": {}}, {"link": "https://www.wsj.com/articles/pharma-giants-get-their-pennies-pinched-on-drug-pricing-11615545006", "title": "Pharma Giants Get Their Pennies Pinched on Drug Pricing", "date": "2021-03-12 10:01", "summary": "The vaunted ability of pharmaceutical companies to name their own price is vanishing as middlemen increasingly call the shots. The pharmaceutical industry's reputation as an omnipotent market force is increasingly out of date. Washington, D.C., hasn't yet caught on, but Mr. Market is in on the secret.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pharma Giants Get Their Pennies Pinched on Drug Pricing. The vaunted ability of pharmaceutical companies to name their own price is vanishing as middlemen increasingly call the shots. The pharmaceutical industry's reputation as an omnipotent market force is increasingly out of date. Washington, D.C., hasn't yet caught on, but Mr. Market is in on the secret.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will decrease because their pricing power is diminishing.\n- Johnson & Johnson (NYSE: JNJ) will decrease because their pricing power is diminishing.\n- Merck & Co., Inc. (NYSE: MRK) will decrease because their pricing power is diminishing.\n- Bristol-Myers Squibb Company (NYSE: BMY) will decrease because their pricing power is diminishing.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [34.73, 34.9574]}, "JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [159.89, 159.98]}, "MRK": {"company": "", "ticker": "MRK", "move": "down", "prices": [74.56, 74.82]}, "BMY": {"company": "", "ticker": "BMY", "move": "down", "prices": [60.83, 60.49]}}}, {"link": "https://www.wsj.com/articles/facebook-backs-underwater-cable-projects-to-boost-internet-connectivity-11629127381", "title": "Facebook Backs Underwater Cable Projects to Boost Internet Connectivity", "date": "2021-08-16 11:23", "summary": "Social media firm to join forces with Google in Asia project, while expanding similar initiative in Africa. Facebook Inc. said it would back two new underwater cable projects-one in Africa and another in Asia in collaboration with Alphabet Inc.'s Google-that aim to give the Silicon Valley giants greater control of the global internet infrastructure that their businesses rely on.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Backs Underwater Cable Projects to Boost Internet Connectivity. Social media firm to join forces with Google in Asia project, while expanding similar initiative in Africa. Facebook Inc. said it would back two new underwater cable projects-one in Africa and another in Asia in collaboration with Alphabet Inc.'s Google-that aim to give the Silicon Valley giants greater control of the global internet infrastructure that their businesses rely on.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc. (NASDAQ: FB) will increase because they are expanding their internet infrastructure.\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because they are collaborating with Facebook on the project.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are expanding their internet infrastructure.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "up", "prices": [361.37, 364.08]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2730.45, 2747.59]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [292.47, 293.5991]}}}, {"link": "https://www.wsj.com/articles/did-you-mean-to-be-green-or-to-buy-that-kuwait-fund-11599228509", "title": "Did You Mean to Be Green or to Buy That Kuwait Fund?", "date": "2020-09-04 10:08", "summary": "A new ETF for investing in the petrostate snagged the ticker of a defunct green energy fund. Stock-market listings might look like alphabet soup, but companies, and especially exchange-traded funds, put a good deal of thought into what letters a buyer types into their brokerage's screen when purchasing it. Ideally, it should be memorable and descriptive.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Did You Mean to Be Green or to Buy That Kuwait Fund?. A new ETF for investing in the petrostate snagged the ticker of a defunct green energy fund. Stock-market listings might look like alphabet soup, but companies, and especially exchange-traded funds, put a good deal of thought into what letters a buyer types into their brokerage's screen when purchasing it. Ideally, it should be memorable and descriptive.\"\n\nStock Prediction(s):", "Prediction": "\n- The Kuwait Fund (NYSE: KW) will increase because there is now a new ETF for investing in the petrostate, and it has the ticker of the defunct green energy fund.\n- SunPower Corporation (NASDAQ: SPWR) will decrease because there is now a new ETF for investing in the petrostate, and it has the ticker of the defunct green energy fund.", "price_info": {"KW": {"company": "", "ticker": "KW", "move": "up", "prices": [14.63, 14.61]}, "SPWR": {"company": "", "ticker": "SPWR", "move": "down", "prices": [10.295, 10.85]}}}, {"link": "https://www.wsj.com/articles/pepsicos-sales-rise-as-brands-resonate-with-consumers-11562669049", "title": "PepsiCo Rides New Flavors and More Ads", "date": "2019-07-09 10:30", "summary": "Quarterly revenue rises in both its snacks and drinks business. PepsiCo Inc. posted higher quarterly profit and sales as the food-and-beverage giant rolled out new products such as Pepsi Mango and ramped up marketing for some of its more established brands.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"PepsiCo Rides New Flavors and More Ads. Quarterly revenue rises in both its snacks and drinks business. PepsiCo Inc. posted higher quarterly profit and sales as the food-and-beverage giant rolled out new products such as Pepsi Mango and ramped up marketing for some of its more established brands.\"\n\nStock Prediction(s):", "Prediction": "\n- PepsiCo, Inc. (NYSE: PEP) will continue to increase because they are releasing new flavors and increasing their marketing efforts.\n- Coca-Cola Company (NYSE: KO) will decrease because they are not releasing any new flavors, and their marketing efforts are not as strong as PepsiCo's.", "price_info": {"PEP": {"company": "", "ticker": "PEP", "move": "up", "prices": [131.34, 131.075]}, "KO": {"company": "", "ticker": "KO", "move": "down", "prices": [51.7, 51.62]}}}, {"link": "https://www.wsj.com/articles/u-s-government-recommends-time-served-for-flash-crash-trader-11579103906", "title": "U.S. Government Recommends Time Served for 'Flash Crash' Trader", "date": "2020-01-15 10:58", "summary": "British trader Navinder Singh Sarao was charged with market manipulation connected to stock-market selloff in May 2010. The U.S. government said Navinder Singh Sarao, the British trader accused of contributing to the 2010 stock-market \"flash crash,\" shouldn't serve any more time in jail.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Government Recommends Time Served for 'Flash Crash' Trader. British trader Navinder Singh Sarao was charged with market manipulation connected to stock-market selloff in May 2010. The U.S. government said Navinder Singh Sarao, the British trader accused of contributing to the 2010 stock-market \"flash crash,\" shouldn't serve any more time in jail.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will not react to this news because it is not significant enough.\n- The market will not react to this news because it is not significant enough.", "price_info": {}}, {"link": "https://www.wsj.com/articles/goldmans-long-term-shift-remains-key-11642530633", "title": "Goldman's Long-Term Shift Remains Key", "date": "2022-01-18 13:30", "summary": "Gains on Wall Street trading desks may be slowing, but Goldman Sachs is still placing bets on a steadier future. Wall Street trading may not be quite the bonanza it was in 2021, but investors don't have to cash in their bets quite yet.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Goldman's Long-Term Shift Remains Key. Gains on Wall Street trading desks may be slowing, but Goldman Sachs is still placing bets on a steadier future. Wall Street trading may not be quite the bonanza it was in 2021, but investors don't have to cash in their bets quite yet.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc (NYSE: GS) will increase because they are still placing bets on a steadier future, and their trading desks are still seeing gains.\n- JPMorgan Chase & Co (NYSE: JPM) will decrease because they are also placing bets on a steadier future, but their trading desks are not seeing the same gains as Goldman Sachs.\n- Bank of America Corp (NYSE: BAC) will decrease because they are also placing bets on a stead", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up", "prices": [349.6, 356.24]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [150.975, 150.9369]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [46.18, 46.345]}}}, {"link": "https://www.wsj.com/articles/gov-kathy-hochul-picks-obama-administration-veteran-to-lead-new-yorks-top-financial-regulator-11630420205", "title": "Gov. Hochul Picks Obama Administration Veteran to Lead New York's Top Financial Regulator", "date": "2021-08-31 10:54", "summary": "Obama administration veteran was nominated to lead Department of Financial Services, which oversees insurance companies and state-chartered banks. New York Gov. Kathy Hochul has tapped an Obama administration veteran to be the state's top financial regulator, officials said Tuesday.", "categories": [["WSJ News Exclusive", "Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gov. Hochul Picks Obama Administration Veteran to Lead New York's Top Financial Regulator. Obama administration veteran was nominated to lead Department of Financial Services, which oversees insurance companies and state-chartered banks. New York Gov. Kathy Hochul has tapped an Obama administration veteran to be the state's top financial regulator, officials said Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Department of Financial Services (DFS) will increase because they have a new leader who is experienced in the financial sector.\n- New York Community Bancorp, Inc. (NYSE: NYCB) will increase because they are based in New York, and the DFS will be more likely to help them out since they have a new leader.\n- The Bank of New York Mellon Corporation (NYSE: BK) will decrease because they are not based in", "price_info": {"DFS": {"company": "Financial Services", "ticker": "DFS", "move": "up", "prices": [128.9999, 128.66]}, "NYCB": {"company": "", "ticker": "NYCB", "move": "up", "prices": [12.56, 12.51]}, "BK": {"company": "", "ticker": "BK", "move": "down", "prices": [55.2469, 55.265]}}}, {"link": "https://www.wsj.com/articles/tesla-halts-online-sales-of-35-000-version-of-model-3-weeks-after-introducing-it-11555050405", "title": "Tesla Halts Online Sales of $35,000 Model 3", "date": "2019-04-12 11:35", "summary": "The lowest-priced model can still be ordered by phone or in stores. Tesla Inc. stopped online sales of the $35,000 base version of its Model 3 compact weeks after introducing it, the latest shift in sales tactics as the electric-car maker struggles to deliver long-promised affordability and avoid losing money.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla Halts Online Sales of $35,000 Model 3. The lowest-priced model can still be ordered by phone or in stores. Tesla Inc. stopped online sales of the $35,000 base version of its Model 3 compact weeks after introducing it, the latest shift in sales tactics as the electric-car maker struggles to deliver long-promised affordability and avoid losing money.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (TSLA) will decrease because they have stopped online sales of their $35,000 Model 3.", "price_info": {"TSLA": {"company": "Tesla, Inc.", "ticker": "TSLA", "move": "down", "prices": [267.36, 268.58]}}}, {"link": "https://www.wsj.com/articles/opec-defers-decision-on-oil-output-reduction-11568298481", "title": "OPEC Defers Decision on Oil Output Reduction", "date": "2019-09-12 10:28", "summary": "Cartel pushes members for 'hidden cuts,' putting off a major decision on production until December. The Organization of the Petroleum Exporting Countries and its oil-producing allies put off any talk of further output reductions at a technical meeting Thursday, despite growing evidence of a mounting global supply glut and slowing demand growth for crude.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"OPEC Defers Decision on Oil Output Reduction. Cartel pushes members for 'hidden cuts,' putting off a major decision on production until December. The Organization of the Petroleum Exporting Countries and its oil-producing allies put off any talk of further output reductions at a technical meeting Thursday, despite growing evidence of a mounting global supply glut and slowing demand growth for crude.\"\n\nStock Prediction(s):", "Prediction": "\n- OPEC will not be able to come to an agreement about production, and oil prices will continue to decrease.\n- Schlumberger Ltd. (NYSE: SLB) will decrease because of the decrease in oil prices.\n- Halliburton Company (NYSE: HAL) will decrease because of the decrease in oil prices.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because of the decrease in oil prices.", "price_info": {"SLB": {"company": "", "ticker": "SLB", "move": "down", "prices": [36.42, 36.87]}, "HAL": {"company": "", "ticker": "HAL", "move": "down", "prices": [19.51, 19.73]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [71.76, 71.82]}}}, {"link": "https://www.wsj.com/articles/astrazeneca-plans-to-double-covid-19-vaccine-output-as-it-fixes-production-issues-11613048354", "title": "AstraZeneca Plans to Double Covid-19 Vaccine Output", "date": "2021-02-11 11:40", "summary": "Drugmaker booked $2 million in sales in 2020 from end-of-year shipments of the shot. LONDON- AstraZeneca PLC said it was fixing problems with the manufacturing of its Covid-19 vaccine and expects to roughly double monthly production to 200 million doses by April, as it seeks to move past a rocky start to the shot's rollout.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AstraZeneca Plans to Double Covid-19 Vaccine Output. Drugmaker booked $2 million in sales in 2020 from end-of-year shipments of the shot. LONDON- AstraZeneca PLC said it was fixing problems with the manufacturing of its Covid-19 vaccine and expects to roughly double monthly production to 200 million doses by April, as it seeks to move past a rocky start to the shot's rollout.\"\n\nStock Prediction(s):", "Prediction": "\n- AstraZeneca plc (NASDAQ: AZN) will increase because they are fixing their manufacturing problems and they expect to roughly double monthly production to 200 million doses by April.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [166.5816, 166.14]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [34.455, 34.33]}, "AZN": {"company": "", "ticker": "AZN", "move": "up", "prices": [50.035, 49.6778]}}}, {"link": "https://www.wsj.com/articles/nike-accuses-stockx-of-trademark-infringement-in-sales-of-nfts-11644001287", "title": "Nike Accuses StockX of Trademark Infringement in Sales of NFTs", "date": "2022-02-04 14:01", "summary": "The online resale marketplace offers customers the chance to buy digital tokens associated with limited-edition sneakers. Nike Inc. has sued StockX LLC, accusing the online marketplace of selling unauthorized digital products based on its sneakers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nike Accuses StockX of Trademark Infringement in Sales of NFTs. The online resale marketplace offers customers the chance to buy digital tokens associated with limited-edition sneakers. Nike Inc. has sued StockX LLC, accusing the online marketplace of selling unauthorized digital products based on its sneakers.\"\n\nStock Prediction(s):", "Prediction": "\n- Nike Inc. (NYSE: NKE) will increase because they are taking legal action to protect their intellectual property.\n- StockX LLC (Private: STX) will decrease because they are being sued by Nike for trademark infringement.", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [145.335, 146.035]}}}, {"link": "https://www.wsj.com/articles/covid-19-drags-on-europes-economies-as-asias-recovery-continues-11606992861", "title": "Activity Picks Up At U.S., Asia Services Businesses, While Europe Contracts", "date": "2020-12-03 11:48", "summary": "Purchasing managers' surveys add to signs economic recovery continues despite Covid's impact. U.S. services businesses, a key driver of economic growth, gained ground for the sixth straight month in November, adding to signs the recovery is continuing.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Activity Picks Up At U.S., Asia Services Businesses, While Europe Contracts. Purchasing managers' surveys add to signs economic recovery continues despite Covid's impact. U.S. services businesses, a key driver of economic growth, gained ground for the sixth straight month in November, adding to signs the recovery is continuing.\"\n\nStock Prediction(s):", "Prediction": "\n- The overall market will increase because the U.S. services businesses are doing well.\n- The technology sector will increase because the U.S. services businesses are doing well.\n- The health care sector will increase because the U.S. services businesses are doing well.\n- The retail sector will increase because the U.S. services businesses are doing well.", "price_info": {}}, {"link": "https://www.wsj.com/articles/fidelity-cashes-in-most-of-gamestop-stake-11612980430", "title": "Fidelity Cashes In Most of GameStop Stake", "date": "2021-02-10 13:07", "summary": "Firm sold nearly all positions in GameStop last month, ending run as volatile stock's largest shareholder. Fidelity Investments sold nearly all of its positions in GameStop Corp. last month, just as shares of the videogame retailer were surging.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fidelity Cashes In Most of GameStop Stake. Firm sold nearly all positions in GameStop last month, ending run as volatile stock's largest shareholder. Fidelity Investments sold nearly all of its positions in GameStop Corp. last month, just as shares of the videogame retailer were surging.\"\n\nStock Prediction(s):", "Prediction": "\n- GameStop Corp. (NYSE: GME) will decrease because their largest shareholder has sold all of their stock.", "price_info": {"GME": {"company": "", "ticker": "GME", "move": "down", "prices": [58.74, 56.26]}}}, {"link": "https://www.wsj.com/articles/gold-edges-lower-as-muted-trading-continues-11548342120", "title": "Gold Edges Lower as Muted Trading Continues", "date": "2019-01-24 14:26", "summary": "Investors are looking ahead to next week's Federal Reserve meeting and jobs report. Gold prices inched lower Thursday, continuing a stretch of subdued trading as stocks and the dollar stayed steady.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold Edges Lower as Muted Trading Continues. Investors are looking ahead to next week's Federal Reserve meeting and jobs report. Gold prices inched lower Thursday, continuing a stretch of subdued trading as stocks and the dollar stayed steady.\"\n\nStock Prediction(s):", "Prediction": "\n- Gold prices will continue to stay subdued because there is not much news to drive the price higher.\n- The dollar will stay steady because the Federal Reserve is not expected to make any changes to their policy.\n- Stocks will stay steady because there is not much news to drive the price higher or lower.", "price_info": {}}, {"link": "https://www.wsj.com/articles/airlines-losses-mount-amid-pandemic-but-travel-demand-shows-some-improvement-11603372966", "title": "Airlines' Losses Mount, but Demand Shows Improvement", "date": "2020-10-22 15:34", "summary": "Executives say passengers aren't likely to return in full force until Covid-19 vaccine becomes widely available. Summer was a bust for U.S. airlines. Now they are anxiously watching a fragile uptick in demand to see if it will hold as the number of new coronavirus cases increases.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Airlines' Losses Mount, but Demand Shows Improvement. Executives say passengers aren't likely to return in full force until Covid-19 vaccine becomes widely available. Summer was a bust for U.S. airlines. Now they are anxiously watching a fragile uptick in demand to see if it will hold as the number of new coronavirus cases increases.\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines, Inc. (NYSE: DAL) will increase because their stock has been dropping recently, and this news will give investors hope that the company is turning around.\n- American Airlines Group, Inc. (NASDAQ: AAL) will increase because their stock has been dropping recently, and this news will give investors hope that the company is turning around.\n- United Airlines Holdings, Inc. (NYSE: UAL) will increase because their stock", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [33.58, 33.67]}, "UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [37.2, 37.29]}, "AAL": {"company": "", "ticker": "AAL", "move": "up", "prices": [13.1002, 13.11]}}}, {"link": "https://www.wsj.com/articles/home-depot-and-lowes-shouldnt-fear-pandemics-end-11614186579", "title": "Home Depot and Lowe's Shouldn't Fear Pandemic's End", "date": "2021-02-24 12:09", "summary": "Investors seem overly jittery about Lowe's and Home Depot's ability to outperform 2020. Home Depot 's Chief Executive Craig Menear boasted on Tuesday that \"for many customers, the home has never been more important.\" Investors are getting anxious about how long that will continue.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Home Depot and Lowe's Shouldn't Fear Pandemic's End. Investors seem overly jittery about Lowe's and Home Depot's ability to outperform 2020. Home Depot 's Chief Executive Craig Menear boasted on Tuesday that \"for many customers, the home has never been more important.\" Investors are getting anxious about how long that will continue.\"\n\nStock Prediction(s):", "Prediction": "\n- Home Depot, Inc. (NYSE: HD) will continue to outperform in 2020 because the pandemic is ending, and people will want to invest in their homes.\n- Lowe's Companies, Inc. (NYSE: LOW) will continue to underperform in 2020 because the pandemic is ending, and people will want to invest in Home Depot instead.", "price_info": {"HD": {"company": "", "ticker": "HD", "move": null, "prices": [255.5399, 259.59]}, "LOW": {"company": "", "ticker": "LOW", "move": null, "prices": [160.43, 163]}}}, {"link": "https://www.wsj.com/articles/spacex-rockets-were-imperiled-by-falsified-reports-prosecutors-say-11558576047", "title": "SpaceX Rockets Were Imperiled by Contractor's Falsified Reports, Prosecutors Say", "date": "2019-05-23 15:48", "summary": "Engineer is accused of forging inspectors' signatures on at least 38 documents. Elon Musk's space venture last year discovered that an employee at one of its contractors falsified product-quality reports for components intended for its rockets, generating concerns at the National Aeronautics and Space Administration, according to federal investigators.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SpaceX Rockets Were Imperiled by Contractor's Falsified Reports, Prosecutors Say. Engineer is accused of forging inspectors' signatures on at least 38 documents. Elon Musk's space venture last year discovered that an employee at one of its contractors falsified product-quality reports for components intended for its rockets, generating concerns at the National Aeronautics and Space Administration, according to federal investigators.\"\n\nStock Prediction(s):", "Prediction": "\n- SpaceX (Private: SPX) will decrease because their contractor's falsified reports put their rockets in jeopardy.\n- Boeing (NYSE: BA) will increase because they are not implicated in the falsified reports.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [354.63, 353.89]}}}, {"link": "https://www.wsj.com/articles/what-you-need-to-know-about-isa-college-loans-11559922173", "title": "What You Need to Know About 'ISA' College Deals", "date": "2019-06-07 11:42", "summary": "How to figure out whether income-share agreements are a good choice for you. Income-share agreements are starting to gain traction as a college-funding option. But because they are so new, many students and families don't know much about them.", "categories": [["Markets", "Journal Reports: Funds/ETFs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What You Need to Know About 'ISA' College Deals. How to figure out whether income-share agreements are a good choice for you. Income-share agreements are starting to gain traction as a college-funding option. But because they are so new, many students and families don't know much about them.\"\n\nStock Prediction(s):", "Prediction": "\n- ISA College Deals (NASDAQ: ASA) will increase because income-share agreements are starting to gain traction as a college-funding option.\n- Other College Funding Options (NASDAQ: OTHR) will decrease because income-share agreements are starting to gain traction as a college-funding option.", "price_info": {"ASA": {"company": "", "ticker": "ASA", "move": "up", "prices": [10.479, 10.43]}, "OTHR": {"company": "", "ticker": "OTHR", "move": "down"}}}, {"link": "https://www.wsj.com/articles/colgate-palmolives-sales-decline-11548430567", "title": "Colgate-Palmolive's Sales Decline", "date": "2019-01-25 10:36", "summary": "Profit rises on lower income-tax costs. Colgate-Palmolive Co. reported Friday that its top line declined in the fourth quarter, and its chief executive said he expects earnings to fall in 2019 amid higher raw-material prices and global economic uncertainty.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Colgate-Palmolive's Sales Decline. Profit rises on lower income-tax costs. Colgate-Palmolive Co. reported Friday that its top line declined in the fourth quarter, and its chief executive said he expects earnings to fall in 2019 amid higher raw-material prices and global economic uncertainty.\"\n\nStock Prediction(s):", "Prediction": "\n- Colgate-Palmolive Co. (NYSE: CL) will decrease because their sales are declining and their CEO expects earnings to fall in 2019.", "price_info": {"CL": {"company": "", "ticker": "CL", "move": "down", "prices": [62.8999, 62.13]}}}, {"link": "https://www.wsj.com/articles/floods-deal-a-new-blow-to-the-farm-belt-11553765402", "title": "Floods Deal New Blow to Farm Belt", "date": "2019-03-28 11:52", "summary": "Farmers, agricultural companies face losses as water swamps fields and transit networks. Severe flooding in the Midwest is damaging fields, disrupting shipments and dealing a costly blow to growers and agribusinesses as a downturn in the farm economy stretches into a sixth year.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Floods Deal New Blow to Farm Belt. Farmers, agricultural companies face losses as water swamps fields and transit networks. Severe flooding in the Midwest is damaging fields, disrupting shipments and dealing a costly blow to growers and agribusinesses as a downturn in the farm economy stretches into a sixth year.\"\n\nStock Prediction(s):", "Prediction": "\n- Archer Daniels Midland Company (NYSE: ADM) will decrease because of the floods and the damage it is doing to the agricultural industry.\n- Bunge Ltd. (NYSE: BG) will decrease because of the floods and the damage it is doing to the agricultural industry.\n- Cargill, Incorporated (NYSE: CARG) will decrease because of the floods and the damage it is doing to the agricultural industry.", "price_info": {"ADM": {"company": "", "ticker": "ADM", "move": "down", "prices": [42.53, 42.5]}, "BG": {"company": "", "ticker": "BG", "move": "down", "prices": [51.83, 51.98]}, "CARG": {"company": "", "ticker": "CARG", "move": "down", "prices": [38.91, 39]}}}, {"link": "https://www.wsj.com/articles/boy-scouts-win-over-key-abuse-survivors-group-on-bankruptcy-plan-11644475135", "title": "Boy Scouts Win Over Key Abuse-Survivors Group on Bankruptcy Plan", "date": "2022-02-10 11:47", "summary": "Lawyers of the official committee, representing 82,200 individual claimants, will now recommend they accept the youth group's offer. The Boy Scouts of America won backing for a landmark sex-abuse compensation plan from the official committee representing 82,200 individual claimants, further solidifying support for ending the largest bankruptcy case ever filed over childhood abuse.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boy Scouts Win Over Key Abuse-Survivors Group on Bankruptcy Plan. Lawyers of the official committee, representing 82,200 individual claimants, will now recommend they accept the youth group's offer. The Boy Scouts of America won backing for a landmark sex-abuse compensation plan from the official committee representing 82,200 individual claimants, further solidifying support for ending the largest bankruptcy case ever filed over childhood abuse.\"\n\nStock Prediction(s):", "Prediction": "\n- The Boy Scouts of America (NYSE: BSA) will increase because they have a plan to pay out compensation to victims of sexual abuse.\n- The claimants (represented by the official committee) will decrease because they are accepting the Boy Scouts of America's offer.", "price_info": {"BSA": {"company": "", "ticker": "BSA", "move": "down"}}}, {"link": "https://www.wsj.com/articles/transcript-wsj-interview-with-dallas-fed-president-robert-kaplan-11574884223", "title": "Transcript: WSJ Interview With Dallas Fed President Robert Kaplan", "date": "2019-11-27 14:50", "summary": "Resume Subscription. Dallas Fed President Robert Kaplan spoke with Wall Street Journal reporter Nick Timiraos on Wednesday, Nov. 27, about his outlook for the economy. He also reviewed how the Federal Reserve had reacted to changes in the outlook over the past year, and what the central bank's ongoing study of its framework and policy strategies should consider. Here is a partial transcript of the interview, lightly edited for clarity and length.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Transcript: WSJ Interview With Dallas Fed President Robert Kaplan. Resume Subscription. Dallas Fed President Robert Kaplan spoke with Wall Street Journal reporter Nick Timiraos on Wednesday, Nov. 27, about his outlook for the economy. He also reviewed how the Federal Reserve had reacted to changes in the outlook over the past year, and what the central bank's ongoing study of its framework and policy strategies should consider. Here is a partial transcript of the interview, lightly edited for clarity and length.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve will decrease because they are still studying their framework and policy strategies.\n- Dallas Fed President Robert Kaplan's outlook for the economy will be positive because he believes that the Federal Reserve has reacted well to changes in the outlook.", "price_info": {}}, {"link": "https://www.wsj.com/articles/intels-fabs-arent-going-anywhere-11595862957", "title": "Intel's Fabs Aren't Going Anywhere", "date": "2020-07-27 11:15", "summary": "Chip maker's latest stumble opens the door to more outsourcing, but advantages of being a manufacturer remain. Intel 's manufacturing prowess has taken a beating. But the chip maker is unlikely to get out of the \"making\" part of the business.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Intel's Fabs Aren't Going Anywhere. Chip maker's latest stumble opens the door to more outsourcing, but advantages of being a manufacturer remain. Intel 's manufacturing prowess has taken a beating. But the chip maker is unlikely to get out of the \"making\" part of the business.\"\n\nStock Prediction(s):", "Prediction": "\n- Intel Corporation (NASDAQ: INTC) will increase because their manufacturing prowess is still unmatched, and they are unlikely to get out of the manufacturing business.\n- Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM) will increase because they are a direct competitor of Intel, and they are unlikely to get out of the manufacturing business.", "price_info": {"TSM": {"company": "", "ticker": "TSM", "move": "up", "prices": [82.53, 82.58]}, "INTC": {"company": "", "ticker": "INTC", "move": "up", "prices": [50.51, 49.895]}}}, {"link": "https://www.wsj.com/articles/job-gains-benefit-hispanic-men-while-women-lag-behind-11604688337", "title": "Job Gains Benefit Hispanic Men", "date": "2020-11-06 13:45", "summary": "Construction and storage industries have fared better than hospitality and restaurants, where more women work. The labor-market recovery from the coronavirus pandemic has been uneven across demographic groups, as Hispanic men benefit from gains in industries such as construction while women-especially from racial minority groups-lag behind, Labor Department data show.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Job Gains Benefit Hispanic Men. Construction and storage industries have fared better than hospitality and restaurants, where more women work. The labor-market recovery from the coronavirus pandemic has been uneven across demographic groups, as Hispanic men benefit from gains in industries such as construction while women-especially from racial minority groups-lag behind, Labor Department data show.\"\n\nStock Prediction(s):", "Prediction": "\n- Hispanic men will continue to benefit from job gains in the construction and storage industries.\n- Women-especially from racial minority groups-will continue to lag behind in terms of job gains.", "price_info": {}}, {"link": "https://www.wsj.com/articles/covid-crisis-drives-historic-drop-in-global-trade-11598368752", "title": "Covid Crisis Drives Historic Drop in Global Trade", "date": "2020-08-25 12:32", "summary": "Trade flows collapsed in the spring. Despite recent signs of a rebound, a reshaping of world trade could follow the pandemic.. Global trade flows collapsed in the spring, marking the largest fall in two decades, as coronavirus lockdowns disrupted air and sea transport and dealt a blow to the demand for many consumer and investment goods.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid Crisis Drives Historic Drop in Global Trade. Trade flows collapsed in the spring. Despite recent signs of a rebound, a reshaping of world trade could follow the pandemic.. Global trade flows collapsed in the spring, marking the largest fall in two decades, as coronavirus lockdowns disrupted air and sea transport and dealt a blow to the demand for many consumer and investment goods.\"\n\nStock Prediction(s):", "Prediction": "\n- International Business Machines Corporation (NYSE: IBM) will decrease because their main business is in technology, and the global trade slowdown will affect their sales.\n- 3M Company (NYSE: MMM) will decrease because their main business is in technology, and the global trade slowdown will affect their sales.\n- The Boeing Company (NYSE: BA) will decrease because their main business is in aviation, and the global trade slowdown will affect their sales.\n- General Electric", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "down", "prices": [124.86, 124.72]}, "MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [163.1828, 163.4331]}, "BA": {"company": "", "ticker": "BA", "move": "down", "prices": [174.06, 173.86]}}}, {"link": "https://www.wsj.com/articles/fannie-freddie-regulator-launches-process-for-new-capital-requirements-at-mortgage-finance-firms-11574193078", "title": "FHFA to Propose Capital Rule for Fannie, Freddie in 2020", "date": "2019-11-19 15:36", "summary": "Under 2018 version of capital requirements, Fannie and Freddie would have been required to raise up to $180 billion. WASHINGTON- Fannie Mae and Freddie Mac 's federal regulator kicked off a process for the mortgage-finance companies to raise enough capital for them to return to private ownership.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FHFA to Propose Capital Rule for Fannie, Freddie in 2020. Under 2018 version of capital requirements, Fannie and Freddie would have been required to raise up to $180 billion. WASHINGTON- Fannie Mae and Freddie Mac 's federal regulator kicked off a process for the mortgage-finance companies to raise enough capital for them to return to private ownership.\"\n\nStock Prediction(s):", "Prediction": "\n- Fannie Mae (OTCQB: FNMA) and Freddie Mac (OTCQB: FMCC) will increase because they will be able to return to private ownership and will have to raise more capital.\n- Bank of America (NYSE: BAC) will increase because they are a direct lender to Fannie Mae and Freddie Mac.\n- Wells Fargo (NYSE: WFC) will decrease because they are a direct lender to Fannie Mae and Freddie Mac", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [32.955, 32.94]}, "WFC": {"company": "", "ticker": "WFC", "move": "down", "prices": [54.095, 54.055]}}}, {"link": "https://www.wsj.com/articles/kraft-heinz-shares-slide-after-3g-capital-trims-stake-11568734091", "title": "Kraft Heinz Shares Slide After 3G Trims Stake", "date": "2019-09-17 11:28", "summary": "Brazilian private-equity firm sells about 9% of its stake in struggling food maker. The private-equity firm that helped create Kraft Heinz Co. has sold about 9% of its stake in the struggling food maker, a move that weighed on the company's shares Tuesday.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Kraft Heinz Shares Slide After 3G Trims Stake. Brazilian private-equity firm sells about 9% of its stake in struggling food maker. The private-equity firm that helped create Kraft Heinz Co. has sold about 9% of its stake in the struggling food maker, a move that weighed on the company's shares Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Kraft Heinz Co. (NASDAQ: KHC) will continue to slide because 3G is selling its stake.\n- Mondelez International Inc. (NASDAQ: MDLZ) will increase because they are not affiliated with 3G.", "price_info": {"KHC": {"company": "", "ticker": "KHC", "move": null, "prices": [28.52, 28.415]}, "MDLZ": {"company": "", "ticker": "MDLZ", "move": "up", "prices": [54.685, 54.7]}}}, {"link": "https://www.wsj.com/articles/barricks-biggest-shareholder-opposes-acquisition-of-newmont-11551803035", "title": "Barrick's Biggest Shareholder Opposes Acquisition of Newmont", "date": "2019-03-05 13:07", "summary": "Joe Foster of VanEck International Investors Gold Fund instead pushes for a joint venture between the two. Barrick Gold Corp.'s largest shareholder said it prefers a joint venture with Newmont Mining Corp. , over a full-blown acquisition, throwing another hurdle in front of the Toronto-based miner's ambitions to buy its closest rival.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Barrick's Biggest Shareholder Opposes Acquisition of Newmont. Joe Foster of VanEck International Investors Gold Fund instead pushes for a joint venture between the two. Barrick Gold Corp.'s largest shareholder said it prefers a joint venture with Newmont Mining Corp. , over a full-blown acquisition, throwing another hurdle in front of the Toronto-based miner's ambitions to buy its closest rival.\"\n\nStock Prediction(s):", "Prediction": "\n- Barrick Gold Corp. (NYSE: ABX) will decrease because their largest shareholder is not in favor of the acquisition.\n- Newmont Mining Corp. (NYSE: NEM) will increase because they may now be in a better position to negotiate a joint venture.", "price_info": {"ABX": {"company": "", "ticker": "ABX", "move": "down"}, "NEM": {"company": "", "ticker": "NEM", "move": "up", "prices": [34.49, 34.51]}}}, {"link": "https://www.wsj.com/articles/july-consumer-prices-rise-amid-increased-demand-for-a-range-of-goods-services-11597236743", "title": "July Consumer Prices Rise Amid Increased Demand for Range of Goods, Services", "date": "2020-08-12 15:21", "summary": "The consumer-price index climbed a seasonally adjusted 0.6% in July, the Labor Department says. WASHINGTON-U.S. consumer prices rose in July on higher costs for a range of products and services, a sign of firming inflation as demand for goods rebounded following steep declines earlier in the coronavirus pandemic.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"July Consumer Prices Rise Amid Increased Demand for Range of Goods, Services. The consumer-price index climbed a seasonally adjusted 0.6% in July, the Labor Department says. WASHINGTON-U.S. consumer prices rose in July on higher costs for a range of products and services, a sign of firming inflation as demand for goods rebounded following steep declines earlier in the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because their prices are rising, and they are one of the main retailers in the United States.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because their prices are rising, and they are one of the main retailers in the United States.\n- Costco Wholesale Corporation (NASDAQ: COST) will increase because their prices are rising, and they are one of", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [131.7, 131.73]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3159.13, 3155.06]}, "COST": {"company": "", "ticker": "COST", "move": "up", "prices": [336.75, 336.74]}}}, {"link": "https://www.wsj.com/articles/dont-be-scared-of-record-low-treasury-yields-11582664085", "title": "Don't Be Scared of Record-Low Treasury Yields", "date": "2020-02-25 15:54", "summary": "Ultralow yields say more about the changing attitudes of central bankers than the outlook for economic growth. Ultralow bond yields tend to spark dark thoughts of \"Japanification\" and economic stagnation. They may say much more about the desire of central bankers to preserve their reputations.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Don't Be Scared of Record-Low Treasury Yields. Ultralow yields say more about the changing attitudes of central bankers than the outlook for economic growth. Ultralow bond yields tend to spark dark thoughts of \"Japanification\" and economic stagnation. They may say much more about the desire of central bankers to preserve their reputations.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will not be significantly affected by the low Treasury yields because they are more a reflection of central banker attitudes than economic growth.", "price_info": {}}, {"link": "https://www.wsj.com/articles/amazon-invests-in-driverless-startup-aurora-valued-at-more-than-2-billion-11549555200", "title": "Amazon Invests in Driverless Startup Aurora", "date": "2019-02-07 11:00", "summary": "Amazon's investment starts a relationship with a company developing technology that could be a natural fit for package delivery. Amazon.com Inc . has invested in high-profile autonomous-vehicle startup Aurora, giving the online retailer insight into the fast-developing world of driverless cars as it navigates its growing logistics operation.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Amazon Invests in Driverless Startup Aurora. Amazon's investment starts a relationship with a company developing technology that could be a natural fit for package delivery. Amazon.com Inc . has invested in high-profile autonomous-vehicle startup Aurora, giving the online retailer insight into the fast-developing world of driverless cars as it navigates its growing logistics operation.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are investing in a driverless startup, which could have implications for their package delivery business.\n- Nvidia Corporation (NASDAQ: NVDA) will increase because they are a direct competitor of Aurora, and this investment gives Amazon a closer relationship to the company.\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because they are a direct competitor of Aurora,", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1609.725, 1602.515]}, "NVDA": {"company": "", "ticker": "NVDA", "move": "up", "prices": [147.91, 146.2732]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1098.3384, 1098.68]}}}, {"link": "https://www.wsj.com/articles/u-s-asked-russia-about-offer-of-bases-to-monitor-afghan-terror-threat-11632767164", "title": "U.S. Asked Russia About Offer of Bases to Monitor Afghan Threats", "date": "2021-09-27 14:28", "summary": "Joint Chiefs chairman Gen. Mark Milley asked his Russian counterpart about Putin's comments at the request of the White House. The Pentagon's top military officer discussed with his Russian counterpart an apparent offer from Russian President Vladimir Putin to use his military's bases in Central Asia to respond to any emerging terrorist threats in Afghanistan, U.S. officials said.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Asked Russia About Offer of Bases to Monitor Afghan Threats. Joint Chiefs chairman Gen. Mark Milley asked his Russian counterpart about Putin's comments at the request of the White House. The Pentagon's top military officer discussed with his Russian counterpart an apparent offer from Russian President Vladimir Putin to use his military's bases in Central Asia to respond to any emerging terrorist threats in Afghanistan, U.S. officials said.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. will increase its military presence in Central Asia in response to the offer from Putin.\n- Russia will increase its military presence in Central Asia in response to the offer from the U.S.", "price_info": {}}, {"link": "https://www.wsj.com/articles/delta-kb-home-taiwan-semiconductor-what-to-watch-in-the-stock-market-today-11642075136", "title": "Delta, Virgin Galactic, KB Home, Taiwan Semiconductor: What to Watch in the Stock Market Today", "date": "2022-01-13 09:41", "summary": "Earnings season is back. Delta Air Lines shares rose after reporting quarterly results.. U.S. stocks and bond yields crept higher as fresh data on inflation and the labor market provided a mixed picture of the economic recovery. Here's what we're watching in Thursday's trading:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Delta, Virgin Galactic, KB Home, Taiwan Semiconductor: What to Watch in the Stock Market Today. Earnings season is back. Delta Air Lines shares rose after reporting quarterly results.. U.S. stocks and bond yields crept higher as fresh data on inflation and the labor market provided a mixed picture of the economic recovery. Here's what we're watching in Thursday's trading:\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines, Inc. (NYSE: DAL) will increase because their earnings report was good.\n- Virgin Galactic Holdings Ltd. (NYSE: SPCE) will increase because their earnings report was good.\n- KB Home (NYSE: KBH) will increase because their earnings report was good.\n- Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM) will increase because their earnings report was good.", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": "up", "prices": [41.03, 41.72]}, "SPCE": {"company": "", "ticker": "SPCE", "move": "up", "prices": [10.525, 10.378]}, "KBH": {"company": "", "ticker": "KBH", "move": "up", "prices": [48.82, 48.04]}, "TSM": {"company": "", "ticker": "TSM", "move": "up", "prices": [143.94, 140.38]}}}, {"link": "https://www.wsj.com/articles/index-firm-mscis-finance-chief-to-leave-11551911615", "title": "Index Firm MSCI's Finance Chief to Join ADP", "date": "2019-03-07 11:43", "summary": "Index provider named Andrew Wiechmann as its interim CFO. Index provider MSCI Inc.'s chief financial officer is leaving the firm later this month to become CFO at payrolls processor Automatic Data Processing Inc.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Index Firm MSCI's Finance Chief to Join ADP. Index provider named Andrew Wiechmann as its interim CFO. Index provider MSCI Inc.'s chief financial officer is leaving the firm later this month to become CFO at payrolls processor Automatic Data Processing Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- MSCI Inc. (NYSE: MSCI) will decrease because their CFO is leaving to join a competitor.\n- Automatic Data Processing Inc. (NASDAQ: ADP) will increase because they are gaining a CFO from a competitor.", "price_info": {"MSCI": {"company": "", "ticker": "MSCI", "move": "down", "prices": [184.25, 183.51]}, "ADP": {"company": "", "ticker": "ADP", "move": "up", "prices": [151.8, 151.71]}}}, {"link": "https://www.wsj.com/articles/dutch-politician-targeted-in-twitter-hack-11595469898", "title": "Dutch Politician Targeted in Twitter Hack", "date": "2020-07-23 10:46", "summary": "A number of high-profile Twitter accounts, including those of Joe Biden, Elon Musk and Apple, were taken over to promote a bitcoin scam. A Dutch politician was among 36 Twitter Inc. users who had their direct messages accessed in a high-profile hacking attack last week, the company said Wednesday.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Dutch Politician Targeted in Twitter Hack. A number of high-profile Twitter accounts, including those of Joe Biden, Elon Musk and Apple, were taken over to promote a bitcoin scam. A Dutch politician was among 36 Twitter Inc. users who had their direct messages accessed in a high-profile hacking attack last week, the company said Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Twitter Inc (NYSE: TWTR) will decrease because their security has been compromised and people are losing trust in the platform.\n- Apple Inc. (NASDAQ: AAPL) will decrease because people are losing trust in technology companies in general.\n- Facebook Inc. (NASDAQ: FB) will decrease because people are losing trust in social media platforms.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because people are", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down", "prices": [39.685, 39.43]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [383.19, 378.61]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [239.9301, 236.735]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3053.87, 3015.375]}}}, {"link": "https://www.wsj.com/articles/nasa-chief-sees-private-spacecraft-potentially-reaching-moon-before-u-s-astronauts-11560962649", "title": "NASA Chief Sees Private Spacecraft Potentially Reaching Moon First", "date": "2019-06-19 12:44", "summary": "Commercial lunar landers could demonstrate technologies before carrying American astronauts. LE BOURGET, France-Despite U.S. government efforts to accelerate human space exploration, private spacecraft could beat American astronauts to the surface of the moon, according to the head of NASA.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"NASA Chief Sees Private Spacecraft Potentially Reaching Moon First. Commercial lunar landers could demonstrate technologies before carrying American astronauts. LE BOURGET, France-Despite U.S. government efforts to accelerate human space exploration, private spacecraft could beat American astronauts to the surface of the moon, according to the head of NASA.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co (NYSE: BA) will increase because they are a major competitor in the space industry.\n- Blue Origin LLC (private) will increase because they are a major competitor in the space industry.\n- SpaceX (private) will increase because they are a major competitor in the space industry.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [370.2892, 369.7888]}}}, {"link": "https://www.wsj.com/articles/kevin-mayer-ex-tiktok-ceo-joins-investment-firm-founded-by-billionaire-len-blavatnik-11604935679", "title": "Kevin Mayer, Ex-TikTok CEO, Joins Investment Firm Founded By Billionaire Len Blavatnik", "date": "2020-11-09 10:28", "summary": "Access Industries said Mr. Mayer will focus on its media-related businesses and identify new potential opportunities for the firm. Kevin Mayer, who had a short-lived stint as chief executive at TikTok and once was seen as a contender for the top job at Walt Disney Co. , has joined investment firm Access Industries in an advisory role.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Kevin Mayer, Ex-TikTok CEO, Joins Investment Firm Founded By Billionaire Len Blavatnik. Access Industries said Mr. Mayer will focus on its media-related businesses and identify new potential opportunities for the firm. Kevin Mayer, who had a short-lived stint as chief executive at TikTok and once was seen as a contender for the top job at Walt Disney Co. , has joined investment firm Access Industries in an advisory role.\"\n\nStock Prediction(s):", "Prediction": "\n- Access Industries (NYSE: ACC) will increase because they have a new advisor, Kevin Mayer, who has a lot of experience in the media industry.\n- The Walt Disney Company (NYSE: DIS) will decrease because Kevin Mayer is no longer with the company, and they are losing a valuable asset.", "price_info": {"ACC": {"company": "", "ticker": "ACC", "move": "up", "prices": [43.16, 41.7]}, "DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [142.99, 139.88]}}}, {"link": "https://www.wsj.com/articles/coronavirus-crisis-legacy-mountains-of-debt-11586447687", "title": "Coronavirus Crisis Legacy: Mountains of Debt", "date": "2020-04-09 11:54", "summary": "The government and the private sector are going deeper in the hole to survive the economic shutdown, which could be a drag on recovery if it spurs a period of thrift. The full impact of the coronavirus pandemic may take years to play out. But one outcome is already clear: Government, businesses and some households will be loaded with mountains of additional debt.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Crisis Legacy: Mountains of Debt. The government and the private sector are going deeper in the hole to survive the economic shutdown, which could be a drag on recovery if it spurs a period of thrift. The full impact of the coronavirus pandemic may take years to play out. But one outcome is already clear: Government, businesses and some households will be loaded with mountains of additional debt.\"\n\nStock Prediction(s):", "Prediction": "\n- The debt crisis will have a negative impact on the stock prices of companies and governments that are in debt.\n- The debt crisis will have a positive impact on the stock prices of companies and governments that are not in debt.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bitcoin-what-to-know-before-investing-11613498045", "title": "Bitcoin: What to Know Before Investing", "date": "2021-02-16 12:54", "summary": "Most Popular News. Bitcoin is a digital currency that operates outside the control of governments and banks. Trading it is fast and cheap. Its volatile price-found by looking at BTCUSD-has made it a favorite of high-stakes, risk-seeking investors eager for the potential of a big payoff.", "categories": [["Markets", "Personal Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/personal-finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bitcoin: What to Know Before Investing. Most Popular News. Bitcoin is a digital currency that operates outside the control of governments and banks. Trading it is fast and cheap. Its volatile price-found by looking at BTCUSD-has made it a favorite of high-stakes, risk-seeking investors eager for the potential of a big payoff.\"\n\nStock Prediction(s):", "Prediction": "\n- Bitcoin Investment Trust (OTC: GBTC) will increase because it is a way to invest in Bitcoin without having to worry about the volatility of the price.\n- Coinbase Inc (OTC: GBTC) will increase because it is a way to invest in Bitcoin without having to worry about the volatility of the price.", "price_info": {}}, {"link": "https://www.wsj.com/articles/south-korea-slumps-into-recession-11595460878", "title": "Pandemic Hits South Korea's Export-Reliant Economy", "date": "2020-07-23 13:52", "summary": "Country slipped into recession as it notched its worst performance since the Asian financial crisis. South Korea fell into a recession in the second quarter as the coronavirus pandemic took a heavy toll on the export-reliant country, which recorded its worst performance since 1998 when it was embroiled in the Asian financial crisis.", "categories": [["Economy", "Asia Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/asia-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pandemic Hits South Korea's Export-Reliant Economy. Country slipped into recession as it notched its worst performance since the Asian financial crisis. South Korea fell into a recession in the second quarter as the coronavirus pandemic took a heavy toll on the export-reliant country, which recorded its worst performance since 1998 when it was embroiled in the Asian financial crisis.\"\n\nStock Prediction(s):", "Prediction": "\n- Samsung Electronics Co Ltd (OTC: SSNLF) will decrease because their main market is South Korea, and the country is in recession.\n- LG Electronics Inc (OTC: LGEAF) will decrease because their main market is South Korea, and the country is in recession.\n- Hyundai Motor Co Ltd (OTC: HYMTF) will decrease because their main market is South Korea, and the country is in recession.\n- Kia", "price_info": {}}, {"link": "https://www.wsj.com/articles/youtube-becomes-latest-tech-giant-to-curb-qanon-11602784617", "title": "YouTube Becomes Latest Tech Giant to Curb QAnon", "date": "2020-10-15 13:56", "summary": "Google-owned video service is taking down conspiracy movement's content that promotes violence. YouTube took action against the conspiracy group QAnon, banning videos that call for violence, following the lead of social-media companies that have cracked down on such content.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"YouTube Becomes Latest Tech Giant to Curb QAnon. Google-owned video service is taking down conspiracy movement's content that promotes violence. YouTube took action against the conspiracy group QAnon, banning videos that call for violence, following the lead of social-media companies that have cracked down on such content.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because YouTube is one of their subsidiaries, and they have been cracking down on violent content.\n- Facebook, Inc. (NASDAQ: FB) will increase because they have been cracking down on violent content.\n- Twitter, Inc. (NYSE: TWTR) will increase because they have been cracking down on violent content.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down", "prices": [45.58, 46.055]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [1551.32, 1554.55]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [264.97, 266.6]}}}, {"link": "https://www.wsj.com/articles/china-gives-neuberger-berman-nod-to-launch-mutual-funds-11632497181", "title": "China Gives Neuberger Berman Nod to Launch Mutual Funds", "date": "2021-09-24 15:25", "summary": "The asset manager joins BlackRock, Fidelity and other Wall Street firms seeking a share of the Chinese market. Neuberger Berman got the green light from Beijing to start its own mutual-fund business in China, paving the way for the American asset manager to manage money for individual Chinese investors.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"China Gives Neuberger Berman Nod to Launch Mutual Funds. The asset manager joins BlackRock, Fidelity and other Wall Street firms seeking a share of the Chinese market. Neuberger Berman got the green light from Beijing to start its own mutual-fund business in China, paving the way for the American asset manager to manage money for individual Chinese investors.\"\n\nStock Prediction(s):", "Prediction": "\n- Neuberger Berman Group LLC (NYSE: NBG) will increase because they have been given the go-ahead to start a mutual fund business in China.\n- BlackRock, Inc. (NYSE: BLK) will decrease because they are a direct competitor of Neuberger Berman.\n- Fidelity Investments (NYSE: FNF) will decrease because they are a direct competitor of Neuberger Berman.\n- Vanguard Group, Inc. (NYSE:", "price_info": {"NBG": {"company": "", "ticker": "NBG", "move": "up"}, "BLK": {"company": "", "ticker": "BLK", "move": "down", "prices": [874.62, 876.17]}, "FNF": {"company": "", "ticker": "FNF", "move": "down"}}}, {"link": "https://www.wsj.com/articles/amc-finds-the-right-price-with-warnermedia-11615491201", "title": "AMC Finds the Right Price with WarnerMedia", "date": "2021-03-11 14:33", "summary": "Theater giant's deal with studio may include break in film-rental fees. WarnerMedia may have bought itself some peace with the world's largest movie theater chain. And that chain could use the good news.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AMC Finds the Right Price with WarnerMedia. Theater giant's deal with studio may include break in film-rental fees. WarnerMedia may have bought itself some peace with the world's largest movie theater chain. And that chain could use the good news.\"\n\nStock Prediction(s):", "Prediction": "\n- AMC Entertainment Holdings, Inc. (NYSE: AMC) will increase because they have a good relationship with WarnerMedia and have avoided any fee hikes.\n- The Walt Disney Company (NYSE: DIS) will decrease because they own Marvel, which is a direct competitor of WarnerMedia.\n- Comcast Corporation (NASDAQ: CMCSA) will decrease because they own NBCUniversal, which is a direct competitor of WarnerMedia.", "price_info": {"AMC": {"company": "", "ticker": "AMC", "move": "up", "prices": [10.305, 10.27]}, "DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [197.25, 196.62]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "down", "prices": [57.475, 57.15]}}}, {"link": "https://www.wsj.com/articles/the-key-to-being-a-successful-leader-its-adaptability-11585242768", "title": "The Key to Being a Successful Leader? It's Adaptability", "date": "2020-03-26 15:34", "summary": "Executives at the most-effective companies, as measured by Drucker Institute, tend to be tolerant of ambiguity and adaptable, new research shows. Twenty-five years ago, Peter Drucker began to notice one thing executives could count on: They couldn't count on much.", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Key to Being a Successful Leader? It's Adaptability. Executives at the most-effective companies, as measured by Drucker Institute, tend to be tolerant of ambiguity and adaptable, new research shows. Twenty-five years ago, Peter Drucker began to notice one thing executives could count on: They couldn't count on much.\"\n\nStock Prediction(s):", "Prediction": "\n- Adaptability will be the key to success in the coming years, and executives who are able to adapt will be more successful.\n- Companies that are intolerant of ambiguity will not be as successful as those that are adaptable and tolerant of ambiguity.", "price_info": {}}, {"link": "https://www.wsj.com/articles/johnson-johnson-shows-health-economy-is-nearing-full-strength-11618931401", "title": "Johnson & Johnson Shows Health Economy Is Nearing Full Strength", "date": "2021-04-20 11:10", "summary": "Covid-19 vaccine hiccups marginal as healthcare giant benefits from recovery. After a year of pandemic-related disruptions, the healthcare industry has nearly returned to business as usual. Wall Street doesn't yet seem to have noticed.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Johnson & Johnson Shows Health Economy Is Nearing Full Strength. Covid-19 vaccine hiccups marginal as healthcare giant benefits from recovery. After a year of pandemic-related disruptions, the healthcare industry has nearly returned to business as usual. Wall Street doesn't yet seem to have noticed.\"\n\nStock Prediction(s):", "Prediction": "\n- Johnson & Johnson (NYSE: JNJ) will increase because their health economy is nearly back to normal, and they are one of the few companies that can benefit from this.\n- AstraZeneca plc (NASDAQ: AZN) will decrease because their vaccine is not yet available for distribution.\n- Pfizer Inc (NYSE: PFE) will decrease because their vaccine is not yet available for distribution.", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "up", "prices": [167.28, 167.735]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [39.09, 39.1938]}, "AZN": {"company": "", "ticker": "AZN", "move": "down", "prices": [52.18, 52.245]}}}, {"link": "https://www.wsj.com/articles/elliott-pushes-crown-castle-to-bolster-fiber-business-11594049271", "title": "Elliott Pushes Crown Castle to Bolster Fiber Business", "date": "2020-07-06 11:27", "summary": "Hedge fund says in letter to the owner of wireless towers and fiber infrastructure that the latter business hasn't paid off for investors. Elliott Management Corp. is pressuring Crown Castle International Corp . to overhaul its approach to its fiber-cable business, which the hedge fund says has weighed on the company's market value despite billions in investment in recent years.", "categories": [["Markets", "Financial Services", "Hedge Funds"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/business/financial-services?mod=breadcrumb", "https://www.wsj.com/news/types/hedge-funds?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Elliott Pushes Crown Castle to Bolster Fiber Business. Hedge fund says in letter to the owner of wireless towers and fiber infrastructure that the latter business hasn't paid off for investors. Elliott Management Corp. is pressuring Crown Castle International Corp . to overhaul its approach to its fiber-cable business, which the hedge fund says has weighed on the company's market value despite billions in investment in recent years.\"\n\nStock Prediction(s):", "Prediction": "\n- Crown Castle International Corp. (NYSE: CCI) will decrease because Elliott Management is pressuring them to overhaul their fiber-cable business.", "price_info": {"CCI": {"company": "", "ticker": "CCI", "move": "down", "prices": [174.41, 174.5069]}}}, {"link": "https://www.wsj.com/articles/wsj-survey-u-s-recovery-from-pandemic-shock-to-begin-by-third-quarter-11591884001", "title": "WSJ Survey: U.S. Recovery From Pandemic Shock to Begin by Third Quarter", "date": "2020-06-11 10:00", "summary": "The labor market will fare better than previously expected, economists say. The U.S. economy will be in recovery by the third quarter of this year, economists said in a survey that also concluded the labor market will fare better than previously expected following the effects of the coronavirus pandemic.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"WSJ Survey: U.S. Recovery From Pandemic Shock to Begin by Third Quarter. The labor market will fare better than previously expected, economists say. The U.S. economy will be in recovery by the third quarter of this year, economists said in a survey that also concluded the labor market will fare better than previously expected following the effects of the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will increase because it is expected that the U.S. economy will be in recovery by the third quarter.\n- The market will decrease because it is also expected that the labor market will fare worse than previously expected.", "price_info": {}}, {"link": "https://www.wsj.com/articles/how-to-work-from-home-effectively-11608571826", "title": "How to Work From Home Effectively", "date": "2020-12-21 12:30", "summary": "Most Popular News. Remote work has been on the rise across the U.S. for years, but the coronavirus pandemic significantly accelerated the shift to remote work. This is especially the case for industries and roles that don't require employees to work in person. \"People have learned that this is more possible in roles that they didn't think it was possible in before,\" says Sara Sutton, chief executive and founder of FlexJobs, a career website for telecommuting, flexible, freelance and part-time jobs. She says getting workers set up to be able to work remotely at any time is like an insurance policy for employers in case they find themselves in a similar situation in the future. \"I don't think there's any organization that is going to realize they should leave this opportunity on the table.\"", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Work From Home Effectively. Most Popular News. Remote work has been on the rise across the U.S. for years, but the coronavirus pandemic significantly accelerated the shift to remote work. This is especially the case for industries and roles that don't require employees to work in person. \"People have learned that this is more possible in roles that they didn't think it was possible in before,\" says Sara Sutton, chief executive and founder of FlexJobs, a career website for telecommuting, flexible, freelance and part-time jobs. She says getting workers set up to be able to work remotely at any time is like an insurance policy for employers in case they find themselves in a similar situation in the future. \"I don't think there's any organization that is going to realize they should leave this opportunity on the table.\"\"\n\nStock Prediction(s):", "Prediction": "\n- Workday, Inc. (NASDAQ: WDAY) will increase because they are a direct competitor of FlexJobs and they offer remote work opportunities.\n- LinkedIn Corporation (NYSE: LNKD) will increase because they are a direct competitor of FlexJobs and they offer remote work opportunities.\n- Facebook, Inc. (NASDAQ: FB) will increase because they are a direct competitor of FlexJobs and they offer remote work opportunities.", "price_info": {"LNKD": {"company": "", "ticker": "LNKD", "move": "up"}, "WDAY": {"company": "", "ticker": "WDAY", "move": "up", "prices": [240.19, 241.7]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [271.7197, 273.36]}}}, {"link": "https://www.wsj.com/articles/blacklisting-of-chinas-top-chip-maker-smic-comes-with-exceptions-11608656929", "title": "Blacklisting of Chinese Chip Maker Comes With Exceptions", "date": "2020-12-22 12:08", "summary": "U.S. lawmakers want tougher curbs on exports to Chinese semiconductor giant. The U.S. government's move to deny China's leading chip maker access to advanced manufacturing technology comes with exceptions that mean its impact may be mainly political and have limited effect on the company's business.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Blacklisting of Chinese Chip Maker Comes With Exceptions. U.S. lawmakers want tougher curbs on exports to Chinese semiconductor giant. The U.S. government's move to deny China's leading chip maker access to advanced manufacturing technology comes with exceptions that mean its impact may be mainly political and have limited effect on the company's business.\"\n\nStock Prediction(s):", "Prediction": "\n- United Microelectronics Corp (NYSE: UMC) will increase because they are not on the blacklist, and they are a direct competitor of the Chinese chip maker.\n- Semiconductor Manufacturing International Corp (NYSE: SMI) will decrease because they are on the blacklist, and they are a direct competitor of the Chinese chip maker.", "price_info": {"UMC": {"company": "", "ticker": "UMC", "move": "up", "prices": [8.08, 8.1]}, "SMI": {"company": "", "ticker": "SMI", "move": "down"}}}, {"link": "https://www.wsj.com/articles/pandemic-puts-l-a-dodgers-unorthodox-ownership-structure-to-the-test-11603897408", "title": "Covid Puts L.A. Dodgers' Unorthodox Ownership Structure to the Test", "date": "2020-10-28 11:52", "summary": "Insurers tied to some of the team's owners provided billions in funding to other owner-controlled entities. The coronavirus pandemic and its effect on the baseball season are providing the biggest test yet of the unusual structure used by a group of business associates to buy the Los Angeles Dodgers.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid Puts L.A. Dodgers' Unorthodox Ownership Structure to the Test. Insurers tied to some of the team's owners provided billions in funding to other owner-controlled entities. The coronavirus pandemic and its effect on the baseball season are providing the biggest test yet of the unusual structure used by a group of business associates to buy the Los Angeles Dodgers.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dodgers will not be affected by the Covid-19 pandemic because their ownership structure is unorthodox.\n- Other teams in MLB will be affected by the Covid-19 pandemic because their ownership structures are not as unorthodox.", "price_info": {}}, {"link": "https://www.wsj.com/articles/hedge-fund-nominates-four-to-tegnas-board-setting-up-proxy-fight-11579116986", "title": "Hedge Fund Nominates Four to Tegna's Board, Setting Up Proxy Fight", "date": "2020-01-15 14:52", "summary": "Standard General pushes for seats after Apollo's failed takeover approach at broadcast company. Tegna Inc. is in the early stages of a potential proxy fight, after hedge fund Standard General LP nominated four candidates to the broadcast company's board of directors.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hedge Fund Nominates Four to Tegna's Board, Setting Up Proxy Fight. Standard General pushes for seats after Apollo's failed takeover approach at broadcast company. Tegna Inc. is in the early stages of a potential proxy fight, after hedge fund Standard General LP nominated four candidates to the broadcast company's board of directors.\"\n\nStock Prediction(s):", "Prediction": "\n- Tegna Inc (NYSE: TGNA) will increase because they are in the early stages of a potential proxy fight, and they may get new board members who are more favorable to shareholders.\n- Apollo Global Management LLC (NYSE: APO) will decrease because they made a failed takeover approach, and they may not be able to get the board members they want.", "price_info": {"TGNA": {"company": "", "ticker": "TGNA", "move": "up", "prices": [17.96, 17.94]}, "APO": {"company": "", "ticker": "APO", "move": "down", "prices": [49.175, 48.86]}}}, {"link": "https://www.wsj.com/articles/oil-prices-to-slide-despite-opec-cuts-banks-predict-11577112085", "title": "Oil to Slide Despite OPEC Cuts, Banks Predict", "date": "2019-12-23 15:09", "summary": "WSJ poll shows December gains aren't expected to last. Oil prices are likely to shed the gains that followed OPEC's decision to deepen output cuts as a global glut of crude continues to weigh on the market, investment banks predict.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil to Slide Despite OPEC Cuts, Banks Predict. WSJ poll shows December gains aren't expected to last. Oil prices are likely to shed the gains that followed OPEC's decision to deepen output cuts as a global glut of crude continues to weigh on the market, investment banks predict.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because oil prices are dropping and they are a direct competitor of other oil companies.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because oil prices are dropping and they are a direct competitor of other oil companies.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because oil prices are dropping and they are a direct competitor of other oil companies.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [120.22, 120.31]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [70.08, 70.24]}}}, {"link": "https://www.wsj.com/articles/more-detail-and-plain-english-auditors-reports-get-a-makeover-11553012005", "title": "More Detail and Plain English: Auditors' Reports Get a Makeover", "date": "2019-03-19 12:13", "summary": "Investors can expect a report offering a glimpse at what the auditor considers the knottiest issues in a company's financial statements. Coming soon: More insights for investors about the biggest concerns lurking in their companies' financial results.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"More Detail and Plain English: Auditors' Reports Get a Makeover. Investors can expect a report offering a glimpse at what the auditor considers the knottiest issues in a company's financial statements. Coming soon: More insights for investors about the biggest concerns lurking in their companies' financial results.\"\n\nStock Prediction(s):", "Prediction": "\n- The Big Four auditing firms (Deloitte, Ernst & Young, KPMG, and PricewaterhouseCoopers) will increase because investors will want to know what the auditors are seeing in financial statements.\n- Other auditing firms will decrease because investors will not be able to differentiate them from the Big Four.", "price_info": {}}, {"link": "https://www.wsj.com/articles/german-court-rules-against-facebook-on-data-protection-11579891532", "title": "Facebook Loses Ruling on Data Protection", "date": "2020-01-24 13:45", "summary": "Complaint from consumer group about user terms is partly upheld. BERLIN-A state court in Berlin ruled that some user terms set by Facebook Inc. violated consumer-data protection law, in the latest example of back-and-forth between companies and courts to define the boundaries of the European Union's extensive privacy rules.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Loses Ruling on Data Protection. Complaint from consumer group about user terms is partly upheld. BERLIN-A state court in Berlin ruled that some user terms set by Facebook Inc. violated consumer-data protection law, in the latest example of back-and-forth between companies and courts to define the boundaries of the European Union's extensive privacy rules.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc. (NASDAQ: FB) will decrease because they were ruled against in a data protection case.\n- Apple Inc. (NASDAQ: AAPL) will increase because they have been seen as a champion of user privacy.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [217.56, 216.9501]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [319.959, 319.96]}}}, {"link": "https://www.wsj.com/articles/wireless-networks-dish-rakuten-cloud-11634000875", "title": "To Lower Costs, Wireless Networks such as Dish and Rakuten Head to the Cloud", "date": "2021-10-12 11:00", "summary": "Upstart operators are trying to get a cost edge over bigger, more-established rivals. The jury is still out on whether they will be successful.. These days, everything from student term papers to company personnel information lives in the cloud, the big computer farms operated by the likes of Amazon.com Inc. that hold and process data.", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"To Lower Costs, Wireless Networks such as Dish and Rakuten Head to the Cloud. Upstart operators are trying to get a cost edge over bigger, more-established rivals. The jury is still out on whether they will be successful.. These days, everything from student term papers to company personnel information lives in the cloud, the big computer farms operated by the likes of Amazon.com Inc. that hold and process data.\"\n\nStock Prediction(s):", "Prediction": "\n- Dish Network Corp (NASDAQ: DISH) will increase because they are moving their operations to the cloud, and this will help them save on costs.\n- Rakuten Inc (TSE: 4755) will increase because they are moving their operations to the cloud, and this will help them save on costs.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are the leading provider of cloud services, and this", "price_info": {"DISH": {"company": "", "ticker": "DISH", "move": "up", "prices": [43.5038, 43.1354]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3249.3989, 3249.6592]}}}, {"link": "https://www.wsj.com/articles/u-s-companies-balk-at-amazons-call-for-covid-19-disclosures-11601997368", "title": "Amazon Pushes for More Covid-19 Disclosures. Companies Say No.", "date": "2020-10-07 10:29", "summary": "E-commerce giant pushes for more transparency on infection and quarantine rates, but firms are reluctant to share more than what is required. Amazon . com Inc. last week called on other large companies to share the results of their workplace Covid-19 testing and disclose the rate at which employees are quarantining. So far, their answer appears to be no.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Amazon Pushes for More Covid-19 Disclosures. Companies Say No.. E-commerce giant pushes for more transparency on infection and quarantine rates, but firms are reluctant to share more than what is required. Amazon . com Inc. last week called on other large companies to share the results of their workplace Covid-19 testing and disclose the rate at which employees are quarantining. So far, their answer appears to be no.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are asking for more transparency than other companies are willing to give.\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are asking for more transparency than other companies are willing to give.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are asking for more transparency than other companies are willing to give.\n- Microsoft Corporation (", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3163.6, 3161.028]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [256.2, 256.295]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [115.06, 114.4]}}}, {"link": "https://www.wsj.com/articles/faa-proposes-safety-fix-for-another-737-max-production-lapse-11582653916", "title": "FAA Proposes Safety Fix for Another 737 MAX Production Lapse", "date": "2020-02-25 13:05", "summary": "Boeing says proposal isn't expected to affect mid-2020 return for the grounded jets. The Federal Aviation Administration is mandating a new round of safety fixes before Boeing Co. 's 737 MAX jets can return to the air, this time targeting assembly-line lapses that could result in dual-engine power loss in the event of a lightning strike.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FAA Proposes Safety Fix for Another 737 MAX Production Lapse. Boeing says proposal isn't expected to affect mid-2020 return for the grounded jets. The Federal Aviation Administration is mandating a new round of safety fixes before Boeing Co. 's 737 MAX jets can return to the air, this time targeting assembly-line lapses that could result in dual-engine power loss in the event of a lightning strike.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will decrease because of the new safety proposal that is expected to delay the return of the 737 MAX jets.\n- United Technologies Corp. (NYSE: UTX) will decrease because of the new safety proposal that is expected to delay the return of the 737 MAX jets.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [308.37, 305.8176]}, "UTX": {"company": "", "ticker": "UTX", "move": "down", "prices": [142.65, 140.5]}}}, {"link": "https://www.wsj.com/articles/brace-for-another-bad-jobs-report-11590077971", "title": "Brace for Another Bad Jobs Report", "date": "2020-05-21 12:19", "summary": "Job losses appear to be slowing, but the May employment picture still looks horrible. The good news is the job market isn't deteriorating quite as badly in May as it did in April. But actual improvement will have to wait.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Brace for Another Bad Jobs Report. Job losses appear to be slowing, but the May employment picture still looks horrible. The good news is the job market isn't deteriorating quite as badly in May as it did in April. But actual improvement will have to wait.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will stay the same.\n- The number of jobs lost will stay the same.\n- The number of hours worked will stay the same.", "price_info": {}}, {"link": "https://www.wsj.com/articles/why-uber-is-shrinking-its-global-food-delivery-menu-11576511818", "title": "Why Uber Is Shrinking Its Global Food-Delivery Menu", "date": "2019-12-16 10:56", "summary": "The online takeout sector has unappetizing economics but can still give investors big gains. Investors' newfound taste for profits instead of growth-at-all-costs is triggering a wave of consolidation in the global meal-delivery sector.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Uber Is Shrinking Its Global Food-Delivery Menu. The online takeout sector has unappetizing economics but can still give investors big gains. Investors' newfound taste for profits instead of growth-at-all-costs is triggering a wave of consolidation in the global meal-delivery sector.\"\n\nStock Prediction(s):", "Prediction": "\n- Uber Technologies Inc (NYSE: UBER) will decrease because they are selling their food-delivery business.\n- Grubhub Inc (NYSE: GRUB) will increase because they are buying Uber's food-delivery business.", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "down", "prices": [30.0152, 30.1004]}, "GRUB": {"company": "", "ticker": "GRUB", "move": "up", "prices": [44.75, 45.11]}}}, {"link": "https://www.wsj.com/articles/crude-prices-fall-on-coronavirus-fears-11579717568", "title": "Crude Prices Fall on Coronavirus Fears", "date": "2020-01-22 15:46", "summary": "IMF predicts slowing economic growth in U.S. and China, helping spark worries about future demand. Crude prices fell to seven-week lows on Wednesday, weighed down by concerns that a deadly strain of coronavirus that originated in China could dent demand for oil and jet fuel.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Crude Prices Fall on Coronavirus Fears. IMF predicts slowing economic growth in U.S. and China, helping spark worries about future demand. Crude prices fell to seven-week lows on Wednesday, weighed down by concerns that a deadly strain of coronavirus that originated in China could dent demand for oil and jet fuel.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because of the fall in crude prices.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because of the fall in crude prices.\n- Schlumberger Limited. (NYSE: SLB) will decrease because of the fall in crude prices.\n- Halliburton Company (NYSE: HAL) will decrease because of the fall in crude prices.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [112.9294, 112.94]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [67.225, 67.18]}, "SLB": {"company": "", "ticker": "SLB", "move": "down", "prices": [36.603, 36.665]}, "HAL": {"company": "", "ticker": "HAL", "move": "down", "prices": [23.92, 23.935]}}}, {"link": "https://www.wsj.com/articles/the-facebook-of-love-11569526504", "title": "Facebook's New Dating App: We're Not Feeling the Love", "date": "2019-09-26 15:35", "summary": "Dating apps abound, but is the tech giant's new matchmaking feature a better way to become more than friends? The jury's out. IN THE NOT-SO-DISTANT future, it will no doubt be commonplace for a father to lean over and tell his kid, \"It's true, Junior, I knew she was the one as soon as I swiped right.\"", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook's New Dating App: We're Not Feeling the Love. Dating apps abound, but is the tech giant's new matchmaking feature a better way to become more than friends? The jury's out. IN THE NOT-SO-DISTANT future, it will no doubt be commonplace for a father to lean over and tell his kid, \"It's true, Junior, I knew she was the one as soon as I swiped right.\"\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will decrease because their new dating app is not being well-received.\n- Match Group, Inc. (NASDAQ: MTCH) will increase because their dating app is being well-received.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [180.08, 180.11]}, "MTCH": {"company": "", "ticker": "MTCH", "move": "up", "prices": [71.44, 71.53]}}}, {"link": "https://www.wsj.com/articles/charlie-munger-the-phone-is-not-ringing-off-the-hook-11587132006", "title": "Charlie Munger: 'The Phone Is Not Ringing Off the Hook'", "date": "2020-04-17 10:00", "summary": "The Berkshire Hathaway vice chairman has always preached the value of being prepared to pounce when there are bargains to be had. Has that time come?. If the coronavirus lockdown has frozen your investing plans, you're in good company. Charlie Munger is watching and waiting, too.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Charlie Munger: 'The Phone Is Not Ringing Off the Hook'. The Berkshire Hathaway vice chairman has always preached the value of being prepared to pounce when there are bargains to be had. Has that time come?. If the coronavirus lockdown has frozen your investing plans, you're in good company. Charlie Munger is watching and waiting, too.\"\n\nStock Prediction(s):", "Prediction": "\n- Berkshire Hathaway Inc. (NYSE: BRK.A) will increase because Charlie Munger is waiting for a good opportunity, and the coronavirus lockdown has created a lot of bargains.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because Charlie Munger is waiting for a good opportunity, and the coronavirus lockdown has created a lot of bargains.\n- Facebook, Inc. (NASDAQ: FB", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [2358.58, 2353.37]}}}, {"link": "https://www.wsj.com/articles/u-s-durable-goods-orders-drop-for-first-time-since-last-spring-11616592333", "title": "U.S. Durable-Goods Orders Drop for First Time Since Last Spring", "date": "2021-03-24 09:57", "summary": "New orders declined 1.1% in February as factories struggle to get parts. Orders for long-lasting manufactured goods fell in February as U.S. factories faced supply-chain challenges.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Durable-Goods Orders Drop for First Time Since Last Spring. New orders declined 1.1% in February as factories struggle to get parts. Orders for long-lasting manufactured goods fell in February as U.S. factories faced supply-chain challenges.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing (NYSE: BA) will decrease because of the decrease in durable-goods orders.\n- Caterpillar (NYSE: CAT) will decrease because of the decrease in durable-goods orders.\n- 3M (NYSE: MMM) will decrease because of the decrease in durable-goods orders.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [247.8, 242.99]}, "CAT": {"company": "", "ticker": "CAT", "move": "down", "prices": [226.31, 225.49]}, "MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [191.5, 192.28]}}}, {"link": "https://www.wsj.com/articles/youtube-becomes-latest-tech-giant-to-curb-qanon-11602784617", "title": "YouTube Becomes Latest Tech Giant to Curb QAnon", "date": "2020-10-15 13:56", "summary": "Google-owned video service is taking down conspiracy movement's content that promotes violence. YouTube took action against the conspiracy group QAnon, banning videos that call for violence, following the lead of social-media companies that have cracked down on such content.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"YouTube Becomes Latest Tech Giant to Curb QAnon. Google-owned video service is taking down conspiracy movement's content that promotes violence. YouTube took action against the conspiracy group QAnon, banning videos that call for violence, following the lead of social-media companies that have cracked down on such content.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because YouTube is one of their subsidiaries, and they have been cracking down on violent content.\n- Facebook, Inc. (NASDAQ: FB) will increase because they have been cracking down on violent content.\n- Twitter, Inc. (NYSE: TWTR) will increase because they have been cracking down on violent content.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down", "prices": [45.58, 46.055]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [1551.32, 1554.55]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [264.97, 266.6]}}}, {"link": "https://www.wsj.com/articles/pfizer-searches-for-new-cfo-as-frank-damelio-retires-11637165409", "title": "Pfizer Searches for New CFO as Frank D'Amelio Retires", "date": "2021-11-17 12:56", "summary": "Mr. D'Amelio, who has been with the drugmaker since 2007, will stay on until his successor is named. Pfizer Inc. is looking for a new chief financial officer following the retirement of its longtime CFO, Frank D'Amelio.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pfizer Searches for New CFO as Frank D'Amelio Retires. Mr. D'Amelio, who has been with the drugmaker since 2007, will stay on until his successor is named. Pfizer Inc. is looking for a new chief financial officer following the retirement of its longtime CFO, Frank D'Amelio.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will decrease because they are losing their CFO.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [50.305, 50.725]}}}, {"link": "https://www.wsj.com/articles/ecb-signals-further-stimulus-ahead-11603976353", "title": "ECB Signals Further Stimulus Ahead", "date": "2020-10-29 14:32", "summary": "European Central Bank indicates likely action in December to soften the economic impact of lockdowns. FRANKFURT-The European Central Bank intends to scale up its support of the eurozone's economy, seeking to cushion the region from the fallout of a new wave of coronavirus infections that threatens to knock back a currency area that was still recovering from spring lockdowns.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"ECB Signals Further Stimulus Ahead. European Central Bank indicates likely action in December to soften the economic impact of lockdowns. FRANKFURT-The European Central Bank intends to scale up its support of the eurozone's economy, seeking to cushion the region from the fallout of a new wave of coronavirus infections that threatens to knock back a currency area that was still recovering from spring lockdowns.\"\n\nStock Prediction(s):", "Prediction": "\n- The European Central Bank (ECB) will increase because they are indicating that they will be taking further action in December.\n- The eurozone will increase because the ECB is increasing their support.\n- The United States will increase because the ECB is increasing their support.", "price_info": {"ECB": {"company": "Central Bank", "ticker": "ECB", "move": "up"}}}, {"link": "https://www.wsj.com/articles/u-s-scores-guilty-plea-in-mozambique-corruption-case-11563894033", "title": "U.S. Scores Guilty Plea in Mozambique Corruption Case", "date": "2019-07-23 11:00", "summary": "Credit Suisse banker also implicates Lebanese businessman Iskandar Safa. The U.S. Department of Justice has gained a key advantage in its prosecution of an alleged global corruption ring involving $2 billion of Mozambican government-debt deals.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Scores Guilty Plea in Mozambique Corruption Case. Credit Suisse banker also implicates Lebanese businessman Iskandar Safa. The U.S. Department of Justice has gained a key advantage in its prosecution of an alleged global corruption ring involving $2 billion of Mozambican government-debt deals.\"\n\nStock Prediction(s):", "Prediction": "\n- Credit Suisse Group AG (NYSE: CS) will increase because they have a banker that has plead guilty, and this will give them a leg up in the prosecution.\n- Iskandar Safa will decrease because he is a Lebanese businessman that has been implicated in the case.", "price_info": {"CS": {"company": "", "ticker": "CS", "move": "down", "prices": [12.555, 12.54]}}}, {"link": "https://www.wsj.com/articles/repsol-targets-net-zero-emissions-in-strategic-shift-11575360545", "title": "Spanish Energy Giant Repsol Writes Down Oil, Gas Assets", "date": "2019-12-03 11:16", "summary": "Along with warnings of a $5 billion impairment charge, the company said it aims to achieve net-zero emissions by 2050. Spanish energy company Repsol SA said it is cutting the value of its assets by billions of dollars because the global transition to a lower carbon economy is weakening the outlook for oil and gas prices.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Spanish Energy Giant Repsol Writes Down Oil, Gas Assets. Along with warnings of a $5 billion impairment charge, the company said it aims to achieve net-zero emissions by 2050. Spanish energy company Repsol SA said it is cutting the value of its assets by billions of dollars because the global transition to a lower carbon economy is weakening the outlook for oil and gas prices.\"\n\nStock Prediction(s):", "Prediction": "\n- Repsol SA (BME: REP) will decrease because they are writing down their assets and their outlook is weakening.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they are not writing down their assets and their outlook is stronger.\n- BP plc (NYSE: BP) will increase because they are not writing down their assets and their outlook is stronger.\n- Exxon Mobil Corporation (NYSE: XOM) will", "price_info": {"BP": {"company": "", "ticker": "BP", "move": "down", "prices": [36.685, 36.81]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [67.75, 68.04]}}}, {"link": "https://www.wsj.com/articles/fed-pumps-70-2-billion-in-short-term-liquidity-into-markets-11575993443", "title": "Fed Pumps $70.2 Billion in Short-Term Liquidity Into Markets", "date": "2019-12-10 10:57", "summary": "Money-market operations are aimed at ensuring the financial system has enough liquidity. The Federal Reserve Bank of New York added $70.2 billion in temporary liquidity to financial markets.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Pumps $70.2 Billion in Short-Term Liquidity Into Markets. Money-market operations are aimed at ensuring the financial system has enough liquidity. The Federal Reserve Bank of New York added $70.2 billion in temporary liquidity to financial markets.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed's injection of liquidity into the markets will cause an increase in most stocks.\n- The exception will be companies that are directly competing with the Fed, such as Goldman Sachs (NYSE: GS) and JPMorgan Chase (NYSE: JPM).", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up", "prices": [222.42, 222.27]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [134.1501, 134.135]}}}, {"link": "https://www.wsj.com/articles/meatpacker-jbs-removed-at-risk-workers-from-beef-plant-amid-covid-19-surge-11607087090", "title": "Meatpacker JBS Removed At-Risk Workers from Plant Amid Virus Surge", "date": "2020-12-04 10:17", "summary": "Company said it sent home about 200 employees as virus cases rise at its Colorado processing facility. ", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Meatpacker JBS Removed At-Risk Workers from Plant Amid Virus Surge. Company said it sent home about 200 employees as virus cases rise at its Colorado processing facility. \"\n\nStock Prediction(s):", "Prediction": "\n- JBS SA (NYSE: JBSAY) will increase because they are taking precautions to stop the spread of the virus.\n- Tyson Foods, Inc. (NYSE: TSN) will decrease because they are not taking the same precautions as JBS SA.", "price_info": {"JBSAY": {"company": "", "ticker": "JBSAY", "move": "up"}, "TSN": {"company": "", "ticker": "TSN", "move": "down", "prices": [69.34, 69.3682]}}}, {"link": "https://www.wsj.com/articles/wework-cfo-departs-after-six-months-in-the-role-11599766848", "title": "WeWork CFO Departs After Six Months in the Role", "date": "2020-09-10 15:40", "summary": "The troubled co-working company named the finance chief of its Americas business to succeed Kimberly Ross. WeWork promoted the finance chief of its Americas business, Benjamin Dunham, as its chief financial officer. Its current CFO, Kimberly Ross, plans to leave the troubled co-working company after about six months in the role.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"WeWork CFO Departs After Six Months in the Role. The troubled co-working company named the finance chief of its Americas business to succeed Kimberly Ross. WeWork promoted the finance chief of its Americas business, Benjamin Dunham, as its chief financial officer. Its current CFO, Kimberly Ross, plans to leave the troubled co-working company after about six months in the role.\"\n\nStock Prediction(s):", "Prediction": "\n- WeWork Co. (NASDAQ: WEWORK) will continue to decline because of their recent financial troubles.\n- The departure of the CFO will only make things worse for the company.", "price_info": {}}, {"link": "https://www.wsj.com/articles/david-spade-lists-beverly-hills-home-for-19-995-million-11641403196", "title": "David Spade Lists Beverly Hills Home for $19.995 Million", "date": "2022-01-05 12:20", "summary": "The comedian and 'Bachelor in Paradise' guest host is moving to the Hollywood Hills. For roughly two decades, comedian David Spade's home-improvement projects kept pace with his acting credits.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"David Spade Lists Beverly Hills Home for $19.995 Million. The comedian and 'Bachelor in Paradise' guest host is moving to the Hollywood Hills. For roughly two decades, comedian David Spade's home-improvement projects kept pace with his acting credits.\"\n\nStock Prediction(s):", "Prediction": "\n- David Spade's Beverly Hills home will increase in value because he is selling it for $19.995 million.\n- Other celebrities' homes in Beverly Hills will also increase in value because of the high demand for luxury housing in the area.", "price_info": {}}, {"link": "https://www.wsj.com/articles/oil-prices-slide-to-five-month-lows-as-lockdowns-hit-demand-11604325947", "title": "Oil Prices Close Higher After Volatile Session", "date": "2020-11-02 15:02", "summary": "Worries over demand, rising output and election volatility are driving gyrations in crude prices. Oil prices ended higher Monday, paring early declines but extending a recent period of volatility as widening restrictions on economic activity in Europe threaten to hit demand for fuel.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Prices Close Higher After Volatile Session. Worries over demand, rising output and election volatility are driving gyrations in crude prices. Oil prices ended higher Monday, paring early declines but extending a recent period of volatility as widening restrictions on economic activity in Europe threaten to hit demand for fuel.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because oil prices are rising, and they are a major producer of oil.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because oil prices are rising, and they are a major producer of oil.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because oil prices are rising, and they are a major producer of oil.\n- BP plc (NYSE: BP", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [72.9201, 72.17]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [34.355, 33.93]}}}, {"link": "https://www.wsj.com/articles/the-markets-that-never-emerge-11577724191", "title": "The Markets That Never Emerge", "date": "2019-12-30 11:43", "summary": "Emerging-market stocks have had a miserable decade. The slowdown in Chinese growth suggests they won't break out as the next one begins.. After 10 years of misery for emerging-market stocks, investors may want to think about another name for the asset class. Equities from outside the world's advanced economies haven't emerged into anything, and the prospects heading into a new decade don't look any better.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Markets That Never Emerge. Emerging-market stocks have had a miserable decade. The slowdown in Chinese growth suggests they won't break out as the next one begins.. After 10 years of misery for emerging-market stocks, investors may want to think about another name for the asset class. Equities from outside the world's advanced economies haven't emerged into anything, and the prospects heading into a new decade don't look any better.\"\n\nStock Prediction(s):", "Prediction": "\n- Vanguard FTSE Emerging Markets ETF (NYSE: VWO) will decrease because the article suggests that emerging-market stocks have had a miserable decade, and there is no indication that this will change in the near future.\n- iShares MSCI Emerging Markets ETF (NYSE: EEM) will decrease because the article suggests that emerging-market stocks have had a miserable decade, and there is no indication that this will change in the near future.", "price_info": {"VWO": {"company": "", "ticker": "VWO", "move": "down", "prices": [44.599, 44.5601]}, "EEM": {"company": "", "ticker": "EEM", "move": "down", "prices": [44.975, 44.95]}}}, {"link": "https://www.wsj.com/articles/london-stock-exchanges-future-depends-on-brussels-11582901598", "title": "London Stock Exchange's Future Depends on Brussels", "date": "2020-02-28 09:53", "summary": "Investors may be too relaxed about two European Union decisions that are crucial to the company's growth plans. London Stock Exchange Group's future isn't quite the sure thing investors seem to think.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"London Stock Exchange's Future Depends on Brussels. Investors may be too relaxed about two European Union decisions that are crucial to the company's growth plans. London Stock Exchange Group's future isn't quite the sure thing investors seem to think.\"\n\nStock Prediction(s):", "Prediction": "\n- LSEG plc (LSE: LSE) will decrease because the future of their company is uncertain.\n- Deutsche Boerse AG (ETR: DB1) will increase because they are a competitor of LSEG, and they are a more stable company.", "price_info": {}}, {"link": "https://www.wsj.com/articles/tiktoks-ex-ceo-on-streaming-music-and-covid-11605114363", "title": "Former TikTok CEO Addresses Streaming, Music and Covid-19", "date": "2020-11-11 12:06", "summary": "The industry veteran is now adviser to Warner Music parent after leaving TikTok in August and Disney in March. Kevin Mayer has held numerous top jobs in the media and entertainment industries-three of them this year alone.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Former TikTok CEO Addresses Streaming, Music and Covid-19. The industry veteran is now adviser to Warner Music parent after leaving TikTok in August and Disney in March. Kevin Mayer has held numerous top jobs in the media and entertainment industries-three of them this year alone.\"\n\nStock Prediction(s):", "Prediction": "\n- Kevin Mayer will be brought on as an adviser to Warner Music Group (NYSE: WMG) because of his experience in the streaming and music industry.\n- Apple Inc. (NASDAQ: AAPL) will increase because they have been struggling to make a dent in the music streaming industry, and Mayer's experience could help them do so.\n- Spotify Technology SA (NYSE: SPOT) will decrease because they have been the dominant player in the music streaming industry", "price_info": {"WMG": {"company": "", "ticker": "WMG", "move": null, "prices": [29.41, 29.49]}, "SPOT": {"company": "", "ticker": "SPOT", "move": "down", "prices": [259.71, 259.01]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [118.66, 119.32]}}}, {"link": "https://www.wsj.com/articles/florida-home-on-six-beachfront-acres-lists-for-90-million-11638216653", "title": "Florida Home on Six Beachfront Acres Lists for $90 Million", "date": "2021-11-29 15:10", "summary": "The Jupiter Island compound, owned by SEI's Alfred West, has a main house, two guest cottages and a beach house, plus a dock. On Florida's affluent Jupiter Island, a waterfront compound that stretches from the Atlantic Ocean to the Intracoastal Waterway is hitting the market for $90 million.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Florida Home on Six Beachfront Acres Lists for $90 Million. The Jupiter Island compound, owned by SEI's Alfred West, has a main house, two guest cottages and a beach house, plus a dock. On Florida's affluent Jupiter Island, a waterfront compound that stretches from the Atlantic Ocean to the Intracoastal Waterway is hitting the market for $90 million.\"\n\nStock Prediction(s):", "Prediction": "\n- The property will sell for more than the asking price because it is a rare find and it is on a prime piece of real estate.\n- The property will sell for less than the asking price because the market for luxury homes is softening.", "price_info": {}}, {"link": "https://www.wsj.com/articles/spacex-projects-faa-review-delayed-after-receiving-18-000-comments-11640811325", "title": "SpaceX Project's FAA Review Delayed by Two Months", "date": "2021-12-29 15:55", "summary": "Environmental review is one part of commercial space licensing process for facility in Boca Chica, Texas. Federal regulators have delayed the release of an environmental review of SpaceX's plan to launch a new rocket from Texas by two months. One of the reasons? Too many comments from the public.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SpaceX Project's FAA Review Delayed by Two Months. Environmental review is one part of commercial space licensing process for facility in Boca Chica, Texas. Federal regulators have delayed the release of an environmental review of SpaceX's plan to launch a new rocket from Texas by two months. One of the reasons? Too many comments from the public.\"\n\nStock Prediction(s):", "Prediction": "\n- SpaceX (Private: SPX) will decrease because their project's FAA review has been delayed by two months.\n- Blue Origin LLC (Private: BLUE) will increase because their project's FAA review has been completed on time.", "price_info": {}}, {"link": "https://www.wsj.com/articles/ge-redesigns-boeing-777x-engine-component-delaying-planes-first-flight-11560793526", "title": "Boeing's New Long-Haul Jet Faces Delay", "date": "2019-06-17 13:45", "summary": "Customers for Boeing's new long-haul jet are planning for delivery delays. LE BOURGET, France- General Electric Co. is having to redesign an engine part for Boeing Co. 's new 777X long-haul jetliner, meaning a delay for its first test flight and potentially for the first delivery of the plane to airline customers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing's New Long-Haul Jet Faces Delay. Customers for Boeing's new long-haul jet are planning for delivery delays. LE BOURGET, France- General Electric Co. is having to redesign an engine part for Boeing Co. 's new 777X long-haul jetliner, meaning a delay for its first test flight and potentially for the first delivery of the plane to airline customers.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will decrease because their new long-haul jet is facing delays.\n- General Electric Co. (NYSE: GE) will increase because they are helping Boeing with the engine part, and they will likely be able to deliver the engines on time.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [355.19, 355.9199]}, "GE": {"company": "", "ticker": "GE", "move": "up", "prices": [10.085, 10.06]}}}, {"link": "https://www.wsj.com/articles/retail-industry-shopping-change-pandemic-11637331502", "title": "The Great Shopping Reset: How the Pandemic Helped Fix Retail", "date": "2021-11-19 12:14", "summary": "With less to sell than usual, department stores and specialty chains were able to rein in discounts and charge more, boosting profits. The Covid-19 pandemic was supposed to deliver a knockout punch to department stores and specialty retailers. Instead, many of them are bouncing back healthier.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Great Shopping Reset: How the Pandemic Helped Fix Retail. With less to sell than usual, department stores and specialty chains were able to rein in discounts and charge more, boosting profits. The Covid-19 pandemic was supposed to deliver a knockout punch to department stores and specialty retailers. Instead, many of them are bouncing back healthier.\"\n\nStock Prediction(s):", "Prediction": "\n- Macy's, Inc. (NYSE: M) will increase because they were able to rein in discounts and charge more, boosting profits.\n- J.C. Penney Company, Inc. (NYSE: JCP) will increase because they were able to rein in discounts and charge more, boosting profits.\n- Nordstrom, Inc. (NYSE: JWN) will increase because they were able to rein in discounts and charge more, boosting profits.\n-", "price_info": {"M": {"company": "", "ticker": "M", "move": "up", "prices": [35.895, 35.49]}, "JCP": {"company": "", "ticker": "JCP", "move": "up"}, "JWN": {"company": "", "ticker": "JWN", "move": "up", "prices": [33.3283, 33.04]}}}, {"link": "https://www.wsj.com/articles/thanksgiving-weekend-shoppers-boosted-spending-by-16-11575395503", "title": "Thanksgiving Weekend Shoppers Boosted Spending by 16%", "date": "2019-12-03 12:51", "summary": "Data show 190 million people made purchases during the five-day period; Black Friday drew more online shoppers than Cyber Monday. American shoppers increased their spending by 16% over the five-day shopping period between Thanksgiving Day and Cyber Monday, according to new data, signaling U.S. consumer confidence hasn't wavered in the face of global political and economic uncertainty.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Thanksgiving Weekend Shoppers Boosted Spending by 16%. Data show 190 million people made purchases during the five-day period; Black Friday drew more online shoppers than Cyber Monday. American shoppers increased their spending by 16% over the five-day shopping period between Thanksgiving Day and Cyber Monday, according to new data, signaling U.S. consumer confidence hasn't wavered in the face of global political and economic uncertainty.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because it is the main beneficiary of increased spending, as it is the largest online retailer.\n- Walmart Inc. (NYSE: WMT) will increase because it is the main beneficiary of increased spending, as it is the largest brick-and-mortar retailer.\n- Target Corporation (NYSE: TGT) will increase because it is the main beneficiary of increased spending, as it", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [118.025, 118.02]}, "TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [123.75, 123.92]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1756.25, 1757.252]}}}, {"link": "https://www.wsj.com/articles/amd-will-need-to-keep-upping-its-game-11578422867", "title": "AMD Will Need to Keep Upping Its Game", "date": "2020-01-07 13:47", "summary": "Chipmaker has masterfully capitalized on Intel's fumbles, but the coming year will be tougher. Investors placed a sizable wager on Advanced Micro Devices long before the chipmaker showed up in Las Vegas on Monday.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AMD Will Need to Keep Upping Its Game. Chipmaker has masterfully capitalized on Intel's fumbles, but the coming year will be tougher. Investors placed a sizable wager on Advanced Micro Devices long before the chipmaker showed up in Las Vegas on Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- AMD (NASDAQ: AMD) will continue to increase because they have been doing well recently and they are a competitor to Intel.\n- Intel (NASDAQ: INTC) will decrease because they have been doing poorly recently and AMD is taking over the market.", "price_info": {"AMD": {"company": "", "ticker": "AMD", "move": "up", "prices": [48.24, 48.415]}, "INTC": {"company": "", "ticker": "INTC", "move": "down", "prices": [59.0225, 59.06]}}}, {"link": "https://www.wsj.com/articles/europes-banks-confront-their-harsh-reality-11572543750", "title": "Europe's Banks Confront Their Harsh Reality", "date": "2019-10-31 13:42", "summary": "As ultralow rates continue to squeeze profit margins, Europe's banks are cutting costs and charging customers to avoid falling further behind stronger U.S. rivals. Ultralow interest rates and political and economic uncertainty are forcing Europe's banks to confront an imperative they have been slow to respond to: cut costs fast or risk falling even further behind U.S. rivals.", "categories": [["Markets", "Stocks", "Europe Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb", "https://www.wsj.com/news/types/europe-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Europe's Banks Confront Their Harsh Reality. As ultralow rates continue to squeeze profit margins, Europe's banks are cutting costs and charging customers to avoid falling further behind stronger U.S. rivals. Ultralow interest rates and political and economic uncertainty are forcing Europe's banks to confront an imperative they have been slow to respond to: cut costs fast or risk falling even further behind U.S. rivals.\"\n\nStock Prediction(s):", "Prediction": "\n- Deutsche Bank AG (NYSE: DB) will decrease because they are struggling to compete with stronger U.S. banks.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are stronger U.S. banks that are doing well in the current market.\n- Bank of America Corp (NYSE: BAC) will increase because they are stronger U.S. banks that are doing well in the current market.", "price_info": {"DB": {"company": "", "ticker": "DB", "move": "down", "prices": [7.22, 7.235]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [124.1923, 124.92]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [31.12, 31.33]}}}, {"link": "https://www.wsj.com/articles/wells-fargo-posts-higher-profit-11563279572", "title": "Wells Fargo Posts Higher Profit", "date": "2019-07-16 13:05", "summary": "The bank is working to dig out of regulatory problems while finding a permanent leader. Wells Fargo & Co. said Tuesday that second-quarter profit rose, though the bank had to pay up to satisfy depositors.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wells Fargo Posts Higher Profit. The bank is working to dig out of regulatory problems while finding a permanent leader. Wells Fargo & Co. said Tuesday that second-quarter profit rose, though the bank had to pay up to satisfy depositors.\"\n\nStock Prediction(s):", "Prediction": "\n- Wells Fargo & Co. (NYSE: WFC) will increase because they have been working to increase their profits and have satisfied depositors.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they have been working to increase their profits and have satisfied depositors.\n- Bank of America Corp (NYSE: BAC) will increase because they have been working to increase their profits and have satisfied depositors.", "price_info": {"WFC": {"company": "", "ticker": "WFC", "move": "up", "prices": [45.485, 45.34]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [114.97, 115.38]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [28.9693, 29.07]}}}, {"link": "https://www.wsj.com/articles/chinese-companies-win-billions-in-european-taxpayer-funded-contracts-11608222716", "title": "Chinese Companies Win Billions in European Taxpayer-Funded Contracts", "date": "2020-12-17 14:55", "summary": "European contractors say Beijing-backed conglomerates undercut rivals in the EU's public-procurement market. Chinese state-backed companies significantly increased their presence in Europe's rich public-procurement market over the past year, according to a Wall Street Journal analysis that for the first time quantifies how Beijing has expanded its global push to rival Western industrial giants in one of the world's most sophisticated economies.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chinese Companies Win Billions in European Taxpayer-Funded Contracts. European contractors say Beijing-backed conglomerates undercut rivals in the EU's public-procurement market. Chinese state-backed companies significantly increased their presence in Europe's rich public-procurement market over the past year, according to a Wall Street Journal analysis that for the first time quantifies how Beijing has expanded its global push to rival Western industrial giants in one of the world's most sophisticated economies.\"\n\nStock Prediction(s):", "Prediction": "\n- Siemens AG (OTCMKTS: SIEGY) will decrease because they are a European contractor and they are being undercut by Chinese companies.\n- Huawei Technologies Co. Ltd. (OTCMKTS: HWTUF) will increase because they are a Chinese company and they are winning contracts in Europe.\n- ABB Ltd. (NYSE: ABB) will decrease because they are a European contractor and they are being undercut by Chinese companies.", "price_info": {"ABB": {"company": "", "ticker": "ABB", "move": "down", "prices": [27.29, 27.32]}}}, {"link": "https://www.wsj.com/articles/senators-pressure-td-bank-to-pay-victims-of-stanford-ponzi-scheme-11560886305", "title": "Senators Pressure TD Bank to Pay Victims of Stanford Ponzi Scheme", "date": "2019-06-18 15:31", "summary": "Canadian bank aided fraud by Stanford International Bank, lawmakers say. U.S. senators from Louisiana urged Toronto-Dominion Bank to compensate victims of R. Allen Stanford's Ponzi scheme over the bank's \"knowing assistance\" in his $5 billion fraud.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Senators Pressure TD Bank to Pay Victims of Stanford Ponzi Scheme. Canadian bank aided fraud by Stanford International Bank, lawmakers say. U.S. senators from Louisiana urged Toronto-Dominion Bank to compensate victims of R. Allen Stanford's Ponzi scheme over the bank's \"knowing assistance\" in his $5 billion fraud.\"\n\nStock Prediction(s):", "Prediction": "\n- Toronto-Dominion Bank (NYSE: TD) will decrease because they are being pressured to pay the victims of the Stanford Ponzi scheme.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are not being pressured to pay the victims of the Stanford Ponzi scheme.", "price_info": {"TD": {"company": "", "ticker": "TD", "move": "down"}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [111.14, 110.65]}}}, {"link": "https://www.wsj.com/articles/buy-now-pay-later-is-just-one-piece-of-the-fintech-puzzle-11640022287", "title": "Buy Now, Pay Later Is Just One Piece of the Fintech Puzzle", "date": "2021-12-20 12:44", "summary": "A regulatory inquiry into split payments sparked a market reaction, but investors should think about these services in a wider context. A recently announced U.S. regulatory inquiry into split-payment services has spooked investors, with shares of players such as Affirm Holdings and Afterpay down sharply in some recent sessions. But investors need to react less now, and more later.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Buy Now, Pay Later Is Just One Piece of the Fintech Puzzle. A regulatory inquiry into split payments sparked a market reaction, but investors should think about these services in a wider context. A recently announced U.S. regulatory inquiry into split-payment services has spooked investors, with shares of players such as Affirm Holdings and Afterpay down sharply in some recent sessions. But investors need to react less now, and more later.\"\n\nStock Prediction(s):", "Prediction": "\n- Affirm Holdings Inc (NYSE: AFFM) will increase because their services are in high demand, and they are a key player in the fintech industry.\n- Afterpay Touch Group Ltd (ASX: APT) will increase because their services are in high demand, and they are a key player in the fintech industry.", "price_info": {"AFFM": {"company": "", "ticker": "AFFM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/chips-biggest-political-pawn-still-has-a-strong-game-11626895036", "title": "Chips' Biggest Political Pawn Still Has a Strong Game", "date": "2021-07-21 15:17", "summary": "ASML's major expansion looks like a solid bet, as subsidies for domestic production could offset limits to sales in China. The extremely expensive nature of chip manufacturing makes efficiency paramount. But for some producers of chip manufacturing equipment, inefficiency could become a saving grace.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chips' Biggest Political Pawn Still Has a Strong Game. ASML's major expansion looks like a solid bet, as subsidies for domestic production could offset limits to sales in China. The extremely expensive nature of chip manufacturing makes efficiency paramount. But for some producers of chip manufacturing equipment, inefficiency could become a saving grace.\"\n\nStock Prediction(s):", "Prediction": "\n- ASML Holding NV (NASDAQ: ASML) will increase because they are the main beneficiary of the political landscape, and they will be able to sell their products in China.\n- Applied Materials, Inc. (NASDAQ: AMAT) will decrease because they are a direct competitor of ASML, and they will not be able to sell their products in China.", "price_info": {"ASML": {"company": "", "ticker": "ASML", "move": "up", "prices": [719.9, 719.73]}, "AMAT": {"company": "", "ticker": "AMAT", "move": "down", "prices": [137.35, 132.84]}}}, {"link": "https://www.wsj.com/articles/andreessen-horowitz-invests-in-visual-analytics-startup-preset-11570724008", "title": "Andreessen Horowitz Invests in Visual-Analytics Startup Preset", "date": "2019-10-10 12:13", "summary": "Company provides more than 50 types of data visualization that can help businesses make decisions. Venture-capital firm Andreessen Horowitz said this week that earlier this year it led a funding round of $12.5 million in nine-month-old Silicon Valley startup Preset Inc., which makes a visual-analytics platform.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Andreessen Horowitz Invests in Visual-Analytics Startup Preset. Company provides more than 50 types of data visualization that can help businesses make decisions. Venture-capital firm Andreessen Horowitz said this week that earlier this year it led a funding round of $12.5 million in nine-month-old Silicon Valley startup Preset Inc., which makes a visual-analytics platform.\"\n\nStock Prediction(s):", "Prediction": "\n- Preset Inc (private) will increase because they have a new investor in Andreessen Horowitz.\n- Tableau Software Inc (NYSE: DATA) will decrease because they are a direct competitor of Preset.", "price_info": {"DATA": {"company": "", "ticker": "DATA", "move": "down"}}}, {"link": "https://www.wsj.com/articles/covid-19-deaths-significantly-reduced-by-use-of-steroids-analysis-says-11599055201", "title": "Covid-19 Deaths Significantly Reduced by Use of Steroids", "date": "2020-09-02 12:28", "summary": "Studies involving 1,700 patients showed consistent benefits from corticosteroid treatment, raising hopes that cheap drugs can help treat severe cases. A new analysis of several studies in which steroid drugs were used to treat severely ill Covid-19 patients found the drugs significantly helped reduce patient deaths, bolstering earlier, preliminary evidence for the benefit of these medications.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Deaths Significantly Reduced by Use of Steroids. Studies involving 1,700 patients showed consistent benefits from corticosteroid treatment, raising hopes that cheap drugs can help treat severe cases. A new analysis of several studies in which steroid drugs were used to treat severely ill Covid-19 patients found the drugs significantly helped reduce patient deaths, bolstering earlier, preliminary evidence for the benefit of these medications.\"\n\nStock Prediction(s):", "Prediction": "\n- Corticosteroid manufacturers will increase because their drugs were shown to be significantly helpful in reducing patient deaths.\n- Covid-19 vaccine manufacturers will decrease because their products were not found to be as beneficial as the corticosteroid drugs.", "price_info": {}}, {"link": "https://www.wsj.com/articles/ge-to-scale-back-boston-headquarters-return-87-million-of-incentives-11550182296", "title": "GE to Scale Back Boston HQ, Return $87 Million of Incentives", "date": "2019-02-15 14:05", "summary": "Company will sell properties and keep executives, smaller staff at Boston waterfront site. BOSTON- General Electric Co. is scaling back its planned Boston headquarters, including selling the property and dropping plans to add hundreds of jobs, because the shrinking conglomerate no longer needs the facilities.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GE to Scale Back Boston HQ, Return $87 Million of Incentives. Company will sell properties and keep executives, smaller staff at Boston waterfront site. BOSTON- General Electric Co. is scaling back its planned Boston headquarters, including selling the property and dropping plans to add hundreds of jobs, because the shrinking conglomerate no longer needs the facilities.\"\n\nStock Prediction(s):", "Prediction": "\n- GE (NYSE: GE) will decrease because they are scaling back their headquarters and returning money to the city of Boston.\n- Boston Properties Inc. (NYSE: BXP) will increase because they are selling the property that GE was going to use for their headquarters.", "price_info": {"GE": {"company": "", "ticker": "GE", "move": "down", "prices": [10.16, 10.105]}, "BXP": {"company": "", "ticker": "BXP", "move": "up", "prices": [133.67, 133.48]}}}, {"link": "https://www.wsj.com/articles/electric-truck-maker-rivian-raises-2-65-billion-ahead-of-first-vehicle-launch-11611075656", "title": "Electric-Truck Maker Rivian Raises $2.65 Billion Ahead of First Vehicle Launch", "date": "2021-01-19 12:00", "summary": "Startup backed by Amazon and Ford is valued at $27.6 billion amid continuing tear for electric-vehicle companies. Electric-vehicle startup Rivian Automotive LLC has raised another $2.65 billion, bolstering its balance sheet as it looks for an edge in the nascent market for electric trucks.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Electric-Truck Maker Rivian Raises $2.65 Billion Ahead of First Vehicle Launch. Startup backed by Amazon and Ford is valued at $27.6 billion amid continuing tear for electric-vehicle companies. Electric-vehicle startup Rivian Automotive LLC has raised another $2.65 billion, bolstering its balance sheet as it looks for an edge in the nascent market for electric trucks.\"\n\nStock Prediction(s):", "Prediction": "\n- Rivian Automotive LLC (private) will increase because they have raised more money and they are getting ready to launch their first electric truck.\n- Tesla, Inc. (NASDAQ: TSLA) will decrease because they are also making electric trucks, but Rivian is a direct competitor.", "price_info": {"TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [838.905, 837.7006]}}}, {"link": "https://www.wsj.com/articles/bonnier-corp-to-sell-its-biggest-u-s-magazines-to-venture-equity-group-11601992861", "title": "Bonnier Corp to Sell Its Biggest U.S. Magazines to Venture Equity Group", "date": "2020-10-06 10:01", "summary": "Deal hands Saveur, Popular Science, Field & Stream and others to North Equity. Magazine publisher Bonnier Corp. has agreed to sell seven of its best-known American titles, including Saveur, Popular Science and Field & Stream, to a venture equity group, the company said.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bonnier Corp to Sell Its Biggest U.S. Magazines to Venture Equity Group. Deal hands Saveur, Popular Science, Field & Stream and others to North Equity. Magazine publisher Bonnier Corp. has agreed to sell seven of its best-known American titles, including Saveur, Popular Science and Field & Stream, to a venture equity group, the company said.\"\n\nStock Prediction(s):", "Prediction": "\n- Bonnier Corp (NYSE: BON) will decrease because they are selling their magazines.\n- North Equity (private) will increase because they are buying the magazines.", "price_info": {"BON": {"company": "", "ticker": "BON", "move": "up"}}}, {"link": "https://www.wsj.com/articles/food-delivery-ipo-puts-profits-back-on-the-menu-11617100519", "title": "Food Delivery IPO Puts Profits Back on the Menu", "date": "2021-03-30 10:11", "summary": "Amazon-backed takeout app has priced its market debut at the bottom of its range. One reason is the threat of higher labor costs.. Shareholders in takeout delivery stocks have a reputation for ignoring losses. That is less true in Europe these days, where there is fresh debate about whether delivery couriers should get a more generous helping.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Food Delivery IPO Puts Profits Back on the Menu. Amazon-backed takeout app has priced its market debut at the bottom of its range. One reason is the threat of higher labor costs.. Shareholders in takeout delivery stocks have a reputation for ignoring losses. That is less true in Europe these days, where there is fresh debate about whether delivery couriers should get a more generous helping.\"\n\nStock Prediction(s):", "Prediction": "\n- Grubhub Inc (NYSE: GRUB) will increase because their IPO is priced lower than their competitors, and they are a dominant player in the food delivery space.\n- DoorDash Inc (NYSE: DOORD) will increase because their IPO is priced lower than their competitors, and they are a dominant player in the food delivery space.\n- Uber Technologies Inc (NYSE: UBER) will decrease because their IPO is priced higher than their competitors, and they", "price_info": {"GRUB": {"company": "", "ticker": "GRUB", "move": "up", "prices": [60.2369, 59.59]}, "DOORD": {"company": "", "ticker": "DOORD", "move": "up"}, "UBER": {"company": "", "ticker": "UBER", "move": "down", "prices": [53.689, 53.7]}}}, {"link": "https://www.wsj.com/articles/kidpik-biogen-block-ally-financial-what-to-watch-when-the-stock-market-opens-today-11641988019", "title": "Biogen, PayPal, Block, Ally Financial: What to Watch in the Stock Market Today", "date": "2022-01-12 09:45", "summary": "Biogen shares were dropping; Ally Financial got a boost from a dividend hike. Wall Street stock indexes edged up after inflation data showed the largest annual jump in consumer prices in decades. Here's what we're watching in Wednesday's trading:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biogen, PayPal, Block, Ally Financial: What to Watch in the Stock Market Today. Biogen shares were dropping; Ally Financial got a boost from a dividend hike. Wall Street stock indexes edged up after inflation data showed the largest annual jump in consumer prices in decades. Here's what we're watching in Wednesday's trading:\"\n\nStock Prediction(s):", "Prediction": "\n- Biogen Inc (NASDAQ: BIIB) will decrease because their stock is dropping.\n- PayPal Holdings, Inc. (NASDAQ: PYPL) will increase because they are partnering with Biogen.\n- The Charles Schwab Corporation (NYSE: SCHW) will increase because they are partnering with Biogen.\n- Ally Financial Inc. (NYSE: ALLY) will increase because they are hiking their dividend.", "price_info": {"SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [93.99, 93.65]}, "ALLY": {"company": "", "ticker": "ALLY", "move": "up", "prices": [52.0641, 52.1583]}, "BIIB": {"company": "", "ticker": "BIIB", "move": "down", "prices": [219.615, 218.2501]}, "PYPL": {"company": "", "ticker": "PYPL", "move": "up", "prices": [187.69, 186.565]}}}, {"link": "https://www.wsj.com/articles/overdraft-fees-are-getting-the-boot-at-ally-financial-11622631600", "title": "Overdraft Fees Are Getting the Boot at Ally Financial", "date": "2021-06-02 12:05", "summary": "Online bank says it will no longer charge the $25 penalty; Ally received positive feedback when it waived the fee early in the pandemic. Overdraft fees are a thing of the past at Ally Financial Inc.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Overdraft Fees Are Getting the Boot at Ally Financial. Online bank says it will no longer charge the $25 penalty; Ally received positive feedback when it waived the fee early in the pandemic. Overdraft fees are a thing of the past at Ally Financial Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Ally Financial Inc (NYSE: ALLY) will increase because they are no longer charging overdraft fees.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are still charging overdraft fees.", "price_info": {"ALLY": {"company": "", "ticker": "ALLY", "move": "up", "prices": [55.2017, 55.56]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [165.88, 165.97]}}}, {"link": "https://www.wsj.com/articles/nike-alphafly-sneakers-will-also-avoid-olympic-ban-11580929200", "title": "Nike Alphafly Sneakers Will Also Avoid Olympic Ban", "date": "2020-02-05 15:26", "summary": "Next generation of Vaporfly technology that sparked a crackdown will go on limited sale at end of month, making them eligible for Tokyo Games. In a crackdown on running sneakers spurred by high-tech Nikes, a clear winner is emerging: Nike Inc.", "categories": [["WSJ News Exclusive", "Sports"]], "category_links": ["https://www.wsj.com/news/sports?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nike Alphafly Sneakers Will Also Avoid Olympic Ban. Next generation of Vaporfly technology that sparked a crackdown will go on limited sale at end of month, making them eligible for Tokyo Games. In a crackdown on running sneakers spurred by high-tech Nikes, a clear winner is emerging: Nike Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Nike Inc (NYSE: NKE) will increase because their sneakers will be allowed in the Olympics.\n- Adidas AG (OTCMKTS: ADDYY) will decrease because their sneakers will not be allowed in the Olympics.", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [100.79, 100.48]}}}, {"link": "https://www.wsj.com/articles/verizon-to-buy-zoom-conferencing-rival-bluejeans-11587041218", "title": "Verizon Buys Zoom Conferencing Rival BlueJeans", "date": "2020-04-16 09:46", "summary": "Acquisition comes as the coronavirus spurs unprecedented work-from-home arrangements. Verizon Communications Inc. has agreed to buy videoconferencing company Blue Jeans Network Inc., as an unprecedented number of people work remotely because of the coronavirus pandemic.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Verizon Buys Zoom Conferencing Rival BlueJeans. Acquisition comes as the coronavirus spurs unprecedented work-from-home arrangements. Verizon Communications Inc. has agreed to buy videoconferencing company Blue Jeans Network Inc., as an unprecedented number of people work remotely because of the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Zoom Video Communications, Inc. (NASDAQ: ZM) will increase because of the acquisition of BlueJeans by Verizon.\n- BlueJeans Network Inc. (NYSE: BJC) will increase because of the acquisition of BlueJeans by Verizon.", "price_info": {"BJC": {"company": "", "ticker": "BJC", "move": "up"}, "ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [150.95, 149.98]}}}, {"link": "https://www.wsj.com/articles/bill-ackmans-playbook-works-against-him-11563994425", "title": "Bill Ackman's Playbook Works Against Him", "date": "2019-07-24 14:53", "summary": "Investors are upset about a decision from the activist's London-listed fund to issue bonds. William Ackman is being hoisted with his own petard.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bill Ackman's Playbook Works Against Him. Investors are upset about a decision from the activist's London-listed fund to issue bonds. William Ackman is being hoisted with his own petard.\"\n\nStock Prediction(s):", "Prediction": "\n- Pershing Square Holdings Ltd. (PSHZF) will decrease because investors are upset about the decision to issue bonds.", "price_info": {"PSHZF": {"company": "Holdings Ltd.", "ticker": "PSHZF", "move": "down"}}}, {"link": "https://www.wsj.com/articles/feds-evans-fed-has-moved-policy-to-slightly-accommodative-stance-11573052575", "title": "Fed's Evans: Fed Has Moved Policy to Slightly Accommodative Stance", "date": "2019-11-06 10:02", "summary": "The Chicago Fed leaders says his assessment of what is likely a neutral rate target may be closer to 2% now. Chicago Fed leader Charles Evans said Wednesday that the U.S. central bank has moved interest-rate policy to a place where it's modestly supportive of the economy.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans: Fed Has Moved Policy to Slightly Accommodative Stance. The Chicago Fed leaders says his assessment of what is likely a neutral rate target may be closer to 2% now. Chicago Fed leader Charles Evans said Wednesday that the U.S. central bank has moved interest-rate policy to a place where it's modestly supportive of the economy.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FED) will increase because they have shifted to a slightly accommodative stance.\n- The Goldman Sachs Group, Inc. (NYSE: GS) will increase because they are a direct beneficiary of the Fed's accommodative stance.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are a direct beneficiary of the Fed's accommodative stance.", "price_info": {"FED": {"company": "", "ticker": "FED", "move": "up"}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [218.885, 218]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [129.69, 129.56]}}}, {"link": "https://www.wsj.com/articles/twitter-loves-your-rage-against-its-machine-11590598400", "title": "Twitter Loves Your Rage Against Its Machine", "date": "2020-05-27 12:53", "summary": "Social media seems to feed off the very contempt it breeds in its users. Social media companies are no strangers to controversy. That might be by design.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Twitter Loves Your Rage Against Its Machine. Social media seems to feed off the very contempt it breeds in its users. Social media companies are no strangers to controversy. That might be by design.\"\n\nStock Prediction(s):", "Prediction": "\n- Twitter, Inc. (NYSE: TWTR) will continue to increase in stock price because they are a social media company that is no stranger to controversy, and this feeds off the contempt that it breeds in its users.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "up", "prices": [32.9699, 32.95]}}}, {"link": "https://www.wsj.com/articles/ecbs-latest-stimulus-will-help-banks-more-than-the-economy-11551973338", "title": "ECB's Latest Stimulus Will Help Banks More Than the Economy", "date": "2019-03-07 10:42", "summary": "Investors were too negative about the recent European Central Bank announcement, which was good news for lenders. After months of pretending to ignore the subject, the European Central Bank has finally confirmed another bout of long-term lending. This won't revive the slowing eurozone economy, but it will help cushion the blow for banks.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"ECB's Latest Stimulus Will Help Banks More Than the Economy. Investors were too negative about the recent European Central Bank announcement, which was good news for lenders. After months of pretending to ignore the subject, the European Central Bank has finally confirmed another bout of long-term lending. This won't revive the slowing eurozone economy, but it will help cushion the blow for banks.\"\n\nStock Prediction(s):", "Prediction": "\n- Banks will increase because the ECB's stimulus will help them more than the economy.\n- Other companies in the financial sector will also increase because of the ECB's stimulus.\n- Other companies that are not in the financial sector will decrease because the ECB's stimulus will help banks more than the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/renault-board-to-vote-friday-on-whether-to-remove-ceo-bollore-11570715556", "title": "Renault Board to Vote on Whether to Remove CEO Bollor\u00e9", "date": "2019-10-10 14:29", "summary": "Board of French auto maker concerned about CEO's tense relationship with its Japanese partner Nissan. PARIS- Renault SA's board is planning a vote Friday on whether to remove Chief Executive Thierry Bollor\u00e9 amid concerns over the car maker's performance and its tense relationship with Nissan Motor Co. , its partner in a globe-spanning alliance, according to people familiar with the matter.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Renault Board to Vote on Whether to Remove CEO Bollor\u00e9. Board of French auto maker concerned about CEO's tense relationship with its Japanese partner Nissan. PARIS- Renault SA's board is planning a vote Friday on whether to remove Chief Executive Thierry Bollor\u00e9 amid concerns over the car maker's performance and its tense relationship with Nissan Motor Co. , its partner in a globe-spanning alliance, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Renault SA (EPA: RNO) will decrease because their CEO is being removed.\n- Nissan Motor Co. (TSE: 7201) will increase because they are Renault's partner, and they may have a more positive relationship with the company now.", "price_info": {}}, {"link": "https://www.wsj.com/articles/money-managers-pledge-portfolios-to-reach-zero-emissions-by-2050-11607707440", "title": "Money Managers Pledge Portfolios to Reach Zero Emissions by 2050", "date": "2020-12-11 12:24", "summary": "Net Zero Asset Managers Initiative in Europe, representing assets of $9 trillion-plus, said it would work with clients to set interim targets. Some of Europe's largest money managers pledged on Friday to make their investment portfolios reach net-zero greenhouse-gas emissions by 2050.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Money Managers Pledge Portfolios to Reach Zero Emissions by 2050. Net Zero Asset Managers Initiative in Europe, representing assets of $9 trillion-plus, said it would work with clients to set interim targets. Some of Europe's largest money managers pledged on Friday to make their investment portfolios reach net-zero greenhouse-gas emissions by 2050.\"\n\nStock Prediction(s):", "Prediction": "\n- All of the money managers who pledged to have net-zero greenhouse-gas emissions by 2050 will increase in value because they are committing to a greener future.\n- Some of the money managers who pledged to have net-zero greenhouse-gas emissions by 2050 will decrease in value because they are not as committed to the cause as others.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-economy-lost-some-steam-at-start-of-second-quarter-11557946053", "title": "U.S. Economy Lost Some Steam at Start of Second Quarter", "date": "2019-05-15 14:47", "summary": "Retail sales and factory output declined in April, data show. The U.S. economy got off to a sluggish start in the second quarter, with both consumers and manufacturers pulling back in April amid trade tensions, a global slowdown and waning effects of the 2017 tax cuts.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Economy Lost Some Steam at Start of Second Quarter. Retail sales and factory output declined in April, data show. The U.S. economy got off to a sluggish start in the second quarter, with both consumers and manufacturers pulling back in April amid trade tensions, a global slowdown and waning effects of the 2017 tax cuts.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. economy will continue to slow down because of the trade tensions, global slowdown, and waning effects of the 2017 tax cuts.\n- The Dow Jones Industrial Average (NYSE: DJIA) will decrease because of the slowing economy.\n- The S&P 500 (NYSE: SPX) will decrease because of the slowing economy.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because of the slowing economy.", "price_info": {"DJIA": {"company": "", "ticker": "DJIA", "move": "down"}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/walgreens-posts-higher-sales-11572262171", "title": "Walgreens to Scale Back In-Store Clinics", "date": "2019-10-28 11:32", "summary": "Drugstore chain looks to shift to outside providers as it pursues chronic-care patients. Walgreens Boots Alliance Inc. is getting out of the walk-in clinic business as it cuts costs and looks to bring in outside providers to deliver medical services in stores.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walgreens to Scale Back In-Store Clinics. Drugstore chain looks to shift to outside providers as it pursues chronic-care patients. Walgreens Boots Alliance Inc. is getting out of the walk-in clinic business as it cuts costs and looks to bring in outside providers to deliver medical services in stores.\"\n\nStock Prediction(s):", "Prediction": "\n- Walgreens Boots Alliance Inc. (NASDAQ: WBA) will decrease because they are scaling back their in-store clinics.", "price_info": {"WBA": {"company": "", "ticker": "WBA", "move": "down", "prices": [55.24, 55.17]}}}, {"link": "https://www.wsj.com/articles/sec-gives-relief-to-mutual-funds-facing-redemption-issues-11585076903", "title": "SEC Gives Relief to Mutual Funds Facing Redemption Issues", "date": "2020-03-24 15:08", "summary": "Order would allow flexibility for the $19 trillion industry until at least June 30. Mutual funds facing stress from the market turmoil caused by coronavirus will be able to tap their parent asset-management companies and other affiliates for funding under relief announced this week by the Securities and Exchange Commission.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SEC Gives Relief to Mutual Funds Facing Redemption Issues. Order would allow flexibility for the $19 trillion industry until at least June 30. Mutual funds facing stress from the market turmoil caused by coronavirus will be able to tap their parent asset-management companies and other affiliates for funding under relief announced this week by the Securities and Exchange Commission.\"\n\nStock Prediction(s):", "Prediction": "\n- The mutual fund industry will rebound because of the SEC's order.\n- Asset-management companies will rebound because of the influx of cash from the mutual funds.\n- The parent companies of the mutual funds (e.g. JPMorgan Chase & Co. (NYSE: JPM), Bank of America Corp. (NYSE: BAC), etc.) will rebound because of the rebound in the mutual fund industry.", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": null, "prices": [88.3, 88.86]}, "BAC": {"company": "", "ticker": "BAC", "move": null, "prices": [20.94, 21.05]}}}, {"link": "https://www.wsj.com/articles/amazon-seeks-to-postpone-alabama-unionization-vote-11611339250", "title": "Amazon Seeks to Postpone Alabama Unionization Vote", "date": "2021-01-22 14:04", "summary": "Tech company pushes for in-person union ballot in place of mail-in option allowed due to pandemic. Amazon.com Inc. is seeking to postpone a unionization vote at a warehouse in Alabama and is asking federal labor authorities to reconsider a decision to allow mail-in voting due to the pandemic.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Amazon Seeks to Postpone Alabama Unionization Vote. Tech company pushes for in-person union ballot in place of mail-in option allowed due to pandemic. Amazon.com Inc. is seeking to postpone a unionization vote at a warehouse in Alabama and is asking federal labor authorities to reconsider a decision to allow mail-in voting due to the pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are trying to postpone a unionization vote.", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3294.5, 3300.25]}}}, {"link": "https://www.wsj.com/articles/intuit-cio-be-strategic-about-the-bots-you-build-11555005312", "title": "Intuit CIO: Be Strategic About the Bots You Build", "date": "2019-04-11 13:55", "summary": "More bots could heighten the risk of automating bad processes, says Atticus Tysen. Automation has become a top priority for Atticus Tysen, chief information officer of financial software company Intuit Inc., which is using software robots to automate repetitive tasks in the finance and human resources departments.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Intuit CIO: Be Strategic About the Bots You Build. More bots could heighten the risk of automating bad processes, says Atticus Tysen. Automation has become a top priority for Atticus Tysen, chief information officer of financial software company Intuit Inc., which is using software robots to automate repetitive tasks in the finance and human resources departments.\"\n\nStock Prediction(s):", "Prediction": "\n- Intuit Inc. (NASDAQ: INTU) will increase because they are using bots to automate repetitive tasks, which will save them time and money.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are also using bots to automate repetitive tasks, and they are a direct competitor of Intuit.", "price_info": {"INTU": {"company": "", "ticker": "INTU", "move": "up", "prices": [259.58, 259.59]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [119.988, 120.26]}}}, {"link": "https://www.wsj.com/articles/pg-e-makes-peace-with-bondholders-strife-with-gov-newsom-continues-11579809128", "title": "PG&E Makes Peace With Bondholders; Strife With Governor Continues", "date": "2020-01-23 14:52", "summary": "Utility deals away threat of a bondholder takeover in bankruptcy, but threat of state takeover perseveres. PG&E Corp. has reached an accord with bondholders that smooths its path out of bankruptcy, but it has yet to win over California Gov. Gavin Newsom, who has threatened a state takeover of the embattled utility.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"PG&E Makes Peace With Bondholders; Strife With Governor Continues. Utility deals away threat of a bondholder takeover in bankruptcy, but threat of state takeover perseveres. PG&E Corp. has reached an accord with bondholders that smooths its path out of bankruptcy, but it has yet to win over California Gov. Gavin Newsom, who has threatened a state takeover of the embattled utility.\"\n\nStock Prediction(s):", "Prediction": "\n- PG&E Corp. (NYSE: PCG) will increase because they have made peace with their bondholders, and the state takeover threat has yet to dissipate.\n- Edison International (NYSE: EIX) will decrease because they are a direct competitor of PG&E Corp.", "price_info": {"PCG": {"company": "", "ticker": "PCG", "move": "up", "prices": [14.0099, 13.81]}, "EIX": {"company": "", "ticker": "EIX", "move": "down", "prices": [77.455, 77.69]}}}, {"link": "https://www.wsj.com/articles/u-s-rebukes-boeing-over-tanker-11552592749", "title": "Boeing Rebuked Over Tanker", "date": "2019-03-14 15:45", "summary": "Air Force won't regain full confidence in plane maker's quality control for at least a year, says top official. The U.S. Air Force has lost confidence in Boeing Co. 's ability to maintain quality control over a new aerial refueling tanker it is building, with a senior Pentagon official saying Thursday that it could take at least a year to rebuild trust in the program.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Rebuked Over Tanker. Air Force won't regain full confidence in plane maker's quality control for at least a year, says top official. The U.S. Air Force has lost confidence in Boeing Co. 's ability to maintain quality control over a new aerial refueling tanker it is building, with a senior Pentagon official saying Thursday that it could take at least a year to rebuild trust in the program.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will decrease because they have lost the Air Force's trust.\n- Lockheed Martin Corp. (NYSE: LMT) will increase because they have a good reputation for quality control.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [373.18, 372.8]}, "LMT": {"company": "", "ticker": "LMT", "move": "up", "prices": [298.65, 298.51]}}}, {"link": "https://www.wsj.com/articles/in-luxury-goods-pandemic-shows-bigger-is-better-11597244267", "title": "In Luxury Goods, Pandemic Shows Bigger Is Better", "date": "2020-08-12 10:57", "summary": "Big brands such as Louis Vuitton and Herm\u00e8s have proved more resilient than smaller, independent Italian labels. The coronavirus crisis is widening the gap between the haves and the have-nots of the luxury goods industry.", "categories": [["Business", "Europe"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/europe-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"In Luxury Goods, Pandemic Shows Bigger Is Better. Big brands such as Louis Vuitton and Herm\u00e8s have proved more resilient than smaller, independent Italian labels. The coronavirus crisis is widening the gap between the haves and the have-nots of the luxury goods industry.\"\n\nStock Prediction(s):", "Prediction": "\n- LVMH Mo\u00ebt Hennessy Louis Vuitton SE (OTC: LVMHF) will increase because they are a big luxury brand and they have shown resilience during the pandemic.\n- Ferragamo SpA (BIT: FRA) will increase because they are a big luxury brand and they have shown resilience during the pandemic.\n- Kering SA (EPA: PPR) will increase because they are a big luxury brand and they", "price_info": {}}, {"link": "https://www.wsj.com/articles/wishful-thinking-in-a-world-without-yield-11624026610", "title": "Wishful Thinking in a World Without Yield", "date": "2021-06-18 10:30", "summary": "The need for higher returns can breed desperation for anyone with a portfolio-large or small. At first glance, the Pennsylvania Public School Employees' Retirement System, one of the largest pension plans in the U.S., doesn't sound anything like you or me. It commands $66 billion in net assets, spent $515 million last year on management fees, and has more than 40% of its net assets in exclusive investments like buyout, venture-capital and hedge funds.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wishful Thinking in a World Without Yield. The need for higher returns can breed desperation for anyone with a portfolio-large or small. At first glance, the Pennsylvania Public School Employees' Retirement System, one of the largest pension plans in the U.S., doesn't sound anything like you or me. It commands $66 billion in net assets, spent $515 million last year on management fees, and has more than 40% of its net assets in exclusive investments like buyout, venture-capital and hedge funds.\"\n\nStock Prediction(s):", "Prediction": "\n- The need for higher returns will breed desperation for anyone with a portfolio, which will negatively affect the stock prices of asset management companies.\n- The need for higher returns will breed desperation for anyone with a portfolio, which will negatively affect the stock prices of investment banks.\n- The need for higher returns will breed desperation for anyone with a portfolio, which will negatively affect the stock prices of mutual funds.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-home-price-growth-accelerated-in-march-11590500015", "title": "U.S. Home-Price Growth Accelerated in March", "date": "2020-05-26 09:33", "summary": "Case-Shiller index rose 4.4% on an annual basis, the highest rate since December 2018. Home-price growth accelerated in March, even as home sales dropped after the coronavirus pandemic shut down economic activity in some regions.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Home-Price Growth Accelerated in March. Case-Shiller index rose 4.4% on an annual basis, the highest rate since December 2018. Home-price growth accelerated in March, even as home sales dropped after the coronavirus pandemic shut down economic activity in some regions.\"\n\nStock Prediction(s):", "Prediction": "\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and KB Home (NYSE: KBH) will increase because the price of homes is increasing.\n- Real estate investment trusts (REITs) such as Simon Property Group, Inc. (NYSE: SPG) and Equity Residential (NYSE: EQR) will increase because the price of homes is increasing.", "price_info": {"LEN": {"company": "", "ticker": "LEN", "move": null, "prices": [62.48, 61.06]}, "KBH": {"company": "", "ticker": "KBH", "move": "up", "prices": [32.37, 31.62]}, "SPG": {"company": "", "ticker": "SPG", "move": null, "prices": [57.4, 57.7472]}, "EQR": {"company": "", "ticker": "EQR", "move": "up", "prices": [60.06, 59.81]}}}, {"link": "https://www.wsj.com/articles/saudis-plan-to-cut-crude-exports-to-7-1-million-barrels-a-day-say-opec-officials-11546877089", "title": "Saudis to Cut Crude Exports in Bid to Boost Prices, Cover Rise in Spending", "date": "2019-01-07 13:12", "summary": "Saudi Arabia to reduce crude exports by up to 800,000 barrels a day from November levels. Saudi Arabia is planning to cut crude exports to around 7.1 million barrels a day by the end of January in hopes of lifting oil prices above $80 a barrel, according to OPEC officials.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudis to Cut Crude Exports in Bid to Boost Prices, Cover Rise in Spending. Saudi Arabia to reduce crude exports by up to 800,000 barrels a day from November levels. Saudi Arabia is planning to cut crude exports to around 7.1 million barrels a day by the end of January in hopes of lifting oil prices above $80 a barrel, according to OPEC officials.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (Private: ARMCO) will increase because they are the main exporter of oil from Saudi Arabia, and they will be reducing exports by up to 800,000 barrels a day.\n- Schlumberger Ltd. (NYSE: SLB) will increase because they are a direct competitor of Saudi Aramco, and they will be benefiting from the reduction in exports.\n- Halliburton Company (NYSE: HAL) will increase because they are a", "price_info": {"SLB": {"company": "", "ticker": "SLB", "move": "up", "prices": [40.04, 40.32]}, "HAL": {"company": "", "ticker": "HAL", "move": "up", "prices": [29.04, 28.82]}}}, {"link": "https://www.wsj.com/articles/youtube-to-remove-videos-containing-vaccine-misinformation-11632927443", "title": "YouTube to Remove Videos With Vaccine Misinformation", "date": "2021-09-29 15:10", "summary": "Tightening goes beyond Covid-19 to target false claims about failings of range of approved vaccines. YouTube said it would remove content that falsely alleges approved vaccines are dangerous and cause severe health effects, expanding the video platform's efforts to curb Covid-19 misinformation to other vaccines.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"YouTube to Remove Videos With Vaccine Misinformation. Tightening goes beyond Covid-19 to target false claims about failings of range of approved vaccines. YouTube said it would remove content that falsely alleges approved vaccines are dangerous and cause severe health effects, expanding the video platform's efforts to curb Covid-19 misinformation to other vaccines.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc (NASDAQ: GOOGL) will increase because YouTube is tightening up their content policies to remove videos with vaccine misinformation.\n- Facebook Inc (NASDAQ: FB) will increase because they are also working on similar content policies.\n- Twitter Inc (NYSE: TWTR) will increase because they are also working on similar content policies.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "up", "prices": [60.07, 60.15]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2690.52, 2690.4]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [340.29, 339.975]}}}, {"link": "https://www.wsj.com/articles/halliburton-cutting-costs-bracing-for-huge-drop-in-u-s-oil-field-activity-11587383530", "title": "Halliburton Cutting Costs, Bracing for Drop in Oil-Field Activity", "date": "2020-04-20 11:05", "summary": "Largest supplier of oil equipment to U.S. drillers is set to be hit particularly hard by downturn in American oil patch. Halliburton Co. is cutting jobs, slashing costs by $1 billion and reducing its debt to gird itself against the dramatic drop in investment happening in the U.S. oil patch.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Halliburton Cutting Costs, Bracing for Drop in Oil-Field Activity. Largest supplier of oil equipment to U.S. drillers is set to be hit particularly hard by downturn in American oil patch. Halliburton Co. is cutting jobs, slashing costs by $1 billion and reducing its debt to gird itself against the dramatic drop in investment happening in the U.S. oil patch.\"\n\nStock Prediction(s):", "Prediction": "\n- Halliburton Co. (NYSE: HAL) will decrease because they are cutting jobs and costs in preparation for a downturn in the oil industry.\n- Schlumberger Ltd. (NYSE: SLB) will decrease because they are a direct competitor of Halliburton.\n- Baker Hughes, a GE company (NYSE: BHGE) will decrease because they are a direct competitor of Halliburton.", "price_info": {"HAL": {"company": "", "ticker": "HAL", "move": "down", "prices": [7.8418, 7.59]}, "SLB": {"company": "", "ticker": "SLB", "move": "down", "prices": [15.535, 15.1887]}, "BHGE": {"company": "", "ticker": "BHGE", "move": "down"}}}, {"link": "https://www.wsj.com/articles/lilly-alzheimers-drug-helped-patients-in-small-trial-11610364603", "title": "Lilly Alzheimer's Drug Helped Patients in Small Trial", "date": "2021-01-11 10:03", "summary": "Donanemab slowed cognitive and functional decline of patients with mild Alzheimer's by 32% compared with placebo. An experimental Alzheimer's drug from Eli Lilly & Co. helped patients in a small trial, the company said Monday, renewing hopes that researchers are closing in on therapies that can fight the disease.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Lilly Alzheimer's Drug Helped Patients in Small Trial. Donanemab slowed cognitive and functional decline of patients with mild Alzheimer's by 32% compared with placebo. An experimental Alzheimer's drug from Eli Lilly & Co. helped patients in a small trial, the company said Monday, renewing hopes that researchers are closing in on therapies that can fight the disease.\"\n\nStock Prediction(s):", "Prediction": "\n- Eli Lilly and Co. (NYSE: LLY) will increase because their Alzheimer's drug showed promising results in a small trial.\n- Biogen Inc. (NASDAQ: BIIB) will decrease because they are also working on an Alzheimer's drug, but their drug is not as promising as Lilly's.", "price_info": {"LLY": {"company": "", "ticker": "LLY", "move": "up", "prices": [186.685, 186.68]}, "BIIB": {"company": "", "ticker": "BIIB", "move": "down", "prices": [254.38, 262.63]}}}, {"link": "https://www.wsj.com/articles/casting-a-negative-light-on-motel-6-11554482368", "title": "Casting a Negative Light on Motel 6", "date": "2019-04-05 12:39", "summary": "The chain has paid a fine and agreed to stop providing information on guests without a warrant, but now it needs to work on quality. \"We'll leave the light on for you\" goes the famous advertising slogan of Motel 6. While radio personality Tom Bodett's folksy line has worked wonders for the roadside budget chain, now owned by G6 Hospitality, it might well be \"we'll leave the lights on so the authorities can find and deport you.\"", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Casting a Negative Light on Motel 6. The chain has paid a fine and agreed to stop providing information on guests without a warrant, but now it needs to work on quality. \"We'll leave the light on for you\" goes the famous advertising slogan of Motel 6. While radio personality Tom Bodett's folksy line has worked wonders for the roadside budget chain, now owned by G6 Hospitality, it might well be \"we'll leave the lights on so the authorities can find and deport you.\"\"\n\nStock Prediction(s):", "Prediction": "\n- G6 Hospitality (NYSE: G6H) will decrease because of the negative publicity it is receiving from the article.", "price_info": {}}, {"link": "https://www.wsj.com/articles/jeff-bezos-fresh-from-space-offers-to-waive-2-billion-for-nasa-moon-contract-11627379891", "title": "Jeff Bezos Offers to Waive $2 Billion for NASA Contract", "date": "2021-07-27 12:39", "summary": "Billionaire says agency should return to an original plan to have two companies provide lunar landers for its Artemis program. Jeff Bezos offered to waive up to $2 billion in fees to NASA in an effort to help his Blue Origin LLC space company become part of a lunar-lander contract that the agency awarded solely to Elon Musk's SpaceX.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jeff Bezos Offers to Waive $2 Billion for NASA Contract. Billionaire says agency should return to an original plan to have two companies provide lunar landers for its Artemis program. Jeff Bezos offered to waive up to $2 billion in fees to NASA in an effort to help his Blue Origin LLC space company become part of a lunar-lander contract that the agency awarded solely to Elon Musk's SpaceX.\"\n\nStock Prediction(s):", "Prediction": "\n- Blue Origin LLC (private) will increase because Jeff Bezos is offering to waive $2 billion in fees to help them become part of a lunar-lander contract.\n- SpaceX (private) will decrease because they are the only company that has been awarded the contract so far.", "price_info": {}}, {"link": "https://www.wsj.com/articles/uber-says-discounts-wont-drive-long-term-growth-in-food-delivery-11571771726", "title": "Uber Says Customer Discounts Won't Drive Long-Term Growth", "date": "2019-10-22 15:15", "summary": "Company's strategy isn't dependent on customer incentives, Uber Everything chief says. LAGUNA BEACH, Calif.-Incentives are a big part of the food-delivery business today but won't be over the long term, the head of Uber Everything said Tuesday.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Uber Says Customer Discounts Won't Drive Long-Term Growth. Company's strategy isn't dependent on customer incentives, Uber Everything chief says. LAGUNA BEACH, Calif.-Incentives are a big part of the food-delivery business today but won't be over the long term, the head of Uber Everything said Tuesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Uber Technologies Inc. (NYSE: UBER) will increase because they are not dependent on customer discounts for long-term growth.", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "up", "prices": [32.53, 32.45]}}}, {"link": "https://www.wsj.com/articles/easyjet-names-new-cfo-to-aid-with-recovery-11600451277", "title": "EasyJet Names New CFO to Aid With Recovery", "date": "2020-09-18 13:47", "summary": "The U.K. airline grounded most of its planes in late March and only resumed some flying in mid-June. U.K. budget carrier EasyJet PLC hired a new finance chief to help navigate the ongoing coronavirus pandemic.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"EasyJet Names New CFO to Aid With Recovery. The U.K. airline grounded most of its planes in late March and only resumed some flying in mid-June. U.K. budget carrier EasyJet PLC hired a new finance chief to help navigate the ongoing coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- EasyJet plc (LON: EZJ) will increase because they have a new CFO who will help with their recovery.\n- Ryanair Holdings plc (LON: RYA) will decrease because EasyJet is a direct competitor and they have been struggling more.", "price_info": {}}, {"link": "https://www.wsj.com/articles/coronavirus-shifts-pricing-power-to-ups-and-fedexand-they-are-using-it-11596026588", "title": "Coronavirus Shifts Pricing Power to UPS and FedEx", "date": "2020-07-29 11:23", "summary": "Amid surge of online deliveries, large shippers are hit with higher rates; 'a carrier market'. Online orders poured into Foot Locker Inc. in March, propping up business after the coronavirus pandemic forced the sneaker seller to close nearly all of its 3,000-plus stores.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Shifts Pricing Power to UPS and FedEx. Amid surge of online deliveries, large shippers are hit with higher rates; 'a carrier market'. Online orders poured into Foot Locker Inc. in March, propping up business after the coronavirus pandemic forced the sneaker seller to close nearly all of its 3,000-plus stores.\"\n\nStock Prediction(s):", "Prediction": "\n- United Parcel Service, Inc. (NYSE: UPS) will increase because they are the only large shipper that is not being impacted by the Covid-19 pandemic.\n- FedEx Corporation (NYSE: FDX) will increase because they are the only large shipper that is not being impacted by the Covid-19 pandemic.", "price_info": {"UPS": {"company": "", "ticker": "UPS", "move": "up", "prices": [123.24, 124.24]}, "FDX": {"company": "", "ticker": "FDX", "move": "up", "prices": [169.3905, 170.26]}}}, {"link": "https://www.wsj.com/articles/sec-chairman-warns-on-practices-that-risk-teachers-retirement-savings-11573829349", "title": "SEC Chairman Warns on Practices That Risk Teachers' Savings", "date": "2019-11-15 09:49", "summary": "Agency launched enforcement initiative after talking to investors at town halls. PHILADELPHIA-A sweeping federal enforcement initiative aimed at sales practices related to retirement savings for teachers began after town halls across the country where the nation's top securities regulator heard things that worried him.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SEC Chairman Warns on Practices That Risk Teachers' Savings. Agency launched enforcement initiative after talking to investors at town halls. PHILADELPHIA-A sweeping federal enforcement initiative aimed at sales practices related to retirement savings for teachers began after town halls across the country where the nation's top securities regulator heard things that worried him.\"\n\nStock Prediction(s):", "Prediction": "\n- Teachers' retirement savings providers will decrease because of the SEC's enforcement initiative.\n- Vanguard Group (NYSE: VNQ) will decrease because they are a major provider of retirement savings for teachers.\n- Fidelity Investments (NYSE: FNF) will decrease because they are a major provider of retirement savings for teachers.\n- Charles Schwab Corp (NYSE: SCHW) will decrease because they are a major provider of retirement savings for teachers.", "price_info": {"VNQ": {"company": "", "ticker": "VNQ", "move": "down", "prices": [92.36, 92.38]}, "FNF": {"company": "", "ticker": "FNF", "move": "down", "prices": [47.84, 47.86]}, "SCHW": {"company": "", "ticker": "SCHW", "move": "down", "prices": [43.88, 44.1]}}}, {"link": "https://www.wsj.com/articles/apollo-earnings-fall-as-ceo-wrangles-with-jeffrey-epstein-ties-11603969209", "title": "Leon Black Offers More Details on Ties to Jeffrey Epstein", "date": "2020-10-29 13:12", "summary": "Apollo chief executive raised the issue after questions swirled about his relationship with the late financier. Leon Black, the billionaire chief executive of Apollo Global Management Inc., on Thursday offered a history of his ties to the late financier Jeffrey Epstein, his most detailed public account yet of a relationship that sparked renewed concern among his firm's shareholders and fund investors in recent weeks.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Leon Black Offers More Details on Ties to Jeffrey Epstein. Apollo chief executive raised the issue after questions swirled about his relationship with the late financier. Leon Black, the billionaire chief executive of Apollo Global Management Inc., on Thursday offered a history of his ties to the late financier Jeffrey Epstein, his most detailed public account yet of a relationship that sparked renewed concern among his firm's shareholders and fund investors in recent weeks.\"\n\nStock Prediction(s):", "Prediction": "\n- Apollo Global Management, Inc. (NYSE: APO) will decrease because of the negative publicity around Leon Black's ties to Jeffrey Epstein.\n- Blackstone Group LP (NYSE: BX) will decrease because of the negative publicity around Leon Black's ties to Jeffrey Epstein.", "price_info": {"APO": {"company": "", "ticker": "APO", "move": "down", "prices": [38.46, 37.87]}, "BX": {"company": "", "ticker": "BX", "move": "down", "prices": [51.45, 51.33]}}}, {"link": "https://www.wsj.com/articles/beware-of-complacency-on-jobs-11596817762", "title": "Beware of Complacency on Jobs", "date": "2020-08-07 12:29", "summary": "Continued job growth in July doesn't change the need for stimulus. Jobs kept bouncing back last month. To figure if the recovery can continue, watch three things: what happens in Congress, what happens in schools and what happens with the virus.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Beware of Complacency on Jobs. Continued job growth in July doesn't change the need for stimulus. Jobs kept bouncing back last month. To figure if the recovery can continue, watch three things: what happens in Congress, what happens in schools and what happens with the virus.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will stay the same because the article is not giving any specific predictions.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-presses-for-strong-swiss-cryptocurrency-rules-11568140998", "title": "U.S. Warns Switzerland on Oversight of Facebook's Libra", "date": "2019-09-10 14:43", "summary": "Officials meet to discuss regulations that would apply to Libra, a digital currency proposed by Facebook. The U.S. urged Switzerland to ensure its regulations governing cryptocurrencies are strong enough to prevent abuse, as the European banking hub prepares to host Libra, a digital currency proposed by Facebook Inc.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Warns Switzerland on Oversight of Facebook's Libra. Officials meet to discuss regulations that would apply to Libra, a digital currency proposed by Facebook. The U.S. urged Switzerland to ensure its regulations governing cryptocurrencies are strong enough to prevent abuse, as the European banking hub prepares to host Libra, a digital currency proposed by Facebook Inc.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc (NASDAQ: FB) will increase because the U.S. is warning other countries to make sure their regulations are strong enough to prevent abuse.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are also working on a digital currency.\n- PayPal Holdings, Inc. (NASDAQ: PYPL) will increase because they are also working on a digital currency.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "up", "prices": [185.33, 186.3]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1813.7267, 1820.52]}, "PYPL": {"company": "", "ticker": "PYPL", "move": "up", "prices": [102.14, 103.25]}}}, {"link": "https://www.wsj.com/articles/growth-is-worth-paying-up-for-at-pfizer-11560785531", "title": "Growth Is Worth Paying Up for at Pfizer", "date": "2019-06-17 11:32", "summary": "A $10 billion price tag for cancer development is a reasonable risk for Pfizer to take. A fact of life for health-care companies, as well as patients: Good health care costs money.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Growth Is Worth Paying Up for at Pfizer. A $10 billion price tag for cancer development is a reasonable risk for Pfizer to take. A fact of life for health-care companies, as well as patients: Good health care costs money.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will continue to grow because they are investing in their future and have a good track record.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are not investing as much in their future.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "up", "prices": [42.61, 42.7188]}, "JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [139.57, 139.6131]}}}, {"link": "https://www.wsj.com/articles/darden-dennys-say-sales-down-sharply-during-coronavirus-11586274442", "title": "Darden and Denny's Hit Sales Slump", "date": "2020-04-07 11:47", "summary": "Dining rooms remain closed amid restrictions to curb spread of Covid-19. Darden Restaurants Inc. and Denny's Corp. said their sales have plummeted in recent weeks, highlighting the threat casual restaurant chains face as their dining rooms remain closed amid restrictions meant to halt the spread of the new coronavirus.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Darden and Denny's Hit Sales Slump. Dining rooms remain closed amid restrictions to curb spread of Covid-19. Darden Restaurants Inc. and Denny's Corp. said their sales have plummeted in recent weeks, highlighting the threat casual restaurant chains face as their dining rooms remain closed amid restrictions meant to halt the spread of the new coronavirus.\"\n\nStock Prediction(s):", "Prediction": "\n- Darden Restaurants, Inc. (NYSE: DRI) will decrease because their sales have plummeted in recent weeks.\n- Denny's Corp. (NASDAQ: DENN) will decrease because their sales have plummeted in recent weeks.", "price_info": {"DRI": {"company": "", "ticker": "DRI", "move": "down", "prices": [60.3254, 59.54]}, "DENN": {"company": "", "ticker": "DENN", "move": "down", "prices": [8.8188, 8.5112]}}}, {"link": "https://www.wsj.com/articles/u-k-companies-risk-ratings-downgrades-in-case-of-no-deal-brexit-11551366000", "title": "U.K. Companies Risk Ratings Downgrades in Case of No-Deal Brexit", "date": "2019-02-28 10:00", "summary": "Automotive, aerospace and transport firms are particularly exposed to credit risks. A disruptive Brexit could trigger ratings downgrades for more than a dozen, mainly U.K. companies, potentially driving up their financing costs and denting investor confidence.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.K. Companies Risk Ratings Downgrades in Case of No-Deal Brexit. Automotive, aerospace and transport firms are particularly exposed to credit risks. A disruptive Brexit could trigger ratings downgrades for more than a dozen, mainly U.K. companies, potentially driving up their financing costs and denting investor confidence.\"\n\nStock Prediction(s):", "Prediction": "\n- Rolls-Royce Holdings plc (OTCPK:RYCEY) will decrease because they are a British company that is particularly exposed to credit risks in the event of a no-deal Brexit.\n- Airbus SE (OTCPK:EADSF) will decrease because they are a French company that is particularly exposed to credit risks in the event of a no-deal Brexit.\n- GKN plc (OTCPK:GKNLY)", "price_info": {}}, {"link": "https://www.wsj.com/articles/need-financing-here-have-a-blank-check-11597417430", "title": "Need Financing? Here, Have a Blank Check", "date": "2020-08-14 11:03", "summary": "Upstarts are turning to reverse mergers as a way of going public during the economic downturn. These 'blank check' deals offer opportunities-and plenty of risk.. Kim Brady, the chief financial officer of an under-the-radar commercial-truck startup, watched Plan A to raise $1 billion crumble last year after private markets grew wary of pumping money into untested companies.", "categories": [["Business", "On Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/on-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Need Financing? Here, Have a Blank Check. Upstarts are turning to reverse mergers as a way of going public during the economic downturn. These 'blank check' deals offer opportunities-and plenty of risk.. Kim Brady, the chief financial officer of an under-the-radar commercial-truck startup, watched Plan A to raise $1 billion crumble last year after private markets grew wary of pumping money into untested companies.\"\n\nStock Prediction(s):", "Prediction": "\n- Blank check companies (NASDAQ: BLNK) will increase because they offer a way for startups to go public.\n- Private markets (NASDAQ: PRIV) will decrease because they are no longer willing to invest in untested companies.", "price_info": {"BLNK": {"company": "", "ticker": "BLNK", "move": "up", "prices": [10.89, 11.135]}, "PRIV": {"company": "", "ticker": "PRIV", "move": "down"}}}, {"link": "https://www.wsj.com/articles/kkr-earnings-rise-as-private-equity-portfolio-climbs-11635850320", "title": "KKR Earnings Rise, as Private-Equity Portfolio Climbs 9%", "date": "2021-11-02 11:52", "summary": "Firm says the part of profit that could be returned to shareholders surged in the third quarter. KKR & Co. reported an increase in third-quarter earnings, and the portion of profit that it could return to shareholders more than doubled.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"KKR Earnings Rise, as Private-Equity Portfolio Climbs 9%. Firm says the part of profit that could be returned to shareholders surged in the third quarter. KKR & Co. reported an increase in third-quarter earnings, and the portion of profit that it could return to shareholders more than doubled.\"\n\nStock Prediction(s):", "Prediction": "\n- KKR & Co. LP (NYSE: KKR) will increase because they are reporting an increase in earnings, and the portion of profit that could be returned to shareholders surged.\n- Blackstone Group LP (NYSE: BX) will increase because they are reporting an increase in earnings, and the portion of profit that could be returned to shareholders surged.\n- Carlyle Group LP (NASDAQ: CG) will increase because they are reporting an increase in earnings", "price_info": {"KKR": {"company": "", "ticker": "KKR", "move": "up", "prices": [80.21, 80.675]}, "BX": {"company": "", "ticker": "BX", "move": "up", "prices": [142.02, 143.2]}, "CG": {"company": "", "ticker": "CG", "move": "up", "prices": [55.47, 55.25]}}}, {"link": "https://www.wsj.com/articles/consumer-sentiment-fell-in-first-half-of-november-11605283662", "title": "Consumer Sentiment Soured in First Half of November", "date": "2020-11-13 11:07", "summary": "Mood of Americans darkened amid Republicans' post-election pessimism and a national coronavirus surge. Americans' outlook on the economy soured in the two weeks straddling the national elections, as Republicans grew more pessimistic and Democrats worried about a surge in coronavirus infections, according to survey findings released Friday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer Sentiment Soured in First Half of November. Mood of Americans darkened amid Republicans' post-election pessimism and a national coronavirus surge. Americans' outlook on the economy soured in the two weeks straddling the national elections, as Republicans grew more pessimistic and Democrats worried about a surge in coronavirus infections, according to survey findings released Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DOW) will decrease because of the news about the consumer sentiment.\n- The S&P 500 (NYSE: SPX) will decrease because of the news about the consumer sentiment.\n- The Nasdaq Composite (NASDAQ: COMP) will decrease because of the news about the consumer sentiment.", "price_info": {"DOW": {"company": "", "ticker": "DOW", "move": "down", "prices": [51.19, 51.3311]}, "SPX": {"company": "", "ticker": "SPX", "move": "down"}, "COMP": {"company": "", "ticker": "COMP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/airlines-add-routes-in-fight-for-americans-ready-to-travel-again-11616711549", "title": "Airlines Add Routes in Fight for Americans Ready to Travel Again", "date": "2021-03-26 11:22", "summary": "Carriers increase flights to U.S. vacation spots as international borders remain closed and business travel is low. Airlines are adding scores of U.S. routes as they battle for travelers looking to move around the country after being cooped up because of the coronavirus pandemic.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Airlines Add Routes in Fight for Americans Ready to Travel Again. Carriers increase flights to U.S. vacation spots as international borders remain closed and business travel is low. Airlines are adding scores of U.S. routes as they battle for travelers looking to move around the country after being cooped up because of the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- American Airlines Group Inc (NASDAQ: AAL) will increase because they are adding new routes, and business travel will pick up.\n- Delta Air Lines, Inc. (NYSE: DAL) will increase because they are adding new routes, and business travel will pick up.\n- United Airlines Holdings, Inc. (NYSE: UAL) will increase because they are adding new routes, and business travel will pick up.\n- JetBlue Airways Corporation (", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [47.26, 47.15]}, "UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [56.42, 56.26]}, "AAL": {"company": "", "ticker": "AAL", "move": "up", "prices": [22.795, 22.6]}}}, {"link": "https://www.wsj.com/articles/industry-group-recommends-new-rules-for-miners-after-brazil-dam-collapse-11573829109", "title": "Brazil Dam Collapse Prompts Potential Rule Shakeup for Miners", "date": "2019-11-15 11:04", "summary": "Proposal by industry group calls for strict standards on how companies build and operate mine-waste dams in wake of deadly Brumadinho accident. A group representing the world's largest miners published draft proposals for strict new standards to govern how companies build and operate the sort of mine-waste dam that collapsed in Brazil early this year, killing 270 people.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Brazil Dam Collapse Prompts Potential Rule Shakeup for Miners. Proposal by industry group calls for strict standards on how companies build and operate mine-waste dams in wake of deadly Brumadinho accident. A group representing the world's largest miners published draft proposals for strict new standards to govern how companies build and operate the sort of mine-waste dam that collapsed in Brazil early this year, killing 270 people.\"\n\nStock Prediction(s):", "Prediction": "\n- Vale SA (NYSE: VALE) will increase because they are being proactive about safety and have published new proposals for stricter standards.\n- BHP Group Ltd. (NYSE: BHP) will increase because they are being proactive about safety and have published new proposals for stricter standards.\n- Rio Tinto plc (NYSE: RIO) will increase because they are being proactive about safety and have published new proposals for stricter standards.\n- Newmont Mining Corporation", "price_info": {"VALE": {"company": "", "ticker": "VALE", "move": "up", "prices": [11.42, 11.49]}, "BHP": {"company": "", "ticker": "BHP", "move": "up", "prices": [50.44, 50.745]}, "RIO": {"company": "", "ticker": "RIO", "move": "up", "prices": [53.395, 53.72]}}}, {"link": "https://www.wsj.com/articles/robinhood-settles-claims-it-didnt-ensure-best-prices-for-customer-trades-11576776167", "title": "Robinhood Settles Claims It Didn't Ensure Best Prices for Customer Trades", "date": "2019-12-19 12:22", "summary": "The online brokerage agreed to pay $1.25 million. WASHINGTON-Robinhood Financial Inc. the online brokerage that has targeted millennials with commission-free trades, agreed to pay $1.25 million to settle regulatory claims it didn't take steps to ensure it was getting the best prices for customer orders.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Robinhood Settles Claims It Didn't Ensure Best Prices for Customer Trades. The online brokerage agreed to pay $1.25 million. WASHINGTON-Robinhood Financial Inc. the online brokerage that has targeted millennials with commission-free trades, agreed to pay $1.25 million to settle regulatory claims it didn't take steps to ensure it was getting the best prices for customer orders.\"\n\nStock Prediction(s):", "Prediction": "\n- Robinhood Financial Inc. (NASDAQ: Robinhood) will decrease because they have to pay $1.25 million to settle regulatory claims.\n- Charles Schwab Corp. (NYSE: SCHW) will increase because they are not part of the settlement, and they are a direct competitor of Robinhood.", "price_info": {"SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [48.41, 48.385]}}}, {"link": "https://www.wsj.com/articles/twitters-snapchat-rival-fleets-feature-comes-to-fleeting-end-11626283397", "title": "Twitter's Snapchat-Rival Fleets Feature Comes to Fleeting End", "date": "2021-07-14 15:51", "summary": "Disappearing posts failed to deliver sought-after increase in user engagement. That was fleeting.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Twitter's Snapchat-Rival Fleets Feature Comes to Fleeting End. Disappearing posts failed to deliver sought-after increase in user engagement. That was fleeting.\"\n\nStock Prediction(s):", "Prediction": "\n- Twitter, Inc. (NYSE: TWTR) will decrease because their Snapchat-rival feature, Fleets, has failed to deliver the increase in user engagement that they were hoping for.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "up", "prices": [70.27, 70.27]}}}, {"link": "https://www.wsj.com/articles/never-mind-peak-oil-global-forecaster-calls-peak-gasoline-11615988228", "title": "Gasoline Demand Has Peaked, Global Forecaster Says", "date": "2021-03-17 13:03", "summary": "IEA says shift to electric vehicles and rising fuel savings will outstrip developing-world demand growth. The world's thirst for gasoline isn't likely to return to pre-pandemic levels, the International Energy Agency forecast, calling a peak for the fuel that has powered personal transportation for more than a century.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gasoline Demand Has Peaked, Global Forecaster Says. IEA says shift to electric vehicles and rising fuel savings will outstrip developing-world demand growth. The world's thirst for gasoline isn't likely to return to pre-pandemic levels, the International Energy Agency forecast, calling a peak for the fuel that has powered personal transportation for more than a century.\"\n\nStock Prediction(s):", "Prediction": "\n- BP plc (NYSE: BP) will increase because they are a major player in the gasoline market.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they are a major player in the gasoline market.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because they are a major player in the gasoline market.\n- Chevron Corporation (NYSE: CVX) will decrease because they are a major player in the gasoline", "price_info": {"BP": {"company": "", "ticker": "BP", "move": "up", "prices": [26.41, 26.43]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [59.45, 59.32]}, "CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [108.05, 107.99]}}}, {"link": "https://www.wsj.com/articles/sanofi-fighting-back-in-insulin-price-debate-says-its-net-prices-fell-11-11583340721", "title": "Sanofi, Fighting Back in Insulin Price Debate, Says Its Net Prices Fell 11%", "date": "2020-03-04 15:40", "summary": "Politicians have called price increases egregious, while large insulin makers have become prime targets for criticism in the presidential race. Sanofi SA, maker of the world's bestselling insulin, said the price it received for its drugs fell on average just over 11% last year, including rebates it pays to insurers and health pharmacy-benefit managers.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Sanofi, Fighting Back in Insulin Price Debate, Says Its Net Prices Fell 11%. Politicians have called price increases egregious, while large insulin makers have become prime targets for criticism in the presidential race. Sanofi SA, maker of the world's bestselling insulin, said the price it received for its drugs fell on average just over 11% last year, including rebates it pays to insurers and health pharmacy-benefit managers.\"\n\nStock Prediction(s):", "Prediction": "\n- Sanofi SA (NYSE: SNY) will increase because they have shown that their net prices have fallen, and they are fighting back against the criticism.\n- Novo Nordisk A/S (NYSE: NVO) will decrease because they are a direct competitor of Sanofi, and they have not shown the same commitment to reducing prices.", "price_info": {"SNY": {"company": "", "ticker": "SNY", "move": "up", "prices": [50.495, 50.54]}, "NVO": {"company": "", "ticker": "NVO", "move": "down", "prices": [64.64, 64.82]}}}, {"link": "https://www.wsj.com/articles/why-are-n95-masks-so-important-11591026684", "title": "Why Are N95 Masks So Important?", "date": "2020-06-01 11:51", "summary": "Answers to some common questions about the coveted protective gear. What makes an N95 different from other face masks?", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Are N95 Masks So Important?. Answers to some common questions about the coveted protective gear. What makes an N95 different from other face masks?\"\n\nStock Prediction(s):", "Prediction": "\n- 3M Co (NYSE: MMM) will increase because they are one of the leading manufacturers of N95 masks.\n- Honeywell International Inc. (NYSE: HON) will increase because they are one of the leading manufacturers of N95 masks.\n- Kimberly-Clark Corp. (NYSE: KMB) will increase because they are one of the leading manufacturers of N95 masks.\n- Owens-Illinois, Inc. (NYSE: OI", "price_info": {"MMM": {"company": "", "ticker": "MMM", "move": "up", "prices": [156.48, 156.0815]}, "HON": {"company": "", "ticker": "HON", "move": "up", "prices": [146.86, 146.28]}, "KMB": {"company": "", "ticker": "KMB", "move": "up", "prices": [142.27, 142.2323]}}}, {"link": "https://www.wsj.com/articles/fed-minutes-officials-last-month-saw-strengthening-case-for-rate-cuts-11562781908", "title": "Fed Saw Strengthening Case for Rate Cuts Last Month, Minutes Show", "date": "2019-07-10 14:05", "summary": "By the time officials met in June, they judged that the risks of weaker growth had shifted notably. WASHINGTON-Federal Reserve officials grew more concerned about the economic outlook last month and discussed reasons why lower interest rates might be warranted in the coming months, according to minutes of their June meeting released Wednesday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Saw Strengthening Case for Rate Cuts Last Month, Minutes Show. By the time officials met in June, they judged that the risks of weaker growth had shifted notably. WASHINGTON-Federal Reserve officials grew more concerned about the economic outlook last month and discussed reasons why lower interest rates might be warranted in the coming months, according to minutes of their June meeting released Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will cut rates because of the weakening economy, which will cause most stocks to decrease.\n- The only exception will be companies that are directly benefiting from the rate cuts, such as banks and mortgage companies.", "price_info": {}}, {"link": "https://www.wsj.com/articles/garmin-says-cyberattack-made-its-software-unavailable-11595876400", "title": "Garmin Says Cyberattack Made Its Software Unavailable", "date": "2020-07-27 15:00", "summary": "Navigation-systems company says no customer data was compromised over several days. Garmin Ltd. , the maker of navigation systems for cars, boats and planes, said it was the target of a cyberattack that made its software unavailable for several days.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Garmin Says Cyberattack Made Its Software Unavailable. Navigation-systems company says no customer data was compromised over several days. Garmin Ltd. , the maker of navigation systems for cars, boats and planes, said it was the target of a cyberattack that made its software unavailable for several days.\"\n\nStock Prediction(s):", "Prediction": "\n- Garmin Ltd. (NASDAQ: GRMN) will decrease because their software was unavailable for several days.", "price_info": {"GRMN": {"company": "", "ticker": "GRMN", "move": "down", "prices": [100.29, 100.29]}}}, {"link": "https://www.wsj.com/articles/funds-get-put-on-mute-due-to-lack-of-need-11600877169", "title": "Funds Get Put on 'MUTE' Due to 'LACK' of 'NEED'", "date": "2020-09-23 12:06", "summary": "As exchange-traded funds bite the dust, so do some clever ticker symbols.. It is a \"DOG\" eat dog world for exchange-traded funds.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Funds Get Put on 'MUTE' Due to 'LACK' of 'NEED'. As exchange-traded funds bite the dust, so do some clever ticker symbols.. It is a \"DOG\" eat dog world for exchange-traded funds.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because people are selling their stocks in order to invest in other things.\n- The market will go up because some clever investors are buying stocks at a discount.", "price_info": {}}, {"link": "https://www.wsj.com/articles/peloton-thriller-will-keep-on-cycling-11644334521", "title": "Peloton Thriller Will Keep on Cycling", "date": "2022-02-08 10:35", "summary": "Subscription to Peloton drama seems like better investment than stock itself. First Big, now Foley. The casualties of the Peloton Interactive drama are getting more real by the day. Don't expect a happily ever after to come overnight.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Peloton Thriller Will Keep on Cycling. Subscription to Peloton drama seems like better investment than stock itself. First Big, now Foley. The casualties of the Peloton Interactive drama are getting more real by the day. Don't expect a happily ever after to come overnight.\"\n\nStock Prediction(s):", "Prediction": "\n- Peloton Interactive Inc (NASDAQ: PTON) will continue to decrease because of the negative publicity the company is receiving.", "price_info": {"PTON": {"company": "", "ticker": "PTON", "move": "down", "prices": [35.23, 35.67]}}}, {"link": "https://www.wsj.com/articles/luckin-coffee-terminates-ceo-jenny-zhiya-qian-amid-investigation-into-fabricated-sales-11589297382", "title": "Luckin Coffee Terminates CEO", "date": "2020-05-12 13:35", "summary": "Chinese coffee chain names director Jinyi Guo as acting chief executive. Luckin Coffee Inc. said its board of directors has terminated chief executive Jenny Qian amid a deepening internal investigation into the company's fabricated sales, suggesting she played a role in a scheme to inflate its revenue.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Luckin Coffee Terminates CEO. Chinese coffee chain names director Jinyi Guo as acting chief executive. Luckin Coffee Inc. said its board of directors has terminated chief executive Jenny Qian amid a deepening internal investigation into the company's fabricated sales, suggesting she played a role in a scheme to inflate its revenue.\"\n\nStock Prediction(s):", "Prediction": "\n- Luckin Coffee Inc. (NASDAQ: LK) will decrease because their CEO was terminated.\n- Starbucks Corporation (NASDAQ: SBUX) will increase because they are not involved in the internal investigation, and they are a direct competitor of Luckin Coffee.", "price_info": {"LK": {"company": "", "ticker": "LK", "move": "down"}, "SBUX": {"company": "", "ticker": "SBUX", "move": "up", "prices": [75.895, 74.35]}}}, {"link": "https://www.wsj.com/articles/white-house-to-push-infrastructure-plan-in-summit-meeting-on-chip-shortage-11617984000", "title": "White House to Push Infrastructure Plan at Chip Meeting", "date": "2021-04-09 12:00", "summary": "Ford, GM and Intel are among companies slated to meet with administration officials on Monday. ", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"White House to Push Infrastructure Plan at Chip Meeting. Ford, GM and Intel are among companies slated to meet with administration officials on Monday. \"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because they are one of the companies meeting with the administration officials.\n- General Motors Company (NYSE: GM) will increase because they are one of the companies meeting with the administration officials.\n- Intel Corporation (NASDAQ: INTC) will increase because they are one of the companies meeting with the administration officials.", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [12.48, 12.4779]}, "GM": {"company": "", "ticker": "GM", "move": "up", "prices": [60.1285, 60.0544]}, "INTC": {"company": "", "ticker": "INTC", "move": "up", "prices": [67.88, 68.01]}}}, {"link": "https://www.wsj.com/articles/bill-gates-tweets-that-he-and-wife-melinda-are-seeking-a-divorce-11620075934", "title": "Bill and Melinda Gates to Divorce After 27 Years", "date": "2021-05-04 09:48", "summary": "The Microsoft co-founder and his wife, who is co-chair of their philanthropic foundation, say they will continue their work there. Microsoft Corp. co-founder Bill Gates and his wife, Melinda Gates, who is co-chair of their philanthropic foundation, are ending their 27-year marriage, according to a statement posted on both their verified Twitter accounts.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bill and Melinda Gates to Divorce After 27 Years. The Microsoft co-founder and his wife, who is co-chair of their philanthropic foundation, say they will continue their work there. Microsoft Corp. co-founder Bill Gates and his wife, Melinda Gates, who is co-chair of their philanthropic foundation, are ending their 27-year marriage, according to a statement posted on both their verified Twitter accounts.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because one of their co-founders is getting a divorce.\n- The Gates Foundation (private) will not be affected.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [248.1, 246.23]}}}, {"link": "https://www.wsj.com/articles/southwest-american-say-leisure-travel-is-rebounding-as-summer-season-approaches-11619101590", "title": "Southwest, American Say Leisure Travel Is Rebounding", "date": "2021-04-22 15:02", "summary": "Airlines don't expect business travel to resume in earnest until more employees return to offices. Major airlines this week reiterated confidence that the travel market, at least for leisure, is rebounding from the deep losses suffered during the coronavirus pandemic. Executives said they hope the trend will continue into the summer vacation season.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Southwest, American Say Leisure Travel Is Rebounding. Airlines don't expect business travel to resume in earnest until more employees return to offices. Major airlines this week reiterated confidence that the travel market, at least for leisure, is rebounding from the deep losses suffered during the coronavirus pandemic. Executives said they hope the trend will continue into the summer vacation season.\"\n\nStock Prediction(s):", "Prediction": "\n- Airlines will increase because it looks like the travel market is rebounding.\n- Hotel chains will increase because it looks like the travel market is rebounding.\n- Cruise lines will increase because it looks like the travel market is rebounding.", "price_info": {}}, {"link": "https://www.wsj.com/articles/facebook-ceo-to-testify-at-house-panelabout-libra-11570638146", "title": "Facebook CEO to Testify at House Panel About Libra", "date": "2019-10-09 15:24", "summary": "Mark Zuckerberg will be asked about Facebook's foray into cryptocurrency and its impact on the financial-services sector. Facebook Inc. Chief Executive Mark Zuckerberg is slated to return to Capitol Hill this month to testify before a House panel about the company's foray into cryptocurrency, just weeks after facing a chilly reception from lawmakers about his vision for internet regulation.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook CEO to Testify at House Panel About Libra. Mark Zuckerberg will be asked about Facebook's foray into cryptocurrency and its impact on the financial-services sector. Facebook Inc. Chief Executive Mark Zuckerberg is slated to return to Capitol Hill this month to testify before a House panel about the company's foray into cryptocurrency, just weeks after facing a chilly reception from lawmakers about his vision for internet regulation.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because their CEO is testifying and they are a major player in the cryptocurrency space.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are also a major player in the cryptocurrency space.\n- Mastercard Incorporated (NYSE: MA) will increase because they are also a major player in the cryptocurrency space.\n- Visa Inc. (NYSE: V) will increase because they are", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [112.63, 112.63]}, "MA": {"company": "", "ticker": "MA", "move": "up", "prices": [272, 271.85]}, "V": {"company": "", "ticker": "V", "move": "up", "prices": [174.88, 174.88]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [179.75, 179.76]}}}, {"link": "https://www.wsj.com/articles/global-fund-investing-find-out-fund-manager-from-11643850101", "title": "Investing in a Global Equity Stock Fund? Find Out Where the Fund Manager Is From", "date": "2022-02-04 10:00", "summary": "A study suggests that some portfolio managers are overconfident in their own countries' equities-to the detriment of the fund. In theory, a \"world\" or \"global\" stock fund should be roughly the same no matter what country you are investing from. A world fund in Germany, for instance, should be nearly the same as a world fund in the U.S., because they both have the same objective: to track the capitalization-weighted global stock market-unlike the many varieties of international funds that take more-focused approaches.", "categories": [["Markets", "Journal Reports: Personal Investing"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-personal-investing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investing in a Global Equity Stock Fund? Find Out Where the Fund Manager Is From. A study suggests that some portfolio managers are overconfident in their own countries' equities-to the detriment of the fund. In theory, a \"world\" or \"global\" stock fund should be roughly the same no matter what country you are investing from. A world fund in Germany, for instance, should be nearly the same as a world fund in the U.S., because they both have the same objective: to track the capitalization-weighted global stock market-unlike the many varieties of international funds that take more-focused approaches.\"\n\nStock Prediction(s):", "Prediction": "\n- Vanguard Total World Stock ETF (NYSE: VT) will increase because it is a global equity stock fund that is not biased towards any one country.\n- iShares MSCI ACWI Index Fund (NASDAQ: ACWI) will increase because it is a global equity stock fund that is not biased towards any one country.\n- SPDR S&P World ex-US ETF (NYSE: GWL) will decrease because it is a global equity stock fund", "price_info": {"VT": {"company": "", "ticker": "VT", "move": "up", "prices": [101.94, 101.73]}, "GWL": {"company": "", "ticker": "GWL", "move": "down"}, "ACWI": {"company": "MSCI", "ticker": "ACWI", "move": "up", "prices": [100.48, 100.27]}}}, {"link": "https://www.wsj.com/articles/dont-take-stock-in-oils-rebound-11547143758", "title": "Don't Take Stock in Oil's Rebound", "date": "2019-01-10 13:09", "summary": "The return of risk appetite has lifted crude oil and stocks in tandem, but the fundamental reasons to push oil even higher look iffy. Oil's post-Christmas rally may be peaking.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Don't Take Stock in Oil's Rebound. The return of risk appetite has lifted crude oil and stocks in tandem, but the fundamental reasons to push oil even higher look iffy. Oil's post-Christmas rally may be peaking.\"\n\nStock Prediction(s):", "Prediction": "\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because the fundamental reasons to push oil even higher look iffy.\n- Chevron Corporation (NYSE: CVX) will decrease because the fundamental reasons to push oil even higher look iffy.\n- BP plc (NYSE: BP) will decrease because the fundamental reasons to push oil even higher look iffy.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because the fundamental", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [71.175, 71.73]}, "CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [112.05, 112.95]}, "BP": {"company": "", "ticker": "BP", "move": "down", "prices": [40.42, 40.63]}}}, {"link": "https://www.wsj.com/articles/jonathan-karp-named-ceo-of-simon-schuster-11590673071", "title": "Jonathan Karp Named CEO of Simon & Schuster", "date": "2020-05-28 10:02", "summary": "Publishing veteran to lead unit that ViacomCBS put on the sale block. Jonathan Karp has been named president and chief executive officer of book publisher Simon & Schuster, succeeding Carolyn Reidy, who died of a heart attack earlier this month.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jonathan Karp Named CEO of Simon & Schuster. Publishing veteran to lead unit that ViacomCBS put on the sale block. Jonathan Karp has been named president and chief executive officer of book publisher Simon & Schuster, succeeding Carolyn Reidy, who died of a heart attack earlier this month.\"\n\nStock Prediction(s):", "Prediction": "\n- Simon & Schuster (NASDAQ: CBS) will increase because they have a new CEO, and he is a publishing veteran.\n- ViacomCBS (NASDAQ: VIAC) will decrease because they are selling their publishing unit.", "price_info": {"CBS": {"company": "", "ticker": "CBS", "move": "up"}, "VIAC": {"company": "", "ticker": "VIAC", "move": "down", "prices": [21.2784, 21.385]}}}, {"link": "https://www.wsj.com/articles/kidnappednigerianschoolboys-say-ransom-was-paid-tell-of-beatings-11608747119", "title": "Kidnapped Nigerian Boys Say Ransom Was Paid for Freedom", "date": "2020-12-23 13:12", "summary": "Freed captives recount mistreatment by Boko Haram, as group's terrorism and criminality appear to coalesce. KATSINA, Nigeria-It was on the third day in captivity that the Lawal brothers thought they would be executed.", "categories": [["WSJ News Exclusive", "Africa"]], "category_links": ["https://www.wsj.com/news/types/africa-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Kidnapped Nigerian Boys Say Ransom Was Paid for Freedom. Freed captives recount mistreatment by Boko Haram, as group's terrorism and criminality appear to coalesce. KATSINA, Nigeria-It was on the third day in captivity that the Lawal brothers thought they would be executed.\"\n\nStock Prediction(s):", "Prediction": "\n- The kidnapping will have a negative effect on the stock prices of companies operating in Nigeria, such as:\n- African Minerals Ltd. (LON: AML)\n- Seplat Petroleum Development Company Plc (LON: SEPL)\n- Sterling Energy Plc (LON: SEY)\n- SBM Offshore NV (AMS: SBM)\n- Transocean Ltd. (NYSE: RIG)", "price_info": {"RIG": {"company": "", "ticker": "RIG", "move": null, "prices": [2.28, 2.29]}}}, {"link": "https://www.wsj.com/articles/gold-bonds-failed-to-protect-investors-amid-stock-market-swoon-11604056455", "title": "Gold, Bonds Failed to Protect Investors Amid Stock-Market Swoon", "date": "2020-10-30 13:15", "summary": "Investors worry that a lack of protection from traditional safe havens leaves them exposed during the U.S. election and an upsurge in Covid-19 cases. Investors found few places to shelter when stocks tumbled this week, illustrating the limitations of traditional havens following a run-up in prices across markets.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold, Bonds Failed to Protect Investors Amid Stock-Market Swoon. Investors worry that a lack of protection from traditional safe havens leaves them exposed during the U.S. election and an upsurge in Covid-19 cases. Investors found few places to shelter when stocks tumbled this week, illustrating the limitations of traditional havens following a run-up in prices across markets.\"\n\nStock Prediction(s):", "Prediction": "\n- Gold (NYSE: GLD) will decrease because it failed to protect investors from the stock market swoon.\n- Bonds (NYSE: BND) will decrease because it failed to protect investors from the stock market swoon.", "price_info": {"GLD": {"company": "", "ticker": "GLD", "move": "down", "prices": [176.5, 176.4]}, "BND": {"company": "", "ticker": "BND", "move": "down", "prices": [87.625, 87.51]}}}, {"link": "https://www.wsj.com/articles/saudis-threaten-new-oil-price-war-with-opec-brethren-11593619230", "title": "Saudis Threaten New Oil-Price War With OPEC Brethren", "date": "2020-07-01 12:52", "summary": "As major producers look to curb output, the kingdom takes a tough stance with laggards. Saudi Arabia has threatened to ignite an oil-price war unless fellow OPEC members make up for their failure to abide by the cartel's recent production cuts, delegates said.", "categories": [["WSJ News Exclusive", "Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudis Threaten New Oil-Price War With OPEC Brethren. As major producers look to curb output, the kingdom takes a tough stance with laggards. Saudi Arabia has threatened to ignite an oil-price war unless fellow OPEC members make up for their failure to abide by the cartel's recent production cuts, delegates said.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (Private: ARMCO) will increase because they are a major producer and they are looking to curb output.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are a major producer and they are looking to curb output.\n- Chevron Corporation (NYSE: CVX) will increase because they are a major producer and they are looking to curb output.\n- BP plc (NYSE: BP) will increase because they are a", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [44.025, 43.95]}, "CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [88.01, 88.07]}, "BP": {"company": "", "ticker": "BP", "move": "up", "prices": [23.19, 23.275]}}}, {"link": "https://www.wsj.com/articles/sweetgreen-bet-big-on-naomi-osaka-then-it-doubled-down-11622825074", "title": "Sweetgreen Bet Big on Naomi Osaka. Then Doubled Down.", "date": "2021-06-04 12:44", "summary": "Salad company backs tennis star's openness on mental health, retaining endorsement deal after she pulls out of French Open. Hours after Naomi Osakawithdrew from the French Open on Monday, the three founders of Sweetgreen Inc. gathered on a phone call.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Sweetgreen Bet Big on Naomi Osaka. Then Doubled Down.. Salad company backs tennis star's openness on mental health, retaining endorsement deal after she pulls out of French Open. Hours after Naomi Osakawithdrew from the French Open on Monday, the three founders of Sweetgreen Inc. gathered on a phone call.\"\n\nStock Prediction(s):", "Prediction": "\n- Sweetgreen Inc (NASDAQ: SGEN) will increase because they are continuing to back Naomi Osaka, and they are a company that is open about mental health.\n- Nike Inc (NYSE: NKE) will decrease because they are a direct competitor of Sweetgreen.", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [133.0799, 133.4982]}, "SGEN": {"company": "", "ticker": "SGEN", "move": "up", "prices": [148.39, 148.15]}}}, {"link": "https://www.wsj.com/articles/jon-bon-jovi-sells-palm-beach-manse-for-roughly-20-million-11594998024", "title": "Jon Bon Jovi Sells Palm Beach Manse for Roughly $20 Million", "date": "2020-07-17 11:00", "summary": "The rocker had just completed construction on the 5,000-square-foot home with ocean views from nearly every room. A contemporary Palm Beach home newly built by the rocker Jon Bon Jovi has sold to an unknown buyer for roughly $20 million, according to a person familiar with the transaction.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jon Bon Jovi Sells Palm Beach Manse for Roughly $20 Million. The rocker had just completed construction on the 5,000-square-foot home with ocean views from nearly every room. A contemporary Palm Beach home newly built by the rocker Jon Bon Jovi has sold to an unknown buyer for roughly $20 million, according to a person familiar with the transaction.\"\n\nStock Prediction(s):", "Prediction": "\n- The sale of Jon Bon Jovi's Palm Beach manse will have no effect on the stock prices of any of the companies mentioned.", "price_info": {}}, {"link": "https://www.wsj.com/articles/durable-goods-orders-rose-11-2-in-july-for-third-monthly-gain-11598447386", "title": "Durable-Goods Orders Rose 11.2% in July", "date": "2020-08-26 10:03", "summary": "Surge led by transportation equipment reflects recovery from pandemic-related shutdowns. Orders for long-lasting factory goods rose for a third straight month in July as manufacturers boosted output and the economy continued its climb back from disruptions related to the coronavirus pandemic.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Durable-Goods Orders Rose 11.2% in July. Surge led by transportation equipment reflects recovery from pandemic-related shutdowns. Orders for long-lasting factory goods rose for a third straight month in July as manufacturers boosted output and the economy continued its climb back from disruptions related to the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co (NYSE: BA) will increase because their main client is the government, and the government is ordering more planes due to the increase in demand.\n- Honeywell International Inc. (NYSE: HON) will increase because their main client is the government, and the government is ordering more planes due to the increase in demand.\n- United Technologies Corp. (NYSE: UTX) will increase because their main client is the government, and the government is", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [171.73, 171.9001]}, "HON": {"company": "", "ticker": "HON", "move": "up", "prices": [165.01, 165.2256]}, "UTX": {"company": "", "ticker": "UTX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/d-wave-opens-quantum-computing-resources-to-coronavirus-research-11585763422", "title": "D-Wave Opens Quantum-Computing Resources to Coronavirus Research", "date": "2020-04-01 13:50", "summary": "Still years away from large-scale commercial use, the company's technology will be tested on combating the pandemic. Quantum-computing vendor D-Wave Systems Inc. said Tuesday it is giving researchers and companies studying the novel coronavirus free access to its early-stage, experimental machines over the cloud.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/undefined?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"D-Wave Opens Quantum-Computing Resources to Coronavirus Research. Still years away from large-scale commercial use, the company's technology will be tested on combating the pandemic. Quantum-computing vendor D-Wave Systems Inc. said Tuesday it is giving researchers and companies studying the novel coronavirus free access to its early-stage, experimental machines over the cloud.\"\n\nStock Prediction(s):", "Prediction": "\n- D-Wave Systems Inc. (TSX: DWAV) will increase because they are opening up their quantum-computing resources to help with coronavirus research.\n- IBM (NYSE: IBM) will decrease because they are also working on quantum-computing resources, but they are a direct competitor of D-Wave Systems.", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "down", "prices": [105.87, 105.24]}}}, {"link": "https://www.wsj.com/articles/house-committee-takes-on-pricing-patents-for-top-selling-drug-humira-11621345740", "title": "House Committee Takes On Pricing, Patents for Top-Selling Drug Humira", "date": "2021-05-18 15:40", "summary": "Oversight committee explores the numerous price increases and patent applications that AbbVie has filed for the immune drug. AbbVie Inc.'s pricing practices for some of its top-selling medicines faced fresh scrutiny from federal lawmakers Tuesday, the latest effort by members of Congress probing the cost of prescription drugs.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"House Committee Takes On Pricing, Patents for Top-Selling Drug Humira. Oversight committee explores the numerous price increases and patent applications that AbbVie has filed for the immune drug. AbbVie Inc.'s pricing practices for some of its top-selling medicines faced fresh scrutiny from federal lawmakers Tuesday, the latest effort by members of Congress probing the cost of prescription drugs.\"\n\nStock Prediction(s):", "Prediction": "\n- AbbVie Inc. (NYSE: ABBV) will decrease because of the scrutiny from lawmakers.\n- Amgen Inc. (NASDAQ: AMGN) will increase because they are not under the same scrutiny as AbbVie.", "price_info": {"ABBV": {"company": "", "ticker": "ABBV", "move": "down", "prices": [117.21, 117.06]}, "AMGN": {"company": "", "ticker": "AMGN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/trump-administration-considering-paying-hospitals-for-treating-uninsured-coronavirus-patients-11583258943", "title": "U.S. Weighs Paying Hospitals to Treat Uninsured Patients", "date": "2020-03-03 15:12", "summary": "Trump administration may use disaster recovery reimbursement program that would pay providers 110% of Medicare for treating patients. The Trump administration is considering using a national disaster program to pay hospitals and doctors for their care of uninsured people infected with the new coronavirus as concerns rise over costs of treating some of the 27 million Americans without health coverage, a person familiar with the conversations said.", "categories": [["WSJ News Exclusive", "Health Policy"]], "category_links": ["https://www.wsj.com/news/types/health-policy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Weighs Paying Hospitals to Treat Uninsured Patients. Trump administration may use disaster recovery reimbursement program that would pay providers 110% of Medicare for treating patients. The Trump administration is considering using a national disaster program to pay hospitals and doctors for their care of uninsured people infected with the new coronavirus as concerns rise over costs of treating some of the 27 million Americans without health coverage, a person familiar with the conversations said.\"\n\nStock Prediction(s):", "Prediction": "\n- Health insurers will increase because they will have to pay hospitals more to cover the costs of treating uninsured patients.\n- Hospital companies will increase because they will be receiving more money from the government to cover the costs of treating uninsured patients.\n- Pharmaceutical companies will decrease because they will have to pay more for hospital services, which will eat into their profits.", "price_info": {}}, {"link": "https://www.wsj.com/articles/space-race-nvidia-and-ibm-what-to-watch-when-the-market-opens-11626778707", "title": "Space Race, Nvidia and IBM: What to Watch When the Market Opens", "date": "2021-08-06 11:30", "summary": "Stock futures are higher after Monday's slide on Wall Street. To the moon! Well, not quite, but into space at least today for Jeff Bezos, the billionaire baron of ecommerce. Also not going to the moon is Amazon stock, though it is 0.3% up premarket on Tuesday morning.", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Space Race, Nvidia and IBM: What to Watch When the Market Opens. Stock futures are higher after Monday's slide on Wall Street. To the moon! Well, not quite, but into space at least today for Jeff Bezos, the billionaire baron of ecommerce. Also not going to the moon is Amazon stock, though it is 0.3% up premarket on Tuesday morning.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because Jeff Bezos is going into space, and this could lead to more innovation from the company.\n- Nvidia Corporation (NASDAQ: NVDA) will increase because they are a direct competitor of IBM, and IBM is going into space.\n- IBM (NYSE: IBM) will decrease because they are a direct competitor of Nvidia, and Nvidia is going into space.", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "down", "prices": [143.95, 144.06]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3339.08, 3334.4]}, "NVDA": {"company": "", "ticker": "NVDA", "move": "up", "prices": [204.5318, 204.18]}}}, {"link": "https://www.wsj.com/articles/why-we-seem-to-damage-our-smartphones-just-when-a-new-model-comes-out-11603461600", "title": "Why We Seem to Damage Our Smartphones Just When a New Model Comes Out", "date": "2020-10-23 10:00", "summary": "People need to justify a new purchase when their old phone works just fine. So they get careless.. A new iPhone comes on the market, and you accidentally damage your old one. Sound familiar?", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why We Seem to Damage Our Smartphones Just When a New Model Comes Out. People need to justify a new purchase when their old phone works just fine. So they get careless.. A new iPhone comes on the market, and you accidentally damage your old one. Sound familiar?\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because people are more likely to buy a new phone when the old one is damaged.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will increase because they are the main competitor to Apple.\n- LG Electronics Inc (OTC: LGEAF) will increase because they are the main competitor to Samsung.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [115.04, 114.4857]}}}, {"link": "https://www.wsj.com/articles/fannie-mae-earnings-rise-during-third-quarter-on-mortgage-refinance-boom-11603976426", "title": "Fannie Mae, Freddie Mac Third-Quarter Earnings Rise on Mortgage Refinance Boom", "date": "2020-10-29 11:39", "summary": "Earnings for 2020 as a whole are expected to be lower than last year, Fannie Mae says. WASHINGTON-Government-controlled mortgage giants Fannie Mae and Freddie Mac reported improved earnings in the third quarter, as record-low interest rates fueled a refinancing boom that buoyed the companies' results.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fannie Mae, Freddie Mac Third-Quarter Earnings Rise on Mortgage Refinance Boom. Earnings for 2020 as a whole are expected to be lower than last year, Fannie Mae says. WASHINGTON-Government-controlled mortgage giants Fannie Mae and Freddie Mac reported improved earnings in the third quarter, as record-low interest rates fueled a refinancing boom that buoyed the companies' results.\"\n\nStock Prediction(s):", "Prediction": "\n- Fannie Mae (OTCQB: FNMA) and Freddie Mac (OTCQB: FMCC) will continue to increase because the refinancing boom is still going strong.\n- Bank of America (NYSE: BAC) will increase because they are one of the leading lenders in the mortgage refinancing market.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are one of the leading lenders in the mortgage refinancing market.\n", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [23.38, 23.65]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [96.71, 97.63]}}}, {"link": "https://www.wsj.com/articles/have-online-reviews-lost-all-value-11569606584", "title": "Have Online Reviews Lost All Value?", "date": "2019-09-27 13:49", "summary": "The internet is so saturated with 5-Star praise-some genuine, much paid for-that it's difficult to know which sites you can trust. TRY TO SHOP for toothpaste on Amazon and dozens of brands pop up with identical 4.5-star ratings. Crest? Colgate? Tom's? Does it matter? Even if you try to differentiate based on reviews, you face thousands to comb through-and odds are a good number of those are fake.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets", "That's Debatable"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Have Online Reviews Lost All Value?. The internet is so saturated with 5-Star praise-some genuine, much paid for-that it's difficult to know which sites you can trust. TRY TO SHOP for toothpaste on Amazon and dozens of brands pop up with identical 4.5-star ratings. Crest? Colgate? Tom's? Does it matter? Even if you try to differentiate based on reviews, you face thousands to comb through-and odds are a good number of those are fake.\"\n\nStock Prediction(s):", "Prediction": "\n- The entire online review industry will decrease in value because it is difficult to determine which sites are trustworthy.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because their review system is being called into question.", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1716.9333, 1722.43]}}}, {"link": "https://www.wsj.com/articles/cbs-and-viacom-strike-deal-for-long-thwarted-merger-11565719110", "title": "CBS, Viacom Strike Deal for Long-Thwarted Merger", "date": "2019-08-13 15:40", "summary": "Companies seek greater scale to survive in a media landscape dominated by major tech companies and bulked-up rivals. ", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"CBS, Viacom Strike Deal for Long-Thwarted Merger. Companies seek greater scale to survive in a media landscape dominated by major tech companies and bulked-up rivals. \"\n\nStock Prediction(s):", "Prediction": "\n- CBS Corporation (NYSE: CBS) will increase because they will be able to compete better in the media landscape.\n- ViacomCBS Inc (NASDAQ: VIAC) will increase because they will be able to compete better in the media landscape.\n- The Walt Disney Company (NYSE: DIS) will decrease because they will have one less competitor in the media landscape.\n- Comcast Corporation (NASDAQ: CMCSA) will decrease because they will have", "price_info": {"CBS": {"company": "", "ticker": "CBS", "move": "up", "prices": [48.7, 48.44]}, "DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [137.07, 137.48]}, "VIAC": {"company": "", "ticker": "VIAC", "move": "up"}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "down", "prices": [43.46, 43.73]}}}, {"link": "https://www.wsj.com/articles/help-for-taxpayers-who-need-to-prove-where-they-live-11552059340", "title": "Help for Taxpayers Who Need to Prove Where They Live", "date": "2019-03-08 10:35", "summary": "For people who own homes in different states, apps track your whereabouts to establish residency in one or the other. When Jim Stamos and his wife retired to Florida in 2015, they left behind the snowstorms of Connecticut. But because they kept their old house, they had a problem: If they couldn't prove they lived and spent most of their time in Florida, which has no state income tax, they might have to pay Connecticut, which does.", "categories": [["Markets", "Journal Reports: Wealth Management"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-wealth-management?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Help for Taxpayers Who Need to Prove Where They Live. For people who own homes in different states, apps track your whereabouts to establish residency in one or the other. When Jim Stamos and his wife retired to Florida in 2015, they left behind the snowstorms of Connecticut. But because they kept their old house, they had a problem: If they couldn't prove they lived and spent most of their time in Florida, which has no state income tax, they might have to pay Connecticut, which does.\"\n\nStock Prediction(s):", "Prediction": "\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and KB Home (NYSE: KBH) will increase because more people will be moving to states with no income tax.\n- Real estate companies such as Realtor.com operator Move Inc (NASDAQ: MOVE) and Zillow Group Inc (NASDAQ: Z) will increase because more people will be moving to states with no income tax.", "price_info": {"LEN": {"company": "", "ticker": "LEN", "move": null, "prices": [47.76, 47.72]}, "KBH": {"company": "", "ticker": "KBH", "move": "up", "prices": [23.22, 23.385]}, "MOVE": {"company": "", "ticker": "MOVE", "move": null}, "Z": {"company": "", "ticker": "Z", "move": "up", "prices": [37.55, 38.0677]}}}, {"link": "https://www.wsj.com/articles/home-price-growth-hit-record-in-july-11632834044", "title": "Home-Price Growth Hit Record in July", "date": "2021-09-28 11:09", "summary": "Case-Shiller index rose 19.7%, the fourth consecutive month of record price appreciation, but the market could be starting to cool. Home-price growth climbed to a new record in July as buyers continued to compete fiercely amid a shortage of homes for sale, but there are signs the market frenzy might be starting to ease.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Home-Price Growth Hit Record in July. Case-Shiller index rose 19.7%, the fourth consecutive month of record price appreciation, but the market could be starting to cool. Home-price growth climbed to a new record in July as buyers continued to compete fiercely amid a shortage of homes for sale, but there are signs the market frenzy might be starting to ease.\"\n\nStock Prediction(s):", "Prediction": "\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and KB Home (NYSE: KBH) will increase because the market is still hot and there is more demand than ever.\n- Real estate investment trusts such as Realty Income Corporation (NYSE: O) and Ventas, Inc. (NYSE: VTR) will increase because there is more demand for real estate and the prices are going up.\n- Mortgage lenders such as Wells Fargo & Company", "price_info": {"LEN": {"company": "", "ticker": "LEN", "move": null, "prices": [95.61, 95.5981]}, "KBH": {"company": "", "ticker": "KBH", "move": "up", "prices": [40.3, 40.23]}, "O": {"company": "", "ticker": "O", "move": null, "prices": [65.195, 65.1877]}, "VTR": {"company": "", "ticker": "VTR", "move": "up", "prices": [55.385, 55.47]}}}, {"link": "https://www.wsj.com/articles/levis-leaves-board-of-fashion-coalition-at-center-of-china-controversy-11628265905", "title": "Levi's Leaves Board of Fashion Coalition at Center of China Controversy", "date": "2021-08-06 15:46", "summary": "Jeans maker stands down from Better Cotton Initiative's leadership amid debate over coalition's response to alleged human-rights abuses in Xinjiang. Levi Strauss & Co. is leaving the board of a high-profile fashion-industry coalition, according to people familiar with the matter, in a move that presents a leadership gap in a group divided over how to respond to alleged human-rights abuses in China's cotton-rich Xinjiang region.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Levi's Leaves Board of Fashion Coalition at Center of China Controversy. Jeans maker stands down from Better Cotton Initiative's leadership amid debate over coalition's response to alleged human-rights abuses in Xinjiang. Levi Strauss & Co. is leaving the board of a high-profile fashion-industry coalition, according to people familiar with the matter, in a move that presents a leadership gap in a group divided over how to respond to alleged human-rights abuses in China's cotton-rich Xinjiang region.\"\n\nStock Prediction(s):", "Prediction": "\n- Levi Strauss & Co. (NYSE: LEVI) will decrease because they are leaving the board of a high-profile fashion-industry coalition.\n- H&M Hennes & Mauritz AB (OTCMKTS: HNNMY) will decrease because they are a direct competitor of Levi's.\n- Gap Inc. (NYSE: GPS) will decrease because they are a direct competitor of Levi's.", "price_info": {"LEVI": {"company": "", "ticker": "LEVI", "move": "down", "prices": [27.58, 27.3]}, "GPS": {"company": "", "ticker": "GPS", "move": "down", "prices": [29.1, 29.11]}}}, {"link": "https://www.wsj.com/articles/who-is-frances-haugen-facebook-whistleblower-11633409993", "title": "Who Is Facebook Whistleblower Frances Haugen? What to Know as She Testifies", "date": "2021-10-06 10:31", "summary": "A look at the former Facebook employee who gathered documents that formed the foundation of the Journal's Facebook Files series. Frances Haugen, the former Facebook Inc. employee who gathered documents that formed the foundation of The Wall Street Journal's Facebook Files series showing its platforms are riddled with flaws that cause harm, appeared Tuesday before a Senate panel that is looking to toughen the law protecting children online.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Who Is Facebook Whistleblower Frances Haugen? What to Know as She Testifies. A look at the former Facebook employee who gathered documents that formed the foundation of the Journal's Facebook Files series. Frances Haugen, the former Facebook Inc. employee who gathered documents that formed the foundation of The Wall Street Journal's Facebook Files series showing its platforms are riddled with flaws that cause harm, appeared Tuesday before a Senate panel that is looking to toughen the law protecting children online.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because they are trying to fix their image after being called out by the media.\n- The Walt Disney Company (NYSE: DIS) will increase because they own ABC, which is one of the news sources that published the Facebook Files series.\n- Snap Inc. (NYSE: SNAP) will decrease because they are Facebook's main competitor and this will give Facebook an edge.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "up", "prices": [173.165, 173.8019]}, "SNAP": {"company": "", "ticker": "SNAP", "move": "down", "prices": [74.02, 73.63]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [331.2949, 331.6601]}}}, {"link": "https://www.wsj.com/articles/going-from-big-fish-to-small-fish-how-executives-can-deal-with-the-change-11559138901", "title": "Going From Big Fish to Small Fish: How Executives Can Deal With the Change", "date": "2019-05-29 10:08", "summary": "Understanding the new company's culture and finding connections can help a leader's switch to a larger company from a smaller one. Andy Dunn has found it hard to work for Walmart Inc., the biggest retailer in the world, following its 2017 purchase of Bonobos, a small men's clothing retailer that he co-founded and led for years.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/your-executive-career?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Going From Big Fish to Small Fish: How Executives Can Deal With the Change. Understanding the new company's culture and finding connections can help a leader's switch to a larger company from a smaller one. Andy Dunn has found it hard to work for Walmart Inc., the biggest retailer in the world, following its 2017 purchase of Bonobos, a small men's clothing retailer that he co-founded and led for years.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because they are the biggest retailer in the world, and they are looking to expand their business.\n- Bonobos (private) will increase because they were bought by Walmart, and they will now have the resources to expand their business.\n- The Gap Inc. (NYSE: GPS) will decrease because they are a direct competitor of Bonobos.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [102.204, 101.675]}, "GPS": {"company": "", "ticker": "GPS", "move": "down", "prices": [20.79, 20.73]}}}, {"link": "https://www.wsj.com/articles/citadel-closing-stock-focused-aptigon-unit-11551975507", "title": "Citadel Closing Stock-Focused Aptigon Unit", "date": "2019-03-07 13:52", "summary": "Eric Felder, who ran the unit, leaving after less than two years at the firm. Chicago hedge-fund giant Citadel is closing one of its stock-focused units, Aptigon Capital, according to people familiar with the matter.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Citadel Closing Stock-Focused Aptigon Unit. Eric Felder, who ran the unit, leaving after less than two years at the firm. Chicago hedge-fund giant Citadel is closing one of its stock-focused units, Aptigon Capital, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Citadel LLC (NASDAQ: CLL) will decrease because they are closing a stock-focused unit.", "price_info": {"CLL": {"company": "", "ticker": "CLL", "move": "down"}}}, {"link": "https://www.wsj.com/articles/tesla-awaits-green-light-for-production-in-germany-11634039224", "title": "Tesla Awaits Green Light for Production in Germany", "date": "2021-10-12 09:51", "summary": "Plant near Berlin would boost Elon Musk's efforts to turn the electric-vehicle maker into one with a global footprint. GR\u00dcNHEIDE, Germany-Elon Musk's push to turn Tesla Inc. into a global car maker and energize its electric-vehicles sales in Europe through a new plant in Germany is nearing what could be its final hurdle.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla Awaits Green Light for Production in Germany. Plant near Berlin would boost Elon Musk's efforts to turn the electric-vehicle maker into one with a global footprint. GR\u00dcNHEIDE, Germany-Elon Musk's push to turn Tesla Inc. into a global car maker and energize its electric-vehicles sales in Europe through a new plant in Germany is nearing what could be its final hurdle.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (TSLA) will increase because they are getting ready to start production in Germany, and this will help them expand their global footprint.\n- Volkswagen AG (OTCMKTS: VOW3) will decrease because they are a direct competitor of Tesla, and this will take market share away from them.", "price_info": {"TSLA": {"company": "Tesla, Inc.", "ticker": "TSLA", "move": "down", "prices": [805.695, 806.47]}}}, {"link": "https://www.wsj.com/articles/from-buzzfeed-to-axios-digital-media-players-prepare-for-deal-frenzy-11608324855", "title": "BuzzFeed, Axios Among Digital Media Players Eyeing Deals", "date": "2020-12-18 15:54", "summary": "Big players explore acquiring rivals and going public through blank-check companies. Momentum is building toward consolidation in the digital media sector as big and small players alike look for potential combinations.", "categories": [["WSJ News Exclusive", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"BuzzFeed, Axios Among Digital Media Players Eyeing Deals. Big players explore acquiring rivals and going public through blank-check companies. Momentum is building toward consolidation in the digital media sector as big and small players alike look for potential combinations.\"\n\nStock Prediction(s):", "Prediction": "\n- BuzzFeed (NYSE: BUZZ) will increase because they are a big player in the digital media sector, and they are exploring deals with other big players.\n- Axios (NYSE: AXIOS) will increase because they are a big player in the digital media sector, and they are exploring deals with other big players.\n- Vox Media (NYSE: VOX) will increase because they are a big player in the digital media sector, and they are exploring", "price_info": {"BUZZ": {"company": "", "ticker": "BUZZ", "move": "up"}, "AXIOS": {"company": "", "ticker": "AXIOS", "move": "up"}, "VOX": {"company": "", "ticker": "VOX", "move": "up", "prices": [119.32, 119.11]}}}, {"link": "https://www.wsj.com/articles/macys-to-reopen-68-stores-on-mondaywith-limits-on-staff-and-shoppers-11588243500", "title": "Macy's to Begin Reopening Stores on Monday", "date": "2020-04-30 11:04", "summary": "The retailer will start with 68 stores in states that have loosened coronavirus restrictions; 'no-touch' beauty consultations. Macy's Inc. plans to reopen 68 stores on Monday in states that have loosened restrictions, joining a handful of other retailers that are limping back to life after the coronavirus forced them to shut stores.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Macy's to Begin Reopening Stores on Monday. The retailer will start with 68 stores in states that have loosened coronavirus restrictions; 'no-touch' beauty consultations. Macy's Inc. plans to reopen 68 stores on Monday in states that have loosened restrictions, joining a handful of other retailers that are limping back to life after the coronavirus forced them to shut stores.\"\n\nStock Prediction(s):", "Prediction": "\n- Macy's, Inc. (NYSE: M) will increase because they are reopening stores, and this will help to boost their revenue.\n- J.C. Penney Company, Inc. (NYSE: JCP) will decrease because they are not reopening stores, and they will continue to lose revenue.\n- Nordstrom, Inc. (NYSE: JWN) will decrease because they are not reopening stores, and they will continue to lose revenue", "price_info": {"M": {"company": "", "ticker": "M", "move": "up", "prices": [5.6375, 5.9181]}, "JCP": {"company": "", "ticker": "JCP", "move": "down", "prices": [0.2501, 0.2511]}, "JWN": {"company": "", "ticker": "JWN", "move": "down", "prices": [18.84, 18.84]}}}, {"link": "https://www.wsj.com/articles/want-to-be-a-better-spouse-these-apps-teach-thoughtfulness-11568223031", "title": "Want to Be a Better Spouse? These Apps Teach Thoughtfulness.", "date": "2019-09-11 13:30", "summary": "Struggling to be a more considerate and engaged partner? These new apps make suggestions, effectively training you in love. TODAY, SMARTPHONE apps can spur new friendships, diverting love affairs, even stable marriages. In his book \"Dataclysm,\" OkCupid co-founder Christian Rudder analyzes data that suggests meeting digitally may even be the most efficient route.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Want to Be a Better Spouse? These Apps Teach Thoughtfulness.. Struggling to be a more considerate and engaged partner? These new apps make suggestions, effectively training you in love. TODAY, SMARTPHONE apps can spur new friendships, diverting love affairs, even stable marriages. In his book \"Dataclysm,\" OkCupid co-founder Christian Rudder analyzes data that suggests meeting digitally may even be the most efficient route.\"\n\nStock Prediction(s):", "Prediction": "\n- The app industry will continue to grow as people become more and more reliant on their phones.\n- Dating apps will continue to grow in popularity, as people look for more efficient and convenient ways to meet potential partners.\n- Social media apps will continue to grow in popularity, as people look for more efficient and convenient ways to stay connected with friends and family.", "price_info": {}}, {"link": "https://www.wsj.com/articles/judge-denies-ratepayers-bid-for-representation-in-pg-e-bankruptcy-11559149313", "title": "Judge Denies Ratepayers' Bid for Representation in PG&E Bankruptcy", "date": "2019-05-29 13:01", "summary": "Ratepayers aren't creditors and don't need separate representation, bankruptcy judge rules. The bankruptcy court presiding over PG&E Corp.'s chapter 11 case denied California ratepayers' attempt to gain a seat at the negotiating table as an official committee.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Judge Denies Ratepayers' Bid for Representation in PG&E Bankruptcy. Ratepayers aren't creditors and don't need separate representation, bankruptcy judge rules. The bankruptcy court presiding over PG&E Corp.'s chapter 11 case denied California ratepayers' attempt to gain a seat at the negotiating table as an official committee.\"\n\nStock Prediction(s):", "Prediction": "\n- PG&E Corp. (NYSE: PCG) will increase because the judge ruled that ratepayers don't need separate representation.\n- Edison International (NYSE: EIX) will decrease because they are a direct competitor of PG&E.\n- Sempra Energy (NYSE: SRE) will decrease because they are a direct competitor of PG&E.", "price_info": {"PCG": {"company": "", "ticker": "PCG", "move": "up", "prices": [17.16, 17.005]}, "EIX": {"company": "", "ticker": "EIX", "move": "down", "prices": [59.26, 58.82]}, "SRE": {"company": "", "ticker": "SRE", "move": "down", "prices": [131.0832, 130.59]}}}, {"link": "https://www.wsj.com/articles/rush-street-interactive-to-go-public-as-part-of-a-1-8-billion-deal-11595811601", "title": "Rush Street Interactive to Go Public as Part of a $1.8 Billion Deal", "date": "2020-07-27 09:33", "summary": "Online sports-and-casino betting company to merge with blank-check vehicle dMY Technology. Rush Street Interactive LP agreed to go public via a merger with a blank-check company that will value the online sports-and-casino betting company at about $1.8 billion including debt.", "categories": [["WSJ News Exclusive", "Deals"]], "category_links": ["https://www.wsj.com/news/types/deals-deal-makers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Rush Street Interactive to Go Public as Part of a $1.8 Billion Deal. Online sports-and-casino betting company to merge with blank-check vehicle dMY Technology. Rush Street Interactive LP agreed to go public via a merger with a blank-check company that will value the online sports-and-casino betting company at about $1.8 billion including debt.\"\n\nStock Prediction(s):", "Prediction": "\n- Rush Street Interactive LP (NASDAQ: RSI) will increase because they are going public and will have more resources to grow their business.\n- dMY Technology (NASDAQ: DMY) will increase because they are the blank-check company that is merging with Rush Street Interactive LP.", "price_info": {"RSI": {"company": "", "ticker": "RSI", "move": "up"}, "DMY": {"company": "", "ticker": "DMY", "move": "up"}}}, {"link": "https://www.wsj.com/articles/health-coverage-costs-continued-steady-rise-pre-pandemic-11602165793", "title": "Health Coverage Costs Continued Steady Rise Pre-Pandemic", "date": "2020-10-08 10:03", "summary": "Employers hold deductibles at 2019 levels, survey shows.. The average cost of employer health coverage surpassed $21,000 for a family plan this year, according to a new survey, a rise reflecting rates calculated before the pandemic upended normal patterns of medical care.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Health Coverage Costs Continued Steady Rise Pre-Pandemic. Employers hold deductibles at 2019 levels, survey shows.. The average cost of employer health coverage surpassed $21,000 for a family plan this year, according to a new survey, a rise reflecting rates calculated before the pandemic upended normal patterns of medical care.\"\n\nStock Prediction(s):", "Prediction": "\n- UnitedHealth Group Inc (NYSE: UNH) will increase because their stock is already high and they are a major player in the health insurance market.\n- Aetna Inc. (NYSE: AET) will increase because their stock is already high and they are a major player in the health insurance market.\n- Cigna Corporation (NYSE: CI) will increase because their stock is already high and they are a major player in the health insurance market.", "price_info": {"UNH": {"company": "", "ticker": "UNH", "move": "up", "prices": [321.7404, 323.685]}, "AET": {"company": "", "ticker": "AET", "move": "up"}, "CI": {"company": "", "ticker": "CI", "move": "up", "prices": [175.58, 176.38]}}}, {"link": "https://www.wsj.com/articles/barnes-noble-education-cfo-eyes-more-cuts-as-campuses-remain-closed-11609165800", "title": "Barnes & Noble Education CFO Eyes More Cuts as Campuses Remain Closed", "date": "2020-12-28 09:30", "summary": "The university bookstore chain has slashed jobs and other expenses during the pandemic. Thomas Donohue, the chief financial officer of Barnes & Noble Education Inc., has been slashing costs since the early days of the pandemic. He expects to keep doing so as another semester of remote learning approaches, forcing the campus bookstore chain to keep some of its outlets closed.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Barnes & Noble Education CFO Eyes More Cuts as Campuses Remain Closed. The university bookstore chain has slashed jobs and other expenses during the pandemic. Thomas Donohue, the chief financial officer of Barnes & Noble Education Inc., has been slashing costs since the early days of the pandemic. He expects to keep doing so as another semester of remote learning approaches, forcing the campus bookstore chain to keep some of its outlets closed.\"\n\nStock Prediction(s):", "Prediction": "\n- Barnes & Noble Education Inc. (NYSE: BNED) will continue to decrease because they are still losing money from the pandemic and have to keep cutting costs.", "price_info": {"BNED": {"company": "", "ticker": "BNED", "move": "down", "prices": [5.16, 5.46]}}}, {"link": "https://www.wsj.com/articles/oil-glut-returns-to-near-pre-pandemic-levels-11620809325", "title": "Oil Glut Returns to Near Pre-Pandemic Levels", "date": "2021-05-12 15:37", "summary": "IEA cuts global demand growth forecast as India battles Covid-19 wave. The oil supply glut that built up after the pandemic forced producing countries to slash output has almost returned to normal levels, the International Energy Agency said Wednesday.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Glut Returns to Near Pre-Pandemic Levels. IEA cuts global demand growth forecast as India battles Covid-19 wave. The oil supply glut that built up after the pandemic forced producing countries to slash output has almost returned to normal levels, the International Energy Agency said Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Schlumberger Ltd. (NYSE: SLB) will increase because they are a major oilfield services company and this news means that they will have more work.\n- Halliburton Company (NYSE: HAL) will increase because they are a major oilfield services company and this news means that they will have more work.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because this news means that oil prices will be lower, and they are a", "price_info": {"SLB": {"company": "", "ticker": "SLB", "move": "up", "prices": [32.03, 32.1]}, "HAL": {"company": "", "ticker": "HAL", "move": "up", "prices": [22.69, 22.56]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [59.96, 60]}}}, {"link": "https://www.wsj.com/articles/boeing-plane-deliveries-tumble-so-far-in-2019-11565714502", "title": "Boeing Plane Deliveries Tumble So Far in 2019", "date": "2019-08-13 14:57", "summary": "U.S. plane maker at risk of falling behind Airbus as the world's biggest aircraft manufacturer this year. Boeing Co. delivered fewer planes in July than in any month for the past decade, furthering the financial blow to the aerospace giant brought by the grounding of its 737 MAX jetliner.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Plane Deliveries Tumble So Far in 2019. U.S. plane maker at risk of falling behind Airbus as the world's biggest aircraft manufacturer this year. Boeing Co. delivered fewer planes in July than in any month for the past decade, furthering the financial blow to the aerospace giant brought by the grounding of its 737 MAX jetliner.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will continue to decrease because of the 737 MAX grounding.\n- Airbus SE (EPA: AIR) will increase because they are not affected by the grounding.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [332.76, 333]}}}, {"link": "https://www.wsj.com/articles/oil-swings-on-demand-uncertainty-11592489020", "title": "Oil Prices Rise Amid Supply Cuts", "date": "2020-06-18 15:13", "summary": "Recent data, concerns about fresh spike in global coronavirus cases create tug-of-war between supply cuts and demand anxiety. Oil prices climbed Thursday, nearing their highest levels since early March with traders expecting supply cuts to help balance the crude market.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Prices Rise Amid Supply Cuts. Recent data, concerns about fresh spike in global coronavirus cases create tug-of-war between supply cuts and demand anxiety. Oil prices climbed Thursday, nearing their highest levels since early March with traders expecting supply cuts to help balance the crude market.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because oil prices are rising and they are a big player in the oil market.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because oil prices are rising and they are a big player in the oil market.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because oil prices are rising and they are a big player in the oil market.\n- BP plc (", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [92.15, 92.1498]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [46.9002, 47.0602]}}}, {"link": "https://www.wsj.com/articles/oil-futures-fall-sharply-amid-building-u-s-inventories-11558626283", "title": "Oil Notches Biggest Plunge of 2019 as Demand Concerns Mount", "date": "2019-05-23 15:34", "summary": "U.S. and global oil prices tumble on concerns over rising inventories and global trade.. Oil prices closed out their worst trading day of the year on Thursday as demand concerns grew amid increasing global supply.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Notches Biggest Plunge of 2019 as Demand Concerns Mount. U.S. and global oil prices tumble on concerns over rising inventories and global trade.. Oil prices closed out their worst trading day of the year on Thursday as demand concerns grew amid increasing global supply.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because of the falling oil prices.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because of the falling oil prices.\n- Schlumberger Limited. (NYSE: SLB) will decrease because of the falling oil prices.\n- Halliburton Company (NYSE: HAL) will decrease because of the falling oil prices.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [117.72, 117.87]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [73.79, 73.79]}, "SLB": {"company": "", "ticker": "SLB", "move": "down", "prices": [37.49, 37.49]}, "HAL": {"company": "", "ticker": "HAL", "move": "down", "prices": [23.58, 23.6]}}}, {"link": "https://www.wsj.com/articles/how-to-get-rid-of-carbon-emissions-pay-farmers-to-bury-them-11568211869", "title": "How to Get Rid of Carbon Emissions: Pay Farmers to Bury Them", "date": "2019-09-11 10:24", "summary": "'Regenerative growing practices' sequester in the soil carbon released from burning fossil fuels. ", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Get Rid of Carbon Emissions: Pay Farmers to Bury Them. 'Regenerative growing practices' sequester in the soil carbon released from burning fossil fuels. \"\n\nStock Prediction(s):", "Prediction": "\n- Monsanto Company (NYSE: MON) will increase because they are a major player in the agriculture industry, and they are working on a project to help reduce carbon emissions.\n- Archer Daniels Midland Company (NYSE: ADM) will increase because they are a major player in the agriculture industry, and they are working on a project to help reduce carbon emissions.\n- Bunge Limited (NYSE: BG) will increase because they are a major player in the agriculture industry", "price_info": {"MON": {"company": "", "ticker": "MON", "move": "up"}, "ADM": {"company": "", "ticker": "ADM", "move": "up", "prices": [40.52, 40.56]}, "BG": {"company": "", "ticker": "BG", "move": "up", "prices": [57.11, 57.45]}}}, {"link": "https://www.wsj.com/articles/global-economic-warfare-intensifies-as-military-conflict-recedes-11631109600", "title": "Global Economic Warfare Intensifies as Military Conflict Recedes", "date": "2021-09-08 10:00", "summary": "Biden, like Trump, embraces sanctions, though they may be losing effectiveness and increasing the risk of conflict. The last American soldier had barely left Afghanistan when President Biden pledged that pressure on the Taliban would continue through other means, in particular what he described as economic tools. He has since maintained sanctions on the Taliban, though the action imperils Afghanistan's aid-dependent economy.", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Global Economic Warfare Intensifies as Military Conflict Recedes. Biden, like Trump, embraces sanctions, though they may be losing effectiveness and increasing the risk of conflict. The last American soldier had barely left Afghanistan when President Biden pledged that pressure on the Taliban would continue through other means, in particular what he described as economic tools. He has since maintained sanctions on the Taliban, though the action imperils Afghanistan's aid-dependent economy.\"\n\nStock Prediction(s):", "Prediction": "\n- The United States will increase because they are increasing sanctions on the Taliban.\n- Russia will increase because they are increasing sanctions on the Taliban.\n- China will increase because they are increasing sanctions on the Taliban.\n- The United Kingdom will increase because they are increasing sanctions on the Taliban.\n- The European Union will increase because they are increasing sanctions on the Taliban.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-trade-gap-widened-in-august-11570192406", "title": "U.S. Trade Gap Widened in August", "date": "2019-10-04 14:11", "summary": "Deficit rose to $54.9 billion as Americans bought more goods from abroad, exports grew too. WASHINGTON-The U.S. trade gap widened in August as American consumers bought more cellphones and other goods from abroad while businesses exported more oil and autos, a sign of the economy's resilience amid a global economic slowdown.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Trade Gap Widened in August. Deficit rose to $54.9 billion as Americans bought more goods from abroad, exports grew too. WASHINGTON-The U.S. trade gap widened in August as American consumers bought more cellphones and other goods from abroad while businesses exported more oil and autos, a sign of the economy's resilience amid a global economic slowdown.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co (NYSE: BA) will increase because they are a major exporter of goods.\n- Apple Inc. (NASDAQ: AAPL) will increase because they are a major exporter of goods.\n- General Motors Co. (NYSE: GM) will increase because they are a major exporter of goods.\n- Ford Motor Co. (NYSE: F) will increase because they are a major exporter of goods.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [374.54, 375.7]}, "GM": {"company": "", "ticker": "GM", "move": "up", "prices": [34.79, 34.91]}, "F": {"company": "", "ticker": "F", "move": "up", "prices": [8.735, 8.74]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [226.54, 227.01]}}}, {"link": "https://www.wsj.com/articles/pilgrim-s-pride-reaches-plea-agreement-with-justice-department-on-chicken-price-fixing-allegations-11602649655", "title": "Pilgrim's Pride Reaches Plea Deal on Chicken Price-Fixing Allegations", "date": "2020-10-14 12:36", "summary": "Second-largest U.S. chicken processor to pay $110.5 million fine. Chicken processor Pilgrim's Pride Corp. said it has agreed to a plea deal with the U.S. Justice Department to resolve price-fixing charges, and will pay a fine of $110.5 million.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pilgrim's Pride Reaches Plea Deal on Chicken Price-Fixing Allegations. Second-largest U.S. chicken processor to pay $110.5 million fine. Chicken processor Pilgrim's Pride Corp. said it has agreed to a plea deal with the U.S. Justice Department to resolve price-fixing charges, and will pay a fine of $110.5 million.\"\n\nStock Prediction(s):", "Prediction": "\n- Pilgrim's Pride Corp. (NASDAQ: PPC) will increase because they have resolved their price-fixing allegations, and will pay a $110.5 million fine.\n- Tyson Foods, Inc. (NYSE: TSN) will decrease because they are a direct competitor of Pilgrim's Pride.", "price_info": {"TSN": {"company": "", "ticker": "TSN", "move": "down", "prices": [59.41, 59.265]}, "PPC": {"company": "", "ticker": "PPC", "move": "up", "prices": [16.63, 16.7]}}}, {"link": "https://www.wsj.com/articles/golds-volatile-run-continues-in-december-11607528667", "title": "Gold's Volatile Run Continues in December", "date": "2020-12-09 14:51", "summary": "Precious metal still up more than 20% for the year. Gold prices fell Wednesday, paring some of the December rally and continuing a stretch of volatility as traders weigh a recent rise in coronavirus cases against upbeat vaccine trial results and prospects for further stimulus.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold's Volatile Run Continues in December. Precious metal still up more than 20% for the year. Gold prices fell Wednesday, paring some of the December rally and continuing a stretch of volatility as traders weigh a recent rise in coronavirus cases against upbeat vaccine trial results and prospects for further stimulus.\"\n\nStock Prediction(s):", "Prediction": "\n- Gold prices will continue to be volatile as traders weigh the pros and cons of the various factors involved.\n- Gold prices will continue to increase as the global pandemic worsens.", "price_info": {}}, {"link": "https://www.wsj.com/articles/apple-postpones-return-to-office-until-january-11629485876", "title": "Apple Postpones Return to Office Until January", "date": "2021-08-20 14:57", "summary": "The company previously set October as a target, but concerns about Covid-19 Delta variant have mounted. Apple Inc. is delaying back-to-work plans for its U.S. corporate offices until early next year as a rise in Covid-19 cases in the country continues to disrupt companies' efforts to have employees back in place.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Postpones Return to Office Until January. The company previously set October as a target, but concerns about Covid-19 Delta variant have mounted. Apple Inc. is delaying back-to-work plans for its U.S. corporate offices until early next year as a rise in Covid-19 cases in the country continues to disrupt companies' efforts to have employees back in place.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are postponing their return to the office.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are not postponing their return to the office.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [148.21, 148.21]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [304.54, 304.2]}}}, {"link": "https://www.wsj.com/articles/nucor-to-replace-ceo-at-year-end-11567788699", "title": "Nucor to Replace CEO at Year-End", "date": "2019-09-06 13:37", "summary": "Top U.S. steelmaker faces falling prices, slackening demand from manufacturers. Nucor Corp. said Chief Executive John Ferriola will retire at the end of the year and be replaced by veteran executive Leon Topalian, as the largest U.S. steelmaker navigates weakening demand from a decelerating industrial sector.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nucor to Replace CEO at Year-End. Top U.S. steelmaker faces falling prices, slackening demand from manufacturers. Nucor Corp. said Chief Executive John Ferriola will retire at the end of the year and be replaced by veteran executive Leon Topalian, as the largest U.S. steelmaker navigates weakening demand from a decelerating industrial sector.\"\n\nStock Prediction(s):", "Prediction": "\n- Nucor Corporation (NYSE: NUE) will decrease because their CEO is retiring and they are facing falling prices and slackening demand.", "price_info": {"NUE": {"company": "", "ticker": "NUE", "move": "down", "prices": [50.245, 50.19]}}}, {"link": "https://www.wsj.com/articles/spotify-strikes-new-deal-for-warner-music-catalog-11585750007", "title": "Spotify Strikes New Deal for Warner Music Catalog", "date": "2020-04-01 10:06", "summary": "Long-term licensing agreement covers existing territories and Spotify's expansion into new markets. Spotify Technology SA and Warner Music Group have reached a new global licensing agreement, the companies said, ending a contentious yearslong negotiation between the streaming giant and the third-largest music label.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Spotify Strikes New Deal for Warner Music Catalog. Long-term licensing agreement covers existing territories and Spotify's expansion into new markets. Spotify Technology SA and Warner Music Group have reached a new global licensing agreement, the companies said, ending a contentious yearslong negotiation between the streaming giant and the third-largest music label.\"\n\nStock Prediction(s):", "Prediction": "\n- Spotify Technology SA (NYSE: SPOT) will increase because they have secured a new licensing agreement with Warner Music.\n- Warner Music Group (NYSE: WMG) will increase because they have secured a new licensing agreement with Spotify.", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "up", "prices": [123.795, 120.5233]}, "WMG": {"company": "", "ticker": "WMG", "move": "up"}}}, {"link": "https://www.wsj.com/articles/jobs-report-offers-little-reason-for-fed-to-change-its-view-11578664895", "title": "Jobs Report Offers Little Reason for Fed to Change Its View", "date": "2020-01-10 09:41", "summary": "Steady payroll gains but few signs of accelerating wages could keep central bank rate policy on hold. The December employment report is likely to keep the Federal Reserve comfortable with its make-no-moves posture as officials look for evidence that last year's slowdown in manufacturing, investment and trade hasn't spilled into the broader consumer-driven economy.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jobs Report Offers Little Reason for Fed to Change Its View. Steady payroll gains but few signs of accelerating wages could keep central bank rate policy on hold. The December employment report is likely to keep the Federal Reserve comfortable with its make-no-moves posture as officials look for evidence that last year's slowdown in manufacturing, investment and trade hasn't spilled into the broader consumer-driven economy.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will not change their stance on interest rates because the jobs report showed that there is little evidence of an accelerating wage growth.\n- The market will not react to the jobs report because it was largely expected.", "price_info": {}}, {"link": "https://www.wsj.com/articles/samsung-galaxy-s22-ultra-reveal-release-date-11644366366", "title": "Missing the Galaxy Note? This New Samsung Phone Is for You", "date": "2022-02-09 10:00", "summary": "In addition to appealing to the most devoted Samsung nerds, the company added two smaller, more-affordable phones, the Galaxy S22+ and S22, to its flagship line. It's getting harder for phone makers to wow buyers. Samsung Electronics Co. hopes its latest models will stoke excitement in its most loyal fan base: users of its recently discontinued Galaxy Note.", "categories": [["Tech", "Personal Tech", "Personal Technology"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Missing the Galaxy Note? This New Samsung Phone Is for You. In addition to appealing to the most devoted Samsung nerds, the company added two smaller, more-affordable phones, the Galaxy S22+ and S22, to its flagship line. It's getting harder for phone makers to wow buyers. Samsung Electronics Co. hopes its latest models will stoke excitement in its most loyal fan base: users of its recently discontinued Galaxy Note.\"\n\nStock Prediction(s):", "Prediction": "\n- Samsung Electronics Co. Ltd. (OTC: SSNLF) will increase because they are releasing new phones that are more affordable and will appeal to their most loyal fan base.\n- Apple Inc. (NASDAQ: AAPL) will decrease because their newest phone, the iPhone 11, is not as affordable as Samsung's newest phones and does not have the same features.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [175.25, 175.592]}}}, {"link": "https://www.wsj.com/articles/treasury-to-sell-88-billion-in-debt-11547145580", "title": "Treasury to Sell $88 Billion in Debt", "date": "2019-01-10 13:39", "summary": "U.S. Treasury Department's auctions next week comprise 13- and 26-week bills and 10-year TIPS. The U.S. Treasury Department will auction $88 billion in securities next week. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury to Sell $88 Billion in Debt. U.S. Treasury Department's auctions next week comprise 13- and 26-week bills and 10-year TIPS. The U.S. Treasury Department will auction $88 billion in securities next week. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Treasury Department will auction $88 billion in securities next week, and this will have a positive effect on the stock prices of the companies that are involved in this auction.\n- The U.S. Treasury Department will auction $88 billion in securities next week, and this will have a negative effect on the stock prices of the companies that are involved in this auction.", "price_info": {}}, {"link": "https://www.wsj.com/articles/fintech-startup-checkout-com-scores-40-billion-valuation-in-latest-share-sale-11641988805", "title": "Checkout.com Scores $40 Billion Valuation in Latest Share Sale", "date": "2022-01-12 10:40", "summary": "The $1 billion deal vaults the digital-payments processor past all but a handful of other startups. Checkout.com didn't raise money from outside investors until 2019. Today, it is one of the most valuable startups in the world.", "categories": [["WSJ News Exclusive", "Finance"]], "category_links": ["https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Checkout.com Scores $40 Billion Valuation in Latest Share Sale. The $1 billion deal vaults the digital-payments processor past all but a handful of other startups. Checkout.com didn't raise money from outside investors until 2019. Today, it is one of the most valuable startups in the world.\"\n\nStock Prediction(s):", "Prediction": "\n- Checkout.com (NYSE: CHX) will increase because they are one of the most valuable startups in the world, and they are only getting bigger.\n- Square Inc (NYSE: SQ) will decrease because they are a direct competitor of Checkout.com.", "price_info": {"CHX": {"company": "", "ticker": "CHX", "move": "up", "prices": [23.3, 23.24]}, "SQ": {"company": "", "ticker": "SQ", "move": "down", "prices": [147.8514, 147.58]}}}, {"link": "https://www.wsj.com/articles/feds-quarles-regulatory-tools-better-suited-than-interest-rates-to-promote-financial-stability-11559234708", "title": "Fed's Quarles: Regulatory Tools Better Suited Than Interest Rates to Promote Financial Stability", "date": "2019-05-30 12:45", "summary": "Central bank's point man on bank regulation said interest rates should be used to achieve inflation and employment goals. WASHINGTON-The Federal Reserve's point man on bank regulation said Thursday that interest rates should be used to achieve the central bank's inflation and employment goals rather than to address concerns about financial stability.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Quarles: Regulatory Tools Better Suited Than Interest Rates to Promote Financial Stability. Central bank's point man on bank regulation said interest rates should be used to achieve inflation and employment goals. WASHINGTON-The Federal Reserve's point man on bank regulation said Thursday that interest rates should be used to achieve the central bank's inflation and employment goals rather than to address concerns about financial stability.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve's (NYSE: FED) stock will decrease because they are not using interest rates to address concerns about financial stability, which is their primary goal.\n- Goldman Sachs Group Inc (NYSE: GS) will increase because they are a direct beneficiary of the Federal Reserve's decision.\n- J.P. Morgan Chase & Co. (NYSE: JPM) will increase because they are a direct beneficiary of the Federal Reserve's decision.\n- Bank of", "price_info": {"FED": {"company": "", "ticker": "FED", "move": "down"}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [187.17, 186.51]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [107.57, 106.75]}}}, {"link": "https://www.wsj.com/articles/evs-could-revive-detroits-supply-chain-woes-11641319000", "title": "EVs Could Revive Detroit's Supply-Chain Woes", "date": "2022-01-04 12:56", "summary": "Toyota outsold GM last year due to a superior supply chain. The lesson that supply matters will likely apply to electric vehicles next.. Last year was a highly unusual one for car makers: Supply mattered more than demand, reversing a pattern set by decades of overproduction. The experience is worth remembering as electric-vehicle sales take off.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"EVs Could Revive Detroit's Supply-Chain Woes. Toyota outsold GM last year due to a superior supply chain. The lesson that supply matters will likely apply to electric vehicles next.. Last year was a highly unusual one for car makers: Supply mattered more than demand, reversing a pattern set by decades of overproduction. The experience is worth remembering as electric-vehicle sales take off.\"\n\nStock Prediction(s):", "Prediction": "\n- General Motors Company (NYSE: GM) will increase because they have been working on their supply chain for electric vehicles, and they will be able to capitalize on the increasing demand.\n- Ford Motor Company (NYSE: F) will increase because they have been working on their supply chain for electric vehicles, and they will be able to capitalize on the increasing demand.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they have been working on", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "up", "prices": [65.9599, 65.7]}, "F": {"company": "", "ticker": "F", "move": "up", "prices": [24.535, 24.3424]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [1162.69, 1139.27]}}}, {"link": "https://www.wsj.com/articles/virgin-galactic-didi-lionheart-acquisition-what-to-watch-when-the-stock-market-opens-today-11626087836", "title": "Virgin Galactic, Didi, Lionheart Acquisition: What to Watch When the Stock Market Opens Today", "date": "2021-07-12 09:35", "summary": "U.S. stock futures were mixed after Friday's record close on Wall Street. Earnings season is set to kick off this week, starting with big banks, and investors will be watching to see if they can deliver on high expectations. Here's what we're watching ahead of Monday's open.", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Virgin Galactic, Didi, Lionheart Acquisition: What to Watch When the Stock Market Opens Today. U.S. stock futures were mixed after Friday's record close on Wall Street. Earnings season is set to kick off this week, starting with big banks, and investors will be watching to see if they can deliver on high expectations. Here's what we're watching ahead of Monday's open.\"\n\nStock Prediction(s):", "Prediction": "\n- Virgin Galactic Holdings Inc (NYSE: VGC) will increase because they announced a partnership with Didi Chuxing, and they are also working on a vaccine.\n- Lionheart Acquisition Corp (NASDAQ: LHC) will increase because they announced a merger with Didi Chuxing, and they are also working on a vaccine.\n- JPMorgan Chase & Co (NYSE: JPM) will increase because they are the first big bank to report earnings this week", "price_info": {"VGC": {"company": "", "ticker": "VGC", "move": "up"}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [157.3162, 158.1599]}, "LHC": {"company": "", "ticker": "LHC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/a-boozy-guide-to-dating-apps-11553102804", "title": "Why Tinder Is the Long Island Iced Tea of Dating Apps", "date": "2019-03-20 13:26", "summary": "To help you choose the digital matchmaker that's right for you, we asked: 'What kind of drink would each one be?'. WHILE I can't point to the single most important lesson that dating in New York has taught me, I now know that the first drink you or your companion chooses can make a statement. Whether it's a craft IPA or a pi\u00f1a colada, brown liquor drowning one big cube, or a few shots of Patr\u00f3n, it sets a certain vibe, helping you write the story of an evening before your glasses clink.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Tinder Is the Long Island Iced Tea of Dating Apps. To help you choose the digital matchmaker that's right for you, we asked: 'What kind of drink would each one be?'. WHILE I can't point to the single most important lesson that dating in New York has taught me, I now know that the first drink you or your companion chooses can make a statement. Whether it's a craft IPA or a pi\u00f1a colada, brown liquor drowning one big cube, or a few shots of Patr\u00f3n, it sets a certain vibe, helping you write the story of an evening before your glasses clink.\"\n\nStock Prediction(s):", "Prediction": "\n- Match Group, Inc. (NASDAQ: MTCH) will increase because they are the Long Island Iced Tea of Dating Apps. They are the most popular, and they have the widest variety of options.\n- Bumble (NYSE: BUMBLE) will increase because they are the Long Island Iced Tea of Dating Apps. They are the most popular, and they have the widest variety of options.\n- The Dating Company (OTC: TDC", "price_info": {"MTCH": {"company": "", "ticker": "MTCH", "move": "up", "prices": [58.35, 58.065]}}}, {"link": "https://www.wsj.com/articles/high-speed-traders-back-exchanges-in-fight-with-sec-over-rebates-plan-11560522862", "title": "High-Speed Traders Back Exchanges in Fight With SEC", "date": "2019-06-14 10:34", "summary": "Citadel Securities, GTS and IMC say regulator's initiative is 'ill-conceived' and would harm investors. Three big high-speed trading firms asked a federal court to halt a Securities and Exchange Commission initiative that would limit the rebates that U.S. stock exchanges pay to attract investors' orders.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"High-Speed Traders Back Exchanges in Fight With SEC. Citadel Securities, GTS and IMC say regulator's initiative is 'ill-conceived' and would harm investors. Three big high-speed trading firms asked a federal court to halt a Securities and Exchange Commission initiative that would limit the rebates that U.S. stock exchanges pay to attract investors' orders.\"\n\nStock Prediction(s):", "Prediction": "\n- Citadel Securities LLC (NASDAQ: CLLC) will increase because they are fighting for the best interests of their investors.\n- GTS Inc. (NYSE: GTS) will increase because they are fighting for the best interests of their investors.\n- IMC Financial Markets LLC (NYSE: IMC) will increase because they are fighting for the best interests of their investors.", "price_info": {"GTS": {"company": "", "ticker": "GTS", "move": "up", "prices": [23.74, 23.33]}, "IMC": {"company": "", "ticker": "IMC", "move": "up"}, "CLLC": {"company": "", "ticker": "CLLC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/disney-critics-are-no-phantom-menace-11576856170", "title": "Disney Critics Are No Phantom Menace", "date": "2019-12-20 10:36", "summary": "Latest Star Wars installment falling flat with reviewers. It's not a million voices crying out in terror. But for Walt Disney Co. , 296 voices might be scary enough.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Disney Critics Are No Phantom Menace. Latest Star Wars installment falling flat with reviewers. It's not a million voices crying out in terror. But for Walt Disney Co. , 296 voices might be scary enough.\"\n\nStock Prediction(s):", "Prediction": "\n- Disney (NYSE: DIS) will decrease because their latest installment of Star Wars is falling flat with reviewers.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [146.9223, 147.045]}}}, {"link": "https://www.wsj.com/articles/apollo-to-buy-majority-stake-in-cox-tv-stations-11550259225", "title": "Apollo to Buy Majority Stake in Cox TV Stations", "date": "2019-02-15 15:56", "summary": "The deal will also include a majority stake in Ohio newspapers and radio stations. Apollo Global Management LLC has taken the first step to becoming one of the nation's biggest owners of local television stations.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apollo to Buy Majority Stake in Cox TV Stations. The deal will also include a majority stake in Ohio newspapers and radio stations. Apollo Global Management LLC has taken the first step to becoming one of the nation's biggest owners of local television stations.\"\n\nStock Prediction(s):", "Prediction": "\n- Apollo Global Management LLC (NYSE: APO) will increase because they are buying a majority stake in Cox TV stations.\n- Cox Enterprises, Inc. (NYSE: COX) will decrease because they are selling their TV stations to Apollo.", "price_info": {"APO": {"company": "", "ticker": "APO", "move": "up", "prices": [30.2097, 30.24]}, "COX": {"company": "", "ticker": "COX", "move": "down"}}}, {"link": "https://www.wsj.com/articles/commodities-traders-face-limits-on-speculative-positions-under-u-s-proposal-11580410142", "title": "Commodities Traders Face Limits on Speculative Positions Under U.S. Proposal", "date": "2020-01-30 15:41", "summary": "The aim is to prevent speculators from causing unjustified price swings that could hurt consumers. WASHINGTON-Federal regulators on Thursday proposed so-called position limits in markets for commodities such as gold, sugar and crude oil while leaving exchanges with considerable leeway in deciding how to contain speculative bets.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Commodities Traders Face Limits on Speculative Positions Under U.S. Proposal. The aim is to prevent speculators from causing unjustified price swings that could hurt consumers. WASHINGTON-Federal regulators on Thursday proposed so-called position limits in markets for commodities such as gold, sugar and crude oil while leaving exchanges with considerable leeway in deciding how to contain speculative bets.\"\n\nStock Prediction(s):", "Prediction": "\n- Agricultural commodities traders will increase because the proposal limits the amount of speculative positions that traders can hold, which will prevent price swings.\n- Energy commodities traders will decrease because the proposal limits the amount of speculative positions that traders can hold, which will prevent price swings.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-industrial-production-points-to-slowing-manufacturing-recovery-11600177062", "title": "Industrial Production Points to Slowing Manufacturing Recovery", "date": "2020-09-15 10:32", "summary": "Federal Reserve's reading on output at factories, mines and utilities rose for fourth straight month, but at a much slower pace in August. U.S. industrial production rose for the fourth consecutive month in August but at a much lower rate than earlier in the summer, a sign that the manufacturing recovery is slowing.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Industrial Production Points to Slowing Manufacturing Recovery. Federal Reserve's reading on output at factories, mines and utilities rose for fourth straight month, but at a much slower pace in August. U.S. industrial production rose for the fourth consecutive month in August but at a much lower rate than earlier in the summer, a sign that the manufacturing recovery is slowing.\"\n\nStock Prediction(s):", "Prediction": "\n- General Electric Company (NYSE: GE) will decrease because their main industry is manufacturing, and this news suggests that the manufacturing sector is slowing down.\n- 3M Company (NYSE: MMM) will decrease because their main industry is manufacturing, and this news suggests that the manufacturing sector is slowing down.\n- Caterpillar Inc. (NYSE: CAT) will decrease because their main industry is manufacturing, and this news suggests that the manufacturing sector is slowing down.", "price_info": {"GE": {"company": "", "ticker": "GE", "move": "down", "prices": [6.055, 6.04]}, "MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [167.48, 166.32]}, "CAT": {"company": "", "ticker": "CAT", "move": "down", "prices": [149.79, 149.47]}}}, {"link": "https://www.wsj.com/articles/aston-martin-stalls-again-11578425158", "title": "Aston Martin Stalls Again", "date": "2020-01-07 14:25", "summary": "British sports car maker could pick up pace in 2020, but stock remains highly risky. Aston Martin Lagonda capped a dire first full year as a public company, appropriately enough, with a profit warning. 2020 should be better, but the bar is set very low.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Aston Martin Stalls Again. British sports car maker could pick up pace in 2020, but stock remains highly risky. Aston Martin Lagonda capped a dire first full year as a public company, appropriately enough, with a profit warning. 2020 should be better, but the bar is set very low.\"\n\nStock Prediction(s):", "Prediction": "\n- Aston Martin Lagonda (OTC: AZNLY) will continue to decrease because they have been issuing profit warnings.\n- Ferrari NV (NYSE: RACE) will increase because they are not issuing profit warnings, and they are a direct competitor of Aston Martin.", "price_info": {"RACE": {"company": "", "ticker": "RACE", "move": "up", "prices": [165.56, 165.32]}}}, {"link": "https://www.wsj.com/articles/buzzfeed-nears-deal-to-go-public-via-spac-eyeing-digital-media-rollup-11624485898", "title": "BuzzFeed Reaches Deal to Go Public Via SPAC", "date": "2021-06-24 11:38", "summary": "Company says agreement values combined entity at $1.5 billion after transaction. BuzzFeed Inc. said Thursday it has reached a deal to go public through a merger with a special-purpose acquisition company, part of a plan to consolidate other players in digital media.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"BuzzFeed Reaches Deal to Go Public Via SPAC. Company says agreement values combined entity at $1.5 billion after transaction. BuzzFeed Inc. said Thursday it has reached a deal to go public through a merger with a special-purpose acquisition company, part of a plan to consolidate other players in digital media.\"\n\nStock Prediction(s):", "Prediction": "\n- BuzzFeed (NYSE: BUZZ) will increase because they are going public and this will give them more resources to compete in the digital media space.\n- Vice Media (NASDAQ: VICEM) will decrease because they are a direct competitor of BuzzFeed.\n- Group Nine Media (NASDAQ: GIII) will decrease because they are a direct competitor of BuzzFeed.", "price_info": {"BUZZ": {"company": "", "ticker": "BUZZ", "move": "up", "prices": [26.3977, 26.2999]}, "VICEM": {"company": "", "ticker": "VICEM", "move": "down"}, "GIII": {"company": "", "ticker": "GIII", "move": "down", "prices": [33.12, 33.43]}}}, {"link": "https://www.wsj.com/articles/googles-biggest-business-doesnt-click-11556575750", "title": "Google's Biggest Business Doesn't Click", "date": "2019-04-30 12:12", "summary": "Surprising slowdown in advertising revenue undercuts internet giant's key strength. Google's ad machine seems to have slipped a gear.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Google's Biggest Business Doesn't Click. Surprising slowdown in advertising revenue undercuts internet giant's key strength. Google's ad machine seems to have slipped a gear.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease because their main business (advertising) is not doing as well as expected.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [1188.99, 1193.7163]}}}, {"link": "https://www.wsj.com/articles/communication-hybrid-workplace-11628795958", "title": "How to Bridge the Communications Gap in a Hybrid Office", "date": "2021-08-13 10:00", "summary": "Too often, remote and in-office employees aren't even speaking the same language. I recently met a woman who quit her job after 11 years working for the same organization. The pandemic was stressful, but it was the hybrid meetings that did her in.", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Bridge the Communications Gap in a Hybrid Office. Too often, remote and in-office employees aren't even speaking the same language. I recently met a woman who quit her job after 11 years working for the same organization. The pandemic was stressful, but it was the hybrid meetings that did her in.\"\n\nStock Prediction(s):", "Prediction": "\n- Zoom Video Communications, Inc. (NASDAQ: ZM) will increase because their video conferencing software is perfect for bridging the communication gap in a hybrid office.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because their video conferencing software is perfect for bridging the communication gap in a hybrid office.\n- Facebook, Inc. (NASDAQ: FB) will increase because their video conferencing software is perfect for bridging", "price_info": {"ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [359.385, 362.205]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [291.69, 291.38]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [363.2336, 362.9355]}}}, {"link": "https://www.wsj.com/articles/u-s-consumer-sentiment-rose-in-recent-weeks-11607703437", "title": "Consumer Sentiment Rose in Recent Weeks", "date": "2020-12-11 11:17", "summary": "Americans' outlook brightened as people expect better economic conditions beyond the pandemic. U.S. consumers grew more confident in the economy in late November and early December, with many expecting the economic conditions to improve when the country begins to exit from the coronavirus pandemic.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Consumer Sentiment Rose in Recent Weeks. Americans' outlook brightened as people expect better economic conditions beyond the pandemic. U.S. consumers grew more confident in the economy in late November and early December, with many expecting the economic conditions to improve when the country begins to exit from the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because consumer sentiment is rising, and Walmart is one of the main beneficiaries of this trend.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because consumer sentiment is rising, and Amazon is one of the main beneficiaries of this trend.\n- Apple Inc. (NASDAQ: AAPL) will increase because consumer sentiment is rising, and Apple is one of the main beneficiaries of", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [146.8, 146.825]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3095.47, 3073.836]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [121.45, 121.025]}}}, {"link": "https://www.wsj.com/articles/a-private-beachfront-estate-in-the-bahamas-asks-45-million-11588268723", "title": "A Private Beachfront Estate in the Bahamas Asks $45 Million", "date": "2020-04-30 13:45", "summary": "If the roughly 3.5-acre property in Lyford Cay fetches that price, it would be one of the priciest homes ever sold in the country. A beachfront Bahamas estate asking $45 million would be one of the most expensive homes ever sold in the country if it fetches that price.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Private Beachfront Estate in the Bahamas Asks $45 Million. If the roughly 3.5-acre property in Lyford Cay fetches that price, it would be one of the priciest homes ever sold in the country. A beachfront Bahamas estate asking $45 million would be one of the most expensive homes ever sold in the country if it fetches that price.\"\n\nStock Prediction(s):", "Prediction": "\n- The estate will not sell for $45 million because it is overpriced.\n- The estate will not sell for $45 million because it is overpriced.\n- The estate will not sell for $45 million because it is overpriced.", "price_info": {}}, {"link": "https://www.wsj.com/articles/german-chip-maker-infineon-names-finance-chief-11552572694", "title": "German Chip Maker Infineon Names Finance Chief", "date": "2019-03-14 10:11", "summary": "Sven Schneider will join the company from gases specialist Linde. German semiconductor manufacturer Infineon Technologies AG on Thursday appointed Sven Schneider as its new finance chief, a move that comes as the industry is suffering a downturn.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"German Chip Maker Infineon Names Finance Chief. Sven Schneider will join the company from gases specialist Linde. German semiconductor manufacturer Infineon Technologies AG on Thursday appointed Sven Schneider as its new finance chief, a move that comes as the industry is suffering a downturn.\"\n\nStock Prediction(s):", "Prediction": "\n- Infineon Technologies AG (OTCMKTS: IFNNY) will decrease because their industry is suffering a downturn.", "price_info": {}}, {"link": "https://www.wsj.com/articles/do-the-latest-wireless-chargers-beat-plugging-in-your-phone-11635965007", "title": "Do the Latest Wireless Chargers Beat Plugging In Your Phone?", "date": "2021-11-03 14:43", "summary": "Wireless charging tech is finally reliable, but the question is whether eliminating a mess of charging cords is worth the trade-offs. A debate. For the recurring series, That's Debatable, we take on a contentious issue of the day and present two spirited arguments-one in favor and the other emphatically opposed. Previous installments from the series are here.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Do the Latest Wireless Chargers Beat Plugging In Your Phone?. Wireless charging tech is finally reliable, but the question is whether eliminating a mess of charging cords is worth the trade-offs. A debate. For the recurring series, That's Debatable, we take on a contentious issue of the day and present two spirited arguments-one in favor and the other emphatically opposed. Previous installments from the series are here.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they are releasing a new wireless charger that is more reliable and eliminates the need for charging cords.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will increase because they are releasing a new wireless charger that is more reliable and eliminates the need for charging cords.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [151.705, 151.42]}}}, {"link": "https://www.wsj.com/articles/aluminum-prices-push-toward-2020-high-on-sanction-worries-demand-11608308859", "title": "Aluminum Prices Push Toward 2020 High", "date": "2020-12-18 15:35", "summary": "The metal has gained more than 13% year-to-date. Aluminum prices are trading near their highest levels in almost two years, fueled by soaring demand for raw materials and worries that potential new U.S. sanctions on one of the world's largest producers could limit global supplies of the metal.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Aluminum Prices Push Toward 2020 High. The metal has gained more than 13% year-to-date. Aluminum prices are trading near their highest levels in almost two years, fueled by soaring demand for raw materials and worries that potential new U.S. sanctions on one of the world's largest producers could limit global supplies of the metal.\"\n\nStock Prediction(s):", "Prediction": "\n- Alcoa Corporation (NYSE: AA) will increase because of the high demand for aluminum.\n- Century Aluminum Company (NASDAQ: CENX) will increase because of the high demand for aluminum.\n- Kaiser Aluminum Corporation (NASDAQ: KALU) will increase because of the high demand for aluminum.", "price_info": {"AA": {"company": "", "ticker": "AA", "move": "up", "prices": [21.98, 22.09]}, "CENX": {"company": "", "ticker": "CENX", "move": "up"}, "KALU": {"company": "", "ticker": "KALU", "move": "up", "prices": [94.0818, 93.73]}}}, {"link": "https://www.wsj.com/articles/durable-goods-orders-advanced-in-june-as-u-s-economy-continues-to-grow-11627390155", "title": "U.S. Durable-Goods Orders Advanced in June", "date": "2021-07-27 10:36", "summary": "New orders rose 0.8%; gains have been recorded in 13 of the last 14 months. Orders for cars, appliances and other durable goods increased in June, signaling continued strength in the U.S. economy as manufacturers continue to deal with shortages in parts and labor and confront higher material costs.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Durable-Goods Orders Advanced in June. New orders rose 0.8%; gains have been recorded in 13 of the last 14 months. Orders for cars, appliances and other durable goods increased in June, signaling continued strength in the U.S. economy as manufacturers continue to deal with shortages in parts and labor and confront higher material costs.\"\n\nStock Prediction(s):", "Prediction": "\n- General Motors Company (NYSE: GM) will increase because they are one of the largest car manufacturers in the United States.\n- Ford Motor Company (NYSE: F) will increase because they are one of the largest car manufacturers in the United States.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are one of the largest car manufacturers in the United States.\n- Home Depot, Inc. (NYSE: HD) will increase", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "up", "prices": [54.62, 54.5696]}, "F": {"company": "", "ticker": "F", "move": "up", "prices": [13.7156, 13.71]}, "HD": {"company": "", "ticker": "HD", "move": "up", "prices": [326.46, 327.32]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [634.8999, 631.0916]}}}, {"link": "https://www.wsj.com/articles/investors-to-big-oil-make-it-rain-11572612256", "title": "Investors to Big Oil: Make It Rain", "date": "2019-11-01 12:11", "summary": "Shareholders skeptical of fossil-fuel companies want more cash, but the pressure is straining balance sheets. Investors want just one thing from the world's biggest oil companies: cold, hard cash. But it is becoming harder for the oil giants to deliver.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors to Big Oil: Make It Rain. Shareholders skeptical of fossil-fuel companies want more cash, but the pressure is straining balance sheets. Investors want just one thing from the world's biggest oil companies: cold, hard cash. But it is becoming harder for the oil giants to deliver.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because they are one of the few oil companies that is increasing its dividend.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because they are not increasing their dividend, and they are also investing in renewable energy.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because they are not increasing their dividend, and they are also investing in renewable energy.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [116.215, 116.09]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [69.1544, 69.32]}}}, {"link": "https://www.wsj.com/articles/tidjane-thiams-ouster-raises-more-questions-at-credit-suisse-11581087614", "title": "Tidjane Thiam's Ouster Raises More Questions at Credit Suisse", "date": "2020-02-07 10:00", "summary": "Chairman Urs Rohner and his choice of new CEO need to set out a vision for growth. Tidjane Thiam's ouster from the helm of Credit Suisse solves one problem for the board but creates others. The chairman who pushed him out and his chief executive elect need to work quickly to offer investors a vision for growth.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tidjane Thiam's Ouster Raises More Questions at Credit Suisse. Chairman Urs Rohner and his choice of new CEO need to set out a vision for growth. Tidjane Thiam's ouster from the helm of Credit Suisse solves one problem for the board but creates others. The chairman who pushed him out and his chief executive elect need to work quickly to offer investors a vision for growth.\"\n\nStock Prediction(s):", "Prediction": "\n- Credit Suisse Group AG (NYSE: CS) will decrease because their CEO was just ousted, and they don't have a clear vision for the future.\n- UBS Group AG (NYSE: UBS) will increase because they are a direct competitor of Credit Suisse, and they have a clear vision for the future.", "price_info": {"CS": {"company": "", "ticker": "CS", "move": "down", "prices": [13.01, 13.02]}, "UBS": {"company": "", "ticker": "UBS", "move": "up", "prices": [12.9334, 12.96]}}}, {"link": "https://www.wsj.com/articles/surging-fertilizer-costs-push-farmers-to-shift-planting-plans-raise-prices-11639580768", "title": "Surging Fertilizer Costs Push Farms to Shift Planting Plans, Raise Prices", "date": "2021-12-15 14:51", "summary": "Higher prices for commodities like corn would further inflate prices cereal, cooking oil, beef and other meat. Fertilizer prices have more than doubled over the past year, frustrating U.S. farmers, who now are adjusting spring planting plans and warning about the potential for higher food prices.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Surging Fertilizer Costs Push Farms to Shift Planting Plans, Raise Prices. Higher prices for commodities like corn would further inflate prices cereal, cooking oil, beef and other meat. Fertilizer prices have more than doubled over the past year, frustrating U.S. farmers, who now are adjusting spring planting plans and warning about the potential for higher food prices.\"\n\nStock Prediction(s):", "Prediction": "\n- CF Industries Holdings, Inc. (NYSE: CF) will increase because they are one of the main producers of fertilizer, and they will benefit from the price increase.\n- Mosaic Company (NYSE: MOS) will increase because they are one of the main producers of fertilizer, and they will benefit from the price increase.\n- Potash Corporation of Saskatchewan Inc. (NYSE: POT) will increase because they are one of the main producers of fertilizer,", "price_info": {"CF": {"company": "", "ticker": "CF", "move": "up"}, "MOS": {"company": "", "ticker": "MOS", "move": "up", "prices": [35.78, 36.05]}, "POT": {"company": "", "ticker": "POT", "move": "up"}}}, {"link": "https://www.wsj.com/articles/time-for-a-faster-turnaround-at-ford-11588168063", "title": "Time for a Faster Turnaround at Ford", "date": "2020-04-29 09:47", "summary": "The Covid shutdowns are a test and opportunity alike for the Detroit auto maker, whose slow restructuring plans already made it a focus of investor frustration. The upheaval caused by Detroit's coronavirus shutdowns may offer Ford Chief Executive Jim Hackett his last chance to show investors he can turn the U.S. industrial icon around.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Time for a Faster Turnaround at Ford. The Covid shutdowns are a test and opportunity alike for the Detroit auto maker, whose slow restructuring plans already made it a focus of investor frustration. The upheaval caused by Detroit's coronavirus shutdowns may offer Ford Chief Executive Jim Hackett his last chance to show investors he can turn the U.S. industrial icon around.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because they have a good chance of turning around under the new CEO, Jim Hackett.\n- General Motors Company (NYSE: GM) will decrease because they are a direct competitor of Ford.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will decrease because they are a direct competitor of Ford.", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [5.475, 5.371]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [24.0498, 24.24]}, "FCAU": {"company": "", "ticker": "FCAU", "move": "down", "prices": [8.86, 8.84]}}}, {"link": "https://www.wsj.com/articles/facebook-removed-nearly-40-more-terrorist-content-in-second-quarter-11597162013", "title": "Facebook Removed Nearly 40% More Terrorist Content in Second Quarter", "date": "2020-08-11 15:24", "summary": "Social-media giant says increase was driven by improvements in detection efforts. Facebook Inc. removed nearly 40% more content that it categorized as terrorism in the second quarter compared with the first three months of the year, the company said.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Removed Nearly 40% More Terrorist Content in Second Quarter. Social-media giant says increase was driven by improvements in detection efforts. Facebook Inc. removed nearly 40% more content that it categorized as terrorism in the second quarter compared with the first three months of the year, the company said.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because they are removing more terrorist content.\n- Twitter, Inc. (NYSE: TWTR) will decrease because they are not removing as much terrorist content.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down", "prices": [37.13, 37.33]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [256.6, 256.93]}}}, {"link": "https://www.wsj.com/articles/texas-livestock-industry-reels-from-storm-outages-11613508000", "title": "Texas Livestock Industry Reels From Storm, Outages", "date": "2021-02-16 15:40", "summary": "Exposure and frozen pipes threaten cattle; dairy farmers are forced to dump milk after plant shutdowns. Bitter cold and power outages have created a crisis for some Texan farms and ranches, leaving livestock dead from exposure and raising fears that herds could run short of food and water.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Texas Livestock Industry Reels From Storm, Outages. Exposure and frozen pipes threaten cattle; dairy farmers are forced to dump milk after plant shutdowns. Bitter cold and power outages have created a crisis for some Texan farms and ranches, leaving livestock dead from exposure and raising fears that herds could run short of food and water.\"\n\nStock Prediction(s):", "Prediction": "\n- Texas cattle industry will decrease because of the storm and power outages.\n- Dairy farmers in Texas will decrease because they are forced to dump milk.", "price_info": {}}, {"link": "https://www.wsj.com/articles/youtube-content-for-children-should-be-barred-advocacy-groups-tell-ftc-11561478754", "title": "YouTube Content for Children Should Be Barred, Advocacy Groups Tell FTC", "date": "2019-06-25 12:23", "summary": "The pair of parent organizations, which filed a complaint against Google and YouTube over privacy concerns, are calling for billions of dollars in fines. WASHINGTON-Privacy advocates are calling on the Federal Trade Commission to remove all YouTube content directed at kids and impose tens of billions in fines against the video-streaming service run by Alphabet Inc.'s Google unit for alleged children's privacy violations.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"YouTube Content for Children Should Be Barred, Advocacy Groups Tell FTC. The pair of parent organizations, which filed a complaint against Google and YouTube over privacy concerns, are calling for billions of dollars in fines. WASHINGTON-Privacy advocates are calling on the Federal Trade Commission to remove all YouTube content directed at kids and impose tens of billions in fines against the video-streaming service run by Alphabet Inc.'s Google unit for alleged children's privacy violations.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease because of the complaint filed against them by the privacy advocates.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because of the complaint filed against them by the privacy advocates.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [1094.3417, 1091.57]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1891.28, 1884.3]}}}, {"link": "https://www.wsj.com/articles/credit-suisse-coo-resigns-over-surveillance-scandal-11569908569", "title": "Credit Suisse Puts Spy-Scandal Blame on CEO's Top Lieutenant", "date": "2019-10-01 11:59", "summary": "Chief operating officer resigns as probe finds no evidence CEO was involved in hiring investigators. A probe ordered by Credit Suisse Group AG cleared Chief Executive Tidjane Thiam of involvement in a spy scandal that has enveloped the bank, and laid primary blame for the affair on a close deputy, who resigned.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Credit Suisse Puts Spy-Scandal Blame on CEO's Top Lieutenant. Chief operating officer resigns as probe finds no evidence CEO was involved in hiring investigators. A probe ordered by Credit Suisse Group AG cleared Chief Executive Tidjane Thiam of involvement in a spy scandal that has enveloped the bank, and laid primary blame for the affair on a close deputy, who resigned.\"\n\nStock Prediction(s):", "Prediction": "\n- Credit Suisse Group AG (NYSE: CS) will increase because the COO resigned, and the CEO was cleared of any involvement.\n- UBS Group AG (NYSE: UBS) will increase because the COO resigned, and the CEO was cleared of any involvement.", "price_info": {"CS": {"company": "", "ticker": "CS", "move": "up", "prices": [11.9, 11.835]}, "UBS": {"company": "", "ticker": "UBS", "move": "up", "prices": [11.2, 11.145]}}}, {"link": "https://www.wsj.com/articles/covid-19-pandemic-triggers-wave-of-long-term-unemployment-11596817137", "title": "Covid-19 Pandemic Triggers Wave of Long-Term Unemployment", "date": "2020-08-07 12:18", "summary": "Numbers of people unemployed between 15 and 26 weeks rose to record high in July. An increasing number of workers were unemployed for more than three months in July, a signal that the coronavirus pandemic is likely to have a lasting economic impact on many people.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Covid-19 Pandemic Triggers Wave of Long-Term Unemployment. Numbers of people unemployed between 15 and 26 weeks rose to record high in July. An increasing number of workers were unemployed for more than three months in July, a signal that the coronavirus pandemic is likely to have a lasting economic impact on many people.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will continue to increase because of Covid-19.\n- The stock prices of companies that produce unemployment benefits or other services for the unemployed will increase.\n- The stock prices of companies that produce consumer goods will decrease.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-regulators-raise-concern-with-stablecoin-digital-currency-11639760446", "title": "U.S. Regulators Raise Concern With Stablecoin Digital Currency", "date": "2021-12-17 13:49", "summary": "Financial Stability Oversight Council is prepared to regulate space, but prefers Congressional action. Top U.S. financial regulators said they are prepared to take action to address risks to the financial system posed by stablecoins, but first are pushing Congress to enact comprehensive legislation providing oversight of the form of digital currency.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Regulators Raise Concern With Stablecoin Digital Currency. Financial Stability Oversight Council is prepared to regulate space, but prefers Congressional action. Top U.S. financial regulators said they are prepared to take action to address risks to the financial system posed by stablecoins, but first are pushing Congress to enact comprehensive legislation providing oversight of the form of digital currency.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are working on a stablecoin and this news signals that regulators may not be happy with the project.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are also working on a stablecoin and this news signals that regulators may not be happy with the project.\n- Goldman Sachs Group, Inc. (NYSE: GS) will decrease because they are also working on a stable", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [156.65, 156.9227]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [383.44, 384.382]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [335.17, 334.53]}}}, {"link": "https://www.wsj.com/articles/powell-says-fed-faces-difficult-trade-off-if-inflation-doesnt-moderate-11633017666", "title": "Powell Sees 'Difficult Trade-Off' for Fed if Inflation Doesn't Ease", "date": "2021-09-30 12:01", "summary": "'Our expectations is that inflation will come down,' central bank leader tells lawmakers. WASHINGTON-Federal Reserve Chairman Jerome Powell told lawmakers Thursday that the central bank still expects a recent spell of high inflation to reverse but said it was difficult to pinpoint when that might happen.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Powell Sees 'Difficult Trade-Off' for Fed if Inflation Doesn't Ease. 'Our expectations is that inflation will come down,' central bank leader tells lawmakers. WASHINGTON-Federal Reserve Chairman Jerome Powell told lawmakers Thursday that the central bank still expects a recent spell of high inflation to reverse but said it was difficult to pinpoint when that might happen.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FFR) will decrease because they are expecting inflation to come down, and they don't want to raise interest rates if it doesn't.\n- The Goldman Sachs Group, Inc. (NYSE: GS) will increase because they are expecting inflation to come down, and they want to raise interest rates if it doesn't.", "price_info": {"FFR": {"company": "", "ticker": "FFR", "move": "up", "prices": [50.4099, 50.3935]}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [377.905, 379.3]}}}, {"link": "https://www.wsj.com/articles/the-defense-haven-isnt-overcrowded-yet-11588862193", "title": "The Defense Haven Isn't Overcrowded Yet", "date": "2020-05-07 10:36", "summary": "The Covid-19 crisis highlights the attractiveness of defense contractors, but unwarranted fears about the U.S. government's borrowing capacity are still holding back valuations. Defense companies are widely acknowledged to be a good place for investors to hide in an economic downturn. In the Covid-19 crisis, though, investors have yet to put much of their money where their mouth is.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Defense Haven Isn't Overcrowded Yet. The Covid-19 crisis highlights the attractiveness of defense contractors, but unwarranted fears about the U.S. government's borrowing capacity are still holding back valuations. Defense companies are widely acknowledged to be a good place for investors to hide in an economic downturn. In the Covid-19 crisis, though, investors have yet to put much of their money where their mouth is.\"\n\nStock Prediction(s):", "Prediction": "\n- Lockheed Martin Corporation (NYSE: LMT) will increase because they are a defense contractor and the Covid-19 crisis is highlighting their attractiveness.\n- Northrop Grumman Corporation (NYSE: NOC) will increase because they are a defense contractor and the Covid-19 crisis is highlighting their attractiveness.\n- Raytheon Company (NYSE: RTN) will increase because they are a defense contractor and the Covid-19 crisis is highlighting their attractiveness", "price_info": {"LMT": {"company": "", "ticker": "LMT", "move": "up", "prices": [380.5935, 382.15]}, "NOC": {"company": "", "ticker": "NOC", "move": "up", "prices": [324.4865, 326.08]}, "RTN": {"company": "", "ticker": "RTN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/comcast-offers-web-connected-tv-service-to-its-internet-customers-11553197471", "title": "Comcast Offers Web-Connected TV Service to Its Internet Customers", "date": "2019-03-21 15:44", "summary": "The 'Xfinity Flex' service, which will cost $5 a month, is being rolled out next week. Comcast Corp. on Thursday unveiled a $5-a-month service for its internet-only customers that will allow access to ad-supported streaming video channels like YouTube and Cheddar, an initiative that could bring in more revenue from people who aren't subscribing to the cable giant's pay-TV service.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Comcast Offers Web-Connected TV Service to Its Internet Customers. The 'Xfinity Flex' service, which will cost $5 a month, is being rolled out next week. Comcast Corp. on Thursday unveiled a $5-a-month service for its internet-only customers that will allow access to ad-supported streaming video channels like YouTube and Cheddar, an initiative that could bring in more revenue from people who aren't subscribing to the cable giant's pay-TV service.\"\n\nStock Prediction(s):", "Prediction": "\n- Comcast Corporation (NASDAQ: CMCSA) will increase because they are expanding their services to include web-connected TV.\n- Roku, Inc. (NASDAQ: ROKU) will increase because they are a direct competitor of Comcast and this will put them at a disadvantage.\n- Disney (NYSE: DIS) will increase because they own ESPN and this will give them an advantage in the streaming market.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "up", "prices": [108.89, 108.95]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "up", "prices": [40.0501, 40.05]}, "ROKU": {"company": "", "ticker": "ROKU", "move": "up", "prices": [67, 66.92]}}}, {"link": "https://www.wsj.com/articles/mcdonalds-sales-drop-6-11588248343", "title": "McDonald's Sales Fall Amid Changing Dining Habits", "date": "2020-04-30 10:38", "summary": "Burger chain sees disruptions lasting for months; 'getting back that breakfast business will be critical for us'. McDonald's Corp. said dramatic changes in consumer behavior during the coronavirus pandemic hurt its profit and sales, disruptions that the burger chain expects to continue for months.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"McDonald's Sales Fall Amid Changing Dining Habits. Burger chain sees disruptions lasting for months; 'getting back that breakfast business will be critical for us'. McDonald's Corp. said dramatic changes in consumer behavior during the coronavirus pandemic hurt its profit and sales, disruptions that the burger chain expects to continue for months.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corp. (NYSE: MCD) will decrease because their sales are down due to the pandemic.\n- Yum! Brands, Inc. (NYSE: YUM) will decrease because their sales are down due to the pandemic.\n- Wendy's Co. (NASDAQ: WEN) will decrease because their sales are down due to the pandemic.", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "down", "prices": [183.49, 184.02]}, "YUM": {"company": "", "ticker": "YUM", "move": "down", "prices": [86.82, 86.41]}, "WEN": {"company": "", "ticker": "WEN", "move": "down", "prices": [19.77, 19.57]}}}, {"link": "https://www.wsj.com/articles/what-i-learned-from-the-hacker-who-spied-on-me-11549559728", "title": "What I Learned From the Hacker Who Spied on Me", "date": "2019-02-07 12:15", "summary": "Our columnist asked an ethical hacker to get into as many of her webcams as he could. Along the way she identified important tips for keeping our computers safe.. When my nanny sends me a photo of my 18-month-old son busy at play, my immediate thought: He's a genius.", "categories": [["Tech", "Personal Tech", "Personal Technology: Joanna Stern"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What I Learned From the Hacker Who Spied on Me. Our columnist asked an ethical hacker to get into as many of her webcams as he could. Along the way she identified important tips for keeping our computers safe.. When my nanny sends me a photo of my 18-month-old son busy at play, my immediate thought: He's a genius.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because their products are seen as being more secure than other competitors.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because their products are seen as being more secure than other competitors.\n- Facebook, Inc. (NASDAQ: FB) will decrease because their products are seen as being less secure than other competitors.\n- Google LLC (NASDAQ: GOOGL", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [171.39, 170.8401]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1599.2259, 1603.6404]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [165.705, 166.3401]}}}, {"link": "https://www.wsj.com/articles/cravath-law-firm-to-alter-partner-pay-structure-11638801000", "title": "Cravath Law Firm to Alter Partner Pay Structure", "date": "2021-12-06 09:30", "summary": "Cravath, long regarded as one of the nation's most elite firms, to move from longstanding 'lockstep' compensation model. New York law firm Cravath, Swaine & Moore LLP is moving away from its seniority-based compensation system, upending a hallmark of the firm's culture that has made it a rarity in the cutthroat world of modern-day law firms.", "categories": [["WSJ News Exclusive", "Law"]], "category_links": ["https://www.wsj.com/news/business/law-legal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Cravath Law Firm to Alter Partner Pay Structure. Cravath, long regarded as one of the nation's most elite firms, to move from longstanding 'lockstep' compensation model. New York law firm Cravath, Swaine & Moore LLP is moving away from its seniority-based compensation system, upending a hallmark of the firm's culture that has made it a rarity in the cutthroat world of modern-day law firms.\"\n\nStock Prediction(s):", "Prediction": "\n- Cravath, Swaine & Moore LLP (NYSE: CS) will increase because they are changing their partner pay structure.\n- Other law firms will decrease because they will not be able to compete with the new pay structure at Cravath.", "price_info": {"CS": {"company": "", "ticker": "CS", "move": "down", "prices": [9.515, 9.625]}}}, {"link": "https://www.wsj.com/articles/fintech-apps-beyond-robinhood-2022-11642799820", "title": "Beyond Robinhood: 4 Financial Apps That Help Individual Investors Get Started in 2022", "date": "2022-01-25 10:00", "summary": "A look at what these apps do-and don't-offer, and how much they cost. While Robinhood Markets Inc.'s trading app gets all the attention, most financial professionals agree that short-term trading isn't the way to build long-term wealth.", "categories": [["Markets", "Journal Reports: Wealth Management"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-wealth-management?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Beyond Robinhood: 4 Financial Apps That Help Individual Investors Get Started in 2022. A look at what these apps do-and don't-offer, and how much they cost. While Robinhood Markets Inc.'s trading app gets all the attention, most financial professionals agree that short-term trading isn't the way to build long-term wealth.\"\n\nStock Prediction(s):", "Prediction": "\n- Robinhood Markets Inc. (NASDAQ: Robinhood) will decrease because there are other apps that offer the same services, but for a lower price.\n- Charles Schwab Corp. (NYSE: SCHW) will increase because they offer a wide range of services that are beneficial for long-term investors.\n- Fidelity Investments (NYSE: FID) will increase because they offer a wide range of services that are beneficial for long-term investors.\n", "price_info": {"SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [86.545, 88.158]}, "FID": {"company": "", "ticker": "FID", "move": "up", "prices": [17.57, 17.63]}}}, {"link": "https://www.wsj.com/articles/temperatures-are-falling-and-so-are-heating-costs-11573665587", "title": "Temperatures Are Falling, and so Are Heating Costs", "date": "2019-11-13 15:13", "summary": "Winter weather has arrived, but heating fuels are priced like Americans still have their windows open. Winter weather has arrived, blanketing much of the country in snow and freezing temperatures. But heating fuels are priced like Americans still have their windows open.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Temperatures Are Falling, and so Are Heating Costs. Winter weather has arrived, but heating fuels are priced like Americans still have their windows open. Winter weather has arrived, blanketing much of the country in snow and freezing temperatures. But heating fuels are priced like Americans still have their windows open.\"\n\nStock Prediction(s):", "Prediction": "\n- Heating oil and natural gas prices will decrease because of falling demand.\n- Coal prices will decrease because of falling demand.\n- Electricity prices will decrease because of falling demand.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-home-price-growth-lost-steam-in-march-continuing-housing-slowdown-11559048432", "title": "U.S. Home-Price Growth Slowed in March", "date": "2019-05-28 11:16", "summary": "The Case-Shiller 10-city index gained 2.3% over the year ended in March, down from a 2.5% annual pace in February. Home-price growth sputtered in March, the latest sign that lower mortgage rates and a booming economy are doing little to boost prices during the critical spring selling season.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Home-Price Growth Slowed in March. The Case-Shiller 10-city index gained 2.3% over the year ended in March, down from a 2.5% annual pace in February. Home-price growth sputtered in March, the latest sign that lower mortgage rates and a booming economy are doing little to boost prices during the critical spring selling season.\"\n\nStock Prediction(s):", "Prediction": "\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and KB Home (NYSE: KBH) will decrease because home-price growth is slowing.\n- Real estate investment trusts (REITs) such as Simon Property Group, Inc. (NYSE: SPG) and Equity Residential (NYSE: EQR) will decrease because home-price growth is slowing.", "price_info": {"LEN": {"company": "", "ticker": "LEN", "move": null, "prices": [51.87, 51.73]}, "KBH": {"company": "", "ticker": "KBH", "move": "down", "prices": [26.7, 26.66]}, "SPG": {"company": "", "ticker": "SPG", "move": null, "prices": [170.895, 169.9837]}, "EQR": {"company": "", "ticker": "EQR", "move": "down", "prices": [77.36, 77.21]}}}, {"link": "https://www.wsj.com/articles/gamestops-high-score-got-run-up-too-soon-11607531939", "title": "GameStop's High Score Got Run Up Too Soon", "date": "2020-12-09 11:39", "summary": "Limited supply of new Xbox and PlayStation consoles will slow retailer's reboot. GameStop 's race to slim down has seen some success. But investors binged too early on a complicated recovery story.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GameStop's High Score Got Run Up Too Soon. Limited supply of new Xbox and PlayStation consoles will slow retailer's reboot. GameStop 's race to slim down has seen some success. But investors binged too early on a complicated recovery story.\"\n\nStock Prediction(s):", "Prediction": "\n- GameStop Corp. (NYSE: GME) will decrease because they overestimated their demand for new Xbox and PlayStation consoles.", "price_info": {"GME": {"company": "", "ticker": "GME", "move": "down", "prices": [14.27, 14.0289]}}}, {"link": "https://www.wsj.com/articles/nations-biggest-egg-producer-hurt-by-rising-feed-labor-costs-11640797867", "title": "Biggest U.S. Egg Producer Hurt by Feed, Labor Costs", "date": "2021-12-29 15:22", "summary": "Cal-Maine Foods reports lackluster earnings, sending shares down. Shares in Cal-Maine Foods Inc. fell as much as 8% in early trading Wednesday after the egg producer posted lower-than-expected quarterly earnings, hurt by rising feed and labor costs.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biggest U.S. Egg Producer Hurt by Feed, Labor Costs. Cal-Maine Foods reports lackluster earnings, sending shares down. Shares in Cal-Maine Foods Inc. fell as much as 8% in early trading Wednesday after the egg producer posted lower-than-expected quarterly earnings, hurt by rising feed and labor costs.\"\n\nStock Prediction(s):", "Prediction": "\n- Cal-Maine Foods Inc. (NASDAQ: CALM) will decrease because their earnings were lower than expected, and they are being hurt by rising feed and labor costs.", "price_info": {"CALM": {"company": "", "ticker": "CALM", "move": "down", "prices": [36.68, 36.27]}}}, {"link": "https://www.wsj.com/articles/leading-a-digital-overhaul-heres-some-advice-11614889050", "title": "Leading a Digital Overhaul? Here's Some Advice", "date": "2021-03-04 15:17", "summary": "Executive recruiters explain how new tech hires can drive a major revamp. GameStop Corp. , under pressure to digitally transform its operations, announced in early February that it hired former Amazon.com Inc. executive Matt Francis as its first chief technology officer. Mr. Francis was brought in to oversee e-commerce and technology functions.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Leading a Digital Overhaul? Here's Some Advice. Executive recruiters explain how new tech hires can drive a major revamp. GameStop Corp. , under pressure to digitally transform its operations, announced in early February that it hired former Amazon.com Inc. executive Matt Francis as its first chief technology officer. Mr. Francis was brought in to oversee e-commerce and technology functions.\"\n\nStock Prediction(s):", "Prediction": "\n- GameStop Corp. (NYSE: GME) will increase because they are making a digital transformation and they hired a former Amazon executive.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a direct competitor of GameStop and they are making a digital transformation.", "price_info": {"GME": {"company": "", "ticker": "GME", "move": "up", "prices": [130.22, 132.85]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [2986, 2980.64]}}}, {"link": "https://www.wsj.com/articles/zoom-eyes-ways-to-earn-from-its-pandemic-fueled-mass-appeal-11603137505", "title": "Zoom Seeks Ways to Earn From Its Pandemic-Fueled Mass Appeal", "date": "2020-10-19 15:58", "summary": "Company is still assessing how best to target smaller consumers, Chief Operating Officer Aparna Bawa tells WSJ's Tech Live conference. Zoom Video Communications Inc. plans to capitalize more broadly on its massive surge in popularity but is still assessing how best to target smaller consumers, Chief Operating Officer Aparna Bawa said Monday.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Zoom Seeks Ways to Earn From Its Pandemic-Fueled Mass Appeal. Company is still assessing how best to target smaller consumers, Chief Operating Officer Aparna Bawa tells WSJ's Tech Live conference. Zoom Video Communications Inc. plans to capitalize more broadly on its massive surge in popularity but is still assessing how best to target smaller consumers, Chief Operating Officer Aparna Bawa said Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- Zoom Video Communications Inc. (NASDAQ: ZM) will increase because they are still assessing how best to target smaller consumers, and they are seeing a surge in popularity.\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are a direct competitor of Zoom Video Communications Inc.", "price_info": {"ZM": {"company": "", "ticker": "ZM", "move": "up", "prices": [575.5, 575]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [262.21, 262.68]}}}, {"link": "https://www.wsj.com/articles/irelands-privacy-regulator-moves-closer-to-decisions-in-whatsapp-twitter-cases-11570462640", "title": "Ireland's Privacy Regulator Moves Closer to Decisions in WhatsApp, Twitter Cases", "date": "2019-10-07 13:16", "summary": "The cases involve compliance with Europe's transparency and breach-notification rules. A top European Union privacy regulator is moving closer to making draft decisions involving Facebook Inc . 's WhatsApp and Twitter Inc. under the bloc's new privacy law.", "categories": [["Tech", "Consumer Technology"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/consumer-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ireland's Privacy Regulator Moves Closer to Decisions in WhatsApp, Twitter Cases. The cases involve compliance with Europe's transparency and breach-notification rules. A top European Union privacy regulator is moving closer to making draft decisions involving Facebook Inc . 's WhatsApp and Twitter Inc. under the bloc's new privacy law.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc (NASDAQ: FB) will decrease because of the Irish privacy regulator's draft decisions involving WhatsApp and Twitter.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [180.12, 180.06]}}}, {"link": "https://www.wsj.com/articles/joshua-kushner-karlie-kloss-puck-penthouse-new-york-11632234647", "title": "Joshua Kushner, Karlie Kloss List New York Penthouse for $23.5 Million", "date": "2021-09-21 10:31", "summary": "The couple recently agreed to buy the building's top unit, which had been asking $42.5 million. After striking a deal to buy the top unit at the Puck Penthouses in New York City, Joshua Kushner and Karlie Kloss are listing a smaller unit in the building for $23.5 million.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Joshua Kushner, Karlie Kloss List New York Penthouse for $23.5 Million. The couple recently agreed to buy the building's top unit, which had been asking $42.5 million. After striking a deal to buy the top unit at the Puck Penthouses in New York City, Joshua Kushner and Karlie Kloss are listing a smaller unit in the building for $23.5 million.\"\n\nStock Prediction(s):", "Prediction": "\n- Kushner Properties (NYSE: KPR) will increase because Joshua Kushner is the founder, and this is good publicity for the company.\n- Klossy LLC (private) will increase because Karlie Kloss is the founder, and this is good publicity for the company.", "price_info": {"KPR": {"company": "", "ticker": "KPR", "move": "up"}}}, {"link": "https://www.wsj.com/articles/gannett-stands-firm-in-rejecting-digital-firsts-takeover-proposal-11549909135", "title": "Gannett Stands Firm in Rejecting Digital First's Takeover Proposal", "date": "2019-02-11 15:12", "summary": "Both sides held meeting last week on $1.4 billion offer. Gannett Co. said it continues to find a takeover proposal from Digital First Media inadequate after meeting with representatives from the hedge-fund backed newspaper chain last week.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gannett Stands Firm in Rejecting Digital First's Takeover Proposal. Both sides held meeting last week on $1.4 billion offer. Gannett Co. said it continues to find a takeover proposal from Digital First Media inadequate after meeting with representatives from the hedge-fund backed newspaper chain last week.\"\n\nStock Prediction(s):", "Prediction": "\n- Gannett Co. (NYSE: GCI) will stay the same because they have rejected the takeover proposal from Digital First Media.\n- Digital First Media (NYSE: DFM) will increase because they are still interested in Gannett Co., and they have the financial resources to make a successful bid.", "price_info": {"GCI": {"company": "", "ticker": "GCI", "move": null, "prices": [10.899, 10.93]}, "DFM": {"company": "", "ticker": "DFM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/movie-industrys-troubles-still-far-from-wrapping-up-11601906091", "title": "Movie Industry's Troubles Still Far From Wrapping Up", "date": "2020-10-05 09:54", "summary": "Production delays, lack of insurance could lengthen recovery for already-battered industry. James Bond won't be saving the movie business this year, and the industry may be facing longer-term problems that even the super spy can't fix.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Movie Industry's Troubles Still Far From Wrapping Up. Production delays, lack of insurance could lengthen recovery for already-battered industry. James Bond won't be saving the movie business this year, and the industry may be facing longer-term problems that even the super spy can't fix.\"\n\nStock Prediction(s):", "Prediction": "\n- The movie industry will continue to have troubles because of production delays and a lack of insurance.\n- AMC Entertainment Holdings Inc (NYSE: AMC) will decrease because of the movie industry's troubles.\n- Cinemark Holdings, Inc. (NYSE: CNK) will decrease because of the movie industry's troubles.\n- Regal Entertainment Group (NYSE: RGC) will decrease because of the movie industry's troubles.", "price_info": {"AMC": {"company": "", "ticker": "AMC", "move": "down", "prices": [4.1699, 4.1291]}, "CNK": {"company": "", "ticker": "CNK", "move": "down", "prices": [8.515, 8.305]}, "RGC": {"company": "", "ticker": "RGC", "move": "down"}}}, {"link": "https://www.wsj.com/articles/oil-is-steady-headed-for-second-weekly-decline-in-a-row-11556895327", "title": "Oil Notches Second-Straight Weekly Decline", "date": "2019-05-03 15:18", "summary": "Concerns rise over surging U.S. oil inventories. \u2022 Oil rose slightly Friday after a strong U.S. jobs report, but fell weekly for a second consecutive week amid growing concerns over bulging domestic oil inventories.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Notches Second-Straight Weekly Decline. Concerns rise over surging U.S. oil inventories. \u2022 Oil rose slightly Friday after a strong U.S. jobs report, but fell weekly for a second consecutive week amid growing concerns over bulging domestic oil inventories.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because oil prices are rising, and they are a major player in the oil industry.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because oil prices are rising, and they are a major player in the oil industry.\n- Schlumberger Limited. (NYSE: SLB) will increase because oil prices are rising, and they are a major player in the oil industry.\n- Halliburton", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [117.18, 117.38]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [77.57, 77.52]}, "SLB": {"company": "", "ticker": "SLB", "move": "up", "prices": [41.28, 41.37]}}}, {"link": "https://www.wsj.com/articles/john-legend-and-chrissy-teigen-ask-18-million-for-their-new-york-home-11642698081", "title": "John Legend and Chrissy Teigen Ask $18 Million for New York Home", "date": "2022-01-20 12:01", "summary": "Now based in Los Angeles, the celebrity couple planned to combine two penthouses, but never did. Celebrity couple John Legend and Chrissy Teigen are planning to list a pair of apartments they own in New York's Nolita neighborhood for $18 million.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"John Legend and Chrissy Teigen Ask $18 Million for New York Home. Now based in Los Angeles, the celebrity couple planned to combine two penthouses, but never did. Celebrity couple John Legend and Chrissy Teigen are planning to list a pair of apartments they own in New York's Nolita neighborhood for $18 million.\"\n\nStock Prediction(s):", "Prediction": "\n- The celebrity couple's asking price for their New York home will cause other celebrities to list their homes at a higher price, which will in turn cause the stock prices of real estate companies to increase.\n- The celebrity couple's asking price for their New York home will cause other celebrities to list their homes at a lower price, which will in turn cause the stock prices of real estate companies to decrease.", "price_info": {}}, {"link": "https://www.wsj.com/articles/ubisoft-chief-pledges-changes-to-culture-after-executives-were-accused-of-misconduct-11595518009", "title": "Ubisoft Chief Pledges Changes to Culture After Executives Were Accused of Misconduct", "date": "2020-07-23 12:56", "summary": "Videogame maker defends its handling of allegations of harassment and abuse against senior leaders after several resigned. PARIS-Videogame maker Ubisoft Entertainment SA promised to overhaul its workplace culture following allegations of misconduct and inappropriate behavior that have led several senior executives to leave the company in recent weeks.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ubisoft Chief Pledges Changes to Culture After Executives Were Accused of Misconduct. Videogame maker defends its handling of allegations of harassment and abuse against senior leaders after several resigned. PARIS-Videogame maker Ubisoft Entertainment SA promised to overhaul its workplace culture following allegations of misconduct and inappropriate behavior that have led several senior executives to leave the company in recent weeks.\"\n\nStock Prediction(s):", "Prediction": "\n- Ubisoft Entertainment SA (EPA: UBI) will increase because they have pledged to change their workplace culture, and they are currently undervalued.\n- Activision Blizzard, Inc. (NASDAQ: ATVI) will decrease because they are a direct competitor of Ubisoft, and they have not made any public statements about workplace culture.", "price_info": {"ATVI": {"company": "", "ticker": "ATVI", "move": "down", "prices": [80.1501, 80.0502]}}}, {"link": "https://www.wsj.com/articles/investors-assumed-democracy-would-endure-theyve-been-right-so-far-11610110801", "title": "Investors Assumed Democracy Would Endure; They've Been Right, So Far", "date": "2021-01-08 10:02", "summary": "Markets, quick to pick up on any threat to a country's economic health, are a poor barometer of its democratic health. Washington and Wall Street are different places, but this week they seemed like different planets.", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors Assumed Democracy Would Endure; They've Been Right, So Far. Markets, quick to pick up on any threat to a country's economic health, are a poor barometer of its democratic health. Washington and Wall Street are different places, but this week they seemed like different planets.\"\n\nStock Prediction(s):", "Prediction": "\n- S&P 500 will stay the same because the article is talking about how the markets are a poor barometer of a country's democratic health.", "price_info": {}}, {"link": "https://www.wsj.com/articles/treasury-to-begin-redistributing-rental-assistance-funds-to-high-need-communities-11633359674", "title": "Treasury to Begin Redistributing Rental-Assistance Money", "date": "2021-10-04 12:05", "summary": "Groups that haven't spent at least 30% of the money could lose it. WASHINGTON-The Treasury Department is set to soon claw back federal rental assistance from groups that haven't acted to spend enough of the money so it can be given to other communities with greater need, according to new guidance published Monday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury to Begin Redistributing Rental-Assistance Money. Groups that haven't spent at least 30% of the money could lose it. WASHINGTON-The Treasury Department is set to soon claw back federal rental assistance from groups that haven't acted to spend enough of the money so it can be given to other communities with greater need, according to new guidance published Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- Community Development Financial Institutions (CDFIs) will increase because they are a direct beneficiary of the Treasury's redistribution of money.\n- Other rental assistance groups will decrease because they are not direct beneficiaries of the Treasury's redistribution of money.", "price_info": {}}, {"link": "https://www.wsj.com/articles/helicopter-merger-is-industrys-response-to-offshore-slowdown-11579887131", "title": "Helicopter Merger Is Industry's Response to Offshore Slowdown", "date": "2020-01-24 14:44", "summary": "Bristow Group and Era Group to combine to create the world's largest operator of commercial helicopters. The planned merger of helicopter operators Bristow Group Inc. and Era Group Inc. marks the troubled industry's latest response to slumping demand for offshore choppers by oil-and-gas drillers after a string of bankruptcy filings.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Helicopter Merger Is Industry's Response to Offshore Slowdown. Bristow Group and Era Group to combine to create the world's largest operator of commercial helicopters. The planned merger of helicopter operators Bristow Group Inc. and Era Group Inc. marks the troubled industry's latest response to slumping demand for offshore choppers by oil-and-gas drillers after a string of bankruptcy filings.\"\n\nStock Prediction(s):", "Prediction": "\n- Bristow Group Inc. (NYSE: BRS) will increase because they are the largest helicopter operator in the world, and this will give them a competitive edge.\n- Era Group Inc. (NYSE: ERA) will increase because they are being acquired by Bristow Group, and this will give them a competitive edge.\n- Textron Inc. (NYSE: TXT) will decrease because they are a direct competitor of Bristow Group and Era Group.", "price_info": {"BRS": {"company": "", "ticker": "BRS", "move": "up"}, "ERA": {"company": "", "ticker": "ERA", "move": "up"}, "TXT": {"company": "", "ticker": "TXT", "move": "down", "prices": [44.28, 44.625]}}}, {"link": "https://www.wsj.com/articles/u-s-to-sell-150-billion-in-debt-11559839298", "title": "U.S. to Sell $150 Billion in Debt", "date": "2019-06-06 12:41", "summary": "Treasury Department will auction next week $74 billion in new debt and $76 billion in previously sold debt. The U.S. will auction $150 billion in securities next week, comprising $74 billion in new debt and $76 billion in previously sold debt. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. to Sell $150 Billion in Debt. Treasury Department will auction next week $74 billion in new debt and $76 billion in previously sold debt. The U.S. will auction $150 billion in securities next week, comprising $74 billion in new debt and $76 billion in previously sold debt. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Treasury Department will increase because they are selling a lot of debt.\n- The U.S. dollar will decrease because of the increase in supply.\n- The interest rates on the debt will decrease because of the increase in supply.", "price_info": {}}, {"link": "https://www.wsj.com/articles/lucid-tesla-nvidia-cisco-what-to-watch-when-the-stock-market-opens-today-11637150687", "title": "Lucid, Tesla, Nvidia, Cisco: What to Watch in the Stock Market Today", "date": "2021-11-17 09:47", "summary": "Lucid shares were extending their climb; Cisco and Nvidia are due to report after the close. Wall Street indexes opened lower amid another set of earnings reports from retailers and technology firms. Here's what we're watching on Wednesday:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Lucid, Tesla, Nvidia, Cisco: What to Watch in the Stock Market Today. Lucid shares were extending their climb; Cisco and Nvidia are due to report after the close. Wall Street indexes opened lower amid another set of earnings reports from retailers and technology firms. Here's what we're watching on Wednesday:\"\n\nStock Prediction(s):", "Prediction": "\n- Lucid Motors Inc (NASDAQ: LUCID) will continue to increase because they have a great product and they are doing well in the market.\n- Tesla, Inc. (NASDAQ: TSLA) will continue to decrease because they have been having a lot of production issues.\n- Nvidia Corporation (NASDAQ: NVDA) will continue to increase because they are a leader in the graphics card market, and they are doing well in the market", "price_info": {"LUCID": {"company": "", "ticker": "LUCID", "move": "up"}, "TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [1062.53, 1107.86]}, "NVDA": {"company": "", "ticker": "NVDA", "move": "up", "prices": [297.72, 299.87]}}}, {"link": "https://www.wsj.com/articles/how-to-prevent-and-cope-with-job-burnout-11611696061", "title": "How to Prevent and Recover From Job Burnout", "date": "2021-03-16 15:55", "summary": "Most Popular News. More and more people are talking about burnout at work, but there are still misconceptions about what the term means and its implications. The term goes beyond feeling emotionally and mentally exhausted. \"I may mean I'm bored, and you mean you're tired, and somebody else means they hate their job,\" says Christina Maslach, professor of psychology at the University of California, Berkeley and creator of the Maslach Burnout Inventory, a measurement tool used to diagnose the syndrome. \"It's not just about the individual, but it's also about the team or workplace or organization.\"", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Prevent and Recover From Job Burnout. Most Popular News. More and more people are talking about burnout at work, but there are still misconceptions about what the term means and its implications. The term goes beyond feeling emotionally and mentally exhausted. \"I may mean I'm bored, and you mean you're tired, and somebody else means they hate their job,\" says Christina Maslach, professor of psychology at the University of California, Berkeley and creator of the Maslach Burnout Inventory, a measurement tool used to diagnose the syndrome. \"It's not just about the individual, but it's also about the team or workplace or organization.\"\"\n\nStock Prediction(s):", "Prediction": "\n- Workplace productivity will increase because people will be more mindful of preventing and recovering from job burnout.\n- Organizational consulting firms will increase in value because they offer services that help prevent and recover from job burnout.\n- Job-search websites will decrease in value because fewer people will be looking for new jobs.", "price_info": {}}, {"link": "https://www.wsj.com/articles/skip-this-nigerian-money-making-opportunity-11597079329", "title": "Skip This Nigerian Money-Making Opportunity", "date": "2020-08-10 13:08", "summary": "The exchange-traded fund with the largest discount to net asset value on the market is less than meets the eye. Dear Beloved Friend, I know this email about a USD 32,000,000 ($32 million) exchange-traded fund that can be bought for USD 26,176,000 ($26.176 million) will come as a surprise to you.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Skip This Nigerian Money-Making Opportunity. The exchange-traded fund with the largest discount to net asset value on the market is less than meets the eye. Dear Beloved Friend, I know this email about a USD 32,000,000 ($32 million) exchange-traded fund that can be bought for USD 26,176,000 ($26.176 million) will come as a surprise to you.\"\n\nStock Prediction(s):", "Prediction": "\n- The stock price of the ETF mentioned in the email will decrease because it is not as good of a deal as it seems.", "price_info": {}}, {"link": "https://www.wsj.com/articles/big-banks-flash-warning-light-11547569413", "title": "Big Banks Flash Warning Light", "date": "2019-01-15 11:23", "summary": "The latest signs of weakness in the U.S. economy come from big banks JPMorgan Chase and Wells Fargo. Two of America's largest banks sent cautious signals on the economy Tuesday. Investors should listen.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Big Banks Flash Warning Light. The latest signs of weakness in the U.S. economy come from big banks JPMorgan Chase and Wells Fargo. Two of America's largest banks sent cautious signals on the economy Tuesday. Investors should listen.\"\n\nStock Prediction(s):", "Prediction": "\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because of the weak economy.\n- Wells Fargo & Co. (NYSE: WFC) will decrease because of the weak economy.\n- Bank of America Corp (NYSE: BAC) will decrease because of the weak economy.", "price_info": {"JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [100.0041, 102.27]}, "WFC": {"company": "", "ticker": "WFC", "move": "down", "prices": [47.26, 47.84]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [26.25, 26.76]}}}, {"link": "https://www.wsj.com/articles/european-union-aims-for-clarity-in-murky-world-of-sustainable-investing-11619020300", "title": "EU Aims for Clarity in Murky World of Sustainable Investing", "date": "2021-04-21 11:51", "summary": "Large U.S. banks are bracing for more ESG regulation in Europe and America. The European Union put forward a package of measures that took aim at the patchy data available around sustainable investing, seen as one of the fast-growing market's biggest problems.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"EU Aims for Clarity in Murky World of Sustainable Investing. Large U.S. banks are bracing for more ESG regulation in Europe and America. The European Union put forward a package of measures that took aim at the patchy data available around sustainable investing, seen as one of the fast-growing market's biggest problems.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc (NYSE: GS) will increase because they are one of the few banks that have been proactive in sustainable investing.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are one of the few banks that have been proactive in sustainable investing.\n- Bank of America Corp (NYSE: BAC) will increase because they are one of the few banks that have been proactive in sustainable investing.\n- Citigroup Inc (NYSE", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up", "prices": [333.035, 333.71]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [149.66, 150.3699]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [38.52, 38.675]}}}, {"link": "https://www.wsj.com/articles/medicare-enrollment-can-be-confusing-and-lead-to-unexpected-costs-11576155600", "title": "Medicare Enrollment Can Be Confusing and Lead to Unexpected Costs", "date": "2019-12-12 11:18", "summary": "More Americans are working past 65 and delaying Social Security, which makes enrolling in Medicare complicated. As more Americans postpone retirement, a growing number are experiencing Medicare enrollment problems that can saddle them with hefty penalties and monthslong coverage gaps.", "categories": [["Markets", "Your Money"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/undefined?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Medicare Enrollment Can Be Confusing and Lead to Unexpected Costs. More Americans are working past 65 and delaying Social Security, which makes enrolling in Medicare complicated. As more Americans postpone retirement, a growing number are experiencing Medicare enrollment problems that can saddle them with hefty penalties and monthslong coverage gaps.\"\n\nStock Prediction(s):", "Prediction": "\n- UnitedHealth Group Inc (NYSE: UNH) will increase because they are the largest health insurance company in the United States.\n- Humana Inc (NYSE: HUM) will increase because they are the second largest health insurance company in the United States.\n- Aetna Inc (NYSE: AET) will increase because they are the third largest health insurance company in the United States.\n- Cigna Corp (NYSE: CI) will increase because they", "price_info": {"UNH": {"company": "", "ticker": "UNH", "move": "up", "prices": [281.5061, 282.33]}, "HUM": {"company": "", "ticker": "HUM", "move": "up", "prices": [344.88, 345.52]}, "AET": {"company": "", "ticker": "AET", "move": "up"}, "CI": {"company": "", "ticker": "CI", "move": "up", "prices": [193.257, 193.1887]}}}, {"link": "https://www.wsj.com/articles/why-rufus-wainwright-stashes-headphones-around-his-house-11605205036", "title": "Why Rufus Wainwright Stashes Headphones Around His House", "date": "2020-11-12 13:17", "summary": "The singer, whose musical audiobook 'Road Trip Elegies' centers on recorded conversations with his therapist, talks treadmills, turntables and why he prefers (a lot of) wired headphones. FOR RUFUS Wainwright-torch singer, opera composer and now audiobook author-life in 2020 isn't terribly different from the \"before times.\" He's missing out on his usual touring commitments, trips to the gym and summer getaways in Montauk with his husband and daughter, but he's still creating at a furious pace while holed up in his Laurel Canyon, Calif., home. His recent album, \"Unfollow The Rules,\" was released this summer. And Mr. Wainwright's new musical audiobook, \"Road Trip Elegies,\" combines new covers of some favorite songs with conversations between him and his therapist recorded during a ride the two took from Montreal to New York. Here, Mr. Wainwright talks about buying a new treadmill to stay active at home, his love of vinyl and why he has pairs of wired Apple EarBuds tucked here and there all over his house.", "categories": [["Tech", "Personal Tech", "Technology Essentials"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/my-tech-essentials?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Rufus Wainwright Stashes Headphones Around His House. The singer, whose musical audiobook 'Road Trip Elegies' centers on recorded conversations with his therapist, talks treadmills, turntables and why he prefers (a lot of) wired headphones. FOR RUFUS Wainwright-torch singer, opera composer and now audiobook author-life in 2020 isn't terribly different from the \"before times.\" He's missing out on his usual touring commitments, trips to the gym and summer getaways in Montauk with his husband and daughter, but he's still creating at a furious pace while holed up in his Laurel Canyon, Calif., home. His recent album, \"Unfollow The Rules,\" was released this summer. And Mr. Wainwright's new musical audiobook, \"Road Trip Elegies,\" combines new covers of some favorite songs with conversations between him and his therapist recorded during a ride the two took from Montreal to New York. Here, Mr. Wainwright talks about buying a new treadmill to stay active at home, his love of vinyl and why he has pairs of wired Apple EarBuds tucked here and there all over his house.\"\n\nStock Prediction(s):", "Prediction": "\n- Rufus Wainwright (OTCQB: RWTH) will increase because he is a singer, and his new audiobook is about recorded conversations with his therapist.\n- Apple Inc. (NASDAQ: AAPL) will increase because they make wired headphones, which Rufus Wainwright prefers.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [119.29, 118.626]}}}, {"link": "https://www.wsj.com/articles/coronaviruss-worst-impact-on-oil-demand-has-passed-iea-says-11594369412", "title": "Coronavirus's Worst Impact on Oil Demand Has Passed, IEA Says", "date": "2020-07-10 14:51", "summary": "Oil prices have traded in a narrow range in recent weeks, held back by worries over upticks in Covid-19 cases. LONDON-The worst effects of the coronavirus on global oil demand have passed but will continue to echo as the market slowly recovers in the second half of 2020, the International Energy Agency said Friday.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus's Worst Impact on Oil Demand Has Passed, IEA Says. Oil prices have traded in a narrow range in recent weeks, held back by worries over upticks in Covid-19 cases. LONDON-The worst effects of the coronavirus on global oil demand have passed but will continue to echo as the market slowly recovers in the second half of 2020, the International Energy Agency said Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because the IEA believes that the worst effects of the coronavirus have passed, and that the market will slowly recover in the second half of 2020.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because the IEA believes that the worst effects of the coronavirus have passed, and that the market will slowly recover in the second half of 2020.\n- Royal Dutch Shell plc (NYSE", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [85.24, 85.35]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [42.635, 42.71]}}}, {"link": "https://www.wsj.com/articles/intel-ceo-calls-chip-maker-willing-buyer-as-industry-consolidates-11629382046", "title": "Intel CEO Calls Chip Maker 'Willing Buyer' as Industry Consolidates", "date": "2021-08-19 15:49", "summary": "The economics of the industry make deals among chip makers likely, Pat Gelsinger says. Intel Corp. Chief Executive Pat Gelsinger is committed to buying other chip-makers as the industry consolidates, despite a leading acquisition candidate's plan to go public.", "categories": [["WSJ News Exclusive", "Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Intel CEO Calls Chip Maker 'Willing Buyer' as Industry Consolidates. The economics of the industry make deals among chip makers likely, Pat Gelsinger says. Intel Corp. Chief Executive Pat Gelsinger is committed to buying other chip-makers as the industry consolidates, despite a leading acquisition candidate's plan to go public.\"\n\nStock Prediction(s):", "Prediction": "\n- Intel Corporation (NASDAQ: INTC) will increase because they are a willing buyer and they have the resources to make acquisitions.\n- Broadcom Inc (NASDAQ: AVGO) will decrease because they are a direct competitor of Intel, and they just announced their intention to go public.", "price_info": {"INTC": {"company": "", "ticker": "INTC", "move": "up", "prices": [52.44, 52.48]}, "AVGO": {"company": "", "ticker": "AVGO", "move": "down", "prices": [473.53, 473.055]}}}, {"link": "https://www.wsj.com/articles/moviepass-parent-hopes-to-spin-off-cinema-subscription-business-11547751742", "title": "MoviePass Parent Hopes to Spin Off Cinema-Subscription Business", "date": "2019-01-17 14:02", "summary": "Helios & Matheson forms a new entity to take possession of its MoviePass shares. The parent company of MoviePass wants to spin off the struggling movie-theater subscription service.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"MoviePass Parent Hopes to Spin Off Cinema-Subscription Business. Helios & Matheson forms a new entity to take possession of its MoviePass shares. The parent company of MoviePass wants to spin off the struggling movie-theater subscription service.\"\n\nStock Prediction(s):", "Prediction": "\n- Helios & Matheson Analytics Inc. (NASDAQ: HMNY) will decrease because their MoviePass business is struggling.", "price_info": {"HMNY": {"company": "", "ticker": "HMNY", "move": "down", "prices": [0.0144, 0.0144]}}}, {"link": "https://www.wsj.com/articles/lenders-enjoy-a-mini-refinancing-boom-but-it-might-not-last-long-11554317469", "title": "Lenders Enjoy a Mini Refinancing Boom, but It Might Not Last Long", "date": "2019-04-03 14:51", "summary": "Mortgage-refi resurgence could boost the outlook for banks that are also big mortgage lenders. Falling mortgage rates have spurred a mini refinancing boom, a piece of good news for banks and other lenders that have been grappling with a cooling housing market.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Lenders Enjoy a Mini Refinancing Boom, but It Might Not Last Long. Mortgage-refi resurgence could boost the outlook for banks that are also big mortgage lenders. Falling mortgage rates have spurred a mini refinancing boom, a piece of good news for banks and other lenders that have been grappling with a cooling housing market.\"\n\nStock Prediction(s):", "Prediction": "\n- Bank of America Corporation (NYSE: BAC) will increase because they are a big mortgage lender and will benefit from the mini refinancing boom.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are a big mortgage lender and will benefit from the mini refinancing boom.\n- Wells Fargo & Company (NYSE: WFC) will increase because they are a big mortgage lender and will benefit from the mini refinancing boom.\n- Cit", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [28.805, 28.85]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [105.365, 105.42]}, "WFC": {"company": "", "ticker": "WFC", "move": "up", "prices": [48.745, 48.86]}}}, {"link": "https://www.wsj.com/articles/snap-says-it-won-t-promote-snapchat-account-of-president-trump-11591207352", "title": "Snap Says It Won't Promote Trump's Snapchat Account", "date": "2020-06-03 15:42", "summary": "Social-media company determines president's public comments could incite violence. Social-media company Snap Inc. said Wednesday that it would no longer promote the Snapchat account of President Trump on its home page after finding that his public remarks could incite racial violence, a spokeswoman said.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Snap Says It Won't Promote Trump's Snapchat Account. Social-media company determines president's public comments could incite violence. Social-media company Snap Inc. said Wednesday that it would no longer promote the Snapchat account of President Trump on its home page after finding that his public remarks could incite racial violence, a spokeswoman said.\"\n\nStock Prediction(s):", "Prediction": "\n- Snap Inc. (NYSE: SNAP) will decrease because they are no longer promoting Trump's Snapchat account.\n- Facebook Inc. (NASDAQ: FB) will increase because they are still promoting Trump's Snapchat account.", "price_info": {"SNAP": {"company": "", "ticker": "SNAP", "move": "down", "prices": [19.73, 19.6902]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [230.16, 229.85]}}}, {"link": "https://www.wsj.com/articles/bunge-posts-wider-loss-11550750754", "title": "Bunge May Sell Assets", "date": "2019-02-21 11:20", "summary": "Grain-trading company, which reported a wider quarterly loss, was hurt by a drop in soybean prices. Bunge Ltd. said it is reviewing its businesses and may sell assets to improve profits at a volatile time for agricultural markets.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bunge May Sell Assets. Grain-trading company, which reported a wider quarterly loss, was hurt by a drop in soybean prices. Bunge Ltd. said it is reviewing its businesses and may sell assets to improve profits at a volatile time for agricultural markets.\"\n\nStock Prediction(s):", "Prediction": "\n- Bunge Ltd. (NYSE: BG) will decrease because they are selling assets.\n- Archer Daniels Midland Company (NYSE: ADM) will increase because they are not selling assets, and they are a competitor of Bunge.", "price_info": {"BG": {"company": "", "ticker": "BG", "move": "down", "prices": [51.0744, 52.7]}, "ADM": {"company": "", "ticker": "ADM", "move": "up", "prices": [42.3919, 42.675]}}}, {"link": "https://www.wsj.com/articles/tesla-to-locate-china-design-center-in-beijing-11644508456", "title": "Tesla to Locate China Design Center in Beijing", "date": "2022-02-10 10:54", "summary": "The electric-car maker's placement for the center, which it first disclosed in 2020, was cited in a Beijing government document. Tesla Inc. is placing a design center in China's capital, according to a Beijing government document.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tesla to Locate China Design Center in Beijing. The electric-car maker's placement for the center, which it first disclosed in 2020, was cited in a Beijing government document. Tesla Inc. is placing a design center in China's capital, according to a Beijing government document.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (TSLA) will increase because they are expanding their business to China.\n- BYD Company Ltd. (HKG: 1211) will decrease because they are a direct competitor of Tesla.", "price_info": {"TSLA": {"company": "Tesla, Inc.", "ticker": "TSLA", "move": "down", "prices": [936.44, 934.005]}}}, {"link": "https://www.wsj.com/articles/transcript-a-conversation-with-new-york-fed-president-john-williams-11573152096", "title": "Transcript: A Conversation With New York Fed President John Williams", "date": "2019-11-07 13:41", "summary": "Resume Subscription. Federal Reserve Bank of New York President John Williams discussed the labor market, inflation, the reasons behind the Fed's rate cuts and monetary policy tools in a world of lower interest rates at a Wall Street Journal event in New York on Wednesday, Nov. 6. Nick Timiraos, chief economics correspondent at the Journal, served as moderator. Here is a transcript, lightly edited for clarity and length.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Transcript: A Conversation With New York Fed President John Williams. Resume Subscription. Federal Reserve Bank of New York President John Williams discussed the labor market, inflation, the reasons behind the Fed's rate cuts and monetary policy tools in a world of lower interest rates at a Wall Street Journal event in New York on Wednesday, Nov. 6. Nick Timiraos, chief economics correspondent at the Journal, served as moderator. Here is a transcript, lightly edited for clarity and length.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of New York (NYSE: FRBNY) will increase because they are John Williams' employer, and he is the President of the Federal Reserve Bank of New York.\n- The Federal Reserve System (NYSE: FRS) will decrease because they are not the employer of John Williams, and they are not the President of the Federal Reserve Bank of New York.", "price_info": {"FRBNY": {"company": "", "ticker": "FRBNY", "move": "up"}, "FRS": {"company": "", "ticker": "FRS", "move": "down"}}}, {"link": "https://www.wsj.com/articles/blue-aprons-beyond-meat-deal-lacks-substance-11563293103", "title": "Blue Apron's Beyond Meat Deal Lacks Substance", "date": "2019-07-16 12:05", "summary": "Partnership sent meal kit's stock flying, but appetite for company's vegan meals likely to be short-lived. Everything Beyond Meat touches turns to gold, it seems.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Blue Apron's Beyond Meat Deal Lacks Substance. Partnership sent meal kit's stock flying, but appetite for company's vegan meals likely to be short-lived. Everything Beyond Meat touches turns to gold, it seems.\"\n\nStock Prediction(s):", "Prediction": "\n- Blue Apron Holdings Inc (NYSE: APRN) will decrease because their partnership with Beyond Meat is not as substantial as investors thought it would be.\n- Beyond Meat, Inc. (NASDAQ: BYND) will increase because their partnership with Blue Apron Holdings is very substantial.", "price_info": {"APRN": {"company": "", "ticker": "APRN", "move": "down", "prices": [12.68, 11.69]}, "BYND": {"company": "", "ticker": "BYND", "move": "up", "prices": [170.66, 171.8965]}}}, {"link": "https://www.wsj.com/articles/gm-makes-the-most-of-a-bad-business-11596043304", "title": "GM Makes the Most of a Bad Business", "date": "2020-07-29 13:21", "summary": "Aggressive cost control helped Detroit's largest car maker keep second-quarter losses to a minimum, but Ford might have more scope to surprise investors. The second quarter could have been much worse for General Motors . Yet the Detroit car maker most likely to give investors a lift this earnings season is, surprisingly, Ford .", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GM Makes the Most of a Bad Business. Aggressive cost control helped Detroit's largest car maker keep second-quarter losses to a minimum, but Ford might have more scope to surprise investors. The second quarter could have been much worse for General Motors . Yet the Detroit car maker most likely to give investors a lift this earnings season is, surprisingly, Ford .\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because they have more scope to surprise investors than GM.\n- GM will decrease because they are not doing as well as Ford.", "price_info": {"F": {"company": "", "ticker": "F", "move": "down", "prices": [6.875, 6.91]}}}, {"link": "https://www.wsj.com/articles/weekly-jobless-claims-07-22-2021-11626901031", "title": "Unemployment Benefit Rolls Shrink, But New Applications Rise", "date": "2021-07-22 13:12", "summary": "New applications for benefits rise as supply-chain issues continue in the auto industry. The number of Americans receiving jobless payments fell this month to the lowest level since early in the coronavirus pandemic, but first-time applications rose as supply constraints persist in the auto industry.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Unemployment Benefit Rolls Shrink, But New Applications Rise. New applications for benefits rise as supply-chain issues continue in the auto industry. The number of Americans receiving jobless payments fell this month to the lowest level since early in the coronavirus pandemic, but first-time applications rose as supply constraints persist in the auto industry.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Company (NYSE: F) will increase because they are one of the companies that is being impacted by the supply-chain issues.\n- General Motors Company (NYSE: GM) will increase because they are one of the companies that is being impacted by the supply-chain issues.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are one of the companies that is being impacted by the supply-chain issues.", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [13.93, 13.885]}, "GM": {"company": "", "ticker": "GM", "move": "up", "prices": [55.88, 55.66]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [651.4, 650.96]}}}, {"link": "https://www.wsj.com/articles/apples-october-event-expect-new-macbook-pro-and-airpods-11634566798", "title": "Apple Unveils Redesigned MacBook Pro, New AirPods", "date": "2021-10-18 14:54", "summary": "At 'Unleashed' streamed event, company reveals newest high-end laptops and Apple-designed chips. A pair of MacBook Pro laptops-and a pair of chips-shared center stage at Apple Inc.'s streamed Monday event, which also included the debut of new AirPods.", "categories": [["Tech", "Personal Tech", "Personal Technology: Review"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-wilson-rothman?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple Unveils Redesigned MacBook Pro, New AirPods. At 'Unleashed' streamed event, company reveals newest high-end laptops and Apple-designed chips. A pair of MacBook Pro laptops-and a pair of chips-shared center stage at Apple Inc.'s streamed Monday event, which also included the debut of new AirPods.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will increase because they have released a new design for the MacBook Pro, and they have also released a new design for the AirPods.\n- Dell Technologies Inc. (NYSE: DVMT) will decrease because they are a direct competitor of Apple Inc.", "price_info": {"DVMT": {"company": "", "ticker": "DVMT", "move": "down"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [146.7, 146.68]}}}, {"link": "https://www.wsj.com/articles/colonial-pipeline-ordering-system-disrupted-but-still-moving-fuel-11621358203", "title": "Colonial Pipeline Moving Fuel Despite Disruptions to Orders System", "date": "2021-05-18 15:08", "summary": "Gasoline conduit suffered outages to ordering system Tuesday morning unrelated to recent cyberattack; it was back online by Tuesday afternoon. The Colonial Pipeline's ordering system suffered intermittent disruptions Tuesday morning, but the pipeline's operator said it was still moving fuel through the key conduit to the East Coast.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Colonial Pipeline Moving Fuel Despite Disruptions to Orders System. Gasoline conduit suffered outages to ordering system Tuesday morning unrelated to recent cyberattack; it was back online by Tuesday afternoon. The Colonial Pipeline's ordering system suffered intermittent disruptions Tuesday morning, but the pipeline's operator said it was still moving fuel through the key conduit to the East Coast.\"\n\nStock Prediction(s):", "Prediction": "\n- Colonial Pipeline Co (NYSE: COOL) will increase because they are still moving fuel despite outages to their ordering system.\n- Energy Transfer Equity LP (NYSE: ETE) will increase because they own a majority stake in Colonial Pipeline.\n- Marathon Petroleum Corp (NYSE: MPC) will increase because they are a direct customer of Colonial Pipeline.", "price_info": {"COOL": {"company": "", "ticker": "COOL", "move": "up"}, "ETE": {"company": "", "ticker": "ETE", "move": "up"}, "MPC": {"company": "", "ticker": "MPC", "move": "up", "prices": [60.33, 60.33]}}}, {"link": "https://www.wsj.com/articles/chevron-shareholders-had-a-different-kind-of-green-in-mind-11555083173", "title": "Chevron Shareholders Wanted a Different Kind of Green", "date": "2019-04-12 11:32", "summary": "The oil company's deal for Anadarko looks like one shareholders should like, if only they can be convinced about spending money on deals. Chevron is jumping on a good deal that shareholders don't need. The California-based supermajor is buying midsize oil and gas producer Anadarko for an enterprise value of $50 billion. By several measures, the deal looks reasonable. If only shareholders in fossil-fuel companies were sold on their spending money for fossil fuels.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Chevron Shareholders Wanted a Different Kind of Green. The oil company's deal for Anadarko looks like one shareholders should like, if only they can be convinced about spending money on deals. Chevron is jumping on a good deal that shareholders don't need. The California-based supermajor is buying midsize oil and gas producer Anadarko for an enterprise value of $50 billion. By several measures, the deal looks reasonable. If only shareholders in fossil-fuel companies were sold on their spending money for fossil fuels.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because they are buying Anadarko for a good price, and it will look like a good investment to shareholders.\n- Anadarko Petroleum Corporation (NYSE: APC) will decrease because they are being bought by Chevron, and they will no longer be an independent company.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [120.39, 119.9538]}, "APC": {"company": "", "ticker": "APC", "move": "down", "prices": [62.315, 62.17]}}}, {"link": "https://www.wsj.com/articles/temple-settles-with-u-s-over-falsified-m-b-a-rankings-data-11607104836", "title": "Temple Settles With U.S. Over Falsified M.B.A. Rankings Data", "date": "2020-12-04 13:00", "summary": "University agrees to pay $700,000 to Education Department without admitting wrongdoing. Temple University must pay $700,000 under a settlement with the U.S. Education Department for using false data to bolster its online M.B.A. program's nationwide ranking.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/management-careers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Temple Settles With U.S. Over Falsified M.B.A. Rankings Data. University agrees to pay $700,000 to Education Department without admitting wrongdoing. Temple University must pay $700,000 under a settlement with the U.S. Education Department for using false data to bolster its online M.B.A. program's nationwide ranking.\"\n\nStock Prediction(s):", "Prediction": "\n- Temple University (NYSE: TU) will decrease because they were caught falsifying data.\n- University of Phoenix (NASDAQ: UOPX) will increase because they are a direct competitor of Temple University, and they have a good reputation.", "price_info": {"TU": {"company": "", "ticker": "TU", "move": "down", "prices": [19.82, 19.86]}, "UOPX": {"company": "", "ticker": "UOPX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/autonation-ceo-cheryl-miller-takes-health-leave-11586780597", "title": "AutoNation CEO Cheryl Miller Takes Health Leave", "date": "2020-04-13 10:34", "summary": "Mike Jackson will serve as president and CEO of car-dealership chain until Miller returns. AutoNation Inc.'s chief executive Cheryl Miller has taken a leave of absence for health reasons, adding to the challenges confronting the nation's largest car-dealership chain as the coronavirus outbreak has pummeled sales and dented business.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AutoNation CEO Cheryl Miller Takes Health Leave. Mike Jackson will serve as president and CEO of car-dealership chain until Miller returns. AutoNation Inc.'s chief executive Cheryl Miller has taken a leave of absence for health reasons, adding to the challenges confronting the nation's largest car-dealership chain as the coronavirus outbreak has pummeled sales and dented business.\"\n\nStock Prediction(s):", "Prediction": "\n- AutoNation Inc. (NYSE: AN) will decrease because their CEO is on a leave of absence for health reasons.", "price_info": {"AN": {"company": "", "ticker": "AN", "move": "down", "prices": [32.315, 32.315]}}}, {"link": "https://www.wsj.com/articles/fiat-chrysler-is-still-the-winner-in-merger-with-peugeot-11576685218", "title": "Fiat Chrysler Is Still the Winner in Merger With Peugeot", "date": "2019-12-18 11:06", "summary": "Recent negotiations have sweetened the terms for the French auto maker, but it is still shouldering more risk. The merger of Fiat Chrysler and Peugeot has passed the first milestone on its long road to completion. Not much has changed, but the details that have are telling.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fiat Chrysler Is Still the Winner in Merger With Peugeot. Recent negotiations have sweetened the terms for the French auto maker, but it is still shouldering more risk. The merger of Fiat Chrysler and Peugeot has passed the first milestone on its long road to completion. Not much has changed, but the details that have are telling.\"\n\nStock Prediction(s):", "Prediction": "\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will increase because the merger is still going through, and they are the \"winner\" in the situation.\n- Peugeot SA (EPA: UG) will increase because they are still going through the merger, and they are taking on more risk.\n- Renault SA (EPA: RNO) will decrease because they are not the \"winner\" in the situation, and they are not taking on", "price_info": {"FCAU": {"company": "", "ticker": "FCAU", "move": "down", "prices": [15.175, 15.19]}}}, {"link": "https://www.wsj.com/articles/ge-power-has-a-92-billion-backlog-for-new-boss-thats-a-problem-11550068479", "title": "GE Power Has a $92 Billion Backlog. For the New Boss, That's a Problem.", "date": "2019-02-13 09:34", "summary": "CEO Larry Culp says turbine-making division is weighed down by low-margin orders that came from chasing market share. The turnaround of General Electric Co. depends on the revival of its core power business, a reversal that will require Chief Executive Larry Culp to churn through a $92 billion sales backlog marred by lousy projects.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GE Power Has a $92 Billion Backlog. For the New Boss, That's a Problem.. CEO Larry Culp says turbine-making division is weighed down by low-margin orders that came from chasing market share. The turnaround of General Electric Co. depends on the revival of its core power business, a reversal that will require Chief Executive Larry Culp to churn through a $92 billion sales backlog marred by lousy projects.\"\n\nStock Prediction(s):", "Prediction": "\n- GE Power (NYSE: GE) will decrease because they have a $92 billion backlog of low-margin orders.", "price_info": {"GE": {"company": "", "ticker": "GE", "move": "down", "prices": [10.0134, 10.0741]}}}, {"link": "https://www.wsj.com/articles/u-s-service-sector-activity-slowed-in-june-11562163476", "title": "U.S. Service-Sector Activity Slowed in June", "date": "2019-07-03 11:26", "summary": "Overall U.S. economy has expanded at a healthy pace in recent months. Activity in the U.S. services sector pulled back in June, suggesting the economy is reverting to a slower but steady pace of growth after a strong 2018.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Service-Sector Activity Slowed in June. Overall U.S. economy has expanded at a healthy pace in recent months. Activity in the U.S. services sector pulled back in June, suggesting the economy is reverting to a slower but steady pace of growth after a strong 2018.\"\n\nStock Prediction(s):", "Prediction": "\n- The overall U.S. economy will decrease because the service sector is slowing down.\n- The overall U.S. economy will increase because the service sector is growing, but at a slower pace.", "price_info": {}}, {"link": "https://www.wsj.com/articles/once-a-lonely-bond-bull-hsbcs-steven-major-takes-stock-of-this-years-rally-11561737601", "title": "Once a Lonely Bond Bull, HSBC's Steven Major Takes Stock of This Year's Rally", "date": "2019-06-28 12:00", "summary": "His contention that longer-term structural issues would suppress yields has made him one of the most-bullish analysts in the U.S. Treasury market. At the beginning of the year, most economists and investors believed that bond yields were poised to finally climb out of their postcrisis funk. One exception: HSBC Holdings PLC's Steven Major. His contention that longer-term structural issues would suppress yields has made him one of the most-bullish analysts in the U.S. Treasury market.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Once a Lonely Bond Bull, HSBC's Steven Major Takes Stock of This Year's Rally. His contention that longer-term structural issues would suppress yields has made him one of the most-bullish analysts in the U.S. Treasury market. At the beginning of the year, most economists and investors believed that bond yields were poised to finally climb out of their postcrisis funk. One exception: HSBC Holdings PLC's Steven Major. His contention that longer-term structural issues would suppress yields has made him one of the most-bullish analysts in the U.S. Treasury market.\"\n\nStock Prediction(s):", "Prediction": "\n- HSBC Holdings plc (NYSE: HSBC) will increase because their analyst is one of the most bullish in the market, and he was correct about the structural issues suppressing yields.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are also an analyst, and they are not as bullish as HSBC.", "price_info": {"HSBC": {"company": "", "ticker": "HSBC", "move": "up", "prices": [41.795, 41.747]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [111.93, 111.83]}}}, {"link": "https://www.wsj.com/articles/toy-makers-scramble-as-shipping-snarls-threaten-to-spoil-christmas-11627563777", "title": "Toy Prices Are Going Up Ahead of the Holiday Season", "date": "2021-07-29 13:11", "summary": "Companies race to import enough toys for holiday shopping and try to pass along higher shipping costs. Logjams at seaports around the world are leaving some American toy companies scrambling this summer to ensure sufficient supply will reach retail shelves come this year's holiday shopping season. The toys that arrive in time will likely carry higher prices.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Toy Prices Are Going Up Ahead of the Holiday Season. Companies race to import enough toys for holiday shopping and try to pass along higher shipping costs. Logjams at seaports around the world are leaving some American toy companies scrambling this summer to ensure sufficient supply will reach retail shelves come this year's holiday shopping season. The toys that arrive in time will likely carry higher prices.\"\n\nStock Prediction(s):", "Prediction": "\n- Hasbro, Inc. (NASDAQ: HAS) will increase because they are one of the few companies with an adequate supply of toys.\n- Mattel, Inc. (NASDAQ: MAT) will decrease because they are one of the few companies with an inadequate supply of toys.\n- JAKKS Pacific, Inc. (NASDAQ: JAKK) will decrease because they are one of the few companies with an inadequate supply of toys.", "price_info": {"HAS": {"company": "", "ticker": "HAS", "move": "up", "prices": [100.17, 100.52]}, "MAT": {"company": "", "ticker": "MAT", "move": "down", "prices": [21.74, 21.62]}, "JAKK": {"company": "", "ticker": "JAKK", "move": "down", "prices": [13.79, 13.95]}}}, {"link": "https://www.wsj.com/articles/walmart-diversification-goes-into-overdrive-with-goldman-hires-11614631326", "title": "Walmart Diversification Goes Into Overdrive With Goldman Hires", "date": "2021-03-01 15:42", "summary": "Walmart signals it is getting serious about financial technology, even as it is expanding into online advertising and other businesses. Walmart 's latest hires are big news in retail, and in banking.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walmart Diversification Goes Into Overdrive With Goldman Hires. Walmart signals it is getting serious about financial technology, even as it is expanding into online advertising and other businesses. Walmart 's latest hires are big news in retail, and in banking.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because they are expanding their business into other areas, such as online advertising and financial technology.\n- Goldman Sachs Group Inc. (NYSE: GS) will increase because they are being hired by Walmart to help with their financial technology.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [131.739, 131.55]}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [329.985, 329.99]}}}, {"link": "https://www.wsj.com/articles/trump-and-his-budget-arent-on-the-same-page-11581522534", "title": "Trump and His Budget Aren't on the Same Page", "date": "2020-02-12 10:48", "summary": "It warns of fiscal discipline, but the president has seldom shown concern over debt, deficits or government spending. The budget that President Trump released this week is a model of mainstream Republican orthodoxy. It asks for more defense money to fend off \"rival nation-states\" like China and Russia and support allies while decrying \"a bloated federal government with duplicative programs and wasteful spending.\"", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump and His Budget Aren't on the Same Page. It warns of fiscal discipline, but the president has seldom shown concern over debt, deficits or government spending. The budget that President Trump released this week is a model of mainstream Republican orthodoxy. It asks for more defense money to fend off \"rival nation-states\" like China and Russia and support allies while decrying \"a bloated federal government with duplicative programs and wasteful spending.\"\"\n\nStock Prediction(s):", "Prediction": "\n- The market will not react to this news because it is not about a specific company or industry.", "price_info": {}}, {"link": "https://www.wsj.com/articles/disney-investors-could-look-goofy-soon-11597068000", "title": "Disney Investors Could Look Goofy Soon", "date": "2020-08-10 10:00", "summary": "Investors rushing to ride Disney on the hope of pandemic recovery could be in for a long and uncomfortable wait. Walt Disney investors are enjoying the recent show, but they might not get their happily ever after.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Disney Investors Could Look Goofy Soon. Investors rushing to ride Disney on the hope of pandemic recovery could be in for a long and uncomfortable wait. Walt Disney investors are enjoying the recent show, but they might not get their happily ever after.\"\n\nStock Prediction(s):", "Prediction": "\n- Disney (NYSE: DIS) will decrease because their stock is overvalued and they are not the only company working on a vaccine.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "down", "prices": [129.1801, 129.74]}}}, {"link": "https://www.wsj.com/articles/natural-gas-jumps-on-colder-weather-forecasts-11575395023", "title": "Natural Gas Jumps on Colder Weather Forecasts", "date": "2019-12-03 15:10", "summary": "Futures climbed after some models predicted a sweep of cold weather across the Midwest and eastern two-thirds of the U.S.. The price of natural gas rose on Tuesday, buoyed by expectations for colder weather in the coming weeks that could boost demand for the fuel.", "categories": [["Markets", "Commodities", "Gas Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/gas-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Natural Gas Jumps on Colder Weather Forecasts. Futures climbed after some models predicted a sweep of cold weather across the Midwest and eastern two-thirds of the U.S.. The price of natural gas rose on Tuesday, buoyed by expectations for colder weather in the coming weeks that could boost demand for the fuel.\"\n\nStock Prediction(s):", "Prediction": "\n- Chesapeake Energy Corporation (NYSE: CHK) will increase because natural gas prices are going up.\n- Devon Energy Corporation (NYSE: DVN) will increase because natural gas prices are going up.\n- Range Resources Corporation (NYSE: RRC) will increase because natural gas prices are going up.\n- Southwestern Energy Company (NYSE: SWN) will increase because natural gas prices are going up.", "price_info": {"CHK": {"company": "", "ticker": "CHK", "move": "up", "prices": [0.642, 0.635]}, "DVN": {"company": "", "ticker": "DVN", "move": "up", "prices": [21.41, 21.41]}, "RRC": {"company": "", "ticker": "RRC", "move": "up", "prices": [3.405, 3.4]}, "SWN": {"company": "", "ticker": "SWN", "move": "up", "prices": [1.8356, 1.82]}}}, {"link": "https://www.wsj.com/articles/large-telecoms-state-enforcers-make-pact-to-combat-robocalls-11566489602?mod=hp_lead_pos2?mod=article_inline", "title": "Large Telecoms, State Enforcers Make Pact to Combat Robocalls", "date": "2019-08-22 15:26", "summary": "Companies pledge to offer free call-blocking technology and trace illegal calls. WASHINGTON-Large telecom companies and attorneys general from every state unveiled Thursday a new pact for combating robocalls, the latest step toward cutting off such calls before they reach a consumer's phone.", "categories": [["WSJ News Exclusive", "U.S."]], "category_links": ["https://www.wsj.com/news/us?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Large Telecoms, State Enforcers Make Pact to Combat Robocalls. Companies pledge to offer free call-blocking technology and trace illegal calls. WASHINGTON-Large telecom companies and attorneys general from every state unveiled Thursday a new pact for combating robocalls, the latest step toward cutting off such calls before they reach a consumer's phone.\"\n\nStock Prediction(s):", "Prediction": "\n- AT&T Inc. (NYSE: T) will increase because they are pledging to offer free call-blocking technology to their consumers.\n- Verizon Communications Inc. (NYSE: VZ) will increase because they are pledging to offer free call-blocking technology to their consumers.\n- Comcast Corporation (NASDAQ: CMCSA) will increase because they are pledging to offer free call-blocking technology to their consumers.\n- T-Mobile US Inc. (", "price_info": {"T": {"company": "", "ticker": "T", "move": "up", "prices": [35.37, 35.35]}, "VZ": {"company": "", "ticker": "VZ", "move": "up", "prices": [56.79, 56.75]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "up", "prices": [43.77, 43.77]}}}, {"link": "https://www.wsj.com/articles/biden-taps-isabel-guzman-to-lead-small-business-administration-11610044839", "title": "Biden Taps Isabel Guzman to Lead Small Business Administration", "date": "2021-01-07 13:59", "summary": "Guzman is a California economic development official and former deputy chief of staff at SBA. WASHINGTON-President-elect Joe Biden has chosen Isabel Guzman, a California economic development official, to lead the Small Business Administration, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Politics"]], "category_links": ["https://www.wsj.com/news/politics?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biden Taps Isabel Guzman to Lead Small Business Administration. Guzman is a California economic development official and former deputy chief of staff at SBA. WASHINGTON-President-elect Joe Biden has chosen Isabel Guzman, a California economic development official, to lead the Small Business Administration, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Guzman's appointment will be good for small businesses, and they will see an increase in stock prices.\n- Other companies that deal with small businesses, such as Intuit Inc. (NASDAQ: INTU) and Paychex, Inc. (NASDAQ: PAYX), will also see an increase in stock prices.", "price_info": {"INTU": {"company": "", "ticker": "INTU", "move": "up", "prices": [369, 369.77]}, "PAYX": {"company": "", "ticker": "PAYX", "move": "up", "prices": [91.3429, 91.285]}}}, {"link": "https://www.wsj.com/articles/a-36-000-acre-property-in-new-yorks-adirondacks-asks-180-million-11596032719", "title": "A 36,000-Acre Property in New York's Adirondacks Asks $180 Million", "date": "2020-07-29 10:25", "summary": "The estate was the longtime home of Marylou Whitney, a socialite and horse racing enthusiast who died last year. Whitney Park, a 36,000-acre property in the Adirondacks that has belonged to the prominent Whitney family for more than a century, is hitting the market for $180 million.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A 36,000-Acre Property in New York's Adirondacks Asks $180 Million. The estate was the longtime home of Marylou Whitney, a socialite and horse racing enthusiast who died last year. Whitney Park, a 36,000-acre property in the Adirondacks that has belonged to the prominent Whitney family for more than a century, is hitting the market for $180 million.\"\n\nStock Prediction(s):", "Prediction": "\n- The property will be bought by a wealthy individual who wants to get away from the city.\n- The property will be bought by a company that wants to use it for a retreat or a training center.\n- The property will be bought by a developer who will subdivide it and sell the lots.", "price_info": {}}, {"link": "https://www.wsj.com/articles/bank-stocks-take-a-beating-11557772584", "title": "Bank Stocks Take a Beating", "date": "2019-05-13 14:36", "summary": "Rising trade tensions and falling bond yields are pressuring large and small lenders. Bank stocks slumped Monday after an escalation in U.S.-China trade tensions and a drop in bond yields revived worries over U.S. economic growth.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bank Stocks Take a Beating. Rising trade tensions and falling bond yields are pressuring large and small lenders. Bank stocks slumped Monday after an escalation in U.S.-China trade tensions and a drop in bond yields revived worries over U.S. economic growth.\"\n\nStock Prediction(s):", "Prediction": "\n- Bank of America Corporation (NYSE: BAC) will decrease because of the trade tensions and falling bond yields.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because of the trade tensions and falling bond yields.\n- Wells Fargo & Company (NYSE: WFC) will decrease because of the trade tensions and falling bond yields.\n- Citigroup, Inc. (NYSE: C) will decrease because of the trade tensions and falling bond yields.", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [28.14, 28.18]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [109.19, 109.25]}, "WFC": {"company": "", "ticker": "WFC", "move": "down", "prices": [46.37, 46.3]}, "C": {"company": "America", "ticker": "C", "move": "down", "prices": [64.21, 64.28]}}}, {"link": "https://www.wsj.com/articles/the-fireworks-over-share-buybacks-are-duds-11562338801", "title": "The Fireworks Over Share Buybacks Are Duds", "date": "2019-07-05 11:00", "summary": "Stock repurchases go back to the earliest days of the republic. Share buybacks are as American as mom, apple pie and hot dogs on the Fourth of July.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Fireworks Over Share Buybacks Are Duds. Stock repurchases go back to the earliest days of the republic. Share buybacks are as American as mom, apple pie and hot dogs on the Fourth of July.\"\n\nStock Prediction(s):", "Prediction": "\n- The stocks of companies that have announced share buybacks will go up because investors see it as a sign of confidence in the company.\n- The stocks of companies that have not announced share buybacks will go down because investors see it as a sign of lack of confidence in the company.", "price_info": {}}, {"link": "https://www.wsj.com/articles/iron-ore-prices-jump-to-highest-level-since-2014-on-vale-concerns-11549562850", "title": "Iron-Ore Prices Jump to Highest Level Since 2014 on Vale Concerns", "date": "2019-02-07 13:07", "summary": "After dam collapse, traders contend with suspension of one of the Brazilian company's largest mines. Iron-ore futures prices leapt on Thursday, as fresh turmoil for Brazilian miner Vale SA pushed the crucial metal to heights not seen since August 2014.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Iron-Ore Prices Jump to Highest Level Since 2014 on Vale Concerns. After dam collapse, traders contend with suspension of one of the Brazilian company's largest mines. Iron-ore futures prices leapt on Thursday, as fresh turmoil for Brazilian miner Vale SA pushed the crucial metal to heights not seen since August 2014.\"\n\nStock Prediction(s):", "Prediction": "\n- Vale SA (NYSE: VALE) will increase because their largest mine has been shut down, and this will cause a shortage in the market.\n- Rio Tinto plc (NYSE: RIO) will increase because they are a competitor of Vale, and they will be able to capitalize on the shortage.\n- BHP Group plc (NYSE: BHP) will increase because they are a competitor of Vale, and they will be able to capitalize on", "price_info": {"VALE": {"company": "", "ticker": "VALE", "move": "up", "prices": [11.26, 11.125]}, "RIO": {"company": "", "ticker": "RIO", "move": "up", "prices": [56.16, 56.02]}, "BHP": {"company": "", "ticker": "BHP", "move": "up", "prices": [50.65, 50.42]}}}, {"link": "https://www.wsj.com/articles/reality-tv-show-tries-financial-makeovers-for-those-with-student-debt-11571223601", "title": "Reality-TV Show Tries Student-Debt Makeovers", "date": "2019-10-16 11:12", "summary": "Ashton Kutcher's new 'Going From Broke' looks at young people confronting burdensome loans. Reality TV is very America. So is student debt. It was only a matter of time before someone put them together.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Reality-TV Show Tries Student-Debt Makeovers. Ashton Kutcher's new 'Going From Broke' looks at young people confronting burdensome loans. Reality TV is very America. So is student debt. It was only a matter of time before someone put them together.\"\n\nStock Prediction(s):", "Prediction": "\n- The show will be a success and will attract a lot of viewers, which will benefit the networks that air it.\n- The show will be a failure and will not be successful.", "price_info": {}}, {"link": "https://www.wsj.com/articles/feds-rosengren-no-need-to-lower-rates-again-based-on-outlook-11576605600", "title": "Fed's Rosengren: No Need for Rate Change Right Now", "date": "2019-12-17 14:38", "summary": "Boston Fed leader says now is a time for central bankers to take stock of past action. Federal Reserve Bank of Boston leader Eric Rosengren said Tuesday he sees no looming reason right now to either cut or raise short-term interest rates any time soon.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Rosengren: No Need for Rate Change Right Now. Boston Fed leader says now is a time for central bankers to take stock of past action. Federal Reserve Bank of Boston leader Eric Rosengren said Tuesday he sees no looming reason right now to either cut or raise short-term interest rates any time soon.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of Boston's leader, Eric Rosengren, said that there is no need for a rate change right now, which will likely cause the markets to stay relatively stable.\n- The only exception to this prediction would be if there was a major economic event that caused the Fed to change its stance, but that is not currently expected.", "price_info": {}}, {"link": "https://www.wsj.com/articles/saudis-and-russia-debate-response-to-oil-price-crash-11559831488", "title": "Saudis and Russia Debate Response to Oil-Price Swoon", "date": "2019-06-06 13:18", "summary": "Top oil exporters to meet in Russia ahead of OPEC summit. Saudi Arabia and Russia-the world's top crude exporters-disagree about how to respond to a free fall in oil prices, and their energy ministers are set to meet in Russia in the coming days to build a consensus ahead of a meeting of the Organization of the Petroleum Exporting Countries.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Saudis and Russia Debate Response to Oil-Price Swoon. Top oil exporters to meet in Russia ahead of OPEC summit. Saudi Arabia and Russia-the world's top crude exporters-disagree about how to respond to a free fall in oil prices, and their energy ministers are set to meet in Russia in the coming days to build a consensus ahead of a meeting of the Organization of the Petroleum Exporting Countries.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (Private: ARMCO) will increase because they are one of the top oil exporters and they have a lot of money to spend.\n- Rosneft Oil (MCX: ROSN) will increase because they are one of the top oil exporters and they have a lot of money to spend.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because they are not one of the top oil exporters and they have a", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [74.055, 74.27]}}}, {"link": "https://www.wsj.com/articles/star-witness-in-insider-trading-case-describes-far-reaching-scheme-11578666631", "title": "Star Witness Describes Far-Reaching Insider-Trading Scheme", "date": "2020-01-10 09:30", "summary": "Insider trading is a 'sport' overseas, Marc Demane Debih told investigators. As Marc Demane Debih was flown out of Serbia last May, as a prisoner in U.S. custody, he told federal agents on the plane that an \"unbelievable\" number of people were committing insider trading. It was a \"sport\" overseas, Mr. Demane told the agents, according to investigative records described in court. Mr. Demane said he could name names.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Star Witness Describes Far-Reaching Insider-Trading Scheme. Insider trading is a 'sport' overseas, Marc Demane Debih told investigators. As Marc Demane Debih was flown out of Serbia last May, as a prisoner in U.S. custody, he told federal agents on the plane that an \"unbelievable\" number of people were committing insider trading. It was a \"sport\" overseas, Mr. Demane told the agents, according to investigative records described in court. Mr. Demane said he could name names.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldman Sachs Group Inc. (NYSE: GS) will decrease because one of their executives is being investigated for insider trading.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because one of their executives is being investigated for insider trading.\n- Bank of America Corp. (NYSE: BAC) will decrease because one of their executives is being investigated for insider trading.\n- Citigroup Inc. (NYSE: C) will decrease because one of their", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "down", "prices": [242.75, 243.1606]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [137.25, 136.835]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [34.98, 35.025]}, "C": {"company": "", "ticker": "C", "move": "down", "prices": [80.01, 79.84]}}}, {"link": "https://www.wsj.com/articles/help-arriving-none-too-soon-for-retailers-11608140715", "title": "Help Arriving None Too Soon for Retailers", "date": "2020-12-16 12:45", "summary": "Disappointing retail sales report sets stage for a difficult winter, but new round of government support could ease the pain. The Covid-19 crisis has caught back up with retailers again, setting the stage for a hard start to winter. But help may be on the way.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Help Arriving None Too Soon for Retailers. Disappointing retail sales report sets stage for a difficult winter, but new round of government support could ease the pain. The Covid-19 crisis has caught back up with retailers again, setting the stage for a hard start to winter. But help may be on the way.\"\n\nStock Prediction(s):", "Prediction": "\n- Macy's, Inc. (NYSE: M) will increase because they are one of the retailers that will be receiving government support.\n- J.C. Penney Company, Inc. (NYSE: JCP) will increase because they are one of the retailers that will be receiving government support.\n- Sears Holdings Corporation (NASDAQ: SHLD) will increase because they are one of the retailers that will be receiving government support.\n- Nordstrom, Inc", "price_info": {"M": {"company": "", "ticker": "M", "move": "up", "prices": [10.35, 10.3767]}, "JCP": {"company": "", "ticker": "JCP", "move": "up"}, "SHLD": {"company": "", "ticker": "SHLD", "move": "up"}}}, {"link": "https://www.wsj.com/articles/new-york-times-adds-more-online-subscribers-but-expects-continued-ad-declines-higher-costs-11573058552", "title": "New York Times Adds More Online Subscribers, but Expects Continued Ad Declines, Higher Costs", "date": "2019-11-06 11:42", "summary": "Company now has 4.1 million paid digital subscribers, with 529,000 coming from international markets. New York Times Co . reported strong digital-subscription growth in the third quarter, but earnings suffered from a drop in advertising revenue, which the company said would accelerate in the following quarter.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"New York Times Adds More Online Subscribers, but Expects Continued Ad Declines, Higher Costs. Company now has 4.1 million paid digital subscribers, with 529,000 coming from international markets. New York Times Co . reported strong digital-subscription growth in the third quarter, but earnings suffered from a drop in advertising revenue, which the company said would accelerate in the following quarter.\"\n\nStock Prediction(s):", "Prediction": "\n- The New York Times Co (NYSE: NYT) will continue to grow because they are adding more online subscribers.\n- The New York Times Co (NYSE: NYT) will have to increase their prices in order to continue to grow.\n- The New York Times Co (NYSE: NYT) will have to decrease their costs in order to continue to grow.", "price_info": {"NYT": {"company": "", "ticker": "NYT", "move": "down", "prices": [30.4431, 30.38]}}}, {"link": "https://www.wsj.com/articles/flower-delivery-firm-ftd-says-it-could-go-out-of-business-by-summer-11552934843", "title": "Flower Delivery Firm FTD Says It Could Go Out of Business by Summer", "date": "2019-03-18 14:47", "summary": "Chicago-based company says it needs to find a buyer or pay down its $217.7 million in debt by June 1. Flower-delivery provider FTD Cos. on Monday warned that it could go out of business by this summer if it doesn't raise enough money to meet its debt obligations.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Flower Delivery Firm FTD Says It Could Go Out of Business by Summer. Chicago-based company says it needs to find a buyer or pay down its $217.7 million in debt by June 1. Flower-delivery provider FTD Cos. on Monday warned that it could go out of business by this summer if it doesn't raise enough money to meet its debt obligations.\"\n\nStock Prediction(s):", "Prediction": "\n- FTD Companies, Inc. (NASDAQ: FTD) will decrease because they may go out of business if they can't find a buyer.", "price_info": {"FTD": {"company": "", "ticker": "FTD", "move": "down"}}}, {"link": "https://www.wsj.com/articles/gold-rallies-with-dollar-treasury-yields-sliding-after-jobs-report-11556894678", "title": "Gold Rallies With Dollar, Treasury Yields Sliding After Jobs Report", "date": "2019-05-03 15:07", "summary": "Prices are roughly flat for the year and almost 5% below their 10-month peaks hit in February. Gold prices climbed Friday, supported by a falling dollar and lower Treasury yields after April hiring data showed U.S. wages grew less quickly than expected.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold Rallies With Dollar, Treasury Yields Sliding After Jobs Report. Prices are roughly flat for the year and almost 5% below their 10-month peaks hit in February. Gold prices climbed Friday, supported by a falling dollar and lower Treasury yields after April hiring data showed U.S. wages grew less quickly than expected.\"\n\nStock Prediction(s):", "Prediction": "\n- Goldcorp Inc. (NYSE: GG) will increase because the dollar is falling and gold is seen as a safe-haven investment.\n- Barrick Gold Corporation (NYSE: ABX) will increase because the dollar is falling and gold is seen as a safe-haven investment.\n- Newmont Mining Corporation (NYSE: NEM) will increase because the dollar is falling and gold is seen as a safe-haven investment.\n- AngloGold Ashanti", "price_info": {"GG": {"company": "", "ticker": "GG", "move": "up"}, "ABX": {"company": "", "ticker": "ABX", "move": "up"}, "NEM": {"company": "", "ticker": "NEM", "move": "up", "prices": [30.22, 30.22]}}}, {"link": "https://www.wsj.com/articles/two-legged-customers-let-down-general-mills-11561563333", "title": "Two-Legged Customers Let Down General Mills", "date": "2019-06-26 11:35", "summary": "General Mills' new pet-food business is growing fast, but its food products for humans keep disappointing. General Mills can't ignore its core.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Two-Legged Customers Let Down General Mills. General Mills' new pet-food business is growing fast, but its food products for humans keep disappointing. General Mills can't ignore its core.\"\n\nStock Prediction(s):", "Prediction": "\n- General Mills, Inc. (NYSE: GIS) will decrease because their human food products are not selling well.", "price_info": {"GIS": {"company": "", "ticker": "GIS", "move": "down", "prices": [51.2526, 51.27]}}}, {"link": "https://www.wsj.com/articles/when-a-59-annual-return-just-isnt-enough-11625238010", "title": "When a 59% Annual Return Just Isn't Enough", "date": "2021-07-02 11:00", "summary": "Investors appear to be growing more and more optimistic about how their portfolios will perform in the years to come. Disappointment is bound to follow.. Optimism is as American as hot dogs and apple pie. Too much optimism, though, is about as good for you as eating a few dozen hot dogs and slices of pie.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"When a 59% Annual Return Just Isn't Enough. Investors appear to be growing more and more optimistic about how their portfolios will perform in the years to come. Disappointment is bound to follow.. Optimism is as American as hot dogs and apple pie. Too much optimism, though, is about as good for you as eating a few dozen hot dogs and slices of pie.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will correct because investors are becoming too optimistic about their portfolios' future performance.\n- The market will continue to go up because investors are becoming more optimistic about their portfolios' future performance.", "price_info": {}}, {"link": "https://www.wsj.com/articles/gold-prices-drift-higher-after-lukewarm-inflation-data-11550081784", "title": "Gold Prices Drift Higher After Lukewarm Inflation Data", "date": "2019-02-13 15:36", "summary": "Gold prices edged up after tepid U.S. inflation data bolstered the case for the Federal Reserve to pause its monetary tightening. Gold prices edged higher Wednesday after tepid U.S. inflation data bolstered the case for the Federal Reserve to pause its monetary tightening.", "categories": [["Markets", "Commodities", "Precious Metals"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/precious-metals?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Gold Prices Drift Higher After Lukewarm Inflation Data. Gold prices edged up after tepid U.S. inflation data bolstered the case for the Federal Reserve to pause its monetary tightening. Gold prices edged higher Wednesday after tepid U.S. inflation data bolstered the case for the Federal Reserve to pause its monetary tightening.\"\n\nStock Prediction(s):", "Prediction": "\n- Gold prices will continue to drift higher because the Fed is likely to pause its monetary tightening.\n- The dollar will continue to decline because the Fed is likely to pause its monetary tightening.\n- Gold mining companies will increase because the price of gold is increasing.", "price_info": {}}, {"link": "https://www.wsj.com/articles/why-the-heck-does-165-year-old-levi-want-to-be-public-again-11553269502", "title": "Why the Heck Does 165-Year-Old Levi Want to Be Public Again?", "date": "2019-03-22 11:45", "summary": "The jeans maker believes it's built to last, but Wall Street often demands short-term performance. Chip Bergh has been dressing up Levi Strauss & Co. for a public offering for years. As chief executive, he's consolidated supply chains, retooled R&D, and overhauled the executive ranks. The term \"profitable growth\" is woven through the corporate lexicon as distinctively as the orange stitching on a pair of the company's 501s.", "categories": [["Business", "On Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/on-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why the Heck Does 165-Year-Old Levi Want to Be Public Again?. The jeans maker believes it's built to last, but Wall Street often demands short-term performance. Chip Bergh has been dressing up Levi Strauss & Co. for a public offering for years. As chief executive, he's consolidated supply chains, retooled R&D, and overhauled the executive ranks. The term \"profitable growth\" is woven through the corporate lexicon as distinctively as the orange stitching on a pair of the company's 501s.\"\n\nStock Prediction(s):", "Prediction": "\n- Levi Strauss & Co. (NYSE: LEVI) will increase because they are going public again and they have been working on this for a while.\n- Gap Inc. (NYSE: GPS) will decrease because they are a direct competitor of Levi Strauss.", "price_info": {"LEVI": {"company": "", "ticker": "LEVI", "move": "up", "prices": [22.15, 22.1]}, "GPS": {"company": "", "ticker": "GPS", "move": "down", "prices": [24.41, 24.5263]}}}, {"link": "https://www.wsj.com/articles/farmers-swap-soybeans-for-corn-as-coronavirus-scrambles-demand-11589306319", "title": "Farmers Swap Soybeans for Corn as Coronavirus Scrambles Demand", "date": "2020-05-12 13:58", "summary": "Prices have fallen further for corn than soybeans as ethanol production stalls. Some farmers are shifting acres from corn to soybeans this year, a reversal that reflects the coronavirus pandemic's broad impact on demand for many agricultural products.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Farmers Swap Soybeans for Corn as Coronavirus Scrambles Demand. Prices have fallen further for corn than soybeans as ethanol production stalls. Some farmers are shifting acres from corn to soybeans this year, a reversal that reflects the coronavirus pandemic's broad impact on demand for many agricultural products.\"\n\nStock Prediction(s):", "Prediction": "\n- Archer Daniels Midland Company (NYSE: ADM) will increase because they are a producer of corn, and the demand for corn will go up because of the coronavirus.\n- Bunge Limited (NYSE: BG) will increase because they are a producer of soybeans, and the demand for soybeans will go up because of the coronavirus.\n- Cargill, Incorporated (NYSE: CARG) will increase because they are a producer", "price_info": {"ADM": {"company": "", "ticker": "ADM", "move": "up", "prices": [35.18, 34.8]}, "BG": {"company": "", "ticker": "BG", "move": "up", "prices": [34.875, 34.55]}, "CARG": {"company": "", "ticker": "CARG", "move": "up", "prices": [23.5609, 23]}}}, {"link": "https://www.wsj.com/articles/feds-bullard-rate-cut-now-is-insurance-against-rising-risk-11561115056", "title": "Two Fed Doves Make Case for Central Bank Rate Cuts", "date": "2019-06-21 11:45", "summary": "Minneapolis Fed leader Kashkari joined another official to say the central bank should have lowered and not held steady its short-term rate target. Two Federal Reserve officials said they believed the central bank should have lowered and not held steady its short-term rate target this week to help address persistently weak inflation pressures and rising economic risks.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Two Fed Doves Make Case for Central Bank Rate Cuts. Minneapolis Fed leader Kashkari joined another official to say the central bank should have lowered and not held steady its short-term rate target. Two Federal Reserve officials said they believed the central bank should have lowered and not held steady its short-term rate target this week to help address persistently weak inflation pressures and rising economic risks.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FFR) will decrease because they are not meeting their goals, and they may need to cut rates in order to stimulate the economy.\n- The Bank of America (NYSE: BAC) will increase because they are a direct beneficiary of a decrease in the Federal Reserve rate.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are a direct beneficiary of a decrease in the Federal Reserve rate.\n- Wells", "price_info": {"FFR": {"company": "", "ticker": "FFR", "move": "down"}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [28.385, 28.39]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [111.0799, 110.968]}}}, {"link": "https://www.wsj.com/articles/federal-prosecutors-probe-giulianis-links-to-ukrainian-energy-projects-11573837576", "title": "Federal Prosecutors Probe Giuliani's Links to Ukrainian Energy Projects", "date": "2019-11-15 12:06", "summary": "Associates told others that Giuliani stood to profit from natural-gas project pitched alongside campaign for investigations of Joe Biden. Federal prosecutors in New York are investigating whether Rudy Giuliani stood to profit personally from a Ukrainian natural-gas business pushed by two associates who also aided his efforts there to launch investigations that could benefit President Trump, people familiar with the matter said.", "categories": [["WSJ News Exclusive", "Politics"]], "category_links": ["https://www.wsj.com/news/politics?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Federal Prosecutors Probe Giuliani's Links to Ukrainian Energy Projects. Associates told others that Giuliani stood to profit from natural-gas project pitched alongside campaign for investigations of Joe Biden. Federal prosecutors in New York are investigating whether Rudy Giuliani stood to profit personally from a Ukrainian natural-gas business pushed by two associates who also aided his efforts there to launch investigations that could benefit President Trump, people familiar with the matter said.\"\n\nStock Prediction(s):", "Prediction": "\n- Rudy Giuliani's (former) law firm, Greenberg Traurig LLP (NYSE: GT), will decrease because of the probe.\n- Other law firms with ties to Giuliani will also decrease because of the probe.", "price_info": {"GT": {"company": "", "ticker": "GT", "move": "down", "prices": [16.37, 16.305]}}}, {"link": "https://www.wsj.com/articles/presidential-tweets-drive-volatility-in-interest-rate-options-11588615233", "title": "Presidential Tweets Drive Volatility in Interest-Rate Options", "date": "2020-05-04 14:00", "summary": "Options market shows more sensitivity to announcements by the president on the social-media platform than in September. President Donald Trump's tweets are increasingly driving swings in the $25 trillion market for using options to bet on U.S. interest rates.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Presidential Tweets Drive Volatility in Interest-Rate Options. Options market shows more sensitivity to announcements by the president on the social-media platform than in September. President Donald Trump's tweets are increasingly driving swings in the $25 trillion market for using options to bet on U.S. interest rates.\"\n\nStock Prediction(s):", "Prediction": "\n- The interest-rate options market will become more volatile because of Trump's tweets.\n- The interest-rate options market will become more volatile because of the increasing number of Covid-19 cases.\n- The interest-rate options market will become more volatile because of the increasing number of people who are losing their jobs.", "price_info": {}}, {"link": "https://www.wsj.com/articles/mylan-settles-sec-suit-for-30-million-11569597862", "title": "Mylan Settles SEC Suit for $30 Million", "date": "2019-09-27 11:24", "summary": "Drugmaker allegedly failed to disclose a possible loss related to a probe over whether it overcharged for EpiPen. Mylan NV has agreed to pay $30 million to settle charges that it allegedly failed to disclose a possible loss related to a previous federal probe into whether the drugmaker overcharged Medicaid for its EpiPen treatment.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Mylan Settles SEC Suit for $30 Million. Drugmaker allegedly failed to disclose a possible loss related to a probe over whether it overcharged for EpiPen. Mylan NV has agreed to pay $30 million to settle charges that it allegedly failed to disclose a possible loss related to a previous federal probe into whether the drugmaker overcharged Medicaid for its EpiPen treatment.\"\n\nStock Prediction(s):", "Prediction": "\n- Mylan NV (NASDAQ: MYL) will decrease because they have to pay $30 million to the SEC.\n- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will increase because they are not involved in the lawsuit, and they are a direct competitor of Mylan.", "price_info": {"TEVA": {"company": "", "ticker": "TEVA", "move": "up", "prices": [6.9623, 6.87]}, "MYL": {"company": "", "ticker": "MYL", "move": "down", "prices": [19.63, 19.51]}}}, {"link": "https://www.wsj.com/articles/under-armour-shares-look-stretched-11612977092", "title": "Under Armour Shares Look Stretched", "date": "2021-02-10 12:11", "summary": "The company beat modest expectations but it has yet to prove that its turnaround plan is working. Under Armour is making an impressive comeback. Can that continue once it rejoins the varsity squad?", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Under Armour Shares Look Stretched. The company beat modest expectations but it has yet to prove that its turnaround plan is working. Under Armour is making an impressive comeback. Can that continue once it rejoins the varsity squad?\"\n\nStock Prediction(s):", "Prediction": "\n- Under Armour, Inc. (NYSE: UA) will continue to increase because their turnaround plan is working, and they have yet to prove that it is not working.\n- Nike, Inc. (NYSE: NKE) will decrease because they are a direct competitor of Under Armour.", "price_info": {"UA": {"company": "", "ticker": "UA", "move": "up", "prices": [18.87, 19.05]}, "NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [141.0624, 141.44]}}}, {"link": "https://www.wsj.com/articles/journalist-group-scraps-coronavirus-panel-after-flak-over-huawei-sponsorship-11589384096", "title": "Star-Studded Coronavirus Panel Canceled After Flak Over Huawei Sponsorship", "date": "2020-05-13 12:58", "summary": "National Association of Black Journalists cancels webinar on impact on minorities of false misinformation about pandemic. An effort by Huawei Technologies Co. to dip its toe into the stormy waters of a U.S. political debate backfired after organizers canceled a star-studded online panel sponsored by the Chinese company to discuss the coronavirus and its impact on minority communities.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Star-Studded Coronavirus Panel Canceled After Flak Over Huawei Sponsorship. National Association of Black Journalists cancels webinar on impact on minorities of false misinformation about pandemic. An effort by Huawei Technologies Co. to dip its toe into the stormy waters of a U.S. political debate backfired after organizers canceled a star-studded online panel sponsored by the Chinese company to discuss the coronavirus and its impact on minority communities.\"\n\nStock Prediction(s):", "Prediction": "\n- Huawei Technologies Co. Ltd. (SHE: 002502) will decrease because their name was dragged through the mud in relation to this event.\n- Apple Inc. (NASDAQ: AAPL) will increase because they have been largely unaffected by the negative press around Huawei.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [304.8026, 304.2675]}}}, {"link": "https://www.wsj.com/articles/treasury-to-sell-226-billion-in-debt-11550769232", "title": "Treasury to Sell $226 Billion in Debt", "date": "2019-02-21 12:13", "summary": "U.S. Treasury Department's auctions planned for next week range from 13-week bills to seven-year notes. The U.S. Treasury Department will auction $226 billion in securities next week, comprising $178 billion in new debt and $48 billion in previously sold debt. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury to Sell $226 Billion in Debt. U.S. Treasury Department's auctions planned for next week range from 13-week bills to seven-year notes. The U.S. Treasury Department will auction $226 billion in securities next week, comprising $178 billion in new debt and $48 billion in previously sold debt. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Treasury Department will auction off $226 billion in securities next week, and this will have a positive effect on the stock prices of the companies that are involved in this process.\n- The U.S. Treasury Department will auction off $226 billion in securities next week, and this will have a negative effect on the stock prices of the companies that are involved in this process.", "price_info": {}}, {"link": "https://www.wsj.com/articles/florida-power-light-to-build-worlds-largest-solar-powered-battery-system-11553783071", "title": "FP&L to Build World's Largest Solar-Powered Battery System", "date": "2019-03-28 15:14", "summary": "Utility company says it will be four times larger than any existing battery. Florida Power & Light said it plans to build the world's largest battery, which would collect electricity from solar panels during the day and discharge it as needed during periods of high power demand.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FP&L to Build World's Largest Solar-Powered Battery System. Utility company says it will be four times larger than any existing battery. Florida Power & Light said it plans to build the world's largest battery, which would collect electricity from solar panels during the day and discharge it as needed during periods of high power demand.\"\n\nStock Prediction(s):", "Prediction": "\n- Florida Power & Light Co (NYSE: FP&L) will increase because they are building the world's largest solar-powered battery system.\n- SunPower Corporation (NASDAQ: SPWR) will increase because they are a supplier of solar panels for the battery system.\n- Tesla, Inc. (NASDAQ: TSLA) will decrease because they are a competitor of Florida Power & Light.", "price_info": {"SPWR": {"company": "", "ticker": "SPWR", "move": "up", "prices": [6.43, 6.37]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [278.8, 279.07]}}}, {"link": "https://www.wsj.com/articles/glass-of-weedkiller-is-half-empty-for-bayer-11557852625", "title": "Glass of Weedkiller Is Half Empty for Bayer", "date": "2019-05-14 12:50", "summary": "Lawyers for Bayer probably shouldn't drink glyphosate, but the sentiment is hard to combat. Defense lawyers for chemical giant Bayer probably aren't familiar with the uniquely Teutonic word backpfeifengesicht, but executives back in Germany are.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Glass of Weedkiller Is Half Empty for Bayer. Lawyers for Bayer probably shouldn't drink glyphosate, but the sentiment is hard to combat. Defense lawyers for chemical giant Bayer probably aren't familiar with the uniquely Teutonic word backpfeifengesicht, but executives back in Germany are.\"\n\nStock Prediction(s):", "Prediction": "\n- Bayer Aktiengesellschaft (OTC: BAYRY) will decrease because of the negative sentiment around their product.\n- Monsanto Company (NYSE: MON) will decrease because of the negative sentiment around their product.", "price_info": {"MON": {"company": "", "ticker": "MON", "move": "down"}}}, {"link": "https://www.wsj.com/articles/ge-projects-coronavirus-hit-in-first-quarter-backs-full-year-goals-11583324889", "title": "GE Projects Coronavirus Hit in First Quarter", "date": "2020-03-04 15:14", "summary": "Conglomerate sees virus reducing quarterly cash flow by up to $500 million. General Electric Co. said the coronavirus epidemic would reduce the company's first-quarter free cash flow by $300 million to $500 million, but backed its full-year target for the closely watched metric.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GE Projects Coronavirus Hit in First Quarter. Conglomerate sees virus reducing quarterly cash flow by up to $500 million. General Electric Co. said the coronavirus epidemic would reduce the company's first-quarter free cash flow by $300 million to $500 million, but backed its full-year target for the closely watched metric.\"\n\nStock Prediction(s):", "Prediction": "\n- GE will decrease because the coronavirus is reducing their quarterly cash flow.", "price_info": {}}, {"link": "https://www.wsj.com/articles/square-cfo-bitcoin-afterpay-cashapp-11635359050", "title": "Square Inc.'s CFO Talks Bitcoin, Afterpay and Cash App", "date": "2021-10-28 12:00", "summary": "Amrita Ahuja believes that the internet is likely to have a 'native' currency, and that bitcoin is the strongest contender.. Square Inc. started out in 2009 as a payment-services provider, enabling small businesses to process card payments with inexpensive white card readers and tablets. Since then, the Jack Dorsey-led company has added more services for businesses, a digital-payments service for consumers known as Cash App, a payments platform for artists and a developer platform that plans to build a decentralized bitcoin exchange.", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Square Inc.'s CFO Talks Bitcoin, Afterpay and Cash App. Amrita Ahuja believes that the internet is likely to have a 'native' currency, and that bitcoin is the strongest contender.. Square Inc. started out in 2009 as a payment-services provider, enabling small businesses to process card payments with inexpensive white card readers and tablets. Since then, the Jack Dorsey-led company has added more services for businesses, a digital-payments service for consumers known as Cash App, a payments platform for artists and a developer platform that plans to build a decentralized bitcoin exchange.\"\n\nStock Prediction(s):", "Prediction": "\n- Square Inc. (NYSE: SQ) will increase because they are expanding their services to include a bitcoin exchange.\n- Bitcoin (BTC) will increase because Square Inc. is backing it, and it is likely to become the 'native' currency of the internet.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "up"}, "SQ": {"company": "", "ticker": "SQ", "move": "up", "prices": [256.6723, 256.325]}}}, {"link": "https://www.wsj.com/articles/united-airlines-removes-max-from-schedules-until-june-11576861200", "title": "United Removes 737 MAX From Schedules Until June", "date": "2019-12-20 12:01", "summary": "Boeing recently paused production of best-selling jet as recertification timeline slips. ", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"United Removes 737 MAX From Schedules Until June. Boeing recently paused production of best-selling jet as recertification timeline slips. \"\n\nStock Prediction(s):", "Prediction": "\n- Boeing (NYSE: BA) will increase because they have a best-selling jet that has been taken out of schedules, and they are only waiting for regulatory approval before being deployed.\n- United Airlines (NYSE: UAL) will increase because they are a direct competitor of Boeing.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [329.295, 330.3049]}, "UAL": {"company": "", "ticker": "UAL", "move": "up", "prices": [89.51, 89.66]}}}, {"link": "https://www.wsj.com/articles/the-key-to-getting-people-to-be-safer-online-make-the-appeals-more-personal-11623085201", "title": "The Key to Getting People to Be Safer Online: Make the Appeals More Personal", "date": "2021-06-07 13:00", "summary": "The nudges we currently use to prod people to use stronger passwords are aimed at the 'average' user. But few people are average.. Many of us know that strong passwords are crucial protection against hackers, yet many people still routinely use weak ones. So, how can they be encouraged to create stronger passwords? Our research suggests the answer is to make the appeal more personal.", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Key to Getting People to Be Safer Online: Make the Appeals More Personal. The nudges we currently use to prod people to use stronger passwords are aimed at the 'average' user. But few people are average.. Many of us know that strong passwords are crucial protection against hackers, yet many people still routinely use weak ones. So, how can they be encouraged to create stronger passwords? Our research suggests the answer is to make the appeal more personal.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because they are working on a project to make the appeals more personal.\n- Google, Inc. (NASDAQ: GOOGL) will increase because they are working on a project to make the appeals more personal.\n- Apple, Inc. (NASDAQ: AAPL) will increase because they are working on a project to make the appeals more personal.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "up", "prices": [335.95, 337.06]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2382.0001, 2401.27]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [125.0791, 125.6803]}}}, {"link": "https://www.wsj.com/articles/inflation-pops-up-but-will-it-stick-around-11599841833", "title": "Inflation Pops Up, But Will It Stick Around?", "date": "2020-09-11 12:30", "summary": "That will depend on how sustainable the rebound in the economy proves to be. With the Covid-19 crisis, it is harder than ever to precisely gauge what inflation is doing right now. But it is clear enough that it has been heading back up.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Inflation Pops Up, But Will It Stick Around?. That will depend on how sustainable the rebound in the economy proves to be. With the Covid-19 crisis, it is harder than ever to precisely gauge what inflation is doing right now. But it is clear enough that it has been heading back up.\"\n\nStock Prediction(s):", "Prediction": "\n- The overall market will decrease because of the potential for inflation.\n- The companies that will be most affected by inflation are those that produce goods that are directly impacted by it, such as basic materials and food.", "price_info": {}}, {"link": "https://www.wsj.com/articles/speak-no-evil-of-the-s-p-500s-neverending-records-11630590653", "title": "Speak No Evil of the S&P 500's Neverending Records", "date": "2021-09-02 09:53", "summary": "Investors buying stocks no matter what shouldn't fool themselves that the future will deliver the chunky returns of the past decade. The S&P 500 is like the three wise monkeys: See no evil, hear no evil, speak no evil. Whatever happens, it just goes up. The market has gone up almost in a straight line since November despite a troubling list of events that could each have justified at least a 5% correction. Investors are incredibly resilient.", "categories": [["Markets", "Streetwise"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/streetwise?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Speak No Evil of the S&P 500's Neverending Records. Investors buying stocks no matter what shouldn't fool themselves that the future will deliver the chunky returns of the past decade. The S&P 500 is like the three wise monkeys: See no evil, hear no evil, speak no evil. Whatever happens, it just goes up. The market has gone up almost in a straight line since November despite a troubling list of events that could each have justified at least a 5% correction. Investors are incredibly resilient.\"\n\nStock Prediction(s):", "Prediction": "\n- The S&P 500 will continue to go up because investors are resilient and believe that the future will deliver the same chunky returns as the past decade.\n- The S&P 500 will correct because there are a lot of troubling events that have not been resolved yet.", "price_info": {}}, {"link": "https://www.wsj.com/articles/shell-can-keep-doing-well-by-doing-good-11572538306", "title": "Shell Can Keep Doing Well by Doing Good", "date": "2019-10-31 12:11", "summary": "Energy giant's positioning as a lower-carbon player has helped it beat peers. Thursday's share drop looks like a buying opportunity.. Royal Dutch Shell reported third-quarter results that beat expectations on earnings and cash flow despite low oil and gas prices but warned that it may take longer to complete its $25 billion share-buyback program.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Shell Can Keep Doing Well by Doing Good. Energy giant's positioning as a lower-carbon player has helped it beat peers. Thursday's share drop looks like a buying opportunity.. Royal Dutch Shell reported third-quarter results that beat expectations on earnings and cash flow despite low oil and gas prices but warned that it may take longer to complete its $25 billion share-buyback program.\"\n\nStock Prediction(s):", "Prediction": "\n- Shell (NYSE: RDS.A) will increase because they are a lower-carbon player and they have beaten peers.\n- Exxon Mobil (NYSE: XOM) will decrease because they are not a lower-carbon player and they have not beaten peers.", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [67.28, 67.32]}}}, {"link": "https://www.wsj.com/articles/uaw-board-elects-fourth-president-in-three-years-11624898811", "title": "UAW Board Elects Fourth President in Three Years", "date": "2021-06-28 13:28", "summary": "Finance chief Ray Curry gets top job, as auto union tries to overcome a corruption scandal and address the industry's shift to electric vehicles. The United Auto Workers' board elected a new president Monday, as the union looks to overcome a corruption scandal and tries to navigate disruption playing out in the car business.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"UAW Board Elects Fourth President in Three Years. Finance chief Ray Curry gets top job, as auto union tries to overcome a corruption scandal and address the industry's shift to electric vehicles. The United Auto Workers' board elected a new president Monday, as the union looks to overcome a corruption scandal and tries to navigate disruption playing out in the car business.\"\n\nStock Prediction(s):", "Prediction": "\n- The UAW will increase because they have a new president, and they are trying to overcome a corruption scandal.\n- Ford Motor Company (NYSE: F) will increase because the UAW is their main labor union.\n- General Motors Company (NYSE: GM) will increase because the UAW is their main labor union.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will increase because the UAW is their main labor union.", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [15.04, 14.95]}, "GM": {"company": "", "ticker": "GM", "move": "up", "prices": [58.81, 58.595]}, "FCAU": {"company": "", "ticker": "FCAU", "move": "up"}}}, {"link": "https://www.wsj.com/articles/weak-oversight-plagues-audits-of-billions-in-private-assets-11628847000", "title": "Weak Oversight Plagues Audits of Billions in Private Assets", "date": "2021-08-13 12:17", "summary": "Self-regulatory audit system fails to safeguard charities, pension funds and private companies, a WSJ analysis finds. Six months before Los Angeles-based Shepherd University collapsed into bankruptcy in 2017, accounting firm BW CPA Group Inc. gave the school's finances a clean bill of health.", "categories": [["WSJ News Exclusive", "Finance"]], "category_links": ["https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Weak Oversight Plagues Audits of Billions in Private Assets. Self-regulatory audit system fails to safeguard charities, pension funds and private companies, a WSJ analysis finds. Six months before Los Angeles-based Shepherd University collapsed into bankruptcy in 2017, accounting firm BW CPA Group Inc. gave the school's finances a clean bill of health.\"\n\nStock Prediction(s):", "Prediction": "\n- Shepherd University (OTCQB: SHRP) will increase because it was revealed that the accounting firm gave them a clean bill of health, and investors were not aware of the financial troubles the school was in.\n- BW CPA Group Inc. (OTCQB: BWCP) will decrease because they were responsible for auditing the school, and they gave them a clean bill of health even though the school was in financial trouble.", "price_info": {}}, {"link": "https://www.wsj.com/articles/health-care-investor-makes-new-bankruptcy-bid-for-bay-area-hospital-11584477661", "title": "Health-Care Investor Makes New Bankruptcy Bid for Bay Area Hospital", "date": "2020-03-18 10:18", "summary": "Failed suitor for Verity Health's Seton Medical Center floats $50 million cash offer, says owner is blocking it from bidding. Health-care company Strategic Global Management Inc. said it would pay $50 million in cash for two bankrupt Bay Area hospitals owned by Verity Health System of California Inc. but is being blocked by the owner from bidding on the properties.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Health-Care Investor Makes New Bankruptcy Bid for Bay Area Hospital. Failed suitor for Verity Health's Seton Medical Center floats $50 million cash offer, says owner is blocking it from bidding. Health-care company Strategic Global Management Inc. said it would pay $50 million in cash for two bankrupt Bay Area hospitals owned by Verity Health System of California Inc. but is being blocked by the owner from bidding on the properties.\"\n\nStock Prediction(s):", "Prediction": "\n- Verity Health System of California Inc. (OTC: VRTY) will increase because a new investor is interested in the company and is willing to pay $50 million cash.\n- HCA Healthcare Inc (NYSE: HCA) will decrease because they are a direct competitor of Verity Health System of California Inc.", "price_info": {"HCA": {"company": "", "ticker": "HCA", "move": "down", "prices": [63.5599, 62.96]}}}, {"link": "https://www.wsj.com/articles/u-s-government-bonds-fall-ahead-of-fed-minutes-11547048526", "title": "Treasury Yields Rise Ahead of Fed Minutes", "date": "2019-01-09 10:42", "summary": "Bond yields are on track to notch their fourth straight advance. U.S. government-bond prices weakened Wednesday ahead of the release of minutes from the Federal Reserve's December meeting and hopes of progress on the U.S. and China's trade talks.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury Yields Rise Ahead of Fed Minutes. Bond yields are on track to notch their fourth straight advance. U.S. government-bond prices weakened Wednesday ahead of the release of minutes from the Federal Reserve's December meeting and hopes of progress on the U.S. and China's trade talks.\"\n\nStock Prediction(s):", "Prediction": "\n- The yield on the 10-year Treasury note will continue to rise because the market expects the Fed to hike rates in 2019.\n- The yield on the 2-year Treasury note will continue to rise because the market expects the Fed to hike rates in 2019.\n- The yield on the 30-year Treasury note will continue to rise because the market expects the Fed to hike rates in 2019.", "price_info": {}}, {"link": "https://www.wsj.com/articles/credit-suisse-chief-faces-spy-scandal-aftermath-without-trusted-adviser-11570023136", "title": "Credit Suisse Chief Faces Spy Scandal Aftermath Without Trusted Adviser", "date": "2019-10-02 09:32", "summary": "Tidjane Thiam leans heavily on a close inner circle to enforce and execute strategy at Switzerland's second-biggest bank. Tidjane Thiam arrived at Credit Suisse Group AG in 2015 and quickly established a tight inner circle of trusted lieutenants as he set about trying to revive the ailing Swiss lender.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Credit Suisse Chief Faces Spy Scandal Aftermath Without Trusted Adviser. Tidjane Thiam leans heavily on a close inner circle to enforce and execute strategy at Switzerland's second-biggest bank. Tidjane Thiam arrived at Credit Suisse Group AG in 2015 and quickly established a tight inner circle of trusted lieutenants as he set about trying to revive the ailing Swiss lender.\"\n\nStock Prediction(s):", "Prediction": "\n- Tidjane Thiam will leave Credit Suisse because he is unable to execute strategy without his close inner circle.\n- Credit Suisse will decrease because they will be unable to execute strategy without Tidjane Thiam.", "price_info": {}}, {"link": "https://www.wsj.com/articles/daycare-centers-are-very-low-risk-for-covid-19-transmission-study-says-11602699914", "title": "Day-Care Centers Are Very Low Risk for Covid-19 Transmission, Study Says", "date": "2020-10-14 14:25", "summary": "Paper adds new evidence that young children aren't major vectors in coronavirus transmission. Children in day-care programs present virtually no risk of transmitting Covid-19 to adults, according to a new Yale University study of more than 57,000 U.S. child-care providers.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Day-Care Centers Are Very Low Risk for Covid-19 Transmission, Study Says. Paper adds new evidence that young children aren't major vectors in coronavirus transmission. Children in day-care programs present virtually no risk of transmitting Covid-19 to adults, according to a new Yale University study of more than 57,000 U.S. child-care providers.\"\n\nStock Prediction(s):", "Prediction": "\n- None", "price_info": {}}, {"link": "https://www.wsj.com/articles/the-battle-to-lure-back-premium-travellers-has-begun-11624977777", "title": "The Battle to Lure Back Premium Travelers Has Begun", "date": "2021-06-29 10:42", "summary": "One reason for United Airlines' big move to renew its fleet may be the need to give its most lucrative clients a reason to leave home. Even as tourists fill U.S. planes again, business travelers have been slow to return to their old habits. Airlines may be willing to spend heavily to speed things up.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Battle to Lure Back Premium Travelers Has Begun. One reason for United Airlines' big move to renew its fleet may be the need to give its most lucrative clients a reason to leave home. Even as tourists fill U.S. planes again, business travelers have been slow to return to their old habits. Airlines may be willing to spend heavily to speed things up.\"\n\nStock Prediction(s):", "Prediction": "\n- United Airlines Holdings, Inc. (NYSE: UAL) will increase because they are renewing their fleet and they need to give their most lucrative clients a reason to come back.\n- American Airlines Group Inc. (NASDAQ: AAL) will decrease because they are not renewing their fleet and they are not doing as well as United Airlines.\n- Delta Air Lines, Inc. (NYSE: DAL) will decrease because they are not renewing their", "price_info": {"UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [52.79, 52.7489]}, "DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [43.265, 43.185]}, "AAL": {"company": "", "ticker": "AAL", "move": "down", "prices": [21.2301, 21.235]}}}, {"link": "https://www.wsj.com/articles/the-bottom-line-on-chromebooks-11602616153", "title": "The Bottom Line on Chromebooks", "date": "2020-10-13 15:09", "summary": "School-driven demand for cheap laptops boosts PC sales again, but margins will likely take a hit. For PC makers, a business propped up by Chromebooks is very definitely a mixed blessing.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Bottom Line on Chromebooks. School-driven demand for cheap laptops boosts PC sales again, but margins will likely take a hit. For PC makers, a business propped up by Chromebooks is very definitely a mixed blessing.\"\n\nStock Prediction(s):", "Prediction": "\n- Acer Inc (TPE: 2353) will increase because Chromebooks are popular in the education market, and Acer is one of the leading providers of Chromebooks.\n- Dell Technologies Inc. (NYSE: DVMT) will increase because Chromebooks are popular in the education market, and Dell is one of the leading providers of Chromebooks.\n- HP Inc. (NYSE: HPQ) will increase because Chromebooks are popular in the education market, and HP", "price_info": {"DVMT": {"company": "", "ticker": "DVMT", "move": "up"}, "HPQ": {"company": "", "ticker": "HPQ", "move": "up", "prices": [19.77, 19.7]}}}, {"link": "https://www.wsj.com/articles/in-gannett-proxy-fight-iss-adviser-backs-one-digital-first-nominee-11556796345", "title": "In Gannett Proxy Fight, ISS Adviser Backs One Digital First Nominee", "date": "2019-05-02 12:25", "summary": "ISS said electing one of Digital First's nominees will ensure Gannett properly considers Digital First's unsolicited January bid. Digital First Media, the hedge fund-backed media company pushing Gannett Co. to sell itself, picked up some support as it seeks board seats at the USA Today publisher in a proxy vote this month.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"In Gannett Proxy Fight, ISS Adviser Backs One Digital First Nominee. ISS said electing one of Digital First's nominees will ensure Gannett properly considers Digital First's unsolicited January bid. Digital First Media, the hedge fund-backed media company pushing Gannett Co. to sell itself, picked up some support as it seeks board seats at the USA Today publisher in a proxy vote this month.\"\n\nStock Prediction(s):", "Prediction": "\n- Gannett Co. (NYSE: GCI) will increase because they are being pressured to sell themselves, and Digital First Media is a major player in the media industry.\n- Meredith Corporation (NYSE: MDP) will increase because they are a potential buyer of Gannett Co.\n- Apollo Global Management LLC (NYSE: APO) will increase because they are a major shareholder in Digital First Media.", "price_info": {"GCI": {"company": "", "ticker": "GCI", "move": "up", "prices": [9.335, 9.32]}, "MDP": {"company": "", "ticker": "MDP", "move": "up", "prices": [59.26, 59.08]}, "APO": {"company": "", "ticker": "APO", "move": "up", "prices": [33.15, 33]}}}, {"link": "https://www.wsj.com/articles/lululemon-athletica-names-new-cfo-11605896445", "title": "Lululemon Names New CFO", "date": "2020-11-20 13:20", "summary": "Meghan Frank, who shared the role of interim finance chief with a colleague, will become sole CFO. Lululemon Athletica Inc. named a new chief financial officer Friday, selecting Meghan Frank, one of the interim CFOs the athleisure-wear company named in April.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Lululemon Names New CFO. Meghan Frank, who shared the role of interim finance chief with a colleague, will become sole CFO. Lululemon Athletica Inc. named a new chief financial officer Friday, selecting Meghan Frank, one of the interim CFOs the athleisure-wear company named in April.\"\n\nStock Prediction(s):", "Prediction": "\n- Lululemon Athletica Inc. (NASDAQ: LULU) will increase because they have a new CFO.\n- Nike Inc. (NYSE: NKE) will decrease because Lululemon is a direct competitor of Nike.", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [133.048, 132.928]}, "LULU": {"company": "", "ticker": "LULU", "move": "up", "prices": [349.25, 348.43]}}}, {"link": "https://www.wsj.com/articles/cybersecurity-firm-crowdstrike-prices-ipo-above-expected-range-11560313619", "title": "Cybersecurity Firm CrowdStrike Prices IPO Above Expected Range", "date": "2019-06-12 15:54", "summary": "Startup that revealed hacking against the Democratic National Committee is valued at $6.8 billion and previously raised $481 million in venture capital. Cybersecurity company CrowdStrike Holdings Inc. priced its initial public offering above its expected price range, raising $612 million and valuing the company at $6.8 billion, if underwriters exercise all their options to purchase shares.", "categories": [["Markets", "Stocks", "IPOs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb", "https://www.wsj.com/news/types/ipos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Cybersecurity Firm CrowdStrike Prices IPO Above Expected Range. Startup that revealed hacking against the Democratic National Committee is valued at $6.8 billion and previously raised $481 million in venture capital. Cybersecurity company CrowdStrike Holdings Inc. priced its initial public offering above its expected price range, raising $612 million and valuing the company at $6.8 billion, if underwriters exercise all their options to purchase shares.\"\n\nStock Prediction(s):", "Prediction": "\n- CrowdStrike Holdings Inc. (NASDAQ: CRWD) will increase because they are a cybersecurity firm and their IPO was successful.\n- Palo Alto Networks Inc. (NYSE: PANW) will decrease because they are a cybersecurity firm and their IPO was not as successful.", "price_info": {"PANW": {"company": "", "ticker": "PANW", "move": "down", "prices": [203.5, 203.5]}, "CRWD": {"company": "", "ticker": "CRWD", "move": "up", "prices": [58.89, 59.2]}}}, {"link": "https://www.wsj.com/articles/coca-cola-posts-higher-quarterly-sales-11580387057", "title": "Coca-Cola Posts Higher Sales", "date": "2020-01-30 14:29", "summary": "The beverage giant will reopen some China factories amid coronavirus outbreak. Coca-Cola Co. reported higher sales that beat analysts' estimates, and said it was working with Chinese authorities to reopen factories that faced extended downtime amid the country's health crisis.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coca-Cola Posts Higher Sales. The beverage giant will reopen some China factories amid coronavirus outbreak. Coca-Cola Co. reported higher sales that beat analysts' estimates, and said it was working with Chinese authorities to reopen factories that faced extended downtime amid the country's health crisis.\"\n\nStock Prediction(s):", "Prediction": "\n- Coca-Cola Co. (NYSE: KO) will increase because they have higher sales and are reopening factories in China.\n- PepsiCo, Inc. (NASDAQ: PEP) will decrease because they are also working on a vaccine, but they are a direct competitor of Coca-Cola.", "price_info": {"KO": {"company": "", "ticker": "KO", "move": "up", "prices": [58.6103, 58.9]}, "PEP": {"company": "", "ticker": "PEP", "move": "down", "prices": [142.675, 143.375]}}}, {"link": "https://www.wsj.com/articles/u-s-sanctions-on-hong-kong-security-law-puts-banks-in-a-quandary-11594825638", "title": "U.S. Sanctions on Hong Kong Security Law Put Banks in a Quandary", "date": "2020-07-15 11:07", "summary": "International businesses face conflicting rules of both Washington's coming sanctions regime and the territory's broad new national-security law. As the U.S. moves to punish Chinese officials involved in the clampdown on Hong Kong, international banks and other businesses have a problem: how to obey conflicting rules of both Washington's coming sanctions regime and the territory's broad new national-security law.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Sanctions on Hong Kong Security Law Put Banks in a Quandary. International businesses face conflicting rules of both Washington's coming sanctions regime and the territory's broad new national-security law. As the U.S. moves to punish Chinese officials involved in the clampdown on Hong Kong, international banks and other businesses have a problem: how to obey conflicting rules of both Washington's coming sanctions regime and the territory's broad new national-security law.\"\n\nStock Prediction(s):", "Prediction": "\n- HSBC Holdings plc (NYSE: HSBC) will decrease because they have a lot of business in Hong Kong, and they may have to pull out because of the new sanctions.\n- Standard Chartered plc (LON: STAN) will decrease because they have a lot of business in Hong Kong, and they may have to pull out because of the new sanctions.\n- Bank of East Asia Ltd. (HKG: 0023) will decrease because they", "price_info": {"HSBC": {"company": "", "ticker": "HSBC", "move": "down", "prices": [24.23, 24.215]}}}, {"link": "https://www.wsj.com/articles/u-s-offers-afghanistan-3-million-j-j-covid-19-vaccine-doses-11624551266", "title": "U.S. Offers Afghanistan 3 Million Covid Vaccine Doses", "date": "2021-06-24 12:32", "summary": "Washington pledges to ship single-dose shots, ahead of President Biden's meeting with Afghan leaders. KABUL-The Biden administration plans to deliver three million doses of the Johnson & Johnson coronavirus vaccine next week to Afghanistan, which is battling its deadliest wave of the pandemic amid a rapidly deteriorating security situation.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Offers Afghanistan 3 Million Covid Vaccine Doses. Washington pledges to ship single-dose shots, ahead of President Biden's meeting with Afghan leaders. KABUL-The Biden administration plans to deliver three million doses of the Johnson & Johnson coronavirus vaccine next week to Afghanistan, which is battling its deadliest wave of the pandemic amid a rapidly deteriorating security situation.\"\n\nStock Prediction(s):", "Prediction": "\n- Johnson & Johnson (NYSE: JNJ) will increase because they are being deployed to Afghanistan.\n- AstraZeneca plc (NASDAQ: AZN) will decrease because they are a direct competitor of Johnson & Johnson.\n- Pfizer Inc (NYSE: PFE) will decrease because they are a direct competitor of Johnson & Johnson.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are a direct competitor of Johnson &", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "up", "prices": [163.04, 163.09]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [39.2, 39.195]}, "AZN": {"company": "", "ticker": "AZN", "move": "down", "prices": [58.3972, 58.415]}, "MRNA": {"company": "", "ticker": "MRNA", "move": "down", "prices": [218.53, 219.5805]}}}, {"link": "https://www.wsj.com/articles/oil-demand-takes-a-hit-from-cooling-economic-growth-11560499201", "title": "Oil Demand Takes a Hit From Cooling Economic Growth", "date": "2019-06-14 15:45", "summary": "IEA downgrades its forecast for global oil demand for a second straight month. A cooling global economy could mean slower oil demand growth in 2019 even while oil producers maintain plentiful supply, the International Energy Agency said Friday.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Demand Takes a Hit From Cooling Economic Growth. IEA downgrades its forecast for global oil demand for a second straight month. A cooling global economy could mean slower oil demand growth in 2019 even while oil producers maintain plentiful supply, the International Energy Agency said Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because their main product is oil, and if the global economy is cooling then demand for oil will decrease as well.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because their main product is oil, and if the global economy is cooling then demand for oil will decrease as well.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because their main product is oil, and", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [120.9, 120.81]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [74.38, 74.335]}}}, {"link": "https://www.wsj.com/articles/big-tech-wants-you-to-live-in-a-virtual-world-prepare-for-real-problems-11630056626", "title": "The Real Problems of Living in a Virtual World", "date": "2021-08-30 13:23", "summary": "Facebook and other companies view the 'metaverse' as the next big thing, but user discretion is advised. Heard of the \"metaverse\" lately? It has been hard not to.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Real Problems of Living in a Virtual World. Facebook and other companies view the 'metaverse' as the next big thing, but user discretion is advised. Heard of the \"metaverse\" lately? It has been hard not to.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will increase because they are one of the companies investing in the metaverse.\n- Other companies that are investing in the metaverse will also increase in stock prices.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "up", "prices": [380.8306, 380.65]}}}, {"link": "https://www.wsj.com/articles/intel-to-release-neuromorphic-computing-system-11584540000", "title": "Intel to Release Neuromorphic-Computing System", "date": "2020-03-18 10:00", "summary": "Pohoiki Springs, an experimental system to be rolled out this month, mimics the way human brains work to do computations faster with less energy. Intel Corp. is releasing an experimental research system for neuromorphic computing, a cutting-edge method that simulates the way human brains work to perform computations faster, using significantly less energy.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Intel to Release Neuromorphic-Computing System. Pohoiki Springs, an experimental system to be rolled out this month, mimics the way human brains work to do computations faster with less energy. Intel Corp. is releasing an experimental research system for neuromorphic computing, a cutting-edge method that simulates the way human brains work to perform computations faster, using significantly less energy.\"\n\nStock Prediction(s):", "Prediction": "\n- Intel Corporation (NASDAQ: INTC) will increase because they are releasing a new product that is faster and uses less energy.\n- Nvidia Corporation (NASDAQ: NVDA) will decrease because they are a direct competitor of Intel.", "price_info": {"INTC": {"company": "", "ticker": "INTC", "move": "up", "prices": [48.63, 48.59]}, "NVDA": {"company": "", "ticker": "NVDA", "move": "down", "prices": [201.82, 203.9761]}}}, {"link": "https://www.wsj.com/articles/fasb-delays-implementation-of-accounting-standards-for-some-companies-11571253821", "title": "FASB Delays Implementation of Accounting Standards for Some Companies", "date": "2019-10-16 15:23", "summary": "Accounting standard-setter approved proposals extended deadlines over new rules on leasing, hedging, loans and insurance contracts. The Financial Accounting Standards Board has extended the implementation deadline for several accounting standards, giving many U.S. companies additional time to prepare.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"FASB Delays Implementation of Accounting Standards for Some Companies. Accounting standard-setter approved proposals extended deadlines over new rules on leasing, hedging, loans and insurance contracts. The Financial Accounting Standards Board has extended the implementation deadline for several accounting standards, giving many U.S. companies additional time to prepare.\"\n\nStock Prediction(s):", "Prediction": "\n- The delay of implementation will be good for companies who are not ready for the new standards, such as General Electric Company (NYSE: GE) and Honeywell International Inc. (NYSE: HON).\n- Companies who are ready for the new standards, such as Microsoft Corporation (NASDAQ: MSFT) and Amazon.com, Inc. (NASDAQ: AMZN), will not be affected.", "price_info": {"GE": {"company": "", "ticker": "GE", "move": null, "prices": [8.88, 8.89]}, "HON": {"company": "", "ticker": "HON", "move": null, "prices": [164.25, 164.1]}, "MSFT": {"company": "", "ticker": "MSFT", "move": null, "prices": [140.53, 140.54]}, "AMZN": {"company": "", "ticker": "AMZN", "move": null, "prices": [1783, 1785.85]}}}, {"link": "https://www.wsj.com/articles/london-stock-exchanges-future-depends-on-brussels-11582901598", "title": "London Stock Exchange's Future Depends on Brussels", "date": "2020-02-28 09:53", "summary": "Investors may be too relaxed about two European Union decisions that are crucial to the company's growth plans. London Stock Exchange Group's future isn't quite the sure thing investors seem to think.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"London Stock Exchange's Future Depends on Brussels. Investors may be too relaxed about two European Union decisions that are crucial to the company's growth plans. London Stock Exchange Group's future isn't quite the sure thing investors seem to think.\"\n\nStock Prediction(s):", "Prediction": "\n- LSEG plc (LSE: LSE) will decrease because the future of their company is uncertain.\n- Deutsche Boerse AG (OTC: DBOEY) will increase because they are LSEG's main competitor, and they are not facing the same uncertainty.", "price_info": {}}, {"link": "https://www.wsj.com/articles/toast-test-are-high-tech-toasters-worth-the-price-11581449564", "title": "Toast Test: Are High-Tech Toasters Worth the Price?", "date": "2020-02-11 14:32", "summary": "Do premium toasters-at premium prices-really yield a superior slice? We pitted six smart devices against a classic two-slice machine. THE CA-CHUNK of a triumphant toaster is one of the great All-American sounds. First sold in the 1890s, toasters predate even the advent of sliced bread, itself a response to a turn-of-the-century toasting craze. Most toasters do an adequate job, but since startup culture can't leave even the simplest devices alone, a new breed has popped up to disrupt the searing status quo.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Toast Test: Are High-Tech Toasters Worth the Price?. Do premium toasters-at premium prices-really yield a superior slice? We pitted six smart devices against a classic two-slice machine. THE CA-CHUNK of a triumphant toaster is one of the great All-American sounds. First sold in the 1890s, toasters predate even the advent of sliced bread, itself a response to a turn-of-the-century toasting craze. Most toasters do an adequate job, but since startup culture can't leave even the simplest devices alone, a new breed has popped up to disrupt the searing status quo.\"\n\nStock Prediction(s):", "Prediction": "\n- The high-tech toasters will increase in price because they are a better product.\n- The classic two-slice machine will decrease in price because it is an inferior product.", "price_info": {}}, {"link": "https://www.wsj.com/articles/shell-leaves-behind-its-century-old-dutch-identity-11636987120", "title": "Shell Leaves Behind Its Century-Old Dutch Identity", "date": "2021-11-15 10:39", "summary": "Oil giant breaks with Dutch roots as it seeks to pivot to greener energy. Royal Dutch Shell PLC's plan to consolidate its share structure, move its headquarters to London and drop Royal Dutch from its name would end its identity as an Anglo-Dutch company after more than a century.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Shell Leaves Behind Its Century-Old Dutch Identity. Oil giant breaks with Dutch roots as it seeks to pivot to greener energy. Royal Dutch Shell PLC's plan to consolidate its share structure, move its headquarters to London and drop Royal Dutch from its name would end its identity as an Anglo-Dutch company after more than a century.\"\n\nStock Prediction(s):", "Prediction": "\n- Shell (NYSE: RDS.A) will decrease because they are breaking away from their Dutch identity.\n- Exxon Mobil (NYSE: XOM) will increase because they are a direct competitor of Shell, and they have not made any similar moves to break away from their identity.", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [63.8536, 64.08]}}}, {"link": "https://www.wsj.com/articles/discovery-revenue-falls-as-coronavirus-pandemic-hits-ad-revenue-11596629343", "title": "Discovery Revenue Falls as Covid-19 Pandemic Hits Ad Revenue", "date": "2020-08-05 09:50", "summary": "Revenue at parent company of networks HGTV, Food Network and TLC decreased by about 12% to $2.54 billion. Discovery Inc.'s revenue in the second quarter decreased by nearly 12%, as the coronavirus pandemic took a toll on the company's advertising business.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Discovery Revenue Falls as Covid-19 Pandemic Hits Ad Revenue. Revenue at parent company of networks HGTV, Food Network and TLC decreased by about 12% to $2.54 billion. Discovery Inc.'s revenue in the second quarter decreased by nearly 12%, as the coronavirus pandemic took a toll on the company's advertising business.\"\n\nStock Prediction(s):", "Prediction": "\n- Discovery Inc. (NASDAQ: DISCA) will decrease because their main source of revenue, advertising, is being impacted by the pandemic.\n- ViacomCBS Inc. (NYSE: VIAC) will decrease because their main source of revenue, advertising, is being impacted by the pandemic.\n- Comcast Corporation (NASDAQ: CMCSA) will decrease because their main source of revenue, advertising, is being impacted by the pandemic.", "price_info": {"VIAC": {"company": "", "ticker": "VIAC", "move": "down", "prices": [26.27, 26.33]}, "DISCA": {"company": "", "ticker": "DISCA", "move": "down", "prices": [21.335, 21.13]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "down", "prices": [42.755, 42.59]}}}, {"link": "https://www.wsj.com/articles/judges-approve-settlement-between-mckinsey-and-justice-department-11555523681", "title": "Judges Approve Settlement Between McKinsey and Justice Department", "date": "2019-04-17 13:54", "summary": "Consulting firm to pay $15 million as it settles with bankruptcy watchdog over allegations it failed to disclose conflicts. A panel of three judges approved a $15 million settlement between McKinsey & Co. and the Justice Department, resolving the government's allegations that the consulting firm didn't disclose conflicts of interest in bankruptcy cases it helped steer.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Judges Approve Settlement Between McKinsey and Justice Department. Consulting firm to pay $15 million as it settles with bankruptcy watchdog over allegations it failed to disclose conflicts. A panel of three judges approved a $15 million settlement between McKinsey & Co. and the Justice Department, resolving the government's allegations that the consulting firm didn't disclose conflicts of interest in bankruptcy cases it helped steer.\"\n\nStock Prediction(s):", "Prediction": "\n- McKinsey & Co. (NYSE: MCK) will increase because they have settled with the Justice Department and have been cleared of any wrong-doing.\n- Booz Allen Hamilton Holding Corporation (NYSE: BAH) will decrease because they are a direct competitor of McKinsey.", "price_info": {"MCK": {"company": "", "ticker": "MCK", "move": "up", "prices": [112.61, 112.49]}, "BAH": {"company": "", "ticker": "BAH", "move": "down", "prices": [56.95, 56.925]}}}, {"link": "https://www.wsj.com/articles/walmart-to-try-thinning-store-manager-ranks-11556807421", "title": "Walmart to Try Thinning Store Manager Ranks", "date": "2019-05-02 12:42", "summary": "In test, some stores have fewer, higher paid managers overseeing teams in an effort to give front-line workers more ownerships over their jobs. Walmart Inc. is testing a new store employee structure, in some cases using fewer midlevel, in-store managers to oversee workers while boosting pay and responsibilities for those roles.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Walmart to Try Thinning Store Manager Ranks. In test, some stores have fewer, higher paid managers overseeing teams in an effort to give front-line workers more ownerships over their jobs. Walmart Inc. is testing a new store employee structure, in some cases using fewer midlevel, in-store managers to oversee workers while boosting pay and responsibilities for those roles.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because they are trying to give their employees more ownership over their jobs.\n- Target Corporation (NYSE: TGT) will decrease because they are not trying to give their employees more ownership over their jobs.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [100.855, 100.815]}, "TGT": {"company": "", "ticker": "TGT", "move": "down", "prices": [76.9575, 76.7759]}}}, {"link": "https://www.wsj.com/articles/in-russia-agreement-breaks-you-11549386513", "title": "In Russia, Agreement Breaks You", "date": "2019-02-05 12:08", "summary": "Oil prices face pressure as dispute with OPEC seems to emerge over timing of production cuts. As those familiar with Russian history know, the October Revolution actually happened in November.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"In Russia, Agreement Breaks You. Oil prices face pressure as dispute with OPEC seems to emerge over timing of production cuts. As those familiar with Russian history know, the October Revolution actually happened in November.\"\n\nStock Prediction(s):", "Prediction": "\n- Lukoil PJSC (OTCMKTS: LUKOY) will increase because they are not part of OPEC, and they have a good relationship with Russia.\n- Rosneft PJSC (OTCMKTS: RNFTF) will increase because they are not part of OPEC, and they have a good relationship with Russia.\n- Gazprom PJSC (OTCMKTS: OGZPY) will increase because they are not part of", "price_info": {}}, {"link": "https://www.wsj.com/articles/fiat-chrysler-to-invest-4-5-billion-in-manufacturing-in-michigan-create-nearly-6-500-jobs-11551198601", "title": "Fiat Chrysler to Invest $4.5 Billion in Manufacturing in Michigan", "date": "2019-02-26 14:42", "summary": "Plans include $1.6 billion to build a Jeep factory in Detroit; auto maker to eliminate 1,370 jobs in Illinois. Fiat Chrysler Automobiles NV plans to spend $4.5 billion to expand factory production in Michigan, including a new Jeep assembly plant in Detroit, but also said Tuesday it will lay off workers at a plant in Illinois.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fiat Chrysler to Invest $4.5 Billion in Manufacturing in Michigan. Plans include $1.6 billion to build a Jeep factory in Detroit; auto maker to eliminate 1,370 jobs in Illinois. Fiat Chrysler Automobiles NV plans to spend $4.5 billion to expand factory production in Michigan, including a new Jeep assembly plant in Detroit, but also said Tuesday it will lay off workers at a plant in Illinois.\"\n\nStock Prediction(s):", "Prediction": "\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will increase because they are expanding production in Michigan.\n- Ford Motor Company (NYSE: F) will decrease because they are not expanding production in Michigan.", "price_info": {"FCAU": {"company": "", "ticker": "FCAU", "move": "up", "prices": [14.875, 14.94]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [8.91, 8.895]}}}, {"link": "https://www.wsj.com/articles/conagra-starts-to-thaw-out-11553183146", "title": "Conagra Starts to Thaw Out", "date": "2019-03-21 11:45", "summary": "Investors are reassured by strong results that Conagra can digest Pinnacle Foods. Conagra Brands got the chilliest of receptions three months ago, and no wonder.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Conagra Starts to Thaw Out. Investors are reassured by strong results that Conagra can digest Pinnacle Foods. Conagra Brands got the chilliest of receptions three months ago, and no wonder.\"\n\nStock Prediction(s):", "Prediction": "\n- Conagra Brands, Inc. (NYSE: CAG) will increase because they have strong results and are able to digest Pinnacle Foods.", "price_info": {"CAG": {"company": "", "ticker": "CAG", "move": "up", "prices": [25.5, 25.96]}}}, {"link": "https://www.wsj.com/articles/oil-drops-to-12-month-low-on-coronavirus-concerns-11582726174", "title": "Oil Falls to 12-Month Low on Coronavirus Concerns", "date": "2020-02-26 15:41", "summary": "Analysts slash demand forecasts for oil amid worries that the virus would stymie global demand. U.S. crude hit its lowest price in more than a year on Wednesday as concerns about the spread of the coronavirus outside China once again dragged oil markets down and began to affect operations of some key oil players in Europe.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Falls to 12-Month Low on Coronavirus Concerns. Analysts slash demand forecasts for oil amid worries that the virus would stymie global demand. U.S. crude hit its lowest price in more than a year on Wednesday as concerns about the spread of the coronavirus outside China once again dragged oil markets down and began to affect operations of some key oil players in Europe.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because of the fall in oil prices.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because of the fall in oil prices.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because of the fall in oil prices.\n- BP plc (NYSE: BP) will decrease because of the fall in oil prices.", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "down", "prices": [98.51, 98.16]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [53.12, 53.05]}, "BP": {"company": "", "ticker": "BP", "move": "down", "prices": [32.76, 32.7282]}}}, {"link": "https://www.wsj.com/articles/hollywood-stars-want-guarantees-their-films-will-play-in-theaters-11556809200", "title": "Hollywood Stars Want Guarantees Their Films Will Play in Theaters", "date": "2019-05-02 11:52", "summary": "Actors urge big-screen releases as Disney, WarnerMedia embrace streaming; Oscars eligibility at stake. To win the rights to a new movie starring Will Smith as Serena and Venus Williams's father, AT&T Inc.'s Warner Bros. had to agree to a nonnegotiable demand from the star, according to people familiar with the talks: The studio would release the film theatrically before streaming it online.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hollywood Stars Want Guarantees Their Films Will Play in Theaters. Actors urge big-screen releases as Disney, WarnerMedia embrace streaming; Oscars eligibility at stake. To win the rights to a new movie starring Will Smith as Serena and Venus Williams's father, AT&T Inc.'s Warner Bros. had to agree to a nonnegotiable demand from the star, according to people familiar with the talks: The studio would release the film theatrically before streaming it online.\"\n\nStock Prediction(s):", "Prediction": "\n- Disney (NYSE: DIS) will increase because they are embracing streaming, but they are still releasing films in theaters.\n- WarnerMedia (NYSE: T) will increase because they are embracing streaming, and they are releasing films in theaters.\n- Sony (NYSE: SNE) will decrease because they are not embracing streaming, and they are not releasing films in theaters.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "up", "prices": [133.6, 134.365]}, "T": {"company": "", "ticker": "T", "move": "up", "prices": [30.6906, 30.71]}, "SNE": {"company": "", "ticker": "SNE", "move": "down", "prices": [51.2, 51.34]}}}, {"link": "https://www.wsj.com/articles/2020-2021-capital-gains-and-dividend-tax-rates-11617907245", "title": "2020-2021 Capital Gains and Dividend Tax Rates", "date": "2021-04-08 14:40", "summary": "Most Popular News. For investors using taxable accounts-as opposed to tax-sheltered retirement accounts such as IRAs or 401(k)s-the tax law has special rules that offer benefits and pitfalls. Congress hasn't changed these rules recently.", "categories": [["Markets", "Personal Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/personal-finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"2020-2021 Capital Gains and Dividend Tax Rates. Most Popular News. For investors using taxable accounts-as opposed to tax-sheltered retirement accounts such as IRAs or 401(k)s-the tax law has special rules that offer benefits and pitfalls. Congress hasn't changed these rules recently.\"\n\nStock Prediction(s):", "Prediction": "\n- The tax rates for 2020-2021 will not have a significant impact on most stocks.\n- There may be a slight decrease in the value of stocks for investors who are in the higher tax brackets.\n- Investors who are in the lower tax brackets may see a slight increase in the value of their stocks.", "price_info": {}}, {"link": "https://www.wsj.com/articles/ge-prepares-for-the-next-rainy-day-11556636823", "title": "GE Prepares for the Next Rainy Day", "date": "2019-04-30 11:07", "summary": "The industrial conglomerate's performance was better than expected, but it is still burning through cash and cracks remain in aviation and power businesses. General Electric is making the most of a hard time. The industrial conglomerate boosted its cash position and improved operating performance during the first quarter, swinging to a quarterly profit. Although Chief Executive Officer Larry Culp's tone was cautious on the company's earnings call, investors mostly liked what they heard, and GE shares rose 5% in early trading.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GE Prepares for the Next Rainy Day. The industrial conglomerate's performance was better than expected, but it is still burning through cash and cracks remain in aviation and power businesses. General Electric is making the most of a hard time. The industrial conglomerate boosted its cash position and improved operating performance during the first quarter, swinging to a quarterly profit. Although Chief Executive Officer Larry Culp's tone was cautious on the company's earnings call, investors mostly liked what they heard, and GE shares rose 5% in early trading.\"\n\nStock Prediction(s):", "Prediction": "\n- GE will continue to rise because they are making the most of a hard time and their performance was better than expected.\n- Honeywell International Inc. (NYSE: HON) will decrease because they are a direct competitor of GE.\n- United Technologies Corporation (NYSE: UTX) will decrease because they are a direct competitor of GE.", "price_info": {"HON": {"company": "", "ticker": "HON", "move": "down", "prices": [173.64, 173.4]}, "UTX": {"company": "", "ticker": "UTX", "move": "down", "prices": [142.44, 142.24]}}}, {"link": "https://www.wsj.com/articles/u-s-budget-gap-nearly-tripled-in-first-11-months-of-fiscal-2020-11599847247", "title": "As Budget Gap Soars, Costs of Servicing Federal Debt Shrink", "date": "2020-09-11 15:31", "summary": "U.S. deficit nearly tripled in first 11 months of fiscal 2020, Treasury Department says, but low rates reduce net interest costs by more than 10%. WASHINGTON-The cost of servicing the nation's growing debt load is shrinking despite a historic rise in government red ink this year, suggesting the U.S. still has room to borrow to fight the coronavirus pandemic.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"As Budget Gap Soars, Costs of Servicing Federal Debt Shrink. U.S. deficit nearly tripled in first 11 months of fiscal 2020, Treasury Department says, but low rates reduce net interest costs by more than 10%. WASHINGTON-The cost of servicing the nation's growing debt load is shrinking despite a historic rise in government red ink this year, suggesting the U.S. still has room to borrow to fight the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. government will continue to borrow in order to finance the growing deficit, which will have a positive effect on the stock prices of companies such as Goldman Sachs Group Inc. (NYSE: GS) and JPMorgan Chase & Co. (NYSE: JPM).\n- The U.S. government will eventually have to raise interest rates in order to finance the growing deficit, which will have a negative effect on the stock prices of companies such as Goldman Sachs Group Inc", "price_info": {"GS": {"company": "", "ticker": "GS", "move": "up", "prices": [200.75, 200.92]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [100.98, 100.97]}}}, {"link": "https://www.wsj.com/articles/hyundai-merchant-marines-chief-to-step-down-11550764079", "title": "Hyundai Merchant Marine's Chief to Step Down", "date": "2019-02-21 10:48", "summary": "Decision comes amid pressure from top creditor KDB over failures in company's turnaround. ", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hyundai Merchant Marine's Chief to Step Down. Decision comes amid pressure from top creditor KDB over failures in company's turnaround. \"\n\nStock Prediction(s):", "Prediction": "\n- Hyundai Merchant Marine Co Ltd (011200.KS) will increase because the company's CEO is stepping down.\n- KDB Holdings Inc (002380.KS) will increase because they are the top creditor of Hyundai Merchant Marine.\n- Hanjin Shipping Co Ltd (006890.KS) will increase because they are a direct competitor of Hyundai Merchant Marine.", "price_info": {}}, {"link": "https://www.wsj.com/articles/trumps-businesses-face-debt-deadlines-amid-economic-slowdown-11602252225", "title": "Trump's Businesses Face Debt Deadlines Amid Economic Slowdown", "date": "2020-10-09 10:04", "summary": "The Trump Organization could see tougher terms on loans or have to sell assets to raise cash. The Trump Organization faces the prospect of paying more to borrow, getting smaller loans or selling some of its assets to manage more than $400 million of debt coming due on properties hit hard by the economic downturn.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump's Businesses Face Debt Deadlines Amid Economic Slowdown. The Trump Organization could see tougher terms on loans or have to sell assets to raise cash. The Trump Organization faces the prospect of paying more to borrow, getting smaller loans or selling some of its assets to manage more than $400 million of debt coming due on properties hit hard by the economic downturn.\"\n\nStock Prediction(s):", "Prediction": "\n- Trump's businesses will have to sell assets to pay off their debts, which will cause their stock prices to decrease.\n- Other businesses that are not related to Trump will have an increase in stock prices because the economy is slowing down.", "price_info": {}}, {"link": "https://www.wsj.com/articles/kendra-scott-on-curbside-jewelry-pickup-and-other-pandemic-business-strategies-11591032138", "title": "Jeweler Kendra Scott Discusses Pandemic Business Strategies", "date": "2020-06-01 14:12", "summary": "Austin entrepreneur discusses how the coronavirus has changed online shopping, and ways to help retailers make it through the crisis. Kendra Scott knows the challenges of working from home. The founder, chief executive and chairman of Kendra Scott LLC launched her eponymous jewelry business in 2002 with pieces she designed in her spare bedroom in Austin, Texas, three months after the birth of her first child.", "categories": [["Business", "Management", "Management & Careers"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/management?mod=breadcrumb", "https://www.wsj.com/news/types/boss-talk?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Jeweler Kendra Scott Discusses Pandemic Business Strategies. Austin entrepreneur discusses how the coronavirus has changed online shopping, and ways to help retailers make it through the crisis. Kendra Scott knows the challenges of working from home. The founder, chief executive and chairman of Kendra Scott LLC launched her eponymous jewelry business in 2002 with pieces she designed in her spare bedroom in Austin, Texas, three months after the birth of her first child.\"\n\nStock Prediction(s):", "Prediction": "\n- Kendra Scott LLC (private) will increase because they are a direct competitor of Tiffany & Co. (NYSE: TIF) and they have a better online presence.\n- Tiffany & Co. (NYSE: TIF) will decrease because they are a direct competitor of Kendra Scott LLC and they have a worse online presence.", "price_info": {"TIF": {"company": "", "ticker": "TIF", "move": "down", "prices": [128.2, 128.5]}}}, {"link": "https://www.wsj.com/articles/portugal-joins-negative-rates-club-with-benchmark-bond-11607450825", "title": "Portugal Joins Negative-Rates Club With Benchmark Bond", "date": "2020-12-08 13:07", "summary": "The country's 10-year government bond yield slips below zero, joining certain other European countries. Portugal's benchmark bond traded with a negative yield, signaling investors' increasingly relaxed attitudes toward a country that was once among the worst-hit by the European debt crisis.", "categories": [["Markets", "Stocks", "Europe Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb", "https://www.wsj.com/news/types/europe-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Portugal Joins Negative-Rates Club With Benchmark Bond. The country's 10-year government bond yield slips below zero, joining certain other European countries. Portugal's benchmark bond traded with a negative yield, signaling investors' increasingly relaxed attitudes toward a country that was once among the worst-hit by the European debt crisis.\"\n\nStock Prediction(s):", "Prediction": "\n- Portugal (OTCPK: PTGCY) will increase because they are now in the negative-rates club, and this signals investors' increasingly relaxed attitudes.\n- Spain (OTCPK: ESYPY) will increase because they are now in the negative-rates club, and this signals investors' increasingly relaxed attitudes.\n- Italy (OTCPK: ITLYY) will increase because they are now in the negative-rates club, and this signals", "price_info": {}}, {"link": "https://www.wsj.com/articles/planet-fitness-needs-to-flatten-more-curves-11607969275", "title": "Planet Fitness Needs to Flatten More Curves", "date": "2020-12-14 13:07", "summary": "The gym chain has survived in a disastrous year for competitors, but investors seem unaware that the pandemic has seriously dented its business prospects. Planet Fitness Inc. kicked off 2020 by announcing that it would sponsor the television show \"The Biggest Loser.\" Little did it know that Covid-19 would soon make that an apt label for itself-a crash diet that left its market value 70% lighter in less than a month.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Planet Fitness Needs to Flatten More Curves. The gym chain has survived in a disastrous year for competitors, but investors seem unaware that the pandemic has seriously dented its business prospects. Planet Fitness Inc. kicked off 2020 by announcing that it would sponsor the television show \"The Biggest Loser.\" Little did it know that Covid-19 would soon make that an apt label for itself-a crash diet that left its market value 70% lighter in less than a month.\"\n\nStock Prediction(s):", "Prediction": "\n- Planet Fitness, Inc. (NYSE: PLNT) will decrease because the pandemic has seriously dented its business prospects.", "price_info": {"PLNT": {"company": "", "ticker": "PLNT", "move": "down", "prices": [77.1, 77.16]}}}, {"link": "https://www.wsj.com/articles/facebook-takes-down-china-linked-hacking-campaign-targeting-uyghurs-11616608878", "title": "Facebook Takes Down China-Linked Hacking Campaign Targeting Uyghurs", "date": "2021-03-24 15:09", "summary": "The effort included setting up fake news sites and compromising real ones to infect people's devices. Facebook Inc. has taken down a network of China-based accounts being used to spread malware meant to spy on journalists and dissidents in the overseas Uyghur Muslim community, the company said on Wednesday.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Takes Down China-Linked Hacking Campaign Targeting Uyghurs. The effort included setting up fake news sites and compromising real ones to infect people's devices. Facebook Inc. has taken down a network of China-based accounts being used to spread malware meant to spy on journalists and dissidents in the overseas Uyghur Muslim community, the company said on Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc. (NASDAQ: FB) will increase because they are taking down malicious accounts and protecting their users.\n- Apple Inc. (NASDAQ: AAPL) will increase because they are also taking down malicious accounts and protecting their users.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are also taking down malicious accounts and protecting their users.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [282.07, 281.9]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [120.17, 120.095]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3085, 3086.585]}}}, {"link": "https://www.wsj.com/articles/indian-sugar-glut-pushes-prices-close-to-decade-lows-11566820801", "title": "Indian Sugar Glut Pushes Prices Close to Decade Lows", "date": "2019-08-26 15:05", "summary": "New Delhi is expected to renew subsidy program that will boost exports from the world's biggest sugar producer. August has been a bitter month for sugar traders as a potential surfeit of Indian exports, the strong dollar and a slowing world economy combined to push prices toward their lowest level in a decade.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Indian Sugar Glut Pushes Prices Close to Decade Lows. New Delhi is expected to renew subsidy program that will boost exports from the world's biggest sugar producer. August has been a bitter month for sugar traders as a potential surfeit of Indian exports, the strong dollar and a slowing world economy combined to push prices toward their lowest level in a decade.\"\n\nStock Prediction(s):", "Prediction": "\n- Associated British Foods plc (LON: ABF) will increase because their main sugar producer, AB Sugar, is based in the United Kingdom.\n- Wilmar International Ltd (SGX: F34) will increase because they are a major sugar producer and trader.\n- Louis Dreyfus Company B.V. (AMS: LDC) will increase because they are a major sugar producer and trader.\n- Bunge Ltd. (NYSE:", "price_info": {}}, {"link": "https://www.wsj.com/articles/gopro-can-avoid-an-inventory-wipeout-11636659193", "title": "GoPro Can Avoid an Inventory Wipeout", "date": "2021-11-11 14:33", "summary": "Action camera maker learns from past inventory mistakes as it moves to subscription model. GoPro may be selling fewer cameras these days, but at least it has learned how not to be left holding the bag.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GoPro Can Avoid an Inventory Wipeout. Action camera maker learns from past inventory mistakes as it moves to subscription model. GoPro may be selling fewer cameras these days, but at least it has learned how not to be left holding the bag.\"\n\nStock Prediction(s):", "Prediction": "\n- GoPro, Inc. (NASDAQ: GPRO) will increase because they have learned from their past inventory mistakes and are now a subscription-based company.\n- Sony Corporation (NYSE: SNE) will decrease because they are a direct competitor of GoPro and have not made the same changes to their business model.", "price_info": {"SNE": {"company": "", "ticker": "SNE", "move": "down"}, "GPRO": {"company": "", "ticker": "GPRO", "move": "up", "prices": [10.635, 10.41]}}}, {"link": "https://www.wsj.com/articles/careerist-toys-from-your-past-that-children-still-love-11588352114", "title": "'Careerist' Toys From Your Past That Children Still Love", "date": "2020-05-01 12:55", "summary": "The microscope. The rock tumbler. The rocket kit. As a kid, you loved toys that let you mimic adult work. Despite the rise of videogames, here's why today's kids gravitate to them, too.. WHY ARE TOYS that let children mimic the quotidian chores of adult careers-such as counting cash like a bank teller or peering through microscope slides like a yawning researcher-so appealing to little ones? You'd think they'd have better things to do.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"'Careerist' Toys From Your Past That Children Still Love. The microscope. The rock tumbler. The rocket kit. As a kid, you loved toys that let you mimic adult work. Despite the rise of videogames, here's why today's kids gravitate to them, too.. WHY ARE TOYS that let children mimic the quotidian chores of adult careers-such as counting cash like a bank teller or peering through microscope slides like a yawning researcher-so appealing to little ones? You'd think they'd have better things to do.\"\n\nStock Prediction(s):", "Prediction": "\n- Toys \"R\" Us, Inc. (NYSE: TOY) will increase because children are still interested in toys that let them mimic adult work, and this company has a wide variety of such toys.\n- Mattel, Inc. (NASDAQ: MAT) will decrease because children are moving away from traditional toys and towards videogames.", "price_info": {"TOY": {"company": "", "ticker": "TOY", "move": "up"}, "MAT": {"company": "", "ticker": "MAT", "move": "down", "prices": [8.37, 8.4216]}}}, {"link": "https://www.wsj.com/articles/riskiest-european-government-debt-rallies-to-pre-coronavirus-crisis-levels-11594214121", "title": "Riskiest European Government Debt Rallies to Pre-Coronavirus Crisis Levels", "date": "2020-07-08 13:28", "summary": "The difference between the cost of borrowing for Italy or Greece compared with Germany has fallen to pre-lockdown levels. Despite European Central Bank President Christine Lagarde's statement earlier this year that it isn't the central bank's job to close spreads, that is precisely what it has done.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Riskiest European Government Debt Rallies to Pre-Coronavirus Crisis Levels. The difference between the cost of borrowing for Italy or Greece compared with Germany has fallen to pre-lockdown levels. Despite European Central Bank President Christine Lagarde's statement earlier this year that it isn't the central bank's job to close spreads, that is precisely what it has done.\"\n\nStock Prediction(s):", "Prediction": "\n- Italian government debt (BTP) will rally because the riskiest debt is now at pre-crisis levels.\n- Greek government debt (BTP) will rally because the riskiest debt is now at pre-crisis levels.\n- German government debt (Bund) will rally because the riskiest debt is now at pre-crisis levels.", "price_info": {"BTP": {"company": "", "ticker": "BTP", "move": null}}}, {"link": "https://www.wsj.com/articles/europes-covid-19-lockdowns-hit-oil-prices-regions-stocks-11602780226", "title": "Europe's Covid-19 Lockdowns Hit Stocks, Fuel-Demand Outlook", "date": "2020-10-15 15:08", "summary": "Restrictions on travel and leisure threaten to sap fuel consumption and tap the brakes on economic recovery. New coronavirus lockdown measures in Europe dragged the region's stocks lower Thursday and threatened to hamper fuel demand, reigniting worries about slowing economic growth around the world.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Europe's Covid-19 Lockdowns Hit Stocks, Fuel-Demand Outlook. Restrictions on travel and leisure threaten to sap fuel consumption and tap the brakes on economic recovery. New coronavirus lockdown measures in Europe dragged the region's stocks lower Thursday and threatened to hamper fuel demand, reigniting worries about slowing economic growth around the world.\"\n\nStock Prediction(s):", "Prediction": "\n- Airlines (e.g. Delta Air Lines, Inc. (NYSE: DAL)) will decrease because of the lockdown measures and the potential for decreased fuel demand.\n- Auto Manufacturers (e.g. Ford Motor Company (NYSE: F)) will decrease because of the lockdown measures and the potential for decreased fuel demand.\n- Oil & Gas Producers (e.g. Exxon Mobil Corporation (NYSE: XOM)) will decrease because of the lockdown measures", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": "down", "prices": [31.33, 31.36]}, "F": {"company": "", "ticker": "F", "move": null, "prices": [7.63, 7.62]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [34.4, 34.37]}}}, {"link": "https://www.wsj.com/articles/bain-led-group-to-list-japanese-chip-maker-valued-at-20-billion-11598540348", "title": "Bain-Led Group to List Japanese Chip Maker Valued at $20 Billion", "date": "2020-08-27 10:59", "summary": "Kioxia Holdings sets IPO in Tokyo for Oct. 6, testing investor appetite for volatile semiconductor industry. A Japanese memory-chip maker owned by a Bain Capital-led consortium said it planned to list its shares on Oct. 6 and estimated its value at $20 billion, making it one of the year's largest initial public offerings.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bain-Led Group to List Japanese Chip Maker Valued at $20 Billion. Kioxia Holdings sets IPO in Tokyo for Oct. 6, testing investor appetite for volatile semiconductor industry. A Japanese memory-chip maker owned by a Bain Capital-led consortium said it planned to list its shares on Oct. 6 and estimated its value at $20 billion, making it one of the year's largest initial public offerings.\"\n\nStock Prediction(s):", "Prediction": "\n- Kioxia Holdings Co Ltd (TSE: 6875) will increase because they are a valuable chip maker, and they are being listed on the Tokyo Stock Exchange.\n- Toshiba Memory Corp (TSE: 6458) will decrease because they are a direct competitor of Kioxia Holdings.", "price_info": {}}, {"link": "https://www.wsj.com/articles/this-twitter-storm-could-soak-social-media-11590763018", "title": "Trump's Twitter Storm Could Soak Social Media", "date": "2020-05-29 10:37", "summary": "President's executive order faces many legal questions, but could still cause Twitter and Facebook some pain. President Trump may not succeed in ending social media as we know it, but he can certainly rain on the sector's latest socially distant parade.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump's Twitter Storm Could Soak Social Media. President's executive order faces many legal questions, but could still cause Twitter and Facebook some pain. President Trump may not succeed in ending social media as we know it, but he can certainly rain on the sector's latest socially distant parade.\"\n\nStock Prediction(s):", "Prediction": "\n- Twitter, Inc. (NYSE: TWTR) will decrease because of the potential legal issues with Trump's executive order.\n- Facebook, Inc. (NASDAQ: FB) will decrease because of the potential legal issues with Trump's executive order.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down", "prices": [30.6383, 30.5]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [224.7698, 224.65]}}}, {"link": "https://www.wsj.com/articles/new-covid-19-strains-what-scientists-know-about-coronavirus-variants-11609466017", "title": "What Is Known About Virus Variants", "date": "2021-02-26 14:03", "summary": "New versions of the novel coronavirus are spreading across the globe. Researchers fear the new lineages may spread more easily-and one may be more deadly.. Scientists around the world are scrambling to learn more about previously unknown variants of the coronavirus that seem to spread from person to person more readily than other versions of the Covid-19-causing pathogen-including one variant that may also be more deadly.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What Is Known About Virus Variants. New versions of the novel coronavirus are spreading across the globe. Researchers fear the new lineages may spread more easily-and one may be more deadly.. Scientists around the world are scrambling to learn more about previously unknown variants of the coronavirus that seem to spread from person to person more readily than other versions of the Covid-19-causing pathogen-including one variant that may also be more deadly.\"\n\nStock Prediction(s):", "Prediction": "\n- All stocks will decrease because of the potential for a more deadly variant of the virus.", "price_info": {}}, {"link": "https://www.wsj.com/articles/new-york-fed-finds-big-deterioration-in-consumer-views-in-april-11589209825", "title": "Fed Survey Finds Big Deterioration in Consumer Views", "date": "2020-05-11 11:10", "summary": "Expected earnings growth hit a record low for the report, at a projected increase of 1.8%. Americans' outlook for the job market and their personal finances suffered substantial deterioration in April as the coronavirus crisis left much of the U.S. economy on lockdown, new data from the Federal Reserve Bank of New York said.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Survey Finds Big Deterioration in Consumer Views. Expected earnings growth hit a record low for the report, at a projected increase of 1.8%. Americans' outlook for the job market and their personal finances suffered substantial deterioration in April as the coronavirus crisis left much of the U.S. economy on lockdown, new data from the Federal Reserve Bank of New York said.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will generally decrease because of the negative outlook in the Fed Survey.\n- Walmart Inc. (NYSE: WMT) will decrease because of the negative outlook in the Fed Survey.\n- Nike Inc. (NYSE: NKE) will decrease because of the negative outlook in the Fed Survey.\n- Home Depot Inc. (NYSE: HD) will decrease because of the negative outlook in the Fed Survey.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [123.4664, 123.7999]}, "NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [90.43, 91.23]}, "HD": {"company": "", "ticker": "HD", "move": "down", "prices": [235.53, 237.6299]}}}, {"link": "https://www.wsj.com/articles/richard-branson-plans-next-spac-deal-this-time-for-virgin-orbit-11615569059", "title": "Richard Branson Plans Next SPAC Deal, This Time for Virgin Orbit", "date": "2021-03-12 12:30", "summary": "Branson's Virgin Group has played both sides of the SPAC craze and is now seeking a $3 billion valuation for its satellite-launch business. LONDON-Richard Branson's Virgin Orbit has hired bankers to help it go public this year through a special-purpose acquisition company, aiming for a valuation for the satellite launching startup of up to $3 billion, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Richard Branson Plans Next SPAC Deal, This Time for Virgin Orbit. Branson's Virgin Group has played both sides of the SPAC craze and is now seeking a $3 billion valuation for its satellite-launch business. LONDON-Richard Branson's Virgin Orbit has hired bankers to help it go public this year through a special-purpose acquisition company, aiming for a valuation for the satellite launching startup of up to $3 billion, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Virgin Group Ltd. (OTC: VGRP) will increase because they are planning to go public soon, and they are looking for a $3 billion valuation.\n- Other space companies will also increase because this news will bring more attention to the space industry.", "price_info": {}}, {"link": "https://www.wsj.com/articles/spotify-adds-subscribers-swings-to-loss-as-it-invests-in-podcasts-11580900543", "title": "Spotify Agrees to Buy Ringer and Reports Growth in Users", "date": "2020-02-05 10:51", "summary": "Company to add to its podcast lineup with purchase of sports and pop-culture outlet. Spotify Technology SA has agreed to buy sports and pop-culture outlet the Ringer, the company said Wednesday, as it posted better-than-expected growth in users and said its investment in podcasts is helping convert people who use its free tier into paying subscribers.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Spotify Agrees to Buy Ringer and Reports Growth in Users. Company to add to its podcast lineup with purchase of sports and pop-culture outlet. Spotify Technology SA has agreed to buy sports and pop-culture outlet the Ringer, the company said Wednesday, as it posted better-than-expected growth in users and said its investment in podcasts is helping convert people who use its free tier into paying subscribers.\"\n\nStock Prediction(s):", "Prediction": "\n- Spotify Technology SA (NYSE: SPOT) will increase because they are continuing to expand their podcast lineup, and this will help convert more people from the free tier to the paid tier.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they have been lagging in the podcast market, and this acquisition by Spotify will give them a competitive edge.", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "up", "prices": [147.07, 149.42]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [319.745, 320.7864]}}}, {"link": "https://www.wsj.com/articles/poor-communication-helped-lead-to-ceos-departure-at-rio-tinto-11599839970", "title": "Poor Communication Helped Lead to CEO's Departure at Rio Tinto", "date": "2020-09-11 11:59", "summary": "A phone call accelerated events that cost Jean-S\u00e9bastien Jacques his job after the mining company blew up caves of archaeological importance. SYDNEY-A phone call on the evening of May 21 accelerated a chain of events that cost Rio Tinto PLC Chief Executive Jean-S\u00e9bastien Jacques his job.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Poor Communication Helped Lead to CEO's Departure at Rio Tinto. A phone call accelerated events that cost Jean-S\u00e9bastien Jacques his job after the mining company blew up caves of archaeological importance. SYDNEY-A phone call on the evening of May 21 accelerated a chain of events that cost Rio Tinto PLC Chief Executive Jean-S\u00e9bastien Jacques his job.\"\n\nStock Prediction(s):", "Prediction": "\n- Rio Tinto plc (NYSE: RIO) will decrease because their CEO was forced to resign after a phone call.\n- BHP Group plc (NYSE: BHP) will increase because they are not associated with the phone call that led to the CEO's resignation.", "price_info": {"RIO": {"company": "", "ticker": "RIO", "move": "down", "prices": [64.17, 63.8713]}, "BHP": {"company": "", "ticker": "BHP", "move": "up", "prices": [54.31, 54.06]}}}, {"link": "https://www.wsj.com/articles/three-questions-with-small-business-owner-cate-luzio-11588354499", "title": "Three Questions With Small-Business Owner Cate Luzio", "date": "2020-05-01 13:35", "summary": "In less than a month, she's converted a company that stressed in-person networking into a virtual business. Like many other small-business owners, Cate Luzio has made some tough choices in recent weeks.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Three Questions With Small-Business Owner Cate Luzio. In less than a month, she's converted a company that stressed in-person networking into a virtual business. Like many other small-business owners, Cate Luzio has made some tough choices in recent weeks.\"\n\nStock Prediction(s):", "Prediction": "\n- None", "price_info": {}}, {"link": "https://www.wsj.com/articles/nextdoor-founder-lists-san-francisco-home-11597072120", "title": "Nextdoor Founder Lists San Francisco Home for $25 Million", "date": "2020-08-10 11:10", "summary": "Nirav Tolia, who bought the Pacific Heights property as a wedding present for his wife, is temporarily moving to Italy with his family. A founder of Nextdoor, the hyperlocal social network where neighbors go to scout baby-sitter recommendations, grumble about each other and search for lost pets, is listing his San Francisco home for $25 million.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nextdoor Founder Lists San Francisco Home for $25 Million. Nirav Tolia, who bought the Pacific Heights property as a wedding present for his wife, is temporarily moving to Italy with his family. A founder of Nextdoor, the hyperlocal social network where neighbors go to scout baby-sitter recommendations, grumble about each other and search for lost pets, is listing his San Francisco home for $25 million.\"\n\nStock Prediction(s):", "Prediction": "\n- Nextdoor (NASDAQ: NEXT) will increase because their founder is selling his home for $25 million.\n- Facebook (NASDAQ: FB) will decrease because they are also working on a hyperlocal social network, but they are a direct competitor of Nextdoor.", "price_info": {"NEXT": {"company": "", "ticker": "NEXT", "move": "up", "prices": [1.43, 1.47]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [264.34, 263.98]}}}, {"link": "https://www.wsj.com/articles/u-s-orders-for-long-lasting-goods-gained-in-june-11595860966", "title": "U.S. Orders for Long-Lasting Goods Gained in June", "date": "2020-07-27 12:11", "summary": "New orders for durable goods rose 7.3%, the second consecutive monthly gain. Orders for long-lasting U.S. factory goods rose in June as the economy continued its climb back from disruptions related to the coronavirus pandemic, though a summer surge in virus infections could damp future gains.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Orders for Long-Lasting Goods Gained in June. New orders for durable goods rose 7.3%, the second consecutive monthly gain. Orders for long-lasting U.S. factory goods rose in June as the economy continued its climb back from disruptions related to the coronavirus pandemic, though a summer surge in virus infections could damp future gains.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co (NYSE: BA) will increase because their products are long-lasting and in high demand.\n- Caterpillar Inc (NYSE: CAT) will increase because their products are long-lasting and in high demand.\n- 3M Co (NYSE: MMM) will increase because their products are long-lasting and in high demand.\n- General Electric Co (NYSE: GE) will decrease because their products are long-lasting and in high demand.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [169.22, 169.74]}, "CAT": {"company": "", "ticker": "CAT", "move": "up", "prices": [139.739, 139.21]}, "MMM": {"company": "", "ticker": "MMM", "move": "up", "prices": [162.19, 162.42]}, "GE": {"company": "", "ticker": "GE", "move": "down", "prices": [6.75, 6.765]}}}, {"link": "https://www.wsj.com/articles/ecb-eases-stimulus-program-amid-robust-growth-11631188908", "title": "ECB Sticks With Easy-Money Policies to Counter Delta's Impact", "date": "2021-09-09 14:35", "summary": "Central bank says it will conduct bond purchases as a 'moderately lower pace'. FRANKFURT-European Central Bank President Christine Lagarde signaled that the bank will keep monetary policy loose for some time amid a resurgence in Covid-19 cases globally and signs of economic slowdown in China and the U.S. that have prompted caution from the Federal Reserve.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"ECB Sticks With Easy-Money Policies to Counter Delta's Impact. Central bank says it will conduct bond purchases as a 'moderately lower pace'. FRANKFURT-European Central Bank President Christine Lagarde signaled that the bank will keep monetary policy loose for some time amid a resurgence in Covid-19 cases globally and signs of economic slowdown in China and the U.S. that have prompted caution from the Federal Reserve.\"\n\nStock Prediction(s):", "Prediction": "\n- The ECB will keep interest rates low in order to combat the global economic slowdown caused by Covid-19.\n- The Fed will also keep interest rates low in order to combat the global economic slowdown caused by Covid-19.\n- Bank of America Corp (NYSE: BAC) will increase because they are a direct beneficiary of low interest rates.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are a direct beneficiary of low", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [40.955, 40.96]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [159.25, 159.155]}}}, {"link": "https://www.wsj.com/articles/deliveroo-shares-plunge-in-market-debut-11617180583", "title": "Deliveroo Shares Plunge in London IPO", "date": "2021-03-31 12:55", "summary": "Selloff comes amid concerns about the Amazon-backed food-delivery startup's ability to sustain growth. LONDON-Shares of Deliveroo Holdings PLC dropped 26% on their first day of trading, as investors shunned a landmark offering from the Amazon.com Inc. -backed food-delivery startup amid concerns over whether it can maintain its pandemic momentum.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Deliveroo Shares Plunge in London IPO. Selloff comes amid concerns about the Amazon-backed food-delivery startup's ability to sustain growth. LONDON-Shares of Deliveroo Holdings PLC dropped 26% on their first day of trading, as investors shunned a landmark offering from the Amazon.com Inc. -backed food-delivery startup amid concerns over whether it can maintain its pandemic momentum.\"\n\nStock Prediction(s):", "Prediction": "\n- Deliveroo Holdings plc (LON: DOOO) will continue to drop because of investor concerns about the company's ability to sustain growth.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because of its investment in Deliveroo Holdings plc.", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3109.07, 3102.65]}}}, {"link": "https://www.wsj.com/articles/europes-banks-warn-about-prospects-11565195627", "title": "Europe's Banks Warn About Prospects", "date": "2019-08-07 12:33", "summary": "Continent's lenders are grappling with lower interest rates and geopolitical tensions. For Europe's lenders, the hits keep on coming.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Europe's Banks Warn About Prospects. Continent's lenders are grappling with lower interest rates and geopolitical tensions. For Europe's lenders, the hits keep on coming.\"\n\nStock Prediction(s):", "Prediction": "\n- European banks will continue to struggle as interest rates remain low and geopolitical tensions increase.\n- Deutsche Bank AG (NYSE: DB) will be the most affected as it is already in a precarious position.\n- Credit Suisse Group AG (NYSE: CS) will also struggle as it is in a similar position to Deutsche Bank.\n- Barclays PLC (NYSE: BCS) will be less affected as it is in a better financial position than its European counterparts.", "price_info": {"DB": {"company": "", "ticker": "DB", "move": null, "prices": [7.395, 7.4]}, "CS": {"company": "", "ticker": "CS", "move": null, "prices": [11.3581, 11.385]}, "BCS": {"company": "", "ticker": "BCS", "move": null, "prices": [7.125, 7.145]}}}, {"link": "https://www.wsj.com/articles/citrix-spotify-knightscope-what-to-watch-when-the-stock-market-opens-today-11643630575", "title": "Citrix, Spotify, Knightscope, Tesla: What to Watch in the Stock Market Today", "date": "2022-01-31 09:53", "summary": "Citrix is nearing a deal to be taken private; Spotify made public its content policies. Wall Street indexes were mixed in morning trading. Here's what we're watching on Monday:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Citrix, Spotify, Knightscope, Tesla: What to Watch in the Stock Market Today. Citrix is nearing a deal to be taken private; Spotify made public its content policies. Wall Street indexes were mixed in morning trading. Here's what we're watching on Monday:\"\n\nStock Prediction(s):", "Prediction": "\n- Citrix Systems, Inc. (NASDAQ: CTXS) will increase because they are being taken private.\n- Spotify Technology S.A. (NYSE: SPOT) will increase because they made their content policies public.\n- Knightscope, Inc. (NYSE: KSI) will increase because they are a direct competitor of Tesla, Inc. (NASDAQ: TSLA).\n- Tesla, Inc. will decrease because they are a direct", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "up", "prices": [187.36, 193.52]}, "KSI": {"company": "", "ticker": "KSI", "move": "up"}, "CTXS": {"company": "", "ticker": "CTXS", "move": "up", "prices": [101.65, 101.52]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [897.06, 917.265]}}}, {"link": "https://www.wsj.com/articles/amazon-rolls-out-halo-a-wellness-tracker-that-it-says-can-also-sense-moods-11598543692", "title": "Amazon Rolls Out a Wellness Tracker That It Says Can Also Sense Moods", "date": "2020-08-27 11:54", "summary": "Product is the e-commerce giant's latest foray into wearables. Amazon.com Inc. rolled out Amazon Halo, a health and wellness tracker that the company said also tracks its users' emotions, in its latest foray into wearable products as the company seeks to expand its reach into users' everyday lives.", "categories": [["Tech", "Consumer Technology"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/consumer-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Amazon Rolls Out a Wellness Tracker That It Says Can Also Sense Moods. Product is the e-commerce giant's latest foray into wearables. Amazon.com Inc. rolled out Amazon Halo, a health and wellness tracker that the company said also tracks its users' emotions, in its latest foray into wearable products as the company seeks to expand its reach into users' everyday lives.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are expanding their product line into wearables, which is a growing market.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are not expanding into wearables, and they are a direct competitor of Amazon.", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3381.7875, 3415.15]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [495.395, 498.703]}}}, {"link": "https://www.wsj.com/articles/how-to-estimate-what-youll-spend-on-long-term-care-11572535052", "title": "How to Estimate What You'll Spend on Long-Term Care", "date": "2019-10-31 11:17", "summary": "Retirement columnist Glenn Ruffenach also offers advice about IRA distributions. In your column about unexpected bills in retirement, you didn't address the possibility of long-term care. How can I estimate what those expenses might be in later life? I need this for my parents and me.", "categories": [["Markets", "Journal Reports: Funds/ETFs", "Ask Encore"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-funds-etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Estimate What You'll Spend on Long-Term Care. Retirement columnist Glenn Ruffenach also offers advice about IRA distributions. In your column about unexpected bills in retirement, you didn't address the possibility of long-term care. How can I estimate what those expenses might be in later life? I need this for my parents and me.\"\n\nStock Prediction(s):", "Prediction": "\n- Genworth Financial Inc (NYSE: GNW) will increase because they are a long-term care insurance company and will benefit from the increase in demand.\n- Molina Healthcare, Inc. (NYSE: MOH) will increase because they are a long-term care insurance company and will benefit from the increase in demand.\n- American International Group, Inc. (NYSE: AIG) will increase because they are a long-term care insurance company and will", "price_info": {"GNW": {"company": "", "ticker": "GNW", "move": "up", "prices": [4.28, 4.23]}, "MOH": {"company": "", "ticker": "MOH", "move": "up", "prices": [120.02, 120.08]}, "AIG": {"company": "", "ticker": "AIG", "move": "up", "prices": [52.445, 52.58]}}}, {"link": "https://www.wsj.com/articles/hertz-names-paul-stone-as-ceo-11589808292", "title": "Hertz Names Paul Stone as CEO as Firm Fights for Survival Amid Covid-19", "date": "2020-05-18 11:08", "summary": "Car-rental firm has been hit hard by downturn in global travel. Hertz Global Holdings Inc. named a new leader as the car-rental company's future is in jeopardy amid the decimation of global travel caused by the Covid-19 pandemic.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hertz Names Paul Stone as CEO as Firm Fights for Survival Amid Covid-19. Car-rental firm has been hit hard by downturn in global travel. Hertz Global Holdings Inc. named a new leader as the car-rental company's future is in jeopardy amid the decimation of global travel caused by the Covid-19 pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Hertz Global Holdings Inc. (NYSE: HTZ) will decrease because they are in a difficult situation with the Covid-19 pandemic.", "price_info": {"HTZ": {"company": "", "ticker": "HTZ", "move": "down", "prices": [3.27, 3.16]}}}, {"link": "https://www.wsj.com/articles/volvo-cars-unveils-plan-to-list-in-stockholm-11633346350", "title": "Volvo Cars Unveils IPO That Could Value It at $25 Billion", "date": "2021-10-04 11:00", "summary": "Stockholm listing would represent one of the car industry's most striking turnarounds. Volvo Cars, the Swedish auto maker owned by China's Zhejiang Geely Holding, said Monday it would proceed with an initial public offering in Stockholm, in a deal that people familiar with the matter say could value it at upward of $25 billion.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Volvo Cars Unveils IPO That Could Value It at $25 Billion. Stockholm listing would represent one of the car industry's most striking turnarounds. Volvo Cars, the Swedish auto maker owned by China's Zhejiang Geely Holding, said Monday it would proceed with an initial public offering in Stockholm, in a deal that people familiar with the matter say could value it at upward of $25 billion.\"\n\nStock Prediction(s):", "Prediction": "\n- Volvo Cars AB (OTC: VLVLY) will increase because they are going public and will be valued at $25 billion.\n- Zhejiang Geely Holding Group Co Ltd (OTC: GELYF) will decrease because they are the owner of Volvo Cars, and when Volvo Cars goes public, their value will decrease.", "price_info": {}}, {"link": "https://www.wsj.com/articles/can-an-ai-system-be-given-a-patent-11570801500", "title": "Can an AI System Be Given a Patent?", "date": "2019-10-11 09:45", "summary": "An artificially intelligent system purportedly has created two new products. Now patent offices must decide if it can be named as the inventor.. If an artificially intelligent system creates a new product, should patent offices recognize it as the inventor?", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Can an AI System Be Given a Patent?. An artificially intelligent system purportedly has created two new products. Now patent offices must decide if it can be named as the inventor.. If an artificially intelligent system creates a new product, should patent offices recognize it as the inventor?\"\n\nStock Prediction(s):", "Prediction": "\n- IBM (NYSE: IBM) will increase because they have been a leader in AI for a long time, and this could be a major breakthrough for them.\n- Google (NASDAQ: GOOGL) will increase because they have been a leader in AI for a long time, and this could be a major breakthrough for them.\n- Microsoft (NASDAQ: MSFT) will increase because they have been a leader in AI for a long time, and this", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "up", "prices": [143.81, 143.44]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1223.19, 1225.7701]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [140.63, 140.3202]}}}, {"link": "https://www.wsj.com/articles/ibm-revenue-trends-in-reverse-11548153000", "title": "IBM Revenue Trends in Reverse", "date": "2019-01-22 12:23", "summary": "Red Hat, move toward cloud computing to be scrutinized in earnings report. International Business Machines Corp. is scheduled to report fourth-quarter earnings after the close of trading Tuesday. Here is what to expect:", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"IBM Revenue Trends in Reverse. Red Hat, move toward cloud computing to be scrutinized in earnings report. International Business Machines Corp. is scheduled to report fourth-quarter earnings after the close of trading Tuesday. Here is what to expect:\"\n\nStock Prediction(s):", "Prediction": "\n- IBM (NYSE: IBM) will decrease because their revenue is in reverse, and they are moving away from cloud computing.", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "down", "prices": [122.3, 122.16]}}}, {"link": "https://www.wsj.com/articles/princes-heirs-music-publisher-seek-to-make-it-rain-purpleand-green-11627653444", "title": "Publisher Buys Stakes From Prince's Heirs in Bid to Steer Singer's Legacy", "date": "2021-07-30 13:53", "summary": "Prince's estate remains in probate five years after his death; music owner Primary Wave seeks to help end that. In a sign o' the times, Prince's music is attracting new investment.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Publisher Buys Stakes From Prince's Heirs in Bid to Steer Singer's Legacy. Prince's estate remains in probate five years after his death; music owner Primary Wave seeks to help end that. In a sign o' the times, Prince's music is attracting new investment.\"\n\nStock Prediction(s):", "Prediction": "\n- Prince's estate will remain in probate because of the new investment.\n- Prince's music will continue to be popular because of the new investment.\n- Primary Wave will benefit from the new investment because they now own a stake in Prince's estate.", "price_info": {}}, {"link": "https://www.wsj.com/articles/metals-tycoon-gupta-hires-advisers-to-navigate-greensill-fallout-11615394876", "title": "Metals Tycoon Gupta Hires Advisers to Navigate Greensill Fallout", "date": "2021-03-10 13:58", "summary": "U.K. tycoon and GFG Alliance tap trio of financing and restructuring firms to help negotiate with Greensill, raise fresh funding. LONDON-U.K. metals tycoon Sanjeev Gupta has hired a trio of financing and restructuring advisers to help his GFG Alliance group of companies negotiate with its main creditor, Greensill Capital, and raise fresh funding, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Finance"]], "category_links": ["https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Metals Tycoon Gupta Hires Advisers to Navigate Greensill Fallout. U.K. tycoon and GFG Alliance tap trio of financing and restructuring firms to help negotiate with Greensill, raise fresh funding. LONDON-U.K. metals tycoon Sanjeev Gupta has hired a trio of financing and restructuring advisers to help his GFG Alliance group of companies negotiate with its main creditor, Greensill Capital, and raise fresh funding, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Liberty House Group (LON: LHG) will increase because they are a major creditor of Greensill, and they will likely help them renegotiate their debt.\n- GFG Alliance (LON: GFG) will increase because they are a major creditor of Greensill, and they will likely help them renegotiate their debt.\n- Greensill Capital (LON: GSC) will decrease because they are a creditor of GFG Alliance, and they", "price_info": {}}, {"link": "https://www.wsj.com/articles/videogame-makers-get-no-home-field-advantage-11631801360", "title": "Videogame Makers Get No Home-Field Advantage", "date": "2021-09-16 10:09", "summary": "Electronic Arts' 'Battlefield' delay just the latest as game publishers still struggle with remote work challenges. Staying home to play videogames is a fantasy for many. Making those games at home has turned out to be more of a nightmare.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Videogame Makers Get No Home-Field Advantage. Electronic Arts' 'Battlefield' delay just the latest as game publishers still struggle with remote work challenges. Staying home to play videogames is a fantasy for many. Making those games at home has turned out to be more of a nightmare.\"\n\nStock Prediction(s):", "Prediction": "\n- Electronic Arts Inc. (NASDAQ: EA) will decrease because their game, Battlefield, is being delayed.\n- Activision Blizzard, Inc. (NASDAQ: ATVI) will decrease because their game, Call of Duty, is being delayed.\n- Take-Two Interactive Software, Inc. (NASDAQ: TTWO) will decrease because their game, Grand Theft Auto, is being delayed.\n- Ubisoft Entertainment SA (EPA: UBI) will", "price_info": {"EA": {"company": "", "ticker": "EA", "move": "down", "prices": [137.2645, 136.825]}, "ATVI": {"company": "", "ticker": "ATVI", "move": "down", "prices": [79.2, 79.32]}, "TTWO": {"company": "", "ticker": "TTWO", "move": "down", "prices": [152.6371, 152.05]}}}, {"link": "https://www.wsj.com/articles/general-motors-fourth-quarter-operating-profit-drops-11549459920", "title": "GM Leans on U.S. Truck Buyers to Counter Weakness in China", "date": "2019-02-06 13:27", "summary": "Strong pricing on pickups and SUVs in North America drove results, but soft China sales hurt the bottom line. General Motors Co. is counting on U.S. buyers of pickup trucks and SUVs to bolster its bottom line.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GM Leans on U.S. Truck Buyers to Counter Weakness in China. Strong pricing on pickups and SUVs in North America drove results, but soft China sales hurt the bottom line. General Motors Co. is counting on U.S. buyers of pickup trucks and SUVs to bolster its bottom line.\"\n\nStock Prediction(s):", "Prediction": "\n- General Motors Co. (NYSE: GM) will increase because their truck sales are doing well in North America.\n- Ford Motor Company (NYSE: F) will decrease because their truck sales are not doing as well as General Motors.", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "up", "prices": [39.9, 39.82]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [8.71, 8.695]}}}, {"link": "https://www.wsj.com/articles/why-2-trillion-could-be-just-the-start-11585154741", "title": "Why $2 Trillion Could Be Just the Start", "date": "2020-03-25 12:45", "summary": "If federal stimulus isn't distributed quickly enough, or if the fear of coronavirus infection drags on too long, even the mammoth government package may not be enough to avoid huge job losses. The U.S. government is about to pour $2 trillion on the pandemic-stricken economy. It might not be its last trip to the well.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why $2 Trillion Could Be Just the Start. If federal stimulus isn't distributed quickly enough, or if the fear of coronavirus infection drags on too long, even the mammoth government package may not be enough to avoid huge job losses. The U.S. government is about to pour $2 trillion on the pandemic-stricken economy. It might not be its last trip to the well.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because the stimulus package might not be enough.\n- The market will go up because the stimulus package is a lot of money, and it will help the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/stocks-to-watch-bed-bath-beyond-sherwin-williams-pricesmart-simulations-plus-aar-11562843265", "title": "Stocks to Watch: Delta, Cigna, Fastenal, Bed Bath & Beyond and More", "date": "2019-07-11 09:50", "summary": "Resume Subscription. Here are some of the companies with shares expected to trade actively in Thursday's session. Stock movements noted by ticker reflect movements during regular trading hours; premarket trading is specified separately.", "categories": [["Markets", "MoneyBeat"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/moneybeat?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Stocks to Watch: Delta, Cigna, Fastenal, Bed Bath & Beyond and More. Resume Subscription. Here are some of the companies with shares expected to trade actively in Thursday's session. Stock movements noted by ticker reflect movements during regular trading hours; premarket trading is specified separately.\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines, Inc. (NYSE: DAL) will increase because they are expecting a surge in travel due to the vaccine being available.\n- Cigna Corporation (NYSE: CI) will increase because they are expecting a surge in travel due to the vaccine being available.\n- Fastenal Company (NASDAQ: FAST) will increase because they are expecting a surge in demand for their products due to the vaccine being available.\n- Bed Bath", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": "up", "prices": [60.2146, 60.335]}, "CI": {"company": "", "ticker": "CI", "move": "up", "prices": [178.98, 177.7199]}, "FAST": {"company": "", "ticker": "FAST", "move": "up", "prices": [29.77, 30.03]}}}, {"link": "https://www.wsj.com/articles/uber-jackpot-inside-one-of-the-greatest-startup-investments-of-all-time-11557496421", "title": "Uber Jackpot: Inside One of the Greatest Startup Investments of All Time", "date": "2019-05-10 12:14", "summary": "In 2010, 18 funds and individuals valued Uber at $5.4 million. Today, that same company is worth $82 billion. In 2010, a group of entrepreneurs and venture capitalists invested about $1.6 million in an unknown startup called UberCab, which aimed to let people hail a luxury black car through a smartphone app.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Uber Jackpot: Inside One of the Greatest Startup Investments of All Time. In 2010, 18 funds and individuals valued Uber at $5.4 million. Today, that same company is worth $82 billion. In 2010, a group of entrepreneurs and venture capitalists invested about $1.6 million in an unknown startup called UberCab, which aimed to let people hail a luxury black car through a smartphone app.\"\n\nStock Prediction(s):", "Prediction": "\n- Uber Technologies Inc (NYSE: UBER) will continue to increase in value because they are a major player in the ride-sharing industry, and they show no signs of slowing down.\n- Lyft Inc (NASDAQ: LYFT) will decrease in value because they are Uber's main competitor, and Uber is currently dominating the market.", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "up", "prices": [44.629, 43.85]}, "LYFT": {"company": "", "ticker": "LYFT", "move": "down", "prices": [53.6002, 53.16]}}}, {"link": "https://www.wsj.com/articles/feds-kaplan-more-clarity-needed-before-fed-can-decide-next-rate-move-11549389606", "title": "Fed's Kaplan: More Clarity Needed Before Next Rate Move", "date": "2019-02-05 13:00", "summary": "Dallas Fed leader says the Federal Reserve needs to resolve uncertainties around the economy and financial conditions. Federal Reserve Bank of Dallas President Robert Kaplan reiterated Tuesday his support for the central bank holding off for now on further rate rises and said changes in its balance sheet drawdown should be on the table as well.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Kaplan: More Clarity Needed Before Next Rate Move. Dallas Fed leader says the Federal Reserve needs to resolve uncertainties around the economy and financial conditions. Federal Reserve Bank of Dallas President Robert Kaplan reiterated Tuesday his support for the central bank holding off for now on further rate rises and said changes in its balance sheet drawdown should be on the table as well.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve will hold off on raising interest rates because there are still uncertainties around the economy and financial conditions.\n- The Federal Reserve will also consider changing its balance sheet drawdown because there are still uncertainties around the economy and financial conditions.", "price_info": {}}, {"link": "https://www.wsj.com/articles/volvo-cars-needs-investors-to-value-brain-over-brawn-11627051135", "title": "Volvo Cars Needs Investors to Value Brain Over Brawn", "date": "2021-07-23 10:38", "summary": "As the Swedish car maker gears up for an initial public offering, a hyperactive first half showcases both its strategic flexibility and financial limitations. The mooted initial public offering of Volvo Cars is a must-watch test case of investor appetite for smaller car manufacturers as the industry's technological transition accelerates.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Volvo Cars Needs Investors to Value Brain Over Brawn. As the Swedish car maker gears up for an initial public offering, a hyperactive first half showcases both its strategic flexibility and financial limitations. The mooted initial public offering of Volvo Cars is a must-watch test case of investor appetite for smaller car manufacturers as the industry's technological transition accelerates.\"\n\nStock Prediction(s):", "Prediction": "\n- Volvo Cars AB (OTC: VLVLY) will increase because they are a smaller car manufacturer that is transitioning to electric, and they are gearing up for an IPO.\n- Geely Automobile Holdings Ltd. (OTC: GELYY) will decrease because they are a larger car manufacturer, and they are not transitioning to electric.", "price_info": {}}, {"link": "https://www.wsj.com/articles/saudis-russia-discuss-joint-oil-output-raise-ahead-of-opec-meeting-11614857084", "title": "OPEC-Plus Keeps Lid on Oil Output, and Prices Rise", "date": "2021-03-04 14:38", "summary": "Saudi Arabia and Russia have careened between optimism and dire warnings amid pandemic's ebb and flow. OPEC and a Russia-led coalition of oil producers kept most of their production cuts in place, surprising traders and sending oil prices up dramatically.", "categories": [["WSJ News Exclusive", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"OPEC-Plus Keeps Lid on Oil Output, and Prices Rise. Saudi Arabia and Russia have careened between optimism and dire warnings amid pandemic's ebb and flow. OPEC and a Russia-led coalition of oil producers kept most of their production cuts in place, surprising traders and sending oil prices up dramatically.\"\n\nStock Prediction(s):", "Prediction": "\n- Saudi Aramco (NYSE: ARAMCO) will increase because they are a part of OPEC and they produce a lot of oil.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are a part of OPEC and they produce a lot of oil.\n- Chevron Corporation (NYSE: CVX) will increase because they are a part of OPEC and they produce a lot of oil.\n- Royal Dutch Shell plc (NYSE: RDS", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [57.76, 58.865]}, "CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [103.44, 104.745]}}}, {"link": "https://www.wsj.com/articles/southwest-airlines-offers-extra-pay-to-avoid-july-travel-snags-11624992632", "title": "Southwest Offers Workers Double Pay to Avoid July Travel Snags", "date": "2021-06-29 15:16", "summary": "Carrier blames bad weather for cancellations, as pilots say the higher wages won't solve a staffing shortage. Southwest Airlines Co. is increasing overtime pay, including offering double-time pay for flight attendants, in an effort to head off potential staffing crunches during the Fourth of July travel weekend.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Southwest Offers Workers Double Pay to Avoid July Travel Snags. Carrier blames bad weather for cancellations, as pilots say the higher wages won't solve a staffing shortage. Southwest Airlines Co. is increasing overtime pay, including offering double-time pay for flight attendants, in an effort to head off potential staffing crunches during the Fourth of July travel weekend.\"\n\nStock Prediction(s):", "Prediction": "\n- Southwest Airlines Co. (NYSE: LUV) will increase because they are trying to incentivize their workers to avoid potential travel issues.\n- American Airlines Group Inc. (NASDAQ: AAL) will decrease because they are not offering the same incentives as Southwest.", "price_info": {"LUV": {"company": "", "ticker": "LUV", "move": "up", "prices": [52.93, 53.03]}, "AAL": {"company": "", "ticker": "AAL", "move": "down", "prices": [21.11, 21.06]}}}, {"link": "https://www.wsj.com/articles/warren-buffetts-berkshire-hathaway-will-host-annual-meeting-in-person-11643138863", "title": "Berkshire Hathaway Will Host Annual Meeting in Person", "date": "2022-01-25 14:40", "summary": "Past two shareholder meetings were held virtually due to Covid-19 pandemic. Warren Buffett's \"Woodstock for Capitalists\" event is coming back in-person this year.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Berkshire Hathaway Will Host Annual Meeting in Person. Past two shareholder meetings were held virtually due to Covid-19 pandemic. Warren Buffett's \"Woodstock for Capitalists\" event is coming back in-person this year.\"\n\nStock Prediction(s):", "Prediction": "\n- Berkshire Hathaway Inc. (NYSE: BRK.A) will increase because their annual meeting is coming back in-person this year.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because Berkshire Hathaway is a major shareholder in Amazon.", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [2821.58, 2771.42]}}}, {"link": "https://www.wsj.com/articles/brace-for-higher-prices-for-ice-cream-tequila-and-bottled-water-11627558364", "title": "Brace for Higher Prices for Ice Cream, Beer and Bottled Water", "date": "2021-07-29 10:30", "summary": "Food and drink companies say pandemic recovery is buoying sales but leading to higher costs for ingredients, packaging and transport. The makers of some of the world's bestselling food and drink brands warned they would keep raising prices as they grapple with the strongest inflation in years.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Brace for Higher Prices for Ice Cream, Beer and Bottled Water. Food and drink companies say pandemic recovery is buoying sales but leading to higher costs for ingredients, packaging and transport. The makers of some of the world's bestselling food and drink brands warned they would keep raising prices as they grapple with the strongest inflation in years.\"\n\nStock Prediction(s):", "Prediction": "\n- Coca-Cola Company (NYSE: KO) will increase because their products are in high demand and they are facing higher costs for ingredients and transport.\n- PepsiCo, Inc. (NASDAQ: PEP) will increase because their products are in high demand and they are facing higher costs for ingredients and transport.\n- Mondelez International, Inc. (NASDAQ: MDLZ) will increase because their products are in high demand and they are facing higher", "price_info": {"KO": {"company": "", "ticker": "KO", "move": "up", "prices": [57.025, 57.09]}, "PEP": {"company": "", "ticker": "PEP", "move": "up", "prices": [156.405, 156.55]}, "MDLZ": {"company": "", "ticker": "MDLZ", "move": "up", "prices": [63.43, 63.4]}}}, {"link": "https://www.wsj.com/articles/metals-escape-worst-of-selloff-on-hopes-for-chinese-demand-11583840466", "title": "Metals Escape Worst of Selloff on Hopes for Chinese Demand", "date": "2020-03-10 14:02", "summary": "Market shows signs that some investors see China's appetite for industrial commodities recovering. Metals prices have yet to join the latest leg down in the coronavirus-prompted market rout, a sign that some investors see China's voracious appetite for industrial commodities recovering even as the epidemic hits the rest of the world.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Metals Escape Worst of Selloff on Hopes for Chinese Demand. Market shows signs that some investors see China's appetite for industrial commodities recovering. Metals prices have yet to join the latest leg down in the coronavirus-prompted market rout, a sign that some investors see China's voracious appetite for industrial commodities recovering even as the epidemic hits the rest of the world.\"\n\nStock Prediction(s):", "Prediction": "\n- Aluminum Corporation of China Ltd. (NYSE: ACH) will increase because it is a Chinese company and it is expected that the Chinese demand for industrial commodities will recover.\n- BHP Group Ltd. (NYSE: BHP) will increase because it is a Australian company and it is expected that the Australian demand for industrial commodities will recover.\n- Rio Tinto plc (NYSE: RIO) will increase because it is a British company and it is expected", "price_info": {"ACH": {"company": "", "ticker": "ACH", "move": "up"}, "BHP": {"company": "", "ticker": "BHP", "move": "up"}, "RIO": {"company": "", "ticker": "RIO", "move": "up", "prices": [45.22, 45.8]}}}, {"link": "https://www.wsj.com/articles/roku-drops-youtube-tv-app-in-carriage-dispute-11619803160", "title": "Roku Drops YouTube TV App in Carriage Dispute", "date": "2021-04-30 13:19", "summary": "The streaming-device maker and Google, YouTube's parent, are at odds over the way search results are displayed on Roku's platform. Streaming device-maker Roku Inc. removed the YouTube TV app from its channel store Friday, the latest example of media carriage disputes entering the streaming era.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Roku Drops YouTube TV App in Carriage Dispute. The streaming-device maker and Google, YouTube's parent, are at odds over the way search results are displayed on Roku's platform. Streaming device-maker Roku Inc. removed the YouTube TV app from its channel store Friday, the latest example of media carriage disputes entering the streaming era.\"\n\nStock Prediction(s):", "Prediction": "\n- Roku, Inc. (NASDAQ: ROKU) will decrease because they are in a carriage dispute with YouTube TV.\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because YouTube TV is a subsidiary of Google, and they are not in a carriage dispute.\n- Apple Inc. (NASDAQ: AAPL) will increase because they are not in a carriage dispute, and they have a large market share in streaming devices.", "price_info": {"ROKU": {"company": "", "ticker": "ROKU", "move": "down", "prices": [342.705, 342.34]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [2354.35, 2353.04]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [131.68, 131.47]}}}, {"link": "https://www.wsj.com/articles/peer-pressure-can-improve-your-financial-life-study-finds-11552328444", "title": "Peer Pressure Can Improve Your Financial Life, Study Finds", "date": "2019-03-11 14:20", "summary": "People cut their spending when told they are spending more than others in similar circumstances, say three economists. How do you get people to make better financial decisions? Peer pressure can help, according to new research by three economists.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Peer Pressure Can Improve Your Financial Life, Study Finds. People cut their spending when told they are spending more than others in similar circumstances, say three economists. How do you get people to make better financial decisions? Peer pressure can help, according to new research by three economists.\"\n\nStock Prediction(s):", "Prediction": "\n- Peer pressure will help people make better financial decisions, and this will help the stock prices of companies such as Visa (NYSE: V), Mastercard (NYSE: MA), and American Express (NYSE: AXP).\n- Other companies that will benefit from people making better financial decisions are Goldman Sachs (NYSE: GS) and JPMorgan Chase (NYSE: JPM).", "price_info": {"V": {"company": "", "ticker": "V", "move": null, "prices": [150.425, 150.7]}, "MA": {"company": "", "ticker": "MA", "move": null, "prices": [225.6286, 225.84]}, "AXP": {"company": "", "ticker": "AXP", "move": "up", "prices": [109.29, 109.56]}, "GS": {"company": "", "ticker": "GS", "move": null, "prices": [196.33, 195.97]}, "JPM": {"company": "", "ticker": "JPM", "move": null, "prices": [104.28, 104.35]}}}, {"link": "https://www.wsj.com/articles/delta-variant-concerns-temper-dinings-summer-return-as-some-americans-stay-home-11628587801", "title": "Delta Variant Threatens Restaurant Rebound", "date": "2021-08-11 14:56", "summary": "Mixed picture emerges in markets hit by Covid-19 outbreaks, renewed coronavirus-related advisories. Some consumers are rethinking their return to dining out, according to executives and industry data, a shift that threatens the U.S. restaurant sector's rebound.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Delta Variant Threatens Restaurant Rebound. Mixed picture emerges in markets hit by Covid-19 outbreaks, renewed coronavirus-related advisories. Some consumers are rethinking their return to dining out, according to executives and industry data, a shift that threatens the U.S. restaurant sector's rebound.\"\n\nStock Prediction(s):", "Prediction": "\n- Restaurant Brands International Inc (NYSE: QSR) will decrease because their rebound is being threatened by the Covid-19 outbreaks.\n- Yum! Brands, Inc. (NYSE: YUM) will decrease because their rebound is being threatened by the Covid-19 outbreaks.\n- Chipotle Mexican Grill, Inc. (NYSE: CMG) will decrease because their rebound is being threatened by the Covid-19 outbreaks.\n- Dunkin' Brands", "price_info": {"QSR": {"company": "", "ticker": "QSR", "move": "down", "prices": [64.91, 64.9]}, "YUM": {"company": "", "ticker": "YUM", "move": "down", "prices": [133.85, 134.05]}, "CMG": {"company": "", "ticker": "CMG", "move": "down", "prices": [1857.135, 1861.025]}}}, {"link": "https://www.wsj.com/articles/feds-evans-sees-two-rate-cuts-needed-this-year-11562951204", "title": "Fed's Evans Sees Two Rate Cuts Needed This Year", "date": "2019-07-12 13:06", "summary": "Chicago central banker with power to vote on policy path expects two interest-rate reductions in 2019. CHICAGO-Lower U.S. interest rates are needed to combat weak inflation, Federal Reserve Bank of Chicago President Charles Evans said Friday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans Sees Two Rate Cuts Needed This Year. Chicago central banker with power to vote on policy path expects two interest-rate reductions in 2019. CHICAGO-Lower U.S. interest rates are needed to combat weak inflation, Federal Reserve Bank of Chicago President Charles Evans said Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of Chicago (NASDAQ: FRB Chicago) will decrease because they predict that there will be two interest-rate reductions this year.", "price_info": {}}, {"link": "https://www.wsj.com/articles/weaker-dollar-lifts-gold-prices-11554730898", "title": "Weaker Dollar Lifts Gold Prices", "date": "2019-04-08 14:40", "summary": "Some analysts expect gold and other assets to continue wobbling until fresh earnings or economic data changes the market backdrop. Gold prices climbed Monday, supported by a weaker dollar.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Weaker Dollar Lifts Gold Prices. Some analysts expect gold and other assets to continue wobbling until fresh earnings or economic data changes the market backdrop. Gold prices climbed Monday, supported by a weaker dollar.\"\n\nStock Prediction(s):", "Prediction": "\n- Gold prices will continue to increase because the dollar is weak and investors are looking for a safe haven.\n- The dollar will continue to be weak because of the Covid-19 pandemic and investors will continue to flock to gold.", "price_info": {}}, {"link": "https://www.wsj.com/articles/broadcom-ordered-by-eu-to-halt-allegedly-anticompetitive-contract-practices-11571221103", "title": "Broadcom Ordered by EU to Halt Allegedly Anticompetitive Practices", "date": "2019-10-16 10:24", "summary": "Move marks the first time European Union regulators have used 'interim measures' since 2001. BRUSSELS-The European Union ordered semiconductor maker Broadcom Inc. to stop requiring contract terms with customers that the bloc alleges are anticompetitive, even as a probe into the practices continues-the first time regulators have used such an injunction in 18 years.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Broadcom Ordered by EU to Halt Allegedly Anticompetitive Practices. Move marks the first time European Union regulators have used 'interim measures' since 2001. BRUSSELS-The European Union ordered semiconductor maker Broadcom Inc. to stop requiring contract terms with customers that the bloc alleges are anticompetitive, even as a probe into the practices continues-the first time regulators have used such an injunction in 18 years.\"\n\nStock Prediction(s):", "Prediction": "\n- Broadcom Inc. (NASDAQ: AVGO) will decrease because they are being forced to stop anticompetitive practices.\n- Qualcomm Inc. (NASDAQ: QCOM) will increase because they are not being forced to stop anticompetitive practices.", "price_info": {"AVGO": {"company": "", "ticker": "AVGO", "move": "down", "prices": [289.98, 288.06]}, "QCOM": {"company": "", "ticker": "QCOM", "move": "up", "prices": [77.84, 77.59]}}}, {"link": "https://www.wsj.com/articles/investors-arent-playing-defense-but-the-military-splurge-isnt-over-11627314643", "title": "Investors Aren't Playing Defense, but the Military Splurge Isn't Over", "date": "2021-07-26 11:50", "summary": "Lockheed Martin's cheap valuation may overestimate the extent of defense budget cuts. Weapons makers are struggling in the current equity market, but their defensive perimeter may be more secure than it seems.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors Aren't Playing Defense, but the Military Splurge Isn't Over. Lockheed Martin's cheap valuation may overestimate the extent of defense budget cuts. Weapons makers are struggling in the current equity market, but their defensive perimeter may be more secure than it seems.\"\n\nStock Prediction(s):", "Prediction": "\n- Lockheed Martin Corporation (NYSE: LMT) will increase because their defensive perimeter is more secure than it seems and investors are underestimating their stock.\n- Northrop Grumman Corporation (NYSE: NOC) will increase because their defensive perimeter is more secure than it seems and investors are underestimating their stock.\n- Raytheon Company (NYSE: RTN) will increase because their defensive perimeter is more secure than it seems and investors are underestimating their stock", "price_info": {"LMT": {"company": "", "ticker": "LMT", "move": "up", "prices": [369.1196, 368.73]}, "NOC": {"company": "", "ticker": "NOC", "move": "up", "prices": [358.82, 358.87]}, "RTN": {"company": "", "ticker": "RTN", "move": "up"}}}, {"link": "https://www.wsj.com/articles/what-the-feds-interest-rate-cut-means-for-you-11583253298", "title": "What the Fed's Interest-Rate Cut Means for You", "date": "2020-03-03 11:34", "summary": "Falling rates can ripple through the cost of mortgages and interest earned on savings accounts. The Federal Reserve cut its short-term benchmark rate by a half percentage point Tuesday morning. The timing of this rate cut, which comes in between the Fed's scheduled policy meeting, hasn't occurred since the 2008 financial crisis.", "categories": [["Markets", "Your Money"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/undefined?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What the Fed's Interest-Rate Cut Means for You. Falling rates can ripple through the cost of mortgages and interest earned on savings accounts. The Federal Reserve cut its short-term benchmark rate by a half percentage point Tuesday morning. The timing of this rate cut, which comes in between the Fed's scheduled policy meeting, hasn't occurred since the 2008 financial crisis.\"\n\nStock Prediction(s):", "Prediction": "\n- The interest rate cut will have a positive effect on the housing market, and will also cause an increase in the stock prices of banks and other lending institutions.\n- The interest rate cut will have a negative effect on the stock prices of companies that rely on consumer spending, such as Walmart Inc. (NYSE: WMT) and Amazon.com, Inc. (NASDAQ: AMZN).", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [114.01, 114.15]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1941.7835, 1939.545]}}}, {"link": "https://www.wsj.com/articles/oil-demand-recovery-expected-to-outstrip-production-11613035778", "title": "Oil Demand Recovery Expected to Pick Up Speed", "date": "2021-02-11 15:44", "summary": "Despite projecting continued rebalancing, IEA increases supply forecast. The recovery in global oil demand will accelerate in the second half of this year as the market continues to rebalance after the turmoil brought by the pandemic, according to OPEC and the International Energy Agency.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Demand Recovery Expected to Pick Up Speed. Despite projecting continued rebalancing, IEA increases supply forecast. The recovery in global oil demand will accelerate in the second half of this year as the market continues to rebalance after the turmoil brought by the pandemic, according to OPEC and the International Energy Agency.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because they are a large oil producer and their products will be in high demand.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are a large oil producer and their products will be in high demand.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they are a large oil producer and their products will be in high demand.\n- BP plc (", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [91.85, 91.85]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [49.62, 49.72]}}}, {"link": "https://www.wsj.com/articles/ev-company-workhorses-finance-operating-chiefs-leave-in-shakeup-11633009015", "title": "EV Company Workhorse's Finance, Operating Chiefs Leave in Shake-Up", "date": "2021-09-30 11:45", "summary": "Electric-vehicle maker last week said it is suspending deliveries of its electric van and recalling 41 vans already sold. Workhorse Group Inc. said a pair of top executives have left the company in a management shake-up as the electric-vehicle maker works to get production back on track.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"EV Company Workhorse's Finance, Operating Chiefs Leave in Shake-Up. Electric-vehicle maker last week said it is suspending deliveries of its electric van and recalling 41 vans already sold. Workhorse Group Inc. said a pair of top executives have left the company in a management shake-up as the electric-vehicle maker works to get production back on track.\"\n\nStock Prediction(s):", "Prediction": "\n- Workhorse Group Inc. (NASDAQ: WKHS) will decrease because their top finance and operating chiefs have left the company.", "price_info": {"WKHS": {"company": "", "ticker": "WKHS", "move": "down", "prices": [7.565, 7.6299]}}}, {"link": "https://www.wsj.com/articles/backlash-brews-in-chinas-startup-culture-against-grueling-hours-11556633929", "title": "Backlash Brews in China's Startup Culture Against Grueling Hours", "date": "2019-04-30 10:18", "summary": "With tech companies retrenching in a slowing economy, workers are souring on elusive dream of becoming the next startup billionaire. BEIJING-China's rapid technology-sector development was built on workers who were willing to endure a grueling schedule in return for high pay and a shot at becoming the next startup billionaire.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Backlash Brews in China's Startup Culture Against Grueling Hours. With tech companies retrenching in a slowing economy, workers are souring on elusive dream of becoming the next startup billionaire. BEIJING-China's rapid technology-sector development was built on workers who were willing to endure a grueling schedule in return for high pay and a shot at becoming the next startup billionaire.\"\n\nStock Prediction(s):", "Prediction": "\n- Alibaba Group Holding Ltd. (NYSE: BABA) will increase because they are a major player in the Chinese tech sector, and they have not been mentioned in the article.\n- Baidu Inc. (NASDAQ: BIDU) will decrease because they are a major player in the Chinese tech sector, and they have been mentioned in the article.\n- Tencent Holdings Ltd. (OTCMKTS: TCEHY) will decrease because they", "price_info": {"BABA": {"company": "", "ticker": "BABA", "move": "up", "prices": [184.36, 185.71]}, "BIDU": {"company": "", "ticker": "BIDU", "move": "down", "prices": [163.74, 165.29]}}}, {"link": "https://www.wsj.com/articles/feds-kaplan-open-to-overshooting-inflation-target-to-provide-more-support-11594995860", "title": "Fed's Kaplan Open to Overshooting Inflation Target to Provide More Support", "date": "2020-07-17 10:24", "summary": "\"We should keep rates lower for longer,\" says Dallas Fed President in an interview. Dallas Fed President Robert Kaplan said he is receptive to changes the central bank has considered to its policy-making framework that would allow interest rates to remain lower for longer by allowing inflation to rise modestly above its 2% target for some time.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Kaplan Open to Overshooting Inflation Target to Provide More Support. \"We should keep rates lower for longer,\" says Dallas Fed President in an interview. Dallas Fed President Robert Kaplan said he is receptive to changes the central bank has considered to its policy-making framework that would allow interest rates to remain lower for longer by allowing inflation to rise modestly above its 2% target for some time.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FED) will increase because they are looking to allow inflation to rise modestly above its 2% target.\n- The bond market will decrease because investors are expecting the Fed to raise rates.", "price_info": {"FED": {"company": "", "ticker": "FED", "move": "up"}}}, {"link": "https://www.wsj.com/articles/pfizer-biontech-seek-fda-clearance-for-covid-19-booster-11629136057", "title": "Pfizer, BioNTech Seek FDA Clearance for Covid-19 Booster", "date": "2021-08-16 13:47", "summary": "Early-stage study shows third dose of vaccine offers a higher level of protection, companies say. Pfizer Inc. and partner BioNTech SE have submitted data to U.S. health regulators needed to clear a Covid-19 booster shot among the general public.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Pfizer, BioNTech Seek FDA Clearance for Covid-19 Booster. Early-stage study shows third dose of vaccine offers a higher level of protection, companies say. Pfizer Inc. and partner BioNTech SE have submitted data to U.S. health regulators needed to clear a Covid-19 booster shot among the general public.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will increase because they are working on a vaccine that could be cleared by the FDA, and they are a direct competitor of AstraZeneca.\n- BioNTech SE (OTC: BNTXF) will increase because they are working on a vaccine with Pfizer, and they are a direct competitor of AstraZeneca.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "up", "prices": [48.72, 48.92]}}}, {"link": "https://www.wsj.com/articles/evergrande-is-in-crisis-but-a-risky-china-still-beckons-to-investors-11632339150", "title": "China Still Beckons U.S. Investors Despite Evergrande Crisis", "date": "2021-09-22 15:32", "summary": "Some view a default by the Chinese property developer as good for markets long-term, while others see rising risks. Some big U.S. investors are looking past the potential failure of a massive Chinese property developer whose debt woes shook global markets this week, giving a vote of confidence to China as an investment destination despite the rising regulatory and political risks foreign investors increasingly face there.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"China Still Beckons U.S. Investors Despite Evergrande Crisis. Some view a default by the Chinese property developer as good for markets long-term, while others see rising risks. Some big U.S. investors are looking past the potential failure of a massive Chinese property developer whose debt woes shook global markets this week, giving a vote of confidence to China as an investment destination despite the rising regulatory and political risks foreign investors increasingly face there.\"\n\nStock Prediction(s):", "Prediction": "\n- Evergrande Group (OTC: EVGNF) will increase because some big U.S. investors are looking past their debt woes, and see them as a good investment destination.\n- American Tower Corp (NYSE: AMT) will increase because they have a lot of exposure to China, and they see the potential failure of Evergrande Group as a good opportunity.\n- Facebook Inc (NASDAQ: FB) will increase because they are trying to", "price_info": {"AMT": {"company": "", "ticker": "AMT", "move": "up", "prices": [297.27, 294.4]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [342.17, 342.8]}}}, {"link": "https://www.wsj.com/articles/treasury-to-sell-132-billion-in-debt-11581624168", "title": "Treasury to Sell $132 Billion in Debt", "date": "2020-02-13 15:02", "summary": "Auctions planned for next week range from 21-day cash-management bills to 30-year TIPS. The U.S. Treasury Department will auction $132 billion in securities next week, comprising $47 billion in new debt and $85 billion in previously sold debt. Details (all with minimum denominations of $100):", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasury to Sell $132 Billion in Debt. Auctions planned for next week range from 21-day cash-management bills to 30-year TIPS. The U.S. Treasury Department will auction $132 billion in securities next week, comprising $47 billion in new debt and $85 billion in previously sold debt. Details (all with minimum denominations of $100):\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Treasury Department will auction $132 billion in securities next week, and the market will react positively because this is a sign of economic stability.\n- The U.S. Treasury Department will auction $132 billion in securities next week, and the market will react negatively because this is a sign of economic instability.", "price_info": {}}, {"link": "https://www.wsj.com/articles/best-buy-growth-slows-after-pandemic-fueled-surge-11637670704", "title": "Best Buy's, Dick's E-Commerce Growth Slows After Pandemic-Fueled Surge", "date": "2021-11-23 10:18", "summary": "Online-sales gains cool from year ago when many mall stores were shut; inventory issues squeeze other chains. Consumers are spending freely on sporting goods and kitchen appliances, but they are doing more of their shopping in stores than they did last year when Covid-19 restrictions upended the holiday shopping season.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Best Buy's, Dick's E-Commerce Growth Slows After Pandemic-Fueled Surge. Online-sales gains cool from year ago when many mall stores were shut; inventory issues squeeze other chains. Consumers are spending freely on sporting goods and kitchen appliances, but they are doing more of their shopping in stores than they did last year when Covid-19 restrictions upended the holiday shopping season.\"\n\nStock Prediction(s):", "Prediction": "\n- Best Buy Co Inc (NYSE: BBY) will decrease because their e-commerce growth has slowed down.\n- Dick's Sporting Goods Inc (NYSE: DKS) will decrease because their e-commerce growth has slowed down.\n- Home Depot Inc (NYSE: HD) will increase because their e-commerce growth has not slowed down.", "price_info": {"BBY": {"company": "", "ticker": "BBY", "move": "down", "prices": [117.3182, 116.3]}, "DKS": {"company": "", "ticker": "DKS", "move": "down", "prices": [128.3772, 126.7897]}, "HD": {"company": "", "ticker": "HD", "move": "up", "prices": [406.1143, 405.2]}}}, {"link": "https://www.wsj.com/articles/how-to-suspend-your-mortgage-payments-during-coronavirus-turmoil-11585909800", "title": "How to Suspend Your Mortgage Payments", "date": "2020-04-06 09:30", "summary": "If your loan is federally backed and you're experiencing hardship caused by the pandemic, lenders are supposed to allow forbearance. If your mortgage is federally backed, lenders are supposed to allow forbearance for those experiencing a financial hardship caused by the coronavirus pandemic. Here are answers to commonly asked questions:", "categories": [["Markets", "Personal Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/personal-finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Suspend Your Mortgage Payments. If your loan is federally backed and you're experiencing hardship caused by the pandemic, lenders are supposed to allow forbearance. If your mortgage is federally backed, lenders are supposed to allow forbearance for those experiencing a financial hardship caused by the coronavirus pandemic. Here are answers to commonly asked questions:\"\n\nStock Prediction(s):", "Prediction": "\n- Bank of America Corporation (NYSE: BAC) will increase because they are one of the largest mortgage lenders in the United States.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are one of the largest mortgage lenders in the United States.\n- Wells Fargo & Company (NYSE: WFC) will increase because they are one of the largest mortgage lenders in the United States.\n- Citigroup, Inc. (NYSE: C)", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [21.12, 21.045]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [89.415, 88.52]}, "WFC": {"company": "", "ticker": "WFC", "move": "up", "prices": [27.982, 27.96]}, "C": {"company": "America", "ticker": "C", "move": null, "prices": [40.63, 39.814]}}}, {"link": "https://www.wsj.com/articles/corporate-tech-in-line-for-its-pandemic-haircut-11594319207", "title": "Corporate Tech in Line for its Pandemic Haircut", "date": "2020-07-09 14:26", "summary": "Surveys find tech budgets are getting cut, but software stocks continue to soar. As the pandemic rages on, corporate technology budgets won't be spared. That could prove a problem for investors who have been banking on business being even better than usual.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Corporate Tech in Line for its Pandemic Haircut. Surveys find tech budgets are getting cut, but software stocks continue to soar. As the pandemic rages on, corporate technology budgets won't be spared. That could prove a problem for investors who have been banking on business being even better than usual.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will decrease because their main product is software, and companies are cutting back on their technology budgets.\n- Apple Inc. (NASDAQ: AAPL) will decrease because their main product is hardware, and companies are cutting back on their technology budgets.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because their main product is e-commerce, and companies are cutting back on their technology", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [214.1199, 214.19]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [382.36, 382.6]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3178.29, 3194]}}}, {"link": "https://www.wsj.com/articles/coke-and-pepsico-post-big-sales-gains-on-big-price-increases-11644500511", "title": "Coke and PepsiCo Earnings Show Big Sales Gains on Big Price Increases", "date": "2022-02-10 12:48", "summary": "Global giants able to tap into robust demand but caution about rising costs for materials and transportation. Coca-Cola Co. and PepsiCo Inc. reported higher quarterly sales as the global soda giants pushed through price increases but also felt the squeeze of higher costs for commodities and transportation.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coke and PepsiCo Earnings Show Big Sales Gains on Big Price Increases. Global giants able to tap into robust demand but caution about rising costs for materials and transportation. Coca-Cola Co. and PepsiCo Inc. reported higher quarterly sales as the global soda giants pushed through price increases but also felt the squeeze of higher costs for commodities and transportation.\"\n\nStock Prediction(s):", "Prediction": "\n- Coca-Cola Co. (NYSE: KO) will increase because they were able to increase prices and have robust demand.\n- PepsiCo Inc. (NYSE: PEP) will increase because they were able to increase prices and have robust demand.", "price_info": {"KO": {"company": "", "ticker": "KO", "move": "up", "prices": [61.975, 61.345]}, "PEP": {"company": "", "ticker": "PEP", "move": "up", "prices": [169.09, 168.22]}}}, {"link": "https://www.wsj.com/articles/tight-labor-market-calls-for-speedier-hiring-process-11549657078", "title": "Tight Labor Market Calls For Speedier Hiring Process", "date": "2019-02-08 15:17", "summary": "Companies are at risk of missing out on scarce top talent as hiring processes get longer. Low unemployment rates mean companies can't risking dragging out their hiring processes. If they do, staffing consultants say, they risk losing the interest of top candidates or worse: losing them to competitors who move faster.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Tight Labor Market Calls For Speedier Hiring Process. Companies are at risk of missing out on scarce top talent as hiring processes get longer. Low unemployment rates mean companies can't risking dragging out their hiring processes. If they do, staffing consultants say, they risk losing the interest of top candidates or worse: losing them to competitors who move faster.\"\n\nStock Prediction(s):", "Prediction": "\n- Hiring processes will speed up because companies do not want to lose out on top talent.\n- Staffing companies will increase because they are the ones who help companies speed up their hiring processes.", "price_info": {}}, {"link": "https://www.wsj.com/articles/biogen-can-bounce-back-from-multiple-sclerosis-blow-11592497508", "title": "Biogen Can Bounce Back from Multiple-Sclerosis Blow", "date": "2020-06-18 12:25", "summary": "Surprise hit to Biogen's blockbuster multiple-sclerosis drug shouldn't sting shareholders for long. Biogen has suffered a surprise blow to its blockbuster multiple-sclerosis franchise. It has a chance to recover, but investors should expect a bumpy ride.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Biogen Can Bounce Back from Multiple-Sclerosis Blow. Surprise hit to Biogen's blockbuster multiple-sclerosis drug shouldn't sting shareholders for long. Biogen has suffered a surprise blow to its blockbuster multiple-sclerosis franchise. It has a chance to recover, but investors should expect a bumpy ride.\"\n\nStock Prediction(s):", "Prediction": "\n- Biogen Inc (NASDAQ: BIIB) will increase because their MS drug was just hit with a surprise, but they have a chance to recover.\n- Novartis AG (NYSE: NVS) will increase because they are a direct competitor of Biogen, and they also have a strong pipeline.\n- Roche Holding AG (OTCQX: RHHBY) will increase because they are a direct competitor of Biogen, and they also", "price_info": {"NVS": {"company": "", "ticker": "NVS", "move": "up", "prices": [89.64, 89.507]}, "BIIB": {"company": "", "ticker": "BIIB", "move": "up", "prices": [262.11, 260.3]}}}, {"link": "https://www.wsj.com/articles/mcdonalds-to-back-diverse-restaurant-owners-11638977402", "title": "McDonald's to Back Diverse Restaurant Owners", "date": "2021-12-08 10:30", "summary": "Chain says it will put millions into loans to boost minority representation. McDonald's Corp. said Wednesday it would offer $250 million in low-interest loans to new franchisees over the next five years as a way to help increase diverse ownership of its U.S. restaurants.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"McDonald's to Back Diverse Restaurant Owners. Chain says it will put millions into loans to boost minority representation. McDonald's Corp. said Wednesday it would offer $250 million in low-interest loans to new franchisees over the next five years as a way to help increase diverse ownership of its U.S. restaurants.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corp. (NYSE: MCD) will increase because they are trying to increase diversity in their restaurant ownership.\n- Other restaurant chains will decrease because they will not be able to compete with McDonald's new initiative.", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "down", "prices": [261.85, 260.63]}}}, {"link": "https://www.wsj.com/articles/marriott-ceo-to-have-surgery-as-part-of-cancer-treatment-11572973507", "title": "Marriott CEO to Have Surgery as Part of Cancer Treatment", "date": "2019-11-05 12:05", "summary": "The hotel company disclosed in May that Arne Sorenson had pancreatic cancer. Marriott International Inc.'s chief executive, Arne Sorenson, said Tuesday that he will have surgery to treat his pancreatic cancer.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Marriott CEO to Have Surgery as Part of Cancer Treatment. The hotel company disclosed in May that Arne Sorenson had pancreatic cancer. Marriott International Inc.'s chief executive, Arne Sorenson, said Tuesday that he will have surgery to treat his pancreatic cancer.\"\n\nStock Prediction(s):", "Prediction": "\n- Marriott International Inc. (NASDAQ: MAR) will decrease because their CEO is undergoing surgery.", "price_info": {"MAR": {"company": "", "ticker": "MAR", "move": "down", "prices": [133.22, 133.57]}}}, {"link": "https://www.wsj.com/articles/what-ceos-cfos-are-saying-about-the-prospects-of-higher-taxes-11618510341", "title": "What CEOs, CFOs Are Saying About Prospects of Higher Taxes", "date": "2021-04-15 14:12", "summary": "Business leaders discuss President Biden's $2.3 trillion infrastructure plan and proposal to raise tax rate on companies. Executives at American companies are bracing for higher taxes following the unveiling of President Biden's $2.3 trillion infrastructure plan, which is proposing to raise the corporate tax rate to 28% from 21%, and increase taxes on companies' foreign earnings.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What CEOs, CFOs Are Saying About Prospects of Higher Taxes. Business leaders discuss President Biden's $2.3 trillion infrastructure plan and proposal to raise tax rate on companies. Executives at American companies are bracing for higher taxes following the unveiling of President Biden's $2.3 trillion infrastructure plan, which is proposing to raise the corporate tax rate to 28% from 21%, and increase taxes on companies' foreign earnings.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co (NYSE: BA) will increase because they have a lot of money overseas and will benefit from the proposed increase in the tax rate on companies' foreign earnings.\n- Apple Inc. (NASDAQ: AAPL) will increase because they have a lot of money overseas and will benefit from the proposed increase in the tax rate on companies' foreign earnings.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they have a lot of money overseas", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "up", "prices": [251.6759, 251.11]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [134.0151, 134.5]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [258.6042, 259.425]}}}, {"link": "https://www.wsj.com/articles/fed-inflation-cpi-rates-11636552015", "title": "Inflation Pickup Makes Fed More Likely to Raise Rates Next Year", "date": "2021-11-10 14:35", "summary": "Consumer prices are rising at their strongest 12-month pace in three decades. The latest rise in inflation helps to explain why investors are increasingly asking not whether the Federal Reserve will raise interest rates next year but rather how much and how quickly it may do so.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Inflation Pickup Makes Fed More Likely to Raise Rates Next Year. Consumer prices are rising at their strongest 12-month pace in three decades. The latest rise in inflation helps to explain why investors are increasingly asking not whether the Federal Reserve will raise interest rates next year but rather how much and how quickly it may do so.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FFR) will increase interest rates next year because of the uptick in inflation.\n- The bond market will react negatively to the news because it means that the cost of borrowing money will increase.\n- The stock market will react positively to the news because it means that the economy is doing well and that the Fed is being proactive in fighting inflation.", "price_info": {"FFR": {"company": "", "ticker": "FFR", "move": "up", "prices": [53.6669, 53.5683]}}}, {"link": "https://www.wsj.com/articles/feds-kashkari-monetary-policy-has-been-too-tight-during-expansion-11558023072", "title": "Fed's Kashkari: Monetary Policy Has Been Too Tight During Expansion", "date": "2019-05-16 12:11", "summary": "Central bank raised rates too early in cycle, he said. Federal Reserve Bank of Minneapolis President Neel Kashkari reiterated Thursday his view that the U.S. central bank raised rates too early in the expansion and has caused inflation to be lower than it might have been, and engineered what was likely too slow a recovery in the job market.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Kashkari: Monetary Policy Has Been Too Tight During Expansion. Central bank raised rates too early in cycle, he said. Federal Reserve Bank of Minneapolis President Neel Kashkari reiterated Thursday his view that the U.S. central bank raised rates too early in the expansion and has caused inflation to be lower than it might have been, and engineered what was likely too slow a recovery in the job market.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of Minneapolis (NYSE: FMN) will decrease because they have been too tight with their monetary policy.\n- The Federal Reserve Bank of Dallas (NYSE: DAL) will increase because they have been more loose with their monetary policy.", "price_info": {"FMN": {"company": "", "ticker": "FMN", "move": "down", "prices": [13.57, 13.57]}, "DAL": {"company": "", "ticker": "DAL", "move": "up", "prices": [55.74, 55.65]}}}, {"link": "https://www.wsj.com/articles/adidas-to-relaunch-beyonces-ivy-park-line-11554395134", "title": "Adidas to Relaunch Beyonc\u00e9's Ivy Park Line", "date": "2019-04-04 12:25", "summary": "Partnership marks another high-profile pairing of an entertainer with an athletic-goods company. BERLIN- Adidas AG said Thursday it has named music icon Beyonc\u00e9\u0301as a creative partner and would relaunch her activewear line Ivy Park under the German sportswear brand, the latest high-profile pairing of an entertainer with an athletic-goods company.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Adidas to Relaunch Beyonc\u00e9's Ivy Park Line. Partnership marks another high-profile pairing of an entertainer with an athletic-goods company. BERLIN- Adidas AG said Thursday it has named music icon Beyonc\u00e9\u0301as a creative partner and would relaunch her activewear line Ivy Park under the German sportswear brand, the latest high-profile pairing of an entertainer with an athletic-goods company.\"\n\nStock Prediction(s):", "Prediction": "\n- Adidas AG (OTCMKTS: ADDYY) will increase because they are partnering with Beyonc\u00e9\u0301.\n- Nike, Inc. (NYSE: NKE) will decrease because they are a direct competitor of Adidas.", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [84.7233, 84.99]}}}, {"link": "https://www.wsj.com/articles/cal-maine-sales-rose-sharply-as-consumers-stocked-up-on-eggs-11595253073", "title": "Cal-Maine Sales Rose as Consumers Stocked Up on Eggs", "date": "2020-07-20 11:59", "summary": "Company expects supply glut to ease as USDA-reported hen numbers have decreased. Cal-Maine Foods Inc. said its sales rose 62% in the latest quarter compared with a year earlier as consumers stocked up on eggs to prepare meals at home during the coronavirus pandemic.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Cal-Maine Sales Rose as Consumers Stocked Up on Eggs. Company expects supply glut to ease as USDA-reported hen numbers have decreased. Cal-Maine Foods Inc. said its sales rose 62% in the latest quarter compared with a year earlier as consumers stocked up on eggs to prepare meals at home during the coronavirus pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Cal-Maine Foods Inc. (NASDAQ: CALM) will continue to increase because of the increase in sales due to the pandemic.\n- Other egg producers such as Rose Acre Farms Inc. (NYSE: ROSE) and Wayne Farms LLC (NASDAQ: WNFM) will also increase because of the increase in demand for eggs.", "price_info": {"ROSE": {"company": "", "ticker": "ROSE", "move": null, "prices": [0.4193, 0.4202]}, "CALM": {"company": "", "ticker": "CALM", "move": "up", "prices": [43.1329, 43.48]}, "WNFM": {"company": "", "ticker": "WNFM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/teradyne-appoints-new-cfo-ahead-of-expansion-11554385216", "title": "Teradyne Appoints New CFO Ahead of Expansion", "date": "2019-04-04 09:40", "summary": "New finance chief Sanjay Mehta joins from Qualcomm. Teradyne Inc. on Thursday named a new finance chief, as the manufacturer of automation equipment plans to expand its test equipment and industrial applications businesses.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Teradyne Appoints New CFO Ahead of Expansion. New finance chief Sanjay Mehta joins from Qualcomm. Teradyne Inc. on Thursday named a new finance chief, as the manufacturer of automation equipment plans to expand its test equipment and industrial applications businesses.\"\n\nStock Prediction(s):", "Prediction": "\n- Teradyne Inc. (NYSE: TER) will increase because they are expanding their business.\n- Qualcomm Inc. (NASDAQ: QCOM) will decrease because Sanjay Mehta, their former CFO, is moving to Teradyne.", "price_info": {"TER": {"company": "", "ticker": "TER", "move": "up", "prices": [43.14, 43.225]}, "QCOM": {"company": "", "ticker": "QCOM", "move": "down", "prices": [58.3, 58.56]}}}, {"link": "https://www.wsj.com/articles/sec-revives-proposal-to-claw-back-executive-pay-11634231515", "title": "SEC Revives Proposal to Claw Back Executive Pay", "date": "2021-10-14 14:33", "summary": "The regulator is asking the public for more feedback on a plan that seeks to punish accounting missteps by revoking pay from top executives. The Securities and Exchange Commission is working to implement a controversial rule proposed in 2015 that would force companies whose financial results contain errors to claw back some of their executives' incentive pay.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SEC Revives Proposal to Claw Back Executive Pay. The regulator is asking the public for more feedback on a plan that seeks to punish accounting missteps by revoking pay from top executives. The Securities and Exchange Commission is working to implement a controversial rule proposed in 2015 that would force companies whose financial results contain errors to claw back some of their executives' incentive pay.\"\n\nStock Prediction(s):", "Prediction": "\n- Companies with poor accounting practices will see a decrease in stock prices as a result of this news.\n- Companies with good accounting practices will see a slight increase in stock prices as a result of this news.", "price_info": {}}, {"link": "https://www.wsj.com/articles/feds-beige-book-shutdown-slowed-economic-activity-in-some-areas-11551899120", "title": "Fed's Beige Book: Shutdown Slowed Economic Activity in Some Areas", "date": "2019-03-06 14:30", "summary": "Ten of the Fed's 12 regional districts reported economic output expanded at a 'slight-to-moderate' pace in recent weeks. WASHINGTON-Economic activity expanded across the U.S. at the beginning of 2019, with many parts of the country noting the government shutdown led to slower economic activity, according to a Federal Reserve report released Wednesday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Beige Book: Shutdown Slowed Economic Activity in Some Areas. Ten of the Fed's 12 regional districts reported economic output expanded at a 'slight-to-moderate' pace in recent weeks. WASHINGTON-Economic activity expanded across the U.S. at the beginning of 2019, with many parts of the country noting the government shutdown led to slower economic activity, according to a Federal Reserve report released Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed's Beige Book suggests that the economy is still growing, so most stocks will continue to increase.\n- The only exception is companies that are directly affected by the government shutdown, such as government contractors.", "price_info": {}}, {"link": "https://www.wsj.com/articles/united-technologies-bet-on-aerospace-is-working-for-now-11563901423", "title": "United Technologies' Bet on Aerospace Is Working, for Now", "date": "2019-07-23 13:03", "summary": "Collins Aerospace, the division created from a $30 billion acquisition last year, helped UTC to beat analysts' expectations in the second quarter. While the merger of United Technologies with Raytheon announced last month has its fair share of critics, the conglomerate's previous big aerospace acquisition is turning out nicely.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"United Technologies' Bet on Aerospace Is Working, for Now. Collins Aerospace, the division created from a $30 billion acquisition last year, helped UTC to beat analysts' expectations in the second quarter. While the merger of United Technologies with Raytheon announced last month has its fair share of critics, the conglomerate's previous big aerospace acquisition is turning out nicely.\"\n\nStock Prediction(s):", "Prediction": "\n- United Technologies Corporation (NYSE: UTX) will increase because their aerospace division is doing well.\n- Raytheon Company (NYSE: RTN) will decrease because they are a direct competitor of United Technologies.", "price_info": {"UTX": {"company": "", "ticker": "UTX", "move": "up", "prices": [134.4268, 134.8158]}, "RTN": {"company": "", "ticker": "RTN", "move": "down", "prices": [181.89, 181.62]}}}, {"link": "https://www.wsj.com/articles/spotifys-fate-is-in-the-stars-11643653878", "title": "Spotify's Fate Is in the Stars", "date": "2022-01-31 13:31", "summary": "Market-value swing from controversy between Joe Rogan and Neil Young underscores new level of risk from podcast focus. Whatever else Joe Rogan may be, no one should accuse him of not being a team player.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Spotify's Fate Is in the Stars. Market-value swing from controversy between Joe Rogan and Neil Young underscores new level of risk from podcast focus. Whatever else Joe Rogan may be, no one should accuse him of not being a team player.\"\n\nStock Prediction(s):", "Prediction": "\n- Spotify Technology SA (NYSE: SPOT) will decrease because of the controversy between Joe Rogan and Neil Young.", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "down", "prices": [191.79, 194.86]}}}, {"link": "https://www.wsj.com/articles/gm-plans-to-idle-factories-longer-amid-chip-shortage-11631819780", "title": "GM Plans to Idle Factories Longer Amid Chip Shortage", "date": "2021-09-16 15:16", "summary": "Auto maker will add to scheduled downtime at seven plants in the U.S., Canada and Mexico. General Motors Co. is extending its plans to idle some of its North American factories, compounding the effects of the world-wide semiconductor shortage on the auto maker's production.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"GM Plans to Idle Factories Longer Amid Chip Shortage. Auto maker will add to scheduled downtime at seven plants in the U.S., Canada and Mexico. General Motors Co. is extending its plans to idle some of its North American factories, compounding the effects of the world-wide semiconductor shortage on the auto maker's production.\"\n\nStock Prediction(s):", "Prediction": "\n- GM (NYSE: GM) will decrease because they are not able to produce their cars because of the chip shortage.\n- Ford Motor Company (NYSE: F) will decrease because they are not able to produce their cars because of the chip shortage.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will decrease because they are not able to produce their cars because of the chip shortage.", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "down", "prices": [51.48, 51.455]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [13.41, 13.41]}, "FCAU": {"company": "", "ticker": "FCAU", "move": "down"}}}, {"link": "https://www.wsj.com/articles/is-president-trump-finally-getting-a-weaker-dollar-11562583605", "title": "Is President Trump Finally Getting a Weaker Dollar?", "date": "2019-07-08 09:51", "summary": "The U.S. currency has slipped from recent highs, and analysts say it may be in for a steady decline. President Trump has repeatedly bashed the dollar's strength in recent years, only for the currency to grind higher. Now, analysts say, the U.S. currency may finally be primed for a decline, albeit a slow and steady one.", "categories": [["Markets", "Currencies", "Foreign Exchange"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/currencies?mod=breadcrumb", "https://www.wsj.com/news/types/foreign-exchange?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Is President Trump Finally Getting a Weaker Dollar?. The U.S. currency has slipped from recent highs, and analysts say it may be in for a steady decline. President Trump has repeatedly bashed the dollar's strength in recent years, only for the currency to grind higher. Now, analysts say, the U.S. currency may finally be primed for a decline, albeit a slow and steady one.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. Dollar Index (DXY) will decrease because the President has been bashing it, and it is primed for a decline.\n- The Euro (EUR) will increase because the Dollar is decreasing, and the Euro is a strong alternative.\n- The British Pound (GBP) will increase because the Dollar is decreasing, and the Pound is a strong alternative.", "price_info": {"DXY": {"company": "Dollar Index", "ticker": "DXY", "move": "down"}, "EUR": {"company": "The Euro", "ticker": "EUR", "move": "up"}, "GBP": {"company": "British Pound", "ticker": "GBP", "move": "up"}}}, {"link": "https://www.wsj.com/articles/metals-tycoon-gupta-hires-advisers-to-navigate-greensill-fallout-11615394876", "title": "Metals Tycoon Gupta Hires Advisers to Navigate Greensill Fallout", "date": "2021-03-10 13:58", "summary": "U.K. tycoon and GFG Alliance tap trio of financing and restructuring firms to help negotiate with Greensill, raise fresh funding. LONDON-U.K. metals tycoon Sanjeev Gupta has hired a trio of financing and restructuring advisers to help his GFG Alliance group of companies negotiate with its main creditor, Greensill Capital, and raise fresh funding, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Finance"]], "category_links": ["https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Metals Tycoon Gupta Hires Advisers to Navigate Greensill Fallout. U.K. tycoon and GFG Alliance tap trio of financing and restructuring firms to help negotiate with Greensill, raise fresh funding. LONDON-U.K. metals tycoon Sanjeev Gupta has hired a trio of financing and restructuring advisers to help his GFG Alliance group of companies negotiate with its main creditor, Greensill Capital, and raise fresh funding, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Liberty House Group (LON: LHG) will increase because they are a direct competitor of Greensill and they have more resources to negotiate.\n- GFG Alliance (LON: GFG) will increase because they are a direct competitor of Greensill and they have more resources to negotiate.\n- Greensill Capital (LON: GSC) will decrease because they are a direct competitor of Liberty House and GFG Alliance, and they will have less resources", "price_info": {}}, {"link": "https://www.wsj.com/articles/minority-owners-pressure-dan-snyder-to-sell-washingtons-nfl-team-11597343129", "title": "Minority Owners Pressure Dan Snyder to Sell Washington's NFL Team", "date": "2020-08-13 14:25", "summary": "A fight among the franchise's owners has intensified while the team faces controversy on multiple fronts. The minority partners of Washington's NFL team are pressuring Dan Snyder to sell the franchise, according to people familiar with the matter, amid a growing fight inside a team facing controversy on multiple fronts.", "categories": [["WSJ News Exclusive", "NFL"]], "category_links": ["https://www.wsj.com/news/types/nfl?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Minority Owners Pressure Dan Snyder to Sell Washington's NFL Team. A fight among the franchise's owners has intensified while the team faces controversy on multiple fronts. The minority partners of Washington's NFL team are pressuring Dan Snyder to sell the franchise, according to people familiar with the matter, amid a growing fight inside a team facing controversy on multiple fronts.\"\n\nStock Prediction(s):", "Prediction": "\n- Washington Redskins owner Dan Snyder will sell the team because of pressure from minority partners.\n- The team's value will decrease because of the controversy and Snyder's potential departure.", "price_info": {}}, {"link": "https://www.wsj.com/articles/progress-on-new-car-quality-stalls-after-years-of-improvement-j-d-power-says-11560963634", "title": "Progress on New-Car Quality Stalls After Years of Improvement", "date": "2019-06-19 14:33", "summary": "Vehicle owners report problems with paint imperfections, check-engine lights and driver-assistance features.. After four years of steady improvement, new-vehicle quality leveled off within the past year as car companies continued to battle problems with both new and old technology, according to an annual survey of U.S. car buyers by research firm J.D. Power.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Progress on New-Car Quality Stalls After Years of Improvement. Vehicle owners report problems with paint imperfections, check-engine lights and driver-assistance features.. After four years of steady improvement, new-vehicle quality leveled off within the past year as car companies continued to battle problems with both new and old technology, according to an annual survey of U.S. car buyers by research firm J.D. Power.\"\n\nStock Prediction(s):", "Prediction": "\n- General Motors Company (NYSE: GM) will decrease because their quality of new cars has stalled.\n- Ford Motor Company (NYSE: F) will decrease because their quality of new cars has stalled.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will decrease because their quality of new cars has stalled.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because they are not included in the survey, and they have a", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "down", "prices": [36.97, 36.75]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [10.055, 10.04]}, "FCAU": {"company": "", "ticker": "FCAU", "move": "down", "prices": [13.635, 13.57]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [226.56, 226.9]}}}, {"link": "https://www.wsj.com/articles/rupert-murdoch-buys-200-million-montana-ranch-from-the-koch-family-11639065752", "title": "Rupert Murdoch Buys $200 Million Montana Ranch From the Koch Family", "date": "2021-12-09 11:02", "summary": "The media mogul and his wife, Jerry Murdoch, purchased a cattle ranch spanning about 340,000 acres near Yellowstone National Park. Media mogul Rupert Murdoch and his wife, Jerry Murdoch, have purchased a Montana cattle ranch spanning about 340,000 acres from Matador Cattle Co., a subsidiary of Koch Industries. The price was roughly $200 million, making it the largest ranch sale in Montana history, according to people with knowledge of the deal.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Rupert Murdoch Buys $200 Million Montana Ranch From the Koch Family. The media mogul and his wife, Jerry Murdoch, purchased a cattle ranch spanning about 340,000 acres near Yellowstone National Park. Media mogul Rupert Murdoch and his wife, Jerry Murdoch, have purchased a Montana cattle ranch spanning about 340,000 acres from Matador Cattle Co., a subsidiary of Koch Industries. The price was roughly $200 million, making it the largest ranch sale in Montana history, according to people with knowledge of the deal.\"\n\nStock Prediction(s):", "Prediction": "\n- Koch Industries, Inc. (NYSE: KHC) will increase because Rupert Murdoch is a big investor in the company and this is a good move for him.\n- News Corporation (NASDAQ: NWSA) will increase because Rupert Murdoch is a big investor in the company and this is a good move for him.\n- Viacom, Inc. (NASDAQ: VIAB) will increase because Rupert Murdoch is a big investor in the company and this", "price_info": {"KHC": {"company": "", "ticker": "KHC", "move": "up", "prices": [33.19, 33.195]}, "NWSA": {"company": "", "ticker": "NWSA", "move": "up", "prices": [22.005, 21.9]}, "VIAB": {"company": "", "ticker": "VIAB", "move": "up"}}}, {"link": "https://www.wsj.com/articles/remote-work-how-to-build-and-maintain-an-office-culture-without-an-office-11600971226", "title": "Remote Work: How to Build and Maintain an Office Culture Without an Office", "date": "2020-09-24 14:13", "summary": "Working from home makes it hard to create norms that every employee knows to follow. But there are ways to do it.. From the moment you start a new job, you're indoctrinated in the culture of your employer.", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Remote Work: How to Build and Maintain an Office Culture Without an Office. Working from home makes it hard to create norms that every employee knows to follow. But there are ways to do it.. From the moment you start a new job, you're indoctrinated in the culture of your employer.\"\n\nStock Prediction(s):", "Prediction": "\n- Workday, Inc. (NASDAQ: WDAY) will increase because they offer a remote work program that helps to build and maintain an office culture.\n- Cisco Systems, Inc. (NASDAQ: CSCO) will increase because they offer a remote work program that helps to build and maintain an office culture.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they offer a remote work program that helps to build and maintain an office culture", "price_info": {"WDAY": {"company": "", "ticker": "WDAY", "move": "up", "prices": [209.1802, 208.69]}, "CSCO": {"company": "", "ticker": "CSCO", "move": "up", "prices": [37.8001, 37.88]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [203.245, 203.31]}}}, {"link": "https://www.wsj.com/articles/petco-roars-back-to-public-markets-11616077967", "title": "Petco Revenue Jumps in First Earnings Report After Going Public", "date": "2021-03-18 10:32", "summary": "Pet-store operator cites surge in pet ownership during the pandemic and logistics shift. At the height of the holiday season, Petco Health and Wellness Co. moved nearly a third of its online business out of struggling delivery networks that were buckling under overwhelming package volumes.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Petco Revenue Jumps in First Earnings Report After Going Public. Pet-store operator cites surge in pet ownership during the pandemic and logistics shift. At the height of the holiday season, Petco Health and Wellness Co. moved nearly a third of its online business out of struggling delivery networks that were buckling under overwhelming package volumes.\"\n\nStock Prediction(s):", "Prediction": "\n- Petco Animal Supplies, Inc. (NASDAQ: PET) will increase because they are seeing a surge in pet ownership and their online business is doing well.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they own Whole Foods, which is a direct competitor of Petco.\n- Walmart Inc. (NYSE: WMT) will increase because they own Sam's Club, which is a direct competitor of Petco", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [130.44, 130.6629]}, "PET": {"company": "", "ticker": "PET", "move": "up"}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3082.96, 3072.845]}}}, {"link": "https://www.wsj.com/articles/state-funds-drop-unilever-after-ben-jerrys-israel-clash-11631903926", "title": "State Funds Drop Unilever After Ben & Jerry's Israel Clash", "date": "2021-09-17 14:38", "summary": "Ice cream brand's decision to stop sales in the West Bank puts pressure on U.K.-based parent company. Two months after Ben & Jerry's said it would stop retailing its products in Jewish settlements located in the Israeli-occupied West Bank, several state funds are selling or threatening to sell their investments in Unilever PLC, the ice cream brand's parent company.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"State Funds Drop Unilever After Ben & Jerry's Israel Clash. Ice cream brand's decision to stop sales in the West Bank puts pressure on U.K.-based parent company. Two months after Ben & Jerry's said it would stop retailing its products in Jewish settlements located in the Israeli-occupied West Bank, several state funds are selling or threatening to sell their investments in Unilever PLC, the ice cream brand's parent company.\"\n\nStock Prediction(s):", "Prediction": "\n- Unilever plc (NYSE: UL) will decrease because of the pressure from state funds to stop selling Ben & Jerry's in the West Bank.\n- PepsiCo, Inc. (NASDAQ: PEP) will increase because they are not selling any products in the West Bank, and they are a direct competitor of Unilever.", "price_info": {"UL": {"company": "", "ticker": "UL", "move": "down", "prices": [54.02, 53.95]}, "PEP": {"company": "", "ticker": "PEP", "move": "up", "prices": [154.38, 153.845]}}}, {"link": "https://www.wsj.com/articles/caesars-and-eldorado-close-8-58-billion-merger-11595263849", "title": "Caesars and Eldorado Close $8.58 Billion Merger", "date": "2020-07-20 12:50", "summary": "New Caesars Entertainment to be largest U.S. casino operator. An $8.58 billion cash-and-stock merger of Eldorado Resorts Inc. and Caesars Entertainment Corp. closed Monday, forging the largest casino operator in the U.S. amid uncertainty across the industry over the continuing spread of Covid-19.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Caesars and Eldorado Close $8.58 Billion Merger. New Caesars Entertainment to be largest U.S. casino operator. An $8.58 billion cash-and-stock merger of Eldorado Resorts Inc. and Caesars Entertainment Corp. closed Monday, forging the largest casino operator in the U.S. amid uncertainty across the industry over the continuing spread of Covid-19.\"\n\nStock Prediction(s):", "Prediction": "\n- Eldorado Resorts, Inc. (NASDAQ: ERI) will increase because they are now the largest casino operator in the U.S.\n- Caesars Entertainment Corp. (NASDAQ: CZR) will decrease because they are now part of Eldorado Resorts, and they are selling off assets.", "price_info": {"ERI": {"company": "", "ticker": "ERI", "move": "up", "prices": [37.5386, 37.58]}, "CZR": {"company": "", "ticker": "CZR", "move": "down", "prices": [12.4062, 12.41]}}}, {"link": "https://www.wsj.com/articles/apples-shine-only-goes-so-far-now-11561731993", "title": "Apple's Shine Goes Only So Far Now", "date": "2019-06-28 10:26", "summary": "Departure of design guru Jony Ive emblematic of big challenges the company now faces. Apple Inc. needs Jony Ive less these days. Just what the iconic device maker really requires now is much less clear.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple's Shine Goes Only So Far Now. Departure of design guru Jony Ive emblematic of big challenges the company now faces. Apple Inc. needs Jony Ive less these days. Just what the iconic device maker really requires now is much less clear.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are losing their design guru, Jony Ive.\n- Samsung Electronics Co Ltd (OTC: SSNLF) will increase because they are gaining market share from Apple.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [197.97, 198.98]}}}, {"link": "https://www.wsj.com/articles/recording-of-trump-phone-call-to-georgia-lead-investigator-reveals-new-details-11615411561", "title": "Trump Call to Georgia Lead Investigator Reveals New Details", "date": "2021-03-11 10:08", "summary": "Then-president says that 'something bad happened' and presses for investigation into Fulton County votes. ATLANTA-Then-President Donald Trump urged the chief investigator of the Georgia Secretary of State's office to look for fraud during an audit of mail-in ballots in a suburban Atlanta county, on a phone call he made to her in late December.", "categories": [["WSJ News Exclusive", "Election 2020"]], "category_links": ["https://www.wsj.com/news/types/election-2020?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump Call to Georgia Lead Investigator Reveals New Details. Then-president says that 'something bad happened' and presses for investigation into Fulton County votes. ATLANTA-Then-President Donald Trump urged the chief investigator of the Georgia Secretary of State's office to look for fraud during an audit of mail-in ballots in a suburban Atlanta county, on a phone call he made to her in late December.\"\n\nStock Prediction(s):", "Prediction": "\n- Fulton County (GA) will increase because they may have been rigged in the election and Trump is pushing for an investigation.\n- Trump will increase because he is fighting for justice and wants to make sure that the election was fair.", "price_info": {"GA": {"company": "Fulton County", "ticker": "GA", "move": "up"}}}, {"link": "https://www.wsj.com/articles/for-boris-johnsons-britain-a-cold-world-awaits-11563976803", "title": "For Boris Johnson's Britain, a Cold World Awaits", "date": "2019-07-24 10:00", "summary": "After leaving the EU, Britain would confront a more protectionist, nationalist world. For new U.K. Prime Minister Boris Johnson, Brexit isn't about Britain turning its back on the world. Quite the opposite: leaving the European Union is a chance for a sovereign Britain to stake out a new, more free position in the global economy.", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"For Boris Johnson's Britain, a Cold World Awaits. After leaving the EU, Britain would confront a more protectionist, nationalist world. For new U.K. Prime Minister Boris Johnson, Brexit isn't about Britain turning its back on the world. Quite the opposite: leaving the European Union is a chance for a sovereign Britain to stake out a new, more free position in the global economy.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.K. will become more protectionist and nationalist, causing a decrease in global trade.\n- This will have a negative effect on companies such as Boeing (NYSE: BA), Airbus SE (EPA: AIR), and Rolls-Royce Holdings plc (LON: RR), which are all major exporters.\n- Conversely, companies such as Amazon.com, Inc. (NASDAQ: AMZN) and Alibaba Group Holding Ltd. (", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [365.2876, 363.177]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1983.02, 1987.8103]}}}, {"link": "https://www.wsj.com/articles/covid-19-vaccine-trial-volunteers-look-to-make-a-difference-11602162001", "title": "Vaccine-Trial Volunteers Look to Make a Difference", "date": "2020-10-08 12:10", "summary": "Stakes are high as participants aim to help people return to their normal lives-and persuade skeptics of vaccines. Victoria Smith had lost three patients to Covid-19, while another patient had lost her husband and brother to the virus. So when the New Orleans-area family physician learned in July that her health system would participate in a vaccine trial, she was in the lab to get her first dose the next day.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Vaccine-Trial Volunteers Look to Make a Difference. Stakes are high as participants aim to help people return to their normal lives-and persuade skeptics of vaccines. Victoria Smith had lost three patients to Covid-19, while another patient had lost her husband and brother to the virus. So when the New Orleans-area family physician learned in July that her health system would participate in a vaccine trial, she was in the lab to get her first dose the next day.\"\n\nStock Prediction(s):", "Prediction": "\n- Merck & Co., Inc. (NYSE: MRK) will increase because they have a vaccine that is being trialed and they are a major pharmaceutical company.\n- GlaxoSmithKline plc (NYSE: GSK) will increase because they have a vaccine that is being trialed and they are a major pharmaceutical company.\n- Sanofi (NYSE: SNY) will increase because they have a vaccine that is being trialed and they are", "price_info": {"MRK": {"company": "", "ticker": "MRK", "move": "up", "prices": [80.5344, 80.5019]}, "GSK": {"company": "", "ticker": "GSK", "move": "up", "prices": [37.09, 37.11]}, "SNY": {"company": "", "ticker": "SNY", "move": "up", "prices": [50.255, 50.26]}}}, {"link": "https://www.wsj.com/articles/columnist-nick-kristof-departs-new-york-times-to-pursue-oregon-governors-seat-11634224301", "title": "New York Times Columnist Nicholas Kristof Departs", "date": "2021-10-14 11:11", "summary": "The 37-year Times veteran has been considering a run for governor of Oregon, whose current Democratic leader faces term limits. Longtime New York Times opinion columnist Nick Kristof is leaving the organization ahead of a potential run for governor in his home state of Oregon, the newspaper's opinion editor said.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"New York Times Columnist Nicholas Kristof Departs. The 37-year Times veteran has been considering a run for governor of Oregon, whose current Democratic leader faces term limits. Longtime New York Times opinion columnist Nick Kristof is leaving the organization ahead of a potential run for governor in his home state of Oregon, the newspaper's opinion editor said.\"\n\nStock Prediction(s):", "Prediction": "\n- New York Times Co (NYSE: NYT) will decrease because one of their most prominent columnists is leaving.\n- The Washington Post Co (WPO) will increase because they are one of the only other major newspapers in the United States.", "price_info": {"WPO": {"company": "Post Co", "ticker": "WPO", "move": "up"}, "NYT": {"company": "", "ticker": "NYT", "move": "down", "prices": [54.075, 54.2]}}}, {"link": "https://www.wsj.com/articles/warner-music-prince-al-waleed-near-deal-over-saudi-tycoons-music-company-11611682109", "title": "Warner Music, Prince Al-Waleed Near Deal Over Saudi Tycoon's Music Company", "date": "2021-01-26 12:28", "summary": "Len Blavatnik's Warner and Rotana Music envision sharing artists, producing cross-cultural content. Warner Music Group Corp. is close to agreeing to buy a minority stake in Saudi billionaire Prince al-Waleed bin Talal's Rotana Music, in a deal that would value the Mideast music company at close to $200 million, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Warner Music, Prince Al-Waleed Near Deal Over Saudi Tycoon's Music Company. Len Blavatnik's Warner and Rotana Music envision sharing artists, producing cross-cultural content. Warner Music Group Corp. is close to agreeing to buy a minority stake in Saudi billionaire Prince al-Waleed bin Talal's Rotana Music, in a deal that would value the Mideast music company at close to $200 million, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Warner Music Group Corp. (NYSE: WMG) will increase because they are expanding their business into the Middle East.\n- Prince al-Waleed bin Talal's (OTC: WALEED) Rotana Music will increase because they are getting a minority stake from Warner Music.", "price_info": {"WMG": {"company": "", "ticker": "WMG", "move": "up", "prices": [37.91, 38.27]}}}, {"link": "https://www.wsj.com/articles/comcast-launches-smart-tv-for-u-s-market-in-bid-to-take-on-roku-amazon-11634658217", "title": "Comcast Launches Smart TV for U.S. Market in Bid to Take On Roku, Amazon", "date": "2021-10-19 11:43", "summary": "China's Hisense will manufacture the XClass TV, which will be sold at Walmart. Comcast Corp. unveiled a smart TV for the U.S. market, as the cable giant looks to become a dominant distributor of streaming apps and give a boost to its homegrown Peacock service.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Comcast Launches Smart TV for U.S. Market in Bid to Take On Roku, Amazon. China's Hisense will manufacture the XClass TV, which will be sold at Walmart. Comcast Corp. unveiled a smart TV for the U.S. market, as the cable giant looks to become a dominant distributor of streaming apps and give a boost to its homegrown Peacock service.\"\n\nStock Prediction(s):", "Prediction": "\n- Comcast Corporation (NASDAQ: CMCSA) will increase because they are releasing their own smart TV, which will compete with Roku and Amazon.\n- Roku, Inc. (NASDAQ: ROKU) will decrease because Comcast is releasing their own smart TV, which will compete with Roku.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because Comcast is releasing their own smart TV, which will compete with Amazon.", "price_info": {"CMCSA": {"company": "", "ticker": "CMCSA", "move": "up", "prices": [53.775, 53.955]}, "ROKU": {"company": "", "ticker": "ROKU", "move": "down", "prices": [348.93, 349.9447]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [3425.89, 3428.44]}}}, {"link": "https://www.wsj.com/articles/renault-board-is-studying-with-interest-fiat-chrysler-bid-11559666972", "title": "Renault Board Is Studying 'With Interest' Fiat Chrysler Proposal", "date": "2019-06-04 15:10", "summary": "French car maker's board to meet again Wednesday to discuss merger. PARIS-The board of Renault SA said it needs more time to weigh a merger proposal from Fiat Chrysler Automobiles NV that would create the world's third-largest auto maker by production, with a market value of about $40 billion.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Renault Board Is Studying 'With Interest' Fiat Chrysler Proposal. French car maker's board to meet again Wednesday to discuss merger. PARIS-The board of Renault SA said it needs more time to weigh a merger proposal from Fiat Chrysler Automobiles NV that would create the world's third-largest auto maker by production, with a market value of about $40 billion.\"\n\nStock Prediction(s):", "Prediction": "\n- Renault SA (EPA: RNO) will increase because they are being pursued by a larger company, Fiat Chrysler Automobiles NV (NYSE: FCAU).\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will increase because they are proposing to merge with Renault SA, and will become the world's third-largest auto maker.", "price_info": {"FCAU": {"company": "", "ticker": "FCAU", "move": "up", "prices": [13.45, 13.69]}}}, {"link": "https://www.wsj.com/articles/metro-bank-shares-tank-after-pulled-bond-issue-11569344319", "title": "Metro Bank Shares Tank After Pulled Bond Issue", "date": "2019-09-24 12:58", "summary": "Bank had been looking to raise upward of \u00a3200 million but investors only placed \u00a3175 million of orders. Shares in London-listed Metro Bank PLC dropped more than 35% on Tuesday, reaching new lows after the company was forced to pull a bond issue.", "categories": [["Markets", "Stocks", "Europe Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/markets/stocks?mod=breadcrumb", "https://www.wsj.com/news/types/europe-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Metro Bank Shares Tank After Pulled Bond Issue. Bank had been looking to raise upward of \u00a3200 million but investors only placed \u00a3175 million of orders. Shares in London-listed Metro Bank PLC dropped more than 35% on Tuesday, reaching new lows after the company was forced to pull a bond issue.\"\n\nStock Prediction(s):", "Prediction": "\n- Metro Bank plc (LON: MTRO) will continue to tank because they were unable to raise the money they needed.\n- Barclays plc (LON: BARC) will increase because they are a competitor of Metro Bank, and they are not experiencing the same financial difficulties.", "price_info": {}}, {"link": "https://www.wsj.com/articles/volkswagen-warns-of-uncertainty-ahead-after-strong-2019-11582907494", "title": "Volkswagen Warns of Uncertainty Ahead After Strong 2019", "date": "2020-02-28 11:31", "summary": "Auto maker provides no forecast of coronavirus impact. BERLIN-German auto manufacturer Volkswagen AG on Friday reported strong growth in sales and earnings in 2019, but warned that any forecast for the current year faced uncertainty from geopolitical turbulence and the impact of the coronavirus epidemic.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Volkswagen Warns of Uncertainty Ahead After Strong 2019. Auto maker provides no forecast of coronavirus impact. BERLIN-German auto manufacturer Volkswagen AG on Friday reported strong growth in sales and earnings in 2019, but warned that any forecast for the current year faced uncertainty from geopolitical turbulence and the impact of the coronavirus epidemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Volkswagen AG (OTCPK: VOW3) will decrease because of the uncertainty around the coronavirus.\n- Ford Motor Company (NYSE: F) will decrease because of the uncertainty around the coronavirus.\n- General Motors Company (NYSE: GM) will decrease because of the uncertainty around the coronavirus.", "price_info": {"F": {"company": "", "ticker": "F", "move": "down", "prices": [6.83, 6.8672]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [29.825, 30.01]}}}, {"link": "https://www.wsj.com/articles/auto-parts-retail-goes-full-throttle-11596132543", "title": "Auto-Parts Retail Goes Full Throttle", "date": "2020-07-30 14:09", "summary": "O'Reilly Auto Parts' results show how resilient auto-parts demand can be, even in the face of depressed driving. Auto-parts retailers haven't been terribly scuffed by the coronavirus pandemic, but no one quite knew they could shine like this.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Auto-Parts Retail Goes Full Throttle. O'Reilly Auto Parts' results show how resilient auto-parts demand can be, even in the face of depressed driving. Auto-parts retailers haven't been terribly scuffed by the coronavirus pandemic, but no one quite knew they could shine like this.\"\n\nStock Prediction(s):", "Prediction": "\n- O'Reilly Automotive, Inc. (NASDAQ: ORLY) will continue to go up because their demand is resilient and they are doing well even in the face of the pandemic.\n- Advance Auto Parts, Inc. (NYSE: AAP) will decrease because they are not doing as well as O'Reilly Automotive, and they are a direct competitor.", "price_info": {"AAP": {"company": "", "ticker": "AAP", "move": "down", "prices": [152.99, 152.87]}, "ORLY": {"company": "", "ticker": "ORLY", "move": "up", "prices": [479.82, 480.52]}}}, {"link": "https://www.wsj.com/articles/unwind-of-bullish-oil-bets-could-limit-crude-price-gains-11578930716", "title": "Unwind of Bullish Oil Bets Could Limit Crude-Price Gains", "date": "2020-01-13 15:22", "summary": "U.S. crude oil logs fifth consecutive decline with U.S., Iran backing away from conflict, analysts projecting ample supply. A pullback in bullish oil bets could tamp down crude prices with tensions in the Middle East subsiding, a rapid shift after the U.S.-ordered killing of a top Iranian military leader had some traders positioning for further gains earlier this month.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Unwind of Bullish Oil Bets Could Limit Crude-Price Gains. U.S. crude oil logs fifth consecutive decline with U.S., Iran backing away from conflict, analysts projecting ample supply. A pullback in bullish oil bets could tamp down crude prices with tensions in the Middle East subsiding, a rapid shift after the U.S.-ordered killing of a top Iranian military leader had some traders positioning for further gains earlier this month.\"\n\nStock Prediction(s):", "Prediction": "\n- Schlumberger Ltd. (NYSE: SLB) will increase because they are a major oilfield services company and will benefit from the unwinding of bullish oil bets.\n- Halliburton Company (NYSE: HAL) will increase because they are a major oilfield services company and will benefit from the unwinding of bullish oil bets.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because they are a major oil producer and will be hurt by the", "price_info": {"SLB": {"company": "", "ticker": "SLB", "move": "up", "prices": [39.245, 39]}, "HAL": {"company": "", "ticker": "HAL", "move": "up", "prices": [23.78, 23.5699]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [69.7, 69.795]}}}, {"link": "https://www.wsj.com/articles/the-feds-inflation-problem-11556737662", "title": "The Fed's Inflation Problem", "date": "2019-05-01 15:10", "summary": "Even if low inflation persists, it might not count as a reason for the central bank to cut rates.. The Federal Reserve is worried that even as the economy continues to do well, inflation is running cold. So what, if anything, should the central bank be doing about its dilemma?", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Fed's Inflation Problem. Even if low inflation persists, it might not count as a reason for the central bank to cut rates.. The Federal Reserve is worried that even as the economy continues to do well, inflation is running cold. So what, if anything, should the central bank be doing about its dilemma?\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed's Inflation Problem will not have a significant impact on the stock prices of the major banks.\n- The Fed's Inflation Problem will have a significant impact on the stock prices of technology companies.\n- The Fed's Inflation Problem will have a significant impact on the stock prices of energy companies.", "price_info": {}}, {"link": "https://www.wsj.com/articles/colleges-can-be-forced-to-return-tuition-when-parents-go-bankrupt-11573675262", "title": "Colleges Can Be Forced to Return Tuition When Parents Go Bankrupt", "date": "2019-11-13 15:01", "summary": "A federal appeals court ruling exposes colleges to lawsuits from bankruptcy trustees seeking to pay creditors. Colleges can be forced to return tuition payments made for students whose parents can't cover their own debts, according to a federal appeals court ruling that opens up higher education institutions to more litigation in bankruptcy courts.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Colleges Can Be Forced to Return Tuition When Parents Go Bankrupt. A federal appeals court ruling exposes colleges to lawsuits from bankruptcy trustees seeking to pay creditors. Colleges can be forced to return tuition payments made for students whose parents can't cover their own debts, according to a federal appeals court ruling that opens up higher education institutions to more litigation in bankruptcy courts.\"\n\nStock Prediction(s):", "Prediction": "\n- University of Phoenix Holdings Inc (NASDAQ: UOPX) will decrease because they are a for-profit college and are more likely to be sued for returning tuition payments.\n- DeVry Education Group Inc (NYSE: DV) will decrease because they are a for-profit college and are more likely to be sued for returning tuition payments.\n- Capella Education Company (NASDAQ: CPLA) will decrease because they are a for-profit college and are", "price_info": {"DV": {"company": "", "ticker": "DV", "move": "down"}, "UOPX": {"company": "", "ticker": "UOPX", "move": "down"}, "CPLA": {"company": "", "ticker": "CPLA", "move": "down"}}}, {"link": "https://www.wsj.com/articles/feds-bullard-says-inflation-could-start-to-pick-up-soon-11600451309", "title": "Fed's Bullard Says Inflation Could Start to Pick Up Soon", "date": "2020-09-18 13:48", "summary": "The St. Louis Fed president also says the economy could grow 30% in the third quarter from its second-quarter depths. Federal Reserve Bank of St. Louis leader James Bullard said higher inflation is coming to the U.S. economy, but didn't indicate that would be a worrisome development.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Bullard Says Inflation Could Start to Pick Up Soon. The St. Louis Fed president also says the economy could grow 30% in the third quarter from its second-quarter depths. Federal Reserve Bank of St. Louis leader James Bullard said higher inflation is coming to the U.S. economy, but didn't indicate that would be a worrisome development.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will stay the same because Bullard's statement is not worrisome to the market.\n- The market will decrease because Bullard's statement means that the Fed may start to raise interest rates soon, which would be bad for the market.", "price_info": {}}, {"link": "https://www.wsj.com/articles/boeing-plans-new-staff-buyouts-11597757758", "title": "Boeing Plans New Staff Buyouts", "date": "2020-08-18 10:37", "summary": "Travel slump leaves aerospace giant looking to cut more jobs than previously planned. Boeing Co. plans more job cuts in response to a pandemic-driven drop in jetliner demand it expects to continue for at least three years.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Plans New Staff Buyouts. Travel slump leaves aerospace giant looking to cut more jobs than previously planned. Boeing Co. plans more job cuts in response to a pandemic-driven drop in jetliner demand it expects to continue for at least three years.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will decrease because they are expecting a three-year slump in jetliner demand.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [169.7292, 169.21]}}}, {"link": "https://www.wsj.com/articles/investors-pour-into-u-k-markets-as-election-result-calms-brexit-jitters-11576238113", "title": "Investors Pour Into U.K. Markets as Election Result Calms Brexit Jitters", "date": "2019-12-13 10:11", "summary": "Stocks rally as markets cheer increased likelihood of split from the European Union by end of next month. A decisive victory for Prime Minister Boris Johnson's Conservative Party in the British election sent investors scrambling to buy U.K. stocks.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors Pour Into U.K. Markets as Election Result Calms Brexit Jitters. Stocks rally as markets cheer increased likelihood of split from the European Union by end of next month. A decisive victory for Prime Minister Boris Johnson's Conservative Party in the British election sent investors scrambling to buy U.K. stocks.\"\n\nStock Prediction(s):", "Prediction": "\n- The FTSE 100 (UKX) will continue to increase because investors are optimistic about the future of the U.K. now that the Brexit situation has been resolved.\n- The pound sterling (GBP) will continue to decrease because there is still a lot of uncertainty about the future of the U.K. economy.", "price_info": {"UKX": {"company": "", "ticker": "UKX", "move": "up"}, "GBP": {"company": "", "ticker": "GBP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/disney-shareholders-support-company-in-say-on-pay-vote-11551982109", "title": "Disney Shareholders Support Company in Say-on-Pay Vote", "date": "2019-03-07 13:08", "summary": "Resolution failed last year, but passed after company twice reduced CEO Robert Iger's compensation package. Walt Disney Co. shareholders narrowly approved a say-on-pay referendum concerning Chief Executive Robert Iger's compensation, one year after voting against his pay package and prompting the company to make changes to it in recent months.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Disney Shareholders Support Company in Say-on-Pay Vote. Resolution failed last year, but passed after company twice reduced CEO Robert Iger's compensation package. Walt Disney Co. shareholders narrowly approved a say-on-pay referendum concerning Chief Executive Robert Iger's compensation, one year after voting against his pay package and prompting the company to make changes to it in recent months.\"\n\nStock Prediction(s):", "Prediction": "\n- Walt Disney Co. (NYSE: DIS) will increase because their shareholders approved Iger's pay package.\n- Comcast Corporation (NASDAQ: CMCSA) will decrease because they are a direct competitor of Walt Disney.", "price_info": {"DIS": {"company": "", "ticker": "DIS", "move": "up", "prices": [114.075, 113.8445]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "down", "prices": [38.6, 38.5]}}}, {"link": "https://www.wsj.com/articles/beyond-meat-sea-millerknoll-gm-what-to-watch-when-the-stock-market-opens-today-11641383533", "title": "Beyond Meat, Sea, Simply Good Foods, GM: What to Watch in the Stock Market Today", "date": "2022-01-05 09:33", "summary": "Beyond Meat's plant-based chicken will be sold in KFC restaurants; Tencent cut its stake in Sea. Stocks on Wall Street are wavering ahead of the release of minutes from the Federal Reserve's latest policy meeting. Here's what's moving in Wednesday's trading:", "categories": [["Markets", "U.S. Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/today-s-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Beyond Meat, Sea, Simply Good Foods, GM: What to Watch in the Stock Market Today. Beyond Meat's plant-based chicken will be sold in KFC restaurants; Tencent cut its stake in Sea. Stocks on Wall Street are wavering ahead of the release of minutes from the Federal Reserve's latest policy meeting. Here's what's moving in Wednesday's trading:\"\n\nStock Prediction(s):", "Prediction": "\n- Beyond Meat, Inc. (NASDAQ: BYND) will increase because they are partnering with KFC, and their plant-based chicken is being sold in their restaurants.\n- Sea Ltd. (NYSE: SE) will decrease because Tencent has cut their stake in the company.\n- Simply Good Foods Co (NASDAQ: SMPL) will increase because they are being acquired by General Mills, and their products are GMO-free.\n- General Motors", "price_info": {"SE": {"company": "Sea Ltd.", "ticker": "SE", "move": "down", "prices": [188.32, 194.24]}, "BYND": {"company": "", "ticker": "BYND", "move": "up", "prices": [64.87, 63.15]}, "SMPL": {"company": "", "ticker": "SMPL", "move": "up", "prices": [40.99, 40.2961]}}}, {"link": "https://www.wsj.com/articles/u-s-industrial-production-rises-for-third-straight-month-11597420400", "title": "U.S. Industrial Production Rises for Third Straight Month", "date": "2020-08-14 11:53", "summary": "The measure of output at factories, mines and utilities rose a seasonally adjusted 3% in July. U.S. industrial production increased in July for the third month in a row, as the economy continues its slow recovery.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Industrial Production Rises for Third Straight Month. The measure of output at factories, mines and utilities rose a seasonally adjusted 3% in July. U.S. industrial production increased in July for the third month in a row, as the economy continues its slow recovery.\"\n\nStock Prediction(s):", "Prediction": "\n- General Electric Company (NYSE: GE) will increase because the economy is slowly recovering, and this will help GE's industrial production.\n- The Boeing Company (NYSE: BA) will increase because the economy is slowly recovering, and this will help BA's industrial production.\n- United Technologies Corporation (NYSE: UTX) will increase because the economy is slowly recovering, and this will help UTX's industrial production.\n- 3M Company (NYSE: MMM", "price_info": {"GE": {"company": "", "ticker": "GE", "move": "up", "prices": [6.65, 6.7048]}, "BA": {"company": "", "ticker": "BA", "move": "up", "prices": [177.2, 178.9299]}, "UTX": {"company": "", "ticker": "UTX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/federal-reserves-bullard-fed-policy-is-in-the-right-place-for-now-11554990000", "title": "Federal Reserve's Bullard: Fed Policy Is in the Right Place for Now", "date": "2019-04-11 09:40", "summary": "St. Louis Fed leader James Bullard expressed satisfaction with the current level of short-term rates. Federal Reserve Bank of St. Louis leader James Bullard expressed satisfaction with the current level of short-term rates, in remarks Thursday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Federal Reserve's Bullard: Fed Policy Is in the Right Place for Now. St. Louis Fed leader James Bullard expressed satisfaction with the current level of short-term rates. Federal Reserve Bank of St. Louis leader James Bullard expressed satisfaction with the current level of short-term rates, in remarks Thursday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve's (NYSE: FED) stock will stay the same because Bullard is satisfied with the current level of short-term rates.", "price_info": {"FED": {"company": "", "ticker": "FED", "move": null}}}, {"link": "https://www.wsj.com/articles/lumentum-in-advanced-talks-to-buy-laser-maker-coherent-11610995619", "title": "Lumentum to Buy Laser Maker Coherent for $5.7 Billion", "date": "2021-01-19 12:35", "summary": "Shareholders would receive $100 and 1.1851 shares of Lumentum stock for each Coherent share. Lumentum Holdings Inc. agreed to buy laser maker Coherent Inc. for $5.7 billion, in a deal that would combine two companies whose products are used in everything from laser eye surgery to semiconductor manufacturing.", "categories": [["Markets", "Deals"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/deals-deal-makers?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Lumentum to Buy Laser Maker Coherent for $5.7 Billion. Shareholders would receive $100 and 1.1851 shares of Lumentum stock for each Coherent share. Lumentum Holdings Inc. agreed to buy laser maker Coherent Inc. for $5.7 billion, in a deal that would combine two companies whose products are used in everything from laser eye surgery to semiconductor manufacturing.\"\n\nStock Prediction(s):", "Prediction": "\n- Lumentum Holdings Inc. (NASDAQ: LITE) will increase because they are buying Coherent Inc. for $5.7 billion, and it will help them expand their product offerings.\n- Coherent Inc. (NASDAQ: COHR) will increase because they are being bought by Lumentum Holdings Inc. for $5.7 billion, and it will help them expand their product offerings.", "price_info": {"LITE": {"company": "", "ticker": "LITE", "move": "up", "prices": [94.67, 94.69]}, "COHR": {"company": "", "ticker": "COHR", "move": "up", "prices": [199.9, 199.9]}}}, {"link": "https://www.wsj.com/articles/greece-once-in-crisis-joins-negative-rates-club-11570640925", "title": "Greece, Once in Crisis, Joins Negative-Rates Club", "date": "2019-10-09 13:08", "summary": "Debt-laden country sells bonds yielding less than 0% for the first time. Greece sold debt offering less than 0% for the first time on Wednesday in the latest sign of how far investors will go in a hunt for returns amid a global slump in yields.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Greece, Once in Crisis, Joins Negative-Rates Club. Debt-laden country sells bonds yielding less than 0% for the first time. Greece sold debt offering less than 0% for the first time on Wednesday in the latest sign of how far investors will go in a hunt for returns amid a global slump in yields.\"\n\nStock Prediction(s):", "Prediction": "\n- Greece (NYSE: GREK) will increase because they are now in the negative-rates club, and investors are looking for returns.\n- Germany (NYSE: EWG) will decrease because they are the main competitor of Greece, and their yields are increasing.", "price_info": {"GREK": {"company": "", "ticker": "GREK", "move": "up", "prices": [9.075, 9.09]}, "EWG": {"company": "", "ticker": "EWG", "move": "down", "prices": [26.42, 26.455]}}}, {"link": "https://www.wsj.com/articles/despite-strong-jobs-report-fed-likely-wont-feel-more-urgency-to-raise-rates-11546613696", "title": "Despite Jobs Report, Fed Likely Won't Feel More Urgency to Raise Rates", "date": "2019-01-04 09:54", "summary": "Central bank had penciled in two hikes before global outlook turned gloomier. The strong December employment report does little to clarify an economic outlook that is cloudier than it was when Federal Reserve officials voted last month to raise their benchmark interest rate.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Despite Jobs Report, Fed Likely Won't Feel More Urgency to Raise Rates. Central bank had penciled in two hikes before global outlook turned gloomier. The strong December employment report does little to clarify an economic outlook that is cloudier than it was when Federal Reserve officials voted last month to raise their benchmark interest rate.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will not feel more urgency to raise rates because the jobs report was strong.\n- The Fed will continue to raise rates because the jobs report was strong.", "price_info": {}}, {"link": "https://www.wsj.com/articles/iacs-relationship-with-google-is-complicated-11607547036", "title": "IAC's Relationship With Google Is Complicated", "date": "2020-12-09 15:50", "summary": "Investors seem unduly relaxed about a lovers' spat between IAC and Alphabet's Google. Investors new to the IAC/InterActiveCorp. story probably know it as a company that kindled online romance through now-independent Match Group Inc. They seem unduly relaxed about a lovers' spat with Alphabet Inc.'s Google.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"IAC's Relationship With Google Is Complicated. Investors seem unduly relaxed about a lovers' spat between IAC and Alphabet's Google. Investors new to the IAC/InterActiveCorp. story probably know it as a company that kindled online romance through now-independent Match Group Inc. They seem unduly relaxed about a lovers' spat with Alphabet Inc.'s Google.\"\n\nStock Prediction(s):", "Prediction": "\n- IAC/InterActiveCorp. (NASDAQ: IAC) will decrease because of their complicated relationship with Google.\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because they are the parent company of Google, and they will benefit from the fallout between IAC and Google.", "price_info": {"IAC": {"company": "", "ticker": "IAC", "move": "down", "prices": [140.39, 140.44]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1771.93, 1777.86]}}}, {"link": "https://www.wsj.com/articles/recorded-music-revenue-hits-12-billion-in-2020-amid-pandemic-streaming-boom-11614364260", "title": "Recorded Music Revenue Hits $12 Billion in 2020 Amid Pandemic Streaming Boom", "date": "2021-02-26 13:31", "summary": "Streaming accounted for 83% of revenue, with subscriptions, social and fitness app use on the rise. Sales of recorded music grew 9.2% last year to $12.2 billion as subscriptions to streaming services reached new highs during the Covid-19 pandemic.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Recorded Music Revenue Hits $12 Billion in 2020 Amid Pandemic Streaming Boom. Streaming accounted for 83% of revenue, with subscriptions, social and fitness app use on the rise. Sales of recorded music grew 9.2% last year to $12.2 billion as subscriptions to streaming services reached new highs during the Covid-19 pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Spotify Technology SA (NYSE: SPOT) will increase because of the increase in streaming revenue.\n- Apple Inc. (NASDAQ: AAPL) will increase because of the increase in streaming revenue.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because of the increase in streaming revenue.\n- Pandora Media, Inc. (NYSE: P) will increase because of the increase in streaming revenue.", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "up", "prices": [307.2, 308]}, "P": {"company": "", "ticker": "P", "move": "up"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [124.14, 123.799]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3102.85, 3094.69]}}}, {"link": "https://www.wsj.com/articles/usps-fedex-ups-release-ship-by-dates-for-holidays-11634046500", "title": "USPS, FedEx, UPS Release Ship-By Dates for Holidays", "date": "2021-10-12 14:37", "summary": "Shipment companies saw onslaught of mail last year. U.S. mail carriers have released their recommended dates for customers to ship mail by in order for packages, letters and other shipments to arrive before the Christmas holidays.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"USPS, FedEx, UPS Release Ship-By Dates for Holidays. Shipment companies saw onslaught of mail last year. U.S. mail carriers have released their recommended dates for customers to ship mail by in order for packages, letters and other shipments to arrive before the Christmas holidays.\"\n\nStock Prediction(s):", "Prediction": "\n- United Parcel Service, Inc. (NYSE: UPS) will increase because they are one of the only companies that have released a ship-by date.\n- The United States Postal Service (NYSE: USPS) will increase because they are one of the only companies that have released a ship-by date.\n- FedEx Corporation (NYSE: FDX) will decrease because they are one of the only companies that have released a ship-by date.", "price_info": {"UPS": {"company": "", "ticker": "UPS", "move": null, "prices": [181.935, 181.41]}, "USPS": {"company": "", "ticker": "USPS", "move": "up"}, "FDX": {"company": "", "ticker": "FDX", "move": "down", "prices": [221.1286, 220.6]}}}, {"link": "https://www.wsj.com/articles/apple-tesla-to-take-hit-from-chip-shortage-a-sign-of-problems-intensity-11627474416", "title": "Apple and Tesla Are the Chip Shortage's Latest Victims", "date": "2021-07-28 12:41", "summary": "The supply-chain woes for microprocessors are hitting those once seen less affected. The chip shortage is about to hit the iPhone.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Apple and Tesla Are the Chip Shortage's Latest Victims. The supply-chain woes for microprocessors are hitting those once seen less affected. The chip shortage is about to hit the iPhone.\"\n\nStock Prediction(s):", "Prediction": "\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are one of the latest companies to be hit by the chip shortage.\n- Tesla, Inc. (NASDAQ: TSLA) will decrease because they are one of the latest companies to be hit by the chip shortage.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [144.1299, 145.05]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [644.39, 645.7]}}}, {"link": "https://www.wsj.com/articles/alicia-keys-is-the-buyer-behind-20-8-million-razor-house-sale-11567619437", "title": "Alicia Keys is the Buyer Behind $20.8 Million Razor House Sale", "date": "2019-09-04 13:50", "summary": "The ultramodern home in La Jolla, Calif., has made appearances in television spots including one for Visa Black Card. Grammy-winning singer Alicia Keys and her husband, hip hop producer Swizz Beatz, have paid $20.8 million for \"Razor House,\" a strikingly modern local landmark in the affluent Southern California town of La Jolla, according to people familiar with the deal.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Alicia Keys is the Buyer Behind $20.8 Million Razor House Sale. The ultramodern home in La Jolla, Calif., has made appearances in television spots including one for Visa Black Card. Grammy-winning singer Alicia Keys and her husband, hip hop producer Swizz Beatz, have paid $20.8 million for \"Razor House,\" a strikingly modern local landmark in the affluent Southern California town of La Jolla, according to people familiar with the deal.\"\n\nStock Prediction(s):", "Prediction": "\n- Alicia Keys and Swizz Beatz will increase because they are now the owners of the Razor House.\n- The previous owner of the Razor House will decrease because they have sold it.", "price_info": {}}, {"link": "https://www.wsj.com/articles/after-courts-kill-a-federal-fiduciary-rule-massachusetts-launches-its-own-11582311348", "title": "After Courts Kill a Federal Fiduciary Rule, Massachusetts Launches Its Own", "date": "2020-02-21 15:25", "summary": "Commonwealth officials will impose the new standard on brokers and agents who are licensed by Massachusetts. Massachusetts said it adopted new rules requiring brokers to act in their clients' best interests, staking its claim as the first U.S. state to raise the bar on investor protections since a federal measure was struck down.", "categories": [["Markets", "Financial Regulation"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/financial-regulation?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"After Courts Kill a Federal Fiduciary Rule, Massachusetts Launches Its Own. Commonwealth officials will impose the new standard on brokers and agents who are licensed by Massachusetts. Massachusetts said it adopted new rules requiring brokers to act in their clients' best interests, staking its claim as the first U.S. state to raise the bar on investor protections since a federal measure was struck down.\"\n\nStock Prediction(s):", "Prediction": "\n- Commonwealth of Massachusetts (BATS: MASS) will increase because they are the first state to have higher investor protections since a federal measure was struck down.\n- Charles Schwab Corporation (NYSE: SCHW) will increase because they are one of the largest brokerages in the United States, and they will need to comply with the new regulations.\n- Raymond James Financial, Inc. (NYSE: RJF) will decrease because they are a smaller brokerage, and", "price_info": {"SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [46.1188, 46.1212]}, "RJF": {"company": "", "ticker": "RJF", "move": "down", "prices": [97.51, 97.48]}}}, {"link": "https://www.wsj.com/articles/feds-evans-sees-coronavirus-casting-a-long-shadow-on-economy-11586368770", "title": "Fed's Evans Sees Coronavirus Casting a Long Shadow on Economy", "date": "2020-04-08 15:18", "summary": "Federal Reserve Bank of Chicago president says consumers, businesses expending resources to stay afloat could impact eventual recovery. Federal Reserve Bank of Chicago President Charles Evans said he's expecting substantial economic pain during the second quarter due to the coronavirus crisis and warned that because companies and households are expending savings and other resources to hold on, that could weigh down a hoped for recovery.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Evans Sees Coronavirus Casting a Long Shadow on Economy. Federal Reserve Bank of Chicago president says consumers, businesses expending resources to stay afloat could impact eventual recovery. Federal Reserve Bank of Chicago President Charles Evans said he's expecting substantial economic pain during the second quarter due to the coronavirus crisis and warned that because companies and households are expending savings and other resources to hold on, that could weigh down a hoped for recovery.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will cut interest rates because of the long-term impact that the coronavirus will have on the economy.\n- The Fed will not cut interest rates because the long-term impact that the coronavirus will have on the economy is still unknown.", "price_info": {}}, {"link": "https://www.wsj.com/articles/grubhub-generates-sales-not-profit-during-pandemic-11596119109", "title": "Grubhub Generates Sales, Not Profit, During Pandemic", "date": "2020-07-30 10:25", "summary": "Delivery company spent millions to operate, aid restaurants in the second quarter. Grubhub Inc. is benefiting from delivery ordering during the coronavirus pandemic but not profiting from it.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Grubhub Generates Sales, Not Profit, During Pandemic. Delivery company spent millions to operate, aid restaurants in the second quarter. Grubhub Inc. is benefiting from delivery ordering during the coronavirus pandemic but not profiting from it.\"\n\nStock Prediction(s):", "Prediction": "\n- Grubhub Inc (NYSE: GRUB) will decrease because they are not making a profit from the pandemic.", "price_info": {"GRUB": {"company": "", "ticker": "GRUB", "move": "down", "prices": [70.3149, 70.42]}}}, {"link": "https://www.wsj.com/articles/meredith-agrees-to-sell-local-tv-business-to-gray-television-in-2-7-billion-deal-11620050980", "title": "Meredith Exiting Local TV Business in $2.7 Billion Deal", "date": "2021-05-03 10:09", "summary": "Company says deal with Gray Television would allow it to better focus on magazine brands, digital-media properties. Meredith Corp. is selling its broadcast-television business to Gray Television Inc., in a deal the company said would allow it to better focus on its magazine brands and digital-media properties.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Meredith Exiting Local TV Business in $2.7 Billion Deal. Company says deal with Gray Television would allow it to better focus on magazine brands, digital-media properties. Meredith Corp. is selling its broadcast-television business to Gray Television Inc., in a deal the company said would allow it to better focus on its magazine brands and digital-media properties.\"\n\nStock Prediction(s):", "Prediction": "\n- Meredith Corp. (NYSE: MDP) will increase because they are selling their broadcast-television business, and they will be able to focus more on their magazine brands and digital-media properties.\n- Gray Television Inc. (NYSE: GTN) will increase because they are buying Meredith Corp.'s broadcast-television business, and they will be able to expand their reach into new markets.", "price_info": {"MDP": {"company": "", "ticker": "MDP", "move": "up", "prices": [32.8843, 32.84]}, "GTN": {"company": "", "ticker": "GTN", "move": "up", "prices": [21.23, 22.81]}}}, {"link": "https://www.wsj.com/articles/italy-wins-back-debt-investors-as-yields-fall-across-europe-11562080145", "title": "Italy Wins Back Debt Investors as Yields Fall Across Europe", "date": "2019-07-02 11:09", "summary": "Renewed faith in nation's finances comes as government bond prices across Europe have been buoyed in recent months. Italy seems to be winning back investor confidence, bringing its borrowing costs down to levels last seen before two populist parties formed an unlikely coalition government last year.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Italy Wins Back Debt Investors as Yields Fall Across Europe. Renewed faith in nation's finances comes as government bond prices across Europe have been buoyed in recent months. Italy seems to be winning back investor confidence, bringing its borrowing costs down to levels last seen before two populist parties formed an unlikely coalition government last year.\"\n\nStock Prediction(s):", "Prediction": "\n- Italy (BTP) will increase because their debt is being bought back by investors.\n- Germany (Bund) will decrease because their debt is being bought back by investors.\n- France (OAT) will decrease because their debt is being bought back by investors.\n- Spain (Bono) will decrease because their debt is being bought back by investors.", "price_info": {"BTP": {"company": "Italy", "ticker": "BTP", "move": "up"}, "OAT": {"company": "France", "ticker": "OAT", "move": "down"}}}, {"link": "https://www.wsj.com/articles/fidelity-taps-bmos-joanna-rotenberg-to-head-4-trillion-personal-investing-business-11632146409", "title": "Fidelity Taps Joanna Rotenberg to Head $4 Trillion Personal-Investing Business", "date": "2021-09-20 10:00", "summary": "The appointment comes amid Americans' renewed interest in stock trading. Fidelity Investments appointed Joanna Rotenberg to head its personal-investing business, picking an outsider to spearhead the division amid unprecedented demand from individual investors.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fidelity Taps Joanna Rotenberg to Head $4 Trillion Personal-Investing Business. The appointment comes amid Americans' renewed interest in stock trading. Fidelity Investments appointed Joanna Rotenberg to head its personal-investing business, picking an outsider to spearhead the division amid unprecedented demand from individual investors.\"\n\nStock Prediction(s):", "Prediction": "\n- Fidelity Investments (NYSE: FIS) will increase because they have a new head of their personal-investing business, and this is a good move for the company.\n- Charles Schwab Corp (NYSE: SCHW) will increase because they are also seeing increased demand from individual investors.\n- TD Ameritrade Holding Corp (NASDAQ: AMTD) will increase because they are also seeing increased demand from individual investors.", "price_info": {"FIS": {"company": "", "ticker": "FIS", "move": "up", "prices": [122.7538, 122.0496]}, "SCHW": {"company": "", "ticker": "SCHW", "move": "up", "prices": [68.22, 67.715]}, "AMTD": {"company": "", "ticker": "AMTD", "move": "up"}}}, {"link": "https://www.wsj.com/articles/bullish-copper-bets-drop-as-once-hot-market-cools-11630599570", "title": "Bullish Copper Bets Drop as Once-Hot Market Cools", "date": "2021-09-02 13:50", "summary": "Speculative wagers on copper decline as concerns grow that higher supply will cool this year's rally. Speculative investors recently pushed bullish wagers on copper prices to their lowest level in more than a year, a sign that traders are worried that higher supply will cool down this year's rally.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bullish Copper Bets Drop as Once-Hot Market Cools. Speculative wagers on copper decline as concerns grow that higher supply will cool this year's rally. Speculative investors recently pushed bullish wagers on copper prices to their lowest level in more than a year, a sign that traders are worried that higher supply will cool down this year's rally.\"\n\nStock Prediction(s):", "Prediction": "\n- Freeport-McMoRan Inc. (NYSE: FCX) will increase because copper prices are dropping, and Freeport-McMoRan is a big producer of copper.\n- Southern Copper Corp. (NYSE: SCCO) will increase because copper prices are dropping, and Southern Copper is a big producer of copper.\n- BHP Group Ltd. (NYSE: BHP) will increase because copper prices are dropping, and BHP Group", "price_info": {"FCX": {"company": "", "ticker": "FCX", "move": "up", "prices": [36.23, 36.27]}, "SCCO": {"company": "", "ticker": "SCCO", "move": "up", "prices": [62.31, 62.4]}, "BHP": {"company": "", "ticker": "BHP", "move": "up", "prices": [61.92, 61.9]}}}, {"link": "https://www.wsj.com/articles/wayfair-posts-profit-as-online-pandemic-shoppers-spend-on-their-homes-11596639930", "title": "Wayfair Posts Profit as Online Pandemic Shoppers Spend on Their Homes", "date": "2020-08-05 11:05", "summary": "Wayfair boosts active customer base to 26 million, a 46% year-over-year increase. Online furniture seller Wayfair Inc. turned a profit for the first time since going public in 2014, breaking a string of losses, as more house-bound online shoppers bought home goods during the pandemic-a trend so new and volatile that Chief Executive Niraj Shah said it's hard to predict whether it will last.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wayfair Posts Profit as Online Pandemic Shoppers Spend on Their Homes. Wayfair boosts active customer base to 26 million, a 46% year-over-year increase. Online furniture seller Wayfair Inc. turned a profit for the first time since going public in 2014, breaking a string of losses, as more house-bound online shoppers bought home goods during the pandemic-a trend so new and volatile that Chief Executive Niraj Shah said it's hard to predict whether it will last.\"\n\nStock Prediction(s):", "Prediction": "\n- Wayfair Inc. (NYSE: W) will continue to increase because people are buying more home goods online during the pandemic.\n- Amazon.com, Inc. (NASDAQ: AMZN) will continue to increase because people are buying more home goods online during the pandemic.", "price_info": {"W": {"company": "", "ticker": "W", "move": "up", "prices": [297.9799, 297.97]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3183.1908, 3203.8865]}}}, {"link": "https://www.wsj.com/articles/four-ways-to-manage-personal-finances-11640645156", "title": "Four Ways to Manage Your Personal Finances by Doing Less", "date": "2021-12-28 11:34", "summary": "Here are some things financial advisers suggest avoiding in 2022. When it comes to your money, sometimes doing nothing is the best thing to do.", "categories": [["Markets", "Personal Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/personal-finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Four Ways to Manage Your Personal Finances by Doing Less. Here are some things financial advisers suggest avoiding in 2022. When it comes to your money, sometimes doing nothing is the best thing to do.\"\n\nStock Prediction(s):", "Prediction": "\n- All four of the stocks listed will decrease because people will be less likely to spend money when they don't need to.", "price_info": {}}, {"link": "https://www.wsj.com/articles/how-citigroup-could-stumble-11547484644", "title": "How Citigroup Could Stumble", "date": "2019-01-14 11:50", "summary": "Investors shook off weakness in fixed-income trading, but Citigroup's exposure to emerging markets could keep it from hitting its financial targets. Citigroup turned in a mediocre set of results on Monday that show how its grand plans for the future could fall short.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How Citigroup Could Stumble. Investors shook off weakness in fixed-income trading, but Citigroup's exposure to emerging markets could keep it from hitting its financial targets. Citigroup turned in a mediocre set of results on Monday that show how its grand plans for the future could fall short.\"\n\nStock Prediction(s):", "Prediction": "\n- Citigroup Inc (NYSE: C) will decrease because of their exposure to emerging markets.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are not as exposed to emerging markets.\n- Bank of America Corp (NYSE: BAC) will increase because they are not as exposed to emerging markets.", "price_info": {"C": {"company": "", "ticker": "C", "move": "down", "prices": [58.835, 59.025]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [100.7301, 101.17]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [26.2636, 26.46]}}}, {"link": "https://www.wsj.com/articles/prosecutors-sue-tevas-u-s-business-over-charitable-donations-11597771982", "title": "Prosecutors Sue Teva's U.S. Business Over Charitable Donations", "date": "2020-08-18 14:18", "summary": "Suit is latest example of federal prosecutors examining relationships between drugmakers and foundations that help patients with drug copays. Federal prosecutors accused Teva Pharmaceutical Industries Ltd. 's U.S. business of violating an anti-kickback law by using charitable donations to shield Medicare patients from rising costs of a multiple sclerosis drug while ensuring the drug's sales.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Prosecutors Sue Teva's U.S. Business Over Charitable Donations. Suit is latest example of federal prosecutors examining relationships between drugmakers and foundations that help patients with drug copays. Federal prosecutors accused Teva Pharmaceutical Industries Ltd. 's U.S. business of violating an anti-kickback law by using charitable donations to shield Medicare patients from rising costs of a multiple sclerosis drug while ensuring the drug's sales.\"\n\nStock Prediction(s):", "Prediction": "\n- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will decrease because of the lawsuit.\n- Novartis AG (NYSE: NVS) will increase because they are not being investigated.", "price_info": {"TEVA": {"company": "", "ticker": "TEVA", "move": "down", "prices": [10.405, 10.48]}, "NVS": {"company": "", "ticker": "NVS", "move": "up", "prices": [85.57, 85.61]}}}, {"link": "https://www.wsj.com/articles/ernst-young-says-it-isnt-responsible-for-luckin-coffees-accounting-misconduct-11594909084", "title": "Ernst & Young Says It Isn't Responsible for Luckin Coffee's Accounting Misconduct", "date": "2020-07-16 10:18", "summary": "Auditor says it hasn't issued any audit report on the chain's 2019 financial statements and shouldn't be held responsible for the coffee company's earlier disclosures on fake sales. HONG KONG-Ernst & Young Hua Ming LLP, the auditor to Luckin Coffee Inc., on Thursday said it bears no responsibility for the Chinese coffee chain's 2019 financial statements and what it called the company's fraudulent misconduct.", "categories": [["Business", "Asia"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/asia-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ernst & Young Says It Isn't Responsible for Luckin Coffee's Accounting Misconduct. Auditor says it hasn't issued any audit report on the chain's 2019 financial statements and shouldn't be held responsible for the coffee company's earlier disclosures on fake sales. HONG KONG-Ernst & Young Hua Ming LLP, the auditor to Luckin Coffee Inc., on Thursday said it bears no responsibility for the Chinese coffee chain's 2019 financial statements and what it called the company's fraudulent misconduct.\"\n\nStock Prediction(s):", "Prediction": "\n- Ernst & Young (NYSE: EY) will decrease because they are being blamed for Luckin Coffee's accounting misconduct.\n- Luckin Coffee (NASDAQ: LK) will decrease because their accounting misconduct has been revealed.", "price_info": {"EY": {"company": "", "ticker": "EY", "move": "down"}, "LK": {"company": "", "ticker": "LK", "move": "down"}}}, {"link": "https://www.wsj.com/articles/libyan-warlords-oil-foray-draws-u-s-u-n-scrutiny-11591206614", "title": "Libyan Warlord's Oil Foray Draws U.S., U.N. Scrutiny", "date": "2020-06-03 13:50", "summary": "Probes come after Khalifa Haftar pursues international oil deals to help fund his siege of Tripoli. The U.S. and other powers are investigating suspected efforts by Libyan militia leader Khalifa Haftar to raise funds through oil deals, including with Emirati brokers and Venezuela, according to U.S., European and Libyan officials.", "categories": [["WSJ News Exclusive", "World"]], "category_links": ["https://www.wsj.com/news/world?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Libyan Warlord's Oil Foray Draws U.S., U.N. Scrutiny. Probes come after Khalifa Haftar pursues international oil deals to help fund his siege of Tripoli. The U.S. and other powers are investigating suspected efforts by Libyan militia leader Khalifa Haftar to raise funds through oil deals, including with Emirati brokers and Venezuela, according to U.S., European and Libyan officials.\"\n\nStock Prediction(s):", "Prediction": "\n- BP plc (NYSE: BP) will increase because they have a stake in the Libyan oil industry, and they will benefit from the increased scrutiny on Haftar.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they have a stake in the Libyan oil industry, and they will benefit from the increased scrutiny on Haftar.\n- Chevron Corporation (NYSE: CVX) will increase because they have a stake in the", "price_info": {"BP": {"company": "", "ticker": "BP", "move": "up", "prices": [25.935, 25.9]}, "CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [97.36, 97.0002]}}}, {"link": "https://www.wsj.com/articles/the-company-that-sparked-a-california-wildfire-a-day-11562348830", "title": "The Company That Sparked a California Wildfire a Day", "date": "2019-07-05 13:47", "summary": "Most Popular News. The Journal is a podcast about money, business and power, hosted by Kate Linebaugh and Ryan Knutson. The Journal is a co-production from Gimlet Media and The Wall Street Journal.", "categories": [["Business", "Podcast"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Company That Sparked a California Wildfire a Day. Most Popular News. The Journal is a podcast about money, business and power, hosted by Kate Linebaugh and Ryan Knutson. The Journal is a co-production from Gimlet Media and The Wall Street Journal.\"\n\nStock Prediction(s):", "Prediction": "\n- PG&E Corporation (NYSE: PCG) will increase because they have been the company that has been sparking the California Wildfires.\n- Edison International (NYSE: EIX) will increase because they are the company that is trying to buy PG&E Corporation.\n- Sempra Energy (NYSE: SRE) will increase because they are the company that is trying to buy Edison International.", "price_info": {"PCG": {"company": "", "ticker": "PCG", "move": "up", "prices": [21.84, 21.8]}, "EIX": {"company": "", "ticker": "EIX", "move": "up", "prices": [67.09, 67.18]}, "SRE": {"company": "", "ticker": "SRE", "move": "up", "prices": [138.33, 138.38]}}}, {"link": "https://www.wsj.com/articles/coronavirus-vaccine-candidate-from-pfizer-biontech-produces-positive-results-in-early-study-11593620774", "title": "Coronavirus Vaccine Candidate From Pfizer, BioNTech Produces Positive Results", "date": "2020-07-01 12:26", "summary": "Those getting experimental vaccine had higher levels of antibodies compared with recovered Covid-19 patients, researchers say. Researchers said an experimental coronavirus vaccine from Pfizer Inc. and partner BioNTech SE showed promising signs of working in an early-stage study.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Vaccine Candidate From Pfizer, BioNTech Produces Positive Results. Those getting experimental vaccine had higher levels of antibodies compared with recovered Covid-19 patients, researchers say. Researchers said an experimental coronavirus vaccine from Pfizer Inc. and partner BioNTech SE showed promising signs of working in an early-stage study.\"\n\nStock Prediction(s):", "Prediction": "\n- Pfizer Inc (NYSE: PFE) will increase because their vaccine is showing positive results.\n- BioNTech SE (BNTX) will increase because they are working with Pfizer on the vaccine.", "price_info": {"BNTX": {"company": "BioNTech SE", "ticker": "BNTX", "move": "up", "prices": [71.32, 70.85]}, "PFE": {"company": "", "ticker": "PFE", "move": null, "prices": [34.3415, 34.255]}}}, {"link": "https://www.wsj.com/articles/is-this-tiny-dishwasher-worth-it-11548779741", "title": "Does the Convenience of a Countertop Dishwasher Outweigh the Hassle?", "date": "2019-01-29 11:35", "summary": "Handwashing dishes is everyone's least favorite chore, but this innovative new kitchen appliance might be as much a nuisance as it is a novelty. FACT: LITERALLY everyone hates doing dishes. A 2018 Council of Contemporary Families report found the disgusting duty to be the least popular of all household chores, affecting even the sex lives of couples who don't equitably share the task. Unfortunately not all households have great big dishwashers to hide grotty plates during the day and run loads at night. In cities like New York and San Francisco, slim, built-in dishwashers have become a coveted feature for anxious apartment hunters.", "categories": [["Tech", "Personal Tech", "Gear & Gadgets"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb", "https://www.wsj.com/news/types/personal-technology-joanna-stern?mod=breadcrumb", "https://www.wsj.com/news/types/gear?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Does the Convenience of a Countertop Dishwasher Outweigh the Hassle?. Handwashing dishes is everyone's least favorite chore, but this innovative new kitchen appliance might be as much a nuisance as it is a novelty. FACT: LITERALLY everyone hates doing dishes. A 2018 Council of Contemporary Families report found the disgusting duty to be the least popular of all household chores, affecting even the sex lives of couples who don't equitably share the task. Unfortunately not all households have great big dishwashers to hide grotty plates during the day and run loads at night. In cities like New York and San Francisco, slim, built-in dishwashers have become a coveted feature for anxious apartment hunters.\"\n\nStock Prediction(s):", "Prediction": "\n- KitchenAid (NYSE: KA) will increase because their dishwashers are more convenient and might outsell other brands.\n- Whirlpool Corporation (NYSE: WHR) will decrease because their dishwashers are not as convenient and might not sell as well.", "price_info": {"KA": {"company": "", "ticker": "KA", "move": "up"}, "WHR": {"company": "", "ticker": "WHR", "move": "down", "prices": [132.06, 131.92]}}}, {"link": "https://www.wsj.com/articles/demand-for-fed-repos-remain-robust-friday-intervention-just-shy-of-90-billion-11583506609", "title": "Demand for Fed Repos Remains Robust", "date": "2020-03-06 10:07", "summary": "Demand for central bank's temporary money surged this week amid highly unsettled markets. Wall Street's biggest banks continued to have strong demand for Federal Reserve cash Friday.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Demand for Fed Repos Remains Robust. Demand for central bank's temporary money surged this week amid highly unsettled markets. Wall Street's biggest banks continued to have strong demand for Federal Reserve cash Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve's (NYSE: FED) stock will increase because the demand for their cash is high.\n- Goldman Sachs Group Inc (NYSE: GS) will increase because they are one of the Wall Street's biggest banks.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are one of the Wall Street's biggest banks.\n- Bank of America Corp (NYSE: BAC) will increase because they are one of the Wall", "price_info": {"FED": {"company": "", "ticker": "FED", "move": "up"}, "GS": {"company": "", "ticker": "GS", "move": "up", "prices": [193.209, 193.3]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [108.71, 107.82]}, "BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [25.72, 25.71]}}}, {"link": "https://www.wsj.com/articles/u-k-audit-regulator-asks-companies-for-more-details-on-covid-19-impact-11595354170", "title": "U.K. Audit Regulator Asks Companies for More Details on Covid-19 Impact", "date": "2020-07-21 13:56", "summary": "The Financial Reporting Council says firms should go beyond just fulfilling mandatory reporting requirements when talking about the pandemic. The U.K. regulator for audit and accounting is urging companies to provide extensive disclosures on the impact of the coronavirus pandemic on their finances.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.K. Audit Regulator Asks Companies for More Details on Covid-19 Impact. The Financial Reporting Council says firms should go beyond just fulfilling mandatory reporting requirements when talking about the pandemic. The U.K. regulator for audit and accounting is urging companies to provide extensive disclosures on the impact of the coronavirus pandemic on their finances.\"\n\nStock Prediction(s):", "Prediction": "\n- The Financial Reporting Council will increase because they are asking for more details on Covid-19's impact.\n- Companies that disclose more information on Covid-19's impact will increase because investors will want to know how the pandemic is affecting them.\n- Companies that do not disclose more information on Covid-19's impact will decrease because investors will not have as much information to make decisions with.", "price_info": {}}, {"link": "https://www.wsj.com/articles/volkswagen-delays-key-electric-car-launch-amid-software-troubles-11591809421", "title": "Volkswagen Delays Key Electric Car Launch Amid Software Troubles", "date": "2020-06-10 13:17", "summary": "World's biggest auto maker stumbles on road to overtake Tesla. BERLIN- Volkswagen AG said its flagship electric car model, the ID.3 hatchback, wouldn't be delivered to customers until September, several months later than originally planned after software glitches delayed production.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Volkswagen Delays Key Electric Car Launch Amid Software Troubles. World's biggest auto maker stumbles on road to overtake Tesla. BERLIN- Volkswagen AG said its flagship electric car model, the ID.3 hatchback, wouldn't be delivered to customers until September, several months later than originally planned after software glitches delayed production.\"\n\nStock Prediction(s):", "Prediction": "\n- Volkswagen AG (OTCPK: VOW3) will decrease because they are having software troubles with their electric car.\n- Tesla, Inc. (TSLA) will increase because they are not having any software troubles with their electric cars.", "price_info": {"TSLA": {"company": "Tesla, Inc.", "ticker": "TSLA", "move": "up", "prices": [1014.97, 1020.01]}}}, {"link": "https://www.wsj.com/articles/india-orders-antitrust-probe-of-amazon-and-walmarts-flipkart-11578932051", "title": "India Orders Antitrust Probe of Amazon and Walmart's Flipkart", "date": "2020-01-13 11:14", "summary": "Investigation into whether companies violated competition laws is New Delhi's latest attempt to curb U.S. tech giants. NEW DELHI-India's antitrust watchdog ordered a probe into whether Amazon.com Inc . and Walmart Inc.'s Flipkart have violated competition laws, New Delhi's latest move to try to rein in American tech giants that dominate its burgeoning internet economy.", "categories": [["Business", "Asia"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/asia-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"India Orders Antitrust Probe of Amazon and Walmart's Flipkart. Investigation into whether companies violated competition laws is New Delhi's latest attempt to curb U.S. tech giants. NEW DELHI-India's antitrust watchdog ordered a probe into whether Amazon.com Inc . and Walmart Inc.'s Flipkart have violated competition laws, New Delhi's latest move to try to rein in American tech giants that dominate its burgeoning internet economy.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are being investigated for violating antitrust laws in India.\n- Walmart Inc. (NYSE: WMT) will decrease because they are being investigated for violating antitrust laws in India.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [115.7399, 115.62]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1887.8862, 1895.14]}}}, {"link": "https://www.wsj.com/articles/coronavirus-sparks-air-travel-nostalgia-11587740332", "title": "Coronavirus Sparks Air Travel Nostalgia", "date": "2020-04-24 10:58", "summary": "Delta's customer satisfaction 'keeps climbing' as its planes stay grounded. They say absence makes the heart grow fonder. Global lockdowns certainly have led to a remarkable change of heart when it comes to airline satisfaction.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Sparks Air Travel Nostalgia. Delta's customer satisfaction 'keeps climbing' as its planes stay grounded. They say absence makes the heart grow fonder. Global lockdowns certainly have led to a remarkable change of heart when it comes to airline satisfaction.\"\n\nStock Prediction(s):", "Prediction": "\n- Delta Air Lines, Inc. (NYSE: DAL) will increase because their planes are grounded, but their customer satisfaction is still high.\n- American Airlines Group Inc. (NASDAQ: AAL) will decrease because their planes are grounded, and their customer satisfaction is lower than Delta's.\n- United Airlines Holdings, Inc. (NYSE: UAL) will decrease because their planes are grounded, and their customer satisfaction is lower than Delta's.", "price_info": {"DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [21.96, 22.18]}, "UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [24.975, 25.39]}, "AAL": {"company": "", "ticker": "AAL", "move": "down", "prices": [10.015, 10.22]}}}, {"link": "https://www.wsj.com/articles/richard-bransons-virgin-raises-480-million-with-spac-11601642288", "title": "Richard Branson's Virgin Turns to SPAC to Raise Cash", "date": "2020-10-02 10:57", "summary": "British billionaire plans to expand at a time when his core businesses have been hit hard by Covid-19. Richard Branson's Virgin Group has floated a special-purpose acquisition company in New York, raising $480 million to expand an empire that has been hobbled by the pandemic, and joining a parade of offerings known as blank-check listings.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Richard Branson's Virgin Turns to SPAC to Raise Cash. British billionaire plans to expand at a time when his core businesses have been hit hard by Covid-19. Richard Branson's Virgin Group has floated a special-purpose acquisition company in New York, raising $480 million to expand an empire that has been hobbled by the pandemic, and joining a parade of offerings known as blank-check listings.\"\n\nStock Prediction(s):", "Prediction": "\n- Virgin Group Ltd (NASDAQ: VIRG) will increase because they are expanding their business in a time when other companies are struggling.\n- SPACs in general (NYSE: SPAC) will increase because they are a hot new investment, and this one is backed by Richard Branson.", "price_info": {"SPAC": {"company": "", "ticker": "SPAC", "move": "up"}, "VIRG": {"company": "", "ticker": "VIRG", "move": "up"}}}, {"link": "https://www.wsj.com/articles/eu-auto-makers-have-to-sell-more-electric-cars-as-new-emission-targets-loom-11561139522", "title": "European Auto Makers Are Under Pressure to Sell More Electric Cars", "date": "2019-06-21 13:52", "summary": "Auto industry in Europe could face fines in the tens of billions of euros unless it ramps up sales of electric cars. BERLIN-An approaching target for tougher new carbon emission standards in the European Union is causing panic among unprepared car makers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"European Auto Makers Are Under Pressure to Sell More Electric Cars. Auto industry in Europe could face fines in the tens of billions of euros unless it ramps up sales of electric cars. BERLIN-An approaching target for tougher new carbon emission standards in the European Union is causing panic among unprepared car makers.\"\n\nStock Prediction(s):", "Prediction": "\n- Volkswagen AG (OTCPK: VOW3) will increase because they are one of the few companies that are already selling electric cars, and they will need to sell more to avoid fines.\n- Daimler AG (OTCPK: DDAIF) will increase because they are one of the few companies that are already selling electric cars, and they will need to sell more to avoid fines.\n- BMW AG (OTCPK: BAMX", "price_info": {}}, {"link": "https://www.wsj.com/articles/financial-planning-cop-needs-to-toughen-up-11565362838", "title": "Investors Need This Cop to Toughen Up", "date": "2019-08-09 11:00", "summary": "Does the Certified Financial Planner Board of Standards have the backbone to improve its scrutiny of financial advice?. Last month, a Page One article in The Wall Street Journal described loose disclosure and disciplinary practices at the Certified Financial Planner Board of Standards Inc., which awards the CFP designation coveted among financial advisers.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors Need This Cop to Toughen Up. Does the Certified Financial Planner Board of Standards have the backbone to improve its scrutiny of financial advice?. Last month, a Page One article in The Wall Street Journal described loose disclosure and disciplinary practices at the Certified Financial Planner Board of Standards Inc., which awards the CFP designation coveted among financial advisers.\"\n\nStock Prediction(s):", "Prediction": "\n- The CFP Board of Standards (CFP) will increase because they are working to improve their disclosure and disciplinary practices.\n- The other financial planning boards (e.g. FINRA, CFA, etc.) will decrease because CFP is becoming a more desirable designation.", "price_info": {"CFP": {"company": "The", "ticker": "CFP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/europes-new-common-bonds-prove-a-hit-with-investors-11624629932", "title": "Europe's New Common Bonds Prove a Hit With Investors", "date": "2021-06-25 10:05", "summary": "Triple-A-rated EU bonds, used to fund Covid-19 recovery efforts, help alleviate a shortage of safe assets. Investors are lapping up Europe's new common bonds, proving strong demand for supersafe assets in a region starved of them.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Europe's New Common Bonds Prove a Hit With Investors. Triple-A-rated EU bonds, used to fund Covid-19 recovery efforts, help alleviate a shortage of safe assets. Investors are lapping up Europe's new common bonds, proving strong demand for supersafe assets in a region starved of them.\"\n\nStock Prediction(s):", "Prediction": "\n- European Union bonds (EUR) will increase because they are a safe investment and there is a shortage of safe assets.\n- United States Treasury bonds (UST) will decrease because they are a less safe investment and there is no shortage of safe assets.", "price_info": {"EUR": {"company": "", "ticker": "EUR", "move": "up"}, "UST": {"company": "", "ticker": "UST", "move": "down", "prices": [67.58, 67.64]}}}, {"link": "https://www.wsj.com/articles/auto-parts-retailers-still-have-room-to-run-11619718748", "title": "Auto-Parts Retailers Still Have Room to Run", "date": "2021-04-29 13:52", "summary": "Harsh winter weather and new-car supply constraints should help prospects for auto-parts retailers. Auto-parts retailers look revved up and ready to go. Their share prices have some catching up to do.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Auto-Parts Retailers Still Have Room to Run. Harsh winter weather and new-car supply constraints should help prospects for auto-parts retailers. Auto-parts retailers look revved up and ready to go. Their share prices have some catching up to do.\"\n\nStock Prediction(s):", "Prediction": "\n- Advance Auto Parts, Inc. (NYSE: AAP) will increase because of the harsh winter weather and new-car supply constraints.\n- O'Reilly Automotive, Inc. (NASDAQ: ORLY) will increase because of the harsh winter weather and new-car supply constraints.\n- AutoZone, Inc. (NYSE: AZO) will increase because of the harsh winter weather and new-car supply constraints.", "price_info": {"AAP": {"company": "", "ticker": "AAP", "move": "up", "prices": [200.42, 200.68]}, "AZO": {"company": "", "ticker": "AZO", "move": "up", "prices": [1471.44, 1474.96]}, "ORLY": {"company": "", "ticker": "ORLY", "move": "up", "prices": [541.675, 546.02]}}}, {"link": "https://www.wsj.com/articles/u-s-employers-added-304-000-jobs-in-january-unemployment-ticked-up-due-to-shutdown-11549028008", "title": "Economy Notches 100th Straight Month of Increased Employment", "date": "2019-02-01 14:58", "summary": "Nonfarm payrolls rose a seasonally adjusted 304,000 in January. WASHINGTON-The U.S. labor market notched its 100th straight month of increased employment in January while sustaining robust wage growth, passing the tests posed by a federal-government shutdown, market volatility and uncertainty about global economies.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Economy Notches 100th Straight Month of Increased Employment. Nonfarm payrolls rose a seasonally adjusted 304,000 in January. WASHINGTON-The U.S. labor market notched its 100th straight month of increased employment in January while sustaining robust wage growth, passing the tests posed by a federal-government shutdown, market volatility and uncertainty about global economies.\"\n\nStock Prediction(s):", "Prediction": "\n- The U.S. labor market will continue to grow, which will benefit companies such as Walmart Inc. (NYSE: WMT) and Amazon.com, Inc. (NASDAQ: AMZN).\n- The U.S. labor market will not grow as quickly, which will benefit companies such as McDonald's Corporation (NYSE: MCD) and Dunkin' Brands Group, Inc. (NASDAQ: DNKN).", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [93.565, 93.71]}, "MCD": {"company": "", "ticker": "MCD", "move": "up", "prices": [177.0815, 176.72]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1628.01, 1622.58]}, "DNKN": {"company": "", "ticker": "DNKN", "move": "up", "prices": [68.03, 68.27]}}}, {"link": "https://www.wsj.com/articles/from-1720-to-tesla-fomo-never-sleeps-11594994422", "title": "From 1720 to Tesla, FOMO Never Sleeps", "date": "2020-07-17 10:00", "summary": "The South Sea bubble is the classic story of an investing mania. Are investors today any wiser?. Back in Business is a new, occasional column that puts the present day in perspective by looking at business history and those who shaped it. Read the first installment here. Mr. Zweig's Intelligent Investor column will return next week.", "categories": [["Business", "Back in Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/back-in-business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"From 1720 to Tesla, FOMO Never Sleeps. The South Sea bubble is the classic story of an investing mania. Are investors today any wiser?. Back in Business is a new, occasional column that puts the present day in perspective by looking at business history and those who shaped it. Read the first installment here. Mr. Zweig's Intelligent Investor column will return next week.\"\n\nStock Prediction(s):", "Prediction": "\n- Tesla, Inc. (NASDAQ: TSLA) will continue to increase because it is a company that is constantly innovating and changing the game.\n- The South Sea Company (OTC: SSNCF) will continue to decrease because it is a company that is based on a mania and has no real value.", "price_info": {"TSLA": {"company": "", "ticker": "TSLA", "move": "down", "prices": [1504.21, 1503.2078]}}}, {"link": "https://www.wsj.com/articles/legal-weed-is-smoking-in-seattle-11561134516", "title": "Legal Weed Is Smoking in Seattle", "date": "2019-06-21 12:28", "summary": "A study analyzed wastewater to gauge the amount of pot consumed locally in the Puget Sound area. Drug dealers probably don't spend much time reading scientific journals, and maybe they shouldn't bother with this one either-it's sort of a buzzkill.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Legal Weed Is Smoking in Seattle. A study analyzed wastewater to gauge the amount of pot consumed locally in the Puget Sound area. Drug dealers probably don't spend much time reading scientific journals, and maybe they shouldn't bother with this one either-it's sort of a buzzkill.\"\n\nStock Prediction(s):", "Prediction": "\n- GW Pharmaceuticals plc (NASDAQ: GWPH) will increase because they are the only company with a legal weed product.\n- Canopy Growth Corporation (NYSE: CGC) will increase because they are the biggest company in the legal weed industry.\n- Aphria Inc (NYSE: APHA) will decrease because they are not in the legal weed industry.", "price_info": {"CGC": {"company": "", "ticker": "CGC", "move": "up", "prices": [40.2839, 40.425]}, "APHA": {"company": "", "ticker": "APHA", "move": "down", "prices": [6.5519, 6.56]}, "GWPH": {"company": "", "ticker": "GWPH", "move": "up", "prices": [173.533, 173.9544]}}}, {"link": "https://www.wsj.com/articles/ford-looks-to-trim-1-400-salaried-employees-in-u-s-through-buyouts-11599059576", "title": "Ford Looks to Trim 1,400 Through U.S. Buyouts", "date": "2020-09-02 11:12", "summary": "Auto maker cut about 7,000 salaried workers globally last year, mostly in Europe. Ford Motor Co. is offering buyouts to salaried employees in the U.S., a move that comes as the car maker works to rebound from coronavirus-related factory closures earlier in the year and prepares for new executive leadership.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ford Looks to Trim 1,400 Through U.S. Buyouts. Auto maker cut about 7,000 salaried workers globally last year, mostly in Europe. Ford Motor Co. is offering buyouts to salaried employees in the U.S., a move that comes as the car maker works to rebound from coronavirus-related factory closures earlier in the year and prepares for new executive leadership.\"\n\nStock Prediction(s):", "Prediction": "\n- Ford Motor Co. (NYSE: F) will decrease because they are trimming 1,400 jobs in the U.S.", "price_info": {"F": {"company": "", "ticker": "F", "move": "down", "prices": [6.9172, 6.9]}}}, {"link": "https://www.wsj.com/articles/johnson-johnson-to-buy-momenta-pharmaceuticals-for-6-5-billion-11597835648", "title": "Johnson & Johnson to Buy Momenta Pharmaceuticals for $6.5 Billion", "date": "2020-08-19 12:12", "summary": "Deal gives J&J a foothold in a new class of drugs that aim to treat autoimmune diseases. Johnson & Johnson said Wednesday it agreed to buy drugmaker Momenta Pharmaceuticals Inc. for about $6.5 billion, giving J&J entry into a potentially big-selling new class of drugs to treat certain autoimmune diseases.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Johnson & Johnson to Buy Momenta Pharmaceuticals for $6.5 Billion. Deal gives J&J a foothold in a new class of drugs that aim to treat autoimmune diseases. Johnson & Johnson said Wednesday it agreed to buy drugmaker Momenta Pharmaceuticals Inc. for about $6.5 billion, giving J&J entry into a potentially big-selling new class of drugs to treat certain autoimmune diseases.\"\n\nStock Prediction(s):", "Prediction": "\n- Johnson & Johnson (NYSE: JNJ) will increase because they are buying Momenta Pharmaceuticals for $6.5 billion, which will give them a foothold in a new class of drugs.\n- Momenta Pharmaceuticals Inc (NASDAQ: MNTA) will increase because they are being bought by Johnson & Johnson for $6.5 billion, which will give them a foothold in a new class of drugs.", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "up", "prices": [150.59, 150.78]}, "MNTA": {"company": "", "ticker": "MNTA", "move": "up", "prices": [52.175, 52.135]}}}, {"link": "https://www.wsj.com/articles/dont-bail-on-brunswick-11566406477", "title": "Don't Bail on Brunswick", "date": "2019-08-21 12:56", "summary": "The boat maker's shares have fallen sharply over the past year, but worries its business could become unmoored should blow over. \"A boat is a hole in the water you throw money into,\" is how the saying goes. Investors who have put money into Brunswick lately can relate.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Don't Bail on Brunswick. The boat maker's shares have fallen sharply over the past year, but worries its business could become unmoored should blow over. \"A boat is a hole in the water you throw money into,\" is how the saying goes. Investors who have put money into Brunswick lately can relate.\"\n\nStock Prediction(s):", "Prediction": "\n- Brunswick Corporation (NYSE: BC) will increase because their business is not tied to the Covid-19 virus, and they have a strong product lineup.\n- MarineMax, Inc. (NYSE: HZO) will decrease because their business is tied to the Covid-19 virus, and they have a weak product lineup.", "price_info": {"BC": {"company": "", "ticker": "BC", "move": "up", "prices": [46, 45.8782]}, "HZO": {"company": "", "ticker": "HZO", "move": "down", "prices": [14.46, 14.4]}}}, {"link": "https://www.wsj.com/articles/u-s-worker-productivity-advances-at-best-rate-since-2010-11556800550", "title": "U.S. Worker Productivity Advances at Best Rate Since 2010", "date": "2019-05-02 13:14", "summary": "Meanwhile, pay increases were mostly offset by better efficiency, a factor helping keep inflation in check. WASHINGTON-U.S. workers' efficiency improved during the past year at the best pace in nearly a decade, laying groundwork for stronger wage growth and continued economic expansion.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Worker Productivity Advances at Best Rate Since 2010. Meanwhile, pay increases were mostly offset by better efficiency, a factor helping keep inflation in check. WASHINGTON-U.S. workers' efficiency improved during the past year at the best pace in nearly a decade, laying groundwork for stronger wage growth and continued economic expansion.\"\n\nStock Prediction(s):", "Prediction": "\n- The productivity increase will be good for the overall economy, and will help to keep inflation in check.\n- The increase in productivity will be good for companies that are able to increase efficiency, but will be bad for companies that are not able to keep up.\n- The increase in productivity will be good for workers, who will see higher wages, and will be bad for workers who are not able to keep up.", "price_info": {}}, {"link": "https://www.wsj.com/articles/for-markets-the-january-selloff-marks-the-end-of-the-pandemic-11643728795", "title": "For Markets, the January Selloff Marks the End of the Pandemic", "date": "2022-02-01 13:02", "summary": "Stock valuations and the 10-year Treasury yield are both back to where they were before the Covid-19 crisis. To look at stock valuations, the pandemic might never have happened.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"For Markets, the January Selloff Marks the End of the Pandemic. Stock valuations and the 10-year Treasury yield are both back to where they were before the Covid-19 crisis. To look at stock valuations, the pandemic might never have happened.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will continue to increase because the selloff was only caused by the pandemic, and now that it is over, the market will go back to where it was before.\n- The market will continue to decrease because the selloff was only caused by the pandemic, and now that it is over, the market will go back to where it was before.", "price_info": {}}, {"link": "https://www.wsj.com/articles/u-s-likely-exceeded-authority-in-tiktok-ban-judge-says-11601321415", "title": "U.S. Likely Exceeded Authority in TikTok Ban, Judge Says", "date": "2020-09-28 15:30", "summary": "Ruling finds government likely overstepped powers under national security law Trump had invoked to pursue ban on video-sharing app. WASHINGTON-The federal judge who stopped the Trump administration's download ban on video-sharing app TikTok determined that the government likely overstepped its authority under national security law, according to his decision made public Monday.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Likely Exceeded Authority in TikTok Ban, Judge Says. Ruling finds government likely overstepped powers under national security law Trump had invoked to pursue ban on video-sharing app. WASHINGTON-The federal judge who stopped the Trump administration's download ban on video-sharing app TikTok determined that the government likely overstepped its authority under national security law, according to his decision made public Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- TikTok (NYSE: TIK) will increase because the judge ruled that the U.S. government likely overstepped their authority in banning the app.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they own TikTok, and the ruling could have a negative impact on their stock.", "price_info": {"TIK": {"company": "", "ticker": "TIK", "move": "up"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [115.1, 115.16]}}}, {"link": "https://www.wsj.com/articles/why-investors-cant-kick-the-past-performance-habit-11627050982", "title": "Why Investors Can't Kick the 'Past Performance' Habit", "date": "2021-07-23 10:45", "summary": "Market history never repeats itself exactly. Trying to convince people otherwise can backfire.. On Monday, July 19, financial markets hit instant replay.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why Investors Can't Kick the 'Past Performance' Habit. Market history never repeats itself exactly. Trying to convince people otherwise can backfire.. On Monday, July 19, financial markets hit instant replay.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because people are still trying to rely on past performance.", "price_info": {}}, {"link": "https://www.wsj.com/articles/at-t-takes-streaming-price-to-the-max-11572451990", "title": "AT&T Takes Streaming Price to the Max", "date": "2019-10-30 12:13", "summary": "New HBO service is priced above most rivals, but telecom giant had little choice. AT&T was between a rock and a hard place with its much-awaited entry into the TV streaming wars. It chose the hard place.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"AT&T Takes Streaming Price to the Max. New HBO service is priced above most rivals, but telecom giant had little choice. AT&T was between a rock and a hard place with its much-awaited entry into the TV streaming wars. It chose the hard place.\"\n\nStock Prediction(s):", "Prediction": "\n- AT&T Inc. (NYSE: T) will decrease because they are pricing their new streaming service too high.\n- Comcast Corporation (NASDAQ: CMCSA) will increase because they have a more affordable streaming service.\n- Netflix, Inc. (NASDAQ: NFLX) will increase because they are the cheapest streaming service.", "price_info": {"T": {"company": "", "ticker": "T", "move": "down", "prices": [38.3648, 38.295]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "up", "prices": [44.74, 44.48]}, "NFLX": {"company": "", "ticker": "NFLX", "move": "up", "prices": [290.69, 290.37]}}}, {"link": "https://www.wsj.com/articles/seaworld-settles-claims-that-it-misled-investors-on-critical-documentarys-effects-11581431646", "title": "SeaWorld Settles Suits Claiming It Misled Investors", "date": "2020-02-11 09:34", "summary": "Company to pay $65 million to settle two lawsuits filed following 2013 film 'Blackfish'. SeaWorld Entertainment Inc. said it would pay $65 million to settle claims that it violated securities laws by not being upfront with investors about the effect a critical documentary had on its business.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SeaWorld Settles Suits Claiming It Misled Investors. Company to pay $65 million to settle two lawsuits filed following 2013 film 'Blackfish'. SeaWorld Entertainment Inc. said it would pay $65 million to settle claims that it violated securities laws by not being upfront with investors about the effect a critical documentary had on its business.\"\n\nStock Prediction(s):", "Prediction": "\n- SeaWorld Entertainment Inc. (NYSE: SEAS) will decrease because they have to pay $65 million to settle lawsuits.", "price_info": {"SEAS": {"company": "", "ticker": "SEAS", "move": "down", "prices": [35.69, 36.27]}}}, {"link": "https://www.wsj.com/articles/ppg-industries-puts-focus-on-m-a-instead-of-share-buybacks-11612382796", "title": "PPG Industries Puts Focus on M&A Instead of Share Buybacks", "date": "2021-02-03 15:06", "summary": "The paint maker has struck three deals in recent months and is trying to do a fourth one. PPG Industries Inc.'s finance chief is helping vet potential new acquisition targets as the paint maker opts for deals over share buybacks in the year ahead.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"PPG Industries Puts Focus on M&A Instead of Share Buybacks. The paint maker has struck three deals in recent months and is trying to do a fourth one. PPG Industries Inc.'s finance chief is helping vet potential new acquisition targets as the paint maker opts for deals over share buybacks in the year ahead.\"\n\nStock Prediction(s):", "Prediction": "\n- PPG Industries Inc. (NYSE: PPG) will increase because they are focusing on M&A instead of share buybacks.\n- Sherwin-Williams Co (NYSE: SHW) will decrease because they are a direct competitor of PPG Industries.", "price_info": {"PPG": {"company": "", "ticker": "PPG", "move": "up", "prices": [140.1292, 139.91]}, "SHW": {"company": "", "ticker": "SHW", "move": "down", "prices": [706.955, 701.21]}}}, {"link": "https://www.wsj.com/articles/probe-of-former-apple-supplier-of-iphone-glass-is-settled-11556907075", "title": "Probe of Former Apple Supplier of iPhone Glass Is Settled", "date": "2019-05-03 14:11", "summary": "GT Advanced Technologies, which emerged from bankruptcy in 2016, settled the SEC probe and its former CEO agreed to pay $140,000. WASHINGTON-A former supplier to Apple Inc. agreed Friday to settle civil fraud claims that it misled investors about its problems making scratch-resistant sapphire glass for iPhones.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Probe of Former Apple Supplier of iPhone Glass Is Settled. GT Advanced Technologies, which emerged from bankruptcy in 2016, settled the SEC probe and its former CEO agreed to pay $140,000. WASHINGTON-A former supplier to Apple Inc. agreed Friday to settle civil fraud claims that it misled investors about its problems making scratch-resistant sapphire glass for iPhones.\"\n\nStock Prediction(s):", "Prediction": "\n- GT Advanced Technologies Inc. (NASDAQ: GTAT) will increase because they have settled the SEC probe and their former CEO has agreed to pay $140,000.\n- Apple Inc. (NASDAQ: AAPL) will increase because they have a new supplier for iPhone glass.", "price_info": {"GTAT": {"company": "", "ticker": "GTAT", "move": "up"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [211.2332, 211.75]}}}, {"link": "https://www.wsj.com/articles/johnson-johnson-posts-higher-quarterly-profit-as-healthcare-demand-returns-11626867300", "title": "Johnson & Johnson Posts Higher Quarterly Profit", "date": "2021-07-21 14:54", "summary": "Company raises guidance for rest of the year, expects sales of its Covid-19 vaccine to pick up. Greater demand for medical devices, drugs and consumer-health products helped boost sales and profit for Johnson & Johnson in the latest quarter, a sign people are returning for healthcare services they deferred earlier in the pandemic.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Johnson & Johnson Posts Higher Quarterly Profit. Company raises guidance for rest of the year, expects sales of its Covid-19 vaccine to pick up. Greater demand for medical devices, drugs and consumer-health products helped boost sales and profit for Johnson & Johnson in the latest quarter, a sign people are returning for healthcare services they deferred earlier in the pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- Johnson & Johnson (NYSE: JNJ) will increase because they have raised guidance for the rest of the year, and they are expecting sales of their Covid-19 vaccine to pick up.\n- AstraZeneca plc (NASDAQ: AZN) will decrease because they are a direct competitor of Johnson & Johnson.\n- Pfizer Inc (NYSE: PFE) will decrease because they are a direct competitor of Johnson & Johnson.\n- Modern", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "up", "prices": [169.29, 169.49]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [41.15, 41.05]}, "AZN": {"company": "", "ticker": "AZN", "move": "down", "prices": [57.825, 57.98]}}}, {"link": "https://www.wsj.com/articles/freddie-mac-ceo-quits-as-prospects-dim-for-exit-from-government-control-11605292952", "title": "Freddie Mac CEO Quits", "date": "2020-11-13 13:42", "summary": "The mortgage giant was taken over during the 2008 financial crisis along with Fannie Mae. WASHINGTON-The chief executive of mortgage-finance company Freddie Mac plans to step down in January, the company said in a securities filing Friday, a surprise move that comes as prospects dim for an exit from government control for the firm and its larger sister, Fannie Mae .", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Freddie Mac CEO Quits. The mortgage giant was taken over during the 2008 financial crisis along with Fannie Mae. WASHINGTON-The chief executive of mortgage-finance company Freddie Mac plans to step down in January, the company said in a securities filing Friday, a surprise move that comes as prospects dim for an exit from government control for the firm and its larger sister, Fannie Mae .\"\n\nStock Prediction(s):", "Prediction": "\n- Freddie Mac (OTCQB: FMCC) will decrease because their CEO is quitting, and they are still under government control.\n- Fannie Mae (OTCQB: FNMA) will decrease because their CEO is quitting, and they are still under government control.", "price_info": {}}, {"link": "https://www.wsj.com/articles/investors-pile-into-once-unloved-greek-debt-11581525420", "title": "Investors Pile Into Once-Unloved Greek Debt", "date": "2020-02-12 11:37", "summary": "Yields on 10-year Greek government bonds fall to an unprecedented level as investors bet on a rating upgrade. The yield on Greek government bonds breached 1% for the first time, marking a dramatic turnaround for an economy that had been viewed by investors as a bet too risky fewer than 15 months ago.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Investors Pile Into Once-Unloved Greek Debt. Yields on 10-year Greek government bonds fall to an unprecedented level as investors bet on a rating upgrade. The yield on Greek government bonds breached 1% for the first time, marking a dramatic turnaround for an economy that had been viewed by investors as a bet too risky fewer than 15 months ago.\"\n\nStock Prediction(s):", "Prediction": "\n- Greece (NYSE: GREK) will increase because investors are piling back in, and the economy is looking up.\n- Spain (NYSE: EWP) will decrease because investors are piling back into Greece, and Spain is seen as a riskier investment.", "price_info": {"GREK": {"company": "", "ticker": "GREK", "move": "up", "prices": [9.37, 9.38]}, "EWP": {"company": "", "ticker": "EWP", "move": "down", "prices": [29.2121, 29.19]}}}, {"link": "https://www.wsj.com/articles/u-s-government-bonds-fall-as-powell-testifies-11551283047", "title": "U.S. Treasurys Weaken as Powell Testifies", "date": "2019-02-27 15:44", "summary": "Analysts attribute moves to heavy corporate issuance and better-than-expected economic data. U.S. government-bond prices fell Wednesday, giving up gains from earlier in the week, after upbeat economic data and a second day of testimony from Federal Reserve Chairman Jerome Powell.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Treasurys Weaken as Powell Testifies. Analysts attribute moves to heavy corporate issuance and better-than-expected economic data. U.S. government-bond prices fell Wednesday, giving up gains from earlier in the week, after upbeat economic data and a second day of testimony from Federal Reserve Chairman Jerome Powell.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will generally trend downwards because of the news.\n- Treasury prices will generally trend downwards because of the news.\n- The market will rebound because of Powell's testimony on Thursday.\n- Treasury prices will rebound because of Powell's testimony on Thursday.", "price_info": {}}, {"link": "https://www.wsj.com/articles/central-banks-warm-to-issuing-digital-currencies-11579796156", "title": "Central Banks Warm to Issuing Digital Currencies", "date": "2020-01-23 11:15", "summary": "One in 10 central banks surveyed says it is likely to roll out digital currencies within three years. More than one-fifth of the world's population could have access to digital money issued by central banks to pay for groceries, movie tickets and even homes in the next few years, as these institutions accelerate plans to issue official cryptocurrencies.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Central Banks Warm to Issuing Digital Currencies. One in 10 central banks surveyed says it is likely to roll out digital currencies within three years. More than one-fifth of the world's population could have access to digital money issued by central banks to pay for groceries, movie tickets and even homes in the next few years, as these institutions accelerate plans to issue official cryptocurrencies.\"\n\nStock Prediction(s):", "Prediction": "\n- Bitcoin (BTC) will increase because more central banks are warming up to the idea of issuing their own digital currencies, which will increase the overall demand for Bitcoin.\n- Facebook (NASDAQ: FB) will increase because they are working on a digital currency called Libra, which will help to increase the overall demand for digital currencies.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are also working on a digital currency called JPM Coin,", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "up"}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [135.14, 135.7795]}, "FB": {"company": "", "ticker": "FB", "move": "up", "prices": [220.314, 219.98]}}}, {"link": "https://www.wsj.com/articles/all-that-glitters-isnt-charmin-11582304026", "title": "All That Glitters Isn't Charmin", "date": "2020-02-21 11:53", "summary": "Toilet paper is scarce in Hong Kong, but it isn't worth its weight in gold. You hear it all the time when people talk about a luxury good or one temporarily in short supply: \"It's worth its weight in gold!\"", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"All That Glitters Isn't Charmin. Toilet paper is scarce in Hong Kong, but it isn't worth its weight in gold. You hear it all the time when people talk about a luxury good or one temporarily in short supply: \"It's worth its weight in gold!\"\"\n\nStock Prediction(s):", "Prediction": "\n- Procter & Gamble Co (NYSE: PG) will increase because their main competitor, Charmin, is in short supply.\n- Kimberly-Clark Corp (NYSE: KMB) will increase because their main competitor, Charmin, is in short supply.\n- Costco Wholesale Corp (NASDAQ: COST) will increase because their main competitor, Charmin, is in short supply.", "price_info": {"PG": {"company": "", "ticker": "PG", "move": "up", "prices": [127.6699, 127.35]}, "KMB": {"company": "", "ticker": "KMB", "move": "up", "prices": [141.7099, 141.4]}, "COST": {"company": "", "ticker": "COST", "move": "up", "prices": [323.3757, 322.25]}}}, {"link": "https://www.wsj.com/articles/europe-remains-a-weak-spot-for-the-global-economy-11579861052", "title": "U.S. Business Activity Increases in Early 2020", "date": "2020-01-24 12:52", "summary": "Europe's economy remains a global weak spot. Business activity in the U.S. improved in early 2020, contrasting with weaker economic performance in some of the world's other major economies.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Business Activity Increases in Early 2020. Europe's economy remains a global weak spot. Business activity in the U.S. improved in early 2020, contrasting with weaker economic performance in some of the world's other major economies.\"\n\nStock Prediction(s):", "Prediction": "\n- The Dow Jones Industrial Average (NYSE: DJIA) will increase because the U.S. economy is doing well.\n- The S&P 500 (NYSE: SPX) will increase because the U.S. economy is doing well.\n- The Nasdaq Composite (NASDAQ: COMP) will increase because the U.S. economy is doing well.", "price_info": {"DJIA": {"company": "", "ticker": "DJIA", "move": "up"}, "SPX": {"company": "", "ticker": "SPX", "move": "up"}, "COMP": {"company": "", "ticker": "COMP", "move": "up"}}}, {"link": "https://www.wsj.com/articles/hackers-linked-to-solarwinds-return-with-phishing-attack-microsoft-says-11622222808", "title": "Hackers Linked to SolarWinds Return With Phishing Attack", "date": "2021-05-28 13:26", "summary": "Reported intrusion comes as summit planned in June for Biden, Putin. The Russia-linked hackers behind the cyberattack on SolarWinds have returned, launching a phishing attack targeting approximately 3,000 email accounts belonging to workers at more than 150 organizations, Microsoft said late Thursday.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hackers Linked to SolarWinds Return With Phishing Attack. Reported intrusion comes as summit planned in June for Biden, Putin. The Russia-linked hackers behind the cyberattack on SolarWinds have returned, launching a phishing attack targeting approximately 3,000 email accounts belonging to workers at more than 150 organizations, Microsoft said late Thursday.\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are a direct competitor of SolarWinds, and they have been working on increasing their security measures.\n- Symantec Corporation (NASDAQ: SYMC) will increase because they are a direct competitor of SolarWinds, and they have been working on increasing their security measures.\n- Palo Alto Networks, Inc. (NYSE: PANW) will increase because they are a direct competitor of Solar", "price_info": {"PANW": {"company": "", "ticker": "PANW", "move": "up", "prices": [366.13, 361.9]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [250.74, 249.86]}, "SYMC": {"company": "", "ticker": "SYMC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/ea-needs-this-mobile-play-to-stick-11612897633", "title": "EA Needs This Mobile Play to Stick", "date": "2021-02-09 14:07", "summary": "Acquisition of Glu Mobile is videogame publisher's latest attempt to buy into a difficult market. Leveling up in mobile games doesn't come cheap these days. For Electronic Arts , the payoff could be worth the price.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"EA Needs This Mobile Play to Stick. Acquisition of Glu Mobile is videogame publisher's latest attempt to buy into a difficult market. Leveling up in mobile games doesn't come cheap these days. For Electronic Arts , the payoff could be worth the price.\"\n\nStock Prediction(s):", "Prediction": "\n- EA will increase because they are trying to get into the mobile gaming market, and this could be a successful move for them.\n- Activision Blizzard, Inc. (NASDAQ: ATVI) will decrease because they are a direct competitor of EA.", "price_info": {"ATVI": {"company": "", "ticker": "ATVI", "move": "down", "prices": [103.1, 102.94]}}}, {"link": "https://www.wsj.com/articles/facebook-live-has-got-to-go-11553007109", "title": "Facebook Live Has Got to Go", "date": "2019-03-19 10:51", "summary": "The social-media giant may be doing more harm than good with live video. Facebook 's live-video feature is becoming a viral problem with no apparent antidote.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Live Has Got to Go. The social-media giant may be doing more harm than good with live video. Facebook 's live-video feature is becoming a viral problem with no apparent antidote.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook, Inc. (NASDAQ: FB) will decrease because people are realizing that the site is more harmful than helpful.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [163.27, 162.25]}}}, {"link": "https://www.wsj.com/articles/five-innovative-ways-cities-are-improving-life-for-seniors-11558450968", "title": "Five Innovative Ways Cities Are Improving Life for Seniors", "date": "2019-05-22 09:50", "summary": "As the 65 and over population grows, urban planners are looking for new approaches to serve the booming demographic. Cities are trying to make life better for their older residents.", "categories": [["Business", "Journal Reports: Technology"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Five Innovative Ways Cities Are Improving Life for Seniors. As the 65 and over population grows, urban planners are looking for new approaches to serve the booming demographic. Cities are trying to make life better for their older residents.\"\n\nStock Prediction(s):", "Prediction": "\n- Age Friendly Cities Inc (OTCQB: AGE) will increase because they provide innovative ways for cities to improve life for seniors.\n- The Silvercrest Group Ltd (OTCQB: SVRG) will increase because they provide innovative ways for cities to improve life for seniors.\n- Sunrise Senior Living, Inc. (NYSE: SRZ) will increase because they provide innovative ways for cities to improve life for seniors.\n- Brookdale Senior Living", "price_info": {"SRZ": {"company": "", "ticker": "SRZ", "move": "up"}}}, {"link": "https://www.wsj.com/articles/bond-investors-shouldnt-fixate-too-much-on-the-alphabet-11550765293", "title": "Bond Investors Shouldn't Fixate Too Much on the Alphabet", "date": "2019-02-21 11:08", "summary": "Corporate debt graded BBB has become investors' bogeyman, but higher-rated paper isn't always safer. Just like a teapot that never whistles while you are looking at it, perhaps the most maligned bit of the corporate bond market isn't where investors will get burned.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Bond Investors Shouldn't Fixate Too Much on the Alphabet. Corporate debt graded BBB has become investors' bogeyman, but higher-rated paper isn't always safer. Just like a teapot that never whistles while you are looking at it, perhaps the most maligned bit of the corporate bond market isn't where investors will get burned.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will not react to this news because it is not about a specific company.", "price_info": {}}, {"link": "https://www.wsj.com/articles/huawei-workers-return-after-coronavirus-but-ceo-sees-financial-hit-11585149231", "title": "Huawei Workers Return After Virus, but CEO Sees Financial Hit", "date": "2020-03-25 11:13", "summary": "Ren Zhengfei says company will likely meet new financial goals and boost R&D budget this year by $5.8 billion to more than $20 billion. Most employees at Huawei Technologies Co. are back at work following the coronavirus outbreak, though the pandemic is likely to hit the Chinese telecom giant's financial results this year, the company's chief executive said.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Huawei Workers Return After Virus, but CEO Sees Financial Hit. Ren Zhengfei says company will likely meet new financial goals and boost R&D budget this year by $5.8 billion to more than $20 billion. Most employees at Huawei Technologies Co. are back at work following the coronavirus outbreak, though the pandemic is likely to hit the Chinese telecom giant's financial results this year, the company's chief executive said.\"\n\nStock Prediction(s):", "Prediction": "\n- Huawei Technologies Co. (SHE: 002502) will increase because their employees are returning and they are increasing their R&D budget.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are a direct competitor of Huawei.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [254.66, 254.9256]}}}, {"link": "https://www.wsj.com/articles/justice-department-appeals-injunction-against-wechat-11601663698", "title": "Justice Department Appeals Injunction Against WeChat App", "date": "2020-10-02 14:34", "summary": "Trump administration ordered ban against the app, saying it poses a national-security risk because data could be shared with China's government. WASHINGTON-The Trump administration filed court papers Friday seeking to overturn a federal magistrate's Sept. 20 ruling that stopped a U.S. ban on China's ubiquitous messaging and e-commerce app WeChat .", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Justice Department Appeals Injunction Against WeChat App. Trump administration ordered ban against the app, saying it poses a national-security risk because data could be shared with China's government. WASHINGTON-The Trump administration filed court papers Friday seeking to overturn a federal magistrate's Sept. 20 ruling that stopped a U.S. ban on China's ubiquitous messaging and e-commerce app WeChat .\"\n\nStock Prediction(s):", "Prediction": "\n- WeChat (OTC: WCHT) will increase because the Trump administration is appealing the injunction against the app.\n- Apple Inc. (NASDAQ: AAPL) will decrease because WeChat is a competitor to Apple's iMessage app.", "price_info": {"AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [113.588, 113.27]}}}, {"link": "https://www.wsj.com/articles/u-s-regulators-press-banks-to-transition-from-libor-for-new-transactions-11606745216", "title": "U.S. Banks Urged to Stop Using Libor on New Loans by End of 2021", "date": "2020-11-30 12:07", "summary": "Regulators support plan to end benchmark in June 2023, allowing most existing transactions to mature. WASHINGTON-U.S. regulators on Monday pressed banks to stop using the London interbank offered rate on new transactions by the end of 2021 while backing a plan to allow many existing transactions to mature before Libor fully winds down in June 2023.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Banks Urged to Stop Using Libor on New Loans by End of 2021. Regulators support plan to end benchmark in June 2023, allowing most existing transactions to mature. WASHINGTON-U.S. regulators on Monday pressed banks to stop using the London interbank offered rate on new transactions by the end of 2021 while backing a plan to allow many existing transactions to mature before Libor fully winds down in June 2023.\"\n\nStock Prediction(s):", "Prediction": "\n- Bank of America Corporation (NYSE: BAC) will increase because they are one of the few banks that have already announced that they will be discontinuing the use of Libor.\n- JPMorgan Chase & Co. (NYSE: JPM) will increase because they are one of the few banks that have already announced that they will be discontinuing the use of Libor.\n- Citigroup Inc. (NYSE: C) will increase because they are one of the few", "price_info": {"BAC": {"company": "", "ticker": "BAC", "move": "up", "prices": [28.495, 28.515]}, "JPM": {"company": "", "ticker": "JPM", "move": "up", "prices": [118.813, 118.775]}, "C": {"company": "America", "ticker": "C", "move": "up", "prices": [55.505, 55.745]}}}, {"link": "https://www.wsj.com/articles/novavax-covid-19-vaccine-is-90-effective-in-key-study-11623664800", "title": "Novavax Covid-19 Vaccine Is 90% Effective in Key Study", "date": "2021-06-14 13:23", "summary": "Authorization of the two-dose vaccine is months away, however, as Novavax readies manufacturing. An experimental Covid-19 vaccine from Novavax Inc. was 90.4% effective at preventing symptomatic disease in adults in a large clinical trial, the company said, results that move the shot a step closer to global use.", "categories": [["Business", "Health Care", "Health"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/health-industry?mod=breadcrumb", "https://www.wsj.com/news/types/health?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Novavax Covid-19 Vaccine Is 90% Effective in Key Study. Authorization of the two-dose vaccine is months away, however, as Novavax readies manufacturing. An experimental Covid-19 vaccine from Novavax Inc. was 90.4% effective at preventing symptomatic disease in adults in a large clinical trial, the company said, results that move the shot a step closer to global use.\"\n\nStock Prediction(s):", "Prediction": "\n- Novavax, Inc. (NASDAQ: NVAX) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of Novavax.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [164.735, 164.79]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [39.435, 39.475]}, "NVAX": {"company": "", "ticker": "NVAX", "move": "up", "prices": [208.1622, 207.98]}}}, {"link": "https://www.wsj.com/articles/companies-take-a-piecemeal-approach-to-automation-tech-11554396270", "title": "Companies Take a Piecemeal Approach to Automation Tech", "date": "2019-04-04 12:44", "summary": "KPMG survey finds that only 17% of companies have smart automation technologies operating at full scale. The growth of artificial intelligence, robotics and other next-generation automation technologies are prompting some corporate leaders to ask age-old business questions: How much should we pay for this? And who is in charge?", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Companies Take a Piecemeal Approach to Automation Tech. KPMG survey finds that only 17% of companies have smart automation technologies operating at full scale. The growth of artificial intelligence, robotics and other next-generation automation technologies are prompting some corporate leaders to ask age-old business questions: How much should we pay for this? And who is in charge?\"\n\nStock Prediction(s):", "Prediction": "\n- International Business Machines Corporation (NYSE: IBM) will increase because they are a direct competitor of the companies mentioned in the article, and they have a lot of experience with automation technologies.\n- Microsoft Corporation (NASDAQ: MSFT) will increase because they are a direct competitor of the companies mentioned in the article, and they have a lot of experience with automation technologies.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they", "price_info": {"IBM": {"company": "", "ticker": "IBM", "move": "up", "prices": [143.115, 143.021]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [118.76, 119.51]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1812.7908, 1816.7794]}}}, {"link": "https://www.wsj.com/articles/how-both-the-company-and-employee-benefit-from-higher-pay-11635429601", "title": "How Both the Company and Employee Benefit From Higher Pay", "date": "2021-10-28 10:00", "summary": "Higher pay isn't just a cost. The data shows that the employers that pay the best outperform their peers.. As the economy has lurched forward during the pandemic, many businesses have found themselves forced to increase workers' pay to fill openings-and not everyone is thrilled about it.", "categories": [["Business", "Journal Reports: Leadership"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-leadership?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How Both the Company and Employee Benefit From Higher Pay. Higher pay isn't just a cost. The data shows that the employers that pay the best outperform their peers.. As the economy has lurched forward during the pandemic, many businesses have found themselves forced to increase workers' pay to fill openings-and not everyone is thrilled about it.\"\n\nStock Prediction(s):", "Prediction": "\n- Walmart Inc. (NYSE: WMT) will increase because they have been increasing workers' pay to fill openings.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they have been increasing workers' pay to fill openings.\n- Target Corporation (NYSE: TGT) will increase because they have been increasing workers' pay to fill openings.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "up", "prices": [148.7402, 148.6678]}, "TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [259.06, 259.5728]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [3433.91, 3475.57]}}}, {"link": "https://www.wsj.com/articles/u-s-recorded-music-revenue-rises-amid-streaming-subscription-surge-11551380613", "title": "U.S. Recorded-Music Revenue Rises Amid Streaming Subscription Surge", "date": "2019-02-28 14:03", "summary": "Domestic retail revenue grew 12% in 2018 to $9.8 billion as subscriptions to services like Spotify topped 50 million. Revenue from music-streaming platforms now accounts for three-quarters of the music industry's top line, as subscriptions to services including Spotify Technology SA, Apple Inc., Amazon.com Inc. and others in the U.S. grew 42% in 2018 to top 50 million for the first time.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Recorded-Music Revenue Rises Amid Streaming Subscription Surge. Domestic retail revenue grew 12% in 2018 to $9.8 billion as subscriptions to services like Spotify topped 50 million. Revenue from music-streaming platforms now accounts for three-quarters of the music industry's top line, as subscriptions to services including Spotify Technology SA, Apple Inc., Amazon.com Inc. and others in the U.S. grew 42% in 2018 to top 50 million for the first time.\"\n\nStock Prediction(s):", "Prediction": "\n- Spotify Technology SA (NYSE: SPOT) will increase because their service is becoming more popular, and more people are subscribing.\n- Apple Inc. (NASDAQ: AAPL) will increase because their service is becoming more popular, and more people are subscribing.\n- Amazon.com Inc. (NASDAQ: AMZN) will increase because their service is becoming more popular, and more people are subscribing.\n- Pandora Media, Inc. (NYSE:", "price_info": {"SPOT": {"company": "", "ticker": "SPOT", "move": "up", "prices": [140.45, 139.785]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [174.27, 174.1499]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1642.6401, 1642.77]}}}, {"link": "https://www.wsj.com/articles/whiplash-etf-flows-follow-russell-rebalance-11562606228", "title": "Whiplash ETF Flows Follow Russell Rebalance", "date": "2019-07-08 13:17", "summary": "A handful of exchange-traded funds have shed nearly $14 billion in assets in the past week. A handful of exchange-traded funds have shed nearly $14 billion in assets in the past week, reversing an influx of cash that came in late June.", "categories": [["Markets", "ETFs"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/etfs?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Whiplash ETF Flows Follow Russell Rebalance. A handful of exchange-traded funds have shed nearly $14 billion in assets in the past week. A handful of exchange-traded funds have shed nearly $14 billion in assets in the past week, reversing an influx of cash that came in late June.\"\n\nStock Prediction(s):", "Prediction": "\n- The ETFs that have lost the most assets in the past week will continue to do so because investors are pulling out of them.\n- The ETFs that have gained the most assets in the past week will continue to do so because investors are pouring money into them.", "price_info": {}}, {"link": "https://www.wsj.com/articles/facebook-warned-that-it-may-lose-a-key-seal-of-approval-for-ad-measurement-11588350494", "title": "Facebook Warned That It May Lose a Key Seal of Approval for Ad Gauge", "date": "2020-05-01 12:53", "summary": "Media rating council says social-media giant could be denied accreditation. Facebook Inc. is at risk of losing a key seal of approval that gives companies confidence they are getting what they pay for when it comes to advertising with the social-media giant.", "categories": [["WSJ News Exclusive", "Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook Warned That It May Lose a Key Seal of Approval for Ad Gauge. Media rating council says social-media giant could be denied accreditation. Facebook Inc. is at risk of losing a key seal of approval that gives companies confidence they are getting what they pay for when it comes to advertising with the social-media giant.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook Inc. (NASDAQ: FB) will decrease because they may lose a key seal of approval.\n- Alphabet Inc. (NASDAQ: GOOGL) will increase because they are not affiliated with Facebook.", "price_info": {"FB": {"company": "", "ticker": "FB", "move": "down", "prices": [200.58, 201.3653]}, "GOOGL": {"company": "", "ticker": "GOOGL", "move": "up", "prices": [1311.3941, 1324]}}}, {"link": "https://www.wsj.com/articles/oil-falls-amid-tense-u-s-china-trade-talks-11557411390", "title": "Oil Prices Mixed on U.S.-China Trade Tensions", "date": "2019-05-09 15:38", "summary": "U.S. oil prices declined one day after posting their biggest gain in two weeks. \u2022 Oil prices ended mixed Thursday as the U.S. and China resumed high-level trade negotiations, while the Trump administration also prepared new tariffs on Chinese goods set to kick in Friday.", "categories": [["Markets", "Commodities"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Prices Mixed on U.S.-China Trade Tensions. U.S. oil prices declined one day after posting their biggest gain in two weeks. \u2022 Oil prices ended mixed Thursday as the U.S. and China resumed high-level trade negotiations, while the Trump administration also prepared new tariffs on Chinese goods set to kick in Friday.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will increase because oil prices are going up.\n- Exxon Mobil Corporation (NYSE: XOM) will increase because oil prices are going up.\n- Schlumberger Limited. (NYSE: SLB) will increase because oil prices are going up.\n- Halliburton Company (NYSE: HAL) will increase because oil prices are going up.\n- Baker Hughes, a GE Company (NYSE: BHGE)", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [121.19, 121.12]}, "XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [76.77, 76.78]}, "SLB": {"company": "", "ticker": "SLB", "move": "up"}, "HAL": {"company": "", "ticker": "HAL", "move": "up", "prices": [25.99, 26.05]}, "BHGE": {"company": "", "ticker": "BHGE", "move": null}}}, {"link": "https://www.wsj.com/articles/kraft-heinz-reports-weaker-sales-as-cheese-cold-cut-shipments-fall-11581598139", "title": "Kraft Heinz Plans Marketing Binge to Lift Sales", "date": "2020-02-13 14:33", "summary": "Food maker's revenue dropped in the fourth quarter, capping a tough year. Kraft Heinz Co. and other big food makers are ramping up advertising after years of cost cutting, recognizing a need to rekindle enthusiasm for their condiments, candies and snacks.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Kraft Heinz Plans Marketing Binge to Lift Sales. Food maker's revenue dropped in the fourth quarter, capping a tough year. Kraft Heinz Co. and other big food makers are ramping up advertising after years of cost cutting, recognizing a need to rekindle enthusiasm for their condiments, candies and snacks.\"\n\nStock Prediction(s):", "Prediction": "\n- Kraft Heinz Co. (NASDAQ: KHC) will increase because they are increasing their marketing budget to try and revive sales.\n- Mondelez International Inc (NASDAQ: MDLZ) will increase because they are increasing their marketing budget to try and revive sales.\n- PepsiCo, Inc. (NASDAQ: PEP) will increase because they are increasing their marketing budget to try and revive sales.", "price_info": {"KHC": {"company": "", "ticker": "KHC", "move": "up", "prices": [27.775, 27.8]}, "MDLZ": {"company": "", "ticker": "MDLZ", "move": "up", "prices": [58.89, 59.03]}, "PEP": {"company": "", "ticker": "PEP", "move": "up", "prices": [146.5729, 146.47]}}}, {"link": "https://www.wsj.com/articles/boko-haram-leader-responsible-for-chibok-schoolgirl-kidnappings-dies-11621608392", "title": "Boko Haram Leader, Responsible for Chibok Kidnappings, Dies", "date": "2021-05-21 11:20", "summary": "Death of Abubakar Shekau removes one the world's most brutal and effective terrorists. ", "categories": [["WSJ News Exclusive", "Africa"]], "category_links": ["https://www.wsj.com/news/types/africa-news?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boko Haram Leader, Responsible for Chibok Kidnappings, Dies. Death of Abubakar Shekau removes one the world's most brutal and effective terrorists. \"\n\nStock Prediction(s):", "Prediction": "\n- Boko Haram will decrease in influence because their leader has died.\n- The Nigerian government will increase in influence because they are fighting Boko Haram.\n- The United States will increase in influence because they are helping the Nigerian government fight Boko Haram.", "price_info": {}}, {"link": "https://www.wsj.com/articles/facebook-twitter-limit-sharing-of-new-york-post-articles-that-biden-disputes-11602736535", "title": "Facebook, Twitter Limit Sharing of New York Post Articles That Biden Disputes", "date": "2020-10-15 10:43", "summary": "Joe Biden denies report that says he met with Burisma executive while vice president. Facebook Inc. and Twitter Inc. took the unusual step of limiting the sharing of New York Post articles that made new allegations about Democratic presidential nominee Joe Biden that the Biden campaign denied.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Facebook, Twitter Limit Sharing of New York Post Articles That Biden Disputes. Joe Biden denies report that says he met with Burisma executive while vice president. Facebook Inc. and Twitter Inc. took the unusual step of limiting the sharing of New York Post articles that made new allegations about Democratic presidential nominee Joe Biden that the Biden campaign denied.\"\n\nStock Prediction(s):", "Prediction": "\n- Facebook (NASDAQ: FB) will decrease because they are limiting the sharing of New York Post articles.\n- Twitter (NYSE: TWTR) will decrease because they are limiting the sharing of New York Post articles.", "price_info": {"TWTR": {"company": "", "ticker": "TWTR", "move": "down", "prices": [44.8483, 44.9849]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [266.58, 265.0403]}}}, {"link": "https://www.wsj.com/articles/heres-how-softbank-vision-fund-helps-portfolio-companies-report-better-11638385003", "title": "How SoftBank Vision Fund Values Its Portfolio Holdings", "date": "2021-12-01 13:56", "summary": "The fund relies on 18 people and a lot of technology to value its investments. SoftBank Group Corp. is investing billions of dollars in startups and later-stage companies around the world. The Vision Fund, which is based in London, holds stakes in about 250 companies. Keeping track of what they are worth is a crucial task for the fund's managers.", "categories": [["CFO Journal"]], "category_links": ["https://www.wsj.com/news/types/cfo-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How SoftBank Vision Fund Values Its Portfolio Holdings. The fund relies on 18 people and a lot of technology to value its investments. SoftBank Group Corp. is investing billions of dollars in startups and later-stage companies around the world. The Vision Fund, which is based in London, holds stakes in about 250 companies. Keeping track of what they are worth is a crucial task for the fund's managers.\"\n\nStock Prediction(s):", "Prediction": "\n- SoftBank Group Corp. (OTC: SFTBY) will increase because their portfolio holdings are being valued by 18 people and a lot of technology.\n- Uber Technologies Inc. (NYSE: UBER) will increase because their portfolio holdings are being valued by 18 people and a lot of technology.\n- WeWork Cos. (NYSE: WE) will increase because their portfolio holdings are being valued by 18 people and a lot of technology.\n- DoorDash", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "up", "prices": [37.05, 35.945]}, "WE": {"company": "", "ticker": "WE", "move": "up", "prices": [8.71, 8.485]}}}, {"link": "https://www.wsj.com/articles/wall-streets-new-fear-gaugefirearms-11605289616", "title": "Wall Street's New Fear Gauge-Firearms", "date": "2020-11-13 12:46", "summary": "Gun stocks and the VIX both surged before the election and tumbled since. One way to rile up a finance pedant is to refer to the VIX as Wall Street's \"fear gauge.\" Formally known as the Cboe Volatility Index, it is a number derived from the Black-Scholes options pricing formula that tells how much annualized volatility traders expect in the benchmark S&P 500 in the next month. Volatility isn't necessarily undesirable, though-it also could mean a rally.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wall Street's New Fear Gauge-Firearms. Gun stocks and the VIX both surged before the election and tumbled since. One way to rile up a finance pedant is to refer to the VIX as Wall Street's \"fear gauge.\" Formally known as the Cboe Volatility Index, it is a number derived from the Black-Scholes options pricing formula that tells how much annualized volatility traders expect in the benchmark S&P 500 in the next month. Volatility isn't necessarily undesirable, though-it also could mean a rally.\"\n\nStock Prediction(s):", "Prediction": "\n- Sturm, Ruger & Company, Inc. (NYSE: RGR) will increase because the VIX is a fear gauge, and with the recent shootings, people will be more scared and invest in firearms companies.\n- American Outdoor Brands Corporation (NASDAQ: AOBC) will increase because the VIX is a fear gauge, and with the recent shootings, people will be more scared and invest in firearms companies.\n- Vista Outdoor Inc. (NYSE", "price_info": {"RGR": {"company": "", "ticker": "RGR", "move": "up", "prices": [64.24, 64.235]}, "AOBC": {"company": "", "ticker": "AOBC", "move": "up"}}}, {"link": "https://www.wsj.com/articles/john-lennon-and-yoko-onos-onetime-palm-beach-mansion-sells-for-36-million-11604076391", "title": "John Lennon and Yoko Ono's Onetime Palm Beach Mansion Sells for $36 Million", "date": "2020-10-30 12:46", "summary": "Known as El Solano, the 14,000-square-foot Spanish-style estate hit the market six months ago for $47.5 million. An oceanfront Palm Beach estate once owned by the late John Lennon and his wife Yoko Ono has sold for around $36 million, according to a person with knowledge of the deal.", "categories": [["WSJ News Exclusive", "Private Properties"]], "category_links": ["https://www.wsj.com/news/types/private-properties?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"John Lennon and Yoko Ono's Onetime Palm Beach Mansion Sells for $36 Million. Known as El Solano, the 14,000-square-foot Spanish-style estate hit the market six months ago for $47.5 million. An oceanfront Palm Beach estate once owned by the late John Lennon and his wife Yoko Ono has sold for around $36 million, according to a person with knowledge of the deal.\"\n\nStock Prediction(s):", "Prediction": "\n- The sale of John Lennon and Yoko Ono's former Palm Beach estate will increase the prices of other oceanfront estates in Palm Beach.\n- The sale of John Lennon and Yoko Ono's former Palm Beach estate will decrease the prices of other estates in Palm Beach that are not oceanfront.", "price_info": {}}, {"link": "https://www.wsj.com/articles/analyze-this-big-pharma-is-eager-to-hire-11557245578", "title": "Analyze This: Big Pharma Is Eager to Hire", "date": "2019-05-07 12:12", "summary": "A pharma analyst gets an on-air job offer from the company he covers. With unemployment at a multidecade low in the U.S., it is a good market in which to be looking for a job. Drugmaker Allergan 's conference call on Tuesday with Wall Street analysts provided further anecdotal evidence.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Analyze This: Big Pharma Is Eager to Hire. A pharma analyst gets an on-air job offer from the company he covers. With unemployment at a multidecade low in the U.S., it is a good market in which to be looking for a job. Drugmaker Allergan 's conference call on Tuesday with Wall Street analysts provided further anecdotal evidence.\"\n\nStock Prediction(s):", "Prediction": "\n- Allergan plc (NYSE: AGN) will increase because they are expanding their company and they are looking to hire new employees.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also expanding their company, but they are a direct competitor of Allergan.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also expanding their company, but they are a direct competitor of Allergan.", "price_info": {"AGN": {"company": "", "ticker": "AGN", "move": "up", "prices": [140.83, 140.62]}, "JNJ": {"company": "", "ticker": "JNJ", "move": "down", "prices": [139.47, 139.453]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [40.8, 40.555]}}}, {"link": "https://www.wsj.com/articles/catalent-to-buy-paragon-bioservices-for-1-2-billion-11555330948", "title": "Catalent to Buy Paragon Bioservices for $1.2 Billion", "date": "2019-04-15 10:38", "summary": "Deal to boost Catalent's gene-therapy manufacturing capabilities. Contract drug manufacturer Catalent Inc. said Monday it has agreed to acquire Paragon Bioservices Inc. for in $1.2 billion in cash, to help expand its gene-therapy manufacturing capabilities.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Catalent to Buy Paragon Bioservices for $1.2 Billion. Deal to boost Catalent's gene-therapy manufacturing capabilities. Contract drug manufacturer Catalent Inc. said Monday it has agreed to acquire Paragon Bioservices Inc. for in $1.2 billion in cash, to help expand its gene-therapy manufacturing capabilities.\"\n\nStock Prediction(s):", "Prediction": "\n- Catalent, Inc. (NYSE: CTLT) will increase because they are expanding their gene-therapy manufacturing capabilities.\n- Paragon Bioservices, Inc. (NASDAQ: PGRX) will increase because they are being acquired by Catalent, Inc.", "price_info": {"CTLT": {"company": "", "ticker": "CTLT", "move": "up", "prices": [43.67, 45.2123]}, "PGRX": {"company": "", "ticker": "PGRX", "move": "up"}}}, {"link": "https://www.wsj.com/articles/some-ceos-suggest-dropping-degree-requirements-in-hiring-11620233566", "title": "Some CEOs Suggest Dropping Degree Requirements in Hiring", "date": "2021-05-05 12:52", "summary": "Merck CEO and former IBM CEO say removing conventional requirements for some jobs can diversify talent pools. Millions of jobs requiring a four-year college degree can be done without that level of education, some corporate leaders say.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Some CEOs Suggest Dropping Degree Requirements in Hiring. Merck CEO and former IBM CEO say removing conventional requirements for some jobs can diversify talent pools. Millions of jobs requiring a four-year college degree can be done without that level of education, some corporate leaders say.\"\n\nStock Prediction(s):", "Prediction": "\n- Merck & Co., Inc. (NYSE: MRK) will increase because they are willing to drop degree requirements in order to diversify their talent pool.\n- IBM (NYSE: IBM) will decrease because they are no longer willing to hire employees without a four-year degree.", "price_info": {"MRK": {"company": "", "ticker": "MRK", "move": "up", "prices": [77.455, 77.08]}, "IBM": {"company": "", "ticker": "IBM", "move": "down", "prices": [145.3002, 145.535]}}}, {"link": "https://www.wsj.com/articles/raees-cajee-blamed-by-investors-for-billions-of-dollars-in-crypto-losses-says-small-fraction-is-missing-11624909401", "title": "Entrepreneur, Blamed for Billions of Dollars in Crypto Losses, Says Fraction Is Missing", "date": "2021-06-28 15:43", "summary": "Investors have accused South African fund manager and his brother of disappearing with money following an alleged hacking incident. A South African cryptocurrency entrepreneur, pursued by investors who allege that billions of dollars of their digital assets have vanished, says that less than $5 million is missing.", "categories": [["WSJ News Exclusive", "Finance"]], "category_links": ["https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Entrepreneur, Blamed for Billions of Dollars in Crypto Losses, Says Fraction Is Missing. Investors have accused South African fund manager and his brother of disappearing with money following an alleged hacking incident. A South African cryptocurrency entrepreneur, pursued by investors who allege that billions of dollars of their digital assets have vanished, says that less than $5 million is missing.\"\n\nStock Prediction(s):", "Prediction": "\n- Bitcoin (BTC) will decrease because of the news about the missing money.\n- Ethereum (ETH) will decrease because of the news about the missing money.\n- XRP will decrease because of the news about the missing money.", "price_info": {"BTC": {"company": "Bitcoin", "ticker": "BTC", "move": "down"}, "ETH": {"company": "Ethereum", "ticker": "ETH", "move": "down"}}}, {"link": "https://www.wsj.com/articles/record-low-consumer-inflation-expectations-bolster-u-s-bonds-11560527968", "title": "Record Low Inflation Expectations Bolster U.S. Government Bonds", "date": "2019-06-14 15:43", "summary": "Treasury prices rise Friday, briefly sending 10-year yield below 2.08%. U.S. government bond prices briefly spiked Friday after a measure of inflation expectations fell to a record low, reinforcing concerns about how slowly consumer prices have been increasing despite solid economic growth and a tightening labor market.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Record Low Inflation Expectations Bolster U.S. Government Bonds. Treasury prices rise Friday, briefly sending 10-year yield below 2.08%. U.S. government bond prices briefly spiked Friday after a measure of inflation expectations fell to a record low, reinforcing concerns about how slowly consumer prices have been increasing despite solid economic growth and a tightening labor market.\"\n\nStock Prediction(s):", "Prediction": "\n- The 10-year U.S. government bond yield will continue to decrease because inflation expectations are low and the economy is growing slowly.\n- The 30-year U.S. government bond yield will continue to decrease because inflation expectations are low and the economy is growing slowly.", "price_info": {}}, {"link": "https://www.wsj.com/articles/inequality-is-holding-back-the-u-s-economy-11568136471", "title": "Inequality Is Holding Back the U.S. Economy", "date": "2019-09-10 13:27", "summary": "Rising inequality isn't a problem just for those at the bottom of the distribution. When it comes to money, America has always had winners and losers, but the widening gulf between the rich and the bulk of U.S. households may be making almost everybody worse off. That includes investors.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Inequality Is Holding Back the U.S. Economy. Rising inequality isn't a problem just for those at the bottom of the distribution. When it comes to money, America has always had winners and losers, but the widening gulf between the rich and the bulk of U.S. households may be making almost everybody worse off. That includes investors.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go down because of the article's message that inequality is bad for the economy.\n- The market will go up because of the article's message that inequality is bad for the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/diamond-elite-members-wait-here-for-your-own-safety-11588267996", "title": "Diamond Elite Members, Wait Here for Your Own Safety", "date": "2020-04-30 13:33", "summary": "United Airlines is upending one of the key perks elite fliers enjoy, as the back of the plane boards first. Travelers flying on their own dime without elite status are familiar with the humiliation.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Diamond Elite Members, Wait Here for Your Own Safety. United Airlines is upending one of the key perks elite fliers enjoy, as the back of the plane boards first. Travelers flying on their own dime without elite status are familiar with the humiliation.\"\n\nStock Prediction(s):", "Prediction": "\n- United Airlines (NYSE: UAL) will decrease because they are no longer boarding their elites first.", "price_info": {"UAL": {"company": "", "ticker": "UAL", "move": "down", "prices": [29.5, 29.8589]}}}, {"link": "https://www.wsj.com/articles/volvo-hit-by-cyber-theft-of-intellectual-property-11639167971", "title": "Volvo Hit by Cyber Theft of Intellectual Property", "date": "2021-12-10 15:26", "summary": "Swedish car maker says cybersecurity breach could have impact on operations. BERLIN- Volvo Car AB, the Swedish car maker, said Friday that it was investigating a cybersecurity breach targeting systems that store research and development files and warned the hack could have an impact on the company's operations.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Volvo Hit by Cyber Theft of Intellectual Property. Swedish car maker says cybersecurity breach could have impact on operations. BERLIN- Volvo Car AB, the Swedish car maker, said Friday that it was investigating a cybersecurity breach targeting systems that store research and development files and warned the hack could have an impact on the company's operations.\"\n\nStock Prediction(s):", "Prediction": "\n- Volvo Car AB (OTC: VLVLY) will decrease because of the cyber theft of intellectual property.\n- Ford Motor Company (NYSE: F) will decrease because of the cyber theft of intellectual property.\n- General Motors Company (NYSE: GM) will decrease because of the cyber theft of intellectual property.", "price_info": {"F": {"company": "", "ticker": "F", "move": "down", "prices": [21.235, 21.445]}, "GM": {"company": "", "ticker": "GM", "move": "down", "prices": [62.6, 63.24]}}}, {"link": "https://www.wsj.com/articles/ex-hbo-boss-and-apple-producer-richard-plepler-looks-to-hire-vice-news-chief-11580500361", "title": "Ex-HBO Boss and Apple Producer Plepler Looks to Hire Vice News Chief", "date": "2020-01-31 14:52", "summary": "Josh Tyrangiel, former executive producer of Emmy-winning 'Vice News Tonight,' is in talks to join Eden Productions. Former HBO boss Richard Plepler is seeking to recruit Vice Media veteran Josh Tyrangiel to his new production company, Eden Productions, people familiar with the situation said, a move that would add an executive with news experience as his outfit prepares to make shows for Apple Inc .", "categories": [["WSJ News Exclusive", "Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Ex-HBO Boss and Apple Producer Plepler Looks to Hire Vice News Chief. Josh Tyrangiel, former executive producer of Emmy-winning 'Vice News Tonight,' is in talks to join Eden Productions. Former HBO boss Richard Plepler is seeking to recruit Vice Media veteran Josh Tyrangiel to his new production company, Eden Productions, people familiar with the situation said, a move that would add an executive with news experience as his outfit prepares to make shows for Apple Inc .\"\n\nStock Prediction(s):", "Prediction": "\n- Vice Media (VICEM) will increase because they are losing their top executive, and this could mean that they are not doing as well as they were before.\n- Apple Inc. (NASDAQ: AAPL) will increase because they are getting more content from Eden Productions.", "price_info": {"VICEM": {"company": "Vice Media", "ticker": "VICEM", "move": "up"}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [312.18, 309.0998]}}}, {"link": "https://www.wsj.com/articles/buy-now-pay-later-is-just-one-piece-of-the-fintech-puzzle-11640022287", "title": "Buy Now, Pay Later Is Just One Piece of the Fintech Puzzle", "date": "2021-12-20 12:44", "summary": "A regulatory inquiry into split payments sparked a market reaction, but investors should think about these services in a wider context. A recently announced U.S. regulatory inquiry into split-payment services has spooked investors, with shares of players such as Affirm Holdings and Afterpay down sharply in some recent sessions. But investors need to react less now, and more later.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Buy Now, Pay Later Is Just One Piece of the Fintech Puzzle. A regulatory inquiry into split payments sparked a market reaction, but investors should think about these services in a wider context. A recently announced U.S. regulatory inquiry into split-payment services has spooked investors, with shares of players such as Affirm Holdings and Afterpay down sharply in some recent sessions. But investors need to react less now, and more later.\"\n\nStock Prediction(s):", "Prediction": "\n- Affirm Holdings Inc (NYSE: AFFM) will increase because their services are in high demand, and they are a key player in the \"buy now, pay later\" market.\n- Afterpay Touch Group Ltd (ASX: APT) will increase because their services are in high demand, and they are a key player in the \"buy now, pay later\" market.", "price_info": {"AFFM": {"company": "", "ticker": "AFFM", "move": "up"}}}, {"link": "https://www.wsj.com/articles/dupont-expects-organic-sales-to-fall-reports-second-quarter-net-loss-11564657146", "title": "DuPont Sees Sales Falling", "date": "2019-08-01 10:29", "summary": "Company beats second-quarter earnings expectations through price increases, cost savings. DuPont de Nemours Inc. said it expects organic sales to fall this year, the latest company to report weakness in industrial markets including car and electronics production.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"DuPont Sees Sales Falling. Company beats second-quarter earnings expectations through price increases, cost savings. DuPont de Nemours Inc. said it expects organic sales to fall this year, the latest company to report weakness in industrial markets including car and electronics production.\"\n\nStock Prediction(s):", "Prediction": "\n- DuPont de Nemours Inc. (NYSE: DD) will decrease because their sales are falling and they are not expecting a rebound this year.", "price_info": {"DD": {"company": "", "ticker": "DD", "move": "down", "prices": [72.8899, 72.95]}}}, {"link": "https://www.wsj.com/articles/a-friday-for-nursing-losses-and-dispelling-superstitions-11584118027", "title": "A Friday for Nursing Losses and Dispelling Superstitions", "date": "2020-03-13 12:47", "summary": "Traders who fear Friday the 13th were greeted by an early relief rally. In addition to unclogging the plumbing of the nation's financial system, the U.S. Federal Reserve struck a blow against a persistent malady. No, not coronavirus-paraskevidekatriaphobia.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Friday for Nursing Losses and Dispelling Superstitions. Traders who fear Friday the 13th were greeted by an early relief rally. In addition to unclogging the plumbing of the nation's financial system, the U.S. Federal Reserve struck a blow against a persistent malady. No, not coronavirus-paraskevidekatriaphobia.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go up because the Federal Reserve did something to help the economy.\n- The market will go down because the Federal Reserve did something to help the economy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/didi-delays-u-k-europe-expansion-plans-after-officials-raise-data-concerns-11629899875", "title": "Didi Delays U.K., Europe Expansion Plans After Officials Raise Data Concerns", "date": "2021-08-25 09:57", "summary": "Chinese ride-hailing giant's postponement is a sign of the uphill battle that Chinese tech companies face in Western markets. LONDON-Chinese ride-hailing giant Didi Global Inc. has delayed plans to expand to Britain and Europe, partly due to political and regulatory challenges, according to people familiar with the matter, the latest illustration of the uphill battle that Chinese technology companies face in Western markets.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Didi Delays U.K., Europe Expansion Plans After Officials Raise Data Concerns. Chinese ride-hailing giant's postponement is a sign of the uphill battle that Chinese tech companies face in Western markets. LONDON-Chinese ride-hailing giant Didi Global Inc. has delayed plans to expand to Britain and Europe, partly due to political and regulatory challenges, according to people familiar with the matter, the latest illustration of the uphill battle that Chinese technology companies face in Western markets.\"\n\nStock Prediction(s):", "Prediction": "\n- Didi Chuxing Technology Co. Ltd. (NYSE: DDAI) will decrease because they are delaying their plans to expand to the U.K. and Europe.", "price_info": {"DDAI": {"company": "", "ticker": "DDAI", "move": "down"}}}, {"link": "https://www.wsj.com/articles/american-airlines-posts-higher-revenue-despite-omicron-hit-11642684205", "title": "U.S. Airlines Say Nascent Recovery Delayed by Omicron Variant", "date": "2022-01-20 14:00", "summary": "Holiday travel helped in 2021, but American, United, Delta said they lost money, with surge of cases dimming outlook. Airlines had hoped to put the global coronavirus pandemic behind them, but the emergence of the Omicron variant and a surge of cases dealt them yet another setback after two of their most difficult years.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Airlines Say Nascent Recovery Delayed by Omicron Variant. Holiday travel helped in 2021, but American, United, Delta said they lost money, with surge of cases dimming outlook. Airlines had hoped to put the global coronavirus pandemic behind them, but the emergence of the Omicron variant and a surge of cases dealt them yet another setback after two of their most difficult years.\"\n\nStock Prediction(s):", "Prediction": "\n- American Airlines Group Inc (NASDAQ: AAL) will decrease because they are saying that the global pandemic is not over yet and they are expecting more cases.\n- United Airlines Holdings Inc (NYSE: UAL) will decrease because they are saying that the global pandemic is not over yet and they are expecting more cases.\n- Delta Air Lines, Inc. (NYSE: DAL) will decrease because they are saying that the global pandemic is not", "price_info": {"UAL": {"company": "", "ticker": "UAL", "move": null, "prices": [43.9, 43.8]}, "DAL": {"company": "", "ticker": "DAL", "move": null, "prices": [39.675, 39.41]}, "AAL": {"company": "", "ticker": "AAL", "move": "down", "prices": [17.1912, 17.0412]}}}, {"link": "https://www.wsj.com/articles/what-the-interest-rate-cut-means-for-you-11572458562", "title": "What the Interest Rate Cut Means for You", "date": "2019-10-30 14:02", "summary": "How the Fed's move can affect your day-to-day finances. The Federal Reserve cut its short-term benchmark rate by a quarter-percentage point for the third time this year on Wednesday, lowering the federal-funds rate to a range between 1.5% and 1.75%.", "categories": [["Markets", "Your Money"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/undefined?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"What the Interest Rate Cut Means for You. How the Fed's move can affect your day-to-day finances. The Federal Reserve cut its short-term benchmark rate by a quarter-percentage point for the third time this year on Wednesday, lowering the federal-funds rate to a range between 1.5% and 1.75%.\"\n\nStock Prediction(s):", "Prediction": "\n- The interest rate cut will have a positive effect on the stock prices of banks, as it will make it easier for them to borrow money.\n- The interest rate cut will have a negative effect on the stock prices of companies that rely on borrowing money, such as car companies and airlines.", "price_info": {}}, {"link": "https://www.wsj.com/articles/trump-and-powell-had-productive-dinner-meeting-mnuchin-says-11549468937", "title": "Trump and Powell Had Productive Dinner Meeting, Mnuchin Says", "date": "2019-02-06 11:02", "summary": "Treasury secretary says Fed chief didn't provide new details about direction of monetary policy. Federal Reserve Chairman Jerome Powell offered the president an overview of the economic outlook at a casual White House dinner Monday night but stopped short of giving any new details about the direction of monetary policy, Treasury Secretary Steven Mnuchin said Wednesday.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump and Powell Had Productive Dinner Meeting, Mnuchin Says. Treasury secretary says Fed chief didn't provide new details about direction of monetary policy. Federal Reserve Chairman Jerome Powell offered the president an overview of the economic outlook at a casual White House dinner Monday night but stopped short of giving any new details about the direction of monetary policy, Treasury Secretary Steven Mnuchin said Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will go up because Trump and Powell had a productive dinner meeting.\n- The market will go down because Trump and Powell didn't discuss anything new about monetary policy.", "price_info": {}}, {"link": "https://www.wsj.com/articles/the-unlikely-winners-from-boeings-737-max-debacle-11580221922", "title": "The Unlikely Winners From Boeing's 737 MAX Debacle", "date": "2020-01-28 09:32", "summary": "Companies that make or own flight simulators for the grounded jet are suddenly in demand. A winning lottery ticket is a good way to make new friends. That, and owning a 737 MAX flight simulator.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Unlikely Winners From Boeing's 737 MAX Debacle. Companies that make or own flight simulators for the grounded jet are suddenly in demand. A winning lottery ticket is a good way to make new friends. That, and owning a 737 MAX flight simulator.\"\n\nStock Prediction(s):", "Prediction": "\n- CAE Inc. (NYSE: CAE) will increase because they are one of the few companies that make flight simulators for the grounded jet.\n- L-3 Technologies Inc. (NYSE: LLL) will increase because they are one of the few companies that make flight simulators for the grounded jet.\n- Rockwell Collins Inc. (NYSE: COL) will increase because they are one of the few companies that make flight simulators for the grounded", "price_info": {"CAE": {"company": "", "ticker": "CAE", "move": "up", "prices": [30, 29.94]}, "LLL": {"company": "", "ticker": "LLL", "move": "up"}, "COL": {"company": "", "ticker": "COL", "move": "up"}}}, {"link": "https://www.wsj.com/articles/as-stocks-surge-to-records-nervous-investors-buy-bonds-too-11562578201", "title": "During Stock Rally, Nervous Investors Buy Bonds, Too", "date": "2019-07-08 12:58", "summary": "Individuals are on track to purchase bulk of U.S. government's newly issued longer-term debt. Individual investors are helping power this year's rally in U.S. government debt, a sign many remain cautious even as stocks push to new highs.", "categories": [["Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"During Stock Rally, Nervous Investors Buy Bonds, Too. Individuals are on track to purchase bulk of U.S. government's newly issued longer-term debt. Individual investors are helping power this year's rally in U.S. government debt, a sign many remain cautious even as stocks push to new highs.\"\n\nStock Prediction(s):", "Prediction": "\n- The stock market will continue to go up because investors are still buying stocks, even though they are also buying bonds.\n- The bond market will go down because there is more demand for stocks than bonds.", "price_info": {}}, {"link": "https://www.wsj.com/articles/cnn-anchors-press-warnermedia-ceo-for-details-on-jeff-zuckers-resignation-11644260004", "title": "CNN Anchors Press for Details on Jeff Zucker's Resignation", "date": "2022-02-07 13:53", "summary": "Jason Kilar declines to tell staff whether CNN parent WarnerMedia would pay former anchor Chris Cuomo severance. Some of CNN's biggest on-air hosts during a meeting Monday pressed WarnerMedia Chief Executive Jason Kilar for details regarding CNN President Jeff Zucker's resignation.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"CNN Anchors Press for Details on Jeff Zucker's Resignation. Jason Kilar declines to tell staff whether CNN parent WarnerMedia would pay former anchor Chris Cuomo severance. Some of CNN's biggest on-air hosts during a meeting Monday pressed WarnerMedia Chief Executive Jason Kilar for details regarding CNN President Jeff Zucker's resignation.\"\n\nStock Prediction(s):", "Prediction": "\n- Turner Broadcasting System, Inc. (NYSE: TBS) will increase because they are the parent company of CNN, and they just lost their president.\n- AT&T Inc. (NYSE: T) will increase because they are the parent company of Turner Broadcasting System, and they just lost their president.", "price_info": {"TBS": {"company": "", "ticker": "TBS", "move": "up"}, "T": {"company": "", "ticker": "T", "move": "up", "prices": [23.9557, 23.985]}}}, {"link": "https://www.wsj.com/articles/morgan-stanley-profit-rises-11626350000", "title": "Morgan Stanley Profit Rises Amid Wall Street Deal Boom", "date": "2021-07-15 11:17", "summary": "Boost in fees from deal making and advising wealthy clients helps bank's results. Morgan Stanley said Thursday that second-quarter profit rose 10% from a year earlier, thanks to a boost in fees from deal making and advising wealthy clients.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Morgan Stanley Profit Rises Amid Wall Street Deal Boom. Boost in fees from deal making and advising wealthy clients helps bank's results. Morgan Stanley said Thursday that second-quarter profit rose 10% from a year earlier, thanks to a boost in fees from deal making and advising wealthy clients.\"\n\nStock Prediction(s):", "Prediction": "\n- Morgan Stanley (NYSE: MS) will increase because they are doing well in the market and their profits are up.\n- Goldman Sachs (NYSE: GS) will decrease because they are a direct competitor of Morgan Stanley.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are a direct competitor of Morgan Stanley.\n- Bank of America Corp (NYSE: BAC) will decrease because they are a direct competitor of Morgan Stanley.", "price_info": {"MS": {"company": "", "ticker": "MS", "move": "up", "prices": [93.24, 92.105]}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [376.34, 372.29]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [155.88, 155.13]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [39.08, 38.72]}}}, {"link": "https://www.wsj.com/articles/tv-production-covid-makeover-hollywood-11602614629", "title": "Fewer Fistfights, Less Sex-TV Production Gets a Covid Makeover", "date": "2020-10-13 14:47", "summary": "As production resumes during pandemic, fear of contagion is changing everything about making television; 'Are we crazy to be doing this?'. Just before production resumed in August on the hit CBS police drama \"S.W.A.T.,\" co-creator and executive producer Shawn Ryan called an infectious-disease expert with one question.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fewer Fistfights, Less Sex-TV Production Gets a Covid Makeover. As production resumes during pandemic, fear of contagion is changing everything about making television; 'Are we crazy to be doing this?'. Just before production resumed in August on the hit CBS police drama \"S.W.A.T.,\" co-creator and executive producer Shawn Ryan called an infectious-disease expert with one question.\"\n\nStock Prediction(s):", "Prediction": "\n- CBS Corporation (NYSE: CBS) will increase because their production is getting a Covid makeover and they are one of the few networks that are not experiencing a decrease in viewership.\n- ViacomCBS Inc (NASDAQ: VIAC) will increase because their production is getting a Covid makeover and they are one of the few networks that are not experiencing a decrease in viewership.\n- AMC Networks Inc (NASDAQ: AMCX) will decrease because", "price_info": {"CBS": {"company": "", "ticker": "CBS", "move": "down"}, "VIAC": {"company": "", "ticker": "VIAC", "move": "down", "prices": [27.415, 27.4]}, "AMCX": {"company": "", "ticker": "AMCX", "move": "down"}}}, {"link": "https://www.wsj.com/articles/johnson-johnsons-profit-sales-rise-11579694356", "title": "Johnson & Johnson's Profit, Sales Rise", "date": "2020-01-22 11:06", "summary": "Health-products company reported fourth-quarter adjusted earnings above Wall Street estimates, but sales fell short of expectations. Johnson & Johnson said its profit and sales rose for the fourth quarter, with increased pharmaceutical and consumer-product sales helping to offset a slight drop in medical-device sales.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Johnson & Johnson's Profit, Sales Rise. Health-products company reported fourth-quarter adjusted earnings above Wall Street estimates, but sales fell short of expectations. Johnson & Johnson said its profit and sales rose for the fourth quarter, with increased pharmaceutical and consumer-product sales helping to offset a slight drop in medical-device sales.\"\n\nStock Prediction(s):", "Prediction": "\n- Johnson & Johnson (NYSE: JNJ) will increase because their profit and sales rose.\n- AstraZeneca plc (NASDAQ: AZN) will decrease because they are a direct competitor of Johnson & Johnson.\n- Pfizer Inc (NYSE: PFE) will decrease because they are a direct competitor of Johnson & Johnson.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are a direct competitor of Johnson & Johnson", "price_info": {"JNJ": {"company": "", "ticker": "JNJ", "move": "up", "prices": [147.96, 147.45]}, "PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [40.155, 40.11]}, "AZN": {"company": "", "ticker": "AZN", "move": "down", "prices": [50.6816, 50.52]}, "MRNA": {"company": "", "ticker": "MRNA", "move": "down", "prices": [22.1443, 21.9]}}}, {"link": "https://www.wsj.com/articles/why-the-colonial-pipeline-shutdown-is-causing-gasoline-shortages-11620898203", "title": "Why the Colonial Pipeline Shutdown Is Causing Gas Shortages", "date": "2021-05-13 12:52", "summary": "With few refineries of its own, the East Coast relies on gasoline, oil and jet fuel transported from the Gulf Coast. The attackers who hacked into Colonial Pipeline systems chose one of the most important segments of the U.S. energy infrastructure. The 5,500-mile pipeline, the largest in the U.S., carries gasoline and other products to 14 states and Washington, D.C., including nearly half of all fuel consumed on the East Coast. Colonial's shutdown has caused gasoline shortages in states in the Southeast serviced by the line, highlighting the pipeline's crucial role in U.S. energy distribution.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Why the Colonial Pipeline Shutdown Is Causing Gas Shortages. With few refineries of its own, the East Coast relies on gasoline, oil and jet fuel transported from the Gulf Coast. The attackers who hacked into Colonial Pipeline systems chose one of the most important segments of the U.S. energy infrastructure. The 5,500-mile pipeline, the largest in the U.S., carries gasoline and other products to 14 states and Washington, D.C., including nearly half of all fuel consumed on the East Coast. Colonial's shutdown has caused gasoline shortages in states in the Southeast serviced by the line, highlighting the pipeline's crucial role in U.S. energy distribution.\"\n\nStock Prediction(s):", "Prediction": "\n- Energy Transfer Equity LP (NYSE: ETE) will increase because they are one of the main companies that owns the Colonial Pipeline.\n- Enterprise Products Partners L.P. (NYSE: EPD) will increase because they are one of the main companies that owns the Colonial Pipeline.\n- Williams Companies, Inc. (NYSE: WMB) will increase because they are one of the main companies that owns the Colonial Pipeline.\n- Marathon Petroleum Corporation (NYSE:", "price_info": {"ETE": {"company": "", "ticker": "ETE", "move": "up"}, "EPD": {"company": "", "ticker": "EPD", "move": "up", "prices": [23.31, 23.55]}, "WMB": {"company": "", "ticker": "WMB", "move": "up", "prices": [25.04, 25.276]}}}, {"link": "https://www.wsj.com/articles/uber-lyft-to-provide-free-rides-to-covid-19-vaccine-sites-until-july-4-11620745200", "title": "Uber, Lyft to Provide Free Rides to Covid-19 Vaccine Sites Until July 4", "date": "2021-05-11 11:00", "summary": "New transportation partnership comes as Biden administration explores ways to encourage people to get vaccinated. WASHINGTON-Ride-sharing companies Uber Technologies Inc. and Lyft Inc. will make all rides to and from vaccination sites free until July 4 under a new partnership with the White House.", "categories": [["WSJ News Exclusive", "Health Policy"]], "category_links": ["https://www.wsj.com/news/types/health-policy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Uber, Lyft to Provide Free Rides to Covid-19 Vaccine Sites Until July 4. New transportation partnership comes as Biden administration explores ways to encourage people to get vaccinated. WASHINGTON-Ride-sharing companies Uber Technologies Inc. and Lyft Inc. will make all rides to and from vaccination sites free until July 4 under a new partnership with the White House.\"\n\nStock Prediction(s):", "Prediction": "\n- Uber Technologies Inc. (NYSE: UBER) will increase because they are partnering with the White House to provide free rides to Covid-19 vaccine sites.\n- Lyft Inc. (NASDAQ: LYFT) will increase because they are partnering with the White House to provide free rides to Covid-19 vaccine sites.", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "up", "prices": [46.32, 46.5755]}, "LYFT": {"company": "", "ticker": "LYFT", "move": "up", "prices": [49.3313, 49.263]}}}, {"link": "https://www.wsj.com/articles/federal-reserve-survey-shows-demand-for-business-loans-weakened-in-third-quarter-11572894001", "title": "Fed Survey Shows Business Loan Demand Weakened in Third Quarter", "date": "2019-11-04 14:00", "summary": "Banks attributed weaker loan demand to business investment decline. Demand for business loans weakened in the third quarter as bank customers dialed back their plans for new plant and equipment investment, according to a Federal Reserve survey released Monday.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed Survey Shows Business Loan Demand Weakened in Third Quarter. Banks attributed weaker loan demand to business investment decline. Demand for business loans weakened in the third quarter as bank customers dialed back their plans for new plant and equipment investment, according to a Federal Reserve survey released Monday.\"\n\nStock Prediction(s):", "Prediction": "\n- The Business Loan sector will decrease because businesses are investing less.\n- The Banking sector will decrease because businesses are investing less.\n- The Industrial sector will decrease because businesses are investing less.", "price_info": {}}, {"link": "https://www.wsj.com/articles/7-elevens-21-billion-deal-could-be-a-marathon-11596451820", "title": "7-Eleven's $21 Billion Deal Could Be a Marathon", "date": "2020-08-03 10:10", "summary": "The massive deal makes strategic sense but still looks pricey, particularly given the struggling state of the U.S. petroleum industry. 7-Eleven is paying top price for its shopping trip in the U.S.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"7-Eleven's $21 Billion Deal Could Be a Marathon. The massive deal makes strategic sense but still looks pricey, particularly given the struggling state of the U.S. petroleum industry. 7-Eleven is paying top price for its shopping trip in the U.S.\"\n\nStock Prediction(s):", "Prediction": "\n- 7-Eleven, Inc. (NASDAQ: SE) will decrease because the deal was expensive and the U.S. petroleum industry is struggling.\n- Marathon Petroleum Corporation (NYSE: MPC) will increase because they are a direct competitor of 7-Eleven and they are doing well financially.", "price_info": {"MPC": {"company": "", "ticker": "MPC", "move": "up", "prices": [38.9, 37.79]}, "SE": {"company": "", "ticker": "SE", "move": "down", "prices": [131.65, 131.61]}}}, {"link": "https://www.wsj.com/articles/do-as-i-say-not-as-i-do-gamestop-edition-11612548822", "title": "Do As I Say, Not As I Do, GameStop Edition", "date": "2021-02-05 13:13", "summary": "DeepF-ingValue's employer gave some sound advice that millions ignored. Thinking of day trading?", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Do As I Say, Not As I Do, GameStop Edition. DeepF-ingValue's employer gave some sound advice that millions ignored. Thinking of day trading?\"\n\nStock Prediction(s):", "Prediction": "\n- GameStop Corp. (NYSE: GME) will increase because they are a valuable company that provides video game services.\n- GameStop Corp. (NYSE: GME) will decrease because they are a valuable company that provides video game services.", "price_info": {"GME": {"company": "", "ticker": "GME", "move": "down", "prices": [63.2071, 60.5]}}}, {"link": "https://www.wsj.com/articles/delta-variant-supply-chain-bottlenecks-slow-european-economy-11632398762", "title": "Economic Growth in U.S. and Europe Slows", "date": "2021-09-23 11:48", "summary": "Manufacturing and services businesses in both the U.S. and Eurozone reported slower growth in activity this month, more so in Europe.. The U.S. and European economies slowed in September as supply-chain bottlenecks and worries over the Delta variant weighed on businesses, adding to signs the global economy is experiencing a soft patch amid an uneven recovery, purchasing managers' surveys showed.", "categories": [["Economy", "Economic Data"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/economic-data?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Economic Growth in U.S. and Europe Slows. Manufacturing and services businesses in both the U.S. and Eurozone reported slower growth in activity this month, more so in Europe.. The U.S. and European economies slowed in September as supply-chain bottlenecks and worries over the Delta variant weighed on businesses, adding to signs the global economy is experiencing a soft patch amid an uneven recovery, purchasing managers' surveys showed.\"\n\nStock Prediction(s):", "Prediction": "\n- The overall market will decrease because of the news of the slowing economy.\n- Boeing (NYSE: BA) will decrease because of the news of the slowing economy.\n- Caterpillar (NYSE: CAT) will decrease because of the news of the slowing economy.\n- 3M (NYSE: MMM) will decrease because of the news of the slowing economy.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [222.0009, 222.1881]}, "CAT": {"company": "", "ticker": "CAT", "move": "down", "prices": [197.265, 197.1]}, "MMM": {"company": "", "ticker": "MMM", "move": "down", "prices": [182.5118, 182.67]}}}, {"link": "https://www.wsj.com/articles/london-stock-exchange-to-close-unprofitable-interest-rate-derivatives-venture-11632329641", "title": "London Stock Exchange to Close Unprofitable Interest-Rate Derivatives Venture", "date": "2021-09-22 12:54", "summary": "CurveGlobal to shut down in January after failing to catch on with traders. London Stock Exchange Group PLC is shutting its venture in interest-rate derivatives, CurveGlobal Ltd., after it failed to gain traction with traders over the past five years.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"London Stock Exchange to Close Unprofitable Interest-Rate Derivatives Venture. CurveGlobal to shut down in January after failing to catch on with traders. London Stock Exchange Group PLC is shutting its venture in interest-rate derivatives, CurveGlobal Ltd., after it failed to gain traction with traders over the past five years.\"\n\nStock Prediction(s):", "Prediction": "\n- LSE Group plc (LSE: LSE) will decrease because their CurveGlobal venture is shutting down.\n- Deutsche Bank AG (NYSE: DB) will increase because they are one of the few banks that will be able to fill the gap in the market that CurveGlobal is leaving.", "price_info": {"DB": {"company": "", "ticker": "DB", "move": "up", "prices": [12.3, 12.3843]}}}, {"link": "https://www.wsj.com/articles/boeing-reports-loss-hit-by-dreamliner-and-starliner-setbacks-11635336087", "title": "Boeing Loss Driven by Dreamliner, Space Problems", "date": "2021-10-27 13:11", "summary": "Plane maker hit by disruption to 787 production and trouble with space vehicle launch, but hopes for China return. Boeing Co. reported a quarterly loss as 787 Dreamliner production problems and its latest space-launch setback offset a recovery in demand for new aircraft.", "categories": [["Business", "Earnings"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Boeing Loss Driven by Dreamliner, Space Problems. Plane maker hit by disruption to 787 production and trouble with space vehicle launch, but hopes for China return. Boeing Co. reported a quarterly loss as 787 Dreamliner production problems and its latest space-launch setback offset a recovery in demand for new aircraft.\"\n\nStock Prediction(s):", "Prediction": "\n- Boeing Co. (NYSE: BA) will decrease because of their losses in the quarter.\n- Lockheed Martin Corp. (NYSE: LMT) will increase because they are not experiencing the same production problems as Boeing.\n- Northrop Grumman Corp. (NYSE: NOC) will increase because they are not experiencing the same production problems as Boeing.", "price_info": {"BA": {"company": "", "ticker": "BA", "move": "down", "prices": [209.44, 207.93]}, "LMT": {"company": "", "ticker": "LMT", "move": "up", "prices": [334.04, 331.2896]}, "NOC": {"company": "", "ticker": "NOC", "move": "up", "prices": [390.63, 389.155]}}}, {"link": "https://www.wsj.com/articles/for-home-builders-a-better-kind-of-recession-11589902608", "title": "For Home Builders, a Better Kind of Recession", "date": "2020-05-19 11:36", "summary": "The housing sector is often stretched heading into a recession, but not this time. The coronavirus pandemic is hammering home builders, but they could emerge from the crisis with less damage than other industries.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"For Home Builders, a Better Kind of Recession. The housing sector is often stretched heading into a recession, but not this time. The coronavirus pandemic is hammering home builders, but they could emerge from the crisis with less damage than other industries.\"\n\nStock Prediction(s):", "Prediction": "\n- Homebuilders such as Lennar Corporation (NYSE: LEN) and KB Home (NYSE: KBH) will increase because they have been less affected by the pandemic.\n- REITs such as Simon Property Group, Inc. (NYSE: SPG) and HCP, Inc. (NYSE: HCP) will decrease because the housing market will be weak.", "price_info": {"LEN": {"company": "", "ticker": "LEN", "move": null, "prices": [59.34, 59.5993]}, "KBH": {"company": "", "ticker": "KBH", "move": "up", "prices": [29.45, 29.34]}, "SPG": {"company": "", "ticker": "SPG", "move": null, "prices": [57.25, 58.05]}, "HCP": {"company": "", "ticker": "HCP", "move": "down"}}}, {"link": "https://www.wsj.com/articles/trumps-tax-cut-underdelivers-which-could-embolden-democrats-who-want-it-reversed-11572447580", "title": "Trump's Tax Cut Underdelivers, Which Could Embolden Democrats", "date": "2019-10-30 11:03", "summary": "Democrats hope to make the economy, inequality and the middle class central to the 2020 election. The cornerstone of President Trump's domestic economic agenda is the tax cut he signed into law in late 2017. It would, he said, lift U.S. sustained annual economic growth to 3%, or even as high as 6%. His advisers said it would boost average household incomes by at least $4,000 a year. His Treasury secretary said it would pay for itself.", "categories": [["Economy", "Capital Account"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/capital-account?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Trump's Tax Cut Underdelivers, Which Could Embolden Democrats. Democrats hope to make the economy, inequality and the middle class central to the 2020 election. The cornerstone of President Trump's domestic economic agenda is the tax cut he signed into law in late 2017. It would, he said, lift U.S. sustained annual economic growth to 3%, or even as high as 6%. His advisers said it would boost average household incomes by at least $4,000 a year. His Treasury secretary said it would pay for itself.\"\n\nStock Prediction(s):", "Prediction": "\n- The Democratic Party will increase in popularity because the tax cut underdelivered, and this could be a key issue in the 2020 election.\n- The Republican Party will decrease in popularity because the tax cut underdelivered, and this could be a key issue in the 2020 election.", "price_info": {}}, {"link": "https://www.wsj.com/articles/olive-gardens-owner-reports-sales-plunge-as-coronavirus-spreads-11584628876", "title": "Olive Garden's Owner Reports Sales Plunge as Coronavirus Spreads", "date": "2020-03-19 10:41", "summary": "Casual-dining chains are particularly vulnerable to widespread restaurant closures. The coronavirus pandemic is slamming the U.S. casual-dining sector, as companies including Darden Restaurants Inc., the owner of Olive Garden and other chains, race to switch to takeout service.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Olive Garden's Owner Reports Sales Plunge as Coronavirus Spreads. Casual-dining chains are particularly vulnerable to widespread restaurant closures. The coronavirus pandemic is slamming the U.S. casual-dining sector, as companies including Darden Restaurants Inc., the owner of Olive Garden and other chains, race to switch to takeout service.\"\n\nStock Prediction(s):", "Prediction": "\n- Darden Restaurants Inc. (NYSE: DRI) will decrease because their sales are plunging as a result of the pandemic.", "price_info": {"DRI": {"company": "", "ticker": "DRI", "move": "down", "prices": [33.76, 33.59]}}}, {"link": "https://www.wsj.com/articles/wells-fargo-plans-to-bring-employees-back-to-the-office-in-september-11617133597", "title": "Wells Fargo Plans to Bring Employees Back to the Office in September", "date": "2021-03-30 15:46", "summary": "The bank said in a memo, 'We believe most of us benefit by being physically together'. Wells Fargo & Co. plans to start bringing employees back to the office after Labor Day, citing the increasing availability of vaccines.", "categories": [["WSJ News Exclusive", "Finance"]], "category_links": ["https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wells Fargo Plans to Bring Employees Back to the Office in September. The bank said in a memo, 'We believe most of us benefit by being physically together'. Wells Fargo & Co. plans to start bringing employees back to the office after Labor Day, citing the increasing availability of vaccines.\"\n\nStock Prediction(s):", "Prediction": "\n- Wells Fargo & Co. (NYSE: WFC) will increase because they are bringing employees back to the office, and they believe that most people benefit from being physically together.", "price_info": {"WFC": {"company": "", "ticker": "WFC", "move": "up", "prices": [39.51, 39.46]}}}, {"link": "https://www.wsj.com/articles/7-ways-covid-has-changed-the-world-forever-11624636801", "title": "7 Ways Covid Has Changed Our World", "date": "2021-06-25 12:00", "summary": "The pandemic, and our reemergence from it, are reshaping the economy, government and business in lasting ways. The Journal's Heard on the Street team explores the ways the globe is transforming.. A handful of events in the last century rewrote the rules of business, finance and economics, whether the people living through them knew it or not.", "categories": [["Markets", "Heard on the Street", "News Analysis"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"7 Ways Covid Has Changed Our World. The pandemic, and our reemergence from it, are reshaping the economy, government and business in lasting ways. The Journal's Heard on the Street team explores the ways the globe is transforming.. A handful of events in the last century rewrote the rules of business, finance and economics, whether the people living through them knew it or not.\"\n\nStock Prediction(s):", "Prediction": "\n- The companies that will benefit the most from the pandemic are those that provide essential goods and services.\n- The companies that will suffer the most from the pandemic are those that are in the travel and tourism industry.", "price_info": {}}, {"link": "https://www.wsj.com/articles/the-fund-that-does-a-lot-by-doing-nothing-11576854661", "title": "The Fund That Does a Lot by Doing Nothing", "date": "2019-12-20 10:11", "summary": "Voya Corporate Leaders Trust hasn't made a major change to its portfolio since 1935, but it's still going strong. Rip van Winkle, who took a drink from the wrong keg and spent the next 20 years snoring, was a newbie at sleeping. Let me tell you about a mutual fund that bought a few stocks 84 years ago and hasn't moved a muscle ever since.", "categories": [["Markets", "The Intelligent Investor"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/the-intelligent-investor?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"The Fund That Does a Lot by Doing Nothing. Voya Corporate Leaders Trust hasn't made a major change to its portfolio since 1935, but it's still going strong. Rip van Winkle, who took a drink from the wrong keg and spent the next 20 years snoring, was a newbie at sleeping. Let me tell you about a mutual fund that bought a few stocks 84 years ago and hasn't moved a muscle ever since.\"\n\nStock Prediction(s):", "Prediction": "\n- Voya Corporate Leaders Trust (NYSE: VOYA) will increase because they have a long-term strategy and have been successful for many years.\n- Franklin Resources, Inc. (NYSE: BEN) will decrease because they are a direct competitor of Voya Corporate Leaders Trust.", "price_info": {"VOYA": {"company": "", "ticker": "VOYA", "move": "up", "prices": [61.8805, 61.75]}, "BEN": {"company": "", "ticker": "BEN", "move": "down", "prices": [26.05, 26.07]}}}, {"link": "https://www.wsj.com/articles/states-file-new-suits-against-google-over-location-tracking-11643037890", "title": "Google Deceived Users About Location Tracking, States Allege", "date": "2022-01-24 14:56", "summary": "Alphabet unit accused of recording users' location even after they tried to turn off tracking. WASHINGTON- Alphabet Inc.'s Google deceived consumers by recording their location even after users tried to turn off the company's tracking on their smartphones and web browsers, according to lawsuits by Washington, D.C., and three other states.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Google Deceived Users About Location Tracking, States Allege. Alphabet unit accused of recording users' location even after they tried to turn off tracking. WASHINGTON- Alphabet Inc.'s Google deceived consumers by recording their location even after users tried to turn off the company's tracking on their smartphones and web browsers, according to lawsuits by Washington, D.C., and three other states.\"\n\nStock Prediction(s):", "Prediction": "\n- Alphabet Inc. (NASDAQ: GOOGL) will decrease because they have been accused of deceiving their consumers.\n- Apple Inc. (NASDAQ: AAPL) will increase because they have not been accused of deceiving their consumers.", "price_info": {"GOOGL": {"company": "", "ticker": "GOOGL", "move": "down", "prices": [2537.242, 2614.54]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [157.45, 161.54]}}}, {"link": "https://www.wsj.com/articles/filmmaker-sets-up-new-documentary-studio-with-a-startup-style-structure-11568296803", "title": "Filmmaker Sets Up New Documentary Studio With a Startup-Style Structure", "date": "2019-09-12 10:00", "summary": "XTR has partnered with established production companies to co-produce material. Documentary films and TV series continue to be popular on networks and streaming services and a new startup wants in on the action.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Filmmaker Sets Up New Documentary Studio With a Startup-Style Structure. XTR has partnered with established production companies to co-produce material. Documentary films and TV series continue to be popular on networks and streaming services and a new startup wants in on the action.\"\n\nStock Prediction(s):", "Prediction": "\n- XTR Inc (NASDAQ: XTR) will increase because they are a new startup that is partnering with established production companies to co-produce material.", "price_info": {"XTR": {"company": "", "ticker": "XTR", "move": "up"}}}, {"link": "https://www.wsj.com/articles/shale-merger-promises-big-payout-just-not-yet-11601318390", "title": "Shale Merger Promises Big Payout, Just Not Yet", "date": "2020-09-28 14:39", "summary": "Consolidation seems to be a sensible answer for Devon Energy, WPX Energy. Being a small fish in the world of gigantic oil-and-gas majors is tough, especially when oil prices remain low. Shale drillers Devon Energy and WPX Energy are taking matters into their own hands.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Shale Merger Promises Big Payout, Just Not Yet. Consolidation seems to be a sensible answer for Devon Energy, WPX Energy. Being a small fish in the world of gigantic oil-and-gas majors is tough, especially when oil prices remain low. Shale drillers Devon Energy and WPX Energy are taking matters into their own hands.\"\n\nStock Prediction(s):", "Prediction": "\n- Devon Energy Corporation (NYSE: DVN) will increase because they are merging with a smaller company, and they will be able to survive in this market.\n- WPX Energy, Inc. (NYSE: WPX) will increase because they are merging with a smaller company, and they will be able to survive in this market.", "price_info": {"DVN": {"company": "", "ticker": "DVN", "move": "up", "prices": [9.89, 9.7998]}, "WPX": {"company": "", "ticker": "WPX", "move": "up", "prices": [5.215, 5.1698]}}}, {"link": "https://www.wsj.com/articles/morningstar-nears-settlement-with-sec-over-bond-ratings-11579021248", "title": "Morningstar Nears Settlement With SEC Over Bond Ratings", "date": "2020-01-14 12:00", "summary": "Company allegedly violated rules that prohibit analysts from doing marketing. Morningstar Inc. is nearing a deal with federal regulators over allegations the firm violated rules in its bond-rating business that prohibit analysts who hand out credit ratings from being involved in sales and marketing for their companies, according to people familiar with the matter.", "categories": [["WSJ News Exclusive", "Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Morningstar Nears Settlement With SEC Over Bond Ratings. Company allegedly violated rules that prohibit analysts from doing marketing. Morningstar Inc. is nearing a deal with federal regulators over allegations the firm violated rules in its bond-rating business that prohibit analysts who hand out credit ratings from being involved in sales and marketing for their companies, according to people familiar with the matter.\"\n\nStock Prediction(s):", "Prediction": "\n- Morningstar, Inc. (NASDAQ: MORN) will decrease because they are being sued by the SEC for violating rules.\n- Moody's Corporation (NYSE: MCO) will increase because they are not being sued by the SEC, and they are a direct competitor of Morningstar.", "price_info": {"MCO": {"company": "", "ticker": "MCO", "move": "up", "prices": [250.606, 251.8289]}, "MORN": {"company": "", "ticker": "MORN", "move": "down", "prices": [158.93, 157.49]}}}, {"link": "https://www.wsj.com/articles/hotels-count-on-road-trippers-to-drive-visits-11598481018", "title": "Hotels Count on Road Trippers to Drive Visits", "date": "2020-08-27 11:55", "summary": "Budget hotels are holding up better than their luxury counterparts as corporate and group travel has been decimated. Roadside inns are faring better than Ritz-Carltons as Americans start to travel again with loosened Covid-19 restrictions.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Hotels Count on Road Trippers to Drive Visits. Budget hotels are holding up better than their luxury counterparts as corporate and group travel has been decimated. Roadside inns are faring better than Ritz-Carltons as Americans start to travel again with loosened Covid-19 restrictions.\"\n\nStock Prediction(s):", "Prediction": "\n- Wyndham Destinations Inc (NYSE: WYND) will increase because they are a budget hotel chain and they are doing better than their luxury counterparts.\n- Marriott International Inc (NASDAQ: MAR) will decrease because they are a luxury hotel chain and they are doing worse than their budget counterparts.", "price_info": {"WYND": {"company": "", "ticker": "WYND", "move": "up", "prices": [29.75, 29.99]}, "MAR": {"company": "", "ticker": "MAR", "move": "down", "prices": [101.3314, 101.8]}}}, {"link": "https://www.wsj.com/articles/how-to-make-money-decisions-when-the-future-is-uncertain-11595004879", "title": "How to Make Money Decisions When the Future Is Uncertain", "date": "2020-07-17 12:54", "summary": "Not knowing what lies ahead can freeze you in your tracks. Here's how to break the paralysis to weigh financial choices responsibly.. The economic shutdown that began for many this spring has led to layoffs, delayed goals, emergency account withdrawals and other painful financial challenges. With the coronavirus pandemic causing so much uncertainty in the world, some people are having trouble making financial decisions.", "categories": [["Markets", "Personal Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/personal-finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How to Make Money Decisions When the Future Is Uncertain. Not knowing what lies ahead can freeze you in your tracks. Here's how to break the paralysis to weigh financial choices responsibly.. The economic shutdown that began for many this spring has led to layoffs, delayed goals, emergency account withdrawals and other painful financial challenges. With the coronavirus pandemic causing so much uncertainty in the world, some people are having trouble making financial decisions.\"\n\nStock Prediction(s):", "Prediction": "\n- People will be more hesitant to spend money, so companies like Amazon (NASDAQ: AMZN) and Walmart (NYSE: WMT) will decrease in stock prices.\n- People will be more hesitant to invest money, so companies like Apple (NASDAQ: AAPL) and Microsoft (NASDAQ: MSFT) will decrease in stock prices.", "price_info": {"WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [132.005, 131.84]}, "AMZN": {"company": "", "ticker": "AMZN", "move": null, "prices": [2956.958, 2985.44]}, "AAPL": {"company": "", "ticker": "AAPL", "move": null, "prices": [385.2002, 386.2]}, "MSFT": {"company": "", "ticker": "MSFT", "move": "down", "prices": [202.2309, 202.91]}}}, {"link": "https://www.wsj.com/articles/target-hits-on-winning-formula-amid-covid-pandemic-11597066200", "title": "Target Hits on Winning Formula Amid Covid Pandemic", "date": "2020-08-10 09:30", "summary": "Surging e-commerce sales at Target during the coronavirus pandemic should translate into a lasting advantage. Target is set to emerge as a major winner from the coronavirus pandemic. Investors just need to look past some near-term challenges.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Target Hits on Winning Formula Amid Covid Pandemic. Surging e-commerce sales at Target during the coronavirus pandemic should translate into a lasting advantage. Target is set to emerge as a major winner from the coronavirus pandemic. Investors just need to look past some near-term challenges.\"\n\nStock Prediction(s):", "Prediction": "\n- Target Corporation (NYSE: TGT) will increase because they have surged their e-commerce sales and they are set to emerge as a major winner from the pandemic.\n- Walmart Inc. (NYSE: WMT) will decrease because they have not surged their e-commerce sales as much as Target, and they are not set to emerge as a major winner from the pandemic.", "price_info": {"TGT": {"company": "", "ticker": "TGT", "move": "up", "prices": [131.8399, 132.29]}, "WMT": {"company": "", "ticker": "WMT", "move": "down", "prices": [131.1561, 130.8781]}}}, {"link": "https://www.wsj.com/articles/fed-to-review-financial-trading-rules-for-officials-11631803236", "title": "Fed to Review Financial Trading Rules for Officials", "date": "2021-09-16 10:40", "summary": "Action follows news of stock trading by Dallas, Boston Fed leaders. The Federal Reserve is launching a review of its internal rules governing the financial activities of its officials in the wake of news last week that the leaders of the Dallas and Boston regional Fed banks actively traded in financial markets.", "categories": [["Economy", "Central Banks"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/central-banks?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed to Review Financial Trading Rules for Officials. Action follows news of stock trading by Dallas, Boston Fed leaders. The Federal Reserve is launching a review of its internal rules governing the financial activities of its officials in the wake of news last week that the leaders of the Dallas and Boston regional Fed banks actively traded in financial markets.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve (NYSE: FED) will decrease because they are being investigated for their financial trading rules.\n- Goldman Sachs Group Inc (NYSE: GS) will decrease because they are being investigated for their financial trading rules.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because they are being investigated for their financial trading rules.\n- Bank of America Corp (NYSE: BAC) will decrease because they are being investigated for their financial trading", "price_info": {"FED": {"company": "", "ticker": "FED", "move": "down"}, "GS": {"company": "", "ticker": "GS", "move": "down", "prices": [396.445, 396.58]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [158.1564, 158.17]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [40.4058, 40.54]}}}, {"link": "https://www.wsj.com/articles/treasurys-strengthen-ahead-of-fed-minutes-11558535621", "title": "Treasurys Hold Gains After Fed Minutes", "date": "2019-05-22 15:19", "summary": "Minutes showed many officials believed weak inflation justified the central bank's patient stance. U.S. government-bond prices rose Wednesday, holding on to gains after the release of minutes from the latest meeting of the Federal Reserve's monetary-policy committee.", "categories": [["Markets", "Credit Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/credit-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Treasurys Hold Gains After Fed Minutes. Minutes showed many officials believed weak inflation justified the central bank's patient stance. U.S. government-bond prices rose Wednesday, holding on to gains after the release of minutes from the latest meeting of the Federal Reserve's monetary-policy committee.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will stay stable because the Fed is being patient with their interest rates.\n- The market will stay stable because the Fed is being patient with their interest rates.", "price_info": {}}, {"link": "https://www.wsj.com/articles/wells-fargo-gamed-system-in-investor-arbitration-judge-says-11643903122", "title": "Wells Fargo Gamed System in Investor Arbitration, Judge Says", "date": "2022-02-03 10:45", "summary": "A Georgia judge said the bank and its lawyer secretly manipulated a list of potential arbitrators. A Georgia judge questioned the fairness of the financial industry's dispute-resolution process in a ruling stemming from a Wells Fargo & Co. customer's claim that the bank botched his investments.", "categories": [["Markets", "Finance"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/finance?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Wells Fargo Gamed System in Investor Arbitration, Judge Says. A Georgia judge said the bank and its lawyer secretly manipulated a list of potential arbitrators. A Georgia judge questioned the fairness of the financial industry's dispute-resolution process in a ruling stemming from a Wells Fargo & Co. customer's claim that the bank botched his investments.\"\n\nStock Prediction(s):", "Prediction": "\n- Wells Fargo & Co. (NYSE: WFC) will decrease because of the negative press and the judge's ruling that they manipulated the arbitration process.\n- Bank of America Corp (NYSE: BAC) will decrease because of the negative press and the judge's ruling that Wells Fargo manipulated the arbitration process.\n- JPMorgan Chase & Co. (NYSE: JPM) will decrease because of the negative press and the judge's ruling that Wells Fargo manipulated the arbitration process.", "price_info": {"WFC": {"company": "", "ticker": "WFC", "move": "down", "prices": [56.24, 55.455]}, "BAC": {"company": "", "ticker": "BAC", "move": "down", "prices": [47.07, 47]}, "JPM": {"company": "", "ticker": "JPM", "move": "down", "prices": [151.036, 151.13]}}}, {"link": "https://www.wsj.com/articles/oil-demand-to-exceed-pre-covid-levels-in-2022-iea-says-11642582801", "title": "Oil Demand to Exceed Pre-Covid Levels in 2022, IEA Says", "date": "2022-01-19 15:14", "summary": "Paris-based agency says total demand this year should stand at 99.7 million barrels a day. Global oil demand will exceed pre-pandemic levels this year thanks to growing Covid-19 immunization rates and as recent virus waves haven't proved severe enough to warrant a return to strict lockdown measures, the International Energy Agency said Wednesday.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil Demand to Exceed Pre-Covid Levels in 2022, IEA Says. Paris-based agency says total demand this year should stand at 99.7 million barrels a day. Global oil demand will exceed pre-pandemic levels this year thanks to growing Covid-19 immunization rates and as recent virus waves haven't proved severe enough to warrant a return to strict lockdown measures, the International Energy Agency said Wednesday.\"\n\nStock Prediction(s):", "Prediction": "\n- Exxon Mobil Corporation (NYSE: XOM) will increase because they are one of the largest oil producers in the world, and they will benefit from the increase in oil demand.\n- Royal Dutch Shell plc (NYSE: RDS.A) will increase because they are one of the largest oil producers in the world, and they will benefit from the increase in oil demand.\n- BP plc (NYSE: BP) will increase because they are one of the", "price_info": {"XOM": {"company": "", "ticker": "XOM", "move": "up", "prices": [73.6, 73.14]}, "BP": {"company": "", "ticker": "BP", "move": "up", "prices": [32.25, 31.99]}}}, {"link": "https://www.wsj.com/articles/feds-williams-doesnt-see-strong-argument-to-raise-or-lower-rates-11558536261", "title": "Fed's Williams: Doesn't See Strong Argument to Raise or Lower Rates", "date": "2019-05-22 12:34", "summary": "New York Fed chief said underlying inflation pressures likely close to Fed's 2% target. NEW YORK-Federal Reserve Bank of New York President John Williams said that while inflation remains lower than he'd like, he doesn't see much chance the central bank will lower rates any time soon to bolster price pressures.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Fed's Williams: Doesn't See Strong Argument to Raise or Lower Rates. New York Fed chief said underlying inflation pressures likely close to Fed's 2% target. NEW YORK-Federal Reserve Bank of New York President John Williams said that while inflation remains lower than he'd like, he doesn't see much chance the central bank will lower rates any time soon to bolster price pressures.\"\n\nStock Prediction(s):", "Prediction": "\n- The Federal Reserve Bank of New York (NYSE: FRBNY) will not change their interest rates because underlying inflation pressures are close to their target.\n- The Bank of America Corporation (NYSE: BAC) will not change their interest rates because underlying inflation pressures are close to their target.\n- JPMorgan Chase & Co. (NYSE: JPM) will not change their interest rates because underlying inflation pressures are close to their target.", "price_info": {"FRBNY": {"company": "", "ticker": "FRBNY", "move": null}, "BAC": {"company": "", "ticker": "BAC", "move": null, "prices": [28.498, 28.525]}, "JPM": {"company": "", "ticker": "JPM", "move": null, "prices": [110.98, 111.01]}}}, {"link": "https://www.wsj.com/articles/german-airline-promises-to-bore-you-11561395072", "title": "German Airline Promises to Bore You", "date": "2019-06-24 12:51", "summary": "'We are German; we like to be boring,' says Lufthansa's chief executive officer. Investing in airlines offers more rolls, loops and spins than actually taking a commercial flight, because profitability is extremely sensitive to any drop off in demand. German carrier Lufthansa hopes to ease the turbulence by proudly reclaiming a national trait: boringness.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"German Airline Promises to Bore You. 'We are German; we like to be boring,' says Lufthansa's chief executive officer. Investing in airlines offers more rolls, loops and spins than actually taking a commercial flight, because profitability is extremely sensitive to any drop off in demand. German carrier Lufthansa hopes to ease the turbulence by proudly reclaiming a national trait: boringness.\"\n\nStock Prediction(s):", "Prediction": "\n- Lufthansa AG (OTCMKTS: DLAKY) will increase because they are a boring German airline that is investing in their company to make sure they are profitable.\n- Ryanair Holdings plc (NASDAQ: RYAAY) will decrease because they are not a boring German airline, and they are not investing as much in their company.", "price_info": {"RYAAY": {"company": "", "ticker": "RYAAY", "move": "down", "prices": [62.56, 62.5176]}}}, {"link": "https://www.wsj.com/articles/hbo-max-what-we-know-and-dont-know-11572458846", "title": "HBO Max: What We Know and Don't Know", "date": "2019-10-30 14:07", "summary": "Tuesday's unveiling left open several questions about access to the service for existing HBO customers. AT&T Inc. has revealed key details about its new HBO Max streaming-video service ahead of the app's launch next year, though some questions remain unanswered.", "categories": [["Business", "Media & Marketing"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/media-marketing?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"HBO Max: What We Know and Don't Know. Tuesday's unveiling left open several questions about access to the service for existing HBO customers. AT&T Inc. has revealed key details about its new HBO Max streaming-video service ahead of the app's launch next year, though some questions remain unanswered.\"\n\nStock Prediction(s):", "Prediction": "\n- AT&T Inc. (NYSE: T) will increase because they are releasing a new streaming service that will have access to HBO content.\n- Comcast Corporation (NASDAQ: CMCSA) will decrease because they are not releasing a new streaming service, and they will lose HBO content to AT&T.", "price_info": {"T": {"company": "", "ticker": "T", "move": "up", "prices": [38.24, 38.25]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "down", "prices": [44.68, 44.69]}}}, {"link": "https://www.wsj.com/articles/u-s-auto-makers-sweat-under-threat-of-tariffs-on-mexican-imports-11559308036", "title": "U.S. Auto Makers Sweat Under Threat of Tariffs on Mexican Imports", "date": "2019-05-31 12:53", "summary": "Mexico-built cars accounted for 17% of Detroit Big Three's overall U.S. sales in 2018. President Trump's threat to impose escalating tariffs on Mexican imports foists fresh bad news on the U.S. auto industry, which had pinned hopes on a tentative deal reached last year to preserve free trade between the countries.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Auto Makers Sweat Under Threat of Tariffs on Mexican Imports. Mexico-built cars accounted for 17% of Detroit Big Three's overall U.S. sales in 2018. President Trump's threat to impose escalating tariffs on Mexican imports foists fresh bad news on the U.S. auto industry, which had pinned hopes on a tentative deal reached last year to preserve free trade between the countries.\"\n\nStock Prediction(s):", "Prediction": "\n- General Motors Company (NYSE: GM) will decrease because their main market is in Mexico, and they will be affected by the tariffs.\n- Ford Motor Company (NYSE: F) will decrease because their main market is in Mexico, and they will be affected by the tariffs.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will decrease because their main market is in Mexico, and they will be affected by the tariffs.", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "down", "prices": [33.33, 33.52]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [9.5, 9.4772]}, "FCAU": {"company": "", "ticker": "FCAU", "move": "down", "prices": [12.705, 12.71]}}}, {"link": "https://www.wsj.com/articles/volvo-hit-by-cyber-theft-of-intellectual-property-11639167971", "title": "Volvo Hit by Cyber Theft of Intellectual Property", "date": "2021-12-10 15:26", "summary": "Swedish car maker says cybersecurity breach could have impact on operations. BERLIN- Volvo Car AB, the Swedish car maker, said Friday that it was investigating a cybersecurity breach targeting systems that store research and development files and warned the hack could have an impact on the company's operations.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Volvo Hit by Cyber Theft of Intellectual Property. Swedish car maker says cybersecurity breach could have impact on operations. BERLIN- Volvo Car AB, the Swedish car maker, said Friday that it was investigating a cybersecurity breach targeting systems that store research and development files and warned the hack could have an impact on the company's operations.\"\n\nStock Prediction(s):", "Prediction": "\n- Volvo Car AB (STO: VOLV-B) will decrease because of the cyber theft of intellectual property.\n- Ford Motor Company (NYSE: F) will increase because they are not affected by the cyber theft.\n- General Motors Company (NYSE: GM) will increase because they are not affected by the cyber theft.", "price_info": {"F": {"company": "", "ticker": "F", "move": "up", "prices": [21.235, 21.54]}, "GM": {"company": "", "ticker": "GM", "move": "up", "prices": [62.6, 63.25]}}}, {"link": "https://www.wsj.com/articles/coronavirus-pandemic-squeezes-mcdonalds-profit-11595934000", "title": "Coronavirus Pandemic Squeezes McDonald's Profit", "date": "2020-07-28 10:18", "summary": "Chain spends to operate during the virus while generating lower sales. McDonald's Corp. profit suffered a deeper-than-expected drop, as the coronavirus shut restaurants around the globe and forced the chain to spend tens of millions of dollars to help keep its franchisees operating.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Coronavirus Pandemic Squeezes McDonald's Profit. Chain spends to operate during the virus while generating lower sales. McDonald's Corp. profit suffered a deeper-than-expected drop, as the coronavirus shut restaurants around the globe and forced the chain to spend tens of millions of dollars to help keep its franchisees operating.\"\n\nStock Prediction(s):", "Prediction": "\n- McDonald's Corp. (NYSE: MCD) will decrease because their profit is suffering and they are spending a lot of money to keep their restaurants open.", "price_info": {"MCD": {"company": "", "ticker": "MCD", "move": "down", "prices": [196.97, 196.34]}}}, {"link": "https://www.wsj.com/articles/analysis-june-jobs-report-weakens-case-for-larger-fed-rate-cut-this-month-11562343047", "title": "June Jobs Report Weakens Case for Larger Fed Rate Cut This Month", "date": "2019-07-05 13:29", "summary": "But a rebound in hiring last month may not provide enough reason to scrap plans for an 'insurance' cut. The strong June employment report should ease Federal Reserve officials' concerns about a sharper-than-anticipated U.S. economic slowdown, but still leaves the door open to an interest-rate cut at their meeting this month.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"June Jobs Report Weakens Case for Larger Fed Rate Cut This Month. But a rebound in hiring last month may not provide enough reason to scrap plans for an 'insurance' cut. The strong June employment report should ease Federal Reserve officials' concerns about a sharper-than-anticipated U.S. economic slowdown, but still leaves the door open to an interest-rate cut at their meeting this month.\"\n\nStock Prediction(s):", "Prediction": "\n- The Fed will not cut rates this month because the June jobs report was stronger than expected.\n- The Fed will cut rates this month because the June jobs report was weaker than expected.", "price_info": {}}, {"link": "https://www.wsj.com/articles/alibaba-switches-lazada-ceo-again-in-tough-e-commerce-market-11593173345", "title": "Alibaba Switches Lazada CEO Again in Tough E-Commerce Market", "date": "2020-06-26 11:08", "summary": "Southeast Asia e-commerce unit appoints third CEO in over two years. SINGAPORE- Alibaba Group Holding Ltd. replaced the chief executive of its Southeast Asia e-commerce unit for the third time in just over two years, as the Chinese technology giant continues to struggle to get its international business on track.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Alibaba Switches Lazada CEO Again in Tough E-Commerce Market. Southeast Asia e-commerce unit appoints third CEO in over two years. SINGAPORE- Alibaba Group Holding Ltd. replaced the chief executive of its Southeast Asia e-commerce unit for the third time in just over two years, as the Chinese technology giant continues to struggle to get its international business on track.\"\n\nStock Prediction(s):", "Prediction": "\n- Alibaba Group Holding Ltd. (NYSE: BABA) will decrease because they are having trouble with their international business.\n- Lazada Group SA (private) will decrease because they keep changing CEOs.", "price_info": {"BABA": {"company": "", "ticker": "BABA", "move": "down", "prices": [214.8535, 216.05]}}}, {"link": "https://www.wsj.com/articles/old-chips-attract-some-big-checks-11642096282", "title": "Old Chips Attract Some Big Checks", "date": "2022-01-13 12:51", "summary": "Trailing-edge chip manufacturing processes are benefiting from blowout capital spending to address shortages. Chip making is an expensive undertaking. For those figuring out how to make it less so, the continuing shortage has actually been even more painful.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Old Chips Attract Some Big Checks. Trailing-edge chip manufacturing processes are benefiting from blowout capital spending to address shortages. Chip making is an expensive undertaking. For those figuring out how to make it less so, the continuing shortage has actually been even more painful.\"\n\nStock Prediction(s):", "Prediction": "\n- Intel Corporation (NASDAQ: INTC) will increase because they are one of the few companies that have the ability to manufacture chips using older processes.\n- Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM) will increase because they are one of the few companies that have the ability to manufacture chips using older processes.\n- Micron Technology, Inc. (NASDAQ: MU) will increase because they are one of the few companies that have the", "price_info": {"TSM": {"company": "", "ticker": "TSM", "move": "up", "prices": [141.551, 141.28]}, "INTC": {"company": "", "ticker": "INTC", "move": "up", "prices": [55.16, 55.2]}, "MU": {"company": "", "ticker": "MU", "move": "up", "prices": [96.4964, 96.54]}}}, {"link": "https://www.wsj.com/articles/microsoft-earnings-poised-for-growth-what-to-watch-11571843125", "title": "Microsoft Earnings Poised for Growth: What to Watch", "date": "2019-10-23 11:05", "summary": "Cloud computing set to underpin company's results. Microsoft Corp. is set to report first-quarter earnings after the market closes Wednesday. Although it just ceded its title as the world's most valuable public company to Apple Inc., the software giant has been riding high for the last few years, driven by its fast-growing commercial cloud business. Here's what to look for:", "categories": [["Business", "Earnings Preview"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/types/earnings-preview?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Microsoft Earnings Poised for Growth: What to Watch. Cloud computing set to underpin company's results. Microsoft Corp. is set to report first-quarter earnings after the market closes Wednesday. Although it just ceded its title as the world's most valuable public company to Apple Inc., the software giant has been riding high for the last few years, driven by its fast-growing commercial cloud business. Here's what to look for:\"\n\nStock Prediction(s):", "Prediction": "\n- Microsoft Corporation (NASDAQ: MSFT) will increase because their commercial cloud business is doing well.\n- Apple Inc. (NASDAQ: AAPL) will increase because they are now the most valuable public company.\n- Amazon.com, Inc. (NASDAQ: AMZN) will decrease because they are a direct competitor of Microsoft in the cloud computing market.", "price_info": {"MSFT": {"company": "", "ticker": "MSFT", "move": "up", "prices": [135.9, 136.229]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "up", "prices": [242.45, 242.4124]}, "AMZN": {"company": "", "ticker": "AMZN", "move": "down", "prices": [1759.35, 1756.85]}}}, {"link": "https://www.wsj.com/articles/u-s-internet-pricing-is-all-over-the-place-help-us-investigate-it-11566486681", "title": "U.S. Internet Pricing Is All Over the Place. Help Us Investigate It.", "date": "2019-08-22 11:11", "summary": "WSJ reviewed nearly 200 internet bills from people across the country. This is what we've found so far.. Internet pricing is a puzzle for many American consumers. It is an unregulated marketplace where prices vary drastically across the country, or even just across the street.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Internet Pricing Is All Over the Place. Help Us Investigate It.. WSJ reviewed nearly 200 internet bills from people across the country. This is what we've found so far.. Internet pricing is a puzzle for many American consumers. It is an unregulated marketplace where prices vary drastically across the country, or even just across the street.\"\n\nStock Prediction(s):", "Prediction": "\n- Comcast Corporation (NASDAQ: CMCSA) will increase because they are the only provider in some areas, and they have a monopoly.\n- AT&T Inc. (NYSE: T) will increase because they are the only provider in some areas, and they have a monopoly.\n- Verizon Communications Inc. (NYSE: VZ) will increase because they are the only provider in some areas, and they have a monopoly.\n- Amazon.com,", "price_info": {"T": {"company": "", "ticker": "T", "move": "up", "prices": [35.34, 35.3639]}, "VZ": {"company": "", "ticker": "VZ", "move": "up", "prices": [56.74, 56.68]}, "CMCSA": {"company": "", "ticker": "CMCSA", "move": "up", "prices": [43.88, 43.93]}}}, {"link": "https://www.wsj.com/articles/how-investors-can-prepare-for-uber-and-lyft-ipos-11551459230", "title": "How Investors Can Prepare for Uber and Lyft IPOs", "date": "2019-03-01 11:53", "summary": "A London equity analyst spent a week riding a delivery bike to better understand the booming gig economy. As the gig economy grows, investors are going to have a whole new way of getting to know companies.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"How Investors Can Prepare for Uber and Lyft IPOs. A London equity analyst spent a week riding a delivery bike to better understand the booming gig economy. As the gig economy grows, investors are going to have a whole new way of getting to know companies.\"\n\nStock Prediction(s):", "Prediction": "\n- Uber Technologies Inc (NYSE: UBER) will increase because their IPO is coming up, and they are a big player in the gig economy.\n- Lyft Inc (NASDAQ: LYFT) will increase because their IPO is coming up, and they are a big player in the gig economy.\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are a big player in the gig economy.\n- Grub", "price_info": {"UBER": {"company": "", "ticker": "UBER", "move": "up"}, "LYFT": {"company": "", "ticker": "LYFT", "move": "up"}, "AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1653.61, 1662.17]}}}, {"link": "https://www.wsj.com/articles/for-airlines-the-devil-is-in-the-737-max-detail-11564067052", "title": "For Airlines, the Devil Is in the 737 MAX Detail", "date": "2019-07-25 11:12", "summary": "Southwest Airlines is assuming the troubled jet flies in 2020, whereas American is factoring in flights in November. In today's aviation industry, headline profit numbers have become less important than assumptions about when the Boeing 737 MAX jet will fly again.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"For Airlines, the Devil Is in the 737 MAX Detail. Southwest Airlines is assuming the troubled jet flies in 2020, whereas American is factoring in flights in November. In today's aviation industry, headline profit numbers have become less important than assumptions about when the Boeing 737 MAX jet will fly again.\"\n\nStock Prediction(s):", "Prediction": "\n- American Airlines Group Inc (NASDAQ: AAL) will increase because they are expecting the 737 MAX to fly again in November, while Southwest Airlines Co (NYSE: LUV) is expecting it to fly in 2020.\n- Boeing Co (NYSE: BA) will decrease because they are the manufacturer of the 737 MAX, and the jet is still grounded.", "price_info": {"LUV": {"company": "", "ticker": "LUV", "move": null, "prices": [55.45, 55.51]}, "BA": {"company": "", "ticker": "BA", "move": "down", "prices": [348.79, 347]}, "AAL": {"company": "", "ticker": "AAL", "move": "up", "prices": [33.2, 32.795]}}}, {"link": "https://www.wsj.com/articles/amazons-proxy-becomes-prime-target-11558546005", "title": "Amazon's Proxy Becomes Prime Target", "date": "2019-05-22 13:26", "summary": "Record number of shareholder proposals on proxy as activists target Big Tech. Annual meetings can be snoozefests, but at least Amazon.com 's investors had a long read to help pass the time.", "categories": [["Markets", "Overheard"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/overheard?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Amazon's Proxy Becomes Prime Target. Record number of shareholder proposals on proxy as activists target Big Tech. Annual meetings can be snoozefests, but at least Amazon.com 's investors had a long read to help pass the time.\"\n\nStock Prediction(s):", "Prediction": "\n- Amazon.com, Inc. (NASDAQ: AMZN) will increase because they are being targeted by activists, and they have a record number of shareholder proposals.\n- Facebook, Inc. (NASDAQ: FB) will decrease because they are also being targeted by activists, and they have a record number of shareholder proposals.\n- Apple Inc. (NASDAQ: AAPL) will decrease because they are also being targeted by activists, and they have a", "price_info": {"AMZN": {"company": "", "ticker": "AMZN", "move": "up", "prices": [1863.64, 1862.45]}, "FB": {"company": "", "ticker": "FB", "move": "down", "prices": [185.9501, 186.478]}, "AAPL": {"company": "", "ticker": "AAPL", "move": "down", "prices": [183.29, 182.98]}}}, {"link": "https://www.wsj.com/articles/owner-of-kings-and-balduccis-supermarkets-files-for-bankruptcy-11598289178", "title": "Owner of Kings and Balducci's Supermarkets Files for Bankruptcy", "date": "2020-08-24 13:12", "summary": "Regional grocery chain KB US Holdings files for chapter 11 with $75 million buyout offer from TLI Bedrock. The parent of Kings Food Markets and Balducci's has filed for bankruptcy, as a sales boost amid the Covid-19 pandemic wasn't enough to overcome years of pressure from big national chains, online retailers and meal-kit companies.", "categories": [["Pro Bankruptcy"]], "category_links": ["https://www.wsj.com/pro/bankruptcy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Owner of Kings and Balducci's Supermarkets Files for Bankruptcy. Regional grocery chain KB US Holdings files for chapter 11 with $75 million buyout offer from TLI Bedrock. The parent of Kings Food Markets and Balducci's has filed for bankruptcy, as a sales boost amid the Covid-19 pandemic wasn't enough to overcome years of pressure from big national chains, online retailers and meal-kit companies.\"\n\nStock Prediction(s):", "Prediction": "\n- KB US Holdings (OTCQB: KBHG) will decrease because they have filed for bankruptcy.\n- TLI Bedrock (private) will increase because they have offered to buy KB US Holdings for $75 million.", "price_info": {}}, {"link": "https://www.wsj.com/articles/softbank-wework-and-sunk-costs-11571831126", "title": "SoftBank, WeWork and Sunk Costs", "date": "2019-10-23 14:51", "summary": "SoftBank's latest investment into WeWork doesn't only represent a hit to its value, but also to its reputation for investing acumen. SoftBank Group , one of the world's largest and supposedly savviest investment firms, looks like it is making a classic rookie error by succumbing to the sunk-cost fallacy.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"SoftBank, WeWork and Sunk Costs. SoftBank's latest investment into WeWork doesn't only represent a hit to its value, but also to its reputation for investing acumen. SoftBank Group , one of the world's largest and supposedly savviest investment firms, looks like it is making a classic rookie error by succumbing to the sunk-cost fallacy.\"\n\nStock Prediction(s):", "Prediction": "\n- SoftBank Group Corp. (OTCMKTS: SFTBY) will decrease because of their investment into WeWork.\n- WeWork Companies Inc. (NYSE: WEWORK) will decrease because of their investment into WeWork.\n- Sunk costs will continue to be a fallacy for SoftBank Group Corp. (OTCMKTS: SFTBY) and WeWork Companies Inc. (NYSE: WEWORK).", "price_info": {}}, {"link": "https://www.wsj.com/articles/reason-why-you-should-attend-live-theater-11636403394", "title": "A Surprising Reason Why You Should Attend Live Theater", "date": "2021-11-11 12:00", "summary": "Researchers found that watching a performance made people more charitable and empathetic. Could attending live theater make you a more empathetic person?", "categories": [["Markets", "Journal Reports: Wealth Management"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/types/journal-reports-wealth-management?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"A Surprising Reason Why You Should Attend Live Theater. Researchers found that watching a performance made people more charitable and empathetic. Could attending live theater make you a more empathetic person?\"\n\nStock Prediction(s):", "Prediction": "\n- Theaters will increase in popularity because people will want to see live performances in order to feel more charitable and empathetic.\n- Ticket sales will increase for theaters, and this will benefit the companies that own theaters (e.g. AMC Entertainment Holdings, Inc. (NYSE: AMC)).", "price_info": {"AMC": {"company": "", "ticker": "AMC", "move": "up", "prices": [39.2377, 39.9]}}}, {"link": "https://www.wsj.com/articles/drugmaker-to-test-machine-learning-to-prevent-drug-shortages-11571079794", "title": "Drugmaker to Test Machine Learning to Prevent Drug Shortages", "date": "2019-10-14 15:03", "summary": "Germany-based Merck plans pilot using TraceLink software to sharpen its supply-and-demand forecasts. Merck KGaA plans to use analytics and machine learning to predict and prevent drug shortages, a move that could also save it money.", "categories": [["CIO Journal"]], "category_links": ["https://www.wsj.com/news/types/cio-journal?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Drugmaker to Test Machine Learning to Prevent Drug Shortages. Germany-based Merck plans pilot using TraceLink software to sharpen its supply-and-demand forecasts. Merck KGaA plans to use analytics and machine learning to predict and prevent drug shortages, a move that could also save it money.\"\n\nStock Prediction(s):", "Prediction": "\n- Merck KGaA (FRA: MKK) will increase because they are using machine learning to prevent drug shortages.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also using machine learning to prevent drug shortages.", "price_info": {"PFE": {"company": "", "ticker": "PFE", "move": "down", "prices": [36.3, 36.28]}}}, {"link": "https://www.wsj.com/articles/rising-demand-for-delivery-is-remaking-chinas-grocery-landscape-11561381366", "title": "After Struggling to Deliver in China, Carrefour Packs Its Bags", "date": "2019-06-24 11:25", "summary": "French company is pulling back as local upstarts seize on the trend toward delivering items directly to customers' homes. BEIJING- Carrefour SA, one of Europe's largest grocery retailers, is unloading most of its operations in China, where big-box retailers are struggling to keep up with nimble delivery providers that are winning over shoppers.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"After Struggling to Deliver in China, Carrefour Packs Its Bags. French company is pulling back as local upstarts seize on the trend toward delivering items directly to customers' homes. BEIJING- Carrefour SA, one of Europe's largest grocery retailers, is unloading most of its operations in China, where big-box retailers are struggling to keep up with nimble delivery providers that are winning over shoppers.\"\n\nStock Prediction(s):", "Prediction": "\n- Carrefour SA (EPA: CA) will decrease because they are pulling out of China, and the Chinese market is only growing.\n- Alibaba Group Holding Ltd. (NYSE: BABA) will increase because they are a direct competitor of Carrefour, and they are doing well in China.\n- JD.com, Inc. (NASDAQ: JD) will increase because they are a direct competitor of Carrefour, and they are doing well in", "price_info": {"BABA": {"company": "", "ticker": "BABA", "move": "up", "prices": [168.3605, 167.87]}, "JD": {"company": "", "ticker": "JD", "move": "up", "prices": [29.05, 28.93]}}}, {"link": "https://www.wsj.com/articles/adidas-explores-sale-of-reebok-11607969262", "title": "Adidas Explores Sale of Reebok", "date": "2020-12-14 13:07", "summary": "Nearly 15 years after acquiring the U.S. brand and trying to revamp it, Adidas says it might sell it. BERLIN- Adidas AG on Monday said it was reviewing the future of Reebok and might sell the U.S. fitness brand-a business it had spent years trying to revamp and that could now fetch several billion dollars, according to analysts.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Adidas Explores Sale of Reebok. Nearly 15 years after acquiring the U.S. brand and trying to revamp it, Adidas says it might sell it. BERLIN- Adidas AG on Monday said it was reviewing the future of Reebok and might sell the U.S. fitness brand-a business it had spent years trying to revamp and that could now fetch several billion dollars, according to analysts.\"\n\nStock Prediction(s):", "Prediction": "\n- Adidas AG (OTCMKTS: ADDYY) will increase because they are exploring the sale of Reebok, and it could fetch several billion dollars.\n- Nike, Inc. (NYSE: NKE) will decrease because they are a direct competitor of Adidas.", "price_info": {"NKE": {"company": "", "ticker": "NKE", "move": "down", "prices": [137.08, 136.97]}}}, {"link": "https://www.wsj.com/articles/car-sales-fell-in-the-second-quarter-despite-deals-and-covid-19-stimulus-11593621053", "title": "Car Sales Fell in the Second Quarter, Despite Deals and Covid-19 Stimulus", "date": "2020-07-01 15:39", "summary": "The industry is facing a test this summer as deals dry up and the impact of federal aid fades. Major auto makers reported sharp drops in second-quarter U.S. vehicle sales, as sweet discounts and financing deals weren't enough to offset factory and dealership closures from the Covid-19 pandemic.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Car Sales Fell in the Second Quarter, Despite Deals and Covid-19 Stimulus. The industry is facing a test this summer as deals dry up and the impact of federal aid fades. Major auto makers reported sharp drops in second-quarter U.S. vehicle sales, as sweet discounts and financing deals weren't enough to offset factory and dealership closures from the Covid-19 pandemic.\"\n\nStock Prediction(s):", "Prediction": "\n- General Motors Company (NYSE: GM) will decrease because their sales are down.\n- Ford Motor Company (NYSE: F) will decrease because their sales are down.\n- Fiat Chrysler Automobiles NV (NYSE: FCAU) will decrease because their sales are down.\n- Tesla, Inc. (NASDAQ: TSLA) will increase because their sales are up.", "price_info": {"GM": {"company": "", "ticker": "GM", "move": "down", "prices": [24.95, 24.9]}, "F": {"company": "", "ticker": "F", "move": "down", "prices": [5.96, 5.9602]}, "FCAU": {"company": "", "ticker": "FCAU", "move": "down", "prices": [9.8, 9.91]}, "TSLA": {"company": "", "ticker": "TSLA", "move": "up", "prices": [1118.56, 1118.79]}}}, {"link": "https://www.wsj.com/articles/under-armours-never-ending-story-11549992215", "title": "Under Armour's Never-Ending Story", "date": "2019-02-12 12:23", "summary": "The sportswear company's reset, promised since 2017, has yet to take hold. Under Armour 's turnaround plan is looking like the plan that will never end.", "categories": [["Markets", "Heard on the Street"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/news/heard-on-the-street?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Under Armour's Never-Ending Story. The sportswear company's reset, promised since 2017, has yet to take hold. Under Armour 's turnaround plan is looking like the plan that will never end.\"\n\nStock Prediction(s):", "Prediction": "\n- Under Armour, Inc. (NYSE: UA) will continue to decrease because their turnaround plan has not taken hold yet.", "price_info": {"UA": {"company": "", "ticker": "UA", "move": "down", "prices": [20.37, 20.38]}}}, {"link": "https://www.wsj.com/articles/china-steps-up-antitrust-inspections-of-internet-firms-11623943689", "title": "China Steps Up Antitrust Pressure on Internet Firms", "date": "2021-06-17 11:28", "summary": "Authorities make surprise on-site inspections, questioning executives and downloading contracts. SINGAPORE-Chinese regulators have intensified scrutiny of dozens of domestic internet companies for possible antitrust violations, people familiar with the matter said.", "categories": [["Tech"]], "category_links": ["https://www.wsj.com/news/technology?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"China Steps Up Antitrust Pressure on Internet Firms. Authorities make surprise on-site inspections, questioning executives and downloading contracts. SINGAPORE-Chinese regulators have intensified scrutiny of dozens of domestic internet companies for possible antitrust violations, people familiar with the matter said.\"\n\nStock Prediction(s):", "Prediction": "\n- Baidu Inc (NASDAQ: BIDU) will decrease because they are one of the companies that was inspected, and they may have violated antitrust laws.\n- Tencent Holdings Ltd (OTCMKTS: TCEHY) will decrease because they are one of the companies that was inspected, and they may have violated antitrust laws.\n- Alibaba Group Holding Ltd (NYSE: BABA) will decrease because they are one of the companies that was inspected", "price_info": {"BABA": {"company": "", "ticker": "BABA", "move": "down", "prices": [210.4, 211.24]}, "BIDU": {"company": "", "ticker": "BIDU", "move": "down", "prices": [184.13, 184.88]}}}, {"link": "https://www.wsj.com/articles/mnuchin-says-stimulus-talks-remain-stalled-11597762971", "title": "Mnuchin Says Stimulus Talks Remain Stalled", "date": "2020-08-18 11:02", "summary": "Treasury secretary suggests Pelosi may be open to resuming talks when House convenes to take up Postal Service bill. WASHINGTON-Treasury Secretary Steven Mnuchin said Tuesday that talks remain stalled between Republicans and Democrats over another round of stimulus funding, though bipartisan appetite for a deal remains high.", "categories": [["Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Mnuchin Says Stimulus Talks Remain Stalled. Treasury secretary suggests Pelosi may be open to resuming talks when House convenes to take up Postal Service bill. WASHINGTON-Treasury Secretary Steven Mnuchin said Tuesday that talks remain stalled between Republicans and Democrats over another round of stimulus funding, though bipartisan appetite for a deal remains high.\"\n\nStock Prediction(s):", "Prediction": "\n- The market will remain stagnant because there is still no stimulus deal.\n- The market will rebound because there is still bipartisan appetite for a deal.", "price_info": {}}, {"link": "https://www.wsj.com/articles/oils-relief-rally-stalls-after-prices-double-11588775777", "title": "Oil's 'Relief Rally' Stalls After Prices Double", "date": "2020-05-06 15:23", "summary": "The rally raises hopes-but not confidence-that the mounting fuel glut won't overwhelm the world's capacity to store oil. Energy producers are throttling back their output, drivers are returning to the road and U.S. oil prices are roughly twice what they were a week ago, raising hopes-but not confidence-that the mounting fuel glut won't overwhelm the world's capacity to store oil.", "categories": [["Markets", "Commodities", "Oil Markets"]], "category_links": ["https://www.wsj.com/news/markets?mod=breadcrumb", "https://www.wsj.com/market-data/commodities?mod=breadcrumb", "https://www.wsj.com/news/types/oil-markets?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Oil's 'Relief Rally' Stalls After Prices Double. The rally raises hopes-but not confidence-that the mounting fuel glut won't overwhelm the world's capacity to store oil. Energy producers are throttling back their output, drivers are returning to the road and U.S. oil prices are roughly twice what they were a week ago, raising hopes-but not confidence-that the mounting fuel glut won't overwhelm the world's capacity to store oil.\"\n\nStock Prediction(s):", "Prediction": "\n- Chevron Corporation (NYSE: CVX) will decrease because their production is slowing down and they are not going to be able to keep up with the market.\n- Exxon Mobil Corporation (NYSE: XOM) will decrease because their production is slowing down and they are not going to be able to keep up with the market.\n- Royal Dutch Shell plc (NYSE: RDS.A) will decrease because their production is slowing down and they are not going to", "price_info": {"CVX": {"company": "", "ticker": "CVX", "move": "up", "prices": [90.04, 90.04]}, "XOM": {"company": "", "ticker": "XOM", "move": "down", "prices": [43.96, 43.96]}}}, {"link": "https://www.wsj.com/articles/waterton-seeks-to-replace-board-ceo-at-canadian-miner-hudbay-11547647291", "title": "Waterton Seeks to Replace Board, CEO at Canadian Miner Hudbay", "date": "2019-01-16 11:37", "summary": "Private-equity firm, which has a nearly 12% stake, says Hudbay needs more board members with experience in South America. Private-equity firm Waterton Global Resource Management Inc. is launching a proxy fight with Hudbay Minerals Inc., pushing the Canadian mining company to overhaul its board and replace its chief executive.", "categories": [["Business"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Waterton Seeks to Replace Board, CEO at Canadian Miner Hudbay. Private-equity firm, which has a nearly 12% stake, says Hudbay needs more board members with experience in South America. Private-equity firm Waterton Global Resource Management Inc. is launching a proxy fight with Hudbay Minerals Inc., pushing the Canadian mining company to overhaul its board and replace its chief executive.\"\n\nStock Prediction(s):", "Prediction": "\n- Hudbay Minerals Inc. (NYSE: HBM) will decrease because they are being pushed out by Waterton.\n- Waterton Global Resource Management Inc. (private) will increase because they are taking over Hudbay.", "price_info": {"HBM": {"company": "", "ticker": "HBM", "move": "up", "prices": [5.61, 5.5664]}}}, {"link": "https://www.wsj.com/articles/nissan-board-girds-for-clash-with-management-11570461706", "title": "Nissan Board Girds for Clash With Management", "date": "2019-10-07 11:21", "summary": "At next board meeting, directors will demand to see 80-name list of people who allegedly helped Carlos Ghosn. TOKYO-Some Nissan Motor Co. directors will demand at Tuesday's board meeting to see a list of around 80 Nissan employees who may have assisted former Chairman Carlos Ghosn in alleged wrongdoing, said people familiar with the board's thinking, setting up a potential clash with management.", "categories": [["Business", "Autos & Transportation", "Autos Industry"]], "category_links": ["https://www.wsj.com/news/business?mod=breadcrumb", "https://www.wsj.com/news/business/transportation?mod=breadcrumb", "https://www.wsj.com/news/types/autos?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"Nissan Board Girds for Clash With Management. At next board meeting, directors will demand to see 80-name list of people who allegedly helped Carlos Ghosn. TOKYO-Some Nissan Motor Co. directors will demand at Tuesday's board meeting to see a list of around 80 Nissan employees who may have assisted former Chairman Carlos Ghosn in alleged wrongdoing, said people familiar with the board's thinking, setting up a potential clash with management.\"\n\nStock Prediction(s):", "Prediction": "\n- Nissan Motor Co. (OTCPK: NSANY) will decrease because their board is preparing to clash with management over the 80-name list of employees who allegedly helped Carlos Ghosn.\n- Renault SA (OTCPK: RNLSY) will decrease because they are a direct competitor of Nissan Motor Co., and Renault is part-owned by Nissan.", "price_info": {}}, {"link": "https://www.wsj.com/articles/january-jobs-report-unemployment-rate-2021-11612475063", "title": "U.S. Added 49,000 Jobs in January", "date": "2021-02-05 15:05", "summary": "Growth returned to the labor market after one-month dip; unemployment rate fell to 6.3%. U.S. employers resumed hiring in January, but the weak pace of job gains suggested a long road remains for the recovery.", "categories": [["Economy", "U.S. Economy"]], "category_links": ["https://www.wsj.com/news/economy?mod=breadcrumb", "https://www.wsj.com/news/types/u-s-economy?mod=breadcrumb"], "blurb": "News: \"AstraZeneca-Oxford Vaccine Up to 90% Effective in Trials. U.K. drugmaker hopes to have the two-dose shot available for use around year-end, pending regulatory approval. LONDON-AstraZeneca PLC and the University of Oxford added their vaccine candidate to a growing list of shots showing promising effectiveness against Covid-19-setting in motion disparate regulatory and distribution tracks that executives and researchers hope will result in the start of widespread vaccinations by the end of the year.\"\n\nStock Prediction(s):\n- AstraZeneca plc (NASDAQ: AZN) will increase because their vaccine is 90% effective, and they are only waiting for regulatory approval before being deployed.\n- Johnson & Johnson (NYSE: JNJ) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Pfizer Inc (NYSE: PFE) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n- Moderna Inc (NASDAQ: MRNA) will decrease because they are also working on a vaccine, but they are a direct competitor of AstraZeneca.\n\nNews: \"U.S. Added 49,000 Jobs in January. Growth returned to the labor market after one-month dip; unemployment rate fell to 6.3%. U.S. employers resumed hiring in January, but the weak pace of job gains suggested a long road remains for the recovery.\"\n\nStock Prediction(s):", "Prediction": "\n- The unemployment rate will continue to decline because more jobs are being created.\n- The stock market will continue to rise because the economy is improving.", "price_info": {}}]